[
    {
        "nctid": "NCT04440033",
        "study_official_title": "Factors Associated With Falling in Parkinson's Disease: a Multidisciplinary Prospective Study ",
        "study_brief_summary": " The objective of this study will be to identify multidisciplinary fall risk factors in persons with stage 3 idiopathic Parkinson's Disease compared to age and sex-matched healthy adults. Both the relative contribution of each independent factor, as well as the interaction between these factors, will be examined. The study will include multidisciplinary assessments, including locomotor, speech, auditory, vestibular and opthalmologic assessments.",
        "text": "Factors Associated With Falling in Parkinson's Disease: a Multidisciplinary Prospective Study | The objective of this study will be to identify multidisciplinary fall risk factors in persons with stage 3 idiopathic Parkinson's Disease compared to age and sex-matched healthy adults. Both the relative contribution of each independent factor, as well as the interaction between these factors, will be examined. The study will include multidisciplinary assessments, including locomotor, speech, auditory, vestibular and opthalmologic assessments.",
        "tokens": "['Factors', 'Associated', 'With', 'Falling', 'in', 'Parkinson', \"'s\", 'Disease', ':', 'a', 'Multidisciplinary', 'Prospective', 'Study', '|', 'The', 'objective', 'of', 'this', 'study', 'will', 'be', 'to', 'identify', 'multidisciplinary', 'fall', 'risk', 'factors', 'in', 'persons', 'with', 'stage', '3', 'idiopathic', 'Parkinson', \"'s\", 'Disease', 'compared', 'to', 'age', 'and', 'sex', '-', 'matched', 'healthy', 'adults', '.', 'Both', 'the', 'relative', 'contribution', 'of', 'each', 'independent', 'factor', ',', 'as', 'well', 'as', 'the', 'interaction', 'between', 'these', 'factors', ',', 'will', 'be', 'examined', '.', 'The', 'study', 'will', 'include', 'multidisciplinary', 'assessments', ',', 'including', 'locomotor', ',', 'speech', ',', 'auditory', ',', 'vestibular', 'and', 'opthalmologic', 'assessments', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 54,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 196,
                "end": 234,
                "text": "stage 3 idiopathic Parkinson's Disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01344447",
        "study_official_title": "Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels ",
        "study_brief_summary": " Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required.\n\nThis study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study.\n\nMRA and CTA images will be collected for an independent review (blinded read).",
        "text": "Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels | Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required.\n\nThis study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study.\n\nMRA and CTA images will be collected for an independent review (blinded read).",
        "tokens": "['Multicenter', ',', 'Open', '-', 'label', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Efficacy', '(', 'by', 'Blinded', 'Reading', ')', 'of', 'Contrast', '-', 'Enhanced', 'Magnetic', 'Resonance', 'Angiography', '(', 'MRA', ')', 'After', 'a', 'Single', 'Intravenous', 'Injection', 'of', '0.1', 'mmol', '/', 'kg', 'Gadobutrol', 'in', 'Subjects', 'With', 'Known', 'or', 'Suspected', 'Vascular', 'Disease', 'of', 'the', 'Supra', '-', 'aortic', 'Vessels', '|', 'Subjects', 'referred', 'for', 'a', 'routine', 'CTA', '(', 'computed', 'tomography', 'angiography', ')', 'or', 'MRA', '(', 'magnetic', 'resonance', 'angiography', ')', 'will', 'be', 'invited', 'to', 'participate', 'in', 'the', 'study', 'and', 'subjects', 'will', 'be', 'involved', 'in', 'the', 'study', 'for', 'between', '2', 'and', '12', 'days', '.', 'Two', 'to', 'three', 'visits', 'to', 'the', 'study', 'doctor', 'will', 'be', 'required', '.', '\\n\\n', 'This', 'study', 'will', 'compare', 'the', 'diagnostic', 'results', 'of', 'Gadobutrol', 'enhanced', 'MRA', 'images', 'with', 'MRA', 'images', 'taken', 'without', 'contrast', 'agent', 'using', 'images', 'from', 'a', 'CTA', 'as', 'the', 'standard', 'of', 'reference', ',', 'which', 'may', 'have', 'been', 'performed', 'up', 'to', '60', 'days', 'prior', 'to', 'enrolment', '.', 'If', 'a', 'CTA', 'has', 'not', 'been', 'performed', 'in', 'this', 'prior', 'time', 'period', ',', 'a', 'CTA', 'is', 'required', 'for', 'the', 'study', '.', '\\n\\n', 'MRA', 'and', 'CTA', 'images', 'will', 'be', 'collected', 'for', 'an', 'independent', 'review', '(', 'blinded', 'read', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 244,
                "end": 288,
                "text": "Vascular Disease of the Supra-aortic Vessels",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01596608",
        "study_official_title": "Efficacy and Tolerability of Magnetic Seizure Therapy (MST) as an Alternative to Electroconvulsive Therapy (ECT) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder ",
        "study_brief_summary": " Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression, and is also useful in treatment-refractory cases of schizophrenia and obsessive compulsive disorder (OCD). However, its use is limited by significant adverse effects on memory and cognition. In addition, ECT cannot be precisely targeted, since it relies on unpredictable pathways of electrical conduction through the brain. Magnetic seizure therapy (MST) is currently under investigation as a targetable, cognition-sparing alternative to ECT. MST uses magnetic fields rather than electrical stimuli for seizure induction, dramatically reducing the passage of induced current through undesired brain regions. 10 years of experimental studies have established the safety of MST in animal and human subjects. This pilot study will investigate whether MST has similar efficacy to ECT, with fewer cognitive side effects, in patients with severe depression, schizophrenia, and OCD.",
        "text": "Efficacy and Tolerability of Magnetic Seizure Therapy (MST) as an Alternative to Electroconvulsive Therapy (ECT) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder | Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression, and is also useful in treatment-refractory cases of schizophrenia and obsessive compulsive disorder (OCD). However, its use is limited by significant adverse effects on memory and cognition. In addition, ECT cannot be precisely targeted, since it relies on unpredictable pathways of electrical conduction through the brain. Magnetic seizure therapy (MST) is currently under investigation as a targetable, cognition-sparing alternative to ECT. MST uses magnetic fields rather than electrical stimuli for seizure induction, dramatically reducing the passage of induced current through undesired brain regions. 10 years of experimental studies have established the safety of MST in animal and human subjects. This pilot study will investigate whether MST has similar efficacy to ECT, with fewer cognitive side effects, in patients with severe depression, schizophrenia, and OCD.",
        "tokens": "['Efficacy', 'and', 'Tolerability', 'of', 'Magnetic', 'Seizure', 'Therapy', '(', 'MST', ')', 'as', 'an', 'Alternative', 'to', 'Electroconvulsive', 'Therapy', '(', 'ECT', ')', 'for', 'Treatment', 'Resistant', 'Depression', ',', 'Schizophrenia', ',', 'and', 'Obsessive', 'Compulsive', 'Disorder', '|', 'Electroconvulsive', 'therapy', '(', 'ECT', ')', 'has', 'unparalleled', 'efficacy', 'in', 'treating', 'severe', 'depression', ',', 'and', 'is', 'also', 'useful', 'in', 'treatment', '-', 'refractory', 'cases', 'of', 'schizophrenia', 'and', 'obsessive', 'compulsive', 'disorder', '(', 'OCD', ')', '.', 'However', ',', 'its', 'use', 'is', 'limited', 'by', 'significant', 'adverse', 'effects', 'on', 'memory', 'and', 'cognition', '.', 'In', 'addition', ',', 'ECT', 'can', 'not', 'be', 'precisely', 'targeted', ',', 'since', 'it', 'relies', 'on', 'unpredictable', 'pathways', 'of', 'electrical', 'conduction', 'through', 'the', 'brain', '.', 'Magnetic', 'seizure', 'therapy', '(', 'MST', ')', 'is', 'currently', 'under', 'investigation', 'as', 'a', 'targetable', ',', 'cognition', '-', 'sparing', 'alternative', 'to', 'ECT', '.', 'MST', 'uses', 'magnetic', 'fields', 'rather', 'than', 'electrical', 'stimuli', 'for', 'seizure', 'induction', ',', 'dramatically', 'reducing', 'the', 'passage', 'of', 'induced', 'current', 'through', 'undesired', 'brain', 'regions', '.', '10', 'years', 'of', 'experimental', 'studies', 'have', 'established', 'the', 'safety', 'of', 'MST', 'in', 'animal', 'and', 'human', 'subjects', '.', 'This', 'pilot', 'study', 'will', 'investigate', 'whether', 'MST', 'has', 'similar', 'efficacy', 'to', 'ECT', ',', 'with', 'fewer', 'cognitive', 'side', 'effects', ',', 'in', 'patients', 'with', 'severe', 'depression', ',', 'schizophrenia', ',', 'and', 'OCD', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 53,
                "text": "Magnetic Seizure Therapy",
                "type": "OTHER"
            },
            {
                "start": 55,
                "end": 58,
                "text": "MST",
                "type": "OTHER"
            },
            {
                "start": 81,
                "end": 106,
                "text": "Electroconvulsive Therapy",
                "type": "CONTROL"
            },
            {
                "start": 108,
                "end": 111,
                "text": "ECT",
                "type": "CONTROL"
            },
            {
                "start": 117,
                "end": 197,
                "text": "Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 225,
                "text": "Electroconvulsive therapy",
                "type": "CONTROL"
            },
            {
                "start": 227,
                "end": 230,
                "text": "ECT",
                "type": "CONTROL"
            },
            {
                "start": 270,
                "end": 288,
                "text": "severe depression,",
                "type": "CONDITION"
            },
            {
                "start": 311,
                "end": 388,
                "text": "treatment-refractory cases of schizophrenia and obsessive compulsive disorder",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 393,
                "text": "OCD",
                "type": "CONDITION"
            },
            {
                "start": 493,
                "end": 496,
                "text": "ECT",
                "type": "CONTROL"
            },
            {
                "start": 613,
                "end": 637,
                "text": "Magnetic seizure therapy",
                "type": "OTHER"
            },
            {
                "start": 639,
                "end": 642,
                "text": "MST",
                "type": "OTHER"
            },
            {
                "start": 727,
                "end": 730,
                "text": "ECT",
                "type": "CONTROL"
            },
            {
                "start": 732,
                "end": 735,
                "text": "MST",
                "type": "OTHER"
            },
            {
                "start": 961,
                "end": 964,
                "text": "MST",
                "type": "OTHER"
            },
            {
                "start": 1037,
                "end": 1040,
                "text": "MST",
                "type": "OTHER"
            },
            {
                "start": 1065,
                "end": 1068,
                "text": "ECT",
                "type": "CONTROL"
            },
            {
                "start": 1122,
                "end": 1163,
                "text": "severe depression, schizophrenia, and OCD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03454646",
        "study_official_title": "Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial ",
        "study_brief_summary": " Cholinesterase inhibitors (CI) remain the only drugs with a recognized efficacy in mild to moderate Alzheimer's disease (AD) in spite of enormous research efforts. However, these drugs presented as \"symptomatic treatment\" of AD are considered as having only a weak effect on the course of AD. The reimbursement of these drugs is regularly challenged due to the lack of evidence for the impact of these drugs on milestones stages of AD evolution (survival without severe dementia, restriction in Basic Activities of Daily Living - BADL) and on major consequences in public health (hospitalization and institutionalization). The great majority of previous randomized controlled trials conducted with CI have had a too short duration and the end points were limited to cognition (ADAS Cog scale), IADL (Instrumental Activities of Daily Living) function and Global Impression of Change. New evidences from the DOMINO trial (1) conducted in UK, independently of the pharmaceutical industry, showed that the true effect of CI might be more to avoid or to delay the cognitive or functional decline in AD than to improve patients; the institutionalisation (2) was also delayed. However, this trial was conducted in patients with moderate to severe AD, and the interest of the drugs at the mild to moderate stage remains questionable.\n\nThe investigators have shown that a good surrogate marker of survival without severe dementia would be an increase of ADAS Cog scale of more than six points (3). A post hoc reanalysis of the pivotal RCT with two CI showed that in mild to moderate patients, CI was associated with a 15% decrease of patients with a deterioration of ADAS-Cog of more than six points in six months. Thus at the beginning of dementia the real effect of CI might be more of delaying the cognitive and functional decline, than to improve the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase.",
        "text": "Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial | Cholinesterase inhibitors (CI) remain the only drugs with a recognized efficacy in mild to moderate Alzheimer's disease (AD) in spite of enormous research efforts. However, these drugs presented as \"symptomatic treatment\" of AD are considered as having only a weak effect on the course of AD. The reimbursement of these drugs is regularly challenged due to the lack of evidence for the impact of these drugs on milestones stages of AD evolution (survival without severe dementia, restriction in Basic Activities of Daily Living - BADL) and on major consequences in public health (hospitalization and institutionalization). The great majority of previous randomized controlled trials conducted with CI have had a too short duration and the end points were limited to cognition (ADAS Cog scale), IADL (Instrumental Activities of Daily Living) function and Global Impression of Change. New evidences from the DOMINO trial (1) conducted in UK, independently of the pharmaceutical industry, showed that the true effect of CI might be more to avoid or to delay the cognitive or functional decline in AD than to improve patients; the institutionalisation (2) was also delayed. However, this trial was conducted in patients with moderate to severe AD, and the interest of the drugs at the mild to moderate stage remains questionable.\n\nThe investigators have shown that a good surrogate marker of survival without severe dementia would be an increase of ADAS Cog scale of more than six points (3). A post hoc reanalysis of the pivotal RCT with two CI showed that in mild to moderate patients, CI was associated with a 15% decrease of patients with a deterioration of ADAS-Cog of more than six points in six months. Thus at the beginning of dementia the real effect of CI might be more of delaying the cognitive and functional decline, than to improve the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase.",
        "tokens": "['Comparison', 'of', 'Therapeutic', 'Strategies', 'With', 'Cholinesterase', 'Inhibitors', ':', 'Stop', 'or', 'Still', '(', 'SOS', ')', 'Trial', '|', 'Cholinesterase', 'inhibitors', '(', 'CI', ')', 'remain', 'the', 'only', 'drugs', 'with', 'a', 'recognized', 'efficacy', 'in', 'mild', 'to', 'moderate', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', 'in', 'spite', 'of', 'enormous', 'research', 'efforts', '.', 'However', ',', 'these', 'drugs', 'presented', 'as', '\"', 'symptomatic', 'treatment', '\"', 'of', 'AD', 'are', 'considered', 'as', 'having', 'only', 'a', 'weak', 'effect', 'on', 'the', 'course', 'of', 'AD', '.', 'The', 'reimbursement', 'of', 'these', 'drugs', 'is', 'regularly', 'challenged', 'due', 'to', 'the', 'lack', 'of', 'evidence', 'for', 'the', 'impact', 'of', 'these', 'drugs', 'on', 'milestones', 'stages', 'of', 'AD', 'evolution', '(', 'survival', 'without', 'severe', 'dementia', ',', 'restriction', 'in', 'Basic', 'Activities', 'of', 'Daily', 'Living', '-', 'BADL', ')', 'and', 'on', 'major', 'consequences', 'in', 'public', 'health', '(', 'hospitalization', 'and', 'institutionalization', ')', '.', 'The', 'great', 'majority', 'of', 'previous', 'randomized', 'controlled', 'trials', 'conducted', 'with', 'CI', 'have', 'had', 'a', 'too', 'short', 'duration', 'and', 'the', 'end', 'points', 'were', 'limited', 'to', 'cognition', '(', 'ADAS', 'Cog', 'scale', ')', ',', 'IADL', '(', 'Instrumental', 'Activities', 'of', 'Daily', 'Living', ')', 'function', 'and', 'Global', 'Impression', 'of', 'Change', '.', 'New', 'evidences', 'from', 'the', 'DOMINO', 'trial', '(', '1', ')', 'conducted', 'in', 'UK', ',', 'independently', 'of', 'the', 'pharmaceutical', 'industry', ',', 'showed', 'that', 'the', 'true', 'effect', 'of', 'CI', 'might', 'be', 'more', 'to', 'avoid', 'or', 'to', 'delay', 'the', 'cognitive', 'or', 'functional', 'decline', 'in', 'AD', 'than', 'to', 'improve', 'patients', ';', 'the', 'institutionalisation', '(', '2', ')', 'was', 'also', 'delayed', '.', 'However', ',', 'this', 'trial', 'was', 'conducted', 'in', 'patients', 'with', 'moderate', 'to', 'severe', 'AD', ',', 'and', 'the', 'interest', 'of', 'the', 'drugs', 'at', 'the', 'mild', 'to', 'moderate', 'stage', 'remains', 'questionable', '.', '\\n\\n', 'The', 'investigators', 'have', 'shown', 'that', 'a', 'good', 'surrogate', 'marker', 'of', 'survival', 'without', 'severe', 'dementia', 'would', 'be', 'an', 'increase', 'of', 'ADAS', 'Cog', 'scale', 'of', 'more', 'than', 'six', 'points', '(', '3', ')', '.', 'A', 'post', 'hoc', 'reanalysis', 'of', 'the', 'pivotal', 'RCT', 'with', 'two', 'CI', 'showed', 'that', 'in', 'mild', 'to', 'moderate', 'patients', ',', 'CI', 'was', 'associated', 'with', 'a', '15', '%', 'decrease', 'of', 'patients', 'with', 'a', 'deterioration', 'of', 'ADAS', '-', 'Cog', 'of', 'more', 'than', 'six', 'points', 'in', 'six', 'months', '.', 'Thus', 'at', 'the', 'beginning', 'of', 'dementia', 'the', 'real', 'effect', 'of', 'CI', 'might', 'be', 'more', 'of', 'delaying', 'the', 'cognitive', 'and', 'functional', 'decline', ',', 'than', 'to', 'improve', 'the', 'patients', '.', 'The', 'main', 'objective', 'of', 'the', 'SOS', 'trial', 'is', 'to', 'demonstrate', 'that', 'the', 'benefit', 'of', 'CI', 'at', 'the', 'early', 'phase', 'of', 'dementia', 'is', 'the', 'same', 'as', 'at', 'the', 'later', 'phase', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 67,
                "text": "Cholinesterase Inhibitors",
                "type": "DRUG"
            },
            {
                "start": 97,
                "end": 122,
                "text": "Cholinesterase inhibitors",
                "type": "DRUG"
            },
            {
                "start": 124,
                "end": 126,
                "text": "CI",
                "type": "DRUG"
            },
            {
                "start": 180,
                "end": 216,
                "text": "mild to moderate Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 218,
                "end": 220,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 324,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 386,
                "end": 388,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 529,
                "end": 531,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 560,
                "end": 575,
                "text": "severe dementia",
                "type": "CONDITION"
            },
            {
                "start": 795,
                "end": 797,
                "text": "CI",
                "type": "DRUG"
            },
            {
                "start": 1114,
                "end": 1116,
                "text": "CI",
                "type": "DRUG"
            },
            {
                "start": 1191,
                "end": 1193,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 1318,
                "end": 1339,
                "text": "moderate to severe AD",
                "type": "CONDITION"
            },
            {
                "start": 1502,
                "end": 1517,
                "text": "severe dementia",
                "type": "CONDITION"
            },
            {
                "start": 1636,
                "end": 1638,
                "text": "CI",
                "type": "DRUG"
            },
            {
                "start": 1681,
                "end": 1683,
                "text": "CI",
                "type": "DRUG"
            },
            {
                "start": 1828,
                "end": 1836,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 1856,
                "end": 1858,
                "text": "CI",
                "type": "DRUG"
            },
            {
                "start": 1889,
                "end": 1921,
                "text": "cognitive and functional decline",
                "type": "CONDITION"
            },
            {
                "start": 2027,
                "end": 2029,
                "text": "CI",
                "type": "DRUG"
            },
            {
                "start": 2037,
                "end": 2060,
                "text": "early phase of dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02555215",
        "study_official_title": "A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis ",
        "study_brief_summary": " The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200). Secondary objectives are as follows: To evaluate the long-term efficacy of BG00012 and to describe the long-term Multiple Sclerosis (MS) outcomes in subjects who completed Study 109MS202 (NCT02410200).",
        "text": "A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis | The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200). Secondary objectives are as follows: To evaluate the long-term efficacy of BG00012 and to describe the long-term Multiple Sclerosis (MS) outcomes in subjects who completed Study 109MS202 (NCT02410200).",
        "tokens": "['A', 'Multicenter', 'Extension', 'Study', 'to', 'Determine', 'the', 'Long', '-', 'Term', 'Safety', 'and', 'Efficacy', 'of', 'BG00012', 'in', 'Pediatric', 'Subjects', 'With', 'Relapsing', '-', 'Remitting', 'Multiple', 'Sclerosis', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'of', 'BG00012', 'in', 'subjects', 'who', 'completed', 'Study', '109MS202', '(', 'NCT02410200', ')', '.', 'Secondary', 'objectives', 'are', 'as', 'follows', ':', 'To', 'evaluate', 'the', 'long', '-', 'term', 'efficacy', 'of', 'BG00012', 'and', 'to', 'describe', 'the', 'long', '-', 'term', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'outcomes', 'in', 'subjects', 'who', 'completed', 'Study', '109MS202', '(', 'NCT02410200', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 80,
                "end": 87,
                "text": "BG00012",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 153,
                "text": "Relapsing-Remitting Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 230,
                "end": 237,
                "text": "BG00012",
                "type": "DRUG"
            },
            {
                "start": 369,
                "end": 376,
                "text": "BG00012",
                "type": "DRUG"
            },
            {
                "start": 407,
                "end": 425,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 427,
                "end": 429,
                "text": "MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04086810",
        "study_official_title": "An Open-Label Study of Diazoxide Choline Controlled-Release Tablet in Patients With Prader-Willi Syndrome ",
        "study_brief_summary": " The primary objective of this study is to monitor the long-term safety of DCCR in PWS patients.",
        "text": "An Open-Label Study of Diazoxide Choline Controlled-Release Tablet in Patients With Prader-Willi Syndrome | The primary objective of this study is to monitor the long-term safety of DCCR in PWS patients.",
        "tokens": "['An', 'Open', '-', 'Label', 'Study', 'of', 'Diazoxide', 'Choline', 'Controlled', '-', 'Release', 'Tablet', 'in', 'Patients', 'With', 'Prader', '-', 'Willi', 'Syndrome', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'monitor', 'the', 'long', '-', 'term', 'safety', 'of', 'DCCR', 'in', 'PWS', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 23,
                "end": 40,
                "text": "Diazoxide Choline",
                "type": "DRUG"
            },
            {
                "start": 84,
                "end": 105,
                "text": "Prader-Willi Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 186,
                "text": "DCCR",
                "type": "DRUG"
            },
            {
                "start": 190,
                "end": 193,
                "text": "PWS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03900247",
        "study_official_title": "Restore Motor Function Through Robotic Arm Exoskeleton and Brain Computer Interface ",
        "study_brief_summary": " The current project will aid patients with motor impairment to reduce the need for homecare. Specifically the aim is to develop and implement a robotic exoskeleton and brain computer interface to assist and eventually perform arm and hand movement in patients with the progressive neurodegenerative disease ALS. This proposal brings together state-of-the-art robotic technology, EEG-based brain computer interface (BCI) know-how, clinical expertise, patient perspective and industrial partners to develop and implement a robotic arm/hand device that will adapt, with increasing brain-computer control, based on the need of the patient. In short the BCI will measure electroencephalography (EEG) from the surface of the scalp and recognize signature EEG as the patient intents to move. As the patient loses muscle power the BCI robotic-device will gradually take over and support motor activity, even when the patient is totally paralyzed. As the device supports hand/arm function only, the investigators aim to address ADLs associated to hand function, specifically eating activities.",
        "text": "Restore Motor Function Through Robotic Arm Exoskeleton and Brain Computer Interface | The current project will aid patients with motor impairment to reduce the need for homecare. Specifically the aim is to develop and implement a robotic exoskeleton and brain computer interface to assist and eventually perform arm and hand movement in patients with the progressive neurodegenerative disease ALS. This proposal brings together state-of-the-art robotic technology, EEG-based brain computer interface (BCI) know-how, clinical expertise, patient perspective and industrial partners to develop and implement a robotic arm/hand device that will adapt, with increasing brain-computer control, based on the need of the patient. In short the BCI will measure electroencephalography (EEG) from the surface of the scalp and recognize signature EEG as the patient intents to move. As the patient loses muscle power the BCI robotic-device will gradually take over and support motor activity, even when the patient is totally paralyzed. As the device supports hand/arm function only, the investigators aim to address ADLs associated to hand function, specifically eating activities.",
        "tokens": "['Restore', 'Motor', 'Function', 'Through', 'Robotic', 'Arm', 'Exoskeleton', 'and', 'Brain', 'Computer', 'Interface', '|', 'The', 'current', 'project', 'will', 'aid', 'patients', 'with', 'motor', 'impairment', 'to', 'reduce', 'the', 'need', 'for', 'homecare', '.', 'Specifically', 'the', 'aim', 'is', 'to', 'develop', 'and', 'implement', 'a', 'robotic', 'exoskeleton', 'and', 'brain', 'computer', 'interface', 'to', 'assist', 'and', 'eventually', 'perform', 'arm', 'and', 'hand', 'movement', 'in', 'patients', 'with', 'the', 'progressive', 'neurodegenerative', 'disease', 'ALS', '.', 'This', 'proposal', 'brings', 'together', 'state', '-', 'of', '-', 'the', '-', 'art', 'robotic', 'technology', ',', 'EEG', '-', 'based', 'brain', 'computer', 'interface', '(', 'BCI', ')', 'know', '-', 'how', ',', 'clinical', 'expertise', ',', 'patient', 'perspective', 'and', 'industrial', 'partners', 'to', 'develop', 'and', 'implement', 'a', 'robotic', 'arm', '/', 'hand', 'device', 'that', 'will', 'adapt', ',', 'with', 'increasing', 'brain', '-', 'computer', 'control', ',', 'based', 'on', 'the', 'need', 'of', 'the', 'patient', '.', 'In', 'short', 'the', 'BCI', 'will', 'measure', 'electroencephalography', '(', 'EEG', ')', 'from', 'the', 'surface', 'of', 'the', 'scalp', 'and', 'recognize', 'signature', 'EEG', 'as', 'the', 'patient', 'intents', 'to', 'move', '.', 'As', 'the', 'patient', 'loses', 'muscle', 'power', 'the', 'BCI', 'robotic', '-', 'device', 'will', 'gradually', 'take', 'over', 'and', 'support', 'motor', 'activity', ',', 'even', 'when', 'the', 'patient', 'is', 'totally', 'paralyzed', '.', 'As', 'the', 'device', 'supports', 'hand', '/', 'arm', 'function', 'only', ',', 'the', 'investigators', 'aim', 'to', 'address', 'ADLs', 'associated', 'to', 'hand', 'function', ',', 'specifically', 'eating', 'activities', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 54,
                "text": "Robotic Arm Exoskeleton",
                "type": "OTHER"
            },
            {
                "start": 59,
                "end": 83,
                "text": "Brain Computer Interface",
                "type": "OTHER"
            },
            {
                "start": 129,
                "end": 145,
                "text": "motor impairment",
                "type": "CONDITION"
            },
            {
                "start": 230,
                "end": 249,
                "text": "robotic exoskeleton",
                "type": "OTHER"
            },
            {
                "start": 254,
                "end": 278,
                "text": "brain computer interface",
                "type": "OTHER"
            },
            {
                "start": 393,
                "end": 396,
                "text": "ALS",
                "type": "CONDITION"
            },
            {
                "start": 445,
                "end": 463,
                "text": "robotic technology",
                "type": "OTHER"
            },
            {
                "start": 475,
                "end": 499,
                "text": "brain computer interface",
                "type": "OTHER"
            },
            {
                "start": 501,
                "end": 504,
                "text": "BCI",
                "type": "OTHER"
            },
            {
                "start": 607,
                "end": 630,
                "text": "robotic arm/hand device",
                "type": "OTHER"
            },
            {
                "start": 735,
                "end": 738,
                "text": "BCI",
                "type": "OTHER"
            },
            {
                "start": 909,
                "end": 927,
                "text": "BCI robotic-device",
                "type": "OTHER"
            },
            {
                "start": 1014,
                "end": 1023,
                "text": "paralyzed",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04955249",
        "study_official_title": "Impact of Dexmedetomidine Supplemented Analgesia on Delirium and Long-term Outcomes in Elderly After Hip Fracture Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial ",
        "study_brief_summary": " Delirium is common in the elderly after hip fracture surgery, and is associated with worse outcomes. The investigators hypothesize that, for elderly patients after hip fracture surgery, dexmedetomidine supplemented analgesia can reduce the incidence of delirium and improve the long-term outcomes.",
        "text": "Impact of Dexmedetomidine Supplemented Analgesia on Delirium and Long-term Outcomes in Elderly After Hip Fracture Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial | Delirium is common in the elderly after hip fracture surgery, and is associated with worse outcomes. The investigators hypothesize that, for elderly patients after hip fracture surgery, dexmedetomidine supplemented analgesia can reduce the incidence of delirium and improve the long-term outcomes.",
        "tokens": "['Impact', 'of', 'Dexmedetomidine', 'Supplemented', 'Analgesia', 'on', 'Delirium', 'and', 'Long', '-', 'term', 'Outcomes', 'in', 'Elderly', 'After', 'Hip', 'Fracture', 'Surgery', ':', 'A', 'Multicenter', ',', 'Double', '-', 'blinded', ',', 'Randomized', 'Controlled', 'Trial', '|', 'Delirium', 'is', 'common', 'in', 'the', 'elderly', 'after', 'hip', 'fracture', 'surgery', ',', 'and', 'is', 'associated', 'with', 'worse', 'outcomes', '.', 'The', 'investigators', 'hypothesize', 'that', ',', 'for', 'elderly', 'patients', 'after', 'hip', 'fracture', 'surgery', ',', 'dexmedetomidine', 'supplemented', 'analgesia', 'can', 'reduce', 'the', 'incidence', 'of', 'delirium', 'and', 'improve', 'the', 'long', '-', 'term', 'outcomes', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 25,
                "text": "Dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 52,
                "end": 60,
                "text": "Delirium",
                "type": "CONDITION"
            },
            {
                "start": 101,
                "end": 121,
                "text": "Hip Fracture Surgery",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 192,
                "text": "Delirium",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 244,
                "text": "hip fracture surgery",
                "type": "CONDITION"
            },
            {
                "start": 348,
                "end": 368,
                "text": "hip fracture surgery",
                "type": "CONDITION"
            },
            {
                "start": 370,
                "end": 385,
                "text": "dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 437,
                "end": 445,
                "text": "delirium",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00222742",
        "study_official_title": "Pediatric Traumatic Brain Injury Consortium: Hypothermia ",
        "study_brief_summary": " The primary hypothesis for this application for a multicenter phase III randomized clinical trial (RCT) is that induced moderate hypothermia (HYPO) (32-33 \u00b0C) after severe traumatic brain injury (TBI) in children and maintained for 48 hours will improve mortality at 3 months and 12 month functional outcome as assessed by the Glasgow Outcome Scale (GOS).",
        "text": "Pediatric Traumatic Brain Injury Consortium: Hypothermia | The primary hypothesis for this application for a multicenter phase III randomized clinical trial (RCT) is that induced moderate hypothermia (HYPO) (32-33 \u00b0C) after severe traumatic brain injury (TBI) in children and maintained for 48 hours will improve mortality at 3 months and 12 month functional outcome as assessed by the Glasgow Outcome Scale (GOS).",
        "tokens": "['Pediatric', 'Traumatic', 'Brain', 'Injury', 'Consortium', ':', 'Hypothermia', '|', 'The', 'primary', 'hypothesis', 'for', 'this', 'application', 'for', 'a', 'multicenter', 'phase', 'III', 'randomized', 'clinical', 'trial', '(', 'RCT', ')', 'is', 'that', 'induced', 'moderate', 'hypothermia', '(', 'HYPO', ')', '(', '32', '-', '33', '\u00b0', 'C', ')', 'after', 'severe', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', 'in', 'children', 'and', 'maintained', 'for', '48', 'hours', 'will', 'improve', 'mortality', 'at', '3', 'months', 'and', '12', 'month', 'functional', 'outcome', 'as', 'assessed', 'by', 'the', 'Glasgow', 'Outcome', 'Scale', '(', 'GOS', ')', '.']",
        "token_bio_labels": "['O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 32,
                "text": "Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 45,
                "end": 56,
                "text": "Hypothermia",
                "type": "OTHER"
            },
            {
                "start": 188,
                "end": 199,
                "text": "hypothermia",
                "type": "OTHER"
            },
            {
                "start": 201,
                "end": 205,
                "text": "HYPO",
                "type": "OTHER"
            },
            {
                "start": 224,
                "end": 253,
                "text": "severe traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 255,
                "end": 258,
                "text": "TBI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00248807",
        "study_official_title": "Systemic Hemodynamics and Cerebral Blood Flow in Persons With Tetraplegia ",
        "study_brief_summary": " The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.",
        "text": "Systemic Hemodynamics and Cerebral Blood Flow in Persons With Tetraplegia | The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.",
        "tokens": "['Systemic', 'Hemodynamics', 'and', 'Cerebral', 'Blood', 'Flow', 'in', 'Persons', 'With', 'Tetraplegia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'how', 'blood', 'pressure', 'and', 'blood', 'flow', 'are', 'controlled', 'during', 'head', '-', 'up', 'tilt', 'in', 'a', 'semi', '-', 'upright', 'position', '.', 'In', 'this', 'investigation', 'we', 'are', 'studying', 'blood', 'pressure', 'and', 'blood', 'flow', 'to', 'the', 'brain', ',', 'with', 'and', 'without', 'a', 'medication', 'which', 'lowers', 'blood', 'pressure', '(', 'Vasotec', ')', '.', 'We', 'will', 'determine', 'how', 'persons', 'with', 'a', 'spinal', 'cord', 'injury', 'are', 'able', 'to', 'maintain', 'blood', 'flow', 'to', 'the', 'brain', '(', 'not', 'get', 'dizzy', ')', 'as', 'they', 'assume', 'a', 'more', 'upright', 'position', 'and', 'their', 'blood', 'pressure', 'decreases', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 62,
                "end": 73,
                "text": "Tetraplegia",
                "type": "CONDITION"
            },
            {
                "start": 356,
                "end": 363,
                "text": "Vasotec",
                "type": "DRUG"
            },
            {
                "start": 403,
                "end": 421,
                "text": "spinal cord injury",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00119561",
        "study_official_title": "Testing the Effectiveness of Telephone Support for Dementia Caregivers ",
        "study_brief_summary": " The primary goal of the study is documentation of effectiveness of telephone support groups to reduce caregiver burden and stress. Caregivers who participate in intervention (Telephone Support) should experience lower levels of stress, burden and health care utilization (lower use of psychotropic drugs, fewer scheduled/unscheduled medical visits, lower rates of institutionalization, more efficient use of time in managing care recipient problems) compared to those caregivers in Usual Care.",
        "text": "Testing the Effectiveness of Telephone Support for Dementia Caregivers | The primary goal of the study is documentation of effectiveness of telephone support groups to reduce caregiver burden and stress. Caregivers who participate in intervention (Telephone Support) should experience lower levels of stress, burden and health care utilization (lower use of psychotropic drugs, fewer scheduled/unscheduled medical visits, lower rates of institutionalization, more efficient use of time in managing care recipient problems) compared to those caregivers in Usual Care.",
        "tokens": "['Testing', 'the', 'Effectiveness', 'of', 'Telephone', 'Support', 'for', 'Dementia', 'Caregivers', '|', 'The', 'primary', 'goal', 'of', 'the', 'study', 'is', 'documentation', 'of', 'effectiveness', 'of', 'telephone', 'support', 'groups', 'to', 'reduce', 'caregiver', 'burden', 'and', 'stress', '.', 'Caregivers', 'who', 'participate', 'in', 'intervention', '(', 'Telephone', 'Support', ')', 'should', 'experience', 'lower', 'levels', 'of', 'stress', ',', 'burden', 'and', 'health', 'care', 'utilization', '(', 'lower', 'use', 'of', 'psychotropic', 'drugs', ',', 'fewer', 'scheduled', '/', 'unscheduled', 'medical', 'visits', ',', 'lower', 'rates', 'of', 'institutionalization', ',', 'more', 'efficient', 'use', 'of', 'time', 'in', 'managing', 'care', 'recipient', 'problems', ')', 'compared', 'to', 'those', 'caregivers', 'in', 'Usual', 'Care', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 46,
                "text": "Telephone Support",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 140,
                "end": 157,
                "text": "telephone support",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 196,
                "end": 202,
                "text": "stress",
                "type": "CONDITION"
            },
            {
                "start": 248,
                "end": 265,
                "text": "Telephone Support",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 301,
                "end": 307,
                "text": "stress",
                "type": "CONDITION"
            },
            {
                "start": 555,
                "end": 565,
                "text": "Usual Care",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02167022",
        "study_official_title": "Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy ",
        "study_brief_summary": " Cerebral palsy (CP) is a non-progressive disorder caused by an insult or injury to the brain when the brain is most rapidly developing and which results in some motor dysfunction. Causes for the injury to the brain are numerous and can occur prior to birth, during the birth process, or within the first few months following birth. The motor dysfunction can involve any or all four extremities but most often affects the legs, causing abnormal ambulation. The level of severity depends on the extent of the injury to the brain and can be mild to severe. In severe instances, the child is dependent on others for all his/her care.\n\nThere is no known cure for CP, but physical and occupational therapies are administered in an attempt to improve function. The frequency of these therapies varies from once a week (the standard of care in the Western Hemisphere) to five times a week (the standard of care in Asia and some Eastern European countries). The current understanding of brain plasticity offers a theoretical explanation to justify the more intense approach. Active repetitive motor skill-directed rehabilitation utilizes the plasticity of the brain and can restore some function. Intense active physiotherapy can stimulate non-injured but 'dormant' neurons and prevent their 'natural' degeneration in order for them to substitute for the function of injured neurons. It is the very young brain that is most likely to respond to this therapy.\n\nThe aim of this proposal is to evaluate the effect of administering both physical and occupational therapy five times each week for 12 weeks and compare it with the standard of care (SOC) approach of one time each week in children between the ages of 12 months and 36 months. This is the first randomized crossover trial to both enroll this young a population of children with cerebral palsy as well as to evaluate this approach from both the therapists and the parents perspectives. The number of children that this study will enroll is larger than in most CP studies. The children will be evaluated clinically with two validated instruments, one of which was designed specifically for children with CP and is administered and scored by certified therapists and the other which was designed for children with developmental disabilities and is scored by the child's care provider. A sub-set of children will have a special type of MRI to evaluate any changes in the neurological structure of the brain.\n\nThe Department of Pediatrics at the University of Arizona recently completed a collaborative study with the Neurologic Department at the Beijing Children's Hospital where the intense approach of five therapies per week is the SOC. The positive results prompted another investigation to determine if such an approach would be feasible in the United States. A compliance rate of 81% confirmed feasibility and the perception that parents who have a child diagnosed with CP will do whatever they can to improve their child's motor function.",
        "text": "Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy | Cerebral palsy (CP) is a non-progressive disorder caused by an insult or injury to the brain when the brain is most rapidly developing and which results in some motor dysfunction. Causes for the injury to the brain are numerous and can occur prior to birth, during the birth process, or within the first few months following birth. The motor dysfunction can involve any or all four extremities but most often affects the legs, causing abnormal ambulation. The level of severity depends on the extent of the injury to the brain and can be mild to severe. In severe instances, the child is dependent on others for all his/her care.\n\nThere is no known cure for CP, but physical and occupational therapies are administered in an attempt to improve function. The frequency of these therapies varies from once a week (the standard of care in the Western Hemisphere) to five times a week (the standard of care in Asia and some Eastern European countries). The current understanding of brain plasticity offers a theoretical explanation to justify the more intense approach. Active repetitive motor skill-directed rehabilitation utilizes the plasticity of the brain and can restore some function. Intense active physiotherapy can stimulate non-injured but 'dormant' neurons and prevent their 'natural' degeneration in order for them to substitute for the function of injured neurons. It is the very young brain that is most likely to respond to this therapy.\n\nThe aim of this proposal is to evaluate the effect of administering both physical and occupational therapy five times each week for 12 weeks and compare it with the standard of care (SOC) approach of one time each week in children between the ages of 12 months and 36 months. This is the first randomized crossover trial to both enroll this young a population of children with cerebral palsy as well as to evaluate this approach from both the therapists and the parents perspectives. The number of children that this study will enroll is larger than in most CP studies. The children will be evaluated clinically with two validated instruments, one of which was designed specifically for children with CP and is administered and scored by certified therapists and the other which was designed for children with developmental disabilities and is scored by the child's care provider. A sub-set of children will have a special type of MRI to evaluate any changes in the neurological structure of the brain.\n\nThe Department of Pediatrics at the University of Arizona recently completed a collaborative study with the Neurologic Department at the Beijing Children's Hospital where the intense approach of five therapies per week is the SOC. The positive results prompted another investigation to determine if such an approach would be feasible in the United States. A compliance rate of 81% confirmed feasibility and the perception that parents who have a child diagnosed with CP will do whatever they can to improve their child's motor function.",
        "tokens": "['Intense', 'Physiotherapies', 'to', 'Improve', 'Function', 'in', 'Young', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'Cerebral', 'palsy', '(', 'CP', ')', 'is', 'a', 'non', '-', 'progressive', 'disorder', 'caused', 'by', 'an', 'insult', 'or', 'injury', 'to', 'the', 'brain', 'when', 'the', 'brain', 'is', 'most', 'rapidly', 'developing', 'and', 'which', 'results', 'in', 'some', 'motor', 'dysfunction', '.', 'Causes', 'for', 'the', 'injury', 'to', 'the', 'brain', 'are', 'numerous', 'and', 'can', 'occur', 'prior', 'to', 'birth', ',', 'during', 'the', 'birth', 'process', ',', 'or', 'within', 'the', 'first', 'few', 'months', 'following', 'birth', '.', 'The', 'motor', 'dysfunction', 'can', 'involve', 'any', 'or', 'all', 'four', 'extremities', 'but', 'most', 'often', 'affects', 'the', 'legs', ',', 'causing', 'abnormal', 'ambulation', '.', 'The', 'level', 'of', 'severity', 'depends', 'on', 'the', 'extent', 'of', 'the', 'injury', 'to', 'the', 'brain', 'and', 'can', 'be', 'mild', 'to', 'severe', '.', 'In', 'severe', 'instances', ',', 'the', 'child', 'is', 'dependent', 'on', 'others', 'for', 'all', 'his', '/', 'her', 'care', '.', '\\n\\n', 'There', 'is', 'no', 'known', 'cure', 'for', 'CP', ',', 'but', 'physical', 'and', 'occupational', 'therapies', 'are', 'administered', 'in', 'an', 'attempt', 'to', 'improve', 'function', '.', 'The', 'frequency', 'of', 'these', 'therapies', 'varies', 'from', 'once', 'a', 'week', '(', 'the', 'standard', 'of', 'care', 'in', 'the', 'Western', 'Hemisphere', ')', 'to', 'five', 'times', 'a', 'week', '(', 'the', 'standard', 'of', 'care', 'in', 'Asia', 'and', 'some', 'Eastern', 'European', 'countries', ')', '.', 'The', 'current', 'understanding', 'of', 'brain', 'plasticity', 'offers', 'a', 'theoretical', 'explanation', 'to', 'justify', 'the', 'more', 'intense', 'approach', '.', 'Active', 'repetitive', 'motor', 'skill', '-', 'directed', 'rehabilitation', 'utilizes', 'the', 'plasticity', 'of', 'the', 'brain', 'and', 'can', 'restore', 'some', 'function', '.', 'Intense', 'active', 'physiotherapy', 'can', 'stimulate', 'non', '-', 'injured', 'but', \"'\", 'dormant', \"'\", 'neurons', 'and', 'prevent', 'their', \"'\", 'natural', \"'\", 'degeneration', 'in', 'order', 'for', 'them', 'to', 'substitute', 'for', 'the', 'function', 'of', 'injured', 'neurons', '.', 'It', 'is', 'the', 'very', 'young', 'brain', 'that', 'is', 'most', 'likely', 'to', 'respond', 'to', 'this', 'therapy', '.', '\\n\\n', 'The', 'aim', 'of', 'this', 'proposal', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'administering', 'both', 'physical', 'and', 'occupational', 'therapy', 'five', 'times', 'each', 'week', 'for', '12', 'weeks', 'and', 'compare', 'it', 'with', 'the', 'standard', 'of', 'care', '(', 'SOC', ')', 'approach', 'of', 'one', 'time', 'each', 'week', 'in', 'children', 'between', 'the', 'ages', 'of', '12', 'months', 'and', '36', 'months', '.', 'This', 'is', 'the', 'first', 'randomized', 'crossover', 'trial', 'to', 'both', 'enroll', 'this', 'young', 'a', 'population', 'of', 'children', 'with', 'cerebral', 'palsy', 'as', 'well', 'as', 'to', 'evaluate', 'this', 'approach', 'from', 'both', 'the', 'therapists', 'and', 'the', 'parents', 'perspectives', '.', 'The', 'number', 'of', 'children', 'that', 'this', 'study', 'will', 'enroll', 'is', 'larger', 'than', 'in', 'most', 'CP', 'studies', '.', 'The', 'children', 'will', 'be', 'evaluated', 'clinically', 'with', 'two', 'validated', 'instruments', ',', 'one', 'of', 'which', 'was', 'designed', 'specifically', 'for', 'children', 'with', 'CP', 'and', 'is', 'administered', 'and', 'scored', 'by', 'certified', 'therapists', 'and', 'the', 'other', 'which', 'was', 'designed', 'for', 'children', 'with', 'developmental', 'disabilities', 'and', 'is', 'scored', 'by', 'the', 'child', \"'s\", 'care', 'provider', '.', 'A', 'sub', '-', 'set', 'of', 'children', 'will', 'have', 'a', 'special', 'type', 'of', 'MRI', 'to', 'evaluate', 'any', 'changes', 'in', 'the', 'neurological', 'structure', 'of', 'the', 'brain', '.', '\\n\\n', 'The', 'Department', 'of', 'Pediatrics', 'at', 'the', 'University', 'of', 'Arizona', 'recently', 'completed', 'a', 'collaborative', 'study', 'with', 'the', 'Neurologic', 'Department', 'at', 'the', 'Beijing', 'Children', \"'s\", 'Hospital', 'where', 'the', 'intense', 'approach', 'of', 'five', 'therapies', 'per', 'week', 'is', 'the', 'SOC', '.', 'The', 'positive', 'results', 'prompted', 'another', 'investigation', 'to', 'determine', 'if', 'such', 'an', 'approach', 'would', 'be', 'feasible', 'in', 'the', 'United', 'States', '.', 'A', 'compliance', 'rate', 'of', '81', '%', 'confirmed', 'feasibility', 'and', 'the', 'perception', 'that', 'parents', 'who', 'have', 'a', 'child', 'diagnosed', 'with', 'CP', 'will', 'do', 'whatever', 'they', 'can', 'to', 'improve', 'their', 'child', \"'s\", 'motor', 'function', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 23,
                "text": "Intense Physiotherapies",
                "type": "PHYSICAL"
            },
            {
                "start": 67,
                "end": 81,
                "text": "Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 84,
                "end": 98,
                "text": "Cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 100,
                "end": 102,
                "text": "CP",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 262,
                "text": "motor dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 420,
                "end": 437,
                "text": "motor dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 742,
                "end": 744,
                "text": "CP",
                "type": "CONDITION"
            },
            {
                "start": 750,
                "end": 785,
                "text": "physical and occupational therapies",
                "type": "PHYSICAL"
            },
            {
                "start": 1150,
                "end": 1203,
                "text": "Active repetitive motor skill-directed rehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 1272,
                "end": 1300,
                "text": "Intense active physiotherapy",
                "type": "PHYSICAL"
            },
            {
                "start": 1608,
                "end": 1641,
                "text": "physical and occupational therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 1700,
                "end": 1716,
                "text": "standard of care",
                "type": "CONTROL"
            },
            {
                "start": 1718,
                "end": 1721,
                "text": "SOC",
                "type": "CONTROL"
            },
            {
                "start": 1912,
                "end": 1926,
                "text": "cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 2093,
                "end": 2095,
                "text": "CP",
                "type": "CONDITION"
            },
            {
                "start": 2236,
                "end": 2238,
                "text": "CP",
                "type": "CONDITION"
            },
            {
                "start": 2765,
                "end": 2768,
                "text": "SOC",
                "type": "CONTROL"
            },
            {
                "start": 3006,
                "end": 3008,
                "text": "CP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02249572",
        "study_official_title": "Vestibular Schwannoma - Radiosurgery or Expectation ",
        "study_brief_summary": " The purpose of this study is to compare the outcome of patients with vestibular schwannomas in two groups of randomised to either radiosurgery or expectation.\n\nThe optimal treatment for a small vestibular schwannoma is a matter of controversy and there are no class 1 studies investigating this. Even the natural tumor growth rate remains controversial and is reported to be from near 100% of cases showing growth to 40-60% in various reports. The clinical results of various treatment strategies are documented, but comparative studies are very few. Immediate radiosurgery or wait-and scan with subsequent treatment upon growth are two strategies that have both been used in many different centers. There are only two studies comparing these treatment modalities .These studies indicate significant effect of GKRS in reducing tumor growth, with less differences in hearing and complaint outcomes. None of the studies are blinded or randomised, allowing for bias.\n\nThe present study aims at comparing the two modalities above. To achieve this, we intend to randomise patients with newly diagnosed VS to either of Wait-and Scan or immediate radiosurgery.\n\nThe primary study endpoint is the relative tumor size measured as the ratio between tumor volume at four years compared with volume at inclusion. Secondary endpoints include symptom and sign development measured by clinical examination and by patient's responses to standardised validated questionnaires. In addition, the health economics involved with both strategies will be evaluated and compared, as well as the patient's working status.\n\nPatients will be asked to participate if their VS is diagnosed within the last six months, their age is between 18 and 70, and pending there are no exclusion criteria (see below). A power analysis indicates that about 50 patients per group is sufficient.\n\nIn case of failure to recruit patients, we will change the design to a study based on patient's own choice of treatment.\n\nThe study will be announced according to international guidelines. A steering committee will monitor the study and an intermediate analysis will be performed when the study group has been followed for two years. If the effect aim is already observed, the study should nonetheless continue, as it is too early to evaluate the results after such a short time course.\n\nIt will also be discussed to do a follow-up of all patients ten years after inclusion.",
        "text": "Vestibular Schwannoma - Radiosurgery or Expectation | The purpose of this study is to compare the outcome of patients with vestibular schwannomas in two groups of randomised to either radiosurgery or expectation.\n\nThe optimal treatment for a small vestibular schwannoma is a matter of controversy and there are no class 1 studies investigating this. Even the natural tumor growth rate remains controversial and is reported to be from near 100% of cases showing growth to 40-60% in various reports. The clinical results of various treatment strategies are documented, but comparative studies are very few. Immediate radiosurgery or wait-and scan with subsequent treatment upon growth are two strategies that have both been used in many different centers. There are only two studies comparing these treatment modalities .These studies indicate significant effect of GKRS in reducing tumor growth, with less differences in hearing and complaint outcomes. None of the studies are blinded or randomised, allowing for bias.\n\nThe present study aims at comparing the two modalities above. To achieve this, we intend to randomise patients with newly diagnosed VS to either of Wait-and Scan or immediate radiosurgery.\n\nThe primary study endpoint is the relative tumor size measured as the ratio between tumor volume at four years compared with volume at inclusion. Secondary endpoints include symptom and sign development measured by clinical examination and by patient's responses to standardised validated questionnaires. In addition, the health economics involved with both strategies will be evaluated and compared, as well as the patient's working status.\n\nPatients will be asked to participate if their VS is diagnosed within the last six months, their age is between 18 and 70, and pending there are no exclusion criteria (see below). A power analysis indicates that about 50 patients per group is sufficient.\n\nIn case of failure to recruit patients, we will change the design to a study based on patient's own choice of treatment.\n\nThe study will be announced according to international guidelines. A steering committee will monitor the study and an intermediate analysis will be performed when the study group has been followed for two years. If the effect aim is already observed, the study should nonetheless continue, as it is too early to evaluate the results after such a short time course.\n\nIt will also be discussed to do a follow-up of all patients ten years after inclusion.",
        "tokens": "['Vestibular', 'Schwannoma', '-', 'Radiosurgery', 'or', 'Expectation', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'outcome', 'of', 'patients', 'with', 'vestibular', 'schwannomas', 'in', 'two', 'groups', 'of', 'randomised', 'to', 'either', 'radiosurgery', 'or', 'expectation', '.', '\\n\\n', 'The', 'optimal', 'treatment', 'for', 'a', 'small', 'vestibular', 'schwannoma', 'is', 'a', 'matter', 'of', 'controversy', 'and', 'there', 'are', 'no', 'class', '1', 'studies', 'investigating', 'this', '.', 'Even', 'the', 'natural', 'tumor', 'growth', 'rate', 'remains', 'controversial', 'and', 'is', 'reported', 'to', 'be', 'from', 'near', '100', '%', 'of', 'cases', 'showing', 'growth', 'to', '40', '-', '60', '%', 'in', 'various', 'reports', '.', 'The', 'clinical', 'results', 'of', 'various', 'treatment', 'strategies', 'are', 'documented', ',', 'but', 'comparative', 'studies', 'are', 'very', 'few', '.', 'Immediate', 'radiosurgery', 'or', 'wait', '-', 'and', 'scan', 'with', 'subsequent', 'treatment', 'upon', 'growth', 'are', 'two', 'strategies', 'that', 'have', 'both', 'been', 'used', 'in', 'many', 'different', 'centers', '.', 'There', 'are', 'only', 'two', 'studies', 'comparing', 'these', 'treatment', 'modalities', '.These', 'studies', 'indicate', 'significant', 'effect', 'of', 'GKRS', 'in', 'reducing', 'tumor', 'growth', ',', 'with', 'less', 'differences', 'in', 'hearing', 'and', 'complaint', 'outcomes', '.', 'None', 'of', 'the', 'studies', 'are', 'blinded', 'or', 'randomised', ',', 'allowing', 'for', 'bias', '.', '\\n\\n', 'The', 'present', 'study', 'aims', 'at', 'comparing', 'the', 'two', 'modalities', 'above', '.', 'To', 'achieve', 'this', ',', 'we', 'intend', 'to', 'randomise', 'patients', 'with', 'newly', 'diagnosed', 'VS', 'to', 'either', 'of', 'Wait', '-', 'and', 'Scan', 'or', 'immediate', 'radiosurgery', '.', '\\n\\n', 'The', 'primary', 'study', 'endpoint', 'is', 'the', 'relative', 'tumor', 'size', 'measured', 'as', 'the', 'ratio', 'between', 'tumor', 'volume', 'at', 'four', 'years', 'compared', 'with', 'volume', 'at', 'inclusion', '.', 'Secondary', 'endpoints', 'include', 'symptom', 'and', 'sign', 'development', 'measured', 'by', 'clinical', 'examination', 'and', 'by', 'patient', \"'s\", 'responses', 'to', 'standardised', 'validated', 'questionnaires', '.', 'In', 'addition', ',', 'the', 'health', 'economics', 'involved', 'with', 'both', 'strategies', 'will', 'be', 'evaluated', 'and', 'compared', ',', 'as', 'well', 'as', 'the', 'patient', \"'s\", 'working', 'status', '.', '\\n\\n', 'Patients', 'will', 'be', 'asked', 'to', 'participate', 'if', 'their', 'VS', 'is', 'diagnosed', 'within', 'the', 'last', 'six', 'months', ',', 'their', 'age', 'is', 'between', '18', 'and', '70', ',', 'and', 'pending', 'there', 'are', 'no', 'exclusion', 'criteria', '(', 'see', 'below', ')', '.', 'A', 'power', 'analysis', 'indicates', 'that', 'about', '50', 'patients', 'per', 'group', 'is', 'sufficient', '.', '\\n\\n', 'In', 'case', 'of', 'failure', 'to', 'recruit', 'patients', ',', 'we', 'will', 'change', 'the', 'design', 'to', 'a', 'study', 'based', 'on', 'patient', \"'s\", 'own', 'choice', 'of', 'treatment', '.', '\\n\\n', 'The', 'study', 'will', 'be', 'announced', 'according', 'to', 'international', 'guidelines', '.', 'A', 'steering', 'committee', 'will', 'monitor', 'the', 'study', 'and', 'an', 'intermediate', 'analysis', 'will', 'be', 'performed', 'when', 'the', 'study', 'group', 'has', 'been', 'followed', 'for', 'two', 'years', '.', 'If', 'the', 'effect', 'aim', 'is', 'already', 'observed', ',', 'the', 'study', 'should', 'nonetheless', 'continue', ',', 'as', 'it', 'is', 'too', 'early', 'to', 'evaluate', 'the', 'results', 'after', 'such', 'a', 'short', 'time', 'course', '.', '\\n\\n', 'It', 'will', 'also', 'be', 'discussed', 'to', 'do', 'a', 'follow', '-', 'up', 'of', 'all', 'patients', 'ten', 'years', 'after', 'inclusion', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 21,
                "text": "Vestibular Schwannoma",
                "type": "CONDITION"
            },
            {
                "start": 24,
                "end": 36,
                "text": "Radiosurgery",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 123,
                "end": 145,
                "text": "vestibular schwannomas",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 196,
                "text": "radiosurgery",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 248,
                "end": 269,
                "text": "vestibular schwannoma",
                "type": "CONDITION"
            },
            {
                "start": 367,
                "end": 372,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 615,
                "end": 627,
                "text": "radiosurgery",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 864,
                "end": 868,
                "text": "GKRS",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 881,
                "end": 886,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 1135,
                "end": 1153,
                "text": "newly diagnosed VS",
                "type": "CONDITION"
            },
            {
                "start": 1194,
                "end": 1206,
                "text": "radiosurgery",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 1252,
                "end": 1257,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 1293,
                "end": 1298,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 1699,
                "end": 1701,
                "text": "VS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05669885",
        "study_official_title": "Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache: A Randomized Clinical Trial ",
        "study_brief_summary": " To investigate whether sildenafil (phosphodiesterase 5 inhibitor) induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",
        "text": "Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache: A Randomized Clinical Trial | To investigate whether sildenafil (phosphodiesterase 5 inhibitor) induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",
        "tokens": "['Hypersensitivity', 'to', 'Phosphodiesterase', '5', 'Inhibition', 'in', 'Post', '-', 'Traumatic', 'Headache', ':', 'A', 'Randomized', 'Clinical', 'Trial', '|', 'To', 'investigate', 'whether', 'sildenafil', '(', 'phosphodiesterase', '5', 'inhibitor', ')', 'induces', 'migraine', '-', 'like', 'headache', 'in', 'people', 'with', 'persistent', 'post', '-', 'traumatic', 'headache', '(', 'PTH', ')', 'attributed', 'to', 'mild', 'traumatic', 'brain', 'injury', '(', 'mTBI', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 54,
                "end": 77,
                "text": "Post-Traumatic Headache",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 191,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 197,
                "end": 205,
                "text": "headache",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 255,
                "text": "persistent post-traumatic headache",
                "type": "CONDITION"
            },
            {
                "start": 257,
                "end": 260,
                "text": "PTH",
                "type": "CONDITION"
            },
            {
                "start": 276,
                "end": 303,
                "text": "mild traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 309,
                "text": "mTBI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01308801",
        "study_official_title": "Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia ",
        "study_brief_summary": " The purpose of this study is to determine the analgesic effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) used as an additional procedure to rehabilitation exercises in patient suffering from fibromyalgia.\n\nA double blind clinical trial with two randomized parallel groups:\n\nPlacebo rTMS and rehabilitation exercise\nActive rTMS and rehabilitation exercise",
        "text": "Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia | The purpose of this study is to determine the analgesic effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) used as an additional procedure to rehabilitation exercises in patient suffering from fibromyalgia.\n\nA double blind clinical trial with two randomized parallel groups:\n\nPlacebo rTMS and rehabilitation exercise\nActive rTMS and rehabilitation exercise",
        "tokens": "['Benefice', 'Assessment', 'of', 'Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', 'Used', 'as', 'an', 'Additional', 'Procedure', 'to', 'Rehabilitation', 'Exercises', 'in', 'Patients', 'Suffering', 'From', 'Fibromyalgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'analgesic', 'effectiveness', 'of', 'Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'rTMS', ')', 'used', 'as', 'an', 'additional', 'procedure', 'to', 'rehabilitation', 'exercises', 'in', 'patient', 'suffering', 'from', 'fibromyalgia', '.', '\\n\\n', 'A', 'double', 'blind', 'clinical', 'trial', 'with', 'two', 'randomized', 'parallel', 'groups', ':', '\\n\\n', 'Placebo', 'rTMS', 'and', 'rehabilitation', 'exercise', '\\n', 'Active', 'rTMS', 'and', 'rehabilitation', 'exercise']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS']",
        "entities": [
            {
                "start": 23,
                "end": 67,
                "text": "Repetitive Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 103,
                "end": 127,
                "text": "Rehabilitation Exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 155,
                "end": 167,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 243,
                "end": 287,
                "text": "Repetitive Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 289,
                "end": 293,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 330,
                "end": 354,
                "text": "rehabilitation exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 381,
                "end": 393,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 464,
                "end": 476,
                "text": "Placebo rTMS",
                "type": "CONTROL"
            },
            {
                "start": 481,
                "end": 504,
                "text": "rehabilitation exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 505,
                "end": 516,
                "text": "Active rTMS",
                "type": "OTHER"
            },
            {
                "start": 521,
                "end": 544,
                "text": "rehabilitation exercise",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT03546517",
        "study_official_title": "Effectiveness of Dry Needling (DNHS Technique) in Patients With Chronic Stroke ",
        "study_brief_summary": " Study hypothesis:\n\nThe DNHS technique, performed via one session of deep dry needling of myofascial trigger points applied to the biceps brachii, brachialis, flexor digitorum superficialis, flexor digitorum profundus, triceps brachii, extensor digitorum and adductor pollicis muscle is effective for decreasing spasticity and muscle stiffness (both of which are components of hypertonia) as well as for improving the upper limb function of the previously described muscles in patients with chronic cerebral vascular accident (CVA), assessed both post-intervention and after 15 days.\n\nGeneral aims\n\nTo analyse the immediate therapeutic effect of the DNHS technique and the effect at 15 days follow-up, for the following variables:\n\nSpasticity\nMuscle stiffness\nUpper limb function\nPatient perceived quality of life\n\nMaterials and methods Population: patients from the province of Zaragoza (Spain) diagnosed with a haemorrhagic or ischemic CVA by a neurologist.\n\nRecruitment strategy: recruitment will take place via the Stroke Association in Aragon (AIDA) [Aragon Stroke Association] in the province of Zaragoza, Spain, seeing as the greater proportion of patients who have suffered a stroke and are in the chronic stage of the illness go to this centre to receive treatment. Thus, this avoids patients having to travel elsewhere for the study. Furthermore, in the case of patients who wish to participate in the study after having received information via third persons or via other means and who are not members of the Association or do not attend the centre on a regular basis, the Association AIDA has offered to allow these people to attend for free, making its facilities available and supporting the development of this study.",
        "text": "Effectiveness of Dry Needling (DNHS Technique) in Patients With Chronic Stroke | Study hypothesis:\n\nThe DNHS technique, performed via one session of deep dry needling of myofascial trigger points applied to the biceps brachii, brachialis, flexor digitorum superficialis, flexor digitorum profundus, triceps brachii, extensor digitorum and adductor pollicis muscle is effective for decreasing spasticity and muscle stiffness (both of which are components of hypertonia) as well as for improving the upper limb function of the previously described muscles in patients with chronic cerebral vascular accident (CVA), assessed both post-intervention and after 15 days.\n\nGeneral aims\n\nTo analyse the immediate therapeutic effect of the DNHS technique and the effect at 15 days follow-up, for the following variables:\n\nSpasticity\nMuscle stiffness\nUpper limb function\nPatient perceived quality of life\n\nMaterials and methods Population: patients from the province of Zaragoza (Spain) diagnosed with a haemorrhagic or ischemic CVA by a neurologist.\n\nRecruitment strategy: recruitment will take place via the Stroke Association in Aragon (AIDA) [Aragon Stroke Association] in the province of Zaragoza, Spain, seeing as the greater proportion of patients who have suffered a stroke and are in the chronic stage of the illness go to this centre to receive treatment. Thus, this avoids patients having to travel elsewhere for the study. Furthermore, in the case of patients who wish to participate in the study after having received information via third persons or via other means and who are not members of the Association or do not attend the centre on a regular basis, the Association AIDA has offered to allow these people to attend for free, making its facilities available and supporting the development of this study.",
        "tokens": "['Effectiveness', 'of', 'Dry', 'Needling', '(', 'DNHS', 'Technique', ')', 'in', 'Patients', 'With', 'Chronic', 'Stroke', '|', 'Study', 'hypothesis', ':', '\\n\\n', 'The', 'DNHS', 'technique', ',', 'performed', 'via', 'one', 'session', 'of', 'deep', 'dry', 'needling', 'of', 'myofascial', 'trigger', 'points', 'applied', 'to', 'the', 'biceps', 'brachii', ',', 'brachialis', ',', 'flexor', 'digitorum', 'superficialis', ',', 'flexor', 'digitorum', 'profundus', ',', 'triceps', 'brachii', ',', 'extensor', 'digitorum', 'and', 'adductor', 'pollicis', 'muscle', 'is', 'effective', 'for', 'decreasing', 'spasticity', 'and', 'muscle', 'stiffness', '(', 'both', 'of', 'which', 'are', 'components', 'of', 'hypertonia', ')', 'as', 'well', 'as', 'for', 'improving', 'the', 'upper', 'limb', 'function', 'of', 'the', 'previously', 'described', 'muscles', 'in', 'patients', 'with', 'chronic', 'cerebral', 'vascular', 'accident', '(', 'CVA', ')', ',', 'assessed', 'both', 'post', '-', 'intervention', 'and', 'after', '15', 'days', '.', '\\n\\n', 'General', 'aims', '\\n\\n', 'To', 'analyse', 'the', 'immediate', 'therapeutic', 'effect', 'of', 'the', 'DNHS', 'technique', 'and', 'the', 'effect', 'at', '15', 'days', 'follow', '-', 'up', ',', 'for', 'the', 'following', 'variables', ':', '\\n\\n', 'Spasticity', '\\n', 'Muscle', 'stiffness', '\\n', 'Upper', 'limb', 'function', '\\n', 'Patient', 'perceived', 'quality', 'of', 'life', '\\n\\n', 'Materials', 'and', 'methods', 'Population', ':', 'patients', 'from', 'the', 'province', 'of', 'Zaragoza', '(', 'Spain', ')', 'diagnosed', 'with', 'a', 'haemorrhagic', 'or', 'ischemic', 'CVA', 'by', 'a', 'neurologist', '.', '\\n\\n', 'Recruitment', 'strategy', ':', 'recruitment', 'will', 'take', 'place', 'via', 'the', 'Stroke', 'Association', 'in', 'Aragon', '(', 'AIDA', ')', '[', 'Aragon', 'Stroke', 'Association', ']', 'in', 'the', 'province', 'of', 'Zaragoza', ',', 'Spain', ',', 'seeing', 'as', 'the', 'greater', 'proportion', 'of', 'patients', 'who', 'have', 'suffered', 'a', 'stroke', 'and', 'are', 'in', 'the', 'chronic', 'stage', 'of', 'the', 'illness', 'go', 'to', 'this', 'centre', 'to', 'receive', 'treatment', '.', 'Thus', ',', 'this', 'avoids', 'patients', 'having', 'to', 'travel', 'elsewhere', 'for', 'the', 'study', '.', 'Furthermore', ',', 'in', 'the', 'case', 'of', 'patients', 'who', 'wish', 'to', 'participate', 'in', 'the', 'study', 'after', 'having', 'received', 'information', 'via', 'third', 'persons', 'or', 'via', 'other', 'means', 'and', 'who', 'are', 'not', 'members', 'of', 'the', 'Association', 'or', 'do', 'not', 'attend', 'the', 'centre', 'on', 'a', 'regular', 'basis', ',', 'the', 'Association', 'AIDA', 'has', 'offered', 'to', 'allow', 'these', 'people', 'to', 'attend', 'for', 'free', ',', 'making', 'its', 'facilities', 'available', 'and', 'supporting', 'the', 'development', 'of', 'this', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 29,
                "text": "Dry Needling",
                "type": "OTHER"
            },
            {
                "start": 31,
                "end": 45,
                "text": "DNHS Technique",
                "type": "OTHER"
            },
            {
                "start": 64,
                "end": 78,
                "text": "Chronic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 104,
                "end": 108,
                "text": "DNHS",
                "type": "OTHER"
            },
            {
                "start": 149,
                "end": 195,
                "text": "deep dry needling of myofascial trigger points",
                "type": "OTHER"
            },
            {
                "start": 392,
                "end": 402,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 407,
                "end": 423,
                "text": "muscle stiffness",
                "type": "CONDITION"
            },
            {
                "start": 457,
                "end": 467,
                "text": "hypertonia",
                "type": "CONDITION"
            },
            {
                "start": 571,
                "end": 605,
                "text": "chronic cerebral vascular accident",
                "type": "CONDITION"
            },
            {
                "start": 607,
                "end": 610,
                "text": "CVA",
                "type": "CONDITION"
            },
            {
                "start": 730,
                "end": 734,
                "text": "DNHS",
                "type": "OTHER"
            },
            {
                "start": 812,
                "end": 822,
                "text": "Spasticity",
                "type": "CONDITION"
            },
            {
                "start": 823,
                "end": 839,
                "text": "Muscle stiffness",
                "type": "CONDITION"
            },
            {
                "start": 1018,
                "end": 1021,
                "text": "CVA",
                "type": "CONDITION"
            },
            {
                "start": 1264,
                "end": 1270,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04057677",
        "study_official_title": "Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes ",
        "study_brief_summary": " The purpose of this research is to gather data on how exercise can help recovery of muscle mass, strength, and physical function after bedrest in older adults with pre-diabetes and type 2 diabetes.",
        "text": "Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes | The purpose of this research is to gather data on how exercise can help recovery of muscle mass, strength, and physical function after bedrest in older adults with pre-diabetes and type 2 diabetes.",
        "tokens": "['Exercise', 'Training', 'as', 'an', 'Intervention', 'to', 'Improve', 'Muscle', 'Function', 'and', 'Recovery', 'Following', 'Bed', 'Rest', 'in', 'Older', 'Adults', 'With', 'Type', '2', 'Diabetes', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'gather', 'data', 'on', 'how', 'exercise', 'can', 'help', 'recovery', 'of', 'muscle', 'mass', ',', 'strength', ',', 'and', 'physical', 'function', 'after', 'bedrest', 'in', 'older', 'adults', 'with', 'pre', '-', 'diabetes', 'and', 'type', '2', 'diabetes', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 17,
                "text": "Exercise Training",
                "type": "PHYSICAL"
            },
            {
                "start": 117,
                "end": 132,
                "text": "Type 2 Diabetes",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 197,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 299,
                "end": 311,
                "text": "pre-diabetes",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 331,
                "text": "type 2 diabetes",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03929549",
        "study_official_title": "Use of Remotely Controlled Mandibular Positioner (RCMP) to Predict Treatment Outcomes of Maxillomandibular Advancement Surgery for Obstructive Sleep Apnea (OSA). ",
        "study_brief_summary": " Maxillomandibular advancement (MMA) surgery, one of the most successful surgical procedures for the treatment of obstructive sleep apnea (OSA), is predominantly used to manage patients with moderate to severe OSA. However, limiting factors include incomplete response in some cases, unfavorable facial changes as a result of large advancements, and risk of malocclusion or malunion.\n\nThis study will be done to determine predictors of success with MMA surgery in patients with moderate to severe OSA. Studies have already shown the value of a remote controlled mandibular positioner (RCMP) device to identify the correct level of therapeutic protrusion needed with oral appliance therapy. Moreover, some patients experience a dose dependent improvement in sleep parameters based on the degree of protrusion during the titration study. Use of RCMP as a means to identify potential candidates for MMA, may help customize treatment options for patients with OSA by providing predictive value.",
        "text": "Use of Remotely Controlled Mandibular Positioner (RCMP) to Predict Treatment Outcomes of Maxillomandibular Advancement Surgery for Obstructive Sleep Apnea (OSA). | Maxillomandibular advancement (MMA) surgery, one of the most successful surgical procedures for the treatment of obstructive sleep apnea (OSA), is predominantly used to manage patients with moderate to severe OSA. However, limiting factors include incomplete response in some cases, unfavorable facial changes as a result of large advancements, and risk of malocclusion or malunion.\n\nThis study will be done to determine predictors of success with MMA surgery in patients with moderate to severe OSA. Studies have already shown the value of a remote controlled mandibular positioner (RCMP) device to identify the correct level of therapeutic protrusion needed with oral appliance therapy. Moreover, some patients experience a dose dependent improvement in sleep parameters based on the degree of protrusion during the titration study. Use of RCMP as a means to identify potential candidates for MMA, may help customize treatment options for patients with OSA by providing predictive value.",
        "tokens": "['Use', 'of', 'Remotely', 'Controlled', 'Mandibular', 'Positioner', '(', 'RCMP', ')', 'to', 'Predict', 'Treatment', 'Outcomes', 'of', 'Maxillomandibular', 'Advancement', 'Surgery', 'for', 'Obstructive', 'Sleep', 'Apnea', '(', 'OSA', ')', '.', '|', 'Maxillomandibular', 'advancement', '(', 'MMA', ')', 'surgery', ',', 'one', 'of', 'the', 'most', 'successful', 'surgical', 'procedures', 'for', 'the', 'treatment', 'of', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'is', 'predominantly', 'used', 'to', 'manage', 'patients', 'with', 'moderate', 'to', 'severe', 'OSA', '.', 'However', ',', 'limiting', 'factors', 'include', 'incomplete', 'response', 'in', 'some', 'cases', ',', 'unfavorable', 'facial', 'changes', 'as', 'a', 'result', 'of', 'large', 'advancements', ',', 'and', 'risk', 'of', 'malocclusion', 'or', 'malunion', '.', '\\n\\n', 'This', 'study', 'will', 'be', 'done', 'to', 'determine', 'predictors', 'of', 'success', 'with', 'MMA', 'surgery', 'in', 'patients', 'with', 'moderate', 'to', 'severe', 'OSA', '.', 'Studies', 'have', 'already', 'shown', 'the', 'value', 'of', 'a', 'remote', 'controlled', 'mandibular', 'positioner', '(', 'RCMP', ')', 'device', 'to', 'identify', 'the', 'correct', 'level', 'of', 'therapeutic', 'protrusion', 'needed', 'with', 'oral', 'appliance', 'therapy', '.', 'Moreover', ',', 'some', 'patients', 'experience', 'a', 'dose', 'dependent', 'improvement', 'in', 'sleep', 'parameters', 'based', 'on', 'the', 'degree', 'of', 'protrusion', 'during', 'the', 'titration', 'study', '.', 'Use', 'of', 'RCMP', 'as', 'a', 'means', 'to', 'identify', 'potential', 'candidates', 'for', 'MMA', ',', 'may', 'help', 'customize', 'treatment', 'options', 'for', 'patients', 'with', 'OSA', 'by', 'providing', 'predictive', 'value', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 7,
                "end": 48,
                "text": "Remotely Controlled Mandibular Positioner",
                "type": "OTHER"
            },
            {
                "start": 50,
                "end": 54,
                "text": "RCMP",
                "type": "OTHER"
            },
            {
                "start": 89,
                "end": 126,
                "text": "Maxillomandibular Advancement Surgery",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 154,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 159,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 164,
                "end": 207,
                "text": "Maxillomandibular advancement (MMA) surgery",
                "type": "CONDITION"
            },
            {
                "start": 277,
                "end": 300,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 302,
                "end": 305,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 376,
                "text": "moderate to severe OSA",
                "type": "CONDITION"
            },
            {
                "start": 612,
                "end": 623,
                "text": "MMA surgery",
                "type": "CONDITION"
            },
            {
                "start": 641,
                "end": 663,
                "text": "moderate to severe OSA",
                "type": "CONDITION"
            },
            {
                "start": 707,
                "end": 746,
                "text": "remote controlled mandibular positioner",
                "type": "OTHER"
            },
            {
                "start": 748,
                "end": 752,
                "text": "RCMP",
                "type": "OTHER"
            },
            {
                "start": 829,
                "end": 843,
                "text": "oral appliance",
                "type": "OTHER"
            },
            {
                "start": 1006,
                "end": 1010,
                "text": "RCMP",
                "type": "OTHER"
            },
            {
                "start": 1059,
                "end": 1062,
                "text": "MMA",
                "type": "CONDITION"
            },
            {
                "start": 1119,
                "end": 1122,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04827121",
        "study_official_title": "Transmuscular Quadratus Lumborum Block Versus Supra-inguinal Fascial Iliac Compartment Block for Total Hip Arthroplasty: a Randomized, Prospective Study ",
        "study_brief_summary": " Iliac fascia block has a long history of analgesia in patients with hip fractures. A large number of clinical studies have confirmed its efficacy, and there are also randomized controlled studies supporting its effectiveness in analgesia after total hip replacement surgery.Quadratus lumborum block is a new block technique developed in last decade, and there are also a few randomized controlled studies supporting its effectiveness in postoperative analgesia for total hip replacement.The purpose of the present study was to find out whether these two different approaches of fascial compartment block have similar effects on postoperative analgesia after total hip replacement.",
        "text": "Transmuscular Quadratus Lumborum Block Versus Supra-inguinal Fascial Iliac Compartment Block for Total Hip Arthroplasty: a Randomized, Prospective Study | Iliac fascia block has a long history of analgesia in patients with hip fractures. A large number of clinical studies have confirmed its efficacy, and there are also randomized controlled studies supporting its effectiveness in analgesia after total hip replacement surgery.Quadratus lumborum block is a new block technique developed in last decade, and there are also a few randomized controlled studies supporting its effectiveness in postoperative analgesia for total hip replacement.The purpose of the present study was to find out whether these two different approaches of fascial compartment block have similar effects on postoperative analgesia after total hip replacement.",
        "tokens": "['Transmuscular', 'Quadratus', 'Lumborum', 'Block', 'Versus', 'Supra', '-', 'inguinal', 'Fascial', 'Iliac', 'Compartment', 'Block', 'for', 'Total', 'Hip', 'Arthroplasty', ':', 'a', 'Randomized', ',', 'Prospective', 'Study', '|', 'Iliac', 'fascia', 'block', 'has', 'a', 'long', 'history', 'of', 'analgesia', 'in', 'patients', 'with', 'hip', 'fractures', '.', 'A', 'large', 'number', 'of', 'clinical', 'studies', 'have', 'confirmed', 'its', 'efficacy', ',', 'and', 'there', 'are', 'also', 'randomized', 'controlled', 'studies', 'supporting', 'its', 'effectiveness', 'in', 'analgesia', 'after', 'total', 'hip', 'replacement', 'surgery', '.', 'Quadratus', 'lumborum', 'block', 'is', 'a', 'new', 'block', 'technique', 'developed', 'in', 'last', 'decade', ',', 'and', 'there', 'are', 'also', 'a', 'few', 'randomized', 'controlled', 'studies', 'supporting', 'its', 'effectiveness', 'in', 'postoperative', 'analgesia', 'for', 'total', 'hip', 'replacement', '.', 'The', 'purpose', 'of', 'the', 'present', 'study', 'was', 'to', 'find', 'out', 'whether', 'these', 'two', 'different', 'approaches', 'of', 'fascial', 'compartment', 'block', 'have', 'similar', 'effects', 'on', 'postoperative', 'analgesia', 'after', 'total', 'hip', 'replacement', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 38,
                "text": "Transmuscular Quadratus Lumborum Block",
                "type": "OTHER"
            },
            {
                "start": 46,
                "end": 92,
                "text": "Supra-inguinal Fascial Iliac Compartment Block",
                "type": "OTHER"
            },
            {
                "start": 97,
                "end": 119,
                "text": "Total Hip Arthroplasty",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 173,
                "text": "Iliac fascia block",
                "type": "OTHER"
            },
            {
                "start": 223,
                "end": 236,
                "text": "hip fractures",
                "type": "CONDITION"
            },
            {
                "start": 399,
                "end": 428,
                "text": "total hip replacement surgery",
                "type": "CONDITION"
            },
            {
                "start": 429,
                "end": 453,
                "text": "Quadratus lumborum block",
                "type": "OTHER"
            },
            {
                "start": 620,
                "end": 641,
                "text": "total hip replacement",
                "type": "CONDITION"
            },
            {
                "start": 813,
                "end": 834,
                "text": "total hip replacement",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03767894",
        "study_official_title": "MyHand: An Active Hand Orthosis for Stroke Patients ",
        "study_brief_summary": " This study seeks to explore the efficacy of several control mechanisms for the device and the impact of a device training program on its utility as a neuroprosthetic and training tool for upper limb recovery.",
        "text": "MyHand: An Active Hand Orthosis for Stroke Patients | This study seeks to explore the efficacy of several control mechanisms for the device and the impact of a device training program on its utility as a neuroprosthetic and training tool for upper limb recovery.",
        "tokens": "['MyHand', ':', 'An', 'Active', 'Hand', 'Orthosis', 'for', 'Stroke', 'Patients', '|', 'This', 'study', 'seeks', 'to', 'explore', 'the', 'efficacy', 'of', 'several', 'control', 'mechanisms', 'for', 'the', 'device', 'and', 'the', 'impact', 'of', 'a', 'device', 'training', 'program', 'on', 'its', 'utility', 'as', 'a', 'neuroprosthetic', 'and', 'training', 'tool', 'for', 'upper', 'limb', 'recovery', '.']",
        "token_bio_labels": "['B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 6,
                "text": "MyHand",
                "type": "OTHER"
            },
            {
                "start": 11,
                "end": 31,
                "text": "Active Hand Orthosis",
                "type": "OTHER"
            },
            {
                "start": 36,
                "end": 42,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 160,
                "end": 183,
                "text": "device training program",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04354571",
        "study_official_title": "Evaluation of Post Operative Analgesia of the Erector Spinae Plane Block in Pediatric Patients Undergoing Hip Surgery: a Randomized Control Trial ",
        "study_brief_summary": " Hip Surgery in pediatric patients is considered an extremely painful procedure. Managing pain in this surgery is challenging even with several available options, each with limitations. Erector spinae plane (ESP) block is a novel technique that has been used in different types of surgery, with promising results. Many case reports for use of ESPB are available in the literature but to our knowledge, no cohort studies or randomized controlled trials have been performed on ESPB for hip surgery in pediatrics age group against a traditional method as caudal block.1,2 AIM OF WORK\n\n. The Primary outcome of this study is to compare the efficacy of analgesia resulting from the Erector spinae plane block versus the caudal block in pediatric patients undergoing hip surgery using the FLACC score and the duration of the analgesia of both methods till the first rescue analgesic.\n\nThe Secondary outcome is to compare the analgesic rescue frequency and total dose given in both groups as well as comparing the complications that might occur from each analgesic technique.",
        "text": "Evaluation of Post Operative Analgesia of the Erector Spinae Plane Block in Pediatric Patients Undergoing Hip Surgery: a Randomized Control Trial | Hip Surgery in pediatric patients is considered an extremely painful procedure. Managing pain in this surgery is challenging even with several available options, each with limitations. Erector spinae plane (ESP) block is a novel technique that has been used in different types of surgery, with promising results. Many case reports for use of ESPB are available in the literature but to our knowledge, no cohort studies or randomized controlled trials have been performed on ESPB for hip surgery in pediatrics age group against a traditional method as caudal block.1,2 AIM OF WORK\n\n. The Primary outcome of this study is to compare the efficacy of analgesia resulting from the Erector spinae plane block versus the caudal block in pediatric patients undergoing hip surgery using the FLACC score and the duration of the analgesia of both methods till the first rescue analgesic.\n\nThe Secondary outcome is to compare the analgesic rescue frequency and total dose given in both groups as well as comparing the complications that might occur from each analgesic technique.",
        "tokens": "['Evaluation', 'of', 'Post', 'Operative', 'Analgesia', 'of', 'the', 'Erector', 'Spinae', 'Plane', 'Block', 'in', 'Pediatric', 'Patients', 'Undergoing', 'Hip', 'Surgery', ':', 'a', 'Randomized', 'Control', 'Trial', '|', 'Hip', 'Surgery', 'in', 'pediatric', 'patients', 'is', 'considered', 'an', 'extremely', 'painful', 'procedure', '.', 'Managing', 'pain', 'in', 'this', 'surgery', 'is', 'challenging', 'even', 'with', 'several', 'available', 'options', ',', 'each', 'with', 'limitations', '.', 'Erector', 'spinae', 'plane', '(', 'ESP', ')', 'block', 'is', 'a', 'novel', 'technique', 'that', 'has', 'been', 'used', 'in', 'different', 'types', 'of', 'surgery', ',', 'with', 'promising', 'results', '.', 'Many', 'case', 'reports', 'for', 'use', 'of', 'ESPB', 'are', 'available', 'in', 'the', 'literature', 'but', 'to', 'our', 'knowledge', ',', 'no', 'cohort', 'studies', 'or', 'randomized', 'controlled', 'trials', 'have', 'been', 'performed', 'on', 'ESPB', 'for', 'hip', 'surgery', 'in', 'pediatrics', 'age', 'group', 'against', 'a', 'traditional', 'method', 'as', 'caudal', 'block.1,2', 'AIM', 'OF', 'WORK', '\\n\\n', '.', 'The', 'Primary', 'outcome', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'analgesia', 'resulting', 'from', 'the', 'Erector', 'spinae', 'plane', 'block', 'versus', 'the', 'caudal', 'block', 'in', 'pediatric', 'patients', 'undergoing', 'hip', 'surgery', 'using', 'the', 'FLACC', 'score', 'and', 'the', 'duration', 'of', 'the', 'analgesia', 'of', 'both', 'methods', 'till', 'the', 'first', 'rescue', 'analgesic', '.', '\\n\\n', 'The', 'Secondary', 'outcome', 'is', 'to', 'compare', 'the', 'analgesic', 'rescue', 'frequency', 'and', 'total', 'dose', 'given', 'in', 'both', 'groups', 'as', 'well', 'as', 'comparing', 'the', 'complications', 'that', 'might', 'occur', 'from', 'each', 'analgesic', 'technique', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 46,
                "end": 72,
                "text": "Erector Spinae Plane Block",
                "type": "OTHER"
            },
            {
                "start": 106,
                "end": 117,
                "text": "Hip Surgery",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 159,
                "text": "Hip Surgery",
                "type": "CONDITION"
            },
            {
                "start": 237,
                "end": 241,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 333,
                "end": 365,
                "text": "Erector spinae plane (ESP) block",
                "type": "OTHER"
            },
            {
                "start": 490,
                "end": 494,
                "text": "ESPB",
                "type": "OTHER"
            },
            {
                "start": 622,
                "end": 626,
                "text": "ESPB",
                "type": "OTHER"
            },
            {
                "start": 824,
                "end": 850,
                "text": "Erector spinae plane block",
                "type": "OTHER"
            },
            {
                "start": 862,
                "end": 874,
                "text": "caudal block",
                "type": "CONTROL"
            },
            {
                "start": 908,
                "end": 919,
                "text": "hip surgery",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00257868",
        "study_official_title": "Rivastigmine for the Prevention of Postoperative Delirium After Cardiac Surgery ",
        "study_brief_summary": " The purpose of this study is to determine whether Rivastigmine is effective for the prevention of postoperative delirium in patients undergoing cardiac surgery.",
        "text": "Rivastigmine for the Prevention of Postoperative Delirium After Cardiac Surgery | The purpose of this study is to determine whether Rivastigmine is effective for the prevention of postoperative delirium in patients undergoing cardiac surgery.",
        "tokens": "['Rivastigmine', 'for', 'the', 'Prevention', 'of', 'Postoperative', 'Delirium', 'After', 'Cardiac', 'Surgery', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'Rivastigmine', 'is', 'effective', 'for', 'the', 'prevention', 'of', 'postoperative', 'delirium', 'in', 'patients', 'undergoing', 'cardiac', 'surgery', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 12,
                "text": "Rivastigmine",
                "type": "DRUG"
            },
            {
                "start": 35,
                "end": 57,
                "text": "Postoperative Delirium",
                "type": "CONDITION"
            },
            {
                "start": 64,
                "end": 79,
                "text": "Cardiac Surgery",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 144,
                "text": "Rivastigmine",
                "type": "DRUG"
            },
            {
                "start": 180,
                "end": 202,
                "text": "postoperative delirium",
                "type": "CONDITION"
            },
            {
                "start": 226,
                "end": 241,
                "text": "cardiac surgery",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03549793",
        "study_official_title": "Can Dance Therapy Improve Motor Learning in Parkinson's Disease? ",
        "study_brief_summary": " In order to find the most effective rehabilitative therapies for Parkinsonian patients, the present study is aimed to evaluate whether, in a multidisciplinary intensive rehabilitation treatment, the dance therapy, applied to the motor learning, promote additional benefits.",
        "text": "Can Dance Therapy Improve Motor Learning in Parkinson's Disease? | In order to find the most effective rehabilitative therapies for Parkinsonian patients, the present study is aimed to evaluate whether, in a multidisciplinary intensive rehabilitation treatment, the dance therapy, applied to the motor learning, promote additional benefits.",
        "tokens": "['Can', 'Dance', 'Therapy', 'Improve', 'Motor', 'Learning', 'in', 'Parkinson', \"'s\", 'Disease', '?', '|', 'In', 'order', 'to', 'find', 'the', 'most', 'effective', 'rehabilitative', 'therapies', 'for', 'Parkinsonian', 'patients', ',', 'the', 'present', 'study', 'is', 'aimed', 'to', 'evaluate', 'whether', ',', 'in', 'a', 'multidisciplinary', 'intensive', 'rehabilitation', 'treatment', ',', 'the', 'dance', 'therapy', ',', 'applied', 'to', 'the', 'motor', 'learning', ',', 'promote', 'additional', 'benefits', '.']",
        "token_bio_labels": "['O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 4,
                "end": 17,
                "text": "Dance Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 44,
                "end": 63,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 144,
                "text": "Parkinsonian",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 279,
                "text": "dance therapy",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT00989456",
        "study_official_title": "Structured Patient Education in Combination With Physical Exercise as Part of the Integrated Care to Chronically Ill Patients With Chronic Obstructive Pulmonary Disease, Heart Failure and Stroke. A Randomized Controlled Intervention Trial. ",
        "study_brief_summary": " This study addresses self management and maintenance of health through evaluation of a program of patient education in combination with physical training and with a structured follow-up.\n\nIt is hypothesized that such a program will:\n\nimprove quality of life, physical functioning, coping in everyday-life\nreduce hospitalization and (re-)admissions for patients with chronic disease, reduce consumption of home care services and can increase consumption of general practice and physiotherapy services in primary health care.\nimprove patient satisfaction and health care providers satisfaction",
        "text": "Structured Patient Education in Combination With Physical Exercise as Part of the Integrated Care to Chronically Ill Patients With Chronic Obstructive Pulmonary Disease, Heart Failure and Stroke. A Randomized Controlled Intervention Trial. | This study addresses self management and maintenance of health through evaluation of a program of patient education in combination with physical training and with a structured follow-up.\n\nIt is hypothesized that such a program will:\n\nimprove quality of life, physical functioning, coping in everyday-life\nreduce hospitalization and (re-)admissions for patients with chronic disease, reduce consumption of home care services and can increase consumption of general practice and physiotherapy services in primary health care.\nimprove patient satisfaction and health care providers satisfaction",
        "tokens": "['Structured', 'Patient', 'Education', 'in', 'Combination', 'With', 'Physical', 'Exercise', 'as', 'Part', 'of', 'the', 'Integrated', 'Care', 'to', 'Chronically', 'Ill', 'Patients', 'With', 'Chronic', 'Obstructive', 'Pulmonary', 'Disease', ',', 'Heart', 'Failure', 'and', 'Stroke', '.', 'A', 'Randomized', 'Controlled', 'Intervention', 'Trial', '.', '|', 'This', 'study', 'addresses', 'self', 'management', 'and', 'maintenance', 'of', 'health', 'through', 'evaluation', 'of', 'a', 'program', 'of', 'patient', 'education', 'in', 'combination', 'with', 'physical', 'training', 'and', 'with', 'a', 'structured', 'follow', '-', 'up', '.', '\\n\\n', 'It', 'is', 'hypothesized', 'that', 'such', 'a', 'program', 'will', ':', '\\n\\n', 'improve', 'quality', 'of', 'life', ',', 'physical', 'functioning', ',', 'coping', 'in', 'everyday', '-', 'life', '\\n', 'reduce', 'hospitalization', 'and', '(', 're-)admissions', 'for', 'patients', 'with', 'chronic', 'disease', ',', 'reduce', 'consumption', 'of', 'home', 'care', 'services', 'and', 'can', 'increase', 'consumption', 'of', 'general', 'practice', 'and', 'physiotherapy', 'services', 'in', 'primary', 'health', 'care', '.', '\\n', 'improve', 'patient', 'satisfaction', 'and', 'health', 'care', 'providers', 'satisfaction']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 28,
                "text": "Structured Patient Education",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 49,
                "end": 66,
                "text": "Physical Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 131,
                "end": 168,
                "text": "Chronic Obstructive Pulmonary Disease",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 183,
                "text": "Heart Failure",
                "type": "CONDITION"
            },
            {
                "start": 188,
                "end": 194,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 329,
                "end": 357,
                "text": "program of patient education",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 378,
                "end": 395,
                "text": "physical training",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT04709029",
        "study_official_title": "Effect of Intravenous Versus Intrathecal Dexamethazone in Bupivacaine Spinal Anesthesia on Postdural Puncture Headache ",
        "study_brief_summary": " This study will be conducted at Ain Shams University Hospital in Operating Theatre after ethical committe approval number (MS 32/ 2020). It is a prospective randomized controlled study will be done on patients undergoing lower abdominal and lower limb surgeries under spinal anethesia,Eligible patients will be randomized by computer system to one of two groups, either intravenous dexamethazzoe 8 mg with intrathecal heavy bupivacaine 0.5% or intrathecal 4mg dexamethazone with intrathecal heavy bupivacaine 0.5%. .",
        "text": "Effect of Intravenous Versus Intrathecal Dexamethazone in Bupivacaine Spinal Anesthesia on Postdural Puncture Headache | This study will be conducted at Ain Shams University Hospital in Operating Theatre after ethical committe approval number (MS 32/ 2020). It is a prospective randomized controlled study will be done on patients undergoing lower abdominal and lower limb surgeries under spinal anethesia,Eligible patients will be randomized by computer system to one of two groups, either intravenous dexamethazzoe 8 mg with intrathecal heavy bupivacaine 0.5% or intrathecal 4mg dexamethazone with intrathecal heavy bupivacaine 0.5%. .",
        "tokens": "['Effect', 'of', 'Intravenous', 'Versus', 'Intrathecal', 'Dexamethazone', 'in', 'Bupivacaine', 'Spinal', 'Anesthesia', 'on', 'Postdural', 'Puncture', 'Headache', '|', 'This', 'study', 'will', 'be', 'conducted', 'at', 'Ain', 'Shams', 'University', 'Hospital', 'in', 'Operating', 'Theatre', 'after', 'ethical', 'committe', 'approval', 'number', '(', 'MS', '32/', '2020', ')', '.', 'It', 'is', 'a', 'prospective', 'randomized', 'controlled', 'study', 'will', 'be', 'done', 'on', 'patients', 'undergoing', 'lower', 'abdominal', 'and', 'lower', 'limb', 'surgeries', 'under', 'spinal', 'anethesia', ',', 'Eligible', 'patients', 'will', 'be', 'randomized', 'by', 'computer', 'system', 'to', 'one', 'of', 'two', 'groups', ',', 'either', 'intravenous', 'dexamethazzoe', '8', 'mg', 'with', 'intrathecal', 'heavy', 'bupivacaine', '0.5', '%', 'or', 'intrathecal', '4', 'mg', 'dexamethazone', 'with', 'intrathecal', 'heavy', 'bupivacaine', '0.5', '%', '.', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 54,
                "text": "Dexamethazone",
                "type": "DRUG"
            },
            {
                "start": 58,
                "end": 69,
                "text": "Bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 91,
                "end": 118,
                "text": "Postdural Puncture Headache",
                "type": "CONDITION"
            },
            {
                "start": 342,
                "end": 382,
                "text": "lower abdominal and lower limb surgeries",
                "type": "CONDITION"
            },
            {
                "start": 503,
                "end": 516,
                "text": "dexamethazzoe",
                "type": "DRUG"
            },
            {
                "start": 545,
                "end": 556,
                "text": "bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 581,
                "end": 594,
                "text": "dexamethazone",
                "type": "DRUG"
            },
            {
                "start": 618,
                "end": 629,
                "text": "bupivacaine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02149823",
        "study_official_title": "Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations ",
        "study_brief_summary": " Social cognition impairment is critical to the pathology and morbidity of a number of psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and the personality disorders, thus representing a dimension consistent with RDoC. As such, this study aims to a) further characterize the unique deficits in social cognition (recognition and interpretation of social cues and representation of thoughts, intentions, and feelings of others) across disorders, including the schizophrenia spectrum (which includes schizophrenia, SCZ, schizoaffective disorder, SAD, bipolar disorder, BD, and schizotypal personality disorder, SPD), the autism spectrum disorders (ASD), and borderline personality disorder (BPD) compared to healthy controls (HC); b) assess the effect of intranasal oxytocin (OXT) as a regulator and novel treatment of social cognition impairment in these disorders; and c) enhance our understanding of the specificity and exact mechanisms of impairment to inform the accurate dosing of OXT required to modulate social cognition in these disorders and identify a model of optimum social cognitive function. Addressing these questions will further catalyze research into a model of optimum social cognitive activity, and accelerate industry development of agents suited to routine clinical administration.",
        "text": "Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations | Social cognition impairment is critical to the pathology and morbidity of a number of psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and the personality disorders, thus representing a dimension consistent with RDoC. As such, this study aims to a) further characterize the unique deficits in social cognition (recognition and interpretation of social cues and representation of thoughts, intentions, and feelings of others) across disorders, including the schizophrenia spectrum (which includes schizophrenia, SCZ, schizoaffective disorder, SAD, bipolar disorder, BD, and schizotypal personality disorder, SPD), the autism spectrum disorders (ASD), and borderline personality disorder (BPD) compared to healthy controls (HC); b) assess the effect of intranasal oxytocin (OXT) as a regulator and novel treatment of social cognition impairment in these disorders; and c) enhance our understanding of the specificity and exact mechanisms of impairment to inform the accurate dosing of OXT required to modulate social cognition in these disorders and identify a model of optimum social cognitive function. Addressing these questions will further catalyze research into a model of optimum social cognitive activity, and accelerate industry development of agents suited to routine clinical administration.",
        "tokens": "['Examining', 'Dose', '-', 'Related', 'Effects', 'of', 'Oxytocin', 'on', 'Social', 'Cognition', 'Across', 'Populations', '|', 'Social', 'cognition', 'impairment', 'is', 'critical', 'to', 'the', 'pathology', 'and', 'morbidity', 'of', 'a', 'number', 'of', 'psychiatric', 'disorders', ',', 'including', 'the', 'schizophrenia', 'spectrum', ',', 'the', 'autism', 'spectrum', 'and', 'the', 'personality', 'disorders', ',', 'thus', 'representing', 'a', 'dimension', 'consistent', 'with', 'RDoC.', 'As', 'such', ',', 'this', 'study', 'aims', 'to', 'a', ')', 'further', 'characterize', 'the', 'unique', 'deficits', 'in', 'social', 'cognition', '(', 'recognition', 'and', 'interpretation', 'of', 'social', 'cues', 'and', 'representation', 'of', 'thoughts', ',', 'intentions', ',', 'and', 'feelings', 'of', 'others', ')', 'across', 'disorders', ',', 'including', 'the', 'schizophrenia', 'spectrum', '(', 'which', 'includes', 'schizophrenia', ',', 'SCZ', ',', 'schizoaffective', 'disorder', ',', 'SAD', ',', 'bipolar', 'disorder', ',', 'BD', ',', 'and', 'schizotypal', 'personality', 'disorder', ',', 'SPD', ')', ',', 'the', 'autism', 'spectrum', 'disorders', '(', 'ASD', ')', ',', 'and', 'borderline', 'personality', 'disorder', '(', 'BPD', ')', 'compared', 'to', 'healthy', 'controls', '(', 'HC', ')', ';', 'b', ')', 'assess', 'the', 'effect', 'of', 'intranasal', 'oxytocin', '(', 'OXT', ')', 'as', 'a', 'regulator', 'and', 'novel', 'treatment', 'of', 'social', 'cognition', 'impairment', 'in', 'these', 'disorders', ';', 'and', 'c', ')', 'enhance', 'our', 'understanding', 'of', 'the', 'specificity', 'and', 'exact', 'mechanisms', 'of', 'impairment', 'to', 'inform', 'the', 'accurate', 'dosing', 'of', 'OXT', 'required', 'to', 'modulate', 'social', 'cognition', 'in', 'these', 'disorders', 'and', 'identify', 'a', 'model', 'of', 'optimum', 'social', 'cognitive', 'function', '.', 'Addressing', 'these', 'questions', 'will', 'further', 'catalyze', 'research', 'into', 'a', 'model', 'of', 'optimum', 'social', 'cognitive', 'activity', ',', 'and', 'accelerate', 'industry', 'development', 'of', 'agents', 'suited', 'to', 'routine', 'clinical', 'administration', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 34,
                "end": 42,
                "text": "Oxytocin",
                "type": "DRUG"
            },
            {
                "start": 84,
                "end": 111,
                "text": "Social cognition impairment",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 229,
                "text": "schizophrenia spectrum",
                "type": "CONDITION"
            },
            {
                "start": 235,
                "end": 250,
                "text": "autism spectrum",
                "type": "CONDITION"
            },
            {
                "start": 259,
                "end": 280,
                "text": "personality disorders",
                "type": "CONDITION"
            },
            {
                "start": 612,
                "end": 625,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 627,
                "end": 630,
                "text": "SCZ",
                "type": "CONDITION"
            },
            {
                "start": 632,
                "end": 656,
                "text": "schizoaffective disorder",
                "type": "CONDITION"
            },
            {
                "start": 658,
                "end": 661,
                "text": "SAD",
                "type": "CONDITION"
            },
            {
                "start": 663,
                "end": 679,
                "text": "bipolar disorder",
                "type": "CONDITION"
            },
            {
                "start": 681,
                "end": 683,
                "text": "BD",
                "type": "CONDITION"
            },
            {
                "start": 689,
                "end": 721,
                "text": "schizotypal personality disorder",
                "type": "CONDITION"
            },
            {
                "start": 723,
                "end": 726,
                "text": "SPD",
                "type": "CONDITION"
            },
            {
                "start": 733,
                "end": 758,
                "text": "autism spectrum disorders",
                "type": "CONDITION"
            },
            {
                "start": 760,
                "end": 763,
                "text": "ASD",
                "type": "CONDITION"
            },
            {
                "start": 770,
                "end": 801,
                "text": "borderline personality disorder",
                "type": "CONDITION"
            },
            {
                "start": 803,
                "end": 806,
                "text": "BPD",
                "type": "CONDITION"
            },
            {
                "start": 878,
                "end": 886,
                "text": "oxytocin",
                "type": "DRUG"
            },
            {
                "start": 888,
                "end": 891,
                "text": "OXT",
                "type": "DRUG"
            },
            {
                "start": 931,
                "end": 958,
                "text": "social cognition impairment",
                "type": "CONDITION"
            },
            {
                "start": 1099,
                "end": 1102,
                "text": "OXT",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00000146",
        "study_official_title": "To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis.\n\nTo determine the natural history of vision in patients who suffer optic neuritis.\n\nTo identify risk factors for the development of multiple sclerosis in patients with optic neuritis.",
        "study_brief_summary": null,
        "text": "To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis.\n\nTo determine the natural history of vision in patients who suffer optic neuritis.\n\nTo identify risk factors for the development of multiple sclerosis in patients with optic neuritis.",
        "tokens": "['To', 'assess', 'the', 'beneficial', 'and', 'adverse', 'effects', 'of', 'corticosteroid', 'treatment', 'for', 'optic', 'neuritis', '.', '\\n\\n', 'To', 'determine', 'the', 'natural', 'history', 'of', 'vision', 'in', 'patients', 'who', 'suffer', 'optic', 'neuritis', '.', '\\n\\n', 'To', 'identify', 'risk', 'factors', 'for', 'the', 'development', 'of', 'multiple', 'sclerosis', 'in', 'patients', 'with', 'optic', 'neuritis', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 48,
                "end": 62,
                "text": "corticosteroid",
                "type": "DRUG"
            },
            {
                "start": 77,
                "end": 91,
                "text": "optic neuritis",
                "type": "CONDITION"
            },
            {
                "start": 160,
                "end": 174,
                "text": "optic neuritis",
                "type": "CONDITION"
            },
            {
                "start": 225,
                "end": 243,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 275,
                "text": "optic neuritis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02127606",
        "study_official_title": "The Effect of Whole Body Vibration on Spasticity in Spinal Cord Injury Patients ",
        "study_brief_summary": " Extended periods of tilt table standing have been observed to improve spasticity in individuals with spinal cord injury (SCI). The purpose of this study is to determine the effect of three sessions of whole body vibration while tilt table standing on spasticity in individuals with a complete or incomplete SCI above the neurological level of T10. Participants in this study will undergo whole body vibration while standing on a tilt table for a total of approximately 14 minutes for a total of 3 sessions on 3 separate days. Spasticity monitoring will be evaluated prior to and after the intervention with the Modified Penn Spasm Frequency Scale, an interview to obtain the individual's perception and impression of the effect of whole body vibration on the performance of activities of daily living, quality of life, pain scale, and global impression of change.",
        "text": "The Effect of Whole Body Vibration on Spasticity in Spinal Cord Injury Patients | Extended periods of tilt table standing have been observed to improve spasticity in individuals with spinal cord injury (SCI). The purpose of this study is to determine the effect of three sessions of whole body vibration while tilt table standing on spasticity in individuals with a complete or incomplete SCI above the neurological level of T10. Participants in this study will undergo whole body vibration while standing on a tilt table for a total of approximately 14 minutes for a total of 3 sessions on 3 separate days. Spasticity monitoring will be evaluated prior to and after the intervention with the Modified Penn Spasm Frequency Scale, an interview to obtain the individual's perception and impression of the effect of whole body vibration on the performance of activities of daily living, quality of life, pain scale, and global impression of change.",
        "tokens": "['The', 'Effect', 'of', 'Whole', 'Body', 'Vibration', 'on', 'Spasticity', 'in', 'Spinal', 'Cord', 'Injury', 'Patients', '|', 'Extended', 'periods', 'of', 'tilt', 'table', 'standing', 'have', 'been', 'observed', 'to', 'improve', 'spasticity', 'in', 'individuals', 'with', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'three', 'sessions', 'of', 'whole', 'body', 'vibration', 'while', 'tilt', 'table', 'standing', 'on', 'spasticity', 'in', 'individuals', 'with', 'a', 'complete', 'or', 'incomplete', 'SCI', 'above', 'the', 'neurological', 'level', 'of', 'T10', '.', 'Participants', 'in', 'this', 'study', 'will', 'undergo', 'whole', 'body', 'vibration', 'while', 'standing', 'on', 'a', 'tilt', 'table', 'for', 'a', 'total', 'of', 'approximately', '14', 'minutes', 'for', 'a', 'total', 'of', '3', 'sessions', 'on', '3', 'separate', 'days', '.', 'Spasticity', 'monitoring', 'will', 'be', 'evaluated', 'prior', 'to', 'and', 'after', 'the', 'intervention', 'with', 'the', 'Modified', 'Penn', 'Spasm', 'Frequency', 'Scale', ',', 'an', 'interview', 'to', 'obtain', 'the', 'individual', \"'s\", 'perception', 'and', 'impression', 'of', 'the', 'effect', 'of', 'whole', 'body', 'vibration', 'on', 'the', 'performance', 'of', 'activities', 'of', 'daily', 'living', ',', 'quality', 'of', 'life', ',', 'pain', 'scale', ',', 'and', 'global', 'impression', 'of', 'change', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 34,
                "text": "Whole Body Vibration",
                "type": "OTHER"
            },
            {
                "start": 38,
                "end": 48,
                "text": "Spasticity",
                "type": "CONDITION"
            },
            {
                "start": 52,
                "end": 70,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 201,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 203,
                "end": 206,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 303,
                "text": "whole body vibration",
                "type": "OTHER"
            },
            {
                "start": 333,
                "end": 343,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 366,
                "end": 392,
                "text": "complete or incomplete SCI",
                "type": "CONDITION"
            },
            {
                "start": 470,
                "end": 490,
                "text": "whole body vibration",
                "type": "OTHER"
            },
            {
                "start": 608,
                "end": 618,
                "text": "Spasticity",
                "type": "CONDITION"
            },
            {
                "start": 813,
                "end": 833,
                "text": "whole body vibration",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01168466",
        "study_official_title": "Pilot Study of EEG and Cerebral Blood Flow Biofeedback Training in Remediating Cognitive and Behavioral Deficits in Adults With a Dementing Illness. ",
        "study_brief_summary": " This study measures whether the symptoms of frontotemporal dementia (FTD) can be successfully treated by (a) biofeedback training to increase brain blood flow, (b) biofeedback to increase the frequency of the brain's dominant brainwave rhythm, and (c) rhythmic stimulation to increase the brain's dominant brainwave frequency.",
        "text": "Pilot Study of EEG and Cerebral Blood Flow Biofeedback Training in Remediating Cognitive and Behavioral Deficits in Adults With a Dementing Illness. | This study measures whether the symptoms of frontotemporal dementia (FTD) can be successfully treated by (a) biofeedback training to increase brain blood flow, (b) biofeedback to increase the frequency of the brain's dominant brainwave rhythm, and (c) rhythmic stimulation to increase the brain's dominant brainwave frequency.",
        "tokens": "['Pilot', 'Study', 'of', 'EEG', 'and', 'Cerebral', 'Blood', 'Flow', 'Biofeedback', 'Training', 'in', 'Remediating', 'Cognitive', 'and', 'Behavioral', 'Deficits', 'in', 'Adults', 'With', 'a', 'Dementing', 'Illness', '.', '|', 'This', 'study', 'measures', 'whether', 'the', 'symptoms', 'of', 'frontotemporal', 'dementia', '(', 'FTD', ')', 'can', 'be', 'successfully', 'treated', 'by', '(', 'a', ')', 'biofeedback', 'training', 'to', 'increase', 'brain', 'blood', 'flow', ',', '(', 'b', ')', 'biofeedback', 'to', 'increase', 'the', 'frequency', 'of', 'the', 'brain', \"'s\", 'dominant', 'brainwave', 'rhythm', ',', 'and', '(', 'c', ')', 'rhythmic', 'stimulation', 'to', 'increase', 'the', 'brain', \"'s\", 'dominant', 'brainwave', 'frequency', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 23,
                "end": 63,
                "text": "Cerebral Blood Flow Biofeedback Training",
                "type": "OTHER"
            },
            {
                "start": 79,
                "end": 112,
                "text": "Cognitive and Behavioral Deficits",
                "type": "CONDITION"
            },
            {
                "start": 130,
                "end": 139,
                "text": "Dementing",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 218,
                "text": "frontotemporal dementia",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 223,
                "text": "FTD",
                "type": "CONDITION"
            },
            {
                "start": 260,
                "end": 280,
                "text": "biofeedback training",
                "type": "OTHER"
            },
            {
                "start": 315,
                "end": 326,
                "text": "biofeedback",
                "type": "OTHER"
            },
            {
                "start": 403,
                "end": 423,
                "text": "rhythmic stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00041717",
        "study_official_title": "Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury ",
        "study_brief_summary": " Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrical impulses. As a result, subjects with an incomplete spinal cord injury may have spasticity which is muscle spasms or muscle stiffness that makes movement difficult. Fampridine-SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will examine the effects of Fampridine-SR on moderate to severe lower-limb spasticity, as well as the effects on bodily functions such as bladder control, bowel function and sexual function. The study will also examine the possible risks of taking Fampridine-SR.",
        "text": "Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury | Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrical impulses. As a result, subjects with an incomplete spinal cord injury may have spasticity which is muscle spasms or muscle stiffness that makes movement difficult. Fampridine-SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will examine the effects of Fampridine-SR on moderate to severe lower-limb spasticity, as well as the effects on bodily functions such as bladder control, bowel function and sexual function. The study will also examine the possible risks of taking Fampridine-SR.",
        "tokens": "['Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', '12', '-', 'Week', 'Parallel', 'Group', 'Study', 'to', 'Evaluate', 'Safety', 'and', 'Efficacy', 'of', 'Oral', 'Fampridine', '-', 'SR', 'in', 'Subjects', 'With', 'Moderate', 'to', 'Severe', 'Spasticity', 'Resulting', 'From', 'Chronic', ',', 'Incomplete', 'Spinal', 'Cord', 'Injury', '|', 'Normally', ',', 'nerve', 'fibers', 'carry', 'electrical', 'impulses', 'through', 'the', 'spinal', 'cord', ',', 'providing', 'communication', 'between', 'the', 'brain', 'and', 'the', 'arms', 'and', 'legs', '.', 'In', 'people', 'with', 'spinal', 'cord', 'injury', ',', 'some', 'fibers', 'may', 'be', 'destroyed', 'at', 'the', 'site', 'of', 'injury', ',', 'while', 'others', 'remain', 'connected', 'but', 'do', 'not', 'work', 'correctly', 'to', 'carry', 'electrical', 'impulses', '.', 'As', 'a', 'result', ',', 'subjects', 'with', 'an', 'incomplete', 'spinal', 'cord', 'injury', 'may', 'have', 'spasticity', 'which', 'is', 'muscle', 'spasms', 'or', 'muscle', 'stiffness', 'that', 'makes', 'movement', 'difficult', '.', 'Fampridine', '-', 'SR', 'is', 'an', 'experimental', 'drug', 'that', 'increases', 'the', 'ability', 'of', 'the', 'nerve', 'to', 'conduct', 'electrical', 'impulses', '.', 'This', 'study', 'will', 'examine', 'the', 'effects', 'of', 'Fampridine', '-', 'SR', 'on', 'moderate', 'to', 'severe', 'lower', '-', 'limb', 'spasticity', ',', 'as', 'well', 'as', 'the', 'effects', 'on', 'bodily', 'functions', 'such', 'as', 'bladder', 'control', ',', 'bowel', 'function', 'and', 'sexual', 'function', '.', 'The', 'study', 'will', 'also', 'examine', 'the', 'possible', 'risks', 'of', 'taking', 'Fampridine', '-', 'SR', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 21,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 103,
                "end": 113,
                "text": "Fampridine",
                "type": "DRUG"
            },
            {
                "start": 134,
                "end": 163,
                "text": "Moderate to Severe Spasticity",
                "type": "CONDITION"
            },
            {
                "start": 179,
                "end": 217,
                "text": "Chronic, Incomplete Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 374,
                "end": 392,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 562,
                "end": 591,
                "text": "incomplete spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 601,
                "end": 611,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 621,
                "end": 634,
                "text": "muscle spasms",
                "type": "CONDITION"
            },
            {
                "start": 638,
                "end": 654,
                "text": "muscle stiffness",
                "type": "CONDITION"
            },
            {
                "start": 686,
                "end": 696,
                "text": "Fampridine",
                "type": "DRUG"
            },
            {
                "start": 835,
                "end": 845,
                "text": "Fampridine",
                "type": "DRUG"
            },
            {
                "start": 852,
                "end": 892,
                "text": "moderate to severe lower-limb spasticity",
                "type": "CONDITION"
            },
            {
                "start": 1055,
                "end": 1065,
                "text": "Fampridine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00112398",
        "study_official_title": "Randomised, Controlled Trial of Physician Prehospital Management of Severe Blunt Head Injury ",
        "study_brief_summary": " The study hypothesis is that advanced interventions as provided by a physician at an accident scene will decrease the death rate and the rate of severe disability in survivors of severe head injury. Extended interventions by advanced level prehospital providers may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.",
        "text": "Randomised, Controlled Trial of Physician Prehospital Management of Severe Blunt Head Injury | The study hypothesis is that advanced interventions as provided by a physician at an accident scene will decrease the death rate and the rate of severe disability in survivors of severe head injury. Extended interventions by advanced level prehospital providers may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.",
        "tokens": "['Randomised', ',', 'Controlled', 'Trial', 'of', 'Physician', 'Prehospital', 'Management', 'of', 'Severe', 'Blunt', 'Head', 'Injury', '|', 'The', 'study', 'hypothesis', 'is', 'that', 'advanced', 'interventions', 'as', 'provided', 'by', 'a', 'physician', 'at', 'an', 'accident', 'scene', 'will', 'decrease', 'the', 'death', 'rate', 'and', 'the', 'rate', 'of', 'severe', 'disability', 'in', 'survivors', 'of', 'severe', 'head', 'injury', '.', 'Extended', 'interventions', 'by', 'advanced', 'level', 'prehospital', 'providers', 'may', 'include', 'rapid', 'sequence', 'intubation', '(', 'RSI', ')', 'airway', 'management', ',', 'blood', 'transfusions', ',', 'surgical', 'procedures', ',', 'etc', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 64,
                "text": "Physician Prehospital Management",
                "type": "OTHER"
            },
            {
                "start": 68,
                "end": 92,
                "text": "Severe Blunt Head Injury",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 194,
                "text": "advanced interventions as provided by a physician at an accident scene",
                "type": "OTHER"
            },
            {
                "start": 274,
                "end": 292,
                "text": "severe head injury",
                "type": "CONDITION"
            },
            {
                "start": 369,
                "end": 418,
                "text": "rapid sequence intubation (RSI) airway management",
                "type": "OTHER"
            },
            {
                "start": 420,
                "end": 438,
                "text": "blood transfusions",
                "type": "OTHER"
            },
            {
                "start": 440,
                "end": 459,
                "text": "surgical procedures",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT05318586",
        "study_official_title": "Effect of Individualized rTMS Based on fNIRS on the Upper Limb Spasticity After Stroke ",
        "study_brief_summary": " Stroke is of high morbidity and mortality, and surviving patients are often unable to take care of themselves because of severe motor dysfunction. The brain has plasticity, and makes adaptive changes after stroke, resulting in the reorganization and compensation of neural networks. However, the muscle tone of some patients will significantly increase during the recovery process, which affects the rehabilitation effect. Neuromodulation techniques such as repetitive transcranial magnetic stimulation (rTMS) have been widely used to promote brain network remodeling after stroke. The investigators attempted to evaluate the motor brain network characteristics of spastic patients by fNIRS, and used the most active brain regions as rTMS stimulation regions to evaluate the improvement effect of this individualized treatment on post-stroke spasticity.",
        "text": "Effect of Individualized rTMS Based on fNIRS on the Upper Limb Spasticity After Stroke | Stroke is of high morbidity and mortality, and surviving patients are often unable to take care of themselves because of severe motor dysfunction. The brain has plasticity, and makes adaptive changes after stroke, resulting in the reorganization and compensation of neural networks. However, the muscle tone of some patients will significantly increase during the recovery process, which affects the rehabilitation effect. Neuromodulation techniques such as repetitive transcranial magnetic stimulation (rTMS) have been widely used to promote brain network remodeling after stroke. The investigators attempted to evaluate the motor brain network characteristics of spastic patients by fNIRS, and used the most active brain regions as rTMS stimulation regions to evaluate the improvement effect of this individualized treatment on post-stroke spasticity.",
        "tokens": "['Effect', 'of', 'Individualized', 'rTMS', 'Based', 'on', 'fNIRS', 'on', 'the', 'Upper', 'Limb', 'Spasticity', 'After', 'Stroke', '|', 'Stroke', 'is', 'of', 'high', 'morbidity', 'and', 'mortality', ',', 'and', 'surviving', 'patients', 'are', 'often', 'unable', 'to', 'take', 'care', 'of', 'themselves', 'because', 'of', 'severe', 'motor', 'dysfunction', '.', 'The', 'brain', 'has', 'plasticity', ',', 'and', 'makes', 'adaptive', 'changes', 'after', 'stroke', ',', 'resulting', 'in', 'the', 'reorganization', 'and', 'compensation', 'of', 'neural', 'networks', '.', 'However', ',', 'the', 'muscle', 'tone', 'of', 'some', 'patients', 'will', 'significantly', 'increase', 'during', 'the', 'recovery', 'process', ',', 'which', 'affects', 'the', 'rehabilitation', 'effect', '.', 'Neuromodulation', 'techniques', 'such', 'as', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'have', 'been', 'widely', 'used', 'to', 'promote', 'brain', 'network', 'remodeling', 'after', 'stroke', '.', 'The', 'investigators', 'attempted', 'to', 'evaluate', 'the', 'motor', 'brain', 'network', 'characteristics', 'of', 'spastic', 'patients', 'by', 'fNIRS', ',', 'and', 'used', 'the', 'most', 'active', 'brain', 'regions', 'as', 'rTMS', 'stimulation', 'regions', 'to', 'evaluate', 'the', 'improvement', 'effect', 'of', 'this', 'individualized', 'treatment', 'on', 'post', '-', 'stroke', 'spasticity', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 29,
                "text": "Individualized rTMS",
                "type": "OTHER"
            },
            {
                "start": 63,
                "end": 73,
                "text": "Spasticity",
                "type": "CONDITION"
            },
            {
                "start": 80,
                "end": 86,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 89,
                "end": 95,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 547,
                "end": 591,
                "text": "repetitive transcranial magnetic stimulation",
                "type": "OTHER"
            },
            {
                "start": 593,
                "end": 597,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 663,
                "end": 669,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 754,
                "end": 761,
                "text": "spastic",
                "type": "CONDITION"
            },
            {
                "start": 823,
                "end": 827,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 924,
                "end": 930,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 931,
                "end": 941,
                "text": "spasticity",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02117726",
        "study_official_title": "Impact of Various Sedation Regimens on the Incidence of Post-sedation Delirium in Patients Receiving Mechanical Ventilation ",
        "study_brief_summary": " Sedation drugs that are commonly used in ICU in treatment of ARDS, includes propofol, midazolam and dexmedetomidine . Among these, both dexmedetomidine and propofol have been reported to be used together with midazolam in ICU and the combination of propofol and midazolam is most commonly used, but things follow include a high incidence rate of delirium, But the combination of midazolam and dexmedetomidine may have complementary advantages and could have be a better choice for sedation. In this study, we attempted to observe the effects of two different drug regimens on delirium incidence rates in severe ARDS patients' : midazolam and propofol vs propofol and dexmedetomidine .",
        "text": "Impact of Various Sedation Regimens on the Incidence of Post-sedation Delirium in Patients Receiving Mechanical Ventilation | Sedation drugs that are commonly used in ICU in treatment of ARDS, includes propofol, midazolam and dexmedetomidine . Among these, both dexmedetomidine and propofol have been reported to be used together with midazolam in ICU and the combination of propofol and midazolam is most commonly used, but things follow include a high incidence rate of delirium, But the combination of midazolam and dexmedetomidine may have complementary advantages and could have be a better choice for sedation. In this study, we attempted to observe the effects of two different drug regimens on delirium incidence rates in severe ARDS patients' : midazolam and propofol vs propofol and dexmedetomidine .",
        "tokens": "['Impact', 'of', 'Various', 'Sedation', 'Regimens', 'on', 'the', 'Incidence', 'of', 'Post', '-', 'sedation', 'Delirium', 'in', 'Patients', 'Receiving', 'Mechanical', 'Ventilation', '|', 'Sedation', 'drugs', 'that', 'are', 'commonly', 'used', 'in', 'ICU', 'in', 'treatment', 'of', 'ARDS', ',', 'includes', 'propofol', ',', 'midazolam', 'and', 'dexmedetomidine', '.', 'Among', 'these', ',', 'both', 'dexmedetomidine', 'and', 'propofol', 'have', 'been', 'reported', 'to', 'be', 'used', 'together', 'with', 'midazolam', 'in', 'ICU', 'and', 'the', 'combination', 'of', 'propofol', 'and', 'midazolam', 'is', 'most', 'commonly', 'used', ',', 'but', 'things', 'follow', 'include', 'a', 'high', 'incidence', 'rate', 'of', 'delirium', ',', 'But', 'the', 'combination', 'of', 'midazolam', 'and', 'dexmedetomidine', 'may', 'have', 'complementary', 'advantages', 'and', 'could', 'have', 'be', 'a', 'better', 'choice', 'for', 'sedation', '.', 'In', 'this', 'study', ',', 'we', 'attempted', 'to', 'observe', 'the', 'effects', 'of', 'two', 'different', 'drug', 'regimens', 'on', 'delirium', 'incidence', 'rates', 'in', 'severe', 'ARDS', 'patients', \"'\", ':', 'midazolam', 'and', 'propofol', 'vs', 'propofol', 'and', 'dexmedetomidine', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 35,
                "text": "Sedation Regimens",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 78,
                "text": "Post-sedation Delirium",
                "type": "CONDITION"
            },
            {
                "start": 101,
                "end": 123,
                "text": "Mechanical Ventilation",
                "type": "CONDITION"
            },
            {
                "start": 187,
                "end": 191,
                "text": "ARDS",
                "type": "CONDITION"
            },
            {
                "start": 202,
                "end": 210,
                "text": "propofol",
                "type": "DRUG"
            },
            {
                "start": 212,
                "end": 221,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 226,
                "end": 241,
                "text": "dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 262,
                "end": 277,
                "text": "dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 282,
                "end": 290,
                "text": "propofol",
                "type": "DRUG"
            },
            {
                "start": 335,
                "end": 344,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 375,
                "end": 383,
                "text": "propofol",
                "type": "DRUG"
            },
            {
                "start": 388,
                "end": 397,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 472,
                "end": 480,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 505,
                "end": 514,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 519,
                "end": 534,
                "text": "dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 675,
                "end": 698,
                "text": "different drug regimens",
                "type": "OTHER"
            },
            {
                "start": 702,
                "end": 710,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 737,
                "end": 741,
                "text": "ARDS",
                "type": "CONDITION"
            },
            {
                "start": 754,
                "end": 763,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 768,
                "end": 776,
                "text": "propofol",
                "type": "DRUG"
            },
            {
                "start": 780,
                "end": 788,
                "text": "propofol",
                "type": "DRUG"
            },
            {
                "start": 793,
                "end": 808,
                "text": "dexmedetomidine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00918320",
        "study_official_title": "Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours ",
        "study_brief_summary": " The purpose of the study is to determine whether the combination of Hycamtin (Topotecan) and Temozolomide is effective in the treatment of relapsed and refractory neuroblastoma and other paediatric solid tumors.",
        "text": "Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours | The purpose of the study is to determine whether the combination of Hycamtin (Topotecan) and Temozolomide is effective in the treatment of relapsed and refractory neuroblastoma and other paediatric solid tumors.",
        "tokens": "['Phase', '2', 'Single-', 'Arm', 'Studies', 'of', 'Temozolomide', 'in', 'Combination', 'With', 'Topotecan', 'in', 'Refractory', 'and', 'Relapsed', 'Neuroblastoma', 'and', 'Other', 'Paediatric', 'Solid', 'Tumours', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'whether', 'the', 'combination', 'of', 'Hycamtin', '(', 'Topotecan', ')', 'and', 'Temozolomide', 'is', 'effective', 'in', 'the', 'treatment', 'of', 'relapsed', 'and', 'refractory', 'neuroblastoma', 'and', 'other', 'paediatric', 'solid', 'tumors', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 43,
                "text": "Temozolomide",
                "type": "DRUG"
            },
            {
                "start": 64,
                "end": 73,
                "text": "Topotecan",
                "type": "DRUG"
            },
            {
                "start": 77,
                "end": 114,
                "text": "Refractory and Relapsed Neuroblastoma",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 149,
                "text": "Solid Tumours",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 228,
                "text": "Hycamtin",
                "type": "DRUG"
            },
            {
                "start": 230,
                "end": 239,
                "text": "Topotecan",
                "type": "DRUG"
            },
            {
                "start": 245,
                "end": 257,
                "text": "Temozolomide",
                "type": "DRUG"
            },
            {
                "start": 291,
                "end": 328,
                "text": "relapsed and refractory neuroblastoma",
                "type": "CONDITION"
            },
            {
                "start": 350,
                "end": 362,
                "text": "solid tumors",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03926832",
        "study_official_title": "Prevalence of Obstructive Sleep Apnea Syndrome in Sarcoidosis and Impact of CPAP Treatment on Associated Fatigue Status ",
        "study_brief_summary": " Sarcoidosis is a multisystemic granulomatous disease that affects individuals worldwide without known pathogenesis, and the role of comorbidities has not been fully assessed in the scientific literature. An increased incidence of Obstructive Sleep Apnea Syndrome (OSAS) has been described in Sarcoidosis although this association has not been explained yet and no data is available about the effect of treatment with Continuous Positive Airway Pressure (CPAP) in Sarcoidosis. Also, patients affected by Sarcoidosis usually experience a state of physical and mental weariness called fatigue and reported in approximately 60-80% sarcoid patients and thought to be a consequence of inflammatory mediators but the high prevalence of OSAS could be a remarkable bias in clinical evaluation because fatigue is also strongly associated with sleep disorders.\n\nThus, there is a real need for assessing not only the real prevalence of OSAS in Sarcoidosis but also the effect of CPAP treatment on fatigue status experienced by sarcoidotic patients.",
        "text": "Prevalence of Obstructive Sleep Apnea Syndrome in Sarcoidosis and Impact of CPAP Treatment on Associated Fatigue Status | Sarcoidosis is a multisystemic granulomatous disease that affects individuals worldwide without known pathogenesis, and the role of comorbidities has not been fully assessed in the scientific literature. An increased incidence of Obstructive Sleep Apnea Syndrome (OSAS) has been described in Sarcoidosis although this association has not been explained yet and no data is available about the effect of treatment with Continuous Positive Airway Pressure (CPAP) in Sarcoidosis. Also, patients affected by Sarcoidosis usually experience a state of physical and mental weariness called fatigue and reported in approximately 60-80% sarcoid patients and thought to be a consequence of inflammatory mediators but the high prevalence of OSAS could be a remarkable bias in clinical evaluation because fatigue is also strongly associated with sleep disorders.\n\nThus, there is a real need for assessing not only the real prevalence of OSAS in Sarcoidosis but also the effect of CPAP treatment on fatigue status experienced by sarcoidotic patients.",
        "tokens": "['Prevalence', 'of', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', 'in', 'Sarcoidosis', 'and', 'Impact', 'of', 'CPAP', 'Treatment', 'on', 'Associated', 'Fatigue', 'Status', '|', 'Sarcoidosis', 'is', 'a', 'multisystemic', 'granulomatous', 'disease', 'that', 'affects', 'individuals', 'worldwide', 'without', 'known', 'pathogenesis', ',', 'and', 'the', 'role', 'of', 'comorbidities', 'has', 'not', 'been', 'fully', 'assessed', 'in', 'the', 'scientific', 'literature', '.', 'An', 'increased', 'incidence', 'of', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', '(', 'OSAS', ')', 'has', 'been', 'described', 'in', 'Sarcoidosis', 'although', 'this', 'association', 'has', 'not', 'been', 'explained', 'yet', 'and', 'no', 'data', 'is', 'available', 'about', 'the', 'effect', 'of', 'treatment', 'with', 'Continuous', 'Positive', 'Airway', 'Pressure', '(', 'CPAP', ')', 'in', 'Sarcoidosis', '.', 'Also', ',', 'patients', 'affected', 'by', 'Sarcoidosis', 'usually', 'experience', 'a', 'state', 'of', 'physical', 'and', 'mental', 'weariness', 'called', 'fatigue', 'and', 'reported', 'in', 'approximately', '60', '-', '80', '%', 'sarcoid', 'patients', 'and', 'thought', 'to', 'be', 'a', 'consequence', 'of', 'inflammatory', 'mediators', 'but', 'the', 'high', 'prevalence', 'of', 'OSAS', 'could', 'be', 'a', 'remarkable', 'bias', 'in', 'clinical', 'evaluation', 'because', 'fatigue', 'is', 'also', 'strongly', 'associated', 'with', 'sleep', 'disorders', '.', '\\n\\n', 'Thus', ',', 'there', 'is', 'a', 'real', 'need', 'for', 'assessing', 'not', 'only', 'the', 'real', 'prevalence', 'of', 'OSAS', 'in', 'Sarcoidosis', 'but', 'also', 'the', 'effect', 'of', 'CPAP', 'treatment', 'on', 'fatigue', 'status', 'experienced', 'by', 'sarcoidotic', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 46,
                "text": "Obstructive Sleep Apnea Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 50,
                "end": 61,
                "text": "Sarcoidosis",
                "type": "CONDITION"
            },
            {
                "start": 76,
                "end": 80,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 105,
                "end": 112,
                "text": "Fatigue",
                "type": "CONDITION"
            },
            {
                "start": 122,
                "end": 133,
                "text": "Sarcoidosis",
                "type": "CONDITION"
            },
            {
                "start": 352,
                "end": 384,
                "text": "Obstructive Sleep Apnea Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 386,
                "end": 390,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 414,
                "end": 425,
                "text": "Sarcoidosis",
                "type": "CONDITION"
            },
            {
                "start": 539,
                "end": 574,
                "text": "Continuous Positive Airway Pressure",
                "type": "OTHER"
            },
            {
                "start": 576,
                "end": 580,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 585,
                "end": 596,
                "text": "Sarcoidosis",
                "type": "CONDITION"
            },
            {
                "start": 625,
                "end": 636,
                "text": "Sarcoidosis",
                "type": "CONDITION"
            },
            {
                "start": 704,
                "end": 711,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 749,
                "end": 756,
                "text": "sarcoid",
                "type": "CONDITION"
            },
            {
                "start": 851,
                "end": 855,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 914,
                "end": 921,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 955,
                "end": 970,
                "text": "sleep disorders",
                "type": "CONDITION"
            },
            {
                "start": 1046,
                "end": 1050,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 1054,
                "end": 1065,
                "text": "Sarcoidosis",
                "type": "CONDITION"
            },
            {
                "start": 1089,
                "end": 1093,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 1107,
                "end": 1114,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 1137,
                "end": 1148,
                "text": "sarcoidotic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01726998",
        "study_official_title": "The investigators aimed in this study to investigate the effects of 4 weeks robot-assisted locomotor training on motor recovery of lower extremities and walking ability compared with the conventional gait training in subacute post-stroke non-ambulatory hemiplegic patients.\n\n72 first-ever stroke patients who could not walk independently (FAC < 2), and suffered within 6 months were enrolled and randomly assigned into 2 groups. The subjects with congestive heart failure, malignancies, cardiopulmonary dysfunctions, and who could not walk independently before stroke attack were excluded.\n\nTwo groups received 30 minutes conventional gait training including Neurodevelopmental Treatment (NDT) basically. The robotic assisted locomotor training group received additional robotic-assisted gait therapy for 30minutes with Lokomat\u00ae (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods. The independent walking ability(FAC \u2265 3), Functional Ambulation Category (FAC), Motricity index (MI), Fugl-Meyer assessment (FMA), Modified Barthel Index (MBI), Medical Research Council (MRC) for each lower extremity muscles were assessed before, during (2weeks) and after training. And the independent walking ability were followed until 3 months.",
        "study_brief_summary": null,
        "text": "The investigators aimed in this study to investigate the effects of 4 weeks robot-assisted locomotor training on motor recovery of lower extremities and walking ability compared with the conventional gait training in subacute post-stroke non-ambulatory hemiplegic patients.\n\n72 first-ever stroke patients who could not walk independently (FAC < 2), and suffered within 6 months were enrolled and randomly assigned into 2 groups. The subjects with congestive heart failure, malignancies, cardiopulmonary dysfunctions, and who could not walk independently before stroke attack were excluded.\n\nTwo groups received 30 minutes conventional gait training including Neurodevelopmental Treatment (NDT) basically. The robotic assisted locomotor training group received additional robotic-assisted gait therapy for 30minutes with Lokomat\u00ae (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods. The independent walking ability(FAC \u2265 3), Functional Ambulation Category (FAC), Motricity index (MI), Fugl-Meyer assessment (FMA), Modified Barthel Index (MBI), Medical Research Council (MRC) for each lower extremity muscles were assessed before, during (2weeks) and after training. And the independent walking ability were followed until 3 months.",
        "tokens": "['The', 'investigators', 'aimed', 'in', 'this', 'study', 'to', 'investigate', 'the', 'effects', 'of', '4', 'weeks', 'robot', '-', 'assisted', 'locomotor', 'training', 'on', 'motor', 'recovery', 'of', 'lower', 'extremities', 'and', 'walking', 'ability', 'compared', 'with', 'the', 'conventional', 'gait', 'training', 'in', 'subacute', 'post', '-', 'stroke', 'non', '-', 'ambulatory', 'hemiplegic', 'patients', '.', '\\n\\n', '72', 'first', '-', 'ever', 'stroke', 'patients', 'who', 'could', 'not', 'walk', 'independently', '(', 'FAC', '<', '2', ')', ',', 'and', 'suffered', 'within', '6', 'months', 'were', 'enrolled', 'and', 'randomly', 'assigned', 'into', '2', 'groups', '.', 'The', 'subjects', 'with', 'congestive', 'heart', 'failure', ',', 'malignancies', ',', 'cardiopulmonary', 'dysfunctions', ',', 'and', 'who', 'could', 'not', 'walk', 'independently', 'before', 'stroke', 'attack', 'were', 'excluded', '.', '\\n\\n', 'Two', 'groups', 'received', '30', 'minutes', 'conventional', 'gait', 'training', 'including', 'Neurodevelopmental', 'Treatment', '(', 'NDT', ')', 'basically', '.', 'The', 'robotic', 'assisted', 'locomotor', 'training', 'group', 'received', 'additional', 'robotic', '-', 'assisted', 'gait', 'therapy', 'for', '30minutes', 'with', 'Lokomat', '\u00ae', '(', 'Hocoma', ',', 'Zurich', ',', 'Switzerland', ')', 'daily', 'for', '4', 'weeks', ',', 'and', 'the', 'conventional', 'gait', 'training', 'group', 'received', 'additional', 'daily', 'conventional', 'gait', 'training', 'with', 'NDT', 'for', 'the', 'same', 'periods', '.', 'The', 'independent', 'walking', 'ability(FAC', '\u2265', '3', ')', ',', 'Functional', 'Ambulation', 'Category', '(', 'FAC', ')', ',', 'Motricity', 'index', '(', 'MI', ')', ',', 'Fugl', '-', 'Meyer', 'assessment', '(', 'FMA', ')', ',', 'Modified', 'Barthel', 'Index', '(', 'MBI', ')', ',', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'for', 'each', 'lower', 'extremity', 'muscles', 'were', 'assessed', 'before', ',', 'during', '(', '2weeks', ')', 'and', 'after', 'training', '.', 'And', 'the', 'independent', 'walking', 'ability', 'were', 'followed', 'until', '3', 'months', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 76,
                "end": 109,
                "text": "robot-assisted locomotor training",
                "type": "PHYSICAL"
            },
            {
                "start": 187,
                "end": 213,
                "text": "conventional gait training",
                "type": "CONTROL"
            },
            {
                "start": 217,
                "end": 263,
                "text": "subacute post-stroke non-ambulatory hemiplegic",
                "type": "CONDITION"
            },
            {
                "start": 278,
                "end": 295,
                "text": "first-ever stroke",
                "type": "CONDITION"
            },
            {
                "start": 561,
                "end": 567,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 622,
                "end": 648,
                "text": "conventional gait training",
                "type": "CONTROL"
            },
            {
                "start": 659,
                "end": 687,
                "text": "Neurodevelopmental Treatment",
                "type": "CONTROL"
            },
            {
                "start": 689,
                "end": 692,
                "text": "NDT",
                "type": "CONTROL"
            },
            {
                "start": 709,
                "end": 744,
                "text": "robotic assisted locomotor training",
                "type": "PHYSICAL"
            },
            {
                "start": 771,
                "end": 800,
                "text": "robotic-assisted gait therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 820,
                "end": 827,
                "text": "Lokomat",
                "type": "PHYSICAL"
            },
            {
                "start": 945,
                "end": 971,
                "text": "conventional gait training",
                "type": "CONTROL"
            },
            {
                "start": 977,
                "end": 980,
                "text": "NDT",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT02116140",
        "study_official_title": "Effects of Long Term Adaptive Servo Ventilation Therapy on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea. The AMEND Sub-study ",
        "study_brief_summary": " Obstructive sleep apnea (OSA), central sleep apnea (CSA) and heart failure (HF) are states of metabolic demand and sympathetic nervous system (SNS) activation. In patients with sleep apnea and HF, continuous positive airway pressure (CPAP) initially may reduce left ventricular (LV)stroke volume (SV) but subsequently improves and LV function. This may relate to an early beneficial effect on myocardial energetics through early reduction in metabolic demand that subsequently leads to improved efficiency of LV contraction. However, it is not clear whether long-term adaptive servo-ventilation (ASV) favorably affects cardiac energetics. Any such benefit may also relate to reduced sympathetic nervous system (SNS) activation. However its effect on myocardial SNS function is also not well studied.\n\nIn a pilot study we demonstrated early (6 week) beneficial effects of CPAP in patients with OSA and HF. The current proposal (AMEND) is a unique substudy of the recently funded ADVENT-HF trial (Adaptive Servo Ventilation for Therapy of Sleep Apnea in HeartFailure) (NCT01128816; CIHR; D. Bradley, PI).\n\nWe propose to evaluate the long-term (6 month) effects of ASV on daytime 1) oxidative metabolism; 2) the work metabolic index (WMI) as an estimate of mechanical efficiency; 3) myocardial sympathetic nerve (SN) pre-synaptic function; and 4) heart rate (HR) variability in patients with HF and coexisting OSA or CSA. In conjunction with echocardiographic measures of LV stroke work, positron emission tomography (PET) derived [11C] acetate kinetics will be used as a measure of oxidative metabolism, to determine the WMI. [11C] hydroxyephedrine (HED) retention will be used to measure cardiac SN pre-synaptic function.\n\nPrimary Hypotheses: In patients with chronic stable HF and CSA or OSA without excessive daytime sleepiness (EDS), long-term (6-month) ASV therapy yields:\n\nBeneficial effects on daytime myocardial metabolism leading to a reduction in the rate of oxidative metabolism as measured by [11C]acetate kinetics using PET imaging;\nImprovement in energy transduction from oxidative metabolism to stroke work as measured by an increase in the daytime work-metabolic index.",
        "text": "Effects of Long Term Adaptive Servo Ventilation Therapy on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea. The AMEND Sub-study | Obstructive sleep apnea (OSA), central sleep apnea (CSA) and heart failure (HF) are states of metabolic demand and sympathetic nervous system (SNS) activation. In patients with sleep apnea and HF, continuous positive airway pressure (CPAP) initially may reduce left ventricular (LV)stroke volume (SV) but subsequently improves and LV function. This may relate to an early beneficial effect on myocardial energetics through early reduction in metabolic demand that subsequently leads to improved efficiency of LV contraction. However, it is not clear whether long-term adaptive servo-ventilation (ASV) favorably affects cardiac energetics. Any such benefit may also relate to reduced sympathetic nervous system (SNS) activation. However its effect on myocardial SNS function is also not well studied.\n\nIn a pilot study we demonstrated early (6 week) beneficial effects of CPAP in patients with OSA and HF. The current proposal (AMEND) is a unique substudy of the recently funded ADVENT-HF trial (Adaptive Servo Ventilation for Therapy of Sleep Apnea in HeartFailure) (NCT01128816; CIHR; D. Bradley, PI).\n\nWe propose to evaluate the long-term (6 month) effects of ASV on daytime 1) oxidative metabolism; 2) the work metabolic index (WMI) as an estimate of mechanical efficiency; 3) myocardial sympathetic nerve (SN) pre-synaptic function; and 4) heart rate (HR) variability in patients with HF and coexisting OSA or CSA. In conjunction with echocardiographic measures of LV stroke work, positron emission tomography (PET) derived [11C] acetate kinetics will be used as a measure of oxidative metabolism, to determine the WMI. [11C] hydroxyephedrine (HED) retention will be used to measure cardiac SN pre-synaptic function.\n\nPrimary Hypotheses: In patients with chronic stable HF and CSA or OSA without excessive daytime sleepiness (EDS), long-term (6-month) ASV therapy yields:\n\nBeneficial effects on daytime myocardial metabolism leading to a reduction in the rate of oxidative metabolism as measured by [11C]acetate kinetics using PET imaging;\nImprovement in energy transduction from oxidative metabolism to stroke work as measured by an increase in the daytime work-metabolic index.",
        "tokens": "['Effects', 'of', 'Long', 'Term', 'Adaptive', 'Servo', 'Ventilation', 'Therapy', 'on', 'Myocardial', 'Energetics', 'and', 'Sympathetic', 'Nerve', 'Function', 'in', 'Heart', 'Failure', 'and', 'Sleep', 'Apnea', '.', 'The', 'AMEND', 'Sub', '-', 'study', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'central', 'sleep', 'apnea', '(', 'CSA', ')', 'and', 'heart', 'failure', '(', 'HF', ')', 'are', 'states', 'of', 'metabolic', 'demand', 'and', 'sympathetic', 'nervous', 'system', '(', 'SNS', ')', 'activation', '.', 'In', 'patients', 'with', 'sleep', 'apnea', 'and', 'HF', ',', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'initially', 'may', 'reduce', 'left', 'ventricular', '(', 'LV)stroke', 'volume', '(', 'SV', ')', 'but', 'subsequently', 'improves', 'and', 'LV', 'function', '.', 'This', 'may', 'relate', 'to', 'an', 'early', 'beneficial', 'effect', 'on', 'myocardial', 'energetics', 'through', 'early', 'reduction', 'in', 'metabolic', 'demand', 'that', 'subsequently', 'leads', 'to', 'improved', 'efficiency', 'of', 'LV', 'contraction', '.', 'However', ',', 'it', 'is', 'not', 'clear', 'whether', 'long', '-', 'term', 'adaptive', 'servo', '-', 'ventilation', '(', 'ASV', ')', 'favorably', 'affects', 'cardiac', 'energetics', '.', 'Any', 'such', 'benefit', 'may', 'also', 'relate', 'to', 'reduced', 'sympathetic', 'nervous', 'system', '(', 'SNS', ')', 'activation', '.', 'However', 'its', 'effect', 'on', 'myocardial', 'SNS', 'function', 'is', 'also', 'not', 'well', 'studied', '.', '\\n\\n', 'In', 'a', 'pilot', 'study', 'we', 'demonstrated', 'early', '(', '6', 'week', ')', 'beneficial', 'effects', 'of', 'CPAP', 'in', 'patients', 'with', 'OSA', 'and', 'HF', '.', 'The', 'current', 'proposal', '(', 'AMEND', ')', 'is', 'a', 'unique', 'substudy', 'of', 'the', 'recently', 'funded', 'ADVENT', '-', 'HF', 'trial', '(', 'Adaptive', 'Servo', 'Ventilation', 'for', 'Therapy', 'of', 'Sleep', 'Apnea', 'in', 'HeartFailure', ')', '(', 'NCT01128816', ';', 'CIHR', ';', 'D.', 'Bradley', ',', 'PI', ')', '.', '\\n\\n', 'We', 'propose', 'to', 'evaluate', 'the', 'long', '-', 'term', '(', '6', 'month', ')', 'effects', 'of', 'ASV', 'on', 'daytime', '1', ')', 'oxidative', 'metabolism', ';', '2', ')', 'the', 'work', 'metabolic', 'index', '(', 'WMI', ')', 'as', 'an', 'estimate', 'of', 'mechanical', 'efficiency', ';', '3', ')', 'myocardial', 'sympathetic', 'nerve', '(', 'SN', ')', 'pre', '-', 'synaptic', 'function', ';', 'and', '4', ')', 'heart', 'rate', '(', 'HR', ')', 'variability', 'in', 'patients', 'with', 'HF', 'and', 'coexisting', 'OSA', 'or', 'CSA', '.', 'In', 'conjunction', 'with', 'echocardiographic', 'measures', 'of', 'LV', 'stroke', 'work', ',', 'positron', 'emission', 'tomography', '(', 'PET', ')', 'derived', '[', '11C', ']', 'acetate', 'kinetics', 'will', 'be', 'used', 'as', 'a', 'measure', 'of', 'oxidative', 'metabolism', ',', 'to', 'determine', 'the', 'WMI', '.', '[', '11C', ']', 'hydroxyephedrine', '(', 'HED', ')', 'retention', 'will', 'be', 'used', 'to', 'measure', 'cardiac', 'SN', 'pre', '-', 'synaptic', 'function', '.', '\\n\\n', 'Primary', 'Hypotheses', ':', 'In', 'patients', 'with', 'chronic', 'stable', 'HF', 'and', 'CSA', 'or', 'OSA', 'without', 'excessive', 'daytime', 'sleepiness', '(', 'EDS', ')', ',', 'long', '-', 'term', '(', '6', '-', 'month', ')', 'ASV', 'therapy', 'yields', ':', '\\n\\n', 'Beneficial', 'effects', 'on', 'daytime', 'myocardial', 'metabolism', 'leading', 'to', 'a', 'reduction', 'in', 'the', 'rate', 'of', 'oxidative', 'metabolism', 'as', 'measured', 'by', '[', '11C]acetate', 'kinetics', 'using', 'PET', 'imaging', ';', '\\n', 'Improvement', 'in', 'energy', 'transduction', 'from', 'oxidative', 'metabolism', 'to', 'stroke', 'work', 'as', 'measured', 'by', 'an', 'increase', 'in', 'the', 'daytime', 'work', '-', 'metabolic', 'index', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 55,
                "text": "Adaptive Servo Ventilation Therapy",
                "type": "OTHER"
            },
            {
                "start": 115,
                "end": 128,
                "text": "Heart Failure",
                "type": "CONDITION"
            },
            {
                "start": 133,
                "end": 144,
                "text": "Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 168,
                "end": 191,
                "text": "Obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 193,
                "end": 196,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 199,
                "end": 218,
                "text": "central sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 223,
                "text": "CSA",
                "type": "CONDITION"
            },
            {
                "start": 229,
                "end": 242,
                "text": "heart failure",
                "type": "CONDITION"
            },
            {
                "start": 244,
                "end": 246,
                "text": "HF",
                "type": "CONDITION"
            },
            {
                "start": 345,
                "end": 356,
                "text": "sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 361,
                "end": 363,
                "text": "HF",
                "type": "CONDITION"
            },
            {
                "start": 365,
                "end": 400,
                "text": "continuous positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 402,
                "end": 406,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 736,
                "end": 762,
                "text": "adaptive servo-ventilation",
                "type": "OTHER"
            },
            {
                "start": 764,
                "end": 767,
                "text": "ASV",
                "type": "OTHER"
            },
            {
                "start": 1039,
                "end": 1043,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 1061,
                "end": 1064,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 1069,
                "end": 1071,
                "text": "HF",
                "type": "CONDITION"
            },
            {
                "start": 1163,
                "end": 1189,
                "text": "Adaptive Servo Ventilation",
                "type": "OTHER"
            },
            {
                "start": 1205,
                "end": 1216,
                "text": "Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 1220,
                "end": 1232,
                "text": "HeartFailure",
                "type": "CONDITION"
            },
            {
                "start": 1330,
                "end": 1333,
                "text": "ASV",
                "type": "OTHER"
            },
            {
                "start": 1557,
                "end": 1559,
                "text": "HF",
                "type": "CONDITION"
            },
            {
                "start": 1575,
                "end": 1578,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 1582,
                "end": 1585,
                "text": "CSA",
                "type": "CONDITION"
            },
            {
                "start": 1927,
                "end": 1944,
                "text": "chronic stable HF",
                "type": "CONDITION"
            },
            {
                "start": 1949,
                "end": 1952,
                "text": "CSA",
                "type": "CONDITION"
            },
            {
                "start": 1956,
                "end": 1959,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 2024,
                "end": 2027,
                "text": "ASV",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01518439",
        "study_official_title": "Instrumental and Manual Increase of Couch in Neuromuscular Patients: Effects of Different Techniques on the Generated Flow ",
        "study_brief_summary": " Inefficient cough is responsible of respiratory complications in neuromuscular patients which can lead to hospitalisation and can be life threatening. Techniques enhancing cough efficiency are successful in improving the clearance of bronchial secretions and help non invasive ventilation efficiency especially in case of acute respiratory failure. Combining mechanical exsufflation to the manual techniques of physiotherapy might enhance efficiency. Therefore the investigators want to compare cough efficiency under different techniques of instrumental and manual of cough assistance in order to determine the best combination to optimize cough flow.",
        "text": "Instrumental and Manual Increase of Couch in Neuromuscular Patients: Effects of Different Techniques on the Generated Flow | Inefficient cough is responsible of respiratory complications in neuromuscular patients which can lead to hospitalisation and can be life threatening. Techniques enhancing cough efficiency are successful in improving the clearance of bronchial secretions and help non invasive ventilation efficiency especially in case of acute respiratory failure. Combining mechanical exsufflation to the manual techniques of physiotherapy might enhance efficiency. Therefore the investigators want to compare cough efficiency under different techniques of instrumental and manual of cough assistance in order to determine the best combination to optimize cough flow.",
        "tokens": "['Instrumental', 'and', 'Manual', 'Increase', 'of', 'Couch', 'in', 'Neuromuscular', 'Patients', ':', 'Effects', 'of', 'Different', 'Techniques', 'on', 'the', 'Generated', 'Flow', '|', 'Inefficient', 'cough', 'is', 'responsible', 'of', 'respiratory', 'complications', 'in', 'neuromuscular', 'patients', 'which', 'can', 'lead', 'to', 'hospitalisation', 'and', 'can', 'be', 'life', 'threatening', '.', 'Techniques', 'enhancing', 'cough', 'efficiency', 'are', 'successful', 'in', 'improving', 'the', 'clearance', 'of', 'bronchial', 'secretions', 'and', 'help', 'non', 'invasive', 'ventilation', 'efficiency', 'especially', 'in', 'case', 'of', 'acute', 'respiratory', 'failure', '.', 'Combining', 'mechanical', 'exsufflation', 'to', 'the', 'manual', 'techniques', 'of', 'physiotherapy', 'might', 'enhance', 'efficiency', '.', 'Therefore', 'the', 'investigators', 'want', 'to', 'compare', 'cough', 'efficiency', 'under', 'different', 'techniques', 'of', 'instrumental', 'and', 'manual', 'of', 'cough', 'assistance', 'in', 'order', 'to', 'determine', 'the', 'best', 'combination', 'to', 'optimize', 'cough', 'flow', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 45,
                "end": 58,
                "text": "Neuromuscular",
                "type": "CONDITION"
            },
            {
                "start": 125,
                "end": 142,
                "text": "Inefficient cough",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 203,
                "text": "neuromuscular",
                "type": "CONDITION"
            },
            {
                "start": 447,
                "end": 472,
                "text": "acute respiratory failure",
                "type": "CONDITION"
            },
            {
                "start": 484,
                "end": 507,
                "text": "mechanical exsufflation",
                "type": "OTHER"
            },
            {
                "start": 515,
                "end": 549,
                "text": "manual techniques of physiotherapy",
                "type": "OTHER"
            },
            {
                "start": 667,
                "end": 710,
                "text": "instrumental and manual of cough assistance",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04220606",
        "study_official_title": "Glutamate Concentrations in the Brain Over the Course of a Migraine-like Attack ",
        "study_brief_summary": " To investigate the glutaminergic system in the onset of migraine-like attacks.",
        "text": "Glutamate Concentrations in the Brain Over the Course of a Migraine-like Attack | To investigate the glutaminergic system in the onset of migraine-like attacks.",
        "tokens": "['Glutamate', 'Concentrations', 'in', 'the', 'Brain', 'Over', 'the', 'Course', 'of', 'a', 'Migraine', '-', 'like', 'Attack', '|', 'To', 'investigate', 'the', 'glutaminergic', 'system', 'in', 'the', 'onset', 'of', 'migraine', '-', 'like', 'attacks', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 59,
                "end": 79,
                "text": "Migraine-like Attack",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 159,
                "text": "migraine-like attacks",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05747924",
        "study_official_title": "A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) ",
        "study_brief_summary": " A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)",
        "text": "A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Phase', '1/2', 'Study', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', ',', 'Pharmacodynamics', ',', 'and', 'Exploratory', 'Efficacy', 'of', 'AOC', '1020', 'Administered', 'Intravenously', 'to', 'Adult', 'Participants', 'With', 'Facioscapulohumeral', 'Muscular', 'Dystrophy', '(', 'FSHD', ')', '|', 'A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Phase', '1/2', 'Study', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', ',', 'Pharmacodynamics', ',', 'and', 'Exploratory', 'Efficacy', 'of', 'AOC', '1020', 'Administered', 'Intravenously', 'to', 'Adult', 'Participants', 'with', 'Facioscapulohumeral', 'Muscular', 'Dystrophy', '(', 'FSHD', ')']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 166,
                "end": 174,
                "text": "AOC 1020",
                "type": "DRUG"
            },
            {
                "start": 229,
                "end": 267,
                "text": "Facioscapulohumeral Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 269,
                "end": 273,
                "text": "FSHD",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 312,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 443,
                "end": 451,
                "text": "AOC 1020",
                "type": "DRUG"
            },
            {
                "start": 506,
                "end": 544,
                "text": "Facioscapulohumeral Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 546,
                "end": 550,
                "text": "FSHD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01021696",
        "study_official_title": "The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial ",
        "study_brief_summary": " In nursing homes (NHs) 80% of the patients have dementia, between 60%-80% exhibit behavioural disturbances (BPSD), and more than 60% have pain. Both pain and BPSD is more common in those with severe dementia. Since older persons with dementia have less communicative skills, suffer from more pain and exhibit more agitation, pain may be a contributing factor in these patients. More than 40% of patients with BPSD are treated with neuroleptics despite described side-effects. There is an urgent need to investigate the impact of individual pain management on BPSD in patients with dementia.\n\nIt was hypothesized that\n\npain increase BPSD in patients with dementia\nindividual pain treatment decrease BPSD in patients with dementia",
        "text": "The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial | In nursing homes (NHs) 80% of the patients have dementia, between 60%-80% exhibit behavioural disturbances (BPSD), and more than 60% have pain. Both pain and BPSD is more common in those with severe dementia. Since older persons with dementia have less communicative skills, suffer from more pain and exhibit more agitation, pain may be a contributing factor in these patients. More than 40% of patients with BPSD are treated with neuroleptics despite described side-effects. There is an urgent need to investigate the impact of individual pain management on BPSD in patients with dementia.\n\nIt was hypothesized that\n\npain increase BPSD in patients with dementia\nindividual pain treatment decrease BPSD in patients with dementia",
        "tokens": "['The', 'Impact', 'of', 'Pain', 'on', 'Behavioural', 'Disturbances', 'in', 'Patients', 'With', 'Moderate', 'and', 'Severe', 'Dementia', '.', 'A', 'Cluster', 'Randomized', 'Trial', '|', 'In', 'nursing', 'homes', '(', 'NHs', ')', '80', '%', 'of', 'the', 'patients', 'have', 'dementia', ',', 'between', '60%-80', '%', 'exhibit', 'behavioural', 'disturbances', '(', 'BPSD', ')', ',', 'and', 'more', 'than', '60', '%', 'have', 'pain', '.', 'Both', 'pain', 'and', 'BPSD', 'is', 'more', 'common', 'in', 'those', 'with', 'severe', 'dementia', '.', 'Since', 'older', 'persons', 'with', 'dementia', 'have', 'less', 'communicative', 'skills', ',', 'suffer', 'from', 'more', 'pain', 'and', 'exhibit', 'more', 'agitation', ',', 'pain', 'may', 'be', 'a', 'contributing', 'factor', 'in', 'these', 'patients', '.', 'More', 'than', '40', '%', 'of', 'patients', 'with', 'BPSD', 'are', 'treated', 'with', 'neuroleptics', 'despite', 'described', 'side', '-', 'effects', '.', 'There', 'is', 'an', 'urgent', 'need', 'to', 'investigate', 'the', 'impact', 'of', 'individual', 'pain', 'management', 'on', 'BPSD', 'in', 'patients', 'with', 'dementia', '.', '\\n\\n', 'It', 'was', 'hypothesized', 'that', '\\n\\n', 'pain', 'increase', 'BPSD', 'in', 'patients', 'with', 'dementia', '\\n', 'individual', 'pain', 'treatment', 'decrease', 'BPSD', 'in', 'patients', 'with', 'dementia']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND']",
        "entities": [
            {
                "start": 22,
                "end": 46,
                "text": "Behavioural Disturbances",
                "type": "CONDITION"
            },
            {
                "start": 64,
                "end": 92,
                "text": "Moderate and Severe Dementia",
                "type": "CONDITION"
            },
            {
                "start": 171,
                "end": 179,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 205,
                "end": 229,
                "text": "behavioural disturbances",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 235,
                "text": "BPSD",
                "type": "CONDITION"
            },
            {
                "start": 281,
                "end": 285,
                "text": "BPSD",
                "type": "CONDITION"
            },
            {
                "start": 315,
                "end": 330,
                "text": "severe dementia",
                "type": "CONDITION"
            },
            {
                "start": 357,
                "end": 365,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 532,
                "end": 536,
                "text": "BPSD",
                "type": "CONDITION"
            },
            {
                "start": 652,
                "end": 678,
                "text": "individual pain management",
                "type": "OTHER"
            },
            {
                "start": 682,
                "end": 686,
                "text": "BPSD",
                "type": "CONDITION"
            },
            {
                "start": 704,
                "end": 712,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 755,
                "end": 759,
                "text": "BPSD",
                "type": "CONDITION"
            },
            {
                "start": 777,
                "end": 785,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 786,
                "end": 811,
                "text": "individual pain treatment",
                "type": "OTHER"
            },
            {
                "start": 821,
                "end": 825,
                "text": "BPSD",
                "type": "CONDITION"
            },
            {
                "start": 843,
                "end": 851,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02467153",
        "study_official_title": "Influence of Combined Vitamin D Supplementation and Resistance Exercise Training on Musculoskeletal Health in Frail Older Men and Women (EXVITD) ",
        "study_brief_summary": " This study aims to determine whether vitamin D3 supplementation is any more effective in improving musculoskeletal function when combined with exercise training compared with exercise training alone.",
        "text": "Influence of Combined Vitamin D Supplementation and Resistance Exercise Training on Musculoskeletal Health in Frail Older Men and Women (EXVITD) | This study aims to determine whether vitamin D3 supplementation is any more effective in improving musculoskeletal function when combined with exercise training compared with exercise training alone.",
        "tokens": "['Influence', 'of', 'Combined', 'Vitamin', 'D', 'Supplementation', 'and', 'Resistance', 'Exercise', 'Training', 'on', 'Musculoskeletal', 'Health', 'in', 'Frail', 'Older', 'Men', 'and', 'Women', '(', 'EXVITD', ')', '|', 'This', 'study', 'aims', 'to', 'determine', 'whether', 'vitamin', 'D3', 'supplementation', 'is', 'any', 'more', 'effective', 'in', 'improving', 'musculoskeletal', 'function', 'when', 'combined', 'with', 'exercise', 'training', 'compared', 'with', 'exercise', 'training', 'alone', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 31,
                "text": "Vitamin D",
                "type": "DRUG"
            },
            {
                "start": 52,
                "end": 80,
                "text": "Resistance Exercise Training",
                "type": "PHYSICAL"
            },
            {
                "start": 110,
                "end": 115,
                "text": "Frail",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 194,
                "text": "vitamin D3",
                "type": "DRUG"
            },
            {
                "start": 290,
                "end": 307,
                "text": "exercise training",
                "type": "PHYSICAL"
            },
            {
                "start": 322,
                "end": 345,
                "text": "exercise training alone",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02800083",
        "study_official_title": "A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment ",
        "study_brief_summary": " The study primary end point is the decrease in the number of monthly heavy drinking days (HDD) (\u2265 60 g/day in men and \u2265 40 g/d in women) from baseline to the end of the double blind Randomized Treatment (RT).\n\nThe Secondary end points will be designed to assess safety and tolerability and to further investigate the effect of pitolisant on other alcohol use criteria (e.g. total alcohol consumption, number of abstinence days), craving as well as the improvement in mental health (depression, sleep) and quality of life.\n\nTotal alcohol consumption (TAC) from baseline to end of treatment. TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).\nPercent of patients without HDDs during the 24 weeks RT phase of the study. (Continuous Controlled Drinking=CCD)\nPercent of Abstinent Days during RT phase (PAD)\nContinuous Abstinence Duration from baseline during 24 weeks RT phase (CAD)\n4-week point prevalence abstinence at end of treatment\nImprovement in alcohol biomarkers (e.g. ALAT, ASAT, % CDT) during 24 week RT phase\nCraving (Obsessive Compulsive Drinking Scale) during 24 week RT phase\nBeck Depression Inventory (BDI) during 24 week RT phase\nQuality of sleep (Pittsburgh Sleep Quality Index) during RT phase.\nTreatment retention during 24 week RT\nQuality of life (SF-12) during RT phase\nPercent patients without HDDs during the OL follow up period\nQuality of life (SF-12) during OL phase\nQuality of sleep (Pittsburgh Sleep Quality Index) during OL phase\nTreatment retention OL phase Safety will be assessed by evaluation of treatment emergent adverse events (TEAE), physical examinations, clinical laboratory tests (blood chemistry, hematology, and urinalysis), subsequent end of treatment potential withdrawal, evaluation scales and physical examination, measurement of heart rate, blood pressure, and body weight at each study visit )V0-FU5). If at ECG Fridericia's corrected QT interval \u2265 500 ms or if difference to baseline is \u2265 60 ms it will be required to check ECG by second measurement after lying down 10 minutes.",
        "text": "A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment | The study primary end point is the decrease in the number of monthly heavy drinking days (HDD) (\u2265 60 g/day in men and \u2265 40 g/d in women) from baseline to the end of the double blind Randomized Treatment (RT).\n\nThe Secondary end points will be designed to assess safety and tolerability and to further investigate the effect of pitolisant on other alcohol use criteria (e.g. total alcohol consumption, number of abstinence days), craving as well as the improvement in mental health (depression, sleep) and quality of life.\n\nTotal alcohol consumption (TAC) from baseline to end of treatment. TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).\nPercent of patients without HDDs during the 24 weeks RT phase of the study. (Continuous Controlled Drinking=CCD)\nPercent of Abstinent Days during RT phase (PAD)\nContinuous Abstinence Duration from baseline during 24 weeks RT phase (CAD)\n4-week point prevalence abstinence at end of treatment\nImprovement in alcohol biomarkers (e.g. ALAT, ASAT, % CDT) during 24 week RT phase\nCraving (Obsessive Compulsive Drinking Scale) during 24 week RT phase\nBeck Depression Inventory (BDI) during 24 week RT phase\nQuality of sleep (Pittsburgh Sleep Quality Index) during RT phase.\nTreatment retention during 24 week RT\nQuality of life (SF-12) during RT phase\nPercent patients without HDDs during the OL follow up period\nQuality of life (SF-12) during OL phase\nQuality of sleep (Pittsburgh Sleep Quality Index) during OL phase\nTreatment retention OL phase Safety will be assessed by evaluation of treatment emergent adverse events (TEAE), physical examinations, clinical laboratory tests (blood chemistry, hematology, and urinalysis), subsequent end of treatment potential withdrawal, evaluation scales and physical examination, measurement of heart rate, blood pressure, and body weight at each study visit )V0-FU5). If at ECG Fridericia's corrected QT interval \u2265 500 ms or if difference to baseline is \u2265 60 ms it will be required to check ECG by second measurement after lying down 10 minutes.",
        "tokens": "['A', 'Multisite', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Trial', 'Evaluating', 'Pitolisant', '(', 'BF2.649', ')', 'For', 'Alcohol', 'Use', 'Disorder', 'Treatment', '|', 'The', 'study', 'primary', 'end', 'point', 'is', 'the', 'decrease', 'in', 'the', 'number', 'of', 'monthly', 'heavy', 'drinking', 'days', '(', 'HDD', ')', '(', '\u2265', '60', 'g', '/', 'day', 'in', 'men', 'and', '\u2265', '40', 'g', '/', 'd', 'in', 'women', ')', 'from', 'baseline', 'to', 'the', 'end', 'of', 'the', 'double', 'blind', 'Randomized', 'Treatment', '(', 'RT', ')', '.', '\\n\\n', 'The', 'Secondary', 'end', 'points', 'will', 'be', 'designed', 'to', 'assess', 'safety', 'and', 'tolerability', 'and', 'to', 'further', 'investigate', 'the', 'effect', 'of', 'pitolisant', 'on', 'other', 'alcohol', 'use', 'criteria', '(', 'e.g.', 'total', 'alcohol', 'consumption', ',', 'number', 'of', 'abstinence', 'days', ')', ',', 'craving', 'as', 'well', 'as', 'the', 'improvement', 'in', 'mental', 'health', '(', 'depression', ',', 'sleep', ')', 'and', 'quality', 'of', 'life', '.', '\\n\\n', 'Total', 'alcohol', 'consumption', '(', 'TAC', ')', 'from', 'baseline', 'to', 'end', 'of', 'treatment', '.', 'TAC', 'was', 'defined', 'as', 'mean', 'daily', 'alcohol', 'consumption', 'in', 'g', '/', 'day', 'over', 'a', 'month', '(', '28', 'days', ')', '.', '\\n', 'Percent', 'of', 'patients', 'without', 'HDDs', 'during', 'the', '24', 'weeks', 'RT', 'phase', 'of', 'the', 'study', '.', '(', 'Continuous', 'Controlled', 'Drinking', '=', 'CCD', ')', '\\n', 'Percent', 'of', 'Abstinent', 'Days', 'during', 'RT', 'phase', '(', 'PAD', ')', '\\n', 'Continuous', 'Abstinence', 'Duration', 'from', 'baseline', 'during', '24', 'weeks', 'RT', 'phase', '(', 'CAD', ')', '\\n', '4', '-', 'week', 'point', 'prevalence', 'abstinence', 'at', 'end', 'of', 'treatment', '\\n', 'Improvement', 'in', 'alcohol', 'biomarkers', '(', 'e.g.', 'ALAT', ',', 'ASAT', ',', '%', 'CDT', ')', 'during', '24', 'week', 'RT', 'phase', '\\n', 'Craving', '(', 'Obsessive', 'Compulsive', 'Drinking', 'Scale', ')', 'during', '24', 'week', 'RT', 'phase', '\\n', 'Beck', 'Depression', 'Inventory', '(', 'BDI', ')', 'during', '24', 'week', 'RT', 'phase', '\\n', 'Quality', 'of', 'sleep', '(', 'Pittsburgh', 'Sleep', 'Quality', 'Index', ')', 'during', 'RT', 'phase', '.', '\\n', 'Treatment', 'retention', 'during', '24', 'week', 'RT', '\\n', 'Quality', 'of', 'life', '(', 'SF-12', ')', 'during', 'RT', 'phase', '\\n', 'Percent', 'patients', 'without', 'HDDs', 'during', 'the', 'OL', 'follow', 'up', 'period', '\\n', 'Quality', 'of', 'life', '(', 'SF-12', ')', 'during', 'OL', 'phase', '\\n', 'Quality', 'of', 'sleep', '(', 'Pittsburgh', 'Sleep', 'Quality', 'Index', ')', 'during', 'OL', 'phase', '\\n', 'Treatment', 'retention', 'OL', 'phase', 'Safety', 'will', 'be', 'assessed', 'by', 'evaluation', 'of', 'treatment', 'emergent', 'adverse', 'events', '(', 'TEAE', ')', ',', 'physical', 'examinations', ',', 'clinical', 'laboratory', 'tests', '(', 'blood', 'chemistry', ',', 'hematology', ',', 'and', 'urinalysis', ')', ',', 'subsequent', 'end', 'of', 'treatment', 'potential', 'withdrawal', ',', 'evaluation', 'scales', 'and', 'physical', 'examination', ',', 'measurement', 'of', 'heart', 'rate', ',', 'blood', 'pressure', ',', 'and', 'body', 'weight', 'at', 'each', 'study', 'visit', ')', 'V0', '-', 'FU5', ')', '.', 'If', 'at', 'ECG', 'Fridericia', \"'s\", 'corrected', 'QT', 'interval', '\u2265', '500', 'ms', 'or', 'if', 'difference', 'to', 'baseline', 'is', '\u2265', '60', 'ms', 'it', 'will', 'be', 'required', 'to', 'check', 'ECG', 'by', 'second', 'measurement', 'after', 'lying', 'down', '10', 'minutes', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 38,
                "end": 45,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 74,
                "end": 84,
                "text": "Pitolisant",
                "type": "DRUG"
            },
            {
                "start": 86,
                "end": 93,
                "text": "BF2.649",
                "type": "DRUG"
            },
            {
                "start": 99,
                "end": 119,
                "text": "Alcohol Use Disorder",
                "type": "CONDITION"
            },
            {
                "start": 459,
                "end": 469,
                "text": "pitolisant",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03540602",
        "study_official_title": "Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise ",
        "study_brief_summary": " Strength training is commonly used as an intervention to increase muscle mass, thus improving a person's ability to undertake activities of daily living, or enhance athletic performance. The strength training regimen itself, while ultimately having beneficial effects, causes muscle fibers to be damaged, which the body has to recover from. As the body recovers, it rebuilds the muscle tissue and after multiple consecutive bouts of strength training, the muscle eventually becomes larger and stronger. Thus, it is the recovery from strength training exercise that ultimately determines how well the body adapts. Where inadequate recovery could eventually lead to overtraining and/or injury, optimizing the recovery process from strength training could maximize strength training adaptations. This concept of optimizing recovery has led to development of many supplements, including antioxidants, which may reduce the damage associated with strength training activities and therefore enhance positive adaptations. The purpose of this study is to assess the ability of a polyphenol rich supplementation to aid the recovery process from a demanding bout of resistance exercise",
        "text": "Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise | Strength training is commonly used as an intervention to increase muscle mass, thus improving a person's ability to undertake activities of daily living, or enhance athletic performance. The strength training regimen itself, while ultimately having beneficial effects, causes muscle fibers to be damaged, which the body has to recover from. As the body recovers, it rebuilds the muscle tissue and after multiple consecutive bouts of strength training, the muscle eventually becomes larger and stronger. Thus, it is the recovery from strength training exercise that ultimately determines how well the body adapts. Where inadequate recovery could eventually lead to overtraining and/or injury, optimizing the recovery process from strength training could maximize strength training adaptations. This concept of optimizing recovery has led to development of many supplements, including antioxidants, which may reduce the damage associated with strength training activities and therefore enhance positive adaptations. The purpose of this study is to assess the ability of a polyphenol rich supplementation to aid the recovery process from a demanding bout of resistance exercise",
        "tokens": "['Polyphenol', 'Rich', 'Supplementation', 'on', 'Markers', 'of', 'Recovery', 'From', 'Intense', 'Resistance', 'Exercise', '|', 'Strength', 'training', 'is', 'commonly', 'used', 'as', 'an', 'intervention', 'to', 'increase', 'muscle', 'mass', ',', 'thus', 'improving', 'a', 'person', \"'s\", 'ability', 'to', 'undertake', 'activities', 'of', 'daily', 'living', ',', 'or', 'enhance', 'athletic', 'performance', '.', 'The', 'strength', 'training', 'regimen', 'itself', ',', 'while', 'ultimately', 'having', 'beneficial', 'effects', ',', 'causes', 'muscle', 'fibers', 'to', 'be', 'damaged', ',', 'which', 'the', 'body', 'has', 'to', 'recover', 'from', '.', 'As', 'the', 'body', 'recovers', ',', 'it', 'rebuilds', 'the', 'muscle', 'tissue', 'and', 'after', 'multiple', 'consecutive', 'bouts', 'of', 'strength', 'training', ',', 'the', 'muscle', 'eventually', 'becomes', 'larger', 'and', 'stronger', '.', 'Thus', ',', 'it', 'is', 'the', 'recovery', 'from', 'strength', 'training', 'exercise', 'that', 'ultimately', 'determines', 'how', 'well', 'the', 'body', 'adapts', '.', 'Where', 'inadequate', 'recovery', 'could', 'eventually', 'lead', 'to', 'overtraining', 'and/or', 'injury', ',', 'optimizing', 'the', 'recovery', 'process', 'from', 'strength', 'training', 'could', 'maximize', 'strength', 'training', 'adaptations', '.', 'This', 'concept', 'of', 'optimizing', 'recovery', 'has', 'led', 'to', 'development', 'of', 'many', 'supplements', ',', 'including', 'antioxidants', ',', 'which', 'may', 'reduce', 'the', 'damage', 'associated', 'with', 'strength', 'training', 'activities', 'and', 'therefore', 'enhance', 'positive', 'adaptations', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'ability', 'of', 'a', 'polyphenol', 'rich', 'supplementation', 'to', 'aid', 'the', 'recovery', 'process', 'from', 'a', 'demanding', 'bout', 'of', 'resistance', 'exercise']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 10,
                "text": "Polyphenol",
                "type": "DRUG"
            },
            {
                "start": 1160,
                "end": 1170,
                "text": "polyphenol",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04644315",
        "study_official_title": "A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors ",
        "study_brief_summary": " This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.",
        "text": "A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.",
        "tokens": "['A', 'Phase', 'II', ',', 'Open', '-', 'Label', ',', 'Single', 'Arm', 'Decentralized', 'Home', '-', 'Based', 'Approach', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Alectinib', 'in', 'Locally', '-', 'Advanced', 'or', 'Metastatic', 'ALK', '-', 'Positive', 'Solid', 'Tumors', '|', 'This', 'study', 'will', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'alectinib', 'in', 'participants', 'with', 'Anaplastic', 'Lymphoma', 'Kinase', '(', 'ALK)-positive', 'locally', 'advanced', 'or', 'metastatic', 'solid', 'tumors', 'other', 'than', 'lung', 'cancer', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 114,
                "end": 123,
                "text": "Alectinib",
                "type": "DRUG"
            },
            {
                "start": 127,
                "end": 183,
                "text": "Locally-Advanced or Metastatic ALK-Positive Solid Tumors",
                "type": "CONDITION"
            },
            {
                "start": 238,
                "end": 247,
                "text": "alectinib",
                "type": "DRUG"
            },
            {
                "start": 269,
                "end": 354,
                "text": "Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01421056",
        "study_official_title": "A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment ",
        "study_brief_summary": " The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.",
        "text": "A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment | The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.",
        "tokens": "['A', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'Multicenter', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Multiple', 'Dose', 'Regimens', 'of', 'CHF', '5074', '(', '200', ',', '400', ',', '600', 'mg', '/', 'Day', 'for', 'up', 'to', '12', 'Weeks', ')', 'and', 'to', 'Explore', 'the', 'Effects', 'on', 'Potential', 'Markers', 'of', 'Clinical', 'Efficacy', 'in', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'ascending', 'oral', 'doses', 'of', 'CHF', '5074', 'after', 'prolonged', 'administration', 'to', 'patients', 'with', 'mild', 'cognitive', 'impairment', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 21,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 121,
                "end": 129,
                "text": "CHF 5074",
                "type": "DRUG"
            },
            {
                "start": 258,
                "end": 283,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 382,
                "end": 390,
                "text": "CHF 5074",
                "type": "DRUG"
            },
            {
                "start": 439,
                "end": 464,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05696665",
        "study_official_title": "Role of Saffron and Chamomile and Their Active Compounds in the Management of Parkinson Disease in the Context of Psychometric and Biochemical Measures ",
        "study_brief_summary": " In multitudinous preclinical studies, Saffron and Chamomile are found effective in treating PD. They can mitigate the neurodegenerative progression of the disease by curtailing dopaminergic and neuronal loss and by inhibiting alpha-synuclein aggregation. They also possess antioxidant and anti-inflammatory activities. The synergism of both drugs can manage Parkinson's disease and related neurological disorders although, clinical trials are needed for further elaboration. Therefore, the purpose of the study is to evaluate the effects of Saffron and Chamomile and their active compounds in treating Parkinson's disease. This combination may change psychometric measures (MDS-Unified Parkinson's Disease Rating Scale), biomarkers (including Alpha-synuclein), and oxidative stress-related to Parkinson's disease. This combination along with conventional therapy might be beneficial in managing patients with Parkinson's disease",
        "text": "Role of Saffron and Chamomile and Their Active Compounds in the Management of Parkinson Disease in the Context of Psychometric and Biochemical Measures | In multitudinous preclinical studies, Saffron and Chamomile are found effective in treating PD. They can mitigate the neurodegenerative progression of the disease by curtailing dopaminergic and neuronal loss and by inhibiting alpha-synuclein aggregation. They also possess antioxidant and anti-inflammatory activities. The synergism of both drugs can manage Parkinson's disease and related neurological disorders although, clinical trials are needed for further elaboration. Therefore, the purpose of the study is to evaluate the effects of Saffron and Chamomile and their active compounds in treating Parkinson's disease. This combination may change psychometric measures (MDS-Unified Parkinson's Disease Rating Scale), biomarkers (including Alpha-synuclein), and oxidative stress-related to Parkinson's disease. This combination along with conventional therapy might be beneficial in managing patients with Parkinson's disease",
        "tokens": "['Role', 'of', 'Saffron', 'and', 'Chamomile', 'and', 'Their', 'Active', 'Compounds', 'in', 'the', 'Management', 'of', 'Parkinson', 'Disease', 'in', 'the', 'Context', 'of', 'Psychometric', 'and', 'Biochemical', 'Measures', '|', 'In', 'multitudinous', 'preclinical', 'studies', ',', 'Saffron', 'and', 'Chamomile', 'are', 'found', 'effective', 'in', 'treating', 'PD', '.', 'They', 'can', 'mitigate', 'the', 'neurodegenerative', 'progression', 'of', 'the', 'disease', 'by', 'curtailing', 'dopaminergic', 'and', 'neuronal', 'loss', 'and', 'by', 'inhibiting', 'alpha', '-', 'synuclein', 'aggregation', '.', 'They', 'also', 'possess', 'antioxidant', 'and', 'anti', '-', 'inflammatory', 'activities', '.', 'The', 'synergism', 'of', 'both', 'drugs', 'can', 'manage', 'Parkinson', \"'s\", 'disease', 'and', 'related', 'neurological', 'disorders', 'although', ',', 'clinical', 'trials', 'are', 'needed', 'for', 'further', 'elaboration', '.', 'Therefore', ',', 'the', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'of', 'Saffron', 'and', 'Chamomile', 'and', 'their', 'active', 'compounds', 'in', 'treating', 'Parkinson', \"'s\", 'disease', '.', 'This', 'combination', 'may', 'change', 'psychometric', 'measures', '(', 'MDS', '-', 'Unified', 'Parkinson', \"'s\", 'Disease', 'Rating', 'Scale', ')', ',', 'biomarkers', '(', 'including', 'Alpha', '-', 'synuclein', ')', ',', 'and', 'oxidative', 'stress', '-', 'related', 'to', 'Parkinson', \"'s\", 'disease', '.', 'This', 'combination', 'along', 'with', 'conventional', 'therapy', 'might', 'be', 'beneficial', 'in', 'managing', 'patients', 'with', 'Parkinson', \"'s\", 'disease']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 8,
                "end": 15,
                "text": "Saffron",
                "type": "OTHER"
            },
            {
                "start": 20,
                "end": 29,
                "text": "Chamomile",
                "type": "OTHER"
            },
            {
                "start": 78,
                "end": 95,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 192,
                "end": 199,
                "text": "Saffron",
                "type": "OTHER"
            },
            {
                "start": 204,
                "end": 213,
                "text": "Chamomile",
                "type": "OTHER"
            },
            {
                "start": 246,
                "end": 248,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 512,
                "end": 531,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 695,
                "end": 702,
                "text": "Saffron",
                "type": "OTHER"
            },
            {
                "start": 707,
                "end": 716,
                "text": "Chamomile",
                "type": "OTHER"
            },
            {
                "start": 756,
                "end": 775,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 919,
                "end": 935,
                "text": "oxidative stress",
                "type": "CONDITION"
            },
            {
                "start": 947,
                "end": 966,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 1063,
                "end": 1082,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03886675",
        "study_official_title": "Carbon-Dioxide Flushing Versus Saline Flushing in Thoracic Endovascular Aortic Repair to Reduce Neurological Injury: A Pilot Randomised Controlled Trial ",
        "study_brief_summary": " Vascular brain infarction (VBI) occurs in 67% of patients undergoing TEVAR. Overt stroke occurs in 13% of these patients and 88% of patients suffer from neurocognitive impairment.\n\nCerebral air embolisation during the stent-graft deployment phase of TEVAR may be a cause of VBI. Standard treatment to de-air stent-grafts is through the use of a saline flush.\n\nThis study aims to investigate whether carbon-dioxide or saline is the better fluid to de-air TEVAR stent-grafts prior to insertion in to the patient and compare VBI rate in the carbon-dioxide group and saline group.",
        "text": "Carbon-Dioxide Flushing Versus Saline Flushing in Thoracic Endovascular Aortic Repair to Reduce Neurological Injury: A Pilot Randomised Controlled Trial | Vascular brain infarction (VBI) occurs in 67% of patients undergoing TEVAR. Overt stroke occurs in 13% of these patients and 88% of patients suffer from neurocognitive impairment.\n\nCerebral air embolisation during the stent-graft deployment phase of TEVAR may be a cause of VBI. Standard treatment to de-air stent-grafts is through the use of a saline flush.\n\nThis study aims to investigate whether carbon-dioxide or saline is the better fluid to de-air TEVAR stent-grafts prior to insertion in to the patient and compare VBI rate in the carbon-dioxide group and saline group.",
        "tokens": "['Carbon', '-', 'Dioxide', 'Flushing', 'Versus', 'Saline', 'Flushing', 'in', 'Thoracic', 'Endovascular', 'Aortic', 'Repair', 'to', 'Reduce', 'Neurological', 'Injury', ':', 'A', 'Pilot', 'Randomised', 'Controlled', 'Trial', '|', 'Vascular', 'brain', 'infarction', '(', 'VBI', ')', 'occurs', 'in', '67', '%', 'of', 'patients', 'undergoing', 'TEVAR', '.', 'Overt', 'stroke', 'occurs', 'in', '13', '%', 'of', 'these', 'patients', 'and', '88', '%', 'of', 'patients', 'suffer', 'from', 'neurocognitive', 'impairment', '.', '\\n\\n', 'Cerebral', 'air', 'embolisation', 'during', 'the', 'stent', '-', 'graft', 'deployment', 'phase', 'of', 'TEVAR', 'may', 'be', 'a', 'cause', 'of', 'VBI', '.', 'Standard', 'treatment', 'to', 'de', '-', 'air', 'stent', '-', 'grafts', 'is', 'through', 'the', 'use', 'of', 'a', 'saline', 'flush', '.', '\\n\\n', 'This', 'study', 'aims', 'to', 'investigate', 'whether', 'carbon', '-', 'dioxide', 'or', 'saline', 'is', 'the', 'better', 'fluid', 'to', 'de', '-', 'air', 'TEVAR', 'stent', '-', 'grafts', 'prior', 'to', 'insertion', 'in', 'to', 'the', 'patient', 'and', 'compare', 'VBI', 'rate', 'in', 'the', 'carbon', '-', 'dioxide', 'group', 'and', 'saline', 'group', '.']",
        "token_bio_labels": "['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 14,
                "text": "Carbon-Dioxide",
                "type": "DRUG"
            },
            {
                "start": 31,
                "end": 37,
                "text": "Saline",
                "type": "CONTROL"
            },
            {
                "start": 50,
                "end": 85,
                "text": "Thoracic Endovascular Aortic Repair",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 115,
                "text": "Neurological Injury",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 180,
                "text": "Vascular brain infarction",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 185,
                "text": "VBI",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 229,
                "text": "TEVAR",
                "type": "CONDITION"
            },
            {
                "start": 237,
                "end": 243,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 308,
                "end": 333,
                "text": "neurocognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 405,
                "end": 410,
                "text": "TEVAR",
                "type": "CONDITION"
            },
            {
                "start": 429,
                "end": 432,
                "text": "VBI",
                "type": "CONDITION"
            },
            {
                "start": 500,
                "end": 506,
                "text": "saline",
                "type": "CONTROL"
            },
            {
                "start": 554,
                "end": 568,
                "text": "carbon-dioxide",
                "type": "DRUG"
            },
            {
                "start": 572,
                "end": 578,
                "text": "saline",
                "type": "CONTROL"
            },
            {
                "start": 609,
                "end": 614,
                "text": "TEVAR",
                "type": "CONDITION"
            },
            {
                "start": 677,
                "end": 680,
                "text": "VBI",
                "type": "CONDITION"
            },
            {
                "start": 693,
                "end": 707,
                "text": "carbon-dioxide",
                "type": "DRUG"
            },
            {
                "start": 718,
                "end": 724,
                "text": "saline",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02761330",
        "study_official_title": "Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia Reconstitution of Consciousness and Cognition (Phase 2) ",
        "study_brief_summary": " This study is geared toward characterizing the recovery of brain activity and cognitive function following treatments of electroconvulsive therapy and ketamine general anesthesia.",
        "text": "Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia Reconstitution of Consciousness and Cognition (Phase 2) | This study is geared toward characterizing the recovery of brain activity and cognitive function following treatments of electroconvulsive therapy and ketamine general anesthesia.",
        "tokens": "['Cognitive', 'Recovery', 'After', 'Electroconvulsive', 'Therapy', 'and', 'General', 'Anesthesia', 'Reconstitution', 'of', 'Consciousness', 'and', 'Cognition', '(', 'Phase', '2', ')', '|', 'This', 'study', 'is', 'geared', 'toward', 'characterizing', 'the', 'recovery', 'of', 'brain', 'activity', 'and', 'cognitive', 'function', 'following', 'treatments', 'of', 'electroconvulsive', 'therapy', 'and', 'ketamine', 'general', 'anesthesia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 50,
                "text": "Electroconvulsive Therapy",
                "type": "CONDITION"
            },
            {
                "start": 55,
                "end": 73,
                "text": "General Anesthesia",
                "type": "CONDITION"
            },
            {
                "start": 253,
                "end": 278,
                "text": "electroconvulsive therapy",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 310,
                "text": "ketamine general anesthesia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03959449",
        "study_official_title": "Action Observation and Motor Imagery Induced Hypoalgesia in Asymptomatic Subjects ",
        "study_brief_summary": " This study evaluates the influence of motor imagery and the observation of actions on pain perception. Participants in this study are asymptomatic subjects who will perform an IM and AO protocol of an aerobic exercise.",
        "text": "Action Observation and Motor Imagery Induced Hypoalgesia in Asymptomatic Subjects | This study evaluates the influence of motor imagery and the observation of actions on pain perception. Participants in this study are asymptomatic subjects who will perform an IM and AO protocol of an aerobic exercise.",
        "tokens": "['Action', 'Observation', 'and', 'Motor', 'Imagery', 'Induced', 'Hypoalgesia', 'in', 'Asymptomatic', 'Subjects', '|', 'This', 'study', 'evaluates', 'the', 'influence', 'of', 'motor', 'imagery', 'and', 'the', 'observation', 'of', 'actions', 'on', 'pain', 'perception', '.', 'Participants', 'in', 'this', 'study', 'are', 'asymptomatic', 'subjects', 'who', 'will', 'perform', 'an', 'IM', 'and', 'AO', 'protocol', 'of', 'an', 'aerobic', 'exercise', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 18,
                "text": "Action Observation",
                "type": "OTHER"
            },
            {
                "start": 23,
                "end": 36,
                "text": "Motor Imagery",
                "type": "OTHER"
            },
            {
                "start": 122,
                "end": 135,
                "text": "motor imagery",
                "type": "OTHER"
            },
            {
                "start": 144,
                "end": 166,
                "text": "observation of actions",
                "type": "OTHER"
            },
            {
                "start": 170,
                "end": 174,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 260,
                "end": 262,
                "text": "IM",
                "type": "OTHER"
            },
            {
                "start": 267,
                "end": 269,
                "text": "AO",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00152997",
        "study_official_title": "A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome. ",
        "study_brief_summary": " The objective of this trial is to investigate the efficacy and safety of pramipexole (0.125-0.75 mg) orally once daily as compared with placebo for 6 weeks in patients with primary restless legs syndrome (RLS) and to investigate the reliability of the Japanese version of the RLS rating scale by the International Restless Legs Syndrome Study Group (IRLSSG) as a sub-study.",
        "text": "A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome. | The objective of this trial is to investigate the efficacy and safety of pramipexole (0.125-0.75 mg) orally once daily as compared with placebo for 6 weeks in patients with primary restless legs syndrome (RLS) and to investigate the reliability of the Japanese version of the RLS rating scale by the International Restless Legs Syndrome Study Group (IRLSSG) as a sub-study.",
        "tokens": "['A', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Pramipexole', 'With', 'the', 'Dose', 'Range', 'From', '0.125', 'mg', 'to', '0.75', 'mg', 'Orally', 'Once', 'Daily', 'for', '6', 'Weeks', 'in', 'Patients', 'With', 'Primary', 'Restless', 'Legs', 'Syndrome', '.', '|', 'The', 'objective', 'of', 'this', 'trial', 'is', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'pramipexole', '(', '0.125', '-', '0.75', 'mg', ')', 'orally', 'once', 'daily', 'as', 'compared', 'with', 'placebo', 'for', '6', 'weeks', 'in', 'patients', 'with', 'primary', 'restless', 'legs', 'syndrome', '(', 'RLS', ')', 'and', 'to', 'investigate', 'the', 'reliability', 'of', 'the', 'Japanese', 'version', 'of', 'the', 'RLS', 'rating', 'scale', 'by', 'the', 'International', 'Restless', 'Legs', 'Syndrome', 'Study', 'Group', '(', 'IRLSSG', ')', 'as', 'a', 'sub', '-', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 92,
                "end": 103,
                "text": "Pramipexole",
                "type": "DRUG"
            },
            {
                "start": 196,
                "end": 226,
                "text": "Primary Restless Legs Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 303,
                "end": 314,
                "text": "pramipexole",
                "type": "DRUG"
            },
            {
                "start": 366,
                "end": 373,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 403,
                "end": 433,
                "text": "primary restless legs syndrome",
                "type": "CONDITION"
            },
            {
                "start": 435,
                "end": 438,
                "text": "RLS",
                "type": "CONDITION"
            },
            {
                "start": 506,
                "end": 509,
                "text": "RLS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00101634",
        "study_official_title": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia ",
        "study_brief_summary": " The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.",
        "text": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia | The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', '-', 'group', ',', 'Dose', '-', 'response', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', '3', 'Fixed', 'Doses', '(', '25', 'mg', 'eq', ',', '50', 'mg', 'eq', ',', 'and', '100', 'mg', 'eq', ')', 'of', 'Paliperidone', 'Palmitate', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'efficacy', '(', 'how', 'well', 'the', 'drug', 'works', ')', ',', 'safety', ',', 'and', 'side', 'effects', 'of', 'paliperidone', 'palmitate', 'compared', 'to', 'placebo', 'in', 'the', 'treatment', 'of', 'the', 'symptoms', 'of', 'schizophrenia', 'in', 'adults', '.', 'The', 'placebo', 'used', 'in', 'this', 'study', 'was', 'a', 'nutritional', 'substance', 'known', 'as', '20', '%', 'Intralipid', 'emulsion', 'given', 'to', 'patients', 'requiring', 'intravenous', 'feedings', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 176,
                "end": 198,
                "text": "Paliperidone Palmitate",
                "type": "DRUG"
            },
            {
                "start": 216,
                "end": 229,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 342,
                "end": 364,
                "text": "paliperidone palmitate",
                "type": "DRUG"
            },
            {
                "start": 377,
                "end": 384,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 421,
                "end": 434,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 450,
                "end": 457,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 518,
                "end": 537,
                "text": "Intralipid emulsion",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04433377",
        "study_official_title": "Comparison of the Effects of Ultrasound-guided Suprascapular Nerve Block and Subacromial Injection in Hemiplegic Shoulder Pain: a Randomized Controlled Trial ",
        "study_brief_summary": " Hemiplegic shoulder pain is the most common poststroke painful condition. Hemiplegic shoulder pain reduces range of motion (ROM) and hand function, resulting in limited daily life activity and decreased quality of life.\n\nIn the literature, the effectiveness of suprascapular nerve block and subacromial injection in hemiplegia patients with shoulder pain has been previously evaluated, but these injection treatments have not been compared.\n\nTherefore, the aim of this study is to compare the effectiveness of suprascapular nerve block and subacromial injection on pain, shoulder (ROM), function and quality of life in hemiplegia patients with shoulder pain.",
        "text": "Comparison of the Effects of Ultrasound-guided Suprascapular Nerve Block and Subacromial Injection in Hemiplegic Shoulder Pain: a Randomized Controlled Trial | Hemiplegic shoulder pain is the most common poststroke painful condition. Hemiplegic shoulder pain reduces range of motion (ROM) and hand function, resulting in limited daily life activity and decreased quality of life.\n\nIn the literature, the effectiveness of suprascapular nerve block and subacromial injection in hemiplegia patients with shoulder pain has been previously evaluated, but these injection treatments have not been compared.\n\nTherefore, the aim of this study is to compare the effectiveness of suprascapular nerve block and subacromial injection on pain, shoulder (ROM), function and quality of life in hemiplegia patients with shoulder pain.",
        "tokens": "['Comparison', 'of', 'the', 'Effects', 'of', 'Ultrasound', '-', 'guided', 'Suprascapular', 'Nerve', 'Block', 'and', 'Subacromial', 'Injection', 'in', 'Hemiplegic', 'Shoulder', 'Pain', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Hemiplegic', 'shoulder', 'pain', 'is', 'the', 'most', 'common', 'poststroke', 'painful', 'condition', '.', 'Hemiplegic', 'shoulder', 'pain', 'reduces', 'range', 'of', 'motion', '(', 'ROM', ')', 'and', 'hand', 'function', ',', 'resulting', 'in', 'limited', 'daily', 'life', 'activity', 'and', 'decreased', 'quality', 'of', 'life', '.', '\\n\\n', 'In', 'the', 'literature', ',', 'the', 'effectiveness', 'of', 'suprascapular', 'nerve', 'block', 'and', 'subacromial', 'injection', 'in', 'hemiplegia', 'patients', 'with', 'shoulder', 'pain', 'has', 'been', 'previously', 'evaluated', ',', 'but', 'these', 'injection', 'treatments', 'have', 'not', 'been', 'compared', '.', '\\n\\n', 'Therefore', ',', 'the', 'aim', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'suprascapular', 'nerve', 'block', 'and', 'subacromial', 'injection', 'on', 'pain', ',', 'shoulder', '(', 'ROM', ')', ',', 'function', 'and', 'quality', 'of', 'life', 'in', 'hemiplegia', 'patients', 'with', 'shoulder', 'pain', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 72,
                "text": "Ultrasound-guided Suprascapular Nerve Block",
                "type": "OTHER"
            },
            {
                "start": 77,
                "end": 98,
                "text": "Subacromial Injection",
                "type": "OTHER"
            },
            {
                "start": 102,
                "end": 112,
                "text": "Hemiplegic",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 126,
                "text": "Shoulder Pain",
                "type": "CONDITION"
            },
            {
                "start": 160,
                "end": 170,
                "text": "Hemiplegic",
                "type": "CONDITION"
            },
            {
                "start": 171,
                "end": 184,
                "text": "shoulder pain",
                "type": "CONDITION"
            },
            {
                "start": 204,
                "end": 214,
                "text": "poststroke",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 244,
                "text": "Hemiplegic",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 258,
                "text": "shoulder pain",
                "type": "CONDITION"
            },
            {
                "start": 421,
                "end": 446,
                "text": "suprascapular nerve block",
                "type": "OTHER"
            },
            {
                "start": 451,
                "end": 472,
                "text": "subacromial injection",
                "type": "OTHER"
            },
            {
                "start": 476,
                "end": 486,
                "text": "hemiplegia",
                "type": "CONDITION"
            },
            {
                "start": 501,
                "end": 514,
                "text": "shoulder pain",
                "type": "CONDITION"
            },
            {
                "start": 670,
                "end": 695,
                "text": "suprascapular nerve block",
                "type": "OTHER"
            },
            {
                "start": 700,
                "end": 721,
                "text": "subacromial injection",
                "type": "OTHER"
            },
            {
                "start": 725,
                "end": 729,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 779,
                "end": 789,
                "text": "hemiplegia",
                "type": "CONDITION"
            },
            {
                "start": 804,
                "end": 817,
                "text": "shoulder pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05714449",
        "study_official_title": "OCT Eccentric Fixation, Fixation Stability, and Amblyopia in Children ",
        "study_brief_summary": " The objectives of this proposal are to characterize the relationship between OCT eccentric fixation (OCT-EF), fixation eye movement (FEM), macular sensitivity in children with amblyopia.",
        "text": "OCT Eccentric Fixation, Fixation Stability, and Amblyopia in Children | The objectives of this proposal are to characterize the relationship between OCT eccentric fixation (OCT-EF), fixation eye movement (FEM), macular sensitivity in children with amblyopia.",
        "tokens": "['OCT', 'Eccentric', 'Fixation', ',', 'Fixation', 'Stability', ',', 'and', 'Amblyopia', 'in', 'Children', '|', 'The', 'objectives', 'of', 'this', 'proposal', 'are', 'to', 'characterize', 'the', 'relationship', 'between', 'OCT', 'eccentric', 'fixation', '(', 'OCT', '-', 'EF', ')', ',', 'fixation', 'eye', 'movement', '(', 'FEM', ')', ',', 'macular', 'sensitivity', 'in', 'children', 'with', 'amblyopia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 48,
                "end": 57,
                "text": "Amblyopia",
                "type": "CONDITION"
            },
            {
                "start": 248,
                "end": 257,
                "text": "amblyopia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02069314",
        "study_official_title": "Diet and Muscle Function In Older Adults ",
        "study_brief_summary": " This research study was conducted to investigate the effects of a high protein diet on the efficiency of energy use at rest and at low-levels of physical activity. The hypothesis was that a high intake of dietary protein would result in a less efficient use of energy in skeletal muscle in older adults.",
        "text": "Diet and Muscle Function In Older Adults | This research study was conducted to investigate the effects of a high protein diet on the efficiency of energy use at rest and at low-levels of physical activity. The hypothesis was that a high intake of dietary protein would result in a less efficient use of energy in skeletal muscle in older adults.",
        "tokens": "['Diet', 'and', 'Muscle', 'Function', 'In', 'Older', 'Adults', '|', 'This', 'research', 'study', 'was', 'conducted', 'to', 'investigate', 'the', 'effects', 'of', 'a', 'high', 'protein', 'diet', 'on', 'the', 'efficiency', 'of', 'energy', 'use', 'at', 'rest', 'and', 'at', 'low', '-', 'levels', 'of', 'physical', 'activity', '.', 'The', 'hypothesis', 'was', 'that', 'a', 'high', 'intake', 'of', 'dietary', 'protein', 'would', 'result', 'in', 'a', 'less', 'efficient', 'use', 'of', 'energy', 'in', 'skeletal', 'muscle', 'in', 'older', 'adults', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 109,
                "end": 126,
                "text": "high protein diet",
                "type": "OTHER"
            },
            {
                "start": 233,
                "end": 263,
                "text": "high intake of dietary protein",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05462340",
        "study_official_title": "PET Imaging Study of \u03b17 and \u03b14\u03b22-nAChR in Schizophrenia: Cognitive Relationships ",
        "study_brief_summary": " The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to healthy controls.",
        "text": "PET Imaging Study of \u03b17 and \u03b14\u03b22-nAChR in Schizophrenia: Cognitive Relationships | The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to healthy controls.",
        "tokens": "['PET', 'Imaging', 'Study', 'of', '\u03b17', 'and', '\u03b14\u03b22', '-', 'nAChR', 'in', 'Schizophrenia', ':', 'Cognitive', 'Relationships', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'use', 'specialized', 'brain', 'imaging', 'techniques', ',', 'Positron', 'Emission', 'Tomography', '(', 'PET', ')', 'scan', 'and', 'Magnetic', 'Resonance', 'Imaging', '(', 'MRI', ')', ',', 'to', 'learn', 'more', 'about', 'the', 'brain', 'chemistry', ',', 'e.g.', ',', 'how', 'neurotransmitters', 'and', 'receptors', 'in', 'the', 'brain', 'function', 'in', 'people', 'with', 'schizophrenia', 'compared', 'to', 'healthy', 'controls', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 55,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 358,
                "end": 371,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04849741",
        "study_official_title": "A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease ",
        "study_brief_summary": " The purpose of this study is to evaluate the safety and efficacy of ION373 in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.",
        "text": "A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease | The purpose of this study is to evaluate the safety and efficacy of ION373 in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.",
        "tokens": "['A', 'Phase', '1', '-', '3', ',', 'Double', '-', 'Blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', ',', 'Safety', ',', 'Pharmacokinetics', 'and', 'Pharmacodynamics', 'of', 'Intrathecally', 'Administered', 'ION373', 'in', 'Patients', 'With', 'Alexander', 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'ION373', 'in', 'improving', 'or', 'stabilizing', 'gross', 'motor', 'function', 'across', 'the', 'full', 'range', 'of', 'affected', 'domains', 'in', 'patients', 'with', 'AxD.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND']",
        "entities": [
            {
                "start": 39,
                "end": 46,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 166,
                "end": 172,
                "text": "ION373",
                "type": "DRUG"
            },
            {
                "start": 190,
                "end": 207,
                "text": "Alexander Disease",
                "type": "CONDITION"
            },
            {
                "start": 278,
                "end": 284,
                "text": "ION373",
                "type": "DRUG"
            },
            {
                "start": 393,
                "end": 397,
                "text": "AxD.",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05014841",
        "study_official_title": "The Neural Coding of Speech Across Human Languages ",
        "study_brief_summary": " The overall goal of this study is to reveal the fundamental neural mechanisms that underlie comprehension across human spoken languages. An understanding of how speech is coded in the brain has significant implications for the development of new diagnostic and rehabilitative strategies for language disorders (e.g. aphasia, dyslexia, autism, et alia). The basic mechanisms underlying comprehension of spoken language are unknown. Researchers are only beginning to understand how the human brain extracts the most fundamental linguistic elements (consonants and vowels) from a complex and highly variable acoustic signal. Traditional theories have posited a 'universal' phonetic inventory shared by all humans, but this has been challenged by other newer theories that each language has its own unique and specialized code. An investigation of the cortical representation of speech sounds across languages can likely shed light on this fundamental question. Previous research has implicated the superior temporal cortex in the processing of speech sounds. Most of this work has been entirely carried out in English. The recording of neural activity directly from the cortical surface from individuals with different language experience is a promising approach since it can provide both high spatial and temporal resolution. This study will examine the mechanisms of phonetic encoding, by utilizing neurophysiological recordings obtained during neurosurgical procedures. High-density electrode arrays, advanced signal processing, and direct electrocortical stimulation will be utilized to unravel both local and population encoding of speech sounds in the lateral temporal cortex. This study will also examine the neural encoding of speech in patients who are monolingual and bilingual in Mandarin, Spanish, and English, the most common spoken languages worldwide, and feature important contrastive differences of pitch, formant, and temporal envelope. A cross-linguistic approach is critical for a true understanding of language, while also striving to achieve a broader approach of diversity and inclusion in neuroscience of language.",
        "text": "The Neural Coding of Speech Across Human Languages | The overall goal of this study is to reveal the fundamental neural mechanisms that underlie comprehension across human spoken languages. An understanding of how speech is coded in the brain has significant implications for the development of new diagnostic and rehabilitative strategies for language disorders (e.g. aphasia, dyslexia, autism, et alia). The basic mechanisms underlying comprehension of spoken language are unknown. Researchers are only beginning to understand how the human brain extracts the most fundamental linguistic elements (consonants and vowels) from a complex and highly variable acoustic signal. Traditional theories have posited a 'universal' phonetic inventory shared by all humans, but this has been challenged by other newer theories that each language has its own unique and specialized code. An investigation of the cortical representation of speech sounds across languages can likely shed light on this fundamental question. Previous research has implicated the superior temporal cortex in the processing of speech sounds. Most of this work has been entirely carried out in English. The recording of neural activity directly from the cortical surface from individuals with different language experience is a promising approach since it can provide both high spatial and temporal resolution. This study will examine the mechanisms of phonetic encoding, by utilizing neurophysiological recordings obtained during neurosurgical procedures. High-density electrode arrays, advanced signal processing, and direct electrocortical stimulation will be utilized to unravel both local and population encoding of speech sounds in the lateral temporal cortex. This study will also examine the neural encoding of speech in patients who are monolingual and bilingual in Mandarin, Spanish, and English, the most common spoken languages worldwide, and feature important contrastive differences of pitch, formant, and temporal envelope. A cross-linguistic approach is critical for a true understanding of language, while also striving to achieve a broader approach of diversity and inclusion in neuroscience of language.",
        "tokens": "['The', 'Neural', 'Coding', 'of', 'Speech', 'Across', 'Human', 'Languages', '|', 'The', 'overall', 'goal', 'of', 'this', 'study', 'is', 'to', 'reveal', 'the', 'fundamental', 'neural', 'mechanisms', 'that', 'underlie', 'comprehension', 'across', 'human', 'spoken', 'languages', '.', 'An', 'understanding', 'of', 'how', 'speech', 'is', 'coded', 'in', 'the', 'brain', 'has', 'significant', 'implications', 'for', 'the', 'development', 'of', 'new', 'diagnostic', 'and', 'rehabilitative', 'strategies', 'for', 'language', 'disorders', '(', 'e.g.', 'aphasia', ',', 'dyslexia', ',', 'autism', ',', 'et', 'alia', ')', '.', 'The', 'basic', 'mechanisms', 'underlying', 'comprehension', 'of', 'spoken', 'language', 'are', 'unknown', '.', 'Researchers', 'are', 'only', 'beginning', 'to', 'understand', 'how', 'the', 'human', 'brain', 'extracts', 'the', 'most', 'fundamental', 'linguistic', 'elements', '(', 'consonants', 'and', 'vowels', ')', 'from', 'a', 'complex', 'and', 'highly', 'variable', 'acoustic', 'signal', '.', 'Traditional', 'theories', 'have', 'posited', 'a', \"'\", 'universal', \"'\", 'phonetic', 'inventory', 'shared', 'by', 'all', 'humans', ',', 'but', 'this', 'has', 'been', 'challenged', 'by', 'other', 'newer', 'theories', 'that', 'each', 'language', 'has', 'its', 'own', 'unique', 'and', 'specialized', 'code', '.', 'An', 'investigation', 'of', 'the', 'cortical', 'representation', 'of', 'speech', 'sounds', 'across', 'languages', 'can', 'likely', 'shed', 'light', 'on', 'this', 'fundamental', 'question', '.', 'Previous', 'research', 'has', 'implicated', 'the', 'superior', 'temporal', 'cortex', 'in', 'the', 'processing', 'of', 'speech', 'sounds', '.', 'Most', 'of', 'this', 'work', 'has', 'been', 'entirely', 'carried', 'out', 'in', 'English', '.', 'The', 'recording', 'of', 'neural', 'activity', 'directly', 'from', 'the', 'cortical', 'surface', 'from', 'individuals', 'with', 'different', 'language', 'experience', 'is', 'a', 'promising', 'approach', 'since', 'it', 'can', 'provide', 'both', 'high', 'spatial', 'and', 'temporal', 'resolution', '.', 'This', 'study', 'will', 'examine', 'the', 'mechanisms', 'of', 'phonetic', 'encoding', ',', 'by', 'utilizing', 'neurophysiological', 'recordings', 'obtained', 'during', 'neurosurgical', 'procedures', '.', 'High', '-', 'density', 'electrode', 'arrays', ',', 'advanced', 'signal', 'processing', ',', 'and', 'direct', 'electrocortical', 'stimulation', 'will', 'be', 'utilized', 'to', 'unravel', 'both', 'local', 'and', 'population', 'encoding', 'of', 'speech', 'sounds', 'in', 'the', 'lateral', 'temporal', 'cortex', '.', 'This', 'study', 'will', 'also', 'examine', 'the', 'neural', 'encoding', 'of', 'speech', 'in', 'patients', 'who', 'are', 'monolingual', 'and', 'bilingual', 'in', 'Mandarin', ',', 'Spanish', ',', 'and', 'English', ',', 'the', 'most', 'common', 'spoken', 'languages', 'worldwide', ',', 'and', 'feature', 'important', 'contrastive', 'differences', 'of', 'pitch', ',', 'formant', ',', 'and', 'temporal', 'envelope', '.', 'A', 'cross', '-', 'linguistic', 'approach', 'is', 'critical', 'for', 'a', 'true', 'understanding', 'of', 'language', ',', 'while', 'also', 'striving', 'to', 'achieve', 'a', 'broader', 'approach', 'of', 'diversity', 'and', 'inclusion', 'in', 'neuroscience', 'of', 'language', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT02991235",
        "study_official_title": "Evaluation of the Efficacy and Safety of PRJ212 on Improving the Memory of Patients With Mild Severity Alzheimer's Disease: A 6-month Randomized, Double-blind and Placebo-controlled, Followed by a 6-month Open Label Extension Study ",
        "study_brief_summary": " A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.",
        "text": "Evaluation of the Efficacy and Safety of PRJ212 on Improving the Memory of Patients With Mild Severity Alzheimer's Disease: A 6-month Randomized, Double-blind and Placebo-controlled, Followed by a 6-month Open Label Extension Study | A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.",
        "tokens": "['Evaluation', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', 'PRJ212', 'on', 'Improving', 'the', 'Memory', 'of', 'Patients', 'With', 'Mild', 'Severity', 'Alzheimer', \"'s\", 'Disease', ':', 'A', '6', '-', 'month', 'Randomized', ',', 'Double', '-', 'blind', 'and', 'Placebo', '-', 'controlled', ',', 'Followed', 'by', 'a', '6', '-', 'month', 'Open', 'Label', 'Extension', 'Study', '|', 'A', '6', '-', 'month', 'randomized', ',', 'double', '-', 'blind', 'and', 'placebo', '-', 'controlled', ',', 'followed', 'by', 'a', '6', '-', 'month', 'open', 'label', 'extension', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 47,
                "text": "PRJ212",
                "type": "DRUG"
            },
            {
                "start": 89,
                "end": 122,
                "text": "Mild Severity Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 163,
                "end": 170,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 273,
                "end": 280,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05086809",
        "study_official_title": "BC109 - Investigation of an Updated Bone-anchored Sound Processor ",
        "study_brief_summary": " The study is a prospective, single-center, comparative, cross-over study with within-subject control design. In the investigation an updated sound processor will be tested at compared to the CE marked Ponto 3 SuperPower sound processor (available on the market since December 2016) in order to establish marketing claim(s) on the updated sound processor.\n\nThe performance of the two sound processors will be evaluated via speech and hearing tests, and patient reported outcomes.",
        "text": "BC109 - Investigation of an Updated Bone-anchored Sound Processor | The study is a prospective, single-center, comparative, cross-over study with within-subject control design. In the investigation an updated sound processor will be tested at compared to the CE marked Ponto 3 SuperPower sound processor (available on the market since December 2016) in order to establish marketing claim(s) on the updated sound processor.\n\nThe performance of the two sound processors will be evaluated via speech and hearing tests, and patient reported outcomes.",
        "tokens": "['BC109', '-', 'Investigation', 'of', 'an', 'Updated', 'Bone', '-', 'anchored', 'Sound', 'Processor', '|', 'The', 'study', 'is', 'a', 'prospective', ',', 'single', '-', 'center', ',', 'comparative', ',', 'cross', '-', 'over', 'study', 'with', 'within', '-', 'subject', 'control', 'design', '.', 'In', 'the', 'investigation', 'an', 'updated', 'sound', 'processor', 'will', 'be', 'tested', 'at', 'compared', 'to', 'the', 'CE', 'marked', 'Ponto', '3', 'SuperPower', 'sound', 'processor', '(', 'available', 'on', 'the', 'market', 'since', 'December', '2016', ')', 'in', 'order', 'to', 'establish', 'marketing', 'claim(s', ')', 'on', 'the', 'updated', 'sound', 'processor', '.', '\\n\\n', 'The', 'performance', 'of', 'the', 'two', 'sound', 'processors', 'will', 'be', 'evaluated', 'via', 'speech', 'and', 'hearing', 'tests', ',', 'and', 'patient', 'reported', 'outcomes', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 65,
                "text": "Updated Bone-anchored Sound Processor",
                "type": "OTHER"
            },
            {
                "start": 201,
                "end": 224,
                "text": "updated sound processor",
                "type": "OTHER"
            },
            {
                "start": 259,
                "end": 303,
                "text": "CE marked Ponto 3 SuperPower sound processor",
                "type": "CONTROL"
            },
            {
                "start": 398,
                "end": 421,
                "text": "updated sound processor",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03828383",
        "study_official_title": "Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers ",
        "study_brief_summary": " This study aims to develop and evaluate in-home assistive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease and frontotemporal dementia.",
        "text": "Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers | This study aims to develop and evaluate in-home assistive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease and frontotemporal dementia.",
        "tokens": "['Developing', 'and', 'Evaluating', 'In', '-', 'Home', 'Supportive', 'Technology', 'for', 'Dementia', 'Caregivers', '|', 'This', 'study', 'aims', 'to', 'develop', 'and', 'evaluate', 'in', '-', 'home', 'assistive', 'technology', 'that', 'is', 'designed', 'to', 'alleviate', 'anxiety', ',', 'burden', ',', 'and', 'loneliness', 'in', 'spousal', 'and', 'familial', 'caregivers', 'of', 'individuals', 'with', 'Alzheimer', \"'s\", 'disease', 'and', 'frontotemporal', 'dementia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 55,
                "text": "In-Home Supportive Technology",
                "type": "OTHER"
            },
            {
                "start": 60,
                "end": 68,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 122,
                "end": 150,
                "text": "in-home assistive technology",
                "type": "OTHER"
            },
            {
                "start": 181,
                "end": 188,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 202,
                "end": 212,
                "text": "loneliness",
                "type": "CONDITION"
            },
            {
                "start": 268,
                "end": 287,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 292,
                "end": 315,
                "text": "frontotemporal dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04481217",
        "study_official_title": "The Mediating Role of Dissociative Symptoms and Early Maladaptive Schemas in the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia ",
        "study_brief_summary": " BACKGROUND It is demonstrated that strong associations between trauma suffered in childhood and having schizophrenia, and more specifically to experience acoustic-verbal hallucinations (AVH). A second generation of research is currently examining the cognitive and affective processes likely to play a mediating role in this association. These mediators appear to include early maladaptive personality patterns and dissociative experiences. Although these factors have most often been explored separately, recent research indicates that they could be associated, and thus contribute to AVH. More specifically, another study has shown that the association between childhood trauma and predisposition to AVH is not direct but depends on cognitive factors including the impact of violence suffered during childhood on early maladaptive schemas and dissociation. However, this study was carried out on a non-clinical sample of subjects with a predisposition to AVH.\n\nOBJECTIVES: testing a structural model of AVH, childhood trauma, early maladaptive schemas and dissociative symptoms in large multicentric sample of inpatients diagnosed with schizophrenia and AVH (n=350). Secondary objectives are (i) test in the model the role of all the early patterns described by Jeffrey Young instead of targeting only the schemes that are part of the model tested in previous study as the one by Bortolon and colleagues, (ii) compare the quality of the adjustment of the confirmatory model to the quality of the adjustment of the exploratory model.\n\nMETHODS: one single visit in which subjects will receive self-reported questionnaires (Childhood trauma questionnaire, The Young schema questionnaire short form, Dissociative experiences scale, Launay-Slade hallucination scale and Cardiff Anomalous Perceptions Scale.\n\nANALYSES: Structural equation model performed additional analysis using Partial Least Squares Structural Equation Modelling. The primary endpoint corresponds to significant associations between the variables. The quality of the model will be assessed using a fit quality measure. The secondary endpoints are significant associations between the different variables (p <0.05) and the model quality assessed with a quality measure of the fit.\n\nMAIN HYPOTHESIS: the association between childhood trauma and predisposition to AVH is not direct, but depends on the impact of violence suffered during childhood on early maladaptive schemas and dissociative symptoms in patients with schizophrenia.",
        "text": "The Mediating Role of Dissociative Symptoms and Early Maladaptive Schemas in the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia | BACKGROUND It is demonstrated that strong associations between trauma suffered in childhood and having schizophrenia, and more specifically to experience acoustic-verbal hallucinations (AVH). A second generation of research is currently examining the cognitive and affective processes likely to play a mediating role in this association. These mediators appear to include early maladaptive personality patterns and dissociative experiences. Although these factors have most often been explored separately, recent research indicates that they could be associated, and thus contribute to AVH. More specifically, another study has shown that the association between childhood trauma and predisposition to AVH is not direct but depends on cognitive factors including the impact of violence suffered during childhood on early maladaptive schemas and dissociation. However, this study was carried out on a non-clinical sample of subjects with a predisposition to AVH.\n\nOBJECTIVES: testing a structural model of AVH, childhood trauma, early maladaptive schemas and dissociative symptoms in large multicentric sample of inpatients diagnosed with schizophrenia and AVH (n=350). Secondary objectives are (i) test in the model the role of all the early patterns described by Jeffrey Young instead of targeting only the schemes that are part of the model tested in previous study as the one by Bortolon and colleagues, (ii) compare the quality of the adjustment of the confirmatory model to the quality of the adjustment of the exploratory model.\n\nMETHODS: one single visit in which subjects will receive self-reported questionnaires (Childhood trauma questionnaire, The Young schema questionnaire short form, Dissociative experiences scale, Launay-Slade hallucination scale and Cardiff Anomalous Perceptions Scale.\n\nANALYSES: Structural equation model performed additional analysis using Partial Least Squares Structural Equation Modelling. The primary endpoint corresponds to significant associations between the variables. The quality of the model will be assessed using a fit quality measure. The secondary endpoints are significant associations between the different variables (p <0.05) and the model quality assessed with a quality measure of the fit.\n\nMAIN HYPOTHESIS: the association between childhood trauma and predisposition to AVH is not direct, but depends on the impact of violence suffered during childhood on early maladaptive schemas and dissociative symptoms in patients with schizophrenia.",
        "tokens": "['The', 'Mediating', 'Role', 'of', 'Dissociative', 'Symptoms', 'and', 'Early', 'Maladaptive', 'Schemas', 'in', 'the', 'Relationship', 'Between', 'Childhood', 'Trauma', 'and', 'Auditory', 'Hallucinations', 'in', 'Schizophrenia', '|', 'BACKGROUND', 'It', 'is', 'demonstrated', 'that', 'strong', 'associations', 'between', 'trauma', 'suffered', 'in', 'childhood', 'and', 'having', 'schizophrenia', ',', 'and', 'more', 'specifically', 'to', 'experience', 'acoustic', '-', 'verbal', 'hallucinations', '(', 'AVH', ')', '.', 'A', 'second', 'generation', 'of', 'research', 'is', 'currently', 'examining', 'the', 'cognitive', 'and', 'affective', 'processes', 'likely', 'to', 'play', 'a', 'mediating', 'role', 'in', 'this', 'association', '.', 'These', 'mediators', 'appear', 'to', 'include', 'early', 'maladaptive', 'personality', 'patterns', 'and', 'dissociative', 'experiences', '.', 'Although', 'these', 'factors', 'have', 'most', 'often', 'been', 'explored', 'separately', ',', 'recent', 'research', 'indicates', 'that', 'they', 'could', 'be', 'associated', ',', 'and', 'thus', 'contribute', 'to', 'AVH', '.', 'More', 'specifically', ',', 'another', 'study', 'has', 'shown', 'that', 'the', 'association', 'between', 'childhood', 'trauma', 'and', 'predisposition', 'to', 'AVH', 'is', 'not', 'direct', 'but', 'depends', 'on', 'cognitive', 'factors', 'including', 'the', 'impact', 'of', 'violence', 'suffered', 'during', 'childhood', 'on', 'early', 'maladaptive', 'schemas', 'and', 'dissociation', '.', 'However', ',', 'this', 'study', 'was', 'carried', 'out', 'on', 'a', 'non', '-', 'clinical', 'sample', 'of', 'subjects', 'with', 'a', 'predisposition', 'to', 'AVH', '.', '\\n\\n', 'OBJECTIVES', ':', 'testing', 'a', 'structural', 'model', 'of', 'AVH', ',', 'childhood', 'trauma', ',', 'early', 'maladaptive', 'schemas', 'and', 'dissociative', 'symptoms', 'in', 'large', 'multicentric', 'sample', 'of', 'inpatients', 'diagnosed', 'with', 'schizophrenia', 'and', 'AVH', '(', 'n=350', ')', '.', 'Secondary', 'objectives', 'are', '(', 'i', ')', 'test', 'in', 'the', 'model', 'the', 'role', 'of', 'all', 'the', 'early', 'patterns', 'described', 'by', 'Jeffrey', 'Young', 'instead', 'of', 'targeting', 'only', 'the', 'schemes', 'that', 'are', 'part', 'of', 'the', 'model', 'tested', 'in', 'previous', 'study', 'as', 'the', 'one', 'by', 'Bortolon', 'and', 'colleagues', ',', '(', 'ii', ')', 'compare', 'the', 'quality', 'of', 'the', 'adjustment', 'of', 'the', 'confirmatory', 'model', 'to', 'the', 'quality', 'of', 'the', 'adjustment', 'of', 'the', 'exploratory', 'model', '.', '\\n\\n', 'METHODS', ':', 'one', 'single', 'visit', 'in', 'which', 'subjects', 'will', 'receive', 'self', '-', 'reported', 'questionnaires', '(', 'Childhood', 'trauma', 'questionnaire', ',', 'The', 'Young', 'schema', 'questionnaire', 'short', 'form', ',', 'Dissociative', 'experiences', 'scale', ',', 'Launay', '-', 'Slade', 'hallucination', 'scale', 'and', 'Cardiff', 'Anomalous', 'Perceptions', 'Scale', '.', '\\n\\n', 'ANALYSES', ':', 'Structural', 'equation', 'model', 'performed', 'additional', 'analysis', 'using', 'Partial', 'Least', 'Squares', 'Structural', 'Equation', 'Modelling', '.', 'The', 'primary', 'endpoint', 'corresponds', 'to', 'significant', 'associations', 'between', 'the', 'variables', '.', 'The', 'quality', 'of', 'the', 'model', 'will', 'be', 'assessed', 'using', 'a', 'fit', 'quality', 'measure', '.', 'The', 'secondary', 'endpoints', 'are', 'significant', 'associations', 'between', 'the', 'different', 'variables', '(', 'p', '<', '0.05', ')', 'and', 'the', 'model', 'quality', 'assessed', 'with', 'a', 'quality', 'measure', 'of', 'the', 'fit', '.', '\\n\\n', 'MAIN', 'HYPOTHESIS', ':', 'the', 'association', 'between', 'childhood', 'trauma', 'and', 'predisposition', 'to', 'AVH', 'is', 'not', 'direct', ',', 'but', 'depends', 'on', 'the', 'impact', 'of', 'violence', 'suffered', 'during', 'childhood', 'on', 'early', 'maladaptive', 'schemas', 'and', 'dissociative', 'symptoms', 'in', 'patients', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 123,
                "end": 146,
                "text": "Auditory Hallucinations",
                "type": "CONDITION"
            },
            {
                "start": 150,
                "end": 163,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 269,
                "end": 282,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 320,
                "end": 350,
                "text": "acoustic-verbal hallucinations",
                "type": "CONDITION"
            },
            {
                "start": 352,
                "end": 355,
                "text": "AVH",
                "type": "CONDITION"
            },
            {
                "start": 752,
                "end": 755,
                "text": "AVH",
                "type": "CONDITION"
            },
            {
                "start": 868,
                "end": 871,
                "text": "AVH",
                "type": "CONDITION"
            },
            {
                "start": 1123,
                "end": 1126,
                "text": "AVH",
                "type": "CONDITION"
            },
            {
                "start": 1171,
                "end": 1174,
                "text": "AVH",
                "type": "CONDITION"
            },
            {
                "start": 1224,
                "end": 1245,
                "text": "dissociative symptoms",
                "type": "CONDITION"
            },
            {
                "start": 1304,
                "end": 1317,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 1322,
                "end": 1325,
                "text": "AVH",
                "type": "CONDITION"
            },
            {
                "start": 2493,
                "end": 2496,
                "text": "AVH",
                "type": "CONDITION"
            },
            {
                "start": 2648,
                "end": 2661,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01124617",
        "study_official_title": "Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia ",
        "study_brief_summary": " The purpose of this study is to investigate the efficacy and safety of tapentadol extended-release (ER) tablets in Japanese participants with moderate to severe chronic (lasting a long time) pain due to painful diabetic peripheral neuropathy (pain in the extremities related to diabetes-induced nerve damage) or postherpetic neuralgia (pain lasting after condition has healed).",
        "text": "Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia | The purpose of this study is to investigate the efficacy and safety of tapentadol extended-release (ER) tablets in Japanese participants with moderate to severe chronic (lasting a long time) pain due to painful diabetic peripheral neuropathy (pain in the extremities related to diabetes-induced nerve damage) or postherpetic neuralgia (pain lasting after condition has healed).",
        "tokens": "['Phase', 'II', 'Study', 'of', 'JNS024ER', 'in', 'Japanese', 'Subjects', 'With', 'Chronic', 'Pain', 'Due', 'to', 'Diabetic', 'Neuropathic', 'Pain', 'or', 'Postherpetic', 'Neuralgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'tapentadol', 'extended', '-', 'release', '(', 'ER', ')', 'tablets', 'in', 'Japanese', 'participants', 'with', 'moderate', 'to', 'severe', 'chronic', '(', 'lasting', 'a', 'long', 'time', ')', 'pain', 'due', 'to', 'painful', 'diabetic', 'peripheral', 'neuropathy', '(', 'pain', 'in', 'the', 'extremities', 'related', 'to', 'diabetes', '-', 'induced', 'nerve', 'damage', ')', 'or', 'postherpetic', 'neuralgia', '(', 'pain', 'lasting', 'after', 'condition', 'has', 'healed', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 26,
                "text": "JNS024ER",
                "type": "DRUG"
            },
            {
                "start": 53,
                "end": 65,
                "text": "Chronic Pain",
                "type": "CONDITION"
            },
            {
                "start": 73,
                "end": 98,
                "text": "Diabetic Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 102,
                "end": 124,
                "text": "Postherpetic Neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 198,
                "end": 208,
                "text": "tapentadol",
                "type": "DRUG"
            },
            {
                "start": 269,
                "end": 322,
                "text": "moderate to severe chronic (lasting a long time) pain",
                "type": "CONDITION"
            },
            {
                "start": 330,
                "end": 368,
                "text": "painful diabetic peripheral neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 370,
                "end": 374,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 405,
                "end": 413,
                "text": "diabetes",
                "type": "CONDITION"
            },
            {
                "start": 439,
                "end": 461,
                "text": "postherpetic neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 463,
                "end": 467,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00875316",
        "study_official_title": "A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane\u2122 Over One Month ",
        "study_brief_summary": " Phytopharm plc is developing Cogane\u2122 which is a new medicine for the treatment of Parkinson's disease (PD). The purpose of the study is to find out if Cogane is safe and well tolerated in both healthy volunteers and Parkinson's disease patients and to determine if there is a difference in the way that the body deals with Cogane (pharmacokinetics) between these two groups.\n\nIt is expected that the study will prove that Cogane\u2122 is safe and well tolerated and will provide us with a pharmacokinetic profile for both subject groups.",
        "text": "A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane\u2122 Over One Month | Phytopharm plc is developing Cogane\u2122 which is a new medicine for the treatment of Parkinson's disease (PD). The purpose of the study is to find out if Cogane is safe and well tolerated in both healthy volunteers and Parkinson's disease patients and to determine if there is a difference in the way that the body deals with Cogane (pharmacokinetics) between these two groups.\n\nIt is expected that the study will prove that Cogane\u2122 is safe and well tolerated and will provide us with a pharmacokinetic profile for both subject groups.",
        "tokens": "['A', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Multiple', 'Dose', '-', 'ascending', ',', 'Placebo', '-', 'controlled', 'Study', 'in', 'Healthy', 'Volunteers', 'and', 'Parkinson', \"'s\", 'Disease', 'Patients', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', 'and', 'PK', 'of', 'Daily', 'Oral', 'Administration', 'of', 'Cogane', '\u2122', 'Over', 'One', 'Month', '|', 'Phytopharm', 'plc', 'is', 'developing', 'Cogane', '\u2122', 'which', 'is', 'a', 'new', 'medicine', 'for', 'the', 'treatment', 'of', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'find', 'out', 'if', 'Cogane', 'is', 'safe', 'and', 'well', 'tolerated', 'in', 'both', 'healthy', 'volunteers', 'and', 'Parkinson', \"'s\", 'disease', 'patients', 'and', 'to', 'determine', 'if', 'there', 'is', 'a', 'difference', 'in', 'the', 'way', 'that', 'the', 'body', 'deals', 'with', 'Cogane', '(', 'pharmacokinetics', ')', 'between', 'these', 'two', 'groups', '.', '\\n\\n', 'It', 'is', 'expected', 'that', 'the', 'study', 'will', 'prove', 'that', 'Cogane', '\u2122', 'is', 'safe', 'and', 'well', 'tolerated', 'and', 'will', 'provide', 'us', 'with', 'a', 'pharmacokinetic', 'profile', 'for', 'both', 'subject', 'groups', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 53,
                "end": 60,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 104,
                "end": 123,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 213,
                "text": "Cogane",
                "type": "DRUG"
            },
            {
                "start": 261,
                "end": 267,
                "text": "Cogane",
                "type": "DRUG"
            },
            {
                "start": 314,
                "end": 333,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 335,
                "end": 337,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 383,
                "end": 389,
                "text": "Cogane",
                "type": "DRUG"
            },
            {
                "start": 448,
                "end": 467,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 555,
                "end": 561,
                "text": "Cogane",
                "type": "DRUG"
            },
            {
                "start": 654,
                "end": 660,
                "text": "Cogane",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05451459",
        "study_official_title": "Fit Families Program: A Multisite Study ",
        "study_brief_summary": " The purpose of the study is twofold. First, the investigator wants to identify the effect of a 12-week online fundamental motor skills (FMS) (e.g., throwing, catching, running) intervention on active participation in physical recreation activities as well as a variety of other factors(parental stress, parental self-efficacy, and children's adaptive skills). Second, the investigator also wants to identify patterns, benefits, constraints, and strategies to active participation in physical recreation activities among families of children with developmental disabilities such as autism, down syndrome, etc (post-program) via focus groups interviews (via zoom) with parents. Participants will be randomly assigned to one of two protocols: 1) Intervention group and 2) wait-listed home-based group. Participants in both groups will receive an activity booklet (in the form of an App) and physical education-related activity items (e.g., ball, hoop). The investigator hypothesizes that both the intervention group will improve in all measures from pre to post compared to the wait-list control group. The study team wants to determine if the differences in the intervention group differ significantly or are equitable in terms of gains in all areas.",
        "text": "Fit Families Program: A Multisite Study | The purpose of the study is twofold. First, the investigator wants to identify the effect of a 12-week online fundamental motor skills (FMS) (e.g., throwing, catching, running) intervention on active participation in physical recreation activities as well as a variety of other factors(parental stress, parental self-efficacy, and children's adaptive skills). Second, the investigator also wants to identify patterns, benefits, constraints, and strategies to active participation in physical recreation activities among families of children with developmental disabilities such as autism, down syndrome, etc (post-program) via focus groups interviews (via zoom) with parents. Participants will be randomly assigned to one of two protocols: 1) Intervention group and 2) wait-listed home-based group. Participants in both groups will receive an activity booklet (in the form of an App) and physical education-related activity items (e.g., ball, hoop). The investigator hypothesizes that both the intervention group will improve in all measures from pre to post compared to the wait-list control group. The study team wants to determine if the differences in the intervention group differ significantly or are equitable in terms of gains in all areas.",
        "tokens": "['Fit', 'Families', 'Program', ':', 'A', 'Multisite', 'Study', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'twofold', '.', 'First', ',', 'the', 'investigator', 'wants', 'to', 'identify', 'the', 'effect', 'of', 'a', '12', '-', 'week', 'online', 'fundamental', 'motor', 'skills', '(', 'FMS', ')', '(', 'e.g.', ',', 'throwing', ',', 'catching', ',', 'running', ')', 'intervention', 'on', 'active', 'participation', 'in', 'physical', 'recreation', 'activities', 'as', 'well', 'as', 'a', 'variety', 'of', 'other', 'factors(parental', 'stress', ',', 'parental', 'self', '-', 'efficacy', ',', 'and', 'children', \"'s\", 'adaptive', 'skills', ')', '.', 'Second', ',', 'the', 'investigator', 'also', 'wants', 'to', 'identify', 'patterns', ',', 'benefits', ',', 'constraints', ',', 'and', 'strategies', 'to', 'active', 'participation', 'in', 'physical', 'recreation', 'activities', 'among', 'families', 'of', 'children', 'with', 'developmental', 'disabilities', 'such', 'as', 'autism', ',', 'down', 'syndrome', ',', 'etc', '(', 'post', '-', 'program', ')', 'via', 'focus', 'groups', 'interviews', '(', 'via', 'zoom', ')', 'with', 'parents', '.', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'two', 'protocols', ':', '1', ')', 'Intervention', 'group', 'and', '2', ')', 'wait', '-', 'listed', 'home', '-', 'based', 'group', '.', 'Participants', 'in', 'both', 'groups', 'will', 'receive', 'an', 'activity', 'booklet', '(', 'in', 'the', 'form', 'of', 'an', 'App', ')', 'and', 'physical', 'education', '-', 'related', 'activity', 'items', '(', 'e.g.', ',', 'ball', ',', 'hoop', ')', '.', 'The', 'investigator', 'hypothesizes', 'that', 'both', 'the', 'intervention', 'group', 'will', 'improve', 'in', 'all', 'measures', 'from', 'pre', 'to', 'post', 'compared', 'to', 'the', 'wait', '-', 'list', 'control', 'group', '.', 'The', 'study', 'team', 'wants', 'to', 'determine', 'if', 'the', 'differences', 'in', 'the', 'intervention', 'group', 'differ', 'significantly', 'or', 'are', 'equitable', 'in', 'terms', 'of', 'gains', 'in', 'all', 'areas', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 145,
                "end": 176,
                "text": "online fundamental motor skills",
                "type": "PHYSICAL"
            },
            {
                "start": 178,
                "end": 181,
                "text": "FMS",
                "type": "PHYSICAL"
            },
            {
                "start": 623,
                "end": 629,
                "text": "autism",
                "type": "CONDITION"
            },
            {
                "start": 631,
                "end": 644,
                "text": "down syndrome",
                "type": "CONDITION"
            },
            {
                "start": 811,
                "end": 833,
                "text": "wait-listed home-based",
                "type": "CONTROL"
            },
            {
                "start": 930,
                "end": 971,
                "text": "physical education-related activity items",
                "type": "PHYSICAL"
            },
            {
                "start": 1117,
                "end": 1126,
                "text": "wait-list",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03064048",
        "study_official_title": "Effect of Nitric Oxide (NO) Supplementation on Neurocognitive Measures in Argininosuccinate Lyase Deficiency (ASLD) ",
        "study_brief_summary": " This is a study involving a dietary supplement. Patients with argininosuccinate lyase deficiency (ASLD) will be randomly assigned to receive either a nitric oxide dietary supplement or placebo for 24 weeks, and then crossed-over to receive the other treatment for 24 weeks. The investigators will assess the effects of the supplement in domains of general cognition, memory, executive functioning, and fine motor functioning in individuals with ASLD.",
        "text": "Effect of Nitric Oxide (NO) Supplementation on Neurocognitive Measures in Argininosuccinate Lyase Deficiency (ASLD) | This is a study involving a dietary supplement. Patients with argininosuccinate lyase deficiency (ASLD) will be randomly assigned to receive either a nitric oxide dietary supplement or placebo for 24 weeks, and then crossed-over to receive the other treatment for 24 weeks. The investigators will assess the effects of the supplement in domains of general cognition, memory, executive functioning, and fine motor functioning in individuals with ASLD.",
        "tokens": "['Effect', 'of', 'Nitric', 'Oxide', '(', 'NO', ')', 'Supplementation', 'on', 'Neurocognitive', 'Measures', 'in', 'Argininosuccinate', 'Lyase', 'Deficiency', '(', 'ASLD', ')', '|', 'This', 'is', 'a', 'study', 'involving', 'a', 'dietary', 'supplement', '.', 'Patients', 'with', 'argininosuccinate', 'lyase', 'deficiency', '(', 'ASLD', ')', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', 'either', 'a', 'nitric', 'oxide', 'dietary', 'supplement', 'or', 'placebo', 'for', '24', 'weeks', ',', 'and', 'then', 'crossed', '-', 'over', 'to', 'receive', 'the', 'other', 'treatment', 'for', '24', 'weeks', '.', 'The', 'investigators', 'will', 'assess', 'the', 'effects', 'of', 'the', 'supplement', 'in', 'domains', 'of', 'general', 'cognition', ',', 'memory', ',', 'executive', 'functioning', ',', 'and', 'fine', 'motor', 'functioning', 'in', 'individuals', 'with', 'ASLD', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 22,
                "text": "Nitric Oxide",
                "type": "DRUG"
            },
            {
                "start": 24,
                "end": 26,
                "text": "NO",
                "type": "DRUG"
            },
            {
                "start": 74,
                "end": 108,
                "text": "Argininosuccinate Lyase Deficiency",
                "type": "CONDITION"
            },
            {
                "start": 110,
                "end": 114,
                "text": "ASLD",
                "type": "CONDITION"
            },
            {
                "start": 180,
                "end": 214,
                "text": "argininosuccinate lyase deficiency",
                "type": "CONDITION"
            },
            {
                "start": 216,
                "end": 220,
                "text": "ASLD",
                "type": "CONDITION"
            },
            {
                "start": 268,
                "end": 280,
                "text": "nitric oxide",
                "type": "DRUG"
            },
            {
                "start": 303,
                "end": 310,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 563,
                "end": 567,
                "text": "ASLD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03835702",
        "study_official_title": "Impact of a Novel Sleep Apnea Management Group Intervention on Positive Airway Pressure Adherence: A Randomized Controlled Trial ",
        "study_brief_summary": " This randomized controlled trial will evaluate people who have moderate-to-severe obstructive sleep apnea (OSA), and have been newly prescribed a Positive Airway Pressure (PAP) machine. Patients with suboptimal adherence, defined by the Center of Medicare and Medicaid criteria (<70 % usage and <4 hours of average daily PAP usage) will be identified. The purpose of this research is to examine the impact of the sleep apnea management (SAM) grouped based-intervention on positive airway pressure adherence and patient report outcomes questionnaires (quality of life, daytime sleepiness and depressive symptoms) and PAP barrier questionnaire compared to a patient group managed by regular non-sleep prescribing provider.",
        "text": "Impact of a Novel Sleep Apnea Management Group Intervention on Positive Airway Pressure Adherence: A Randomized Controlled Trial | This randomized controlled trial will evaluate people who have moderate-to-severe obstructive sleep apnea (OSA), and have been newly prescribed a Positive Airway Pressure (PAP) machine. Patients with suboptimal adherence, defined by the Center of Medicare and Medicaid criteria (<70 % usage and <4 hours of average daily PAP usage) will be identified. The purpose of this research is to examine the impact of the sleep apnea management (SAM) grouped based-intervention on positive airway pressure adherence and patient report outcomes questionnaires (quality of life, daytime sleepiness and depressive symptoms) and PAP barrier questionnaire compared to a patient group managed by regular non-sleep prescribing provider.",
        "tokens": "['Impact', 'of', 'a', 'Novel', 'Sleep', 'Apnea', 'Management', 'Group', 'Intervention', 'on', 'Positive', 'Airway', 'Pressure', 'Adherence', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'randomized', 'controlled', 'trial', 'will', 'evaluate', 'people', 'who', 'have', 'moderate', '-', 'to', '-', 'severe', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'and', 'have', 'been', 'newly', 'prescribed', 'a', 'Positive', 'Airway', 'Pressure', '(', 'PAP', ')', 'machine', '.', 'Patients', 'with', 'suboptimal', 'adherence', ',', 'defined', 'by', 'the', 'Center', 'of', 'Medicare', 'and', 'Medicaid', 'criteria', '(', '<', '70', '%', 'usage', 'and', '<', '4', 'hours', 'of', 'average', 'daily', 'PAP', 'usage', ')', 'will', 'be', 'identified', '.', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'examine', 'the', 'impact', 'of', 'the', 'sleep', 'apnea', 'management', '(', 'SAM', ')', 'grouped', 'based', '-', 'intervention', 'on', 'positive', 'airway', 'pressure', 'adherence', 'and', 'patient', 'report', 'outcomes', 'questionnaires', '(', 'quality', 'of', 'life', ',', 'daytime', 'sleepiness', 'and', 'depressive', 'symptoms', ')', 'and', 'PAP', 'barrier', 'questionnaire', 'compared', 'to', 'a', 'patient', 'group', 'managed', 'by', 'regular', 'non', '-', 'sleep', 'prescribing', 'provider', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 46,
                "text": "Sleep Apnea Management Group",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 63,
                "end": 87,
                "text": "Positive Airway Pressure",
                "type": "OTHER"
            },
            {
                "start": 194,
                "end": 236,
                "text": "moderate-to-severe obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 238,
                "end": 241,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 277,
                "end": 301,
                "text": "Positive Airway Pressure",
                "type": "OTHER"
            },
            {
                "start": 303,
                "end": 306,
                "text": "PAP",
                "type": "OTHER"
            },
            {
                "start": 452,
                "end": 455,
                "text": "PAP",
                "type": "OTHER"
            },
            {
                "start": 544,
                "end": 599,
                "text": "sleep apnea management (SAM) grouped based-intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 603,
                "end": 627,
                "text": "positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 747,
                "end": 750,
                "text": "PAP",
                "type": "OTHER"
            },
            {
                "start": 812,
                "end": 850,
                "text": "regular non-sleep prescribing provider",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03014050",
        "study_official_title": "Effectiveness of Bio-Electro Stimulation Therapy for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease - A Pilot Study ",
        "study_brief_summary": " Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction and non-motor symptoms. Here, the investigators propose in a pilot device feasibility trial to examine whether \"Bio Electro Stimulation Therapy\" (B.E.S.T.) with a small, non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hand can ameliorate some of the symptoms of PD.",
        "text": "Effectiveness of Bio-Electro Stimulation Therapy for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease - A Pilot Study | Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction and non-motor symptoms. Here, the investigators propose in a pilot device feasibility trial to examine whether \"Bio Electro Stimulation Therapy\" (B.E.S.T.) with a small, non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hand can ameliorate some of the symptoms of PD.",
        "tokens": "['Effectiveness', 'of', 'Bio', '-', 'Electro', 'Stimulation', 'Therapy', 'for', 'the', 'Treatment', 'of', 'Motor', 'and', 'Non', '-', 'Motor', 'Symptoms', 'in', 'Parkinson', \"'s\", 'Disease', '-', 'A', 'Pilot', 'Study', '|', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'is', 'a', 'neurodegenerative', 'disorder', 'characterized', 'by', 'motor', 'dysfunction', 'and', 'non', '-', 'motor', 'symptoms', '.', 'Here', ',', 'the', 'investigators', 'propose', 'in', 'a', 'pilot', 'device', 'feasibility', 'trial', 'to', 'examine', 'whether', '\"', 'Bio', 'Electro', 'Stimulation', 'Therapy', '\"', '(', 'B.E.S.T.', ')', 'with', 'a', 'small', ',', 'non', '-', 'invasive', ',', 'handheld', 'electronic', 'device', 'designed', 'to', 'apply', 'micro', 'current', 'stimulation', 'to', 'a', 'person', \"'s\", 'hand', 'can', 'ameliorate', 'some', 'of', 'the', 'symptoms', 'of', 'PD', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 48,
                "text": "Bio-Electro Stimulation Therapy",
                "type": "OTHER"
            },
            {
                "start": 102,
                "end": 121,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 140,
                "end": 159,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 163,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 344,
                "end": 375,
                "text": "Bio Electro Stimulation Therapy",
                "type": "OTHER"
            },
            {
                "start": 378,
                "end": 386,
                "text": "B.E.S.T.",
                "type": "OTHER"
            },
            {
                "start": 545,
                "end": 547,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02065284",
        "study_official_title": "Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation on Walking and Cortical Activation in Patients With Multiple Sclerosis. ",
        "study_brief_summary": " Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.\n\nThe purpose of this study is to compare the effect on walking performance of a home based walking program (HBWP) with Rhythmic Auditory Stimulation (RAS), to that of a HBWP without RAS, or to RAS without walking exercise.\n\nA second part of this study will assess the effects of Rhythmic Auditory Stimulation (RAS) on brain activity in patients with Multiple Sclerosis while performing mental imagery of walking.",
        "text": "Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation on Walking and Cortical Activation in Patients With Multiple Sclerosis. | Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.\n\nThe purpose of this study is to compare the effect on walking performance of a home based walking program (HBWP) with Rhythmic Auditory Stimulation (RAS), to that of a HBWP without RAS, or to RAS without walking exercise.\n\nA second part of this study will assess the effects of Rhythmic Auditory Stimulation (RAS) on brain activity in patients with Multiple Sclerosis while performing mental imagery of walking.",
        "tokens": "['Effects', 'of', 'a', 'Home', 'Based', 'Walking', 'Program', 'Using', 'Rhythmic', 'Auditory', 'Stimulation', 'on', 'Walking', 'and', 'Cortical', 'Activation', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '.', '|', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', 'is', 'a', 'music', 'therapy', 'technique', 'that', 'provides', 'rhythmic', 'auditory', 'cues', '(', 'like', 'a', 'beat', ')', 'to', 'help', 'improve', 'patients', \"'\", 'movements', ',', 'especially', 'when', 'walking', '.', '\\n\\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effect', 'on', 'walking', 'performance', 'of', 'a', 'home', 'based', 'walking', 'program', '(', 'HBWP', ')', 'with', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', ',', 'to', 'that', 'of', 'a', 'HBWP', 'without', 'RAS', ',', 'or', 'to', 'RAS', 'without', 'walking', 'exercise', '.', '\\n\\n', 'A', 'second', 'part', 'of', 'this', 'study', 'will', 'assess', 'the', 'effects', 'of', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', 'on', 'brain', 'activity', 'in', 'patients', 'with', 'Multiple', 'Sclerosis', 'while', 'performing', 'mental', 'imagery', 'of', 'walking', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 39,
                "text": "Home Based Walking Program",
                "type": "PHYSICAL"
            },
            {
                "start": 46,
                "end": 75,
                "text": "Rhythmic Auditory Stimulation",
                "type": "OTHER"
            },
            {
                "start": 128,
                "end": 146,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 150,
                "end": 179,
                "text": "Rhythmic Auditory Stimulation",
                "type": "OTHER"
            },
            {
                "start": 181,
                "end": 184,
                "text": "RAS",
                "type": "OTHER"
            },
            {
                "start": 408,
                "end": 434,
                "text": "home based walking program",
                "type": "PHYSICAL"
            },
            {
                "start": 436,
                "end": 440,
                "text": "HBWP",
                "type": "PHYSICAL"
            },
            {
                "start": 447,
                "end": 476,
                "text": "Rhythmic Auditory Stimulation",
                "type": "OTHER"
            },
            {
                "start": 478,
                "end": 481,
                "text": "RAS",
                "type": "OTHER"
            },
            {
                "start": 497,
                "end": 513,
                "text": "HBWP without RAS",
                "type": "CONTROL"
            },
            {
                "start": 521,
                "end": 549,
                "text": "RAS without walking exercise",
                "type": "CONTROL"
            },
            {
                "start": 607,
                "end": 636,
                "text": "Rhythmic Auditory Stimulation",
                "type": "OTHER"
            },
            {
                "start": 638,
                "end": 641,
                "text": "RAS",
                "type": "OTHER"
            },
            {
                "start": 678,
                "end": 696,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 714,
                "end": 739,
                "text": "mental imagery of walking",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT04280484",
        "study_official_title": "Evaluating the Use of Acute Intermittent Hypoxia to Improve Symptoms in Persons With Multiple Sclerosis ",
        "study_brief_summary": " The overall objective of this project is to investigate the effectiveness of Acute Intermittent Hypoxia (AIH), to improve muscle strength and activity level in individuals with relapsing-remitting MS.",
        "text": "Evaluating the Use of Acute Intermittent Hypoxia to Improve Symptoms in Persons With Multiple Sclerosis | The overall objective of this project is to investigate the effectiveness of Acute Intermittent Hypoxia (AIH), to improve muscle strength and activity level in individuals with relapsing-remitting MS.",
        "tokens": "['Evaluating', 'the', 'Use', 'of', 'Acute', 'Intermittent', 'Hypoxia', 'to', 'Improve', 'Symptoms', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', '|', 'The', 'overall', 'objective', 'of', 'this', 'project', 'is', 'to', 'investigate', 'the', 'effectiveness', 'of', 'Acute', 'Intermittent', 'Hypoxia', '(', 'AIH', ')', ',', 'to', 'improve', 'muscle', 'strength', 'and', 'activity', 'level', 'in', 'individuals', 'with', 'relapsing', '-', 'remitting', 'MS', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 48,
                "text": "Acute Intermittent Hypoxia",
                "type": "OTHER"
            },
            {
                "start": 85,
                "end": 103,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 209,
                "text": "Acute Intermittent Hypoxia",
                "type": "OTHER"
            },
            {
                "start": 211,
                "end": 214,
                "text": "AIH",
                "type": "OTHER"
            },
            {
                "start": 283,
                "end": 305,
                "text": "relapsing-remitting MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01118637",
        "study_official_title": "Stepped Care in the Treatment of Trichotillomania ",
        "study_brief_summary": " Trichotillomania (TTM), repetitive pulling out of one's own hair to the extent that noticeable hair loss occurs, is a distressing condition interfering substantially with functioning and quality of life. The longterm objective of this research is to determine whether psychological treatment of TTM could be disseminated more effectively by using a stepped care model in which less intensive interventions are tried first, with more intensive interventions used only if initial treatment proves insufficient. This project is a pilot study of the first two steps in a stepped care model of treatment. After baseline assessment, 50 participants with TTM will be randomly assigned to (a) Immediate condition, in which they are offered 10-week self-help treatment via an interactive website (Step 1) or (b) Wait List/Delayed Start condition, a 10-week wait list prior to being offered Step 1. In each condition, at the end of Step 1, participants will be offered 8 weeks of in-person habit reversal training provided by psychology graduate students (Step 2). TTM symptoms will be measured from baseline through a follow-up 3 months after the end of Step 2, as will depression, anxiety, quality of life, functional impairment , treatment utilization, and treatment satisfaction.\n\nThe specific aims of the study are:\n\nTo gather preliminary data on the efficacy of web-based self-help, compared to wait list control;\nTo characterize the acceptability of stepped care to patients with TTM by assessing the proportion of enrolled participants who proceed from step 1 to step 2 treatment;\nTo evaluate the convergent validity of four decision rules for concluding that a patient with TTM has benefited sufficiently from a treatment step: (a) No longer meeting TTM diagnostic criteria; (b) Showing a 25% or greater reduction in total scores on self-report and clinician-rated TTM symptoms; (c) achieving complete abstinence from hair-pulling; and (d) clinically significant response on both self-report and clinician-rated TTM symptom measures\nTo evaluate the concurrent and predictive validity of criteria for sufficient benefit from a treatment step by relating them to treatment satisfaction, treatment utilization, and scores on a measure of functional impairment from TTM.",
        "text": "Stepped Care in the Treatment of Trichotillomania | Trichotillomania (TTM), repetitive pulling out of one's own hair to the extent that noticeable hair loss occurs, is a distressing condition interfering substantially with functioning and quality of life. The longterm objective of this research is to determine whether psychological treatment of TTM could be disseminated more effectively by using a stepped care model in which less intensive interventions are tried first, with more intensive interventions used only if initial treatment proves insufficient. This project is a pilot study of the first two steps in a stepped care model of treatment. After baseline assessment, 50 participants with TTM will be randomly assigned to (a) Immediate condition, in which they are offered 10-week self-help treatment via an interactive website (Step 1) or (b) Wait List/Delayed Start condition, a 10-week wait list prior to being offered Step 1. In each condition, at the end of Step 1, participants will be offered 8 weeks of in-person habit reversal training provided by psychology graduate students (Step 2). TTM symptoms will be measured from baseline through a follow-up 3 months after the end of Step 2, as will depression, anxiety, quality of life, functional impairment , treatment utilization, and treatment satisfaction.\n\nThe specific aims of the study are:\n\nTo gather preliminary data on the efficacy of web-based self-help, compared to wait list control;\nTo characterize the acceptability of stepped care to patients with TTM by assessing the proportion of enrolled participants who proceed from step 1 to step 2 treatment;\nTo evaluate the convergent validity of four decision rules for concluding that a patient with TTM has benefited sufficiently from a treatment step: (a) No longer meeting TTM diagnostic criteria; (b) Showing a 25% or greater reduction in total scores on self-report and clinician-rated TTM symptoms; (c) achieving complete abstinence from hair-pulling; and (d) clinically significant response on both self-report and clinician-rated TTM symptom measures\nTo evaluate the concurrent and predictive validity of criteria for sufficient benefit from a treatment step by relating them to treatment satisfaction, treatment utilization, and scores on a measure of functional impairment from TTM.",
        "tokens": "['Stepped', 'Care', 'in', 'the', 'Treatment', 'of', 'Trichotillomania', '|', 'Trichotillomania', '(', 'TTM', ')', ',', 'repetitive', 'pulling', 'out', 'of', 'one', \"'s\", 'own', 'hair', 'to', 'the', 'extent', 'that', 'noticeable', 'hair', 'loss', 'occurs', ',', 'is', 'a', 'distressing', 'condition', 'interfering', 'substantially', 'with', 'functioning', 'and', 'quality', 'of', 'life', '.', 'The', 'longterm', 'objective', 'of', 'this', 'research', 'is', 'to', 'determine', 'whether', 'psychological', 'treatment', 'of', 'TTM', 'could', 'be', 'disseminated', 'more', 'effectively', 'by', 'using', 'a', 'stepped', 'care', 'model', 'in', 'which', 'less', 'intensive', 'interventions', 'are', 'tried', 'first', ',', 'with', 'more', 'intensive', 'interventions', 'used', 'only', 'if', 'initial', 'treatment', 'proves', 'insufficient', '.', 'This', 'project', 'is', 'a', 'pilot', 'study', 'of', 'the', 'first', 'two', 'steps', 'in', 'a', 'stepped', 'care', 'model', 'of', 'treatment', '.', 'After', 'baseline', 'assessment', ',', '50', 'participants', 'with', 'TTM', 'will', 'be', 'randomly', 'assigned', 'to', '(', 'a', ')', 'Immediate', 'condition', ',', 'in', 'which', 'they', 'are', 'offered', '10', '-', 'week', 'self', '-', 'help', 'treatment', 'via', 'an', 'interactive', 'website', '(', 'Step', '1', ')', 'or', '(', 'b', ')', 'Wait', 'List', '/', 'Delayed', 'Start', 'condition', ',', 'a', '10', '-', 'week', 'wait', 'list', 'prior', 'to', 'being', 'offered', 'Step', '1', '.', 'In', 'each', 'condition', ',', 'at', 'the', 'end', 'of', 'Step', '1', ',', 'participants', 'will', 'be', 'offered', '8', 'weeks', 'of', 'in', '-', 'person', 'habit', 'reversal', 'training', 'provided', 'by', 'psychology', 'graduate', 'students', '(', 'Step', '2', ')', '.', 'TTM', 'symptoms', 'will', 'be', 'measured', 'from', 'baseline', 'through', 'a', 'follow', '-', 'up', '3', 'months', 'after', 'the', 'end', 'of', 'Step', '2', ',', 'as', 'will', 'depression', ',', 'anxiety', ',', 'quality', 'of', 'life', ',', 'functional', 'impairment', ',', 'treatment', 'utilization', ',', 'and', 'treatment', 'satisfaction', '.', '\\n\\n', 'The', 'specific', 'aims', 'of', 'the', 'study', 'are', ':', '\\n\\n', 'To', 'gather', 'preliminary', 'data', 'on', 'the', 'efficacy', 'of', 'web', '-', 'based', 'self', '-', 'help', ',', 'compared', 'to', 'wait', 'list', 'control', ';', '\\n', 'To', 'characterize', 'the', 'acceptability', 'of', 'stepped', 'care', 'to', 'patients', 'with', 'TTM', 'by', 'assessing', 'the', 'proportion', 'of', 'enrolled', 'participants', 'who', 'proceed', 'from', 'step', '1', 'to', 'step', '2', 'treatment', ';', '\\n', 'To', 'evaluate', 'the', 'convergent', 'validity', 'of', 'four', 'decision', 'rules', 'for', 'concluding', 'that', 'a', 'patient', 'with', 'TTM', 'has', 'benefited', 'sufficiently', 'from', 'a', 'treatment', 'step', ':', '(', 'a', ')', 'No', 'longer', 'meeting', 'TTM', 'diagnostic', 'criteria', ';', '(', 'b', ')', 'Showing', 'a', '25', '%', 'or', 'greater', 'reduction', 'in', 'total', 'scores', 'on', 'self', '-', 'report', 'and', 'clinician', '-', 'rated', 'TTM', 'symptoms', ';', '(', 'c', ')', 'achieving', 'complete', 'abstinence', 'from', 'hair', '-', 'pulling', ';', 'and', '(', 'd', ')', 'clinically', 'significant', 'response', 'on', 'both', 'self', '-', 'report', 'and', 'clinician', '-', 'rated', 'TTM', 'symptom', 'measures', '\\n', 'To', 'evaluate', 'the', 'concurrent', 'and', 'predictive', 'validity', 'of', 'criteria', 'for', 'sufficient', 'benefit', 'from', 'a', 'treatment', 'step', 'by', 'relating', 'them', 'to', 'treatment', 'satisfaction', ',', 'treatment', 'utilization', ',', 'and', 'scores', 'on', 'a', 'measure', 'of', 'functional', 'impairment', 'from', 'TTM', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 12,
                "text": "Stepped Care",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 33,
                "end": 49,
                "text": "Trichotillomania",
                "type": "CONDITION"
            },
            {
                "start": 52,
                "end": 68,
                "text": "Trichotillomania",
                "type": "CONDITION"
            },
            {
                "start": 70,
                "end": 73,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 320,
                "end": 343,
                "text": "psychological treatment",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 347,
                "end": 350,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 401,
                "end": 419,
                "text": "stepped care model",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 619,
                "end": 637,
                "text": "stepped care model",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 700,
                "end": 703,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 819,
                "end": 838,
                "text": "interactive website",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 855,
                "end": 878,
                "text": "Wait List/Delayed Start",
                "type": "CONTROL"
            },
            {
                "start": 1022,
                "end": 1055,
                "text": "in-person habit reversal training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1107,
                "end": 1110,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 1213,
                "end": 1223,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 1225,
                "end": 1232,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 1410,
                "end": 1429,
                "text": "web-based self-help",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1443,
                "end": 1452,
                "text": "wait list",
                "type": "CONTROL"
            },
            {
                "start": 1499,
                "end": 1511,
                "text": "stepped care",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1529,
                "end": 1532,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 1725,
                "end": 1728,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 1801,
                "end": 1804,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 1916,
                "end": 1919,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 2063,
                "end": 2066,
                "text": "TTM",
                "type": "CONDITION"
            },
            {
                "start": 2313,
                "end": 2316,
                "text": "TTM",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00668837",
        "study_official_title": "Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia. ",
        "study_brief_summary": " Open-Label Extension to the double-blind effectiveness and safety study R076477-SCH-305 to evaluate long-term safety and tolerability in patients with schizophrenia.",
        "text": "Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia. | Open-Label Extension to the double-blind effectiveness and safety study R076477-SCH-305 to evaluate long-term safety and tolerability in patients with schizophrenia.",
        "tokens": "['Open', 'Label', 'Extension', 'to', 'R076477', '-', 'SCH-305', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Paliperidone', 'ER', 'in', 'Subjects', 'With', 'Schizophrenia', '.', '|', 'Open', '-', 'Label', 'Extension', 'to', 'the', 'double', '-', 'blind', 'effectiveness', 'and', 'safety', 'study', 'R076477', '-', 'SCH-305', 'to', 'evaluate', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'in', 'patients', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 83,
                "end": 95,
                "text": "Paliperidone",
                "type": "DRUG"
            },
            {
                "start": 116,
                "end": 129,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 284,
                "end": 297,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03107884",
        "study_official_title": "Metformin to Prevent Inactivity-induced Loss of Muscle Health During Aging ",
        "study_brief_summary": " Muscle atrophy and insulin resistance are common after bed rest in healthy older adults. Metformin treatment has been shown to improve insulin sensitivity and attenuate muscle loss in insulin resistance adults though the mechanisms are not fully known. Metformin used as a preventive strategy to maintain muscle and metabolic health in bed ridden older adults has not been investigated.",
        "text": "Metformin to Prevent Inactivity-induced Loss of Muscle Health During Aging | Muscle atrophy and insulin resistance are common after bed rest in healthy older adults. Metformin treatment has been shown to improve insulin sensitivity and attenuate muscle loss in insulin resistance adults though the mechanisms are not fully known. Metformin used as a preventive strategy to maintain muscle and metabolic health in bed ridden older adults has not been investigated.",
        "tokens": "['Metformin', 'to', 'Prevent', 'Inactivity', '-', 'induced', 'Loss', 'of', 'Muscle', 'Health', 'During', 'Aging', '|', 'Muscle', 'atrophy', 'and', 'insulin', 'resistance', 'are', 'common', 'after', 'bed', 'rest', 'in', 'healthy', 'older', 'adults', '.', 'Metformin', 'treatment', 'has', 'been', 'shown', 'to', 'improve', 'insulin', 'sensitivity', 'and', 'attenuate', 'muscle', 'loss', 'in', 'insulin', 'resistance', 'adults', 'though', 'the', 'mechanisms', 'are', 'not', 'fully', 'known', '.', 'Metformin', 'used', 'as', 'a', 'preventive', 'strategy', 'to', 'maintain', 'muscle', 'and', 'metabolic', 'health', 'in', 'bed', 'ridden', 'older', 'adults', 'has', 'not', 'been', 'investigated', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 9,
                "text": "Metformin",
                "type": "DRUG"
            },
            {
                "start": 40,
                "end": 61,
                "text": "Loss of Muscle Health",
                "type": "CONDITION"
            },
            {
                "start": 77,
                "end": 91,
                "text": "Muscle atrophy",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 114,
                "text": "insulin resistance",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 175,
                "text": "Metformin",
                "type": "DRUG"
            },
            {
                "start": 246,
                "end": 257,
                "text": "muscle loss",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 279,
                "text": "insulin resistance",
                "type": "CONDITION"
            },
            {
                "start": 330,
                "end": 339,
                "text": "Metformin",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04118907",
        "study_official_title": "Effects of Sound Stimulation, Somatosensory Stimulation, Vestibular Stimulation and the Combinations on Tinnitus Loudness and Tinnitus Related Distress in Patients ",
        "study_brief_summary": " In this experiment, patients with chronic pure tone tinnitus were divided into three groups to receive auditory stimulation, somatosensory stimulation, vestibular stimulation and combined stimulation, in order to find an effective way to treat tinnitus",
        "text": "Effects of Sound Stimulation, Somatosensory Stimulation, Vestibular Stimulation and the Combinations on Tinnitus Loudness and Tinnitus Related Distress in Patients | In this experiment, patients with chronic pure tone tinnitus were divided into three groups to receive auditory stimulation, somatosensory stimulation, vestibular stimulation and combined stimulation, in order to find an effective way to treat tinnitus",
        "tokens": "['Effects', 'of', 'Sound', 'Stimulation', ',', 'Somatosensory', 'Stimulation', ',', 'Vestibular', 'Stimulation', 'and', 'the', 'Combinations', 'on', 'Tinnitus', 'Loudness', 'and', 'Tinnitus', 'Related', 'Distress', 'in', 'Patients', '|', 'In', 'this', 'experiment', ',', 'patients', 'with', 'chronic', 'pure', 'tone', 'tinnitus', 'were', 'divided', 'into', 'three', 'groups', 'to', 'receive', 'auditory', 'stimulation', ',', 'somatosensory', 'stimulation', ',', 'vestibular', 'stimulation', 'and', 'combined', 'stimulation', ',', 'in', 'order', 'to', 'find', 'an', 'effective', 'way', 'to', 'treat', 'tinnitus']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND']",
        "entities": [
            {
                "start": 11,
                "end": 28,
                "text": "Sound Stimulation",
                "type": "OTHER"
            },
            {
                "start": 30,
                "end": 55,
                "text": "Somatosensory Stimulation",
                "type": "OTHER"
            },
            {
                "start": 57,
                "end": 79,
                "text": "Vestibular Stimulation",
                "type": "OTHER"
            },
            {
                "start": 104,
                "end": 112,
                "text": "Tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 134,
                "text": "Tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 226,
                "text": "chronic pure tone tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 269,
                "end": 289,
                "text": "auditory stimulation",
                "type": "OTHER"
            },
            {
                "start": 291,
                "end": 316,
                "text": "somatosensory stimulation",
                "type": "OTHER"
            },
            {
                "start": 318,
                "end": 340,
                "text": "vestibular stimulation",
                "type": "OTHER"
            },
            {
                "start": 345,
                "end": 365,
                "text": "combined stimulation",
                "type": "OTHER"
            },
            {
                "start": 410,
                "end": 418,
                "text": "tinnitus",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01810640",
        "study_official_title": "Pre-recovery Percutaneous Biopsy of Livers in Neurological Death Organ Donors - A Pilot Study ",
        "study_brief_summary": " This study's objective is to obtain preliminary data to test the hypotheses that percutaneous liver biopsy in brain death donors is safe and provides reliable histological information. Furthermore, that information when disseminated fully and widely many hours before organ recovery would not only decrease economic costs of wasteful recovery of livers that are not ultimately transplanted but also increase transplantation and decrease cold ischemia times of recovered livers.",
        "text": "Pre-recovery Percutaneous Biopsy of Livers in Neurological Death Organ Donors - A Pilot Study | This study's objective is to obtain preliminary data to test the hypotheses that percutaneous liver biopsy in brain death donors is safe and provides reliable histological information. Furthermore, that information when disseminated fully and widely many hours before organ recovery would not only decrease economic costs of wasteful recovery of livers that are not ultimately transplanted but also increase transplantation and decrease cold ischemia times of recovered livers.",
        "tokens": "['Pre', '-', 'recovery', 'Percutaneous', 'Biopsy', 'of', 'Livers', 'in', 'Neurological', 'Death', 'Organ', 'Donors', '-', 'A', 'Pilot', 'Study', '|', 'This', 'study', \"'s\", 'objective', 'is', 'to', 'obtain', 'preliminary', 'data', 'to', 'test', 'the', 'hypotheses', 'that', 'percutaneous', 'liver', 'biopsy', 'in', 'brain', 'death', 'donors', 'is', 'safe', 'and', 'provides', 'reliable', 'histological', 'information', '.', 'Furthermore', ',', 'that', 'information', 'when', 'disseminated', 'fully', 'and', 'widely', 'many', 'hours', 'before', 'organ', 'recovery', 'would', 'not', 'only', 'decrease', 'economic', 'costs', 'of', 'wasteful', 'recovery', 'of', 'livers', 'that', 'are', 'not', 'ultimately', 'transplanted', 'but', 'also', 'increase', 'transplantation', 'and', 'decrease', 'cold', 'ischemia', 'times', 'of', 'recovered', 'livers', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 42,
                "text": "Percutaneous Biopsy of Livers",
                "type": "OTHER"
            },
            {
                "start": 46,
                "end": 64,
                "text": "Neurological Death",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 202,
                "text": "percutaneous liver biopsy",
                "type": "OTHER"
            },
            {
                "start": 206,
                "end": 217,
                "text": "brain death",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02731365",
        "study_official_title": "Concurrent Deep Brain Stimulation (DBS) Local Field Potential Analysis and Stimulation in a Closed-Loop Neuromodulation Device ",
        "study_brief_summary": " The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming. The data collected and LFP markers identified will serve as guidelines for future stimulation predicted programming.",
        "text": "Concurrent Deep Brain Stimulation (DBS) Local Field Potential Analysis and Stimulation in a Closed-Loop Neuromodulation Device | The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming. The data collected and LFP markers identified will serve as guidelines for future stimulation predicted programming.",
        "tokens": "['Concurrent', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'Local', 'Field', 'Potential', 'Analysis', 'and', 'Stimulation', 'in', 'a', 'Closed', '-', 'Loop', 'Neuromodulation', 'Device', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'study', 'is', 'to', 'allow', 'the', 'investigation', 'of', 'local', 'field', 'potential', '(', 'LFP', ')', 'signals', 'in', 'patients', 'treated', 'with', 'DBS', 'of', 'the', 'STN', '.', 'This', 'study', 'will', 'identify', 'common', 'LFP', 'biomarkers', 'observed', 'as', 'a', 'function', 'of', 'disease', 'symptoms', ',', 'medication', 'effect', ',', 'fluctuations', 'in', 'disease', ',', 'and', 'changes', 'resulting', 'from', 'adjustments', 'from', 'current', 'standard', 'practices', 'of', 'DBS', 'programming', '.', 'The', 'data', 'collected', 'and', 'LFP', 'markers', 'identified', 'will', 'serve', 'as', 'guidelines', 'for', 'future', 'stimulation', 'predicted', 'programming', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 33,
                "text": "Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 35,
                "end": 38,
                "text": "DBS",
                "type": "OTHER"
            },
            {
                "start": 92,
                "end": 126,
                "text": "Closed-Loop Neuromodulation Device",
                "type": "OTHER"
            },
            {
                "start": 258,
                "end": 261,
                "text": "DBS",
                "type": "OTHER"
            },
            {
                "start": 461,
                "end": 498,
                "text": "standard practices of DBS programming",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02021903",
        "study_official_title": "Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies: the Model of an Oral Glucose Load ",
        "study_brief_summary": " Excessive daytime sleepiness (EDS) is observed in 30 to 50 % of patients with Parkinson's disease (PD) patients, Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA). It is a major complain and represents a socially relevant problem as unintended episodes of sleep can also occur while driving for example. Arterial hypotension is frequently observed in patients with PD, DLB and MSA and considered as a marker of autonomic failure. Sleepiness is known to occur preferentially when patients are having arterial hypotension whatever the cause (i.e. postprandial period, administration of hypotensive medication such as dopamine agonists). We hypothesize that arterial hypotension is associated with abnormal sleepiness. We have observed this association in an on-going epidemiological survey Hyperglycaemia induced by oral glucose load - a standardized model simulating food intake during a meal - provokes arterial hypotension in the majority of Parkinson's disease patients with dysautonomia. It can be hypothesised that sleep attacks in these patients could be mediated by this fall in blood pressure.",
        "text": "Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies: the Model of an Oral Glucose Load | Excessive daytime sleepiness (EDS) is observed in 30 to 50 % of patients with Parkinson's disease (PD) patients, Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA). It is a major complain and represents a socially relevant problem as unintended episodes of sleep can also occur while driving for example. Arterial hypotension is frequently observed in patients with PD, DLB and MSA and considered as a marker of autonomic failure. Sleepiness is known to occur preferentially when patients are having arterial hypotension whatever the cause (i.e. postprandial period, administration of hypotensive medication such as dopamine agonists). We hypothesize that arterial hypotension is associated with abnormal sleepiness. We have observed this association in an on-going epidemiological survey Hyperglycaemia induced by oral glucose load - a standardized model simulating food intake during a meal - provokes arterial hypotension in the majority of Parkinson's disease patients with dysautonomia. It can be hypothesised that sleep attacks in these patients could be mediated by this fall in blood pressure.",
        "tokens": "['Post', '-', 'prandial', 'Hypotension', 'and', 'Sleepiness', 'in', 'Parkinson', \"'s\", 'Disease', 'and', 'Other', 'Synucleinopathies', ':', 'the', 'Model', 'of', 'an', 'Oral', 'Glucose', 'Load', '|', 'Excessive', 'daytime', 'sleepiness', '(', 'EDS', ')', 'is', 'observed', 'in', '30', 'to', '50', '%', 'of', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'patients', ',', 'Dementia', 'with', 'Lewy', 'Bodies', '(', 'DLB', ')', 'and', 'Multiple', 'System', 'Atrophy', '(', 'MSA', ')', '.', 'It', 'is', 'a', 'major', 'complain', 'and', 'represents', 'a', 'socially', 'relevant', 'problem', 'as', 'unintended', 'episodes', 'of', 'sleep', 'can', 'also', 'occur', 'while', 'driving', 'for', 'example', '.', 'Arterial', 'hypotension', 'is', 'frequently', 'observed', 'in', 'patients', 'with', 'PD', ',', 'DLB', 'and', 'MSA', 'and', 'considered', 'as', 'a', 'marker', 'of', 'autonomic', 'failure', '.', 'Sleepiness', 'is', 'known', 'to', 'occur', 'preferentially', 'when', 'patients', 'are', 'having', 'arterial', 'hypotension', 'whatever', 'the', 'cause', '(', 'i.e.', 'postprandial', 'period', ',', 'administration', 'of', 'hypotensive', 'medication', 'such', 'as', 'dopamine', 'agonists', ')', '.', 'We', 'hypothesize', 'that', 'arterial', 'hypotension', 'is', 'associated', 'with', 'abnormal', 'sleepiness', '.', 'We', 'have', 'observed', 'this', 'association', 'in', 'an', 'on', '-', 'going', 'epidemiological', 'survey', 'Hyperglycaemia', 'induced', 'by', 'oral', 'glucose', 'load', '-', 'a', 'standardized', 'model', 'simulating', 'food', 'intake', 'during', 'a', 'meal', '-', 'provokes', 'arterial', 'hypotension', 'in', 'the', 'majority', 'of', 'Parkinson', \"'s\", 'disease', 'patients', 'with', 'dysautonomia', '.', 'It', 'can', 'be', 'hypothesised', 'that', 'sleep', 'attacks', 'in', 'these', 'patients', 'could', 'be', 'mediated', 'by', 'this', 'fall', 'in', 'blood', 'pressure', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 25,
                "text": "Post-prandial Hypotension",
                "type": "CONDITION"
            },
            {
                "start": 30,
                "end": 40,
                "text": "Sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 44,
                "end": 63,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 74,
                "end": 91,
                "text": "Synucleinopathies",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 157,
                "text": "Excessive daytime sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 159,
                "end": 162,
                "text": "EDS",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 226,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 228,
                "end": 230,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 267,
                "text": "Dementia with Lewy Bodies",
                "type": "CONDITION"
            },
            {
                "start": 269,
                "end": 272,
                "text": "DLB",
                "type": "CONDITION"
            },
            {
                "start": 278,
                "end": 301,
                "text": "Multiple System Atrophy",
                "type": "CONDITION"
            },
            {
                "start": 303,
                "end": 306,
                "text": "MSA",
                "type": "CONDITION"
            },
            {
                "start": 449,
                "end": 469,
                "text": "Arterial hypotension",
                "type": "CONDITION"
            },
            {
                "start": 510,
                "end": 512,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 514,
                "end": 517,
                "text": "DLB",
                "type": "CONDITION"
            },
            {
                "start": 522,
                "end": 525,
                "text": "MSA",
                "type": "CONDITION"
            },
            {
                "start": 575,
                "end": 585,
                "text": "Sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 644,
                "end": 664,
                "text": "arterial hypotension",
                "type": "CONDITION"
            },
            {
                "start": 800,
                "end": 820,
                "text": "arterial hypotension",
                "type": "CONDITION"
            },
            {
                "start": 849,
                "end": 859,
                "text": "sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 1048,
                "end": 1068,
                "text": "arterial hypotension",
                "type": "CONDITION"
            },
            {
                "start": 1088,
                "end": 1107,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 1164,
                "end": 1177,
                "text": "sleep attacks",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04550650",
        "study_official_title": "Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients ",
        "study_brief_summary": " Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant. We compared the effects of exergaming (EXE), balance (BAL), cycling (CYC), proprioceptive neuromuscular facilitation (PNF), and a standard care wait-listed control group (CON) on clinical and motor symptoms and quality of life (QoL) in people with MS (PwMS).\n\nMethods: PwMS (n = 68, 90% female; age, 47.0 yr; Expanded Disability Status Scale score 5-6) were randomized into five groups. Before and after the interventions (five times a week for 5 wk), PwMS were tested for MS-related clinical and motor symptoms (Multiple Sclerosis Impact Scale-29 (MSIS-29), primary outcome), QoL (EuroQol Five Dimensions Questionnaire), symptoms of depression, gait and balance ability (Tinetti Assessment Tool), static and dynamic balance and fall risk (Berg Balance Scale), walking capacity (6-min walk test), and standing posturography on a force platform.\n\nPatients were followed up for 2 years after 5 weeks of intensive care. Tests are performed every six months.",
        "text": "Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients | Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant. We compared the effects of exergaming (EXE), balance (BAL), cycling (CYC), proprioceptive neuromuscular facilitation (PNF), and a standard care wait-listed control group (CON) on clinical and motor symptoms and quality of life (QoL) in people with MS (PwMS).\n\nMethods: PwMS (n = 68, 90% female; age, 47.0 yr; Expanded Disability Status Scale score 5-6) were randomized into five groups. Before and after the interventions (five times a week for 5 wk), PwMS were tested for MS-related clinical and motor symptoms (Multiple Sclerosis Impact Scale-29 (MSIS-29), primary outcome), QoL (EuroQol Five Dimensions Questionnaire), symptoms of depression, gait and balance ability (Tinetti Assessment Tool), static and dynamic balance and fall risk (Berg Balance Scale), walking capacity (6-min walk test), and standing posturography on a force platform.\n\nPatients were followed up for 2 years after 5 weeks of intensive care. Tests are performed every six months.",
        "tokens": "['Follow', '-', 'up', 'Study', 'of', 'the', 'Effectiveness', 'of', 'Virtual', 'Reality', 'Therapy', 'in', 'MS', 'Patients', '|', 'Different', 'therapies', 'can', 'improve', 'clinical', 'and', 'motor', 'symptoms', 'of', 'multiple', 'sclerosis', '(', 'MS', ')', 'similarly', ',', 'but', 'studies', 'comparing', 'the', 'effects', 'of', 'different', 'exercise', 'therapies', 'on', 'clinical', 'and', 'motor', 'outcomes', 'are', 'scant', '.', 'We', 'compared', 'the', 'effects', 'of', 'exergaming', '(', 'EXE', ')', ',', 'balance', '(', 'BAL', ')', ',', 'cycling', '(', 'CYC', ')', ',', 'proprioceptive', 'neuromuscular', 'facilitation', '(', 'PNF', ')', ',', 'and', 'a', 'standard', 'care', 'wait', '-', 'listed', 'control', 'group', '(', 'CON', ')', 'on', 'clinical', 'and', 'motor', 'symptoms', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'people', 'with', 'MS', '(', 'PwMS', ')', '.', '\\n\\n', 'Methods', ':', 'PwMS', '(', 'n', '=', '68', ',', '90', '%', 'female', ';', 'age', ',', '47.0', 'yr', ';', 'Expanded', 'Disability', 'Status', 'Scale', 'score', '5', '-', '6', ')', 'were', 'randomized', 'into', 'five', 'groups', '.', 'Before', 'and', 'after', 'the', 'interventions', '(', 'five', 'times', 'a', 'week', 'for', '5', 'wk', ')', ',', 'PwMS', 'were', 'tested', 'for', 'MS', '-', 'related', 'clinical', 'and', 'motor', 'symptoms', '(', 'Multiple', 'Sclerosis', 'Impact', 'Scale-29', '(', 'MSIS-29', ')', ',', 'primary', 'outcome', ')', ',', 'QoL', '(', 'EuroQol', 'Five', 'Dimensions', 'Questionnaire', ')', ',', 'symptoms', 'of', 'depression', ',', 'gait', 'and', 'balance', 'ability', '(', 'Tinetti', 'Assessment', 'Tool', ')', ',', 'static', 'and', 'dynamic', 'balance', 'and', 'fall', 'risk', '(', 'Berg', 'Balance', 'Scale', ')', ',', 'walking', 'capacity', '(', '6', '-', 'min', 'walk', 'test', ')', ',', 'and', 'standing', 'posturography', 'on', 'a', 'force', 'platform', '.', '\\n\\n', 'Patients', 'were', 'followed', 'up', 'for', '2', 'years', 'after', '5', 'weeks', 'of', 'intensive', 'care', '.', 'Tests', 'are', 'performed', 'every', 'six', 'months', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 40,
                "end": 63,
                "text": "Virtual Reality Therapy",
                "type": "OTHER"
            },
            {
                "start": 67,
                "end": 69,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 162,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 164,
                "end": 166,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 324,
                "text": "exergaming",
                "type": "PHYSICAL"
            },
            {
                "start": 326,
                "end": 329,
                "text": "EXE",
                "type": "PHYSICAL"
            },
            {
                "start": 332,
                "end": 339,
                "text": "balance",
                "type": "PHYSICAL"
            },
            {
                "start": 341,
                "end": 344,
                "text": "BAL",
                "type": "PHYSICAL"
            },
            {
                "start": 347,
                "end": 354,
                "text": "cycling",
                "type": "PHYSICAL"
            },
            {
                "start": 356,
                "end": 359,
                "text": "CYC",
                "type": "PHYSICAL"
            },
            {
                "start": 362,
                "end": 403,
                "text": "proprioceptive neuromuscular facilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 405,
                "end": 408,
                "text": "PNF",
                "type": "PHYSICAL"
            },
            {
                "start": 417,
                "end": 442,
                "text": "standard care wait-listed",
                "type": "CONTROL"
            },
            {
                "start": 535,
                "end": 537,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 760,
                "end": 762,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 800,
                "end": 818,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 921,
                "end": 931,
                "text": "depression",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04543448",
        "study_official_title": "Investigation the Effect of Cervical Mobilization on Balance and Plantar Pressure Distribution in Multiple Sclerosis Patients: A Randomized Crossover Controlled Study ",
        "study_brief_summary": " MS patients were randomly divided into traditional therapy and traditional therapy + cervical mobilization groups. While muscle strengthening, stretching, balance and coordination exercises were given to the traditional group, cervical mobilization was applied in addition to these in cervical group. Patients received treatments twice a week for 4 weeks. The effect of the applied treatment on the tonus and plantar pressure distribution was analyzed. Treatments were interrupted for 4 weeks and the groups continued with the treatment they did not receive (crossover design). The group that received traditional treatment in the first period completed traditional + cervical mobilization, and the other group with traditional + cervical mobilization traditionally completed the treatment.",
        "text": "Investigation the Effect of Cervical Mobilization on Balance and Plantar Pressure Distribution in Multiple Sclerosis Patients: A Randomized Crossover Controlled Study | MS patients were randomly divided into traditional therapy and traditional therapy + cervical mobilization groups. While muscle strengthening, stretching, balance and coordination exercises were given to the traditional group, cervical mobilization was applied in addition to these in cervical group. Patients received treatments twice a week for 4 weeks. The effect of the applied treatment on the tonus and plantar pressure distribution was analyzed. Treatments were interrupted for 4 weeks and the groups continued with the treatment they did not receive (crossover design). The group that received traditional treatment in the first period completed traditional + cervical mobilization, and the other group with traditional + cervical mobilization traditionally completed the treatment.",
        "tokens": "['Investigation', 'the', 'Effect', 'of', 'Cervical', 'Mobilization', 'on', 'Balance', 'and', 'Plantar', 'Pressure', 'Distribution', 'in', 'Multiple', 'Sclerosis', 'Patients', ':', 'A', 'Randomized', 'Crossover', 'Controlled', 'Study', '|', 'MS', 'patients', 'were', 'randomly', 'divided', 'into', 'traditional', 'therapy', 'and', 'traditional', 'therapy', '+', 'cervical', 'mobilization', 'groups', '.', 'While', 'muscle', 'strengthening', ',', 'stretching', ',', 'balance', 'and', 'coordination', 'exercises', 'were', 'given', 'to', 'the', 'traditional', 'group', ',', 'cervical', 'mobilization', 'was', 'applied', 'in', 'addition', 'to', 'these', 'in', 'cervical', 'group', '.', 'Patients', 'received', 'treatments', 'twice', 'a', 'week', 'for', '4', 'weeks', '.', 'The', 'effect', 'of', 'the', 'applied', 'treatment', 'on', 'the', 'tonus', 'and', 'plantar', 'pressure', 'distribution', 'was', 'analyzed', '.', 'Treatments', 'were', 'interrupted', 'for', '4', 'weeks', 'and', 'the', 'groups', 'continued', 'with', 'the', 'treatment', 'they', 'did', 'not', 'receive', '(', 'crossover', 'design', ')', '.', 'The', 'group', 'that', 'received', 'traditional', 'treatment', 'in', 'the', 'first', 'period', 'completed', 'traditional', '+', 'cervical', 'mobilization', ',', 'and', 'the', 'other', 'group', 'with', 'traditional', '+', 'cervical', 'mobilization', 'traditionally', 'completed', 'the', 'treatment', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 49,
                "text": "Cervical Mobilization",
                "type": "PHYSICAL"
            },
            {
                "start": 98,
                "end": 116,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 169,
                "end": 171,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 208,
                "end": 227,
                "text": "traditional therapy",
                "type": "CONTROL"
            },
            {
                "start": 232,
                "end": 251,
                "text": "traditional therapy",
                "type": "CONTROL"
            },
            {
                "start": 254,
                "end": 275,
                "text": "cervical mobilization",
                "type": "PHYSICAL"
            },
            {
                "start": 290,
                "end": 310,
                "text": "muscle strengthening",
                "type": "CONTROL"
            },
            {
                "start": 312,
                "end": 322,
                "text": "stretching",
                "type": "CONTROL"
            },
            {
                "start": 324,
                "end": 358,
                "text": "balance and coordination exercises",
                "type": "CONTROL"
            },
            {
                "start": 396,
                "end": 417,
                "text": "cervical mobilization",
                "type": "PHYSICAL"
            },
            {
                "start": 771,
                "end": 792,
                "text": "traditional treatment",
                "type": "CONTROL"
            },
            {
                "start": 823,
                "end": 858,
                "text": "traditional + cervical mobilization",
                "type": "PHYSICAL"
            },
            {
                "start": 885,
                "end": 920,
                "text": "traditional + cervical mobilization",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT04653688",
        "study_official_title": "A Prospective Study on Markers of Disease Progression and Gait Within the Parkinsonian Population ",
        "study_brief_summary": " The aim of the project is to evaluate disease progression of patients with Parkinsonian syndrome of various severity through regular home-based gait parameters analysis.\n\nWe identified several steps in this project:\n\nAcquisition of gait data in 120 patients with Parkinsonism at different stages in hospital and ecological condition (during 10 days at home), in a repetitive manner:\n\n30 Early PD patients, before 3 years of disease duration (MDS criteria, 2018)\n30 PD patients with motor fluctuations (5 to 8 years of disease duration) (MDS criteria, 2018)\n30 PD patients with FoG (10 years of disease duration) (MDS criteria, 2018)\n30 patients with MSA (less than 5 years after the first symptom)\nControl groups will be composed by 30 healthy volunteers Correlation analysis with clinical measurements and biomarkers, namely blood biomarkers for neurodegeneration (4HN, NFLT \u2026) and multimodal MRI repeated assessments (Iron overload, inflammation and degeneration) and genetic panel for common haplotypes involved in Parkinsonism.",
        "text": "A Prospective Study on Markers of Disease Progression and Gait Within the Parkinsonian Population | The aim of the project is to evaluate disease progression of patients with Parkinsonian syndrome of various severity through regular home-based gait parameters analysis.\n\nWe identified several steps in this project:\n\nAcquisition of gait data in 120 patients with Parkinsonism at different stages in hospital and ecological condition (during 10 days at home), in a repetitive manner:\n\n30 Early PD patients, before 3 years of disease duration (MDS criteria, 2018)\n30 PD patients with motor fluctuations (5 to 8 years of disease duration) (MDS criteria, 2018)\n30 PD patients with FoG (10 years of disease duration) (MDS criteria, 2018)\n30 patients with MSA (less than 5 years after the first symptom)\nControl groups will be composed by 30 healthy volunteers Correlation analysis with clinical measurements and biomarkers, namely blood biomarkers for neurodegeneration (4HN, NFLT \u2026) and multimodal MRI repeated assessments (Iron overload, inflammation and degeneration) and genetic panel for common haplotypes involved in Parkinsonism.",
        "tokens": "['A', 'Prospective', 'Study', 'on', 'Markers', 'of', 'Disease', 'Progression', 'and', 'Gait', 'Within', 'the', 'Parkinsonian', 'Population', '|', 'The', 'aim', 'of', 'the', 'project', 'is', 'to', 'evaluate', 'disease', 'progression', 'of', 'patients', 'with', 'Parkinsonian', 'syndrome', 'of', 'various', 'severity', 'through', 'regular', 'home', '-', 'based', 'gait', 'parameters', 'analysis', '.', '\\n\\n', 'We', 'identified', 'several', 'steps', 'in', 'this', 'project', ':', '\\n\\n', 'Acquisition', 'of', 'gait', 'data', 'in', '120', 'patients', 'with', 'Parkinsonism', 'at', 'different', 'stages', 'in', 'hospital', 'and', 'ecological', 'condition', '(', 'during', '10', 'days', 'at', 'home', ')', ',', 'in', 'a', 'repetitive', 'manner', ':', '\\n\\n', '30', 'Early', 'PD', 'patients', ',', 'before', '3', 'years', 'of', 'disease', 'duration', '(', 'MDS', 'criteria', ',', '2018', ')', '\\n', '30', 'PD', 'patients', 'with', 'motor', 'fluctuations', '(', '5', 'to', '8', 'years', 'of', 'disease', 'duration', ')', '(', 'MDS', 'criteria', ',', '2018', ')', '\\n', '30', 'PD', 'patients', 'with', 'FoG', '(', '10', 'years', 'of', 'disease', 'duration', ')', '(', 'MDS', 'criteria', ',', '2018', ')', '\\n', '30', 'patients', 'with', 'MSA', '(', 'less', 'than', '5', 'years', 'after', 'the', 'first', 'symptom', ')', '\\n', 'Control', 'groups', 'will', 'be', 'composed', 'by', '30', 'healthy', 'volunteers', 'Correlation', 'analysis', 'with', 'clinical', 'measurements', 'and', 'biomarkers', ',', 'namely', 'blood', 'biomarkers', 'for', 'neurodegeneration', '(', '4HN', ',', 'NFLT', '\u2026', ')', 'and', 'multimodal', 'MRI', 'repeated', 'assessments', '(', 'Iron', 'overload', ',', 'inflammation', 'and', 'degeneration', ')', 'and', 'genetic', 'panel', 'for', 'common', 'haplotypes', 'involved', 'in', 'Parkinsonism', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 74,
                "end": 86,
                "text": "Parkinsonian",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 196,
                "text": "Parkinsonian syndrome",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 375,
                "text": "Parkinsonism",
                "type": "CONDITION"
            },
            {
                "start": 487,
                "end": 495,
                "text": "Early PD",
                "type": "CONDITION"
            },
            {
                "start": 565,
                "end": 567,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 660,
                "end": 662,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1118,
                "end": 1130,
                "text": "Parkinsonism",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05191966",
        "study_official_title": "Comparison of the Effects of Subcostal Anterior Quadratus Lumborum Block and Thoracic Paravertebral Block on Postoperative Acute Pain in Laparoscopic Nephrectomy Surgery ",
        "study_brief_summary": " In this study, it was aimed to evaluate the effects of subcostal anterior quadratus lumborum block (S-QLB3) and thoracic paravertebral block (TPVB) on postoperative acute pain scores and opioid consumption in the first 24 hours after laparoscopic nephrectomy surgery.",
        "text": "Comparison of the Effects of Subcostal Anterior Quadratus Lumborum Block and Thoracic Paravertebral Block on Postoperative Acute Pain in Laparoscopic Nephrectomy Surgery | In this study, it was aimed to evaluate the effects of subcostal anterior quadratus lumborum block (S-QLB3) and thoracic paravertebral block (TPVB) on postoperative acute pain scores and opioid consumption in the first 24 hours after laparoscopic nephrectomy surgery.",
        "tokens": "['Comparison', 'of', 'the', 'Effects', 'of', 'Subcostal', 'Anterior', 'Quadratus', 'Lumborum', 'Block', 'and', 'Thoracic', 'Paravertebral', 'Block', 'on', 'Postoperative', 'Acute', 'Pain', 'in', 'Laparoscopic', 'Nephrectomy', 'Surgery', '|', 'In', 'this', 'study', ',', 'it', 'was', 'aimed', 'to', 'evaluate', 'the', 'effects', 'of', 'subcostal', 'anterior', 'quadratus', 'lumborum', 'block', '(', 'S', '-', 'QLB3', ')', 'and', 'thoracic', 'paravertebral', 'block', '(', 'TPVB', ')', 'on', 'postoperative', 'acute', 'pain', 'scores', 'and', 'opioid', 'consumption', 'in', 'the', 'first', '24', 'hours', 'after', 'laparoscopic', 'nephrectomy', 'surgery', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 72,
                "text": "Subcostal Anterior Quadratus Lumborum Block",
                "type": "SURGICAL"
            },
            {
                "start": 77,
                "end": 105,
                "text": "Thoracic Paravertebral Block",
                "type": "SURGICAL"
            },
            {
                "start": 109,
                "end": 133,
                "text": "Postoperative Acute Pain",
                "type": "CONDITION"
            },
            {
                "start": 137,
                "end": 169,
                "text": "Laparoscopic Nephrectomy Surgery",
                "type": "CONDITION"
            },
            {
                "start": 227,
                "end": 270,
                "text": "subcostal anterior quadratus lumborum block",
                "type": "SURGICAL"
            },
            {
                "start": 272,
                "end": 279,
                "text": "S-QLB3)",
                "type": "SURGICAL"
            },
            {
                "start": 284,
                "end": 312,
                "text": "thoracic paravertebral block",
                "type": "SURGICAL"
            },
            {
                "start": 314,
                "end": 318,
                "text": "TPVB",
                "type": "SURGICAL"
            },
            {
                "start": 406,
                "end": 438,
                "text": "laparoscopic nephrectomy surgery",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05126862",
        "study_official_title": "Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3) ",
        "study_brief_summary": " The purpose of this study is conduct a pilot open trial of a web-based cognitive bias modification intervention to reduce anxiety symptoms in persons with Huntington's disease and persons with Parkinson's disease.",
        "text": "Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3) | The purpose of this study is conduct a pilot open trial of a web-based cognitive bias modification intervention to reduce anxiety symptoms in persons with Huntington's disease and persons with Parkinson's disease.",
        "tokens": "['Measurement', 'and', 'Modification', 'of', 'Threat', 'Interpretation', 'Bias', 'in', 'Neurodegenerative', 'Movement', 'Disorders', '(', 'Aims', '2', '&', '3', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'conduct', 'a', 'pilot', 'open', 'trial', 'of', 'a', 'web', '-', 'based', 'cognitive', 'bias', 'modification', 'intervention', 'to', 'reduce', 'anxiety', 'symptoms', 'in', 'persons', 'with', 'Huntington', \"'s\", 'disease', 'and', 'persons', 'with', 'Parkinson', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 58,
                "text": "Modification of Threat Interpretation Bias",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 62,
                "end": 98,
                "text": "Neurodegenerative Movement Disorders",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 225,
                "text": "web-based cognitive bias modification intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 236,
                "end": 243,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 269,
                "end": 289,
                "text": "Huntington's disease",
                "type": "CONDITION"
            },
            {
                "start": 307,
                "end": 326,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02850055",
        "study_official_title": "Effectiveness Specific Manual Therapy in a Multimodal Physical Therapy Treatment in Patients With Tinnitus and Temporomandibular Joint Disorder. ",
        "study_brief_summary": " Tinnitus is one of the most prevalent symptoms that causes more disability in patients with temporomandibular disorder (TMD). The present study postulates a possible link between temporomandibular joint (TMJ) and inner ear based on their anatomical, biomechanical and physiological relationship, proposing a physiotherapy treatment for the temporomandibular joint to improve tinnitus. The aim of the study is to evaluate the effectiveness of adding specific manual therapy to a multimodal physiotherapy treatment in patients with tinnitus and temporomandibular disorder.",
        "text": "Effectiveness Specific Manual Therapy in a Multimodal Physical Therapy Treatment in Patients With Tinnitus and Temporomandibular Joint Disorder. | Tinnitus is one of the most prevalent symptoms that causes more disability in patients with temporomandibular disorder (TMD). The present study postulates a possible link between temporomandibular joint (TMJ) and inner ear based on their anatomical, biomechanical and physiological relationship, proposing a physiotherapy treatment for the temporomandibular joint to improve tinnitus. The aim of the study is to evaluate the effectiveness of adding specific manual therapy to a multimodal physiotherapy treatment in patients with tinnitus and temporomandibular disorder.",
        "tokens": "['Effectiveness', 'Specific', 'Manual', 'Therapy', 'in', 'a', 'Multimodal', 'Physical', 'Therapy', 'Treatment', 'in', 'Patients', 'With', 'Tinnitus', 'and', 'Temporomandibular', 'Joint', 'Disorder', '.', '|', 'Tinnitus', 'is', 'one', 'of', 'the', 'most', 'prevalent', 'symptoms', 'that', 'causes', 'more', 'disability', 'in', 'patients', 'with', 'temporomandibular', 'disorder', '(', 'TMD', ')', '.', 'The', 'present', 'study', 'postulates', 'a', 'possible', 'link', 'between', 'temporomandibular', 'joint', '(', 'TMJ', ')', 'and', 'inner', 'ear', 'based', 'on', 'their', 'anatomical', ',', 'biomechanical', 'and', 'physiological', 'relationship', ',', 'proposing', 'a', 'physiotherapy', 'treatment', 'for', 'the', 'temporomandibular', 'joint', 'to', 'improve', 'tinnitus', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'adding', 'specific', 'manual', 'therapy', 'to', 'a', 'multimodal', 'physiotherapy', 'treatment', 'in', 'patients', 'with', 'tinnitus', 'and', 'temporomandibular', 'disorder', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 37,
                "text": "Specific Manual Therapy",
                "type": "OTHER"
            },
            {
                "start": 43,
                "end": 80,
                "text": "Multimodal Physical Therapy Treatment",
                "type": "OTHER"
            },
            {
                "start": 98,
                "end": 106,
                "text": "Tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 111,
                "end": 143,
                "text": "Temporomandibular Joint Disorder",
                "type": "CONDITION"
            },
            {
                "start": 147,
                "end": 155,
                "text": "Tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 239,
                "end": 265,
                "text": "temporomandibular disorder",
                "type": "CONDITION"
            },
            {
                "start": 267,
                "end": 270,
                "text": "TMD",
                "type": "CONDITION"
            },
            {
                "start": 455,
                "end": 510,
                "text": "physiotherapy treatment for the temporomandibular joint",
                "type": "OTHER"
            },
            {
                "start": 522,
                "end": 530,
                "text": "tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 596,
                "end": 619,
                "text": "specific manual therapy",
                "type": "OTHER"
            },
            {
                "start": 625,
                "end": 659,
                "text": "multimodal physiotherapy treatment",
                "type": "OTHER"
            },
            {
                "start": 677,
                "end": 685,
                "text": "tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 690,
                "end": 716,
                "text": "temporomandibular disorder",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03314116",
        "study_official_title": "Assessment of Risk Factors for Hearing Loss as a Result of Exposure to Noise During Military Training in the IDF (Israel Defense Forces), and Examination of the Effectiveness of Hearing Protection Video vs Formal Training. ",
        "study_brief_summary": " As part of the proposed work, the investigators would like to examine whether there is a need to use a training video to train IDF combat soldiers to improve the use of ear plugs and to prevent hearing loss from exposure to noise, and to characterize the hearing impaired epidemiology of recruits and the basic rate of hearing loss During basic training.",
        "text": "Assessment of Risk Factors for Hearing Loss as a Result of Exposure to Noise During Military Training in the IDF (Israel Defense Forces), and Examination of the Effectiveness of Hearing Protection Video vs Formal Training. | As part of the proposed work, the investigators would like to examine whether there is a need to use a training video to train IDF combat soldiers to improve the use of ear plugs and to prevent hearing loss from exposure to noise, and to characterize the hearing impaired epidemiology of recruits and the basic rate of hearing loss During basic training.",
        "tokens": "['Assessment', 'of', 'Risk', 'Factors', 'for', 'Hearing', 'Loss', 'as', 'a', 'Result', 'of', 'Exposure', 'to', 'Noise', 'During', 'Military', 'Training', 'in', 'the', 'IDF', '(', 'Israel', 'Defense', 'Forces', ')', ',', 'and', 'Examination', 'of', 'the', 'Effectiveness', 'of', 'Hearing', 'Protection', 'Video', 'vs', 'Formal', 'Training', '.', '|', 'As', 'part', 'of', 'the', 'proposed', 'work', ',', 'the', 'investigators', 'would', 'like', 'to', 'examine', 'whether', 'there', 'is', 'a', 'need', 'to', 'use', 'a', 'training', 'video', 'to', 'train', 'IDF', 'combat', 'soldiers', 'to', 'improve', 'the', 'use', 'of', 'ear', 'plugs', 'and', 'to', 'prevent', 'hearing', 'loss', 'from', 'exposure', 'to', 'noise', ',', 'and', 'to', 'characterize', 'the', 'hearing', 'impaired', 'epidemiology', 'of', 'recruits', 'and', 'the', 'basic', 'rate', 'of', 'hearing', 'loss', 'During', 'basic', 'training', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 43,
                "text": "Hearing Loss",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 202,
                "text": "Hearing Protection Video",
                "type": "OTHER"
            },
            {
                "start": 206,
                "end": 221,
                "text": "Formal Training",
                "type": "OTHER"
            },
            {
                "start": 328,
                "end": 342,
                "text": "training video",
                "type": "OTHER"
            },
            {
                "start": 394,
                "end": 403,
                "text": "ear plugs",
                "type": "OTHER"
            },
            {
                "start": 419,
                "end": 431,
                "text": "hearing loss",
                "type": "CONDITION"
            },
            {
                "start": 480,
                "end": 496,
                "text": "hearing impaired",
                "type": "CONDITION"
            },
            {
                "start": 544,
                "end": 556,
                "text": "hearing loss",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05212194",
        "study_official_title": "The Relationship Between Post Dural Puncture Headache and Joint Laxity ",
        "study_brief_summary": " Post-spinal headache is divided into 3 according to the severity scale. It is divided into 3 groups as mild, moderate and severe according to the presence of symptoms such as nausea, vomiting, and dizziness that prevent daily activity.\n\nIt has been reported that CSF leakage may be higher due to the weakness of the regional dural sac in primary connective tissue diseases with joint laxity and isolated joint hypermobility. Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.\n\nIn this study, it was aimed to investigate whether joint laxity contributes to the development of post-spinal headache by questioning the correlation between joint laxity examination score and postspinal headache in patients with post-spinal headache.",
        "text": "The Relationship Between Post Dural Puncture Headache and Joint Laxity | Post-spinal headache is divided into 3 according to the severity scale. It is divided into 3 groups as mild, moderate and severe according to the presence of symptoms such as nausea, vomiting, and dizziness that prevent daily activity.\n\nIt has been reported that CSF leakage may be higher due to the weakness of the regional dural sac in primary connective tissue diseases with joint laxity and isolated joint hypermobility. Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.\n\nIn this study, it was aimed to investigate whether joint laxity contributes to the development of post-spinal headache by questioning the correlation between joint laxity examination score and postspinal headache in patients with post-spinal headache.",
        "tokens": "['The', 'Relationship', 'Between', 'Post', 'Dural', 'Puncture', 'Headache', 'and', 'Joint', 'Laxity', '|', 'Post', '-', 'spinal', 'headache', 'is', 'divided', 'into', '3', 'according', 'to', 'the', 'severity', 'scale', '.', 'It', 'is', 'divided', 'into', '3', 'groups', 'as', 'mild', ',', 'moderate', 'and', 'severe', 'according', 'to', 'the', 'presence', 'of', 'symptoms', 'such', 'as', 'nausea', ',', 'vomiting', ',', 'and', 'dizziness', 'that', 'prevent', 'daily', 'activity', '.', '\\n\\n', 'It', 'has', 'been', 'reported', 'that', 'CSF', 'leakage', 'may', 'be', 'higher', 'due', 'to', 'the', 'weakness', 'of', 'the', 'regional', 'dural', 'sac', 'in', 'primary', 'connective', 'tissue', 'diseases', 'with', 'joint', 'laxity', 'and', 'isolated', 'joint', 'hypermobility', '.', 'Joint', 'laxity', 'is', 'scored', 'according', 'to', 'the', 'level', 'of', 'motion', 'in', '5', 'different', 'joints', 'and', 'a', 'maximum', 'of', '9', 'points', 'is', 'obtained', '.', '\\n\\n', 'In', 'this', 'study', ',', 'it', 'was', 'aimed', 'to', 'investigate', 'whether', 'joint', 'laxity', 'contributes', 'to', 'the', 'development', 'of', 'post', '-', 'spinal', 'headache', 'by', 'questioning', 'the', 'correlation', 'between', 'joint', 'laxity', 'examination', 'score', 'and', 'postspinal', 'headache', 'in', 'patients', 'with', 'post', '-', 'spinal', 'headache', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 53,
                "text": "Post Dural Puncture Headache",
                "type": "CONDITION"
            },
            {
                "start": 58,
                "end": 70,
                "text": "Joint Laxity",
                "type": "CONDITION"
            },
            {
                "start": 73,
                "end": 93,
                "text": "Post-spinal headache",
                "type": "CONDITION"
            },
            {
                "start": 451,
                "end": 463,
                "text": "joint laxity",
                "type": "CONDITION"
            },
            {
                "start": 477,
                "end": 496,
                "text": "joint hypermobility",
                "type": "CONDITION"
            },
            {
                "start": 498,
                "end": 510,
                "text": "Joint laxity",
                "type": "CONDITION"
            },
            {
                "start": 667,
                "end": 679,
                "text": "joint laxity",
                "type": "CONDITION"
            },
            {
                "start": 714,
                "end": 734,
                "text": "post-spinal headache",
                "type": "CONDITION"
            },
            {
                "start": 774,
                "end": 786,
                "text": "joint laxity",
                "type": "CONDITION"
            },
            {
                "start": 809,
                "end": 828,
                "text": "postspinal headache",
                "type": "CONDITION"
            },
            {
                "start": 846,
                "end": 866,
                "text": "post-spinal headache",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05353452",
        "study_official_title": "Collaborative Care for Anxiety and Depression in Posttraumatic Epilepsy ",
        "study_brief_summary": " The purpose of this research is to evaluate a 6 month change in quality of life in subjects who receive collaborative care calls compared to those subjects who receive usual neurology care. This is a 2-site trial comparing a 24 week neurology-based collaborative care program to usual neurology care among a total of 60 adults with post-traumatic epilepsy.",
        "text": "Collaborative Care for Anxiety and Depression in Posttraumatic Epilepsy | The purpose of this research is to evaluate a 6 month change in quality of life in subjects who receive collaborative care calls compared to those subjects who receive usual neurology care. This is a 2-site trial comparing a 24 week neurology-based collaborative care program to usual neurology care among a total of 60 adults with post-traumatic epilepsy.",
        "tokens": "['Collaborative', 'Care', 'for', 'Anxiety', 'and', 'Depression', 'in', 'Posttraumatic', 'Epilepsy', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'evaluate', 'a', '6', 'month', 'change', 'in', 'quality', 'of', 'life', 'in', 'subjects', 'who', 'receive', 'collaborative', 'care', 'calls', 'compared', 'to', 'those', 'subjects', 'who', 'receive', 'usual', 'neurology', 'care', '.', 'This', 'is', 'a', '2', '-', 'site', 'trial', 'comparing', 'a', '24', 'week', 'neurology', '-', 'based', 'collaborative', 'care', 'program', 'to', 'usual', 'neurology', 'care', 'among', 'a', 'total', 'of', '60', 'adults', 'with', 'post', '-', 'traumatic', 'epilepsy', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 18,
                "text": "Collaborative Care",
                "type": "OTHER"
            },
            {
                "start": 23,
                "end": 30,
                "text": "Anxiety",
                "type": "CONDITION"
            },
            {
                "start": 35,
                "end": 45,
                "text": "Depression",
                "type": "CONDITION"
            },
            {
                "start": 49,
                "end": 71,
                "text": "Posttraumatic Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 196,
                "text": "collaborative care",
                "type": "OTHER"
            },
            {
                "start": 242,
                "end": 262,
                "text": "usual neurology care",
                "type": "OTHER"
            },
            {
                "start": 307,
                "end": 341,
                "text": "neurology-based collaborative care",
                "type": "OTHER"
            },
            {
                "start": 353,
                "end": 373,
                "text": "usual neurology care",
                "type": "OTHER"
            },
            {
                "start": 406,
                "end": 429,
                "text": "post-traumatic epilepsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05018234",
        "study_official_title": "Safety Monitoring for a Novel 3D Printed Mandibular Advancement Device ",
        "study_brief_summary": " The purpose of this study is to evaluate the safety profile of the novel oral appliance (OA )device and to assess patient comfort of the novel OA device.",
        "text": "Safety Monitoring for a Novel 3D Printed Mandibular Advancement Device | The purpose of this study is to evaluate the safety profile of the novel oral appliance (OA )device and to assess patient comfort of the novel OA device.",
        "tokens": "['Safety', 'Monitoring', 'for', 'a', 'Novel', '3D', 'Printed', 'Mandibular', 'Advancement', 'Device', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'profile', 'of', 'the', 'novel', 'oral', 'appliance', '(', 'OA', ')', 'device', 'and', 'to', 'assess', 'patient', 'comfort', 'of', 'the', 'novel', 'OA', 'device', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 70,
                "text": "3D Printed Mandibular Advancement Device",
                "type": "OTHER"
            },
            {
                "start": 146,
                "end": 160,
                "text": "oral appliance",
                "type": "OTHER"
            },
            {
                "start": 162,
                "end": 164,
                "text": "OA",
                "type": "OTHER"
            },
            {
                "start": 216,
                "end": 225,
                "text": "OA device",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00883402",
        "study_official_title": "Asymptomatic Carotid Surgery Trial-2 (ACST-2): an International Randomised Trial to Compare Carotid Endarterectomy With Carotid Artery Stenting to Prevent Stroke ",
        "study_brief_summary": " The trial randomise patients with asymptomatic carotid artery narrowing in whom prompt physical intervention is thought to be needed, but there there is still substantial uncertainty shared by patient and doctor about whether surgery or stenting is the more appropriate choice.\n\nThe study is looking at immediate risks (within one month)and at long term benefits",
        "text": "Asymptomatic Carotid Surgery Trial-2 (ACST-2): an International Randomised Trial to Compare Carotid Endarterectomy With Carotid Artery Stenting to Prevent Stroke | The trial randomise patients with asymptomatic carotid artery narrowing in whom prompt physical intervention is thought to be needed, but there there is still substantial uncertainty shared by patient and doctor about whether surgery or stenting is the more appropriate choice.\n\nThe study is looking at immediate risks (within one month)and at long term benefits",
        "tokens": "['Asymptomatic', 'Carotid', 'Surgery', 'Trial-2', '(', 'ACST-2', '):', 'an', 'International', 'Randomised', 'Trial', 'to', 'Compare', 'Carotid', 'Endarterectomy', 'With', 'Carotid', 'Artery', 'Stenting', 'to', 'Prevent', 'Stroke', '|', 'The', 'trial', 'randomise', 'patients', 'with', 'asymptomatic', 'carotid', 'artery', 'narrowing', 'in', 'whom', 'prompt', 'physical', 'intervention', 'is', 'thought', 'to', 'be', 'needed', ',', 'but', 'there', 'there', 'is', 'still', 'substantial', 'uncertainty', 'shared', 'by', 'patient', 'and', 'doctor', 'about', 'whether', 'surgery', 'or', 'stenting', 'is', 'the', 'more', 'appropriate', 'choice', '.', '\\n\\n', 'The', 'study', 'is', 'looking', 'at', 'immediate', 'risks', '(', 'within', 'one', 'month)and', 'at', 'long', 'term', 'benefits']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 92,
                "end": 114,
                "text": "Carotid Endarterectomy",
                "type": "SURGICAL"
            },
            {
                "start": 120,
                "end": 143,
                "text": "Carotid Artery Stenting",
                "type": "SURGICAL"
            },
            {
                "start": 155,
                "end": 161,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 198,
                "end": 235,
                "text": "asymptomatic carotid artery narrowing",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 397,
                "text": "surgery",
                "type": "SURGICAL"
            },
            {
                "start": 401,
                "end": 409,
                "text": "stenting",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT02801630",
        "study_official_title": "An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia ",
        "study_brief_summary": " This is a double blinded randomized control trial of a Surface Acoustic Wave Patch device for the treatment of Trigeminal Neuralgia. This will be a crossover study for the group that receives the sham device. Subjects will be monitored for subjective criteria of pain and quality of life, as well as objective measurement of analgesic usage.",
        "text": "An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia | This is a double blinded randomized control trial of a Surface Acoustic Wave Patch device for the treatment of Trigeminal Neuralgia. This will be a crossover study for the group that receives the sham device. Subjects will be monitored for subjective criteria of pain and quality of life, as well as objective measurement of analgesic usage.",
        "tokens": "['An', 'Evaluation', 'of', 'the', 'Effect', 'of', 'a', 'Surface', 'Acoustic', 'Wave', 'Patch', 'Device', 'on', 'the', 'Symptons', 'of', 'Trigeminal', 'Neuralgia', '|', 'This', 'is', 'a', 'double', 'blinded', 'randomized', 'control', 'trial', 'of', 'a', 'Surface', 'Acoustic', 'Wave', 'Patch', 'device', 'for', 'the', 'treatment', 'of', 'Trigeminal', 'Neuralgia', '.', 'This', 'will', 'be', 'a', 'crossover', 'study', 'for', 'the', 'group', 'that', 'receives', 'the', 'sham', 'device', '.', 'Subjects', 'will', 'be', 'monitored', 'for', 'subjective', 'criteria', 'of', 'pain', 'and', 'quality', 'of', 'life', ',', 'as', 'well', 'as', 'objective', 'measurement', 'of', 'analgesic', 'usage', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 67,
                "text": "Surface Acoustic Wave Patch Device",
                "type": "OTHER"
            },
            {
                "start": 87,
                "end": 107,
                "text": "Trigeminal Neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 165,
                "end": 199,
                "text": "Surface Acoustic Wave Patch device",
                "type": "OTHER"
            },
            {
                "start": 221,
                "end": 241,
                "text": "Trigeminal Neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 306,
                "end": 317,
                "text": "sham device",
                "type": "CONTROL"
            },
            {
                "start": 373,
                "end": 377,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00018811",
        "study_official_title": "Psychological Assessment and Treatment of Chronic Benign Headache ",
        "study_brief_summary": " Subjects with chronic migraine or tension headaches will receive 12 sessions of biofeedback or relaxation training after fulfilling screening, intake interviews, & psychological testing requirements. They will chart headache pain, anger level, & medication usage throughout baseline, treatment, and 3 month follow-up periods.\n\nMigraine sufferers will receive a combination of progressive muscle relaxation training and thermal biofeedback (learning to warm hands). Subjects are randomly assigned to receive treatment either in the office with the therapist or from another room (where communication will be over a computer). The research is designed to compare the effectiveness of treatment based on location.\n\nTension headache sufferers will receive training in how to reduce their muscle tension levels. They will be randomly assigned to have equipment monitor muscle tension levels either in the forehead or shoulder regions. The research is designed to compare the effectiveness of feedback to the forehead versus the shoulder muscles.",
        "text": "Psychological Assessment and Treatment of Chronic Benign Headache | Subjects with chronic migraine or tension headaches will receive 12 sessions of biofeedback or relaxation training after fulfilling screening, intake interviews, & psychological testing requirements. They will chart headache pain, anger level, & medication usage throughout baseline, treatment, and 3 month follow-up periods.\n\nMigraine sufferers will receive a combination of progressive muscle relaxation training and thermal biofeedback (learning to warm hands). Subjects are randomly assigned to receive treatment either in the office with the therapist or from another room (where communication will be over a computer). The research is designed to compare the effectiveness of treatment based on location.\n\nTension headache sufferers will receive training in how to reduce their muscle tension levels. They will be randomly assigned to have equipment monitor muscle tension levels either in the forehead or shoulder regions. The research is designed to compare the effectiveness of feedback to the forehead versus the shoulder muscles.",
        "tokens": "['Psychological', 'Assessment', 'and', 'Treatment', 'of', 'Chronic', 'Benign', 'Headache', '|', 'Subjects', 'with', 'chronic', 'migraine', 'or', 'tension', 'headaches', 'will', 'receive', '12', 'sessions', 'of', 'biofeedback', 'or', 'relaxation', 'training', 'after', 'fulfilling', 'screening', ',', 'intake', 'interviews', ',', '&', 'psychological', 'testing', 'requirements', '.', 'They', 'will', 'chart', 'headache', 'pain', ',', 'anger', 'level', ',', '&', 'medication', 'usage', 'throughout', 'baseline', ',', 'treatment', ',', 'and', '3', 'month', 'follow', '-', 'up', 'periods', '.', '\\n\\n', 'Migraine', 'sufferers', 'will', 'receive', 'a', 'combination', 'of', 'progressive', 'muscle', 'relaxation', 'training', 'and', 'thermal', 'biofeedback', '(', 'learning', 'to', 'warm', 'hands', ')', '.', 'Subjects', 'are', 'randomly', 'assigned', 'to', 'receive', 'treatment', 'either', 'in', 'the', 'office', 'with', 'the', 'therapist', 'or', 'from', 'another', 'room', '(', 'where', 'communication', 'will', 'be', 'over', 'a', 'computer', ')', '.', 'The', 'research', 'is', 'designed', 'to', 'compare', 'the', 'effectiveness', 'of', 'treatment', 'based', 'on', 'location', '.', '\\n\\n', 'Tension', 'headache', 'sufferers', 'will', 'receive', 'training', 'in', 'how', 'to', 'reduce', 'their', 'muscle', 'tension', 'levels', '.', 'They', 'will', 'be', 'randomly', 'assigned', 'to', 'have', 'equipment', 'monitor', 'muscle', 'tension', 'levels', 'either', 'in', 'the', 'forehead', 'or', 'shoulder', 'regions', '.', 'The', 'research', 'is', 'designed', 'to', 'compare', 'the', 'effectiveness', 'of', 'feedback', 'to', 'the', 'forehead', 'versus', 'the', 'shoulder', 'muscles', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 65,
                "text": "Chronic Benign Headache",
                "type": "CONDITION"
            },
            {
                "start": 82,
                "end": 98,
                "text": "chronic migraine",
                "type": "CONDITION"
            },
            {
                "start": 102,
                "end": 119,
                "text": "tension headaches",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 159,
                "text": "biofeedback",
                "type": "OTHER"
            },
            {
                "start": 163,
                "end": 182,
                "text": "relaxation training",
                "type": "OTHER"
            },
            {
                "start": 284,
                "end": 297,
                "text": "headache pain",
                "type": "CONDITION"
            },
            {
                "start": 299,
                "end": 304,
                "text": "anger",
                "type": "CONDITION"
            },
            {
                "start": 395,
                "end": 403,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 444,
                "end": 482,
                "text": "progressive muscle relaxation training",
                "type": "OTHER"
            },
            {
                "start": 487,
                "end": 506,
                "text": "thermal biofeedback",
                "type": "OTHER"
            },
            {
                "start": 780,
                "end": 796,
                "text": "Tension headache",
                "type": "CONDITION"
            },
            {
                "start": 932,
                "end": 946,
                "text": "muscle tension",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01788774",
        "study_official_title": "Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM\u00ae at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder ",
        "study_brief_summary": " This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.",
        "text": "Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM\u00ae at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder | This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.",
        "tokens": "['Phase', 'I', ',', 'Open', '-', 'Label', ',', 'Randomized', ',', 'Parallel', 'Study', 'to', 'Evaluate', 'the', 'Pharmacokinetics', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'One', 'Intramuscular', 'Injection', 'of', 'Risperidone', 'ISM', '\u00ae', 'at', 'Different', 'Dose', 'Strengths', 'in', 'Subjects', 'With', 'Schizophrenia', 'or', 'Schizoaffective', 'Disorder', '|', 'This', 'clinical', 'trial', 'is', 'designed', 'to', 'evaluate', 'different', 'dosages', 'of', 'risperidone', 'ISM', ',', 'a', 'new', 'long', '-', 'acting', 'injectable', 'form', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 141,
                "end": 152,
                "text": "Risperidone",
                "type": "DRUG"
            },
            {
                "start": 203,
                "end": 216,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 244,
                "text": "Schizoaffective Disorder",
                "type": "CONDITION"
            },
            {
                "start": 312,
                "end": 323,
                "text": "risperidone",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02842853",
        "study_official_title": "Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years ",
        "study_brief_summary": " The purpose of the study was to evaluate immune lot consistency of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine and the immune non-inferiority compared to the licensed vaccine Menactra\u00ae, and describe the safety and additional immunogenicity of these study vaccines in adolescents and adults 10 to 55 years of age in the United States (US).\n\nPrimary Objectives:\n\nTo demonstrate the immune lot consistency of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine with respect to serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).\nTo demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra\u00ae.\n\nSecondary Objective:\n\nTo demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra\u00ae in the adult population (18 to 55 years old).\nTo demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra\u00ae in the adolescent population (10 to 17 years old).\nTo compare the hSBA vaccine seroresponses of meningococcal serogroups A, C, Y, and W for each of 3 lots of MenACYW Conjugate vaccine 30 days (+14 days) after vaccination.\nTo compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of Menactra\u00ae.\n\nObservational Objectives:\n\nTo describe the safety profile of MenACYW Conjugate vaccine and that of the licensed Menactra\u00ae.",
        "text": "Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years | The purpose of the study was to evaluate immune lot consistency of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine and the immune non-inferiority compared to the licensed vaccine Menactra\u00ae, and describe the safety and additional immunogenicity of these study vaccines in adolescents and adults 10 to 55 years of age in the United States (US).\n\nPrimary Objectives:\n\nTo demonstrate the immune lot consistency of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine with respect to serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).\nTo demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra\u00ae.\n\nSecondary Objective:\n\nTo demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra\u00ae in the adult population (18 to 55 years old).\nTo demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of MenACYW Conjugate vaccine (pooled Lots 1 to 3) compared to those observed following the administration of a single dose of Menactra\u00ae in the adolescent population (10 to 17 years old).\nTo compare the hSBA vaccine seroresponses of meningococcal serogroups A, C, Y, and W for each of 3 lots of MenACYW Conjugate vaccine 30 days (+14 days) after vaccination.\nTo compare the hSBA antibody GMTs of meningococcal serogroups A, C, Y, and W following the administration of MenACYW Conjugate vaccine to those observed following the administration of Menactra\u00ae.\n\nObservational Objectives:\n\nTo describe the safety profile of MenACYW Conjugate vaccine and that of the licensed Menactra\u00ae.",
        "tokens": "['Immune', 'Lot', 'Consistency', ',', 'Immunogenicity', ',', 'and', 'Safety', 'of', 'an', 'Investigational', 'Quadrivalent', 'Meningococcal', 'Conjugate', 'Vaccine', 'in', 'Adolescents', 'and', 'Adults', 'Aged', '10', 'to', '55', 'Years', '|', 'The', 'purpose', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'immune', 'lot', 'consistency', 'of', 'Meningococcal', 'Polysaccharide', '(', 'Serogroups', 'A', ',', 'C', ',', 'Y', 'and', 'W', ')', 'Tetanus', 'Toxoid', '(', 'MenACYW', ')', 'Conjugate', 'vaccine', 'and', 'the', 'immune', 'non', '-', 'inferiority', 'compared', 'to', 'the', 'licensed', 'vaccine', 'Menactra', '\u00ae', ',', 'and', 'describe', 'the', 'safety', 'and', 'additional', 'immunogenicity', 'of', 'these', 'study', 'vaccines', 'in', 'adolescents', 'and', 'adults', '10', 'to', '55', 'years', 'of', 'age', 'in', 'the', 'United', 'States', '(', 'US', ')', '.', '\\n\\n', 'Primary', 'Objectives', ':', '\\n\\n', 'To', 'demonstrate', 'the', 'immune', 'lot', 'consistency', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'with', 'respect', 'to', 'serum', 'bactericidal', 'assay', 'using', 'human', 'complement', '(', 'hSBA', ')', 'geometric', 'mean', 'titers', '(', 'GMTs', ')', '.', '\\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '\u00ae', '.', '\\n\\n', 'Secondary', 'Objective', ':', '\\n\\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '\u00ae', 'in', 'the', 'adult', 'population', '(', '18', 'to', '55', 'years', 'old', ')', '.', '\\n', 'To', 'demonstrate', 'the', 'non', '-', 'inferiority', 'of', 'the', 'antibody', 'responses', 'to', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'MenACYW', 'Conjugate', 'vaccine', '(', 'pooled', 'Lots', '1', 'to', '3', ')', 'compared', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'a', 'single', 'dose', 'of', 'Menactra', '\u00ae', 'in', 'the', 'adolescent', 'population', '(', '10', 'to', '17', 'years', 'old', ')', '.', '\\n', 'To', 'compare', 'the', 'hSBA', 'vaccine', 'seroresponses', 'of', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'for', 'each', 'of', '3', 'lots', 'of', 'MenACYW', 'Conjugate', 'vaccine', '30', 'days', '(', '+14', 'days', ')', 'after', 'vaccination', '.', '\\n', 'To', 'compare', 'the', 'hSBA', 'antibody', 'GMTs', 'of', 'meningococcal', 'serogroups', 'A', ',', 'C', ',', 'Y', ',', 'and', 'W', 'following', 'the', 'administration', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'to', 'those', 'observed', 'following', 'the', 'administration', 'of', 'Menactra', '\u00ae', '.', '\\n\\n', 'Observational', 'Objectives', ':', '\\n\\n', 'To', 'describe', 'the', 'safety', 'profile', 'of', 'MenACYW', 'Conjugate', 'vaccine', 'and', 'that', 'of', 'the', 'licensed', 'Menactra', '\u00ae', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O']",
        "entities": [
            {
                "start": 73,
                "end": 117,
                "text": "Quadrivalent Meningococcal Conjugate Vaccine",
                "type": "DRUG"
            },
            {
                "start": 233,
                "end": 331,
                "text": "Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 396,
                "end": 404,
                "text": "Menactra",
                "type": "DRUG"
            },
            {
                "start": 742,
                "end": 767,
                "text": "MenACYW Conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 1022,
                "end": 1047,
                "text": "MenACYW Conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 1145,
                "end": 1153,
                "text": "Menactra",
                "type": "DRUG"
            },
            {
                "start": 1332,
                "end": 1357,
                "text": "MenACYW Conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 1455,
                "end": 1463,
                "text": "Menactra",
                "type": "DRUG"
            },
            {
                "start": 1664,
                "end": 1689,
                "text": "MenACYW Conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 1787,
                "end": 1795,
                "text": "Menactra",
                "type": "DRUG"
            },
            {
                "start": 1955,
                "end": 1980,
                "text": "MenACYW Conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 2128,
                "end": 2153,
                "text": "MenACYW Conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 2204,
                "end": 2212,
                "text": "Menactra",
                "type": "DRUG"
            },
            {
                "start": 2277,
                "end": 2302,
                "text": "MenACYW Conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 2328,
                "end": 2336,
                "text": "Menactra",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04032431",
        "study_official_title": "The Effect of a Telerehabilitation Virtual Reality Intervention on Functional Upper Limb Activities in People With Multiple Sclerosis ",
        "study_brief_summary": " This study aims to investigate the effectiveness of a home-based telerehabilitation program specifically designed for upper limbs, based on Virtual Reality (VR) in individuals affected by Multiple Sclerosis.",
        "text": "The Effect of a Telerehabilitation Virtual Reality Intervention on Functional Upper Limb Activities in People With Multiple Sclerosis | This study aims to investigate the effectiveness of a home-based telerehabilitation program specifically designed for upper limbs, based on Virtual Reality (VR) in individuals affected by Multiple Sclerosis.",
        "tokens": "['The', 'Effect', 'of', 'a', 'Telerehabilitation', 'Virtual', 'Reality', 'Intervention', 'on', 'Functional', 'Upper', 'Limb', 'Activities', 'in', 'People', 'With', 'Multiple', 'Sclerosis', '|', 'This', 'study', 'aims', 'to', 'investigate', 'the', 'effectiveness', 'of', 'a', 'home', '-', 'based', 'telerehabilitation', 'program', 'specifically', 'designed', 'for', 'upper', 'limbs', ',', 'based', 'on', 'Virtual', 'Reality', '(', 'VR', ')', 'in', 'individuals', 'affected', 'by', 'Multiple', 'Sclerosis', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 50,
                "text": "Telerehabilitation Virtual Reality",
                "type": "OTHER"
            },
            {
                "start": 115,
                "end": 133,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 291,
                "text": "telerehabilitation program specifically designed for upper limbs, based on Virtual Reality",
                "type": "OTHER"
            },
            {
                "start": 293,
                "end": 295,
                "text": "VR",
                "type": "OTHER"
            },
            {
                "start": 324,
                "end": 342,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05346471",
        "study_official_title": "Infra- and Supratentorial Neuromonitoring in Patients With Posterior Fossa Lesions: DUAL-ICP Trial ",
        "study_brief_summary": " Invasive neuromonitoring of intracranial pressure (ICP) is an important element of neurosurgical critical care that is used primarily as an indicator of adequate cerebral perfusion in patients, when clinical observation is not an option. Due to the constraint in size and the critical structures within the posterior fossa, detection of intracranial pressure particularly in the postoperative phase has been deemed desirable in patients with surgery in this region, particularly in those subjected to prolonged procedures and critical care.\n\nThe posterior fossa is an anatomically constricted compartment with narrow spaces and intracranial hypertension quickly leads to brainstem damage and neurological dysfunction. ICP in the supratentorial space not necessarily correlates with ICP in the infratentorial space. Some authors claim that it would be beneficial to measure ICP in infratentorial space after posterior fossa surgery in some cases.\n\nThe relationship between the intracranial pressure profiles in the supratentorial and infratentorial compartments remain unclear. After a neurosurgical operation in the posterior fossa there are most likely pressure differences between supra- and infratentorial spaces. It is well known that the pressure within the skull is unevenly distributed, with appreciable ICP gradients.\n\nThus, the investigators intend to apply the intracranial multimodal monitoring in both infratentorial and supratentorial compartments simultaneously. Such coincident measurements most likely will be the most sensitive way to assess focal swelling, ischemia and tissue perfusion, or other relevant complications in the posterior fossa structures.\n\nThe goal of this study is to test whether direct infratentorial monitoring is a more efficacious method for detecting dynamic changes in the operative compartment and whether it is safe, in view of the critical structures within the region.",
        "text": "Infra- and Supratentorial Neuromonitoring in Patients With Posterior Fossa Lesions: DUAL-ICP Trial | Invasive neuromonitoring of intracranial pressure (ICP) is an important element of neurosurgical critical care that is used primarily as an indicator of adequate cerebral perfusion in patients, when clinical observation is not an option. Due to the constraint in size and the critical structures within the posterior fossa, detection of intracranial pressure particularly in the postoperative phase has been deemed desirable in patients with surgery in this region, particularly in those subjected to prolonged procedures and critical care.\n\nThe posterior fossa is an anatomically constricted compartment with narrow spaces and intracranial hypertension quickly leads to brainstem damage and neurological dysfunction. ICP in the supratentorial space not necessarily correlates with ICP in the infratentorial space. Some authors claim that it would be beneficial to measure ICP in infratentorial space after posterior fossa surgery in some cases.\n\nThe relationship between the intracranial pressure profiles in the supratentorial and infratentorial compartments remain unclear. After a neurosurgical operation in the posterior fossa there are most likely pressure differences between supra- and infratentorial spaces. It is well known that the pressure within the skull is unevenly distributed, with appreciable ICP gradients.\n\nThus, the investigators intend to apply the intracranial multimodal monitoring in both infratentorial and supratentorial compartments simultaneously. Such coincident measurements most likely will be the most sensitive way to assess focal swelling, ischemia and tissue perfusion, or other relevant complications in the posterior fossa structures.\n\nThe goal of this study is to test whether direct infratentorial monitoring is a more efficacious method for detecting dynamic changes in the operative compartment and whether it is safe, in view of the critical structures within the region.",
        "tokens": "['Infra-', 'and', 'Supratentorial', 'Neuromonitoring', 'in', 'Patients', 'With', 'Posterior', 'Fossa', 'Lesions', ':', 'DUAL', '-', 'ICP', 'Trial', '|', 'Invasive', 'neuromonitoring', 'of', 'intracranial', 'pressure', '(', 'ICP', ')', 'is', 'an', 'important', 'element', 'of', 'neurosurgical', 'critical', 'care', 'that', 'is', 'used', 'primarily', 'as', 'an', 'indicator', 'of', 'adequate', 'cerebral', 'perfusion', 'in', 'patients', ',', 'when', 'clinical', 'observation', 'is', 'not', 'an', 'option', '.', 'Due', 'to', 'the', 'constraint', 'in', 'size', 'and', 'the', 'critical', 'structures', 'within', 'the', 'posterior', 'fossa', ',', 'detection', 'of', 'intracranial', 'pressure', 'particularly', 'in', 'the', 'postoperative', 'phase', 'has', 'been', 'deemed', 'desirable', 'in', 'patients', 'with', 'surgery', 'in', 'this', 'region', ',', 'particularly', 'in', 'those', 'subjected', 'to', 'prolonged', 'procedures', 'and', 'critical', 'care', '.', '\\n\\n', 'The', 'posterior', 'fossa', 'is', 'an', 'anatomically', 'constricted', 'compartment', 'with', 'narrow', 'spaces', 'and', 'intracranial', 'hypertension', 'quickly', 'leads', 'to', 'brainstem', 'damage', 'and', 'neurological', 'dysfunction', '.', 'ICP', 'in', 'the', 'supratentorial', 'space', 'not', 'necessarily', 'correlates', 'with', 'ICP', 'in', 'the', 'infratentorial', 'space', '.', 'Some', 'authors', 'claim', 'that', 'it', 'would', 'be', 'beneficial', 'to', 'measure', 'ICP', 'in', 'infratentorial', 'space', 'after', 'posterior', 'fossa', 'surgery', 'in', 'some', 'cases', '.', '\\n\\n', 'The', 'relationship', 'between', 'the', 'intracranial', 'pressure', 'profiles', 'in', 'the', 'supratentorial', 'and', 'infratentorial', 'compartments', 'remain', 'unclear', '.', 'After', 'a', 'neurosurgical', 'operation', 'in', 'the', 'posterior', 'fossa', 'there', 'are', 'most', 'likely', 'pressure', 'differences', 'between', 'supra-', 'and', 'infratentorial', 'spaces', '.', 'It', 'is', 'well', 'known', 'that', 'the', 'pressure', 'within', 'the', 'skull', 'is', 'unevenly', 'distributed', ',', 'with', 'appreciable', 'ICP', 'gradients', '.', '\\n\\n', 'Thus', ',', 'the', 'investigators', 'intend', 'to', 'apply', 'the', 'intracranial', 'multimodal', 'monitoring', 'in', 'both', 'infratentorial', 'and', 'supratentorial', 'compartments', 'simultaneously', '.', 'Such', 'coincident', 'measurements', 'most', 'likely', 'will', 'be', 'the', 'most', 'sensitive', 'way', 'to', 'assess', 'focal', 'swelling', ',', 'ischemia', 'and', 'tissue', 'perfusion', ',', 'or', 'other', 'relevant', 'complications', 'in', 'the', 'posterior', 'fossa', 'structures', '.', '\\n\\n', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'test', 'whether', 'direct', 'infratentorial', 'monitoring', 'is', 'a', 'more', 'efficacious', 'method', 'for', 'detecting', 'dynamic', 'changes', 'in', 'the', 'operative', 'compartment', 'and', 'whether', 'it', 'is', 'safe', ',', 'in', 'view', 'of', 'the', 'critical', 'structures', 'within', 'the', 'region', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 59,
                "end": 82,
                "text": "Posterior Fossa Lesions",
                "type": "CONDITION"
            },
            {
                "start": 1676,
                "end": 1684,
                "text": "ischemia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01497652",
        "study_official_title": "A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy ",
        "study_brief_summary": " The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg daily for twelve weeks. The secondary objective is to assess changes in the SCOPA-COG, FAB, and UPDRS II & III at the end of week 14.",
        "text": "A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy | The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg daily for twelve weeks. The secondary objective is to assess changes in the SCOPA-COG, FAB, and UPDRS II & III at the end of week 14.",
        "tokens": "['A', 'Double', 'Blind', 'Placebo', 'Controlled', 'Trial', 'Evaluating', 'Rasagiline', 'Effects', 'on', 'Cognition', 'in', 'Parkinson', \"'s\", 'Disease', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', 'Receiving', 'Dopaminergic', 'Therapy', '|', 'The', 'present', 'pilot', 'study', 'is', 'designed', 'to', 'assess', 'the', 'extent', 'to', 'which', 'rasagiline', 'may', 'improve', 'cognition', 'in', 'Parkinson', \"'s\", 'disease', 'patients', 'requiring', 'dopaminergic', 'therapy', '.', 'The', 'primary', 'objective', 'is', 'to', 'assess', 'improvement', 'in', 'the', 'Montreal', 'Cognitive', 'Assessment', '(', 'MoCA', ')', 'in', 'patients', 'who', 'have', 'been', 'on', 'rasagiline', 'at', '1', 'mg', 'daily', 'for', 'twelve', 'weeks', '.', 'The', 'secondary', 'objective', 'is', 'to', 'assess', 'changes', 'in', 'the', 'SCOPA', '-', 'COG', ',', 'FAB', ',', 'and', 'UPDRS', 'II', '&', 'III', 'at', 'the', 'end', 'of', 'week', '14', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 22,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 51,
                "end": 61,
                "text": "Rasagiline",
                "type": "DRUG"
            },
            {
                "start": 86,
                "end": 105,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 145,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 176,
                "text": "Dopaminergic Therapy",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 255,
                "text": "rasagiline",
                "type": "DRUG"
            },
            {
                "start": 281,
                "end": 300,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 320,
                "end": 340,
                "text": "dopaminergic therapy",
                "type": "CONDITION"
            },
            {
                "start": 462,
                "end": 472,
                "text": "rasagiline",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04373616",
        "study_official_title": "A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Target Engagement of ACI-24 in Adults With Down Syndrome ",
        "study_brief_summary": " This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.",
        "text": "A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Target Engagement of ACI-24 in Adults With Down Syndrome | This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.",
        "tokens": "['A', 'Phase', '2', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', '-', 'controlled', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', 'and', 'Target', 'Engagement', 'of', 'ACI-24', 'in', 'Adults', 'With', 'Down', 'Syndrome', '|', 'This', 'study', 'is', 'a', 'prospective', 'multicenter', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', ',', 'randomized', 'study', 'to', 'assess', 'the', 'effect', 'of', 'one', 'dose', 'ACI-24', 'versus', 'placebo', 'over', 'a', '74', '-', 'week', 'treatment', 'period', 'and', '26', '-', 'week', 'safety', 'follow', '-', 'up', 'period', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 36,
                "end": 43,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 121,
                "end": 127,
                "text": "ACI-24",
                "type": "DRUG"
            },
            {
                "start": 143,
                "end": 156,
                "text": "Down Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 207,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 284,
                "end": 290,
                "text": "ACI-24",
                "type": "DRUG"
            },
            {
                "start": 298,
                "end": 305,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03119311",
        "study_official_title": "A Novel Diagnostic Method for Exotropia Using Video-oculography ",
        "study_brief_summary": " Thirty-four subjects with constant exotropia were included. Two independent ophthalmologists measured the angle of ocular deviation using alternate prism cover test (APCT). The video files and data with the changes in ocular deviation during the alternate cover test were obtained using video-oculography (VOG). To verify the accuracy of VOG, Investigator compared the value obtained using VOG and the angle of a rotating model eye, and subsequently made a new linear equation using these data. The calculated values obtained using VOG were compared with those obtained using APCT to determine the diagnostic accuracy of VOG.",
        "text": "A Novel Diagnostic Method for Exotropia Using Video-oculography | Thirty-four subjects with constant exotropia were included. Two independent ophthalmologists measured the angle of ocular deviation using alternate prism cover test (APCT). The video files and data with the changes in ocular deviation during the alternate cover test were obtained using video-oculography (VOG). To verify the accuracy of VOG, Investigator compared the value obtained using VOG and the angle of a rotating model eye, and subsequently made a new linear equation using these data. The calculated values obtained using VOG were compared with those obtained using APCT to determine the diagnostic accuracy of VOG.",
        "tokens": "['A', 'Novel', 'Diagnostic', 'Method', 'for', 'Exotropia', 'Using', 'Video', '-', 'oculography', '|', 'Thirty', '-', 'four', 'subjects', 'with', 'constant', 'exotropia', 'were', 'included', '.', 'Two', 'independent', 'ophthalmologists', 'measured', 'the', 'angle', 'of', 'ocular', 'deviation', 'using', 'alternate', 'prism', 'cover', 'test', '(', 'APCT', ')', '.', 'The', 'video', 'files', 'and', 'data', 'with', 'the', 'changes', 'in', 'ocular', 'deviation', 'during', 'the', 'alternate', 'cover', 'test', 'were', 'obtained', 'using', 'video', '-', 'oculography', '(', 'VOG', ')', '.', 'To', 'verify', 'the', 'accuracy', 'of', 'VOG', ',', 'Investigator', 'compared', 'the', 'value', 'obtained', 'using', 'VOG', 'and', 'the', 'angle', 'of', 'a', 'rotating', 'model', 'eye', ',', 'and', 'subsequently', 'made', 'a', 'new', 'linear', 'equation', 'using', 'these', 'data', '.', 'The', 'calculated', 'values', 'obtained', 'using', 'VOG', 'were', 'compared', 'with', 'those', 'obtained', 'using', 'APCT', 'to', 'determine', 'the', 'diagnostic', 'accuracy', 'of', 'VOG', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 39,
                "text": "Exotropia",
                "type": "CONDITION"
            },
            {
                "start": 92,
                "end": 110,
                "text": "constant exotropia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02632279",
        "study_official_title": "Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions ",
        "study_brief_summary": " The purpose of this study is to assess the effect of tryptophan depletion on mood and behavior in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN). By doing this, the investigators hope to be able to identify risk factors for and mechanisms underlying psychiatric side effects of STN DBS. The study will be an intervention study with a placebo controlled, randomized cross-over design.",
        "text": "Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions | The purpose of this study is to assess the effect of tryptophan depletion on mood and behavior in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN). By doing this, the investigators hope to be able to identify risk factors for and mechanisms underlying psychiatric side effects of STN DBS. The study will be an intervention study with a placebo controlled, randomized cross-over design.",
        "tokens": "['Tryptophan', 'Depletion', 'in', 'Parkinson', \"'s\", 'Disease', 'Patients', 'Treated', 'With', 'Deep', 'Brain', 'Stimulation', 'of', 'the', 'Subthalamic', 'Nucleus', ':', 'Effects', 'on', 'Mood', 'and', 'Motor', 'Functions', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effect', 'of', 'tryptophan', 'depletion', 'on', 'mood', 'and', 'behavior', 'in', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'patients', 'treated', 'with', 'deep', 'brain', 'stimulation', '(', 'DBS', ')', 'of', 'the', 'subthalamic', 'nucleus', '(', 'STN', ')', '.', 'By', 'doing', 'this', ',', 'the', 'investigators', 'hope', 'to', 'be', 'able', 'to', 'identify', 'risk', 'factors', 'for', 'and', 'mechanisms', 'underlying', 'psychiatric', 'side', 'effects', 'of', 'STN', 'DBS', '.', 'The', 'study', 'will', 'be', 'an', 'intervention', 'study', 'with', 'a', 'placebo', 'controlled', ',', 'randomized', 'cross', '-', 'over', 'design', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 20,
                "text": "Tryptophan Depletion",
                "type": "OTHER"
            },
            {
                "start": 24,
                "end": 43,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 66,
                "end": 88,
                "text": "Deep Brain Stimulation",
                "type": "CONDITION"
            },
            {
                "start": 208,
                "end": 228,
                "text": "tryptophan depletion",
                "type": "OTHER"
            },
            {
                "start": 253,
                "end": 272,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 276,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 300,
                "end": 322,
                "text": "deep brain stimulation",
                "type": "CONDITION"
            },
            {
                "start": 324,
                "end": 327,
                "text": "DBS",
                "type": "CONDITION"
            },
            {
                "start": 499,
                "end": 502,
                "text": "DBS",
                "type": "CONDITION"
            },
            {
                "start": 551,
                "end": 558,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02415127",
        "study_official_title": "Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of ACTIMMUNE\u00ae (Interferon \u03b3-1b) in Children and Young Adults With Friedreich's Ataxia ",
        "study_brief_summary": " The purpose of this phase 3 randomized, multi-center, double-blind, placebo-controlled study is to evaluate the efficacy and safety of ACTIMMUNE\u00ae (interferon-\u03b3 1b) in the treatment of Friedreich's Ataxia (FA) and to evaluate the pharmacokinetic (PK) characteristics of ACTIMMUNE\u00ae in FA patients.",
        "text": "Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of ACTIMMUNE\u00ae (Interferon \u03b3-1b) in Children and Young Adults With Friedreich's Ataxia | The purpose of this phase 3 randomized, multi-center, double-blind, placebo-controlled study is to evaluate the efficacy and safety of ACTIMMUNE\u00ae (interferon-\u03b3 1b) in the treatment of Friedreich's Ataxia (FA) and to evaluate the pharmacokinetic (PK) characteristics of ACTIMMUNE\u00ae in FA patients.",
        "tokens": "['Randomized', ',', 'Multicenter', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Efficacy', ',', 'Safety', ',', 'and', 'Pharmacokinetic', 'Study', 'of', 'ACTIMMUNE', '\u00ae', '(', 'Interferon', '\u03b3-1b', ')', 'in', 'Children', 'and', 'Young', 'Adults', 'With', 'Friedreich', \"'s\", 'Ataxia', '|', 'The', 'purpose', 'of', 'this', 'phase', '3', 'randomized', ',', 'multi', '-', 'center', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'ACTIMMUNE', '\u00ae', '(', 'interferon', '-', '\u03b3', '1b', ')', 'in', 'the', 'treatment', 'of', 'Friedreich', \"'s\", 'Ataxia', '(', 'FA', ')', 'and', 'to', 'evaluate', 'the', 'pharmacokinetic', '(', 'PK', ')', 'characteristics', 'of', 'ACTIMMUNE', '\u00ae', 'in', 'FA', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 46,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 106,
                "end": 115,
                "text": "ACTIMMUNE",
                "type": "DRUG"
            },
            {
                "start": 118,
                "end": 133,
                "text": "Interferon \u03b3-1b",
                "type": "DRUG"
            },
            {
                "start": 169,
                "end": 188,
                "text": "Friedreich's Ataxia",
                "type": "CONDITION"
            },
            {
                "start": 259,
                "end": 266,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 326,
                "end": 335,
                "text": "ACTIMMUNE",
                "type": "DRUG"
            },
            {
                "start": 338,
                "end": 353,
                "text": "interferon-\u03b3 1b",
                "type": "DRUG"
            },
            {
                "start": 375,
                "end": 394,
                "text": "Friedreich's Ataxia",
                "type": "CONDITION"
            },
            {
                "start": 396,
                "end": 398,
                "text": "FA",
                "type": "CONDITION"
            },
            {
                "start": 460,
                "end": 469,
                "text": "ACTIMMUNE",
                "type": "DRUG"
            },
            {
                "start": 474,
                "end": 476,
                "text": "FA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04546737",
        "study_official_title": "Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients ",
        "study_brief_summary": " Viral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and / or delayed neurological complications. At the actual context of the pandemic Coronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmed since in 85% of COVID-19 patients, present neurological symptoms, including anosmia, ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memory and/or behavioral disorders.\n\nHowever, these neurological manifestations are not well studied and their radiological features are not well described. It is therefore important to assess these potential neurological complications in COVID-19 patients. To the investigator knowledge, there is no previous study in the literature describing spectral brain changes in COVID + patients. Thus, the goal of this work is to describe the radiological semiology using MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation of acute and / or delayed brain damage in COVID + patients presenting a neurological manifestations that are initially related to the cranial nerves damage.",
        "text": "Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients | Viral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and / or delayed neurological complications. At the actual context of the pandemic Coronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmed since in 85% of COVID-19 patients, present neurological symptoms, including anosmia, ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memory and/or behavioral disorders.\n\nHowever, these neurological manifestations are not well studied and their radiological features are not well described. It is therefore important to assess these potential neurological complications in COVID-19 patients. To the investigator knowledge, there is no previous study in the literature describing spectral brain changes in COVID + patients. Thus, the goal of this work is to describe the radiological semiology using MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation of acute and / or delayed brain damage in COVID + patients presenting a neurological manifestations that are initially related to the cranial nerves damage.",
        "tokens": "['Study', 'of', 'Morphological', ',', 'Spectral', 'and', 'Metabolic', 'Manifestations', 'of', 'Neurological', 'Complications', 'in', 'Covid-19', 'Patients', '|', 'Viral', 'pandemics', ',', 'such', 'as', 'HIV', 'and', 'SARS', '-', 'Cov', '-', 'V1', ',', 'have', 'shown', 'that', 'they', 'can', 'lead', 'to', 'acute', 'and', '/', 'or', 'delayed', 'neurological', 'complications', '.', 'At', 'the', 'actual', 'context', 'of', 'the', 'pandemic', 'Coronavirus', 'disease', '2019', '(', 'COVID-19', ')', ',', 'neurological', 'manifestations', 'seem', 'to', 'be', 'confirmed', 'since', 'in', '85', '%', 'of', 'COVID-19', 'patients', ',', 'present', 'neurological', 'symptoms', ',', 'including', 'anosmia', ',', 'ageusia', ',', 'periorbital', 'pain', ',', 'dizziness', ',', 'fatigue', ',', 'even', 'moderate', 'headache', ',', 'moderate', 'memory', 'and/or', 'behavioral', 'disorders', '.', '\\n\\n', 'However', ',', 'these', 'neurological', 'manifestations', 'are', 'not', 'well', 'studied', 'and', 'their', 'radiological', 'features', 'are', 'not', 'well', 'described', '.', 'It', 'is', 'therefore', 'important', 'to', 'assess', 'these', 'potential', 'neurological', 'complications', 'in', 'COVID-19', 'patients', '.', 'To', 'the', 'investigator', 'knowledge', ',', 'there', 'is', 'no', 'previous', 'study', 'in', 'the', 'literature', 'describing', 'spectral', 'brain', 'changes', 'in', 'COVID', '+', 'patients', '.', 'Thus', ',', 'the', 'goal', 'of', 'this', 'work', 'is', 'to', 'describe', 'the', 'radiological', 'semiology', 'using', 'MRI', 'and', 'particularly', 'Magnetic', 'Resonance', 'Spectroscopic', '(', 'MRS', ')', 'biomarkers', 'in', 'the', 'evaluation', 'of', 'acute', 'and', '/', 'or', 'delayed', 'brain', 'damage', 'in', 'COVID', '+', 'patients', 'presenting', 'a', 'neurological', 'manifestations', 'that', 'are', 'initially', 'related', 'to', 'the', 'cranial', 'nerves', 'damage', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 95,
                "end": 103,
                "text": "Covid-19",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 307,
                "text": "Coronavirus disease 2019",
                "type": "CONDITION"
            },
            {
                "start": 309,
                "end": 317,
                "text": "COVID-19",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 393,
                "text": "COVID-19",
                "type": "CONDITION"
            },
            {
                "start": 773,
                "end": 781,
                "text": "COVID-19",
                "type": "CONDITION"
            },
            {
                "start": 905,
                "end": 910,
                "text": "COVID",
                "type": "CONDITION"
            },
            {
                "start": 1091,
                "end": 1126,
                "text": "acute and / or delayed brain damage",
                "type": "CONDITION"
            },
            {
                "start": 1130,
                "end": 1135,
                "text": "COVID",
                "type": "CONDITION"
            },
            {
                "start": 1222,
                "end": 1243,
                "text": "cranial nerves damage",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01544738",
        "study_official_title": "Aponeurotic Stimulation Effect on Parkinson Bradykinesia ",
        "study_brief_summary": " Movement slowness (bradykinesia) is one of the main motor symptoms in Parkinson Disease (PD). Several studies have shown that patients with PD exhibit slowness because they are unable to modulate, in an optimal way, the velocity of voluntary motor acts not induced by external stimulation. Indeed, these patients have difficulties to integrate multi-sensorial information, mainly proprioception.\n\nThe investigators investigated changes in shoulder velocity during pointing movements by patients with PD after stimulation of soft tissues (aponeurosis) of upper limb muscles. The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the upper limb muscles. This technique has previously been shown to decrease passive tension and the tendon reflex response of the manipulated muscle group. The investigators hypothesis is that aponeurotic manipulation of shoulder muscles therefore creates a modification in the proprioceptive information, which in return temporarily decreases the bradykinesia of shoulder movements.",
        "text": "Aponeurotic Stimulation Effect on Parkinson Bradykinesia | Movement slowness (bradykinesia) is one of the main motor symptoms in Parkinson Disease (PD). Several studies have shown that patients with PD exhibit slowness because they are unable to modulate, in an optimal way, the velocity of voluntary motor acts not induced by external stimulation. Indeed, these patients have difficulties to integrate multi-sensorial information, mainly proprioception.\n\nThe investigators investigated changes in shoulder velocity during pointing movements by patients with PD after stimulation of soft tissues (aponeurosis) of upper limb muscles. The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the upper limb muscles. This technique has previously been shown to decrease passive tension and the tendon reflex response of the manipulated muscle group. The investigators hypothesis is that aponeurotic manipulation of shoulder muscles therefore creates a modification in the proprioceptive information, which in return temporarily decreases the bradykinesia of shoulder movements.",
        "tokens": "['Aponeurotic', 'Stimulation', 'Effect', 'on', 'Parkinson', 'Bradykinesia', '|', 'Movement', 'slowness', '(', 'bradykinesia', ')', 'is', 'one', 'of', 'the', 'main', 'motor', 'symptoms', 'in', 'Parkinson', 'Disease', '(', 'PD', ')', '.', 'Several', 'studies', 'have', 'shown', 'that', 'patients', 'with', 'PD', 'exhibit', 'slowness', 'because', 'they', 'are', 'unable', 'to', 'modulate', ',', 'in', 'an', 'optimal', 'way', ',', 'the', 'velocity', 'of', 'voluntary', 'motor', 'acts', 'not', 'induced', 'by', 'external', 'stimulation', '.', 'Indeed', ',', 'these', 'patients', 'have', 'difficulties', 'to', 'integrate', 'multi', '-', 'sensorial', 'information', ',', 'mainly', 'proprioception', '.', '\\n\\n', 'The', 'investigators', 'investigated', 'changes', 'in', 'shoulder', 'velocity', 'during', 'pointing', 'movements', 'by', 'patients', 'with', 'PD', 'after', 'stimulation', 'of', 'soft', 'tissues', '(', 'aponeurosis', ')', 'of', 'upper', 'limb', 'muscles', '.', 'The', 'stimulation', 'consisted', 'of', 'manipulating', ',', 'with', 'a', 'hook', '(', 'the', 'diacutaneous', 'fibrolysis', 'method', ')', ',', 'the', 'aponeurotic', 'tissues', 'enrobing', 'the', 'heads', 'of', 'the', 'upper', 'limb', 'muscles', '.', 'This', 'technique', 'has', 'previously', 'been', 'shown', 'to', 'decrease', 'passive', 'tension', 'and', 'the', 'tendon', 'reflex', 'response', 'of', 'the', 'manipulated', 'muscle', 'group', '.', 'The', 'investigators', 'hypothesis', 'is', 'that', 'aponeurotic', 'manipulation', 'of', 'shoulder', 'muscles', 'therefore', 'creates', 'a', 'modification', 'in', 'the', 'proprioceptive', 'information', ',', 'which', 'in', 'return', 'temporarily', 'decreases', 'the', 'bradykinesia', 'of', 'shoulder', 'movements', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 23,
                "text": "Aponeurotic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 34,
                "end": 43,
                "text": "Parkinson",
                "type": "CONDITION"
            },
            {
                "start": 44,
                "end": 56,
                "text": "Bradykinesia",
                "type": "CONDITION"
            },
            {
                "start": 59,
                "end": 76,
                "text": "Movement slowness",
                "type": "CONDITION"
            },
            {
                "start": 78,
                "end": 90,
                "text": "bradykinesia",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 146,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 150,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 199,
                "end": 201,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 559,
                "end": 561,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 568,
                "end": 631,
                "text": "stimulation of soft tissues (aponeurosis) of upper limb muscles",
                "type": "OTHER"
            },
            {
                "start": 693,
                "end": 716,
                "text": "diacutaneous fibrolysis",
                "type": "OTHER"
            },
            {
                "start": 966,
                "end": 1010,
                "text": "aponeurotic manipulation of shoulder muscles",
                "type": "OTHER"
            },
            {
                "start": 1121,
                "end": 1133,
                "text": "bradykinesia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01278433",
        "study_official_title": "Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study ",
        "study_brief_summary": " The aim of the study is to collect post marketing safety data on IMOVAX Polio vaccine in China.\n\nObjective:\n\nTo describe serious adverse events 30 days after each dose of IMOVAX Polio\u2122 administered at 2, 3, and 4 months of age among infants living in the study cities of China.",
        "text": "Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study | The aim of the study is to collect post marketing safety data on IMOVAX Polio vaccine in China.\n\nObjective:\n\nTo describe serious adverse events 30 days after each dose of IMOVAX Polio\u2122 administered at 2, 3, and 4 months of age among infants living in the study cities of China.",
        "tokens": "['Large', 'Scale', 'Safety', 'Study', 'of', 'IMOVAX', 'Polio', 'in', 'Selected', 'Cities', 'in', 'China', ',', 'an', 'Observational', 'Post', 'Marketing', 'Study', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'collect', 'post', 'marketing', 'safety', 'data', 'on', 'IMOVAX', 'Polio', 'vaccine', 'in', 'China', '.', '\\n\\n', 'Objective', ':', '\\n\\n', 'To', 'describe', 'serious', 'adverse', 'events', '30', 'days', 'after', 'each', 'dose', 'of', 'IMOVAX', 'Polio', '\u2122', 'administered', 'at', '2', ',', '3', ',', 'and', '4', 'months', 'of', 'age', 'among', 'infants', 'living', 'in', 'the', 'study', 'cities', 'of', 'China', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 40,
                "text": "IMOVAX Polio",
                "type": "DRUG"
            },
            {
                "start": 175,
                "end": 187,
                "text": "IMOVAX Polio",
                "type": "DRUG"
            },
            {
                "start": 281,
                "end": 293,
                "text": "IMOVAX Polio",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00241670",
        "study_official_title": "Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection ",
        "study_brief_summary": " The aim of the study \"Fluorescence-guided resection of malignant gliomas with 5-Aminolevulinic acid (5-ALA) vs. conventional resection\" is to determine how accurately contrast agent-accumulating tumour can be removed by primary surgery and to assess the clinical usefulness of this method.",
        "text": "Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection | The aim of the study \"Fluorescence-guided resection of malignant gliomas with 5-Aminolevulinic acid (5-ALA) vs. conventional resection\" is to determine how accurately contrast agent-accumulating tumour can be removed by primary surgery and to assess the clinical usefulness of this method.",
        "tokens": "['Fluorescence', '-', 'guided', 'Resection', 'of', 'Malignant', 'Gliomas', 'With', '5', '-', 'Aminolevulinic', 'Acid', '(', '5', '-', 'ALA', ')', 'vs.', 'Conventional', 'Resection', '|', 'The', 'aim', 'of', 'the', 'study', '\"', 'Fluorescence', '-', 'guided', 'resection', 'of', 'malignant', 'gliomas', 'with', '5', '-', 'Aminolevulinic', 'acid', '(', '5', '-', 'ALA', ')', 'vs.', 'conventional', 'resection', '\"', 'is', 'to', 'determine', 'how', 'accurately', 'contrast', 'agent', '-', 'accumulating', 'tumour', 'can', 'be', 'removed', 'by', 'primary', 'surgery', 'and', 'to', 'assess', 'the', 'clinical', 'usefulness', 'of', 'this', 'method', '.']",
        "token_bio_labels": "['B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 29,
                "text": "Fluorescence-guided Resection",
                "type": "SURGICAL"
            },
            {
                "start": 33,
                "end": 50,
                "text": "Malignant Gliomas",
                "type": "CONDITION"
            },
            {
                "start": 56,
                "end": 77,
                "text": "5-Aminolevulinic Acid",
                "type": "DRUG"
            },
            {
                "start": 79,
                "end": 84,
                "text": "5-ALA",
                "type": "DRUG"
            },
            {
                "start": 90,
                "end": 112,
                "text": "Conventional Resection",
                "type": "CONTROL"
            },
            {
                "start": 137,
                "end": 166,
                "text": "Fluorescence-guided resection",
                "type": "SURGICAL"
            },
            {
                "start": 170,
                "end": 187,
                "text": "malignant gliomas",
                "type": "CONDITION"
            },
            {
                "start": 193,
                "end": 214,
                "text": "5-Aminolevulinic acid",
                "type": "DRUG"
            },
            {
                "start": 216,
                "end": 221,
                "text": "5-ALA",
                "type": "DRUG"
            },
            {
                "start": 227,
                "end": 249,
                "text": "conventional resection",
                "type": "CONTROL"
            },
            {
                "start": 310,
                "end": 316,
                "text": "tumour",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01236209",
        "study_official_title": "Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback ",
        "study_brief_summary": " The overall objective of this randomized controlled study (RCT) financed by the Norwegian Research Council (grant no. 182012/V50) is to establish the effectiveness of situational feedback to the self-management of fibromyalgia syndrome (FMS) using innovative means of patient-provider communication in a randomized controlled study (RCT). Thereby this project will contribute to the knowledge of treatment of patients with FMS. The effectiveness of the intervention will be expressed in terms of a) reduced pain, b) psychometric outcomes, c) quality of life, d) improved engagement in daily activities and e) prevented transition to chronic disability. We furthermore aim to 1) determine the effectiveness of providing regular situational feedback in enhancing self-management and, consequently 2) study the effectiveness of enhancing self-management in reducing pain and physical disability.\n\nSelf-management of chronic pain is increasingly seen as an important tool in providing adequate care to patients with FMS and other types of Chronic Non-malignant Pain. Enhancing the patient's self-management of her/his condition is thought to be effective in reducing pain and disability. However, sufficient empirical evidence to support this is yet unavailable. This may be due to the non-situational nature of many interventions studied so far: Patients are taught management skills in a clinical setting, and may not be able to successfully use these skills in daily care. Therefore, enhancing self-management of chronic pain, by providing immediate feedback that is directly related to patient's daily life (\"situational\" feedback) complementary to care-as usual, is thought to be more effective than conventional interventions in a clinical setting. This may even be even more effective when the patient receives quick response feedback using mobile communication technology, i.e. any place any time.",
        "text": "Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback | The overall objective of this randomized controlled study (RCT) financed by the Norwegian Research Council (grant no. 182012/V50) is to establish the effectiveness of situational feedback to the self-management of fibromyalgia syndrome (FMS) using innovative means of patient-provider communication in a randomized controlled study (RCT). Thereby this project will contribute to the knowledge of treatment of patients with FMS. The effectiveness of the intervention will be expressed in terms of a) reduced pain, b) psychometric outcomes, c) quality of life, d) improved engagement in daily activities and e) prevented transition to chronic disability. We furthermore aim to 1) determine the effectiveness of providing regular situational feedback in enhancing self-management and, consequently 2) study the effectiveness of enhancing self-management in reducing pain and physical disability.\n\nSelf-management of chronic pain is increasingly seen as an important tool in providing adequate care to patients with FMS and other types of Chronic Non-malignant Pain. Enhancing the patient's self-management of her/his condition is thought to be effective in reducing pain and disability. However, sufficient empirical evidence to support this is yet unavailable. This may be due to the non-situational nature of many interventions studied so far: Patients are taught management skills in a clinical setting, and may not be able to successfully use these skills in daily care. Therefore, enhancing self-management of chronic pain, by providing immediate feedback that is directly related to patient's daily life (\"situational\" feedback) complementary to care-as usual, is thought to be more effective than conventional interventions in a clinical setting. This may even be even more effective when the patient receives quick response feedback using mobile communication technology, i.e. any place any time.",
        "tokens": "['Stimulating', 'Self', 'Management', 'in', 'Patients', 'With', 'Fibromyalgia', 'Through', 'Web', '-', 'based', 'Situational', 'Feedback', '|', 'The', 'overall', 'objective', 'of', 'this', 'randomized', 'controlled', 'study', '(', 'RCT', ')', 'financed', 'by', 'the', 'Norwegian', 'Research', 'Council', '(', 'grant', 'no', '.', '182012', '/', 'V50', ')', 'is', 'to', 'establish', 'the', 'effectiveness', 'of', 'situational', 'feedback', 'to', 'the', 'self', '-', 'management', 'of', 'fibromyalgia', 'syndrome', '(', 'FMS', ')', 'using', 'innovative', 'means', 'of', 'patient', '-', 'provider', 'communication', 'in', 'a', 'randomized', 'controlled', 'study', '(', 'RCT', ')', '.', 'Thereby', 'this', 'project', 'will', 'contribute', 'to', 'the', 'knowledge', 'of', 'treatment', 'of', 'patients', 'with', 'FMS', '.', 'The', 'effectiveness', 'of', 'the', 'intervention', 'will', 'be', 'expressed', 'in', 'terms', 'of', 'a', ')', 'reduced', 'pain', ',', 'b', ')', 'psychometric', 'outcomes', ',', 'c', ')', 'quality', 'of', 'life', ',', 'd', ')', 'improved', 'engagement', 'in', 'daily', 'activities', 'and', 'e', ')', 'prevented', 'transition', 'to', 'chronic', 'disability', '.', 'We', 'furthermore', 'aim', 'to', '1', ')', 'determine', 'the', 'effectiveness', 'of', 'providing', 'regular', 'situational', 'feedback', 'in', 'enhancing', 'self', '-', 'management', 'and', ',', 'consequently', '2', ')', 'study', 'the', 'effectiveness', 'of', 'enhancing', 'self', '-', 'management', 'in', 'reducing', 'pain', 'and', 'physical', 'disability', '.', '\\n\\n', 'Self', '-', 'management', 'of', 'chronic', 'pain', 'is', 'increasingly', 'seen', 'as', 'an', 'important', 'tool', 'in', 'providing', 'adequate', 'care', 'to', 'patients', 'with', 'FMS', 'and', 'other', 'types', 'of', 'Chronic', 'Non', '-', 'malignant', 'Pain', '.', 'Enhancing', 'the', 'patient', \"'s\", 'self', '-', 'management', 'of', 'her', '/', 'his', 'condition', 'is', 'thought', 'to', 'be', 'effective', 'in', 'reducing', 'pain', 'and', 'disability', '.', 'However', ',', 'sufficient', 'empirical', 'evidence', 'to', 'support', 'this', 'is', 'yet', 'unavailable', '.', 'This', 'may', 'be', 'due', 'to', 'the', 'non', '-', 'situational', 'nature', 'of', 'many', 'interventions', 'studied', 'so', 'far', ':', 'Patients', 'are', 'taught', 'management', 'skills', 'in', 'a', 'clinical', 'setting', ',', 'and', 'may', 'not', 'be', 'able', 'to', 'successfully', 'use', 'these', 'skills', 'in', 'daily', 'care', '.', 'Therefore', ',', 'enhancing', 'self', '-', 'management', 'of', 'chronic', 'pain', ',', 'by', 'providing', 'immediate', 'feedback', 'that', 'is', 'directly', 'related', 'to', 'patient', \"'s\", 'daily', 'life', '(', '\"', 'situational', '\"', 'feedback', ')', 'complementary', 'to', 'care', '-', 'as', 'usual', ',', 'is', 'thought', 'to', 'be', 'more', 'effective', 'than', 'conventional', 'interventions', 'in', 'a', 'clinical', 'setting', '.', 'This', 'may', 'even', 'be', 'even', 'more', 'effective', 'when', 'the', 'patient', 'receives', 'quick', 'response', 'feedback', 'using', 'mobile', 'communication', 'technology', ',', 'i.e.', 'any', 'place', 'any', 'time', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 45,
                "end": 57,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 66,
                "end": 96,
                "text": "Web-based Situational Feedback",
                "type": "OTHER"
            },
            {
                "start": 266,
                "end": 286,
                "text": "situational feedback",
                "type": "OTHER"
            },
            {
                "start": 313,
                "end": 334,
                "text": "fibromyalgia syndrome",
                "type": "CONDITION"
            },
            {
                "start": 336,
                "end": 339,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 367,
                "end": 397,
                "text": "patient-provider communication",
                "type": "OTHER"
            },
            {
                "start": 522,
                "end": 525,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 606,
                "end": 610,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 818,
                "end": 846,
                "text": "regular situational feedback",
                "type": "OTHER"
            },
            {
                "start": 924,
                "end": 949,
                "text": "enhancing self-management",
                "type": "OTHER"
            },
            {
                "start": 962,
                "end": 966,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1012,
                "end": 1024,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 1111,
                "end": 1114,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 1134,
                "end": 1160,
                "text": "Chronic Non-malignant Pain",
                "type": "CONDITION"
            },
            {
                "start": 1262,
                "end": 1266,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1611,
                "end": 1623,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 1707,
                "end": 1729,
                "text": "\"situational\" feedback",
                "type": "OTHER"
            },
            {
                "start": 1800,
                "end": 1848,
                "text": "conventional interventions in a clinical setting",
                "type": "CONTROL"
            },
            {
                "start": 1913,
                "end": 1974,
                "text": "quick response feedback using mobile communication technology",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05163886",
        "study_official_title": "A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis ",
        "study_brief_summary": " This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).",
        "text": "A Phase IIa Trial to Evaluate the Safety, Tolerability, and Biological Activity of LAM-002A (Apilimod Dimesylate Capsules) in C9ORF72-Associated Amyotrophic Lateral Sclerosis | This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).",
        "tokens": "['A', 'Phase', 'IIa', 'Trial', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Biological', 'Activity', 'of', 'LAM-002A', '(', 'Apilimod', 'Dimesylate', 'Capsules', ')', 'in', 'C9ORF72', '-', 'Associated', 'Amyotrophic', 'Lateral', 'Sclerosis', '|', 'This', 'is', 'a', 'clinical', 'trial', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'and', 'biological', 'effect', 'of', 'LAM-002A', 'in', 'adults', 'with', 'C9ORF72', '-', 'associated', 'ALS', '(', 'C9ALS', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 83,
                "end": 91,
                "text": "LAM-002A",
                "type": "DRUG"
            },
            {
                "start": 93,
                "end": 112,
                "text": "Apilimod Dimesylate",
                "type": "DRUG"
            },
            {
                "start": 126,
                "end": 174,
                "text": "C9ORF72-Associated Amyotrophic Lateral Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 265,
                "end": 273,
                "text": "LAM-002A",
                "type": "DRUG"
            },
            {
                "start": 289,
                "end": 311,
                "text": "C9ORF72-associated ALS",
                "type": "CONDITION"
            },
            {
                "start": 313,
                "end": 318,
                "text": "C9ALS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01714349",
        "study_official_title": "Restoring Hand Function Using Nerve Transfers in Persons With Spinal Cord Injury ",
        "study_brief_summary": " Nerve Transfer surgery can provide improved hand function following cervical spinal cord injuries",
        "text": "Restoring Hand Function Using Nerve Transfers in Persons With Spinal Cord Injury | Nerve Transfer surgery can provide improved hand function following cervical spinal cord injuries",
        "tokens": "['Restoring', 'Hand', 'Function', 'Using', 'Nerve', 'Transfers', 'in', 'Persons', 'With', 'Spinal', 'Cord', 'Injury', '|', 'Nerve', 'Transfer', 'surgery', 'can', 'provide', 'improved', 'hand', 'function', 'following', 'cervical', 'spinal', 'cord', 'injuries']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 30,
                "end": 45,
                "text": "Nerve Transfers",
                "type": "SURGICAL"
            },
            {
                "start": 62,
                "end": 80,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 83,
                "end": 97,
                "text": "Nerve Transfer",
                "type": "SURGICAL"
            },
            {
                "start": 151,
                "end": 180,
                "text": "cervical spinal cord injuries",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03058965",
        "study_official_title": "Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers ",
        "study_brief_summary": " The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).",
        "text": "Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers | The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).",
        "tokens": "['Phase', '0', 'Evaluation', 'of', '[', '18F]MNI-958', 'as', 'a', 'Potential', 'PET', 'Radioligand', 'for', 'Imaging', 'Tau', 'Protein', 'in', 'the', 'Brain', 'of', 'Patients', 'With', 'Probable', 'Alzheimer', \"'s\", 'Disease', 'or', 'Progressive', 'Supranuclear', 'Palsy', 'Compared', 'With', 'Healthy', 'Volunteers', '|', 'The', 'overall', 'goal', 'of', 'this', 'imaging', 'trial', 'is', 'to', 'evaluate', '[', '18F]MNI-958', ',', 'a', 'tau', 'targeted', 'PET', 'radioligand', ',', 'in', 'individuals', 'with', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', ',', 'Progressive', 'Supranuclear', 'Palsy', '(', 'PSP', ')', ',', 'and', 'healthy', 'volunteers', '(', 'HV', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 120,
                "end": 182,
                "text": "Probable Alzheimer's Disease or Progressive Supranuclear Palsy",
                "type": "CONDITION"
            },
            {
                "start": 338,
                "end": 357,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 359,
                "end": 361,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 364,
                "end": 394,
                "text": "Progressive Supranuclear Palsy",
                "type": "CONDITION"
            },
            {
                "start": 396,
                "end": 399,
                "text": "PSP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05448469",
        "study_official_title": "Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block for Perioperative Analgesia, a Randomized Double Blinded Controlled Trial ",
        "study_brief_summary": " There are very few randomized controlled trials in open splenectomy surgery, which compare paravertebral block with ESP block. The purpose of this randomized controlled trial is to compare the efficacy of ultrasound-guided paravertebral block with ESP block for perioperative analgesia in open splenectomy .",
        "text": "Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block for Perioperative Analgesia, a Randomized Double Blinded Controlled Trial | There are very few randomized controlled trials in open splenectomy surgery, which compare paravertebral block with ESP block. The purpose of this randomized controlled trial is to compare the efficacy of ultrasound-guided paravertebral block with ESP block for perioperative analgesia in open splenectomy .",
        "tokens": "['Ultrasound', '-', 'guided', 'Erector', 'Spinae', 'Plane', 'Block', 'Versus', 'Paravertebral', 'Block', 'for', 'Perioperative', 'Analgesia', ',', 'a', 'Randomized', 'Double', 'Blinded', 'Controlled', 'Trial', '|', 'There', 'are', 'very', 'few', 'randomized', 'controlled', 'trials', 'in', 'open', 'splenectomy', 'surgery', ',', 'which', 'compare', 'paravertebral', 'block', 'with', 'ESP', 'block', '.', 'The', 'purpose', 'of', 'this', 'randomized', 'controlled', 'trial', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'ultrasound', '-', 'guided', 'paravertebral', 'block', 'with', 'ESP', 'block', 'for', 'perioperative', 'analgesia', 'in', 'open', 'splenectomy', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 44,
                "text": "Ultrasound-guided Erector Spinae Plane Block",
                "type": "OTHER"
            },
            {
                "start": 52,
                "end": 71,
                "text": "Paravertebral Block",
                "type": "OTHER"
            },
            {
                "start": 199,
                "end": 223,
                "text": "open splenectomy surgery",
                "type": "CONDITION"
            },
            {
                "start": 239,
                "end": 258,
                "text": "paravertebral block",
                "type": "OTHER"
            },
            {
                "start": 264,
                "end": 273,
                "text": "ESP block",
                "type": "OTHER"
            },
            {
                "start": 353,
                "end": 390,
                "text": "ultrasound-guided paravertebral block",
                "type": "OTHER"
            },
            {
                "start": 396,
                "end": 405,
                "text": "ESP block",
                "type": "OTHER"
            },
            {
                "start": 437,
                "end": 453,
                "text": "open splenectomy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04788992",
        "study_official_title": "Evaluation of a Dementia Care Training With Virtual Reality and Support Program for Home Care Staff ",
        "study_brief_summary": " This study aims to evaluate a dementia care training with virtual reality and peer support program on dementia care knowledge, attitude, care competence, work stress, and empathy of home care staff.",
        "text": "Evaluation of a Dementia Care Training With Virtual Reality and Support Program for Home Care Staff | This study aims to evaluate a dementia care training with virtual reality and peer support program on dementia care knowledge, attitude, care competence, work stress, and empathy of home care staff.",
        "tokens": "['Evaluation', 'of', 'a', 'Dementia', 'Care', 'Training', 'With', 'Virtual', 'Reality', 'and', 'Support', 'Program', 'for', 'Home', 'Care', 'Staff', '|', 'This', 'study', 'aims', 'to', 'evaluate', 'a', 'dementia', 'care', 'training', 'with', 'virtual', 'reality', 'and', 'peer', 'support', 'program', 'on', 'dementia', 'care', 'knowledge', ',', 'attitude', ',', 'care', 'competence', ',', 'work', 'stress', ',', 'and', 'empathy', 'of', 'home', 'care', 'staff', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 59,
                "text": "Dementia Care Training With Virtual Reality",
                "type": "OTHER"
            },
            {
                "start": 64,
                "end": 99,
                "text": "Support Program for Home Care Staff",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 132,
                "end": 175,
                "text": "dementia care training with virtual reality",
                "type": "OTHER"
            },
            {
                "start": 180,
                "end": 200,
                "text": "peer support program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 204,
                "end": 212,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02383004",
        "study_official_title": "Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement ",
        "study_brief_summary": " Myringotomy tube placement is one of the most commonly performed operations in children. Emergence delirium after such procedures is common. During emergence delirium children can become both a danger to themselves and others around them, including family members and hospital staff.\n\nThe primary objective of this study is to determine if acupuncture, when used in combination with standard anesthetic management, decreases the incidence of emergence delirium in pediatric patients following myringotomy tube placement. Patients with and without premedication of midazolam will be included. A secondary objective of this study is to determine our institution's actual incidence of emergence delirium for this operation using a validated scale, the Pediatric Anesthesia Emergence Delirium (PAED) scale. We will also compare rates of emergence delirium in patients that received a premedication of midazolam versus (V) those that did not (NV).\n\nThis is a randomized double-blinded trial. We will enroll 100 children aged 1-6 years old. Premedication with midazolam will be decided by the anesthesiologist. If needed, the patient will receive a standard does of oral midazolam plus acetaminophen (V). If the patient does not require premedication with midazolam, oral acetaminophen will be given alone (NV).\n\nPatients will then be randomized to receive either acupuncture with standard general anesthesia care (A) or to receive standard anesthetic care alone (S). Patients, their family members and recovery registered nurses (RNs) will not know if acupuncture was performed. Intraoperative anesthetic techniques will be standardized and include inhaled inductions with nitrous oxide and sevoflurane. Anesthesia maintenance will be inhaled sevoflurane and the usual pain medication ketorolac will be given intramuscularly prior to emergence. Acupuncture needles will be placed after anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the Heart 7 (HT7) point and one in each ear at the Shen Men point. The needles will be inserted bilaterally to a depth of 1.8 mm.\n\nIn the PACU, a blinded study observer will evaluate the patient at four time points using the PAED scale: time of awakening and 5, 10 & 15 minutes after awakening. Follow up phone calls will be made one day and one week after surgery. Families will be asked about behavior after discharge, sleep and bed-wetting.",
        "text": "Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement | Myringotomy tube placement is one of the most commonly performed operations in children. Emergence delirium after such procedures is common. During emergence delirium children can become both a danger to themselves and others around them, including family members and hospital staff.\n\nThe primary objective of this study is to determine if acupuncture, when used in combination with standard anesthetic management, decreases the incidence of emergence delirium in pediatric patients following myringotomy tube placement. Patients with and without premedication of midazolam will be included. A secondary objective of this study is to determine our institution's actual incidence of emergence delirium for this operation using a validated scale, the Pediatric Anesthesia Emergence Delirium (PAED) scale. We will also compare rates of emergence delirium in patients that received a premedication of midazolam versus (V) those that did not (NV).\n\nThis is a randomized double-blinded trial. We will enroll 100 children aged 1-6 years old. Premedication with midazolam will be decided by the anesthesiologist. If needed, the patient will receive a standard does of oral midazolam plus acetaminophen (V). If the patient does not require premedication with midazolam, oral acetaminophen will be given alone (NV).\n\nPatients will then be randomized to receive either acupuncture with standard general anesthesia care (A) or to receive standard anesthetic care alone (S). Patients, their family members and recovery registered nurses (RNs) will not know if acupuncture was performed. Intraoperative anesthetic techniques will be standardized and include inhaled inductions with nitrous oxide and sevoflurane. Anesthesia maintenance will be inhaled sevoflurane and the usual pain medication ketorolac will be given intramuscularly prior to emergence. Acupuncture needles will be placed after anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the Heart 7 (HT7) point and one in each ear at the Shen Men point. The needles will be inserted bilaterally to a depth of 1.8 mm.\n\nIn the PACU, a blinded study observer will evaluate the patient at four time points using the PAED scale: time of awakening and 5, 10 & 15 minutes after awakening. Follow up phone calls will be made one day and one week after surgery. Families will be asked about behavior after discharge, sleep and bed-wetting.",
        "tokens": "['Acupuncture', 'for', 'the', 'Prevention', 'of', 'Emergence', 'Delirium', 'in', 'Children', 'Undergoing', 'Myringotomy', 'Tube', 'Placement', '|', 'Myringotomy', 'tube', 'placement', 'is', 'one', 'of', 'the', 'most', 'commonly', 'performed', 'operations', 'in', 'children', '.', 'Emergence', 'delirium', 'after', 'such', 'procedures', 'is', 'common', '.', 'During', 'emergence', 'delirium', 'children', 'can', 'become', 'both', 'a', 'danger', 'to', 'themselves', 'and', 'others', 'around', 'them', ',', 'including', 'family', 'members', 'and', 'hospital', 'staff', '.', '\\n\\n', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'acupuncture', ',', 'when', 'used', 'in', 'combination', 'with', 'standard', 'anesthetic', 'management', ',', 'decreases', 'the', 'incidence', 'of', 'emergence', 'delirium', 'in', 'pediatric', 'patients', 'following', 'myringotomy', 'tube', 'placement', '.', 'Patients', 'with', 'and', 'without', 'premedication', 'of', 'midazolam', 'will', 'be', 'included', '.', 'A', 'secondary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'our', 'institution', \"'s\", 'actual', 'incidence', 'of', 'emergence', 'delirium', 'for', 'this', 'operation', 'using', 'a', 'validated', 'scale', ',', 'the', 'Pediatric', 'Anesthesia', 'Emergence', 'Delirium', '(', 'PAED', ')', 'scale', '.', 'We', 'will', 'also', 'compare', 'rates', 'of', 'emergence', 'delirium', 'in', 'patients', 'that', 'received', 'a', 'premedication', 'of', 'midazolam', 'versus', '(', 'V', ')', 'those', 'that', 'did', 'not', '(', 'NV', ')', '.', '\\n\\n', 'This', 'is', 'a', 'randomized', 'double', '-', 'blinded', 'trial', '.', 'We', 'will', 'enroll', '100', 'children', 'aged', '1', '-', '6', 'years', 'old', '.', 'Premedication', 'with', 'midazolam', 'will', 'be', 'decided', 'by', 'the', 'anesthesiologist', '.', 'If', 'needed', ',', 'the', 'patient', 'will', 'receive', 'a', 'standard', 'does', 'of', 'oral', 'midazolam', 'plus', 'acetaminophen', '(', 'V', ')', '.', 'If', 'the', 'patient', 'does', 'not', 'require', 'premedication', 'with', 'midazolam', ',', 'oral', 'acetaminophen', 'will', 'be', 'given', 'alone', '(', 'NV', ')', '.', '\\n\\n', 'Patients', 'will', 'then', 'be', 'randomized', 'to', 'receive', 'either', 'acupuncture', 'with', 'standard', 'general', 'anesthesia', 'care', '(', 'A', ')', 'or', 'to', 'receive', 'standard', 'anesthetic', 'care', 'alone', '(', 'S', ')', '.', 'Patients', ',', 'their', 'family', 'members', 'and', 'recovery', 'registered', 'nurses', '(', 'RNs', ')', 'will', 'not', 'know', 'if', 'acupuncture', 'was', 'performed', '.', 'Intraoperative', 'anesthetic', 'techniques', 'will', 'be', 'standardized', 'and', 'include', 'inhaled', 'inductions', 'with', 'nitrous', 'oxide', 'and', 'sevoflurane', '.', 'Anesthesia', 'maintenance', 'will', 'be', 'inhaled', 'sevoflurane', 'and', 'the', 'usual', 'pain', 'medication', 'ketorolac', 'will', 'be', 'given', 'intramuscularly', 'prior', 'to', 'emergence', '.', 'Acupuncture', 'needles', 'will', 'be', 'placed', 'after', 'anesthesia', 'induction', 'and', 'removed', 'prior', 'to', 'leaving', 'the', 'operating', 'room', '.', 'A', 'total', 'of', '4', 'needles', 'will', 'be', 'placed', ',', 'one', 'in', 'each', 'wrist', 'at', 'the', 'Heart', '7', '(', 'HT7', ')', 'point', 'and', 'one', 'in', 'each', 'ear', 'at', 'the', 'Shen', 'Men', 'point', '.', 'The', 'needles', 'will', 'be', 'inserted', 'bilaterally', 'to', 'a', 'depth', 'of', '1.8', 'mm', '.', '\\n\\n', 'In', 'the', 'PACU', ',', 'a', 'blinded', 'study', 'observer', 'will', 'evaluate', 'the', 'patient', 'at', 'four', 'time', 'points', 'using', 'the', 'PAED', 'scale', ':', 'time', 'of', 'awakening', 'and', '5', ',', '10', '&', '15', 'minutes', 'after', 'awakening', '.', 'Follow', 'up', 'phone', 'calls', 'will', 'be', 'made', 'one', 'day', 'and', 'one', 'week', 'after', 'surgery', '.', 'Families', 'will', 'be', 'asked', 'about', 'behavior', 'after', 'discharge', ',', 'sleep', 'and', 'bed', '-', 'wetting', '.']",
        "token_bio_labels": "['B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 11,
                "text": "Acupuncture",
                "type": "OTHER"
            },
            {
                "start": 34,
                "end": 52,
                "text": "Emergence Delirium",
                "type": "CONDITION"
            },
            {
                "start": 76,
                "end": 102,
                "text": "Myringotomy Tube Placement",
                "type": "CONDITION"
            },
            {
                "start": 105,
                "end": 131,
                "text": "Myringotomy tube placement",
                "type": "CONDITION"
            },
            {
                "start": 194,
                "end": 212,
                "text": "Emergence delirium",
                "type": "CONDITION"
            },
            {
                "start": 253,
                "end": 271,
                "text": "emergence delirium",
                "type": "CONDITION"
            },
            {
                "start": 445,
                "end": 456,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 488,
                "end": 518,
                "text": "standard anesthetic management",
                "type": "OTHER"
            },
            {
                "start": 598,
                "end": 624,
                "text": "myringotomy tube placement",
                "type": "CONDITION"
            },
            {
                "start": 669,
                "end": 678,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 787,
                "end": 805,
                "text": "emergence delirium",
                "type": "CONDITION"
            },
            {
                "start": 938,
                "end": 956,
                "text": "emergence delirium",
                "type": "CONDITION"
            },
            {
                "start": 1002,
                "end": 1011,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 1159,
                "end": 1168,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 1270,
                "end": 1279,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 1285,
                "end": 1298,
                "text": "acetaminophen",
                "type": "DRUG"
            },
            {
                "start": 1355,
                "end": 1364,
                "text": "midazolam",
                "type": "DRUG"
            },
            {
                "start": 1371,
                "end": 1384,
                "text": "acetaminophen",
                "type": "DRUG"
            },
            {
                "start": 1463,
                "end": 1474,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 1480,
                "end": 1512,
                "text": "standard general anesthesia care",
                "type": "OTHER"
            },
            {
                "start": 1531,
                "end": 1561,
                "text": "standard anesthetic care alone",
                "type": "CONTROL"
            },
            {
                "start": 1652,
                "end": 1663,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 1773,
                "end": 1786,
                "text": "nitrous oxide",
                "type": "DRUG"
            },
            {
                "start": 1791,
                "end": 1802,
                "text": "sevoflurane",
                "type": "DRUG"
            },
            {
                "start": 1843,
                "end": 1854,
                "text": "sevoflurane",
                "type": "DRUG"
            },
            {
                "start": 1885,
                "end": 1894,
                "text": "ketorolac",
                "type": "DRUG"
            },
            {
                "start": 1945,
                "end": 1956,
                "text": "Acupuncture",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00672945",
        "study_official_title": "Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil ",
        "study_brief_summary": " A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.",
        "text": "Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil | A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.",
        "tokens": "['Phase', '2', 'Double', '-', 'Blind', 'Study', 'of', 'PRX-03140', 'in', 'Subjects', 'With', 'Alzheimer', \"'s\", 'Disease', 'Receiving', 'a', 'Stable', 'Dose', 'of', 'Donepezil', '|', 'A', 'randomized', 'placebo', '-', 'controlled', 'study', 'to', 'evaluate', 'the', 'efficacy', 'of', 'PRX-03140', 'in', 'subjects', 'with', 'Alzheimer', \"'s\", 'Disease', 'receiving', 'a', 'stable', 'dose', 'of', 'donepezil', '.', 'The', 'study', 'consists', 'of', 'a', '26', '-', 'week', 'double', '-', 'blind', 'treatment', 'period', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 39,
                "text": "PRX-03140",
                "type": "DRUG"
            },
            {
                "start": 57,
                "end": 76,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 104,
                "end": 113,
                "text": "Donepezil",
                "type": "DRUG"
            },
            {
                "start": 129,
                "end": 136,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 182,
                "end": 191,
                "text": "PRX-03140",
                "type": "DRUG"
            },
            {
                "start": 209,
                "end": 228,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 256,
                "end": 265,
                "text": "donepezil",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00099528",
        "study_official_title": "REN-1654 in Post-Herpetic Neuralgia: a Multi-Center, Placebo Controlled, 3-week Dose-Finding Study, With a 3-Week Active-Treatment Extension ",
        "study_brief_summary": " The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with painful post-herpetic neuralgia (PHN).",
        "text": "REN-1654 in Post-Herpetic Neuralgia: a Multi-Center, Placebo Controlled, 3-week Dose-Finding Study, With a 3-Week Active-Treatment Extension | The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with painful post-herpetic neuralgia (PHN).",
        "tokens": "['REN-1654', 'in', 'Post', '-', 'Herpetic', 'Neuralgia', ':', 'a', 'Multi', '-', 'Center', ',', 'Placebo', 'Controlled', ',', '3', '-', 'week', 'Dose', '-', 'Finding', 'Study', ',', 'With', 'a', '3', '-', 'Week', 'Active', '-', 'Treatment', 'Extension', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'gain', 'initial', 'safety', 'and', 'efficacy', 'data', 'on', 'the', 'experimental', 'agent', 'REN-1654', 'in', 'patients', 'with', 'painful', 'post', '-', 'herpetic', 'neuralgia', '(', 'PHN', ')', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "REN-1654",
                "type": "DRUG"
            },
            {
                "start": 12,
                "end": 35,
                "text": "Post-Herpetic Neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 53,
                "end": 60,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 239,
                "end": 247,
                "text": "REN-1654",
                "type": "DRUG"
            },
            {
                "start": 273,
                "end": 296,
                "text": "post-herpetic neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 301,
                "text": "PHN",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00216502",
        "study_official_title": "Long Term Treatment With Galantamine In Dementia ",
        "study_brief_summary": " The purpose of this study is to evaluate the long-term efficacy and safety of galantamine in patients with Alzheimer's disease.",
        "text": "Long Term Treatment With Galantamine In Dementia | The purpose of this study is to evaluate the long-term efficacy and safety of galantamine in patients with Alzheimer's disease.",
        "tokens": "['Long', 'Term', 'Treatment', 'With', 'Galantamine', 'In', 'Dementia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'efficacy', 'and', 'safety', 'of', 'galantamine', 'in', 'patients', 'with', 'Alzheimer', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 36,
                "text": "Galantamine",
                "type": "DRUG"
            },
            {
                "start": 40,
                "end": 48,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 140,
                "text": "galantamine",
                "type": "DRUG"
            },
            {
                "start": 158,
                "end": 177,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03631953",
        "study_official_title": "Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study ",
        "study_brief_summary": " Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy constitute an unmet pharmaceutical need in neurooncology, leading to a fatal issue within a few months. Grade II-III meningiomas progression-free survival (PFS) 6 is at 10-15%. Median PFS grade III meningioma is approximate 3 years.\n\nAlpelisib is a well-tolerated Phosphoinositide 3-kinase \u03b1 (Pi3K\u03b1) specific inhibitor. However, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) inhibition does not induce apoptosis in vitro and induces an antiproliferative effect without any radiologic response in most treated patients.\n\nTrametinib, a mekinist (MEK) inhibitor is currently used in combined treatment for recurrent melanomas in clinical practice with a good clinical tolerance at 1-2 mg daily. In vitro, on meningioma primary cell culture, Trametinib induces cell apoptosis via caspase activity.\n\nThese results strongly suggest the relevance to combine Alpelisib and Trametinib in aggressive and recurrent meningiomas.\n\nAlpelisib and Trametinib combination has not been studied to date, despite each drugs have been separately studied in phase 3.\n\nMulticenter, open label, dose-finding phase I study of Alpelisib in combination with Trametinib administered at a fixed dose (1.5 mg daily), both drugs will be administered daily. Starting dose of Alpelisib will be 160mg/day and will be increased to 200mg/day or decreased to 120mg/day depending of grade 3-4 adverse events occurrence, to determine maximal tolerated dose (MTD) and recommended dose.\n\nPrimary Objective is to determine the safety profile and tolerability of Alpelisib and Trametinib given in combination in patients with aggressive and refractory meningiomas in terms of Dose-Limiting Toxicities (DLT, assessed during cycle 1).",
        "text": "Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study | Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy constitute an unmet pharmaceutical need in neurooncology, leading to a fatal issue within a few months. Grade II-III meningiomas progression-free survival (PFS) 6 is at 10-15%. Median PFS grade III meningioma is approximate 3 years.\n\nAlpelisib is a well-tolerated Phosphoinositide 3-kinase \u03b1 (Pi3K\u03b1) specific inhibitor. However, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) inhibition does not induce apoptosis in vitro and induces an antiproliferative effect without any radiologic response in most treated patients.\n\nTrametinib, a mekinist (MEK) inhibitor is currently used in combined treatment for recurrent melanomas in clinical practice with a good clinical tolerance at 1-2 mg daily. In vitro, on meningioma primary cell culture, Trametinib induces cell apoptosis via caspase activity.\n\nThese results strongly suggest the relevance to combine Alpelisib and Trametinib in aggressive and recurrent meningiomas.\n\nAlpelisib and Trametinib combination has not been studied to date, despite each drugs have been separately studied in phase 3.\n\nMulticenter, open label, dose-finding phase I study of Alpelisib in combination with Trametinib administered at a fixed dose (1.5 mg daily), both drugs will be administered daily. Starting dose of Alpelisib will be 160mg/day and will be increased to 200mg/day or decreased to 120mg/day depending of grade 3-4 adverse events occurrence, to determine maximal tolerated dose (MTD) and recommended dose.\n\nPrimary Objective is to determine the safety profile and tolerability of Alpelisib and Trametinib given in combination in patients with aggressive and refractory meningiomas in terms of Dose-Limiting Toxicities (DLT, assessed during cycle 1).",
        "tokens": "['Combination', 'of', 'Alpelisib', 'and', 'Trametinib', 'in', 'Progressive', 'Refractory', 'Meningiomas', ':', 'Phase', '1', 'Study', '|', 'Aggressive', 'growing', 'meningiomas', 'resistant', 'to', 'multiple', 'surgeries', 'and', 'radiotherapy', 'constitute', 'an', 'unmet', 'pharmaceutical', 'need', 'in', 'neurooncology', ',', 'leading', 'to', 'a', 'fatal', 'issue', 'within', 'a', 'few', 'months', '.', 'Grade', 'II', '-', 'III', 'meningiomas', 'progression', '-', 'free', 'survival', '(', 'PFS', ')', '6', 'is', 'at', '10', '-', '15', '%', '.', 'Median', 'PFS', 'grade', 'III', 'meningioma', 'is', 'approximate', '3', 'years', '.', '\\n\\n', 'Alpelisib', 'is', 'a', 'well', '-', 'tolerated', 'Phosphoinositide', '3', '-', 'kinase', '\u03b1', '(', 'Pi3K\u03b1', ')', 'specific', 'inhibitor', '.', 'However', ',', 'phosphatidylinositol-3', '-', 'kinase', '(', 'PI3', 'K', ')', 'and', 'the', 'mammalian', 'target', 'of', 'rapamycin', '(', 'mTOR', ')', 'inhibition', 'does', 'not', 'induce', 'apoptosis', 'in', 'vitro', 'and', 'induces', 'an', 'antiproliferative', 'effect', 'without', 'any', 'radiologic', 'response', 'in', 'most', 'treated', 'patients', '.', '\\n\\n', 'Trametinib', ',', 'a', 'mekinist', '(', 'MEK', ')', 'inhibitor', 'is', 'currently', 'used', 'in', 'combined', 'treatment', 'for', 'recurrent', 'melanomas', 'in', 'clinical', 'practice', 'with', 'a', 'good', 'clinical', 'tolerance', 'at', '1', '-', '2', 'mg', 'daily', '.', 'In', 'vitro', ',', 'on', 'meningioma', 'primary', 'cell', 'culture', ',', 'Trametinib', 'induces', 'cell', 'apoptosis', 'via', 'caspase', 'activity', '.', '\\n\\n', 'These', 'results', 'strongly', 'suggest', 'the', 'relevance', 'to', 'combine', 'Alpelisib', 'and', 'Trametinib', 'in', 'aggressive', 'and', 'recurrent', 'meningiomas', '.', '\\n\\n', 'Alpelisib', 'and', 'Trametinib', 'combination', 'has', 'not', 'been', 'studied', 'to', 'date', ',', 'despite', 'each', 'drugs', 'have', 'been', 'separately', 'studied', 'in', 'phase', '3', '.', '\\n\\n', 'Multicenter', ',', 'open', 'label', ',', 'dose', '-', 'finding', 'phase', 'I', 'study', 'of', 'Alpelisib', 'in', 'combination', 'with', 'Trametinib', 'administered', 'at', 'a', 'fixed', 'dose', '(', '1.5', 'mg', 'daily', ')', ',', 'both', 'drugs', 'will', 'be', 'administered', 'daily', '.', 'Starting', 'dose', 'of', 'Alpelisib', 'will', 'be', '160mg', '/', 'day', 'and', 'will', 'be', 'increased', 'to', '200mg', '/', 'day', 'or', 'decreased', 'to', '120mg', '/', 'day', 'depending', 'of', 'grade', '3', '-', '4', 'adverse', 'events', 'occurrence', ',', 'to', 'determine', 'maximal', 'tolerated', 'dose', '(', 'MTD', ')', 'and', 'recommended', 'dose', '.', '\\n\\n', 'Primary', 'Objective', 'is', 'to', 'determine', 'the', 'safety', 'profile', 'and', 'tolerability', 'of', 'Alpelisib', 'and', 'Trametinib', 'given', 'in', 'combination', 'in', 'patients', 'with', 'aggressive', 'and', 'refractory', 'meningiomas', 'in', 'terms', 'of', 'Dose', '-', 'Limiting', 'Toxicities', '(', 'DLT', ',', 'assessed', 'during', 'cycle', '1', ')', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 24,
                "text": "Alpelisib",
                "type": "DRUG"
            },
            {
                "start": 29,
                "end": 39,
                "text": "Trametinib",
                "type": "DRUG"
            },
            {
                "start": 43,
                "end": 77,
                "text": "Progressive Refractory Meningiomas",
                "type": "CONDITION"
            },
            {
                "start": 95,
                "end": 174,
                "text": "Aggressive growing meningiomas resistant to multiple surgeries and radiotherapy",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 303,
                "text": "Grade II-III meningiomas",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 383,
                "text": "grade III meningioma",
                "type": "CONDITION"
            },
            {
                "start": 409,
                "end": 418,
                "text": "Alpelisib",
                "type": "DRUG"
            },
            {
                "start": 731,
                "end": 741,
                "text": "Trametinib",
                "type": "DRUG"
            },
            {
                "start": 916,
                "end": 926,
                "text": "meningioma",
                "type": "CONDITION"
            },
            {
                "start": 949,
                "end": 959,
                "text": "Trametinib",
                "type": "DRUG"
            },
            {
                "start": 1062,
                "end": 1071,
                "text": "Alpelisib",
                "type": "DRUG"
            },
            {
                "start": 1076,
                "end": 1086,
                "text": "Trametinib",
                "type": "DRUG"
            },
            {
                "start": 1090,
                "end": 1126,
                "text": "aggressive and recurrent meningiomas",
                "type": "CONDITION"
            },
            {
                "start": 1129,
                "end": 1138,
                "text": "Alpelisib",
                "type": "DRUG"
            },
            {
                "start": 1143,
                "end": 1153,
                "text": "Trametinib",
                "type": "DRUG"
            },
            {
                "start": 1312,
                "end": 1321,
                "text": "Alpelisib",
                "type": "DRUG"
            },
            {
                "start": 1342,
                "end": 1352,
                "text": "Trametinib",
                "type": "DRUG"
            },
            {
                "start": 1454,
                "end": 1463,
                "text": "Alpelisib",
                "type": "DRUG"
            },
            {
                "start": 1731,
                "end": 1740,
                "text": "Alpelisib",
                "type": "DRUG"
            },
            {
                "start": 1745,
                "end": 1755,
                "text": "Trametinib",
                "type": "DRUG"
            },
            {
                "start": 1794,
                "end": 1831,
                "text": "aggressive and refractory meningiomas",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05258500",
        "study_official_title": "Strength Training in Hospitalized Patients Using the Ghostly App: a Feasibility Study ",
        "study_brief_summary": " The goal of this feasibility study is to evaluate the use of the Ghostly app in rehabilitation of stroke patients, elderly and patients recovering from COVID-19 or ICU patients. In three randomized controlled trials, the effect of a strength training program incorporated in the Ghostly app will be assessed for 1) stroke patients suffering from weakness of the lower limb, 2) frail elderly with gait difficulties and 3) patients recovering from COVID-19 or ICU patients who suffer from muscle weakness. Additionally, the effect of BFR on strength gain in all these three populations will be tested.",
        "text": "Strength Training in Hospitalized Patients Using the Ghostly App: a Feasibility Study | The goal of this feasibility study is to evaluate the use of the Ghostly app in rehabilitation of stroke patients, elderly and patients recovering from COVID-19 or ICU patients. In three randomized controlled trials, the effect of a strength training program incorporated in the Ghostly app will be assessed for 1) stroke patients suffering from weakness of the lower limb, 2) frail elderly with gait difficulties and 3) patients recovering from COVID-19 or ICU patients who suffer from muscle weakness. Additionally, the effect of BFR on strength gain in all these three populations will be tested.",
        "tokens": "['Strength', 'Training', 'in', 'Hospitalized', 'Patients', 'Using', 'the', 'Ghostly', 'App', ':', 'a', 'Feasibility', 'Study', '|', 'The', 'goal', 'of', 'this', 'feasibility', 'study', 'is', 'to', 'evaluate', 'the', 'use', 'of', 'the', 'Ghostly', 'app', 'in', 'rehabilitation', 'of', 'stroke', 'patients', ',', 'elderly', 'and', 'patients', 'recovering', 'from', 'COVID-19', 'or', 'ICU', 'patients', '.', 'In', 'three', 'randomized', 'controlled', 'trials', ',', 'the', 'effect', 'of', 'a', 'strength', 'training', 'program', 'incorporated', 'in', 'the', 'Ghostly', 'app', 'will', 'be', 'assessed', 'for', '1', ')', 'stroke', 'patients', 'suffering', 'from', 'weakness', 'of', 'the', 'lower', 'limb', ',', '2', ')', 'frail', 'elderly', 'with', 'gait', 'difficulties', 'and', '3', ')', 'patients', 'recovering', 'from', 'COVID-19', 'or', 'ICU', 'patients', 'who', 'suffer', 'from', 'muscle', 'weakness', '.', 'Additionally', ',', 'the', 'effect', 'of', 'BFR', 'on', 'strength', 'gain', 'in', 'all', 'these', 'three', 'populations', 'will', 'be', 'tested', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 17,
                "text": "Strength Training",
                "type": "PHYSICAL"
            },
            {
                "start": 53,
                "end": 64,
                "text": "Ghostly App",
                "type": "OTHER"
            },
            {
                "start": 153,
                "end": 164,
                "text": "Ghostly app",
                "type": "OTHER"
            },
            {
                "start": 186,
                "end": 192,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 240,
                "end": 248,
                "text": "COVID-19",
                "type": "CONDITION"
            },
            {
                "start": 321,
                "end": 338,
                "text": "strength training",
                "type": "PHYSICAL"
            },
            {
                "start": 367,
                "end": 378,
                "text": "Ghostly app",
                "type": "OTHER"
            },
            {
                "start": 403,
                "end": 409,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 434,
                "end": 460,
                "text": "weakness of the lower limb",
                "type": "CONDITION"
            },
            {
                "start": 484,
                "end": 501,
                "text": "gait difficulties",
                "type": "CONDITION"
            },
            {
                "start": 534,
                "end": 542,
                "text": "COVID-19",
                "type": "CONDITION"
            },
            {
                "start": 575,
                "end": 590,
                "text": "muscle weakness",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04426188",
        "study_official_title": "\" Brain Changes After Repetitive Head Impacts in Soccer and the Effects of a Protective Device: Biomechanical, Cognitive, Electrophysiological and Multimodal Neuroimaging Study \" ",
        "study_brief_summary": " Soccer, the most popular sport in the world, exposes players to repeated head impacts and concussions, due to contact with another player or with the ground. Moreover, routine game-play in soccer involves intentional and repeated head impacts through ball \"heading\", with frequent high velocities, which might cause a transient brain dysfunction. In this pre-post prospective interventional study, 22 soccer players will perform 10 headers from machine-projected soccer balls at standardized speeds, modelling routine soccer practice. They will perform heading series in 2 different oral conditions, on different days at least 1 week apart: 1) Without mouthguard and tight jaws ; 2) With mouthguard and tight jaws. The strength of the neck muscles will be measured before the heading series. The kinematic of the movement will be recorded during each impact during the 2 heading series, as well as the activity of the jaw muscles which will be recorded by electromyogram. Before and after each heading series, electrophysiological data, multimodal magnetic resonance imaging (MRI), and cognitive computerized assessment will be acquired",
        "text": "\" Brain Changes After Repetitive Head Impacts in Soccer and the Effects of a Protective Device: Biomechanical, Cognitive, Electrophysiological and Multimodal Neuroimaging Study \" | Soccer, the most popular sport in the world, exposes players to repeated head impacts and concussions, due to contact with another player or with the ground. Moreover, routine game-play in soccer involves intentional and repeated head impacts through ball \"heading\", with frequent high velocities, which might cause a transient brain dysfunction. In this pre-post prospective interventional study, 22 soccer players will perform 10 headers from machine-projected soccer balls at standardized speeds, modelling routine soccer practice. They will perform heading series in 2 different oral conditions, on different days at least 1 week apart: 1) Without mouthguard and tight jaws ; 2) With mouthguard and tight jaws. The strength of the neck muscles will be measured before the heading series. The kinematic of the movement will be recorded during each impact during the 2 heading series, as well as the activity of the jaw muscles which will be recorded by electromyogram. Before and after each heading series, electrophysiological data, multimodal magnetic resonance imaging (MRI), and cognitive computerized assessment will be acquired",
        "tokens": "['\"', 'Brain', 'Changes', 'After', 'Repetitive', 'Head', 'Impacts', 'in', 'Soccer', 'and', 'the', 'Effects', 'of', 'a', 'Protective', 'Device', ':', 'Biomechanical', ',', 'Cognitive', ',', 'Electrophysiological', 'and', 'Multimodal', 'Neuroimaging', 'Study', '\"', '|', 'Soccer', ',', 'the', 'most', 'popular', 'sport', 'in', 'the', 'world', ',', 'exposes', 'players', 'to', 'repeated', 'head', 'impacts', 'and', 'concussions', ',', 'due', 'to', 'contact', 'with', 'another', 'player', 'or', 'with', 'the', 'ground', '.', 'Moreover', ',', 'routine', 'game', '-', 'play', 'in', 'soccer', 'involves', 'intentional', 'and', 'repeated', 'head', 'impacts', 'through', 'ball', '\"', 'heading', '\"', ',', 'with', 'frequent', 'high', 'velocities', ',', 'which', 'might', 'cause', 'a', 'transient', 'brain', 'dysfunction', '.', 'In', 'this', 'pre', '-', 'post', 'prospective', 'interventional', 'study', ',', '22', 'soccer', 'players', 'will', 'perform', '10', 'headers', 'from', 'machine', '-', 'projected', 'soccer', 'balls', 'at', 'standardized', 'speeds', ',', 'modelling', 'routine', 'soccer', 'practice', '.', 'They', 'will', 'perform', 'heading', 'series', 'in', '2', 'different', 'oral', 'conditions', ',', 'on', 'different', 'days', 'at', 'least', '1', 'week', 'apart', ':', '1', ')', 'Without', 'mouthguard', 'and', 'tight', 'jaws', ';', '2', ')', 'With', 'mouthguard', 'and', 'tight', 'jaws', '.', 'The', 'strength', 'of', 'the', 'neck', 'muscles', 'will', 'be', 'measured', 'before', 'the', 'heading', 'series', '.', 'The', 'kinematic', 'of', 'the', 'movement', 'will', 'be', 'recorded', 'during', 'each', 'impact', 'during', 'the', '2', 'heading', 'series', ',', 'as', 'well', 'as', 'the', 'activity', 'of', 'the', 'jaw', 'muscles', 'which', 'will', 'be', 'recorded', 'by', 'electromyogram', '.', 'Before', 'and', 'after', 'each', 'heading', 'series', ',', 'electrophysiological', 'data', ',', 'multimodal', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', ',', 'and', 'cognitive', 'computerized', 'assessment', 'will', 'be', 'acquired']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 45,
                "text": "Repetitive Head Impacts",
                "type": "CONDITION"
            },
            {
                "start": 77,
                "end": 94,
                "text": "Protective Device",
                "type": "OTHER"
            },
            {
                "start": 245,
                "end": 266,
                "text": "repeated head impacts",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 282,
                "text": "concussions",
                "type": "CONDITION"
            },
            {
                "start": 402,
                "end": 423,
                "text": "repeated head impacts",
                "type": "CONDITION"
            },
            {
                "start": 825,
                "end": 858,
                "text": "Without mouthguard and tight jaws",
                "type": "CONTROL"
            },
            {
                "start": 869,
                "end": 879,
                "text": "mouthguard",
                "type": "OTHER"
            },
            {
                "start": 884,
                "end": 894,
                "text": "tight jaws",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00271596",
        "study_official_title": "A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) ",
        "study_brief_summary": " This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims:\n\nTo determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variables including functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status,\nTo study the relationship between executive function and functional status in patients with early HD after selective serotonin reuptake inhibitor (SSRI) treatment, and\nTo examine the effect of citalopram treatment on volumetric and metabolic (i.e, N-acetyl-aspartate concentration) measures in the neostriatum among patients with recently diagnosed Huntington's disease.",
        "text": "A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) | This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims:\n\nTo determine the effect of citalopram compared to placebo in patients with early HD on executive function and other outcome variables including functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status,\nTo study the relationship between executive function and functional status in patients with early HD after selective serotonin reuptake inhibitor (SSRI) treatment, and\nTo examine the effect of citalopram treatment on volumetric and metabolic (i.e, N-acetyl-aspartate concentration) measures in the neostriatum among patients with recently diagnosed Huntington's disease.",
        "tokens": "['A', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Pilot', 'Study', 'in', 'Huntington', \"'s\", 'Disease', '(', 'CIT', '-', 'HD', ')', '|', 'This', 'research', 'plan', 'proposes', 'to', 'conduct', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'pilot', 'clinical', 'trial', 'in', '36', 'adults', 'with', 'mild', 'Huntington', \"'s\", 'disease', '(', 'HD', ')', 'to', 'address', 'the', 'following', 'research', 'aims', ':', '\\n\\n', 'To', 'determine', 'the', 'effect', 'of', 'citalopram', 'compared', 'to', 'placebo', 'in', 'patients', 'with', 'early', 'HD', 'on', 'executive', 'function', 'and', 'other', 'outcome', 'variables', 'including', 'functional', 'measures', '(', 'health', '-', 'related', 'quality', 'of', 'life', ',', 'work', 'productivity', ',', 'and', 'self', '-', 'reported', 'attention', ')', ',', 'motor', 'performance', ',', 'and', 'psychiatric', 'status', ',', '\\n', 'To', 'study', 'the', 'relationship', 'between', 'executive', 'function', 'and', 'functional', 'status', 'in', 'patients', 'with', 'early', 'HD', 'after', 'selective', 'serotonin', 'reuptake', 'inhibitor', '(', 'SSRI', ')', 'treatment', ',', 'and', '\\n', 'To', 'examine', 'the', 'effect', 'of', 'citalopram', 'treatment', 'on', 'volumetric', 'and', 'metabolic', '(', 'i.e', ',', 'N', '-', 'acetyl', '-', 'aspartate', 'concentration', ')', 'measures', 'in', 'the', 'neostriatum', 'among', 'patients', 'with', 'recently', 'diagnosed', 'Huntington', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 21,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 48,
                "end": 68,
                "text": "Huntington's Disease",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 142,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 193,
                "end": 218,
                "text": "mild Huntington's disease",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 222,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 292,
                "end": 302,
                "text": "citalopram",
                "type": "DRUG"
            },
            {
                "start": 315,
                "end": 322,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 340,
                "end": 348,
                "text": "early HD",
                "type": "CONDITION"
            },
            {
                "start": 646,
                "end": 654,
                "text": "early HD",
                "type": "CONDITION"
            },
            {
                "start": 671,
                "end": 699,
                "text": "serotonin reuptake inhibitor",
                "type": "DRUG"
            },
            {
                "start": 701,
                "end": 705,
                "text": "SSRI",
                "type": "DRUG"
            },
            {
                "start": 747,
                "end": 757,
                "text": "citalopram",
                "type": "DRUG"
            },
            {
                "start": 903,
                "end": 923,
                "text": "Huntington's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01450423",
        "study_official_title": "Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy Aged 15-50: A Randomized Controlled Trial ",
        "study_brief_summary": " Epilepsy is a chronic neurologic disorder characterized by seizures. Beside seizures people suffering from epilepsy experience several challenges related to education, work and everyday life such as learning-, problem-solving-, memory-, concentration-, attention difficulties and fatigue.\n\nIt is generally approved that physical activity (PA) has a positive effect on physical as well as mental factors. However, people with epilepsy are found to be less active and PA is rarely offered or recommended as supplement to anti-epileptic medical treatment. Few studies have investigated the effect of PA in subjects with epilepsy and additional studies of high methodical quality are needed to enable evidence-based information and counselling.\n\nThis study is carried through as a randomized controlled trial which investigates the effect of participation in a 10-week cardio exercise program in people with Juvenile Myoclonic Epilepsy aged 15-50.\n\nThe study hypothesis is that participation in a 10-week cardio exercise program will induce a positive change in cognitive function (concentration and attention) and possibly in brain-derived neurotrophic factor (BDNF). In addition it is expected that the intensity and duration of the 10-week cardio exercise program is sufficient to cause changes in physiological parameters related to a reduced risk of lifestyle diseases.",
        "text": "Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy Aged 15-50: A Randomized Controlled Trial | Epilepsy is a chronic neurologic disorder characterized by seizures. Beside seizures people suffering from epilepsy experience several challenges related to education, work and everyday life such as learning-, problem-solving-, memory-, concentration-, attention difficulties and fatigue.\n\nIt is generally approved that physical activity (PA) has a positive effect on physical as well as mental factors. However, people with epilepsy are found to be less active and PA is rarely offered or recommended as supplement to anti-epileptic medical treatment. Few studies have investigated the effect of PA in subjects with epilepsy and additional studies of high methodical quality are needed to enable evidence-based information and counselling.\n\nThis study is carried through as a randomized controlled trial which investigates the effect of participation in a 10-week cardio exercise program in people with Juvenile Myoclonic Epilepsy aged 15-50.\n\nThe study hypothesis is that participation in a 10-week cardio exercise program will induce a positive change in cognitive function (concentration and attention) and possibly in brain-derived neurotrophic factor (BDNF). In addition it is expected that the intensity and duration of the 10-week cardio exercise program is sufficient to cause changes in physiological parameters related to a reduced risk of lifestyle diseases.",
        "tokens": "['Physical', 'Exercise', 'in', 'Subjects', 'With', 'Juvenile', 'Myoclonic', 'Epilepsy', 'Aged', '15', '-', '50', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'Epilepsy', 'is', 'a', 'chronic', 'neurologic', 'disorder', 'characterized', 'by', 'seizures', '.', 'Beside', 'seizures', 'people', 'suffering', 'from', 'epilepsy', 'experience', 'several', 'challenges', 'related', 'to', 'education', ',', 'work', 'and', 'everyday', 'life', 'such', 'as', 'learning-', ',', 'problem', '-', 'solving-', ',', 'memory-', ',', 'concentration-', ',', 'attention', 'difficulties', 'and', 'fatigue', '.', '\\n\\n', 'It', 'is', 'generally', 'approved', 'that', 'physical', 'activity', '(', 'PA', ')', 'has', 'a', 'positive', 'effect', 'on', 'physical', 'as', 'well', 'as', 'mental', 'factors', '.', 'However', ',', 'people', 'with', 'epilepsy', 'are', 'found', 'to', 'be', 'less', 'active', 'and', 'PA', 'is', 'rarely', 'offered', 'or', 'recommended', 'as', 'supplement', 'to', 'anti', '-', 'epileptic', 'medical', 'treatment', '.', 'Few', 'studies', 'have', 'investigated', 'the', 'effect', 'of', 'PA', 'in', 'subjects', 'with', 'epilepsy', 'and', 'additional', 'studies', 'of', 'high', 'methodical', 'quality', 'are', 'needed', 'to', 'enable', 'evidence', '-', 'based', 'information', 'and', 'counselling', '.', '\\n\\n', 'This', 'study', 'is', 'carried', 'through', 'as', 'a', 'randomized', 'controlled', 'trial', 'which', 'investigates', 'the', 'effect', 'of', 'participation', 'in', 'a', '10', '-', 'week', 'cardio', 'exercise', 'program', 'in', 'people', 'with', 'Juvenile', 'Myoclonic', 'Epilepsy', 'aged', '15', '-', '50', '.', '\\n\\n', 'The', 'study', 'hypothesis', 'is', 'that', 'participation', 'in', 'a', '10', '-', 'week', 'cardio', 'exercise', 'program', 'will', 'induce', 'a', 'positive', 'change', 'in', 'cognitive', 'function', '(', 'concentration', 'and', 'attention', ')', 'and', 'possibly', 'in', 'brain', '-', 'derived', 'neurotrophic', 'factor', '(', 'BDNF', ')', '.', 'In', 'addition', 'it', 'is', 'expected', 'that', 'the', 'intensity', 'and', 'duration', 'of', 'the', '10', '-', 'week', 'cardio', 'exercise', 'program', 'is', 'sufficient', 'to', 'cause', 'changes', 'in', 'physiological', 'parameters', 'related', 'to', 'a', 'reduced', 'risk', 'of', 'lifestyle', 'diseases', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 17,
                "text": "Physical Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 35,
                "end": 62,
                "text": "Juvenile Myoclonic Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 115,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 174,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 191,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 214,
                "end": 222,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 427,
                "end": 444,
                "text": "physical activity",
                "type": "PHYSICAL"
            },
            {
                "start": 446,
                "end": 448,
                "text": "PA",
                "type": "PHYSICAL"
            },
            {
                "start": 532,
                "end": 540,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 573,
                "end": 575,
                "text": "PA",
                "type": "PHYSICAL"
            },
            {
                "start": 704,
                "end": 706,
                "text": "PA",
                "type": "PHYSICAL"
            },
            {
                "start": 724,
                "end": 732,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 972,
                "end": 995,
                "text": "cardio exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 1011,
                "end": 1038,
                "text": "Juvenile Myoclonic Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 1108,
                "end": 1131,
                "text": "cardio exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 1346,
                "end": 1369,
                "text": "cardio exercise program",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT00259974",
        "study_official_title": "Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy ",
        "study_brief_summary": " Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will test the safety and efficacy of rituximab in the treatment of patients with anti-MAG polyneuropathy.",
        "text": "Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy | Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will test the safety and efficacy of rituximab in the treatment of patients with anti-MAG polyneuropathy.",
        "tokens": "['Double', '-', 'blind', 'Randomized', 'Trial', 'of', 'Rituximab', 'Versus', 'Placebo', 'in', 'Polyneuropathy', 'Associated', 'With', 'Anti', '-', 'MAG', 'IgM', 'Monoclonal', 'Gammopathy', '|', 'Polyneuropathy', 'associated', 'with', 'anti', '-', 'MAG', 'monoclonal', 'IgM', 'gammopathy', 'is', 'responsive', 'of', 'mainly', 'a', 'sensory', 'deficit', 'in', 'predominantly', 'males', ',', 'aged', '40', '-', '70', 'years', '.', 'Significantly', 'high', 'serum', 'anti', '-', 'MAG', 'antibodies', 'are', 'linked', 'with', 'demyelinating', 'features', 'of', 'the', 'peripheral', 'nerves', '.', 'Rituximab', ',', 'an', 'anti', '-', 'CD', '20', 'monoclonal', 'antibody', 'is', 'a', 'new', 'drug', 'which', 'reduces', 'B', '-', 'lymphocytes', '.', 'This', 'study', 'will', 'test', 'the', 'safety', 'and', 'efficacy', 'of', 'rituximab', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'anti', '-', 'MAG', 'polyneuropathy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 42,
                "text": "Rituximab",
                "type": "DRUG"
            },
            {
                "start": 50,
                "end": 57,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 61,
                "end": 75,
                "text": "Polyneuropathy",
                "type": "CONDITION"
            },
            {
                "start": 92,
                "end": 126,
                "text": "Anti-MAG IgM Monoclonal Gammopathy",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 143,
                "text": "Polyneuropathy",
                "type": "CONDITION"
            },
            {
                "start": 160,
                "end": 194,
                "text": "anti-MAG monoclonal IgM gammopathy",
                "type": "CONDITION"
            },
            {
                "start": 388,
                "end": 397,
                "text": "Rituximab",
                "type": "DRUG"
            },
            {
                "start": 402,
                "end": 432,
                "text": "anti-CD 20 monoclonal antibody",
                "type": "DRUG"
            },
            {
                "start": 524,
                "end": 533,
                "text": "rituximab",
                "type": "DRUG"
            },
            {
                "start": 568,
                "end": 591,
                "text": "anti-MAG polyneuropathy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01945151",
        "study_official_title": "Analysis of the Electrical Muscle Activity and Resistance to Movement After Pplication Neuromuscular Electrical Stimulation (EENM) in Patients With Hemiparesis Spastic. ",
        "study_brief_summary": " To evaluate and compare the effects of Neuromuscular Electrical Stimulation when applied in the agonist and antagonist muscles of spastic hemiparetic patients.\n\nThe specific objectives are:\n\nEvaluate the resistance movement, strength and muscle electrical activity before and after application of Neuromuscular Electrical Stimulation in spastic muscle (gastrocnemius).\nEvaluate the resistance movement, strength and muscle electrical activity before and after application of Neuromuscular Electrical Stimulation in the spastic antagonist muscle (tibialis anterior).\nCompare the risk of falls after application of Neuromuscular Electrical Stimulation in both muscles studied.",
        "text": "Analysis of the Electrical Muscle Activity and Resistance to Movement After Pplication Neuromuscular Electrical Stimulation (EENM) in Patients With Hemiparesis Spastic. | To evaluate and compare the effects of Neuromuscular Electrical Stimulation when applied in the agonist and antagonist muscles of spastic hemiparetic patients.\n\nThe specific objectives are:\n\nEvaluate the resistance movement, strength and muscle electrical activity before and after application of Neuromuscular Electrical Stimulation in spastic muscle (gastrocnemius).\nEvaluate the resistance movement, strength and muscle electrical activity before and after application of Neuromuscular Electrical Stimulation in the spastic antagonist muscle (tibialis anterior).\nCompare the risk of falls after application of Neuromuscular Electrical Stimulation in both muscles studied.",
        "tokens": "['Analysis', 'of', 'the', 'Electrical', 'Muscle', 'Activity', 'and', 'Resistance', 'to', 'Movement', 'After', 'Pplication', 'Neuromuscular', 'Electrical', 'Stimulation', '(', 'EENM', ')', 'in', 'Patients', 'With', 'Hemiparesis', 'Spastic', '.', '|', 'To', 'evaluate', 'and', 'compare', 'the', 'effects', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'when', 'applied', 'in', 'the', 'agonist', 'and', 'antagonist', 'muscles', 'of', 'spastic', 'hemiparetic', 'patients', '.', '\\n\\n', 'The', 'specific', 'objectives', 'are', ':', '\\n\\n', 'Evaluate', 'the', 'resistance', 'movement', ',', 'strength', 'and', 'muscle', 'electrical', 'activity', 'before', 'and', 'after', 'application', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'in', 'spastic', 'muscle', '(', 'gastrocnemius', ')', '.', '\\n', 'Evaluate', 'the', 'resistance', 'movement', ',', 'strength', 'and', 'muscle', 'electrical', 'activity', 'before', 'and', 'after', 'application', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'in', 'the', 'spastic', 'antagonist', 'muscle', '(', 'tibialis', 'anterior', ')', '.', '\\n', 'Compare', 'the', 'risk', 'of', 'falls', 'after', 'application', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'in', 'both', 'muscles', 'studied', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 87,
                "end": 123,
                "text": "Neuromuscular Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 125,
                "end": 129,
                "text": "EENM",
                "type": "OTHER"
            },
            {
                "start": 148,
                "end": 167,
                "text": "Hemiparesis Spastic",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 246,
                "text": "Neuromuscular Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 301,
                "end": 320,
                "text": "spastic hemiparetic",
                "type": "CONDITION"
            },
            {
                "start": 468,
                "end": 504,
                "text": "Neuromuscular Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 508,
                "end": 522,
                "text": "spastic muscle",
                "type": "CONDITION"
            },
            {
                "start": 646,
                "end": 682,
                "text": "Neuromuscular Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 690,
                "end": 715,
                "text": "spastic antagonist muscle",
                "type": "CONDITION"
            },
            {
                "start": 784,
                "end": 820,
                "text": "Neuromuscular Electrical Stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04856384",
        "study_official_title": "Understanding the Effect of Variances on Precision in Predictive Coding When Walking to Music and Metronomes in Persons With Multiple Sclerosis With Progressive Subtypes. ",
        "study_brief_summary": " This study is a case-control study, involving persons with progressive multiple sclerosis and healthy controls. The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations. In the latter twp sessions, apart from outcome measures of synchronization the following will be collected as well: brain activity using EEG recordings, spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.",
        "text": "Understanding the Effect of Variances on Precision in Predictive Coding When Walking to Music and Metronomes in Persons With Multiple Sclerosis With Progressive Subtypes. | This study is a case-control study, involving persons with progressive multiple sclerosis and healthy controls. The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations. In the latter twp sessions, apart from outcome measures of synchronization the following will be collected as well: brain activity using EEG recordings, spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.",
        "tokens": "['Understanding', 'the', 'Effect', 'of', 'Variances', 'on', 'Precision', 'in', 'Predictive', 'Coding', 'When', 'Walking', 'to', 'Music', 'and', 'Metronomes', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', 'With', 'Progressive', 'Subtypes', '.', '|', 'This', 'study', 'is', 'a', 'case', '-', 'control', 'study', ',', 'involving', 'persons', 'with', 'progressive', 'multiple', 'sclerosis', 'and', 'healthy', 'controls', '.', 'The', 'study', 'contains', '1', 'descriptive', 'and', '3', 'experimental', 'sessions', '.', 'In', 'the', 'descriptive', 'session', ',', 'participant', \"'s\", 'clinical', 'motor', 'and', 'cognitive', 'functions', 'are', 'collected', '.', 'In', 'the', 'first', 'experimental', 'session', ',', 'participant', \"'s\", 'beat', 'perception', 'and', 'synchronisation', 'abilities', 'is', 'examined', 'within', 'a', 'finger', 'tapping', 'paradigm', '.', 'In', 'the', 'following', 'experimental', 'sessions', 'participants', 'synchronsiation', 'abilities', 'is', 'examined', 'during', 'walking', 'paradigms', ',', 'to', 'music', 'and', 'metronomes', ',', 'with', 'period', 'and', 'phase', 'auditory', 'manipulations', '.', 'In', 'the', 'latter', 'twp', 'sessions', ',', 'apart', 'from', 'outcome', 'measures', 'of', 'synchronization', 'the', 'following', 'will', 'be', 'collected', 'as', 'well', ':', 'brain', 'activity', 'using', 'EEG', 'recordings', ',', 'spatio', '-', 'temporal', 'gait', 'parameters', ',', 'perceived', 'fatigue', ',', 'perceived', 'motivation', 'and', 'perceived', 'speed', 'of', 'walking', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 125,
                "end": 169,
                "text": "Multiple Sclerosis With Progressive Subtypes",
                "type": "CONDITION"
            },
            {
                "start": 232,
                "end": 262,
                "text": "progressive multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 967,
                "end": 974,
                "text": "fatigue",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05563402",
        "study_official_title": "\"Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis\" ",
        "study_brief_summary": " Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), affecting more than 2 million people worldwide,1 it is a degenerative disease that selectively affects the central nervous system and represents the main cause of non-traumatic disability in young adults.\n\nGait and balance disturbances in MS are common even in the early stages of the disease. Half of the patients report some alteration in the quality of walking within the first month after diagnosis, reaching 90% after 10 years of evolution. 4 5 In addition, it is the symptom to which patients give the most importance 6 and the one that most conditions their activity and participation. 7 The causes of gait disturbance are multifactorial and are influenced by different aspects such as muscle strength, balance, coordination, proprioception, vision, spasticity, fatigue and even cognitive aspects4.\n\nThere are multiple interventions, including aerobic, resistance training, yoga, and combined exercise, that have shown significant improvements in walking endurance, regardless of outcome measures (six-minute walking test (6MWT), two-minute walking test 2MWT). 8\n\nIn recent years, evidence has been growing around rehabilitation with robotic equipment in people with multiple sclerosis (PwMS), in their study Ye et al. concluded that robotic locomotor training has limited impact on motor functions in multiple sclerosis, but improves fatigue and spasticity, is safe and well-tolerated for PwMS, and less demanding for physical therapists.10 Bowman et al. concluded that robot-assisted gait therapy (RAGT) improves balance and gait outcomes in a clinically significant way in PwMS, RAGT appears more effective compared to non-specific rehabilitation, while showing similar effects compared to non-specific rehabilitation. specific balance and gait training in studies with level 2 evidence. RAGT has several advantages in terms of patient motor assistance, training intensity, safety and the possibility of combining other therapeutic approaches and should be promoted for PwMS with disability in a multimodal rehabilitation setting as an opportunity to maximize recovery.11 In this setting, more larger-scale and better-designed studies with longer training duration and more studies evaluating satisfaction, usability, and effectiveness are needed. of RAGT.",
        "text": "\"Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis\" | Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), affecting more than 2 million people worldwide,1 it is a degenerative disease that selectively affects the central nervous system and represents the main cause of non-traumatic disability in young adults.\n\nGait and balance disturbances in MS are common even in the early stages of the disease. Half of the patients report some alteration in the quality of walking within the first month after diagnosis, reaching 90% after 10 years of evolution. 4 5 In addition, it is the symptom to which patients give the most importance 6 and the one that most conditions their activity and participation. 7 The causes of gait disturbance are multifactorial and are influenced by different aspects such as muscle strength, balance, coordination, proprioception, vision, spasticity, fatigue and even cognitive aspects4.\n\nThere are multiple interventions, including aerobic, resistance training, yoga, and combined exercise, that have shown significant improvements in walking endurance, regardless of outcome measures (six-minute walking test (6MWT), two-minute walking test 2MWT). 8\n\nIn recent years, evidence has been growing around rehabilitation with robotic equipment in people with multiple sclerosis (PwMS), in their study Ye et al. concluded that robotic locomotor training has limited impact on motor functions in multiple sclerosis, but improves fatigue and spasticity, is safe and well-tolerated for PwMS, and less demanding for physical therapists.10 Bowman et al. concluded that robot-assisted gait therapy (RAGT) improves balance and gait outcomes in a clinically significant way in PwMS, RAGT appears more effective compared to non-specific rehabilitation, while showing similar effects compared to non-specific rehabilitation. specific balance and gait training in studies with level 2 evidence. RAGT has several advantages in terms of patient motor assistance, training intensity, safety and the possibility of combining other therapeutic approaches and should be promoted for PwMS with disability in a multimodal rehabilitation setting as an opportunity to maximize recovery.11 In this setting, more larger-scale and better-designed studies with longer training duration and more studies evaluating satisfaction, usability, and effectiveness are needed. of RAGT.",
        "tokens": "['\"', 'Evaluation', 'of', 'Usability', 'and', 'Safety', 'of', 'the', 'Self', '-', 'balancing', 'Walking', 'System', 'Atalante', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '\"', '|', 'Multiple', 'sclerosis', '(', 'MS', ')', 'is', 'the', 'most', 'prevalent', 'chronic', 'inflammatory', 'disease', 'of', 'the', 'central', 'nervous', 'system', '(', 'CNS', ')', ',', 'affecting', 'more', 'than', '2', 'million', 'people', 'worldwide,1', 'it', 'is', 'a', 'degenerative', 'disease', 'that', 'selectively', 'affects', 'the', 'central', 'nervous', 'system', 'and', 'represents', 'the', 'main', 'cause', 'of', 'non', '-', 'traumatic', 'disability', 'in', 'young', 'adults', '.', '\\n\\n', 'Gait', 'and', 'balance', 'disturbances', 'in', 'MS', 'are', 'common', 'even', 'in', 'the', 'early', 'stages', 'of', 'the', 'disease', '.', 'Half', 'of', 'the', 'patients', 'report', 'some', 'alteration', 'in', 'the', 'quality', 'of', 'walking', 'within', 'the', 'first', 'month', 'after', 'diagnosis', ',', 'reaching', '90', '%', 'after', '10', 'years', 'of', 'evolution', '.', '4', '5', 'In', 'addition', ',', 'it', 'is', 'the', 'symptom', 'to', 'which', 'patients', 'give', 'the', 'most', 'importance', '6', 'and', 'the', 'one', 'that', 'most', 'conditions', 'their', 'activity', 'and', 'participation', '.', '7', 'The', 'causes', 'of', 'gait', 'disturbance', 'are', 'multifactorial', 'and', 'are', 'influenced', 'by', 'different', 'aspects', 'such', 'as', 'muscle', 'strength', ',', 'balance', ',', 'coordination', ',', 'proprioception', ',', 'vision', ',', 'spasticity', ',', 'fatigue', 'and', 'even', 'cognitive', 'aspects4', '.', '\\n\\n', 'There', 'are', 'multiple', 'interventions', ',', 'including', 'aerobic', ',', 'resistance', 'training', ',', 'yoga', ',', 'and', 'combined', 'exercise', ',', 'that', 'have', 'shown', 'significant', 'improvements', 'in', 'walking', 'endurance', ',', 'regardless', 'of', 'outcome', 'measures', '(', 'six', '-', 'minute', 'walking', 'test', '(', '6MWT', ')', ',', 'two', '-', 'minute', 'walking', 'test', '2MWT', ')', '.', '8', '\\n\\n', 'In', 'recent', 'years', ',', 'evidence', 'has', 'been', 'growing', 'around', 'rehabilitation', 'with', 'robotic', 'equipment', 'in', 'people', 'with', 'multiple', 'sclerosis', '(', 'PwMS', ')', ',', 'in', 'their', 'study', 'Ye', 'et', 'al', '.', 'concluded', 'that', 'robotic', 'locomotor', 'training', 'has', 'limited', 'impact', 'on', 'motor', 'functions', 'in', 'multiple', 'sclerosis', ',', 'but', 'improves', 'fatigue', 'and', 'spasticity', ',', 'is', 'safe', 'and', 'well', '-', 'tolerated', 'for', 'PwMS', ',', 'and', 'less', 'demanding', 'for', 'physical', 'therapists.10', 'Bowman', 'et', 'al', '.', 'concluded', 'that', 'robot', '-', 'assisted', 'gait', 'therapy', '(', 'RAGT', ')', 'improves', 'balance', 'and', 'gait', 'outcomes', 'in', 'a', 'clinically', 'significant', 'way', 'in', 'PwMS', ',', 'RAGT', 'appears', 'more', 'effective', 'compared', 'to', 'non', '-', 'specific', 'rehabilitation', ',', 'while', 'showing', 'similar', 'effects', 'compared', 'to', 'non', '-', 'specific', 'rehabilitation', '.', 'specific', 'balance', 'and', 'gait', 'training', 'in', 'studies', 'with', 'level', '2', 'evidence', '.', 'RAGT', 'has', 'several', 'advantages', 'in', 'terms', 'of', 'patient', 'motor', 'assistance', ',', 'training', 'intensity', ',', 'safety', 'and', 'the', 'possibility', 'of', 'combining', 'other', 'therapeutic', 'approaches', 'and', 'should', 'be', 'promoted', 'for', 'PwMS', 'with', 'disability', 'in', 'a', 'multimodal', 'rehabilitation', 'setting', 'as', 'an', 'opportunity', 'to', 'maximize', 'recovery.11', 'In', 'this', 'setting', ',', 'more', 'larger', '-', 'scale', 'and', 'better', '-', 'designed', 'studies', 'with', 'longer', 'training', 'duration', 'and', 'more', 'studies', 'evaluating', 'satisfaction', ',', 'usability', ',', 'and', 'effectiveness', 'are', 'needed', '.', 'of', 'RAGT', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 81,
                "text": "Self-balancing Walking System Atalante",
                "type": "PHYSICAL"
            },
            {
                "start": 99,
                "end": 117,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 121,
                "end": 139,
                "text": "Multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 141,
                "end": 143,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 472,
                "end": 474,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1407,
                "end": 1425,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 1474,
                "end": 1500,
                "text": "robotic locomotor training",
                "type": "PHYSICAL"
            },
            {
                "start": 1711,
                "end": 1738,
                "text": "robot-assisted gait therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 1740,
                "end": 1744,
                "text": "RAGT",
                "type": "PHYSICAL"
            },
            {
                "start": 1822,
                "end": 1826,
                "text": "RAGT",
                "type": "PHYSICAL"
            },
            {
                "start": 2031,
                "end": 2035,
                "text": "RAGT",
                "type": "PHYSICAL"
            },
            {
                "start": 2494,
                "end": 2498,
                "text": "RAGT",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT01534130",
        "study_official_title": "Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome ",
        "study_brief_summary": " The investigators will conduct acupuncture for participants with chronic fatigue syndrome(CFS). Firstly the investigators aim to figure out the characteristic of sleep structure of CFS and the changes caused by acupuncture. Secondly the investigators seek to investigate the characteristic of sleep-wake rhythm, slow wave sleep(SWS)-rapid eye movement(REM)sleep rhythm, and REM sleep rhythm of CFS and the readjusting of acupuncture for it. Thirdly the investigators want to know the efficacy of acupuncture for relieving the fatigue, reducing accompanying symptoms and for improving the life quality of CFS.",
        "text": "Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome | The investigators will conduct acupuncture for participants with chronic fatigue syndrome(CFS). Firstly the investigators aim to figure out the characteristic of sleep structure of CFS and the changes caused by acupuncture. Secondly the investigators seek to investigate the characteristic of sleep-wake rhythm, slow wave sleep(SWS)-rapid eye movement(REM)sleep rhythm, and REM sleep rhythm of CFS and the readjusting of acupuncture for it. Thirdly the investigators want to know the efficacy of acupuncture for relieving the fatigue, reducing accompanying symptoms and for improving the life quality of CFS.",
        "tokens": "['Acupuncture', 'for', 'the', 'Sleep', 'Disorder', 'of', 'Chronic', 'Fatigue', 'Syndrome', '|', 'The', 'investigators', 'will', 'conduct', 'acupuncture', 'for', 'participants', 'with', 'chronic', 'fatigue', 'syndrome(CFS', ')', '.', 'Firstly', 'the', 'investigators', 'aim', 'to', 'figure', 'out', 'the', 'characteristic', 'of', 'sleep', 'structure', 'of', 'CFS', 'and', 'the', 'changes', 'caused', 'by', 'acupuncture', '.', 'Secondly', 'the', 'investigators', 'seek', 'to', 'investigate', 'the', 'characteristic', 'of', 'sleep', '-', 'wake', 'rhythm', ',', 'slow', 'wave', 'sleep(SWS)-rapid', 'eye', 'movement(REM)sleep', 'rhythm', ',', 'and', 'REM', 'sleep', 'rhythm', 'of', 'CFS', 'and', 'the', 'readjusting', 'of', 'acupuncture', 'for', 'it', '.', 'Thirdly', 'the', 'investigators', 'want', 'to', 'know', 'the', 'efficacy', 'of', 'acupuncture', 'for', 'relieving', 'the', 'fatigue', ',', 'reducing', 'accompanying', 'symptoms', 'and', 'for', 'improving', 'the', 'life', 'quality', 'of', 'CFS', '.']",
        "token_bio_labels": "['B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 11,
                "text": "Acupuncture",
                "type": "OTHER"
            },
            {
                "start": 20,
                "end": 34,
                "text": "Sleep Disorder",
                "type": "CONDITION"
            },
            {
                "start": 38,
                "end": 62,
                "text": "Chronic Fatigue Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 107,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 130,
                "end": 145,
                "text": "chronic fatigue",
                "type": "CONDITION"
            },
            {
                "start": 246,
                "end": 249,
                "text": "CFS",
                "type": "CONDITION"
            },
            {
                "start": 276,
                "end": 287,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 459,
                "end": 462,
                "text": "CFS",
                "type": "CONDITION"
            },
            {
                "start": 486,
                "end": 497,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 561,
                "end": 572,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 591,
                "end": 598,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 669,
                "end": 672,
                "text": "CFS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05698017",
        "study_official_title": "Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300 ",
        "study_brief_summary": " Purpose of this phase 1/2a study is to assess the safety and efficacy of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA) .",
        "text": "Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300 | Purpose of this phase 1/2a study is to assess the safety and efficacy of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA) .",
        "tokens": "['Phase', '1/2a', 'Randomized', 'Controlled', 'Study', 'for', 'Treatment', 'of', 'Early-', 'to', 'Moderate', 'Stage', 'Multiple', 'System', 'Atrophy', 'Patients', 'With', 'the', 'Investigational', 'Allogeneic', 'Cell', 'Therapy', 'Product', ',', 'hOMSC300', '|', 'Purpose', 'of', 'this', 'phase', '1/2a', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'efficacy', 'of', 'intrathecal', 'administration', 'of', 'allogeneic', 'human', 'oral', 'mucosa', 'stem', 'cells', '(', 'hOMSCs', ')', 'in', 'patients', 'suffering', 'from', 'early', 'to', 'moderate', 'stage', 'Multiple', 'System', 'Atrophy', '(', 'MSA', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 56,
                "end": 104,
                "text": "Early- to Moderate Stage Multiple System Atrophy",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 170,
                "text": "Allogeneic Cell Therapy Product",
                "type": "SURGICAL"
            },
            {
                "start": 172,
                "end": 180,
                "text": "hOMSC300",
                "type": "SURGICAL"
            },
            {
                "start": 286,
                "end": 325,
                "text": "allogeneic human oral mucosa stem cells",
                "type": "SURGICAL"
            },
            {
                "start": 327,
                "end": 333,
                "text": "hOMSCs",
                "type": "SURGICAL"
            },
            {
                "start": 362,
                "end": 409,
                "text": "early to moderate stage Multiple System Atrophy",
                "type": "CONDITION"
            },
            {
                "start": 411,
                "end": 414,
                "text": "MSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04606420",
        "study_official_title": "Lifestyle Intervention for Early Alzheimer's Disease ",
        "study_brief_summary": " The objective of this study is to determine if comprehensive lifestyle changes may slow, stop, or reverse the progression of early-stage Alzheimer's disease.",
        "text": "Lifestyle Intervention for Early Alzheimer's Disease | The objective of this study is to determine if comprehensive lifestyle changes may slow, stop, or reverse the progression of early-stage Alzheimer's disease.",
        "tokens": "['Lifestyle', 'Intervention', 'for', 'Early', 'Alzheimer', \"'s\", 'Disease', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'comprehensive', 'lifestyle', 'changes', 'may', 'slow', ',', 'stop', ',', 'or', 'reverse', 'the', 'progression', 'of', 'early', '-', 'stage', 'Alzheimer', \"'s\", 'disease', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "Lifestyle Intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 27,
                "end": 52,
                "text": "Early Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 116,
                "end": 133,
                "text": "lifestyle changes",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 180,
                "end": 211,
                "text": "early-stage Alzheimer's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04604951",
        "study_official_title": "Below the Belt: Non-invasive Neuromodulation to Treat Bladder, Bowel, and Sexual Dysfunction Following Spinal Cord Injury ",
        "study_brief_summary": " Recent findings have demonstrated that electrical stimulation to the spinal cord (i.e. implanted electrodes) can significantly recover bladder, bowel, and sexual function after injury. While promising, a major drawback is that individuals must undergo a highly invasive and expensive surgical procedure to implant the stimulator on top of the spinal cord. Moreover, the inability to re-position the implanted stimulator considerably limits the flexibility of this procedure.\n\nIn this project, the investigators propose a comprehensive clinical study examining the effects of TCSCS in promoting recovery of these crucial functions in individuals with spinal cord injury (SCI). This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.",
        "text": "Below the Belt: Non-invasive Neuromodulation to Treat Bladder, Bowel, and Sexual Dysfunction Following Spinal Cord Injury | Recent findings have demonstrated that electrical stimulation to the spinal cord (i.e. implanted electrodes) can significantly recover bladder, bowel, and sexual function after injury. While promising, a major drawback is that individuals must undergo a highly invasive and expensive surgical procedure to implant the stimulator on top of the spinal cord. Moreover, the inability to re-position the implanted stimulator considerably limits the flexibility of this procedure.\n\nIn this project, the investigators propose a comprehensive clinical study examining the effects of TCSCS in promoting recovery of these crucial functions in individuals with spinal cord injury (SCI). This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.",
        "tokens": "['Below', 'the', 'Belt', ':', 'Non', '-', 'invasive', 'Neuromodulation', 'to', 'Treat', 'Bladder', ',', 'Bowel', ',', 'and', 'Sexual', 'Dysfunction', 'Following', 'Spinal', 'Cord', 'Injury', '|', 'Recent', 'findings', 'have', 'demonstrated', 'that', 'electrical', 'stimulation', 'to', 'the', 'spinal', 'cord', '(', 'i.e.', 'implanted', 'electrodes', ')', 'can', 'significantly', 'recover', 'bladder', ',', 'bowel', ',', 'and', 'sexual', 'function', 'after', 'injury', '.', 'While', 'promising', ',', 'a', 'major', 'drawback', 'is', 'that', 'individuals', 'must', 'undergo', 'a', 'highly', 'invasive', 'and', 'expensive', 'surgical', 'procedure', 'to', 'implant', 'the', 'stimulator', 'on', 'top', 'of', 'the', 'spinal', 'cord', '.', 'Moreover', ',', 'the', 'inability', 'to', 're', '-', 'position', 'the', 'implanted', 'stimulator', 'considerably', 'limits', 'the', 'flexibility', 'of', 'this', 'procedure', '.', '\\n\\n', 'In', 'this', 'project', ',', 'the', 'investigators', 'propose', 'a', 'comprehensive', 'clinical', 'study', 'examining', 'the', 'effects', 'of', 'TCSCS', 'in', 'promoting', 'recovery', 'of', 'these', 'crucial', 'functions', 'in', 'individuals', 'with', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'This', 'non', '-', 'invasive', 'therapeutic', 'modality', 'uses', 'electrodes', 'applied', 'over', 'the', 'skin', 'to', 'deliver', 'electrical', 'stimulation', '.', 'It', 'is', 'based', 'on', 'the', 'same', 'principles', 'of', 'ground', '-', 'breaking', 'work', 'from', 'the', 'investigator', \"'s\", 'group', 'and', 'others', ',', 'showing', 'that', 'stimulation', 'of', 'the', 'spinal', 'cord', 'can', 'promote', 'motor', 'and', 'autonomic', '(', 'cardiovascular', ',', 'bladder', ',', 'bowel', ')', 'recovery', 'in', 'individuals', 'with', 'chronic', 'SCI', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 44,
                "text": "Non-invasive Neuromodulation",
                "type": "OTHER"
            },
            {
                "start": 54,
                "end": 92,
                "text": "Bladder, Bowel, and Sexual Dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 121,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 163,
                "end": 204,
                "text": "electrical stimulation to the spinal cord",
                "type": "OTHER"
            },
            {
                "start": 699,
                "end": 704,
                "text": "TCSCS",
                "type": "OTHER"
            },
            {
                "start": 774,
                "end": 792,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 794,
                "end": 797,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 844,
                "end": 910,
                "text": "electrodes applied over the skin to deliver electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 1026,
                "end": 1056,
                "text": "stimulation of the spinal cord",
                "type": "OTHER"
            },
            {
                "start": 1151,
                "end": 1162,
                "text": "chronic SCI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01283347",
        "study_official_title": "Phase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging ",
        "study_brief_summary": " The primary objective of this protocol is to analyze the sensitivity and specificity of 18F-DTBZ PET to the differential diagnosis of Parkinson's Disease (PD) and normality. Secondary, the investigators will analyze the correlation between the 18F-DTBZ binding and the severity of disease of PD and the role of 18F-DTBZ PET in the monitoring disease severity.",
        "text": "Phase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging | The primary objective of this protocol is to analyze the sensitivity and specificity of 18F-DTBZ PET to the differential diagnosis of Parkinson's Disease (PD) and normality. Secondary, the investigators will analyze the correlation between the 18F-DTBZ binding and the severity of disease of PD and the role of 18F-DTBZ PET in the monitoring disease severity.",
        "tokens": "['Phase', 'II', 'Study', 'of', '18F', '-', 'DTBZ', ':', 'The', 'Differential', 'Diagnosis', 'of', 'Parkinson', \"'s\", 'Disease', 'and', 'Monitoring', 'the', 'Severity', 'of', 'Disease', 'by', 'VMAT2', 'PET', 'Imaging', '|', 'The', 'primary', 'objective', 'of', 'this', 'protocol', 'is', 'to', 'analyze', 'the', 'sensitivity', 'and', 'specificity', 'of', '18F', '-', 'DTBZ', 'PET', 'to', 'the', 'differential', 'diagnosis', 'of', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', 'and', 'normality', '.', 'Secondary', ',', 'the', 'investigators', 'will', 'analyze', 'the', 'correlation', 'between', 'the', '18F', '-', 'DTBZ', 'binding', 'and', 'the', 'severity', 'of', 'disease', 'of', 'PD', 'and', 'the', 'role', 'of', '18F', '-', 'DTBZ', 'PET', 'in', 'the', 'monitoring', 'disease', 'severity', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 58,
                "end": 77,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 293,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 295,
                "end": 297,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 432,
                "end": 434,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00498849",
        "study_official_title": "The Changes of Patterns of Microarray in Patients With Obstructive Sleep Apnea ",
        "study_brief_summary": " The aim of this study are (1) To genome-wide profile the gene expression patterns of peripheral blood mononuclear cell (PBMC) in patients with obstructive sleep apnea (OSA) (2) To profile the gene expression patterns change before and after treatment with continuous positive airway pressure (CPAP) (3) To correlate the altered gene expression with the severity of the disease and outcome of OSA patients",
        "text": "The Changes of Patterns of Microarray in Patients With Obstructive Sleep Apnea | The aim of this study are (1) To genome-wide profile the gene expression patterns of peripheral blood mononuclear cell (PBMC) in patients with obstructive sleep apnea (OSA) (2) To profile the gene expression patterns change before and after treatment with continuous positive airway pressure (CPAP) (3) To correlate the altered gene expression with the severity of the disease and outcome of OSA patients",
        "tokens": "['The', 'Changes', 'of', 'Patterns', 'of', 'Microarray', 'in', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'aim', 'of', 'this', 'study', 'are', '(', '1', ')', 'To', 'genome', '-', 'wide', 'profile', 'the', 'gene', 'expression', 'patterns', 'of', 'peripheral', 'blood', 'mononuclear', 'cell', '(', 'PBMC', ')', 'in', 'patients', 'with', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', '(', '2', ')', 'To', 'profile', 'the', 'gene', 'expression', 'patterns', 'change', 'before', 'and', 'after', 'treatment', 'with', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', '(', '3', ')', 'To', 'correlate', 'the', 'altered', 'gene', 'expression', 'with', 'the', 'severity', 'of', 'the', 'disease', 'and', 'outcome', 'of', 'OSA', 'patients']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 55,
                "end": 78,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 247,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 249,
                "end": 252,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 337,
                "end": 372,
                "text": "continuous positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 374,
                "end": 378,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 473,
                "end": 476,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03649477",
        "study_official_title": "Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS) ",
        "study_brief_summary": " This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made chemical that is like oxytocin). This study will also evaluate the safety and tolerability of LV-101.",
        "text": "Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS) | This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made chemical that is like oxytocin). This study will also evaluate the safety and tolerability of LV-101.",
        "tokens": "['Phase', '3', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', '8', '-', 'week', 'Clinical', 'Study', 'to', 'Assess', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', ',', 'of', 'Intranasal', 'Carbetocin', '(', 'LV-101', ')', 'in', 'Prader', '-', 'Willi', 'Syndrome', '(', 'PWS', ')', 'With', 'Long', 'Term', 'Follow', '-', 'Up', '(', 'CARE', '-', 'PWS', ')', '|', 'This', 'Phase', '3', 'study', 'is', 'designed', 'to', 'test', 'the', 'effectiveness', 'of', 'intranasal', 'carbetocin', '(', 'LV-101', ')', 'in', 'participants', 'with', 'Prader', '-', 'Willi', 'syndrome', '(', 'PWS', ')', '.', 'Carbetocin', 'is', 'an', 'oxytocin', 'analog', '(', 'a', 'man', '-', 'made', 'chemical', 'that', 'is', 'like', 'oxytocin', ')', '.', 'This', 'study', 'will', 'also', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'LV-101', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 42,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 141,
                "end": 151,
                "text": "Carbetocin",
                "type": "DRUG"
            },
            {
                "start": 153,
                "end": 159,
                "text": "LV-101",
                "type": "DRUG"
            },
            {
                "start": 164,
                "end": 185,
                "text": "Prader-Willi Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 187,
                "end": 190,
                "text": "PWS",
                "type": "CONDITION"
            },
            {
                "start": 301,
                "end": 311,
                "text": "carbetocin",
                "type": "DRUG"
            },
            {
                "start": 313,
                "end": 319,
                "text": "LV-101",
                "type": "DRUG"
            },
            {
                "start": 342,
                "end": 363,
                "text": "Prader-Willi syndrome",
                "type": "CONDITION"
            },
            {
                "start": 365,
                "end": 368,
                "text": "PWS",
                "type": "CONDITION"
            },
            {
                "start": 371,
                "end": 381,
                "text": "Carbetocin",
                "type": "DRUG"
            },
            {
                "start": 510,
                "end": 516,
                "text": "LV-101",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02474407",
        "study_official_title": "An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat\u00ae) in Patients With Refractory Epilepsy ",
        "study_brief_summary": " This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)",
        "text": "An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat\u00ae) in Patients With Refractory Epilepsy | This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Randomized', ',', 'Crossover', 'Pharmacokinetic', 'Study', 'to', 'Determine', 'the', 'Bioavailability', ',', 'Safety', 'and', 'Tolerability', 'of', 'Single', 'Doses', 'of', 'Diazepam', 'Nasal', 'Spray', 'Versus', 'Diazepam', 'Rectal', 'Gel', '(', 'Diastat', '\u00ae', ')', 'in', 'Patients', 'With', 'Refractory', 'Epilepsy', '|', 'This', 'is', 'a', 'multi', '-', 'center', ',', 'open', '-', 'label', ',', 'crossover', ',', 'pharmacokinetic', ',', 'bio', '-', 'availability', 'study', 'involving', 'adolescents', 'and', 'adults', 'with', 'refractory', '(', 'drug', '-', 'resistant', ')', 'epilepsy', '.', 'Cohort', '1', 'comprises', 'the', 'subjects', 'used', 'to', 'determine', 'the', 'relative', 'bioavailability', 'of', 'DZNS', 'versus', 'DRG', '(', 'Diastat', ')']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 136,
                "end": 144,
                "text": "Diazepam",
                "type": "DRUG"
            },
            {
                "start": 164,
                "end": 172,
                "text": "Diazepam",
                "type": "DRUG"
            },
            {
                "start": 185,
                "end": 192,
                "text": "Diastat",
                "type": "DRUG"
            },
            {
                "start": 212,
                "end": 231,
                "text": "Refractory Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 359,
                "end": 395,
                "text": "refractory (drug-resistant) epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 496,
                "end": 503,
                "text": "Diastat",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03974997",
        "study_official_title": "TNF-related Weak Inducer of Apoptosis (TWEAK), a New Biomarker Predicting Inflammatory Thrust in Multiple Sclerosis ",
        "study_brief_summary": " A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS. Study the concentration variations of the serum soluble form of cytokine TWEAK during the first year of MS and to analyze their correlation with the occurrence of an inflammatory disease outbreak.",
        "text": "TNF-related Weak Inducer of Apoptosis (TWEAK), a New Biomarker Predicting Inflammatory Thrust in Multiple Sclerosis | A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS. Study the concentration variations of the serum soluble form of cytokine TWEAK during the first year of MS and to analyze their correlation with the occurrence of an inflammatory disease outbreak.",
        "tokens": "['TNF', '-', 'related', 'Weak', 'Inducer', 'of', 'Apoptosis', '(', 'TWEAK', ')', ',', 'a', 'New', 'Biomarker', 'Predicting', 'Inflammatory', 'Thrust', 'in', 'Multiple', 'Sclerosis', '|', 'A', 'significant', 'variation', 'in', 'the', 'serum', 'concentration', 'of', 'the', 'circulating', 'cytokine', 'TWEAK', 'is', 'associated', 'with', 'the', 'onset', 'of', 'an', 'inflammatory', 'attack', 'of', 'MS', '.', 'Study', 'the', 'concentration', 'variations', 'of', 'the', 'serum', 'soluble', 'form', 'of', 'cytokine', 'TWEAK', 'during', 'the', 'first', 'year', 'of', 'MS', 'and', 'to', 'analyze', 'their', 'correlation', 'with', 'the', 'occurrence', 'of', 'an', 'inflammatory', 'disease', 'outbreak', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 97,
                "end": 115,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 263,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 369,
                "end": 371,
                "text": "MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02775136",
        "study_official_title": "An Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Brain Monitor ",
        "study_brief_summary": " HS-1000 device, a proprietary new non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians. Investigators hypothesis that the HS-1000 is capable of detecting and monitoring various neuropathologies, using the acoustic raw data derived from the noninvasive procedure.",
        "text": "An Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Brain Monitor | HS-1000 device, a proprietary new non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians. Investigators hypothesis that the HS-1000 is capable of detecting and monitoring various neuropathologies, using the acoustic raw data derived from the noninvasive procedure.",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Non', '-', 'Randomized', ',', 'Comparative', 'Study', 'Designed', 'to', 'Evaluate', 'the', 'Accuracy', 'and', 'Safety', 'of', 'HS-1000', 'Device', ',', 'a', 'Non', '-', 'Invasive', 'Brain', 'Monitor', '|', 'HS-1000', 'device', ',', 'a', 'proprietary', 'new', 'non', '-', 'invasive', 'brain', 'monitor', ',', 'is', 'expected', 'to', 'safely', 'and', 'accurately', 'monitor', 'physiological', 'signs', 'of', 'the', 'brain', 'with', 'minimal', 'discomfort', 'to', 'patients', ',', 'providing', 'information', 'about', 'normal', 'or', 'abnormal', 'brain', '-', 'related', 'conditions', 'and', 'providing', 'decision', '-', 'making', 'support', 'for', 'physicians', '.', 'Investigators', 'hypothesis', 'that', 'the', 'HS-1000', 'is', 'capable', 'of', 'detecting', 'and', 'monitoring', 'various', 'neuropathologies', ',', 'using', 'the', 'acoustic', 'raw', 'data', 'derived', 'from', 'the', 'noninvasive', 'procedure', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT03107871",
        "study_official_title": "Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial ",
        "study_brief_summary": " The overall goal of this study is to determine the clinical benefit and safety of antiviral therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants. We will conduct a multi-center double-blind randomized placebo-controlled trial to determine whether hearing-impaired infants with asymptomatic cCMV have better hearing and language outcomes if they receive valganciclovir antiviral treatment. We will also determine the safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired infants. This study will be unique in that the cohort enrolled will only include hearing-impaired infants with asymptomatic cCMV.\n\nPrimary Objective: To determine if treatment of cCMV-infected hearing impaired infants with isolated hearing loss with the antiviral drug valganciclovir reduces the mean slope of total hearing thresholds over the 20 months after randomization compared to untreated cCMV-infected infants with isolated hearing loss.\n\nMain Secondary Objectives:\n\nTo determine if valganciclovir treatment improves the following outcomes when compared to the control group:\n\nThe slope of best ear hearing thresholds over the 20 months after randomization.\nThe MacArthur-Bates Communicative Development Inventory (CDI) percentile score for words produced at 20 months of age.\nTo evaluate safety measures based on all grade 3 or greater new adverse events designated by the NIAID Division of AIDS (DAIDS) toxicity tables.",
        "text": "Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial | The overall goal of this study is to determine the clinical benefit and safety of antiviral therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants. We will conduct a multi-center double-blind randomized placebo-controlled trial to determine whether hearing-impaired infants with asymptomatic cCMV have better hearing and language outcomes if they receive valganciclovir antiviral treatment. We will also determine the safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired infants. This study will be unique in that the cohort enrolled will only include hearing-impaired infants with asymptomatic cCMV.\n\nPrimary Objective: To determine if treatment of cCMV-infected hearing impaired infants with isolated hearing loss with the antiviral drug valganciclovir reduces the mean slope of total hearing thresholds over the 20 months after randomization compared to untreated cCMV-infected infants with isolated hearing loss.\n\nMain Secondary Objectives:\n\nTo determine if valganciclovir treatment improves the following outcomes when compared to the control group:\n\nThe slope of best ear hearing thresholds over the 20 months after randomization.\nThe MacArthur-Bates Communicative Development Inventory (CDI) percentile score for words produced at 20 months of age.\nTo evaluate safety measures based on all grade 3 or greater new adverse events designated by the NIAID Division of AIDS (DAIDS) toxicity tables.",
        "tokens": "['Randomized', 'Controlled', 'Trial', 'of', 'Valganciclovir', 'for', 'Cytomegalovirus', 'Infected', 'Hearing', 'Impaired', 'Infants', ':', 'ValEAR', 'Trial', '|', 'The', 'overall', 'goal', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'clinical', 'benefit', 'and', 'safety', 'of', 'antiviral', 'therapy', 'for', 'asymptomatic', 'congenital', 'cytomegalovirus', '(', 'cCMV', ')', 'infected', 'hearing', '-', 'impaired', 'infants', '.', 'We', 'will', 'conduct', 'a', 'multi', '-', 'center', 'double', '-', 'blind', 'randomized', 'placebo', '-', 'controlled', 'trial', 'to', 'determine', 'whether', 'hearing', '-', 'impaired', 'infants', 'with', 'asymptomatic', 'cCMV', 'have', 'better', 'hearing', 'and', 'language', 'outcomes', 'if', 'they', 'receive', 'valganciclovir', 'antiviral', 'treatment', '.', 'We', 'will', 'also', 'determine', 'the', 'safety', 'of', 'antiviral', 'valganciclovir', 'therapy', 'for', 'asymptomatic', 'cCMV', '-', 'infected', 'hearing', 'impaired', 'infants', '.', 'This', 'study', 'will', 'be', 'unique', 'in', 'that', 'the', 'cohort', 'enrolled', 'will', 'only', 'include', 'hearing', '-', 'impaired', 'infants', 'with', 'asymptomatic', 'cCMV', '.', '\\n\\n', 'Primary', 'Objective', ':', 'To', 'determine', 'if', 'treatment', 'of', 'cCMV', '-', 'infected', 'hearing', 'impaired', 'infants', 'with', 'isolated', 'hearing', 'loss', 'with', 'the', 'antiviral', 'drug', 'valganciclovir', 'reduces', 'the', 'mean', 'slope', 'of', 'total', 'hearing', 'thresholds', 'over', 'the', '20', 'months', 'after', 'randomization', 'compared', 'to', 'untreated', 'cCMV', '-', 'infected', 'infants', 'with', 'isolated', 'hearing', 'loss', '.', '\\n\\n', 'Main', 'Secondary', 'Objectives', ':', '\\n\\n', 'To', 'determine', 'if', 'valganciclovir', 'treatment', 'improves', 'the', 'following', 'outcomes', 'when', 'compared', 'to', 'the', 'control', 'group', ':', '\\n\\n', 'The', 'slope', 'of', 'best', 'ear', 'hearing', 'thresholds', 'over', 'the', '20', 'months', 'after', 'randomization', '.', '\\n', 'The', 'MacArthur', '-', 'Bates', 'Communicative', 'Development', 'Inventory', '(', 'CDI', ')', 'percentile', 'score', 'for', 'words', 'produced', 'at', '20', 'months', 'of', 'age', '.', '\\n', 'To', 'evaluate', 'safety', 'measures', 'based', 'on', 'all', 'grade', '3', 'or', 'greater', 'new', 'adverse', 'events', 'designated', 'by', 'the', 'NIAID', 'Division', 'of', 'AIDS', '(', 'DAIDS', ')', 'toxicity', 'tables', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 45,
                "text": "Valganciclovir",
                "type": "DRUG"
            },
            {
                "start": 50,
                "end": 65,
                "text": "Cytomegalovirus",
                "type": "CONDITION"
            },
            {
                "start": 75,
                "end": 91,
                "text": "Hearing Impaired",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 259,
                "text": "asymptomatic congenital cytomegalovirus",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 265,
                "text": "cCMV",
                "type": "CONDITION"
            },
            {
                "start": 276,
                "end": 292,
                "text": "hearing-impaired",
                "type": "CONDITION"
            },
            {
                "start": 357,
                "end": 364,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 403,
                "end": 419,
                "text": "hearing-impaired",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 450,
                "text": "asymptomatic cCMV",
                "type": "CONDITION"
            },
            {
                "start": 509,
                "end": 523,
                "text": "valganciclovir",
                "type": "DRUG"
            },
            {
                "start": 592,
                "end": 606,
                "text": "valganciclovir",
                "type": "DRUG"
            },
            {
                "start": 619,
                "end": 636,
                "text": "asymptomatic cCMV",
                "type": "CONDITION"
            },
            {
                "start": 646,
                "end": 662,
                "text": "hearing impaired",
                "type": "CONDITION"
            },
            {
                "start": 744,
                "end": 760,
                "text": "hearing-impaired",
                "type": "CONDITION"
            },
            {
                "start": 774,
                "end": 791,
                "text": "asymptomatic cCMV",
                "type": "CONDITION"
            },
            {
                "start": 842,
                "end": 855,
                "text": "cCMV-infected",
                "type": "CONDITION"
            },
            {
                "start": 856,
                "end": 872,
                "text": "hearing impaired",
                "type": "CONDITION"
            },
            {
                "start": 932,
                "end": 946,
                "text": "valganciclovir",
                "type": "DRUG"
            },
            {
                "start": 1059,
                "end": 1072,
                "text": "cCMV-infected",
                "type": "CONDITION"
            },
            {
                "start": 1154,
                "end": 1168,
                "text": "valganciclovir",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02957708",
        "study_official_title": "Effectiveness of Modified Constraint-induced Movement Therapy and Self-regulation Learning for Children With Hemiplegic Cerebral Palsy ",
        "study_brief_summary": " This study examines the effect of combining modified constraint-induced movement therapy (mCIMT) and self-regulation (SR) in promoting upper limb function of children with hemiplegic cerebral palsy (CP) studying in a school-based setting.",
        "text": "Effectiveness of Modified Constraint-induced Movement Therapy and Self-regulation Learning for Children With Hemiplegic Cerebral Palsy | This study examines the effect of combining modified constraint-induced movement therapy (mCIMT) and self-regulation (SR) in promoting upper limb function of children with hemiplegic cerebral palsy (CP) studying in a school-based setting.",
        "tokens": "['Effectiveness', 'of', 'Modified', 'Constraint', '-', 'induced', 'Movement', 'Therapy', 'and', 'Self', '-', 'regulation', 'Learning', 'for', 'Children', 'With', 'Hemiplegic', 'Cerebral', 'Palsy', '|', 'This', 'study', 'examines', 'the', 'effect', 'of', 'combining', 'modified', 'constraint', '-', 'induced', 'movement', 'therapy', '(', 'mCIMT', ')', 'and', 'self', '-', 'regulation', '(', 'SR', ')', 'in', 'promoting', 'upper', 'limb', 'function', 'of', 'children', 'with', 'hemiplegic', 'cerebral', 'palsy', '(', 'CP', ')', 'studying', 'in', 'a', 'school', '-', 'based', 'setting', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 61,
                "text": "Modified Constraint-induced Movement Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 66,
                "end": 90,
                "text": "Self-regulation Learning",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 109,
                "end": 134,
                "text": "Hemiplegic Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 181,
                "end": 225,
                "text": "modified constraint-induced movement therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 227,
                "end": 232,
                "text": "mCIMT",
                "type": "PHYSICAL"
            },
            {
                "start": 238,
                "end": 253,
                "text": "self-regulation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 255,
                "end": 257,
                "text": "SR",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 309,
                "end": 334,
                "text": "hemiplegic cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 336,
                "end": 338,
                "text": "CP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04524338",
        "study_official_title": "Longitudinal Study Examining At-Home Transcranial Direct Current Stimulation ",
        "study_brief_summary": " Participants with dementia have reported improvements after receiving tDCS in a study at our lab. Although we make an effort to enroll such participants in further tDCS research studies, some participants are ineligible for further studies or simply unwilling to continue being a research participant. These same individuals, however, are interested in purchasing their own tDCS machine and have approached us for advice on how to purchase their own machine. Because these devices are commercially available, there is nothing theoretically stopping these participants from purchasing their own machine. Therefore, we have chosen to carry out a longitudinal study that will allow us to serve as an advisory role for participants who have decided to continue administering tDCS at home. We will recommend the tDCS related items that should be purchased, and train participants on how to properly administer tDCS. Monthly reports will also be collected, which will allow us to monitor the person's condition. We plan to monitor participants for at least two years. From these reports, we will be able determine to what extent tDCS is beneficial when done at home as a treatment for dementia symptoms.",
        "text": "Longitudinal Study Examining At-Home Transcranial Direct Current Stimulation | Participants with dementia have reported improvements after receiving tDCS in a study at our lab. Although we make an effort to enroll such participants in further tDCS research studies, some participants are ineligible for further studies or simply unwilling to continue being a research participant. These same individuals, however, are interested in purchasing their own tDCS machine and have approached us for advice on how to purchase their own machine. Because these devices are commercially available, there is nothing theoretically stopping these participants from purchasing their own machine. Therefore, we have chosen to carry out a longitudinal study that will allow us to serve as an advisory role for participants who have decided to continue administering tDCS at home. We will recommend the tDCS related items that should be purchased, and train participants on how to properly administer tDCS. Monthly reports will also be collected, which will allow us to monitor the person's condition. We plan to monitor participants for at least two years. From these reports, we will be able determine to what extent tDCS is beneficial when done at home as a treatment for dementia symptoms.",
        "tokens": "['Longitudinal', 'Study', 'Examining', 'At', '-', 'Home', 'Transcranial', 'Direct', 'Current', 'Stimulation', '|', 'Participants', 'with', 'dementia', 'have', 'reported', 'improvements', 'after', 'receiving', 'tDCS', 'in', 'a', 'study', 'at', 'our', 'lab', '.', 'Although', 'we', 'make', 'an', 'effort', 'to', 'enroll', 'such', 'participants', 'in', 'further', 'tDCS', 'research', 'studies', ',', 'some', 'participants', 'are', 'ineligible', 'for', 'further', 'studies', 'or', 'simply', 'unwilling', 'to', 'continue', 'being', 'a', 'research', 'participant', '.', 'These', 'same', 'individuals', ',', 'however', ',', 'are', 'interested', 'in', 'purchasing', 'their', 'own', 'tDCS', 'machine', 'and', 'have', 'approached', 'us', 'for', 'advice', 'on', 'how', 'to', 'purchase', 'their', 'own', 'machine', '.', 'Because', 'these', 'devices', 'are', 'commercially', 'available', ',', 'there', 'is', 'nothing', 'theoretically', 'stopping', 'these', 'participants', 'from', 'purchasing', 'their', 'own', 'machine', '.', 'Therefore', ',', 'we', 'have', 'chosen', 'to', 'carry', 'out', 'a', 'longitudinal', 'study', 'that', 'will', 'allow', 'us', 'to', 'serve', 'as', 'an', 'advisory', 'role', 'for', 'participants', 'who', 'have', 'decided', 'to', 'continue', 'administering', 'tDCS', 'at', 'home', '.', 'We', 'will', 'recommend', 'the', 'tDCS', 'related', 'items', 'that', 'should', 'be', 'purchased', ',', 'and', 'train', 'participants', 'on', 'how', 'to', 'properly', 'administer', 'tDCS', '.', 'Monthly', 'reports', 'will', 'also', 'be', 'collected', ',', 'which', 'will', 'allow', 'us', 'to', 'monitor', 'the', 'person', \"'s\", 'condition', '.', 'We', 'plan', 'to', 'monitor', 'participants', 'for', 'at', 'least', 'two', 'years', '.', 'From', 'these', 'reports', ',', 'we', 'will', 'be', 'able', 'determine', 'to', 'what', 'extent', 'tDCS', 'is', 'beneficial', 'when', 'done', 'at', 'home', 'as', 'a', 'treatment', 'for', 'dementia', 'symptoms', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 76,
                "text": "At-Home Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 97,
                "end": 105,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 149,
                "end": 153,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 243,
                "end": 247,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 453,
                "end": 457,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 850,
                "end": 862,
                "text": "tDCS at home",
                "type": "OTHER"
            },
            {
                "start": 886,
                "end": 890,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 984,
                "end": 988,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 1202,
                "end": 1206,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 1258,
                "end": 1266,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04903171",
        "study_official_title": "Effects of Enriched Gardens on Cognition and Independence of Nursing Home Residents With Dementia: a Cluster-controlled Trial ",
        "study_brief_summary": " Comparing the effect of the frequentation of an enriched garden vs sensory conventional garden by nursing home residents with Alzheimer disease. The effects will be evaluated as regards to cognitive impairment (MMSE), autonomy (ADL) and prevention of falls (Unipodal stance and UpandGo Test)",
        "text": "Effects of Enriched Gardens on Cognition and Independence of Nursing Home Residents With Dementia: a Cluster-controlled Trial | Comparing the effect of the frequentation of an enriched garden vs sensory conventional garden by nursing home residents with Alzheimer disease. The effects will be evaluated as regards to cognitive impairment (MMSE), autonomy (ADL) and prevention of falls (Unipodal stance and UpandGo Test)",
        "tokens": "['Effects', 'of', 'Enriched', 'Gardens', 'on', 'Cognition', 'and', 'Independence', 'of', 'Nursing', 'Home', 'Residents', 'With', 'Dementia', ':', 'a', 'Cluster', '-', 'controlled', 'Trial', '|', 'Comparing', 'the', 'effect', 'of', 'the', 'frequentation', 'of', 'an', 'enriched', 'garden', 'vs', 'sensory', 'conventional', 'garden', 'by', 'nursing', 'home', 'residents', 'with', 'Alzheimer', 'disease', '.', 'The', 'effects', 'will', 'be', 'evaluated', 'as', 'regards', 'to', 'cognitive', 'impairment', '(', 'MMSE', ')', ',', 'autonomy', '(', 'ADL', ')', 'and', 'prevention', 'of', 'falls', '(', 'Unipodal', 'stance', 'and', 'UpandGo', 'Test', ')']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 27,
                "text": "Enriched Gardens",
                "type": "OTHER"
            },
            {
                "start": 89,
                "end": 97,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 191,
                "text": "enriched garden",
                "type": "OTHER"
            },
            {
                "start": 195,
                "end": 222,
                "text": "sensory conventional garden",
                "type": "CONTROL"
            },
            {
                "start": 254,
                "end": 271,
                "text": "Alzheimer disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05231538",
        "study_official_title": "Effects of Neurodevelopment Therapy on Gross Motor Function and Postural Control in Children With Spastic Cerebral Palsy: A Randomized Controlled Trial ",
        "study_brief_summary": " This study was conducted to find out the Effects of Neurodevelopment therapy (a rehabilitative program designed by Bobath) on Gross Motor Function and Postural Control in Children with Spastic Cerebral Palsy. To investigate either there was a significant difference between the effects of neurodevelopment therapy and routine physical therapy on gross motor function and postural control in children with Spastic Cerebral Palsy.",
        "text": "Effects of Neurodevelopment Therapy on Gross Motor Function and Postural Control in Children With Spastic Cerebral Palsy: A Randomized Controlled Trial | This study was conducted to find out the Effects of Neurodevelopment therapy (a rehabilitative program designed by Bobath) on Gross Motor Function and Postural Control in Children with Spastic Cerebral Palsy. To investigate either there was a significant difference between the effects of neurodevelopment therapy and routine physical therapy on gross motor function and postural control in children with Spastic Cerebral Palsy.",
        "tokens": "['Effects', 'of', 'Neurodevelopment', 'Therapy', 'on', 'Gross', 'Motor', 'Function', 'and', 'Postural', 'Control', 'in', 'Children', 'With', 'Spastic', 'Cerebral', 'Palsy', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'was', 'conducted', 'to', 'find', 'out', 'the', 'Effects', 'of', 'Neurodevelopment', 'therapy', '(', 'a', 'rehabilitative', 'program', 'designed', 'by', 'Bobath', ')', 'on', 'Gross', 'Motor', 'Function', 'and', 'Postural', 'Control', 'in', 'Children', 'with', 'Spastic', 'Cerebral', 'Palsy', '.', 'To', 'investigate', 'either', 'there', 'was', 'a', 'significant', 'difference', 'between', 'the', 'effects', 'of', 'neurodevelopment', 'therapy', 'and', 'routine', 'physical', 'therapy', 'on', 'gross', 'motor', 'function', 'and', 'postural', 'control', 'in', 'children', 'with', 'Spastic', 'Cerebral', 'Palsy', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 35,
                "text": "Neurodevelopment Therapy",
                "type": "OTHER"
            },
            {
                "start": 98,
                "end": 120,
                "text": "Spastic Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 206,
                "end": 230,
                "text": "Neurodevelopment therapy",
                "type": "OTHER"
            },
            {
                "start": 339,
                "end": 361,
                "text": "Spastic Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 443,
                "end": 467,
                "text": "neurodevelopment therapy",
                "type": "OTHER"
            },
            {
                "start": 559,
                "end": 581,
                "text": "Spastic Cerebral Palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05253079",
        "study_official_title": "Erector Spinae Plane Block Versus Subcostal Transversus Abdominis Plane Block in Patients Undergoing Open Liver Resection Surgery: A Randomized Controlled Trial ",
        "study_brief_summary": " Liver resection surgery is a common surgical procedure which is performed on patients with benign, malignant or metastatic hepatic tumor as well as for living liver donor. Liver resection surgery is usually performed through either right subcostal or inversed L-shaped incision; both approaches are associated with a significant postoperative pain which requires intensive analgesic plan to facilitate early mobilization and minimize complications.\n\nThere are various lines for pain management in liver resection surgery such as systemic analgesic drugs, neuraxial blocks (e.g., thoracic epidural analgesia) and transversus abdominis plane [TAP] block).\n\nSystemic analgesic drugs are nearly constantly used in liver resection. However, being systemically administered, these drugs have many side effects on many organs and cannot totally eliminate postoperative pain. Thoracic epidural block is commonly associated with hypotension; furthermore, its use has other limitations such as delaying postoperative mobilization and possible hematoma and cord compression in patients with coagulopathy which is expected following liver resection. Therefore, there had been an increased interest in the use of abdominal field blocks to avoid disadvantages of neuraxial blocks and minimize the use of parenteral analgesic drugs.\n\nTAP block is one of the classic field blocks which is extensively used in laparotomies including liver resection. However, the lack of visceral pain control TAP block influences the quality of its analgesic effect in this type of patients. Nevertheless, TAP block, namely the subcostal approach, is still the recommended field block in the latest procedure-specific recommendations for pain management in liver resection as it is the only block which showed good evidence.\n\nIn recent years, there has been increased interest in a newer field block, the erector spinae plane block (ESPB), due its easy performance and the possible coverage of visceral pain in addition to the somatic pain. ESPB showed promising results in liver resection surgery. ESBP was superior to TAP block in various abdominal surgeries. However, its analgesic efficacy had not been previously compared in relation to TAP in patients undergoing open liver resection surgery.",
        "text": "Erector Spinae Plane Block Versus Subcostal Transversus Abdominis Plane Block in Patients Undergoing Open Liver Resection Surgery: A Randomized Controlled Trial | Liver resection surgery is a common surgical procedure which is performed on patients with benign, malignant or metastatic hepatic tumor as well as for living liver donor. Liver resection surgery is usually performed through either right subcostal or inversed L-shaped incision; both approaches are associated with a significant postoperative pain which requires intensive analgesic plan to facilitate early mobilization and minimize complications.\n\nThere are various lines for pain management in liver resection surgery such as systemic analgesic drugs, neuraxial blocks (e.g., thoracic epidural analgesia) and transversus abdominis plane [TAP] block).\n\nSystemic analgesic drugs are nearly constantly used in liver resection. However, being systemically administered, these drugs have many side effects on many organs and cannot totally eliminate postoperative pain. Thoracic epidural block is commonly associated with hypotension; furthermore, its use has other limitations such as delaying postoperative mobilization and possible hematoma and cord compression in patients with coagulopathy which is expected following liver resection. Therefore, there had been an increased interest in the use of abdominal field blocks to avoid disadvantages of neuraxial blocks and minimize the use of parenteral analgesic drugs.\n\nTAP block is one of the classic field blocks which is extensively used in laparotomies including liver resection. However, the lack of visceral pain control TAP block influences the quality of its analgesic effect in this type of patients. Nevertheless, TAP block, namely the subcostal approach, is still the recommended field block in the latest procedure-specific recommendations for pain management in liver resection as it is the only block which showed good evidence.\n\nIn recent years, there has been increased interest in a newer field block, the erector spinae plane block (ESPB), due its easy performance and the possible coverage of visceral pain in addition to the somatic pain. ESPB showed promising results in liver resection surgery. ESBP was superior to TAP block in various abdominal surgeries. However, its analgesic efficacy had not been previously compared in relation to TAP in patients undergoing open liver resection surgery.",
        "tokens": "['Erector', 'Spinae', 'Plane', 'Block', 'Versus', 'Subcostal', 'Transversus', 'Abdominis', 'Plane', 'Block', 'in', 'Patients', 'Undergoing', 'Open', 'Liver', 'Resection', 'Surgery', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'Liver', 'resection', 'surgery', 'is', 'a', 'common', 'surgical', 'procedure', 'which', 'is', 'performed', 'on', 'patients', 'with', 'benign', ',', 'malignant', 'or', 'metastatic', 'hepatic', 'tumor', 'as', 'well', 'as', 'for', 'living', 'liver', 'donor', '.', 'Liver', 'resection', 'surgery', 'is', 'usually', 'performed', 'through', 'either', 'right', 'subcostal', 'or', 'inversed', 'L', '-', 'shaped', 'incision', ';', 'both', 'approaches', 'are', 'associated', 'with', 'a', 'significant', 'postoperative', 'pain', 'which', 'requires', 'intensive', 'analgesic', 'plan', 'to', 'facilitate', 'early', 'mobilization', 'and', 'minimize', 'complications', '.', '\\n\\n', 'There', 'are', 'various', 'lines', 'for', 'pain', 'management', 'in', 'liver', 'resection', 'surgery', 'such', 'as', 'systemic', 'analgesic', 'drugs', ',', 'neuraxial', 'blocks', '(', 'e.g.', ',', 'thoracic', 'epidural', 'analgesia', ')', 'and', 'transversus', 'abdominis', 'plane', '[', 'TAP', ']', 'block', ')', '.', '\\n\\n', 'Systemic', 'analgesic', 'drugs', 'are', 'nearly', 'constantly', 'used', 'in', 'liver', 'resection', '.', 'However', ',', 'being', 'systemically', 'administered', ',', 'these', 'drugs', 'have', 'many', 'side', 'effects', 'on', 'many', 'organs', 'and', 'can', 'not', 'totally', 'eliminate', 'postoperative', 'pain', '.', 'Thoracic', 'epidural', 'block', 'is', 'commonly', 'associated', 'with', 'hypotension', ';', 'furthermore', ',', 'its', 'use', 'has', 'other', 'limitations', 'such', 'as', 'delaying', 'postoperative', 'mobilization', 'and', 'possible', 'hematoma', 'and', 'cord', 'compression', 'in', 'patients', 'with', 'coagulopathy', 'which', 'is', 'expected', 'following', 'liver', 'resection', '.', 'Therefore', ',', 'there', 'had', 'been', 'an', 'increased', 'interest', 'in', 'the', 'use', 'of', 'abdominal', 'field', 'blocks', 'to', 'avoid', 'disadvantages', 'of', 'neuraxial', 'blocks', 'and', 'minimize', 'the', 'use', 'of', 'parenteral', 'analgesic', 'drugs', '.', '\\n\\n', 'TAP', 'block', 'is', 'one', 'of', 'the', 'classic', 'field', 'blocks', 'which', 'is', 'extensively', 'used', 'in', 'laparotomies', 'including', 'liver', 'resection', '.', 'However', ',', 'the', 'lack', 'of', 'visceral', 'pain', 'control', 'TAP', 'block', 'influences', 'the', 'quality', 'of', 'its', 'analgesic', 'effect', 'in', 'this', 'type', 'of', 'patients', '.', 'Nevertheless', ',', 'TAP', 'block', ',', 'namely', 'the', 'subcostal', 'approach', ',', 'is', 'still', 'the', 'recommended', 'field', 'block', 'in', 'the', 'latest', 'procedure', '-', 'specific', 'recommendations', 'for', 'pain', 'management', 'in', 'liver', 'resection', 'as', 'it', 'is', 'the', 'only', 'block', 'which', 'showed', 'good', 'evidence', '.', '\\n\\n', 'In', 'recent', 'years', ',', 'there', 'has', 'been', 'increased', 'interest', 'in', 'a', 'newer', 'field', 'block', ',', 'the', 'erector', 'spinae', 'plane', 'block', '(', 'ESPB', ')', ',', 'due', 'its', 'easy', 'performance', 'and', 'the', 'possible', 'coverage', 'of', 'visceral', 'pain', 'in', 'addition', 'to', 'the', 'somatic', 'pain', '.', 'ESPB', 'showed', 'promising', 'results', 'in', 'liver', 'resection', 'surgery', '.', 'ESBP', 'was', 'superior', 'to', 'TAP', 'block', 'in', 'various', 'abdominal', 'surgeries', '.', 'However', ',', 'its', 'analgesic', 'efficacy', 'had', 'not', 'been', 'previously', 'compared', 'in', 'relation', 'to', 'TAP', 'in', 'patients', 'undergoing', 'open', 'liver', 'resection', 'surgery', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 26,
                "text": "Erector Spinae Plane Block",
                "type": "OTHER"
            },
            {
                "start": 34,
                "end": 77,
                "text": "Subcostal Transversus Abdominis Plane Block",
                "type": "OTHER"
            },
            {
                "start": 101,
                "end": 121,
                "text": "Open Liver Resection",
                "type": "CONDITION"
            },
            {
                "start": 163,
                "end": 186,
                "text": "Liver resection surgery",
                "type": "CONDITION"
            },
            {
                "start": 254,
                "end": 299,
                "text": "benign, malignant or metastatic hepatic tumor",
                "type": "CONDITION"
            },
            {
                "start": 335,
                "end": 358,
                "text": "Liver resection surgery",
                "type": "CONDITION"
            },
            {
                "start": 492,
                "end": 510,
                "text": "postoperative pain",
                "type": "CONDITION"
            },
            {
                "start": 641,
                "end": 645,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 660,
                "end": 683,
                "text": "liver resection surgery",
                "type": "CONDITION"
            },
            {
                "start": 775,
                "end": 814,
                "text": "transversus abdominis plane [TAP] block",
                "type": "OTHER"
            },
            {
                "start": 873,
                "end": 888,
                "text": "liver resection",
                "type": "CONDITION"
            },
            {
                "start": 1284,
                "end": 1299,
                "text": "liver resection",
                "type": "CONDITION"
            },
            {
                "start": 1482,
                "end": 1491,
                "text": "TAP block",
                "type": "OTHER"
            },
            {
                "start": 1579,
                "end": 1594,
                "text": "liver resection",
                "type": "CONDITION"
            },
            {
                "start": 1617,
                "end": 1630,
                "text": "visceral pain",
                "type": "CONDITION"
            },
            {
                "start": 1639,
                "end": 1648,
                "text": "TAP block",
                "type": "OTHER"
            },
            {
                "start": 1736,
                "end": 1745,
                "text": "TAP block",
                "type": "OTHER"
            },
            {
                "start": 1887,
                "end": 1902,
                "text": "liver resection",
                "type": "CONDITION"
            },
            {
                "start": 2035,
                "end": 2061,
                "text": "erector spinae plane block",
                "type": "OTHER"
            },
            {
                "start": 2063,
                "end": 2067,
                "text": "ESPB",
                "type": "OTHER"
            },
            {
                "start": 2124,
                "end": 2137,
                "text": "visceral pain",
                "type": "CONDITION"
            },
            {
                "start": 2157,
                "end": 2169,
                "text": "somatic pain",
                "type": "CONDITION"
            },
            {
                "start": 2171,
                "end": 2175,
                "text": "ESPB",
                "type": "OTHER"
            },
            {
                "start": 2204,
                "end": 2219,
                "text": "liver resection",
                "type": "CONDITION"
            },
            {
                "start": 2229,
                "end": 2233,
                "text": "ESBP",
                "type": "OTHER"
            },
            {
                "start": 2250,
                "end": 2259,
                "text": "TAP block",
                "type": "OTHER"
            },
            {
                "start": 2372,
                "end": 2375,
                "text": "TAP",
                "type": "OTHER"
            },
            {
                "start": 2399,
                "end": 2427,
                "text": "open liver resection surgery",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02758990",
        "study_official_title": "Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application ",
        "study_brief_summary": " The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized medical equipment in order to develop lifestyle recommendations tailored to individual genetics for a host of common chronic health conditions.",
        "text": "Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application | The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized medical equipment in order to develop lifestyle recommendations tailored to individual genetics for a host of common chronic health conditions.",
        "tokens": "['Interventional', 'Testing', 'of', 'Gene', '-', 'environment', 'Interactions', 'Via', 'the', 'Verifomics', 'Mobile', 'Application', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'study', 'interactions', 'between', 'genes', ',', 'lifestyle', 'environmental', 'factors', 'like', 'foods', ',', 'nutritional', 'supplements', 'and', 'non', '-', 'invasive', 'medical', 'devices', 'and', 'health', 'factors', 'that', 'can', 'be', 'measured', 'without', 'specialized', 'medical', 'equipment', 'in', 'order', 'to', 'develop', 'lifestyle', 'recommendations', 'tailored', 'to', 'individual', 'genetics', 'for', 'a', 'host', 'of', 'common', 'chronic', 'health', 'conditions', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT04316208",
        "study_official_title": "The Effect of Intraoperative Variations in Positive-End Expiratory Pressure on Subdural Pressure, Optic Nerve Sheath Diameter, Lung Compliance and Brain Perfusion Pressure in Supratentorial Tumor Surgery ",
        "study_brief_summary": " We aim to determine the level of intraoperative PEEP that optimizes lung compliance without causing a rise in subdural pressure and if we can utilize optic nerve sheath diameter measurement as an indicator for ICP while optimizing lung compliance during supratentorial tumor surgeries.",
        "text": "The Effect of Intraoperative Variations in Positive-End Expiratory Pressure on Subdural Pressure, Optic Nerve Sheath Diameter, Lung Compliance and Brain Perfusion Pressure in Supratentorial Tumor Surgery | We aim to determine the level of intraoperative PEEP that optimizes lung compliance without causing a rise in subdural pressure and if we can utilize optic nerve sheath diameter measurement as an indicator for ICP while optimizing lung compliance during supratentorial tumor surgeries.",
        "tokens": "['The', 'Effect', 'of', 'Intraoperative', 'Variations', 'in', 'Positive', '-', 'End', 'Expiratory', 'Pressure', 'on', 'Subdural', 'Pressure', ',', 'Optic', 'Nerve', 'Sheath', 'Diameter', ',', 'Lung', 'Compliance', 'and', 'Brain', 'Perfusion', 'Pressure', 'in', 'Supratentorial', 'Tumor', 'Surgery', '|', 'We', 'aim', 'to', 'determine', 'the', 'level', 'of', 'intraoperative', 'PEEP', 'that', 'optimizes', 'lung', 'compliance', 'without', 'causing', 'a', 'rise', 'in', 'subdural', 'pressure', 'and', 'if', 'we', 'can', 'utilize', 'optic', 'nerve', 'sheath', 'diameter', 'measurement', 'as', 'an', 'indicator', 'for', 'ICP', 'while', 'optimizing', 'lung', 'compliance', 'during', 'supratentorial', 'tumor', 'surgeries', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 75,
                "text": "Intraoperative Variations in Positive-End Expiratory Pressure",
                "type": "OTHER"
            },
            {
                "start": 175,
                "end": 203,
                "text": "Supratentorial Tumor Surgery",
                "type": "CONDITION"
            },
            {
                "start": 239,
                "end": 258,
                "text": "intraoperative PEEP",
                "type": "OTHER"
            },
            {
                "start": 460,
                "end": 490,
                "text": "supratentorial tumor surgeries",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04249869",
        "study_official_title": "The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study ",
        "study_brief_summary": " This randomized, double-blinded, placebo-controlled, crossover clinical trial aims to investigate the effect of VGH-AD1, a scientific Chinese medicine powder prescription, on patients with Alzheimer's disease.",
        "text": "The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study | This randomized, double-blinded, placebo-controlled, crossover clinical trial aims to investigate the effect of VGH-AD1, a scientific Chinese medicine powder prescription, on patients with Alzheimer's disease.",
        "tokens": "['The', 'Effect', 'of', 'Traditional', 'Chinese', 'Medicine', '(', 'VGH', '-', 'AD1', ')', 'on', 'Patients', 'With', 'Alzheimer', \"'s\", 'Disease', ':', 'A', 'Double', '-', 'blinded', 'Randomized', 'Placebo', '-', 'controlled', 'Cross', '-', 'over', 'Study', '|', 'This', 'randomized', ',', 'double', '-', 'blinded', ',', 'placebo', '-', 'controlled', ',', 'crossover', 'clinical', 'trial', 'aims', 'to', 'investigate', 'the', 'effect', 'of', 'VGH', '-', 'AD1', ',', 'a', 'scientific', 'Chinese', 'medicine', 'powder', 'prescription', ',', 'on', 'patients', 'with', 'Alzheimer', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 42,
                "text": "Traditional Chinese Medicine",
                "type": "OTHER"
            },
            {
                "start": 44,
                "end": 51,
                "text": "VGH-AD1",
                "type": "OTHER"
            },
            {
                "start": 70,
                "end": 89,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 126,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 190,
                "end": 197,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 269,
                "end": 276,
                "text": "VGH-AD1",
                "type": "OTHER"
            },
            {
                "start": 291,
                "end": 314,
                "text": "Chinese medicine powder",
                "type": "OTHER"
            },
            {
                "start": 346,
                "end": 365,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02956148",
        "study_official_title": "Follow-up Measurement of Brain Phosphodiesterase 10 A (PDE10A) Enzyme Levels in Huntington\u00b4s Disease Gene Expansion Carriers, 18 to 28 Months After Initial Positron Emission Tomography (PET) Measurement in CHDIKI1201/PET-HD-PDE10A (NCT02061722) ",
        "study_brief_summary": " The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in HDGECs using the radioligand [18F]MNI-659. The study will be a follow-up, examining HDGECs from the CHDIKI1201/PET-HD-PDE10A (NCT02061722) study from 18 to 28 months after the initial PET measurement.",
        "text": "Follow-up Measurement of Brain Phosphodiesterase 10 A (PDE10A) Enzyme Levels in Huntington\u00b4s Disease Gene Expansion Carriers, 18 to 28 Months After Initial Positron Emission Tomography (PET) Measurement in CHDIKI1201/PET-HD-PDE10A (NCT02061722) | The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in HDGECs using the radioligand [18F]MNI-659. The study will be a follow-up, examining HDGECs from the CHDIKI1201/PET-HD-PDE10A (NCT02061722) study from 18 to 28 months after the initial PET measurement.",
        "tokens": "['Follow', '-', 'up', 'Measurement', 'of', 'Brain', 'Phosphodiesterase', '10', 'A', '(', 'PDE10A', ')', 'Enzyme', 'Levels', 'in', 'Huntington\u00b4s', 'Disease', 'Gene', 'Expansion', 'Carriers', ',', '18', 'to', '28', 'Months', 'After', 'Initial', 'Positron', 'Emission', 'Tomography', '(', 'PET', ')', 'Measurement', 'in', 'CHDIKI1201', '/', 'PET', '-', 'HD', '-', 'PDE10A', '(', 'NCT02061722', ')', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'measure', 'longitudinally', 'the', 'availability', 'of', 'the', 'PDE10A', 'enzyme', 'in', 'HDGECs', 'using', 'the', 'radioligand', '[', '18F]MNI-659', '.', 'The', 'study', 'will', 'be', 'a', 'follow', '-', 'up', ',', 'examining', 'HDGECs', 'from', 'the', 'CHDIKI1201', '/', 'PET', '-', 'HD', '-', 'PDE10A', '(', 'NCT02061722', ')', 'study', 'from', '18', 'to', '28', 'months', 'after', 'the', 'initial', 'PET', 'measurement', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 80,
                "end": 124,
                "text": "Huntington\u00b4s Disease Gene Expansion Carriers",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00729963",
        "study_official_title": "Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea ",
        "study_brief_summary": " The primary objective of this study is to observe if Sibutramine is effective in improving the symptoms and signs of sleep apnea in obese patients. The secondary objectives are to document the effects of Sibutramine on heart rate variability and 24-h arterial pressure values. We hypothesized that sibutramine will improve sleep disordered breathing, cardiac autonomic function and systemic blood pressure in obese patients with obstructive sleep apnea (OSA).",
        "text": "Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea | The primary objective of this study is to observe if Sibutramine is effective in improving the symptoms and signs of sleep apnea in obese patients. The secondary objectives are to document the effects of Sibutramine on heart rate variability and 24-h arterial pressure values. We hypothesized that sibutramine will improve sleep disordered breathing, cardiac autonomic function and systemic blood pressure in obese patients with obstructive sleep apnea (OSA).",
        "tokens": "['Efficacy', 'of', 'Sibutramine', '-', 'induced', 'Weight', 'Loss', 'vs.', 'Continuous', 'Positive', 'Airway', 'Pressure', '(', 'CPAP', ')', 'in', 'the', 'Treatment', 'of', 'Obese', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'observe', 'if', 'Sibutramine', 'is', 'effective', 'in', 'improving', 'the', 'symptoms', 'and', 'signs', 'of', 'sleep', 'apnea', 'in', 'obese', 'patients', '.', 'The', 'secondary', 'objectives', 'are', 'to', 'document', 'the', 'effects', 'of', 'Sibutramine', 'on', 'heart', 'rate', 'variability', 'and', '24', '-', 'h', 'arterial', 'pressure', 'values', '.', 'We', 'hypothesized', 'that', 'sibutramine', 'will', 'improve', 'sleep', 'disordered', 'breathing', ',', 'cardiac', 'autonomic', 'function', 'and', 'systemic', 'blood', 'pressure', 'in', 'obese', 'patients', 'with', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 23,
                "text": "Sibutramine",
                "type": "DRUG"
            },
            {
                "start": 48,
                "end": 83,
                "text": "Continuous Positive Airway Pressure",
                "type": "OTHER"
            },
            {
                "start": 85,
                "end": 89,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 111,
                "end": 116,
                "text": "Obese",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 154,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 221,
                "text": "Sibutramine",
                "type": "DRUG"
            },
            {
                "start": 274,
                "end": 285,
                "text": "sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 289,
                "end": 294,
                "text": "obese",
                "type": "CONDITION"
            },
            {
                "start": 361,
                "end": 372,
                "text": "Sibutramine",
                "type": "DRUG"
            },
            {
                "start": 455,
                "end": 466,
                "text": "sibutramine",
                "type": "DRUG"
            },
            {
                "start": 566,
                "end": 571,
                "text": "obese",
                "type": "CONDITION"
            },
            {
                "start": 586,
                "end": 609,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 611,
                "end": 614,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05183152",
        "study_official_title": "Non-invasive Brain-computer Interfaces for Control of Assistive Devices ",
        "study_brief_summary": " A brain-computer interface (BCI) decodes users' behavioral intentions or mental states directly from their brain activity, thus allowing operation of devices without requiring any overt motor action. One major modality for BCI control is based on motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. MI-based BCIs translate motor intents into control commands for external devices. A major challenge in such BCIs is differentiating MI patterns corresponding to fine hand movements of the same limb from non-invasive EEG recordings with low spatial resolution since the cortical sources responsible for these movements are overlapping. In this study, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to the voluntary activation of the primary motor cortex through MI can help differentiate patterns of activity associated with different hand movements of the same limb by consistently recruiting the separate neural pathways associated with each of the movements within a closed-loop BCI setup. This is expected to be associated with neuroplastic changes at the cortical or corticospinal levels.",
        "text": "Non-invasive Brain-computer Interfaces for Control of Assistive Devices | A brain-computer interface (BCI) decodes users' behavioral intentions or mental states directly from their brain activity, thus allowing operation of devices without requiring any overt motor action. One major modality for BCI control is based on motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. MI-based BCIs translate motor intents into control commands for external devices. A major challenge in such BCIs is differentiating MI patterns corresponding to fine hand movements of the same limb from non-invasive EEG recordings with low spatial resolution since the cortical sources responsible for these movements are overlapping. In this study, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to the voluntary activation of the primary motor cortex through MI can help differentiate patterns of activity associated with different hand movements of the same limb by consistently recruiting the separate neural pathways associated with each of the movements within a closed-loop BCI setup. This is expected to be associated with neuroplastic changes at the cortical or corticospinal levels.",
        "tokens": "['Non', '-', 'invasive', 'Brain', '-', 'computer', 'Interfaces', 'for', 'Control', 'of', 'Assistive', 'Devices', '|', 'A', 'brain', '-', 'computer', 'interface', '(', 'BCI', ')', 'decodes', 'users', \"'\", 'behavioral', 'intentions', 'or', 'mental', 'states', 'directly', 'from', 'their', 'brain', 'activity', ',', 'thus', 'allowing', 'operation', 'of', 'devices', 'without', 'requiring', 'any', 'overt', 'motor', 'action', '.', 'One', 'major', 'modality', 'for', 'BCI', 'control', 'is', 'based', 'on', 'motor', 'imagery', '(', 'MI', ')', ',', 'which', 'is', 'the', 'mental', 'rehearsal', 'of', 'the', 'kinesthetics', 'of', 'a', 'movement', 'without', 'actually', 'performing', 'it', '.', 'MI', '-', 'based', 'BCIs', 'translate', 'motor', 'intents', 'into', 'control', 'commands', 'for', 'external', 'devices', '.', 'A', 'major', 'challenge', 'in', 'such', 'BCIs', 'is', 'differentiating', 'MI', 'patterns', 'corresponding', 'to', 'fine', 'hand', 'movements', 'of', 'the', 'same', 'limb', 'from', 'non', '-', 'invasive', 'EEG', 'recordings', 'with', 'low', 'spatial', 'resolution', 'since', 'the', 'cortical', 'sources', 'responsible', 'for', 'these', 'movements', 'are', 'overlapping', '.', 'In', 'this', 'study', ',', 'the', 'investigators', 'hypothesize', 'that', 'neuromuscular', 'electrical', 'stimulation', '(', 'NMES', ')', 'applied', 'contingent', 'to', 'the', 'voluntary', 'activation', 'of', 'the', 'primary', 'motor', 'cortex', 'through', 'MI', 'can', 'help', 'differentiate', 'patterns', 'of', 'activity', 'associated', 'with', 'different', 'hand', 'movements', 'of', 'the', 'same', 'limb', 'by', 'consistently', 'recruiting', 'the', 'separate', 'neural', 'pathways', 'associated', 'with', 'each', 'of', 'the', 'movements', 'within', 'a', 'closed', '-', 'loop', 'BCI', 'setup', '.', 'This', 'is', 'expected', 'to', 'be', 'associated', 'with', 'neuroplastic', 'changes', 'at', 'the', 'cortical', 'or', 'corticospinal', 'levels', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 38,
                "text": "Brain-computer Interfaces",
                "type": "OTHER"
            },
            {
                "start": 54,
                "end": 71,
                "text": "Assistive Devices",
                "type": "OTHER"
            },
            {
                "start": 76,
                "end": 100,
                "text": "brain-computer interface",
                "type": "OTHER"
            },
            {
                "start": 102,
                "end": 105,
                "text": "BCI",
                "type": "OTHER"
            },
            {
                "start": 297,
                "end": 300,
                "text": "BCI",
                "type": "OTHER"
            },
            {
                "start": 321,
                "end": 334,
                "text": "motor imagery",
                "type": "OTHER"
            },
            {
                "start": 336,
                "end": 338,
                "text": "MI",
                "type": "OTHER"
            },
            {
                "start": 437,
                "end": 450,
                "text": "MI-based BCIs",
                "type": "OTHER"
            },
            {
                "start": 545,
                "end": 549,
                "text": "BCIs",
                "type": "OTHER"
            },
            {
                "start": 569,
                "end": 571,
                "text": "MI",
                "type": "OTHER"
            },
            {
                "start": 822,
                "end": 858,
                "text": "neuromuscular electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 860,
                "end": 864,
                "text": "NMES",
                "type": "OTHER"
            },
            {
                "start": 949,
                "end": 951,
                "text": "MI",
                "type": "OTHER"
            },
            {
                "start": 1157,
                "end": 1172,
                "text": "closed-loop BCI",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04238000",
        "study_official_title": "Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease:a Double Blind Cross-over Sham-controlled Study Using Wearing Sensors Technology ",
        "study_brief_summary": " Objective of the study:\n\nTo test the efficacy of theta burst cerebellar stimulation on dual task walking in Parkinson's disease using a cross-over design and wearing sensors technology\n\nDesign:\n\nTwenty Parkinson's disease patients with no dementia will be recruited for a cross-over sham-controlled study. Each patient will undergo a sham stimulation or a single session of cerebellar theta burst stimulation with a wash out period of at least 14 days.\n\nEach patient will be evaluated before and after stimulation by a battery of gait and movement tests using wearing sensors technology .",
        "text": "Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease:a Double Blind Cross-over Sham-controlled Study Using Wearing Sensors Technology | Objective of the study:\n\nTo test the efficacy of theta burst cerebellar stimulation on dual task walking in Parkinson's disease using a cross-over design and wearing sensors technology\n\nDesign:\n\nTwenty Parkinson's disease patients with no dementia will be recruited for a cross-over sham-controlled study. Each patient will undergo a sham stimulation or a single session of cerebellar theta burst stimulation with a wash out period of at least 14 days.\n\nEach patient will be evaluated before and after stimulation by a battery of gait and movement tests using wearing sensors technology .",
        "tokens": "['Cerebellar', 'rTMS', 'Theta', 'Burst', 'for', 'Dual', '-', 'task', 'Walking', 'in', 'Parkinson', \"'s\", 'Disease', ':', 'a', 'Double', 'Blind', 'Cross', '-', 'over', 'Sham', '-', 'controlled', 'Study', 'Using', 'Wearing', 'Sensors', 'Technology', '|', 'Objective', 'of', 'the', 'study', ':', '\\n\\n', 'To', 'test', 'the', 'efficacy', 'of', 'theta', 'burst', 'cerebellar', 'stimulation', 'on', 'dual', 'task', 'walking', 'in', 'Parkinson', \"'s\", 'disease', 'using', 'a', 'cross', '-', 'over', 'design', 'and', 'wearing', 'sensors', 'technology', '\\n\\n', 'Design', ':', '\\n\\n', 'Twenty', 'Parkinson', \"'s\", 'disease', 'patients', 'with', 'no', 'dementia', 'will', 'be', 'recruited', 'for', 'a', 'cross', '-', 'over', 'sham', '-', 'controlled', 'study', '.', 'Each', 'patient', 'will', 'undergo', 'a', 'sham', 'stimulation', 'or', 'a', 'single', 'session', 'of', 'cerebellar', 'theta', 'burst', 'stimulation', 'with', 'a', 'wash', 'out', 'period', 'of', 'at', 'least', '14', 'days', '.', '\\n\\n', 'Each', 'patient', 'will', 'be', 'evaluated', 'before', 'and', 'after', 'stimulation', 'by', 'a', 'battery', 'of', 'gait', 'and', 'movement', 'tests', 'using', 'wearing', 'sensors', 'technology', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 27,
                "text": "Cerebellar rTMS Theta Burst",
                "type": "OTHER"
            },
            {
                "start": 53,
                "end": 72,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 99,
                "end": 103,
                "text": "Sham",
                "type": "CONTROL"
            },
            {
                "start": 135,
                "end": 153,
                "text": "Sensors Technology",
                "type": "OTHER"
            },
            {
                "start": 205,
                "end": 239,
                "text": "theta burst cerebellar stimulation",
                "type": "OTHER"
            },
            {
                "start": 264,
                "end": 283,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 340,
                "text": "sensors technology",
                "type": "OTHER"
            },
            {
                "start": 358,
                "end": 377,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 439,
                "end": 443,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 490,
                "end": 506,
                "text": "sham stimulation",
                "type": "CONTROL"
            },
            {
                "start": 530,
                "end": 564,
                "text": "cerebellar theta burst stimulation",
                "type": "OTHER"
            },
            {
                "start": 724,
                "end": 742,
                "text": "sensors technology",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00315250",
        "study_official_title": "Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease ",
        "study_brief_summary": " We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD).\n\nDevelopment of reliable biomarkers for both dopaminergic and non-dopaminergic manifestations of Parkinson disease (PD) and related disorders may dramatically accelerate research on PD etiology, pathophysiology, and therapeutics. Biomarkers are broadly defined as characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Specific biomarkers may be useful at the onset of neurodegeneration, the onset of disease, and/or to mark disease progression.",
        "text": "Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease | We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD).\n\nDevelopment of reliable biomarkers for both dopaminergic and non-dopaminergic manifestations of Parkinson disease (PD) and related disorders may dramatically accelerate research on PD etiology, pathophysiology, and therapeutics. Biomarkers are broadly defined as characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Specific biomarkers may be useful at the onset of neurodegeneration, the onset of disease, and/or to mark disease progression.",
        "tokens": "['Development', 'of', 'Imaging', ',', 'Clinical', 'and', 'Biochemical', 'Bio', '-', 'Markers', 'for', 'Parkinson', \"'s\", 'Disease', '|', 'We', 'propose', 'to', 'build', 'on', 'preliminary', 'data', 'evaluating', 'non', '-', 'dopaminergic', '/', 'non', '-', 'motor', 'clinical', 'biomarkers', 'to', 'more', 'fully', 'assess', 'these', 'markers', 'at', 'the', 'threshold', 'of', 'Parkinson', 'disease', '(', 'PD', ')', '.', '\\n\\n', 'Development', 'of', 'reliable', 'biomarkers', 'for', 'both', 'dopaminergic', 'and', 'non', '-', 'dopaminergic', 'manifestations', 'of', 'Parkinson', 'disease', '(', 'PD', ')', 'and', 'related', 'disorders', 'may', 'dramatically', 'accelerate', 'research', 'on', 'PD', 'etiology', ',', 'pathophysiology', ',', 'and', 'therapeutics', '.', 'Biomarkers', 'are', 'broadly', 'defined', 'as', 'characteristics', 'that', 'are', 'objectively', 'measured', 'and', 'evaluated', 'as', 'indicators', 'of', 'normal', 'biological', 'processes', ',', 'pathogenic', 'processes', ',', 'or', 'pharmacologic', 'responses', 'to', 'a', 'therapeutic', 'intervention', '.', 'Specific', 'biomarkers', 'may', 'be', 'useful', 'at', 'the', 'onset', 'of', 'neurodegeneration', ',', 'the', 'onset', 'of', 'disease', ',', 'and/or', 'to', 'mark', 'disease', 'progression', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 65,
                "end": 84,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 240,
                "end": 257,
                "text": "Parkinson disease",
                "type": "CONDITION"
            },
            {
                "start": 259,
                "end": 261,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 361,
                "end": 378,
                "text": "Parkinson disease",
                "type": "CONDITION"
            },
            {
                "start": 380,
                "end": 382,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 446,
                "end": 448,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04005131",
        "study_official_title": "Effects of Upper Extremity Rehabilitation Robot and Transcranial Direct Current Stimulation on Upper Extremity Function Among Subjects With Chronic Stroke ",
        "study_brief_summary": " Comparison of real transcranial direct current stimulation (tDCS) and sham tDCS combined with robot training for upper extremity rehabilitation in subjects with chronic stroke - delayed start study.",
        "text": "Effects of Upper Extremity Rehabilitation Robot and Transcranial Direct Current Stimulation on Upper Extremity Function Among Subjects With Chronic Stroke | Comparison of real transcranial direct current stimulation (tDCS) and sham tDCS combined with robot training for upper extremity rehabilitation in subjects with chronic stroke - delayed start study.",
        "tokens": "['Effects', 'of', 'Upper', 'Extremity', 'Rehabilitation', 'Robot', 'and', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'on', 'Upper', 'Extremity', 'Function', 'Among', 'Subjects', 'With', 'Chronic', 'Stroke', '|', 'Comparison', 'of', 'real', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'and', 'sham', 'tDCS', 'combined', 'with', 'robot', 'training', 'for', 'upper', 'extremity', 'rehabilitation', 'in', 'subjects', 'with', 'chronic', 'stroke', '-', 'delayed', 'start', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 27,
                "end": 47,
                "text": "Rehabilitation Robot",
                "type": "PHYSICAL"
            },
            {
                "start": 52,
                "end": 91,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 140,
                "end": 154,
                "text": "Chronic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 215,
                "text": "transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 217,
                "end": 221,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 227,
                "end": 236,
                "text": "sham tDCS",
                "type": "CONTROL"
            },
            {
                "start": 251,
                "end": 265,
                "text": "robot training",
                "type": "PHYSICAL"
            },
            {
                "start": 318,
                "end": 332,
                "text": "chronic stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05659121",
        "study_official_title": "Evaluating Evidence-based and Sustainable Application of Robotic Exoskeletons in Rehabilitation for Those With Impaired Mobility ",
        "study_brief_summary": " The programme is designed to investigate the application of robotic exoskeleton in different levels of local rehabilitation facilities. Feasibilities, efficacy, cost-effectiveness, patient and therapist's view of the application of robotic exoskeleton will be evaluated.",
        "text": "Evaluating Evidence-based and Sustainable Application of Robotic Exoskeletons in Rehabilitation for Those With Impaired Mobility | The programme is designed to investigate the application of robotic exoskeleton in different levels of local rehabilitation facilities. Feasibilities, efficacy, cost-effectiveness, patient and therapist's view of the application of robotic exoskeleton will be evaluated.",
        "tokens": "['Evaluating', 'Evidence', '-', 'based', 'and', 'Sustainable', 'Application', 'of', 'Robotic', 'Exoskeletons', 'in', 'Rehabilitation', 'for', 'Those', 'With', 'Impaired', 'Mobility', '|', 'The', 'programme', 'is', 'designed', 'to', 'investigate', 'the', 'application', 'of', 'robotic', 'exoskeleton', 'in', 'different', 'levels', 'of', 'local', 'rehabilitation', 'facilities', '.', 'Feasibilities', ',', 'efficacy', ',', 'cost', '-', 'effectiveness', ',', 'patient', 'and', 'therapist', \"'s\", 'view', 'of', 'the', 'application', 'of', 'robotic', 'exoskeleton', 'will', 'be', 'evaluated', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 57,
                "end": 77,
                "text": "Robotic Exoskeletons",
                "type": "PHYSICAL"
            },
            {
                "start": 111,
                "end": 128,
                "text": "Impaired Mobility",
                "type": "CONDITION"
            },
            {
                "start": 191,
                "end": 210,
                "text": "robotic exoskeleton",
                "type": "PHYSICAL"
            },
            {
                "start": 363,
                "end": 382,
                "text": "robotic exoskeleton",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT04360044",
        "study_official_title": "Efficacy of Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial ",
        "study_brief_summary": " This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.",
        "text": "Efficacy of Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial | This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.",
        "tokens": "['Efficacy', 'of', 'Inhaled', 'Cannabis', 'Versus', 'Placebo', 'for', 'the', 'Acute', 'Treatment', 'of', 'Migraine', ':', 'a', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Crossover', 'Trial', '|', 'This', 'crossover', 'study', 'will', 'evaluate', '3', 'different', 'treatments', 'of', 'vaporized', 'cannabis', '(', 'THC', ',', 'THC', '/', 'CBD', 'mix', ',', 'and', 'CBD', ')', 'and', 'vaporized', 'placebo', 'cannabis', 'for', 'the', 'acute', 'treatment', 'of', 'migraine', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 28,
                "text": "Cannabis",
                "type": "OTHER"
            },
            {
                "start": 36,
                "end": 43,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 71,
                "end": 79,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 109,
                "end": 116,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 218,
                "end": 226,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 228,
                "end": 231,
                "text": "THC",
                "type": "DRUG"
            },
            {
                "start": 233,
                "end": 236,
                "text": "THC",
                "type": "DRUG"
            },
            {
                "start": 237,
                "end": 240,
                "text": "CBD",
                "type": "DRUG"
            },
            {
                "start": 250,
                "end": 253,
                "text": "CBD",
                "type": "DRUG"
            },
            {
                "start": 259,
                "end": 285,
                "text": "vaporized placebo cannabis",
                "type": "CONTROL"
            },
            {
                "start": 313,
                "end": 321,
                "text": "migraine",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05207865",
        "study_official_title": "A Phase 4, Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention ",
        "study_brief_summary": " The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.",
        "text": "A Phase 4, Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention | The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.",
        "tokens": "['A', 'Phase', '4', ',', 'Open', '-', 'Label', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Daily', 'Dosing', 'of', 'Rimegepant', 'in', 'Episodic', 'Migraine', 'Prevention', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'further', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'daily', 'dosing', 'of', 'rimegepant', 'for', 'the', 'prevention', 'of', 'episodic', 'migraine', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 87,
                "end": 97,
                "text": "Rimegepant",
                "type": "DRUG"
            },
            {
                "start": 101,
                "end": 118,
                "text": "Episodic Migraine",
                "type": "CONDITION"
            },
            {
                "start": 238,
                "end": 248,
                "text": "rimegepant",
                "type": "DRUG"
            },
            {
                "start": 271,
                "end": 288,
                "text": "episodic migraine",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03282370",
        "study_official_title": "Evaluate the Safety and Immunogenicity of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by VABIOTECH (Vietnam) in Vietnamese Children Aged 9-24 Months ",
        "study_brief_summary": " A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced vaccine. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of study / control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose and from the second dose to 28-34 days after 2nd dose. SAE (from start of first dose to 28-34 days after second dose).",
        "text": "Evaluate the Safety and Immunogenicity of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by VABIOTECH (Vietnam) in Vietnamese Children Aged 9-24 Months | A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced vaccine. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of study / control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose and from the second dose to 28-34 days after 2nd dose. SAE (from start of first dose to 28-34 days after second dose).",
        "tokens": "['Evaluate', 'the', 'Safety', 'and', 'Immunogenicity', 'of', 'a', 'Vero', 'Cell', '-', 'Derived', 'Inactivated', 'Japanese', 'Encephalitis', 'Vaccine', '(', 'JECEVAX', ')', 'Produced', 'by', 'VABIOTECH', '(', 'Vietnam', ')', 'in', 'Vietnamese', 'Children', 'Aged', '9', '-', '24', 'Months', '|', 'A', 'study', 'of', 'the', 'study', 'vaccine', '(', 'JECEVAX-', 'VABIOTECH', '-', 'Vietnam', ')', 'and', 'a', 'licensed', 'vaccine', '(', 'JEVAX', '-', 'VABIOTECH', '-', 'Vietnam', ')', 'is', 'conducted', 'in', 'Vietnamese', 'children', ',', 'aged', '9', 'to', '24', 'months', 'to', 'assess', 'the', 'safety', 'of', 'the', 'study', 'vaccine', 'compares', 'to', 'licenced', 'vaccine', '.', 'Two', 'hundred', 'and', 'twenty', 'children', 'are', 'enrolled', 'and', 'randomly', 'assigned', 'into', '2', 'groups', '(', '110', 'children', '/', 'group', ')', ',', 'each', 'of', 'which', 'receive', '2', 'doses', 'of', 'study', '/', 'control', 'vaccine', 'subcutaneously', ',', 'at', '28', '-', '34', 'days', 'interval', '.', 'Safety', 'data', 'included', 'immediate', 'reaction', 'at', 'the', 'injection', 'site', 'and', 'systemic', 'reaction', 'within', '30', 'min', 'of', 'administration', ',', 'solicited', 'and', 'unsolicited', 'adverse', 'events', 'occurs', 'from', 'the', '1st', 'dose', 'to', '28', '-', '34', 'days', 'after', 'first', 'dose', 'and', 'from', 'the', 'second', 'dose', 'to', '28', '-', '34', 'days', 'after', '2nd', 'dose', '.', 'SAE', '(', 'from', 'start', 'of', 'first', 'dose', 'to', '28', '-', '34', 'days', 'after', 'second', 'dose', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 44,
                "end": 105,
                "text": "Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine",
                "type": "DRUG"
            },
            {
                "start": 107,
                "end": 114,
                "text": "JECEVAX",
                "type": "DRUG"
            },
            {
                "start": 220,
                "end": 228,
                "text": "JECEVAX-",
                "type": "DRUG"
            },
            {
                "start": 254,
                "end": 270,
                "text": "licensed vaccine",
                "type": "CONTROL"
            },
            {
                "start": 272,
                "end": 277,
                "text": "JEVAX",
                "type": "DRUG"
            },
            {
                "start": 408,
                "end": 424,
                "text": "licenced vaccine",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00796432",
        "study_official_title": "Open-label Positron Emission Tomography (PET) Study of Central D2-receptor Occupancy in Healthy Subjects Following a Single Oral Dose of OROS Paliperidone ",
        "study_brief_summary": " The purposes of this study are to estimate the relationship of D2-receptor occupancy to plasma concentration and to assess the safety of OROS paliperidone.",
        "text": "Open-label Positron Emission Tomography (PET) Study of Central D2-receptor Occupancy in Healthy Subjects Following a Single Oral Dose of OROS Paliperidone | The purposes of this study are to estimate the relationship of D2-receptor occupancy to plasma concentration and to assess the safety of OROS paliperidone.",
        "tokens": "['Open', '-', 'label', 'Positron', 'Emission', 'Tomography', '(', 'PET', ')', 'Study', 'of', 'Central', 'D2', '-', 'receptor', 'Occupancy', 'in', 'Healthy', 'Subjects', 'Following', 'a', 'Single', 'Oral', 'Dose', 'of', 'OROS', 'Paliperidone', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', 'to', 'estimate', 'the', 'relationship', 'of', 'D2', '-', 'receptor', 'occupancy', 'to', 'plasma', 'concentration', 'and', 'to', 'assess', 'the', 'safety', 'of', 'OROS', 'paliperidone', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 142,
                "end": 154,
                "text": "Paliperidone",
                "type": "DRUG"
            },
            {
                "start": 299,
                "end": 311,
                "text": "paliperidone",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02886663",
        "study_official_title": "Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia ",
        "study_brief_summary": " This study will assess the effectiveness of a stimulus, in the blind field of hemianopsic patients, to restore the vision of patients with homonymous hemianopsia consecutive to stroke (unilateral occipital lesion). Hemianopsia occurs in 30% of strokes regardless of the cerebral localization and in 60% of stroke interesting the territory of the posterior cerebral artery.",
        "text": "Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia | This study will assess the effectiveness of a stimulus, in the blind field of hemianopsic patients, to restore the vision of patients with homonymous hemianopsia consecutive to stroke (unilateral occipital lesion). Hemianopsia occurs in 30% of strokes regardless of the cerebral localization and in 60% of stroke interesting the territory of the posterior cerebral artery.",
        "tokens": "['Visual', 'Field', 'Restoration', 'in', 'Patients', 'With', 'Post', '-', 'stroke', 'Homonymous', 'Hemianopsia', '|', 'This', 'study', 'will', 'assess', 'the', 'effectiveness', 'of', 'a', 'stimulus', ',', 'in', 'the', 'blind', 'field', 'of', 'hemianopsic', 'patients', ',', 'to', 'restore', 'the', 'vision', 'of', 'patients', 'with', 'homonymous', 'hemianopsia', 'consecutive', 'to', 'stroke', '(', 'unilateral', 'occipital', 'lesion', ')', '.', 'Hemianopsia', 'occurs', 'in', '30', '%', 'of', 'strokes', 'regardless', 'of', 'the', 'cerebral', 'localization', 'and', 'in', '60', '%', 'of', 'stroke', 'interesting', 'the', 'territory', 'of', 'the', 'posterior', 'cerebral', 'artery', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 24,
                "text": "Visual Field Restoration",
                "type": "OTHER"
            },
            {
                "start": 42,
                "end": 53,
                "text": "Post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 54,
                "end": 76,
                "text": "Homonymous Hemianopsia",
                "type": "CONDITION"
            },
            {
                "start": 125,
                "end": 133,
                "text": "stimulus",
                "type": "OTHER"
            },
            {
                "start": 157,
                "end": 168,
                "text": "hemianopsic",
                "type": "CONDITION"
            },
            {
                "start": 218,
                "end": 240,
                "text": "homonymous hemianopsia",
                "type": "CONDITION"
            },
            {
                "start": 256,
                "end": 262,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 294,
                "end": 305,
                "text": "Hemianopsia",
                "type": "CONDITION"
            },
            {
                "start": 323,
                "end": 330,
                "text": "strokes",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 391,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04299893",
        "study_official_title": "Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ) ",
        "study_brief_summary": " The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy",
        "text": "Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ) | The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy",
        "tokens": "['Effectiveness', 'and', 'Cost', '-', 'effectiveness', 'of', 'Ozone', 'Therapy', 'in', 'Patients', 'With', 'Pain', 'Secondary', 'to', 'Chemotherapy', '-', 'induced', 'Peripheral', 'Neuropathy', '.', 'Randomized', ',', 'Triple', '-', 'blind', 'Clinical', 'Trial', '(', 'O3NPIQ', ')', '|', 'The', 'main', 'objective', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'cost', '-', 'effectiveness', 'of', 'adding', 'ozone', 'therapy', 'to', 'the', 'clinical', 'management', 'of', 'patients', 'with', 'pain', 'secondary', 'to', 'chemotherapy', '-', 'induced', 'peripheral', 'neuropathy']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 40,
                "end": 45,
                "text": "Ozone",
                "type": "DRUG"
            },
            {
                "start": 71,
                "end": 75,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 89,
                "end": 131,
                "text": "Chemotherapy-induced Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 292,
                "end": 297,
                "text": "ozone",
                "type": "DRUG"
            },
            {
                "start": 350,
                "end": 354,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 368,
                "end": 410,
                "text": "chemotherapy-induced peripheral neuropathy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02396953",
        "study_official_title": "Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel ",
        "study_brief_summary": " The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.",
        "text": "Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel | The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.",
        "tokens": "['Phase', 'IIa', ',', 'Open', 'Label', ',', 'Dose', 'Ascending', 'Study', 'to', 'Determine', 'the', 'Maximum', 'Tolerated', 'Dose', ',', 'Safety', 'and', 'Tolerability', ',', 'Pharmacokinetics', 'and', 'Pharmacodynamics', 'of', 'a', 'Single', 'Dose', 'of', 'Lanreotide', 'PRF', 'in', 'Subjects', 'With', 'Acromegaly', 'Previously', 'Treated', 'and', 'Controlled', 'With', 'Either', 'Octreotide', 'LAR', 'or', 'Lanreotide', 'Autogel', '|', 'The', 'objectives', 'of', 'the', 'protocol', 'is', 'to', 'determine', 'the', 'maximum', 'tolerated', 'dose', 'and', 'to', 'investigate', 'the', 'pharmacokinetics', 'of', 'a', 'single', 'dose', 'of', 'lanreotide', 'PRF', 'in', 'subjects', 'with', 'acromegaly', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 168,
                "end": 178,
                "text": "Lanreotide",
                "type": "DRUG"
            },
            {
                "start": 200,
                "end": 210,
                "text": "Acromegaly",
                "type": "CONDITION"
            },
            {
                "start": 257,
                "end": 267,
                "text": "Octreotide",
                "type": "DRUG"
            },
            {
                "start": 275,
                "end": 285,
                "text": "Lanreotide",
                "type": "DRUG"
            },
            {
                "start": 430,
                "end": 440,
                "text": "lanreotide",
                "type": "DRUG"
            },
            {
                "start": 462,
                "end": 472,
                "text": "acromegaly",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00261508",
        "study_official_title": "Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study ",
        "study_brief_summary": " The purpose of the study is to evaluate the effectiveness of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral symptoms in children with Pervasive Developmental Disorders (PDD).",
        "text": "Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study | The purpose of the study is to evaluate the effectiveness of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral symptoms in children with Pervasive Developmental Disorders (PDD).",
        "tokens": "['Efficacy', 'And', 'Safety', 'Of', 'Risperidone', 'In', 'The', 'Treatment', 'Of', 'Children', 'With', 'Autistic', 'Disorder', 'And', 'Other', 'Pervasive', 'Developmental', 'Disorders', ':', 'A', 'Canadian', ',', 'Multicenter', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'an', 'oral', 'solution', 'of', 'risperidone', '(', 'an', 'antipsychotic', 'medication', ')', 'versus', 'placebo', 'in', 'the', 'treatment', 'of', 'behavioral', 'symptoms', 'in', 'children', 'with', 'Pervasive', 'Developmental', 'Disorders', '(', 'PDD', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 23,
                "end": 34,
                "text": "Risperidone",
                "type": "DRUG"
            },
            {
                "start": 69,
                "end": 86,
                "text": "Autistic Disorder",
                "type": "CONDITION"
            },
            {
                "start": 97,
                "end": 130,
                "text": "Pervasive Developmental Disorders",
                "type": "CONDITION"
            },
            {
                "start": 171,
                "end": 178,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 279,
                "end": 290,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 295,
                "end": 319,
                "text": "antipsychotic medication",
                "type": "DRUG"
            },
            {
                "start": 328,
                "end": 335,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 393,
                "end": 426,
                "text": "Pervasive Developmental Disorders",
                "type": "CONDITION"
            },
            {
                "start": 428,
                "end": 431,
                "text": "PDD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00201461",
        "study_official_title": "A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex\u00ae Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale ",
        "study_brief_summary": " The primary objective of the study is to determine whether the STARFlex\u00ae septal closure system will safely and effectively prevent a recurrent embolic stroke/transient ischemic attack (TIA) and mortality in patients with a PFO and to demonstrate superiority of the STARFlex\u00ae device compared to best medical therapy.",
        "text": "A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex\u00ae Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale | The primary objective of the study is to determine whether the STARFlex\u00ae septal closure system will safely and effectively prevent a recurrent embolic stroke/transient ischemic attack (TIA) and mortality in patients with a PFO and to demonstrate superiority of the STARFlex\u00ae device compared to best medical therapy.",
        "tokens": "['A', 'Prospective', ',', 'Multicenter', ',', 'Randomized', 'Controlled', 'Trial', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Efficacy', 'of', 'the', 'STARFlex', '\u00ae', 'Septal', 'Closure', 'System', 'Versus', 'Best', 'Medical', 'Therapy', 'in', 'Patients', 'With', 'a', 'Stroke', 'and/or', 'Transient', 'Ischemic', 'Attack', 'Due', 'to', 'Presumed', 'Paradoxical', 'Embolism', 'Through', 'a', 'Patent', 'Foramen', 'Ovale', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'determine', 'whether', 'the', 'STARFlex', '\u00ae', 'septal', 'closure', 'system', 'will', 'safely', 'and', 'effectively', 'prevent', 'a', 'recurrent', 'embolic', 'stroke', '/', 'transient', 'ischemic', 'attack', '(', 'TIA', ')', 'and', 'mortality', 'in', 'patients', 'with', 'a', 'PFO', 'and', 'to', 'demonstrate', 'superiority', 'of', 'the', 'STARFlex', '\u00ae', 'device', 'compared', 'to', 'best', 'medical', 'therapy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 99,
                "end": 130,
                "text": "STARFlex\u00ae Septal Closure System",
                "type": "OTHER"
            },
            {
                "start": 138,
                "end": 158,
                "text": "Best Medical Therapy",
                "type": "CONTROL"
            },
            {
                "start": 178,
                "end": 184,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 192,
                "end": 217,
                "text": "Transient Ischemic Attack",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 254,
                "text": "Paradoxical Embolism",
                "type": "CONDITION"
            },
            {
                "start": 265,
                "end": 285,
                "text": "Patent Foramen Ovale",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 382,
                "text": "STARFlex\u00ae septal closure system",
                "type": "OTHER"
            },
            {
                "start": 421,
                "end": 445,
                "text": "recurrent embolic stroke",
                "type": "CONDITION"
            },
            {
                "start": 446,
                "end": 471,
                "text": "transient ischemic attack",
                "type": "CONDITION"
            },
            {
                "start": 473,
                "end": 476,
                "text": "TIA",
                "type": "CONDITION"
            },
            {
                "start": 511,
                "end": 514,
                "text": "PFO",
                "type": "CONDITION"
            },
            {
                "start": 553,
                "end": 569,
                "text": "STARFlex\u00ae device",
                "type": "OTHER"
            },
            {
                "start": 582,
                "end": 602,
                "text": "best medical therapy",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02808156",
        "study_official_title": "Effectiveness of Unilateral Versus Bilateral Intensive Training in Children With Cerebral Palsy ",
        "study_brief_summary": " This 3-year research project aims to investigate and compare the immediate and long-term treatment effectiveness as well as motor improving curve and potential predictors of the unimanual intensive training and bimanual intensive training protocols with an equivalent intervention period in children with hemiplegic CP and children with CP with apparently one side affected. In addition, based on the ICF-CY model, comprehensive outcome measures including motor functions as well as psychological functions will be included.",
        "text": "Effectiveness of Unilateral Versus Bilateral Intensive Training in Children With Cerebral Palsy | This 3-year research project aims to investigate and compare the immediate and long-term treatment effectiveness as well as motor improving curve and potential predictors of the unimanual intensive training and bimanual intensive training protocols with an equivalent intervention period in children with hemiplegic CP and children with CP with apparently one side affected. In addition, based on the ICF-CY model, comprehensive outcome measures including motor functions as well as psychological functions will be included.",
        "tokens": "['Effectiveness', 'of', 'Unilateral', 'Versus', 'Bilateral', 'Intensive', 'Training', 'in', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'This', '3', '-', 'year', 'research', 'project', 'aims', 'to', 'investigate', 'and', 'compare', 'the', 'immediate', 'and', 'long', '-', 'term', 'treatment', 'effectiveness', 'as', 'well', 'as', 'motor', 'improving', 'curve', 'and', 'potential', 'predictors', 'of', 'the', 'unimanual', 'intensive', 'training', 'and', 'bimanual', 'intensive', 'training', 'protocols', 'with', 'an', 'equivalent', 'intervention', 'period', 'in', 'children', 'with', 'hemiplegic', 'CP', 'and', 'children', 'with', 'CP', 'with', 'apparently', 'one', 'side', 'affected', '.', 'In', 'addition', ',', 'based', 'on', 'the', 'ICF', '-', 'CY', 'model', ',', 'comprehensive', 'outcome', 'measures', 'including', 'motor', 'functions', 'as', 'well', 'as', 'psychological', 'functions', 'will', 'be', 'included', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 63,
                "text": "Unilateral Versus Bilateral Intensive Training",
                "type": "PHYSICAL"
            },
            {
                "start": 81,
                "end": 95,
                "text": "Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 276,
                "end": 304,
                "text": "unimanual intensive training",
                "type": "PHYSICAL"
            },
            {
                "start": 309,
                "end": 336,
                "text": "bimanual intensive training",
                "type": "PHYSICAL"
            },
            {
                "start": 403,
                "end": 416,
                "text": "hemiplegic CP",
                "type": "CONDITION"
            },
            {
                "start": 435,
                "end": 437,
                "text": "CP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04241679",
        "study_official_title": "Feasibility of Auditory Nerve Test System for Optimization of Simultaneous Translabyrinthine Vestibular Schwannoma Resection With Cochlear Implantation ",
        "study_brief_summary": " The Auditory Nerve Test System (ANTS) is a novel device that stimulates the auditory nerve much like a cochlear implant. The purpose of this study is to demonstrate feasibility of the ANTS during translabyrinthine surgery for vestibular schwannoma resection. If the auditory nerve is kept intact, then the patients will also receive a cochlear implant at the same time potentially alleviating the morbidities caused by a vestibular schwannoma and asymmetric sensorineural hearing loss.",
        "text": "Feasibility of Auditory Nerve Test System for Optimization of Simultaneous Translabyrinthine Vestibular Schwannoma Resection With Cochlear Implantation | The Auditory Nerve Test System (ANTS) is a novel device that stimulates the auditory nerve much like a cochlear implant. The purpose of this study is to demonstrate feasibility of the ANTS during translabyrinthine surgery for vestibular schwannoma resection. If the auditory nerve is kept intact, then the patients will also receive a cochlear implant at the same time potentially alleviating the morbidities caused by a vestibular schwannoma and asymmetric sensorineural hearing loss.",
        "tokens": "['Feasibility', 'of', 'Auditory', 'Nerve', 'Test', 'System', 'for', 'Optimization', 'of', 'Simultaneous', 'Translabyrinthine', 'Vestibular', 'Schwannoma', 'Resection', 'With', 'Cochlear', 'Implantation', '|', 'The', 'Auditory', 'Nerve', 'Test', 'System', '(', 'ANTS', ')', 'is', 'a', 'novel', 'device', 'that', 'stimulates', 'the', 'auditory', 'nerve', 'much', 'like', 'a', 'cochlear', 'implant', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'demonstrate', 'feasibility', 'of', 'the', 'ANTS', 'during', 'translabyrinthine', 'surgery', 'for', 'vestibular', 'schwannoma', 'resection', '.', 'If', 'the', 'auditory', 'nerve', 'is', 'kept', 'intact', ',', 'then', 'the', 'patients', 'will', 'also', 'receive', 'a', 'cochlear', 'implant', 'at', 'the', 'same', 'time', 'potentially', 'alleviating', 'the', 'morbidities', 'caused', 'by', 'a', 'vestibular', 'schwannoma', 'and', 'asymmetric', 'sensorineural', 'hearing', 'loss', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 41,
                "text": "Auditory Nerve Test System",
                "type": "OTHER"
            },
            {
                "start": 75,
                "end": 124,
                "text": "Translabyrinthine Vestibular Schwannoma Resection",
                "type": "CONDITION"
            },
            {
                "start": 130,
                "end": 151,
                "text": "Cochlear Implantation",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 184,
                "text": "Auditory Nerve Test System",
                "type": "OTHER"
            },
            {
                "start": 186,
                "end": 190,
                "text": "ANTS",
                "type": "OTHER"
            },
            {
                "start": 338,
                "end": 342,
                "text": "ANTS",
                "type": "OTHER"
            },
            {
                "start": 350,
                "end": 411,
                "text": "translabyrinthine surgery for vestibular schwannoma resection",
                "type": "CONDITION"
            },
            {
                "start": 489,
                "end": 505,
                "text": "cochlear implant",
                "type": "CONDITION"
            },
            {
                "start": 575,
                "end": 596,
                "text": "vestibular schwannoma",
                "type": "CONDITION"
            },
            {
                "start": 601,
                "end": 638,
                "text": "asymmetric sensorineural hearing loss",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02245724",
        "study_official_title": "The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.",
        "study_brief_summary": null,
        "text": "The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.",
        "tokens": "['The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'analyze', 'the', 'benefit', 'of', 'autologous', 'mononuclear', 'cell', 'therapy', 'in', 'mental', 'retardation', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 56,
                "end": 91,
                "text": "autologous mononuclear cell therapy",
                "type": "SURGICAL"
            },
            {
                "start": 95,
                "end": 113,
                "text": "mental retardation",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04894461",
        "study_official_title": "Efficacy of Moxibustion in Diabetes Peripheral Neuropathy ",
        "study_brief_summary": " This pragmatic randomized controlled study aimed to evaluate the effectiveness and safety of moxibustion therapy on diabetes peripheral neuropathy.",
        "text": "Efficacy of Moxibustion in Diabetes Peripheral Neuropathy | This pragmatic randomized controlled study aimed to evaluate the effectiveness and safety of moxibustion therapy on diabetes peripheral neuropathy.",
        "tokens": "['Efficacy', 'of', 'Moxibustion', 'in', 'Diabetes', 'Peripheral', 'Neuropathy', '|', 'This', 'pragmatic', 'randomized', 'controlled', 'study', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'moxibustion', 'therapy', 'on', 'diabetes', 'peripheral', 'neuropathy', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 23,
                "text": "Moxibustion",
                "type": "OTHER"
            },
            {
                "start": 27,
                "end": 35,
                "text": "Diabetes",
                "type": "CONDITION"
            },
            {
                "start": 36,
                "end": 57,
                "text": "Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 172,
                "text": "moxibustion therapy",
                "type": "OTHER"
            },
            {
                "start": 176,
                "end": 184,
                "text": "diabetes",
                "type": "CONDITION"
            },
            {
                "start": 185,
                "end": 206,
                "text": "peripheral neuropathy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00031590",
        "study_official_title": "Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma) ",
        "study_brief_summary": " RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children. Combining low-dose radiation therapy in combination with chemotherapy should be effective in treating medulloblastoma while avoiding the long-term side effects of giving higher dose radiation to children with newly diagnosed average risk medulloblastoma.",
        "text": "Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma) | RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children. Combining low-dose radiation therapy in combination with chemotherapy should be effective in treating medulloblastoma while avoiding the long-term side effects of giving higher dose radiation to children with newly diagnosed average risk medulloblastoma.",
        "tokens": "['Study', 'Of', 'Reduced', 'Dose', 'Craniospinal', 'Radiotherapy', '(', '1800', 'cGy', ')', 'And', 'Chemotherapy', 'In', 'Children', 'With', 'Newly', '-', 'Diagnosed', 'Standard', '-', 'Risk', 'Posterior', 'Fossa', 'Primitive', 'Neuro', '-', 'ectodermal', 'Tumor', '(', 'PNET', '/', 'Medulloblastoma', ')', '|', 'RATIONALE', ':', 'Radiation', 'therapy', 'uses', 'high', '-', 'energy', 'x', '-', 'rays', 'to', 'damage', 'tumor', 'cells', ',', 'but', 'also', 'damages', 'normal', 'cells', 'in', 'the', 'developing', 'brains', 'of', 'children', '.', 'Combining', 'low', '-', 'dose', 'radiation', 'therapy', 'in', 'combination', 'with', 'chemotherapy', 'should', 'be', 'effective', 'in', 'treating', 'medulloblastoma', 'while', 'avoiding', 'the', 'long', '-', 'term', 'side', 'effects', 'of', 'giving', 'higher', 'dose', 'radiation', 'to', 'children', 'with', 'newly', 'diagnosed', 'average', 'risk', 'medulloblastoma', '.']",
        "token_bio_labels": "['O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 9,
                "end": 47,
                "text": "Reduced Dose Craniospinal Radiotherapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 63,
                "end": 75,
                "text": "Chemotherapy",
                "type": "DRUG"
            },
            {
                "start": 93,
                "end": 171,
                "text": "Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 177,
                "text": "PNET",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 193,
                "text": "Medulloblastoma",
                "type": "CONDITION"
            },
            {
                "start": 208,
                "end": 225,
                "text": "Radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 351,
                "end": 377,
                "text": "low-dose radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 398,
                "end": 410,
                "text": "chemotherapy",
                "type": "DRUG"
            },
            {
                "start": 443,
                "end": 458,
                "text": "medulloblastoma",
                "type": "CONDITION"
            },
            {
                "start": 523,
                "end": 532,
                "text": "radiation",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 550,
                "end": 594,
                "text": "newly diagnosed average risk medulloblastoma",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03026231",
        "study_official_title": "A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease ",
        "study_brief_summary": " The purpose of this study is to characterize the intestinal flora in subjects with Parkinson's Disease (PD) and to determine safety and trends in improvements in diversity of colonic microbiome following fecal microbiota transplantation.",
        "text": "A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease | The purpose of this study is to characterize the intestinal flora in subjects with Parkinson's Disease (PD) and to determine safety and trends in improvements in diversity of colonic microbiome following fecal microbiota transplantation.",
        "tokens": "['A', 'Prospective', ',', 'Randomized', 'Placebo', 'Controlled', 'Pilot', 'Study', 'to', 'Characterize', 'the', 'Intestinal', 'Microbiome', 'and', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Fecal', 'Microbiome', 'Changes', 'Following', 'Weekly', 'Administration', 'of', 'Lyophilized', 'PRIM', '-', 'DJ2727', 'Given', 'Orally', 'in', 'Subjects', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'characterize', 'the', 'intestinal', 'flora', 'in', 'subjects', 'with', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', 'and', 'to', 'determine', 'safety', 'and', 'trends', 'in', 'improvements', 'in', 'diversity', 'of', 'colonic', 'microbiome', 'following', 'fecal', 'microbiota', 'transplantation', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 33,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 202,
                "end": 213,
                "text": "PRIM-DJ2727",
                "type": "DRUG"
            },
            {
                "start": 244,
                "end": 263,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 349,
                "end": 368,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 370,
                "end": 372,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 470,
                "end": 502,
                "text": "fecal microbiota transplantation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00230698",
        "study_official_title": "Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures ",
        "study_brief_summary": " The purposes of this study are (1) to compare the effectiveness of two doses of topiramate and (2) to assess the safety of topiramate alone in the treatment of pediatric and adult patients with recently diagnosed epilepsy characterized by partial-onset seizures.",
        "text": "Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures | The purposes of this study are (1) to compare the effectiveness of two doses of topiramate and (2) to assess the safety of topiramate alone in the treatment of pediatric and adult patients with recently diagnosed epilepsy characterized by partial-onset seizures.",
        "tokens": "['Topiramate', '(', 'RWJ-17021', '-', '000', ')', 'Monotherapy', 'Clinical', 'Trial', 'in', 'Patients', 'With', 'Recently', 'Diagnosed', 'Partial', '-', 'Onset', 'Seizures', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', '(', '1', ')', 'to', 'compare', 'the', 'effectiveness', 'of', 'two', 'doses', 'of', 'topiramate', 'and', '(', '2', ')', 'to', 'assess', 'the', 'safety', 'of', 'topiramate', 'alone', 'in', 'the', 'treatment', 'of', 'pediatric', 'and', 'adult', 'patients', 'with', 'recently', 'diagnosed', 'epilepsy', 'characterized', 'by', 'partial', '-', 'onset', 'seizures', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 10,
                "text": "Topiramate",
                "type": "DRUG"
            },
            {
                "start": 12,
                "end": 25,
                "text": "RWJ-17021-000",
                "type": "DRUG"
            },
            {
                "start": 90,
                "end": 112,
                "text": "Partial-Onset Seizures",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 205,
                "text": "topiramate",
                "type": "DRUG"
            },
            {
                "start": 238,
                "end": 248,
                "text": "topiramate",
                "type": "DRUG"
            },
            {
                "start": 328,
                "end": 336,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 376,
                "text": "partial-onset seizures",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03794908",
        "study_official_title": "Bright Light Treatment at Home to Improve Symptom Management of Fibromyalgia Syndrome ",
        "study_brief_summary": " The purpose of this study is to determine the effect a morning light treatment has on improving physical function, pain intensity, and pain sensitivity in people with fibromyalgia syndrome (FMS).",
        "text": "Bright Light Treatment at Home to Improve Symptom Management of Fibromyalgia Syndrome | The purpose of this study is to determine the effect a morning light treatment has on improving physical function, pain intensity, and pain sensitivity in people with fibromyalgia syndrome (FMS).",
        "tokens": "['Bright', 'Light', 'Treatment', 'at', 'Home', 'to', 'Improve', 'Symptom', 'Management', 'of', 'Fibromyalgia', 'Syndrome', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'a', 'morning', 'light', 'treatment', 'has', 'on', 'improving', 'physical', 'function', ',', 'pain', 'intensity', ',', 'and', 'pain', 'sensitivity', 'in', 'people', 'with', 'fibromyalgia', 'syndrome', '(', 'FMS', ')', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "Bright Light Treatment",
                "type": "OTHER"
            },
            {
                "start": 64,
                "end": 85,
                "text": "Fibromyalgia Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 143,
                "end": 166,
                "text": "morning light treatment",
                "type": "OTHER"
            },
            {
                "start": 203,
                "end": 207,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 227,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 255,
                "end": 276,
                "text": "fibromyalgia syndrome",
                "type": "CONDITION"
            },
            {
                "start": 278,
                "end": 281,
                "text": "FMS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00316563",
        "study_official_title": "A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study ",
        "study_brief_summary": " To investigate delta-9-tetrahydrocannabinol's (THC) ability to increase food intake and improve food enjoyment for advanced cancer patients with taste and/or smell (chemosensory) abnormalities.",
        "text": "A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study | To investigate delta-9-tetrahydrocannabinol's (THC) ability to increase food intake and improve food enjoyment for advanced cancer patients with taste and/or smell (chemosensory) abnormalities.",
        "tokens": "['A', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', 'Controlled', 'Clinical', 'Trial', 'to', 'Evaluate', 'the', 'Efficacy', 'of', 'Orexigenic', 'Therapy', 'With', 'Delta-9', '-', 'tetrahydrocannabinol', 'in', 'Advanced', 'Cancer', 'Patients', 'With', 'Chemosensory', 'Abnormalities', '-', 'a', 'Pilot', 'Study', '|', 'To', 'investigate', 'delta-9', '-', 'tetrahydrocannabinol', \"'s\", '(', 'THC', ')', 'ability', 'to', 'increase', 'food', 'intake', 'and', 'improve', 'food', 'enjoyment', 'for', 'advanced', 'cancer', 'patients', 'with', 'taste', 'and/or', 'smell', '(', 'chemosensory', ')', 'abnormalities', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 90,
                "end": 108,
                "text": "Orexigenic Therapy",
                "type": "OTHER"
            },
            {
                "start": 114,
                "end": 142,
                "text": "Delta-9-tetrahydrocannabinol",
                "type": "DRUG"
            },
            {
                "start": 146,
                "end": 161,
                "text": "Advanced Cancer",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 202,
                "text": "Chemosensory Abnormalities",
                "type": "CONDITION"
            },
            {
                "start": 236,
                "end": 264,
                "text": "delta-9-tetrahydrocannabinol",
                "type": "DRUG"
            },
            {
                "start": 268,
                "end": 271,
                "text": "THC",
                "type": "DRUG"
            },
            {
                "start": 336,
                "end": 351,
                "text": "advanced cancer",
                "type": "CONDITION"
            },
            {
                "start": 366,
                "end": 413,
                "text": "taste and/or smell (chemosensory) abnormalities",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02552277",
        "study_official_title": "A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy. ",
        "study_brief_summary": " This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have diabetic peripheral neuropathy (DPN). The study will enroll approximately 24 subjects. Subjects will be randomized to receive one of 3 treatments: PDA-002 (3 x 10^6 cells), PDA-002 (30 x 10^6 cells), or placebo (vehicle control) in a 1:1:1 randomization approach. Investigational product or placebo will be administered monthly (3 administrations total on Study Days 1, 29, and 57).",
        "text": "A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy. | This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have diabetic peripheral neuropathy (DPN). The study will enroll approximately 24 subjects. Subjects will be randomized to receive one of 3 treatments: PDA-002 (3 x 10^6 cells), PDA-002 (30 x 10^6 cells), or placebo (vehicle control) in a 1:1:1 randomization approach. Investigational product or placebo will be administered monthly (3 administrations total on Study Days 1, 29, and 57).",
        "tokens": "['A', 'Phase', '2', ',', 'Randomized', ',', 'Double', 'Blind', ',', 'Placebo', 'Controlled', ',', 'Dose', 'Range', 'Finding', 'Study', 'to', 'Access', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Intramuscular', 'Injection', 'of', 'Human', 'Placenta-', 'Derived', 'Cells', '(', 'PDA-002', ')', 'in', 'Subjects', 'With', 'Diabetic', 'Peripheral', 'Neuropathy', '.', '|', 'This', 'is', 'a', 'Phase', '2', ',', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'dose', 'range', 'finding', 'study', 'in', 'subjects', 'who', 'have', 'diabetic', 'peripheral', 'neuropathy', '(', 'DPN', ')', '.', 'The', 'study', 'will', 'enroll', 'approximately', '24', 'subjects', '.', 'Subjects', 'will', 'be', 'randomized', 'to', 'receive', 'one', 'of', '3', 'treatments', ':', 'PDA-002', '(', '3', 'x', '10', '^', '6', 'cells', ')', ',', 'PDA-002', '(', '30', 'x', '10', '^', '6', 'cells', ')', ',', 'or', 'placebo', '(', 'vehicle', 'control', ')', 'in', 'a', '1:1:1', 'randomization', 'approach', '.', 'Investigational', 'product', 'or', 'placebo', 'will', 'be', 'administered', 'monthly', '(', '3', 'administrations', 'total', 'on', 'Study', 'Days', '1', ',', '29', ',', 'and', '57', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 44,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 146,
                "end": 175,
                "text": "Human Placenta- Derived Cells",
                "type": "SURGICAL"
            },
            {
                "start": 177,
                "end": 184,
                "text": "PDA-002",
                "type": "SURGICAL"
            },
            {
                "start": 203,
                "end": 233,
                "text": "Diabetic Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 282,
                "end": 289,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 348,
                "end": 378,
                "text": "diabetic peripheral neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 380,
                "end": 383,
                "text": "DPN",
                "type": "CONDITION"
            },
            {
                "start": 495,
                "end": 502,
                "text": "PDA-002",
                "type": "SURGICAL"
            },
            {
                "start": 521,
                "end": 528,
                "text": "PDA-002",
                "type": "SURGICAL"
            },
            {
                "start": 560,
                "end": 575,
                "text": "vehicle control",
                "type": "CONTROL"
            },
            {
                "start": 639,
                "end": 646,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05117034",
        "study_official_title": "Pre-emptive Intravenous Morphine for Acute Post-craniotomy Pain: a Randomized, Double-blind, Placebo-controlled Trial. ",
        "study_brief_summary": " We propose a double-blind randomized controlled trial to evaluate the effect of intravenously administered morphine at surgery conclusion on acute postoperative pain in patients recovering from craniotomy surgery. Participating adults having craniotomy surgery will be randomized in a 1:1 ratio to intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure, or a matching placebo.",
        "text": "Pre-emptive Intravenous Morphine for Acute Post-craniotomy Pain: a Randomized, Double-blind, Placebo-controlled Trial. | We propose a double-blind randomized controlled trial to evaluate the effect of intravenously administered morphine at surgery conclusion on acute postoperative pain in patients recovering from craniotomy surgery. Participating adults having craniotomy surgery will be randomized in a 1:1 ratio to intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure, or a matching placebo.",
        "tokens": "['Pre', '-', 'emptive', 'Intravenous', 'Morphine', 'for', 'Acute', 'Post', '-', 'craniotomy', 'Pain', ':', 'a', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', '.', '|', 'We', 'propose', 'a', 'double', '-', 'blind', 'randomized', 'controlled', 'trial', 'to', 'evaluate', 'the', 'effect', 'of', 'intravenously', 'administered', 'morphine', 'at', 'surgery', 'conclusion', 'on', 'acute', 'postoperative', 'pain', 'in', 'patients', 'recovering', 'from', 'craniotomy', 'surgery', '.', 'Participating', 'adults', 'having', 'craniotomy', 'surgery', 'will', 'be', 'randomized', 'in', 'a', '1:1', 'ratio', 'to', 'intraoperative', 'intravenous', 'administration', 'of', '0.08', 'mg', '/', 'kg', 'morphine', 'at', 'dura', 'closure', ',', 'or', 'a', 'matching', 'placebo', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 32,
                "text": "Morphine",
                "type": "DRUG"
            },
            {
                "start": 37,
                "end": 63,
                "text": "Acute Post-craniotomy Pain",
                "type": "CONDITION"
            },
            {
                "start": 93,
                "end": 100,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 228,
                "end": 236,
                "text": "morphine",
                "type": "DRUG"
            },
            {
                "start": 240,
                "end": 247,
                "text": "surgery",
                "type": "CONDITION"
            },
            {
                "start": 262,
                "end": 286,
                "text": "acute postoperative pain",
                "type": "CONDITION"
            },
            {
                "start": 315,
                "end": 333,
                "text": "craniotomy surgery",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 381,
                "text": "craniotomy surgery",
                "type": "CONDITION"
            },
            {
                "start": 475,
                "end": 483,
                "text": "morphine",
                "type": "DRUG"
            },
            {
                "start": 515,
                "end": 522,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03065192",
        "study_official_title": "An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa ",
        "study_brief_summary": " Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.",
        "text": "An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa | Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.",
        "tokens": "['An', 'Open', '-', 'label', 'Safety', 'and', 'Efficacy', 'Study', 'of', 'VY', '-', 'AADC01', 'Administered', 'by', 'MRI', '-', 'Guided', 'Convective', 'Infusion', 'Using', 'a', 'Posterior', 'Trajectory', 'Into', 'the', 'Putamen', 'of', 'Participants', 'With', 'Parkinson', \"'s\", 'Disease', 'With', 'Fluctuating', 'Responses', 'to', 'Levodopa', '|', 'Safety', 'and', 'efficacy', 'of', 'AADC', 'gene', 'transfer', 'in', 'participants', 'with', 'Parkinson', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 52,
                "text": "VY-AADC01",
                "type": "OTHER"
            },
            {
                "start": 167,
                "end": 186,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 192,
                "end": 225,
                "text": "Fluctuating Responses to Levodopa",
                "type": "CONDITION"
            },
            {
                "start": 251,
                "end": 269,
                "text": "AADC gene transfer",
                "type": "OTHER"
            },
            {
                "start": 291,
                "end": 310,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05527314",
        "study_official_title": "Effect of Total Intravenous Anesthesia With Remimazolam vs Sevoflurane Inhalation Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery ",
        "study_brief_summary": " As a novel ultra-short-acting benzodiazepines drugs, Remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, Remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aims to investigate whether Remimazolam reduces the incidence of emergence agitation in children after ophthalmic surgery, compared to sevoflurane (RCT).",
        "text": "Effect of Total Intravenous Anesthesia With Remimazolam vs Sevoflurane Inhalation Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery | As a novel ultra-short-acting benzodiazepines drugs, Remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, Remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aims to investigate whether Remimazolam reduces the incidence of emergence agitation in children after ophthalmic surgery, compared to sevoflurane (RCT).",
        "tokens": "['Effect', 'of', 'Total', 'Intravenous', 'Anesthesia', 'With', 'Remimazolam', 'vs', 'Sevoflurane', 'Inhalation', 'Anesthesia', 'on', 'Incidence', 'of', 'Emergence', 'Agitation', 'and', 'Complications', 'in', 'Children', 'Undergoing', 'Ophthalmic', 'Surgery', '|', 'As', 'a', 'novel', 'ultra', '-', 'short', '-', 'acting', 'benzodiazepines', 'drugs', ',', 'Remimazolam', 'has', 'been', 'accepted', 'for', 'induction', 'and', 'maintenance', 'of', 'clinical', 'anesthesia', '.', 'Compared', 'to', 'the', 'traditional', 'benzodiazepines', 'drugs', ',', 'Remimazolam', 'combines', 'the', 'safety', 'of', 'midazolam', 'with', 'the', 'effectiveness', 'of', 'propofol', ',', 'and', 'also', 'has', 'the', 'advantages', 'of', 'acting', 'quickly', ',', 'short', 'half', '-', 'life', ',', 'no', 'injection', 'pain', ',', 'slight', 'respiratory', 'depression', ',', 'independent', 'of', 'liver', 'and', 'kidney', 'metabolism', ',', 'long', '-', 'term', 'infusion', 'without', 'accumulation', ',', 'and', 'has', 'a', 'specific', 'antagonist', ':', 'flumazenil', '.', 'This', 'study', 'aims', 'to', 'investigate', 'whether', 'Remimazolam', 'reduces', 'the', 'incidence', 'of', 'emergence', 'agitation', 'in', 'children', 'after', 'ophthalmic', 'surgery', ',', 'compared', 'to', 'sevoflurane', '(', 'RCT', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 44,
                "end": 55,
                "text": "Remimazolam",
                "type": "DRUG"
            },
            {
                "start": 59,
                "end": 70,
                "text": "Sevoflurane",
                "type": "DRUG"
            },
            {
                "start": 119,
                "end": 128,
                "text": "Agitation",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 188,
                "text": "Ophthalmic Surgery",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 236,
                "text": "benzodiazepines",
                "type": "DRUG"
            },
            {
                "start": 244,
                "end": 255,
                "text": "Remimazolam",
                "type": "DRUG"
            },
            {
                "start": 356,
                "end": 371,
                "text": "benzodiazepines",
                "type": "DRUG"
            },
            {
                "start": 379,
                "end": 390,
                "text": "Remimazolam",
                "type": "DRUG"
            },
            {
                "start": 741,
                "end": 752,
                "text": "Remimazolam",
                "type": "DRUG"
            },
            {
                "start": 778,
                "end": 797,
                "text": "emergence agitation",
                "type": "CONDITION"
            },
            {
                "start": 816,
                "end": 834,
                "text": "ophthalmic surgery",
                "type": "CONDITION"
            },
            {
                "start": 848,
                "end": 859,
                "text": "sevoflurane",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT01586455",
        "study_official_title": "A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders ",
        "study_brief_summary": " The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.",
        "text": "A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders | The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.",
        "tokens": "['A', 'Single', '-', 'Arm', 'Study', 'to', 'Assess', 'the', 'Safety', 'of', 'Transplantation', 'With', 'Human', 'Placental', '-', 'Derived', 'Stem', '-', 'Cells', 'Combined', 'With', 'Unrelated', 'and', 'Related', 'Cord', 'Blood', 'in', 'Subjects', 'With', 'Certain', 'Malignant', 'Hematologic', 'Diseases', 'and', 'Non', '-', 'Malignant', 'Disorders', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'investigate', 'the', 'safety', 'of', 'human', 'placental', '-', 'derived', 'stem', 'cells', '(', 'HPDSC', ')', 'given', 'in', 'conjunction', 'with', 'umbilical', 'cord', 'blood', '(', 'UCB', ')', 'stem', 'cells', 'in', 'patients', 'with', 'various', 'malignant', 'or', 'nonmalignant', 'disorders', 'who', 'require', 'a', 'stem', 'cell', 'transplant', '.', 'Patients', 'will', 'get', 'either', 'full', 'dose', '(', 'high', '-', 'intensity', ')', 'or', 'lower', 'dose', '(', 'low', 'intensity', ')', 'chemo-', 'and', 'immunotherapy', 'followed', 'by', 'a', 'stem', 'cell', 'transplantation', 'with', 'UCB', 'and', 'HPDSC', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-SURG', 'O']",
        "entities": [
            {
                "start": 64,
                "end": 98,
                "text": "Human Placental-Derived Stem-Cells",
                "type": "SURGICAL"
            },
            {
                "start": 113,
                "end": 145,
                "text": "Unrelated and Related Cord Blood",
                "type": "SURGICAL"
            },
            {
                "start": 171,
                "end": 201,
                "text": "Malignant Hematologic Diseases",
                "type": "CONDITION"
            },
            {
                "start": 206,
                "end": 229,
                "text": "Non-Malignant Disorders",
                "type": "CONDITION"
            },
            {
                "start": 299,
                "end": 333,
                "text": "human placental-derived stem cells",
                "type": "SURGICAL"
            },
            {
                "start": 335,
                "end": 340,
                "text": "HPDSC",
                "type": "SURGICAL"
            },
            {
                "start": 368,
                "end": 405,
                "text": "umbilical cord blood (UCB) stem cells",
                "type": "SURGICAL"
            },
            {
                "start": 444,
                "end": 466,
                "text": "nonmalignant disorders",
                "type": "CONDITION"
            },
            {
                "start": 585,
                "end": 609,
                "text": "chemo- and immunotherapy",
                "type": "DRUG"
            },
            {
                "start": 655,
                "end": 658,
                "text": "UCB",
                "type": "SURGICAL"
            },
            {
                "start": 663,
                "end": 668,
                "text": "HPDSC",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT03092570",
        "study_official_title": "Assessment of Cerebellar Stimulation Effect on Motor Learning in Ageing Population and Stroke Patients ",
        "study_brief_summary": " This study will assess the putative advantages of cerebellar stimulation on motor learning abilities of stroke patients. In order to have a control group to refer to, the effect of cerebellar stimulation on healthy young and old participants will also be assessed.",
        "text": "Assessment of Cerebellar Stimulation Effect on Motor Learning in Ageing Population and Stroke Patients | This study will assess the putative advantages of cerebellar stimulation on motor learning abilities of stroke patients. In order to have a control group to refer to, the effect of cerebellar stimulation on healthy young and old participants will also be assessed.",
        "tokens": "['Assessment', 'of', 'Cerebellar', 'Stimulation', 'Effect', 'on', 'Motor', 'Learning', 'in', 'Ageing', 'Population', 'and', 'Stroke', 'Patients', '|', 'This', 'study', 'will', 'assess', 'the', 'putative', 'advantages', 'of', 'cerebellar', 'stimulation', 'on', 'motor', 'learning', 'abilities', 'of', 'stroke', 'patients', '.', 'In', 'order', 'to', 'have', 'a', 'control', 'group', 'to', 'refer', 'to', ',', 'the', 'effect', 'of', 'cerebellar', 'stimulation', 'on', 'healthy', 'young', 'and', 'old', 'participants', 'will', 'also', 'be', 'assessed', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 36,
                "text": "Cerebellar Stimulation",
                "type": "OTHER"
            },
            {
                "start": 87,
                "end": 93,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 177,
                "text": "cerebellar stimulation",
                "type": "OTHER"
            },
            {
                "start": 209,
                "end": 215,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 286,
                "end": 308,
                "text": "cerebellar stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05733312",
        "study_official_title": "Intraoperative Evaluation of Focused Ultrasound-induced Blood-brain Barrier Disruption ",
        "study_brief_summary": " This study seeks to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment. Researchers will evaluate regions that are very abnormal, as well as regions that have less evidence of disease. A sub-portion of each of these areas will be targeted by focused ultrasound. Microdialysis catheters will then be placd into each region that has and has not been exposed to FUS (total of 4 catheters) to determine how FUS impacts the the brain and tumor extracellular metabolome, including concentration of routine drugs systemically administered prior to, and during surgery. Researchers hope that this information will help reveal the relative contribution of blood-derived compounds to the tumor microenvironment. If successful, microdialysis could be leveraged in the future to simultaneously evaluate pharmacokinetic and pharmacodynamic impacts of future candidate therapies, including those delivered with the aid of FUS.",
        "text": "Intraoperative Evaluation of Focused Ultrasound-induced Blood-brain Barrier Disruption | This study seeks to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment. Researchers will evaluate regions that are very abnormal, as well as regions that have less evidence of disease. A sub-portion of each of these areas will be targeted by focused ultrasound. Microdialysis catheters will then be placd into each region that has and has not been exposed to FUS (total of 4 catheters) to determine how FUS impacts the the brain and tumor extracellular metabolome, including concentration of routine drugs systemically administered prior to, and during surgery. Researchers hope that this information will help reveal the relative contribution of blood-derived compounds to the tumor microenvironment. If successful, microdialysis could be leveraged in the future to simultaneously evaluate pharmacokinetic and pharmacodynamic impacts of future candidate therapies, including those delivered with the aid of FUS.",
        "tokens": "['Intraoperative', 'Evaluation', 'of', 'Focused', 'Ultrasound', '-', 'induced', 'Blood', '-', 'brain', 'Barrier', 'Disruption', '|', 'This', 'study', 'seeks', 'to', 'determine', 'the', 'impact', 'of', 'focused', 'ultrasound', '(', 'FUS', ')', 'on', 'the', 'composition', 'of', 'the', 'tumor', 'extracellular', 'microenvironment', '.', 'Researchers', 'will', 'evaluate', 'regions', 'that', 'are', 'very', 'abnormal', ',', 'as', 'well', 'as', 'regions', 'that', 'have', 'less', 'evidence', 'of', 'disease', '.', 'A', 'sub', '-', 'portion', 'of', 'each', 'of', 'these', 'areas', 'will', 'be', 'targeted', 'by', 'focused', 'ultrasound', '.', 'Microdialysis', 'catheters', 'will', 'then', 'be', 'placd', 'into', 'each', 'region', 'that', 'has', 'and', 'has', 'not', 'been', 'exposed', 'to', 'FUS', '(', 'total', 'of', '4', 'catheters', ')', 'to', 'determine', 'how', 'FUS', 'impacts', 'the', 'the', 'brain', 'and', 'tumor', 'extracellular', 'metabolome', ',', 'including', 'concentration', 'of', 'routine', 'drugs', 'systemically', 'administered', 'prior', 'to', ',', 'and', 'during', 'surgery', '.', 'Researchers', 'hope', 'that', 'this', 'information', 'will', 'help', 'reveal', 'the', 'relative', 'contribution', 'of', 'blood', '-', 'derived', 'compounds', 'to', 'the', 'tumor', 'microenvironment', '.', 'If', 'successful', ',', 'microdialysis', 'could', 'be', 'leveraged', 'in', 'the', 'future', 'to', 'simultaneously', 'evaluate', 'pharmacokinetic', 'and', 'pharmacodynamic', 'impacts', 'of', 'future', 'candidate', 'therapies', ',', 'including', 'those', 'delivered', 'with', 'the', 'aid', 'of', 'FUS', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 86,
                "text": "Focused Ultrasound-induced Blood-brain Barrier Disruption",
                "type": "OTHER"
            },
            {
                "start": 133,
                "end": 151,
                "text": "focused ultrasound",
                "type": "OTHER"
            },
            {
                "start": 153,
                "end": 156,
                "text": "FUS",
                "type": "OTHER"
            },
            {
                "start": 184,
                "end": 189,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 392,
                "end": 410,
                "text": "focused ultrasound",
                "type": "OTHER"
            },
            {
                "start": 509,
                "end": 512,
                "text": "FUS",
                "type": "OTHER"
            },
            {
                "start": 553,
                "end": 556,
                "text": "FUS",
                "type": "OTHER"
            },
            {
                "start": 583,
                "end": 588,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 828,
                "end": 833,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 1058,
                "end": 1061,
                "text": "FUS",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05281120",
        "study_official_title": "Low-level Mechanical Vibration, Bone Density, Bone Resorption and Muscular Strength in Ambulant Children Affected by Duchenne Muscular Dystrophy ",
        "study_brief_summary": " Duchenne muscular dystrophy (DMD) is a X-linked recessive disorder due to a mutation of the dystrophin gene (Xp21). Dystrophin is a sarcolemmal protein of skeletal and cardiac muscle, and its absence causes progressive muscle degeneration and substitution with fat and connective tissue. The progressive muscle degeneration leads to loss of autonomous walking before the age of 15 years and death for cardiac and/or respiratory failure. There are no specific treatment for DMD, and the standard of care is now based on long-term corticosteroid (CS) use. The studies on bone mass in DMD are very few, but they agree in reporting the presence of a reduced bone mass and an increased rate of fractures probably due to long-term steroid therapy and disuse-osteopenia. The aim of this study, involving 20 ambulant DMD boys (age 7-10 years) has been the evaluation of the effects of low-level mechanical vibrations on bone in a group of ambulant DMD children for 1 year, with RDA-adjusted dietary calcium intake and 25OH vitamin D supplementation.",
        "text": "Low-level Mechanical Vibration, Bone Density, Bone Resorption and Muscular Strength in Ambulant Children Affected by Duchenne Muscular Dystrophy | Duchenne muscular dystrophy (DMD) is a X-linked recessive disorder due to a mutation of the dystrophin gene (Xp21). Dystrophin is a sarcolemmal protein of skeletal and cardiac muscle, and its absence causes progressive muscle degeneration and substitution with fat and connective tissue. The progressive muscle degeneration leads to loss of autonomous walking before the age of 15 years and death for cardiac and/or respiratory failure. There are no specific treatment for DMD, and the standard of care is now based on long-term corticosteroid (CS) use. The studies on bone mass in DMD are very few, but they agree in reporting the presence of a reduced bone mass and an increased rate of fractures probably due to long-term steroid therapy and disuse-osteopenia. The aim of this study, involving 20 ambulant DMD boys (age 7-10 years) has been the evaluation of the effects of low-level mechanical vibrations on bone in a group of ambulant DMD children for 1 year, with RDA-adjusted dietary calcium intake and 25OH vitamin D supplementation.",
        "tokens": "['Low', '-', 'level', 'Mechanical', 'Vibration', ',', 'Bone', 'Density', ',', 'Bone', 'Resorption', 'and', 'Muscular', 'Strength', 'in', 'Ambulant', 'Children', 'Affected', 'by', 'Duchenne', 'Muscular', 'Dystrophy', '|', 'Duchenne', 'muscular', 'dystrophy', '(', 'DMD', ')', 'is', 'a', 'X', '-', 'linked', 'recessive', 'disorder', 'due', 'to', 'a', 'mutation', 'of', 'the', 'dystrophin', 'gene', '(', 'Xp21', ')', '.', 'Dystrophin', 'is', 'a', 'sarcolemmal', 'protein', 'of', 'skeletal', 'and', 'cardiac', 'muscle', ',', 'and', 'its', 'absence', 'causes', 'progressive', 'muscle', 'degeneration', 'and', 'substitution', 'with', 'fat', 'and', 'connective', 'tissue', '.', 'The', 'progressive', 'muscle', 'degeneration', 'leads', 'to', 'loss', 'of', 'autonomous', 'walking', 'before', 'the', 'age', 'of', '15', 'years', 'and', 'death', 'for', 'cardiac', 'and/or', 'respiratory', 'failure', '.', 'There', 'are', 'no', 'specific', 'treatment', 'for', 'DMD', ',', 'and', 'the', 'standard', 'of', 'care', 'is', 'now', 'based', 'on', 'long', '-', 'term', 'corticosteroid', '(', 'CS', ')', 'use', '.', 'The', 'studies', 'on', 'bone', 'mass', 'in', 'DMD', 'are', 'very', 'few', ',', 'but', 'they', 'agree', 'in', 'reporting', 'the', 'presence', 'of', 'a', 'reduced', 'bone', 'mass', 'and', 'an', 'increased', 'rate', 'of', 'fractures', 'probably', 'due', 'to', 'long', '-', 'term', 'steroid', 'therapy', 'and', 'disuse', '-', 'osteopenia', '.', 'The', 'aim', 'of', 'this', 'study', ',', 'involving', '20', 'ambulant', 'DMD', 'boys', '(', 'age', '7', '-', '10', 'years', ')', 'has', 'been', 'the', 'evaluation', 'of', 'the', 'effects', 'of', 'low', '-', 'level', 'mechanical', 'vibrations', 'on', 'bone', 'in', 'a', 'group', 'of', 'ambulant', 'DMD', 'children', 'for', '1', 'year', ',', 'with', 'RDA', '-', 'adjusted', 'dietary', 'calcium', 'intake', 'and', '25OH', 'vitamin', 'D', 'supplementation', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 30,
                "text": "Low-level Mechanical Vibration",
                "type": "OTHER"
            },
            {
                "start": 117,
                "end": 144,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 147,
                "end": 174,
                "text": "Duchenne muscular dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 179,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 385,
                "text": "progressive muscle degeneration",
                "type": "CONDITION"
            },
            {
                "start": 439,
                "end": 470,
                "text": "progressive muscle degeneration",
                "type": "CONDITION"
            },
            {
                "start": 620,
                "end": 623,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 729,
                "end": 732,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 956,
                "end": 959,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 1024,
                "end": 1055,
                "text": "low-level mechanical vibrations",
                "type": "OTHER"
            },
            {
                "start": 1087,
                "end": 1090,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 1138,
                "end": 1145,
                "text": "calcium",
                "type": "DRUG"
            },
            {
                "start": 1157,
                "end": 1171,
                "text": "25OH vitamin D",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05539287",
        "study_official_title": "Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy ",
        "study_brief_summary": " Animal and human studies have brought up evidence supporting Gut microbial disbalance, namely dysbiosis, as a causative factor of epilepsy, especially the refractory form. thus, probiotics might constitute a safe, low-cost, and effective supplementary therapy in patients with DRE.\n\nThe Lactobacillus population is probiotic bacteria that have a beneficial role in epilepsy. Lactobacillus can influence brain function through the modulation of GABA, as shown in rodent models. Moreover, it has been demonstrated in animal models of epilepsy and in human epileptic patients that probiotic treatment aimed at restoring gut microbiota equilibrium has beneficial effects on epileptic symptoms by increasing GABA in animals and the levels of Bifidobacteria and Lactobacillus in humans.",
        "text": "Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy | Animal and human studies have brought up evidence supporting Gut microbial disbalance, namely dysbiosis, as a causative factor of epilepsy, especially the refractory form. thus, probiotics might constitute a safe, low-cost, and effective supplementary therapy in patients with DRE.\n\nThe Lactobacillus population is probiotic bacteria that have a beneficial role in epilepsy. Lactobacillus can influence brain function through the modulation of GABA, as shown in rodent models. Moreover, it has been demonstrated in animal models of epilepsy and in human epileptic patients that probiotic treatment aimed at restoring gut microbiota equilibrium has beneficial effects on epileptic symptoms by increasing GABA in animals and the levels of Bifidobacteria and Lactobacillus in humans.",
        "tokens": "['Clinical', 'Study', 'Evaluating', 'the', 'Safety', 'of', 'Lactobacillus', 'Probiotic', 'in', 'Children', 'With', 'Drug', 'Resistant', 'Epilepsy', '|', 'Animal', 'and', 'human', 'studies', 'have', 'brought', 'up', 'evidence', 'supporting', 'Gut', 'microbial', 'disbalance', ',', 'namely', 'dysbiosis', ',', 'as', 'a', 'causative', 'factor', 'of', 'epilepsy', ',', 'especially', 'the', 'refractory', 'form', '.', 'thus', ',', 'probiotics', 'might', 'constitute', 'a', 'safe', ',', 'low', '-', 'cost', ',', 'and', 'effective', 'supplementary', 'therapy', 'in', 'patients', 'with', 'DRE', '.', '\\n\\n', 'The', 'Lactobacillus', 'population', 'is', 'probiotic', 'bacteria', 'that', 'have', 'a', 'beneficial', 'role', 'in', 'epilepsy', '.', 'Lactobacillus', 'can', 'influence', 'brain', 'function', 'through', 'the', 'modulation', 'of', 'GABA', ',', 'as', 'shown', 'in', 'rodent', 'models', '.', 'Moreover', ',', 'it', 'has', 'been', 'demonstrated', 'in', 'animal', 'models', 'of', 'epilepsy', 'and', 'in', 'human', 'epileptic', 'patients', 'that', 'probiotic', 'treatment', 'aimed', 'at', 'restoring', 'gut', 'microbiota', 'equilibrium', 'has', 'beneficial', 'effects', 'on', 'epileptic', 'symptoms', 'by', 'increasing', 'GABA', 'in', 'animals', 'and', 'the', 'levels', 'of', 'Bifidobacteria', 'and', 'Lactobacillus', 'in', 'humans', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 40,
                "end": 63,
                "text": "Lactobacillus Probiotic",
                "type": "OTHER"
            },
            {
                "start": 81,
                "end": 104,
                "text": "Drug Resistant Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 210,
                "text": "dysbiosis",
                "type": "CONDITION"
            },
            {
                "start": 237,
                "end": 245,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 285,
                "end": 295,
                "text": "probiotics",
                "type": "OTHER"
            },
            {
                "start": 384,
                "end": 387,
                "text": "DRE",
                "type": "CONDITION"
            },
            {
                "start": 394,
                "end": 418,
                "text": "Lactobacillus population",
                "type": "OTHER"
            },
            {
                "start": 422,
                "end": 440,
                "text": "probiotic bacteria",
                "type": "OTHER"
            },
            {
                "start": 472,
                "end": 480,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 482,
                "end": 495,
                "text": "Lactobacillus",
                "type": "OTHER"
            },
            {
                "start": 639,
                "end": 647,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 661,
                "end": 670,
                "text": "epileptic",
                "type": "CONDITION"
            },
            {
                "start": 685,
                "end": 704,
                "text": "probiotic treatment",
                "type": "OTHER"
            },
            {
                "start": 777,
                "end": 786,
                "text": "epileptic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00599469",
        "study_official_title": "Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease. ",
        "study_brief_summary": " Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.",
        "text": "Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease. | Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.",
        "tokens": "['Phase', '1', 'Study', 'to', 'Determine', 'the', 'Efficacy', 'of', 'Using', 'Far', 'Infrared', 'Radiation', 'for', 'the', 'Treatment', 'of', 'Alzheimer', \"'s\", 'Disease', '.', '|', 'Alzheimer', \"'s\", 'disease', 'is', 'a', 'progressive', 'and', 'fatal', 'brain', 'disease', '.', 'This', 'study', 'will', 'investigate', 'the', 'use', 'of', 'far', 'infrared', 'radiation', 'treatment', 'for', 'the', 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 49,
                "end": 71,
                "text": "Far Infrared Radiation",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 93,
                "end": 112,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 116,
                "end": 135,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 217,
                "end": 239,
                "text": "far infrared radiation",
                "type": "RADIOTHERAPY"
            }
        ]
    },
    {
        "nctid": "NCT01822938",
        "study_official_title": "Follow-up of Patients' Physical Activity in Post-hospitalization by Implementation of Systems of Active Monitoring. ",
        "study_brief_summary": " Physical exercise has been identified as a major item of many affecting many chronic diseases and stroke rehabilitation. It contributes to an improvement in the quality of life and to a decrease in the current treatment side-effects and mortality. Stroke in association with an inactive lifestyle lead to a decrease in physical capability and causes problems in daily activities. The physical capacity and the tolerance for exercise fall simultaneously leading to vicious circle of less and less mobility. Therefore, physical activity for the health is a valid and relevant way to improve the quality of life and to recover functional capacity. The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke.",
        "text": "Follow-up of Patients' Physical Activity in Post-hospitalization by Implementation of Systems of Active Monitoring. | Physical exercise has been identified as a major item of many affecting many chronic diseases and stroke rehabilitation. It contributes to an improvement in the quality of life and to a decrease in the current treatment side-effects and mortality. Stroke in association with an inactive lifestyle lead to a decrease in physical capability and causes problems in daily activities. The physical capacity and the tolerance for exercise fall simultaneously leading to vicious circle of less and less mobility. Therefore, physical activity for the health is a valid and relevant way to improve the quality of life and to recover functional capacity. The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke.",
        "tokens": "['Follow', '-', 'up', 'of', 'Patients', \"'\", 'Physical', 'Activity', 'in', 'Post', '-', 'hospitalization', 'by', 'Implementation', 'of', 'Systems', 'of', 'Active', 'Monitoring', '.', '|', 'Physical', 'exercise', 'has', 'been', 'identified', 'as', 'a', 'major', 'item', 'of', 'many', 'affecting', 'many', 'chronic', 'diseases', 'and', 'stroke', 'rehabilitation', '.', 'It', 'contributes', 'to', 'an', 'improvement', 'in', 'the', 'quality', 'of', 'life', 'and', 'to', 'a', 'decrease', 'in', 'the', 'current', 'treatment', 'side', '-', 'effects', 'and', 'mortality', '.', 'Stroke', 'in', 'association', 'with', 'an', 'inactive', 'lifestyle', 'lead', 'to', 'a', 'decrease', 'in', 'physical', 'capability', 'and', 'causes', 'problems', 'in', 'daily', 'activities', '.', 'The', 'physical', 'capacity', 'and', 'the', 'tolerance', 'for', 'exercise', 'fall', 'simultaneously', 'leading', 'to', 'vicious', 'circle', 'of', 'less', 'and', 'less', 'mobility', '.', 'Therefore', ',', 'physical', 'activity', 'for', 'the', 'health', 'is', 'a', 'valid', 'and', 'relevant', 'way', 'to', 'improve', 'the', 'quality', 'of', 'life', 'and', 'to', 'recover', 'functional', 'capacity', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'the', 'assessment', 'of', 'the', 'effects', 'of', 'a', 'incentive', 'program', 'for', 'physical', 'activity', 'on', 'people', 'following', '/', 'with', 'stroke', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 86,
                "end": 114,
                "text": "Systems of Active Monitoring",
                "type": "OTHER"
            },
            {
                "start": 216,
                "end": 222,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 366,
                "end": 372,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 822,
                "end": 861,
                "text": "incentive program for physical activity",
                "type": "OTHER"
            },
            {
                "start": 887,
                "end": 893,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02899858",
        "study_official_title": "Restoration of Standing and Walking With ISMS in Humans ",
        "study_brief_summary": " Spinal cord neural circuitry exists in the lumbar enlargement that makes it possible to stand and create synergistic, rhythmic stepping activity in the lower limbs. In the past 20 years, clinicians have tried to reengage such these circuits for standing and walking in the lower spinal cord of paralyzed humans through novel paradigms of physical therapy, pharmacological stimulation of the spinal cord, or recently - epidural stimulation of the spinal cord. Although standing and stepping with these maneuvers are rudimentary at best, these human studies offer promise to restore controlled, lower extremity movement to the spinal cord injured (SCI) individual. Evidence from animal data suggests that more focal activation of intraspinal circuitry (IntraSpinal Micro-Stimulation - ISMS) would produce more fatigue resistant, natural standing and stepping activity in humans. To date, there has been no direct confirmation of such circuitry in the spinal cord of bipedal humans who have been paralyzed. Furthermore, mapping of such circuitry would provide the basis of a novel intraspinal neuroprosthetic that should be able to restore control of standing or walking in a manner that is much more physiologically normal and tolerable than by stimulating each individual muscle group. Proof of the existence of these spinal circuits in man, and the ability to activate and control these circuits by first mapping the spinal cord is the basis of this proposal.",
        "text": "Restoration of Standing and Walking With ISMS in Humans | Spinal cord neural circuitry exists in the lumbar enlargement that makes it possible to stand and create synergistic, rhythmic stepping activity in the lower limbs. In the past 20 years, clinicians have tried to reengage such these circuits for standing and walking in the lower spinal cord of paralyzed humans through novel paradigms of physical therapy, pharmacological stimulation of the spinal cord, or recently - epidural stimulation of the spinal cord. Although standing and stepping with these maneuvers are rudimentary at best, these human studies offer promise to restore controlled, lower extremity movement to the spinal cord injured (SCI) individual. Evidence from animal data suggests that more focal activation of intraspinal circuitry (IntraSpinal Micro-Stimulation - ISMS) would produce more fatigue resistant, natural standing and stepping activity in humans. To date, there has been no direct confirmation of such circuitry in the spinal cord of bipedal humans who have been paralyzed. Furthermore, mapping of such circuitry would provide the basis of a novel intraspinal neuroprosthetic that should be able to restore control of standing or walking in a manner that is much more physiologically normal and tolerable than by stimulating each individual muscle group. Proof of the existence of these spinal circuits in man, and the ability to activate and control these circuits by first mapping the spinal cord is the basis of this proposal.",
        "tokens": "['Restoration', 'of', 'Standing', 'and', 'Walking', 'With', 'ISMS', 'in', 'Humans', '|', 'Spinal', 'cord', 'neural', 'circuitry', 'exists', 'in', 'the', 'lumbar', 'enlargement', 'that', 'makes', 'it', 'possible', 'to', 'stand', 'and', 'create', 'synergistic', ',', 'rhythmic', 'stepping', 'activity', 'in', 'the', 'lower', 'limbs', '.', 'In', 'the', 'past', '20', 'years', ',', 'clinicians', 'have', 'tried', 'to', 'reengage', 'such', 'these', 'circuits', 'for', 'standing', 'and', 'walking', 'in', 'the', 'lower', 'spinal', 'cord', 'of', 'paralyzed', 'humans', 'through', 'novel', 'paradigms', 'of', 'physical', 'therapy', ',', 'pharmacological', 'stimulation', 'of', 'the', 'spinal', 'cord', ',', 'or', 'recently', '-', 'epidural', 'stimulation', 'of', 'the', 'spinal', 'cord', '.', 'Although', 'standing', 'and', 'stepping', 'with', 'these', 'maneuvers', 'are', 'rudimentary', 'at', 'best', ',', 'these', 'human', 'studies', 'offer', 'promise', 'to', 'restore', 'controlled', ',', 'lower', 'extremity', 'movement', 'to', 'the', 'spinal', 'cord', 'injured', '(', 'SCI', ')', 'individual', '.', 'Evidence', 'from', 'animal', 'data', 'suggests', 'that', 'more', 'focal', 'activation', 'of', 'intraspinal', 'circuitry', '(', 'IntraSpinal', 'Micro', '-', 'Stimulation', '-', 'ISMS', ')', 'would', 'produce', 'more', 'fatigue', 'resistant', ',', 'natural', 'standing', 'and', 'stepping', 'activity', 'in', 'humans', '.', 'To', 'date', ',', 'there', 'has', 'been', 'no', 'direct', 'confirmation', 'of', 'such', 'circuitry', 'in', 'the', 'spinal', 'cord', 'of', 'bipedal', 'humans', 'who', 'have', 'been', 'paralyzed', '.', 'Furthermore', ',', 'mapping', 'of', 'such', 'circuitry', 'would', 'provide', 'the', 'basis', 'of', 'a', 'novel', 'intraspinal', 'neuroprosthetic', 'that', 'should', 'be', 'able', 'to', 'restore', 'control', 'of', 'standing', 'or', 'walking', 'in', 'a', 'manner', 'that', 'is', 'much', 'more', 'physiologically', 'normal', 'and', 'tolerable', 'than', 'by', 'stimulating', 'each', 'individual', 'muscle', 'group', '.', 'Proof', 'of', 'the', 'existence', 'of', 'these', 'spinal', 'circuits', 'in', 'man', ',', 'and', 'the', 'ability', 'to', 'activate', 'and', 'control', 'these', 'circuits', 'by', 'first', 'mapping', 'the', 'spinal', 'cord', 'is', 'the', 'basis', 'of', 'this', 'proposal', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 45,
                "text": "ISMS",
                "type": "OTHER"
            },
            {
                "start": 352,
                "end": 361,
                "text": "paralyzed",
                "type": "CONDITION"
            },
            {
                "start": 683,
                "end": 702,
                "text": "spinal cord injured",
                "type": "CONDITION"
            },
            {
                "start": 704,
                "end": 707,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 766,
                "end": 807,
                "text": "focal activation of intraspinal circuitry",
                "type": "OTHER"
            },
            {
                "start": 809,
                "end": 838,
                "text": "IntraSpinal Micro-Stimulation",
                "type": "OTHER"
            },
            {
                "start": 841,
                "end": 845,
                "text": "ISMS",
                "type": "OTHER"
            },
            {
                "start": 1051,
                "end": 1060,
                "text": "paralyzed",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01458470",
        "study_official_title": "A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study ",
        "study_brief_summary": " Huntington disease is characterized by difficulties in movement and thinking. Psychological disturbances including irritability, aggression, loss of interest, depressed mood, obsessions and compulsions, also represent common symptoms of HD. These symptoms are distressing both for HD patients and their caregivers, contribute to the loss of ability to carry out activities of daily living, and present a major treatment challenge for physicians. The goal of this study is to determine the effect of memantine on movement, thinking and emotional difficulties in HD patients. Memantine is a medication originally approved for the treatment of aggression and agitation in patients with moderate-to-severe Alzheimer's disease (AD), which has also recently been shown to improve the behavioural and neuropathological symptoms in a mouse model of Huntington Disease (HD).",
        "text": "A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study | Huntington disease is characterized by difficulties in movement and thinking. Psychological disturbances including irritability, aggression, loss of interest, depressed mood, obsessions and compulsions, also represent common symptoms of HD. These symptoms are distressing both for HD patients and their caregivers, contribute to the loss of ability to carry out activities of daily living, and present a major treatment challenge for physicians. The goal of this study is to determine the effect of memantine on movement, thinking and emotional difficulties in HD patients. Memantine is a medication originally approved for the treatment of aggression and agitation in patients with moderate-to-severe Alzheimer's disease (AD), which has also recently been shown to improve the behavioural and neuropathological symptoms in a mouse model of Huntington Disease (HD).",
        "tokens": "['A', 'Trial', 'of', 'Memantine', 'as', 'Symptomatic', 'Treatment', 'for', 'Early', 'Huntington', 'Disease', ';', 'a', 'Phase', 'IIb', 'Study', '|', 'Huntington', 'disease', 'is', 'characterized', 'by', 'difficulties', 'in', 'movement', 'and', 'thinking', '.', 'Psychological', 'disturbances', 'including', 'irritability', ',', 'aggression', ',', 'loss', 'of', 'interest', ',', 'depressed', 'mood', ',', 'obsessions', 'and', 'compulsions', ',', 'also', 'represent', 'common', 'symptoms', 'of', 'HD', '.', 'These', 'symptoms', 'are', 'distressing', 'both', 'for', 'HD', 'patients', 'and', 'their', 'caregivers', ',', 'contribute', 'to', 'the', 'loss', 'of', 'ability', 'to', 'carry', 'out', 'activities', 'of', 'daily', 'living', ',', 'and', 'present', 'a', 'major', 'treatment', 'challenge', 'for', 'physicians', '.', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'memantine', 'on', 'movement', ',', 'thinking', 'and', 'emotional', 'difficulties', 'in', 'HD', 'patients', '.', 'Memantine', 'is', 'a', 'medication', 'originally', 'approved', 'for', 'the', 'treatment', 'of', 'aggression', 'and', 'agitation', 'in', 'patients', 'with', 'moderate', '-', 'to', '-', 'severe', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', ',', 'which', 'has', 'also', 'recently', 'been', 'shown', 'to', 'improve', 'the', 'behavioural', 'and', 'neuropathological', 'symptoms', 'in', 'a', 'mouse', 'model', 'of', 'Huntington', 'Disease', '(', 'HD', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 20,
                "text": "Memantine",
                "type": "DRUG"
            },
            {
                "start": 50,
                "end": 74,
                "text": "Early Huntington Disease",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 114,
                "text": "Huntington disease",
                "type": "CONDITION"
            },
            {
                "start": 211,
                "end": 223,
                "text": "irritability",
                "type": "CONDITION"
            },
            {
                "start": 225,
                "end": 235,
                "text": "aggression",
                "type": "CONDITION"
            },
            {
                "start": 237,
                "end": 253,
                "text": "loss of interest",
                "type": "CONDITION"
            },
            {
                "start": 255,
                "end": 264,
                "text": "depressed",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 281,
                "text": "obsessions",
                "type": "CONDITION"
            },
            {
                "start": 286,
                "end": 297,
                "text": "compulsions",
                "type": "CONDITION"
            },
            {
                "start": 333,
                "end": 335,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 377,
                "end": 379,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 595,
                "end": 604,
                "text": "memantine",
                "type": "DRUG"
            },
            {
                "start": 657,
                "end": 659,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 670,
                "end": 679,
                "text": "Memantine",
                "type": "DRUG"
            },
            {
                "start": 737,
                "end": 747,
                "text": "aggression",
                "type": "CONDITION"
            },
            {
                "start": 752,
                "end": 761,
                "text": "agitation",
                "type": "CONDITION"
            },
            {
                "start": 937,
                "end": 955,
                "text": "Huntington Disease",
                "type": "CONDITION"
            },
            {
                "start": 957,
                "end": 959,
                "text": "HD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03985761",
        "study_official_title": "Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke ",
        "study_brief_summary": " This trial studies the impact of motivational strategies designed by the gaming industry on adherence to a home tele-rehabilitation program designed to improve hand function in persons with stroke. A growing literature suggests that the extended practice of challenging hand tasks can produce measurable changes in hand function in persons with stroke. Current health care delivery systems do not support this volume of directly supervised rehabilitation, making it necessary for patients to perform a substantial amount of activity at home, unsupervised. Unfortunately, adherence to unsupervised home exercise regimens is quite poor in this population. The investigator's goal is to assess the impact of several well-established game design strategies: 1) Scaffolded increases in game difficulty 2) In-game rewards 3) Quests with enhanced narrative. The investigator's will utilize these enhancements to study their impact on motivation to perform a tele-rehabilitation- based home exercise program, adherence to the program and changes in hand function. The proposed study will utilize a system of novel rehabilitation technologies designed to facilitate home exercise performance. Subjects will perform 3 simulated rehabilitation activities supported by a passive exoskeleton, an infrared camera and software that will allow subjects to exercise at home. The investigator's will investigate: 1) Differences in measures of motivation elicited by motivationally enhanced simulations and un-enhanced control versions.2) The impact of motivational enhancements on actual adherence to a tele-rehabilitation program in persons with stroke and 3) The impact of motivational enhancement on improvements in hand function achieved by these subjects. This proposal will address a critical gap in modern rehabilitation - adherence to autonomous rehabilitation programs. Patient participation in unsupervised rehabilitation is one of the assumptions underpinning our health care system. This said, no data collected to date supports that adherence is acceptable. The technology and methodology in this proposal are an important step towards leveraging extensive research and development done by the computer gaming industry into improved rehabilitation practice.",
        "text": "Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke | This trial studies the impact of motivational strategies designed by the gaming industry on adherence to a home tele-rehabilitation program designed to improve hand function in persons with stroke. A growing literature suggests that the extended practice of challenging hand tasks can produce measurable changes in hand function in persons with stroke. Current health care delivery systems do not support this volume of directly supervised rehabilitation, making it necessary for patients to perform a substantial amount of activity at home, unsupervised. Unfortunately, adherence to unsupervised home exercise regimens is quite poor in this population. The investigator's goal is to assess the impact of several well-established game design strategies: 1) Scaffolded increases in game difficulty 2) In-game rewards 3) Quests with enhanced narrative. The investigator's will utilize these enhancements to study their impact on motivation to perform a tele-rehabilitation- based home exercise program, adherence to the program and changes in hand function. The proposed study will utilize a system of novel rehabilitation technologies designed to facilitate home exercise performance. Subjects will perform 3 simulated rehabilitation activities supported by a passive exoskeleton, an infrared camera and software that will allow subjects to exercise at home. The investigator's will investigate: 1) Differences in measures of motivation elicited by motivationally enhanced simulations and un-enhanced control versions.2) The impact of motivational enhancements on actual adherence to a tele-rehabilitation program in persons with stroke and 3) The impact of motivational enhancement on improvements in hand function achieved by these subjects. This proposal will address a critical gap in modern rehabilitation - adherence to autonomous rehabilitation programs. Patient participation in unsupervised rehabilitation is one of the assumptions underpinning our health care system. This said, no data collected to date supports that adherence is acceptable. The technology and methodology in this proposal are an important step towards leveraging extensive research and development done by the computer gaming industry into improved rehabilitation practice.",
        "tokens": "['Utilizing', 'Gaming', 'Mechanics', 'to', 'Optimize', 'Telerehabilitation', 'Adherence', 'in', 'Persons', 'With', 'Stroke', '|', 'This', 'trial', 'studies', 'the', 'impact', 'of', 'motivational', 'strategies', 'designed', 'by', 'the', 'gaming', 'industry', 'on', 'adherence', 'to', 'a', 'home', 'tele', '-', 'rehabilitation', 'program', 'designed', 'to', 'improve', 'hand', 'function', 'in', 'persons', 'with', 'stroke', '.', 'A', 'growing', 'literature', 'suggests', 'that', 'the', 'extended', 'practice', 'of', 'challenging', 'hand', 'tasks', 'can', 'produce', 'measurable', 'changes', 'in', 'hand', 'function', 'in', 'persons', 'with', 'stroke', '.', 'Current', 'health', 'care', 'delivery', 'systems', 'do', 'not', 'support', 'this', 'volume', 'of', 'directly', 'supervised', 'rehabilitation', ',', 'making', 'it', 'necessary', 'for', 'patients', 'to', 'perform', 'a', 'substantial', 'amount', 'of', 'activity', 'at', 'home', ',', 'unsupervised', '.', 'Unfortunately', ',', 'adherence', 'to', 'unsupervised', 'home', 'exercise', 'regimens', 'is', 'quite', 'poor', 'in', 'this', 'population', '.', 'The', 'investigator', \"'s\", 'goal', 'is', 'to', 'assess', 'the', 'impact', 'of', 'several', 'well', '-', 'established', 'game', 'design', 'strategies', ':', '1', ')', 'Scaffolded', 'increases', 'in', 'game', 'difficulty', '2', ')', 'In', '-', 'game', 'rewards', '3', ')', 'Quests', 'with', 'enhanced', 'narrative', '.', 'The', 'investigator', \"'s\", 'will', 'utilize', 'these', 'enhancements', 'to', 'study', 'their', 'impact', 'on', 'motivation', 'to', 'perform', 'a', 'tele', '-', 'rehabilitation-', 'based', 'home', 'exercise', 'program', ',', 'adherence', 'to', 'the', 'program', 'and', 'changes', 'in', 'hand', 'function', '.', 'The', 'proposed', 'study', 'will', 'utilize', 'a', 'system', 'of', 'novel', 'rehabilitation', 'technologies', 'designed', 'to', 'facilitate', 'home', 'exercise', 'performance', '.', 'Subjects', 'will', 'perform', '3', 'simulated', 'rehabilitation', 'activities', 'supported', 'by', 'a', 'passive', 'exoskeleton', ',', 'an', 'infrared', 'camera', 'and', 'software', 'that', 'will', 'allow', 'subjects', 'to', 'exercise', 'at', 'home', '.', 'The', 'investigator', \"'s\", 'will', 'investigate', ':', '1', ')', 'Differences', 'in', 'measures', 'of', 'motivation', 'elicited', 'by', 'motivationally', 'enhanced', 'simulations', 'and', 'un', '-', 'enhanced', 'control', 'versions.2', ')', 'The', 'impact', 'of', 'motivational', 'enhancements', 'on', 'actual', 'adherence', 'to', 'a', 'tele', '-', 'rehabilitation', 'program', 'in', 'persons', 'with', 'stroke', 'and', '3', ')', 'The', 'impact', 'of', 'motivational', 'enhancement', 'on', 'improvements', 'in', 'hand', 'function', 'achieved', 'by', 'these', 'subjects', '.', 'This', 'proposal', 'will', 'address', 'a', 'critical', 'gap', 'in', 'modern', 'rehabilitation', '-', 'adherence', 'to', 'autonomous', 'rehabilitation', 'programs', '.', 'Patient', 'participation', 'in', 'unsupervised', 'rehabilitation', 'is', 'one', 'of', 'the', 'assumptions', 'underpinning', 'our', 'health', 'care', 'system', '.', 'This', 'said', ',', 'no', 'data', 'collected', 'to', 'date', 'supports', 'that', 'adherence', 'is', 'acceptable', '.', 'The', 'technology', 'and', 'methodology', 'in', 'this', 'proposal', 'are', 'an', 'important', 'step', 'towards', 'leveraging', 'extensive', 'research', 'and', 'development', 'done', 'by', 'the', 'computer', 'gaming', 'industry', 'into', 'improved', 'rehabilitation', 'practice', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 26,
                "text": "Gaming Mechanics",
                "type": "OTHER"
            },
            {
                "start": 39,
                "end": 57,
                "text": "Telerehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 84,
                "end": 90,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 149,
                "text": "motivational strategies",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 200,
                "end": 232,
                "text": "home tele-rehabilitation program",
                "type": "PHYSICAL"
            },
            {
                "start": 283,
                "end": 289,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 438,
                "end": 444,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1044,
                "end": 1092,
                "text": "tele-rehabilitation- based home exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 1250,
                "end": 1263,
                "text": "home exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1301,
                "end": 1336,
                "text": "simulated rehabilitation activities",
                "type": "PHYSICAL"
            },
            {
                "start": 1352,
                "end": 1371,
                "text": "passive exoskeleton",
                "type": "PHYSICAL"
            },
            {
                "start": 1433,
                "end": 1449,
                "text": "exercise at home",
                "type": "PHYSICAL"
            },
            {
                "start": 1541,
                "end": 1576,
                "text": "motivationally enhanced simulations",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1581,
                "end": 1600,
                "text": "un-enhanced control",
                "type": "CONTROL"
            },
            {
                "start": 1627,
                "end": 1652,
                "text": "motivational enhancements",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1678,
                "end": 1705,
                "text": "tele-rehabilitation program",
                "type": "PHYSICAL"
            },
            {
                "start": 1722,
                "end": 1728,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1750,
                "end": 1774,
                "text": "motivational enhancement",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1918,
                "end": 1952,
                "text": "autonomous rehabilitation programs",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT04118829",
        "study_official_title": "Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER ",
        "study_brief_summary": " Perampanel is a drug used to treat patients with epilepsy/seizures. This study is designed to determine how much perampanel actually crosses the blood brain barrier into the cerebral spinal fluid when the drug is taken.",
        "text": "Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER | Perampanel is a drug used to treat patients with epilepsy/seizures. This study is designed to determine how much perampanel actually crosses the blood brain barrier into the cerebral spinal fluid when the drug is taken.",
        "tokens": "['Correlation', 'of', 'Serum', 'Level', 'of', 'Perampanel', '(', 'PER', ')', 'Level', 'to', 'Cerebrospinal', 'Fluid', '(', 'CSF', ')', 'Levels', 'of', 'PER', '|', 'Perampanel', 'is', 'a', 'drug', 'used', 'to', 'treat', 'patients', 'with', 'epilepsy', '/', 'seizures', '.', 'This', 'study', 'is', 'designed', 'to', 'determine', 'how', 'much', 'perampanel', 'actually', 'crosses', 'the', 'blood', 'brain', 'barrier', 'into', 'the', 'cerebral', 'spinal', 'fluid', 'when', 'the', 'drug', 'is', 'taken', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 40,
                "text": "Perampanel",
                "type": "DRUG"
            },
            {
                "start": 42,
                "end": 45,
                "text": "PER",
                "type": "DRUG"
            },
            {
                "start": 92,
                "end": 95,
                "text": "PER",
                "type": "DRUG"
            },
            {
                "start": 98,
                "end": 108,
                "text": "Perampanel",
                "type": "DRUG"
            },
            {
                "start": 147,
                "end": 155,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 164,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 211,
                "end": 221,
                "text": "perampanel",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03132259",
        "study_official_title": "Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach ",
        "study_brief_summary": " Transnasal transsphenoidal (TNTS) resection of pituitary tumors involves wide fluctuation in hemodynamic parameter and causes hypertension and tachycardia due to intense noxious stimuli during various stages of surgery. None of routinely used anesthetic agents effectively blunts the undesirable hemodynamic responses, and therefore usually there is a need to use increased doses of anesthetic agents. Dexmedetomidine (DEX) an \u03b1-2 adrenergic receptor agonist, because its sympatholytic and antinociceptive properties may ensure optimal intraoperative hemodynamic stability during critical moments of surgical manipulation. In addition, DEX reduced the anesthetic requirement with rapid recovery at the end of surgery. The main aim of the study was to evaluate the effect of DEX on perioperative hemodynamics, anesthetic requirements",
        "text": "Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach | Transnasal transsphenoidal (TNTS) resection of pituitary tumors involves wide fluctuation in hemodynamic parameter and causes hypertension and tachycardia due to intense noxious stimuli during various stages of surgery. None of routinely used anesthetic agents effectively blunts the undesirable hemodynamic responses, and therefore usually there is a need to use increased doses of anesthetic agents. Dexmedetomidine (DEX) an \u03b1-2 adrenergic receptor agonist, because its sympatholytic and antinociceptive properties may ensure optimal intraoperative hemodynamic stability during critical moments of surgical manipulation. In addition, DEX reduced the anesthetic requirement with rapid recovery at the end of surgery. The main aim of the study was to evaluate the effect of DEX on perioperative hemodynamics, anesthetic requirements",
        "tokens": "['Comparative', 'Low', 'and', 'High', 'Dose', 'of', 'Dexmedethomidine', 'Can', 'Stabilize', 'Hemodynamics', 'and', 'Blood', 'Loss', 'in', 'Pituitary', 'Tumor', 'Removal', 'by', 'Transphenoid', 'Approach', '|', 'Transnasal', 'transsphenoidal', '(', 'TNTS', ')', 'resection', 'of', 'pituitary', 'tumors', 'involves', 'wide', 'fluctuation', 'in', 'hemodynamic', 'parameter', 'and', 'causes', 'hypertension', 'and', 'tachycardia', 'due', 'to', 'intense', 'noxious', 'stimuli', 'during', 'various', 'stages', 'of', 'surgery', '.', 'None', 'of', 'routinely', 'used', 'anesthetic', 'agents', 'effectively', 'blunts', 'the', 'undesirable', 'hemodynamic', 'responses', ',', 'and', 'therefore', 'usually', 'there', 'is', 'a', 'need', 'to', 'use', 'increased', 'doses', 'of', 'anesthetic', 'agents', '.', 'Dexmedetomidine', '(', 'DEX', ')', 'an', '\u03b1-2', 'adrenergic', 'receptor', 'agonist', ',', 'because', 'its', 'sympatholytic', 'and', 'antinociceptive', 'properties', 'may', 'ensure', 'optimal', 'intraoperative', 'hemodynamic', 'stability', 'during', 'critical', 'moments', 'of', 'surgical', 'manipulation', '.', 'In', 'addition', ',', 'DEX', 'reduced', 'the', 'anesthetic', 'requirement', 'with', 'rapid', 'recovery', 'at', 'the', 'end', 'of', 'surgery', '.', 'The', 'main', 'aim', 'of', 'the', 'study', 'was', 'to', 'evaluate', 'the', 'effect', 'of', 'DEX', 'on', 'perioperative', 'hemodynamics', ',', 'anesthetic', 'requirements']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 49,
                "text": "Dexmedethomidine",
                "type": "DRUG"
            },
            {
                "start": 95,
                "end": 143,
                "text": "Pituitary Tumor Removal by Transphenoid Approach",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 209,
                "text": "Transnasal transsphenoidal (TNTS) resection of pituitary tumors",
                "type": "CONDITION"
            },
            {
                "start": 272,
                "end": 284,
                "text": "hypertension",
                "type": "CONDITION"
            },
            {
                "start": 289,
                "end": 300,
                "text": "tachycardia",
                "type": "CONDITION"
            },
            {
                "start": 548,
                "end": 563,
                "text": "Dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 565,
                "end": 568,
                "text": "DEX",
                "type": "DRUG"
            },
            {
                "start": 573,
                "end": 604,
                "text": "\u03b1-2 adrenergic receptor agonist",
                "type": "DRUG"
            },
            {
                "start": 782,
                "end": 785,
                "text": "DEX",
                "type": "DRUG"
            },
            {
                "start": 920,
                "end": 923,
                "text": "DEX",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02490943",
        "study_official_title": "A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in Multiple Sclerosis ",
        "study_brief_summary": " Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.",
        "text": "A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in Multiple Sclerosis | Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.",
        "tokens": "['A', 'Pilot', 'Study', 'of', 'Warm', 'and', 'Cold', 'Compress', 'to', 'Reduce', 'Injection', 'Site', 'Erythema', 'Due', 'to', 'Peginterferon', '-', 'beta-1a', 'in', 'Multiple', 'Sclerosis', '|', 'Peginterferon', '-', 'beta-1a', '(', 'PEG', ')', 'is', 'an', 'approved', 'treatment', 'for', 'relapsing', 'forms', 'of', 'MS', 'that', 'may', 'cause', 'injection', 'related', 'erythema', '.', 'This', 'is', 'a', 'randomized', 'controlled', 'cross', '-', 'over', 'trial', 'of', 'superficial', 'hot', 'and', 'cold', 'modalities', 'to', 'reduce', 'injection', 'site', 'erythema', 'caused', 'by', 'PEG', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 39,
                "text": "Warm and Cold Compress",
                "type": "OTHER"
            },
            {
                "start": 50,
                "end": 73,
                "text": "Injection Site Erythema",
                "type": "CONDITION"
            },
            {
                "start": 106,
                "end": 124,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 205,
                "text": "relapsing forms of MS",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 247,
                "text": "injection related erythema",
                "type": "CONDITION"
            },
            {
                "start": 301,
                "end": 336,
                "text": "superficial hot and cold modalities",
                "type": "OTHER"
            },
            {
                "start": 347,
                "end": 370,
                "text": "injection site erythema",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00078988",
        "study_official_title": "A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support ",
        "study_brief_summary": " RATIONALE: Drugs used in chemotherapy, such as carboplatin, thiotepa, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Isotretinoin may be effective in preventing recurrence of glioma. It is not yet known which regimen of chemotherapy plus autologous stem cell transplantation with or without isotretinoin is more effective in treating recurrent high-grade glioma.\n\nPURPOSE: This randomized phase III trial is studying high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation to see how well it works compared to high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation and isotretinoin in treating young patients with recurrent high-grade glioma.",
        "text": "A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support | RATIONALE: Drugs used in chemotherapy, such as carboplatin, thiotepa, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Isotretinoin may be effective in preventing recurrence of glioma. It is not yet known which regimen of chemotherapy plus autologous stem cell transplantation with or without isotretinoin is more effective in treating recurrent high-grade glioma.\n\nPURPOSE: This randomized phase III trial is studying high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation to see how well it works compared to high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation and isotretinoin in treating young patients with recurrent high-grade glioma.",
        "tokens": "['A', 'Phase', 'III', 'Randomized', 'Trial', 'for', 'the', 'Treatment', 'of', 'Pediatric', 'High', 'Grade', 'Gliomas', 'at', 'First', 'Recurrence', 'With', 'a', 'Single', 'High', 'Dose', 'Chemotherapy', 'and', 'Autologous', 'Stem', 'Cell', 'Transplant', 'Versus', 'Three', 'Courses', 'of', 'Intermediate', 'Dose', 'Chemotherapy', 'With', 'Peripheral', 'Blood', 'Stem', 'Cell', '(', 'PBSC', ')', 'Support', '|', 'RATIONALE', ':', 'Drugs', 'used', 'in', 'chemotherapy', ',', 'such', 'as', 'carboplatin', ',', 'thiotepa', ',', 'and', 'etoposide', ',', 'work', 'in', 'different', 'ways', 'to', 'stop', 'tumor', 'cells', 'from', 'dividing', 'so', 'they', 'stop', 'growing', 'or', 'die', '.', 'Combining', 'chemotherapy', 'with', 'autologous', 'stem', 'cell', 'transplantation', 'may', 'allow', 'the', 'doctor', 'to', 'give', 'higher', 'doses', 'of', 'chemotherapy', 'drugs', 'and', 'kill', 'more', 'tumor', 'cells', '.', 'Isotretinoin', 'may', 'be', 'effective', 'in', 'preventing', 'recurrence', 'of', 'glioma', '.', 'It', 'is', 'not', 'yet', 'known', 'which', 'regimen', 'of', 'chemotherapy', 'plus', 'autologous', 'stem', 'cell', 'transplantation', 'with', 'or', 'without', 'isotretinoin', 'is', 'more', 'effective', 'in', 'treating', 'recurrent', 'high', '-', 'grade', 'glioma', '.', '\\n\\n', 'PURPOSE', ':', 'This', 'randomized', 'phase', 'III', 'trial', 'is', 'studying', 'high', '-', 'dose', 'chemotherapy', 'or', 'intermediate', '-', 'dose', 'chemotherapy', 'followed', 'by', 'autologous', 'stem', 'cell', 'transplantation', 'to', 'see', 'how', 'well', 'it', 'works', 'compared', 'to', 'high', '-', 'dose', 'chemotherapy', 'or', 'intermediate', '-', 'dose', 'chemotherapy', 'followed', 'by', 'autologous', 'stem', 'cell', 'transplantation', 'and', 'isotretinoin', 'in', 'treating', 'young', 'patients', 'with', 'recurrent', 'high', '-', 'grade', 'glioma', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 98,
                "text": "Pediatric High Grade Gliomas at First Recurrence",
                "type": "CONDITION"
            },
            {
                "start": 123,
                "end": 135,
                "text": "Chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 140,
                "end": 171,
                "text": "Autologous Stem Cell Transplant",
                "type": "SURGICAL"
            },
            {
                "start": 214,
                "end": 226,
                "text": "Chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 232,
                "end": 258,
                "text": "Peripheral Blood Stem Cell",
                "type": "SURGICAL"
            },
            {
                "start": 260,
                "end": 264,
                "text": "PBSC",
                "type": "SURGICAL"
            },
            {
                "start": 301,
                "end": 313,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 323,
                "end": 334,
                "text": "carboplatin",
                "type": "DRUG"
            },
            {
                "start": 336,
                "end": 344,
                "text": "thiotepa",
                "type": "DRUG"
            },
            {
                "start": 350,
                "end": 359,
                "text": "etoposide",
                "type": "DRUG"
            },
            {
                "start": 392,
                "end": 397,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 457,
                "end": 469,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 475,
                "end": 511,
                "text": "autologous stem cell transplantation",
                "type": "SURGICAL"
            },
            {
                "start": 557,
                "end": 569,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 590,
                "end": 595,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 603,
                "end": 615,
                "text": "Isotretinoin",
                "type": "DRUG"
            },
            {
                "start": 661,
                "end": 667,
                "text": "glioma",
                "type": "CONDITION"
            },
            {
                "start": 706,
                "end": 718,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 724,
                "end": 760,
                "text": "autologous stem cell transplantation",
                "type": "SURGICAL"
            },
            {
                "start": 777,
                "end": 789,
                "text": "isotretinoin",
                "type": "DRUG"
            },
            {
                "start": 820,
                "end": 847,
                "text": "recurrent high-grade glioma",
                "type": "CONDITION"
            },
            {
                "start": 913,
                "end": 925,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 947,
                "end": 959,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 972,
                "end": 1008,
                "text": "autologous stem cell transplantation",
                "type": "SURGICAL"
            },
            {
                "start": 1056,
                "end": 1068,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 1090,
                "end": 1102,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 1115,
                "end": 1151,
                "text": "autologous stem cell transplantation",
                "type": "SURGICAL"
            },
            {
                "start": 1156,
                "end": 1168,
                "text": "isotretinoin",
                "type": "DRUG"
            },
            {
                "start": 1201,
                "end": 1228,
                "text": "recurrent high-grade glioma",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01556165",
        "study_official_title": "Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China ",
        "study_brief_summary": " Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor fluctuations.\n\nThe rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in Chinese PD patients not treated with levodopa.",
        "text": "Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China | Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor fluctuations.\n\nThe rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in Chinese PD patients not treated with levodopa.",
        "tokens": "['Randomised', ',', 'Double', '-', 'blind', ',', 'Parallel', '-', 'group', ',', 'Placebo', '-', 'controlled', ',', 'Fixed', '-', 'dose', 'Study', 'of', 'Rasagiline', 'in', 'Early', 'Parkinson', \"'s\", 'Disease', 'Patients', 'Not', 'Treated', 'With', 'Levodopa', 'in', 'China', '|', 'Rasagiline', 'has', 'been', 'developed', 'for', 'the', 'treatment', 'of', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', ',', 'as', 'monotherapy', 'in', 'early', 'PD', 'patients', 'not', 'treated', 'with', 'levodopa', ',', 'and', 'as', 'adjunct', 'therapy', 'to', 'levodopa', 'in', 'levodopa', '-', 'treated', 'PD', 'patients', 'with', 'motor', 'fluctuations', '.', '\\n\\n', 'The', 'rationale', 'for', 'conducting', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', ',', 'tolerability', ',', 'and', 'safety', 'of', 'rasagiline', 'compared', 'to', 'placebo', 'in', 'Chinese', 'PD', 'patients', 'not', 'treated', 'with', 'levodopa', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 49,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 82,
                "end": 92,
                "text": "Rasagiline",
                "type": "DRUG"
            },
            {
                "start": 96,
                "end": 121,
                "text": "Early Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 156,
                "text": "Levodopa",
                "type": "DRUG"
            },
            {
                "start": 168,
                "end": 178,
                "text": "Rasagiline",
                "type": "DRUG"
            },
            {
                "start": 219,
                "end": 238,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 240,
                "end": 242,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 263,
                "end": 271,
                "text": "early PD",
                "type": "CONDITION"
            },
            {
                "start": 334,
                "end": 342,
                "text": "levodopa",
                "type": "DRUG"
            },
            {
                "start": 346,
                "end": 354,
                "text": "levodopa",
                "type": "DRUG"
            },
            {
                "start": 363,
                "end": 365,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 498,
                "end": 508,
                "text": "rasagiline",
                "type": "DRUG"
            },
            {
                "start": 521,
                "end": 528,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 540,
                "end": 542,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 569,
                "end": 577,
                "text": "levodopa",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05747989",
        "study_official_title": "A Comparison of Tissue Adhesive Material and Suture as Wound-closure Techniques ",
        "study_brief_summary": " Participants will be randomly assigned to suture-based wound closure (n=50) or tissue adhesive-based wound closure (n=50) with two-component skin adhesive Glubran Tiss 2\u00ae. The outcomes will be assessed during the follow-up period at intervals of 2, 6, and 12 weeks postoperatively. A scar assessment will be using the POSAS (Patient and Observer Scar Assessment Scale) and cosmetic VAS (Visual Analog Scale). The VNRS (Verbal Number Rating Scale) will used to assess pain.",
        "text": "A Comparison of Tissue Adhesive Material and Suture as Wound-closure Techniques | Participants will be randomly assigned to suture-based wound closure (n=50) or tissue adhesive-based wound closure (n=50) with two-component skin adhesive Glubran Tiss 2\u00ae. The outcomes will be assessed during the follow-up period at intervals of 2, 6, and 12 weeks postoperatively. A scar assessment will be using the POSAS (Patient and Observer Scar Assessment Scale) and cosmetic VAS (Visual Analog Scale). The VNRS (Verbal Number Rating Scale) will used to assess pain.",
        "tokens": "['A', 'Comparison', 'of', 'Tissue', 'Adhesive', 'Material', 'and', 'Suture', 'as', 'Wound', '-', 'closure', 'Techniques', '|', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'suture', '-', 'based', 'wound', 'closure', '(', 'n=50', ')', 'or', 'tissue', 'adhesive', '-', 'based', 'wound', 'closure', '(', 'n=50', ')', 'with', 'two', '-', 'component', 'skin', 'adhesive', 'Glubran', 'Tiss', '2', '\u00ae', '.', 'The', 'outcomes', 'will', 'be', 'assessed', 'during', 'the', 'follow', '-', 'up', 'period', 'at', 'intervals', 'of', '2', ',', '6', ',', 'and', '12', 'weeks', 'postoperatively', '.', 'A', 'scar', 'assessment', 'will', 'be', 'using', 'the', 'POSAS', '(', 'Patient', 'and', 'Observer', 'Scar', 'Assessment', 'Scale', ')', 'and', 'cosmetic', 'VAS', '(', 'Visual', 'Analog', 'Scale', ')', '.', 'The', 'VNRS', '(', 'Verbal', 'Number', 'Rating', 'Scale', ')', 'will', 'used', 'to', 'assess', 'pain', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 40,
                "text": "Tissue Adhesive Material",
                "type": "SURGICAL"
            },
            {
                "start": 45,
                "end": 51,
                "text": "Suture",
                "type": "SURGICAL"
            },
            {
                "start": 55,
                "end": 60,
                "text": "Wound",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 150,
                "text": "suture-based wound closure",
                "type": "SURGICAL"
            },
            {
                "start": 161,
                "end": 196,
                "text": "tissue adhesive-based wound closure",
                "type": "SURGICAL"
            },
            {
                "start": 209,
                "end": 251,
                "text": "two-component skin adhesive Glubran Tiss 2",
                "type": "SURGICAL"
            },
            {
                "start": 366,
                "end": 370,
                "text": "scar",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01715194",
        "study_official_title": "Telemedicine to Enhance Adherence to Continuous Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea Syndrome; a Randomized Placebo-controlled Prospective Study ",
        "study_brief_summary": " We hypothesize that the use of telemedicine combined with support interventions by short messages, telephone calls and ambulatory visits to control CPAP treatment during the first month improves adherence and reduces unresolved side effects of therapy.\n\nThe primary objective of an OSAS treatment program is to successfully implement indicated CPAP in the highest possible proportion of patients in order to lower the proportion of untreated OSAS in the population. On an individual basis, it has been shown that a longer duration of CPAP use is associated with better outcomes in terms of daytime functioning and in the control of metabolic and blood pressure effects of CPAP. For our study, we have therefore decided to use 2 co-primary endpoints, taking into account both aspects of adherence mentioned. Cardiovascular complications are a major concern in OSAS patients. Effective CPAP treatment has been shown to reduce surrogate measures of cardiovascular risk. We hypothesize that intensified efforts for CPAP adherence with telemedicine has a positive impact on a number of surrogate measures of the cardiovascular risk at 1 and 6 months of treatment.",
        "text": "Telemedicine to Enhance Adherence to Continuous Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea Syndrome; a Randomized Placebo-controlled Prospective Study | We hypothesize that the use of telemedicine combined with support interventions by short messages, telephone calls and ambulatory visits to control CPAP treatment during the first month improves adherence and reduces unresolved side effects of therapy.\n\nThe primary objective of an OSAS treatment program is to successfully implement indicated CPAP in the highest possible proportion of patients in order to lower the proportion of untreated OSAS in the population. On an individual basis, it has been shown that a longer duration of CPAP use is associated with better outcomes in terms of daytime functioning and in the control of metabolic and blood pressure effects of CPAP. For our study, we have therefore decided to use 2 co-primary endpoints, taking into account both aspects of adherence mentioned. Cardiovascular complications are a major concern in OSAS patients. Effective CPAP treatment has been shown to reduce surrogate measures of cardiovascular risk. We hypothesize that intensified efforts for CPAP adherence with telemedicine has a positive impact on a number of surrogate measures of the cardiovascular risk at 1 and 6 months of treatment.",
        "tokens": "['Telemedicine', 'to', 'Enhance', 'Adherence', 'to', 'Continuous', 'Positive', 'Airway', 'Pressure', 'Therapy', 'in', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', ';', 'a', 'Randomized', 'Placebo', '-', 'controlled', 'Prospective', 'Study', '|', 'We', 'hypothesize', 'that', 'the', 'use', 'of', 'telemedicine', 'combined', 'with', 'support', 'interventions', 'by', 'short', 'messages', ',', 'telephone', 'calls', 'and', 'ambulatory', 'visits', 'to', 'control', 'CPAP', 'treatment', 'during', 'the', 'first', 'month', 'improves', 'adherence', 'and', 'reduces', 'unresolved', 'side', 'effects', 'of', 'therapy', '.', '\\n\\n', 'The', 'primary', 'objective', 'of', 'an', 'OSAS', 'treatment', 'program', 'is', 'to', 'successfully', 'implement', 'indicated', 'CPAP', 'in', 'the', 'highest', 'possible', 'proportion', 'of', 'patients', 'in', 'order', 'to', 'lower', 'the', 'proportion', 'of', 'untreated', 'OSAS', 'in', 'the', 'population', '.', 'On', 'an', 'individual', 'basis', ',', 'it', 'has', 'been', 'shown', 'that', 'a', 'longer', 'duration', 'of', 'CPAP', 'use', 'is', 'associated', 'with', 'better', 'outcomes', 'in', 'terms', 'of', 'daytime', 'functioning', 'and', 'in', 'the', 'control', 'of', 'metabolic', 'and', 'blood', 'pressure', 'effects', 'of', 'CPAP', '.', 'For', 'our', 'study', ',', 'we', 'have', 'therefore', 'decided', 'to', 'use', '2', 'co', '-', 'primary', 'endpoints', ',', 'taking', 'into', 'account', 'both', 'aspects', 'of', 'adherence', 'mentioned', '.', 'Cardiovascular', 'complications', 'are', 'a', 'major', 'concern', 'in', 'OSAS', 'patients', '.', 'Effective', 'CPAP', 'treatment', 'has', 'been', 'shown', 'to', 'reduce', 'surrogate', 'measures', 'of', 'cardiovascular', 'risk', '.', 'We', 'hypothesize', 'that', 'intensified', 'efforts', 'for', 'CPAP', 'adherence', 'with', 'telemedicine', 'has', 'a', 'positive', 'impact', 'on', 'a', 'number', 'of', 'surrogate', 'measures', 'of', 'the', 'cardiovascular', 'risk', 'at', '1', 'and', '6', 'months', 'of', 'treatment', '.']",
        "token_bio_labels": "['B-BEH', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 12,
                "text": "Telemedicine",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 37,
                "end": 72,
                "text": "Continuous Positive Airway Pressure",
                "type": "OTHER"
            },
            {
                "start": 98,
                "end": 130,
                "text": "Obstructive Sleep Apnea Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 152,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 215,
                "end": 227,
                "text": "telemedicine",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 242,
                "end": 320,
                "text": "support interventions by short messages, telephone calls and ambulatory visits",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 332,
                "end": 336,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 466,
                "end": 470,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 528,
                "end": 532,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 626,
                "end": 630,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 718,
                "end": 722,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 856,
                "end": 860,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 1043,
                "end": 1047,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 1068,
                "end": 1072,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 1195,
                "end": 1199,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 1215,
                "end": 1227,
                "text": "telemedicine",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT01770678",
        "study_official_title": "Randomised Controlled Trial to Compare Two Methods of Constraint Induced Movement Therapy to Improve Functional Ability in the Affected Upper Limb in Pre-school Children With Hemiplegic Cerebral Palsy ",
        "study_brief_summary": " Cerebral palsy remains a major cause of lifelong disability affecting approximately 2 per 1,000 children. Of those about 30% have hemiplegic cerebral palsy (HPC),a unilateral impairment, which can often lead to major difficulties with manual dexterity and upper limb,functional ability and independence. Therapists employ a number of strategies in upper limb rehabilitation however they are poorly understood and their efficacy has been questioned. Constraint induced movement therapy (CIMT)has been found to be an effective intervention with HCP however its use in the preschool child within a national health service (NHS) setting has not been evaluated. The investigators aim is to compare CIMT using prolonged restraint with CIMT using brief manual restraint which may be standard practice and acts as the control. This age group has been targeted as there may be greatest neural plasticity (change)and minimal disruption to compulsory education. The investigators intend to recruit 60 patients from treatment databases of participating trusts. Patients will be randomised following baseline assessments which will include 2 upper limb assessments(The Assisting Hand Assessment and the Quality of Upper Extremity Skills Test) and a quality of life questionnaire (PedsQL Generic Core Scales and the Cerebral Palsy Module) for parents. The intervention period will be for 6 weeks offered intermittently (2week blocks) over 10 weeks. Parents /guardians and possibly preschool workers will be expected to carry out a therapy guided programme. The amount of intervention and compliance will be recorded by parents/guardians and therapists. Assessments will be repeated at 10 weeks and 24 weeks from the beginning of the trial. The results of the trial will contribute to the evidence on the effectiveness of CIMT in the preschool child with HCP, and will also provide evidence on the implementation of CIMT delivery within the current NHS therapy services.\n\n.",
        "text": "Randomised Controlled Trial to Compare Two Methods of Constraint Induced Movement Therapy to Improve Functional Ability in the Affected Upper Limb in Pre-school Children With Hemiplegic Cerebral Palsy | Cerebral palsy remains a major cause of lifelong disability affecting approximately 2 per 1,000 children. Of those about 30% have hemiplegic cerebral palsy (HPC),a unilateral impairment, which can often lead to major difficulties with manual dexterity and upper limb,functional ability and independence. Therapists employ a number of strategies in upper limb rehabilitation however they are poorly understood and their efficacy has been questioned. Constraint induced movement therapy (CIMT)has been found to be an effective intervention with HCP however its use in the preschool child within a national health service (NHS) setting has not been evaluated. The investigators aim is to compare CIMT using prolonged restraint with CIMT using brief manual restraint which may be standard practice and acts as the control. This age group has been targeted as there may be greatest neural plasticity (change)and minimal disruption to compulsory education. The investigators intend to recruit 60 patients from treatment databases of participating trusts. Patients will be randomised following baseline assessments which will include 2 upper limb assessments(The Assisting Hand Assessment and the Quality of Upper Extremity Skills Test) and a quality of life questionnaire (PedsQL Generic Core Scales and the Cerebral Palsy Module) for parents. The intervention period will be for 6 weeks offered intermittently (2week blocks) over 10 weeks. Parents /guardians and possibly preschool workers will be expected to carry out a therapy guided programme. The amount of intervention and compliance will be recorded by parents/guardians and therapists. Assessments will be repeated at 10 weeks and 24 weeks from the beginning of the trial. The results of the trial will contribute to the evidence on the effectiveness of CIMT in the preschool child with HCP, and will also provide evidence on the implementation of CIMT delivery within the current NHS therapy services.\n\n.",
        "tokens": "['Randomised', 'Controlled', 'Trial', 'to', 'Compare', 'Two', 'Methods', 'of', 'Constraint', 'Induced', 'Movement', 'Therapy', 'to', 'Improve', 'Functional', 'Ability', 'in', 'the', 'Affected', 'Upper', 'Limb', 'in', 'Pre', '-', 'school', 'Children', 'With', 'Hemiplegic', 'Cerebral', 'Palsy', '|', 'Cerebral', 'palsy', 'remains', 'a', 'major', 'cause', 'of', 'lifelong', 'disability', 'affecting', 'approximately', '2', 'per', '1,000', 'children', '.', 'Of', 'those', 'about', '30', '%', 'have', 'hemiplegic', 'cerebral', 'palsy', '(', 'HPC),a', 'unilateral', 'impairment', ',', 'which', 'can', 'often', 'lead', 'to', 'major', 'difficulties', 'with', 'manual', 'dexterity', 'and', 'upper', 'limb', ',', 'functional', 'ability', 'and', 'independence', '.', 'Therapists', 'employ', 'a', 'number', 'of', 'strategies', 'in', 'upper', 'limb', 'rehabilitation', 'however', 'they', 'are', 'poorly', 'understood', 'and', 'their', 'efficacy', 'has', 'been', 'questioned', '.', 'Constraint', 'induced', 'movement', 'therapy', '(', 'CIMT)has', 'been', 'found', 'to', 'be', 'an', 'effective', 'intervention', 'with', 'HCP', 'however', 'its', 'use', 'in', 'the', 'preschool', 'child', 'within', 'a', 'national', 'health', 'service', '(', 'NHS', ')', 'setting', 'has', 'not', 'been', 'evaluated', '.', 'The', 'investigators', 'aim', 'is', 'to', 'compare', 'CIMT', 'using', 'prolonged', 'restraint', 'with', 'CIMT', 'using', 'brief', 'manual', 'restraint', 'which', 'may', 'be', 'standard', 'practice', 'and', 'acts', 'as', 'the', 'control', '.', 'This', 'age', 'group', 'has', 'been', 'targeted', 'as', 'there', 'may', 'be', 'greatest', 'neural', 'plasticity', '(', 'change)and', 'minimal', 'disruption', 'to', 'compulsory', 'education', '.', 'The', 'investigators', 'intend', 'to', 'recruit', '60', 'patients', 'from', 'treatment', 'databases', 'of', 'participating', 'trusts', '.', 'Patients', 'will', 'be', 'randomised', 'following', 'baseline', 'assessments', 'which', 'will', 'include', '2', 'upper', 'limb', 'assessments(The', 'Assisting', 'Hand', 'Assessment', 'and', 'the', 'Quality', 'of', 'Upper', 'Extremity', 'Skills', 'Test', ')', 'and', 'a', 'quality', 'of', 'life', 'questionnaire', '(', 'PedsQL', 'Generic', 'Core', 'Scales', 'and', 'the', 'Cerebral', 'Palsy', 'Module', ')', 'for', 'parents', '.', 'The', 'intervention', 'period', 'will', 'be', 'for', '6', 'weeks', 'offered', 'intermittently', '(', '2week', 'blocks', ')', 'over', '10', 'weeks', '.', 'Parents', '/guardians', 'and', 'possibly', 'preschool', 'workers', 'will', 'be', 'expected', 'to', 'carry', 'out', 'a', 'therapy', 'guided', 'programme', '.', 'The', 'amount', 'of', 'intervention', 'and', 'compliance', 'will', 'be', 'recorded', 'by', 'parents', '/', 'guardians', 'and', 'therapists', '.', 'Assessments', 'will', 'be', 'repeated', 'at', '10', 'weeks', 'and', '24', 'weeks', 'from', 'the', 'beginning', 'of', 'the', 'trial', '.', 'The', 'results', 'of', 'the', 'trial', 'will', 'contribute', 'to', 'the', 'evidence', 'on', 'the', 'effectiveness', 'of', 'CIMT', 'in', 'the', 'preschool', 'child', 'with', 'HCP', ',', 'and', 'will', 'also', 'provide', 'evidence', 'on', 'the', 'implementation', 'of', 'CIMT', 'delivery', 'within', 'the', 'current', 'NHS', 'therapy', 'services', '.', '\\n\\n', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 54,
                "end": 89,
                "text": "Constraint Induced Movement Therapy",
                "type": "OTHER"
            },
            {
                "start": 175,
                "end": 200,
                "text": "Hemiplegic Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 203,
                "end": 217,
                "text": "Cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 333,
                "end": 358,
                "text": "hemiplegic cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 652,
                "end": 687,
                "text": "Constraint induced movement therapy",
                "type": "OTHER"
            },
            {
                "start": 746,
                "end": 749,
                "text": "HCP",
                "type": "CONDITION"
            },
            {
                "start": 896,
                "end": 926,
                "text": "CIMT using prolonged restraint",
                "type": "OTHER"
            },
            {
                "start": 932,
                "end": 965,
                "text": "CIMT using brief manual restraint",
                "type": "OTHER"
            },
            {
                "start": 2010,
                "end": 2014,
                "text": "CIMT",
                "type": "OTHER"
            },
            {
                "start": 2043,
                "end": 2046,
                "text": "HCP",
                "type": "CONDITION"
            },
            {
                "start": 2104,
                "end": 2108,
                "text": "CIMT",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02576587",
        "study_official_title": "Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation ",
        "study_brief_summary": " The Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation study.\n\nThe study involves a case control design to investigate the extent to which there is an independent relationship of sleep disordered breathing (SDB) and paroxysmal atrial fibrillation (PAF). Cases will be defined as clinically identified patients with PAF and controls as those without AF. In order to rigorously address important biologic confounding influences, the cases and controls will be individually matched based upon age, gender, race, and body mass index. Those participants with both PAF and SDB (Apnea Hypopnea Index, AHI>=15) will be asked to return for a follow up exam after 3 months of SDB treatment in the Clinical Research Unit (CRU) for collection of the same measures collected at the baseline exam to observe for any significant changes with the purpose of collecting effect size data to inform future clinical trials.\n\nThe total duration of the study is 4 years. The duration for any individual participant is up to from one to 13 weeks months, including a 3-month treatment period for those with moderate to severe SDB, i.e. AHI>15.",
        "text": "Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation | The Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation study.\n\nThe study involves a case control design to investigate the extent to which there is an independent relationship of sleep disordered breathing (SDB) and paroxysmal atrial fibrillation (PAF). Cases will be defined as clinically identified patients with PAF and controls as those without AF. In order to rigorously address important biologic confounding influences, the cases and controls will be individually matched based upon age, gender, race, and body mass index. Those participants with both PAF and SDB (Apnea Hypopnea Index, AHI>=15) will be asked to return for a follow up exam after 3 months of SDB treatment in the Clinical Research Unit (CRU) for collection of the same measures collected at the baseline exam to observe for any significant changes with the purpose of collecting effect size data to inform future clinical trials.\n\nThe total duration of the study is 4 years. The duration for any individual participant is up to from one to 13 weeks months, including a 3-month treatment period for those with moderate to severe SDB, i.e. AHI>15.",
        "tokens": "['Elucidation', 'of', 'the', 'Influence', 'of', 'Sleep', 'Apnea', 'on', 'Risk', 'of', 'Atrial', 'Fibrillation', '|', 'The', 'Elucidation', 'of', 'the', 'Influence', 'of', 'Sleep', 'Apnea', 'on', 'Risk', 'of', 'Atrial', 'Fibrillation', 'study', '.', '\\n\\n', 'The', 'study', 'involves', 'a', 'case', 'control', 'design', 'to', 'investigate', 'the', 'extent', 'to', 'which', 'there', 'is', 'an', 'independent', 'relationship', 'of', 'sleep', 'disordered', 'breathing', '(', 'SDB', ')', 'and', 'paroxysmal', 'atrial', 'fibrillation', '(', 'PAF', ')', '.', 'Cases', 'will', 'be', 'defined', 'as', 'clinically', 'identified', 'patients', 'with', 'PAF', 'and', 'controls', 'as', 'those', 'without', 'AF', '.', 'In', 'order', 'to', 'rigorously', 'address', 'important', 'biologic', 'confounding', 'influences', ',', 'the', 'cases', 'and', 'controls', 'will', 'be', 'individually', 'matched', 'based', 'upon', 'age', ',', 'gender', ',', 'race', ',', 'and', 'body', 'mass', 'index', '.', 'Those', 'participants', 'with', 'both', 'PAF', 'and', 'SDB', '(', 'Apnea', 'Hypopnea', 'Index', ',', 'AHI>=15', ')', 'will', 'be', 'asked', 'to', 'return', 'for', 'a', 'follow', 'up', 'exam', 'after', '3', 'months', 'of', 'SDB', 'treatment', 'in', 'the', 'Clinical', 'Research', 'Unit', '(', 'CRU', ')', 'for', 'collection', 'of', 'the', 'same', 'measures', 'collected', 'at', 'the', 'baseline', 'exam', 'to', 'observe', 'for', 'any', 'significant', 'changes', 'with', 'the', 'purpose', 'of', 'collecting', 'effect', 'size', 'data', 'to', 'inform', 'future', 'clinical', 'trials', '.', '\\n\\n', 'The', 'total', 'duration', 'of', 'the', 'study', 'is', '4', 'years', '.', 'The', 'duration', 'for', 'any', 'individual', 'participant', 'is', 'up', 'to', 'from', 'one', 'to', '13', 'weeks', 'months', ',', 'including', 'a', '3', '-', 'month', 'treatment', 'period', 'for', 'those', 'with', 'moderate', 'to', 'severe', 'SDB', ',', 'i.e.', 'AHI>15', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 43,
                "text": "Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 55,
                "end": 74,
                "text": "Atrial Fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 124,
                "text": "Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 155,
                "text": "Atrial Fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 280,
                "end": 306,
                "text": "sleep disordered breathing",
                "type": "CONDITION"
            },
            {
                "start": 308,
                "end": 311,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 317,
                "end": 347,
                "text": "paroxysmal atrial fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 349,
                "end": 352,
                "text": "PAF",
                "type": "CONDITION"
            },
            {
                "start": 416,
                "end": 419,
                "text": "PAF",
                "type": "CONDITION"
            },
            {
                "start": 450,
                "end": 452,
                "text": "AF",
                "type": "CONDITION"
            },
            {
                "start": 660,
                "end": 663,
                "text": "PAF",
                "type": "CONDITION"
            },
            {
                "start": 668,
                "end": 671,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 767,
                "end": 770,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 1184,
                "end": 1206,
                "text": "moderate to severe SDB",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05132543",
        "study_official_title": "Studying Human Cognition and Neurological Disorders Using \u00c2\u00b5ECoG Electrodes ",
        "study_brief_summary": " The overall purpose of this study is to better understand human cognition and human epilepsy by working with patients undergoing clinical treatment for pharmacologically resistant epilepsy. The investigators will investigate human cognition by conducting controlled experiments that focus on sensory, motor, and cognitive phenomena such as sensory processing, memory, and language. The investigators will also examine the neural underpinnings of epilepsy during both sleep and wakefulness to better understand both the foundations of epilepsy and how epilepsy affects cognition. The investigators hope to use these data to have a better understanding of cognition, epilepsy, and how the two interact. This will potentially lead to better markers for seizure onsets as well as epilepsy more generally. For this research, the investigators will use \u03bcECoG arrays manufactured by commercial partners. These arrays have passed all major ISO 10993 bio-compatibility tests. Based on this characterization and use in the intraoperative setting (limited duration and supervised usage), these devices pose a minimal risk to participants. Data will be analyzed and protected using the Duke SSRI protected research data network.",
        "text": "Studying Human Cognition and Neurological Disorders Using \u00c2\u00b5ECoG Electrodes | The overall purpose of this study is to better understand human cognition and human epilepsy by working with patients undergoing clinical treatment for pharmacologically resistant epilepsy. The investigators will investigate human cognition by conducting controlled experiments that focus on sensory, motor, and cognitive phenomena such as sensory processing, memory, and language. The investigators will also examine the neural underpinnings of epilepsy during both sleep and wakefulness to better understand both the foundations of epilepsy and how epilepsy affects cognition. The investigators hope to use these data to have a better understanding of cognition, epilepsy, and how the two interact. This will potentially lead to better markers for seizure onsets as well as epilepsy more generally. For this research, the investigators will use \u03bcECoG arrays manufactured by commercial partners. These arrays have passed all major ISO 10993 bio-compatibility tests. Based on this characterization and use in the intraoperative setting (limited duration and supervised usage), these devices pose a minimal risk to participants. Data will be analyzed and protected using the Duke SSRI protected research data network.",
        "tokens": "['Studying', 'Human', 'Cognition', 'and', 'Neurological', 'Disorders', 'Using', '\u00c2\u00b5ECoG', 'Electrodes', '|', 'The', 'overall', 'purpose', 'of', 'this', 'study', 'is', 'to', 'better', 'understand', 'human', 'cognition', 'and', 'human', 'epilepsy', 'by', 'working', 'with', 'patients', 'undergoing', 'clinical', 'treatment', 'for', 'pharmacologically', 'resistant', 'epilepsy', '.', 'The', 'investigators', 'will', 'investigate', 'human', 'cognition', 'by', 'conducting', 'controlled', 'experiments', 'that', 'focus', 'on', 'sensory', ',', 'motor', ',', 'and', 'cognitive', 'phenomena', 'such', 'as', 'sensory', 'processing', ',', 'memory', ',', 'and', 'language', '.', 'The', 'investigators', 'will', 'also', 'examine', 'the', 'neural', 'underpinnings', 'of', 'epilepsy', 'during', 'both', 'sleep', 'and', 'wakefulness', 'to', 'better', 'understand', 'both', 'the', 'foundations', 'of', 'epilepsy', 'and', 'how', 'epilepsy', 'affects', 'cognition', '.', 'The', 'investigators', 'hope', 'to', 'use', 'these', 'data', 'to', 'have', 'a', 'better', 'understanding', 'of', 'cognition', ',', 'epilepsy', ',', 'and', 'how', 'the', 'two', 'interact', '.', 'This', 'will', 'potentially', 'lead', 'to', 'better', 'markers', 'for', 'seizure', 'onsets', 'as', 'well', 'as', 'epilepsy', 'more', 'generally', '.', 'For', 'this', 'research', ',', 'the', 'investigators', 'will', 'use', '\u03bcECoG', 'arrays', 'manufactured', 'by', 'commercial', 'partners', '.', 'These', 'arrays', 'have', 'passed', 'all', 'major', 'ISO', '10993', 'bio', '-', 'compatibility', 'tests', '.', 'Based', 'on', 'this', 'characterization', 'and', 'use', 'in', 'the', 'intraoperative', 'setting', '(', 'limited', 'duration', 'and', 'supervised', 'usage', ')', ',', 'these', 'devices', 'pose', 'a', 'minimal', 'risk', 'to', 'participants', '.', 'Data', 'will', 'be', 'analyzed', 'and', 'protected', 'using', 'the', 'Duke', 'SSRI', 'protected', 'research', 'data', 'network', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT00990093",
        "study_official_title": "A Randomised, Cross-over, Open-labelled Study Evaluating the Acceptance of Test Catheters Compared to SpeediCath Catheters ",
        "study_brief_summary": " The purpose of this study is to evaluate that the test catheter is no less accepted than the SpeediCath (SC) catheter.",
        "text": "A Randomised, Cross-over, Open-labelled Study Evaluating the Acceptance of Test Catheters Compared to SpeediCath Catheters | The purpose of this study is to evaluate that the test catheter is no less accepted than the SpeediCath (SC) catheter.",
        "tokens": "['A', 'Randomised', ',', 'Cross', '-', 'over', ',', 'Open', '-', 'labelled', 'Study', 'Evaluating', 'the', 'Acceptance', 'of', 'Test', 'Catheters', 'Compared', 'to', 'SpeediCath', 'Catheters', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'that', 'the', 'test', 'catheter', 'is', 'no', 'less', 'accepted', 'than', 'the', 'SpeediCath', '(', 'SC', ')', 'catheter', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 75,
                "end": 89,
                "text": "Test Catheters",
                "type": "OTHER"
            },
            {
                "start": 102,
                "end": 122,
                "text": "SpeediCath Catheters",
                "type": "OTHER"
            },
            {
                "start": 175,
                "end": 188,
                "text": "test catheter",
                "type": "OTHER"
            },
            {
                "start": 218,
                "end": 242,
                "text": "SpeediCath (SC) catheter",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02351921",
        "study_official_title": "Repetitive Transcranial Magnetic Stimulation in Individuals With Spinal Cord Injury: A Pilot Study ",
        "study_brief_summary": " This study will investigate how repetitive transcranial magnetic stimulation delivered as a protocol called 'continuous theta-burst stimulation (cTBS)' alters motor output and force control to a muscle in the forearm and touch perception in individuals with chronic, incomplete spinal cord injury. CTBS is a non-invasive technique that involved repetitive delivery of transcranial magnetic stimulation at a frequency of 30 Hz over the arm representation in the primary motor or sensory cortex. The purpose of this study is to determine whether cTBS is an effective intervention to increase motor output to a muscle and increase force control of that muscle and also improve the sense of touch.",
        "text": "Repetitive Transcranial Magnetic Stimulation in Individuals With Spinal Cord Injury: A Pilot Study | This study will investigate how repetitive transcranial magnetic stimulation delivered as a protocol called 'continuous theta-burst stimulation (cTBS)' alters motor output and force control to a muscle in the forearm and touch perception in individuals with chronic, incomplete spinal cord injury. CTBS is a non-invasive technique that involved repetitive delivery of transcranial magnetic stimulation at a frequency of 30 Hz over the arm representation in the primary motor or sensory cortex. The purpose of this study is to determine whether cTBS is an effective intervention to increase motor output to a muscle and increase force control of that muscle and also improve the sense of touch.",
        "tokens": "['Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', 'in', 'Individuals', 'With', 'Spinal', 'Cord', 'Injury', ':', 'A', 'Pilot', 'Study', '|', 'This', 'study', 'will', 'investigate', 'how', 'repetitive', 'transcranial', 'magnetic', 'stimulation', 'delivered', 'as', 'a', 'protocol', 'called', \"'\", 'continuous', 'theta', '-', 'burst', 'stimulation', '(', 'cTBS', ')', \"'\", 'alters', 'motor', 'output', 'and', 'force', 'control', 'to', 'a', 'muscle', 'in', 'the', 'forearm', 'and', 'touch', 'perception', 'in', 'individuals', 'with', 'chronic', ',', 'incomplete', 'spinal', 'cord', 'injury', '.', 'CTBS', 'is', 'a', 'non', '-', 'invasive', 'technique', 'that', 'involved', 'repetitive', 'delivery', 'of', 'transcranial', 'magnetic', 'stimulation', 'at', 'a', 'frequency', 'of', '30', 'Hz', 'over', 'the', 'arm', 'representation', 'in', 'the', 'primary', 'motor', 'or', 'sensory', 'cortex', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'cTBS', 'is', 'an', 'effective', 'intervention', 'to', 'increase', 'motor', 'output', 'to', 'a', 'muscle', 'and', 'increase', 'force', 'control', 'of', 'that', 'muscle', 'and', 'also', 'improve', 'the', 'sense', 'of', 'touch', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 44,
                "text": "Repetitive Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 65,
                "end": 83,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 133,
                "end": 177,
                "text": "repetitive transcranial magnetic stimulation",
                "type": "OTHER"
            },
            {
                "start": 210,
                "end": 244,
                "text": "continuous theta-burst stimulation",
                "type": "OTHER"
            },
            {
                "start": 246,
                "end": 250,
                "text": "cTBS",
                "type": "OTHER"
            },
            {
                "start": 359,
                "end": 397,
                "text": "chronic, incomplete spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 399,
                "end": 403,
                "text": "CTBS",
                "type": "OTHER"
            },
            {
                "start": 469,
                "end": 502,
                "text": "transcranial magnetic stimulation",
                "type": "OTHER"
            },
            {
                "start": 645,
                "end": 649,
                "text": "cTBS",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02438553",
        "study_official_title": "A Prospective, Randomized, Single Blind, Parallel-group, Placebo Controlled Clinical Study to Evaluate the Short-term Effectiveness of Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation (OS-TNS) in Reducing Migraine Related Pain ",
        "study_brief_summary": " The purpose of this study is to evaluate the short-term effectiveness of combined occipital and supraorbital transcutaneous nerve stimulation in reducing migraine related pain.",
        "text": "A Prospective, Randomized, Single Blind, Parallel-group, Placebo Controlled Clinical Study to Evaluate the Short-term Effectiveness of Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation (OS-TNS) in Reducing Migraine Related Pain | The purpose of this study is to evaluate the short-term effectiveness of combined occipital and supraorbital transcutaneous nerve stimulation in reducing migraine related pain.",
        "tokens": "['A', 'Prospective', ',', 'Randomized', ',', 'Single', 'Blind', ',', 'Parallel', '-', 'group', ',', 'Placebo', 'Controlled', 'Clinical', 'Study', 'to', 'Evaluate', 'the', 'Short', '-', 'term', 'Effectiveness', 'of', 'Combined', 'Occipital', 'and', 'Supraorbital', 'Transcutaneous', 'Nerve', 'Stimulation', '(', 'OS', '-', 'TNS', ')', 'in', 'Reducing', 'Migraine', 'Related', 'Pain', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'short', '-', 'term', 'effectiveness', 'of', 'combined', 'occipital', 'and', 'supraorbital', 'transcutaneous', 'nerve', 'stimulation', 'in', 'reducing', 'migraine', 'related', 'pain', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 57,
                "end": 64,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 135,
                "end": 203,
                "text": "Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 205,
                "end": 211,
                "text": "OS-TNS",
                "type": "OTHER"
            },
            {
                "start": 225,
                "end": 233,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 246,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 390,
                "text": "combined occipital and supraorbital transcutaneous nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 403,
                "end": 411,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 420,
                "end": 424,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02644980",
        "study_official_title": "Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery,A Randomized Controlled Double-Blinded Study ",
        "study_brief_summary": " For patients requiring the heart valve replacement surgery, heart function is injured in different degree.Thus, minimizing the impact of the anesthesia drug on the cardiovascular system has important clinical meanings. Etomidate has slight effect on the cardiovascular system, often used in the induction of anesthesia, however target controlled infusion etomidate in maintenance of anesthesia is less used. So, the trial is designed to observe the application value of TCI etomidate in thoracoscopic mitral valve replacement surgery.",
        "text": "Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery,A Randomized Controlled Double-Blinded Study | For patients requiring the heart valve replacement surgery, heart function is injured in different degree.Thus, minimizing the impact of the anesthesia drug on the cardiovascular system has important clinical meanings. Etomidate has slight effect on the cardiovascular system, often used in the induction of anesthesia, however target controlled infusion etomidate in maintenance of anesthesia is less used. So, the trial is designed to observe the application value of TCI etomidate in thoracoscopic mitral valve replacement surgery.",
        "tokens": "['Target', 'Controlled', 'Infusion', 'of', 'Etomidate', 'or', 'Propofol', 'for', 'Anesthesia', 'of', 'Thoracoscopic', 'Mitral', 'Valve', 'Replacement', 'Surgery', ',', 'A', 'Randomized', 'Controlled', 'Double', '-', 'Blinded', 'Study', '|', 'For', 'patients', 'requiring', 'the', 'heart', 'valve', 'replacement', 'surgery', ',', 'heart', 'function', 'is', 'injured', 'in', 'different', 'degree', '.', 'Thus', ',', 'minimizing', 'the', 'impact', 'of', 'the', 'anesthesia', 'drug', 'on', 'the', 'cardiovascular', 'system', 'has', 'important', 'clinical', 'meanings', '.', 'Etomidate', 'has', 'slight', 'effect', 'on', 'the', 'cardiovascular', 'system', ',', 'often', 'used', 'in', 'the', 'induction', 'of', 'anesthesia', ',', 'however', 'target', 'controlled', 'infusion', 'etomidate', 'in', 'maintenance', 'of', 'anesthesia', 'is', 'less', 'used', '.', 'So', ',', 'the', 'trial', 'is', 'designed', 'to', 'observe', 'the', 'application', 'value', 'of', 'TCI', 'etomidate', 'in', 'thoracoscopic', 'mitral', 'valve', 'replacement', 'surgery', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 39,
                "text": "Etomidate",
                "type": "DRUG"
            },
            {
                "start": 43,
                "end": 51,
                "text": "Propofol",
                "type": "DRUG"
            },
            {
                "start": 70,
                "end": 108,
                "text": "Thoracoscopic Mitral Valve Replacement",
                "type": "CONDITION"
            },
            {
                "start": 191,
                "end": 214,
                "text": "heart valve replacement",
                "type": "CONDITION"
            },
            {
                "start": 383,
                "end": 392,
                "text": "Etomidate",
                "type": "DRUG"
            },
            {
                "start": 519,
                "end": 528,
                "text": "etomidate",
                "type": "DRUG"
            },
            {
                "start": 638,
                "end": 647,
                "text": "etomidate",
                "type": "DRUG"
            },
            {
                "start": 651,
                "end": 689,
                "text": "thoracoscopic mitral valve replacement",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03359772",
        "study_official_title": "Effectiveness of Balance Training With Kinesthetic Ability Trainer-KAT2000 in Patients With Peripheral Neuropathic Pain: a Randomized Controlled Study ",
        "study_brief_summary": " Objective: To determine the effectiveness of balance training with Kinesthetic Ability Trainer 2000 (KAT 2000) in patients with peripheral neuropathic pain related balance disorder.\n\nMethods: A total of 60 patients who developed peripheral neuropathic pain-related balance impairment in the chronic phase due to lumber disc herniation, lumber spondylosis and gonarthrosis were included into this randomized controlled prospective study and randomized into either balance exercises groups or KAT 2000 exercises groups. Balance exercises were given all patients in Group 1 (n=30). In addition to balance exercises, KAT 2000 balance exercises were given all patients in group 2 (n=30). All patients received 45-min individualized training session for three times a week for 4 weeks. Patients were evaluated according to pain, static and dynamic balance and quality of life (QoL).",
        "text": "Effectiveness of Balance Training With Kinesthetic Ability Trainer-KAT2000 in Patients With Peripheral Neuropathic Pain: a Randomized Controlled Study | Objective: To determine the effectiveness of balance training with Kinesthetic Ability Trainer 2000 (KAT 2000) in patients with peripheral neuropathic pain related balance disorder.\n\nMethods: A total of 60 patients who developed peripheral neuropathic pain-related balance impairment in the chronic phase due to lumber disc herniation, lumber spondylosis and gonarthrosis were included into this randomized controlled prospective study and randomized into either balance exercises groups or KAT 2000 exercises groups. Balance exercises were given all patients in Group 1 (n=30). In addition to balance exercises, KAT 2000 balance exercises were given all patients in group 2 (n=30). All patients received 45-min individualized training session for three times a week for 4 weeks. Patients were evaluated according to pain, static and dynamic balance and quality of life (QoL).",
        "tokens": "['Effectiveness', 'of', 'Balance', 'Training', 'With', 'Kinesthetic', 'Ability', 'Trainer', '-', 'KAT2000', 'in', 'Patients', 'With', 'Peripheral', 'Neuropathic', 'Pain', ':', 'a', 'Randomized', 'Controlled', 'Study', '|', 'Objective', ':', 'To', 'determine', 'the', 'effectiveness', 'of', 'balance', 'training', 'with', 'Kinesthetic', 'Ability', 'Trainer', '2000', '(', 'KAT', '2000', ')', 'in', 'patients', 'with', 'peripheral', 'neuropathic', 'pain', 'related', 'balance', 'disorder', '.', '\\n\\n', 'Methods', ':', 'A', 'total', 'of', '60', 'patients', 'who', 'developed', 'peripheral', 'neuropathic', 'pain', '-', 'related', 'balance', 'impairment', 'in', 'the', 'chronic', 'phase', 'due', 'to', 'lumber', 'disc', 'herniation', ',', 'lumber', 'spondylosis', 'and', 'gonarthrosis', 'were', 'included', 'into', 'this', 'randomized', 'controlled', 'prospective', 'study', 'and', 'randomized', 'into', 'either', 'balance', 'exercises', 'groups', 'or', 'KAT', '2000', 'exercises', 'groups', '.', 'Balance', 'exercises', 'were', 'given', 'all', 'patients', 'in', 'Group', '1', '(', 'n=30', ')', '.', 'In', 'addition', 'to', 'balance', 'exercises', ',', 'KAT', '2000', 'balance', 'exercises', 'were', 'given', 'all', 'patients', 'in', 'group', '2', '(', 'n=30', ')', '.', 'All', 'patients', 'received', '45', '-', 'min', 'individualized', 'training', 'session', 'for', 'three', 'times', 'a', 'week', 'for', '4', 'weeks', '.', 'Patients', 'were', 'evaluated', 'according', 'to', 'pain', ',', 'static', 'and', 'dynamic', 'balance', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 74,
                "text": "Kinesthetic Ability Trainer-KAT2000",
                "type": "PHYSICAL"
            },
            {
                "start": 92,
                "end": 119,
                "text": "Peripheral Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 252,
                "text": "Kinesthetic Ability Trainer 2000",
                "type": "PHYSICAL"
            },
            {
                "start": 254,
                "end": 262,
                "text": "KAT 2000",
                "type": "PHYSICAL"
            },
            {
                "start": 281,
                "end": 308,
                "text": "peripheral neuropathic pain",
                "type": "CONDITION"
            },
            {
                "start": 317,
                "end": 333,
                "text": "balance disorder",
                "type": "CONDITION"
            },
            {
                "start": 382,
                "end": 409,
                "text": "peripheral neuropathic pain",
                "type": "CONDITION"
            },
            {
                "start": 418,
                "end": 425,
                "text": "balance",
                "type": "CONDITION"
            },
            {
                "start": 465,
                "end": 487,
                "text": "lumber disc herniation",
                "type": "CONDITION"
            },
            {
                "start": 489,
                "end": 507,
                "text": "lumber spondylosis",
                "type": "CONDITION"
            },
            {
                "start": 512,
                "end": 524,
                "text": "gonarthrosis",
                "type": "CONDITION"
            },
            {
                "start": 616,
                "end": 633,
                "text": "balance exercises",
                "type": "CONTROL"
            },
            {
                "start": 644,
                "end": 662,
                "text": "KAT 2000 exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 671,
                "end": 688,
                "text": "Balance exercises",
                "type": "CONTROL"
            },
            {
                "start": 747,
                "end": 764,
                "text": "balance exercises",
                "type": "CONTROL"
            },
            {
                "start": 766,
                "end": 792,
                "text": "KAT 2000 balance exercises",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT05527587",
        "study_official_title": "Examining the Effects of an 8-Week Open Label Nature-Based Park Visit Program on the Quality of Life, Behaviors and Cognitive Symptoms of Individuals With Dementia and Their Caregivers ",
        "study_brief_summary": " The overall goals of our project is to understand the effects of participating in park visits and nature-based activities for people living with dementia and their caregivers. Nature-based activities such as park visits can have beneficial effects on quality of life, psychological symptoms and physical health. However, there may be barriers for people with dementia and their caregivers that may prevent them from engaging in park visits. The Nature Connections park visit program will provide education sessions for 10 persons living with dementia and 10 caregivers highlighting the beneficial effects of park visits and address common barriers to participating in park visits. Following the education session participants will be provided with weekly telephone/internet support meetings for participants to share their experiences with park visits and to address any challenges individuals encountered when trying to complete their visits. The impact of park visits on quality of life, behaviours, and measures of stress for people with dementia and their caregivers will be assessed over 8 weeks. Following completion of the program participants will provide an evaluation of the program to understand their experience and satisfaction with the program. This project will provide new information about the effects of park visits as a practical strategy to improve the quality of life, psychological symptoms and measures of stress for both people with dementia and caregivers.",
        "text": "Examining the Effects of an 8-Week Open Label Nature-Based Park Visit Program on the Quality of Life, Behaviors and Cognitive Symptoms of Individuals With Dementia and Their Caregivers | The overall goals of our project is to understand the effects of participating in park visits and nature-based activities for people living with dementia and their caregivers. Nature-based activities such as park visits can have beneficial effects on quality of life, psychological symptoms and physical health. However, there may be barriers for people with dementia and their caregivers that may prevent them from engaging in park visits. The Nature Connections park visit program will provide education sessions for 10 persons living with dementia and 10 caregivers highlighting the beneficial effects of park visits and address common barriers to participating in park visits. Following the education session participants will be provided with weekly telephone/internet support meetings for participants to share their experiences with park visits and to address any challenges individuals encountered when trying to complete their visits. The impact of park visits on quality of life, behaviours, and measures of stress for people with dementia and their caregivers will be assessed over 8 weeks. Following completion of the program participants will provide an evaluation of the program to understand their experience and satisfaction with the program. This project will provide new information about the effects of park visits as a practical strategy to improve the quality of life, psychological symptoms and measures of stress for both people with dementia and caregivers.",
        "tokens": "['Examining', 'the', 'Effects', 'of', 'an', '8', '-', 'Week', 'Open', 'Label', 'Nature', '-', 'Based', 'Park', 'Visit', 'Program', 'on', 'the', 'Quality', 'of', 'Life', ',', 'Behaviors', 'and', 'Cognitive', 'Symptoms', 'of', 'Individuals', 'With', 'Dementia', 'and', 'Their', 'Caregivers', '|', 'The', 'overall', 'goals', 'of', 'our', 'project', 'is', 'to', 'understand', 'the', 'effects', 'of', 'participating', 'in', 'park', 'visits', 'and', 'nature', '-', 'based', 'activities', 'for', 'people', 'living', 'with', 'dementia', 'and', 'their', 'caregivers', '.', 'Nature', '-', 'based', 'activities', 'such', 'as', 'park', 'visits', 'can', 'have', 'beneficial', 'effects', 'on', 'quality', 'of', 'life', ',', 'psychological', 'symptoms', 'and', 'physical', 'health', '.', 'However', ',', 'there', 'may', 'be', 'barriers', 'for', 'people', 'with', 'dementia', 'and', 'their', 'caregivers', 'that', 'may', 'prevent', 'them', 'from', 'engaging', 'in', 'park', 'visits', '.', 'The', 'Nature', 'Connections', 'park', 'visit', 'program', 'will', 'provide', 'education', 'sessions', 'for', '10', 'persons', 'living', 'with', 'dementia', 'and', '10', 'caregivers', 'highlighting', 'the', 'beneficial', 'effects', 'of', 'park', 'visits', 'and', 'address', 'common', 'barriers', 'to', 'participating', 'in', 'park', 'visits', '.', 'Following', 'the', 'education', 'session', 'participants', 'will', 'be', 'provided', 'with', 'weekly', 'telephone', '/', 'internet', 'support', 'meetings', 'for', 'participants', 'to', 'share', 'their', 'experiences', 'with', 'park', 'visits', 'and', 'to', 'address', 'any', 'challenges', 'individuals', 'encountered', 'when', 'trying', 'to', 'complete', 'their', 'visits', '.', 'The', 'impact', 'of', 'park', 'visits', 'on', 'quality', 'of', 'life', ',', 'behaviours', ',', 'and', 'measures', 'of', 'stress', 'for', 'people', 'with', 'dementia', 'and', 'their', 'caregivers', 'will', 'be', 'assessed', 'over', '8', 'weeks', '.', 'Following', 'completion', 'of', 'the', 'program', 'participants', 'will', 'provide', 'an', 'evaluation', 'of', 'the', 'program', 'to', 'understand', 'their', 'experience', 'and', 'satisfaction', 'with', 'the', 'program', '.', 'This', 'project', 'will', 'provide', 'new', 'information', 'about', 'the', 'effects', 'of', 'park', 'visits', 'as', 'a', 'practical', 'strategy', 'to', 'improve', 'the', 'quality', 'of', 'life', ',', 'psychological', 'symptoms', 'and', 'measures', 'of', 'stress', 'for', 'both', 'people', 'with', 'dementia', 'and', 'caregivers', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 46,
                "end": 77,
                "text": "Nature-Based Park Visit Program",
                "type": "OTHER"
            },
            {
                "start": 155,
                "end": 163,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 269,
                "end": 280,
                "text": "park visits",
                "type": "OTHER"
            },
            {
                "start": 285,
                "end": 308,
                "text": "nature-based activities",
                "type": "OTHER"
            },
            {
                "start": 332,
                "end": 340,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 386,
                "text": "Nature-based activities",
                "type": "OTHER"
            },
            {
                "start": 395,
                "end": 406,
                "text": "park visits",
                "type": "OTHER"
            },
            {
                "start": 546,
                "end": 554,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 615,
                "end": 626,
                "text": "park visits",
                "type": "OTHER"
            },
            {
                "start": 632,
                "end": 669,
                "text": "Nature Connections park visit program",
                "type": "OTHER"
            },
            {
                "start": 729,
                "end": 737,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 795,
                "end": 806,
                "text": "park visits",
                "type": "OTHER"
            },
            {
                "start": 855,
                "end": 866,
                "text": "park visits",
                "type": "OTHER"
            },
            {
                "start": 935,
                "end": 977,
                "text": "weekly telephone/internet support meetings",
                "type": "OTHER"
            },
            {
                "start": 1027,
                "end": 1038,
                "text": "park visits",
                "type": "OTHER"
            },
            {
                "start": 1145,
                "end": 1156,
                "text": "park visits",
                "type": "OTHER"
            },
            {
                "start": 1228,
                "end": 1236,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 1509,
                "end": 1520,
                "text": "park visits",
                "type": "OTHER"
            },
            {
                "start": 1644,
                "end": 1652,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02118701",
        "study_official_title": "SHARED DECISION MAKING ON A 'LIFE-AND-CARE PLAN' IN LONG-TERM CARE FACILITIES ",
        "study_brief_summary": " Shared Decision Making (SDM) is defined as a process where healthcare professionals and patients make decisions together, using the best available evidence. SDM, as a communication and decision method, can be used also with persons suffering from dementia. Yet, SDM with persons with dementia or even with their family caregivers is not widespread.\n\nThe present research project aims to develop and evaluate an SDM framework in care planning to be implemented in long-term care facilities, in order to obtain a constantly developing care plan that focuses not only on the medical, physical, psychosocial and spiritual needs of the resident, but that considers and documents his preferences and the actions taken by caregivers to meet them.\n\nThe current project is a controlled exploratory study. Case studies that involve a triad in each case, composed by the resident with moderate or severe dementia, his family caregiver and the professional usually taking care for the resident, will be used (n=16 professionals; n=40 residents; n=40 family caregivers). Professional caregivers of two nursing homes, one located in Italy and one in the Netherlands, will receive a specific training in SDM principles and will guide the SDM interview within the triad. Primary outcome will be the proportion of residents whose preferences and needs, together with the related actions to meet them, are known, documented and satisfied in their 'life-and-care plans'. Secondary outcomes are the residents' and family caregivers' quality of life; the family caregivers' sense of competence and the healthcare professionals' job satisfaction. Semi-structured interviews and focus group interviews will be performed to assess satisfaction with the intervention and barriers and facilitators to its implementation. Assessments are performed at baseline and six months after the intervention.\n\nWe hypothesize that the use of the SDM process in care planning will increase the number of met needs and will improve the residents' and family caregivers quality of life, the family caregivers' sense of competence and the healthcare professionals' job satisfaction.\n\nThe key element of this study is that it will contribute to our knowledge about the efficacy and feasibility of an SDM framework in care planning in long-term care facilities with persons with moderate to severe dementia.",
        "text": "SHARED DECISION MAKING ON A 'LIFE-AND-CARE PLAN' IN LONG-TERM CARE FACILITIES | Shared Decision Making (SDM) is defined as a process where healthcare professionals and patients make decisions together, using the best available evidence. SDM, as a communication and decision method, can be used also with persons suffering from dementia. Yet, SDM with persons with dementia or even with their family caregivers is not widespread.\n\nThe present research project aims to develop and evaluate an SDM framework in care planning to be implemented in long-term care facilities, in order to obtain a constantly developing care plan that focuses not only on the medical, physical, psychosocial and spiritual needs of the resident, but that considers and documents his preferences and the actions taken by caregivers to meet them.\n\nThe current project is a controlled exploratory study. Case studies that involve a triad in each case, composed by the resident with moderate or severe dementia, his family caregiver and the professional usually taking care for the resident, will be used (n=16 professionals; n=40 residents; n=40 family caregivers). Professional caregivers of two nursing homes, one located in Italy and one in the Netherlands, will receive a specific training in SDM principles and will guide the SDM interview within the triad. Primary outcome will be the proportion of residents whose preferences and needs, together with the related actions to meet them, are known, documented and satisfied in their 'life-and-care plans'. Secondary outcomes are the residents' and family caregivers' quality of life; the family caregivers' sense of competence and the healthcare professionals' job satisfaction. Semi-structured interviews and focus group interviews will be performed to assess satisfaction with the intervention and barriers and facilitators to its implementation. Assessments are performed at baseline and six months after the intervention.\n\nWe hypothesize that the use of the SDM process in care planning will increase the number of met needs and will improve the residents' and family caregivers quality of life, the family caregivers' sense of competence and the healthcare professionals' job satisfaction.\n\nThe key element of this study is that it will contribute to our knowledge about the efficacy and feasibility of an SDM framework in care planning in long-term care facilities with persons with moderate to severe dementia.",
        "tokens": "['SHARED', 'DECISION', 'MAKING', 'ON', 'A', \"'\", 'LIFE', '-', 'AND', '-', 'CARE', 'PLAN', \"'\", 'IN', 'LONG', '-', 'TERM', 'CARE', 'FACILITIES', '|', 'Shared', 'Decision', 'Making', '(', 'SDM', ')', 'is', 'defined', 'as', 'a', 'process', 'where', 'healthcare', 'professionals', 'and', 'patients', 'make', 'decisions', 'together', ',', 'using', 'the', 'best', 'available', 'evidence', '.', 'SDM', ',', 'as', 'a', 'communication', 'and', 'decision', 'method', ',', 'can', 'be', 'used', 'also', 'with', 'persons', 'suffering', 'from', 'dementia', '.', 'Yet', ',', 'SDM', 'with', 'persons', 'with', 'dementia', 'or', 'even', 'with', 'their', 'family', 'caregivers', 'is', 'not', 'widespread', '.', '\\n\\n', 'The', 'present', 'research', 'project', 'aims', 'to', 'develop', 'and', 'evaluate', 'an', 'SDM', 'framework', 'in', 'care', 'planning', 'to', 'be', 'implemented', 'in', 'long', '-', 'term', 'care', 'facilities', ',', 'in', 'order', 'to', 'obtain', 'a', 'constantly', 'developing', 'care', 'plan', 'that', 'focuses', 'not', 'only', 'on', 'the', 'medical', ',', 'physical', ',', 'psychosocial', 'and', 'spiritual', 'needs', 'of', 'the', 'resident', ',', 'but', 'that', 'considers', 'and', 'documents', 'his', 'preferences', 'and', 'the', 'actions', 'taken', 'by', 'caregivers', 'to', 'meet', 'them', '.', '\\n\\n', 'The', 'current', 'project', 'is', 'a', 'controlled', 'exploratory', 'study', '.', 'Case', 'studies', 'that', 'involve', 'a', 'triad', 'in', 'each', 'case', ',', 'composed', 'by', 'the', 'resident', 'with', 'moderate', 'or', 'severe', 'dementia', ',', 'his', 'family', 'caregiver', 'and', 'the', 'professional', 'usually', 'taking', 'care', 'for', 'the', 'resident', ',', 'will', 'be', 'used', '(', 'n=16', 'professionals', ';', 'n=40', 'residents', ';', 'n=40', 'family', 'caregivers', ')', '.', 'Professional', 'caregivers', 'of', 'two', 'nursing', 'homes', ',', 'one', 'located', 'in', 'Italy', 'and', 'one', 'in', 'the', 'Netherlands', ',', 'will', 'receive', 'a', 'specific', 'training', 'in', 'SDM', 'principles', 'and', 'will', 'guide', 'the', 'SDM', 'interview', 'within', 'the', 'triad', '.', 'Primary', 'outcome', 'will', 'be', 'the', 'proportion', 'of', 'residents', 'whose', 'preferences', 'and', 'needs', ',', 'together', 'with', 'the', 'related', 'actions', 'to', 'meet', 'them', ',', 'are', 'known', ',', 'documented', 'and', 'satisfied', 'in', 'their', \"'\", 'life', '-', 'and', '-', 'care', 'plans', \"'\", '.', 'Secondary', 'outcomes', 'are', 'the', 'residents', \"'\", 'and', 'family', 'caregivers', \"'\", 'quality', 'of', 'life', ';', 'the', 'family', 'caregivers', \"'\", 'sense', 'of', 'competence', 'and', 'the', 'healthcare', 'professionals', \"'\", 'job', 'satisfaction', '.', 'Semi', '-', 'structured', 'interviews', 'and', 'focus', 'group', 'interviews', 'will', 'be', 'performed', 'to', 'assess', 'satisfaction', 'with', 'the', 'intervention', 'and', 'barriers', 'and', 'facilitators', 'to', 'its', 'implementation', '.', 'Assessments', 'are', 'performed', 'at', 'baseline', 'and', 'six', 'months', 'after', 'the', 'intervention', '.', '\\n\\n', 'We', 'hypothesize', 'that', 'the', 'use', 'of', 'the', 'SDM', 'process', 'in', 'care', 'planning', 'will', 'increase', 'the', 'number', 'of', 'met', 'needs', 'and', 'will', 'improve', 'the', 'residents', \"'\", 'and', 'family', 'caregivers', 'quality', 'of', 'life', ',', 'the', 'family', 'caregivers', \"'\", 'sense', 'of', 'competence', 'and', 'the', 'healthcare', 'professionals', \"'\", 'job', 'satisfaction', '.', '\\n\\n', 'The', 'key', 'element', 'of', 'this', 'study', 'is', 'that', 'it', 'will', 'contribute', 'to', 'our', 'knowledge', 'about', 'the', 'efficacy', 'and', 'feasibility', 'of', 'an', 'SDM', 'framework', 'in', 'care', 'planning', 'in', 'long', '-', 'term', 'care', 'facilities', 'with', 'persons', 'with', 'moderate', 'to', 'severe', 'dementia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 80,
                "end": 102,
                "text": "Shared Decision Making",
                "type": "OTHER"
            },
            {
                "start": 104,
                "end": 107,
                "text": "SDM",
                "type": "OTHER"
            },
            {
                "start": 327,
                "end": 335,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 342,
                "end": 345,
                "text": "SDM",
                "type": "OTHER"
            },
            {
                "start": 364,
                "end": 372,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 491,
                "end": 494,
                "text": "SDM",
                "type": "OTHER"
            },
            {
                "start": 954,
                "end": 981,
                "text": "moderate or severe dementia",
                "type": "CONDITION"
            },
            {
                "start": 1269,
                "end": 1272,
                "text": "SDM",
                "type": "OTHER"
            },
            {
                "start": 1303,
                "end": 1316,
                "text": "SDM interview",
                "type": "OTHER"
            },
            {
                "start": 1988,
                "end": 1991,
                "text": "SDM",
                "type": "OTHER"
            },
            {
                "start": 2337,
                "end": 2340,
                "text": "SDM",
                "type": "OTHER"
            },
            {
                "start": 2415,
                "end": 2442,
                "text": "moderate to severe dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01104792",
        "study_official_title": "Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia ",
        "study_brief_summary": " The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.",
        "text": "Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia | The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.",
        "tokens": "['Evaluation', 'of', 'the', 'Long', '-', 'term', 'Safety', ',', 'Tolerability', ',', 'and', 'Pharmacokinetics', 'of', 'Cariprazine', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'cariprazine', 'in', 'patients', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 74,
                "end": 85,
                "text": "Cariprazine",
                "type": "DRUG"
            },
            {
                "start": 103,
                "end": 116,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 222,
                "end": 233,
                "text": "cariprazine",
                "type": "DRUG"
            },
            {
                "start": 251,
                "end": 264,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04620876",
        "study_official_title": "Bimodal and Coaxial High Resolution Ophtalmic Imaging ",
        "study_brief_summary": " The knowledge of the pathogenesis of retinal affections, a major cause of blindness, has greatly benefited from recent advances in retinal imaging. However, optical aberrations of the ocular media limit the resolution that can be achieved by current techniques.\n\nThe use of an adaptive optics system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many retinal microstructures: photoreceptors, vessels, bundles of nerve fibers.\n\nRecently, the development of the coupling of the two main imaging techniques, the Adaptive Optics Ophthalmoscope with Optical Coherence Tomography, enables unparalleled three-dimensional in vivo cell-scale imaging, while remaining comfortable for the patients.\n\nThe purpose of this project is to evaluate the performance of this system for imaging micrometric retinal structures.",
        "text": "Bimodal and Coaxial High Resolution Ophtalmic Imaging | The knowledge of the pathogenesis of retinal affections, a major cause of blindness, has greatly benefited from recent advances in retinal imaging. However, optical aberrations of the ocular media limit the resolution that can be achieved by current techniques.\n\nThe use of an adaptive optics system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many retinal microstructures: photoreceptors, vessels, bundles of nerve fibers.\n\nRecently, the development of the coupling of the two main imaging techniques, the Adaptive Optics Ophthalmoscope with Optical Coherence Tomography, enables unparalleled three-dimensional in vivo cell-scale imaging, while remaining comfortable for the patients.\n\nThe purpose of this project is to evaluate the performance of this system for imaging micrometric retinal structures.",
        "tokens": "['Bimodal', 'and', 'Coaxial', 'High', 'Resolution', 'Ophtalmic', 'Imaging', '|', 'The', 'knowledge', 'of', 'the', 'pathogenesis', 'of', 'retinal', 'affections', ',', 'a', 'major', 'cause', 'of', 'blindness', ',', 'has', 'greatly', 'benefited', 'from', 'recent', 'advances', 'in', 'retinal', 'imaging', '.', 'However', ',', 'optical', 'aberrations', 'of', 'the', 'ocular', 'media', 'limit', 'the', 'resolution', 'that', 'can', 'be', 'achieved', 'by', 'current', 'techniques', '.', '\\n\\n', 'The', 'use', 'of', 'an', 'adaptive', 'optics', 'system', 'improves', 'the', 'resolution', 'of', 'ophthalmoscopes', 'by', 'several', 'orders', 'of', 'magnitude', ',', 'allowing', 'the', 'visualization', 'of', 'many', 'retinal', 'microstructures', ':', 'photoreceptors', ',', 'vessels', ',', 'bundles', 'of', 'nerve', 'fibers', '.', '\\n\\n', 'Recently', ',', 'the', 'development', 'of', 'the', 'coupling', 'of', 'the', 'two', 'main', 'imaging', 'techniques', ',', 'the', 'Adaptive', 'Optics', 'Ophthalmoscope', 'with', 'Optical', 'Coherence', 'Tomography', ',', 'enables', 'unparalleled', 'three', '-', 'dimensional', 'in', 'vivo', 'cell', '-', 'scale', 'imaging', ',', 'while', 'remaining', 'comfortable', 'for', 'the', 'patients', '.', '\\n\\n', 'The', 'purpose', 'of', 'this', 'project', 'is', 'to', 'evaluate', 'the', 'performance', 'of', 'this', 'system', 'for', 'imaging', 'micrometric', 'retinal', 'structures', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 130,
                "end": 139,
                "text": "blindness",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00469664",
        "study_official_title": "A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia ",
        "study_brief_summary": " Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than any of those medications alone in treating some of the cognitive impairment in schizophrenia.",
        "text": "A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia | Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than any of those medications alone in treating some of the cognitive impairment in schizophrenia.",
        "tokens": "['A', 'Double', 'Blind', 'Placebo', 'Controlled', 'Study', 'of', 'Guanfacine', 'Adjunctive', 'Treatment', 'to', 'Atypical', 'Antipsychotics', 'for', 'Cognitive', 'Dysfunction', 'in', 'Schizophrenia', '|', 'Our', 'overall', 'aim', 'is', 'to', 'determine', 'if', 'the', 'administration', 'of', 'guanfacine', 'in', 'combination', 'with', 'aripiprazole', ',', 'olanzapine', ',', 'quetiapine', ',', 'and/or', 'risperidone', 'is', 'significantly', 'more', 'effective', 'than', 'any', 'of', 'those', 'medications', 'alone', 'in', 'treating', 'some', 'of', 'the', 'cognitive', 'impairment', 'in', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 22,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 43,
                "end": 53,
                "text": "Guanfacine",
                "type": "DRUG"
            },
            {
                "start": 131,
                "end": 144,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 204,
                "end": 214,
                "text": "guanfacine",
                "type": "DRUG"
            },
            {
                "start": 235,
                "end": 247,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 249,
                "end": 259,
                "text": "olanzapine",
                "type": "DRUG"
            },
            {
                "start": 261,
                "end": 271,
                "text": "quetiapine",
                "type": "DRUG"
            },
            {
                "start": 280,
                "end": 291,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 384,
                "end": 404,
                "text": "cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 408,
                "end": 421,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03737214",
        "study_official_title": "A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease ",
        "study_brief_summary": " A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease",
        "text": "A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease",
        "tokens": "['A', 'Multi', '-', 'center', ',', 'Open', '-', 'label', ',', 'Uncontrolled', ',', 'Single', '-', 'arm', ',', 'Extension', 'Study', 'to', 'Determine', 'the', 'Long', '-', 'term', 'Safety', 'and', 'Tolerability', 'of', 'Oral', 'Lucerastat', 'in', 'Adult', 'Subjects', 'With', 'Fabry', 'Disease', '|', 'A', 'study', 'to', 'determine', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'oral', 'lucerastat', 'in', 'adult', 'subjects', 'with', 'Fabry', 'disease']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",
        "entities": [
            {
                "start": 129,
                "end": 139,
                "text": "Lucerastat",
                "type": "DRUG"
            },
            {
                "start": 163,
                "end": 176,
                "text": "Fabry Disease",
                "type": "CONDITION"
            },
            {
                "start": 246,
                "end": 256,
                "text": "lucerastat",
                "type": "DRUG"
            },
            {
                "start": 280,
                "end": 293,
                "text": "Fabry disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03276494",
        "study_official_title": "Intraosseous Administration of Hypertonic Saline in Acute Brain-injured Patients: A Prospective Case Series and Literature Review ",
        "study_brief_summary": " Hypertonic saline is used to treat elevated intracranial pressure. Intraosseous vascular access has been used to administer fluids and medications. This study combines these to administer 3% hypertonic saline via IO.",
        "text": "Intraosseous Administration of Hypertonic Saline in Acute Brain-injured Patients: A Prospective Case Series and Literature Review | Hypertonic saline is used to treat elevated intracranial pressure. Intraosseous vascular access has been used to administer fluids and medications. This study combines these to administer 3% hypertonic saline via IO.",
        "tokens": "['Intraosseous', 'Administration', 'of', 'Hypertonic', 'Saline', 'in', 'Acute', 'Brain', '-', 'injured', 'Patients', ':', 'A', 'Prospective', 'Case', 'Series', 'and', 'Literature', 'Review', '|', 'Hypertonic', 'saline', 'is', 'used', 'to', 'treat', 'elevated', 'intracranial', 'pressure', '.', 'Intraosseous', 'vascular', 'access', 'has', 'been', 'used', 'to', 'administer', 'fluids', 'and', 'medications', '.', 'This', 'study', 'combines', 'these', 'to', 'administer', '3', '%', 'hypertonic', 'saline', 'via', 'IO', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 48,
                "text": "Hypertonic Saline",
                "type": "DRUG"
            },
            {
                "start": 52,
                "end": 71,
                "text": "Acute Brain-injured",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 149,
                "text": "Hypertonic saline",
                "type": "DRUG"
            },
            {
                "start": 167,
                "end": 197,
                "text": "elevated intracranial pressure",
                "type": "CONDITION"
            },
            {
                "start": 323,
                "end": 340,
                "text": "hypertonic saline",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT01495923",
        "study_official_title": "Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy ",
        "study_brief_summary": " The purpose of this study is to determine whether pharmacotherapy or epidural steroid injections are a better treatment for lumbosacral radicular pain.\n\n142 patients referred to a participating pain clinic with lumbosacral radiculopathy will be randomized in a 1:1 ratio to receive one of two treatments. Half (n=71) of the patients will be allocated to receive an epidural steroid injection (ESI; group I), with an equal number allocated to receive gabapentin (group II). Patients & evaluating physicians will be blinded. Follow-up will be through 3-months after treatment.",
        "text": "Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy | The purpose of this study is to determine whether pharmacotherapy or epidural steroid injections are a better treatment for lumbosacral radicular pain.\n\n142 patients referred to a participating pain clinic with lumbosacral radiculopathy will be randomized in a 1:1 ratio to receive one of two treatments. Half (n=71) of the patients will be allocated to receive an epidural steroid injection (ESI; group I), with an equal number allocated to receive gabapentin (group II). Patients & evaluating physicians will be blinded. Follow-up will be through 3-months after treatment.",
        "tokens": "['Randomized', ',', 'Double', '-', 'blind', ',', 'Comparative', '-', 'effectiveness', 'Study', 'Comparing', 'Epidural', 'Steroid', 'Injections', 'to', 'Gabapentin', 'in', 'Patients', 'With', 'Lumbosacral', 'Radiculopathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'pharmacotherapy', 'or', 'epidural', 'steroid', 'injections', 'are', 'a', 'better', 'treatment', 'for', 'lumbosacral', 'radicular', 'pain', '.', '\\n\\n', '142', 'patients', 'referred', 'to', 'a', 'participating', 'pain', 'clinic', 'with', 'lumbosacral', 'radiculopathy', 'will', 'be', 'randomized', 'in', 'a', '1:1', 'ratio', 'to', 'receive', 'one', 'of', 'two', 'treatments', '.', 'Half', '(', 'n=71', ')', 'of', 'the', 'patients', 'will', 'be', 'allocated', 'to', 'receive', 'an', 'epidural', 'steroid', 'injection', '(', 'ESI', ';', 'group', 'I', ')', ',', 'with', 'an', 'equal', 'number', 'allocated', 'to', 'receive', 'gabapentin', '(', 'group', 'II', ')', '.', 'Patients', '&', 'evaluating', 'physicians', 'will', 'be', 'blinded', '.', 'Follow', '-', 'up', 'will', 'be', 'through', '3', '-', 'months', 'after', 'treatment', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 77,
                "end": 84,
                "text": "Steroid",
                "type": "DRUG"
            },
            {
                "start": 99,
                "end": 109,
                "text": "Gabapentin",
                "type": "DRUG"
            },
            {
                "start": 127,
                "end": 152,
                "text": "Lumbosacral Radiculopathy",
                "type": "CONDITION"
            },
            {
                "start": 233,
                "end": 240,
                "text": "steroid",
                "type": "DRUG"
            },
            {
                "start": 279,
                "end": 305,
                "text": "lumbosacral radicular pain",
                "type": "CONDITION"
            },
            {
                "start": 366,
                "end": 391,
                "text": "lumbosacral radiculopathy",
                "type": "CONDITION"
            },
            {
                "start": 529,
                "end": 536,
                "text": "steroid",
                "type": "DRUG"
            },
            {
                "start": 605,
                "end": 615,
                "text": "gabapentin",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05125081",
        "study_official_title": "RCT Study of Liuwei Dihuang Pill Preventing and Treating Presbycusis With Shen (Kidney)-Yin Deficiency ",
        "study_brief_summary": " The objective of this study is to examine the effects and safety of Liuwei Dihuang pill and placebo in presbycusis with Shen (kidney)-yin deficiency.",
        "text": "RCT Study of Liuwei Dihuang Pill Preventing and Treating Presbycusis With Shen (Kidney)-Yin Deficiency | The objective of this study is to examine the effects and safety of Liuwei Dihuang pill and placebo in presbycusis with Shen (kidney)-yin deficiency.",
        "tokens": "['RCT', 'Study', 'of', 'Liuwei', 'Dihuang', 'Pill', 'Preventing', 'and', 'Treating', 'Presbycusis', 'With', 'Shen', '(', 'Kidney)-Yin', 'Deficiency', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'effects', 'and', 'safety', 'of', 'Liuwei', 'Dihuang', 'pill', 'and', 'placebo', 'in', 'presbycusis', 'with', 'Shen', '(', 'kidney)-yin', 'deficiency', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 32,
                "text": "Liuwei Dihuang Pill",
                "type": "OTHER"
            },
            {
                "start": 57,
                "end": 68,
                "text": "Presbycusis",
                "type": "CONDITION"
            },
            {
                "start": 74,
                "end": 102,
                "text": "Shen (Kidney)-Yin Deficiency",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 192,
                "text": "Liuwei Dihuang pill",
                "type": "OTHER"
            },
            {
                "start": 197,
                "end": 204,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 208,
                "end": 219,
                "text": "presbycusis",
                "type": "CONDITION"
            },
            {
                "start": 225,
                "end": 253,
                "text": "Shen (kidney)-yin deficiency",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03356639",
        "study_official_title": "A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Patients With Schizophrenia ",
        "study_brief_summary": " The primary purpose is to evaluate the safety and tolerability of ASP6981 in participants with schizophrenia.\n\nAlso primary purpose is to evaluate the pharmacodynamics of ASP6981 in participants with schizophrenia as measured by cognitive function and neurophysiological biomarkers.\n\nThe secondary purpose of this study is to evaluate the pharmacokinetics of ASP6981 in participants with schizophrenia.",
        "text": "A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Patients With Schizophrenia | The primary purpose is to evaluate the safety and tolerability of ASP6981 in participants with schizophrenia.\n\nAlso primary purpose is to evaluate the pharmacodynamics of ASP6981 in participants with schizophrenia as measured by cognitive function and neurophysiological biomarkers.\n\nThe secondary purpose of this study is to evaluate the pharmacokinetics of ASP6981 in participants with schizophrenia.",
        "tokens": "['A', 'Phase', '1', 'Randomized', ',', '2', '-', 'way', ',', 'Crossover', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacodynamics', 'and', 'Pharmacokinetics', 'of', 'ASP6981', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'primary', 'purpose', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'ASP6981', 'in', 'participants', 'with', 'schizophrenia', '.', '\\n\\n', 'Also', 'primary', 'purpose', 'is', 'to', 'evaluate', 'the', 'pharmacodynamics', 'of', 'ASP6981', 'in', 'participants', 'with', 'schizophrenia', 'as', 'measured', 'by', 'cognitive', 'function', 'and', 'neurophysiological', 'biomarkers', '.', '\\n\\n', 'The', 'secondary', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'pharmacokinetics', 'of', 'ASP6981', 'in', 'participants', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 122,
                "end": 129,
                "text": "ASP6981",
                "type": "DRUG"
            },
            {
                "start": 147,
                "end": 160,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 229,
                "end": 236,
                "text": "ASP6981",
                "type": "DRUG"
            },
            {
                "start": 258,
                "end": 271,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 334,
                "end": 341,
                "text": "ASP6981",
                "type": "DRUG"
            },
            {
                "start": 363,
                "end": 376,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 522,
                "end": 529,
                "text": "ASP6981",
                "type": "DRUG"
            },
            {
                "start": 551,
                "end": 564,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04238260",
        "study_official_title": "Enhancing Physical Therapy Best Practice for Improving Walking After Stroke ",
        "study_brief_summary": " The aim of this study is to assess the effect of implementing best practices into current stroke rehabilitation physical therapy on walking outcomes. Participants will also be provided an activity monitor to help them track and target their walking practice to determine if this can improve walking ability.",
        "text": "Enhancing Physical Therapy Best Practice for Improving Walking After Stroke | The aim of this study is to assess the effect of implementing best practices into current stroke rehabilitation physical therapy on walking outcomes. Participants will also be provided an activity monitor to help them track and target their walking practice to determine if this can improve walking ability.",
        "tokens": "['Enhancing', 'Physical', 'Therapy', 'Best', 'Practice', 'for', 'Improving', 'Walking', 'After', 'Stroke', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effect', 'of', 'implementing', 'best', 'practices', 'into', 'current', 'stroke', 'rehabilitation', 'physical', 'therapy', 'on', 'walking', 'outcomes', '.', 'Participants', 'will', 'also', 'be', 'provided', 'an', 'activity', 'monitor', 'to', 'help', 'them', 'track', 'and', 'target', 'their', 'walking', 'practice', 'to', 'determine', 'if', 'this', 'can', 'improve', 'walking', 'ability', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 40,
                "text": "Physical Therapy Best Practice",
                "type": "OTHER"
            },
            {
                "start": 69,
                "end": 75,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 140,
                "end": 206,
                "text": "best practices into current stroke rehabilitation physical therapy",
                "type": "OTHER"
            },
            {
                "start": 266,
                "end": 282,
                "text": "activity monitor",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02507986",
        "study_official_title": "Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation ",
        "study_brief_summary": " The main objective of this study is to compare the incidence of detected atrial fibrillation (AF) in cryptogenic stroke patients by a single lead ECG device with the incidence of detected AF by a 7-Day Holter ECG.",
        "text": "Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation | The main objective of this study is to compare the incidence of detected atrial fibrillation (AF) in cryptogenic stroke patients by a single lead ECG device with the incidence of detected AF by a 7-Day Holter ECG.",
        "tokens": "['Mobile', 'Phones', 'in', 'Cryptogenic', 'Stroke', 'Patients', 'Bringing', 'Single', 'Lead', 'ECGs', 'to', 'Detect', 'Atrial', 'Fibrillation', '|', 'The', 'main', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'incidence', 'of', 'detected', 'atrial', 'fibrillation', '(', 'AF', ')', 'in', 'cryptogenic', 'stroke', 'patients', 'by', 'a', 'single', 'lead', 'ECG', 'device', 'with', 'the', 'incidence', 'of', 'detected', 'AF', 'by', 'a', '7', '-', 'Day', 'Holter', 'ECG', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 35,
                "text": "Cryptogenic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 81,
                "end": 100,
                "text": "Atrial Fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 195,
                "text": "atrial fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 197,
                "end": 199,
                "text": "AF",
                "type": "CONDITION"
            },
            {
                "start": 204,
                "end": 222,
                "text": "cryptogenic stroke",
                "type": "CONDITION"
            },
            {
                "start": 291,
                "end": 293,
                "text": "AF",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05624866",
        "study_official_title": "Dexmedetomidine Versus Triamcinolone Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial. ",
        "study_brief_summary": " Carpal tunnel syndrome (CTS) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modalities are available for treatment of mild to moderate CTS.",
        "text": "Dexmedetomidine Versus Triamcinolone Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial. | Carpal tunnel syndrome (CTS) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modalities are available for treatment of mild to moderate CTS.",
        "tokens": "['Dexmedetomidine', 'Versus', 'Triamcinolone', 'Local', 'Injection', 'for', 'Pain', 'Alleviation', 'in', 'Patients', 'With', 'Carpal', 'Tunnel', 'Syndrome', ';', 'A', 'Randomized', 'Clinical', 'Trial', '.', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'a', 'common', 'mononeuropathy', 'due', 'to', 'entrapment', 'of', 'the', 'median', 'nerve', 'in', 'the', 'carpal', 'tunnel', '.', 'a', 'lot', 'of', 'modalities', 'are', 'available', 'for', 'treatment', 'of', 'mild', 'to', 'moderate', 'CTS', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 15,
                "text": "Dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 23,
                "end": 36,
                "text": "Triamcinolone",
                "type": "DRUG"
            },
            {
                "start": 57,
                "end": 61,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 91,
                "end": 113,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 168,
                "text": "Carpal tunnel syndrome",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 173,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 187,
                "end": 201,
                "text": "mononeuropathy",
                "type": "CONDITION"
            },
            {
                "start": 313,
                "end": 333,
                "text": "mild to moderate CTS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05512884",
        "study_official_title": "Testing the Effect of Speeded Anomia Therapy in Patients With Chronic Post-stroke Aphasia: a Cross-over Randomized Controlled Trial ",
        "study_brief_summary": " The main aim of the study is to investigate the effect of a novel, speeded anomia therapy (Conroy et al., 2018) in a large population of patients with chronic post-stroke aphasia. The treatment will be delivered via a web application (QuickWord).",
        "text": "Testing the Effect of Speeded Anomia Therapy in Patients With Chronic Post-stroke Aphasia: a Cross-over Randomized Controlled Trial | The main aim of the study is to investigate the effect of a novel, speeded anomia therapy (Conroy et al., 2018) in a large population of patients with chronic post-stroke aphasia. The treatment will be delivered via a web application (QuickWord).",
        "tokens": "['Testing', 'the', 'Effect', 'of', 'Speeded', 'Anomia', 'Therapy', 'in', 'Patients', 'With', 'Chronic', 'Post', '-', 'stroke', 'Aphasia', ':', 'a', 'Cross', '-', 'over', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'main', 'aim', 'of', 'the', 'study', 'is', 'to', 'investigate', 'the', 'effect', 'of', 'a', 'novel', ',', 'speeded', 'anomia', 'therapy', '(', 'Conroy', 'et', 'al', '.', ',', '2018', ')', 'in', 'a', 'large', 'population', 'of', 'patients', 'with', 'chronic', 'post', '-', 'stroke', 'aphasia', '.', 'The', 'treatment', 'will', 'be', 'delivered', 'via', 'a', 'web', 'application', '(', 'QuickWord', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 44,
                "text": "Speeded Anomia Therapy",
                "type": "OTHER"
            },
            {
                "start": 62,
                "end": 89,
                "text": "Chronic Post-stroke Aphasia",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 223,
                "text": "speeded anomia therapy",
                "type": "OTHER"
            },
            {
                "start": 285,
                "end": 312,
                "text": "chronic post-stroke aphasia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02425644",
        "study_official_title": "Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis ",
        "study_brief_summary": " International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis",
        "text": "Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis | International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis",
        "tokens": "['Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Parallel', '-', 'group', ',', 'Active', '-', 'controlled', ',', 'Superiority', 'Study', 'to', 'Compare', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Ponesimod', 'to', 'Teriflunomide', 'in', 'Subjects', 'With', 'Relapsing', 'Multiple', 'Sclerosis', '|', 'International', 'clinical', 'trial', 'to', 'compare', 'ponesimod', 'and', 'teriflunomide', 'in', 'relapsing', 'multiple', 'sclerosis']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 130,
                "end": 139,
                "text": "Ponesimod",
                "type": "DRUG"
            },
            {
                "start": 143,
                "end": 156,
                "text": "Teriflunomide",
                "type": "DRUG"
            },
            {
                "start": 174,
                "end": 202,
                "text": "Relapsing Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 254,
                "text": "ponesimod",
                "type": "DRUG"
            },
            {
                "start": 259,
                "end": 272,
                "text": "teriflunomide",
                "type": "DRUG"
            },
            {
                "start": 276,
                "end": 304,
                "text": "relapsing multiple sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00245674",
        "study_official_title": "Solian Solution to Treat Schizophrenic Patients During an Acute Episode ",
        "study_brief_summary": " During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode.\n\nThe main purpose of the study is to observe the anti-psychotic effect of amisulpride as a solution during the first days of an acute episode of schizophrenia.",
        "text": "Solian Solution to Treat Schizophrenic Patients During an Acute Episode | During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode.\n\nThe main purpose of the study is to observe the anti-psychotic effect of amisulpride as a solution during the first days of an acute episode of schizophrenia.",
        "tokens": "['Solian', 'Solution', 'to', 'Treat', 'Schizophrenic', 'Patients', 'During', 'an', 'Acute', 'Episode', '|', 'During', 'this', 'study', 'the', 'efficacy', 'and', 'safety', 'profile', 'will', 'be', 'evaluated', 'of', 'the', 'use', 'of', 'amisulpride', 'in', 'the', 'form', 'of', 'a', 'solution', 'in', 'schizophrenic', 'patients', 'with', 'an', 'acute', 'episode', '.', '\\n\\n', 'The', 'main', 'purpose', 'of', 'the', 'study', 'is', 'to', 'observe', 'the', 'anti', '-', 'psychotic', 'effect', 'of', 'amisulpride', 'as', 'a', 'solution', 'during', 'the', 'first', 'days', 'of', 'an', 'acute', 'episode', 'of', 'schizophrenia', '.']",
        "token_bio_labels": "['B-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 15,
                "text": "Solian Solution",
                "type": "DRUG"
            },
            {
                "start": 25,
                "end": 38,
                "text": "Schizophrenic",
                "type": "CONDITION"
            },
            {
                "start": 58,
                "end": 71,
                "text": "Acute Episode",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 167,
                "text": "amisulpride",
                "type": "DRUG"
            },
            {
                "start": 197,
                "end": 210,
                "text": "schizophrenic",
                "type": "CONDITION"
            },
            {
                "start": 228,
                "end": 241,
                "text": "acute episode",
                "type": "CONDITION"
            },
            {
                "start": 317,
                "end": 328,
                "text": "amisulpride",
                "type": "DRUG"
            },
            {
                "start": 371,
                "end": 384,
                "text": "acute episode",
                "type": "CONDITION"
            },
            {
                "start": 388,
                "end": 401,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04299009",
        "study_official_title": "Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea ",
        "study_brief_summary": " Sleep apnea is one of the most common chronic condition among US military Veterans, causing sleepiness, reduced psychomotor vigilance and depression, which undermine daytime functioning and quality of life. Persistent daytime symptoms of sleepiness in individuals with Obstructive Sleep Apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Residual daytime sleepiness (RDS) is associated with reduced occupational and family functioning and overall lower quality of life. Napping is a common behavior among individuals with OSA and RDS and has been linked to both benefits to and decline in health and functioning. Longer nap times may maintain, as opposed to decrease, sleepiness by promoting sleep inertia and can contribute to maintaining subclinical circadian alterations that result in higher night-tonight variability in sleep patterns. Preliminary studies in humans and animal models have shown persisting alterations of circadian rhythms in OSA patients, that fail to normalize with CPAP treatment. CPAP treatment, while effective at correcting respiratory events and night time blood oxygen saturation levels, does not necessarily re-align the circadian system. Current treatment options are limited to stimulants and modafinil, whose long-term safety profile, effectiveness and impact on functional recovery is largely unknown. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. However, no study to date has tested the application of BLT to treat daytime symptoms associated with sleep apnea. The investigators' study will be the first to explore the role of Bright Light Therapy (BLT), a well-established non-pharmacological intervention for circadian disturbances, for the treatment of residual daytime symptoms of OSA which do not respond to CPAP.",
        "text": "Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea | Sleep apnea is one of the most common chronic condition among US military Veterans, causing sleepiness, reduced psychomotor vigilance and depression, which undermine daytime functioning and quality of life. Persistent daytime symptoms of sleepiness in individuals with Obstructive Sleep Apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Residual daytime sleepiness (RDS) is associated with reduced occupational and family functioning and overall lower quality of life. Napping is a common behavior among individuals with OSA and RDS and has been linked to both benefits to and decline in health and functioning. Longer nap times may maintain, as opposed to decrease, sleepiness by promoting sleep inertia and can contribute to maintaining subclinical circadian alterations that result in higher night-tonight variability in sleep patterns. Preliminary studies in humans and animal models have shown persisting alterations of circadian rhythms in OSA patients, that fail to normalize with CPAP treatment. CPAP treatment, while effective at correcting respiratory events and night time blood oxygen saturation levels, does not necessarily re-align the circadian system. Current treatment options are limited to stimulants and modafinil, whose long-term safety profile, effectiveness and impact on functional recovery is largely unknown. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. However, no study to date has tested the application of BLT to treat daytime symptoms associated with sleep apnea. The investigators' study will be the first to explore the role of Bright Light Therapy (BLT), a well-established non-pharmacological intervention for circadian disturbances, for the treatment of residual daytime symptoms of OSA which do not respond to CPAP.",
        "tokens": "['Bright', 'Light', 'Therapy', 'for', 'Residual', 'Daytime', 'Symptoms', 'Associated', 'With', 'Obstructive', 'Sleep', 'Apnea', '|', 'Sleep', 'apnea', 'is', 'one', 'of', 'the', 'most', 'common', 'chronic', 'condition', 'among', 'US', 'military', 'Veterans', ',', 'causing', 'sleepiness', ',', 'reduced', 'psychomotor', 'vigilance', 'and', 'depression', ',', 'which', 'undermine', 'daytime', 'functioning', 'and', 'quality', 'of', 'life', '.', 'Persistent', 'daytime', 'symptoms', 'of', 'sleepiness', 'in', 'individuals', 'with', 'Obstructive', 'Sleep', 'Apnea', '(', 'OSA', ')', 'who', 'are', 'using', 'Continuous', 'Positive', 'Airway', 'Pressure', '(', 'CPAP', ')', 'are', 'associated', 'with', 'adverse', 'long', 'term', 'medical', 'and', 'functional', 'outcomes', '.', 'Residual', 'daytime', 'sleepiness', '(', 'RDS', ')', 'is', 'associated', 'with', 'reduced', 'occupational', 'and', 'family', 'functioning', 'and', 'overall', 'lower', 'quality', 'of', 'life', '.', 'Napping', 'is', 'a', 'common', 'behavior', 'among', 'individuals', 'with', 'OSA', 'and', 'RDS', 'and', 'has', 'been', 'linked', 'to', 'both', 'benefits', 'to', 'and', 'decline', 'in', 'health', 'and', 'functioning', '.', 'Longer', 'nap', 'times', 'may', 'maintain', ',', 'as', 'opposed', 'to', 'decrease', ',', 'sleepiness', 'by', 'promoting', 'sleep', 'inertia', 'and', 'can', 'contribute', 'to', 'maintaining', 'subclinical', 'circadian', 'alterations', 'that', 'result', 'in', 'higher', 'night', '-', 'tonight', 'variability', 'in', 'sleep', 'patterns', '.', 'Preliminary', 'studies', 'in', 'humans', 'and', 'animal', 'models', 'have', 'shown', 'persisting', 'alterations', 'of', 'circadian', 'rhythms', 'in', 'OSA', 'patients', ',', 'that', 'fail', 'to', 'normalize', 'with', 'CPAP', 'treatment', '.', 'CPAP', 'treatment', ',', 'while', 'effective', 'at', 'correcting', 'respiratory', 'events', 'and', 'night', 'time', 'blood', 'oxygen', 'saturation', 'levels', ',', 'does', 'not', 'necessarily', 're', '-', 'align', 'the', 'circadian', 'system', '.', 'Current', 'treatment', 'options', 'are', 'limited', 'to', 'stimulants', 'and', 'modafinil', ',', 'whose', 'long', '-', 'term', 'safety', 'profile', ',', 'effectiveness', 'and', 'impact', 'on', 'functional', 'recovery', 'is', 'largely', 'unknown', '.', 'Supplementary', 'exposure', 'to', 'bright', 'light', 'has', 'beneficial', 'effects', 'on', 'sleep', 'quality', 'and', 'daytime', 'vigilance', 'in', 'healthy', 'individuals', 'and', 'it', 'has', 'been', 'increasingly', 'applied', 'in', 'a', 'variety', 'of', 'sleep', 'and', 'neuropsychiatric', 'conditions', '.', 'However', ',', 'no', 'study', 'to', 'date', 'has', 'tested', 'the', 'application', 'of', 'BLT', 'to', 'treat', 'daytime', 'symptoms', 'associated', 'with', 'sleep', 'apnea', '.', 'The', 'investigators', \"'\", 'study', 'will', 'be', 'the', 'first', 'to', 'explore', 'the', 'role', 'of', 'Bright', 'Light', 'Therapy', '(', 'BLT', ')', ',', 'a', 'well', '-', 'established', 'non', '-', 'pharmacological', 'intervention', 'for', 'circadian', 'disturbances', ',', 'for', 'the', 'treatment', 'of', 'residual', 'daytime', 'symptoms', 'of', 'OSA', 'which', 'do', 'not', 'respond', 'to', 'CPAP', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 20,
                "text": "Bright Light Therapy",
                "type": "OTHER"
            },
            {
                "start": 67,
                "end": 90,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 93,
                "end": 104,
                "text": "Sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 185,
                "end": 195,
                "text": "sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 241,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 362,
                "end": 385,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 387,
                "end": 390,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 520,
                "end": 547,
                "text": "Residual daytime sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 549,
                "end": 552,
                "text": "RDS",
                "type": "CONDITION"
            },
            {
                "start": 704,
                "end": 707,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 712,
                "end": 715,
                "text": "RDS",
                "type": "CONDITION"
            },
            {
                "start": 1129,
                "end": 1132,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 1532,
                "end": 1556,
                "text": "exposure to bright light",
                "type": "OTHER"
            },
            {
                "start": 1790,
                "end": 1793,
                "text": "BLT",
                "type": "OTHER"
            },
            {
                "start": 1836,
                "end": 1847,
                "text": "sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 1915,
                "end": 1935,
                "text": "Bright Light Therapy",
                "type": "OTHER"
            },
            {
                "start": 1937,
                "end": 1940,
                "text": "BLT",
                "type": "OTHER"
            },
            {
                "start": 2073,
                "end": 2076,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01716767",
        "study_official_title": "Acute Effect of Topical Menthol on Pain Symptoms in Slaughterhouse Workers With Symptoms of Carpal Tunnel Syndrome: Randomized Controlled Trial ",
        "study_brief_summary": " Topical menthol gels are classified 'topical analgesics' and are used to relieve pain of the musculoskeletal system. However, double-blind randomized controlled trials are lacking. Here the investigators examine - in a double-blind randomized controlled cross-over trial - the acute effect of topical menthol (Biofreeze) and placebo (gel with a menthol scent) on pain symptoms in slaughterhouse workers with symptoms of Carpal Tunnel Syndrome.",
        "text": "Acute Effect of Topical Menthol on Pain Symptoms in Slaughterhouse Workers With Symptoms of Carpal Tunnel Syndrome: Randomized Controlled Trial | Topical menthol gels are classified 'topical analgesics' and are used to relieve pain of the musculoskeletal system. However, double-blind randomized controlled trials are lacking. Here the investigators examine - in a double-blind randomized controlled cross-over trial - the acute effect of topical menthol (Biofreeze) and placebo (gel with a menthol scent) on pain symptoms in slaughterhouse workers with symptoms of Carpal Tunnel Syndrome.",
        "tokens": "['Acute', 'Effect', 'of', 'Topical', 'Menthol', 'on', 'Pain', 'Symptoms', 'in', 'Slaughterhouse', 'Workers', 'With', 'Symptoms', 'of', 'Carpal', 'Tunnel', 'Syndrome', ':', 'Randomized', 'Controlled', 'Trial', '|', 'Topical', 'menthol', 'gels', 'are', 'classified', \"'\", 'topical', 'analgesics', \"'\", 'and', 'are', 'used', 'to', 'relieve', 'pain', 'of', 'the', 'musculoskeletal', 'system', '.', 'However', ',', 'double', '-', 'blind', 'randomized', 'controlled', 'trials', 'are', 'lacking', '.', 'Here', 'the', 'investigators', 'examine', '-', 'in', 'a', 'double', '-', 'blind', 'randomized', 'controlled', 'cross', '-', 'over', 'trial', '-', 'the', 'acute', 'effect', 'of', 'topical', 'menthol', '(', 'Biofreeze', ')', 'and', 'placebo', '(', 'gel', 'with', 'a', 'menthol', 'scent', ')', 'on', 'pain', 'symptoms', 'in', 'slaughterhouse', 'workers', 'with', 'symptoms', 'of', 'Carpal', 'Tunnel', 'Syndrome', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 31,
                "text": "Menthol",
                "type": "DRUG"
            },
            {
                "start": 35,
                "end": 39,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 92,
                "end": 114,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 154,
                "end": 161,
                "text": "menthol",
                "type": "DRUG"
            },
            {
                "start": 227,
                "end": 231,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 447,
                "end": 454,
                "text": "menthol",
                "type": "DRUG"
            },
            {
                "start": 456,
                "end": 465,
                "text": "Biofreeze",
                "type": "DRUG"
            },
            {
                "start": 480,
                "end": 504,
                "text": "gel with a menthol scent",
                "type": "CONTROL"
            },
            {
                "start": 509,
                "end": 513,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 566,
                "end": 588,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03555084",
        "study_official_title": "Quality Control of CE-Certified Phonak Hearing Aids - 2018_07 ",
        "study_brief_summary": " Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials. This is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort. This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in St\u00e4fa (Switzerland).",
        "text": "Quality Control of CE-Certified Phonak Hearing Aids - 2018_07 | Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials. This is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort. This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in St\u00e4fa (Switzerland).",
        "tokens": "['Quality', 'Control', 'of', 'CE', '-', 'Certified', 'Phonak', 'Hearing', 'Aids', '-', '2018_07', '|', 'Phonak', 'Hearing', 'Systems', 'pass', 'through', 'different', 'development', 'and', 'study', 'stages', '.', 'At', 'an', 'early', 'stage', ',', 'feasibility', 'studies', 'are', 'conducted', 'to', 'investigate', 'new', 'algorithms', ',', 'features', 'and', 'functions', 'in', 'an', 'isolated', 'manner', '.', 'If', 'the', 'benefit', 'is', 'proven', ',', 'their', 'performance', 'is', 'then', 'investigated', 'regarding', 'interdependency', 'between', 'all', 'available', 'algorithms', ',', 'features', 'and', 'functions', 'running', 'in', 'parallel', 'in', 'a', 'hearing', 'aid', '(', 'pivotal', '/', 'pre', '-', 'validation', 'studies', ')', 'and', ',', 'as', 'a', 'result', ',', 'they', 'get', 'optimized', '.', 'Afterwards', ',', 'and', 'prior', 'to', 'product', 'launch', ',', 'the', 'Phonak', 'Hearing', 'Systems', 'undergo', 'a', 'final', 'quality', 'control', 'in', 'terms', 'of', 'clinical', 'trials', '.', 'This', 'is', 'a', 'pre', '-', 'validation', 'study', ',', 'investigating', 'optimized', 'algorithms', ',', 'features', ',', 'functions', 'and', 'wearing', 'comfort', '.', 'This', 'will', 'be', 'a', 'clinical', 'evaluation', 'which', 'will', 'be', 'conducted', 'mono', 'centric', 'at', 'Sonova', 'AG', 'Headquarters', 'based', 'in', 'St\u00e4fa', '(', 'Switzerland', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 19,
                "end": 51,
                "text": "CE-Certified Phonak Hearing Aids",
                "type": "OTHER"
            },
            {
                "start": 64,
                "end": 86,
                "text": "Phonak Hearing Systems",
                "type": "OTHER"
            },
            {
                "start": 443,
                "end": 454,
                "text": "hearing aid",
                "type": "OTHER"
            },
            {
                "start": 571,
                "end": 593,
                "text": "Phonak Hearing Systems",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05490576",
        "study_official_title": "Pilot Phase 1 Clinical Trial of PET Scanning in Tau Protein Deposition and Connectome Analysis in Traumatic Encephalopathy Syndrome (TES) Cohort With a Probable Chronic Traumatic Encephalopathy (CTE) Pattern of Neurodegenerative Disease ",
        "study_brief_summary": " This pilot study aims to assess if participants that meet the criteria for a TES diagnosis have a specific tau deposition profile on PET scanning using the PET tau binding ligand - [18F] PI-2620. It is hoped this study will highlight potential diagnostic tests of TES diagnosis, the in-life correlate of CTE.",
        "text": "Pilot Phase 1 Clinical Trial of PET Scanning in Tau Protein Deposition and Connectome Analysis in Traumatic Encephalopathy Syndrome (TES) Cohort With a Probable Chronic Traumatic Encephalopathy (CTE) Pattern of Neurodegenerative Disease | This pilot study aims to assess if participants that meet the criteria for a TES diagnosis have a specific tau deposition profile on PET scanning using the PET tau binding ligand - [18F] PI-2620. It is hoped this study will highlight potential diagnostic tests of TES diagnosis, the in-life correlate of CTE.",
        "tokens": "['Pilot', 'Phase', '1', 'Clinical', 'Trial', 'of', 'PET', 'Scanning', 'in', 'Tau', 'Protein', 'Deposition', 'and', 'Connectome', 'Analysis', 'in', 'Traumatic', 'Encephalopathy', 'Syndrome', '(', 'TES', ')', 'Cohort', 'With', 'a', 'Probable', 'Chronic', 'Traumatic', 'Encephalopathy', '(', 'CTE', ')', 'Pattern', 'of', 'Neurodegenerative', 'Disease', '|', 'This', 'pilot', 'study', 'aims', 'to', 'assess', 'if', 'participants', 'that', 'meet', 'the', 'criteria', 'for', 'a', 'TES', 'diagnosis', 'have', 'a', 'specific', 'tau', 'deposition', 'profile', 'on', 'PET', 'scanning', 'using', 'the', 'PET', 'tau', 'binding', 'ligand', '-', '[', '18F', ']', 'PI-2620', '.', 'It', 'is', 'hoped', 'this', 'study', 'will', 'highlight', 'potential', 'diagnostic', 'tests', 'of', 'TES', 'diagnosis', ',', 'the', 'in', '-', 'life', 'correlate', 'of', 'CTE', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 98,
                "end": 131,
                "text": "Traumatic Encephalopathy Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 133,
                "end": 136,
                "text": "TES",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 193,
                "text": "Chronic Traumatic Encephalopathy",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 198,
                "text": "CTE",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 319,
                "text": "TES",
                "type": "CONDITION"
            },
            {
                "start": 503,
                "end": 506,
                "text": "TES",
                "type": "CONDITION"
            },
            {
                "start": 543,
                "end": 546,
                "text": "CTE",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03878810",
        "study_official_title": "Effects of Video Game-based Physical Activity Training in Persons With Multiple Sclerosis With Restless Legs Syndrome ",
        "study_brief_summary": " In this studly, the effects of an 8-week videogame-based physical activity training in persons with multiple sclerosis will be investigated.",
        "text": "Effects of Video Game-based Physical Activity Training in Persons With Multiple Sclerosis With Restless Legs Syndrome | In this studly, the effects of an 8-week videogame-based physical activity training in persons with multiple sclerosis will be investigated.",
        "tokens": "['Effects', 'of', 'Video', 'Game', '-', 'based', 'Physical', 'Activity', 'Training', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', 'With', 'Restless', 'Legs', 'Syndrome', '|', 'In', 'this', 'studly', ',', 'the', 'effects', 'of', 'an', '8', '-', 'week', 'videogame', '-', 'based', 'physical', 'activity', 'training', 'in', 'persons', 'with', 'multiple', 'sclerosis', 'will', 'be', 'investigated', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 54,
                "text": "Video Game-based Physical Activity Training",
                "type": "PHYSICAL"
            },
            {
                "start": 71,
                "end": 89,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 95,
                "end": 117,
                "text": "Restless Legs Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 203,
                "text": "videogame-based physical activity training",
                "type": "PHYSICAL"
            },
            {
                "start": 220,
                "end": 238,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02899637",
        "study_official_title": "Effects of High-Frequency Transcranial Magnetic Stimulation on Functional Performance of Subjects With Incomplete Spinal Cord Injury: Study Protocol for a Randomized Controlled Trial ",
        "study_brief_summary": " The main objective is to conduct a study protocol to investigate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on sensory and motor performance of individuals with incomplete spinal cord injury (iSCI) . A double-blind randomized sham-controlled trial of patients with iSCI will be conducted.",
        "text": "Effects of High-Frequency Transcranial Magnetic Stimulation on Functional Performance of Subjects With Incomplete Spinal Cord Injury: Study Protocol for a Randomized Controlled Trial | The main objective is to conduct a study protocol to investigate the effects of repetitive Transcranial Magnetic Stimulation (rTMS) on sensory and motor performance of individuals with incomplete spinal cord injury (iSCI) . A double-blind randomized sham-controlled trial of patients with iSCI will be conducted.",
        "tokens": "['Effects', 'of', 'High', '-', 'Frequency', 'Transcranial', 'Magnetic', 'Stimulation', 'on', 'Functional', 'Performance', 'of', 'Subjects', 'With', 'Incomplete', 'Spinal', 'Cord', 'Injury', ':', 'Study', 'Protocol', 'for', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'main', 'objective', 'is', 'to', 'conduct', 'a', 'study', 'protocol', 'to', 'investigate', 'the', 'effects', 'of', 'repetitive', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'rTMS', ')', 'on', 'sensory', 'and', 'motor', 'performance', 'of', 'individuals', 'with', 'incomplete', 'spinal', 'cord', 'injury', '(', 'iSCI', ')', '.', 'A', 'double', '-', 'blind', 'randomized', 'sham', '-', 'controlled', 'trial', 'of', 'patients', 'with', 'iSCI', 'will', 'be', 'conducted', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 59,
                "text": "High-Frequency Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 103,
                "end": 132,
                "text": "Incomplete Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 265,
                "end": 309,
                "text": "repetitive Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 311,
                "end": 315,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 370,
                "end": 399,
                "text": "incomplete spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 401,
                "end": 405,
                "text": "iSCI",
                "type": "CONDITION"
            },
            {
                "start": 435,
                "end": 439,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 474,
                "end": 478,
                "text": "iSCI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03189173",
        "study_official_title": "Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea ",
        "study_brief_summary": " The current study combines two treatments for obstructive sleep apnea (OSA), oral appliances and supplemental inspired oxygen. The following aims will be tested:\n\nAim 1. To determine whether supplemental inspired oxygen further reduces OSA severity (apnea-hypopnea index) in patients using an oral appliance.\n\nAim 2. To determine whether baseline OSA phenotypes can predict the efficacy of oral appliances versus supplemental oxygen versus both treatments in combination. We will test whether responders to oral appliances have distinct pathophysiological characteristics compared with oxygen responders.",
        "text": "Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea | The current study combines two treatments for obstructive sleep apnea (OSA), oral appliances and supplemental inspired oxygen. The following aims will be tested:\n\nAim 1. To determine whether supplemental inspired oxygen further reduces OSA severity (apnea-hypopnea index) in patients using an oral appliance.\n\nAim 2. To determine whether baseline OSA phenotypes can predict the efficacy of oral appliances versus supplemental oxygen versus both treatments in combination. We will test whether responders to oral appliances have distinct pathophysiological characteristics compared with oxygen responders.",
        "tokens": "['Combined', 'Upper', '-', 'airway', 'and', 'Breathing', 'Control', 'Therapies', 'for', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'current', 'study', 'combines', 'two', 'treatments', 'for', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'oral', 'appliances', 'and', 'supplemental', 'inspired', 'oxygen', '.', 'The', 'following', 'aims', 'will', 'be', 'tested', ':', '\\n\\n', 'Aim', '1', '.', 'To', 'determine', 'whether', 'supplemental', 'inspired', 'oxygen', 'further', 'reduces', 'OSA', 'severity', '(', 'apnea', '-', 'hypopnea', 'index', ')', 'in', 'patients', 'using', 'an', 'oral', 'appliance', '.', '\\n\\n', 'Aim', '2', '.', 'To', 'determine', 'whether', 'baseline', 'OSA', 'phenotypes', 'can', 'predict', 'the', 'efficacy', 'of', 'oral', 'appliances', 'versus', 'supplemental', 'oxygen', 'versus', 'both', 'treatments', 'in', 'combination', '.', 'We', 'will', 'test', 'whether', 'responders', 'to', 'oral', 'appliances', 'have', 'distinct', 'pathophysiological', 'characteristics', 'compared', 'with', 'oxygen', 'responders', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O']",
        "entities": [
            {
                "start": 9,
                "end": 53,
                "text": "Upper-airway and Breathing Control Therapies",
                "type": "OTHER"
            },
            {
                "start": 58,
                "end": 81,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 130,
                "end": 153,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 158,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 176,
                "text": "oral appliances",
                "type": "OTHER"
            },
            {
                "start": 181,
                "end": 209,
                "text": "supplemental inspired oxygen",
                "type": "OTHER"
            },
            {
                "start": 275,
                "end": 303,
                "text": "supplemental inspired oxygen",
                "type": "OTHER"
            },
            {
                "start": 320,
                "end": 323,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 377,
                "end": 391,
                "text": "oral appliance",
                "type": "OTHER"
            },
            {
                "start": 431,
                "end": 434,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 474,
                "end": 489,
                "text": "oral appliances",
                "type": "OTHER"
            },
            {
                "start": 497,
                "end": 516,
                "text": "supplemental oxygen",
                "type": "OTHER"
            },
            {
                "start": 591,
                "end": 606,
                "text": "oral appliances",
                "type": "OTHER"
            },
            {
                "start": 670,
                "end": 676,
                "text": "oxygen",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04961021",
        "study_official_title": "Management of Consecutive Exotropia and Its Effect on Ocular Motility ",
        "study_brief_summary": " Patients with consecutive exotropia will be managed by medial rectus muscle advancement +/- resection or medial rectus muscle advancement +/- lateral rectus recession",
        "text": "Management of Consecutive Exotropia and Its Effect on Ocular Motility | Patients with consecutive exotropia will be managed by medial rectus muscle advancement +/- resection or medial rectus muscle advancement +/- lateral rectus recession",
        "tokens": "['Management', 'of', 'Consecutive', 'Exotropia', 'and', 'Its', 'Effect', 'on', 'Ocular', 'Motility', '|', 'Patients', 'with', 'consecutive', 'exotropia', 'will', 'be', 'managed', 'by', 'medial', 'rectus', 'muscle', 'advancement', '+', '/-', 'resection', 'or', 'medial', 'rectus', 'muscle', 'advancement', '+', '/-', 'lateral', 'rectus', 'recession']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER']",
        "entities": [
            {
                "start": 14,
                "end": 35,
                "text": "Consecutive Exotropia",
                "type": "CONDITION"
            },
            {
                "start": 86,
                "end": 107,
                "text": "consecutive exotropia",
                "type": "CONDITION"
            },
            {
                "start": 127,
                "end": 159,
                "text": "medial rectus muscle advancement",
                "type": "OTHER"
            },
            {
                "start": 164,
                "end": 209,
                "text": "resection or medial rectus muscle advancement",
                "type": "OTHER"
            },
            {
                "start": 214,
                "end": 238,
                "text": "lateral rectus recession",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03119246",
        "study_official_title": "Beta Testing of a New Assessment Protocol for Assessment of Complex Therapies in Huntington's Disease (HD) ",
        "study_brief_summary": " Huntington's disease (HD) is an inherited neurodegenerative disease for which there are no existing disease-modifying treatments.\n\nRepair-HD is an EU FP7 consortium that aims to establish all the preclinical requirements for transplantation of stem cell-derived neurons in HD in order to replace those lost to the disease process. These requirements include the generation of new clinical assessments for detailed monitoring of patients with HD who have undergone cell replacement therapy.\n\nThis protocol describes the beta testing of a new clinical assessment battery: Core Assessment Protocol for Intrastriatal Transplantation in HD version 2 (CAPIT-HD beta / CAPIT-HD2). CAPIT-HD beta represents a substantial revision of a previous CAPIT-HD battery published over 20 years ago, which is in need of updating in order to accommodate knowledge from clinical transplant studies over this time and to take advantage of technological advances in patient assessment.\n\nHD is a complex disorder in which there is relentless deterioration of motor, cognitive and behavioural functions, usually from mid-life onwards. The original CAPIT battery aimed to capture elements of change in all three domains, but was based predominantly on subjective semi-quantitative assessment tools that have poor inter-rater reliability. Moreover, a number of deficits, such as impairments in social cognition, were not recognised when the original CAPIT-HD battery was constructed, so we have developed novel assessments of these deficits, some of which are included in CAPIT-HD beta. The beta testing will take place in established HD clinical centres in Cardiff, Manchester, Paris, and Munster by teams of researchers who are experienced in leading clinic research in HD. Patients with early to moderate HD will be assessed at baseline, and at one and twelve months later, to assess the reliability and sensitivity of the CAPIT-HD beta battery. Arrangements for data storage and analysis are in place.",
        "text": "Beta Testing of a New Assessment Protocol for Assessment of Complex Therapies in Huntington's Disease (HD) | Huntington's disease (HD) is an inherited neurodegenerative disease for which there are no existing disease-modifying treatments.\n\nRepair-HD is an EU FP7 consortium that aims to establish all the preclinical requirements for transplantation of stem cell-derived neurons in HD in order to replace those lost to the disease process. These requirements include the generation of new clinical assessments for detailed monitoring of patients with HD who have undergone cell replacement therapy.\n\nThis protocol describes the beta testing of a new clinical assessment battery: Core Assessment Protocol for Intrastriatal Transplantation in HD version 2 (CAPIT-HD beta / CAPIT-HD2). CAPIT-HD beta represents a substantial revision of a previous CAPIT-HD battery published over 20 years ago, which is in need of updating in order to accommodate knowledge from clinical transplant studies over this time and to take advantage of technological advances in patient assessment.\n\nHD is a complex disorder in which there is relentless deterioration of motor, cognitive and behavioural functions, usually from mid-life onwards. The original CAPIT battery aimed to capture elements of change in all three domains, but was based predominantly on subjective semi-quantitative assessment tools that have poor inter-rater reliability. Moreover, a number of deficits, such as impairments in social cognition, were not recognised when the original CAPIT-HD battery was constructed, so we have developed novel assessments of these deficits, some of which are included in CAPIT-HD beta. The beta testing will take place in established HD clinical centres in Cardiff, Manchester, Paris, and Munster by teams of researchers who are experienced in leading clinic research in HD. Patients with early to moderate HD will be assessed at baseline, and at one and twelve months later, to assess the reliability and sensitivity of the CAPIT-HD beta battery. Arrangements for data storage and analysis are in place.",
        "tokens": "['Beta', 'Testing', 'of', 'a', 'New', 'Assessment', 'Protocol', 'for', 'Assessment', 'of', 'Complex', 'Therapies', 'in', 'Huntington', \"'s\", 'Disease', '(', 'HD', ')', '|', 'Huntington', \"'s\", 'disease', '(', 'HD', ')', 'is', 'an', 'inherited', 'neurodegenerative', 'disease', 'for', 'which', 'there', 'are', 'no', 'existing', 'disease', '-', 'modifying', 'treatments', '.', '\\n\\n', 'Repair', '-', 'HD', 'is', 'an', 'EU', 'FP7', 'consortium', 'that', 'aims', 'to', 'establish', 'all', 'the', 'preclinical', 'requirements', 'for', 'transplantation', 'of', 'stem', 'cell', '-', 'derived', 'neurons', 'in', 'HD', 'in', 'order', 'to', 'replace', 'those', 'lost', 'to', 'the', 'disease', 'process', '.', 'These', 'requirements', 'include', 'the', 'generation', 'of', 'new', 'clinical', 'assessments', 'for', 'detailed', 'monitoring', 'of', 'patients', 'with', 'HD', 'who', 'have', 'undergone', 'cell', 'replacement', 'therapy', '.', '\\n\\n', 'This', 'protocol', 'describes', 'the', 'beta', 'testing', 'of', 'a', 'new', 'clinical', 'assessment', 'battery', ':', 'Core', 'Assessment', 'Protocol', 'for', 'Intrastriatal', 'Transplantation', 'in', 'HD', 'version', '2', '(', 'CAPIT', '-', 'HD', 'beta', '/', 'CAPIT', '-', 'HD2', ')', '.', 'CAPIT', '-', 'HD', 'beta', 'represents', 'a', 'substantial', 'revision', 'of', 'a', 'previous', 'CAPIT', '-', 'HD', 'battery', 'published', 'over', '20', 'years', 'ago', ',', 'which', 'is', 'in', 'need', 'of', 'updating', 'in', 'order', 'to', 'accommodate', 'knowledge', 'from', 'clinical', 'transplant', 'studies', 'over', 'this', 'time', 'and', 'to', 'take', 'advantage', 'of', 'technological', 'advances', 'in', 'patient', 'assessment', '.', '\\n\\n', 'HD', 'is', 'a', 'complex', 'disorder', 'in', 'which', 'there', 'is', 'relentless', 'deterioration', 'of', 'motor', ',', 'cognitive', 'and', 'behavioural', 'functions', ',', 'usually', 'from', 'mid', '-', 'life', 'onwards', '.', 'The', 'original', 'CAPIT', 'battery', 'aimed', 'to', 'capture', 'elements', 'of', 'change', 'in', 'all', 'three', 'domains', ',', 'but', 'was', 'based', 'predominantly', 'on', 'subjective', 'semi', '-', 'quantitative', 'assessment', 'tools', 'that', 'have', 'poor', 'inter', '-', 'rater', 'reliability', '.', 'Moreover', ',', 'a', 'number', 'of', 'deficits', ',', 'such', 'as', 'impairments', 'in', 'social', 'cognition', ',', 'were', 'not', 'recognised', 'when', 'the', 'original', 'CAPIT', '-', 'HD', 'battery', 'was', 'constructed', ',', 'so', 'we', 'have', 'developed', 'novel', 'assessments', 'of', 'these', 'deficits', ',', 'some', 'of', 'which', 'are', 'included', 'in', 'CAPIT', '-', 'HD', 'beta', '.', 'The', 'beta', 'testing', 'will', 'take', 'place', 'in', 'established', 'HD', 'clinical', 'centres', 'in', 'Cardiff', ',', 'Manchester', ',', 'Paris', ',', 'and', 'Munster', 'by', 'teams', 'of', 'researchers', 'who', 'are', 'experienced', 'in', 'leading', 'clinic', 'research', 'in', 'HD', '.', 'Patients', 'with', 'early', 'to', 'moderate', 'HD', 'will', 'be', 'assessed', 'at', 'baseline', ',', 'and', 'at', 'one', 'and', 'twelve', 'months', 'later', ',', 'to', 'assess', 'the', 'reliability', 'and', 'sensitivity', 'of', 'the', 'CAPIT', '-', 'HD', 'beta', 'battery', '.', 'Arrangements', 'for', 'data', 'storage', 'and', 'analysis', 'are', 'in', 'place', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 81,
                "end": 101,
                "text": "Huntington's Disease",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 105,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 109,
                "end": 129,
                "text": "Huntington's disease",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 133,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 382,
                "end": 384,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 551,
                "end": 553,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 741,
                "end": 743,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 1074,
                "end": 1076,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 1718,
                "end": 1720,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 1855,
                "end": 1857,
                "text": "HD",
                "type": "CONDITION"
            },
            {
                "start": 1873,
                "end": 1893,
                "text": "early to moderate HD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05122650",
        "study_official_title": "A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel Group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor ",
        "study_brief_summary": " This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.",
        "text": "A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel Group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor | This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.",
        "tokens": "['A', 'Phase', '2b', ',', '12', '-', 'week', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Randomized', ',', 'Parallel', 'Group', ',', 'Multicenter', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'JZP385', 'in', 'the', 'Treatment', 'of', 'Adults', 'With', 'Moderate', 'to', 'Severe', 'Essential', 'Tremor', '|', 'This', 'is', 'a', '12', '-', 'week', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'randomized', ',', 'parallel', '-', 'group', ',', 'multicenter', 'study', 'of', 'the', 'safety', 'and', 'efficacy', 'of', 'JZP385', 'in', 'the', 'treatment', 'of', 'adult', 'participants', 'with', 'moderate', 'to', 'severe', 'ET', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 42,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 131,
                "end": 137,
                "text": "JZP385",
                "type": "DRUG"
            },
            {
                "start": 170,
                "end": 205,
                "text": "Moderate to Severe Essential Tremor",
                "type": "CONDITION"
            },
            {
                "start": 241,
                "end": 248,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 337,
                "end": 343,
                "text": "JZP385",
                "type": "DRUG"
            },
            {
                "start": 388,
                "end": 409,
                "text": "moderate to severe ET",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01732289",
        "study_official_title": "Genetic Study of Age Related Hearing Loss ",
        "study_brief_summary": " Age-related hearing loss, or presbyacusis, is one of the most common chronically handicapped conditions for the elderly. Many factors including genetics, diet, diseases, drugs, socioeconomic factors and environmental variables were considered to be related to the development of presbyacusis. Evidences have shown that genetic factors play an important role on presbyacusis. However, which genes or their genotypes are associated with presbycusis remain unknown.\n\nThe aim of this project was to evaluate the association between the genotype of candidate genes and presbyacusis by cross-section and case-control study. In the first stage, the investigators plan to select 700 healthy subjects older than 50 with symmetric, sensorineural hearing loss. The subjects will receive basic otologic examination, pure tone audiometry, questionnaire, and genotype analysis. Because gender and age would affect hearing loss significantly, The investigators will convert the hearing level of all subjects into a gender and age independent Z-score according to ISO 7029 standard. And, The investigators define subjects within higher 30 % of Z-score as the presbyacusis group, and subjects within lower 30% of Z-score as the control group. Finally, The investigators perform Chi square analysis to test the association between genotype of candidate genes or their combinations in both groups, and calculate the odds ratio for presbyacusis between different genotype of candidate genes. Further more, we will evaluate the effect of genotype of candidate genes, environment factors, and gene-environmental interaction on the severity of presbyacusis by multivariate logistic regression.\n\nIn the second stage, The investigators wish to know the pattern of genotype and hearing level in the high risk families, according to results from the first stage, by description and case-control study. The investigators will perform t-test to evaluate the difference of Z-score in both groups. Besides, The investigators try to evaluate the effects of genotypes, environment factors, and gene-environmental interaction on hearing level in high risk families by multivariate logistic regression.",
        "text": "Genetic Study of Age Related Hearing Loss | Age-related hearing loss, or presbyacusis, is one of the most common chronically handicapped conditions for the elderly. Many factors including genetics, diet, diseases, drugs, socioeconomic factors and environmental variables were considered to be related to the development of presbyacusis. Evidences have shown that genetic factors play an important role on presbyacusis. However, which genes or their genotypes are associated with presbycusis remain unknown.\n\nThe aim of this project was to evaluate the association between the genotype of candidate genes and presbyacusis by cross-section and case-control study. In the first stage, the investigators plan to select 700 healthy subjects older than 50 with symmetric, sensorineural hearing loss. The subjects will receive basic otologic examination, pure tone audiometry, questionnaire, and genotype analysis. Because gender and age would affect hearing loss significantly, The investigators will convert the hearing level of all subjects into a gender and age independent Z-score according to ISO 7029 standard. And, The investigators define subjects within higher 30 % of Z-score as the presbyacusis group, and subjects within lower 30% of Z-score as the control group. Finally, The investigators perform Chi square analysis to test the association between genotype of candidate genes or their combinations in both groups, and calculate the odds ratio for presbyacusis between different genotype of candidate genes. Further more, we will evaluate the effect of genotype of candidate genes, environment factors, and gene-environmental interaction on the severity of presbyacusis by multivariate logistic regression.\n\nIn the second stage, The investigators wish to know the pattern of genotype and hearing level in the high risk families, according to results from the first stage, by description and case-control study. The investigators will perform t-test to evaluate the difference of Z-score in both groups. Besides, The investigators try to evaluate the effects of genotypes, environment factors, and gene-environmental interaction on hearing level in high risk families by multivariate logistic regression.",
        "tokens": "['Genetic', 'Study', 'of', 'Age', 'Related', 'Hearing', 'Loss', '|', 'Age', '-', 'related', 'hearing', 'loss', ',', 'or', 'presbyacusis', ',', 'is', 'one', 'of', 'the', 'most', 'common', 'chronically', 'handicapped', 'conditions', 'for', 'the', 'elderly', '.', 'Many', 'factors', 'including', 'genetics', ',', 'diet', ',', 'diseases', ',', 'drugs', ',', 'socioeconomic', 'factors', 'and', 'environmental', 'variables', 'were', 'considered', 'to', 'be', 'related', 'to', 'the', 'development', 'of', 'presbyacusis', '.', 'Evidences', 'have', 'shown', 'that', 'genetic', 'factors', 'play', 'an', 'important', 'role', 'on', 'presbyacusis', '.', 'However', ',', 'which', 'genes', 'or', 'their', 'genotypes', 'are', 'associated', 'with', 'presbycusis', 'remain', 'unknown', '.', '\\n\\n', 'The', 'aim', 'of', 'this', 'project', 'was', 'to', 'evaluate', 'the', 'association', 'between', 'the', 'genotype', 'of', 'candidate', 'genes', 'and', 'presbyacusis', 'by', 'cross', '-', 'section', 'and', 'case', '-', 'control', 'study', '.', 'In', 'the', 'first', 'stage', ',', 'the', 'investigators', 'plan', 'to', 'select', '700', 'healthy', 'subjects', 'older', 'than', '50', 'with', 'symmetric', ',', 'sensorineural', 'hearing', 'loss', '.', 'The', 'subjects', 'will', 'receive', 'basic', 'otologic', 'examination', ',', 'pure', 'tone', 'audiometry', ',', 'questionnaire', ',', 'and', 'genotype', 'analysis', '.', 'Because', 'gender', 'and', 'age', 'would', 'affect', 'hearing', 'loss', 'significantly', ',', 'The', 'investigators', 'will', 'convert', 'the', 'hearing', 'level', 'of', 'all', 'subjects', 'into', 'a', 'gender', 'and', 'age', 'independent', 'Z', '-', 'score', 'according', 'to', 'ISO', '7029', 'standard', '.', 'And', ',', 'The', 'investigators', 'define', 'subjects', 'within', 'higher', '30', '%', 'of', 'Z', '-', 'score', 'as', 'the', 'presbyacusis', 'group', ',', 'and', 'subjects', 'within', 'lower', '30', '%', 'of', 'Z', '-', 'score', 'as', 'the', 'control', 'group', '.', 'Finally', ',', 'The', 'investigators', 'perform', 'Chi', 'square', 'analysis', 'to', 'test', 'the', 'association', 'between', 'genotype', 'of', 'candidate', 'genes', 'or', 'their', 'combinations', 'in', 'both', 'groups', ',', 'and', 'calculate', 'the', 'odds', 'ratio', 'for', 'presbyacusis', 'between', 'different', 'genotype', 'of', 'candidate', 'genes', '.', 'Further', 'more', ',', 'we', 'will', 'evaluate', 'the', 'effect', 'of', 'genotype', 'of', 'candidate', 'genes', ',', 'environment', 'factors', ',', 'and', 'gene', '-', 'environmental', 'interaction', 'on', 'the', 'severity', 'of', 'presbyacusis', 'by', 'multivariate', 'logistic', 'regression', '.', '\\n\\n', 'In', 'the', 'second', 'stage', ',', 'The', 'investigators', 'wish', 'to', 'know', 'the', 'pattern', 'of', 'genotype', 'and', 'hearing', 'level', 'in', 'the', 'high', 'risk', 'families', ',', 'according', 'to', 'results', 'from', 'the', 'first', 'stage', ',', 'by', 'description', 'and', 'case', '-', 'control', 'study', '.', 'The', 'investigators', 'will', 'perform', 't', '-', 'test', 'to', 'evaluate', 'the', 'difference', 'of', 'Z', '-', 'score', 'in', 'both', 'groups', '.', 'Besides', ',', 'The', 'investigators', 'try', 'to', 'evaluate', 'the', 'effects', 'of', 'genotypes', ',', 'environment', 'factors', ',', 'and', 'gene', '-', 'environmental', 'interaction', 'on', 'hearing', 'level', 'in', 'high', 'risk', 'families', 'by', 'multivariate', 'logistic', 'regression', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 41,
                "text": "Hearing Loss",
                "type": "CONDITION"
            },
            {
                "start": 56,
                "end": 68,
                "text": "hearing loss",
                "type": "CONDITION"
            },
            {
                "start": 755,
                "end": 792,
                "text": "symmetric, sensorineural hearing loss",
                "type": "CONDITION"
            },
            {
                "start": 944,
                "end": 956,
                "text": "hearing loss",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02628561",
        "study_official_title": "The purpose is to compare the effects of tDCS and constraint induced movement therapy (CIMT) in the premotor cortex vs. primary motor cortex in severely subacute stroke survivors.",
        "study_brief_summary": null,
        "text": "The purpose is to compare the effects of tDCS and constraint induced movement therapy (CIMT) in the premotor cortex vs. primary motor cortex in severely subacute stroke survivors.",
        "tokens": "['The', 'purpose', 'is', 'to', 'compare', 'the', 'effects', 'of', 'tDCS', 'and', 'constraint', 'induced', 'movement', 'therapy', '(', 'CIMT', ')', 'in', 'the', 'premotor', 'cortex', 'vs.', 'primary', 'motor', 'cortex', 'in', 'severely', 'subacute', 'stroke', 'survivors', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 45,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 50,
                "end": 85,
                "text": "constraint induced movement therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 87,
                "end": 91,
                "text": "CIMT",
                "type": "PHYSICAL"
            },
            {
                "start": 144,
                "end": 168,
                "text": "severely subacute stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01873547",
        "study_official_title": "Different Efficacy Between Rehabilitation Therapy and Umbilical Cord Derived Mesenchymal Stem Cells Transplantation in Patients With Chronic Spinal Cord Injury in China ",
        "study_brief_summary": " The morbidity of spinal cord injury (SCI) is increasing year by year significantly in China. The methods to treat SCI patients in sequela stage update are poor. Though traditional rehabilitation therapy is the routine method to treat SCI in sequela stage, aiming to improve the neurological disorders of these patients, such as sensory disturbance, dyskinesia, autologous adjustment of blood pressure, dysfunction of urination, defecation and perspiration , etc. What's a pity, the efficacy of the rehabilitation therapy is unsatisfactory. Rehabilitation Therapy can prevent the process of muscle atrophy and joint stiffness. However, it can not repair the damaged nerve function. Studies show that mesenchymal stem cell transplantation can remarkably improve the neurological function of SCI in animals without any severe side effect.\n\nIn this study, 300 patients will be divided into three groups and the investigators will use mesenchymal stem cells derived from umbilical cord to treat 100 SCI patients. They will also follow up 100 patients who only receive rehabilitation and another 100 patients who accept neither stem cell therapy nor rehabilitation. On this basis, the investigators can compare the efficacy of these two treatments.",
        "text": "Different Efficacy Between Rehabilitation Therapy and Umbilical Cord Derived Mesenchymal Stem Cells Transplantation in Patients With Chronic Spinal Cord Injury in China | The morbidity of spinal cord injury (SCI) is increasing year by year significantly in China. The methods to treat SCI patients in sequela stage update are poor. Though traditional rehabilitation therapy is the routine method to treat SCI in sequela stage, aiming to improve the neurological disorders of these patients, such as sensory disturbance, dyskinesia, autologous adjustment of blood pressure, dysfunction of urination, defecation and perspiration , etc. What's a pity, the efficacy of the rehabilitation therapy is unsatisfactory. Rehabilitation Therapy can prevent the process of muscle atrophy and joint stiffness. However, it can not repair the damaged nerve function. Studies show that mesenchymal stem cell transplantation can remarkably improve the neurological function of SCI in animals without any severe side effect.\n\nIn this study, 300 patients will be divided into three groups and the investigators will use mesenchymal stem cells derived from umbilical cord to treat 100 SCI patients. They will also follow up 100 patients who only receive rehabilitation and another 100 patients who accept neither stem cell therapy nor rehabilitation. On this basis, the investigators can compare the efficacy of these two treatments.",
        "tokens": "['Different', 'Efficacy', 'Between', 'Rehabilitation', 'Therapy', 'and', 'Umbilical', 'Cord', 'Derived', 'Mesenchymal', 'Stem', 'Cells', 'Transplantation', 'in', 'Patients', 'With', 'Chronic', 'Spinal', 'Cord', 'Injury', 'in', 'China', '|', 'The', 'morbidity', 'of', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'is', 'increasing', 'year', 'by', 'year', 'significantly', 'in', 'China', '.', 'The', 'methods', 'to', 'treat', 'SCI', 'patients', 'in', 'sequela', 'stage', 'update', 'are', 'poor', '.', 'Though', 'traditional', 'rehabilitation', 'therapy', 'is', 'the', 'routine', 'method', 'to', 'treat', 'SCI', 'in', 'sequela', 'stage', ',', 'aiming', 'to', 'improve', 'the', 'neurological', 'disorders', 'of', 'these', 'patients', ',', 'such', 'as', 'sensory', 'disturbance', ',', 'dyskinesia', ',', 'autologous', 'adjustment', 'of', 'blood', 'pressure', ',', 'dysfunction', 'of', 'urination', ',', 'defecation', 'and', 'perspiration', ',', 'etc', '.', 'What', \"'s\", 'a', 'pity', ',', 'the', 'efficacy', 'of', 'the', 'rehabilitation', 'therapy', 'is', 'unsatisfactory', '.', 'Rehabilitation', 'Therapy', 'can', 'prevent', 'the', 'process', 'of', 'muscle', 'atrophy', 'and', 'joint', 'stiffness', '.', 'However', ',', 'it', 'can', 'not', 'repair', 'the', 'damaged', 'nerve', 'function', '.', 'Studies', 'show', 'that', 'mesenchymal', 'stem', 'cell', 'transplantation', 'can', 'remarkably', 'improve', 'the', 'neurological', 'function', 'of', 'SCI', 'in', 'animals', 'without', 'any', 'severe', 'side', 'effect', '.', '\\n\\n', 'In', 'this', 'study', ',', '300', 'patients', 'will', 'be', 'divided', 'into', 'three', 'groups', 'and', 'the', 'investigators', 'will', 'use', 'mesenchymal', 'stem', 'cells', 'derived', 'from', 'umbilical', 'cord', 'to', 'treat', '100', 'SCI', 'patients', '.', 'They', 'will', 'also', 'follow', 'up', '100', 'patients', 'who', 'only', 'receive', 'rehabilitation', 'and', 'another', '100', 'patients', 'who', 'accept', 'neither', 'stem', 'cell', 'therapy', 'nor', 'rehabilitation', '.', 'On', 'this', 'basis', ',', 'the', 'investigators', 'can', 'compare', 'the', 'efficacy', 'of', 'these', 'two', 'treatments', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 27,
                "end": 49,
                "text": "Rehabilitation Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 54,
                "end": 115,
                "text": "Umbilical Cord Derived Mesenchymal Stem Cells Transplantation",
                "type": "SURGICAL"
            },
            {
                "start": 133,
                "end": 159,
                "text": "Chronic Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 188,
                "end": 206,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 208,
                "end": 211,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 285,
                "end": 288,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 373,
                "text": "rehabilitation therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 405,
                "end": 408,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 669,
                "end": 691,
                "text": "rehabilitation therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 711,
                "end": 733,
                "text": "Rehabilitation Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 870,
                "end": 907,
                "text": "mesenchymal stem cell transplantation",
                "type": "SURGICAL"
            },
            {
                "start": 960,
                "end": 963,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 1101,
                "end": 1151,
                "text": "mesenchymal stem cells derived from umbilical cord",
                "type": "SURGICAL"
            },
            {
                "start": 1165,
                "end": 1168,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 1234,
                "end": 1248,
                "text": "rehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 1293,
                "end": 1310,
                "text": "stem cell therapy",
                "type": "SURGICAL"
            },
            {
                "start": 1315,
                "end": 1329,
                "text": "rehabilitation",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT04291716",
        "study_official_title": "Validation of an Algorithm for Identification and Notification of Generalized Major Motor Seizures ",
        "study_brief_summary": " The specificity and sensitivity of a novel seizure-detection mobile software application with a generalized tonic/clonic seizure detection algorithm (Motor Seizure Detection Algorithm [mSDA]) installed on a wearable device to be worn by the subject. The software will be tested using subjects from a patient population in an epilepsy monitoring unit (EMU) undergoing video and electroencephalograph (VEEG) observation. The number of generalized major motor seizures detected by the mSDA will be compared with those detected by VEEG.",
        "text": "Validation of an Algorithm for Identification and Notification of Generalized Major Motor Seizures | The specificity and sensitivity of a novel seizure-detection mobile software application with a generalized tonic/clonic seizure detection algorithm (Motor Seizure Detection Algorithm [mSDA]) installed on a wearable device to be worn by the subject. The software will be tested using subjects from a patient population in an epilepsy monitoring unit (EMU) undergoing video and electroencephalograph (VEEG) observation. The number of generalized major motor seizures detected by the mSDA will be compared with those detected by VEEG.",
        "tokens": "['Validation', 'of', 'an', 'Algorithm', 'for', 'Identification', 'and', 'Notification', 'of', 'Generalized', 'Major', 'Motor', 'Seizures', '|', 'The', 'specificity', 'and', 'sensitivity', 'of', 'a', 'novel', 'seizure', '-', 'detection', 'mobile', 'software', 'application', 'with', 'a', 'generalized', 'tonic', '/', 'clonic', 'seizure', 'detection', 'algorithm', '(', 'Motor', 'Seizure', 'Detection', 'Algorithm', '[', 'mSDA', ']', ')', 'installed', 'on', 'a', 'wearable', 'device', 'to', 'be', 'worn', 'by', 'the', 'subject', '.', 'The', 'software', 'will', 'be', 'tested', 'using', 'subjects', 'from', 'a', 'patient', 'population', 'in', 'an', 'epilepsy', 'monitoring', 'unit', '(', 'EMU', ')', 'undergoing', 'video', 'and', 'electroencephalograph', '(', 'VEEG', ')', 'observation', '.', 'The', 'number', 'of', 'generalized', 'major', 'motor', 'seizures', 'detected', 'by', 'the', 'mSDA', 'will', 'be', 'compared', 'with', 'those', 'detected', 'by', 'VEEG', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 66,
                "end": 98,
                "text": "Generalized Major Motor Seizures",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 151,
                "text": "seizure",
                "type": "CONDITION"
            },
            {
                "start": 197,
                "end": 229,
                "text": "generalized tonic/clonic seizure",
                "type": "CONDITION"
            },
            {
                "start": 426,
                "end": 434,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 534,
                "end": 566,
                "text": "generalized major motor seizures",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04408274",
        "study_official_title": "Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury: A Piolt Study ",
        "study_brief_summary": " This study will examine the efficacy of a clinical intervention for improving emotional processing in individuals with MS and TBI.(1)The main outcome measure will be changes in emotional processing measures from pre to post treatment.\n\n(2)This study will also assess the impact of the emotional processing intervention on changes in pre and post treatment depression and anxiety, as well as fatigue.(3) This study will additionally measure the impact of the emotional processing intervention on cognitive functioning, specifically processing speed, attention and executive abilities. This will be accomplished through the completion of a neuropsychological battery prior to and following the completion of treatment.(4)Finally, the investigators will measure the impact of the intervention on quality of life and social functioning, utilizing a pre and post treatment assessment consisting of measures of self-efficacy, quality of life, functional abilities, and awareness.",
        "text": "Remediation of Emotional Deficits in Multiple Sclerosis and Traumatic Brain Injury: A Piolt Study | This study will examine the efficacy of a clinical intervention for improving emotional processing in individuals with MS and TBI.(1)The main outcome measure will be changes in emotional processing measures from pre to post treatment.\n\n(2)This study will also assess the impact of the emotional processing intervention on changes in pre and post treatment depression and anxiety, as well as fatigue.(3) This study will additionally measure the impact of the emotional processing intervention on cognitive functioning, specifically processing speed, attention and executive abilities. This will be accomplished through the completion of a neuropsychological battery prior to and following the completion of treatment.(4)Finally, the investigators will measure the impact of the intervention on quality of life and social functioning, utilizing a pre and post treatment assessment consisting of measures of self-efficacy, quality of life, functional abilities, and awareness.",
        "tokens": "['Remediation', 'of', 'Emotional', 'Deficits', 'in', 'Multiple', 'Sclerosis', 'and', 'Traumatic', 'Brain', 'Injury', ':', 'A', 'Piolt', 'Study', '|', 'This', 'study', 'will', 'examine', 'the', 'efficacy', 'of', 'a', 'clinical', 'intervention', 'for', 'improving', 'emotional', 'processing', 'in', 'individuals', 'with', 'MS', 'and', 'TBI.(1)The', 'main', 'outcome', 'measure', 'will', 'be', 'changes', 'in', 'emotional', 'processing', 'measures', 'from', 'pre', 'to', 'post', 'treatment', '.', '\\n\\n', '(', '2)This', 'study', 'will', 'also', 'assess', 'the', 'impact', 'of', 'the', 'emotional', 'processing', 'intervention', 'on', 'changes', 'in', 'pre', 'and', 'post', 'treatment', 'depression', 'and', 'anxiety', ',', 'as', 'well', 'as', 'fatigue.(3', ')', 'This', 'study', 'will', 'additionally', 'measure', 'the', 'impact', 'of', 'the', 'emotional', 'processing', 'intervention', 'on', 'cognitive', 'functioning', ',', 'specifically', 'processing', 'speed', ',', 'attention', 'and', 'executive', 'abilities', '.', 'This', 'will', 'be', 'accomplished', 'through', 'the', 'completion', 'of', 'a', 'neuropsychological', 'battery', 'prior', 'to', 'and', 'following', 'the', 'completion', 'of', 'treatment.(4)Finally', ',', 'the', 'investigators', 'will', 'measure', 'the', 'impact', 'of', 'the', 'intervention', 'on', 'quality', 'of', 'life', 'and', 'social', 'functioning', ',', 'utilizing', 'a', 'pre', 'and', 'post', 'treatment', 'assessment', 'consisting', 'of', 'measures', 'of', 'self', '-', 'efficacy', ',', 'quality', 'of', 'life', ',', 'functional', 'abilities', ',', 'and', 'awareness', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 33,
                "text": "Emotional Deficits",
                "type": "CONDITION"
            },
            {
                "start": 37,
                "end": 55,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 60,
                "end": 82,
                "text": "Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 151,
                "end": 198,
                "text": "intervention for improving emotional processing",
                "type": "OTHER"
            },
            {
                "start": 219,
                "end": 221,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 418,
                "text": "emotional processing intervention",
                "type": "OTHER"
            },
            {
                "start": 456,
                "end": 466,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 471,
                "end": 478,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 558,
                "end": 591,
                "text": "emotional processing intervention",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03621878",
        "study_official_title": "Effect of Neural Mobilization Techniques on Pain, and Hip and Knee Range of Motion on Lumbosacral Radiculopathy Patients With Peripheral Sensitization ",
        "study_brief_summary": " The primary purpose of this study was to investigate the effects of slider and tensioner techniques on pain, hip and knee ROM in lumbosacral radiculopathy patients with peripheral sensitization. A secondary purpose was to evaluate the correlation between these outcomes measurements.",
        "text": "Effect of Neural Mobilization Techniques on Pain, and Hip and Knee Range of Motion on Lumbosacral Radiculopathy Patients With Peripheral Sensitization | The primary purpose of this study was to investigate the effects of slider and tensioner techniques on pain, hip and knee ROM in lumbosacral radiculopathy patients with peripheral sensitization. A secondary purpose was to evaluate the correlation between these outcomes measurements.",
        "tokens": "['Effect', 'of', 'Neural', 'Mobilization', 'Techniques', 'on', 'Pain', ',', 'and', 'Hip', 'and', 'Knee', 'Range', 'of', 'Motion', 'on', 'Lumbosacral', 'Radiculopathy', 'Patients', 'With', 'Peripheral', 'Sensitization', '|', 'The', 'primary', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'effects', 'of', 'slider', 'and', 'tensioner', 'techniques', 'on', 'pain', ',', 'hip', 'and', 'knee', 'ROM', 'in', 'lumbosacral', 'radiculopathy', 'patients', 'with', 'peripheral', 'sensitization', '.', 'A', 'secondary', 'purpose', 'was', 'to', 'evaluate', 'the', 'correlation', 'between', 'these', 'outcomes', 'measurements', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 40,
                "text": "Neural Mobilization Techniques",
                "type": "PHYSICAL"
            },
            {
                "start": 44,
                "end": 48,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 86,
                "end": 111,
                "text": "Lumbosacral Radiculopathy",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 150,
                "text": "Peripheral Sensitization",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 252,
                "text": "slider and tensioner techniques",
                "type": "PHYSICAL"
            },
            {
                "start": 256,
                "end": 260,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 282,
                "end": 307,
                "text": "lumbosacral radiculopathy",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 346,
                "text": "peripheral sensitization",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04946682",
        "study_official_title": "Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment ",
        "study_brief_summary": " Encephalitis and meningitis are serious central nervous system diseases. There is currently a lack of comprehensive and accurate diagnosis and treatment pathways. Therefore, we conducted this multicenter, prospective, and randomized controlled study. It was designed to evaluate the diagnostic performance and its impact on the outcomes of the patients enrolled. As such, we came to the results of the optimal process of diagnosis and treatment strategy of encephalitis/meningeal syndromes with improved effective treatments.",
        "text": "Optimal Encephalitis/Meningitis Roadmap Via Precise Diagnosis and Treatment | Encephalitis and meningitis are serious central nervous system diseases. There is currently a lack of comprehensive and accurate diagnosis and treatment pathways. Therefore, we conducted this multicenter, prospective, and randomized controlled study. It was designed to evaluate the diagnostic performance and its impact on the outcomes of the patients enrolled. As such, we came to the results of the optimal process of diagnosis and treatment strategy of encephalitis/meningeal syndromes with improved effective treatments.",
        "tokens": "['Optimal', 'Encephalitis', '/', 'Meningitis', 'Roadmap', 'Via', 'Precise', 'Diagnosis', 'and', 'Treatment', '|', 'Encephalitis', 'and', 'meningitis', 'are', 'serious', 'central', 'nervous', 'system', 'diseases', '.', 'There', 'is', 'currently', 'a', 'lack', 'of', 'comprehensive', 'and', 'accurate', 'diagnosis', 'and', 'treatment', 'pathways', '.', 'Therefore', ',', 'we', 'conducted', 'this', 'multicenter', ',', 'prospective', ',', 'and', 'randomized', 'controlled', 'study', '.', 'It', 'was', 'designed', 'to', 'evaluate', 'the', 'diagnostic', 'performance', 'and', 'its', 'impact', 'on', 'the', 'outcomes', 'of', 'the', 'patients', 'enrolled', '.', 'As', 'such', ',', 'we', 'came', 'to', 'the', 'results', 'of', 'the', 'optimal', 'process', 'of', 'diagnosis', 'and', 'treatment', 'strategy', 'of', 'encephalitis', '/', 'meningeal', 'syndromes', 'with', 'improved', 'effective', 'treatments', '.']",
        "token_bio_labels": "['O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 8,
                "end": 20,
                "text": "Encephalitis",
                "type": "CONDITION"
            },
            {
                "start": 21,
                "end": 31,
                "text": "Meningitis",
                "type": "CONDITION"
            },
            {
                "start": 78,
                "end": 90,
                "text": "Encephalitis",
                "type": "CONDITION"
            },
            {
                "start": 95,
                "end": 105,
                "text": "meningitis",
                "type": "CONDITION"
            },
            {
                "start": 535,
                "end": 547,
                "text": "encephalitis",
                "type": "CONDITION"
            },
            {
                "start": 548,
                "end": 567,
                "text": "meningeal syndromes",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03369587",
        "study_official_title": "Handwriting Interventions for People With Parkinson's ",
        "study_brief_summary": " Background: Problems with handwriting are frustrating and debilitating and affect the majority of people with Parkinson's. Manifest as micrographia it is a distinctive feature of the condition characterised by small handwriting and/or a progressive reduction in size through a sentence[2] coupled with a reduction in writing speed and legibility.\n\nIn Parkinson's impaired automaticity is thought to contribute to handwriting deficits and attention has been shown to improve both 'consistent' (small handwriting) and 'progressive' (progressive reduction in letter size through a sentence) aspects of the symptom. Moreover, recent interventional studies indicate handwriting may be improved through practice. This study is investigating a novel handwriting practice stimulus to improve symptoms of micrograpthia\n\nQuestion: Is a diverging line cued handwriting intervention potentially more effective at improving symptoms of mircograpthia than a parallel line cued handwriting intervention in people with Parkinson's?\n\nSpecifically, an assessor blind randomised controlled exploratory trial will:\n\nEstatimate the effect of the intervention on measures of: Handwriting amplitude (consistent and progressive reduction), hand writing performance and percieved handwriting difficulties.\nExplore the appropriateness of these outcome measures\nExplore the approriateness of eligibilty criteria\nExplore intervention fidelity\nExplore participants views of the intervention\n\nDesign: A phase II exploratory randomised controlled trial of a handwriting intervention with an active comparator control group and blinded assessments\n\nSetting: The intervention will be carried out at home\n\nSample size: This study is not designed to determine efficacy. The aim to recruit a total of 50 people (25 people per group) in order to estimate the effects on outcome measures and achieve the aims of this exploratory trial.\n\nAssessment: Participants will be asked to follow their usual Parkinson's medication regime and if they have ON and OFF periods, assessments will be carried out during ON state.\n\nDuration and follow-up: the assessment is schedule 0Weeks (baseline), 6weeks (end intervention) and 12weeks (follow up). Assessments will be carried out by a researcher blind to trial arm allocation using all outcome measures.",
        "text": "Handwriting Interventions for People With Parkinson's | Background: Problems with handwriting are frustrating and debilitating and affect the majority of people with Parkinson's. Manifest as micrographia it is a distinctive feature of the condition characterised by small handwriting and/or a progressive reduction in size through a sentence[2] coupled with a reduction in writing speed and legibility.\n\nIn Parkinson's impaired automaticity is thought to contribute to handwriting deficits and attention has been shown to improve both 'consistent' (small handwriting) and 'progressive' (progressive reduction in letter size through a sentence) aspects of the symptom. Moreover, recent interventional studies indicate handwriting may be improved through practice. This study is investigating a novel handwriting practice stimulus to improve symptoms of micrograpthia\n\nQuestion: Is a diverging line cued handwriting intervention potentially more effective at improving symptoms of mircograpthia than a parallel line cued handwriting intervention in people with Parkinson's?\n\nSpecifically, an assessor blind randomised controlled exploratory trial will:\n\nEstatimate the effect of the intervention on measures of: Handwriting amplitude (consistent and progressive reduction), hand writing performance and percieved handwriting difficulties.\nExplore the appropriateness of these outcome measures\nExplore the approriateness of eligibilty criteria\nExplore intervention fidelity\nExplore participants views of the intervention\n\nDesign: A phase II exploratory randomised controlled trial of a handwriting intervention with an active comparator control group and blinded assessments\n\nSetting: The intervention will be carried out at home\n\nSample size: This study is not designed to determine efficacy. The aim to recruit a total of 50 people (25 people per group) in order to estimate the effects on outcome measures and achieve the aims of this exploratory trial.\n\nAssessment: Participants will be asked to follow their usual Parkinson's medication regime and if they have ON and OFF periods, assessments will be carried out during ON state.\n\nDuration and follow-up: the assessment is schedule 0Weeks (baseline), 6weeks (end intervention) and 12weeks (follow up). Assessments will be carried out by a researcher blind to trial arm allocation using all outcome measures.",
        "tokens": "['Handwriting', 'Interventions', 'for', 'People', 'With', 'Parkinson', \"'s\", '|', 'Background', ':', 'Problems', 'with', 'handwriting', 'are', 'frustrating', 'and', 'debilitating', 'and', 'affect', 'the', 'majority', 'of', 'people', 'with', 'Parkinson', \"'s\", '.', 'Manifest', 'as', 'micrographia', 'it', 'is', 'a', 'distinctive', 'feature', 'of', 'the', 'condition', 'characterised', 'by', 'small', 'handwriting', 'and/or', 'a', 'progressive', 'reduction', 'in', 'size', 'through', 'a', 'sentence[2', ']', 'coupled', 'with', 'a', 'reduction', 'in', 'writing', 'speed', 'and', 'legibility', '.', '\\n\\n', 'In', 'Parkinson', \"'s\", 'impaired', 'automaticity', 'is', 'thought', 'to', 'contribute', 'to', 'handwriting', 'deficits', 'and', 'attention', 'has', 'been', 'shown', 'to', 'improve', 'both', \"'\", 'consistent', \"'\", '(', 'small', 'handwriting', ')', 'and', \"'\", 'progressive', \"'\", '(', 'progressive', 'reduction', 'in', 'letter', 'size', 'through', 'a', 'sentence', ')', 'aspects', 'of', 'the', 'symptom', '.', 'Moreover', ',', 'recent', 'interventional', 'studies', 'indicate', 'handwriting', 'may', 'be', 'improved', 'through', 'practice', '.', 'This', 'study', 'is', 'investigating', 'a', 'novel', 'handwriting', 'practice', 'stimulus', 'to', 'improve', 'symptoms', 'of', 'micrograpthia', '\\n\\n', 'Question', ':', 'Is', 'a', 'diverging', 'line', 'cued', 'handwriting', 'intervention', 'potentially', 'more', 'effective', 'at', 'improving', 'symptoms', 'of', 'mircograpthia', 'than', 'a', 'parallel', 'line', 'cued', 'handwriting', 'intervention', 'in', 'people', 'with', 'Parkinson', \"'s\", '?', '\\n\\n', 'Specifically', ',', 'an', 'assessor', 'blind', 'randomised', 'controlled', 'exploratory', 'trial', 'will', ':', '\\n\\n', 'Estatimate', 'the', 'effect', 'of', 'the', 'intervention', 'on', 'measures', 'of', ':', 'Handwriting', 'amplitude', '(', 'consistent', 'and', 'progressive', 'reduction', ')', ',', 'hand', 'writing', 'performance', 'and', 'percieved', 'handwriting', 'difficulties', '.', '\\n', 'Explore', 'the', 'appropriateness', 'of', 'these', 'outcome', 'measures', '\\n', 'Explore', 'the', 'approriateness', 'of', 'eligibilty', 'criteria', '\\n', 'Explore', 'intervention', 'fidelity', '\\n', 'Explore', 'participants', 'views', 'of', 'the', 'intervention', '\\n\\n', 'Design', ':', 'A', 'phase', 'II', 'exploratory', 'randomised', 'controlled', 'trial', 'of', 'a', 'handwriting', 'intervention', 'with', 'an', 'active', 'comparator', 'control', 'group', 'and', 'blinded', 'assessments', '\\n\\n', 'Setting', ':', 'The', 'intervention', 'will', 'be', 'carried', 'out', 'at', 'home', '\\n\\n', 'Sample', 'size', ':', 'This', 'study', 'is', 'not', 'designed', 'to', 'determine', 'efficacy', '.', 'The', 'aim', 'to', 'recruit', 'a', 'total', 'of', '50', 'people', '(', '25', 'people', 'per', 'group', ')', 'in', 'order', 'to', 'estimate', 'the', 'effects', 'on', 'outcome', 'measures', 'and', 'achieve', 'the', 'aims', 'of', 'this', 'exploratory', 'trial', '.', '\\n\\n', 'Assessment', ':', 'Participants', 'will', 'be', 'asked', 'to', 'follow', 'their', 'usual', 'Parkinson', \"'s\", 'medication', 'regime', 'and', 'if', 'they', 'have', 'ON', 'and', 'OFF', 'periods', ',', 'assessments', 'will', 'be', 'carried', 'out', 'during', 'ON', 'state', '.', '\\n\\n', 'Duration', 'and', 'follow', '-', 'up', ':', 'the', 'assessment', 'is', 'schedule', '0Weeks', '(', 'baseline', ')', ',', '6weeks', '(', 'end', 'intervention', ')', 'and', '12weeks', '(', 'follow', 'up', ')', '.', 'Assessments', 'will', 'be', 'carried', 'out', 'by', 'a', 'researcher', 'blind', 'to', 'trial', 'arm', 'allocation', 'using', 'all', 'outcome', 'measures', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 25,
                "text": "Handwriting Interventions",
                "type": "OTHER"
            },
            {
                "start": 42,
                "end": 53,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 177,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 191,
                "end": 203,
                "text": "micrographia",
                "type": "CONDITION"
            },
            {
                "start": 407,
                "end": 418,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 799,
                "end": 828,
                "text": "handwriting practice stimulus",
                "type": "OTHER"
            },
            {
                "start": 852,
                "end": 865,
                "text": "micrograpthia",
                "type": "CONDITION"
            },
            {
                "start": 882,
                "end": 926,
                "text": "diverging line cued handwriting intervention",
                "type": "OTHER"
            },
            {
                "start": 1000,
                "end": 1043,
                "text": "parallel line cued handwriting intervention",
                "type": "CONTROL"
            },
            {
                "start": 1059,
                "end": 1070,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 1583,
                "end": 1607,
                "text": "handwriting intervention",
                "type": "OTHER"
            },
            {
                "start": 2016,
                "end": 2027,
                "text": "Parkinson's",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02525172",
        "study_official_title": "Immune Modulation Therapy for ERT-na\u00efve or ERT-treated Pompe Disease Patients ",
        "study_brief_summary": " The purpose of this study is to assess anti-recombinant human acid \u03b1-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.",
        "text": "Immune Modulation Therapy for ERT-na\u00efve or ERT-treated Pompe Disease Patients | The purpose of this study is to assess anti-recombinant human acid \u03b1-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.",
        "tokens": "['Immune', 'Modulation', 'Therapy', 'for', 'ERT', '-', 'na\u00efve', 'or', 'ERT', '-', 'treated', 'Pompe', 'Disease', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'anti', '-', 'recombinant', 'human', 'acid', '\u03b1', '-', 'glucosidase', '(', 'anti', '-', 'rhGAA', ')', 'antibody', 'titers', 'after', 'treatment', 'with', 'immune', 'modulation', 'therapy', 'in', 'patients', 'of', 'Pompe', 'disease', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 25,
                "text": "Immune Modulation Therapy",
                "type": "OTHER"
            },
            {
                "start": 30,
                "end": 68,
                "text": "ERT-na\u00efve or ERT-treated Pompe Disease",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 160,
                "text": "anti-recombinant human acid \u03b1-glucosidase",
                "type": "DRUG"
            },
            {
                "start": 162,
                "end": 172,
                "text": "anti-rhGAA",
                "type": "DRUG"
            },
            {
                "start": 252,
                "end": 265,
                "text": "Pompe disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01741532",
        "study_official_title": "A Randomized, Double-blind, Placebo-controlled Trial of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) ",
        "study_brief_summary": " A multi-center, placebo controlled, double-blind trial comparing the efficacy and safety of 18 months of treatment with deferiprone versus placebo in patients with PKAN.\n\nThis investigator-initiated trial was funded by the European Commission's Seventh Framework Programme (FP7/2007-2013, HEALTH-F2-2011, grant agreement No. 277984) to the TIRCON consortium (Treat Iron-Related Childhood-Onset Neurodegeneration) and by the FDA Office of Orphan Products Development (OOPD) (Dr. Elliott Vichinsky).",
        "text": "A Randomized, Double-blind, Placebo-controlled Trial of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) | A multi-center, placebo controlled, double-blind trial comparing the efficacy and safety of 18 months of treatment with deferiprone versus placebo in patients with PKAN.\n\nThis investigator-initiated trial was funded by the European Commission's Seventh Framework Programme (FP7/2007-2013, HEALTH-F2-2011, grant agreement No. 277984) to the TIRCON consortium (Treat Iron-Related Childhood-Onset Neurodegeneration) and by the FDA Office of Orphan Products Development (OOPD) (Dr. Elliott Vichinsky).",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', 'of', 'Deferiprone', 'in', 'Patients', 'With', 'Pantothenate', 'Kinase', '-', 'associated', 'Neurodegeneration', '(', 'PKAN', ')', '|', 'A', 'multi', '-', 'center', ',', 'placebo', 'controlled', ',', 'double', '-', 'blind', 'trial', 'comparing', 'the', 'efficacy', 'and', 'safety', 'of', '18', 'months', 'of', 'treatment', 'with', 'deferiprone', 'versus', 'placebo', 'in', 'patients', 'with', 'PKAN', '.', '\\n\\n', 'This', 'investigator', '-', 'initiated', 'trial', 'was', 'funded', 'by', 'the', 'European', 'Commission', \"'s\", 'Seventh', 'Framework', 'Programme', '(', 'FP7/2007', '-', '2013', ',', 'HEALTH', '-', 'F2', '-', '2011', ',', 'grant', 'agreement', 'No', '.', '277984', ')', 'to', 'the', 'TIRCON', 'consortium', '(', 'Treat', 'Iron', '-', 'Related', 'Childhood', '-', 'Onset', 'Neurodegeneration', ')', 'and', 'by', 'the', 'FDA', 'Office', 'of', 'Orphan', 'Products', 'Development', '(', 'OOPD', ')', '(', 'Dr.', 'Elliott', 'Vichinsky', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 56,
                "end": 67,
                "text": "Deferiprone",
                "type": "DRUG"
            },
            {
                "start": 85,
                "end": 133,
                "text": "Pantothenate Kinase-associated Neurodegeneration",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 139,
                "text": "PKAN",
                "type": "CONDITION"
            },
            {
                "start": 159,
                "end": 166,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 263,
                "end": 274,
                "text": "deferiprone",
                "type": "DRUG"
            },
            {
                "start": 282,
                "end": 289,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 307,
                "end": 311,
                "text": "PKAN",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04573530",
        "study_official_title": "We Walk Plus Study: A Walking Program Using Physical Activity Monitors and Social Networking for Older Adults With Intellectual Disabilities ",
        "study_brief_summary": " Determine the feasibility and acceptability of We Walk Plus intervention to promote physical activity and improve cognition for older adults with intellectual disabilities (ID).",
        "text": "We Walk Plus Study: A Walking Program Using Physical Activity Monitors and Social Networking for Older Adults With Intellectual Disabilities | Determine the feasibility and acceptability of We Walk Plus intervention to promote physical activity and improve cognition for older adults with intellectual disabilities (ID).",
        "tokens": "['We', 'Walk', 'Plus', 'Study', ':', 'A', 'Walking', 'Program', 'Using', 'Physical', 'Activity', 'Monitors', 'and', 'Social', 'Networking', 'for', 'Older', 'Adults', 'With', 'Intellectual', 'Disabilities', '|', 'Determine', 'the', 'feasibility', 'and', 'acceptability', 'of', 'We', 'Walk', 'Plus', 'intervention', 'to', 'promote', 'physical', 'activity', 'and', 'improve', 'cognition', 'for', 'older', 'adults', 'with', 'intellectual', 'disabilities', '(', 'ID', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 92,
                "text": "Walking Program Using Physical Activity Monitors and Social Networking",
                "type": "OTHER"
            },
            {
                "start": 115,
                "end": 140,
                "text": "Intellectual Disabilities",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 215,
                "text": "We Walk Plus intervention",
                "type": "OTHER"
            },
            {
                "start": 289,
                "end": 314,
                "text": "intellectual disabilities",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 318,
                "text": "ID",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00856661",
        "study_official_title": "A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke ",
        "study_brief_summary": " The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.",
        "text": "A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke | The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.",
        "tokens": "['A', 'Randomised', ',', 'Double', '-', 'Blind', ',', 'Parallel', '-', 'Group', 'Placebo', '-', 'Controlled', 'Phase', 'III', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Desmoteplase', 'in', 'Subjects', 'With', 'Acute', 'Ischemic', 'Stroke', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'whether', 'desmoteplase', 'is', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'acute', 'ischaemic', 'stroke', 'when', 'given', 'within', '3', 'to', '9', 'hours', 'from', 'onset', 'of', 'stroke', 'symptoms', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 50,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 117,
                "end": 129,
                "text": "Desmoteplase",
                "type": "DRUG"
            },
            {
                "start": 147,
                "end": 168,
                "text": "Acute Ischemic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 232,
                "text": "desmoteplase",
                "type": "DRUG"
            },
            {
                "start": 289,
                "end": 311,
                "text": "acute ischaemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 357,
                "end": 363,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03177915",
        "study_official_title": "Median Nerve Hydro-dissection Using Single Injection of Hyalase as a Novel Treatment of Carpal Tunnel Syndrome: Double Blind Randomized Clinical Trial ",
        "study_brief_summary": " Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent hydro-dissection hyalase and saline of the median nerve could offer symptoms and clinical improvement",
        "text": "Median Nerve Hydro-dissection Using Single Injection of Hyalase as a Novel Treatment of Carpal Tunnel Syndrome: Double Blind Randomized Clinical Trial | Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent hydro-dissection hyalase and saline of the median nerve could offer symptoms and clinical improvement",
        "tokens": "['Median', 'Nerve', 'Hydro', '-', 'dissection', 'Using', 'Single', 'Injection', 'of', 'Hyalase', 'as', 'a', 'Novel', 'Treatment', 'of', 'Carpal', 'Tunnel', 'Syndrome', ':', 'Double', 'Blind', 'Randomized', 'Clinical', 'Trial', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'a', 'common', 'peripheral', 'entrapment', 'neuropathy', ',', 'this', 'study', 'aims', 'to', 'investigate', 'if', ',', 'and', 'to', 'what', 'extent', 'hydro', '-', 'dissection', 'hyalase', 'and', 'saline', 'of', 'the', 'median', 'nerve', 'could', 'offer', 'symptoms', 'and', 'clinical', 'improvement']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 29,
                "text": "Median Nerve Hydro-dissection",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 63,
                "text": "Hyalase",
                "type": "DRUG"
            },
            {
                "start": 88,
                "end": 110,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 175,
                "text": "Carpal tunnel syndrome",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 180,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 282,
                "end": 298,
                "text": "hydro-dissection",
                "type": "OTHER"
            },
            {
                "start": 299,
                "end": 306,
                "text": "hyalase",
                "type": "DRUG"
            },
            {
                "start": 311,
                "end": 317,
                "text": "saline",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02724865",
        "study_official_title": "A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA ",
        "study_brief_summary": " Obstructive sleep apnea (OSA) is a common chronic sleep disorder that often requires lifelong care. The prevalence in the Netherlands is estimated around 300.000 patients. Due to longer life expectancy and increase in weight in the general population, its prevalence is expected to rise. Patients with mild and moderate OSA are treated primarily with an oral appliance at present time. Different oral appliances are available, but most used is the mandibular advancement device (MAD). This study focuses on two different types of MAD: the classic Herbst appliance, which is attached to the mandible and the maxilla and has an iron bar to regulate the open space; and the Somnodent, which consists of two separate splints, fixed on the mandible and the maxilla, but has no iron bar attached.",
        "text": "A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA | Obstructive sleep apnea (OSA) is a common chronic sleep disorder that often requires lifelong care. The prevalence in the Netherlands is estimated around 300.000 patients. Due to longer life expectancy and increase in weight in the general population, its prevalence is expected to rise. Patients with mild and moderate OSA are treated primarily with an oral appliance at present time. Different oral appliances are available, but most used is the mandibular advancement device (MAD). This study focuses on two different types of MAD: the classic Herbst appliance, which is attached to the mandible and the maxilla and has an iron bar to regulate the open space; and the Somnodent, which consists of two separate splints, fixed on the mandible and the maxilla, but has no iron bar attached.",
        "tokens": "['A', 'Comparison', 'Between', 'Two', 'Different', 'Oral', 'Appliance', 'Therapies', ':', 'Somnodent', 'vs', 'Herbst', 'Appliance', 'in', 'Patients', 'With', 'Mild', 'and', 'Moderate', 'OSA', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'is', 'a', 'common', 'chronic', 'sleep', 'disorder', 'that', 'often', 'requires', 'lifelong', 'care', '.', 'The', 'prevalence', 'in', 'the', 'Netherlands', 'is', 'estimated', 'around', '300.000', 'patients', '.', 'Due', 'to', 'longer', 'life', 'expectancy', 'and', 'increase', 'in', 'weight', 'in', 'the', 'general', 'population', ',', 'its', 'prevalence', 'is', 'expected', 'to', 'rise', '.', 'Patients', 'with', 'mild', 'and', 'moderate', 'OSA', 'are', 'treated', 'primarily', 'with', 'an', 'oral', 'appliance', 'at', 'present', 'time', '.', 'Different', 'oral', 'appliances', 'are', 'available', ',', 'but', 'most', 'used', 'is', 'the', 'mandibular', 'advancement', 'device', '(', 'MAD', ')', '.', 'This', 'study', 'focuses', 'on', 'two', 'different', 'types', 'of', 'MAD', ':', 'the', 'classic', 'Herbst', 'appliance', ',', 'which', 'is', 'attached', 'to', 'the', 'mandible', 'and', 'the', 'maxilla', 'and', 'has', 'an', 'iron', 'bar', 'to', 'regulate', 'the', 'open', 'space', ';', 'and', 'the', 'Somnodent', ',', 'which', 'consists', 'of', 'two', 'separate', 'splints', ',', 'fixed', 'on', 'the', 'mandible', 'and', 'the', 'maxilla', ',', 'but', 'has', 'no', 'iron', 'bar', 'attached', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 59,
                "text": "Oral Appliance Therapies",
                "type": "OTHER"
            },
            {
                "start": 61,
                "end": 70,
                "text": "Somnodent",
                "type": "OTHER"
            },
            {
                "start": 74,
                "end": 90,
                "text": "Herbst Appliance",
                "type": "OTHER"
            },
            {
                "start": 108,
                "end": 129,
                "text": "Mild and Moderate OSA",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 155,
                "text": "Obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 157,
                "end": 160,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 434,
                "end": 455,
                "text": "mild and moderate OSA",
                "type": "CONDITION"
            },
            {
                "start": 486,
                "end": 500,
                "text": "oral appliance",
                "type": "OTHER"
            },
            {
                "start": 528,
                "end": 543,
                "text": "oral appliances",
                "type": "OTHER"
            },
            {
                "start": 580,
                "end": 609,
                "text": "mandibular advancement device",
                "type": "OTHER"
            },
            {
                "start": 611,
                "end": 614,
                "text": "MAD",
                "type": "OTHER"
            },
            {
                "start": 662,
                "end": 665,
                "text": "MAD",
                "type": "OTHER"
            },
            {
                "start": 679,
                "end": 695,
                "text": "Herbst appliance",
                "type": "OTHER"
            },
            {
                "start": 803,
                "end": 812,
                "text": "Somnodent",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01662310",
        "study_official_title": "Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study ",
        "study_brief_summary": " The purpose of this study is to evaluate the efficacy, tolerability and safety of paliperidone extended release (ER) tablets (between 3 to 12 milligram (mg), once a day) in the prevention of relapse in schizophrenia participants.",
        "text": "Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study | The purpose of this study is to evaluate the efficacy, tolerability and safety of paliperidone extended release (ER) tablets (between 3 to 12 milligram (mg), once a day) in the prevention of relapse in schizophrenia participants.",
        "tokens": "['Paliperidone', 'Extended', 'Release', 'Tablets', 'for', 'the', 'Prevention', 'of', 'Relapse', 'in', 'Subjects', 'With', 'Schizophrenia', ':', 'A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', ',', 'tolerability', 'and', 'safety', 'of', 'paliperidone', 'extended', 'release', '(', 'ER', ')', 'tablets', '(', 'between', '3', 'to', '12', 'milligram', '(', 'mg', ')', ',', 'once', 'a', 'day', ')', 'in', 'the', 'prevention', 'of', 'relapse', 'in', 'schizophrenia', 'participants', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 12,
                "text": "Paliperidone",
                "type": "DRUG"
            },
            {
                "start": 85,
                "end": 98,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 128,
                "end": 135,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 253,
                "end": 265,
                "text": "paliperidone",
                "type": "DRUG"
            },
            {
                "start": 373,
                "end": 386,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02374567",
        "study_official_title": "Pharmacovigilance in Gerontopsychiatric Patients ",
        "study_brief_summary": " The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment.\n\nThe aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises.\n\nTo assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites.\n\nAt Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed.\n\nAfterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system.\n\nIn case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually.\n\n2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.",
        "text": "Pharmacovigilance in Gerontopsychiatric Patients | The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment.\n\nThe aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises.\n\nTo assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites.\n\nAt Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed.\n\nAfterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system.\n\nIn case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually.\n\n2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.",
        "tokens": "['Pharmacovigilance', 'in', 'Gerontopsychiatric', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'multicenter', '-', 'study', 'is', 'to', 'investigate', 'safety', 'of', 'psychopharmacological', 'treatment', 'and', 'rates', 'of', 'adverse', 'drug', 'reactions', 'in', 'gerontopsychiatric', 'inpatients', '.', 'Elderly', 'people', 'are', 'at', 'higher', 'risk', 'for', 'developing', 'side', 'effects', 'under', 'pharmacological', 'treatment', 'due', 'to', 'an', 'altered', 'metabolic', 'situation', ',', 'higher', 'comorbidity', 'rates', 'and', 'often', 'polypharmacy', '.', 'Furthermore', 'gerontopsychiatric', 'patients', 'can', 'often', 'not', 'articulate', 'their', 'symptoms', 'clearly', ',', 'for', 'example', 'due', 'to', 'pronounced', 'cognitive', 'impairment', '.', '\\n\\n', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'gain', 'valid', 'data', 'of', 'possible', 'adverse', 'drug', 'reaction', 'rates', ',', 'their', 'potential', 'risk', 'factors', 'and', 'outcome', ',', 'as', 'well', 'as', 'medical', 'prescription', 'practises', '.', '\\n\\n', 'To', 'assess', 'these', 'outcomes', 'an', 'intensive', 'pharmacovigilance', '-', 'monitoring', 'will', 'be', 'conducted', 'at', 'the', 'five', 'participating', 'study', 'sites', '.', '\\n\\n', 'At', 'Baseline', 'demographic', 'data', ',', 'previous', 'and', 'present', 'disorders', ',', 'use', 'of', 'drugs', ',', 'previous', 'and', 'present', 'medication', ',', 'quality', 'of', 'life', ',', 'cognitive', 'function', ',', 'physical', 'examination', 'results', ',', 'laboratory', 'results', 'and', 'ECG', 'will', 'be', 'assessed', '.', '\\n\\n', 'Afterwards', 'patients', 'are', 'visited', 'weekly', 'and', 'screened', 'for', 'possible', 'adverse', 'drug', 'reactions', '.', 'All', 'adverse', 'drug', 'reactions', 'will', 'be', 'coded', 'in', 'the', 'MedDRA', '-', 'system', '.', '\\n\\n', 'In', 'case', 'of', 'a', 'possible', 'serious', 'adverse', 'drug', 'reaction', 'serum', 'levels', 'of', 'all', 'psychotropic', 'substances', 'applicated', 'will', 'be', 'assessed', '.', 'Drug', 'combinations', 'will', 'be', 'analysed', 'using', 'an', 'established', 'advanced', 'bioinformatic', 'tool', '(', 'mediQ', ')', '.', 'Diagnosis', ',', 'medication', 'intake', 'and', 'possible', 'adverse', 'drug', 'reactions', 'are', 'documented', 'continually', '.', '\\n\\n', '2', 'weeks', 'after', 'discharge', 'from', 'the', 'ward', ',', 'patients', 'will', 'be', 'contacted', 'by', 'phone', 'to', 'assess', 'catamnestic', 'data', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT01171469",
        "study_official_title": "Phase I Study of Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Recurrent or Progressive Malignant Gliomas ",
        "study_brief_summary": " This is a single center Phase I study to determine the safety and maximum tolerated dose (MTD) of autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells administered as a vaccination in children and adults with recurrent brain tumors. Once the MTD has been determined, we will conduct a phase II study to determine efficacy.\n\nClinical trials that utilize DCs for immunotherapy have demonstrated significant survival benefit for patients who exhibit robust immune responses against tumor cells. Unfortunately, at the present time the majority of tumor patients are unable to mount an adequate immune response and thus succumb to their tumors. We postulate that the inability to generate an appropriate immune response in these patients is due to a lack of sufficient numbers of appropriate T cells due to an inadequate source of tumor antigens.",
        "text": "Phase I Study of Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Recurrent or Progressive Malignant Gliomas | This is a single center Phase I study to determine the safety and maximum tolerated dose (MTD) of autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells administered as a vaccination in children and adults with recurrent brain tumors. Once the MTD has been determined, we will conduct a phase II study to determine efficacy.\n\nClinical trials that utilize DCs for immunotherapy have demonstrated significant survival benefit for patients who exhibit robust immune responses against tumor cells. Unfortunately, at the present time the majority of tumor patients are unable to mount an adequate immune response and thus succumb to their tumors. We postulate that the inability to generate an appropriate immune response in these patients is due to a lack of sufficient numbers of appropriate T cells due to an inadequate source of tumor antigens.",
        "tokens": "['Phase', 'I', 'Study', 'of', 'Vaccination', 'With', 'Dendritic', 'Cells', 'Loaded', 'With', 'Brain', 'Tumor', 'Stem', 'Cells', 'for', 'Recurrent', 'or', 'Progressive', 'Malignant', 'Gliomas', '|', 'This', 'is', 'a', 'single', 'center', 'Phase', 'I', 'study', 'to', 'determine', 'the', 'safety', 'and', 'maximum', 'tolerated', 'dose', '(', 'MTD', ')', 'of', 'autologous', 'dendritic', 'cells', '(', 'DCs', ')', 'loaded', 'with', 'allogeneic', 'brain', 'tumor', 'stem', 'cells', 'administered', 'as', 'a', 'vaccination', 'in', 'children', 'and', 'adults', 'with', 'recurrent', 'brain', 'tumors', '.', 'Once', 'the', 'MTD', 'has', 'been', 'determined', ',', 'we', 'will', 'conduct', 'a', 'phase', 'II', 'study', 'to', 'determine', 'efficacy', '.', '\\n\\n', 'Clinical', 'trials', 'that', 'utilize', 'DCs', 'for', 'immunotherapy', 'have', 'demonstrated', 'significant', 'survival', 'benefit', 'for', 'patients', 'who', 'exhibit', 'robust', 'immune', 'responses', 'against', 'tumor', 'cells', '.', 'Unfortunately', ',', 'at', 'the', 'present', 'time', 'the', 'majority', 'of', 'tumor', 'patients', 'are', 'unable', 'to', 'mount', 'an', 'adequate', 'immune', 'response', 'and', 'thus', 'succumb', 'to', 'their', 'tumors', '.', 'We', 'postulate', 'that', 'the', 'inability', 'to', 'generate', 'an', 'appropriate', 'immune', 'response', 'in', 'these', 'patients', 'is', 'due', 'to', 'a', 'lack', 'of', 'sufficient', 'numbers', 'of', 'appropriate', 'T', 'cells', 'due', 'to', 'an', 'inadequate', 'source', 'of', 'tumor', 'antigens', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 34,
                "end": 84,
                "text": "Dendritic Cells Loaded With Brain Tumor Stem Cells",
                "type": "SURGICAL"
            },
            {
                "start": 89,
                "end": 131,
                "text": "Recurrent or Progressive Malignant Gliomas",
                "type": "CONDITION"
            },
            {
                "start": 232,
                "end": 310,
                "text": "autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells",
                "type": "SURGICAL"
            },
            {
                "start": 369,
                "end": 391,
                "text": "recurrent brain tumors",
                "type": "CONDITION"
            },
            {
                "start": 513,
                "end": 534,
                "text": "DCs for immunotherapy",
                "type": "SURGICAL"
            },
            {
                "start": 639,
                "end": 644,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 703,
                "end": 708,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 792,
                "end": 798,
                "text": "tumors",
                "type": "CONDITION"
            },
            {
                "start": 986,
                "end": 991,
                "text": "tumor",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01974635",
        "study_official_title": "Proprioception Testing in Persons With Sensorimotor Impairment ",
        "study_brief_summary": " In this study, an FDA-cleared device and type of treatment called \"AMES,\" which stands for Assisted Movement with Enhanced Sensation, will be used to determine whether sensation in the upper limb of individuals with incomplete spinal cord injuries, acquired brain injury, or stroke improves along with movement through treatment. We hypothesize that measureable improvement in the sensation of the upper limb will precede improvement in functional movement.",
        "text": "Proprioception Testing in Persons With Sensorimotor Impairment | In this study, an FDA-cleared device and type of treatment called \"AMES,\" which stands for Assisted Movement with Enhanced Sensation, will be used to determine whether sensation in the upper limb of individuals with incomplete spinal cord injuries, acquired brain injury, or stroke improves along with movement through treatment. We hypothesize that measureable improvement in the sensation of the upper limb will precede improvement in functional movement.",
        "tokens": "['Proprioception', 'Testing', 'in', 'Persons', 'With', 'Sensorimotor', 'Impairment', '|', 'In', 'this', 'study', ',', 'an', 'FDA', '-', 'cleared', 'device', 'and', 'type', 'of', 'treatment', 'called', '\"', 'AMES', ',', '\"', 'which', 'stands', 'for', 'Assisted', 'Movement', 'with', 'Enhanced', 'Sensation', ',', 'will', 'be', 'used', 'to', 'determine', 'whether', 'sensation', 'in', 'the', 'upper', 'limb', 'of', 'individuals', 'with', 'incomplete', 'spinal', 'cord', 'injuries', ',', 'acquired', 'brain', 'injury', ',', 'or', 'stroke', 'improves', 'along', 'with', 'movement', 'through', 'treatment', '.', 'We', 'hypothesize', 'that', 'measureable', 'improvement', 'in', 'the', 'sensation', 'of', 'the', 'upper', 'limb', 'will', 'precede', 'improvement', 'in', 'functional', 'movement', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 62,
                "text": "Sensorimotor Impairment",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 136,
                "text": "AMES",
                "type": "PHYSICAL"
            },
            {
                "start": 156,
                "end": 197,
                "text": "Assisted Movement with Enhanced Sensation",
                "type": "PHYSICAL"
            },
            {
                "start": 281,
                "end": 312,
                "text": "incomplete spinal cord injuries",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 335,
                "text": "acquired brain injury",
                "type": "CONDITION"
            },
            {
                "start": 340,
                "end": 346,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03840837",
        "study_official_title": "Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease ",
        "study_brief_summary": " This is a single-site non-randomized open label pilot study. The investigators will use accelerometer-based instrumented gait analysis and computerized cognitive testing to study the interaction of motor and cognitive dysfunction in Parkinson disease dementia (PDD), and the effect of rivastigmine on motor and cognitive performance. All study participants will be tested for motor and cognitive performance at baseline (arm 1). A subgroup of study participants will then be treated with rivastigmine for 12 weeks (arm 2), and the effect of this treatment on gait measures and cognitive measures will be analyzed at the follow-up visit 12 weeks after the baseline visit. Specifically, we will determine which components of motor and cognitive impairment are associated with each other, and which components of the two domains respond to rivastigmine-mediated stimulation of cholinergic neurotransmission.",
        "text": "Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease | This is a single-site non-randomized open label pilot study. The investigators will use accelerometer-based instrumented gait analysis and computerized cognitive testing to study the interaction of motor and cognitive dysfunction in Parkinson disease dementia (PDD), and the effect of rivastigmine on motor and cognitive performance. All study participants will be tested for motor and cognitive performance at baseline (arm 1). A subgroup of study participants will then be treated with rivastigmine for 12 weeks (arm 2), and the effect of this treatment on gait measures and cognitive measures will be analyzed at the follow-up visit 12 weeks after the baseline visit. Specifically, we will determine which components of motor and cognitive impairment are associated with each other, and which components of the two domains respond to rivastigmine-mediated stimulation of cholinergic neurotransmission.",
        "tokens": "['Cholinergic', 'Neurotransmission', '-', 'A', 'Common', 'Underlying', 'Mechanism', 'of', 'Cognitive', 'and', 'Gait', 'Impairment', 'in', 'Parkinson', 'Disease', '|', 'This', 'is', 'a', 'single', '-', 'site', 'non', '-', 'randomized', 'open', 'label', 'pilot', 'study', '.', 'The', 'investigators', 'will', 'use', 'accelerometer', '-', 'based', 'instrumented', 'gait', 'analysis', 'and', 'computerized', 'cognitive', 'testing', 'to', 'study', 'the', 'interaction', 'of', 'motor', 'and', 'cognitive', 'dysfunction', 'in', 'Parkinson', 'disease', 'dementia', '(', 'PDD', ')', ',', 'and', 'the', 'effect', 'of', 'rivastigmine', 'on', 'motor', 'and', 'cognitive', 'performance', '.', 'All', 'study', 'participants', 'will', 'be', 'tested', 'for', 'motor', 'and', 'cognitive', 'performance', 'at', 'baseline', '(', 'arm', '1', ')', '.', 'A', 'subgroup', 'of', 'study', 'participants', 'will', 'then', 'be', 'treated', 'with', 'rivastigmine', 'for', '12', 'weeks', '(', 'arm', '2', ')', ',', 'and', 'the', 'effect', 'of', 'this', 'treatment', 'on', 'gait', 'measures', 'and', 'cognitive', 'measures', 'will', 'be', 'analyzed', 'at', 'the', 'follow', '-', 'up', 'visit', '12', 'weeks', 'after', 'the', 'baseline', 'visit', '.', 'Specifically', ',', 'we', 'will', 'determine', 'which', 'components', 'of', 'motor', 'and', 'cognitive', 'impairment', 'are', 'associated', 'with', 'each', 'other', ',', 'and', 'which', 'components', 'of', 'the', 'two', 'domains', 'respond', 'to', 'rivastigmine', '-', 'mediated', 'stimulation', 'of', 'cholinergic', 'neurotransmission', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 65,
                "end": 94,
                "text": "Cognitive and Gait Impairment",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 115,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 347,
                "text": "motor and cognitive dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 377,
                "text": "Parkinson disease dementia",
                "type": "CONDITION"
            },
            {
                "start": 379,
                "end": 382,
                "text": "PDD",
                "type": "CONDITION"
            },
            {
                "start": 403,
                "end": 415,
                "text": "rivastigmine",
                "type": "DRUG"
            },
            {
                "start": 606,
                "end": 618,
                "text": "rivastigmine",
                "type": "DRUG"
            },
            {
                "start": 841,
                "end": 871,
                "text": "motor and cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 955,
                "end": 967,
                "text": "rivastigmine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04942574",
        "study_official_title": "Voice Biomarkers to Predict Excessive Daytime Sleepiness ",
        "study_brief_summary": " This study aims at measuring the impact of a night of sleep deprivation over the vocal characteristics of healthy subjects.To do so, the subjects takes a Multiple Sleep Latency Test (MSLT) the day after a night of total sleep deprivation (or a supervised normal night for the control subjects). Before each iteration of the MSLT, the subjects are recorded during the reading of a text and fill three medical questionnaires : Karolinska Sleepiness Scale (KSS), Visual Analogue Scale for Fatigue (VAS-F) and Visual Analogue Scale for Anxiety (VAS-A), allowing to link variations of vocal markers to the variations of these measures.",
        "text": "Voice Biomarkers to Predict Excessive Daytime Sleepiness | This study aims at measuring the impact of a night of sleep deprivation over the vocal characteristics of healthy subjects.To do so, the subjects takes a Multiple Sleep Latency Test (MSLT) the day after a night of total sleep deprivation (or a supervised normal night for the control subjects). Before each iteration of the MSLT, the subjects are recorded during the reading of a text and fill three medical questionnaires : Karolinska Sleepiness Scale (KSS), Visual Analogue Scale for Fatigue (VAS-F) and Visual Analogue Scale for Anxiety (VAS-A), allowing to link variations of vocal markers to the variations of these measures.",
        "tokens": "['Voice', 'Biomarkers', 'to', 'Predict', 'Excessive', 'Daytime', 'Sleepiness', '|', 'This', 'study', 'aims', 'at', 'measuring', 'the', 'impact', 'of', 'a', 'night', 'of', 'sleep', 'deprivation', 'over', 'the', 'vocal', 'characteristics', 'of', 'healthy', 'subjects', '.', 'To', 'do', 'so', ',', 'the', 'subjects', 'takes', 'a', 'Multiple', 'Sleep', 'Latency', 'Test', '(', 'MSLT', ')', 'the', 'day', 'after', 'a', 'night', 'of', 'total', 'sleep', 'deprivation', '(', 'or', 'a', 'supervised', 'normal', 'night', 'for', 'the', 'control', 'subjects', ')', '.', 'Before', 'each', 'iteration', 'of', 'the', 'MSLT', ',', 'the', 'subjects', 'are', 'recorded', 'during', 'the', 'reading', 'of', 'a', 'text', 'and', 'fill', 'three', 'medical', 'questionnaires', ':', 'Karolinska', 'Sleepiness', 'Scale', '(', 'KSS', ')', ',', 'Visual', 'Analogue', 'Scale', 'for', 'Fatigue', '(', 'VAS', '-', 'F', ')', 'and', 'Visual', 'Analogue', 'Scale', 'for', 'Anxiety', '(', 'VAS', '-', 'A', ')', ',', 'allowing', 'to', 'link', 'variations', 'of', 'vocal', 'markers', 'to', 'the', 'variations', 'of', 'these', 'measures', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 56,
                "text": "Excessive Daytime Sleepiness",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04146285",
        "study_official_title": "A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders ",
        "study_brief_summary": " This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.",
        "text": "A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders | This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.",
        "tokens": "['A', 'Phase', 'I', 'Clinical', 'Trial', 'of', 'BAT4406F', 'Injection', 'on', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Pharmacokinetics', 'in', 'Patients', 'With', 'Neuromyelitis', 'Optica', 'Spectrum', 'Disorders', '|', 'This', 'study', 'is', 'a', 'phase', 'I', 'clinical', 'study', 'of', 'the', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'BAT4406F', 'injection', 'in', 'patients', 'with', 'neuromyelitis', 'optica', 'spectrum', 'disorders', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 36,
                "text": "BAT4406F",
                "type": "DRUG"
            },
            {
                "start": 114,
                "end": 153,
                "text": "Neuromyelitis Optica Spectrum Disorders",
                "type": "CONDITION"
            },
            {
                "start": 248,
                "end": 256,
                "text": "BAT4406F",
                "type": "DRUG"
            },
            {
                "start": 284,
                "end": 323,
                "text": "neuromyelitis optica spectrum disorders",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01738893",
        "study_official_title": "Bioequivalence Study Between Two Medications for Administration of Oral Gabapentin in 300 mg Capsules in Healthy Volunteers ",
        "study_brief_summary": " The objective of this study was to confirm if two formulations of gabapentin (capsules) are bioequivalent.\n\nTest product was Darbetin\u00ae 300 mg (Laboratorios Dermatol\u00f3gicos Darier) and reference product Nerotin\u00ae 300 mg (Pfizer). One capsule was the single dosage.\n\nThe study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions.\n\nThe population was composed of 26 healthy volunteers, both genders, adults between 18-55 years.\n\nThe comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.",
        "text": "Bioequivalence Study Between Two Medications for Administration of Oral Gabapentin in 300 mg Capsules in Healthy Volunteers | The objective of this study was to confirm if two formulations of gabapentin (capsules) are bioequivalent.\n\nTest product was Darbetin\u00ae 300 mg (Laboratorios Dermatol\u00f3gicos Darier) and reference product Nerotin\u00ae 300 mg (Pfizer). One capsule was the single dosage.\n\nThe study was prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods, under fasting conditions.\n\nThe population was composed of 26 healthy volunteers, both genders, adults between 18-55 years.\n\nThe comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.",
        "tokens": "['Bioequivalence', 'Study', 'Between', 'Two', 'Medications', 'for', 'Administration', 'of', 'Oral', 'Gabapentin', 'in', '300', 'mg', 'Capsules', 'in', 'Healthy', 'Volunteers', '|', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', 'confirm', 'if', 'two', 'formulations', 'of', 'gabapentin', '(', 'capsules', ')', 'are', 'bioequivalent', '.', '\\n\\n', 'Test', 'product', 'was', 'Darbetin', '\u00ae', '300', 'mg', '(', 'Laboratorios', 'Dermatol\u00f3gicos', 'Darier', ')', 'and', 'reference', 'product', 'Nerotin', '\u00ae', '300', 'mg', '(', 'Pfizer', ')', '.', 'One', 'capsule', 'was', 'the', 'single', 'dosage', '.', '\\n\\n', 'The', 'study', 'was', 'prospective', ',', 'open', '-', 'label', ',', 'randomized', ',', 'crossover', ',', 'single', 'dose', ',', 'with', '02', 'treatments', ',', '02', 'sequences', 'and', '02', 'periods', ',', 'under', 'fasting', 'conditions', '.', '\\n\\n', 'The', 'population', 'was', 'composed', 'of', '26', 'healthy', 'volunteers', ',', 'both', 'genders', ',', 'adults', 'between', '18', '-', '55', 'years', '.', '\\n\\n', 'The', 'comparative', 'bioavailability', 'of', 'the', 'two', 'formulations', 'was', 'evaluated', 'based', 'in', 'statistical', 'comparisons', 'of', 'relevant', 'pharmacokinetic', 'parameters', ',', 'obtained', 'from', 'data', 'of', 'drug', 'concentrations', 'in', 'blood', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 72,
                "end": 82,
                "text": "Gabapentin",
                "type": "DRUG"
            },
            {
                "start": 192,
                "end": 202,
                "text": "gabapentin",
                "type": "DRUG"
            },
            {
                "start": 251,
                "end": 259,
                "text": "Darbetin",
                "type": "DRUG"
            },
            {
                "start": 327,
                "end": 334,
                "text": "Nerotin",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04839601",
        "study_official_title": "RNS\u00ae System Responsive Stimulation for Adolescents With Epilepsy Study ",
        "study_brief_summary": " To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.",
        "text": "RNS\u00ae System Responsive Stimulation for Adolescents With Epilepsy Study | To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.",
        "tokens": "['RNS', '\u00ae', 'System', 'Responsive', 'Stimulation', 'for', 'Adolescents', 'With', 'Epilepsy', 'Study', '|', 'To', 'demonstrate', 'that', 'the', 'RNS', 'System', 'is', 'safe', 'and', 'effective', 'as', 'an', 'adjunctive', 'therapy', 'in', 'individuals', 'age', '12', 'through', '17', 'years', 'with', 'medically', 'refractory', 'partial', 'onset', 'epilepsy', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 34,
                "text": "RNS\u00ae System Responsive Stimulation",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 64,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 97,
                "end": 107,
                "text": "RNS System",
                "type": "OTHER"
            },
            {
                "start": 209,
                "end": 242,
                "text": "refractory partial onset epilepsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01962779",
        "study_official_title": "Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study ",
        "study_brief_summary": " Our preliminary data show for in cognitively-normal elderly, that Sleep Disordered Breathing (SDB) is associated with the increase of cerebrospinal fluid (CSF) phosphorylated-Tau (P-Tau) and total-Tau (T-Tau), decreases in medial temporal lobe glucose uptake (FDG-PET) and volume (MRI) and progressive memory decline, all of which have been shown to be useful in predicting future dementia in older adults. These findings raise the question as to whether Alzheimer's disease (AD) tissue damage causes SDB in the elderly, or alternatively, if SDB acts as a risk factor for AD neurodegeneration. In the proposed study, we will investigate these mechanistic hypotheses in cognitively normal elderly by examining the longitudinal associations between SDB and cognitive decline, novel MR neuroimaging and CSF biomarkers for neurodegeneration; while our secondary goal is to launch a pilot treatment study to aid in interpreting the mechanistic hypotheses and to examine the effects of nasal continuous positive airway pressure (CPAP) on cognitive decline and neurodegeneration.",
        "text": "Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study | Our preliminary data show for in cognitively-normal elderly, that Sleep Disordered Breathing (SDB) is associated with the increase of cerebrospinal fluid (CSF) phosphorylated-Tau (P-Tau) and total-Tau (T-Tau), decreases in medial temporal lobe glucose uptake (FDG-PET) and volume (MRI) and progressive memory decline, all of which have been shown to be useful in predicting future dementia in older adults. These findings raise the question as to whether Alzheimer's disease (AD) tissue damage causes SDB in the elderly, or alternatively, if SDB acts as a risk factor for AD neurodegeneration. In the proposed study, we will investigate these mechanistic hypotheses in cognitively normal elderly by examining the longitudinal associations between SDB and cognitive decline, novel MR neuroimaging and CSF biomarkers for neurodegeneration; while our secondary goal is to launch a pilot treatment study to aid in interpreting the mechanistic hypotheses and to examine the effects of nasal continuous positive airway pressure (CPAP) on cognitive decline and neurodegeneration.",
        "tokens": "['Sleep', ',', 'Aging', 'and', 'Risk', 'for', 'Alzheimer', \"'s\", 'Disease', '(', 'SARA', ')', 'Study', '|', 'Our', 'preliminary', 'data', 'show', 'for', 'in', 'cognitively', '-', 'normal', 'elderly', ',', 'that', 'Sleep', 'Disordered', 'Breathing', '(', 'SDB', ')', 'is', 'associated', 'with', 'the', 'increase', 'of', 'cerebrospinal', 'fluid', '(', 'CSF', ')', 'phosphorylated', '-', 'Tau', '(', 'P', '-', 'Tau', ')', 'and', 'total', '-', 'Tau', '(', 'T', '-', 'Tau', ')', ',', 'decreases', 'in', 'medial', 'temporal', 'lobe', 'glucose', 'uptake', '(', 'FDG', '-', 'PET', ')', 'and', 'volume', '(', 'MRI', ')', 'and', 'progressive', 'memory', 'decline', ',', 'all', 'of', 'which', 'have', 'been', 'shown', 'to', 'be', 'useful', 'in', 'predicting', 'future', 'dementia', 'in', 'older', 'adults', '.', 'These', 'findings', 'raise', 'the', 'question', 'as', 'to', 'whether', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', 'tissue', 'damage', 'causes', 'SDB', 'in', 'the', 'elderly', ',', 'or', 'alternatively', ',', 'if', 'SDB', 'acts', 'as', 'a', 'risk', 'factor', 'for', 'AD', 'neurodegeneration', '.', 'In', 'the', 'proposed', 'study', ',', 'we', 'will', 'investigate', 'these', 'mechanistic', 'hypotheses', 'in', 'cognitively', 'normal', 'elderly', 'by', 'examining', 'the', 'longitudinal', 'associations', 'between', 'SDB', 'and', 'cognitive', 'decline', ',', 'novel', 'MR', 'neuroimaging', 'and', 'CSF', 'biomarkers', 'for', 'neurodegeneration', ';', 'while', 'our', 'secondary', 'goal', 'is', 'to', 'launch', 'a', 'pilot', 'treatment', 'study', 'to', 'aid', 'in', 'interpreting', 'the', 'mechanistic', 'hypotheses', 'and', 'to', 'examine', 'the', 'effects', 'of', 'nasal', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'on', 'cognitive', 'decline', 'and', 'neurodegeneration', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 45,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 127,
                "end": 153,
                "text": "Sleep Disordered Breathing",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 158,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 377,
                "text": "memory decline",
                "type": "CONDITION"
            },
            {
                "start": 442,
                "end": 450,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 516,
                "end": 535,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 537,
                "end": 539,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 562,
                "end": 565,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 603,
                "end": 606,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 633,
                "end": 635,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 808,
                "end": 811,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 1047,
                "end": 1082,
                "text": "continuous positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 1084,
                "end": 1088,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 1093,
                "end": 1110,
                "text": "cognitive decline",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02609945",
        "study_official_title": "A Phase 1 First in Human Open-Label Study of the Safety and Pharmacokinetics of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults ",
        "study_brief_summary": " This study is the first study in humans with CVT-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and PK of single ascending doses of CVT-427 in adult healthy volunteers.",
        "text": "A Phase 1 First in Human Open-Label Study of the Safety and Pharmacokinetics of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults | This study is the first study in humans with CVT-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and PK of single ascending doses of CVT-427 in adult healthy volunteers.",
        "tokens": "['A', 'Phase', '1', 'First', 'in', 'Human', 'Open', '-', 'Label', 'Study', 'of', 'the', 'Safety', 'and', 'Pharmacokinetics', 'of', 'Single', 'Ascending', 'Doses', 'of', 'CVT-427', '(', 'Zolmitriptan', 'Inhalation', 'Powder', ')', 'In', 'Healthy', 'Adults', '|', 'This', 'study', 'is', 'the', 'first', 'study', 'in', 'humans', 'with', 'CVT-427', '(', 'zolmitriptan', 'inhalation', 'powder', ')', 'and', 'is', 'designed', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'and', 'PK', 'of', 'single', 'ascending', 'doses', 'of', 'CVT-427', 'in', 'adult', 'healthy', 'volunteers', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 106,
                "end": 113,
                "text": "CVT-427",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 127,
                "text": "Zolmitriptan",
                "type": "DRUG"
            },
            {
                "start": 212,
                "end": 219,
                "text": "CVT-427",
                "type": "DRUG"
            },
            {
                "start": 221,
                "end": 233,
                "text": "zolmitriptan",
                "type": "DRUG"
            },
            {
                "start": 343,
                "end": 350,
                "text": "CVT-427",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03152136",
        "study_official_title": "A Pilot Study to Evaluate the Safety and Initial Effectiveness of the Cala ONE Device to Repeatably Aid in the Symptomatic Relief of Essential Tremor ",
        "study_brief_summary": " Prospective, multi-center, randomized, controlled study designed to evaluate safety and repeatable effectiveness. Subjects will be randomized 2:1:1 to transcutaneous afferent patterned stimulation (TAPS), sham, or 'no intervention', respectively. Subjects randomized to the TAPS and sham arms will be blinded to their randomization assignments for the first two weeks of participation (controlled phase). After the first two weeks, all subjects will be crossed over to TAPS (open-label phase) for 2 weeks. During study participation, all subjects are to remain on a stable dosage of medications prescribed for the treatment of essential tremor, if applicable.",
        "text": "A Pilot Study to Evaluate the Safety and Initial Effectiveness of the Cala ONE Device to Repeatably Aid in the Symptomatic Relief of Essential Tremor | Prospective, multi-center, randomized, controlled study designed to evaluate safety and repeatable effectiveness. Subjects will be randomized 2:1:1 to transcutaneous afferent patterned stimulation (TAPS), sham, or 'no intervention', respectively. Subjects randomized to the TAPS and sham arms will be blinded to their randomization assignments for the first two weeks of participation (controlled phase). After the first two weeks, all subjects will be crossed over to TAPS (open-label phase) for 2 weeks. During study participation, all subjects are to remain on a stable dosage of medications prescribed for the treatment of essential tremor, if applicable.",
        "tokens": "['A', 'Pilot', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Initial', 'Effectiveness', 'of', 'the', 'Cala', 'ONE', 'Device', 'to', 'Repeatably', 'Aid', 'in', 'the', 'Symptomatic', 'Relief', 'of', 'Essential', 'Tremor', '|', 'Prospective', ',', 'multi', '-', 'center', ',', 'randomized', ',', 'controlled', 'study', 'designed', 'to', 'evaluate', 'safety', 'and', 'repeatable', 'effectiveness', '.', 'Subjects', 'will', 'be', 'randomized', '2:1:1', 'to', 'transcutaneous', 'afferent', 'patterned', 'stimulation', '(', 'TAPS', ')', ',', 'sham', ',', 'or', \"'\", 'no', 'intervention', \"'\", ',', 'respectively', '.', 'Subjects', 'randomized', 'to', 'the', 'TAPS', 'and', 'sham', 'arms', 'will', 'be', 'blinded', 'to', 'their', 'randomization', 'assignments', 'for', 'the', 'first', 'two', 'weeks', 'of', 'participation', '(', 'controlled', 'phase', ')', '.', 'After', 'the', 'first', 'two', 'weeks', ',', 'all', 'subjects', 'will', 'be', 'crossed', 'over', 'to', 'TAPS', '(', 'open', '-', 'label', 'phase', ')', 'for', '2', 'weeks', '.', 'During', 'study', 'participation', ',', 'all', 'subjects', 'are', 'to', 'remain', 'on', 'a', 'stable', 'dosage', 'of', 'medications', 'prescribed', 'for', 'the', 'treatment', 'of', 'essential', 'tremor', ',', 'if', 'applicable', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 70,
                "end": 85,
                "text": "Cala ONE Device",
                "type": "OTHER"
            },
            {
                "start": 133,
                "end": 149,
                "text": "Essential Tremor",
                "type": "CONDITION"
            },
            {
                "start": 303,
                "end": 348,
                "text": "transcutaneous afferent patterned stimulation",
                "type": "OTHER"
            },
            {
                "start": 350,
                "end": 354,
                "text": "TAPS",
                "type": "OTHER"
            },
            {
                "start": 357,
                "end": 361,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 367,
                "end": 382,
                "text": "no intervention",
                "type": "CONTROL"
            },
            {
                "start": 426,
                "end": 430,
                "text": "TAPS",
                "type": "OTHER"
            },
            {
                "start": 435,
                "end": 439,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 621,
                "end": 625,
                "text": "TAPS",
                "type": "OTHER"
            },
            {
                "start": 779,
                "end": 795,
                "text": "essential tremor",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02634671",
        "study_official_title": "Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation ",
        "study_brief_summary": " Background:\n\nThe present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two disorders. Indeed, despite the clinical overlap between the two syndromes, some of the symptoms appear to be specific to only one of them. In particular, the disturbance of visual functions is specifically observed in the 22q11.2DS. Hence, the difficulties in facial emotion recognition in schizophrenia and in the 22q11.DS are likely accounted by different cognitive impairments. Investigating which mechanisms are disturbed would allow a specialized support for patients.\n\nOur main hypothesis is that the deficit in facial emotion recognition is more related to visual impairments in the 22q11.2DS than in schizophrenia. This hypothesis will be tested in two groups of patients (22q11.2DS and schizophrenic patients) and a control group (healthy subjects) using an experimental paradigm based on electroencephalography (EEG).\n\nA second aim of this study is to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.",
        "text": "Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation | Background:\n\nThe present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two disorders. Indeed, despite the clinical overlap between the two syndromes, some of the symptoms appear to be specific to only one of them. In particular, the disturbance of visual functions is specifically observed in the 22q11.2DS. Hence, the difficulties in facial emotion recognition in schizophrenia and in the 22q11.DS are likely accounted by different cognitive impairments. Investigating which mechanisms are disturbed would allow a specialized support for patients.\n\nOur main hypothesis is that the deficit in facial emotion recognition is more related to visual impairments in the 22q11.2DS than in schizophrenia. This hypothesis will be tested in two groups of patients (22q11.2DS and schizophrenic patients) and a control group (healthy subjects) using an experimental paradigm based on electroencephalography (EEG).\n\nA second aim of this study is to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.",
        "tokens": "['Facial', 'Expression', 'Perception', 'by', 'Intensity', 'in', 'Schizophrenia', 'and', '22q11.2', 'Deletion', 'Syndrome', ':', 'Neural', 'Electrophysiological', 'Evidence', 'by', 'Means', 'of', 'Fast', 'Periodic', 'Visual', 'Stimulation', '|', 'Background', ':', '\\n\\n', 'The', 'present', 'study', 'aims', 'to', 'identify', 'the', 'mechanisms', 'underlying', 'the', 'deficit', 'in', 'facial', 'emotion', 'recognition', 'reported', 'both', 'in', 'schizophrenia', 'and', 'the', '22q11.2', 'deletion', 'syndrome', ',', 'and', 'thus', ',', 'reveal', 'a', 'distinction', 'between', 'the', 'two', 'disorders', '.', 'Indeed', ',', 'despite', 'the', 'clinical', 'overlap', 'between', 'the', 'two', 'syndromes', ',', 'some', 'of', 'the', 'symptoms', 'appear', 'to', 'be', 'specific', 'to', 'only', 'one', 'of', 'them', '.', 'In', 'particular', ',', 'the', 'disturbance', 'of', 'visual', 'functions', 'is', 'specifically', 'observed', 'in', 'the', '22q11.2DS', '.', 'Hence', ',', 'the', 'difficulties', 'in', 'facial', 'emotion', 'recognition', 'in', 'schizophrenia', 'and', 'in', 'the', '22q11.DS', 'are', 'likely', 'accounted', 'by', 'different', 'cognitive', 'impairments', '.', 'Investigating', 'which', 'mechanisms', 'are', 'disturbed', 'would', 'allow', 'a', 'specialized', 'support', 'for', 'patients', '.', '\\n\\n', 'Our', 'main', 'hypothesis', 'is', 'that', 'the', 'deficit', 'in', 'facial', 'emotion', 'recognition', 'is', 'more', 'related', 'to', 'visual', 'impairments', 'in', 'the', '22q11.2DS', 'than', 'in', 'schizophrenia', '.', 'This', 'hypothesis', 'will', 'be', 'tested', 'in', 'two', 'groups', 'of', 'patients', '(', '22q11.2DS', 'and', 'schizophrenic', 'patients', ')', 'and', 'a', 'control', 'group', '(', 'healthy', 'subjects', ')', 'using', 'an', 'experimental', 'paradigm', 'based', 'on', 'electroencephalography', '(', 'EEG', ')', '.', '\\n\\n', 'A', 'second', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'the', 'severity', 'of', 'the', 'two', 'disorders', \"'\", 'symptoms', 'is', 'correlated', 'with', 'the', 'cerebral', 'response', 'to', 'facial', 'expressions', '.', 'To', 'answer', 'this', 'question', ',', 'a', 'set', 'of', 'clinical', 'and', 'neuropsychological', 'tests', 'will', 'be', 'conducted', 'for', 'each', 'patient', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 45,
                "end": 58,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 63,
                "end": 88,
                "text": "22q11.2 Deletion Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 307,
                "end": 320,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 329,
                "end": 354,
                "text": "22q11.2 deletion syndrome",
                "type": "CONDITION"
            },
            {
                "start": 625,
                "end": 634,
                "text": "22q11.2DS",
                "type": "CONDITION"
            },
            {
                "start": 693,
                "end": 706,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 718,
                "end": 726,
                "text": "22q11.DS",
                "type": "CONDITION"
            },
            {
                "start": 993,
                "end": 1002,
                "text": "22q11.2DS",
                "type": "CONDITION"
            },
            {
                "start": 1011,
                "end": 1024,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 1084,
                "end": 1093,
                "text": "22q11.2DS",
                "type": "CONDITION"
            },
            {
                "start": 1098,
                "end": 1111,
                "text": "schizophrenic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03893825",
        "study_official_title": "A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia ",
        "study_brief_summary": " The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events. For new participants, the total duration of participant participation in the study is planned to be up to 80 weeks (including a screening period of up to 4 weeks, a 12-week oral conversion/stabilization stage [Stage 1], a 56-week double-blind maintenance stage [Stage 2], and a follow-up period [8 weeks]). For roll-over participants, the total duration of participant participation in the study is planned to be up to 64 weeks (including up to 56 weeks in the maintenance stage [Stage 2] and a follow-up period [8 weeks]). Participants who started Stage 2 who relapse or meet 1 or more of the withdrawal criteria should be invited to perform the Early Termination visit as soon as possible within 4 weeks of the last injection. Participants who withdraw from the study before completing the 56-week maintenance stage will have follow-up procedures and assessments performed at their follow-up visits. During the follow-up period, participants will be treated according to the investigator's judgment.\n\nAll participants will be treated with active drug.",
        "text": "A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events. For new participants, the total duration of participant participation in the study is planned to be up to 80 weeks (including a screening period of up to 4 weeks, a 12-week oral conversion/stabilization stage [Stage 1], a 56-week double-blind maintenance stage [Stage 2], and a follow-up period [8 weeks]). For roll-over participants, the total duration of participant participation in the study is planned to be up to 64 weeks (including up to 56 weeks in the maintenance stage [Stage 2] and a follow-up period [8 weeks]). Participants who started Stage 2 who relapse or meet 1 or more of the withdrawal criteria should be invited to perform the Early Termination visit as soon as possible within 4 weeks of the last injection. Participants who withdraw from the study before completing the 56-week maintenance stage will have follow-up procedures and assessments performed at their follow-up visits. During the follow-up period, participants will be treated according to the investigator's judgment.\n\nAll participants will be treated with active drug.",
        "tokens": "['A', 'Study', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Effect', 'of', 'Risperidone', 'Extended', '-', 'Release', 'Injectable', 'Suspension', '(', 'TV-46000', ')', 'for', 'Subcutaneous', 'Use', 'as', 'Maintenance', 'Treatment', 'in', 'Adult', 'and', 'Adolescent', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'TV-46000', '.', 'The', 'primary', 'safety', 'and', 'tolerability', 'endpoint', 'is', 'the', 'frequency', 'of', 'all', 'adverse', 'events', ',', 'including', 'serious', 'adverse', 'events', '.', 'For', 'new', 'participants', ',', 'the', 'total', 'duration', 'of', 'participant', 'participation', 'in', 'the', 'study', 'is', 'planned', 'to', 'be', 'up', 'to', '80', 'weeks', '(', 'including', 'a', 'screening', 'period', 'of', 'up', 'to', '4', 'weeks', ',', 'a', '12', '-', 'week', 'oral', 'conversion', '/', 'stabilization', 'stage', '[', 'Stage', '1', ']', ',', 'a', '56', '-', 'week', 'double', '-', 'blind', 'maintenance', 'stage', '[', 'Stage', '2', ']', ',', 'and', 'a', 'follow', '-', 'up', 'period', '[', '8', 'weeks', ']', ')', '.', 'For', 'roll', '-', 'over', 'participants', ',', 'the', 'total', 'duration', 'of', 'participant', 'participation', 'in', 'the', 'study', 'is', 'planned', 'to', 'be', 'up', 'to', '64', 'weeks', '(', 'including', 'up', 'to', '56', 'weeks', 'in', 'the', 'maintenance', 'stage', '[', 'Stage', '2', ']', 'and', 'a', 'follow', '-', 'up', 'period', '[', '8', 'weeks', ']', ')', '.', 'Participants', 'who', 'started', 'Stage', '2', 'who', 'relapse', 'or', 'meet', '1', 'or', 'more', 'of', 'the', 'withdrawal', 'criteria', 'should', 'be', 'invited', 'to', 'perform', 'the', 'Early', 'Termination', 'visit', 'as', 'soon', 'as', 'possible', 'within', '4', 'weeks', 'of', 'the', 'last', 'injection', '.', 'Participants', 'who', 'withdraw', 'from', 'the', 'study', 'before', 'completing', 'the', '56', '-', 'week', 'maintenance', 'stage', 'will', 'have', 'follow', '-', 'up', 'procedures', 'and', 'assessments', 'performed', 'at', 'their', 'follow', '-', 'up', 'visits', '.', 'During', 'the', 'follow', '-', 'up', 'period', ',', 'participants', 'will', 'be', 'treated', 'according', 'to', 'the', 'investigator', \"'s\", 'judgment', '.', '\\n\\n', 'All', 'participants', 'will', 'be', 'treated', 'with', 'active', 'drug', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 60,
                "end": 71,
                "text": "Risperidone",
                "type": "DRUG"
            },
            {
                "start": 112,
                "end": 120,
                "text": "TV-46000",
                "type": "DRUG"
            },
            {
                "start": 206,
                "end": 219,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 313,
                "end": 321,
                "text": "TV-46000",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04856241",
        "study_official_title": "Prep-to-Play: Comparing the Impact of Supported and Unsupported Implementation Strategies on the Use of an Injury Prevention Program in Women's/Girl's Community Football ",
        "study_brief_summary": " The aim of this study is to determine how we can best support coaches to implement an injury prevention (IP) program (Prep-to-Play) in female community Australian Football. We will recruit at least 140 female community football teams from 15 different football leagues in Victoria, Australia. Teams will be competing in U16, U17, U18, U19 or open womens competitions. We will train and support coaches to implement the IP program and evaluate the effects of the IP program on injuries across two football seasons.",
        "text": "Prep-to-Play: Comparing the Impact of Supported and Unsupported Implementation Strategies on the Use of an Injury Prevention Program in Women's/Girl's Community Football | The aim of this study is to determine how we can best support coaches to implement an injury prevention (IP) program (Prep-to-Play) in female community Australian Football. We will recruit at least 140 female community football teams from 15 different football leagues in Victoria, Australia. Teams will be competing in U16, U17, U18, U19 or open womens competitions. We will train and support coaches to implement the IP program and evaluate the effects of the IP program on injuries across two football seasons.",
        "tokens": "['Prep', '-', 'to', '-', 'Play', ':', 'Comparing', 'the', 'Impact', 'of', 'Supported', 'and', 'Unsupported', 'Implementation', 'Strategies', 'on', 'the', 'Use', 'of', 'an', 'Injury', 'Prevention', 'Program', 'in', \"Women's\", '/', 'Girl', \"'s\", 'Community', 'Football', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'how', 'we', 'can', 'best', 'support', 'coaches', 'to', 'implement', 'an', 'injury', 'prevention', '(', 'IP', ')', 'program', '(', 'Prep', '-', 'to', '-', 'Play', ')', 'in', 'female', 'community', 'Australian', 'Football', '.', 'We', 'will', 'recruit', 'at', 'least', '140', 'female', 'community', 'football', 'teams', 'from', '15', 'different', 'football', 'leagues', 'in', 'Victoria', ',', 'Australia', '.', 'Teams', 'will', 'be', 'competing', 'in', 'U16', ',', 'U17', ',', 'U18', ',', 'U19', 'or', 'open', 'womens', 'competitions', '.', 'We', 'will', 'train', 'and', 'support', 'coaches', 'to', 'implement', 'the', 'IP', 'program', 'and', 'evaluate', 'the', 'effects', 'of', 'the', 'IP', 'program', 'on', 'injuries', 'across', 'two', 'football', 'seasons', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 12,
                "text": "Prep-to-Play",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 38,
                "end": 89,
                "text": "Supported and Unsupported Implementation Strategies",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 107,
                "end": 132,
                "text": "Injury Prevention Program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 258,
                "end": 288,
                "text": "injury prevention (IP) program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 290,
                "end": 302,
                "text": "Prep-to-Play",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 591,
                "end": 601,
                "text": "IP program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 634,
                "end": 644,
                "text": "IP program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 648,
                "end": 656,
                "text": "injuries",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05065216",
        "study_official_title": "Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) ",
        "study_brief_summary": " This is a Phase 2/3 study evaluating the safety and efficacy of DM199 in treating participants presenting within 24 hours of Acute Ischemic Stroke (AIS) onset for whom fibrinolytics and/or a catheter-based procedure, mechanical thrombectomy (MT), are not medically appropriate or available due to constraints of clot location, comorbidity risks, and/or time from estimated onset of stroke. The double-blinded study will be randomized, placebo controlled at approximately 75 centers in the U.S.",
        "text": "Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) | This is a Phase 2/3 study evaluating the safety and efficacy of DM199 in treating participants presenting within 24 hours of Acute Ischemic Stroke (AIS) onset for whom fibrinolytics and/or a catheter-based procedure, mechanical thrombectomy (MT), are not medically appropriate or available due to constraints of clot location, comorbidity risks, and/or time from estimated onset of stroke. The double-blinded study will be randomized, placebo controlled at approximately 75 centers in the U.S.",
        "tokens": "['Phase', '2/3', 'Adaptive', 'Design', ',', 'Randomized', 'Double', '-', 'blind', 'Placebo', '-', 'controlled', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Efficacy', 'of', 'DM199', 'for', 'the', 'Treatment', 'of', 'Acute', 'Ischemic', 'Stroke', '(', 'ReMEDy2', 'Trial', ')', '|', 'This', 'is', 'a', 'Phase', '2/3', 'study', 'evaluating', 'the', 'safety', 'and', 'efficacy', 'of', 'DM199', 'in', 'treating', 'participants', 'presenting', 'within', '24', 'hours', 'of', 'Acute', 'Ischemic', 'Stroke', '(', 'AIS', ')', 'onset', 'for', 'whom', 'fibrinolytics', 'and/or', 'a', 'catheter', '-', 'based', 'procedure', ',', 'mechanical', 'thrombectomy', '(', 'MT', ')', ',', 'are', 'not', 'medically', 'appropriate', 'or', 'available', 'due', 'to', 'constraints', 'of', 'clot', 'location', ',', 'comorbidity', 'risks', ',', 'and/or', 'time', 'from', 'estimated', 'onset', 'of', 'stroke', '.', 'The', 'double', '-', 'blinded', 'study', 'will', 'be', 'randomized', ',', 'placebo', 'controlled', 'at', 'approximately', '75', 'centers', 'in', 'the', 'U.S.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 51,
                "end": 58,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 115,
                "end": 120,
                "text": "DM199",
                "type": "DRUG"
            },
            {
                "start": 142,
                "end": 163,
                "text": "Acute Ischemic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 246,
                "end": 251,
                "text": "DM199",
                "type": "DRUG"
            },
            {
                "start": 307,
                "end": 328,
                "text": "Acute Ischemic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 330,
                "end": 333,
                "text": "AIS",
                "type": "CONDITION"
            },
            {
                "start": 564,
                "end": 570,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 617,
                "end": 624,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05805696",
        "study_official_title": "Treatment and Mapping of Self-compassion, Perfectionism, Stress, Anxiety and Impostor Phenomenon in Patients With Different Dermatological Diseases and Pain ",
        "study_brief_summary": " The aim of this study is to evaluate persons/patients with different skin diseases or pain to evaluate whether unhealthy perfectionism, stress, anxiety, impostor phenomenon (inability to realistically assess your competence and skills) and lack of self-compassion (a positive attitude towards ourselves), have impact on symptoms, handling, and treatment regarding some dermatological diseases/pain.",
        "text": "Treatment and Mapping of Self-compassion, Perfectionism, Stress, Anxiety and Impostor Phenomenon in Patients With Different Dermatological Diseases and Pain | The aim of this study is to evaluate persons/patients with different skin diseases or pain to evaluate whether unhealthy perfectionism, stress, anxiety, impostor phenomenon (inability to realistically assess your competence and skills) and lack of self-compassion (a positive attitude towards ourselves), have impact on symptoms, handling, and treatment regarding some dermatological diseases/pain.",
        "tokens": "['Treatment', 'and', 'Mapping', 'of', 'Self', '-', 'compassion', ',', 'Perfectionism', ',', 'Stress', ',', 'Anxiety', 'and', 'Impostor', 'Phenomenon', 'in', 'Patients', 'With', 'Different', 'Dermatological', 'Diseases', 'and', 'Pain', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'persons', '/', 'patients', 'with', 'different', 'skin', 'diseases', 'or', 'pain', 'to', 'evaluate', 'whether', 'unhealthy', 'perfectionism', ',', 'stress', ',', 'anxiety', ',', 'impostor', 'phenomenon', '(', 'inability', 'to', 'realistically', 'assess', 'your', 'competence', 'and', 'skills', ')', 'and', 'lack', 'of', 'self', '-', 'compassion', '(', 'a', 'positive', 'attitude', 'towards', 'ourselves', ')', ',', 'have', 'impact', 'on', 'symptoms', ',', 'handling', ',', 'and', 'treatment', 'regarding', 'some', 'dermatological', 'diseases', '/', 'pain', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 152,
                "end": 156,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 249,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 552,
                "end": 556,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03150563",
        "study_official_title": "Effects of Different Intensities of Passive Static Stretching on Flexibility, Neuromuscular and Functional Performance in Soccer Athletes: A Blinded, Randomized Controlled Trial. ",
        "study_brief_summary": " Intensity is a \"qualitative\" variable of a muscle stretching protocol, which is very little studied due to its inherent characteristic of the individual being stretched. However, it was pointed out as an important factor for ADM gain. To verify the effects of different intensities of static passive stretching on flexibility, neuromuscular and functional performance in soccer athletes.",
        "text": "Effects of Different Intensities of Passive Static Stretching on Flexibility, Neuromuscular and Functional Performance in Soccer Athletes: A Blinded, Randomized Controlled Trial. | Intensity is a \"qualitative\" variable of a muscle stretching protocol, which is very little studied due to its inherent characteristic of the individual being stretched. However, it was pointed out as an important factor for ADM gain. To verify the effects of different intensities of static passive stretching on flexibility, neuromuscular and functional performance in soccer athletes.",
        "tokens": "['Effects', 'of', 'Different', 'Intensities', 'of', 'Passive', 'Static', 'Stretching', 'on', 'Flexibility', ',', 'Neuromuscular', 'and', 'Functional', 'Performance', 'in', 'Soccer', 'Athletes', ':', 'A', 'Blinded', ',', 'Randomized', 'Controlled', 'Trial', '.', '|', 'Intensity', 'is', 'a', '\"', 'qualitative', '\"', 'variable', 'of', 'a', 'muscle', 'stretching', 'protocol', ',', 'which', 'is', 'very', 'little', 'studied', 'due', 'to', 'its', 'inherent', 'characteristic', 'of', 'the', 'individual', 'being', 'stretched', '.', 'However', ',', 'it', 'was', 'pointed', 'out', 'as', 'an', 'important', 'factor', 'for', 'ADM', 'gain', '.', 'To', 'verify', 'the', 'effects', 'of', 'different', 'intensities', 'of', 'static', 'passive', 'stretching', 'on', 'flexibility', ',', 'neuromuscular', 'and', 'functional', 'performance', 'in', 'soccer', 'athletes', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 36,
                "end": 61,
                "text": "Passive Static Stretching",
                "type": "OTHER"
            },
            {
                "start": 224,
                "end": 251,
                "text": "muscle stretching protocol,",
                "type": "OTHER"
            },
            {
                "start": 466,
                "end": 491,
                "text": "static passive stretching",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03005249",
        "study_official_title": "Neural Stem Cells Therapy for Cerebral Palsy: a Prospective, Randomized, Parallel-controlled Trial ",
        "study_brief_summary": " To evaluate the safety and efficacy of neural stem cells (NSCs) therapy for cerebral palsy.",
        "text": "Neural Stem Cells Therapy for Cerebral Palsy: a Prospective, Randomized, Parallel-controlled Trial | To evaluate the safety and efficacy of neural stem cells (NSCs) therapy for cerebral palsy.",
        "tokens": "['Neural', 'Stem', 'Cells', 'Therapy', 'for', 'Cerebral', 'Palsy', ':', 'a', 'Prospective', ',', 'Randomized', ',', 'Parallel', '-', 'controlled', 'Trial', '|', 'To', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'neural', 'stem', 'cells', '(', 'NSCs', ')', 'therapy', 'for', 'cerebral', 'palsy', '.']",
        "token_bio_labels": "['B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 17,
                "text": "Neural Stem Cells",
                "type": "SURGICAL"
            },
            {
                "start": 30,
                "end": 44,
                "text": "Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 140,
                "end": 157,
                "text": "neural stem cells",
                "type": "SURGICAL"
            },
            {
                "start": 159,
                "end": 163,
                "text": "NSCs",
                "type": "SURGICAL"
            },
            {
                "start": 177,
                "end": 191,
                "text": "cerebral palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02937025",
        "study_official_title": "This study mainly evaluated the feasibility and safety of a kind of Left Atrial Appendage Occluders which is to prevent ischemic stroke caused by nonvalvular atrial fibrillation (AF)",
        "study_brief_summary": null,
        "text": "This study mainly evaluated the feasibility and safety of a kind of Left Atrial Appendage Occluders which is to prevent ischemic stroke caused by nonvalvular atrial fibrillation (AF)",
        "tokens": "['This', 'study', 'mainly', 'evaluated', 'the', 'feasibility', 'and', 'safety', 'of', 'a', 'kind', 'of', 'Left', 'Atrial', 'Appendage', 'Occluders', 'which', 'is', 'to', 'prevent', 'ischemic', 'stroke', 'caused', 'by', 'nonvalvular', 'atrial', 'fibrillation', '(', 'AF', ')']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 68,
                "end": 99,
                "text": "Left Atrial Appendage Occluders",
                "type": "OTHER"
            },
            {
                "start": 120,
                "end": 135,
                "text": "ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 177,
                "text": "nonvalvular atrial fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 179,
                "end": 181,
                "text": "AF",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00682838",
        "study_official_title": "Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring ",
        "study_brief_summary": " Obstructive sleep apnea (OSA) is a major chronic condition affecting the quality of life of up to one-fifth of all Veterans. Because of disappointingly low adherence to the gold-standard treatment (continuous positive airway pressure therapy - CPAP), the Institute of Medicine has stated that new adherence strategies are needed that improve the quality of care, reduce social and economic costs, and help OSA patients live happier, healthier, and more productive lives through improved clinical management. The combination of a self-management approach along with emerging wireless technologies has strong potential to increase treatment adherence and improve outcomes.",
        "text": "Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring | Obstructive sleep apnea (OSA) is a major chronic condition affecting the quality of life of up to one-fifth of all Veterans. Because of disappointingly low adherence to the gold-standard treatment (continuous positive airway pressure therapy - CPAP), the Institute of Medicine has stated that new adherence strategies are needed that improve the quality of care, reduce social and economic costs, and help OSA patients live happier, healthier, and more productive lives through improved clinical management. The combination of a self-management approach along with emerging wireless technologies has strong potential to increase treatment adherence and improve outcomes.",
        "tokens": "['Improving', 'Obstructive', 'Sleep', 'Apnea', 'Management', 'Via', 'Wireless', 'Telemonitoring', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'is', 'a', 'major', 'chronic', 'condition', 'affecting', 'the', 'quality', 'of', 'life', 'of', 'up', 'to', 'one', '-', 'fifth', 'of', 'all', 'Veterans', '.', 'Because', 'of', 'disappointingly', 'low', 'adherence', 'to', 'the', 'gold', '-', 'standard', 'treatment', '(', 'continuous', 'positive', 'airway', 'pressure', 'therapy', '-', 'CPAP', ')', ',', 'the', 'Institute', 'of', 'Medicine', 'has', 'stated', 'that', 'new', 'adherence', 'strategies', 'are', 'needed', 'that', 'improve', 'the', 'quality', 'of', 'care', ',', 'reduce', 'social', 'and', 'economic', 'costs', ',', 'and', 'help', 'OSA', 'patients', 'live', 'happier', ',', 'healthier', ',', 'and', 'more', 'productive', 'lives', 'through', 'improved', 'clinical', 'management', '.', 'The', 'combination', 'of', 'a', 'self', '-', 'management', 'approach', 'along', 'with', 'emerging', 'wireless', 'technologies', 'has', 'strong', 'potential', 'to', 'increase', 'treatment', 'adherence', 'and', 'improve', 'outcomes', '.']",
        "token_bio_labels": "['O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 33,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 49,
                "end": 72,
                "text": "Wireless Telemonitoring",
                "type": "OTHER"
            },
            {
                "start": 75,
                "end": 98,
                "text": "Obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 100,
                "end": 103,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 481,
                "end": 484,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 604,
                "end": 628,
                "text": "self-management approach",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 649,
                "end": 670,
                "text": "wireless technologies",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03184467",
        "study_official_title": "A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients ",
        "study_brief_summary": " This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.\n\nAn eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.",
        "text": "A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients | This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.\n\nAn eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.",
        "tokens": "['A', 'Multi', '-', 'center', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', 'Design', ',', 'Prospective', ',', 'Phase', 'II', 'Clinical', 'Trial', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Donepezil', 'and', 'Combined', 'With', 'GV1001', 'in', 'Alzheimer', 'Patients', '|', 'This', 'clinical', 'study', 'is', 'designed', 'as', 'a', 'multi', '-', 'center', ',', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'parallel', 'design', ',', 'prospective', ',', 'phase', 'II', 'clinical', 'trial', '.', '\\n\\n', 'An', 'eligible', 'subject', 'who', 'meets', 'inclusion', 'and', 'exclusion', 'criteria', 'is', 'randomly', 'assigned', 'to', 'three', 'groups', ':', 'study', 'group', '1', '(', 'GV1001', '0.56', 'mg', ')', ',', 'study', 'group', '2', '(', 'GV1001', '1.12', 'mg', ')', 'or', 'placebo', 'group', '.', 'A', 'randomized', 'subject', 'is', 'administered', 'either', 'GV1001', 'or', 'placebo', 'in', 'a', 'total', 'of', '14', 'times', 'and', 'will', 'be', 'evaluated', 'for', 'the', 'efficacy', 'and', 'safety', 'at', 'week', 'of', '24', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 49,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 155,
                "end": 164,
                "text": "Donepezil",
                "type": "DRUG"
            },
            {
                "start": 183,
                "end": 189,
                "text": "GV1001",
                "type": "DRUG"
            },
            {
                "start": 193,
                "end": 202,
                "text": "Alzheimer",
                "type": "CONDITION"
            },
            {
                "start": 291,
                "end": 298,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 483,
                "end": 489,
                "text": "GV1001",
                "type": "DRUG"
            },
            {
                "start": 515,
                "end": 521,
                "text": "GV1001",
                "type": "DRUG"
            },
            {
                "start": 534,
                "end": 541,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 593,
                "end": 599,
                "text": "GV1001",
                "type": "DRUG"
            },
            {
                "start": 603,
                "end": 610,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01270516",
        "study_official_title": "Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients ",
        "study_brief_summary": " The investigators will determine if administration of HMB (hydroxymethylbutyrate) or EPA (eicosapentaenoic acid) will increase diaphragm and limb muscle strength for patients on breathing machines in an intensive care unit. The investigators will first measure the strength of the diaphragm and a limb muscle (the quadriceps)using magnetic stimulators to activate these muscles. Muscle size will be measured by using an ultrasound to measure diaphragm thickness and quadriceps thickness. The investigators will also perform a vastus lateralis muscle biopsy. Patients will then be randomized to receive either placebo (saline 30 ml every 12 hours via the GI tract, EPA (1000 mg given every 12 hours via the GI tract), HMB (1500 mg given every 12 hours via the GI tract), or the combination of EPA (1000 mg given every 12 hours via the GI tract) and HMB (1500 mg given every 12 hours via the GI tract). Drugs will be given for 10 days; at the end of this time (on day 11), strength measurements, ultrasound muscle size measurements, and the vastus lateralis biopsy will be repeated. On day 21 an additional followup set of diaphragm and quadriceps strength and size measurements will be made (the biopsy will not be repeated for this last set of measurements). Patients will be followed clinically and patient outcomes (mortality, duration of mechanical ventilation after study entry) will be recorded.",
        "text": "Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients | The investigators will determine if administration of HMB (hydroxymethylbutyrate) or EPA (eicosapentaenoic acid) will increase diaphragm and limb muscle strength for patients on breathing machines in an intensive care unit. The investigators will first measure the strength of the diaphragm and a limb muscle (the quadriceps)using magnetic stimulators to activate these muscles. Muscle size will be measured by using an ultrasound to measure diaphragm thickness and quadriceps thickness. The investigators will also perform a vastus lateralis muscle biopsy. Patients will then be randomized to receive either placebo (saline 30 ml every 12 hours via the GI tract, EPA (1000 mg given every 12 hours via the GI tract), HMB (1500 mg given every 12 hours via the GI tract), or the combination of EPA (1000 mg given every 12 hours via the GI tract) and HMB (1500 mg given every 12 hours via the GI tract). Drugs will be given for 10 days; at the end of this time (on day 11), strength measurements, ultrasound muscle size measurements, and the vastus lateralis biopsy will be repeated. On day 21 an additional followup set of diaphragm and quadriceps strength and size measurements will be made (the biopsy will not be repeated for this last set of measurements). Patients will be followed clinically and patient outcomes (mortality, duration of mechanical ventilation after study entry) will be recorded.",
        "tokens": "['Effect', 'of', 'EPA', 'and', 'HMB', 'on', 'Diaphragm', 'and', 'Limb', 'Muscle', 'Strength', 'in', 'Mechanically', 'Ventilated', 'Patients', '|', 'The', 'investigators', 'will', 'determine', 'if', 'administration', 'of', 'HMB', '(', 'hydroxymethylbutyrate', ')', 'or', 'EPA', '(', 'eicosapentaenoic', 'acid', ')', 'will', 'increase', 'diaphragm', 'and', 'limb', 'muscle', 'strength', 'for', 'patients', 'on', 'breathing', 'machines', 'in', 'an', 'intensive', 'care', 'unit', '.', 'The', 'investigators', 'will', 'first', 'measure', 'the', 'strength', 'of', 'the', 'diaphragm', 'and', 'a', 'limb', 'muscle', '(', 'the', 'quadriceps)using', 'magnetic', 'stimulators', 'to', 'activate', 'these', 'muscles', '.', 'Muscle', 'size', 'will', 'be', 'measured', 'by', 'using', 'an', 'ultrasound', 'to', 'measure', 'diaphragm', 'thickness', 'and', 'quadriceps', 'thickness', '.', 'The', 'investigators', 'will', 'also', 'perform', 'a', 'vastus', 'lateralis', 'muscle', 'biopsy', '.', 'Patients', 'will', 'then', 'be', 'randomized', 'to', 'receive', 'either', 'placebo', '(', 'saline', '30', 'ml', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ',', 'EPA', '(', '1000', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', ',', 'HMB', '(', '1500', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', ',', 'or', 'the', 'combination', 'of', 'EPA', '(', '1000', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', 'and', 'HMB', '(', '1500', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', '.', 'Drugs', 'will', 'be', 'given', 'for', '10', 'days', ';', 'at', 'the', 'end', 'of', 'this', 'time', '(', 'on', 'day', '11', ')', ',', 'strength', 'measurements', ',', 'ultrasound', 'muscle', 'size', 'measurements', ',', 'and', 'the', 'vastus', 'lateralis', 'biopsy', 'will', 'be', 'repeated', '.', 'On', 'day', '21', 'an', 'additional', 'followup', 'set', 'of', 'diaphragm', 'and', 'quadriceps', 'strength', 'and', 'size', 'measurements', 'will', 'be', 'made', '(', 'the', 'biopsy', 'will', 'not', 'be', 'repeated', 'for', 'this', 'last', 'set', 'of', 'measurements', ')', '.', 'Patients', 'will', 'be', 'followed', 'clinically', 'and', 'patient', 'outcomes', '(', 'mortality', ',', 'duration', 'of', 'mechanical', 'ventilation', 'after', 'study', 'entry', ')', 'will', 'be', 'recorded', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 13,
                "text": "EPA",
                "type": "DRUG"
            },
            {
                "start": 18,
                "end": 21,
                "text": "HMB",
                "type": "DRUG"
            },
            {
                "start": 63,
                "end": 86,
                "text": "Mechanically Ventilated",
                "type": "CONDITION"
            },
            {
                "start": 152,
                "end": 155,
                "text": "HMB",
                "type": "DRUG"
            },
            {
                "start": 157,
                "end": 178,
                "text": "hydroxymethylbutyrate",
                "type": "DRUG"
            },
            {
                "start": 183,
                "end": 186,
                "text": "EPA",
                "type": "DRUG"
            },
            {
                "start": 188,
                "end": 209,
                "text": "eicosapentaenoic acid",
                "type": "DRUG"
            },
            {
                "start": 276,
                "end": 294,
                "text": "breathing machines",
                "type": "CONDITION"
            },
            {
                "start": 716,
                "end": 722,
                "text": "saline",
                "type": "DRUG"
            },
            {
                "start": 762,
                "end": 765,
                "text": "EPA",
                "type": "DRUG"
            },
            {
                "start": 815,
                "end": 818,
                "text": "HMB",
                "type": "DRUG"
            },
            {
                "start": 890,
                "end": 893,
                "text": "EPA",
                "type": "DRUG"
            },
            {
                "start": 946,
                "end": 949,
                "text": "HMB",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00238264",
        "study_official_title": "A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas ",
        "study_brief_summary": " RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.\n\nPURPOSE: This phase II trial is studying how well radiation therapy works in treating young patients with gliomas.",
        "text": "A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas | RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.\n\nPURPOSE: This phase II trial is studying how well radiation therapy works in treating young patients with gliomas.",
        "tokens": "['A', 'Phase', 'II', 'Study', 'of', 'Conformal', 'Radiotherapy', 'In', 'Patients', 'With', 'Low', '-', 'Grade', 'Gliomas', '|', 'RATIONALE', ':', 'Specialized', 'radiation', 'therapy', 'that', 'delivers', 'radiation', 'directly', 'to', 'the', 'tumor', 'may', 'kill', 'more', 'tumor', 'cells', 'and', 'cause', 'less', 'damage', 'to', 'normal', 'tissue', '.', '\\n\\n', 'PURPOSE', ':', 'This', 'phase', 'II', 'trial', 'is', 'studying', 'how', 'well', 'radiation', 'therapy', 'works', 'in', 'treating', 'young', 'patients', 'with', 'gliomas', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 42,
                "text": "Conformal Radiotherapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 60,
                "end": 77,
                "text": "Low-Grade Gliomas",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 120,
                "text": "radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 161,
                "end": 166,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 181,
                "end": 186,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 284,
                "end": 301,
                "text": "radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 340,
                "end": 347,
                "text": "gliomas",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02680704",
        "study_official_title": "Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure ",
        "study_brief_summary": " The purpose of this study is to collect physiologic data from patients with severe brain injury who require mechanical ventilation in order to describe the impact of ventilation, specifically positive end expiratory pressure (PEEP), on intracranial pressure (ICP).",
        "text": "Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure | The purpose of this study is to collect physiologic data from patients with severe brain injury who require mechanical ventilation in order to describe the impact of ventilation, specifically positive end expiratory pressure (PEEP), on intracranial pressure (ICP).",
        "tokens": "['Mechanical', 'Ventilation', 'in', 'Severe', 'Brain', 'Injury', ':', 'The', 'Effect', 'of', 'Positive', 'End', 'Expiratory', 'Pressure', 'on', 'Intracranial', 'Pressure', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'collect', 'physiologic', 'data', 'from', 'patients', 'with', 'severe', 'brain', 'injury', 'who', 'require', 'mechanical', 'ventilation', 'in', 'order', 'to', 'describe', 'the', 'impact', 'of', 'ventilation', ',', 'specifically', 'positive', 'end', 'expiratory', 'pressure', '(', 'PEEP', ')', ',', 'on', 'intracranial', 'pressure', '(', 'ICP', ')', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "Mechanical Ventilation",
                "type": "OTHER"
            },
            {
                "start": 26,
                "end": 45,
                "text": "Severe Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 61,
                "end": 93,
                "text": "Positive End Expiratory Pressure",
                "type": "OTHER"
            },
            {
                "start": 197,
                "end": 216,
                "text": "severe brain injury",
                "type": "CONDITION"
            },
            {
                "start": 229,
                "end": 251,
                "text": "mechanical ventilation",
                "type": "OTHER"
            },
            {
                "start": 313,
                "end": 345,
                "text": "positive end expiratory pressure",
                "type": "OTHER"
            },
            {
                "start": 347,
                "end": 351,
                "text": "PEEP",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02348632",
        "study_official_title": "A Long-Term Safety and Maintenance of Efficacy Study ofJZP-110 [(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or Obstructive Sleep Apnea ",
        "study_brief_summary": " This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.",
        "text": "A Long-Term Safety and Maintenance of Efficacy Study ofJZP-110 [(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or Obstructive Sleep Apnea | This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.",
        "tokens": "['A', 'Long', '-', 'Term', 'Safety', 'and', 'Maintenance', 'of', 'Efficacy', 'Study', 'ofJZP-110', '[', '(', 'R)-2', '-', 'amino-3', 'Phenylpropylcarbamate', 'Hydrochloride', ']', 'in', 'the', 'Treatment', 'of', 'Excessive', 'Sleepiness', 'in', 'Subjects', 'With', 'Narcolepsy', 'or', 'Obstructive', 'Sleep', 'Apnea', '|', 'This', 'is', 'a', 'Phase', '3', 'study', 'to', 'assess', 'the', 'long', '-', 'term', 'safety', 'and', 'maintenance', 'of', 'efficacy', 'of', 'JZP-110', 'in', 'subjects', 'who', 'have', 'completed', 'Study', '14', '-', '002', ',', '14', '-', '003', ',', '14', '-', '004', ',', '15', '-', '004', ',', '15', '-', '005', ',', 'ADX', '-', 'N05', '201', ',', 'or', 'ADX', '-', 'N05', '202', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 64,
                "end": 113,
                "text": "(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride",
                "type": "DRUG"
            },
            {
                "start": 135,
                "end": 155,
                "text": "Excessive Sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 183,
                "text": "Narcolepsy",
                "type": "CONDITION"
            },
            {
                "start": 187,
                "end": 210,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 299,
                "end": 306,
                "text": "JZP-110",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05395494",
        "study_official_title": "A Randomized Controlled Trial of Adjunctive D-Cycloserine to Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation in Fibromyalgia ",
        "study_brief_summary": " Background & Rationale: Fibromyalgia is characterized by widespread pain, fatigue, mood and anxiety as well as cognitive complaints. For an unacceptable proportion of patients, depressive symptoms remain impairing despite multiple treatments.\n\nFor such patients, novel treatments include non-invasive brain stimulation. Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex (M1) is the non-invasive neurostimulation method with the largest evidence base in fibromyalgia. It involves generating magnetic fields outside of the body to change the firing of neurons in the brain, and has a very favorable tolerability profile. Recent meta-analyses indicate that both the DLPFC and M1 targets are associated with improvements in pain, mood and anxiety, however the benefits are more persistent when the DLPFC is targeted (Su et al, 2021 - J Clin Med). The DLPFC is important in fibromyalgia through its implication in several symptoms domains in fibromyalgia, as well as pain catastrophization.\n\nThe researchers neurophysiological data and clinical data in depression suggests that the researchers can enhance the effects of TMS by using an adjunctive medication called D-Cycloserine (DCS, 100mg) in conjunction with a protocol called intermittent theta-burst stimulation (iTBS). Specifically, this data indicated that several converging features of fibromyalgia improve with augmented iTBS, specifically depressive symptoms, anxiety symptoms, fatigue, and cognitive function. The researchers therefore hypothesize that the combination of D-cycloserine and TMS will lead to greater improvements in fibromyalgia symptoms than TMS alone.\n\nAlthough iTBS has not yet been studied in fibromyalgia, it has a well characterized neurophysiological effect and been shown to be non-inferior to conventional TMS protocols in conditions such as depression. More importantly, its physiological basis can be manipulated with D-Cycloserine whereas this has not been convincingly demonstrated with rTMS (see Brown et al, 2019, 2021 Brain Stim).\n\nResearch Question and Objectives: To conduct a randomized placebo-controlled trial of DCS in adjunct with rTMS in Fibromyalgia. Participants will be randomized to receive 100mg of DCS or placebo together with TMS.",
        "text": "A Randomized Controlled Trial of Adjunctive D-Cycloserine to Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation in Fibromyalgia | Background & Rationale: Fibromyalgia is characterized by widespread pain, fatigue, mood and anxiety as well as cognitive complaints. For an unacceptable proportion of patients, depressive symptoms remain impairing despite multiple treatments.\n\nFor such patients, novel treatments include non-invasive brain stimulation. Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex (M1) is the non-invasive neurostimulation method with the largest evidence base in fibromyalgia. It involves generating magnetic fields outside of the body to change the firing of neurons in the brain, and has a very favorable tolerability profile. Recent meta-analyses indicate that both the DLPFC and M1 targets are associated with improvements in pain, mood and anxiety, however the benefits are more persistent when the DLPFC is targeted (Su et al, 2021 - J Clin Med). The DLPFC is important in fibromyalgia through its implication in several symptoms domains in fibromyalgia, as well as pain catastrophization.\n\nThe researchers neurophysiological data and clinical data in depression suggests that the researchers can enhance the effects of TMS by using an adjunctive medication called D-Cycloserine (DCS, 100mg) in conjunction with a protocol called intermittent theta-burst stimulation (iTBS). Specifically, this data indicated that several converging features of fibromyalgia improve with augmented iTBS, specifically depressive symptoms, anxiety symptoms, fatigue, and cognitive function. The researchers therefore hypothesize that the combination of D-cycloserine and TMS will lead to greater improvements in fibromyalgia symptoms than TMS alone.\n\nAlthough iTBS has not yet been studied in fibromyalgia, it has a well characterized neurophysiological effect and been shown to be non-inferior to conventional TMS protocols in conditions such as depression. More importantly, its physiological basis can be manipulated with D-Cycloserine whereas this has not been convincingly demonstrated with rTMS (see Brown et al, 2019, 2021 Brain Stim).\n\nResearch Question and Objectives: To conduct a randomized placebo-controlled trial of DCS in adjunct with rTMS in Fibromyalgia. Participants will be randomized to receive 100mg of DCS or placebo together with TMS.",
        "tokens": "['A', 'Randomized', 'Controlled', 'Trial', 'of', 'Adjunctive', 'D', '-', 'Cycloserine', 'to', 'Intermittent', 'Theta', '-', 'burst', 'Stimulation', 'Transcranial', 'Magnetic', 'Stimulation', 'in', 'Fibromyalgia', '|', 'Background', '&', 'Rationale', ':', 'Fibromyalgia', 'is', 'characterized', 'by', 'widespread', 'pain', ',', 'fatigue', ',', 'mood', 'and', 'anxiety', 'as', 'well', 'as', 'cognitive', 'complaints', '.', 'For', 'an', 'unacceptable', 'proportion', 'of', 'patients', ',', 'depressive', 'symptoms', 'remain', 'impairing', 'despite', 'multiple', 'treatments', '.', '\\n\\n', 'For', 'such', 'patients', ',', 'novel', 'treatments', 'include', 'non', '-', 'invasive', 'brain', 'stimulation', '.', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'TMS', ')', 'targeting', 'the', 'dorsolateral', 'prefrontal', 'cortex', '(', 'DLPFC', ')', 'or', 'the', 'primary', 'motor', 'cortex', '(', 'M1', ')', 'is', 'the', 'non', '-', 'invasive', 'neurostimulation', 'method', 'with', 'the', 'largest', 'evidence', 'base', 'in', 'fibromyalgia', '.', 'It', 'involves', 'generating', 'magnetic', 'fields', 'outside', 'of', 'the', 'body', 'to', 'change', 'the', 'firing', 'of', 'neurons', 'in', 'the', 'brain', ',', 'and', 'has', 'a', 'very', 'favorable', 'tolerability', 'profile', '.', 'Recent', 'meta', '-', 'analyses', 'indicate', 'that', 'both', 'the', 'DLPFC', 'and', 'M1', 'targets', 'are', 'associated', 'with', 'improvements', 'in', 'pain', ',', 'mood', 'and', 'anxiety', ',', 'however', 'the', 'benefits', 'are', 'more', 'persistent', 'when', 'the', 'DLPFC', 'is', 'targeted', '(', 'Su', 'et', 'al', ',', '2021', '-', 'J', 'Clin', 'Med', ')', '.', 'The', 'DLPFC', 'is', 'important', 'in', 'fibromyalgia', 'through', 'its', 'implication', 'in', 'several', 'symptoms', 'domains', 'in', 'fibromyalgia', ',', 'as', 'well', 'as', 'pain', 'catastrophization', '.', '\\n\\n', 'The', 'researchers', 'neurophysiological', 'data', 'and', 'clinical', 'data', 'in', 'depression', 'suggests', 'that', 'the', 'researchers', 'can', 'enhance', 'the', 'effects', 'of', 'TMS', 'by', 'using', 'an', 'adjunctive', 'medication', 'called', 'D', '-', 'Cycloserine', '(', 'DCS', ',', '100', 'mg', ')', 'in', 'conjunction', 'with', 'a', 'protocol', 'called', 'intermittent', 'theta', '-', 'burst', 'stimulation', '(', 'iTBS', ')', '.', 'Specifically', ',', 'this', 'data', 'indicated', 'that', 'several', 'converging', 'features', 'of', 'fibromyalgia', 'improve', 'with', 'augmented', 'iTBS', ',', 'specifically', 'depressive', 'symptoms', ',', 'anxiety', 'symptoms', ',', 'fatigue', ',', 'and', 'cognitive', 'function', '.', 'The', 'researchers', 'therefore', 'hypothesize', 'that', 'the', 'combination', 'of', 'D', '-', 'cycloserine', 'and', 'TMS', 'will', 'lead', 'to', 'greater', 'improvements', 'in', 'fibromyalgia', 'symptoms', 'than', 'TMS', 'alone', '.', '\\n\\n', 'Although', 'iTBS', 'has', 'not', 'yet', 'been', 'studied', 'in', 'fibromyalgia', ',', 'it', 'has', 'a', 'well', 'characterized', 'neurophysiological', 'effect', 'and', 'been', 'shown', 'to', 'be', 'non', '-', 'inferior', 'to', 'conventional', 'TMS', 'protocols', 'in', 'conditions', 'such', 'as', 'depression', '.', 'More', 'importantly', ',', 'its', 'physiological', 'basis', 'can', 'be', 'manipulated', 'with', 'D', '-', 'Cycloserine', 'whereas', 'this', 'has', 'not', 'been', 'convincingly', 'demonstrated', 'with', 'rTMS', '(', 'see', 'Brown', 'et', 'al', ',', '2019', ',', '2021', 'Brain', 'Stim', ')', '.', '\\n\\n', 'Research', 'Question', 'and', 'Objectives', ':', 'To', 'conduct', 'a', 'randomized', 'placebo', '-', 'controlled', 'trial', 'of', 'DCS', 'in', 'adjunct', 'with', 'rTMS', 'in', 'Fibromyalgia', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'receive', '100', 'mg', 'of', 'DCS', 'or', 'placebo', 'together', 'with', 'TMS', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 44,
                "end": 57,
                "text": "D-Cycloserine",
                "type": "DRUG"
            },
            {
                "start": 61,
                "end": 131,
                "text": "Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 135,
                "end": 147,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 174,
                "end": 186,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 218,
                "end": 222,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 231,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 249,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 327,
                "end": 337,
                "text": "depressive",
                "type": "CONDITION"
            },
            {
                "start": 438,
                "end": 468,
                "text": "non-invasive brain stimulation",
                "type": "OTHER"
            },
            {
                "start": 470,
                "end": 595,
                "text": "Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex (M1)",
                "type": "OTHER"
            },
            {
                "start": 674,
                "end": 686,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 884,
                "end": 889,
                "text": "DLPFC",
                "type": "OTHER"
            },
            {
                "start": 894,
                "end": 896,
                "text": "M1",
                "type": "OTHER"
            },
            {
                "start": 941,
                "end": 945,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 956,
                "end": 963,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 1015,
                "end": 1020,
                "text": "DLPFC",
                "type": "OTHER"
            },
            {
                "start": 1068,
                "end": 1073,
                "text": "DLPFC",
                "type": "OTHER"
            },
            {
                "start": 1090,
                "end": 1102,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 1158,
                "end": 1170,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 1183,
                "end": 1205,
                "text": "pain catastrophization",
                "type": "CONDITION"
            },
            {
                "start": 1269,
                "end": 1279,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 1337,
                "end": 1340,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 1382,
                "end": 1395,
                "text": "D-Cycloserine",
                "type": "DRUG"
            },
            {
                "start": 1397,
                "end": 1400,
                "text": "DCS",
                "type": "DRUG"
            },
            {
                "start": 1447,
                "end": 1483,
                "text": "intermittent theta-burst stimulation",
                "type": "OTHER"
            },
            {
                "start": 1485,
                "end": 1489,
                "text": "iTBS",
                "type": "OTHER"
            },
            {
                "start": 1562,
                "end": 1574,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 1598,
                "end": 1602,
                "text": "iTBS",
                "type": "OTHER"
            },
            {
                "start": 1617,
                "end": 1627,
                "text": "depressive",
                "type": "CONDITION"
            },
            {
                "start": 1638,
                "end": 1645,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 1656,
                "end": 1663,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 1751,
                "end": 1764,
                "text": "D-cycloserine",
                "type": "DRUG"
            },
            {
                "start": 1769,
                "end": 1772,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 1810,
                "end": 1822,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 1837,
                "end": 1840,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 1858,
                "end": 1862,
                "text": "iTBS",
                "type": "OTHER"
            },
            {
                "start": 1891,
                "end": 1903,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 2009,
                "end": 2012,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 2045,
                "end": 2055,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 2123,
                "end": 2136,
                "text": "D-Cycloserine",
                "type": "DRUG"
            },
            {
                "start": 2194,
                "end": 2198,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 2300,
                "end": 2307,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 2328,
                "end": 2331,
                "text": "DCS",
                "type": "DRUG"
            },
            {
                "start": 2348,
                "end": 2352,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 2356,
                "end": 2368,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 2422,
                "end": 2425,
                "text": "DCS",
                "type": "DRUG"
            },
            {
                "start": 2429,
                "end": 2454,
                "text": "placebo together with TMS",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00153036",
        "study_official_title": "ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset ",
        "study_brief_summary": " To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.",
        "text": "ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset | To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.",
        "tokens": "['ECASS', 'III', '-', 'European', 'Cooperative', 'Acute', 'Stroke', 'Study', 'III', ':', 'A', 'Placebo', 'Controlled', 'Trial', 'of', 'Alteplase', '(', 'Rt', '-', 'PA', ')', 'in', 'Acute', 'Ischemic', 'Hemispheric', 'Stroke', 'Where', 'Thrombolysis', 'is', 'Initiated', 'Between', '3', 'and', '4', 'Hours', '30', 'Minutes', 'After', 'Stroke', 'Onset', '|', 'To', 'collect', 'additional', 'confirmatory', 'data', 'on', 'alteplase(rt', '-', 'PA', ')', 'in', 'the', 'European', 'setting', 'and', 'to', 'demonstrate', 'that', 'the', 'treatment', 'of', 'patients', 'between', '3', 'and', '4.30', 'hours', 'of', 'onset', 'of', 'symptoms', 'of', 'acute', 'ischemic', 'stroke', 'with', 'rt', '-', 'PA', 'compared', 'to', 'placebo', '-', 'treated', 'patients', 'will', 'result', 'in', 'an', 'improved', 'clinical', 'outcome', 'without', 'increase', 'of', 'fatality', 'rate', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 45,
                "text": "Acute Stroke",
                "type": "CONDITION"
            },
            {
                "start": 59,
                "end": 66,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 87,
                "end": 96,
                "text": "Alteplase",
                "type": "DRUG"
            },
            {
                "start": 98,
                "end": 103,
                "text": "Rt-PA",
                "type": "DRUG"
            },
            {
                "start": 108,
                "end": 141,
                "text": "Acute Ischemic Hemispheric Stroke",
                "type": "CONDITION"
            },
            {
                "start": 213,
                "end": 219,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 287,
                "text": "alteplase(rt-PA)",
                "type": "DRUG"
            },
            {
                "start": 411,
                "end": 432,
                "text": "acute ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 438,
                "end": 443,
                "text": "rt-PA",
                "type": "DRUG"
            },
            {
                "start": 456,
                "end": 463,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03893214",
        "study_official_title": "Virtual Reality Exposure Therapy for Acrophobia in a Single Session Design and the Role of Respiration for Fear Extinction ",
        "study_brief_summary": " In recent years, in the treatment of phobias, exposure therapy in virtual reality is becoming more and more popular as an alternative for in-vivo exposure. Effectiveness of virtual reality exposure therapy (VRET) is comparable to in-vivo exposure therapy, though several characteristics of the VRET have an impact on the outcome of the therapy (e.g., immersion into the virtual environment (VE), familiarity with the VE). Additionally, the use of VRET varies from multiple exposure sessions to single-session VRET. Single-session therapy has an economic advantage and in in-vivo, post therapy outcomes show good results. In virtual reality, the assessment of outcome post therapy and in follow-up of single-session therapies is still needed for an evaluation of this approach. As an outcome measure, behavioral assessments are especially relevant for effectiveness studies as in fear of heights it is closer to the individual's life to know how high they voluntarily go up a building than to have hypothetical self-report questionnaire results.\n\nMuch research has been conducted on physiological correlates of the subjective experience of fear in exposure therapy as they are assumed to be a prerequisite for effective exposure treatment. Skin conductance level (SCL) and heart rate can be used for objective manipulation checks of exposure therapy. SCL is found to increase during fearful situations independent of setting while heart rate only increases during in-vivo exposure. Contrary to heart rate, heart rate variability (HRV) is not thoroughly studied in VRET yet. HRV is associated with the adaptability of an organism to new environments and cognitive functioning. High Frequency HRV is found to be reduced in individuals with mental disorders, and positive and negative mood inductions lead to differential HRV responses overall.\n\nRespiration is a well-studied correlate of emotional experience and especially of the experience of fear and anxiety. In a series of experiments, it was found that sighing is tightly associated with relief in or after fearful or stressful situations and might become maladaptive when used disproportionally often. This study shows that respiration parameters have an impact on the handling of fearful situations in a reciprocal way. On the one hand, fear leads to an increased respiration rate and sigh rate while on the other hand, an altered sigh rate or respiration rate might have an impact on the experience of fear and be used as a defensive reaction to a fearful situation. As such, specific respiration patterns might act as emotion-driven behaviors (EDB). EDBs are responses to emotions that result in a short-term reduction of a negative state while in long-term support the maintenance of the phobia.\n\nThe aim of this study is to examine the effectiveness of a single-session VRET for acrophobia with a multimethod outcome design. Familiarity of the setting will be high with the use of a well-known tower in this area. Immersion into the VE will be assessed with a presence questionnaire. For a manipulation check, physiological data will be assessed, i.e., SCL, heart rate and HRV. Primary outcome measure will be a behavioral approach test (BAT) as behavioral assessment. Additionally, after four weeks, a follow-up assessment will investigate the stability of the effectiveness of the VRET in comparison to a waitlist control group. A second aim of this study is to investigate the impact of respiration as an EDB on the effectiveness of an exposure therapy. Therefore, the association between respiration and outcome of the VRET will be analyzed.\n\nHypothesis 1: Participants in the VRET condition show less height avoidance in the BAT after the intervention than participants in the control condition.\n\nHypothesis 2: Participants in the VRET condition show less height avoidance in the BAT in a four-week follow-up assessment than participants in the control condition.\n\nHypothesis 3: Participants in the VRET condition score significantly lower on the Acrophobia Questionnaire at follow-up than participants in the control condition.\n\nHypothesis 4: During the VRET, breath holding is used as EDB. Participants that hold their breath, profit less from the VRET than participants that do not hold their breath.\n\nHypothesis 5: During the VRET, sighing is used as EDB. Participants that sigh, profit less from the VRET than participants that do not sigh.",
        "text": "Virtual Reality Exposure Therapy for Acrophobia in a Single Session Design and the Role of Respiration for Fear Extinction | In recent years, in the treatment of phobias, exposure therapy in virtual reality is becoming more and more popular as an alternative for in-vivo exposure. Effectiveness of virtual reality exposure therapy (VRET) is comparable to in-vivo exposure therapy, though several characteristics of the VRET have an impact on the outcome of the therapy (e.g., immersion into the virtual environment (VE), familiarity with the VE). Additionally, the use of VRET varies from multiple exposure sessions to single-session VRET. Single-session therapy has an economic advantage and in in-vivo, post therapy outcomes show good results. In virtual reality, the assessment of outcome post therapy and in follow-up of single-session therapies is still needed for an evaluation of this approach. As an outcome measure, behavioral assessments are especially relevant for effectiveness studies as in fear of heights it is closer to the individual's life to know how high they voluntarily go up a building than to have hypothetical self-report questionnaire results.\n\nMuch research has been conducted on physiological correlates of the subjective experience of fear in exposure therapy as they are assumed to be a prerequisite for effective exposure treatment. Skin conductance level (SCL) and heart rate can be used for objective manipulation checks of exposure therapy. SCL is found to increase during fearful situations independent of setting while heart rate only increases during in-vivo exposure. Contrary to heart rate, heart rate variability (HRV) is not thoroughly studied in VRET yet. HRV is associated with the adaptability of an organism to new environments and cognitive functioning. High Frequency HRV is found to be reduced in individuals with mental disorders, and positive and negative mood inductions lead to differential HRV responses overall.\n\nRespiration is a well-studied correlate of emotional experience and especially of the experience of fear and anxiety. In a series of experiments, it was found that sighing is tightly associated with relief in or after fearful or stressful situations and might become maladaptive when used disproportionally often. This study shows that respiration parameters have an impact on the handling of fearful situations in a reciprocal way. On the one hand, fear leads to an increased respiration rate and sigh rate while on the other hand, an altered sigh rate or respiration rate might have an impact on the experience of fear and be used as a defensive reaction to a fearful situation. As such, specific respiration patterns might act as emotion-driven behaviors (EDB). EDBs are responses to emotions that result in a short-term reduction of a negative state while in long-term support the maintenance of the phobia.\n\nThe aim of this study is to examine the effectiveness of a single-session VRET for acrophobia with a multimethod outcome design. Familiarity of the setting will be high with the use of a well-known tower in this area. Immersion into the VE will be assessed with a presence questionnaire. For a manipulation check, physiological data will be assessed, i.e., SCL, heart rate and HRV. Primary outcome measure will be a behavioral approach test (BAT) as behavioral assessment. Additionally, after four weeks, a follow-up assessment will investigate the stability of the effectiveness of the VRET in comparison to a waitlist control group. A second aim of this study is to investigate the impact of respiration as an EDB on the effectiveness of an exposure therapy. Therefore, the association between respiration and outcome of the VRET will be analyzed.\n\nHypothesis 1: Participants in the VRET condition show less height avoidance in the BAT after the intervention than participants in the control condition.\n\nHypothesis 2: Participants in the VRET condition show less height avoidance in the BAT in a four-week follow-up assessment than participants in the control condition.\n\nHypothesis 3: Participants in the VRET condition score significantly lower on the Acrophobia Questionnaire at follow-up than participants in the control condition.\n\nHypothesis 4: During the VRET, breath holding is used as EDB. Participants that hold their breath, profit less from the VRET than participants that do not hold their breath.\n\nHypothesis 5: During the VRET, sighing is used as EDB. Participants that sigh, profit less from the VRET than participants that do not sigh.",
        "tokens": "['Virtual', 'Reality', 'Exposure', 'Therapy', 'for', 'Acrophobia', 'in', 'a', 'Single', 'Session', 'Design', 'and', 'the', 'Role', 'of', 'Respiration', 'for', 'Fear', 'Extinction', '|', 'In', 'recent', 'years', ',', 'in', 'the', 'treatment', 'of', 'phobias', ',', 'exposure', 'therapy', 'in', 'virtual', 'reality', 'is', 'becoming', 'more', 'and', 'more', 'popular', 'as', 'an', 'alternative', 'for', 'in', '-', 'vivo', 'exposure', '.', 'Effectiveness', 'of', 'virtual', 'reality', 'exposure', 'therapy', '(', 'VRET', ')', 'is', 'comparable', 'to', 'in', '-', 'vivo', 'exposure', 'therapy', ',', 'though', 'several', 'characteristics', 'of', 'the', 'VRET', 'have', 'an', 'impact', 'on', 'the', 'outcome', 'of', 'the', 'therapy', '(', 'e.g.', ',', 'immersion', 'into', 'the', 'virtual', 'environment', '(', 'VE', ')', ',', 'familiarity', 'with', 'the', 'VE', ')', '.', 'Additionally', ',', 'the', 'use', 'of', 'VRET', 'varies', 'from', 'multiple', 'exposure', 'sessions', 'to', 'single', '-', 'session', 'VRET', '.', 'Single', '-', 'session', 'therapy', 'has', 'an', 'economic', 'advantage', 'and', 'in', 'in', '-', 'vivo', ',', 'post', 'therapy', 'outcomes', 'show', 'good', 'results', '.', 'In', 'virtual', 'reality', ',', 'the', 'assessment', 'of', 'outcome', 'post', 'therapy', 'and', 'in', 'follow', '-', 'up', 'of', 'single', '-', 'session', 'therapies', 'is', 'still', 'needed', 'for', 'an', 'evaluation', 'of', 'this', 'approach', '.', 'As', 'an', 'outcome', 'measure', ',', 'behavioral', 'assessments', 'are', 'especially', 'relevant', 'for', 'effectiveness', 'studies', 'as', 'in', 'fear', 'of', 'heights', 'it', 'is', 'closer', 'to', 'the', 'individual', \"'s\", 'life', 'to', 'know', 'how', 'high', 'they', 'voluntarily', 'go', 'up', 'a', 'building', 'than', 'to', 'have', 'hypothetical', 'self', '-', 'report', 'questionnaire', 'results', '.', '\\n\\n', 'Much', 'research', 'has', 'been', 'conducted', 'on', 'physiological', 'correlates', 'of', 'the', 'subjective', 'experience', 'of', 'fear', 'in', 'exposure', 'therapy', 'as', 'they', 'are', 'assumed', 'to', 'be', 'a', 'prerequisite', 'for', 'effective', 'exposure', 'treatment', '.', 'Skin', 'conductance', 'level', '(', 'SCL', ')', 'and', 'heart', 'rate', 'can', 'be', 'used', 'for', 'objective', 'manipulation', 'checks', 'of', 'exposure', 'therapy', '.', 'SCL', 'is', 'found', 'to', 'increase', 'during', 'fearful', 'situations', 'independent', 'of', 'setting', 'while', 'heart', 'rate', 'only', 'increases', 'during', 'in', '-', 'vivo', 'exposure', '.', 'Contrary', 'to', 'heart', 'rate', ',', 'heart', 'rate', 'variability', '(', 'HRV', ')', 'is', 'not', 'thoroughly', 'studied', 'in', 'VRET', 'yet', '.', 'HRV', 'is', 'associated', 'with', 'the', 'adaptability', 'of', 'an', 'organism', 'to', 'new', 'environments', 'and', 'cognitive', 'functioning', '.', 'High', 'Frequency', 'HRV', 'is', 'found', 'to', 'be', 'reduced', 'in', 'individuals', 'with', 'mental', 'disorders', ',', 'and', 'positive', 'and', 'negative', 'mood', 'inductions', 'lead', 'to', 'differential', 'HRV', 'responses', 'overall', '.', '\\n\\n', 'Respiration', 'is', 'a', 'well', '-', 'studied', 'correlate', 'of', 'emotional', 'experience', 'and', 'especially', 'of', 'the', 'experience', 'of', 'fear', 'and', 'anxiety', '.', 'In', 'a', 'series', 'of', 'experiments', ',', 'it', 'was', 'found', 'that', 'sighing', 'is', 'tightly', 'associated', 'with', 'relief', 'in', 'or', 'after', 'fearful', 'or', 'stressful', 'situations', 'and', 'might', 'become', 'maladaptive', 'when', 'used', 'disproportionally', 'often', '.', 'This', 'study', 'shows', 'that', 'respiration', 'parameters', 'have', 'an', 'impact', 'on', 'the', 'handling', 'of', 'fearful', 'situations', 'in', 'a', 'reciprocal', 'way', '.', 'On', 'the', 'one', 'hand', ',', 'fear', 'leads', 'to', 'an', 'increased', 'respiration', 'rate', 'and', 'sigh', 'rate', 'while', 'on', 'the', 'other', 'hand', ',', 'an', 'altered', 'sigh', 'rate', 'or', 'respiration', 'rate', 'might', 'have', 'an', 'impact', 'on', 'the', 'experience', 'of', 'fear', 'and', 'be', 'used', 'as', 'a', 'defensive', 'reaction', 'to', 'a', 'fearful', 'situation', '.', 'As', 'such', ',', 'specific', 'respiration', 'patterns', 'might', 'act', 'as', 'emotion', '-', 'driven', 'behaviors', '(', 'EDB', ')', '.', 'EDBs', 'are', 'responses', 'to', 'emotions', 'that', 'result', 'in', 'a', 'short', '-', 'term', 'reduction', 'of', 'a', 'negative', 'state', 'while', 'in', 'long', '-', 'term', 'support', 'the', 'maintenance', 'of', 'the', 'phobia', '.', '\\n\\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'effectiveness', 'of', 'a', 'single', '-', 'session', 'VRET', 'for', 'acrophobia', 'with', 'a', 'multimethod', 'outcome', 'design', '.', 'Familiarity', 'of', 'the', 'setting', 'will', 'be', 'high', 'with', 'the', 'use', 'of', 'a', 'well', '-', 'known', 'tower', 'in', 'this', 'area', '.', 'Immersion', 'into', 'the', 'VE', 'will', 'be', 'assessed', 'with', 'a', 'presence', 'questionnaire', '.', 'For', 'a', 'manipulation', 'check', ',', 'physiological', 'data', 'will', 'be', 'assessed', ',', 'i.e.', ',', 'SCL', ',', 'heart', 'rate', 'and', 'HRV', '.', 'Primary', 'outcome', 'measure', 'will', 'be', 'a', 'behavioral', 'approach', 'test', '(', 'BAT', ')', 'as', 'behavioral', 'assessment', '.', 'Additionally', ',', 'after', 'four', 'weeks', ',', 'a', 'follow', '-', 'up', 'assessment', 'will', 'investigate', 'the', 'stability', 'of', 'the', 'effectiveness', 'of', 'the', 'VRET', 'in', 'comparison', 'to', 'a', 'waitlist', 'control', 'group', '.', 'A', 'second', 'aim', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'impact', 'of', 'respiration', 'as', 'an', 'EDB', 'on', 'the', 'effectiveness', 'of', 'an', 'exposure', 'therapy', '.', 'Therefore', ',', 'the', 'association', 'between', 'respiration', 'and', 'outcome', 'of', 'the', 'VRET', 'will', 'be', 'analyzed', '.', '\\n\\n', 'Hypothesis', '1', ':', 'Participants', 'in', 'the', 'VRET', 'condition', 'show', 'less', 'height', 'avoidance', 'in', 'the', 'BAT', 'after', 'the', 'intervention', 'than', 'participants', 'in', 'the', 'control', 'condition', '.', '\\n\\n', 'Hypothesis', '2', ':', 'Participants', 'in', 'the', 'VRET', 'condition', 'show', 'less', 'height', 'avoidance', 'in', 'the', 'BAT', 'in', 'a', 'four', '-', 'week', 'follow', '-', 'up', 'assessment', 'than', 'participants', 'in', 'the', 'control', 'condition', '.', '\\n\\n', 'Hypothesis', '3', ':', 'Participants', 'in', 'the', 'VRET', 'condition', 'score', 'significantly', 'lower', 'on', 'the', 'Acrophobia', 'Questionnaire', 'at', 'follow', '-', 'up', 'than', 'participants', 'in', 'the', 'control', 'condition', '.', '\\n\\n', 'Hypothesis', '4', ':', 'During', 'the', 'VRET', ',', 'breath', 'holding', 'is', 'used', 'as', 'EDB', '.', 'Participants', 'that', 'hold', 'their', 'breath', ',', 'profit', 'less', 'from', 'the', 'VRET', 'than', 'participants', 'that', 'do', 'not', 'hold', 'their', 'breath', '.', '\\n\\n', 'Hypothesis', '5', ':', 'During', 'the', 'VRET', ',', 'sighing', 'is', 'used', 'as', 'EDB', '.', 'Participants', 'that', 'sigh', ',', 'profit', 'less', 'from', 'the', 'VRET', 'than', 'participants', 'that', 'do', 'not', 'sigh', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 32,
                "text": "Virtual Reality Exposure Therapy",
                "type": "OTHER"
            },
            {
                "start": 37,
                "end": 47,
                "text": "Acrophobia",
                "type": "CONDITION"
            },
            {
                "start": 162,
                "end": 169,
                "text": "phobias",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 330,
                "text": "virtual reality exposure therapy",
                "type": "OTHER"
            },
            {
                "start": 332,
                "end": 336,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 419,
                "end": 423,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 572,
                "end": 576,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 634,
                "end": 638,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 1004,
                "end": 1019,
                "text": "fear of heights",
                "type": "CONDITION"
            },
            {
                "start": 1688,
                "end": 1692,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 2871,
                "end": 2877,
                "text": "phobia",
                "type": "CONDITION"
            },
            {
                "start": 2954,
                "end": 2958,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 2963,
                "end": 2973,
                "text": "acrophobia",
                "type": "CONDITION"
            },
            {
                "start": 3467,
                "end": 3471,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 3491,
                "end": 3499,
                "text": "waitlist",
                "type": "CONTROL"
            },
            {
                "start": 3707,
                "end": 3711,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 3765,
                "end": 3769,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 3790,
                "end": 3806,
                "text": "height avoidance",
                "type": "CONDITION"
            },
            {
                "start": 3920,
                "end": 3924,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 3945,
                "end": 3961,
                "text": "height avoidance",
                "type": "CONDITION"
            },
            {
                "start": 4088,
                "end": 4092,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 4136,
                "end": 4146,
                "text": "Acrophobia",
                "type": "CONDITION"
            },
            {
                "start": 4244,
                "end": 4248,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 4339,
                "end": 4343,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 4419,
                "end": 4423,
                "text": "VRET",
                "type": "OTHER"
            },
            {
                "start": 4494,
                "end": 4498,
                "text": "VRET",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01457508",
        "study_official_title": "Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Vaccine Mixed With Hib Vaccine to Healthy Infants at 3, 5 and 11 Months of Age, Compared to Each Vaccine Administered Separately ",
        "study_brief_summary": " This study will assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' (formerly SB Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa\u2122) vaccine compared with separate administration of DTPa-HBV-IPV (Infanrix penta\u2122) and Hib (Hiberix\u2122) vaccine administered at 3, 5 and 11 (or 12) months of age.",
        "text": "Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Vaccine Mixed With Hib Vaccine to Healthy Infants at 3, 5 and 11 Months of Age, Compared to Each Vaccine Administered Separately | This study will assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' (formerly SB Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa\u2122) vaccine compared with separate administration of DTPa-HBV-IPV (Infanrix penta\u2122) and Hib (Hiberix\u2122) vaccine administered at 3, 5 and 11 (or 12) months of age.",
        "tokens": "['Study', 'to', 'Assess', 'the', 'Immunogenicity', 'and', 'Reactogenicity', 'of', 'DTPa', '-', 'HBV', '-', 'IPV', 'Vaccine', 'Mixed', 'With', 'Hib', 'Vaccine', 'to', 'Healthy', 'Infants', 'at', '3', ',', '5', 'and', '11', 'Months', 'of', 'Age', ',', 'Compared', 'to', 'Each', 'Vaccine', 'Administered', 'Separately', '|', 'This', 'study', 'will', 'assess', 'the', 'immunogenicity', 'and', 'safety', 'of', 'GlaxoSmithKline', '(', 'GSK', ')', 'Biologicals', \"'\", '(', 'formerly', 'SB', 'Biologicals', \"'\", ')', 'DTPa', '-', 'HBV', '-', 'IPV', '/', 'Hib', '(', 'Infanrix', 'hexa', '\u2122', ')', 'vaccine', 'compared', 'with', 'separate', 'administration', 'of', 'DTPa', '-', 'HBV', '-', 'IPV', '(', 'Infanrix', 'penta', '\u2122', ')', 'and', 'Hib', '(', 'Hiberix', '\u2122', ')', 'vaccine', 'administered', 'at', '3', ',', '5', 'and', '11', '(', 'or', '12', ')', 'months', 'of', 'age', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 57,
                "end": 77,
                "text": "DTPa-HBV-IPV Vaccine",
                "type": "DRUG"
            },
            {
                "start": 89,
                "end": 100,
                "text": "Hib Vaccine",
                "type": "DRUG"
            },
            {
                "start": 319,
                "end": 331,
                "text": "DTPa-HBV-IPV",
                "type": "DRUG"
            },
            {
                "start": 332,
                "end": 335,
                "text": "Hib",
                "type": "DRUG"
            },
            {
                "start": 337,
                "end": 350,
                "text": "Infanrix hexa",
                "type": "DRUG"
            },
            {
                "start": 402,
                "end": 414,
                "text": "DTPa-HBV-IPV",
                "type": "DRUG"
            },
            {
                "start": 416,
                "end": 430,
                "text": "Infanrix penta",
                "type": "DRUG"
            },
            {
                "start": 437,
                "end": 440,
                "text": "Hib",
                "type": "DRUG"
            },
            {
                "start": 442,
                "end": 449,
                "text": "Hiberix",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05193539",
        "study_official_title": "Effects of Comprehensive Augmented and Virtual Reality for Upper Limb Rehabilitation in First-Ever Stroke Patients ",
        "study_brief_summary": " The purpose of this study was to assess the efficacy of augmented and virtual reality-based rehabilitation programs on improving upper extremity function in subacute stroke patients.",
        "text": "Effects of Comprehensive Augmented and Virtual Reality for Upper Limb Rehabilitation in First-Ever Stroke Patients | The purpose of this study was to assess the efficacy of augmented and virtual reality-based rehabilitation programs on improving upper extremity function in subacute stroke patients.",
        "tokens": "['Effects', 'of', 'Comprehensive', 'Augmented', 'and', 'Virtual', 'Reality', 'for', 'Upper', 'Limb', 'Rehabilitation', 'in', 'First', '-', 'Ever', 'Stroke', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'assess', 'the', 'efficacy', 'of', 'augmented', 'and', 'virtual', 'reality', '-', 'based', 'rehabilitation', 'programs', 'on', 'improving', 'upper', 'extremity', 'function', 'in', 'subacute', 'stroke', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 54,
                "text": "Comprehensive Augmented and Virtual Reality",
                "type": "OTHER"
            },
            {
                "start": 88,
                "end": 105,
                "text": "First-Ever Stroke",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 232,
                "text": "augmented and virtual reality-based rehabilitation programs",
                "type": "OTHER"
            },
            {
                "start": 274,
                "end": 289,
                "text": "subacute stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03700580",
        "study_official_title": "Application of a Double Blind Clinical Trial Protocol for Evaluation of Healing Action of P1G10, From V Cundinamarcensis to Chronic Neuropathic Wounds in Diabetic Foot Ulcers. ",
        "study_brief_summary": " The aim of the study was to investigate the role of the proteolytic fraction from Vasconcellea cundinamarcensis, designated as P1G10, on healing of chronic foot ulcers in neuropathic patients diagnosed with diabetes type 2. Fifty patients were enrolled in a prospective, randomized, double-blind trial, to verify the ef\ufb01cacy and safety of a topical dressing containing 0.1% P1G10, versus a Hydrogel (positive control) protocol currently applied at the Health Center to treat this condition. Upon completion of the intervention, the outcome evaluated the number of patients attaining full epithelization (100%), or at least 80% healing in both arms (P1G10 versus Hydrogel). Statistical analysis compared the endpoint data on each group to assess the signi\ufb01cance of differences.",
        "text": "Application of a Double Blind Clinical Trial Protocol for Evaluation of Healing Action of P1G10, From V Cundinamarcensis to Chronic Neuropathic Wounds in Diabetic Foot Ulcers. | The aim of the study was to investigate the role of the proteolytic fraction from Vasconcellea cundinamarcensis, designated as P1G10, on healing of chronic foot ulcers in neuropathic patients diagnosed with diabetes type 2. Fifty patients were enrolled in a prospective, randomized, double-blind trial, to verify the ef\ufb01cacy and safety of a topical dressing containing 0.1% P1G10, versus a Hydrogel (positive control) protocol currently applied at the Health Center to treat this condition. Upon completion of the intervention, the outcome evaluated the number of patients attaining full epithelization (100%), or at least 80% healing in both arms (P1G10 versus Hydrogel). Statistical analysis compared the endpoint data on each group to assess the signi\ufb01cance of differences.",
        "tokens": "['Application', 'of', 'a', 'Double', 'Blind', 'Clinical', 'Trial', 'Protocol', 'for', 'Evaluation', 'of', 'Healing', 'Action', 'of', 'P1G10', ',', 'From', 'V', 'Cundinamarcensis', 'to', 'Chronic', 'Neuropathic', 'Wounds', 'in', 'Diabetic', 'Foot', 'Ulcers', '.', '|', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'investigate', 'the', 'role', 'of', 'the', 'proteolytic', 'fraction', 'from', 'Vasconcellea', 'cundinamarcensis', ',', 'designated', 'as', 'P1G10', ',', 'on', 'healing', 'of', 'chronic', 'foot', 'ulcers', 'in', 'neuropathic', 'patients', 'diagnosed', 'with', 'diabetes', 'type', '2', '.', 'Fifty', 'patients', 'were', 'enrolled', 'in', 'a', 'prospective', ',', 'randomized', ',', 'double', '-', 'blind', 'trial', ',', 'to', 'verify', 'the', 'ef\ufb01cacy', 'and', 'safety', 'of', 'a', 'topical', 'dressing', 'containing', '0.1', '%', 'P1G10', ',', 'versus', 'a', 'Hydrogel', '(', 'positive', 'control', ')', 'protocol', 'currently', 'applied', 'at', 'the', 'Health', 'Center', 'to', 'treat', 'this', 'condition', '.', 'Upon', 'completion', 'of', 'the', 'intervention', ',', 'the', 'outcome', 'evaluated', 'the', 'number', 'of', 'patients', 'attaining', 'full', 'epithelization', '(', '100', '%', ')', ',', 'or', 'at', 'least', '80', '%', 'healing', 'in', 'both', 'arms', '(', 'P1G10', 'versus', 'Hydrogel', ')', '.', 'Statistical', 'analysis', 'compared', 'the', 'endpoint', 'data', 'on', 'each', 'group', 'to', 'assess', 'the', 'signi\ufb01cance', 'of', 'differences', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 90,
                "end": 95,
                "text": "P1G10",
                "type": "DRUG"
            },
            {
                "start": 124,
                "end": 150,
                "text": "Chronic Neuropathic Wounds",
                "type": "CONDITION"
            },
            {
                "start": 154,
                "end": 174,
                "text": "Diabetic Foot Ulcers",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 310,
                "text": "P1G10",
                "type": "DRUG"
            },
            {
                "start": 326,
                "end": 345,
                "text": "chronic foot ulcers",
                "type": "CONDITION"
            },
            {
                "start": 349,
                "end": 360,
                "text": "neuropathic",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 401,
                "text": "diabetes type 2.",
                "type": "CONDITION"
            },
            {
                "start": 552,
                "end": 557,
                "text": "P1G10",
                "type": "DRUG"
            },
            {
                "start": 568,
                "end": 576,
                "text": "Hydrogel",
                "type": "CONTROL"
            },
            {
                "start": 827,
                "end": 832,
                "text": "P1G10",
                "type": "DRUG"
            },
            {
                "start": 840,
                "end": 848,
                "text": "Hydrogel",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05660070",
        "study_official_title": "Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness ",
        "study_brief_summary": " This open trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.",
        "text": "Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness | This open trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.",
        "tokens": "['Context', '-', 'Aware', 'Mobile', 'Intervention', 'for', 'Social', 'Recovery', 'in', 'Serious', 'Mental', 'Illness', '|', 'This', 'open', 'trial', 'will', 'test', 'a', 'new', 'technology', '-', 'supported', 'blended', 'intervention', ',', 'mobile', 'Social', 'Interaction', 'Therapy', 'by', 'Exposure', '(', 'mSITE', ')', ',', 'that', 'targets', 'social', 'engagement', 'in', 'consumers', 'with', 'serious', 'mental', 'illness', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 33,
                "text": "Context-Aware Mobile Intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 57,
                "end": 79,
                "text": "Serious Mental Illness",
                "type": "CONDITION"
            },
            {
                "start": 114,
                "end": 155,
                "text": "technology-supported blended intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 157,
                "end": 202,
                "text": "mobile Social Interaction Therapy by Exposure",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 204,
                "end": 209,
                "text": "mSITE",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 261,
                "end": 283,
                "text": "serious mental illness",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05197803",
        "study_official_title": "Clinical Study of Released Unitron RIC (Receiver in Canal) and BTE (Behind the Ear) Hearing Aid Models ",
        "study_brief_summary": " Participants will wear two sets of Unitron released hearing aids (RIC and BTE) programmed based on a prescriptive approach and will perform a standardized speech discrimination test in noise in both aided conditions as well as in unaided condition.",
        "text": "Clinical Study of Released Unitron RIC (Receiver in Canal) and BTE (Behind the Ear) Hearing Aid Models | Participants will wear two sets of Unitron released hearing aids (RIC and BTE) programmed based on a prescriptive approach and will perform a standardized speech discrimination test in noise in both aided conditions as well as in unaided condition.",
        "tokens": "['Clinical', 'Study', 'of', 'Released', 'Unitron', 'RIC', '(', 'Receiver', 'in', 'Canal', ')', 'and', 'BTE', '(', 'Behind', 'the', 'Ear', ')', 'Hearing', 'Aid', 'Models', '|', 'Participants', 'will', 'wear', 'two', 'sets', 'of', 'Unitron', 'released', 'hearing', 'aids', '(', 'RIC', 'and', 'BTE', ')', 'programmed', 'based', 'on', 'a', 'prescriptive', 'approach', 'and', 'will', 'perform', 'a', 'standardized', 'speech', 'discrimination', 'test', 'in', 'noise', 'in', 'both', 'aided', 'conditions', 'as', 'well', 'as', 'in', 'unaided', 'condition', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 102,
                "text": "Released Unitron RIC (Receiver in Canal) and BTE (Behind the Ear) Hearing Aid Models",
                "type": "OTHER"
            },
            {
                "start": 140,
                "end": 169,
                "text": "Unitron released hearing aids",
                "type": "OTHER"
            },
            {
                "start": 171,
                "end": 174,
                "text": "RIC",
                "type": "OTHER"
            },
            {
                "start": 179,
                "end": 182,
                "text": "BTE",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02574234",
        "study_official_title": "Influence of Apelin Levels on Postoperative Cognitive Disorders After Orthopedic Surgery in Elderlies ",
        "study_brief_summary": " No successful strategy is proposed to patients submitted to important surgery to reduce the incidence of postoperative cognitive disorders (POCD) onset. This project propose to measure plasma levels of apelin in wide population submitted to orthopedic surgery. Apelin could be involved in anti-inflammatory processes. Apelin levels before and after surgery correlated to postoperative cognitive disorders symptom measured by PET-Scan could be an important predictive or diagnostic marker to adapt therapeutic strategy to fight against postoperative cognitive disorders.",
        "text": "Influence of Apelin Levels on Postoperative Cognitive Disorders After Orthopedic Surgery in Elderlies | No successful strategy is proposed to patients submitted to important surgery to reduce the incidence of postoperative cognitive disorders (POCD) onset. This project propose to measure plasma levels of apelin in wide population submitted to orthopedic surgery. Apelin could be involved in anti-inflammatory processes. Apelin levels before and after surgery correlated to postoperative cognitive disorders symptom measured by PET-Scan could be an important predictive or diagnostic marker to adapt therapeutic strategy to fight against postoperative cognitive disorders.",
        "tokens": "['Influence', 'of', 'Apelin', 'Levels', 'on', 'Postoperative', 'Cognitive', 'Disorders', 'After', 'Orthopedic', 'Surgery', 'in', 'Elderlies', '|', 'No', 'successful', 'strategy', 'is', 'proposed', 'to', 'patients', 'submitted', 'to', 'important', 'surgery', 'to', 'reduce', 'the', 'incidence', 'of', 'postoperative', 'cognitive', 'disorders', '(', 'POCD', ')', 'onset', '.', 'This', 'project', 'propose', 'to', 'measure', 'plasma', 'levels', 'of', 'apelin', 'in', 'wide', 'population', 'submitted', 'to', 'orthopedic', 'surgery', '.', 'Apelin', 'could', 'be', 'involved', 'in', 'anti', '-', 'inflammatory', 'processes', '.', 'Apelin', 'levels', 'before', 'and', 'after', 'surgery', 'correlated', 'to', 'postoperative', 'cognitive', 'disorders', 'symptom', 'measured', 'by', 'PET', '-', 'Scan', 'could', 'be', 'an', 'important', 'predictive', 'or', 'diagnostic', 'marker', 'to', 'adapt', 'therapeutic', 'strategy', 'to', 'fight', 'against', 'postoperative', 'cognitive', 'disorders', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 63,
                "text": "Postoperative Cognitive Disorders",
                "type": "CONDITION"
            },
            {
                "start": 70,
                "end": 88,
                "text": "Orthopedic Surgery",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 242,
                "text": "postoperative cognitive disorders",
                "type": "CONDITION"
            },
            {
                "start": 244,
                "end": 248,
                "text": "POCD",
                "type": "CONDITION"
            },
            {
                "start": 345,
                "end": 363,
                "text": "orthopedic surgery",
                "type": "CONDITION"
            },
            {
                "start": 475,
                "end": 508,
                "text": "postoperative cognitive disorders",
                "type": "CONDITION"
            },
            {
                "start": 639,
                "end": 672,
                "text": "postoperative cognitive disorders",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00130923",
        "study_official_title": "Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) ",
        "study_brief_summary": " The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.",
        "text": "Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) | The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.",
        "tokens": "['Risperidone', 'Long', '-', 'Acting', 'for', 'Alcohol', 'and', 'Schizophrenia', 'Treatment', '(', 'R', '-', 'LAST', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'oral', 'risperidone', '(', 'Risperdal', ')', 'to', 'risperidone', 'long', '-', 'acting', '(', 'Consta', ')', 'in', 'reducing', 'alcohol', 'use', 'in', 'persons', 'diagnosed', 'with', 'schizophrenia', 'or', 'schizoaffective', 'disorder', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 11,
                "text": "Risperidone",
                "type": "DRUG"
            },
            {
                "start": 40,
                "end": 53,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 147,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 149,
                "end": 158,
                "text": "Risperdal",
                "type": "DRUG"
            },
            {
                "start": 163,
                "end": 174,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 188,
                "end": 194,
                "text": "Consta",
                "type": "DRUG"
            },
            {
                "start": 208,
                "end": 219,
                "text": "alcohol use",
                "type": "CONDITION"
            },
            {
                "start": 246,
                "end": 259,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 263,
                "end": 287,
                "text": "schizoaffective disorder",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03622515",
        "study_official_title": "Xuanwu Hospital Capital Medical University ",
        "study_brief_summary": " Fragile brain is the most common phenomenon seen in the patients undergoing CEA. The patients with fragile brain have a high incidence of postoperative brain dysfunction. This study intends to apply EEG monitoring (Sedline) to CEA to investigate whether EEG monitoring can reduce the incidence of postoperative neurological complications in CEA patients and improve their prognosis.\n\n220 patients with CEA were randomly divided into 2 groups. Group S [Sedline monitoring + Transcranial Doppler (TCD) + regional cerebral oxygen saturation (rS02)\uff0cn=110] and group C [Bispectral index (BIS)/Sedline monitoring + TCD +rSO2,n=110], recording intraoperative and postoperative conditions, neuropsychology scale assessment, blood examination and imaging examination. The incidence of postoperative neurological complications was compared between the two groups.",
        "text": "Xuanwu Hospital Capital Medical University | Fragile brain is the most common phenomenon seen in the patients undergoing CEA. The patients with fragile brain have a high incidence of postoperative brain dysfunction. This study intends to apply EEG monitoring (Sedline) to CEA to investigate whether EEG monitoring can reduce the incidence of postoperative neurological complications in CEA patients and improve their prognosis.\n\n220 patients with CEA were randomly divided into 2 groups. Group S [Sedline monitoring + Transcranial Doppler (TCD) + regional cerebral oxygen saturation (rS02)\uff0cn=110] and group C [Bispectral index (BIS)/Sedline monitoring + TCD +rSO2,n=110], recording intraoperative and postoperative conditions, neuropsychology scale assessment, blood examination and imaging examination. The incidence of postoperative neurological complications was compared between the two groups.",
        "tokens": "['Xuanwu', 'Hospital', 'Capital', 'Medical', 'University', '|', 'Fragile', 'brain', 'is', 'the', 'most', 'common', 'phenomenon', 'seen', 'in', 'the', 'patients', 'undergoing', 'CEA', '.', 'The', 'patients', 'with', 'fragile', 'brain', 'have', 'a', 'high', 'incidence', 'of', 'postoperative', 'brain', 'dysfunction', '.', 'This', 'study', 'intends', 'to', 'apply', 'EEG', 'monitoring', '(', 'Sedline', ')', 'to', 'CEA', 'to', 'investigate', 'whether', 'EEG', 'monitoring', 'can', 'reduce', 'the', 'incidence', 'of', 'postoperative', 'neurological', 'complications', 'in', 'CEA', 'patients', 'and', 'improve', 'their', 'prognosis', '.', '\\n\\n', '220', 'patients', 'with', 'CEA', 'were', 'randomly', 'divided', 'into', '2', 'groups', '.', 'Group', 'S', '[', 'Sedline', 'monitoring', '+', 'Transcranial', 'Doppler', '(', 'TCD', ')', '+', 'regional', 'cerebral', 'oxygen', 'saturation', '(', 'rS02)\uff0cn=110', ']', 'and', 'group', 'C', '[', 'Bispectral', 'index', '(', 'BIS)/Sedline', 'monitoring', '+', 'TCD', '+', 'rSO2,n=110', ']', ',', 'recording', 'intraoperative', 'and', 'postoperative', 'conditions', ',', 'neuropsychology', 'scale', 'assessment', ',', 'blood', 'examination', 'and', 'imaging', 'examination', '.', 'The', 'incidence', 'of', 'postoperative', 'neurological', 'complications', 'was', 'compared', 'between', 'the', 'two', 'groups', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 45,
                "end": 58,
                "text": "Fragile brain",
                "type": "CONDITION"
            },
            {
                "start": 121,
                "end": 124,
                "text": "CEA",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 157,
                "text": "fragile brain",
                "type": "CONDITION"
            },
            {
                "start": 272,
                "end": 275,
                "text": "CEA",
                "type": "CONDITION"
            },
            {
                "start": 386,
                "end": 389,
                "text": "CEA",
                "type": "CONDITION"
            },
            {
                "start": 447,
                "end": 450,
                "text": "CEA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02729311",
        "study_official_title": "Paired Integrative Exercise Program for People With Dementia and Caregivers ",
        "study_brief_summary": " Preventing Loss of Independence through Exercise (PLI\u00c9) is a unique, multimodal movement program for people with dementia (affected individuals) that is taught by trained instructors and combines physical, mental and social activities. The Paired PLI\u00c9 Program is an adapted version designed for pairs of affected individuals and care partners. The goal of this study is to perform a randomized, controlled trial (RCT) with a delayed start design to examine the effects of the Paired PLI\u00c9 Program on function and quality of life in affected individuals and care partners.",
        "text": "Paired Integrative Exercise Program for People With Dementia and Caregivers | Preventing Loss of Independence through Exercise (PLI\u00c9) is a unique, multimodal movement program for people with dementia (affected individuals) that is taught by trained instructors and combines physical, mental and social activities. The Paired PLI\u00c9 Program is an adapted version designed for pairs of affected individuals and care partners. The goal of this study is to perform a randomized, controlled trial (RCT) with a delayed start design to examine the effects of the Paired PLI\u00c9 Program on function and quality of life in affected individuals and care partners.",
        "tokens": "['Paired', 'Integrative', 'Exercise', 'Program', 'for', 'People', 'With', 'Dementia', 'and', 'Caregivers', '|', 'Preventing', 'Loss', 'of', 'Independence', 'through', 'Exercise', '(', 'PLI\u00c9', ')', 'is', 'a', 'unique', ',', 'multimodal', 'movement', 'program', 'for', 'people', 'with', 'dementia', '(', 'affected', 'individuals', ')', 'that', 'is', 'taught', 'by', 'trained', 'instructors', 'and', 'combines', 'physical', ',', 'mental', 'and', 'social', 'activities', '.', 'The', 'Paired', 'PLI\u00c9', 'Program', 'is', 'an', 'adapted', 'version', 'designed', 'for', 'pairs', 'of', 'affected', 'individuals', 'and', 'care', 'partners', '.', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'perform', 'a', 'randomized', ',', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'a', 'delayed', 'start', 'design', 'to', 'examine', 'the', 'effects', 'of', 'the', 'Paired', 'PLI\u00c9', 'Program', 'on', 'function', 'and', 'quality', 'of', 'life', 'in', 'affected', 'individuals', 'and', 'care', 'partners', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 35,
                "text": "Paired Integrative Exercise Program",
                "type": "PHYSICAL"
            },
            {
                "start": 52,
                "end": 60,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 78,
                "end": 126,
                "text": "Preventing Loss of Independence through Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 128,
                "end": 132,
                "text": "PLI\u00c9",
                "type": "PHYSICAL"
            },
            {
                "start": 191,
                "end": 199,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 318,
                "end": 337,
                "text": "Paired PLI\u00c9 Program",
                "type": "PHYSICAL"
            },
            {
                "start": 554,
                "end": 573,
                "text": "Paired PLI\u00c9 Program",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT00822198",
        "study_official_title": "The Effect of Plantar Vibration on the Progression of Peripheral Neuropathy ",
        "study_brief_summary": " The purpose of this study is to assess the effect of vibration of the plantar surface of the foot on peripheral neuropathy.",
        "text": "The Effect of Plantar Vibration on the Progression of Peripheral Neuropathy | The purpose of this study is to assess the effect of vibration of the plantar surface of the foot on peripheral neuropathy.",
        "tokens": "['The', 'Effect', 'of', 'Plantar', 'Vibration', 'on', 'the', 'Progression', 'of', 'Peripheral', 'Neuropathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effect', 'of', 'vibration', 'of', 'the', 'plantar', 'surface', 'of', 'the', 'foot', 'on', 'peripheral', 'neuropathy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 31,
                "text": "Plantar Vibration",
                "type": "OTHER"
            },
            {
                "start": 54,
                "end": 75,
                "text": "Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 175,
                "text": "vibration of the plantar surface of the foot",
                "type": "OTHER"
            },
            {
                "start": 179,
                "end": 200,
                "text": "peripheral neuropathy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03513822",
        "study_official_title": "Ketamine's Efficiency in the Treatment of Chronic Pain With an Added Inflammatory Component Exploring the Kynurenin Pathway. A Randomized, Double Blind, Placebo-controlled Trial ",
        "study_brief_summary": " The kynurenine pathway is involved in hyperalgesia. This pathway is activated by inflammation. Ketamine would interact with the kynurenine pathway and inflammation. Our working hypotheses are: the clinical effects of ketamine on neuropathic pain are greater in the presence of systemic inflammation and the mechanism of action involves an interaction on the kynurenine pathway.\n\nStudy design: Interventional randomized placebo-controlled clinical trial.\n\n\ufffcMain goals:\n\nTo show a better clinical efficacy of ketamine in chronic pain in patients with an inflammatory component.\nExplore the anti-inflammatory activity of ketamine through the Kynurenine pathway.",
        "text": "Ketamine's Efficiency in the Treatment of Chronic Pain With an Added Inflammatory Component Exploring the Kynurenin Pathway. A Randomized, Double Blind, Placebo-controlled Trial | The kynurenine pathway is involved in hyperalgesia. This pathway is activated by inflammation. Ketamine would interact with the kynurenine pathway and inflammation. Our working hypotheses are: the clinical effects of ketamine on neuropathic pain are greater in the presence of systemic inflammation and the mechanism of action involves an interaction on the kynurenine pathway.\n\nStudy design: Interventional randomized placebo-controlled clinical trial.\n\n\ufffcMain goals:\n\nTo show a better clinical efficacy of ketamine in chronic pain in patients with an inflammatory component.\nExplore the anti-inflammatory activity of ketamine through the Kynurenine pathway.",
        "tokens": "['Ketamine', \"'s\", 'Efficiency', 'in', 'the', 'Treatment', 'of', 'Chronic', 'Pain', 'With', 'an', 'Added', 'Inflammatory', 'Component', 'Exploring', 'the', 'Kynurenin', 'Pathway', '.', 'A', 'Randomized', ',', 'Double', 'Blind', ',', 'Placebo', '-', 'controlled', 'Trial', '|', 'The', 'kynurenine', 'pathway', 'is', 'involved', 'in', 'hyperalgesia', '.', 'This', 'pathway', 'is', 'activated', 'by', 'inflammation', '.', 'Ketamine', 'would', 'interact', 'with', 'the', 'kynurenine', 'pathway', 'and', 'inflammation', '.', 'Our', 'working', 'hypotheses', 'are', ':', 'the', 'clinical', 'effects', 'of', 'ketamine', 'on', 'neuropathic', 'pain', 'are', 'greater', 'in', 'the', 'presence', 'of', 'systemic', 'inflammation', 'and', 'the', 'mechanism', 'of', 'action', 'involves', 'an', 'interaction', 'on', 'the', 'kynurenine', 'pathway', '.', '\\n\\n', 'Study', 'design', ':', 'Interventional', 'randomized', 'placebo', '-', 'controlled', 'clinical', 'trial', '.', '\\n\\n', '\ufffc', 'Main', 'goals', ':', '\\n\\n', 'To', 'show', 'a', 'better', 'clinical', 'efficacy', 'of', 'ketamine', 'in', 'chronic', 'pain', 'in', 'patients', 'with', 'an', 'inflammatory', 'component', '.', '\\n', 'Explore', 'the', 'anti', '-', 'inflammatory', 'activity', 'of', 'ketamine', 'through', 'the', 'Kynurenine', 'pathway', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "Ketamine",
                "type": "DRUG"
            },
            {
                "start": 42,
                "end": 54,
                "text": "Chronic Pain",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 160,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 275,
                "end": 283,
                "text": "Ketamine",
                "type": "DRUG"
            },
            {
                "start": 397,
                "end": 405,
                "text": "ketamine",
                "type": "DRUG"
            },
            {
                "start": 409,
                "end": 425,
                "text": "neuropathic pain",
                "type": "CONDITION"
            },
            {
                "start": 599,
                "end": 606,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 687,
                "end": 695,
                "text": "ketamine",
                "type": "DRUG"
            },
            {
                "start": 699,
                "end": 711,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 798,
                "end": 806,
                "text": "ketamine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02501434",
        "study_official_title": "A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients With Significant Hemorrhage Burden ",
        "study_brief_summary": " A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden. - STUDY IS TEMPORARILY SUSPENDED WITH PLAN TO RESUME SOON. NO SAFETY CONCERNS",
        "text": "A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients With Significant Hemorrhage Burden | A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients with Significant Hemorrhage Burden. - STUDY IS TEMPORARILY SUSPENDED WITH PLAN TO RESUME SOON. NO SAFETY CONCERNS",
        "tokens": "['A', 'Blind', '-', 'adjudication', 'Multi', '-', 'center', 'Phase', 'II', 'Randomized', 'Clinical', 'Trial', 'of', 'Continuous', 'Low', '-', 'dose', 'Intravenous', 'Heparin', 'Therapy', 'in', 'Coiled', 'Low', '-', 'grade', 'Aneurysmal', 'Subarachnoid', 'Hemorrhage', 'Patients', 'With', 'Significant', 'Hemorrhage', 'Burden', '|', 'A', 'Blind', '-', 'adjudication', 'Multi', '-', 'center', 'Phase', 'II', 'Randomized', 'Clinical', 'Trial', 'of', 'Continuous', 'Low', '-', 'dose', 'Intravenous', 'Heparin', 'Therapy', 'in', 'Coiled', 'Low', '-', 'grade', 'Aneurysmal', 'Subarachnoid', 'Hemorrhage', 'Patients', 'with', 'Significant', 'Hemorrhage', 'Burden', '.', '-', 'STUDY', 'IS', 'TEMPORARILY', 'SUSPENDED', 'WITH', 'PLAN', 'TO', 'RESUME', 'SOON', '.', 'NO', 'SAFETY', 'CONCERNS']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 104,
                "end": 111,
                "text": "Heparin",
                "type": "DRUG"
            },
            {
                "start": 123,
                "end": 174,
                "text": "Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 218,
                "text": "Significant Hemorrhage Burden",
                "type": "CONDITION"
            },
            {
                "start": 325,
                "end": 332,
                "text": "Heparin",
                "type": "DRUG"
            },
            {
                "start": 344,
                "end": 395,
                "text": "Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 410,
                "end": 439,
                "text": "Significant Hemorrhage Burden",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01918384",
        "study_official_title": "Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study) ",
        "study_brief_summary": " Duchenne Muscular Dystrophy (DMD) is inherited neuromuscular disorders due to mutation in the gene that encodes critical muscle protein called dystrophin. Currently, there is no effective treatment option for the disease. A pharmacological approach by promoting mRNA translation regardless of the presence of premature stop codons by nonsense mutation, called the readthrough strategy, has been developing recently for DMD with nonsense mutation. NPC-14 is a candidate compound for the readthrough strategy, since effective readthrough activities were demonstrated in nonclinical studies. This study is a phase II study designed to assess safety, tolerability, and efficacy of NPC-14 in ambulant DMD patients with nonsense mutation that were confirmed by whole genome analysis. These goals will be accomplished by monitoring adverse events by physical examination, cardiac, pulmonary, auditory, balance, and laboratory tests as safety endpoints, and dystrophin expression in muscle biopsy as primary efficacy endpoint, muscle function (NSAA, timed test, muscle strength (QMT, MMT) , dairy activities by lifecorder), and biomarkers as secondary efficacy endpoints. The study is a randomized, double blind, placebo-controlled study in 21 DMD patients. After screening, eligible patients are allocated dynamically to weekly NPC-14 or a placebo (saline) in a 2:1 ratio and will receive study drugs for 36 weeks.",
        "text": "Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study) | Duchenne Muscular Dystrophy (DMD) is inherited neuromuscular disorders due to mutation in the gene that encodes critical muscle protein called dystrophin. Currently, there is no effective treatment option for the disease. A pharmacological approach by promoting mRNA translation regardless of the presence of premature stop codons by nonsense mutation, called the readthrough strategy, has been developing recently for DMD with nonsense mutation. NPC-14 is a candidate compound for the readthrough strategy, since effective readthrough activities were demonstrated in nonclinical studies. This study is a phase II study designed to assess safety, tolerability, and efficacy of NPC-14 in ambulant DMD patients with nonsense mutation that were confirmed by whole genome analysis. These goals will be accomplished by monitoring adverse events by physical examination, cardiac, pulmonary, auditory, balance, and laboratory tests as safety endpoints, and dystrophin expression in muscle biopsy as primary efficacy endpoint, muscle function (NSAA, timed test, muscle strength (QMT, MMT) , dairy activities by lifecorder), and biomarkers as secondary efficacy endpoints. The study is a randomized, double blind, placebo-controlled study in 21 DMD patients. After screening, eligible patients are allocated dynamically to weekly NPC-14 or a placebo (saline) in a 2:1 ratio and will receive study drugs for 36 weeks.",
        "tokens": "['Phase', 'II', 'Study', 'of', 'Nonsense', 'Readthrough', 'Compound', 'NPC-14', '(', 'Arbekacin', 'Sulfate', ')', 'to', 'Explore', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'in', 'Duchenne', 'Muscular', 'Dystrophy', 'Patients', '(', 'NORTH', 'POLE', 'DMD', 'Study', ')', '|', 'Duchenne', 'Muscular', 'Dystrophy', '(', 'DMD', ')', 'is', 'inherited', 'neuromuscular', 'disorders', 'due', 'to', 'mutation', 'in', 'the', 'gene', 'that', 'encodes', 'critical', 'muscle', 'protein', 'called', 'dystrophin', '.', 'Currently', ',', 'there', 'is', 'no', 'effective', 'treatment', 'option', 'for', 'the', 'disease', '.', 'A', 'pharmacological', 'approach', 'by', 'promoting', 'mRNA', 'translation', 'regardless', 'of', 'the', 'presence', 'of', 'premature', 'stop', 'codons', 'by', 'nonsense', 'mutation', ',', 'called', 'the', 'readthrough', 'strategy', ',', 'has', 'been', 'developing', 'recently', 'for', 'DMD', 'with', 'nonsense', 'mutation', '.', 'NPC-14', 'is', 'a', 'candidate', 'compound', 'for', 'the', 'readthrough', 'strategy', ',', 'since', 'effective', 'readthrough', 'activities', 'were', 'demonstrated', 'in', 'nonclinical', 'studies', '.', 'This', 'study', 'is', 'a', 'phase', 'II', 'study', 'designed', 'to', 'assess', 'safety', ',', 'tolerability', ',', 'and', 'efficacy', 'of', 'NPC-14', 'in', 'ambulant', 'DMD', 'patients', 'with', 'nonsense', 'mutation', 'that', 'were', 'confirmed', 'by', 'whole', 'genome', 'analysis', '.', 'These', 'goals', 'will', 'be', 'accomplished', 'by', 'monitoring', 'adverse', 'events', 'by', 'physical', 'examination', ',', 'cardiac', ',', 'pulmonary', ',', 'auditory', ',', 'balance', ',', 'and', 'laboratory', 'tests', 'as', 'safety', 'endpoints', ',', 'and', 'dystrophin', 'expression', 'in', 'muscle', 'biopsy', 'as', 'primary', 'efficacy', 'endpoint', ',', 'muscle', 'function', '(', 'NSAA', ',', 'timed', 'test', ',', 'muscle', 'strength', '(', 'QMT', ',', 'MMT', ')', ',', 'dairy', 'activities', 'by', 'lifecorder', ')', ',', 'and', 'biomarkers', 'as', 'secondary', 'efficacy', 'endpoints', '.', 'The', 'study', 'is', 'a', 'randomized', ',', 'double', 'blind', ',', 'placebo', '-', 'controlled', 'study', 'in', '21', 'DMD', 'patients', '.', 'After', 'screening', ',', 'eligible', 'patients', 'are', 'allocated', 'dynamically', 'to', 'weekly', 'NPC-14', 'or', 'a', 'placebo', '(', 'saline', ')', 'in', 'a', '2:1', 'ratio', 'and', 'will', 'receive', 'study', 'drugs', 'for', '36', 'weeks', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 48,
                "end": 54,
                "text": "NPC-14",
                "type": "DRUG"
            },
            {
                "start": 56,
                "end": 73,
                "text": "Arbekacin Sulfate",
                "type": "DRUG"
            },
            {
                "start": 124,
                "end": 151,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 186,
                "end": 213,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 215,
                "end": 218,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 605,
                "end": 608,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 633,
                "end": 639,
                "text": "NPC-14",
                "type": "DRUG"
            },
            {
                "start": 863,
                "end": 869,
                "text": "NPC-14",
                "type": "DRUG"
            },
            {
                "start": 882,
                "end": 885,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 1391,
                "end": 1398,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1422,
                "end": 1425,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 1507,
                "end": 1513,
                "text": "NPC-14",
                "type": "DRUG"
            },
            {
                "start": 1519,
                "end": 1526,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1528,
                "end": 1534,
                "text": "saline",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00253136",
        "study_official_title": "Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia ",
        "study_brief_summary": " The purpose of the study is to compare the effectiveness and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) versus placebo for the treatment of the symptoms of schizophrenia over a 12-week period.",
        "text": "Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia | The purpose of the study is to compare the effectiveness and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) versus placebo for the treatment of the symptoms of schizophrenia over a 12-week period.",
        "tokens": "['Risperidone', 'Depot', '(', 'Microspheres', ')', 'vs.', 'Placebo', 'in', 'the', 'Treatment', 'of', 'Subjects', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'and', 'safety', 'of', 'a', 'long', '-', 'acting', 'injectable', 'formulation', 'of', 'risperidone', '(', 'an', 'antipsychotic', 'medication', ')', 'versus', 'placebo', 'for', 'the', 'treatment', 'of', 'the', 'symptoms', 'of', 'schizophrenia', 'over', 'a', '12', '-', 'week', 'period', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 11,
                "text": "Risperidone",
                "type": "DRUG"
            },
            {
                "start": 37,
                "end": 44,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 79,
                "end": 92,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 206,
                "end": 217,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 222,
                "end": 246,
                "text": "antipsychotic medication",
                "type": "DRUG"
            },
            {
                "start": 255,
                "end": 262,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 300,
                "end": 313,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00330863",
        "study_official_title": "Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE) ",
        "study_brief_summary": " This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.",
        "text": "Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE) | This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms.",
        "tokens": "['Preventing', 'Relapse', ':', 'Oral', 'Antipsychotics', 'Compared', 'To', 'Injectables', ':', 'Evaluating', 'Efficacy', '(', 'PROACTIVE', ')', '|', 'This', 'study', 'is', 'designed', 'to', 'find', 'out', 'whether', 'taking', 'antipsychotic', 'medication', 'once', 'every', 'two', 'weeks', 'by', 'injection', 'compared', 'to', 'taking', 'daily', 'oral', 'medication', 'will', 'help', 'people', 'with', 'schizophrenia', 'maintain', 'better', 'control', 'of', 'their', 'symptoms', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 142,
                "end": 207,
                "text": "taking antipsychotic medication once every two weeks by injection",
                "type": "OTHER"
            },
            {
                "start": 220,
                "end": 248,
                "text": "taking daily oral medication",
                "type": "OTHER"
            },
            {
                "start": 271,
                "end": 284,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03088592",
        "study_official_title": "Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia ",
        "study_brief_summary": " The pathology of Parkinson's disease (PD) and the mechanism of Deep Brain Stimulation surgery (DBS) are not completely understood. The recording data that is used routinely as part of the procedure to map the target structures, however, may be analyzed in order to better understand the neural network dynamics in PD. The purpose of the study is to perform simultaneous neural recordings from sub-cortical structures (e.g. subthalamic nucleus [STN] or globus pallidus internus [GPi]) and the cerebral cortex. These simultaneous recordings may provide insight in the pathology of PD and the mechanism of DBS. The researchers will also study the effects of anesthesia level on neuron synchronization . Recordings with micro-ECoG grid electrodes in the cortex show improved spatial resolution and these will be used to gain better understanding of cortical network dynamics and the synchronization with subcortical structures.",
        "text": "Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia | The pathology of Parkinson's disease (PD) and the mechanism of Deep Brain Stimulation surgery (DBS) are not completely understood. The recording data that is used routinely as part of the procedure to map the target structures, however, may be analyzed in order to better understand the neural network dynamics in PD. The purpose of the study is to perform simultaneous neural recordings from sub-cortical structures (e.g. subthalamic nucleus [STN] or globus pallidus internus [GPi]) and the cerebral cortex. These simultaneous recordings may provide insight in the pathology of PD and the mechanism of DBS. The researchers will also study the effects of anesthesia level on neuron synchronization . Recordings with micro-ECoG grid electrodes in the cortex show improved spatial resolution and these will be used to gain better understanding of cortical network dynamics and the synchronization with subcortical structures.",
        "tokens": "['Electrophysiological', 'Recordings', 'of', 'Deep', 'Brain', 'Stimulation', 'in', 'the', 'Basal', 'Ganglia', '|', 'The', 'pathology', 'of', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'and', 'the', 'mechanism', 'of', 'Deep', 'Brain', 'Stimulation', 'surgery', '(', 'DBS', ')', 'are', 'not', 'completely', 'understood', '.', 'The', 'recording', 'data', 'that', 'is', 'used', 'routinely', 'as', 'part', 'of', 'the', 'procedure', 'to', 'map', 'the', 'target', 'structures', ',', 'however', ',', 'may', 'be', 'analyzed', 'in', 'order', 'to', 'better', 'understand', 'the', 'neural', 'network', 'dynamics', 'in', 'PD', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'perform', 'simultaneous', 'neural', 'recordings', 'from', 'sub', '-', 'cortical', 'structures', '(', 'e.g.', 'subthalamic', 'nucleus', '[', 'STN', ']', 'or', 'globus', 'pallidus', 'internus', '[', 'GPi', ']', ')', 'and', 'the', 'cerebral', 'cortex', '.', 'These', 'simultaneous', 'recordings', 'may', 'provide', 'insight', 'in', 'the', 'pathology', 'of', 'PD', 'and', 'the', 'mechanism', 'of', 'DBS', '.', 'The', 'researchers', 'will', 'also', 'study', 'the', 'effects', 'of', 'anesthesia', 'level', 'on', 'neuron', 'synchronization', '.', 'Recordings', 'with', 'micro', '-', 'ECoG', 'grid', 'electrodes', 'in', 'the', 'cortex', 'show', 'improved', 'spatial', 'resolution', 'and', 'these', 'will', 'be', 'used', 'to', 'gain', 'better', 'understanding', 'of', 'cortical', 'network', 'dynamics', 'and', 'the', 'synchronization', 'with', 'subcortical', 'structures', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 78,
                "text": "Deep Brain Stimulation in the Basal Ganglia",
                "type": "OTHER"
            },
            {
                "start": 98,
                "end": 117,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 121,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 174,
                "text": "Deep Brain Stimulation surgery",
                "type": "OTHER"
            },
            {
                "start": 176,
                "end": 179,
                "text": "DBS",
                "type": "OTHER"
            },
            {
                "start": 395,
                "end": 397,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 660,
                "end": 662,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 684,
                "end": 687,
                "text": "DBS",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04405596",
        "study_official_title": "Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia ",
        "study_brief_summary": " This is a randomized, placebo-controlled, double-blind study investigating whether the medication Ambroxol is safe,effectiveness and well tolerated for the treatment of Lewy Body Dementia (LBD). Currently the main treatments for patients with LBD target symptom management. However, none of the medications treat the underlying cause of the disease, which includes the accumulation of protein in the brain. Therefore, even if patients respond well to symptomatic treatment, they continue to deteriorate. Therefore, the purpose of the current study is to make sure Ambroxol is safe to take long term and to test the effects of Ambroxol in treating the cognitive impairments associated with LBD by modifying the underlying causes of the disease.\n\nThere will be a total of 15 people participating this this study, which will last 52 weeks. Over the study period patients will undergo clinical, neuropsychological and neuroimaging assessment to assess changes.",
        "text": "Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia | This is a randomized, placebo-controlled, double-blind study investigating whether the medication Ambroxol is safe,effectiveness and well tolerated for the treatment of Lewy Body Dementia (LBD). Currently the main treatments for patients with LBD target symptom management. However, none of the medications treat the underlying cause of the disease, which includes the accumulation of protein in the brain. Therefore, even if patients respond well to symptomatic treatment, they continue to deteriorate. Therefore, the purpose of the current study is to make sure Ambroxol is safe to take long term and to test the effects of Ambroxol in treating the cognitive impairments associated with LBD by modifying the underlying causes of the disease.\n\nThere will be a total of 15 people participating this this study, which will last 52 weeks. Over the study period patients will undergo clinical, neuropsychological and neuroimaging assessment to assess changes.",
        "tokens": "['Ambroxol', 'as', 'a', 'Novel', 'Disease', 'Modifying', 'Treatment', 'for', 'Lewy', 'Body', 'Dementia', '|', 'This', 'is', 'a', 'randomized', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', 'study', 'investigating', 'whether', 'the', 'medication', 'Ambroxol', 'is', 'safe', ',', 'effectiveness', 'and', 'well', 'tolerated', 'for', 'the', 'treatment', 'of', 'Lewy', 'Body', 'Dementia', '(', 'LBD', ')', '.', 'Currently', 'the', 'main', 'treatments', 'for', 'patients', 'with', 'LBD', 'target', 'symptom', 'management', '.', 'However', ',', 'none', 'of', 'the', 'medications', 'treat', 'the', 'underlying', 'cause', 'of', 'the', 'disease', ',', 'which', 'includes', 'the', 'accumulation', 'of', 'protein', 'in', 'the', 'brain', '.', 'Therefore', ',', 'even', 'if', 'patients', 'respond', 'well', 'to', 'symptomatic', 'treatment', ',', 'they', 'continue', 'to', 'deteriorate', '.', 'Therefore', ',', 'the', 'purpose', 'of', 'the', 'current', 'study', 'is', 'to', 'make', 'sure', 'Ambroxol', 'is', 'safe', 'to', 'take', 'long', 'term', 'and', 'to', 'test', 'the', 'effects', 'of', 'Ambroxol', 'in', 'treating', 'the', 'cognitive', 'impairments', 'associated', 'with', 'LBD', 'by', 'modifying', 'the', 'underlying', 'causes', 'of', 'the', 'disease', '.', '\\n\\n', 'There', 'will', 'be', 'a', 'total', 'of', '15', 'people', 'participating', 'this', 'this', 'study', ',', 'which', 'will', 'last', '52', 'weeks', '.', 'Over', 'the', 'study', 'period', 'patients', 'will', 'undergo', 'clinical', ',', 'neuropsychological', 'and', 'neuroimaging', 'assessment', 'to', 'assess', 'changes', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "Ambroxol",
                "type": "DRUG"
            },
            {
                "start": 52,
                "end": 70,
                "text": "Lewy Body Dementia",
                "type": "CONDITION"
            },
            {
                "start": 95,
                "end": 102,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 171,
                "end": 179,
                "text": "Ambroxol",
                "type": "DRUG"
            },
            {
                "start": 242,
                "end": 260,
                "text": "Lewy Body Dementia",
                "type": "CONDITION"
            },
            {
                "start": 262,
                "end": 265,
                "text": "LBD",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 319,
                "text": "LBD",
                "type": "CONDITION"
            },
            {
                "start": 637,
                "end": 645,
                "text": "Ambroxol",
                "type": "DRUG"
            },
            {
                "start": 699,
                "end": 707,
                "text": "Ambroxol",
                "type": "DRUG"
            },
            {
                "start": 724,
                "end": 745,
                "text": "cognitive impairments",
                "type": "CONDITION"
            },
            {
                "start": 762,
                "end": 765,
                "text": "LBD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02989792",
        "study_official_title": "A Study to Investigate the Genetic Variation of Dopamine Pathway Associated With the Observed Effects of a New Treatment in Former Studies in Patients With Chronic Pain ",
        "study_brief_summary": " Patients having completed former trials T1001-01 or T1001-02 will undergo one blood sampling for genotyping purposes. In addition they will compete the personality questionnaires they had completed in the former trial.",
        "text": "A Study to Investigate the Genetic Variation of Dopamine Pathway Associated With the Observed Effects of a New Treatment in Former Studies in Patients With Chronic Pain | Patients having completed former trials T1001-01 or T1001-02 will undergo one blood sampling for genotyping purposes. In addition they will compete the personality questionnaires they had completed in the former trial.",
        "tokens": "['A', 'Study', 'to', 'Investigate', 'the', 'Genetic', 'Variation', 'of', 'Dopamine', 'Pathway', 'Associated', 'With', 'the', 'Observed', 'Effects', 'of', 'a', 'New', 'Treatment', 'in', 'Former', 'Studies', 'in', 'Patients', 'With', 'Chronic', 'Pain', '|', 'Patients', 'having', 'completed', 'former', 'trials', 'T1001', '-', '01', 'or', 'T1001', '-', '02', 'will', 'undergo', 'one', 'blood', 'sampling', 'for', 'genotyping', 'purposes', '.', 'In', 'addition', 'they', 'will', 'compete', 'the', 'personality', 'questionnaires', 'they', 'had', 'completed', 'in', 'the', 'former', 'trial', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 156,
                "end": 168,
                "text": "Chronic Pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00053625",
        "study_official_title": "Deep Brain Stimulation for Parkinson's Disease Trial ",
        "study_brief_summary": " The purpose of this trial is to evaluate the effect of deep brain stimulation in the the globus pallidus (Gpi) and the subthalamic nucleus (STN) on motor, neuropsychological and psychiatric function, and quality of life in patients with Parkinson's disease.",
        "text": "Deep Brain Stimulation for Parkinson's Disease Trial | The purpose of this trial is to evaluate the effect of deep brain stimulation in the the globus pallidus (Gpi) and the subthalamic nucleus (STN) on motor, neuropsychological and psychiatric function, and quality of life in patients with Parkinson's disease.",
        "tokens": "['Deep', 'Brain', 'Stimulation', 'for', 'Parkinson', \"'s\", 'Disease', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'trial', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'deep', 'brain', 'stimulation', 'in', 'the', 'the', 'globus', 'pallidus', '(', 'Gpi', ')', 'and', 'the', 'subthalamic', 'nucleus', '(', 'STN', ')', 'on', 'motor', ',', 'neuropsychological', 'and', 'psychiatric', 'function', ',', 'and', 'quality', 'of', 'life', 'in', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 27,
                "end": 46,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 110,
                "end": 132,
                "text": "deep brain stimulation",
                "type": "OTHER"
            },
            {
                "start": 292,
                "end": 311,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04159805",
        "study_official_title": "A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis ",
        "study_brief_summary": " Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles.\n\nTAK-079 is a medicine to help people with generalized myasthenia gravis.\n\nThe main aim of this study is to check if people with generalized myasthenia gravis have side effects from 2 doses of TAK-079. Other aims are to learn if TAK-079 improves their clinical condition and lowers their autoantibody levels.\n\nAt the first visit, the study doctor will check if each person can take part. For those who can take part, participants will continue with their standard medicines for this condition during the study. Each participant will have a check-up by the study doctor.\n\nThen, the participants will have 1 of 3 treatments:\n\nA low dose of TAK-079.\nA high dose of TAK-079.\nA placebo. In this study, a placebo looks like TAK-079 but does not have any medicine in it.\n\nParticipants will not know which treatment they received, nor will their study doctors. This is to help make sure the results are more reliable.\n\nFor each treatment, participants will receive injections just under the skin, once a week for 8 weeks. The study doctors will check for side effects from the study treatments. The study doctors can stop or delay the injections in each participant if needed.\n\nThen, the study doctors will continue to check for side effects for up to 24 weeks after treatment. They will also check the clinical condition of the participants, including their autoantibody levels.",
        "text": "A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis | Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles.\n\nTAK-079 is a medicine to help people with generalized myasthenia gravis.\n\nThe main aim of this study is to check if people with generalized myasthenia gravis have side effects from 2 doses of TAK-079. Other aims are to learn if TAK-079 improves their clinical condition and lowers their autoantibody levels.\n\nAt the first visit, the study doctor will check if each person can take part. For those who can take part, participants will continue with their standard medicines for this condition during the study. Each participant will have a check-up by the study doctor.\n\nThen, the participants will have 1 of 3 treatments:\n\nA low dose of TAK-079.\nA high dose of TAK-079.\nA placebo. In this study, a placebo looks like TAK-079 but does not have any medicine in it.\n\nParticipants will not know which treatment they received, nor will their study doctors. This is to help make sure the results are more reliable.\n\nFor each treatment, participants will receive injections just under the skin, once a week for 8 weeks. The study doctors will check for side effects from the study treatments. The study doctors can stop or delay the injections in each participant if needed.\n\nThen, the study doctors will continue to check for side effects for up to 24 weeks after treatment. They will also check the clinical condition of the participants, including their autoantibody levels.",
        "tokens": "['A', 'Phase', '2', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Study', 'to', 'Evaluate', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'TAK-079', 'in', 'Patients', 'With', 'Generalized', 'Myasthenia', 'Gravis', '|', 'Myasthenia', 'gravis', 'is', 'an', 'autoimmune', 'condition', 'that', 'causes', 'muscle', 'weakness', '.', 'Autoimmune', 'means', 'the', 'body', 'makes', 'antibodies', 'that', 'attack', 'its', 'own', 'cells', 'and', 'tissues', '.', 'These', 'types', 'of', 'antibodies', 'are', 'also', 'known', 'as', 'autoantibodies', '.', 'People', 'with', 'generalized', 'myasthenia', 'gravis', 'have', 'a', 'weakness', 'in', 'many', 'muscles', '.', '\\n\\n', 'TAK-079', 'is', 'a', 'medicine', 'to', 'help', 'people', 'with', 'generalized', 'myasthenia', 'gravis', '.', '\\n\\n', 'The', 'main', 'aim', 'of', 'this', 'study', 'is', 'to', 'check', 'if', 'people', 'with', 'generalized', 'myasthenia', 'gravis', 'have', 'side', 'effects', 'from', '2', 'doses', 'of', 'TAK-079', '.', 'Other', 'aims', 'are', 'to', 'learn', 'if', 'TAK-079', 'improves', 'their', 'clinical', 'condition', 'and', 'lowers', 'their', 'autoantibody', 'levels', '.', '\\n\\n', 'At', 'the', 'first', 'visit', ',', 'the', 'study', 'doctor', 'will', 'check', 'if', 'each', 'person', 'can', 'take', 'part', '.', 'For', 'those', 'who', 'can', 'take', 'part', ',', 'participants', 'will', 'continue', 'with', 'their', 'standard', 'medicines', 'for', 'this', 'condition', 'during', 'the', 'study', '.', 'Each', 'participant', 'will', 'have', 'a', 'check', '-', 'up', 'by', 'the', 'study', 'doctor', '.', '\\n\\n', 'Then', ',', 'the', 'participants', 'will', 'have', '1', 'of', '3', 'treatments', ':', '\\n\\n', 'A', 'low', 'dose', 'of', 'TAK-079', '.', '\\n', 'A', 'high', 'dose', 'of', 'TAK-079', '.', '\\n', 'A', 'placebo', '.', 'In', 'this', 'study', ',', 'a', 'placebo', 'looks', 'like', 'TAK-079', 'but', 'does', 'not', 'have', 'any', 'medicine', 'in', 'it', '.', '\\n\\n', 'Participants', 'will', 'not', 'know', 'which', 'treatment', 'they', 'received', ',', 'nor', 'will', 'their', 'study', 'doctors', '.', 'This', 'is', 'to', 'help', 'make', 'sure', 'the', 'results', 'are', 'more', 'reliable', '.', '\\n\\n', 'For', 'each', 'treatment', ',', 'participants', 'will', 'receive', 'injections', 'just', 'under', 'the', 'skin', ',', 'once', 'a', 'week', 'for', '8', 'weeks', '.', 'The', 'study', 'doctors', 'will', 'check', 'for', 'side', 'effects', 'from', 'the', 'study', 'treatments', '.', 'The', 'study', 'doctors', 'can', 'stop', 'or', 'delay', 'the', 'injections', 'in', 'each', 'participant', 'if', 'needed', '.', '\\n\\n', 'Then', ',', 'the', 'study', 'doctors', 'will', 'continue', 'to', 'check', 'for', 'side', 'effects', 'for', 'up', 'to', '24', 'weeks', 'after', 'treatment', '.', 'They', 'will', 'also', 'check', 'the', 'clinical', 'condition', 'of', 'the', 'participants', ',', 'including', 'their', 'autoantibody', 'levels', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 23,
                "end": 30,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 98,
                "end": 105,
                "text": "TAK-079",
                "type": "DRUG"
            },
            {
                "start": 123,
                "end": 152,
                "text": "Generalized Myasthenia Gravis",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 172,
                "text": "Myasthenia gravis",
                "type": "CONDITION"
            },
            {
                "start": 383,
                "end": 412,
                "text": "generalized myasthenia gravis",
                "type": "CONDITION"
            },
            {
                "start": 447,
                "end": 454,
                "text": "TAK-079",
                "type": "DRUG"
            },
            {
                "start": 489,
                "end": 518,
                "text": "generalized myasthenia gravis",
                "type": "CONDITION"
            },
            {
                "start": 575,
                "end": 604,
                "text": "generalized myasthenia gravis",
                "type": "CONDITION"
            },
            {
                "start": 639,
                "end": 646,
                "text": "TAK-079",
                "type": "DRUG"
            },
            {
                "start": 675,
                "end": 682,
                "text": "TAK-079",
                "type": "DRUG"
            },
            {
                "start": 1084,
                "end": 1091,
                "text": "TAK-079",
                "type": "DRUG"
            },
            {
                "start": 1108,
                "end": 1115,
                "text": "TAK-079",
                "type": "DRUG"
            },
            {
                "start": 1119,
                "end": 1126,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1145,
                "end": 1152,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1164,
                "end": 1171,
                "text": "TAK-079",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02195895",
        "study_official_title": "12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide ",
        "study_brief_summary": " The purpose of this study is to determine if a year of alendronate treatment will maintain or increase bone mass density (BMD) compared to baseline BMD values in people with chronic spinal cord injury (SCI).\n\nThis study will also investigate 1) if alendronate therapy will increase bone strength in people with chronic SCI, 2) the number of participants with adverse events from alendronate, and 3) the effects of alendronate on serum markers of bone metabolism.",
        "text": "12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide | The purpose of this study is to determine if a year of alendronate treatment will maintain or increase bone mass density (BMD) compared to baseline BMD values in people with chronic spinal cord injury (SCI).\n\nThis study will also investigate 1) if alendronate therapy will increase bone strength in people with chronic SCI, 2) the number of participants with adverse events from alendronate, and 3) the effects of alendronate on serum markers of bone metabolism.",
        "tokens": "['12', 'Month', 'Open', '-', 'Label', 'Extension', 'Study', 'of', 'the', 'Effect', 'of', 'Alendronate', 'on', 'Bone', 'in', 'People', 'With', 'Chronic', 'SCI', 'Previously', 'Treated', 'With', 'Teriparatide', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'a', 'year', 'of', 'alendronate', 'treatment', 'will', 'maintain', 'or', 'increase', 'bone', 'mass', 'density', '(', 'BMD', ')', 'compared', 'to', 'baseline', 'BMD', 'values', 'in', 'people', 'with', 'chronic', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', '\\n\\n', 'This', 'study', 'will', 'also', 'investigate', '1', ')', 'if', 'alendronate', 'therapy', 'will', 'increase', 'bone', 'strength', 'in', 'people', 'with', 'chronic', 'SCI', ',', '2', ')', 'the', 'number', 'of', 'participants', 'with', 'adverse', 'events', 'from', 'alendronate', ',', 'and', '3', ')', 'the', 'effects', 'of', 'alendronate', 'on', 'serum', 'markers', 'of', 'bone', 'metabolism', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 53,
                "end": 64,
                "text": "Alendronate",
                "type": "DRUG"
            },
            {
                "start": 88,
                "end": 99,
                "text": "Chronic SCI",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 136,
                "text": "Teriparatide",
                "type": "DRUG"
            },
            {
                "start": 194,
                "end": 205,
                "text": "alendronate",
                "type": "DRUG"
            },
            {
                "start": 313,
                "end": 339,
                "text": "chronic spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 341,
                "end": 344,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 387,
                "end": 398,
                "text": "alendronate",
                "type": "DRUG"
            },
            {
                "start": 450,
                "end": 461,
                "text": "chronic SCI",
                "type": "CONDITION"
            },
            {
                "start": 518,
                "end": 529,
                "text": "alendronate",
                "type": "DRUG"
            },
            {
                "start": 553,
                "end": 564,
                "text": "alendronate",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03346265",
        "study_official_title": "Progressive Modular Rebalancing (RMP) System Rehabilitation Combined With Sensory Cues for Rehabilitation of Patients With PD: a Randomized, Controlled Trial With Crossover. ",
        "study_brief_summary": " In the present study, the investigators propose a rehabilitative program for Parkinson' disease based on the combination of a neurocognitive method, i.e. visual sensory cues, with a neurophysiological method, i.e. RMP, in a randomized controlled trial with cross-over. The rationale herein was that the RMP may globally improve patients in terms of trunk control, motor performance, muscle tone, endurance and so on, predisposing them to improvement of the gait rhythm and automaticity induced by use of the visual external cues.\n\nThe primary aim of this pilot, randomized, controlled, trial with crossover was to establish whether a 8-week exercise program focused at improving gait in people with PD was more effective than a same-duration program of standard physiotherapy. The secondary aim was to evaluate the effect on the disease's severity. At this aims investigators used a quantitative 3D motion analysis system to evaluate gait parameters and UPDRS-II and UPDR-III and H-Y staging to evaluate the severity of the disease.\n\nThe investigators hypothesised that the both exercise programs will improve standard physiotherapy, however the proposed program will yield better improvements for the people with PD.",
        "text": "Progressive Modular Rebalancing (RMP) System Rehabilitation Combined With Sensory Cues for Rehabilitation of Patients With PD: a Randomized, Controlled Trial With Crossover. | In the present study, the investigators propose a rehabilitative program for Parkinson' disease based on the combination of a neurocognitive method, i.e. visual sensory cues, with a neurophysiological method, i.e. RMP, in a randomized controlled trial with cross-over. The rationale herein was that the RMP may globally improve patients in terms of trunk control, motor performance, muscle tone, endurance and so on, predisposing them to improvement of the gait rhythm and automaticity induced by use of the visual external cues.\n\nThe primary aim of this pilot, randomized, controlled, trial with crossover was to establish whether a 8-week exercise program focused at improving gait in people with PD was more effective than a same-duration program of standard physiotherapy. The secondary aim was to evaluate the effect on the disease's severity. At this aims investigators used a quantitative 3D motion analysis system to evaluate gait parameters and UPDRS-II and UPDR-III and H-Y staging to evaluate the severity of the disease.\n\nThe investigators hypothesised that the both exercise programs will improve standard physiotherapy, however the proposed program will yield better improvements for the people with PD.",
        "tokens": "['Progressive', 'Modular', 'Rebalancing', '(', 'RMP', ')', 'System', 'Rehabilitation', 'Combined', 'With', 'Sensory', 'Cues', 'for', 'Rehabilitation', 'of', 'Patients', 'With', 'PD', ':', 'a', 'Randomized', ',', 'Controlled', 'Trial', 'With', 'Crossover', '.', '|', 'In', 'the', 'present', 'study', ',', 'the', 'investigators', 'propose', 'a', 'rehabilitative', 'program', 'for', 'Parkinson', \"'\", 'disease', 'based', 'on', 'the', 'combination', 'of', 'a', 'neurocognitive', 'method', ',', 'i.e.', 'visual', 'sensory', 'cues', ',', 'with', 'a', 'neurophysiological', 'method', ',', 'i.e.', 'RMP', ',', 'in', 'a', 'randomized', 'controlled', 'trial', 'with', 'cross', '-', 'over', '.', 'The', 'rationale', 'herein', 'was', 'that', 'the', 'RMP', 'may', 'globally', 'improve', 'patients', 'in', 'terms', 'of', 'trunk', 'control', ',', 'motor', 'performance', ',', 'muscle', 'tone', ',', 'endurance', 'and', 'so', 'on', ',', 'predisposing', 'them', 'to', 'improvement', 'of', 'the', 'gait', 'rhythm', 'and', 'automaticity', 'induced', 'by', 'use', 'of', 'the', 'visual', 'external', 'cues', '.', '\\n\\n', 'The', 'primary', 'aim', 'of', 'this', 'pilot', ',', 'randomized', ',', 'controlled', ',', 'trial', 'with', 'crossover', 'was', 'to', 'establish', 'whether', 'a', '8', '-', 'week', 'exercise', 'program', 'focused', 'at', 'improving', 'gait', 'in', 'people', 'with', 'PD', 'was', 'more', 'effective', 'than', 'a', 'same', '-', 'duration', 'program', 'of', 'standard', 'physiotherapy', '.', 'The', 'secondary', 'aim', 'was', 'to', 'evaluate', 'the', 'effect', 'on', 'the', 'disease', \"'s\", 'severity', '.', 'At', 'this', 'aims', 'investigators', 'used', 'a', 'quantitative', '3D', 'motion', 'analysis', 'system', 'to', 'evaluate', 'gait', 'parameters', 'and', 'UPDRS', '-', 'II', 'and', 'UPDR', '-', 'III', 'and', 'H', '-', 'Y', 'staging', 'to', 'evaluate', 'the', 'severity', 'of', 'the', 'disease', '.', '\\n\\n', 'The', 'investigators', 'hypothesised', 'that', 'the', 'both', 'exercise', 'programs', 'will', 'improve', 'standard', 'physiotherapy', ',', 'however', 'the', 'proposed', 'program', 'will', 'yield', 'better', 'improvements', 'for', 'the', 'people', 'with', 'PD', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 59,
                "text": "Progressive Modular Rebalancing (RMP) System Rehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 74,
                "end": 105,
                "text": "Sensory Cues for Rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 123,
                "end": 125,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 226,
                "end": 248,
                "text": "rehabilitative program",
                "type": "OTHER"
            },
            {
                "start": 253,
                "end": 271,
                "text": "Parkinson' disease",
                "type": "CONDITION"
            },
            {
                "start": 302,
                "end": 323,
                "text": "neurocognitive method",
                "type": "OTHER"
            },
            {
                "start": 330,
                "end": 349,
                "text": "visual sensory cues",
                "type": "OTHER"
            },
            {
                "start": 358,
                "end": 383,
                "text": "neurophysiological method",
                "type": "PHYSICAL"
            },
            {
                "start": 390,
                "end": 393,
                "text": "RMP",
                "type": "PHYSICAL"
            },
            {
                "start": 479,
                "end": 482,
                "text": "RMP",
                "type": "PHYSICAL"
            },
            {
                "start": 817,
                "end": 859,
                "text": "exercise program focused at improving gait",
                "type": "PHYSICAL"
            },
            {
                "start": 875,
                "end": 877,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 929,
                "end": 951,
                "text": "standard physiotherapy",
                "type": "CONTROL"
            },
            {
                "start": 1255,
                "end": 1272,
                "text": "exercise programs",
                "type": "PHYSICAL"
            },
            {
                "start": 1286,
                "end": 1308,
                "text": "standard physiotherapy",
                "type": "CONTROL"
            },
            {
                "start": 1390,
                "end": 1392,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04384172",
        "study_official_title": "Effect of Peripheral Neuromodulation on Vaginal Blood Flow ",
        "study_brief_summary": " The researchers want to see if nerve stimulation interventions cause a change in vaginal blood flow. The effect of this intervention will be compared between women who have neurogenic (spinal cord injury) or non-neurogenic dysfunction and healthy women.",
        "text": "Effect of Peripheral Neuromodulation on Vaginal Blood Flow | The researchers want to see if nerve stimulation interventions cause a change in vaginal blood flow. The effect of this intervention will be compared between women who have neurogenic (spinal cord injury) or non-neurogenic dysfunction and healthy women.",
        "tokens": "['Effect', 'of', 'Peripheral', 'Neuromodulation', 'on', 'Vaginal', 'Blood', 'Flow', '|', 'The', 'researchers', 'want', 'to', 'see', 'if', 'nerve', 'stimulation', 'interventions', 'cause', 'a', 'change', 'in', 'vaginal', 'blood', 'flow', '.', 'The', 'effect', 'of', 'this', 'intervention', 'will', 'be', 'compared', 'between', 'women', 'who', 'have', 'neurogenic', '(', 'spinal', 'cord', 'injury', ')', 'or', 'non', '-', 'neurogenic', 'dysfunction', 'and', 'healthy', 'women', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 36,
                "text": "Peripheral Neuromodulation",
                "type": "OTHER"
            },
            {
                "start": 92,
                "end": 123,
                "text": "nerve stimulation interventions",
                "type": "OTHER"
            },
            {
                "start": 234,
                "end": 295,
                "text": "neurogenic (spinal cord injury) or non-neurogenic dysfunction",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05401994",
        "study_official_title": "Screw Retained Arch Bar Versus Conventional Erich's Arch Bar in Maxillomandibular Fixation ",
        "study_brief_summary": " A randomized prospective clinical study to compare screw Retained Arch Bar and Conventional Erich's Arch Bar in Maxillomandibular Fixation",
        "text": "Screw Retained Arch Bar Versus Conventional Erich's Arch Bar in Maxillomandibular Fixation | A randomized prospective clinical study to compare screw Retained Arch Bar and Conventional Erich's Arch Bar in Maxillomandibular Fixation",
        "tokens": "['Screw', 'Retained', 'Arch', 'Bar', 'Versus', 'Conventional', 'Erich', \"'s\", 'Arch', 'Bar', 'in', 'Maxillomandibular', 'Fixation', '|', 'A', 'randomized', 'prospective', 'clinical', 'study', 'to', 'compare', 'screw', 'Retained', 'Arch', 'Bar', 'and', 'Conventional', 'Erich', \"'s\", 'Arch', 'Bar', 'in', 'Maxillomandibular', 'Fixation']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER']",
        "entities": [
            {
                "start": 0,
                "end": 23,
                "text": "Screw Retained Arch Bar",
                "type": "OTHER"
            },
            {
                "start": 31,
                "end": 60,
                "text": "Conventional Erich's Arch Bar",
                "type": "OTHER"
            },
            {
                "start": 64,
                "end": 90,
                "text": "Maxillomandibular Fixation",
                "type": "OTHER"
            },
            {
                "start": 144,
                "end": 167,
                "text": "screw Retained Arch Bar",
                "type": "OTHER"
            },
            {
                "start": 172,
                "end": 201,
                "text": "Conventional Erich's Arch Bar",
                "type": "OTHER"
            },
            {
                "start": 205,
                "end": 231,
                "text": "Maxillomandibular Fixation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03025230",
        "study_official_title": "Effectiveness of Dry Needling and Intramuscular Electrostimulation in the Treatment of Myofascial Trigger Points in Patients With Neck Pain ",
        "study_brief_summary": " Hypothesis The application of intramuscular electrostimulation will be more effectiveness than the dry needling in myofascial trigger points treatment.\n\nObjetives:\n\nTo determine the effectiveness of intramuscular electrostimulation in the treatment of trigger points of the levator scapula muscle for the improvement of pain in mechanical cervicalgia.\n\nParticipants: Subjects with diagnosed of myofascial pain syndrome in cervical region and active trigger points in levator scapulae muscle, randomly assigned to experimental or control group.\n\nIntervention: Control group: one session of dry needling in active trigger points; experimental group: one session of intramuscular stimulation in active trigger points.\n\nMain Outcomes Measures: Pain, pressure pain threshold (PPT), active cervical range of motion and strength muscle . The measures will be taken before, after and one week after the interventions.",
        "text": "Effectiveness of Dry Needling and Intramuscular Electrostimulation in the Treatment of Myofascial Trigger Points in Patients With Neck Pain | Hypothesis The application of intramuscular electrostimulation will be more effectiveness than the dry needling in myofascial trigger points treatment.\n\nObjetives:\n\nTo determine the effectiveness of intramuscular electrostimulation in the treatment of trigger points of the levator scapula muscle for the improvement of pain in mechanical cervicalgia.\n\nParticipants: Subjects with diagnosed of myofascial pain syndrome in cervical region and active trigger points in levator scapulae muscle, randomly assigned to experimental or control group.\n\nIntervention: Control group: one session of dry needling in active trigger points; experimental group: one session of intramuscular stimulation in active trigger points.\n\nMain Outcomes Measures: Pain, pressure pain threshold (PPT), active cervical range of motion and strength muscle . The measures will be taken before, after and one week after the interventions.",
        "tokens": "['Effectiveness', 'of', 'Dry', 'Needling', 'and', 'Intramuscular', 'Electrostimulation', 'in', 'the', 'Treatment', 'of', 'Myofascial', 'Trigger', 'Points', 'in', 'Patients', 'With', 'Neck', 'Pain', '|', 'Hypothesis', 'The', 'application', 'of', 'intramuscular', 'electrostimulation', 'will', 'be', 'more', 'effectiveness', 'than', 'the', 'dry', 'needling', 'in', 'myofascial', 'trigger', 'points', 'treatment', '.', '\\n\\n', 'Objetives', ':', '\\n\\n', 'To', 'determine', 'the', 'effectiveness', 'of', 'intramuscular', 'electrostimulation', 'in', 'the', 'treatment', 'of', 'trigger', 'points', 'of', 'the', 'levator', 'scapula', 'muscle', 'for', 'the', 'improvement', 'of', 'pain', 'in', 'mechanical', 'cervicalgia', '.', '\\n\\n', 'Participants', ':', 'Subjects', 'with', 'diagnosed', 'of', 'myofascial', 'pain', 'syndrome', 'in', 'cervical', 'region', 'and', 'active', 'trigger', 'points', 'in', 'levator', 'scapulae', 'muscle', ',', 'randomly', 'assigned', 'to', 'experimental', 'or', 'control', 'group', '.', '\\n\\n', 'Intervention', ':', 'Control', 'group', ':', 'one', 'session', 'of', 'dry', 'needling', 'in', 'active', 'trigger', 'points', ';', 'experimental', 'group', ':', 'one', 'session', 'of', 'intramuscular', 'stimulation', 'in', 'active', 'trigger', 'points', '.', '\\n\\n', 'Main', 'Outcomes', 'Measures', ':', 'Pain', ',', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', ',', 'active', 'cervical', 'range', 'of', 'motion', 'and', 'strength', 'muscle', '.', 'The', 'measures', 'will', 'be', 'taken', 'before', ',', 'after', 'and', 'one', 'week', 'after', 'the', 'interventions', '.']",
        "token_bio_labels": "['O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 29,
                "text": "Dry Needling",
                "type": "CONTROL"
            },
            {
                "start": 34,
                "end": 66,
                "text": "Intramuscular Electrostimulation",
                "type": "OTHER"
            },
            {
                "start": 87,
                "end": 112,
                "text": "Myofascial Trigger Points",
                "type": "CONDITION"
            },
            {
                "start": 130,
                "end": 139,
                "text": "Neck Pain",
                "type": "CONDITION"
            },
            {
                "start": 172,
                "end": 204,
                "text": "intramuscular electrostimulation",
                "type": "OTHER"
            },
            {
                "start": 241,
                "end": 253,
                "text": "dry needling",
                "type": "CONTROL"
            },
            {
                "start": 257,
                "end": 282,
                "text": "myofascial trigger points",
                "type": "CONDITION"
            },
            {
                "start": 394,
                "end": 438,
                "text": "trigger points of the levator scapula muscle",
                "type": "CONDITION"
            },
            {
                "start": 462,
                "end": 466,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 470,
                "end": 492,
                "text": "mechanical cervicalgia",
                "type": "CONDITION"
            },
            {
                "start": 536,
                "end": 560,
                "text": "myofascial pain syndrome",
                "type": "CONDITION"
            },
            {
                "start": 591,
                "end": 632,
                "text": "trigger points in levator scapulae muscle",
                "type": "CONDITION"
            },
            {
                "start": 731,
                "end": 743,
                "text": "dry needling",
                "type": "CONTROL"
            },
            {
                "start": 805,
                "end": 830,
                "text": "intramuscular stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01446601",
        "study_official_title": "Pivotal Study of the Apnex Medical\u2122 Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea ",
        "study_brief_summary": " The purpose of this study is to evaluate the benefits and risks of hypoglossal nerve stimulation with the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System as a potential therapeutic option for individuals with moderate to severe Obstructive Sleep Apnea (OSA) that have failed or do not tolerate positive airway pressure (PAP) therapy.",
        "text": "Pivotal Study of the Apnex Medical\u2122 Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea | The purpose of this study is to evaluate the benefits and risks of hypoglossal nerve stimulation with the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System as a potential therapeutic option for individuals with moderate to severe Obstructive Sleep Apnea (OSA) that have failed or do not tolerate positive airway pressure (PAP) therapy.",
        "tokens": "['Pivotal', 'Study', 'of', 'the', 'Apnex', 'Medical', '\u2122', 'Hypoglossal', 'Nerve', 'Stimulation', '(', 'HGNS', ')', 'System', 'to', 'Treat', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'benefits', 'and', 'risks', 'of', 'hypoglossal', 'nerve', 'stimulation', 'with', 'the', 'Apnex', 'Medical', 'Hypoglossal', 'Nerve', 'Stimulation', '(', 'HGNS', ')', 'System', 'as', 'a', 'potential', 'therapeutic', 'option', 'for', 'individuals', 'with', 'moderate', 'to', 'severe', 'Obstructive', 'Sleep', 'Apnea', '(', 'OSA', ')', 'that', 'have', 'failed', 'or', 'do', 'not', 'tolerate', 'positive', 'airway', 'pressure', '(', 'PAP', ')', 'therapy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 65,
                "text": "Apnex Medical\u2122 Hypoglossal Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 67,
                "end": 71,
                "text": "HGNS",
                "type": "OTHER"
            },
            {
                "start": 89,
                "end": 112,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 211,
                "text": "hypoglossal nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 221,
                "end": 264,
                "text": "Apnex Medical Hypoglossal Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 266,
                "end": 270,
                "text": "HGNS",
                "type": "OTHER"
            },
            {
                "start": 334,
                "end": 376,
                "text": "moderate to severe Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 378,
                "end": 381,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00735527",
        "study_official_title": "Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial ",
        "study_brief_summary": " Status epilepticus (SE) is a common pediatric emergency which is potentially life-threatening and requires rapid termination. Early and effective treatment is essential to prevent the morbidity and mortality associated with prolonged convulsive SE. Lorazepam is the standard of care for control of SE when administered by intra-venous (IV) route. The investigators intend to compare efficacy and adverse effect profile of intra-nasal vs. intravenous routes of administration of lorazepam. In resource poor settings, sometimes trained personnel or appropriate equipment for intra-venous cannulation is not available. Alternate routes of administration, if shown equivalent to conventional IV route, will be very useful in such settings or for out of hospital management of seizures in children.",
        "text": "Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial | Status epilepticus (SE) is a common pediatric emergency which is potentially life-threatening and requires rapid termination. Early and effective treatment is essential to prevent the morbidity and mortality associated with prolonged convulsive SE. Lorazepam is the standard of care for control of SE when administered by intra-venous (IV) route. The investigators intend to compare efficacy and adverse effect profile of intra-nasal vs. intravenous routes of administration of lorazepam. In resource poor settings, sometimes trained personnel or appropriate equipment for intra-venous cannulation is not available. Alternate routes of administration, if shown equivalent to conventional IV route, will be very useful in such settings or for out of hospital management of seizures in children.",
        "tokens": "['Intra', '-', 'Nasal', 'vs.', 'Intra', '-', 'Venous', 'Lorazepam', 'for', 'Control', 'of', 'Acute', 'Seizures', 'in', 'Children', ':', 'Prospective', 'Open', 'Labeled', 'Randomized', 'Equivalence', 'Trial', '|', 'Status', 'epilepticus', '(', 'SE', ')', 'is', 'a', 'common', 'pediatric', 'emergency', 'which', 'is', 'potentially', 'life', '-', 'threatening', 'and', 'requires', 'rapid', 'termination', '.', 'Early', 'and', 'effective', 'treatment', 'is', 'essential', 'to', 'prevent', 'the', 'morbidity', 'and', 'mortality', 'associated', 'with', 'prolonged', 'convulsive', 'SE', '.', 'Lorazepam', 'is', 'the', 'standard', 'of', 'care', 'for', 'control', 'of', 'SE', 'when', 'administered', 'by', 'intra', '-', 'venous', '(', 'IV', ')', 'route', '.', 'The', 'investigators', 'intend', 'to', 'compare', 'efficacy', 'and', 'adverse', 'effect', 'profile', 'of', 'intra', '-', 'nasal', 'vs.', 'intravenous', 'routes', 'of', 'administration', 'of', 'lorazepam', '.', 'In', 'resource', 'poor', 'settings', ',', 'sometimes', 'trained', 'personnel', 'or', 'appropriate', 'equipment', 'for', 'intra', '-', 'venous', 'cannulation', 'is', 'not', 'available', '.', 'Alternate', 'routes', 'of', 'administration', ',', 'if', 'shown', 'equivalent', 'to', 'conventional', 'IV', 'route', ',', 'will', 'be', 'very', 'useful', 'in', 'such', 'settings', 'or', 'for', 'out', 'of', 'hospital', 'management', 'of', 'seizures', 'in', 'children', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 38,
                "text": "Lorazepam",
                "type": "DRUG"
            },
            {
                "start": 54,
                "end": 68,
                "text": "Acute Seizures",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 156,
                "text": "Status epilepticus",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 160,
                "text": "SE",
                "type": "CONDITION"
            },
            {
                "start": 362,
                "end": 385,
                "text": "prolonged convulsive SE",
                "type": "CONDITION"
            },
            {
                "start": 387,
                "end": 396,
                "text": "Lorazepam",
                "type": "DRUG"
            },
            {
                "start": 436,
                "end": 438,
                "text": "SE",
                "type": "CONDITION"
            },
            {
                "start": 616,
                "end": 625,
                "text": "lorazepam",
                "type": "DRUG"
            },
            {
                "start": 910,
                "end": 918,
                "text": "seizures",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02553993",
        "study_official_title": "Comparing the Cognitive Effects of Two Exergame Balance Training Systems and Traditional Weight Shifting Training in Patients With Chronic Stroke ",
        "study_brief_summary": " The objective of this study was to: compare the training and maintenance effects of 3 balance training programs (2 kinds of exergame systems and 1 conventional weight-shifting training program) on cognitive function of subjects with chronic stroke.",
        "text": "Comparing the Cognitive Effects of Two Exergame Balance Training Systems and Traditional Weight Shifting Training in Patients With Chronic Stroke | The objective of this study was to: compare the training and maintenance effects of 3 balance training programs (2 kinds of exergame systems and 1 conventional weight-shifting training program) on cognitive function of subjects with chronic stroke.",
        "tokens": "['Comparing', 'the', 'Cognitive', 'Effects', 'of', 'Two', 'Exergame', 'Balance', 'Training', 'Systems', 'and', 'Traditional', 'Weight', 'Shifting', 'Training', 'in', 'Patients', 'With', 'Chronic', 'Stroke', '|', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', ':', 'compare', 'the', 'training', 'and', 'maintenance', 'effects', 'of', '3', 'balance', 'training', 'programs', '(', '2', 'kinds', 'of', 'exergame', 'systems', 'and', '1', 'conventional', 'weight', '-', 'shifting', 'training', 'program', ')', 'on', 'cognitive', 'function', 'of', 'subjects', 'with', 'chronic', 'stroke', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 64,
                "text": "Exergame Balance Training",
                "type": "PHYSICAL"
            },
            {
                "start": 77,
                "end": 113,
                "text": "Traditional Weight Shifting Training",
                "type": "PHYSICAL"
            },
            {
                "start": 131,
                "end": 145,
                "text": "Chronic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 259,
                "text": "balance training programs",
                "type": "PHYSICAL"
            },
            {
                "start": 272,
                "end": 288,
                "text": "exergame systems",
                "type": "PHYSICAL"
            },
            {
                "start": 308,
                "end": 332,
                "text": "weight-shifting training",
                "type": "PHYSICAL"
            },
            {
                "start": 381,
                "end": 395,
                "text": "chronic stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04231396",
        "study_official_title": "Effects of Audiobooks for Hearing Loss App as Auditory Training for Those With CI and HA Users. ",
        "study_brief_summary": " The goal of the proposed project is to create an Audiobooks for Hearing Loss (HL) App - an audiobook App that has a wide array of user-selectable features designed to provide auditory training. The effects of the Audiobooks for Hearing Loss App as Auditory Training for those With CI and HA Users was measured with a 6-week trial of using the app and measuring changes in listener abilities and adherence to the program.",
        "text": "Effects of Audiobooks for Hearing Loss App as Auditory Training for Those With CI and HA Users. | The goal of the proposed project is to create an Audiobooks for Hearing Loss (HL) App - an audiobook App that has a wide array of user-selectable features designed to provide auditory training. The effects of the Audiobooks for Hearing Loss App as Auditory Training for those With CI and HA Users was measured with a 6-week trial of using the app and measuring changes in listener abilities and adherence to the program.",
        "tokens": "['Effects', 'of', 'Audiobooks', 'for', 'Hearing', 'Loss', 'App', 'as', 'Auditory', 'Training', 'for', 'Those', 'With', 'CI', 'and', 'HA', 'Users', '.', '|', 'The', 'goal', 'of', 'the', 'proposed', 'project', 'is', 'to', 'create', 'an', 'Audiobooks', 'for', 'Hearing', 'Loss', '(', 'HL', ')', 'App', '-', 'an', 'audiobook', 'App', 'that', 'has', 'a', 'wide', 'array', 'of', 'user', '-', 'selectable', 'features', 'designed', 'to', 'provide', 'auditory', 'training', '.', 'The', 'effects', 'of', 'the', 'Audiobooks', 'for', 'Hearing', 'Loss', 'App', 'as', 'Auditory', 'Training', 'for', 'those', 'With', 'CI', 'and', 'HA', 'Users', 'was', 'measured', 'with', 'a', '6', '-', 'week', 'trial', 'of', 'using', 'the', 'app', 'and', 'measuring', 'changes', 'in', 'listener', 'abilities', 'and', 'adherence', 'to', 'the', 'program', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 42,
                "text": "Audiobooks for Hearing Loss App",
                "type": "OTHER"
            },
            {
                "start": 46,
                "end": 63,
                "text": "Auditory Training",
                "type": "OTHER"
            },
            {
                "start": 79,
                "end": 94,
                "text": "CI and HA Users",
                "type": "CONDITION"
            },
            {
                "start": 147,
                "end": 183,
                "text": "Audiobooks for Hearing Loss (HL) App",
                "type": "OTHER"
            },
            {
                "start": 273,
                "end": 290,
                "text": "auditory training",
                "type": "OTHER"
            },
            {
                "start": 311,
                "end": 342,
                "text": "Audiobooks for Hearing Loss App",
                "type": "OTHER"
            },
            {
                "start": 379,
                "end": 394,
                "text": "CI and HA Users",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00714571",
        "study_official_title": "Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI ",
        "study_brief_summary": " Memory deficits are common after traumatic brain injuries (TBI) and are characteristic of various forms of dementia, such as Alzheimer's disease and its common precursor mild cognitive impairment (MCI). This project intends to assess the efficacy of cognitive rehabilitation in these patient populations. We will also use neuroimaging (functional magnetic resonance imaging - fMRI) to assess changes in brain activity that occur following cognitive rehabilitation.",
        "text": "Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI | Memory deficits are common after traumatic brain injuries (TBI) and are characteristic of various forms of dementia, such as Alzheimer's disease and its common precursor mild cognitive impairment (MCI). This project intends to assess the efficacy of cognitive rehabilitation in these patient populations. We will also use neuroimaging (functional magnetic resonance imaging - fMRI) to assess changes in brain activity that occur following cognitive rehabilitation.",
        "tokens": "['Behavioral', 'and', 'Neuroimaging', 'Changes', 'After', 'Cognitive', 'Rehab', 'in', 'TBI', 'and', 'MCI', '|', 'Memory', 'deficits', 'are', 'common', 'after', 'traumatic', 'brain', 'injuries', '(', 'TBI', ')', 'and', 'are', 'characteristic', 'of', 'various', 'forms', 'of', 'dementia', ',', 'such', 'as', 'Alzheimer', \"'s\", 'disease', 'and', 'its', 'common', 'precursor', 'mild', 'cognitive', 'impairment', '(', 'MCI', ')', '.', 'This', 'project', 'intends', 'to', 'assess', 'the', 'efficacy', 'of', 'cognitive', 'rehabilitation', 'in', 'these', 'patient', 'populations', '.', 'We', 'will', 'also', 'use', 'neuroimaging', '(', 'functional', 'magnetic', 'resonance', 'imaging', '-', 'fMRI', ')', 'to', 'assess', 'changes', 'in', 'brain', 'activity', 'that', 'occur', 'following', 'cognitive', 'rehabilitation', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 57,
                "text": "Cognitive Rehab",
                "type": "OTHER"
            },
            {
                "start": 61,
                "end": 64,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 69,
                "end": 72,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 75,
                "end": 90,
                "text": "Memory deficits",
                "type": "CONDITION"
            },
            {
                "start": 108,
                "end": 132,
                "text": "traumatic brain injuries",
                "type": "CONDITION"
            },
            {
                "start": 134,
                "end": 137,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 190,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 219,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 270,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 272,
                "end": 275,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 325,
                "end": 349,
                "text": "cognitive rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 514,
                "end": 538,
                "text": "cognitive rehabilitation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00710424",
        "study_official_title": "A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex in the Treatment of Subjects With Pain Due to Diabetic Neuropathy ",
        "study_brief_summary": " The purpose of this study is to evaluate the efficacy of Sativex\u00ae compared with placebo in relieving pain due to Diabetic Neuropathy.",
        "text": "A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex in the Treatment of Subjects With Pain Due to Diabetic Neuropathy | The purpose of this study is to evaluate the efficacy of Sativex\u00ae compared with placebo in relieving pain due to Diabetic Neuropathy.",
        "tokens": "['A', 'Double', 'Blind', ',', 'Randomized', ',', 'Placebo', 'Controlled', ',', 'Parallel', 'Group', 'Study', 'of', 'Sativex', 'in', 'the', 'Treatment', 'of', 'Subjects', 'With', 'Pain', 'Due', 'to', 'Diabetic', 'Neuropathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'Sativex', '\u00ae', 'compared', 'with', 'placebo', 'in', 'relieving', 'pain', 'due', 'to', 'Diabetic', 'Neuropathy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 72,
                "end": 79,
                "text": "Sativex",
                "type": "DRUG"
            },
            {
                "start": 114,
                "end": 118,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 145,
                "text": "Diabetic Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 205,
                "end": 212,
                "text": "Sativex",
                "type": "DRUG"
            },
            {
                "start": 228,
                "end": 235,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 261,
                "end": 280,
                "text": "Diabetic Neuropathy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02928107",
        "study_official_title": "Addressing Barriers to Adult Hearing Healthcare ",
        "study_brief_summary": " The aim of this project is to develop evidence that can inform hearing health care best practices for adults between the ages of 65-75, and determine what level of involvement by the primary care practitioner (PCP) is required to inform and encourage adults age 65-75 to follow through with routine hearing screening.\n\nThis study also aims to evaluate the accuracy of assessment of medical conditions for which the FDA requires physician evaluation and management prior to hearing aid fitting, and determine which medical conditions should require medical evaluation prior to hearing aid fitting.\n\nThe results of this study should provide information to implement changes in health care policy to facilitate accessible and affordable hearing health care.",
        "text": "Addressing Barriers to Adult Hearing Healthcare | The aim of this project is to develop evidence that can inform hearing health care best practices for adults between the ages of 65-75, and determine what level of involvement by the primary care practitioner (PCP) is required to inform and encourage adults age 65-75 to follow through with routine hearing screening.\n\nThis study also aims to evaluate the accuracy of assessment of medical conditions for which the FDA requires physician evaluation and management prior to hearing aid fitting, and determine which medical conditions should require medical evaluation prior to hearing aid fitting.\n\nThe results of this study should provide information to implement changes in health care policy to facilitate accessible and affordable hearing health care.",
        "tokens": "['Addressing', 'Barriers', 'to', 'Adult', 'Hearing', 'Healthcare', '|', 'The', 'aim', 'of', 'this', 'project', 'is', 'to', 'develop', 'evidence', 'that', 'can', 'inform', 'hearing', 'health', 'care', 'best', 'practices', 'for', 'adults', 'between', 'the', 'ages', 'of', '65', '-', '75', ',', 'and', 'determine', 'what', 'level', 'of', 'involvement', 'by', 'the', 'primary', 'care', 'practitioner', '(', 'PCP', ')', 'is', 'required', 'to', 'inform', 'and', 'encourage', 'adults', 'age', '65', '-', '75', 'to', 'follow', 'through', 'with', 'routine', 'hearing', 'screening', '.', '\\n\\n', 'This', 'study', 'also', 'aims', 'to', 'evaluate', 'the', 'accuracy', 'of', 'assessment', 'of', 'medical', 'conditions', 'for', 'which', 'the', 'FDA', 'requires', 'physician', 'evaluation', 'and', 'management', 'prior', 'to', 'hearing', 'aid', 'fitting', ',', 'and', 'determine', 'which', 'medical', 'conditions', 'should', 'require', 'medical', 'evaluation', 'prior', 'to', 'hearing', 'aid', 'fitting', '.', '\\n\\n', 'The', 'results', 'of', 'this', 'study', 'should', 'provide', 'information', 'to', 'implement', 'changes', 'in', 'health', 'care', 'policy', 'to', 'facilitate', 'accessible', 'and', 'affordable', 'hearing', 'health', 'care', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT03288948",
        "study_official_title": "Binocular Amblyopia Treatment ",
        "study_brief_summary": " To evaluate the effectiveness of enhanced binocular amblyopia treatments in achieving a more complete and stable recovery.",
        "text": "Binocular Amblyopia Treatment | To evaluate the effectiveness of enhanced binocular amblyopia treatments in achieving a more complete and stable recovery.",
        "tokens": "['Binocular', 'Amblyopia', 'Treatment', '|', 'To', 'evaluate', 'the', 'effectiveness', 'of', 'enhanced', 'binocular', 'amblyopia', 'treatments', 'in', 'achieving', 'a', 'more', 'complete', 'and', 'stable', 'recovery', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 19,
                "text": "Binocular Amblyopia",
                "type": "CONDITION"
            },
            {
                "start": 74,
                "end": 93,
                "text": "binocular amblyopia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03232697",
        "study_official_title": "French Language Validation of the Phone Version of the Montreal Cognitive Assessment (MoCA) ",
        "study_brief_summary": " The aim of the study is to validate a french version of the 5 minutes version of the Montreal Cognitive Assessment as compared to the french full version of this test.",
        "text": "French Language Validation of the Phone Version of the Montreal Cognitive Assessment (MoCA) | The aim of the study is to validate a french version of the 5 minutes version of the Montreal Cognitive Assessment as compared to the french full version of this test.",
        "tokens": "['French', 'Language', 'Validation', 'of', 'the', 'Phone', 'Version', 'of', 'the', 'Montreal', 'Cognitive', 'Assessment', '(', 'MoCA', ')', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'validate', 'a', 'french', 'version', 'of', 'the', '5', 'minutes', 'version', 'of', 'the', 'Montreal', 'Cognitive', 'Assessment', 'as', 'compared', 'to', 'the', 'french', 'full', 'version', 'of', 'this', 'test', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT02661919",
        "study_official_title": "Assessment of the Emfit Mattress Sensor (L-4060SLC) and Monitor (DVM-GPRS-V2) and Their Acoustic and Cloud Interface Notification Capabilities as a Nocturnal Detection System for Movements Associated With Generalized Tonic-clonic Seizures. ",
        "study_brief_summary": " Sudden unexpected death in epilepsy (SUDEP) is the most important epilepsy-related mode of death. The exact mechanism of SUDEP is not known. It is thought that cardiac and respiratory factors are involved. Several ways of preventing SUDEP have been identified. These include seizure control, stress reduction, physical activity, family's ability to perform CPR, and night supervision.\n\nA mattress alarm system that monitors nocturnal seizures can alert family members of night time seizure activity. Thus, a family member could provide aid and therefore potentially avoid SUDEP. The Emfit monitor is intended to perform these tasks.\n\nInvestigators tested the Emfit mattress monitor DVM-GPRS-V2 in combination with the Emfit bed sensor L-4060SL in the epilepsy monitoring unit and were able to demonstrate that the device has a high predictive value for detection of generalized convulsions and that it can notify caregivers in the early stages of convulsive activity.\n\nThis study will further investigate the upgraded (connected to a cloud server via an integrated cellular GPRS module) Emfit mattress monitor DVM-GPRS-V2 and the upgraded Emfit mattress sensor L-4060SLC in combination with an acoustic and new cloud-based notification system.",
        "text": "Assessment of the Emfit Mattress Sensor (L-4060SLC) and Monitor (DVM-GPRS-V2) and Their Acoustic and Cloud Interface Notification Capabilities as a Nocturnal Detection System for Movements Associated With Generalized Tonic-clonic Seizures. | Sudden unexpected death in epilepsy (SUDEP) is the most important epilepsy-related mode of death. The exact mechanism of SUDEP is not known. It is thought that cardiac and respiratory factors are involved. Several ways of preventing SUDEP have been identified. These include seizure control, stress reduction, physical activity, family's ability to perform CPR, and night supervision.\n\nA mattress alarm system that monitors nocturnal seizures can alert family members of night time seizure activity. Thus, a family member could provide aid and therefore potentially avoid SUDEP. The Emfit monitor is intended to perform these tasks.\n\nInvestigators tested the Emfit mattress monitor DVM-GPRS-V2 in combination with the Emfit bed sensor L-4060SL in the epilepsy monitoring unit and were able to demonstrate that the device has a high predictive value for detection of generalized convulsions and that it can notify caregivers in the early stages of convulsive activity.\n\nThis study will further investigate the upgraded (connected to a cloud server via an integrated cellular GPRS module) Emfit mattress monitor DVM-GPRS-V2 and the upgraded Emfit mattress sensor L-4060SLC in combination with an acoustic and new cloud-based notification system.",
        "tokens": "['Assessment', 'of', 'the', 'Emfit', 'Mattress', 'Sensor', '(', 'L-4060SLC', ')', 'and', 'Monitor', '(', 'DVM', '-', 'GPRS', '-', 'V2', ')', 'and', 'Their', 'Acoustic', 'and', 'Cloud', 'Interface', 'Notification', 'Capabilities', 'as', 'a', 'Nocturnal', 'Detection', 'System', 'for', 'Movements', 'Associated', 'With', 'Generalized', 'Tonic', '-', 'clonic', 'Seizures', '.', '|', 'Sudden', 'unexpected', 'death', 'in', 'epilepsy', '(', 'SUDEP', ')', 'is', 'the', 'most', 'important', 'epilepsy', '-', 'related', 'mode', 'of', 'death', '.', 'The', 'exact', 'mechanism', 'of', 'SUDEP', 'is', 'not', 'known', '.', 'It', 'is', 'thought', 'that', 'cardiac', 'and', 'respiratory', 'factors', 'are', 'involved', '.', 'Several', 'ways', 'of', 'preventing', 'SUDEP', 'have', 'been', 'identified', '.', 'These', 'include', 'seizure', 'control', ',', 'stress', 'reduction', ',', 'physical', 'activity', ',', 'family', \"'s\", 'ability', 'to', 'perform', 'CPR', ',', 'and', 'night', 'supervision', '.', '\\n\\n', 'A', 'mattress', 'alarm', 'system', 'that', 'monitors', 'nocturnal', 'seizures', 'can', 'alert', 'family', 'members', 'of', 'night', 'time', 'seizure', 'activity', '.', 'Thus', ',', 'a', 'family', 'member', 'could', 'provide', 'aid', 'and', 'therefore', 'potentially', 'avoid', 'SUDEP', '.', 'The', 'Emfit', 'monitor', 'is', 'intended', 'to', 'perform', 'these', 'tasks', '.', '\\n\\n', 'Investigators', 'tested', 'the', 'Emfit', 'mattress', 'monitor', 'DVM', '-', 'GPRS', '-', 'V2', 'in', 'combination', 'with', 'the', 'Emfit', 'bed', 'sensor', 'L-4060SL', 'in', 'the', 'epilepsy', 'monitoring', 'unit', 'and', 'were', 'able', 'to', 'demonstrate', 'that', 'the', 'device', 'has', 'a', 'high', 'predictive', 'value', 'for', 'detection', 'of', 'generalized', 'convulsions', 'and', 'that', 'it', 'can', 'notify', 'caregivers', 'in', 'the', 'early', 'stages', 'of', 'convulsive', 'activity', '.', '\\n\\n', 'This', 'study', 'will', 'further', 'investigate', 'the', 'upgraded', '(', 'connected', 'to', 'a', 'cloud', 'server', 'via', 'an', 'integrated', 'cellular', 'GPRS', 'module', ')', 'Emfit', 'mattress', 'monitor', 'DVM', '-', 'GPRS', '-', 'V2', 'and', 'the', 'upgraded', 'Emfit', 'mattress', 'sensor', 'L-4060SLC', 'in', 'combination', 'with', 'an', 'acoustic', 'and', 'new', 'cloud', '-', 'based', 'notification', 'system', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 39,
                "text": "Emfit Mattress Sensor",
                "type": "OTHER"
            },
            {
                "start": 41,
                "end": 50,
                "text": "L-4060SLC",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 63,
                "text": "Monitor",
                "type": "OTHER"
            },
            {
                "start": 65,
                "end": 76,
                "text": "DVM-GPRS-V2",
                "type": "OTHER"
            },
            {
                "start": 205,
                "end": 238,
                "text": "Generalized Tonic-clonic Seizures",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 277,
                "text": "Sudden unexpected death in epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 284,
                "text": "SUDEP",
                "type": "CONDITION"
            },
            {
                "start": 308,
                "end": 316,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 368,
                "text": "SUDEP",
                "type": "CONDITION"
            },
            {
                "start": 475,
                "end": 480,
                "text": "SUDEP",
                "type": "CONDITION"
            },
            {
                "start": 517,
                "end": 524,
                "text": "seizure",
                "type": "CONDITION"
            },
            {
                "start": 630,
                "end": 651,
                "text": "mattress alarm system",
                "type": "OTHER"
            },
            {
                "start": 676,
                "end": 684,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 724,
                "end": 731,
                "text": "seizure",
                "type": "CONDITION"
            },
            {
                "start": 814,
                "end": 819,
                "text": "SUDEP",
                "type": "CONDITION"
            },
            {
                "start": 825,
                "end": 838,
                "text": "Emfit monitor",
                "type": "OTHER"
            },
            {
                "start": 901,
                "end": 935,
                "text": "Emfit mattress monitor DVM-GPRS-V2",
                "type": "OTHER"
            },
            {
                "start": 960,
                "end": 985,
                "text": "Emfit bed sensor L-4060SL",
                "type": "OTHER"
            },
            {
                "start": 993,
                "end": 1001,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 1108,
                "end": 1131,
                "text": "generalized convulsions",
                "type": "CONDITION"
            },
            {
                "start": 1189,
                "end": 1199,
                "text": "convulsive",
                "type": "CONDITION"
            },
            {
                "start": 1329,
                "end": 1363,
                "text": "Emfit mattress monitor DVM-GPRS-V2",
                "type": "OTHER"
            },
            {
                "start": 1381,
                "end": 1412,
                "text": "Emfit mattress sensor L-4060SLC",
                "type": "OTHER"
            },
            {
                "start": 1436,
                "end": 1484,
                "text": "acoustic and new cloud-based notification system",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01561677",
        "study_official_title": "Consequences of Obstructive Sleep Apnea Syndrome (OSAS) on the Outcome and the Survival After Ischemic Subtentorial Stroke. Impact of the Treatment With Continuous Positive Airway Pressure (CPAP) ",
        "study_brief_summary": " Obstructive Sleep Apnea Syndrome (OSAS) is associated with stroke as a risk factor but little is known about the consequences of OSAS on the outcome and the survival after stroke. The aim of the investigators study is first to evaluate the outcome and the survival of patients with stroke depending of OSAS (presence and severity of OSAS) and second to compare the outcome and survival of patients with severe OSAS depending on the treatment of the syndrome with nocturnal continuous positive airway pressure. The investigators hypothesis is that OSAS is associated with worst survival and outcome and needs to be treated at the subacute phase of stroke.",
        "text": "Consequences of Obstructive Sleep Apnea Syndrome (OSAS) on the Outcome and the Survival After Ischemic Subtentorial Stroke. Impact of the Treatment With Continuous Positive Airway Pressure (CPAP) | Obstructive Sleep Apnea Syndrome (OSAS) is associated with stroke as a risk factor but little is known about the consequences of OSAS on the outcome and the survival after stroke. The aim of the investigators study is first to evaluate the outcome and the survival of patients with stroke depending of OSAS (presence and severity of OSAS) and second to compare the outcome and survival of patients with severe OSAS depending on the treatment of the syndrome with nocturnal continuous positive airway pressure. The investigators hypothesis is that OSAS is associated with worst survival and outcome and needs to be treated at the subacute phase of stroke.",
        "tokens": "['Consequences', 'of', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', '(', 'OSAS', ')', 'on', 'the', 'Outcome', 'and', 'the', 'Survival', 'After', 'Ischemic', 'Subtentorial', 'Stroke', '.', 'Impact', 'of', 'the', 'Treatment', 'With', 'Continuous', 'Positive', 'Airway', 'Pressure', '(', 'CPAP', ')', '|', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', '(', 'OSAS', ')', 'is', 'associated', 'with', 'stroke', 'as', 'a', 'risk', 'factor', 'but', 'little', 'is', 'known', 'about', 'the', 'consequences', 'of', 'OSAS', 'on', 'the', 'outcome', 'and', 'the', 'survival', 'after', 'stroke', '.', 'The', 'aim', 'of', 'the', 'investigators', 'study', 'is', 'first', 'to', 'evaluate', 'the', 'outcome', 'and', 'the', 'survival', 'of', 'patients', 'with', 'stroke', 'depending', 'of', 'OSAS', '(', 'presence', 'and', 'severity', 'of', 'OSAS', ')', 'and', 'second', 'to', 'compare', 'the', 'outcome', 'and', 'survival', 'of', 'patients', 'with', 'severe', 'OSAS', 'depending', 'on', 'the', 'treatment', 'of', 'the', 'syndrome', 'with', 'nocturnal', 'continuous', 'positive', 'airway', 'pressure', '.', 'The', 'investigators', 'hypothesis', 'is', 'that', 'OSAS', 'is', 'associated', 'with', 'worst', 'survival', 'and', 'outcome', 'and', 'needs', 'to', 'be', 'treated', 'at', 'the', 'subacute', 'phase', 'of', 'stroke', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 48,
                "text": "Obstructive Sleep Apnea Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 50,
                "end": 54,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 94,
                "end": 122,
                "text": "Ischemic Subtentorial Stroke",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 188,
                "text": "Continuous Positive Airway Pressure",
                "type": "OTHER"
            },
            {
                "start": 190,
                "end": 194,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 198,
                "end": 230,
                "text": "Obstructive Sleep Apnea Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 232,
                "end": 236,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 257,
                "end": 263,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 327,
                "end": 331,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 370,
                "end": 376,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 480,
                "end": 486,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 500,
                "end": 504,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 531,
                "end": 535,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 608,
                "end": 612,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 671,
                "end": 706,
                "text": "continuous positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 745,
                "end": 749,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 827,
                "end": 851,
                "text": "subacute phase of stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01156311",
        "study_official_title": "An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFN\u03b2) or Glatiramer Acetate (GA) ",
        "study_brief_summary": " The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFN\u00df) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).",
        "text": "An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFN\u03b2) or Glatiramer Acetate (GA) | The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFN\u00df) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Multicenter', 'Study', 'in', 'Subjects', 'With', 'Relapsing', '-', 'Remitting', 'Multiple', 'Sclerosis', 'to', 'Evaluate', 'the', 'Safety', 'of', '240', 'mg', 'BG00012', 'TID', 'Administered', 'as', 'Add', '-', 'On', 'Therapy', 'to', 'Beta', 'Interferons', '(', 'IFN\u03b2', ')', 'or', 'Glatiramer', 'Acetate', '(', 'GA', ')', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'BG00012', '(', 'dimethyl', 'fumarate', ')', 'administered', 'in', 'combination', 'with', 'interferon', 'b', '(', 'IFN\u00df', ')', 'or', 'glatiramer', 'acetate', '(', 'GA', ')', 'in', 'participants', 'with', 'relapsing', '-', 'remitting', 'multiple', 'sclerosis', '(', 'RRMS', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 88,
                "text": "Relapsing-Remitting Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 122,
                "end": 129,
                "text": "BG00012",
                "type": "DRUG"
            },
            {
                "start": 168,
                "end": 184,
                "text": "Beta Interferons",
                "type": "DRUG"
            },
            {
                "start": 186,
                "end": 190,
                "text": "IFN\u03b2",
                "type": "DRUG"
            },
            {
                "start": 195,
                "end": 213,
                "text": "Glatiramer Acetate",
                "type": "DRUG"
            },
            {
                "start": 215,
                "end": 217,
                "text": "GA",
                "type": "DRUG"
            },
            {
                "start": 302,
                "end": 309,
                "text": "BG00012",
                "type": "DRUG"
            },
            {
                "start": 311,
                "end": 328,
                "text": "dimethyl fumarate",
                "type": "DRUG"
            },
            {
                "start": 363,
                "end": 375,
                "text": "interferon b",
                "type": "DRUG"
            },
            {
                "start": 377,
                "end": 381,
                "text": "IFN\u00df",
                "type": "DRUG"
            },
            {
                "start": 386,
                "end": 404,
                "text": "glatiramer acetate",
                "type": "DRUG"
            },
            {
                "start": 406,
                "end": 408,
                "text": "GA",
                "type": "DRUG"
            },
            {
                "start": 431,
                "end": 469,
                "text": "relapsing-remitting multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 471,
                "end": 475,
                "text": "RRMS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03526991",
        "study_official_title": "Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease. ",
        "study_brief_summary": " Parkinson Disease (PD) patients experience a variety of motor issues such as walking difficulties, loss of balance, and freezing while walking, which impacts their quality of life. Some symptoms, like freezing of gait (FOG), do not respond to medications typically used to treat PD. Current surgical procedures used to alleviate PD symptoms also do not always improve FOG. Since many traditional therapies have failed for the treatment of FOG, researchers have proposed the use of newer treatments. Recent research in animal models and clinical human data using SCS has produced promising results, specifically showing improvement in FOG with the use of SCS in patients with PD.\n\nThe purpose of this study is to evaluate the effectiveness of spinal cord stimulation (SCS) for the management of freezing of gait (FOG) that does not respond to conventional treatments in subjects with Parkinson's disease (PD). The investigators hypothesize that SCS significantly decreases FOG episodes in patients with PD.\n\nAssess the safety, tolerability and preliminary evidence of effectiveness of upper thoracic spinal cord stimulation for freezing of gait in Parkinson's (PD) patients.\nExplore the effects of two SCS programming paradigms on motor, nonmotor and quality of life measures in PD patients with freezing of gait.",
        "text": "Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease. | Parkinson Disease (PD) patients experience a variety of motor issues such as walking difficulties, loss of balance, and freezing while walking, which impacts their quality of life. Some symptoms, like freezing of gait (FOG), do not respond to medications typically used to treat PD. Current surgical procedures used to alleviate PD symptoms also do not always improve FOG. Since many traditional therapies have failed for the treatment of FOG, researchers have proposed the use of newer treatments. Recent research in animal models and clinical human data using SCS has produced promising results, specifically showing improvement in FOG with the use of SCS in patients with PD.\n\nThe purpose of this study is to evaluate the effectiveness of spinal cord stimulation (SCS) for the management of freezing of gait (FOG) that does not respond to conventional treatments in subjects with Parkinson's disease (PD). The investigators hypothesize that SCS significantly decreases FOG episodes in patients with PD.\n\nAssess the safety, tolerability and preliminary evidence of effectiveness of upper thoracic spinal cord stimulation for freezing of gait in Parkinson's (PD) patients.\nExplore the effects of two SCS programming paradigms on motor, nonmotor and quality of life measures in PD patients with freezing of gait.",
        "tokens": "['Exploring', 'the', 'Effects', 'of', 'Spinal', 'Cord', 'Stimulation', 'in', 'Parkinson', \"'s\", 'Disease', '.', '|', 'Parkinson', 'Disease', '(', 'PD', ')', 'patients', 'experience', 'a', 'variety', 'of', 'motor', 'issues', 'such', 'as', 'walking', 'difficulties', ',', 'loss', 'of', 'balance', ',', 'and', 'freezing', 'while', 'walking', ',', 'which', 'impacts', 'their', 'quality', 'of', 'life', '.', 'Some', 'symptoms', ',', 'like', 'freezing', 'of', 'gait', '(', 'FOG', ')', ',', 'do', 'not', 'respond', 'to', 'medications', 'typically', 'used', 'to', 'treat', 'PD', '.', 'Current', 'surgical', 'procedures', 'used', 'to', 'alleviate', 'PD', 'symptoms', 'also', 'do', 'not', 'always', 'improve', 'FOG', '.', 'Since', 'many', 'traditional', 'therapies', 'have', 'failed', 'for', 'the', 'treatment', 'of', 'FOG', ',', 'researchers', 'have', 'proposed', 'the', 'use', 'of', 'newer', 'treatments', '.', 'Recent', 'research', 'in', 'animal', 'models', 'and', 'clinical', 'human', 'data', 'using', 'SCS', 'has', 'produced', 'promising', 'results', ',', 'specifically', 'showing', 'improvement', 'in', 'FOG', 'with', 'the', 'use', 'of', 'SCS', 'in', 'patients', 'with', 'PD', '.', '\\n\\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'spinal', 'cord', 'stimulation', '(', 'SCS', ')', 'for', 'the', 'management', 'of', 'freezing', 'of', 'gait', '(', 'FOG', ')', 'that', 'does', 'not', 'respond', 'to', 'conventional', 'treatments', 'in', 'subjects', 'with', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', '.', 'The', 'investigators', 'hypothesize', 'that', 'SCS', 'significantly', 'decreases', 'FOG', 'episodes', 'in', 'patients', 'with', 'PD', '.', '\\n\\n', 'Assess', 'the', 'safety', ',', 'tolerability', 'and', 'preliminary', 'evidence', 'of', 'effectiveness', 'of', 'upper', 'thoracic', 'spinal', 'cord', 'stimulation', 'for', 'freezing', 'of', 'gait', 'in', 'Parkinson', \"'s\", '(', 'PD', ')', 'patients', '.', '\\n', 'Explore', 'the', 'effects', 'of', 'two', 'SCS', 'programming', 'paradigms', 'on', 'motor', ',', 'nonmotor', 'and', 'quality', 'of', 'life', 'measures', 'in', 'PD', 'patients', 'with', 'freezing', 'of', 'gait', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 48,
                "text": "Spinal Cord Stimulation",
                "type": "OTHER"
            },
            {
                "start": 52,
                "end": 71,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 75,
                "end": 92,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 94,
                "end": 96,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 217,
                "text": "freezing while walking",
                "type": "CONDITION"
            },
            {
                "start": 276,
                "end": 292,
                "text": "freezing of gait",
                "type": "CONDITION"
            },
            {
                "start": 294,
                "end": 297,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 356,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 404,
                "end": 406,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 443,
                "end": 446,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 514,
                "end": 517,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 637,
                "end": 640,
                "text": "SCS",
                "type": "OTHER"
            },
            {
                "start": 709,
                "end": 712,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 729,
                "end": 732,
                "text": "SCS",
                "type": "OTHER"
            },
            {
                "start": 750,
                "end": 752,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 817,
                "end": 840,
                "text": "spinal cord stimulation",
                "type": "OTHER"
            },
            {
                "start": 842,
                "end": 845,
                "text": "SCS",
                "type": "OTHER"
            },
            {
                "start": 869,
                "end": 885,
                "text": "freezing of gait",
                "type": "CONDITION"
            },
            {
                "start": 887,
                "end": 890,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 958,
                "end": 977,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 979,
                "end": 981,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1019,
                "end": 1022,
                "text": "SCS",
                "type": "OTHER"
            },
            {
                "start": 1047,
                "end": 1050,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 1077,
                "end": 1079,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1159,
                "end": 1197,
                "text": "upper thoracic spinal cord stimulation",
                "type": "OTHER"
            },
            {
                "start": 1202,
                "end": 1218,
                "text": "freezing of gait",
                "type": "CONDITION"
            },
            {
                "start": 1222,
                "end": 1233,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 1235,
                "end": 1237,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1276,
                "end": 1279,
                "text": "SCS",
                "type": "OTHER"
            },
            {
                "start": 1353,
                "end": 1355,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1370,
                "end": 1386,
                "text": "freezing of gait",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00001785",
        "study_official_title": "Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a ",
        "study_brief_summary": " HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body. HTLV-1 has been associated with leukemia and lymphoma. In addition, approximately 1% of all patients infected with HTLV-1 develops a condition known as HTLV-1 associated myelopathy (HAM) / tropical spastic paraparesis (TSP).\n\nCurrently there is no clearly defined, effective treatment for patients with HAM/TSP. Steroids have been used as therapy but have only been able to provide temporary relief of symptoms. Human interferon is a small protein released from different kinds of cells in the body. Interferon has been known to have antiviral and immunological effects and has been used to treat hepatitis and multiple sclerosis. Interferon Beta is released from cells called fibroblasts. These cells play a role in the production of connective tissue.\n\nThe purpose of this study is to evaluate the possible role of recombinant interferon beta (Avonex) in treatment of HAM/TSP. The study is broken into three phases, a pre-treatment phase, a treatment phase, and a post-treatment phase. The total duration of the study will be 44 weeks.\n\nPatients participating in this study will receive injections of Avonex 1 to 2 times a week. Throughout the study patients will regularly submit blood samples and undergo diagnostic tests such as MRI and measures of somatosensory evoked potentials.",
        "text": "Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a | HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body. HTLV-1 has been associated with leukemia and lymphoma. In addition, approximately 1% of all patients infected with HTLV-1 develops a condition known as HTLV-1 associated myelopathy (HAM) / tropical spastic paraparesis (TSP).\n\nCurrently there is no clearly defined, effective treatment for patients with HAM/TSP. Steroids have been used as therapy but have only been able to provide temporary relief of symptoms. Human interferon is a small protein released from different kinds of cells in the body. Interferon has been known to have antiviral and immunological effects and has been used to treat hepatitis and multiple sclerosis. Interferon Beta is released from cells called fibroblasts. These cells play a role in the production of connective tissue.\n\nThe purpose of this study is to evaluate the possible role of recombinant interferon beta (Avonex) in treatment of HAM/TSP. The study is broken into three phases, a pre-treatment phase, a treatment phase, and a post-treatment phase. The total duration of the study will be 44 weeks.\n\nPatients participating in this study will receive injections of Avonex 1 to 2 times a week. Throughout the study patients will regularly submit blood samples and undergo diagnostic tests such as MRI and measures of somatosensory evoked potentials.",
        "tokens": "['Combined', 'Virological', 'and', 'Immunological', 'Evaluation', 'of', 'Treatment', 'of', 'Patients', 'With', 'Early', 'HTLV-1', '-', 'Associated', 'Myelopathy', 'With', 'Recombinant', 'Human', 'Interferon', 'Beta-1a', '|', 'HTLV', 'stands', 'for', 'human', 'T', 'cell', 'leukemia', 'virus', '.', 'HTLV-1', 'is', 'a', 'virus', 'that', 'attacks', 'specific', 'kinds', 'of', 'white', 'blood', 'cells', 'called', 'T', 'cells', '.', 'T', 'cells', 'are', 'part', 'of', 'the', 'natural', 'defense', 'system', 'of', 'the', 'body', '.', 'HTLV-1', 'has', 'been', 'associated', 'with', 'leukemia', 'and', 'lymphoma', '.', 'In', 'addition', ',', 'approximately', '1', '%', 'of', 'all', 'patients', 'infected', 'with', 'HTLV-1', 'develops', 'a', 'condition', 'known', 'as', 'HTLV-1', 'associated', 'myelopathy', '(', 'HAM', ')', '/', 'tropical', 'spastic', 'paraparesis', '(', 'TSP', ')', '.', '\\n\\n', 'Currently', 'there', 'is', 'no', 'clearly', 'defined', ',', 'effective', 'treatment', 'for', 'patients', 'with', 'HAM', '/', 'TSP', '.', 'Steroids', 'have', 'been', 'used', 'as', 'therapy', 'but', 'have', 'only', 'been', 'able', 'to', 'provide', 'temporary', 'relief', 'of', 'symptoms', '.', 'Human', 'interferon', 'is', 'a', 'small', 'protein', 'released', 'from', 'different', 'kinds', 'of', 'cells', 'in', 'the', 'body', '.', 'Interferon', 'has', 'been', 'known', 'to', 'have', 'antiviral', 'and', 'immunological', 'effects', 'and', 'has', 'been', 'used', 'to', 'treat', 'hepatitis', 'and', 'multiple', 'sclerosis', '.', 'Interferon', 'Beta', 'is', 'released', 'from', 'cells', 'called', 'fibroblasts', '.', 'These', 'cells', 'play', 'a', 'role', 'in', 'the', 'production', 'of', 'connective', 'tissue', '.', '\\n\\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'possible', 'role', 'of', 'recombinant', 'interferon', 'beta', '(', 'Avonex', ')', 'in', 'treatment', 'of', 'HAM', '/', 'TSP', '.', 'The', 'study', 'is', 'broken', 'into', 'three', 'phases', ',', 'a', 'pre', '-', 'treatment', 'phase', ',', 'a', 'treatment', 'phase', ',', 'and', 'a', 'post', '-', 'treatment', 'phase', '.', 'The', 'total', 'duration', 'of', 'the', 'study', 'will', 'be', '44', 'weeks', '.', '\\n\\n', 'Patients', 'participating', 'in', 'this', 'study', 'will', 'receive', 'injections', 'of', 'Avonex', '1', 'to', '2', 'times', 'a', 'week', '.', 'Throughout', 'the', 'study', 'patients', 'will', 'regularly', 'submit', 'blood', 'samples', 'and', 'undergo', 'diagnostic', 'tests', 'such', 'as', 'MRI', 'and', 'measures', 'of', 'somatosensory', 'evoked', 'potentials', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 80,
                "end": 114,
                "text": "Early HTLV-1-Associated Myelopathy",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 156,
                "text": "Recombinant Human Interferon Beta-1a",
                "type": "DRUG"
            },
            {
                "start": 159,
                "end": 163,
                "text": "HTLV",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 202,
                "text": "human T cell leukemia virus",
                "type": "CONDITION"
            },
            {
                "start": 204,
                "end": 210,
                "text": "HTLV-1",
                "type": "CONDITION"
            },
            {
                "start": 347,
                "end": 353,
                "text": "HTLV-1",
                "type": "CONDITION"
            },
            {
                "start": 462,
                "end": 468,
                "text": "HTLV-1",
                "type": "CONDITION"
            },
            {
                "start": 499,
                "end": 527,
                "text": "HTLV-1 associated myelopathy",
                "type": "CONDITION"
            },
            {
                "start": 529,
                "end": 532,
                "text": "HAM",
                "type": "CONDITION"
            },
            {
                "start": 536,
                "end": 564,
                "text": "tropical spastic paraparesis",
                "type": "CONDITION"
            },
            {
                "start": 566,
                "end": 569,
                "text": "TSP",
                "type": "CONDITION"
            },
            {
                "start": 650,
                "end": 657,
                "text": "HAM/TSP",
                "type": "CONDITION"
            },
            {
                "start": 978,
                "end": 993,
                "text": "Interferon Beta",
                "type": "DRUG"
            },
            {
                "start": 1164,
                "end": 1191,
                "text": "recombinant interferon beta",
                "type": "DRUG"
            },
            {
                "start": 1193,
                "end": 1199,
                "text": "Avonex",
                "type": "DRUG"
            },
            {
                "start": 1217,
                "end": 1224,
                "text": "HAM/TSP",
                "type": "CONDITION"
            },
            {
                "start": 1450,
                "end": 1456,
                "text": "Avonex",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00101426",
        "study_official_title": "This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.",
        "study_brief_summary": null,
        "text": "This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.",
        "tokens": "['This', 'is', 'a', 'safety', 'and', 'efficacy', 'trial', 'of', 'ranirestat(AS-3201', ')', 'which', 'is', 'an', 'aldose', 'reductase', 'inhibitor', 'in', 'patients', 'with', 'diabetic', 'sensorimotor', 'polyneuropathy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 57,
                "text": "ranirestat(AS-3201",
                "type": "DRUG"
            },
            {
                "start": 71,
                "end": 97,
                "text": "aldose reductase inhibitor",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 123,
                "text": "diabetic",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 151,
                "text": "sensorimotor polyneuropathy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00987688",
        "study_official_title": "Multi-centre Randomised Trial to Evaluate the Effect of Early Hypothermia on Neurological Function in Patients With Severe Traumatic Brain Injury. Including Renal Sub Study ",
        "study_brief_summary": " Traumatic brain injury (TBI) is a leading cause of death and long term disability, particularly in young adults. Studies from Australia have shown that approximately half of those with severe traumatic brain injury will be severely disabled or dead 6 months post injury. Given the young age of many patients with severe TBI and the long term prevalence of major disability, the economic and more importantly the social cost to the community is very high.\n\nPre-hospital and hospital management of patients with severe brain injury focuses on prevention of additional injury due primarily to lack of oxygen and insufficient blood pressure. This includes optimising sedation and ventilation, maintaining the fluid balance and draining Cerebrospinal Fluid (CSF) and performing surgery where appropriate. In recent years there has been a research focus on specific pharmacologic interventions, however, to date, there has been no treatment that has been associated with improvement of neurological outcomes.\n\nOne treatment that shows promise is the application of hypothermia (cooling). This treatment is commonly used in Australia to decrease brain injury in patients with brain injury following out-of-hospital cardiac arrest. Cooling is thought to protect the brain using a number of mechanisms. There have been a number of animal studies that have looked at how cooling is protective and also some clinical research that suggests some benefit. However at the current time there is insufficient evidence to provide enough proof that cooling should be used routinely for patients with brain injury and like all treatments there can be some risks and side effects.\n\nThe POLAR trial has been developed to investigate whether early cooling of patients with severe traumatic brain injury is associated with better outcomes. It is a randomised controlled trial, which is a type of trial that provides the highest quality of evidence.\n\nThe null hypothesis is that there is no difference in the proportion of favourable neurological outcomes six months after severe traumatic brain injury in patients treated with early and sustained hypothermia, compared to standard normothermic management.",
        "text": "Multi-centre Randomised Trial to Evaluate the Effect of Early Hypothermia on Neurological Function in Patients With Severe Traumatic Brain Injury. Including Renal Sub Study | Traumatic brain injury (TBI) is a leading cause of death and long term disability, particularly in young adults. Studies from Australia have shown that approximately half of those with severe traumatic brain injury will be severely disabled or dead 6 months post injury. Given the young age of many patients with severe TBI and the long term prevalence of major disability, the economic and more importantly the social cost to the community is very high.\n\nPre-hospital and hospital management of patients with severe brain injury focuses on prevention of additional injury due primarily to lack of oxygen and insufficient blood pressure. This includes optimising sedation and ventilation, maintaining the fluid balance and draining Cerebrospinal Fluid (CSF) and performing surgery where appropriate. In recent years there has been a research focus on specific pharmacologic interventions, however, to date, there has been no treatment that has been associated with improvement of neurological outcomes.\n\nOne treatment that shows promise is the application of hypothermia (cooling). This treatment is commonly used in Australia to decrease brain injury in patients with brain injury following out-of-hospital cardiac arrest. Cooling is thought to protect the brain using a number of mechanisms. There have been a number of animal studies that have looked at how cooling is protective and also some clinical research that suggests some benefit. However at the current time there is insufficient evidence to provide enough proof that cooling should be used routinely for patients with brain injury and like all treatments there can be some risks and side effects.\n\nThe POLAR trial has been developed to investigate whether early cooling of patients with severe traumatic brain injury is associated with better outcomes. It is a randomised controlled trial, which is a type of trial that provides the highest quality of evidence.\n\nThe null hypothesis is that there is no difference in the proportion of favourable neurological outcomes six months after severe traumatic brain injury in patients treated with early and sustained hypothermia, compared to standard normothermic management.",
        "tokens": "['Multi', '-', 'centre', 'Randomised', 'Trial', 'to', 'Evaluate', 'the', 'Effect', 'of', 'Early', 'Hypothermia', 'on', 'Neurological', 'Function', 'in', 'Patients', 'With', 'Severe', 'Traumatic', 'Brain', 'Injury', '.', 'Including', 'Renal', 'Sub', 'Study', '|', 'Traumatic', 'brain', 'injury', '(', 'TBI', ')', 'is', 'a', 'leading', 'cause', 'of', 'death', 'and', 'long', 'term', 'disability', ',', 'particularly', 'in', 'young', 'adults', '.', 'Studies', 'from', 'Australia', 'have', 'shown', 'that', 'approximately', 'half', 'of', 'those', 'with', 'severe', 'traumatic', 'brain', 'injury', 'will', 'be', 'severely', 'disabled', 'or', 'dead', '6', 'months', 'post', 'injury', '.', 'Given', 'the', 'young', 'age', 'of', 'many', 'patients', 'with', 'severe', 'TBI', 'and', 'the', 'long', 'term', 'prevalence', 'of', 'major', 'disability', ',', 'the', 'economic', 'and', 'more', 'importantly', 'the', 'social', 'cost', 'to', 'the', 'community', 'is', 'very', 'high', '.', '\\n\\n', 'Pre', '-', 'hospital', 'and', 'hospital', 'management', 'of', 'patients', 'with', 'severe', 'brain', 'injury', 'focuses', 'on', 'prevention', 'of', 'additional', 'injury', 'due', 'primarily', 'to', 'lack', 'of', 'oxygen', 'and', 'insufficient', 'blood', 'pressure', '.', 'This', 'includes', 'optimising', 'sedation', 'and', 'ventilation', ',', 'maintaining', 'the', 'fluid', 'balance', 'and', 'draining', 'Cerebrospinal', 'Fluid', '(', 'CSF', ')', 'and', 'performing', 'surgery', 'where', 'appropriate', '.', 'In', 'recent', 'years', 'there', 'has', 'been', 'a', 'research', 'focus', 'on', 'specific', 'pharmacologic', 'interventions', ',', 'however', ',', 'to', 'date', ',', 'there', 'has', 'been', 'no', 'treatment', 'that', 'has', 'been', 'associated', 'with', 'improvement', 'of', 'neurological', 'outcomes', '.', '\\n\\n', 'One', 'treatment', 'that', 'shows', 'promise', 'is', 'the', 'application', 'of', 'hypothermia', '(', 'cooling', ')', '.', 'This', 'treatment', 'is', 'commonly', 'used', 'in', 'Australia', 'to', 'decrease', 'brain', 'injury', 'in', 'patients', 'with', 'brain', 'injury', 'following', 'out', '-', 'of', '-', 'hospital', 'cardiac', 'arrest', '.', 'Cooling', 'is', 'thought', 'to', 'protect', 'the', 'brain', 'using', 'a', 'number', 'of', 'mechanisms', '.', 'There', 'have', 'been', 'a', 'number', 'of', 'animal', 'studies', 'that', 'have', 'looked', 'at', 'how', 'cooling', 'is', 'protective', 'and', 'also', 'some', 'clinical', 'research', 'that', 'suggests', 'some', 'benefit', '.', 'However', 'at', 'the', 'current', 'time', 'there', 'is', 'insufficient', 'evidence', 'to', 'provide', 'enough', 'proof', 'that', 'cooling', 'should', 'be', 'used', 'routinely', 'for', 'patients', 'with', 'brain', 'injury', 'and', 'like', 'all', 'treatments', 'there', 'can', 'be', 'some', 'risks', 'and', 'side', 'effects', '.', '\\n\\n', 'The', 'POLAR', 'trial', 'has', 'been', 'developed', 'to', 'investigate', 'whether', 'early', 'cooling', 'of', 'patients', 'with', 'severe', 'traumatic', 'brain', 'injury', 'is', 'associated', 'with', 'better', 'outcomes', '.', 'It', 'is', 'a', 'randomised', 'controlled', 'trial', ',', 'which', 'is', 'a', 'type', 'of', 'trial', 'that', 'provides', 'the', 'highest', 'quality', 'of', 'evidence', '.', '\\n\\n', 'The', 'null', 'hypothesis', 'is', 'that', 'there', 'is', 'no', 'difference', 'in', 'the', 'proportion', 'of', 'favourable', 'neurological', 'outcomes', 'six', 'months', 'after', 'severe', 'traumatic', 'brain', 'injury', 'in', 'patients', 'treated', 'with', 'early', 'and', 'sustained', 'hypothermia', ',', 'compared', 'to', 'standard', 'normothermic', 'management', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 62,
                "end": 73,
                "text": "Hypothermia",
                "type": "OTHER"
            },
            {
                "start": 116,
                "end": 145,
                "text": "Severe Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 197,
                "text": "Traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 199,
                "end": 202,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 360,
                "end": 389,
                "text": "severe traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 488,
                "end": 498,
                "text": "severe TBI",
                "type": "CONDITION"
            },
            {
                "start": 685,
                "end": 704,
                "text": "severe brain injury",
                "type": "CONDITION"
            },
            {
                "start": 1234,
                "end": 1245,
                "text": "hypothermia",
                "type": "OTHER"
            },
            {
                "start": 1247,
                "end": 1254,
                "text": "cooling",
                "type": "OTHER"
            },
            {
                "start": 1344,
                "end": 1356,
                "text": "brain injury",
                "type": "CONDITION"
            },
            {
                "start": 1399,
                "end": 1406,
                "text": "Cooling",
                "type": "OTHER"
            },
            {
                "start": 1536,
                "end": 1543,
                "text": "cooling",
                "type": "OTHER"
            },
            {
                "start": 1706,
                "end": 1713,
                "text": "cooling",
                "type": "OTHER"
            },
            {
                "start": 1757,
                "end": 1769,
                "text": "brain injury",
                "type": "CONDITION"
            },
            {
                "start": 1901,
                "end": 1908,
                "text": "cooling",
                "type": "OTHER"
            },
            {
                "start": 1926,
                "end": 1955,
                "text": "severe traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 2224,
                "end": 2253,
                "text": "severe traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 2299,
                "end": 2310,
                "text": "hypothermia",
                "type": "OTHER"
            },
            {
                "start": 2324,
                "end": 2356,
                "text": "standard normothermic management",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00298623",
        "study_official_title": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. ",
        "study_brief_summary": " The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).",
        "text": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome. | The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', 'to', 'Assess', 'the', 'Efficacy', 'and', 'Safety', 'of', 'XP13512', 'in', 'Patients', 'With', 'Restless', 'Legs', 'Syndrome', '.', '|', 'The', 'primary', 'objective', 'of', 'this', 'trial', 'is', 'to', 'assess', 'the', 'efficacy', 'of', 'XP13512', 'taken', 'once', 'daily', 'compared', 'to', 'placebo', 'for', 'the', 'treatment', 'of', 'patients', 'suffering', 'from', 'Restless', 'Legs', 'Syndrome', '(', 'RLS', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 90,
                "end": 97,
                "text": "XP13512",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 137,
                "text": "Restless Legs Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 206,
                "end": 213,
                "text": "XP13512",
                "type": "DRUG"
            },
            {
                "start": 243,
                "end": 250,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 296,
                "end": 318,
                "text": "Restless Legs Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 320,
                "end": 323,
                "text": "RLS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00842816",
        "study_official_title": "A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept\u00ae) ",
        "study_brief_summary": " This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept\u00ae (donepezil) per day. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo. All eligible subjects will be provided with bottles of 10 mg Aricept (donepezil) during the study drug administration part of the study.",
        "text": "A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept\u00ae) | This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept\u00ae (donepezil) per day. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo. All eligible subjects will be provided with bottles of 10 mg Aricept (donepezil) during the study drug administration part of the study.",
        "tokens": "['A', 'Double', '-', 'Blind', 'Placebo', '-', 'Controlled', 'Preliminary', 'Study', 'of', 'the', 'Efficacy', ',', 'Safety', 'and', 'Tolerability', 'of', 'ST101', 'Tablets', 'in', 'the', 'Treatment', 'of', 'Alzheimer', \"'s\", 'Disease', 'in', 'Subjects', 'Concurrently', 'Receiving', 'Donepezil', '(', 'Aricept', '\u00ae', ')', '|', 'This', 'study', 'will', 'investigate', 'the', 'ability', 'of', 'ST101', 'to', 'improve', 'memory', 'in', 'people', 'with', 'Alzheimer', \"'s\", 'disease', 'who', 'currently', 'receive', '10', 'mg', 'Aricept', '\u00ae', '(', 'donepezil', ')', 'per', 'day', '.', 'This', 'study', 'also', 'will', 'examine', 'the', 'safety', 'and', 'tolerability', 'of', 'the', 'drug', '.', 'This', 'study', 'is', 'evaluating', '3', 'different', 'dose', 'levels', 'of', 'ST101', 'and', 'placebo', '.', 'Patients', 'will', 'have', 'a', '1', 'in', '4', 'chance', 'of', 'getting', 'placebo', '.', 'All', 'eligible', 'subjects', 'will', 'be', 'provided', 'with', 'bottles', 'of', '10', 'mg', 'Aricept', '(', 'donepezil', ')', 'during', 'the', 'study', 'drug', 'administration', 'part', 'of', 'the', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 22,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 96,
                "end": 101,
                "text": "ST101",
                "type": "DRUG"
            },
            {
                "start": 130,
                "end": 149,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 185,
                "end": 194,
                "text": "Donepezil",
                "type": "DRUG"
            },
            {
                "start": 196,
                "end": 203,
                "text": "Aricept",
                "type": "DRUG"
            },
            {
                "start": 251,
                "end": 256,
                "text": "ST101",
                "type": "DRUG"
            },
            {
                "start": 290,
                "end": 309,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 338,
                "end": 345,
                "text": "Aricept",
                "type": "DRUG"
            },
            {
                "start": 348,
                "end": 357,
                "text": "donepezil",
                "type": "DRUG"
            },
            {
                "start": 490,
                "end": 495,
                "text": "ST101",
                "type": "DRUG"
            },
            {
                "start": 500,
                "end": 507,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 555,
                "end": 562,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 625,
                "end": 632,
                "text": "Aricept",
                "type": "DRUG"
            },
            {
                "start": 634,
                "end": 643,
                "text": "donepezil",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02708485",
        "study_official_title": "Evaluating the Impact of Physical Exercise on Mild Alzheimer's Disease in a Randomized Clinical Trial: Quantification With 18F -FDG and 11C- AcAc PET Imaging ",
        "study_brief_summary": " The aim of this study is to evaluate the effect of a 3-month walking program on brain energy metabolism in patient with mild Alzheimer's disease (AD). Two groups of sedentary patients with mild AD are followed and compared over a 3-month period of time: Control (non-active) and walking (from 15 to 45 minutes of exercise on a treadmill, 3 times a week for 12 weeks) groups. All the participants are evaluated on their cognition, brain volumes (MRI) and brain fuel consumption (PET scan with 18-FDG and 11C-AcAc) at the beginning and at the end of the study.",
        "text": "Evaluating the Impact of Physical Exercise on Mild Alzheimer's Disease in a Randomized Clinical Trial: Quantification With 18F -FDG and 11C- AcAc PET Imaging | The aim of this study is to evaluate the effect of a 3-month walking program on brain energy metabolism in patient with mild Alzheimer's disease (AD). Two groups of sedentary patients with mild AD are followed and compared over a 3-month period of time: Control (non-active) and walking (from 15 to 45 minutes of exercise on a treadmill, 3 times a week for 12 weeks) groups. All the participants are evaluated on their cognition, brain volumes (MRI) and brain fuel consumption (PET scan with 18-FDG and 11C-AcAc) at the beginning and at the end of the study.",
        "tokens": "['Evaluating', 'the', 'Impact', 'of', 'Physical', 'Exercise', 'on', 'Mild', 'Alzheimer', \"'s\", 'Disease', 'in', 'a', 'Randomized', 'Clinical', 'Trial', ':', 'Quantification', 'With', '18F', '-FDG', 'and', '11C-', 'AcAc', 'PET', 'Imaging', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'a', '3', '-', 'month', 'walking', 'program', 'on', 'brain', 'energy', 'metabolism', 'in', 'patient', 'with', 'mild', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', '.', 'Two', 'groups', 'of', 'sedentary', 'patients', 'with', 'mild', 'AD', 'are', 'followed', 'and', 'compared', 'over', 'a', '3', '-', 'month', 'period', 'of', 'time', ':', 'Control', '(', 'non', '-', 'active', ')', 'and', 'walking', '(', 'from', '15', 'to', '45', 'minutes', 'of', 'exercise', 'on', 'a', 'treadmill', ',', '3', 'times', 'a', 'week', 'for', '12', 'weeks', ')', 'groups', '.', 'All', 'the', 'participants', 'are', 'evaluated', 'on', 'their', 'cognition', ',', 'brain', 'volumes', '(', 'MRI', ')', 'and', 'brain', 'fuel', 'consumption', '(', 'PET', 'scan', 'with', '18', '-', 'FDG', 'and', '11C', '-', 'AcAc', ')', 'at', 'the', 'beginning', 'and', 'at', 'the', 'end', 'of', 'the', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 42,
                "text": "Physical Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 46,
                "end": 70,
                "text": "Mild Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 236,
                "text": "walking program",
                "type": "PHYSICAL"
            },
            {
                "start": 280,
                "end": 304,
                "text": "mild Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 306,
                "end": 308,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 356,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 423,
                "end": 433,
                "text": "non-active",
                "type": "CONTROL"
            },
            {
                "start": 439,
                "end": 446,
                "text": "walking",
                "type": "PHYSICAL"
            },
            {
                "start": 473,
                "end": 496,
                "text": "exercise on a treadmill",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT01437644",
        "study_official_title": "Post-operative Pain in Children With Cerebral Palsy Following Major Hip Surgery: a Double Blind Randomised Placebo Controlled Trial of Pre-operative Botulinum Toxin Type A ",
        "study_brief_summary": " Cerebral palsy is common. It affects approximately 3 per 1000 children. Hip displacement due to muscle tightness (spasticity) occurs in up to half of the more severely affected children, and many of these children require major (bony) hip surgery. After bony hip surgery the management of pain is very difficult, as spasticity tends to increase and causes painful spasms which are difficult to control. Botulinum Toxin injections are known to reduce spasticity and therefore should also reduce pain. These injections take at least a week to work, but the effects can last for months. Botulinum Toxin is already an established treatment for chronic hip pain prior to surgery. The investigators aim to find out whether Botulinum Toxin injections can reduce post-operative pain. The identification of the level of pain can be challenging because most of these children are unable to communicate verbally. The investigators are therefore using a validated pain scoring tool that was designed especially for such children. This study will be the first to describe fully the pain experience of children with cerebral palsy undergoing this type of major surgery. The investigators will compare Botulinum Toxin injections with placebo (non-active) injections. There is a high emotional and financial burden on the families of these children. Families describe high levels of emotional distress around the time of surgery, particularly when their child is in pain. Difficulty with pain control post operatively may delay discharge from hospital and parental return to work. It causes disrupted sleep for the child and family and may delay the child's return to school. The results of this study will be shared with professionals and families at international conferences and in scientific and popular (patient-based) publications. This study cannot be undertaken in adults with cerebral palsy as they only rarely undergo this sort of surgery.",
        "text": "Post-operative Pain in Children With Cerebral Palsy Following Major Hip Surgery: a Double Blind Randomised Placebo Controlled Trial of Pre-operative Botulinum Toxin Type A | Cerebral palsy is common. It affects approximately 3 per 1000 children. Hip displacement due to muscle tightness (spasticity) occurs in up to half of the more severely affected children, and many of these children require major (bony) hip surgery. After bony hip surgery the management of pain is very difficult, as spasticity tends to increase and causes painful spasms which are difficult to control. Botulinum Toxin injections are known to reduce spasticity and therefore should also reduce pain. These injections take at least a week to work, but the effects can last for months. Botulinum Toxin is already an established treatment for chronic hip pain prior to surgery. The investigators aim to find out whether Botulinum Toxin injections can reduce post-operative pain. The identification of the level of pain can be challenging because most of these children are unable to communicate verbally. The investigators are therefore using a validated pain scoring tool that was designed especially for such children. This study will be the first to describe fully the pain experience of children with cerebral palsy undergoing this type of major surgery. The investigators will compare Botulinum Toxin injections with placebo (non-active) injections. There is a high emotional and financial burden on the families of these children. Families describe high levels of emotional distress around the time of surgery, particularly when their child is in pain. Difficulty with pain control post operatively may delay discharge from hospital and parental return to work. It causes disrupted sleep for the child and family and may delay the child's return to school. The results of this study will be shared with professionals and families at international conferences and in scientific and popular (patient-based) publications. This study cannot be undertaken in adults with cerebral palsy as they only rarely undergo this sort of surgery.",
        "tokens": "['Post', '-', 'operative', 'Pain', 'in', 'Children', 'With', 'Cerebral', 'Palsy', 'Following', 'Major', 'Hip', 'Surgery', ':', 'a', 'Double', 'Blind', 'Randomised', 'Placebo', 'Controlled', 'Trial', 'of', 'Pre', '-', 'operative', 'Botulinum', 'Toxin', 'Type', 'A', '|', 'Cerebral', 'palsy', 'is', 'common', '.', 'It', 'affects', 'approximately', '3', 'per', '1000', 'children', '.', 'Hip', 'displacement', 'due', 'to', 'muscle', 'tightness', '(', 'spasticity', ')', 'occurs', 'in', 'up', 'to', 'half', 'of', 'the', 'more', 'severely', 'affected', 'children', ',', 'and', 'many', 'of', 'these', 'children', 'require', 'major', '(', 'bony', ')', 'hip', 'surgery', '.', 'After', 'bony', 'hip', 'surgery', 'the', 'management', 'of', 'pain', 'is', 'very', 'difficult', ',', 'as', 'spasticity', 'tends', 'to', 'increase', 'and', 'causes', 'painful', 'spasms', 'which', 'are', 'difficult', 'to', 'control', '.', 'Botulinum', 'Toxin', 'injections', 'are', 'known', 'to', 'reduce', 'spasticity', 'and', 'therefore', 'should', 'also', 'reduce', 'pain', '.', 'These', 'injections', 'take', 'at', 'least', 'a', 'week', 'to', 'work', ',', 'but', 'the', 'effects', 'can', 'last', 'for', 'months', '.', 'Botulinum', 'Toxin', 'is', 'already', 'an', 'established', 'treatment', 'for', 'chronic', 'hip', 'pain', 'prior', 'to', 'surgery', '.', 'The', 'investigators', 'aim', 'to', 'find', 'out', 'whether', 'Botulinum', 'Toxin', 'injections', 'can', 'reduce', 'post', '-', 'operative', 'pain', '.', 'The', 'identification', 'of', 'the', 'level', 'of', 'pain', 'can', 'be', 'challenging', 'because', 'most', 'of', 'these', 'children', 'are', 'unable', 'to', 'communicate', 'verbally', '.', 'The', 'investigators', 'are', 'therefore', 'using', 'a', 'validated', 'pain', 'scoring', 'tool', 'that', 'was', 'designed', 'especially', 'for', 'such', 'children', '.', 'This', 'study', 'will', 'be', 'the', 'first', 'to', 'describe', 'fully', 'the', 'pain', 'experience', 'of', 'children', 'with', 'cerebral', 'palsy', 'undergoing', 'this', 'type', 'of', 'major', 'surgery', '.', 'The', 'investigators', 'will', 'compare', 'Botulinum', 'Toxin', 'injections', 'with', 'placebo', '(', 'non', '-', 'active', ')', 'injections', '.', 'There', 'is', 'a', 'high', 'emotional', 'and', 'financial', 'burden', 'on', 'the', 'families', 'of', 'these', 'children', '.', 'Families', 'describe', 'high', 'levels', 'of', 'emotional', 'distress', 'around', 'the', 'time', 'of', 'surgery', ',', 'particularly', 'when', 'their', 'child', 'is', 'in', 'pain', '.', 'Difficulty', 'with', 'pain', 'control', 'post', 'operatively', 'may', 'delay', 'discharge', 'from', 'hospital', 'and', 'parental', 'return', 'to', 'work', '.', 'It', 'causes', 'disrupted', 'sleep', 'for', 'the', 'child', 'and', 'family', 'and', 'may', 'delay', 'the', 'child', \"'s\", 'return', 'to', 'school', '.', 'The', 'results', 'of', 'this', 'study', 'will', 'be', 'shared', 'with', 'professionals', 'and', 'families', 'at', 'international', 'conferences', 'and', 'in', 'scientific', 'and', 'popular', '(', 'patient', '-', 'based', ')', 'publications', '.', 'This', 'study', 'can', 'not', 'be', 'undertaken', 'in', 'adults', 'with', 'cerebral', 'palsy', 'as', 'they', 'only', 'rarely', 'undergo', 'this', 'sort', 'of', 'surgery', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 19,
                "text": "Post-operative Pain",
                "type": "CONDITION"
            },
            {
                "start": 37,
                "end": 51,
                "text": "Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 62,
                "end": 79,
                "text": "Major Hip Surgery",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 114,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 149,
                "end": 171,
                "text": "Botulinum Toxin Type A",
                "type": "DRUG"
            },
            {
                "start": 174,
                "end": 188,
                "text": "Cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 288,
                "end": 298,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 396,
                "end": 420,
                "text": "major (bony) hip surgery",
                "type": "CONDITION"
            },
            {
                "start": 428,
                "end": 444,
                "text": "bony hip surgery",
                "type": "CONDITION"
            },
            {
                "start": 463,
                "end": 467,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 490,
                "end": 500,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 577,
                "end": 592,
                "text": "Botulinum Toxin",
                "type": "DRUG"
            },
            {
                "start": 624,
                "end": 634,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 668,
                "end": 672,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 758,
                "end": 773,
                "text": "Botulinum Toxin",
                "type": "DRUG"
            },
            {
                "start": 814,
                "end": 830,
                "text": "chronic hip pain",
                "type": "CONDITION"
            },
            {
                "start": 891,
                "end": 906,
                "text": "Botulinum Toxin",
                "type": "DRUG"
            },
            {
                "start": 929,
                "end": 948,
                "text": "post-operative pain",
                "type": "CONDITION"
            },
            {
                "start": 985,
                "end": 989,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1126,
                "end": 1130,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1243,
                "end": 1247,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1276,
                "end": 1290,
                "text": "cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 1361,
                "end": 1376,
                "text": "Botulinum Toxin",
                "type": "DRUG"
            },
            {
                "start": 1393,
                "end": 1424,
                "text": "placebo (non-active) injections",
                "type": "CONTROL"
            },
            {
                "start": 1624,
                "end": 1628,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1646,
                "end": 1650,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 2043,
                "end": 2057,
                "text": "cerebral palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00994695",
        "study_official_title": "A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians ",
        "study_brief_summary": " Primary objective:\n\nTo assess the immunogenicity of the Mencevax ACW135 polysaccharide vaccine at 28 days (+6days) post vaccination in 2-4, 5-14, 15-29 year age groups and compare the immunogenicity between these age groups.\n\nSecondary Objectives:\n\nTo estimate the incidence of common adverse events following immunization (AEFI) of GSK Nm ACW135 polysaccharide vaccine at 1h, 1d, 2d, 3d, 7d and 28 days post-vaccination\nTo assess the persistence of antibody against meningitis A, C and W135 at 11 and 23 months post vaccination in 2-4, 5-14, 15-29 year age groups\n\nStudy site:Two rural communities (Kebele) in Butajira district, Ethiopia.\n\nMethods:\n\nPhase II, open and parallel safety and immunogenicity trial.\n234 younger children (2-4 years), 145 older children (5-14 years) and 33 adults (15-29 years of age) were randomly selected from the demographic surveillance database and enrolled after screening and consenting.\nStudy participant received Mencevax ACW polysaccharide vaccine 50 mg in 0.5ml subcutaneously.\nBlood samples for measuring SBA titres were collected at pre vaccination and on day 28 (+6 days) post vaccination.\nActive follow up for AEFI on post vaccination day 0, 1, 2, 3, 7, & 28.\nPrimary end point was vaccine response defined as sero-conversion (in subjects initially seronegative) or a 4 fold increase (in subjects initially seropositive) in serum bactericidal antibodies (SBA) against serogroups Men A, C and W135) on post vaccination day 28. In addition seroconversion was assessed by ELISA Men A IgG on day 0 and day 28 post vaccination.\nSecondary endpoints were incidence of general and local symptoms and other adverse events following immunisation during the post vaccination period day 0 to 28 and immune persistence on post vaccination month-11 and month-23.\n\nResults:\n\nNo significant difference in the incidence of general or local AEFI was observed between the age groups\nThe statistical analysis for the Immunogenicity data is in progress",
        "text": "A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians | Primary objective:\n\nTo assess the immunogenicity of the Mencevax ACW135 polysaccharide vaccine at 28 days (+6days) post vaccination in 2-4, 5-14, 15-29 year age groups and compare the immunogenicity between these age groups.\n\nSecondary Objectives:\n\nTo estimate the incidence of common adverse events following immunization (AEFI) of GSK Nm ACW135 polysaccharide vaccine at 1h, 1d, 2d, 3d, 7d and 28 days post-vaccination\nTo assess the persistence of antibody against meningitis A, C and W135 at 11 and 23 months post vaccination in 2-4, 5-14, 15-29 year age groups\n\nStudy site:Two rural communities (Kebele) in Butajira district, Ethiopia.\n\nMethods:\n\nPhase II, open and parallel safety and immunogenicity trial.\n234 younger children (2-4 years), 145 older children (5-14 years) and 33 adults (15-29 years of age) were randomly selected from the demographic surveillance database and enrolled after screening and consenting.\nStudy participant received Mencevax ACW polysaccharide vaccine 50 mg in 0.5ml subcutaneously.\nBlood samples for measuring SBA titres were collected at pre vaccination and on day 28 (+6 days) post vaccination.\nActive follow up for AEFI on post vaccination day 0, 1, 2, 3, 7, & 28.\nPrimary end point was vaccine response defined as sero-conversion (in subjects initially seronegative) or a 4 fold increase (in subjects initially seropositive) in serum bactericidal antibodies (SBA) against serogroups Men A, C and W135) on post vaccination day 28. In addition seroconversion was assessed by ELISA Men A IgG on day 0 and day 28 post vaccination.\nSecondary endpoints were incidence of general and local symptoms and other adverse events following immunisation during the post vaccination period day 0 to 28 and immune persistence on post vaccination month-11 and month-23.\n\nResults:\n\nNo significant difference in the incidence of general or local AEFI was observed between the age groups\nThe statistical analysis for the Immunogenicity data is in progress",
        "tokens": "['A', 'Phase', 'II', 'Open', 'and', 'Parallel', 'Safety', ',', 'Immunogenicity', 'and', 'Reactogenicity', 'Trial', 'of', 'Mencevax', 'ACW135', 'Polysaccharide', 'Vaccine', 'Comparing', 'Three', 'Groups', ':', '2', '-', '4', 'Year', ',', '5', '-', '14', 'Year', 'and', '15', '-', '29', 'Year', 'Old', 'Ethiopians', '|', 'Primary', 'objective', ':', '\\n\\n', 'To', 'assess', 'the', 'immunogenicity', 'of', 'the', 'Mencevax', 'ACW135', 'polysaccharide', 'vaccine', 'at', '28', 'days', '(', '+6days', ')', 'post', 'vaccination', 'in', '2', '-', '4', ',', '5', '-', '14', ',', '15', '-', '29', 'year', 'age', 'groups', 'and', 'compare', 'the', 'immunogenicity', 'between', 'these', 'age', 'groups', '.', '\\n\\n', 'Secondary', 'Objectives', ':', '\\n\\n', 'To', 'estimate', 'the', 'incidence', 'of', 'common', 'adverse', 'events', 'following', 'immunization', '(', 'AEFI', ')', 'of', 'GSK', 'Nm', 'ACW135', 'polysaccharide', 'vaccine', 'at', '1h', ',', '1d', ',', '2d', ',', '3d', ',', '7d', 'and', '28', 'days', 'post', '-', 'vaccination', '\\n', 'To', 'assess', 'the', 'persistence', 'of', 'antibody', 'against', 'meningitis', 'A', ',', 'C', 'and', 'W135', 'at', '11', 'and', '23', 'months', 'post', 'vaccination', 'in', '2', '-', '4', ',', '5', '-', '14', ',', '15', '-', '29', 'year', 'age', 'groups', '\\n\\n', 'Study', 'site', ':', 'Two', 'rural', 'communities', '(', 'Kebele', ')', 'in', 'Butajira', 'district', ',', 'Ethiopia', '.', '\\n\\n', 'Methods', ':', '\\n\\n', 'Phase', 'II', ',', 'open', 'and', 'parallel', 'safety', 'and', 'immunogenicity', 'trial', '.', '\\n', '234', 'younger', 'children', '(', '2', '-', '4', 'years', ')', ',', '145', 'older', 'children', '(', '5', '-', '14', 'years', ')', 'and', '33', 'adults', '(', '15', '-', '29', 'years', 'of', 'age', ')', 'were', 'randomly', 'selected', 'from', 'the', 'demographic', 'surveillance', 'database', 'and', 'enrolled', 'after', 'screening', 'and', 'consenting', '.', '\\n', 'Study', 'participant', 'received', 'Mencevax', 'ACW', 'polysaccharide', 'vaccine', '50', 'mg', 'in', '0.5ml', 'subcutaneously', '.', '\\n', 'Blood', 'samples', 'for', 'measuring', 'SBA', 'titres', 'were', 'collected', 'at', 'pre', 'vaccination', 'and', 'on', 'day', '28', '(', '+6', 'days', ')', 'post', 'vaccination', '.', '\\n', 'Active', 'follow', 'up', 'for', 'AEFI', 'on', 'post', 'vaccination', 'day', '0', ',', '1', ',', '2', ',', '3', ',', '7', ',', '&', '28', '.', '\\n', 'Primary', 'end', 'point', 'was', 'vaccine', 'response', 'defined', 'as', 'sero', '-', 'conversion', '(', 'in', 'subjects', 'initially', 'seronegative', ')', 'or', 'a', '4', 'fold', 'increase', '(', 'in', 'subjects', 'initially', 'seropositive', ')', 'in', 'serum', 'bactericidal', 'antibodies', '(', 'SBA', ')', 'against', 'serogroups', 'Men', 'A', ',', 'C', 'and', 'W135', ')', 'on', 'post', 'vaccination', 'day', '28', '.', 'In', 'addition', 'seroconversion', 'was', 'assessed', 'by', 'ELISA', 'Men', 'A', 'IgG', 'on', 'day', '0', 'and', 'day', '28', 'post', 'vaccination', '.', '\\n', 'Secondary', 'endpoints', 'were', 'incidence', 'of', 'general', 'and', 'local', 'symptoms', 'and', 'other', 'adverse', 'events', 'following', 'immunisation', 'during', 'the', 'post', 'vaccination', 'period', 'day', '0', 'to', '28', 'and', 'immune', 'persistence', 'on', 'post', 'vaccination', 'month-11', 'and', 'month-23', '.', '\\n\\n', 'Results', ':', '\\n\\n', 'No', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'general', 'or', 'local', 'AEFI', 'was', 'observed', 'between', 'the', 'age', 'groups', '\\n', 'The', 'statistical', 'analysis', 'for', 'the', 'Immunogenicity', 'data', 'is', 'in', 'progress']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 80,
                "end": 118,
                "text": "Mencevax ACW135 Polysaccharide Vaccine",
                "type": "DRUG"
            },
            {
                "start": 257,
                "end": 295,
                "text": "Mencevax ACW135 polysaccharide vaccine",
                "type": "DRUG"
            },
            {
                "start": 541,
                "end": 570,
                "text": "ACW135 polysaccharide vaccine",
                "type": "DRUG"
            },
            {
                "start": 668,
                "end": 692,
                "text": "meningitis A, C and W135",
                "type": "CONDITION"
            },
            {
                "start": 1152,
                "end": 1187,
                "text": "Mencevax ACW polysaccharide vaccine",
                "type": "DRUG"
            },
            {
                "start": 1624,
                "end": 1641,
                "text": "Men A, C and W135",
                "type": "CONDITION"
            },
            {
                "start": 1720,
                "end": 1725,
                "text": "Men A",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04183998",
        "study_official_title": "Trans-spinal Electrical Stimulation to Restore Upper Extremity Functions in Individuals With Traumatic Brain Injury (TBI) or Spinal Cord Injury (SCI). ",
        "study_brief_summary": " The objective of this research study is to find the efficacy of trans-spinal electrical stimulation, a non-invasive neurostimulation method to modulate the functions of spinal cord neurocircuits, on improving upper-extremity functions such as reaching and grasping in individuals suffering with traumatic brain injury (TBI) or cervical spinal cord injury (SCI); and to find the physiological changes in the neuromuscular systems after this new intervention with high-resolution electrophysiology and biomedical imaging.",
        "text": "Trans-spinal Electrical Stimulation to Restore Upper Extremity Functions in Individuals With Traumatic Brain Injury (TBI) or Spinal Cord Injury (SCI). | The objective of this research study is to find the efficacy of trans-spinal electrical stimulation, a non-invasive neurostimulation method to modulate the functions of spinal cord neurocircuits, on improving upper-extremity functions such as reaching and grasping in individuals suffering with traumatic brain injury (TBI) or cervical spinal cord injury (SCI); and to find the physiological changes in the neuromuscular systems after this new intervention with high-resolution electrophysiology and biomedical imaging.",
        "tokens": "['Trans', '-', 'spinal', 'Electrical', 'Stimulation', 'to', 'Restore', 'Upper', 'Extremity', 'Functions', 'in', 'Individuals', 'With', 'Traumatic', 'Brain', 'Injury', '(', 'TBI', ')', 'or', 'Spinal', 'Cord', 'Injury', '(', 'SCI', ')', '.', '|', 'The', 'objective', 'of', 'this', 'research', 'study', 'is', 'to', 'find', 'the', 'efficacy', 'of', 'trans', '-', 'spinal', 'electrical', 'stimulation', ',', 'a', 'non', '-', 'invasive', 'neurostimulation', 'method', 'to', 'modulate', 'the', 'functions', 'of', 'spinal', 'cord', 'neurocircuits', ',', 'on', 'improving', 'upper', '-', 'extremity', 'functions', 'such', 'as', 'reaching', 'and', 'grasping', 'in', 'individuals', 'suffering', 'with', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', 'or', 'cervical', 'spinal', 'cord', 'injury', '(', 'SCI', ')', ';', 'and', 'to', 'find', 'the', 'physiological', 'changes', 'in', 'the', 'neuromuscular', 'systems', 'after', 'this', 'new', 'intervention', 'with', 'high', '-', 'resolution', 'electrophysiology', 'and', 'biomedical', 'imaging', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 35,
                "text": "Trans-spinal Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 93,
                "end": 115,
                "text": "Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 117,
                "end": 120,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 125,
                "end": 143,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 148,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 217,
                "end": 252,
                "text": "trans-spinal electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 448,
                "end": 470,
                "text": "traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 472,
                "end": 475,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 480,
                "end": 507,
                "text": "cervical spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 509,
                "end": 512,
                "text": "SCI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05618054",
        "study_official_title": "Pediatric POTS: Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities? ",
        "study_brief_summary": " This study is being conducted to see how people with Postural tachycardia syndrome (POTS) make sense of the things they see. The information may help doctors to learn more about how the different parts of people's brains communicate.",
        "text": "Pediatric POTS: Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities? | This study is being conducted to see how people with Postural tachycardia syndrome (POTS) make sense of the things they see. The information may help doctors to learn more about how the different parts of people's brains communicate.",
        "tokens": "['Pediatric', 'POTS', ':', 'Does', 'a', 'Periaqueductal', 'Gray', '-', 'vagus', 'Nerve', 'Interface', 'Malfunction', 'Explain', 'the', 'Natural', 'History', 'With', 'Its', 'Numerous', 'Co', '-', 'morbidities', '?', '|', 'This', 'study', 'is', 'being', 'conducted', 'to', 'see', 'how', 'people', 'with', 'Postural', 'tachycardia', 'syndrome', '(', 'POTS', ')', 'make', 'sense', 'of', 'the', 'things', 'they', 'see', '.', 'The', 'information', 'may', 'help', 'doctors', 'to', 'learn', 'more', 'about', 'how', 'the', 'different', 'parts', 'of', 'people', \"'s\", 'brains', 'communicate', '.']",
        "token_bio_labels": "['O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 14,
                "text": "POTS",
                "type": "CONDITION"
            },
            {
                "start": 194,
                "end": 223,
                "text": "Postural tachycardia syndrome",
                "type": "CONDITION"
            },
            {
                "start": 225,
                "end": 229,
                "text": "POTS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03698149",
        "study_official_title": "A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control ",
        "study_brief_summary": " Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.",
        "text": "A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control | Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.",
        "tokens": "['A', 'High', '-', 'Performance', 'ECoG', '-', 'based', 'Neural', 'Interface', 'for', 'Communication', 'and', 'Neuroprosthetic', 'Control', '|', 'Test', 'the', 'feasibility', 'of', 'using', 'electrocorticography', '(', 'ECoG', ')', 'signals', 'to', 'control', 'complex', 'devices', 'for', 'motor', 'and', 'speech', 'control', 'in', 'adults', 'severely', 'affected', 'by', 'neurological', 'disorders', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 2,
                "end": 46,
                "text": "High-Performance ECoG-based Neural Interface",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02252770",
        "study_official_title": "Nitric Oxide Supplementation as a Therapeutic Intervention in Argininosuccinic Aciduria ",
        "study_brief_summary": " This is a study involving a dietary supplement. Patients with argininosuccinic aciduria will be randomly assigned to receive either a nitric oxide dietary supplement or placebo for 2 weeks, and then crossed-over to receive the other treatment for two weeks.\n\nThe investigators expect to see that : 1) Patients with ASA will have a decreased ability for their arteries to dilate due to nitric oxide deficiency, 2) Treatment of ASA with the nitric oxide supplement will improve the ability of their arteries to dilate, and 3) Through the testing of subjects' fibroblasts (cells in connective tissue that produce collagen and other fibers), the investigators hope to predict which patients may respond NO supplementation.",
        "text": "Nitric Oxide Supplementation as a Therapeutic Intervention in Argininosuccinic Aciduria | This is a study involving a dietary supplement. Patients with argininosuccinic aciduria will be randomly assigned to receive either a nitric oxide dietary supplement or placebo for 2 weeks, and then crossed-over to receive the other treatment for two weeks.\n\nThe investigators expect to see that : 1) Patients with ASA will have a decreased ability for their arteries to dilate due to nitric oxide deficiency, 2) Treatment of ASA with the nitric oxide supplement will improve the ability of their arteries to dilate, and 3) Through the testing of subjects' fibroblasts (cells in connective tissue that produce collagen and other fibers), the investigators hope to predict which patients may respond NO supplementation.",
        "tokens": "['Nitric', 'Oxide', 'Supplementation', 'as', 'a', 'Therapeutic', 'Intervention', 'in', 'Argininosuccinic', 'Aciduria', '|', 'This', 'is', 'a', 'study', 'involving', 'a', 'dietary', 'supplement', '.', 'Patients', 'with', 'argininosuccinic', 'aciduria', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', 'either', 'a', 'nitric', 'oxide', 'dietary', 'supplement', 'or', 'placebo', 'for', '2', 'weeks', ',', 'and', 'then', 'crossed', '-', 'over', 'to', 'receive', 'the', 'other', 'treatment', 'for', 'two', 'weeks', '.', '\\n\\n', 'The', 'investigators', 'expect', 'to', 'see', 'that', ':', '1', ')', 'Patients', 'with', 'ASA', 'will', 'have', 'a', 'decreased', 'ability', 'for', 'their', 'arteries', 'to', 'dilate', 'due', 'to', 'nitric', 'oxide', 'deficiency', ',', '2', ')', 'Treatment', 'of', 'ASA', 'with', 'the', 'nitric', 'oxide', 'supplement', 'will', 'improve', 'the', 'ability', 'of', 'their', 'arteries', 'to', 'dilate', ',', 'and', '3', ')', 'Through', 'the', 'testing', 'of', 'subjects', \"'\", 'fibroblasts', '(', 'cells', 'in', 'connective', 'tissue', 'that', 'produce', 'collagen', 'and', 'other', 'fibers', ')', ',', 'the', 'investigators', 'hope', 'to', 'predict', 'which', 'patients', 'may', 'respond', 'NO', 'supplementation', '.']",
        "token_bio_labels": "['B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 12,
                "text": "Nitric Oxide",
                "type": "DRUG"
            },
            {
                "start": 62,
                "end": 87,
                "text": "Argininosuccinic Aciduria",
                "type": "CONDITION"
            },
            {
                "start": 152,
                "end": 177,
                "text": "argininosuccinic aciduria",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 236,
                "text": "nitric oxide",
                "type": "DRUG"
            },
            {
                "start": 259,
                "end": 266,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 405,
                "end": 408,
                "text": "ASA",
                "type": "CONDITION"
            },
            {
                "start": 475,
                "end": 487,
                "text": "nitric oxide",
                "type": "DRUG"
            },
            {
                "start": 516,
                "end": 519,
                "text": "ASA",
                "type": "CONDITION"
            },
            {
                "start": 529,
                "end": 541,
                "text": "nitric oxide",
                "type": "DRUG"
            },
            {
                "start": 789,
                "end": 791,
                "text": "NO",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05222477",
        "study_official_title": "Effect of Pelvic Floor Versus Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes ",
        "study_brief_summary": " Nocturia is the leading cause of sleep disruption with its subsequent negative impact on general health and QoL for a large proportion of the adult population. Nocturia is prevalent in men and women of all ages but may be particularly bothersome in younger adults, in whom the consequences of sleep disturbance may be more detrimental for daytime functioning and possibly for health and mortality.The underlying causes of nocturia obviously influence the efficacy of different treatment options. Because a major cause of nocturia is overproduction of urine at night, nocturia may not respond to treatments designed to reduce urgency and increase bladder capacity or increase urine flow, such as agents for the management of bladder outlet obstruction.",
        "text": "Effect of Pelvic Floor Versus Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes | Nocturia is the leading cause of sleep disruption with its subsequent negative impact on general health and QoL for a large proportion of the adult population. Nocturia is prevalent in men and women of all ages but may be particularly bothersome in younger adults, in whom the consequences of sleep disturbance may be more detrimental for daytime functioning and possibly for health and mortality.The underlying causes of nocturia obviously influence the efficacy of different treatment options. Because a major cause of nocturia is overproduction of urine at night, nocturia may not respond to treatments designed to reduce urgency and increase bladder capacity or increase urine flow, such as agents for the management of bladder outlet obstruction.",
        "tokens": "['Effect', 'of', 'Pelvic', 'Floor', 'Versus', 'Abdominal', 'Muscle', 'Exercises', 'on', 'Nocturia', 'and', 'Sleep', 'Quality', 'in', 'Women', 'With', 'Type', '2', 'Diabetes', '|', 'Nocturia', 'is', 'the', 'leading', 'cause', 'of', 'sleep', 'disruption', 'with', 'its', 'subsequent', 'negative', 'impact', 'on', 'general', 'health', 'and', 'QoL', 'for', 'a', 'large', 'proportion', 'of', 'the', 'adult', 'population', '.', 'Nocturia', 'is', 'prevalent', 'in', 'men', 'and', 'women', 'of', 'all', 'ages', 'but', 'may', 'be', 'particularly', 'bothersome', 'in', 'younger', 'adults', ',', 'in', 'whom', 'the', 'consequences', 'of', 'sleep', 'disturbance', 'may', 'be', 'more', 'detrimental', 'for', 'daytime', 'functioning', 'and', 'possibly', 'for', 'health', 'and', 'mortality', '.', 'The', 'underlying', 'causes', 'of', 'nocturia', 'obviously', 'influence', 'the', 'efficacy', 'of', 'different', 'treatment', 'options', '.', 'Because', 'a', 'major', 'cause', 'of', 'nocturia', 'is', 'overproduction', 'of', 'urine', 'at', 'night', ',', 'nocturia', 'may', 'not', 'respond', 'to', 'treatments', 'designed', 'to', 'reduce', 'urgency', 'and', 'increase', 'bladder', 'capacity', 'or', 'increase', 'urine', 'flow', ',', 'such', 'as', 'agents', 'for', 'the', 'management', 'of', 'bladder', 'outlet', 'obstruction', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 56,
                "text": "Pelvic Floor Versus Abdominal Muscle Exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 60,
                "end": 68,
                "text": "Nocturia",
                "type": "CONDITION"
            },
            {
                "start": 101,
                "end": 116,
                "text": "Type 2 Diabetes",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 127,
                "text": "Nocturia",
                "type": "CONDITION"
            },
            {
                "start": 152,
                "end": 168,
                "text": "sleep disruption",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 287,
                "text": "Nocturia",
                "type": "CONDITION"
            },
            {
                "start": 412,
                "end": 429,
                "text": "sleep disturbance",
                "type": "CONDITION"
            },
            {
                "start": 541,
                "end": 549,
                "text": "nocturia",
                "type": "CONDITION"
            },
            {
                "start": 640,
                "end": 648,
                "text": "nocturia",
                "type": "CONDITION"
            },
            {
                "start": 686,
                "end": 694,
                "text": "nocturia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02443701",
        "study_official_title": "Low Level Laser Therapy and Neuromuscular Electrical Stimulation on Knee Extension Strength and Jump in Volleyball Athletes: a Randomized Controlled Trial ",
        "study_brief_summary": " Background: Volleyball players constantly perform vertical jumps, the higher the height of the jump is better sports performance of these players. Several methods have been tested to improve jumping performance in these players. It will be investigated the addition of electrical stimulation and phototherapy to jump training in volleyball athletes. DESIGN: randomized controlled trial. METHODS: This study will be conducted with 36 male athletes volleyball with minimum experience of 12 months sport. Will be randomized and assigned to 3 groups (control group, NEMES group and group phototherapy). All 36 healthy volleyball athletes who passed the initial selection and agreed to participate in the study, conduct a muscle strength and jump training program, which is held in both legs simultaneously. The 12 healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation. The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. All selected participants will undergo an assessment of muscle strength of knee extensors and evaluate the jump. These evaluations were baseline, 6 weeks and 8 weeks after baseline.",
        "text": "Low Level Laser Therapy and Neuromuscular Electrical Stimulation on Knee Extension Strength and Jump in Volleyball Athletes: a Randomized Controlled Trial | Background: Volleyball players constantly perform vertical jumps, the higher the height of the jump is better sports performance of these players. Several methods have been tested to improve jumping performance in these players. It will be investigated the addition of electrical stimulation and phototherapy to jump training in volleyball athletes. DESIGN: randomized controlled trial. METHODS: This study will be conducted with 36 male athletes volleyball with minimum experience of 12 months sport. Will be randomized and assigned to 3 groups (control group, NEMES group and group phototherapy). All 36 healthy volleyball athletes who passed the initial selection and agreed to participate in the study, conduct a muscle strength and jump training program, which is held in both legs simultaneously. The 12 healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation. The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. All selected participants will undergo an assessment of muscle strength of knee extensors and evaluate the jump. These evaluations were baseline, 6 weeks and 8 weeks after baseline.",
        "tokens": "['Low', 'Level', 'Laser', 'Therapy', 'and', 'Neuromuscular', 'Electrical', 'Stimulation', 'on', 'Knee', 'Extension', 'Strength', 'and', 'Jump', 'in', 'Volleyball', 'Athletes', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Background', ':', 'Volleyball', 'players', 'constantly', 'perform', 'vertical', 'jumps', ',', 'the', 'higher', 'the', 'height', 'of', 'the', 'jump', 'is', 'better', 'sports', 'performance', 'of', 'these', 'players', '.', 'Several', 'methods', 'have', 'been', 'tested', 'to', 'improve', 'jumping', 'performance', 'in', 'these', 'players', '.', 'It', 'will', 'be', 'investigated', 'the', 'addition', 'of', 'electrical', 'stimulation', 'and', 'phototherapy', 'to', 'jump', 'training', 'in', 'volleyball', 'athletes', '.', 'DESIGN', ':', 'randomized', 'controlled', 'trial', '.', 'METHODS', ':', 'This', 'study', 'will', 'be', 'conducted', 'with', '36', 'male', 'athletes', 'volleyball', 'with', 'minimum', 'experience', 'of', '12', 'months', 'sport', '.', 'Will', 'be', 'randomized', 'and', 'assigned', 'to', '3', 'groups', '(', 'control', 'group', ',', 'NEMES', 'group', 'and', 'group', 'phototherapy', ')', '.', 'All', '36', 'healthy', 'volleyball', 'athletes', 'who', 'passed', 'the', 'initial', 'selection', 'and', 'agreed', 'to', 'participate', 'in', 'the', 'study', ',', 'conduct', 'a', 'muscle', 'strength', 'and', 'jump', 'training', 'program', ',', 'which', 'is', 'held', 'in', 'both', 'legs', 'simultaneously', '.', 'The', '12', 'healthy', 'athletes', 'electrical', 'stimulation', 'group', 'will', 'perform', 'the', 'same', 'training', 'program', 'described', 'above', ',', 'but', 'strength', 'training', 'is', 'associated', 'with', 'electrical', 'stimulation', '.', 'The', '12', 'healthy', 'athletes', 'participating', 'in', 'the', 'phototherapy', 'group', 'will', 'undergo', 'a', 'phototherapy', 'protocol', 'before', 'performing', 'the', 'strength', 'and', 'jump', 'training', '.', 'All', 'selected', 'participants', 'will', 'undergo', 'an', 'assessment', 'of', 'muscle', 'strength', 'of', 'knee', 'extensors', 'and', 'evaluate', 'the', 'jump', '.', 'These', 'evaluations', 'were', 'baseline', ',', '6', 'weeks', 'and', '8', 'weeks', 'after', 'baseline', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 23,
                "text": "Low Level Laser Therapy",
                "type": "OTHER"
            },
            {
                "start": 28,
                "end": 64,
                "text": "Neuromuscular Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 426,
                "end": 448,
                "text": "electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 453,
                "end": 465,
                "text": "phototherapy",
                "type": "OTHER"
            },
            {
                "start": 719,
                "end": 724,
                "text": "NEMES",
                "type": "OTHER"
            },
            {
                "start": 741,
                "end": 753,
                "text": "phototherapy",
                "type": "OTHER"
            },
            {
                "start": 874,
                "end": 915,
                "text": "muscle strength and jump training program",
                "type": "PHYSICAL"
            },
            {
                "start": 984,
                "end": 1006,
                "text": "electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 1035,
                "end": 1043,
                "text": "training",
                "type": "PHYSICAL"
            },
            {
                "start": 1110,
                "end": 1132,
                "text": "electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 1179,
                "end": 1191,
                "text": "phototherapy",
                "type": "OTHER"
            },
            {
                "start": 1213,
                "end": 1225,
                "text": "phototherapy",
                "type": "OTHER"
            },
            {
                "start": 1257,
                "end": 1283,
                "text": "strength and jump training",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT03504150",
        "study_official_title": "Comparative Effectiveness of Two Self-guided Web-based Interventions for Youth and Young Adults With Migraine ",
        "study_brief_summary": " This randomized controlled trial will compare the effectiveness of two online self-guided programs for youth and young adults with migraine against usual care.",
        "text": "Comparative Effectiveness of Two Self-guided Web-based Interventions for Youth and Young Adults With Migraine | This randomized controlled trial will compare the effectiveness of two online self-guided programs for youth and young adults with migraine against usual care.",
        "tokens": "['Comparative', 'Effectiveness', 'of', 'Two', 'Self', '-', 'guided', 'Web', '-', 'based', 'Interventions', 'for', 'Youth', 'and', 'Young', 'Adults', 'With', 'Migraine', '|', 'This', 'randomized', 'controlled', 'trial', 'will', 'compare', 'the', 'effectiveness', 'of', 'two', 'online', 'self', '-', 'guided', 'programs', 'for', 'youth', 'and', 'young', 'adults', 'with', 'migraine', 'against', 'usual', 'care', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 68,
                "text": "Self-guided Web-based Interventions",
                "type": "OTHER"
            },
            {
                "start": 101,
                "end": 109,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 210,
                "text": "online self-guided programs",
                "type": "OTHER"
            },
            {
                "start": 243,
                "end": 251,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 260,
                "end": 270,
                "text": "usual care",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05089422",
        "study_official_title": "Study of Clinical Types and Surgical Out Come of Pediatic Exotropia ",
        "study_brief_summary": " study aiming to evaluate all children presented to strabismus clinic in ophthalmology department at sohag university hospital with divergent squint (exotropia) and to record surgical outcome of those who underwent strabismus surgery in our hospital",
        "text": "Study of Clinical Types and Surgical Out Come of Pediatic Exotropia | study aiming to evaluate all children presented to strabismus clinic in ophthalmology department at sohag university hospital with divergent squint (exotropia) and to record surgical outcome of those who underwent strabismus surgery in our hospital",
        "tokens": "['Study', 'of', 'Clinical', 'Types', 'and', 'Surgical', 'Out', 'Come', 'of', 'Pediatic', 'Exotropia', '|', 'study', 'aiming', 'to', 'evaluate', 'all', 'children', 'presented', 'to', 'strabismus', 'clinic', 'in', 'ophthalmology', 'department', 'at', 'sohag', 'university', 'hospital', 'with', 'divergent', 'squint', '(', 'exotropia', ')', 'and', 'to', 'record', 'surgical', 'outcome', 'of', 'those', 'who', 'underwent', 'strabismus', 'surgery', 'in', 'our', 'hospital']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 58,
                "end": 67,
                "text": "Exotropia",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 217,
                "text": "divergent squint",
                "type": "CONDITION"
            },
            {
                "start": 219,
                "end": 228,
                "text": "exotropia",
                "type": "CONDITION"
            },
            {
                "start": 284,
                "end": 302,
                "text": "strabismus surgery",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT03963258",
        "study_official_title": "Short-Term Effects of Whole-Body Vibration on Upper Extremity Function in Subjects With Poststroke Hemiplegia ",
        "study_brief_summary": " To investigate the effect of whole body vibration on upper limb motor function in hemiplegic patients with subacute stroke",
        "text": "Short-Term Effects of Whole-Body Vibration on Upper Extremity Function in Subjects With Poststroke Hemiplegia | To investigate the effect of whole body vibration on upper limb motor function in hemiplegic patients with subacute stroke",
        "tokens": "['Short', '-', 'Term', 'Effects', 'of', 'Whole', '-', 'Body', 'Vibration', 'on', 'Upper', 'Extremity', 'Function', 'in', 'Subjects', 'With', 'Poststroke', 'Hemiplegia', '|', 'To', 'investigate', 'the', 'effect', 'of', 'whole', 'body', 'vibration', 'on', 'upper', 'limb', 'motor', 'function', 'in', 'hemiplegic', 'patients', 'with', 'subacute', 'stroke']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND']",
        "entities": [
            {
                "start": 22,
                "end": 42,
                "text": "Whole-Body Vibration",
                "type": "OTHER"
            },
            {
                "start": 88,
                "end": 109,
                "text": "Poststroke Hemiplegia",
                "type": "CONDITION"
            },
            {
                "start": 141,
                "end": 161,
                "text": "whole body vibration",
                "type": "OTHER"
            },
            {
                "start": 194,
                "end": 204,
                "text": "hemiplegic",
                "type": "CONDITION"
            },
            {
                "start": 219,
                "end": 234,
                "text": "subacute stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05746104",
        "study_official_title": "Intraoperative Molecular Imaging of Central Nervous System Tumors Using Same Day Second Window Imaging With Indocyanine Green (TumorGlow\u2122 - CNS) ",
        "study_brief_summary": " The study is being conducted to determine if a same-day, low-dose intravenous (into a vein) injection of indocyanine green (ICG) (FDA-approved dye) being detected by using an imaging system can be a useful tool in identifying and differentiating tumor tissue from normal tissues.",
        "text": "Intraoperative Molecular Imaging of Central Nervous System Tumors Using Same Day Second Window Imaging With Indocyanine Green (TumorGlow\u2122 - CNS) | The study is being conducted to determine if a same-day, low-dose intravenous (into a vein) injection of indocyanine green (ICG) (FDA-approved dye) being detected by using an imaging system can be a useful tool in identifying and differentiating tumor tissue from normal tissues.",
        "tokens": "['Intraoperative', 'Molecular', 'Imaging', 'of', 'Central', 'Nervous', 'System', 'Tumors', 'Using', 'Same', 'Day', 'Second', 'Window', 'Imaging', 'With', 'Indocyanine', 'Green', '(', 'TumorGlow', '\u2122', '-', 'CNS', ')', '|', 'The', 'study', 'is', 'being', 'conducted', 'to', 'determine', 'if', 'a', 'same', '-', 'day', ',', 'low', '-', 'dose', 'intravenous', '(', 'into', 'a', 'vein', ')', 'injection', 'of', 'indocyanine', 'green', '(', 'ICG', ')', '(', 'FDA', '-', 'approved', 'dye', ')', 'being', 'detected', 'by', 'using', 'an', 'imaging', 'system', 'can', 'be', 'a', 'useful', 'tool', 'in', 'identifying', 'and', 'differentiating', 'tumor', 'tissue', 'from', 'normal', 'tissues', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 36,
                "end": 65,
                "text": "Central Nervous System Tumors",
                "type": "CONDITION"
            },
            {
                "start": 108,
                "end": 125,
                "text": "Indocyanine Green",
                "type": "OTHER"
            },
            {
                "start": 127,
                "end": 136,
                "text": "TumorGlow",
                "type": "OTHER"
            },
            {
                "start": 252,
                "end": 269,
                "text": "indocyanine green",
                "type": "OTHER"
            },
            {
                "start": 271,
                "end": 274,
                "text": "ICG",
                "type": "OTHER"
            },
            {
                "start": 393,
                "end": 398,
                "text": "tumor",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04759703",
        "study_official_title": "Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD: A Pilot Double-blind, Randomized Clinical Trial ",
        "study_brief_summary": " The investigators propose to test the use of pramipexole in patients being treated for Opioid Use Disorder to test its ability to reduce symptoms of both Restless Legs Syndrome and protracted opioid withdrawal and thereby promote initiation, engagement, and retention in treatment.",
        "text": "Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD: A Pilot Double-blind, Randomized Clinical Trial | The investigators propose to test the use of pramipexole in patients being treated for Opioid Use Disorder to test its ability to reduce symptoms of both Restless Legs Syndrome and protracted opioid withdrawal and thereby promote initiation, engagement, and retention in treatment.",
        "tokens": "['Treatment', 'of', 'Restless', 'Legs', 'Symptoms', 'With', 'Pramipexole', 'to', 'Improve', 'the', 'Outcomes', 'of', 'Protracted', 'Opioid', 'Withdrawal', 'in', 'OUD', ':', 'A', 'Pilot', 'Double', '-', 'blind', ',', 'Randomized', 'Clinical', 'Trial', '|', 'The', 'investigators', 'propose', 'to', 'test', 'the', 'use', 'of', 'pramipexole', 'in', 'patients', 'being', 'treated', 'for', 'Opioid', 'Use', 'Disorder', 'to', 'test', 'its', 'ability', 'to', 'reduce', 'symptoms', 'of', 'both', 'Restless', 'Legs', 'Syndrome', 'and', 'protracted', 'opioid', 'withdrawal', 'and', 'thereby', 'promote', 'initiation', ',', 'engagement', ',', 'and', 'retention', 'in', 'treatment', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 26,
                "text": "Restless Legs",
                "type": "CONDITION"
            },
            {
                "start": 41,
                "end": 52,
                "text": "Pramipexole",
                "type": "DRUG"
            },
            {
                "start": 80,
                "end": 108,
                "text": "Protracted Opioid Withdrawal",
                "type": "CONDITION"
            },
            {
                "start": 112,
                "end": 115,
                "text": "OUD",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 223,
                "text": "pramipexole",
                "type": "DRUG"
            },
            {
                "start": 254,
                "end": 273,
                "text": "Opioid Use Disorder",
                "type": "CONDITION"
            },
            {
                "start": 321,
                "end": 343,
                "text": "Restless Legs Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 348,
                "end": 376,
                "text": "protracted opioid withdrawal",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02500030",
        "study_official_title": "Effects of Air Stacking Versus Glossopharyngeal Breathing on Maximum Insufflation Capacity in Children and Adolescents With Neuromuscular Disease ",
        "study_brief_summary": " Neuromuscular diseases (NMD) are characterized by a reduced maximum insufflation capacity (MIC), which contributes to increased morbidity and mortality from respiratory diseases. Techniques such as glossopharyngeal breathing (GPB) and insufflation using a manual resuscitation bag, or \"air stacking (AS)\", can be used to increase the MIC. These techniques employ different mechanisms, and the ability to learn the technique plays a key role in its proper implementation and effectiveness. The objective is compare the effects of AS and GPB on the MIC in patients with NMD.\n\nChildren and adolescents with NMD who were users of non-invasive mechanical ventilation were recruited. Vital capacity (VC) and MIC were measured prior to and after the intervention with AS and GPB. Values were compared pre- and post-intervention and were considered statistically significant if p <0.05.",
        "text": "Effects of Air Stacking Versus Glossopharyngeal Breathing on Maximum Insufflation Capacity in Children and Adolescents With Neuromuscular Disease | Neuromuscular diseases (NMD) are characterized by a reduced maximum insufflation capacity (MIC), which contributes to increased morbidity and mortality from respiratory diseases. Techniques such as glossopharyngeal breathing (GPB) and insufflation using a manual resuscitation bag, or \"air stacking (AS)\", can be used to increase the MIC. These techniques employ different mechanisms, and the ability to learn the technique plays a key role in its proper implementation and effectiveness. The objective is compare the effects of AS and GPB on the MIC in patients with NMD.\n\nChildren and adolescents with NMD who were users of non-invasive mechanical ventilation were recruited. Vital capacity (VC) and MIC were measured prior to and after the intervention with AS and GPB. Values were compared pre- and post-intervention and were considered statistically significant if p <0.05.",
        "tokens": "['Effects', 'of', 'Air', 'Stacking', 'Versus', 'Glossopharyngeal', 'Breathing', 'on', 'Maximum', 'Insufflation', 'Capacity', 'in', 'Children', 'and', 'Adolescents', 'With', 'Neuromuscular', 'Disease', '|', 'Neuromuscular', 'diseases', '(', 'NMD', ')', 'are', 'characterized', 'by', 'a', 'reduced', 'maximum', 'insufflation', 'capacity', '(', 'MIC', ')', ',', 'which', 'contributes', 'to', 'increased', 'morbidity', 'and', 'mortality', 'from', 'respiratory', 'diseases', '.', 'Techniques', 'such', 'as', 'glossopharyngeal', 'breathing', '(', 'GPB', ')', 'and', 'insufflation', 'using', 'a', 'manual', 'resuscitation', 'bag', ',', 'or', '\"', 'air', 'stacking', '(', 'AS', ')', '\"', ',', 'can', 'be', 'used', 'to', 'increase', 'the', 'MIC', '.', 'These', 'techniques', 'employ', 'different', 'mechanisms', ',', 'and', 'the', 'ability', 'to', 'learn', 'the', 'technique', 'plays', 'a', 'key', 'role', 'in', 'its', 'proper', 'implementation', 'and', 'effectiveness', '.', 'The', 'objective', 'is', 'compare', 'the', 'effects', 'of', 'AS', 'and', 'GPB', 'on', 'the', 'MIC', 'in', 'patients', 'with', 'NMD', '.', '\\n\\n', 'Children', 'and', 'adolescents', 'with', 'NMD', 'who', 'were', 'users', 'of', 'non', '-', 'invasive', 'mechanical', 'ventilation', 'were', 'recruited', '.', 'Vital', 'capacity', '(', 'VC', ')', 'and', 'MIC', 'were', 'measured', 'prior', 'to', 'and', 'after', 'the', 'intervention', 'with', 'AS', 'and', 'GPB', '.', 'Values', 'were', 'compared', 'pre-', 'and', 'post', '-', 'intervention', 'and', 'were', 'considered', 'statistically', 'significant', 'if', 'p', '<', '0.05', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 23,
                "text": "Air Stacking",
                "type": "OTHER"
            },
            {
                "start": 31,
                "end": 57,
                "text": "Glossopharyngeal Breathing",
                "type": "OTHER"
            },
            {
                "start": 124,
                "end": 145,
                "text": "Neuromuscular Disease",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 170,
                "text": "Neuromuscular diseases",
                "type": "CONDITION"
            },
            {
                "start": 172,
                "end": 175,
                "text": "NMD",
                "type": "CONDITION"
            },
            {
                "start": 346,
                "end": 372,
                "text": "glossopharyngeal breathing",
                "type": "OTHER"
            },
            {
                "start": 374,
                "end": 377,
                "text": "GPB",
                "type": "OTHER"
            },
            {
                "start": 434,
                "end": 446,
                "text": "air stacking",
                "type": "OTHER"
            },
            {
                "start": 448,
                "end": 450,
                "text": "AS",
                "type": "OTHER"
            },
            {
                "start": 677,
                "end": 679,
                "text": "AS",
                "type": "OTHER"
            },
            {
                "start": 684,
                "end": 687,
                "text": "GPB",
                "type": "OTHER"
            },
            {
                "start": 716,
                "end": 719,
                "text": "NMD",
                "type": "CONDITION"
            },
            {
                "start": 752,
                "end": 755,
                "text": "NMD",
                "type": "CONDITION"
            },
            {
                "start": 909,
                "end": 911,
                "text": "AS",
                "type": "OTHER"
            },
            {
                "start": 916,
                "end": 919,
                "text": "GPB",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01205607",
        "study_official_title": "IRB-HSR# 14299: The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Cerebral Perfusion Pressure in Patients With Altered Intracranial Elastance ",
        "study_brief_summary": " Patients who have a functioning intracranial pressure-monitoring device (either a subarachnoid bolt, or an intraventricular catheter) in place, and are either sedated, intubated, and mechanically ventilated (i.e. in the NNICU), or are scheduled to undergo an operation or interventional neuroradiological procedure at the University of Virginia. Patients with a contraindication to TTE will be excluded.\n\nFor patients in the NNICU, basic hemodynamic variables (systemic blood pressure, central venous pressure, etc.) will be collected. In addition, left ventricular performance (including estimates of LVEDV, LVESV, EF, FAC, and SV) will be assessed using TTE. Once these baseline data are recorded, the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal rube pressure (ETP) (based on a randomization scheme). After the ITPR has been active for at least five minutes, the same intracranial, hemodynamic, and TTE data obtained above will be gathered. The ITPR will then be turned off for five minutes, and intracranial, hemodynamic, and TTE data will again be recorded. The ITPR will be activated a second time (-9 mm Hg or -5 mm Hg ETP, i.e. whichever value was not used previously), and after five minutes of use data will be recorded again. The ITPR will then be disconnected, data will be collected after waiting two minutes, and no further interventions will be made.\n\nABG's will be obtained before and during the use of the device at each setting.\n\nThis is a proof of concept/feasibility study designed to test the primary hypothesis that use of the ITPR will result in decreased intracranial pressure and increased cerebral perfusion pressure. The effect of the ITPR on secondary indicators of cardiac performance will also be examined. These include but are not limited estimates of ventricular end diastolic volume and pressure (LVEDV/P), ejection fraction (EF), left ventricular end systolic volume and pressure (LVESV/P), fractional area change (FAC), all of which will be assessed by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE).",
        "text": "IRB-HSR# 14299: The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Cerebral Perfusion Pressure in Patients With Altered Intracranial Elastance | Patients who have a functioning intracranial pressure-monitoring device (either a subarachnoid bolt, or an intraventricular catheter) in place, and are either sedated, intubated, and mechanically ventilated (i.e. in the NNICU), or are scheduled to undergo an operation or interventional neuroradiological procedure at the University of Virginia. Patients with a contraindication to TTE will be excluded.\n\nFor patients in the NNICU, basic hemodynamic variables (systemic blood pressure, central venous pressure, etc.) will be collected. In addition, left ventricular performance (including estimates of LVEDV, LVESV, EF, FAC, and SV) will be assessed using TTE. Once these baseline data are recorded, the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal rube pressure (ETP) (based on a randomization scheme). After the ITPR has been active for at least five minutes, the same intracranial, hemodynamic, and TTE data obtained above will be gathered. The ITPR will then be turned off for five minutes, and intracranial, hemodynamic, and TTE data will again be recorded. The ITPR will be activated a second time (-9 mm Hg or -5 mm Hg ETP, i.e. whichever value was not used previously), and after five minutes of use data will be recorded again. The ITPR will then be disconnected, data will be collected after waiting two minutes, and no further interventions will be made.\n\nABG's will be obtained before and during the use of the device at each setting.\n\nThis is a proof of concept/feasibility study designed to test the primary hypothesis that use of the ITPR will result in decreased intracranial pressure and increased cerebral perfusion pressure. The effect of the ITPR on secondary indicators of cardiac performance will also be examined. These include but are not limited estimates of ventricular end diastolic volume and pressure (LVEDV/P), ejection fraction (EF), left ventricular end systolic volume and pressure (LVESV/P), fractional area change (FAC), all of which will be assessed by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE).",
        "tokens": "['IRB', '-', 'HSR', '#', '14299', ':', 'The', 'Use', 'of', 'the', 'Intrathoracic', 'Pressure', 'Regulator', '(', 'ITPR', ')', 'to', 'Improve', 'Cerebral', 'Perfusion', 'Pressure', 'in', 'Patients', 'With', 'Altered', 'Intracranial', 'Elastance', '|', 'Patients', 'who', 'have', 'a', 'functioning', 'intracranial', 'pressure', '-', 'monitoring', 'device', '(', 'either', 'a', 'subarachnoid', 'bolt', ',', 'or', 'an', 'intraventricular', 'catheter', ')', 'in', 'place', ',', 'and', 'are', 'either', 'sedated', ',', 'intubated', ',', 'and', 'mechanically', 'ventilated', '(', 'i.e.', 'in', 'the', 'NNICU', ')', ',', 'or', 'are', 'scheduled', 'to', 'undergo', 'an', 'operation', 'or', 'interventional', 'neuroradiological', 'procedure', 'at', 'the', 'University', 'of', 'Virginia', '.', 'Patients', 'with', 'a', 'contraindication', 'to', 'TTE', 'will', 'be', 'excluded', '.', '\\n\\n', 'For', 'patients', 'in', 'the', 'NNICU', ',', 'basic', 'hemodynamic', 'variables', '(', 'systemic', 'blood', 'pressure', ',', 'central', 'venous', 'pressure', ',', 'etc', '.', ')', 'will', 'be', 'collected', '.', 'In', 'addition', ',', 'left', 'ventricular', 'performance', '(', 'including', 'estimates', 'of', 'LVEDV', ',', 'LVESV', ',', 'EF', ',', 'FAC', ',', 'and', 'SV', ')', 'will', 'be', 'assessed', 'using', 'TTE', '.', 'Once', 'these', 'baseline', 'data', 'are', 'recorded', ',', 'the', 'ITPR', 'will', 'be', 'inserted', 'in', 'the', 'ventilator', 'circuit', 'and', 'activated', 'to', 'provide', 'either', '-5', 'mm', 'Hg', 'or', '-9', 'mm', 'Hg', 'endotracheal', 'rube', 'pressure', '(', 'ETP', ')', '(', 'based', 'on', 'a', 'randomization', 'scheme', ')', '.', 'After', 'the', 'ITPR', 'has', 'been', 'active', 'for', 'at', 'least', 'five', 'minutes', ',', 'the', 'same', 'intracranial', ',', 'hemodynamic', ',', 'and', 'TTE', 'data', 'obtained', 'above', 'will', 'be', 'gathered', '.', 'The', 'ITPR', 'will', 'then', 'be', 'turned', 'off', 'for', 'five', 'minutes', ',', 'and', 'intracranial', ',', 'hemodynamic', ',', 'and', 'TTE', 'data', 'will', 'again', 'be', 'recorded', '.', 'The', 'ITPR', 'will', 'be', 'activated', 'a', 'second', 'time', '(', '-9', 'mm', 'Hg', 'or', '-5', 'mm', 'Hg', 'ETP', ',', 'i.e.', 'whichever', 'value', 'was', 'not', 'used', 'previously', ')', ',', 'and', 'after', 'five', 'minutes', 'of', 'use', 'data', 'will', 'be', 'recorded', 'again', '.', 'The', 'ITPR', 'will', 'then', 'be', 'disconnected', ',', 'data', 'will', 'be', 'collected', 'after', 'waiting', 'two', 'minutes', ',', 'and', 'no', 'further', 'interventions', 'will', 'be', 'made', '.', '\\n\\n', 'ABG', \"'s\", 'will', 'be', 'obtained', 'before', 'and', 'during', 'the', 'use', 'of', 'the', 'device', 'at', 'each', 'setting', '.', '\\n\\n', 'This', 'is', 'a', 'proof', 'of', 'concept', '/', 'feasibility', 'study', 'designed', 'to', 'test', 'the', 'primary', 'hypothesis', 'that', 'use', 'of', 'the', 'ITPR', 'will', 'result', 'in', 'decreased', 'intracranial', 'pressure', 'and', 'increased', 'cerebral', 'perfusion', 'pressure', '.', 'The', 'effect', 'of', 'the', 'ITPR', 'on', 'secondary', 'indicators', 'of', 'cardiac', 'performance', 'will', 'also', 'be', 'examined', '.', 'These', 'include', 'but', 'are', 'not', 'limited', 'estimates', 'of', 'ventricular', 'end', 'diastolic', 'volume', 'and', 'pressure', '(', 'LVEDV', '/', 'P', ')', ',', 'ejection', 'fraction', '(', 'EF', ')', ',', 'left', 'ventricular', 'end', 'systolic', 'volume', 'and', 'pressure', '(', 'LVESV', '/', 'P', ')', ',', 'fractional', 'area', 'change', '(', 'FAC', ')', ',', 'all', 'of', 'which', 'will', 'be', 'assessed', 'by', 'transthoracic', 'echocardiography', '(', 'TTE', ')', 'or', 'transesophageal', 'echocardiography', '(', 'TEE', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 63,
                "text": "Intrathoracic Pressure Regulator",
                "type": "OTHER"
            },
            {
                "start": 65,
                "end": 69,
                "text": "ITPR",
                "type": "OTHER"
            },
            {
                "start": 127,
                "end": 157,
                "text": "Altered Intracranial Elastance",
                "type": "CONDITION"
            },
            {
                "start": 864,
                "end": 868,
                "text": "ITPR",
                "type": "OTHER"
            },
            {
                "start": 1043,
                "end": 1047,
                "text": "ITPR",
                "type": "OTHER"
            },
            {
                "start": 1177,
                "end": 1181,
                "text": "ITPR",
                "type": "OTHER"
            },
            {
                "start": 1296,
                "end": 1300,
                "text": "ITPR",
                "type": "OTHER"
            },
            {
                "start": 1470,
                "end": 1474,
                "text": "ITPR",
                "type": "OTHER"
            },
            {
                "start": 1778,
                "end": 1782,
                "text": "ITPR",
                "type": "OTHER"
            },
            {
                "start": 1891,
                "end": 1895,
                "text": "ITPR",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02463318",
        "study_official_title": "The purpose of this study is to investigate the gene expression and activity of SIRT1, and forkhead box O3 pathway by means of investigating target genes MnSOD and catalase in multiple sclerosis and healthy subjects. Also, we investigate the effect of melatonin on interaction between SIRT1 activity and target genes MnSOD and catalase in multiple sclerosis and healthy subject .Additionally, we evaluate effect the probable effect of melatonin treatment on gene expression and activity of above-mentioned genes in peripheral blood mononuclear cells of healthy subjects-treated with H2O2.",
        "study_brief_summary": null,
        "text": "The purpose of this study is to investigate the gene expression and activity of SIRT1, and forkhead box O3 pathway by means of investigating target genes MnSOD and catalase in multiple sclerosis and healthy subjects. Also, we investigate the effect of melatonin on interaction between SIRT1 activity and target genes MnSOD and catalase in multiple sclerosis and healthy subject .Additionally, we evaluate effect the probable effect of melatonin treatment on gene expression and activity of above-mentioned genes in peripheral blood mononuclear cells of healthy subjects-treated with H2O2.",
        "tokens": "['The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'gene', 'expression', 'and', 'activity', 'of', 'SIRT1', ',', 'and', 'forkhead', 'box', 'O3', 'pathway', 'by', 'means', 'of', 'investigating', 'target', 'genes', 'MnSOD', 'and', 'catalase', 'in', 'multiple', 'sclerosis', 'and', 'healthy', 'subjects', '.', 'Also', ',', 'we', 'investigate', 'the', 'effect', 'of', 'melatonin', 'on', 'interaction', 'between', 'SIRT1', 'activity', 'and', 'target', 'genes', 'MnSOD', 'and', 'catalase', 'in', 'multiple', 'sclerosis', 'and', 'healthy', 'subject', '.Additionally', ',', 'we', 'evaluate', 'effect', 'the', 'probable', 'effect', 'of', 'melatonin', 'treatment', 'on', 'gene', 'expression', 'and', 'activity', 'of', 'above', '-', 'mentioned', 'genes', 'in', 'peripheral', 'blood', 'mononuclear', 'cells', 'of', 'healthy', 'subjects', '-', 'treated', 'with', 'H2O2', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 176,
                "end": 194,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 252,
                "end": 261,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 339,
                "end": 357,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 435,
                "end": 444,
                "text": "melatonin",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05209386",
        "study_official_title": "Flexible Representation of Speech in the Supratemporal Plane ",
        "study_brief_summary": " The overarching goal of this exploratory research is to understand the dynamic and flexible nature of speech processing in the human supratemporal plane. The temporal lobe has long been established as a region of interest in the speech perception and processing literature because it contains the auditory cortex. More recently, research has localized the supratemporal plane as an area that exhibits response specificity to acoustic properties of complex auditory signals like speech. The supratemporal plane, comprised of Heschl's gyrus, the planum polare, and the planum temporale, is capable of the rapid spectrotemporal analysis required to map acoustic information to linguistic representation. Neural activity in this area, however, is rarely studied directly because it is difficult to access with non-invasive measures like scalp electroencephalography (EEG). Capitalizing on the unique opportunity to access these areas via routine clinical stereoelectroencephalography (sEEG) in a patient population, this study seeks to understand how cortical responses reflect the diagnosticity of two acoustic-phonetic dimensions of interest and how responses rapidly and flexibly adapt to changes in listening demands. Examining how neural response to voice onset time (VOT) and fundamental frequency (F0) modulates as a function of perceptual weight carried in signaling phoneme categories, and identifying how changes in listening context shift perceptual weight, will provide invaluable data that indicates how speech processing flexibly adapts to short-term acoustic patterns.",
        "text": "Flexible Representation of Speech in the Supratemporal Plane | The overarching goal of this exploratory research is to understand the dynamic and flexible nature of speech processing in the human supratemporal plane. The temporal lobe has long been established as a region of interest in the speech perception and processing literature because it contains the auditory cortex. More recently, research has localized the supratemporal plane as an area that exhibits response specificity to acoustic properties of complex auditory signals like speech. The supratemporal plane, comprised of Heschl's gyrus, the planum polare, and the planum temporale, is capable of the rapid spectrotemporal analysis required to map acoustic information to linguistic representation. Neural activity in this area, however, is rarely studied directly because it is difficult to access with non-invasive measures like scalp electroencephalography (EEG). Capitalizing on the unique opportunity to access these areas via routine clinical stereoelectroencephalography (sEEG) in a patient population, this study seeks to understand how cortical responses reflect the diagnosticity of two acoustic-phonetic dimensions of interest and how responses rapidly and flexibly adapt to changes in listening demands. Examining how neural response to voice onset time (VOT) and fundamental frequency (F0) modulates as a function of perceptual weight carried in signaling phoneme categories, and identifying how changes in listening context shift perceptual weight, will provide invaluable data that indicates how speech processing flexibly adapts to short-term acoustic patterns.",
        "tokens": "['Flexible', 'Representation', 'of', 'Speech', 'in', 'the', 'Supratemporal', 'Plane', '|', 'The', 'overarching', 'goal', 'of', 'this', 'exploratory', 'research', 'is', 'to', 'understand', 'the', 'dynamic', 'and', 'flexible', 'nature', 'of', 'speech', 'processing', 'in', 'the', 'human', 'supratemporal', 'plane', '.', 'The', 'temporal', 'lobe', 'has', 'long', 'been', 'established', 'as', 'a', 'region', 'of', 'interest', 'in', 'the', 'speech', 'perception', 'and', 'processing', 'literature', 'because', 'it', 'contains', 'the', 'auditory', 'cortex', '.', 'More', 'recently', ',', 'research', 'has', 'localized', 'the', 'supratemporal', 'plane', 'as', 'an', 'area', 'that', 'exhibits', 'response', 'specificity', 'to', 'acoustic', 'properties', 'of', 'complex', 'auditory', 'signals', 'like', 'speech', '.', 'The', 'supratemporal', 'plane', ',', 'comprised', 'of', 'Heschl', \"'s\", 'gyrus', ',', 'the', 'planum', 'polare', ',', 'and', 'the', 'planum', 'temporale', ',', 'is', 'capable', 'of', 'the', 'rapid', 'spectrotemporal', 'analysis', 'required', 'to', 'map', 'acoustic', 'information', 'to', 'linguistic', 'representation', '.', 'Neural', 'activity', 'in', 'this', 'area', ',', 'however', ',', 'is', 'rarely', 'studied', 'directly', 'because', 'it', 'is', 'difficult', 'to', 'access', 'with', 'non', '-', 'invasive', 'measures', 'like', 'scalp', 'electroencephalography', '(', 'EEG', ')', '.', 'Capitalizing', 'on', 'the', 'unique', 'opportunity', 'to', 'access', 'these', 'areas', 'via', 'routine', 'clinical', 'stereoelectroencephalography', '(', 'sEEG', ')', 'in', 'a', 'patient', 'population', ',', 'this', 'study', 'seeks', 'to', 'understand', 'how', 'cortical', 'responses', 'reflect', 'the', 'diagnosticity', 'of', 'two', 'acoustic', '-', 'phonetic', 'dimensions', 'of', 'interest', 'and', 'how', 'responses', 'rapidly', 'and', 'flexibly', 'adapt', 'to', 'changes', 'in', 'listening', 'demands', '.', 'Examining', 'how', 'neural', 'response', 'to', 'voice', 'onset', 'time', '(', 'VOT', ')', 'and', 'fundamental', 'frequency', '(', 'F0', ')', 'modulates', 'as', 'a', 'function', 'of', 'perceptual', 'weight', 'carried', 'in', 'signaling', 'phoneme', 'categories', ',', 'and', 'identifying', 'how', 'changes', 'in', 'listening', 'context', 'shift', 'perceptual', 'weight', ',', 'will', 'provide', 'invaluable', 'data', 'that', 'indicates', 'how', 'speech', 'processing', 'flexibly', 'adapts', 'to', 'short', '-', 'term', 'acoustic', 'patterns', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT02462629",
        "study_official_title": "A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors ",
        "study_brief_summary": " Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in pediatric patients with central nervous system tumors.",
        "text": "A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors | Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in pediatric patients with central nervous system tumors.",
        "tokens": "['A', 'Phase', '1', 'Dose', '-', 'escalation', 'and', 'Expansion', 'Study', 'of', 'BLZ-100', 'in', 'Pediatric', 'Subjects', 'With', 'Primary', 'Central', 'Nervous', 'System', 'Tumors', '|', 'Many', 'types', 'of', 'cancer', 'are', 'primarily', 'treated', 'with', 'surgery', 'and', 'patient', 'survival', 'is', 'directly', 'related', 'to', 'the', 'extent', 'to', 'which', 'the', 'tumor', 'is', 'able', 'to', 'be', 'removed', '.', 'It', 'is', 'often', 'difficult', 'for', 'surgeons', 'to', 'distinguish', 'tumor', 'tissue', 'from', 'normal', 'tissue', 'or', 'to', 'detect', 'tumor', 'cells', 'that', 'have', 'spread', 'from', 'the', 'original', 'tumor', 'site', ',', 'resulting', 'in', 'incomplete', 'removal', 'of', 'the', 'tumor', 'and', 'reduced', 'patient', 'survival', '.', 'In', 'some', 'sites', ',', 'such', 'as', 'the', 'brain', ',', 'it', 'is', 'critical', 'to', 'avoid', 'damage', 'to', 'normal', 'tissue', 'around', 'the', 'tumor', 'to', 'prevent', 'adverse', 'effects', 'of', 'surgery', 'on', 'function', '.', 'The', 'investigators', 'hypothesize', 'that', 'BLZ-100', 'will', 'improve', 'surgical', 'outcomes', 'by', 'allowing', 'surgeons', 'to', 'visualize', 'the', 'edges', 'of', 'the', 'tumor', 'and', 'small', 'groups', 'of', 'cancer', 'cells', 'that', 'have', 'spread', 'to', 'other', 'sites', 'in', 'real', '-', 'time', 'as', 'they', 'operate', '.', 'This', 'is', 'a', 'safety', 'study', 'to', 'assess', 'the', 'safety', 'of', 'BLZ-100', 'in', 'pediatric', 'patients', 'with', 'central', 'nervous', 'system', 'tumors', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 49,
                "end": 56,
                "text": "BLZ-100",
                "type": "DRUG"
            },
            {
                "start": 84,
                "end": 121,
                "text": "Primary Central Nervous System Tumors",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 144,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 248,
                "end": 253,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 372,
                "end": 377,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 419,
                "end": 424,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 470,
                "end": 475,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 599,
                "end": 604,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 691,
                "end": 698,
                "text": "BLZ-100",
                "type": "DRUG"
            },
            {
                "start": 781,
                "end": 786,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 807,
                "end": 813,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 929,
                "end": 936,
                "text": "BLZ-100",
                "type": "DRUG"
            },
            {
                "start": 964,
                "end": 993,
                "text": "central nervous system tumors",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04297540",
        "study_official_title": "Neuromodulation Technique for the Rehabilitation of Social Skills in Childhood Ataxia ",
        "study_brief_summary": " The present study aims to define a protocol of electrical stimulation of the cerebellum via transcranial direct current stimulation (tDCS) combined with a virtual reality protocol to assist the rehabilitation of social skills in adolescents and young adults with childhood ataxia.\n\nTaking into account the high neuronal density of the cerebellum, its strong connection with the cerebral cortex, and its involvement in motor, cognitive and affective processes, as well its involvement in social prediction abilities, the investigators hypothesized that excitatory stimulation of the cerebellum might improve social prediction abilities in adolescents and young adults with childhood ataxia. Moreover, as suggested by previous studies investigating the effect of tDCS in paediatric population, the investigators expected that tDCS will be safe and well tolerated. Such a result would encourage the use of non-invasive brain stimulation in the rehabilitation of social skills in childhood ataxia.",
        "text": "Neuromodulation Technique for the Rehabilitation of Social Skills in Childhood Ataxia | The present study aims to define a protocol of electrical stimulation of the cerebellum via transcranial direct current stimulation (tDCS) combined with a virtual reality protocol to assist the rehabilitation of social skills in adolescents and young adults with childhood ataxia.\n\nTaking into account the high neuronal density of the cerebellum, its strong connection with the cerebral cortex, and its involvement in motor, cognitive and affective processes, as well its involvement in social prediction abilities, the investigators hypothesized that excitatory stimulation of the cerebellum might improve social prediction abilities in adolescents and young adults with childhood ataxia. Moreover, as suggested by previous studies investigating the effect of tDCS in paediatric population, the investigators expected that tDCS will be safe and well tolerated. Such a result would encourage the use of non-invasive brain stimulation in the rehabilitation of social skills in childhood ataxia.",
        "tokens": "['Neuromodulation', 'Technique', 'for', 'the', 'Rehabilitation', 'of', 'Social', 'Skills', 'in', 'Childhood', 'Ataxia', '|', 'The', 'present', 'study', 'aims', 'to', 'define', 'a', 'protocol', 'of', 'electrical', 'stimulation', 'of', 'the', 'cerebellum', 'via', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'combined', 'with', 'a', 'virtual', 'reality', 'protocol', 'to', 'assist', 'the', 'rehabilitation', 'of', 'social', 'skills', 'in', 'adolescents', 'and', 'young', 'adults', 'with', 'childhood', 'ataxia', '.', '\\n\\n', 'Taking', 'into', 'account', 'the', 'high', 'neuronal', 'density', 'of', 'the', 'cerebellum', ',', 'its', 'strong', 'connection', 'with', 'the', 'cerebral', 'cortex', ',', 'and', 'its', 'involvement', 'in', 'motor', ',', 'cognitive', 'and', 'affective', 'processes', ',', 'as', 'well', 'its', 'involvement', 'in', 'social', 'prediction', 'abilities', ',', 'the', 'investigators', 'hypothesized', 'that', 'excitatory', 'stimulation', 'of', 'the', 'cerebellum', 'might', 'improve', 'social', 'prediction', 'abilities', 'in', 'adolescents', 'and', 'young', 'adults', 'with', 'childhood', 'ataxia', '.', 'Moreover', ',', 'as', 'suggested', 'by', 'previous', 'studies', 'investigating', 'the', 'effect', 'of', 'tDCS', 'in', 'paediatric', 'population', ',', 'the', 'investigators', 'expected', 'that', 'tDCS', 'will', 'be', 'safe', 'and', 'well', 'tolerated', '.', 'Such', 'a', 'result', 'would', 'encourage', 'the', 'use', 'of', 'non', '-', 'invasive', 'brain', 'stimulation', 'in', 'the', 'rehabilitation', 'of', 'social', 'skills', 'in', 'childhood', 'ataxia', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 25,
                "text": "Neuromodulation Technique",
                "type": "OTHER"
            },
            {
                "start": 79,
                "end": 85,
                "text": "Ataxia",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 175,
                "text": "electrical stimulation of the cerebellum",
                "type": "OTHER"
            },
            {
                "start": 180,
                "end": 219,
                "text": "transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 221,
                "end": 225,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 243,
                "end": 267,
                "text": "virtual reality protocol",
                "type": "OTHER"
            },
            {
                "start": 361,
                "end": 367,
                "text": "ataxia",
                "type": "CONDITION"
            },
            {
                "start": 640,
                "end": 680,
                "text": "excitatory stimulation of the cerebellum",
                "type": "OTHER"
            },
            {
                "start": 770,
                "end": 776,
                "text": "ataxia",
                "type": "CONDITION"
            },
            {
                "start": 849,
                "end": 853,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 912,
                "end": 916,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 991,
                "end": 1021,
                "text": "non-invasive brain stimulation",
                "type": "OTHER"
            },
            {
                "start": 1074,
                "end": 1080,
                "text": "ataxia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04344132",
        "study_official_title": "Pre- vs. Postoperative Scalp Block for Pain Control After Supratentorial Craniotomy ",
        "study_brief_summary": " Study was designed to evaluate optimal timing for selective scalp block in patients undergoing general anesthesia for supratentorial craniotomy.Pain score assessed by visual analog scale (VAS) preoperatively (baseline) and after extubation at 2, 6, 12 and 24 hours; time first request of a patient for rescue analgesia; intraoperative anesthetics and opioids consumption; awakening time; perioperative complications.",
        "text": "Pre- vs. Postoperative Scalp Block for Pain Control After Supratentorial Craniotomy | Study was designed to evaluate optimal timing for selective scalp block in patients undergoing general anesthesia for supratentorial craniotomy.Pain score assessed by visual analog scale (VAS) preoperatively (baseline) and after extubation at 2, 6, 12 and 24 hours; time first request of a patient for rescue analgesia; intraoperative anesthetics and opioids consumption; awakening time; perioperative complications.",
        "tokens": "['Pre-', 'vs.', 'Postoperative', 'Scalp', 'Block', 'for', 'Pain', 'Control', 'After', 'Supratentorial', 'Craniotomy', '|', 'Study', 'was', 'designed', 'to', 'evaluate', 'optimal', 'timing', 'for', 'selective', 'scalp', 'block', 'in', 'patients', 'undergoing', 'general', 'anesthesia', 'for', 'supratentorial', 'craniotomy', '.', 'Pain', 'score', 'assessed', 'by', 'visual', 'analog', 'scale', '(', 'VAS', ')', 'preoperatively', '(', 'baseline', ')', 'and', 'after', 'extubation', 'at', '2', ',', '6', ',', '12', 'and', '24', 'hours', ';', 'time', 'first', 'request', 'of', 'a', 'patient', 'for', 'rescue', 'analgesia', ';', 'intraoperative', 'anesthetics', 'and', 'opioids', 'consumption', ';', 'awakening', 'time', ';', 'perioperative', 'complications', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 34,
                "text": "Pre- vs. Postoperative Scalp Block",
                "type": "OTHER"
            },
            {
                "start": 39,
                "end": 43,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 58,
                "end": 83,
                "text": "Supratentorial Craniotomy",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 157,
                "text": "selective scalp block",
                "type": "OTHER"
            },
            {
                "start": 204,
                "end": 229,
                "text": "supratentorial craniotomy",
                "type": "CONDITION"
            },
            {
                "start": 230,
                "end": 234,
                "text": "Pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05008484",
        "study_official_title": "Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury. ",
        "study_brief_summary": " Neurogenic osteoporosis is a common complication of spinal cord injury (SCI) that is associated with low impact bone fractures. It is concerning that more than 46,000 Veterans affected with SCI and are at risk of osteoporosis and possible low impact fractures. About fifty percent of all individuals with SCI will develop low impact fracture in their life time. The management of osteoporosis-related fractures can impose substantial economic burden on the health care system, the individual and the families. Previous studies did not succeed in reversing the process of bone loss after SCI. In the present pilot study, we will evaluate the effect of Neuromuscular Electrical Stimulation Resistance Training in combination with oral Vitamin D supplementation, on bone quality in Veterans with chronic SCI, using a randomized experimental design.",
        "text": "Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury. | Neurogenic osteoporosis is a common complication of spinal cord injury (SCI) that is associated with low impact bone fractures. It is concerning that more than 46,000 Veterans affected with SCI and are at risk of osteoporosis and possible low impact fractures. About fifty percent of all individuals with SCI will develop low impact fracture in their life time. The management of osteoporosis-related fractures can impose substantial economic burden on the health care system, the individual and the families. Previous studies did not succeed in reversing the process of bone loss after SCI. In the present pilot study, we will evaluate the effect of Neuromuscular Electrical Stimulation Resistance Training in combination with oral Vitamin D supplementation, on bone quality in Veterans with chronic SCI, using a randomized experimental design.",
        "tokens": "['Effects', 'of', 'Electrical', 'Stimulation', 'and', 'Vitamin', 'D', 'Supplementation', 'on', 'Bone', 'Health', 'Following', 'Spinal', 'Cord', 'Injury', '.', '|', 'Neurogenic', 'osteoporosis', 'is', 'a', 'common', 'complication', 'of', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'that', 'is', 'associated', 'with', 'low', 'impact', 'bone', 'fractures', '.', 'It', 'is', 'concerning', 'that', 'more', 'than', '46,000', 'Veterans', 'affected', 'with', 'SCI', 'and', 'are', 'at', 'risk', 'of', 'osteoporosis', 'and', 'possible', 'low', 'impact', 'fractures', '.', 'About', 'fifty', 'percent', 'of', 'all', 'individuals', 'with', 'SCI', 'will', 'develop', 'low', 'impact', 'fracture', 'in', 'their', 'life', 'time', '.', 'The', 'management', 'of', 'osteoporosis', '-', 'related', 'fractures', 'can', 'impose', 'substantial', 'economic', 'burden', 'on', 'the', 'health', 'care', 'system', ',', 'the', 'individual', 'and', 'the', 'families', '.', 'Previous', 'studies', 'did', 'not', 'succeed', 'in', 'reversing', 'the', 'process', 'of', 'bone', 'loss', 'after', 'SCI', '.', 'In', 'the', 'present', 'pilot', 'study', ',', 'we', 'will', 'evaluate', 'the', 'effect', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'Resistance', 'Training', 'in', 'combination', 'with', 'oral', 'Vitamin', 'D', 'supplementation', ',', 'on', 'bone', 'quality', 'in', 'Veterans', 'with', 'chronic', 'SCI', ',', 'using', 'a', 'randomized', 'experimental', 'design', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 33,
                "text": "Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 38,
                "end": 47,
                "text": "Vitamin D",
                "type": "DRUG"
            },
            {
                "start": 89,
                "end": 107,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 111,
                "end": 134,
                "text": "Neurogenic osteoporosis",
                "type": "CONDITION"
            },
            {
                "start": 163,
                "end": 181,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 186,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 237,
                "text": "low impact bone fractures",
                "type": "CONDITION"
            },
            {
                "start": 301,
                "end": 304,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 324,
                "end": 336,
                "text": "osteoporosis",
                "type": "CONDITION"
            },
            {
                "start": 350,
                "end": 370,
                "text": "low impact fractures",
                "type": "CONDITION"
            },
            {
                "start": 416,
                "end": 419,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 452,
                "text": "low impact fracture",
                "type": "CONDITION"
            },
            {
                "start": 491,
                "end": 521,
                "text": "osteoporosis-related fractures",
                "type": "CONDITION"
            },
            {
                "start": 682,
                "end": 691,
                "text": "bone loss",
                "type": "CONDITION"
            },
            {
                "start": 698,
                "end": 701,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 762,
                "end": 818,
                "text": "Neuromuscular Electrical Stimulation Resistance Training",
                "type": "PHYSICAL"
            },
            {
                "start": 844,
                "end": 853,
                "text": "Vitamin D",
                "type": "DRUG"
            },
            {
                "start": 904,
                "end": 915,
                "text": "chronic SCI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00247533",
        "study_official_title": "The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography ",
        "study_brief_summary": " There are many reports about the association of coronary artery disease (CAD) and cerebral artery stenosis (CAS), which had been proved to induce stroke and cognition decline after the revascularization including coronary bypass surgery (CABG) or percutaneous coronary intervention. Perfusion defect on nuclear brain scan is also noted to correlate with these neurological complications. On the other hand, the perioperative arrhythmia and following cerebral embolism was also attributed to be one factor inducing such neurological hazards.\n\nIn the patients with coexistent CAD and CAS (1st group), and also the patients scheduled for CABG or percutaneous coronary intervention (PCI) (2nd group), we, the researchers at Far Eastern Memorial Hospital, attempted to integrate all the parameters mention above, including angiography of coronary and cerebral system, quantitative analysis of nuclear brain scan, biochemical profile, and signals of a new ambulatory device which could record the electrocardiograph (ECG) and electroencephalograph (EEG) simultaneously, in order to define the correlation between them. A chorological relation between EEG signals and ECG signals is our first target to be worked out. Thereafter, we hope to establish a regression model of all involved parameters according to the relation. Such a model, we believe, is essential not only to explain the post-CABG neurological complications, but to prevent them.\n\nFurthermore, for the undetermined ischemic stroke patients who had no obvious culprit artery or embolism source, the paroxysmal arrhythmia had long been regarded as the cause. Whether a paroxysmal atrial fibrillation, which had not been disclosed by routine ECG, could induce most of such a stroke is still not known. With this new ambulatory device which could record the electrocardiograph (ECG) and electroencephalograph (EEG) simultaneously, we want to answer the question.",
        "text": "The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography | There are many reports about the association of coronary artery disease (CAD) and cerebral artery stenosis (CAS), which had been proved to induce stroke and cognition decline after the revascularization including coronary bypass surgery (CABG) or percutaneous coronary intervention. Perfusion defect on nuclear brain scan is also noted to correlate with these neurological complications. On the other hand, the perioperative arrhythmia and following cerebral embolism was also attributed to be one factor inducing such neurological hazards.\n\nIn the patients with coexistent CAD and CAS (1st group), and also the patients scheduled for CABG or percutaneous coronary intervention (PCI) (2nd group), we, the researchers at Far Eastern Memorial Hospital, attempted to integrate all the parameters mention above, including angiography of coronary and cerebral system, quantitative analysis of nuclear brain scan, biochemical profile, and signals of a new ambulatory device which could record the electrocardiograph (ECG) and electroencephalograph (EEG) simultaneously, in order to define the correlation between them. A chorological relation between EEG signals and ECG signals is our first target to be worked out. Thereafter, we hope to establish a regression model of all involved parameters according to the relation. Such a model, we believe, is essential not only to explain the post-CABG neurological complications, but to prevent them.\n\nFurthermore, for the undetermined ischemic stroke patients who had no obvious culprit artery or embolism source, the paroxysmal arrhythmia had long been regarded as the cause. Whether a paroxysmal atrial fibrillation, which had not been disclosed by routine ECG, could induce most of such a stroke is still not known. With this new ambulatory device which could record the electrocardiograph (ECG) and electroencephalograph (EEG) simultaneously, we want to answer the question.",
        "tokens": "['The', 'Early', 'Diagnosis', 'and', 'Prevention', 'of', 'Ischemic', 'Stroke', 'and', 'Cognition', 'Decline', 'Associated', 'With', 'Coronary', 'Artery', 'Disease', 'Combined', 'With', 'Cerebral', 'Artery', 'Stenosis', 'or', 'Arrhythmia', 'by', '24', '-', 'Hour', 'Simultaneous', 'Recorder', 'of', 'Electrocardiograph', 'and', 'Electroencephalography', '|', 'There', 'are', 'many', 'reports', 'about', 'the', 'association', 'of', 'coronary', 'artery', 'disease', '(', 'CAD', ')', 'and', 'cerebral', 'artery', 'stenosis', '(', 'CAS', ')', ',', 'which', 'had', 'been', 'proved', 'to', 'induce', 'stroke', 'and', 'cognition', 'decline', 'after', 'the', 'revascularization', 'including', 'coronary', 'bypass', 'surgery', '(', 'CABG', ')', 'or', 'percutaneous', 'coronary', 'intervention', '.', 'Perfusion', 'defect', 'on', 'nuclear', 'brain', 'scan', 'is', 'also', 'noted', 'to', 'correlate', 'with', 'these', 'neurological', 'complications', '.', 'On', 'the', 'other', 'hand', ',', 'the', 'perioperative', 'arrhythmia', 'and', 'following', 'cerebral', 'embolism', 'was', 'also', 'attributed', 'to', 'be', 'one', 'factor', 'inducing', 'such', 'neurological', 'hazards', '.', '\\n\\n', 'In', 'the', 'patients', 'with', 'coexistent', 'CAD', 'and', 'CAS', '(', '1st', 'group', ')', ',', 'and', 'also', 'the', 'patients', 'scheduled', 'for', 'CABG', 'or', 'percutaneous', 'coronary', 'intervention', '(', 'PCI', ')', '(', '2nd', 'group', ')', ',', 'we', ',', 'the', 'researchers', 'at', 'Far', 'Eastern', 'Memorial', 'Hospital', ',', 'attempted', 'to', 'integrate', 'all', 'the', 'parameters', 'mention', 'above', ',', 'including', 'angiography', 'of', 'coronary', 'and', 'cerebral', 'system', ',', 'quantitative', 'analysis', 'of', 'nuclear', 'brain', 'scan', ',', 'biochemical', 'profile', ',', 'and', 'signals', 'of', 'a', 'new', 'ambulatory', 'device', 'which', 'could', 'record', 'the', 'electrocardiograph', '(', 'ECG', ')', 'and', 'electroencephalograph', '(', 'EEG', ')', 'simultaneously', ',', 'in', 'order', 'to', 'define', 'the', 'correlation', 'between', 'them', '.', 'A', 'chorological', 'relation', 'between', 'EEG', 'signals', 'and', 'ECG', 'signals', 'is', 'our', 'first', 'target', 'to', 'be', 'worked', 'out', '.', 'Thereafter', ',', 'we', 'hope', 'to', 'establish', 'a', 'regression', 'model', 'of', 'all', 'involved', 'parameters', 'according', 'to', 'the', 'relation', '.', 'Such', 'a', 'model', ',', 'we', 'believe', ',', 'is', 'essential', 'not', 'only', 'to', 'explain', 'the', 'post', '-', 'CABG', 'neurological', 'complications', ',', 'but', 'to', 'prevent', 'them', '.', '\\n\\n', 'Furthermore', ',', 'for', 'the', 'undetermined', 'ischemic', 'stroke', 'patients', 'who', 'had', 'no', 'obvious', 'culprit', 'artery', 'or', 'embolism', 'source', ',', 'the', 'paroxysmal', 'arrhythmia', 'had', 'long', 'been', 'regarded', 'as', 'the', 'cause', '.', 'Whether', 'a', 'paroxysmal', 'atrial', 'fibrillation', ',', 'which', 'had', 'not', 'been', 'disclosed', 'by', 'routine', 'ECG', ',', 'could', 'induce', 'most', 'of', 'such', 'a', 'stroke', 'is', 'still', 'not', 'known', '.', 'With', 'this', 'new', 'ambulatory', 'device', 'which', 'could', 'record', 'the', 'electrocardiograph', '(', 'ECG', ')', 'and', 'electroencephalograph', '(', 'EEG', ')', 'simultaneously', ',', 'we', 'want', 'to', 'answer', 'the', 'question', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 75,
                "text": "Prevention of Ischemic Stroke and Cognition Decline",
                "type": "OTHER"
            },
            {
                "start": 92,
                "end": 115,
                "text": "Coronary Artery Disease",
                "type": "CONDITION"
            },
            {
                "start": 130,
                "end": 154,
                "text": "Cerebral Artery Stenosis",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 168,
                "text": "Arrhythmia",
                "type": "CONDITION"
            },
            {
                "start": 172,
                "end": 250,
                "text": "24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography",
                "type": "OTHER"
            },
            {
                "start": 301,
                "end": 324,
                "text": "coronary artery disease",
                "type": "CONDITION"
            },
            {
                "start": 326,
                "end": 329,
                "text": "CAD",
                "type": "CONDITION"
            },
            {
                "start": 335,
                "end": 359,
                "text": "cerebral artery stenosis",
                "type": "CONDITION"
            },
            {
                "start": 361,
                "end": 364,
                "text": "CAS",
                "type": "CONDITION"
            },
            {
                "start": 399,
                "end": 405,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 466,
                "end": 489,
                "text": "coronary bypass surgery",
                "type": "CONDITION"
            },
            {
                "start": 491,
                "end": 495,
                "text": "CABG",
                "type": "CONDITION"
            },
            {
                "start": 500,
                "end": 534,
                "text": "percutaneous coronary intervention",
                "type": "CONDITION"
            },
            {
                "start": 664,
                "end": 688,
                "text": "perioperative arrhythmia",
                "type": "CONDITION"
            },
            {
                "start": 703,
                "end": 720,
                "text": "cerebral embolism",
                "type": "CONDITION"
            },
            {
                "start": 827,
                "end": 830,
                "text": "CAD",
                "type": "CONDITION"
            },
            {
                "start": 835,
                "end": 838,
                "text": "CAS",
                "type": "CONDITION"
            },
            {
                "start": 888,
                "end": 892,
                "text": "CABG",
                "type": "CONDITION"
            },
            {
                "start": 896,
                "end": 930,
                "text": "percutaneous coronary intervention",
                "type": "CONDITION"
            },
            {
                "start": 932,
                "end": 935,
                "text": "PCI",
                "type": "CONDITION"
            },
            {
                "start": 1633,
                "end": 1669,
                "text": "post-CABG neurological complications",
                "type": "CONDITION"
            },
            {
                "start": 1727,
                "end": 1742,
                "text": "ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 1810,
                "end": 1831,
                "text": "paroxysmal arrhythmia",
                "type": "CONDITION"
            },
            {
                "start": 1879,
                "end": 1909,
                "text": "paroxysmal atrial fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 1984,
                "end": 1990,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04673058",
        "study_official_title": "Effectiveness of Spinal Manipulation in Addition to Standard Pharmacological Treatment in Fibromyalgia : A Blinded Randomized Clinical Trial ",
        "study_brief_summary": " The aim of this study is to evaluate whether spinal manipulation, which is a potential treatment method for musculoskeletal pain, has an additional contribution in patients with fibromyalgia receiving standard pharmacological treatment.",
        "text": "Effectiveness of Spinal Manipulation in Addition to Standard Pharmacological Treatment in Fibromyalgia : A Blinded Randomized Clinical Trial | The aim of this study is to evaluate whether spinal manipulation, which is a potential treatment method for musculoskeletal pain, has an additional contribution in patients with fibromyalgia receiving standard pharmacological treatment.",
        "tokens": "['Effectiveness', 'of', 'Spinal', 'Manipulation', 'in', 'Addition', 'to', 'Standard', 'Pharmacological', 'Treatment', 'in', 'Fibromyalgia', ':', 'A', 'Blinded', 'Randomized', 'Clinical', 'Trial', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'spinal', 'manipulation', ',', 'which', 'is', 'a', 'potential', 'treatment', 'method', 'for', 'musculoskeletal', 'pain', ',', 'has', 'an', 'additional', 'contribution', 'in', 'patients', 'with', 'fibromyalgia', 'receiving', 'standard', 'pharmacological', 'treatment', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 36,
                "text": "Spinal Manipulation",
                "type": "OTHER"
            },
            {
                "start": 90,
                "end": 102,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 188,
                "end": 207,
                "text": "spinal manipulation",
                "type": "OTHER"
            },
            {
                "start": 251,
                "end": 271,
                "text": "musculoskeletal pain",
                "type": "CONDITION"
            },
            {
                "start": 321,
                "end": 333,
                "text": "fibromyalgia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00322426",
        "study_official_title": "Effect of Randomized Patient-Triggered Sensory Cues for Freezing of Gait in Parkinson's Disease ",
        "study_brief_summary": " The purpose of this study is (1) to determine if patient triggered sensory(auditory, visual and tactile) cues can help treat freezing of gait in Parkinson's disease, and (2) to assess if unexpected (randomized) cues are more effective than anticipated ones.",
        "text": "Effect of Randomized Patient-Triggered Sensory Cues for Freezing of Gait in Parkinson's Disease | The purpose of this study is (1) to determine if patient triggered sensory(auditory, visual and tactile) cues can help treat freezing of gait in Parkinson's disease, and (2) to assess if unexpected (randomized) cues are more effective than anticipated ones.",
        "tokens": "['Effect', 'of', 'Randomized', 'Patient', '-', 'Triggered', 'Sensory', 'Cues', 'for', 'Freezing', 'of', 'Gait', 'in', 'Parkinson', \"'s\", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', '(', '1', ')', 'to', 'determine', 'if', 'patient', 'triggered', 'sensory(auditory', ',', 'visual', 'and', 'tactile', ')', 'cues', 'can', 'help', 'treat', 'freezing', 'of', 'gait', 'in', 'Parkinson', \"'s\", 'disease', ',', 'and', '(', '2', ')', 'to', 'assess', 'if', 'unexpected', '(', 'randomized', ')', 'cues', 'are', 'more', 'effective', 'than', 'anticipated', 'ones', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 51,
                "text": "Patient-Triggered Sensory Cues",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 72,
                "text": "Freezing of Gait",
                "type": "CONTROL"
            },
            {
                "start": 76,
                "end": 95,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 147,
                "end": 207,
                "text": "patient triggered sensory(auditory, visual and tactile) cues",
                "type": "OTHER"
            },
            {
                "start": 223,
                "end": 239,
                "text": "freezing of gait",
                "type": "CONTROL"
            },
            {
                "start": 243,
                "end": 262,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 285,
                "end": 313,
                "text": "unexpected (randomized) cues",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05709210",
        "study_official_title": "Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease. ",
        "study_brief_summary": " This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.",
        "text": "Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease. | This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.",
        "tokens": "['Pilot', 'Study', 'on', 'the', 'Feasibility', 'of', 'Using', 'Smartphone', 'Data', 'as', 'a', 'Diagnostic', 'Marker', 'for', 'Alzheimer', \"'s\", 'Disease', '.', '|', 'This', 'study', 'will', 'compare', 'smartphone', 'usage', 'data', 'between', 'three', 'groups', 'of', 'patients', 'diagnosed', 'with', 'either', 'a', 'memory', 'complaint', ',', 'mild', 'cognitive', 'decline', ',', 'or', 'Alzheimer', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 83,
                "end": 102,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 225,
                "text": "memory complaint",
                "type": "CONDITION"
            },
            {
                "start": 227,
                "end": 249,
                "text": "mild cognitive decline",
                "type": "CONDITION"
            },
            {
                "start": 254,
                "end": 273,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03716648",
        "study_official_title": "Determination of the Optimal Mandibular Position During Oral Appliance Therapy With a Mandibular Advancement Device in Patients Diagnosed With Obstructive Sleep Apnea. ",
        "study_brief_summary": " In this prospective randomized cross-over trial, 3 different titration procedures will be compared:\n\ntitration of the mandibular advancement device (MAD) in the home setting based on both the physical limits of the patient's mandibular protrusion and the resolution of subjective complaints, as currently often used in routine clinical practice;\nan overnight titration PSG using the remotely controlled mandibular positioner (RCMP) with stepwise mandibular protrusion until respiratory events are reduced and\nincremental protrusion of the mandible during DISE using the RCMP until upper airway collapse at all collapsible levels is eliminated.\n\nThe aim of this study is to prospectively compare the target protrusion, as well as the treatment outcome in terms of treatment efficacy, of the 3 different titration protocols.",
        "text": "Determination of the Optimal Mandibular Position During Oral Appliance Therapy With a Mandibular Advancement Device in Patients Diagnosed With Obstructive Sleep Apnea. | In this prospective randomized cross-over trial, 3 different titration procedures will be compared:\n\ntitration of the mandibular advancement device (MAD) in the home setting based on both the physical limits of the patient's mandibular protrusion and the resolution of subjective complaints, as currently often used in routine clinical practice;\nan overnight titration PSG using the remotely controlled mandibular positioner (RCMP) with stepwise mandibular protrusion until respiratory events are reduced and\nincremental protrusion of the mandible during DISE using the RCMP until upper airway collapse at all collapsible levels is eliminated.\n\nThe aim of this study is to prospectively compare the target protrusion, as well as the treatment outcome in terms of treatment efficacy, of the 3 different titration protocols.",
        "tokens": "['Determination', 'of', 'the', 'Optimal', 'Mandibular', 'Position', 'During', 'Oral', 'Appliance', 'Therapy', 'With', 'a', 'Mandibular', 'Advancement', 'Device', 'in', 'Patients', 'Diagnosed', 'With', 'Obstructive', 'Sleep', 'Apnea', '.', '|', 'In', 'this', 'prospective', 'randomized', 'cross', '-', 'over', 'trial', ',', '3', 'different', 'titration', 'procedures', 'will', 'be', 'compared', ':', '\\n\\n', 'titration', 'of', 'the', 'mandibular', 'advancement', 'device', '(', 'MAD', ')', 'in', 'the', 'home', 'setting', 'based', 'on', 'both', 'the', 'physical', 'limits', 'of', 'the', 'patient', \"'s\", 'mandibular', 'protrusion', 'and', 'the', 'resolution', 'of', 'subjective', 'complaints', ',', 'as', 'currently', 'often', 'used', 'in', 'routine', 'clinical', 'practice', ';', '\\n', 'an', 'overnight', 'titration', 'PSG', 'using', 'the', 'remotely', 'controlled', 'mandibular', 'positioner', '(', 'RCMP', ')', 'with', 'stepwise', 'mandibular', 'protrusion', 'until', 'respiratory', 'events', 'are', 'reduced', 'and', '\\n', 'incremental', 'protrusion', 'of', 'the', 'mandible', 'during', 'DISE', 'using', 'the', 'RCMP', 'until', 'upper', 'airway', 'collapse', 'at', 'all', 'collapsible', 'levels', 'is', 'eliminated', '.', '\\n\\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'prospectively', 'compare', 'the', 'target', 'protrusion', ',', 'as', 'well', 'as', 'the', 'treatment', 'outcome', 'in', 'terms', 'of', 'treatment', 'efficacy', ',', 'of', 'the', '3', 'different', 'titration', 'protocols', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 56,
                "end": 78,
                "text": "Oral Appliance Therapy",
                "type": "OTHER"
            },
            {
                "start": 86,
                "end": 115,
                "text": "Mandibular Advancement Device",
                "type": "OTHER"
            },
            {
                "start": 143,
                "end": 166,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 288,
                "end": 317,
                "text": "mandibular advancement device",
                "type": "OTHER"
            },
            {
                "start": 319,
                "end": 322,
                "text": "MAD",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04816799",
        "study_official_title": "Efficacy of START (Startle Rehabilitation Therapy) in the Treatment Stroke-induced Aphasia/Apraxia ",
        "study_brief_summary": " A stratified, parallel-group, double-blind, randomized controlled trial of remotely delivered START treatment to individuals with severe-to-moderate stroke (with recruitment focused on individuals with low SES) will be conducted. Subjects and assessors will be blinded to the condition making the experiment double blind. Specifically, subjects will be told that we are exploring a new therapy that using different sounds to improve therapy. Parallel group design will ensure that subjects in the Control group are unaware that their \"sounds\" are softer than the START group. Trainers may become aware that a loud sound is present thus a unique Assessor will evaluate clinical performance before and after training making the study double-blind. Fifty-four subjects will undergo baseline testing in the laboratory to establish their capacity for functional and expressive speech as well as their self-reported health-related quality of life (power analysis below). Next, subjects will participate in a high-frequency, word-picture verification/ auditory-repetition treatment, 2 hr/day for 5 consecutive days focusing on expression of words of functional significance (e.g., water, fall). Subjects will either receive training with START or without (Control). Subjects will be re-tested immediately following training as well as one-month post to assess retention. Aim 1 will evaluate capacity of START to enhance SLT outcomes by assessing the % change in clinical assessment of functional and expressive speech. Our preliminary data points to a robust response [details]. Aim 2 will focus on the capacity of these changes to 1) be retained and 2) impact subject's reported quality of life. NOTE: While we are planning in-person baseline, end, and retention testing, in response to COVID, we have established remote clinical screening using peer-reviewed validated techniques for WAB and ABA-2 (see Alternative Solutions). All preliminary data collected for this proposal were collected remotely via no-contact protocols.",
        "text": "Efficacy of START (Startle Rehabilitation Therapy) in the Treatment Stroke-induced Aphasia/Apraxia | A stratified, parallel-group, double-blind, randomized controlled trial of remotely delivered START treatment to individuals with severe-to-moderate stroke (with recruitment focused on individuals with low SES) will be conducted. Subjects and assessors will be blinded to the condition making the experiment double blind. Specifically, subjects will be told that we are exploring a new therapy that using different sounds to improve therapy. Parallel group design will ensure that subjects in the Control group are unaware that their \"sounds\" are softer than the START group. Trainers may become aware that a loud sound is present thus a unique Assessor will evaluate clinical performance before and after training making the study double-blind. Fifty-four subjects will undergo baseline testing in the laboratory to establish their capacity for functional and expressive speech as well as their self-reported health-related quality of life (power analysis below). Next, subjects will participate in a high-frequency, word-picture verification/ auditory-repetition treatment, 2 hr/day for 5 consecutive days focusing on expression of words of functional significance (e.g., water, fall). Subjects will either receive training with START or without (Control). Subjects will be re-tested immediately following training as well as one-month post to assess retention. Aim 1 will evaluate capacity of START to enhance SLT outcomes by assessing the % change in clinical assessment of functional and expressive speech. Our preliminary data points to a robust response [details]. Aim 2 will focus on the capacity of these changes to 1) be retained and 2) impact subject's reported quality of life. NOTE: While we are planning in-person baseline, end, and retention testing, in response to COVID, we have established remote clinical screening using peer-reviewed validated techniques for WAB and ABA-2 (see Alternative Solutions). All preliminary data collected for this proposal were collected remotely via no-contact protocols.",
        "tokens": "['Efficacy', 'of', 'START', '(', 'Startle', 'Rehabilitation', 'Therapy', ')', 'in', 'the', 'Treatment', 'Stroke', '-', 'induced', 'Aphasia', '/', 'Apraxia', '|', 'A', 'stratified', ',', 'parallel', '-', 'group', ',', 'double', '-', 'blind', ',', 'randomized', 'controlled', 'trial', 'of', 'remotely', 'delivered', 'START', 'treatment', 'to', 'individuals', 'with', 'severe', '-', 'to', '-', 'moderate', 'stroke', '(', 'with', 'recruitment', 'focused', 'on', 'individuals', 'with', 'low', 'SES', ')', 'will', 'be', 'conducted', '.', 'Subjects', 'and', 'assessors', 'will', 'be', 'blinded', 'to', 'the', 'condition', 'making', 'the', 'experiment', 'double', 'blind', '.', 'Specifically', ',', 'subjects', 'will', 'be', 'told', 'that', 'we', 'are', 'exploring', 'a', 'new', 'therapy', 'that', 'using', 'different', 'sounds', 'to', 'improve', 'therapy', '.', 'Parallel', 'group', 'design', 'will', 'ensure', 'that', 'subjects', 'in', 'the', 'Control', 'group', 'are', 'unaware', 'that', 'their', '\"', 'sounds', '\"', 'are', 'softer', 'than', 'the', 'START', 'group', '.', 'Trainers', 'may', 'become', 'aware', 'that', 'a', 'loud', 'sound', 'is', 'present', 'thus', 'a', 'unique', 'Assessor', 'will', 'evaluate', 'clinical', 'performance', 'before', 'and', 'after', 'training', 'making', 'the', 'study', 'double', '-', 'blind', '.', 'Fifty', '-', 'four', 'subjects', 'will', 'undergo', 'baseline', 'testing', 'in', 'the', 'laboratory', 'to', 'establish', 'their', 'capacity', 'for', 'functional', 'and', 'expressive', 'speech', 'as', 'well', 'as', 'their', 'self', '-', 'reported', 'health', '-', 'related', 'quality', 'of', 'life', '(', 'power', 'analysis', 'below', ')', '.', 'Next', ',', 'subjects', 'will', 'participate', 'in', 'a', 'high', '-', 'frequency', ',', 'word', '-', 'picture', 'verification/', 'auditory', '-', 'repetition', 'treatment', ',', '2', 'hr', '/', 'day', 'for', '5', 'consecutive', 'days', 'focusing', 'on', 'expression', 'of', 'words', 'of', 'functional', 'significance', '(', 'e.g.', ',', 'water', ',', 'fall', ')', '.', 'Subjects', 'will', 'either', 'receive', 'training', 'with', 'START', 'or', 'without', '(', 'Control', ')', '.', 'Subjects', 'will', 'be', 're', '-', 'tested', 'immediately', 'following', 'training', 'as', 'well', 'as', 'one', '-', 'month', 'post', 'to', 'assess', 'retention', '.', 'Aim', '1', 'will', 'evaluate', 'capacity', 'of', 'START', 'to', 'enhance', 'SLT', 'outcomes', 'by', 'assessing', 'the', '%', 'change', 'in', 'clinical', 'assessment', 'of', 'functional', 'and', 'expressive', 'speech', '.', 'Our', 'preliminary', 'data', 'points', 'to', 'a', 'robust', 'response', '[', 'details', ']', '.', 'Aim', '2', 'will', 'focus', 'on', 'the', 'capacity', 'of', 'these', 'changes', 'to', '1', ')', 'be', 'retained', 'and', '2', ')', 'impact', 'subject', \"'s\", 'reported', 'quality', 'of', 'life', '.', 'NOTE', ':', 'While', 'we', 'are', 'planning', 'in', '-', 'person', 'baseline', ',', 'end', ',', 'and', 'retention', 'testing', ',', 'in', 'response', 'to', 'COVID', ',', 'we', 'have', 'established', 'remote', 'clinical', 'screening', 'using', 'peer', '-', 'reviewed', 'validated', 'techniques', 'for', 'WAB', 'and', 'ABA-2', '(', 'see', 'Alternative', 'Solutions', ')', '.', 'All', 'preliminary', 'data', 'collected', 'for', 'this', 'proposal', 'were', 'collected', 'remotely', 'via', 'no', '-', 'contact', 'protocols', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 17,
                "text": "START",
                "type": "OTHER"
            },
            {
                "start": 19,
                "end": 49,
                "text": "Startle Rehabilitation Therapy",
                "type": "OTHER"
            },
            {
                "start": 68,
                "end": 74,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 83,
                "end": 90,
                "text": "Aphasia",
                "type": "CONDITION"
            },
            {
                "start": 91,
                "end": 98,
                "text": "Apraxia",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 200,
                "text": "START",
                "type": "OTHER"
            },
            {
                "start": 231,
                "end": 256,
                "text": "severe-to-moderate stroke",
                "type": "CONDITION"
            },
            {
                "start": 500,
                "end": 541,
                "text": "using different sounds to improve therapy",
                "type": "OTHER"
            },
            {
                "start": 636,
                "end": 654,
                "text": "sounds\" are softer",
                "type": "CONTROL"
            },
            {
                "start": 664,
                "end": 669,
                "text": "START",
                "type": "OTHER"
            },
            {
                "start": 1103,
                "end": 1175,
                "text": "high-frequency, word-picture verification/ auditory-repetition treatment",
                "type": "OTHER"
            },
            {
                "start": 1332,
                "end": 1337,
                "text": "START",
                "type": "OTHER"
            },
            {
                "start": 1341,
                "end": 1348,
                "text": "without",
                "type": "CONTROL"
            },
            {
                "start": 1350,
                "end": 1357,
                "text": "Control",
                "type": "CONTROL"
            },
            {
                "start": 1497,
                "end": 1502,
                "text": "START",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03428360",
        "study_official_title": "An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Film (DBF) in Pediatric, Adolescent and Adult Subjects With Epilepsy ",
        "study_brief_summary": " This Phase 3, multicenter, open-label study of chronic, intermittent use of study drug (DBF) is designed to evaluate the safety and tolerability of the buccal formulation of diazepam in children, adolescents and adults with intermittent, stereotypic episodes of frequent seizure activity (eg, seizure clusters) that are distinct from the subject's usual seizure pattern.",
        "text": "An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Film (DBF) in Pediatric, Adolescent and Adult Subjects With Epilepsy | This Phase 3, multicenter, open-label study of chronic, intermittent use of study drug (DBF) is designed to evaluate the safety and tolerability of the buccal formulation of diazepam in children, adolescents and adults with intermittent, stereotypic episodes of frequent seizure activity (eg, seizure clusters) that are distinct from the subject's usual seizure pattern.",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Safety', 'and', 'Tolerability', 'Study', 'of', 'Chronic', 'Intermittent', 'Use', 'of', 'Diazepam', 'Buccal', 'Film', '(', 'DBF', ')', 'in', 'Pediatric', ',', 'Adolescent', 'and', 'Adult', 'Subjects', 'With', 'Epilepsy', '|', 'This', 'Phase', '3', ',', 'multicenter', ',', 'open', '-', 'label', 'study', 'of', 'chronic', ',', 'intermittent', 'use', 'of', 'study', 'drug', '(', 'DBF', ')', 'is', 'designed', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'the', 'buccal', 'formulation', 'of', 'diazepam', 'in', 'children', ',', 'adolescents', 'and', 'adults', 'with', 'intermittent', ',', 'stereotypic', 'episodes', 'of', 'frequent', 'seizure', 'activity', '(', 'eg', ',', 'seizure', 'clusters', ')', 'that', 'are', 'distinct', 'from', 'the', 'subject', \"'s\", 'usual', 'seizure', 'pattern', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 76,
                "end": 84,
                "text": "Diazepam",
                "type": "DRUG"
            },
            {
                "start": 98,
                "end": 101,
                "text": "DBF",
                "type": "DRUG"
            },
            {
                "start": 152,
                "end": 160,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 251,
                "end": 254,
                "text": "DBF",
                "type": "DRUG"
            },
            {
                "start": 337,
                "end": 345,
                "text": "diazepam",
                "type": "DRUG"
            },
            {
                "start": 387,
                "end": 450,
                "text": "intermittent, stereotypic episodes of frequent seizure activity",
                "type": "CONDITION"
            },
            {
                "start": 456,
                "end": 472,
                "text": "seizure clusters",
                "type": "CONDITION"
            },
            {
                "start": 517,
                "end": 524,
                "text": "seizure",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02235974",
        "study_official_title": "Critical Periods After Stroke Study (CPASS); Sensitive Periods and Consumer Preferences: Optimizing Upper Extremity Stroke Rehabilitation ",
        "study_brief_summary": " To perform an exploratory single center randomized study that will form the basis for a larger scale, more definitive randomized clinical trial to determine the optimal time after stroke for intensive motor training. The investigators will perform a prospective exploratory study of upper extremity (UE) motor training delivered at higher than usual intensity at three different time points after stroke:\n\nearly (initiated within 30 days)\nsubacute/outpatient (initiated within 2-3 months)\nchronic (initiated within 6-9 months)\n\nThe control group will not receive the therapy intervention during the 1-year study.\n\nOutcome measures will be assessed at baseline, pre-treatment, post-treatment, 6 months and one year after stroke onset.\n\nCompared to individuals randomized during the outpatient (2-3 months after stroke onset) or chronic (6-9 months after stroke onset) time points, participants randomized to early intensive motor training will show greater upper extremity motor improvement measured at one year post stroke.",
        "text": "Critical Periods After Stroke Study (CPASS); Sensitive Periods and Consumer Preferences: Optimizing Upper Extremity Stroke Rehabilitation | To perform an exploratory single center randomized study that will form the basis for a larger scale, more definitive randomized clinical trial to determine the optimal time after stroke for intensive motor training. The investigators will perform a prospective exploratory study of upper extremity (UE) motor training delivered at higher than usual intensity at three different time points after stroke:\n\nearly (initiated within 30 days)\nsubacute/outpatient (initiated within 2-3 months)\nchronic (initiated within 6-9 months)\n\nThe control group will not receive the therapy intervention during the 1-year study.\n\nOutcome measures will be assessed at baseline, pre-treatment, post-treatment, 6 months and one year after stroke onset.\n\nCompared to individuals randomized during the outpatient (2-3 months after stroke onset) or chronic (6-9 months after stroke onset) time points, participants randomized to early intensive motor training will show greater upper extremity motor improvement measured at one year post stroke.",
        "tokens": "['Critical', 'Periods', 'After', 'Stroke', 'Study', '(', 'CPASS', ')', ';', 'Sensitive', 'Periods', 'and', 'Consumer', 'Preferences', ':', 'Optimizing', 'Upper', 'Extremity', 'Stroke', 'Rehabilitation', '|', 'To', 'perform', 'an', 'exploratory', 'single', 'center', 'randomized', 'study', 'that', 'will', 'form', 'the', 'basis', 'for', 'a', 'larger', 'scale', ',', 'more', 'definitive', 'randomized', 'clinical', 'trial', 'to', 'determine', 'the', 'optimal', 'time', 'after', 'stroke', 'for', 'intensive', 'motor', 'training', '.', 'The', 'investigators', 'will', 'perform', 'a', 'prospective', 'exploratory', 'study', 'of', 'upper', 'extremity', '(', 'UE', ')', 'motor', 'training', 'delivered', 'at', 'higher', 'than', 'usual', 'intensity', 'at', 'three', 'different', 'time', 'points', 'after', 'stroke', ':', '\\n\\n', 'early', '(', 'initiated', 'within', '30', 'days', ')', '\\n', 'subacute', '/', 'outpatient', '(', 'initiated', 'within', '2', '-', '3', 'months', ')', '\\n', 'chronic', '(', 'initiated', 'within', '6', '-', '9', 'months', ')', '\\n\\n', 'The', 'control', 'group', 'will', 'not', 'receive', 'the', 'therapy', 'intervention', 'during', 'the', '1', '-', 'year', 'study', '.', '\\n\\n', 'Outcome', 'measures', 'will', 'be', 'assessed', 'at', 'baseline', ',', 'pre', '-', 'treatment', ',', 'post', '-', 'treatment', ',', '6', 'months', 'and', 'one', 'year', 'after', 'stroke', 'onset', '.', '\\n\\n', 'Compared', 'to', 'individuals', 'randomized', 'during', 'the', 'outpatient', '(', '2', '-', '3', 'months', 'after', 'stroke', 'onset', ')', 'or', 'chronic', '(', '6', '-', '9', 'months', 'after', 'stroke', 'onset', ')', 'time', 'points', ',', 'participants', 'randomized', 'to', 'early', 'intensive', 'motor', 'training', 'will', 'show', 'greater', 'upper', 'extremity', 'motor', 'improvement', 'measured', 'at', 'one', 'year', 'post', 'stroke', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 116,
                "end": 122,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 320,
                "end": 326,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 331,
                "end": 355,
                "text": "intensive motor training",
                "type": "PHYSICAL"
            },
            {
                "start": 423,
                "end": 458,
                "text": "upper extremity (UE) motor training",
                "type": "PHYSICAL"
            },
            {
                "start": 537,
                "end": 543,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 691,
                "end": 714,
                "text": "not receive the therapy",
                "type": "CONTROL"
            },
            {
                "start": 860,
                "end": 866,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 950,
                "end": 956,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1053,
                "end": 1077,
                "text": "intensive motor training",
                "type": "PHYSICAL"
            },
            {
                "start": 1156,
                "end": 1162,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05063708",
        "study_official_title": "To Evaluate the Activity and the Efficacy of Traditional Swallowing Therapy (TST) Plus Neuromuscular Electrostimulation (NMES) vs TST Plus Sham- NMES in Multiple Sclerosis People With Dysphagia ",
        "study_brief_summary": " Dysphagia is a disabling, life-threatening symptom that can cause death in Multiple Sclerosis people (pwMS) through aspiration pneumonia. Speech therapists use behavioural therapies (compensatory and rehabilitative) to alleviate such swallowing problems, with limited benefit. Compensatory strategies such as postural changes and changes in food consistency, have been found to be partially effective, especially in patients with mild dysphagia and may be ineffective in patients with more severe dysphagia. The rehabilitative strategies include \"no swallow exercises\" which aim to strengthen isolated muscles used in swallowing (such as tongue strengthening) and \"swallowing exercises\" that aim at strengthening all the muscles used in swallowing while executing a hard, effortful, or prolonged swallow. To date, no randomized clinical trials have shown that rehabilitative strategies are effective. Neuromuscular electrical stimulation (NMES), often referred to as electrical stimulation, was introduced as a novel therapy for dysphagia in the late 2001. The principles of NMES in the limb rehabilitation literature are well established. However published protocols applying NMES to swallowing function have shown mixed results in people with stroke and only one study was published on MS people. This will be a double blinded, randomized clinical trial (patients and research staff blinded) with two arms: standard speech therapy plus Active NMES vs speech therapy with Sham NMES. The aim of this study is to determine whether NMES added benefit to a therapy program comprised of standard swallowing exercises in dysphagic pwMS.",
        "text": "To Evaluate the Activity and the Efficacy of Traditional Swallowing Therapy (TST) Plus Neuromuscular Electrostimulation (NMES) vs TST Plus Sham- NMES in Multiple Sclerosis People With Dysphagia | Dysphagia is a disabling, life-threatening symptom that can cause death in Multiple Sclerosis people (pwMS) through aspiration pneumonia. Speech therapists use behavioural therapies (compensatory and rehabilitative) to alleviate such swallowing problems, with limited benefit. Compensatory strategies such as postural changes and changes in food consistency, have been found to be partially effective, especially in patients with mild dysphagia and may be ineffective in patients with more severe dysphagia. The rehabilitative strategies include \"no swallow exercises\" which aim to strengthen isolated muscles used in swallowing (such as tongue strengthening) and \"swallowing exercises\" that aim at strengthening all the muscles used in swallowing while executing a hard, effortful, or prolonged swallow. To date, no randomized clinical trials have shown that rehabilitative strategies are effective. Neuromuscular electrical stimulation (NMES), often referred to as electrical stimulation, was introduced as a novel therapy for dysphagia in the late 2001. The principles of NMES in the limb rehabilitation literature are well established. However published protocols applying NMES to swallowing function have shown mixed results in people with stroke and only one study was published on MS people. This will be a double blinded, randomized clinical trial (patients and research staff blinded) with two arms: standard speech therapy plus Active NMES vs speech therapy with Sham NMES. The aim of this study is to determine whether NMES added benefit to a therapy program comprised of standard swallowing exercises in dysphagic pwMS.",
        "tokens": "['To', 'Evaluate', 'the', 'Activity', 'and', 'the', 'Efficacy', 'of', 'Traditional', 'Swallowing', 'Therapy', '(', 'TST', ')', 'Plus', 'Neuromuscular', 'Electrostimulation', '(', 'NMES', ')', 'vs', 'TST', 'Plus', 'Sham-', 'NMES', 'in', 'Multiple', 'Sclerosis', 'People', 'With', 'Dysphagia', '|', 'Dysphagia', 'is', 'a', 'disabling', ',', 'life', '-', 'threatening', 'symptom', 'that', 'can', 'cause', 'death', 'in', 'Multiple', 'Sclerosis', 'people', '(', 'pwMS', ')', 'through', 'aspiration', 'pneumonia', '.', 'Speech', 'therapists', 'use', 'behavioural', 'therapies', '(', 'compensatory', 'and', 'rehabilitative', ')', 'to', 'alleviate', 'such', 'swallowing', 'problems', ',', 'with', 'limited', 'benefit', '.', 'Compensatory', 'strategies', 'such', 'as', 'postural', 'changes', 'and', 'changes', 'in', 'food', 'consistency', ',', 'have', 'been', 'found', 'to', 'be', 'partially', 'effective', ',', 'especially', 'in', 'patients', 'with', 'mild', 'dysphagia', 'and', 'may', 'be', 'ineffective', 'in', 'patients', 'with', 'more', 'severe', 'dysphagia', '.', 'The', 'rehabilitative', 'strategies', 'include', '\"', 'no', 'swallow', 'exercises', '\"', 'which', 'aim', 'to', 'strengthen', 'isolated', 'muscles', 'used', 'in', 'swallowing', '(', 'such', 'as', 'tongue', 'strengthening', ')', 'and', '\"', 'swallowing', 'exercises', '\"', 'that', 'aim', 'at', 'strengthening', 'all', 'the', 'muscles', 'used', 'in', 'swallowing', 'while', 'executing', 'a', 'hard', ',', 'effortful', ',', 'or', 'prolonged', 'swallow', '.', 'To', 'date', ',', 'no', 'randomized', 'clinical', 'trials', 'have', 'shown', 'that', 'rehabilitative', 'strategies', 'are', 'effective', '.', 'Neuromuscular', 'electrical', 'stimulation', '(', 'NMES', ')', ',', 'often', 'referred', 'to', 'as', 'electrical', 'stimulation', ',', 'was', 'introduced', 'as', 'a', 'novel', 'therapy', 'for', 'dysphagia', 'in', 'the', 'late', '2001', '.', 'The', 'principles', 'of', 'NMES', 'in', 'the', 'limb', 'rehabilitation', 'literature', 'are', 'well', 'established', '.', 'However', 'published', 'protocols', 'applying', 'NMES', 'to', 'swallowing', 'function', 'have', 'shown', 'mixed', 'results', 'in', 'people', 'with', 'stroke', 'and', 'only', 'one', 'study', 'was', 'published', 'on', 'MS', 'people', '.', 'This', 'will', 'be', 'a', 'double', 'blinded', ',', 'randomized', 'clinical', 'trial', '(', 'patients', 'and', 'research', 'staff', 'blinded', ')', 'with', 'two', 'arms', ':', 'standard', 'speech', 'therapy', 'plus', 'Active', 'NMES', 'vs', 'speech', 'therapy', 'with', 'Sham', 'NMES', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'NMES', 'added', 'benefit', 'to', 'a', 'therapy', 'program', 'comprised', 'of', 'standard', 'swallowing', 'exercises', 'in', 'dysphagic', 'pwMS', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 45,
                "end": 75,
                "text": "Traditional Swallowing Therapy",
                "type": "OTHER"
            },
            {
                "start": 77,
                "end": 80,
                "text": "TST",
                "type": "OTHER"
            },
            {
                "start": 87,
                "end": 119,
                "text": "Neuromuscular Electrostimulation",
                "type": "OTHER"
            },
            {
                "start": 121,
                "end": 125,
                "text": "NMES",
                "type": "OTHER"
            },
            {
                "start": 130,
                "end": 133,
                "text": "TST",
                "type": "CONTROL"
            },
            {
                "start": 139,
                "end": 149,
                "text": "Sham- NMES",
                "type": "CONTROL"
            },
            {
                "start": 153,
                "end": 171,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 193,
                "text": "Dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 196,
                "end": 205,
                "text": "Dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 289,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 626,
                "end": 640,
                "text": "mild dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 686,
                "end": 702,
                "text": "severe dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 743,
                "end": 763,
                "text": "no swallow exercises",
                "type": "OTHER"
            },
            {
                "start": 861,
                "end": 881,
                "text": "swallowing exercises",
                "type": "OTHER"
            },
            {
                "start": 1097,
                "end": 1133,
                "text": "Neuromuscular electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 1135,
                "end": 1139,
                "text": "NMES",
                "type": "OTHER"
            },
            {
                "start": 1163,
                "end": 1185,
                "text": "electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 1225,
                "end": 1234,
                "text": "dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 1271,
                "end": 1275,
                "text": "NMES",
                "type": "OTHER"
            },
            {
                "start": 1373,
                "end": 1377,
                "text": "NMES",
                "type": "OTHER"
            },
            {
                "start": 1484,
                "end": 1486,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1605,
                "end": 1628,
                "text": "standard speech therapy",
                "type": "OTHER"
            },
            {
                "start": 1634,
                "end": 1645,
                "text": "Active NMES",
                "type": "OTHER"
            },
            {
                "start": 1649,
                "end": 1663,
                "text": "speech therapy",
                "type": "CONTROL"
            },
            {
                "start": 1669,
                "end": 1678,
                "text": "Sham NMES",
                "type": "CONTROL"
            },
            {
                "start": 1726,
                "end": 1730,
                "text": "NMES",
                "type": "OTHER"
            },
            {
                "start": 1812,
                "end": 1821,
                "text": "dysphagic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02059980",
        "study_official_title": "Developing Effective Response Inhibition Training for Symptom Relief in Obsessive-Compulsive and Related Disorders and Trichotillomania ",
        "study_brief_summary": " Obsessive-compulsive disorder (OCD) and its related disorders (e.g., trichotillomania) are characterized by the marked difficulty in inhibiting unwanted or inappropriate responses. There is compelling evidence that poor response inhibition is a core cognitive feature of OCD and its related disorders, but no effective intervention exists that directly attempts to address this problematic cognitive deficiency. This study will examine the feasibility and clinical utility of a computerized cognitive training program designed to improve response inhibition among individuals diagnosed with OCD or trichotillomania.This training program offers systematic practice of response inhibition in the form of a 40-level computer game. Individuals with these conditions will be randomized to either 8 sessions of (a) computerized response inhibition training (RIT) or (b) placebo computer training (PLT). We hypothesize that RIT will outperform PLT in improving response inhibition capabilities and reducing relevant clinical symptoms. In sum, this project is expected to generate important knowledge to guide the development of effective computer-based treatment approaches that may help reduce critical problems of existing treatments such as suboptimal patient retention and treatment under-utilization, thereby improving overall treatment response rates among individuals suffering from OCD and related conditions.",
        "text": "Developing Effective Response Inhibition Training for Symptom Relief in Obsessive-Compulsive and Related Disorders and Trichotillomania | Obsessive-compulsive disorder (OCD) and its related disorders (e.g., trichotillomania) are characterized by the marked difficulty in inhibiting unwanted or inappropriate responses. There is compelling evidence that poor response inhibition is a core cognitive feature of OCD and its related disorders, but no effective intervention exists that directly attempts to address this problematic cognitive deficiency. This study will examine the feasibility and clinical utility of a computerized cognitive training program designed to improve response inhibition among individuals diagnosed with OCD or trichotillomania.This training program offers systematic practice of response inhibition in the form of a 40-level computer game. Individuals with these conditions will be randomized to either 8 sessions of (a) computerized response inhibition training (RIT) or (b) placebo computer training (PLT). We hypothesize that RIT will outperform PLT in improving response inhibition capabilities and reducing relevant clinical symptoms. In sum, this project is expected to generate important knowledge to guide the development of effective computer-based treatment approaches that may help reduce critical problems of existing treatments such as suboptimal patient retention and treatment under-utilization, thereby improving overall treatment response rates among individuals suffering from OCD and related conditions.",
        "tokens": "['Developing', 'Effective', 'Response', 'Inhibition', 'Training', 'for', 'Symptom', 'Relief', 'in', 'Obsessive', '-', 'Compulsive', 'and', 'Related', 'Disorders', 'and', 'Trichotillomania', '|', 'Obsessive', '-', 'compulsive', 'disorder', '(', 'OCD', ')', 'and', 'its', 'related', 'disorders', '(', 'e.g.', ',', 'trichotillomania', ')', 'are', 'characterized', 'by', 'the', 'marked', 'difficulty', 'in', 'inhibiting', 'unwanted', 'or', 'inappropriate', 'responses', '.', 'There', 'is', 'compelling', 'evidence', 'that', 'poor', 'response', 'inhibition', 'is', 'a', 'core', 'cognitive', 'feature', 'of', 'OCD', 'and', 'its', 'related', 'disorders', ',', 'but', 'no', 'effective', 'intervention', 'exists', 'that', 'directly', 'attempts', 'to', 'address', 'this', 'problematic', 'cognitive', 'deficiency', '.', 'This', 'study', 'will', 'examine', 'the', 'feasibility', 'and', 'clinical', 'utility', 'of', 'a', 'computerized', 'cognitive', 'training', 'program', 'designed', 'to', 'improve', 'response', 'inhibition', 'among', 'individuals', 'diagnosed', 'with', 'OCD', 'or', 'trichotillomania', '.', 'This', 'training', 'program', 'offers', 'systematic', 'practice', 'of', 'response', 'inhibition', 'in', 'the', 'form', 'of', 'a', '40', '-', 'level', 'computer', 'game', '.', 'Individuals', 'with', 'these', 'conditions', 'will', 'be', 'randomized', 'to', 'either', '8', 'sessions', 'of', '(', 'a', ')', 'computerized', 'response', 'inhibition', 'training', '(', 'RIT', ')', 'or', '(', 'b', ')', 'placebo', 'computer', 'training', '(', 'PLT', ')', '.', 'We', 'hypothesize', 'that', 'RIT', 'will', 'outperform', 'PLT', 'in', 'improving', 'response', 'inhibition', 'capabilities', 'and', 'reducing', 'relevant', 'clinical', 'symptoms', '.', 'In', 'sum', ',', 'this', 'project', 'is', 'expected', 'to', 'generate', 'important', 'knowledge', 'to', 'guide', 'the', 'development', 'of', 'effective', 'computer', '-', 'based', 'treatment', 'approaches', 'that', 'may', 'help', 'reduce', 'critical', 'problems', 'of', 'existing', 'treatments', 'such', 'as', 'suboptimal', 'patient', 'retention', 'and', 'treatment', 'under', '-', 'utilization', ',', 'thereby', 'improving', 'overall', 'treatment', 'response', 'rates', 'among', 'individuals', 'suffering', 'from', 'OCD', 'and', 'related', 'conditions', '.']",
        "token_bio_labels": "['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 49,
                "text": "Response Inhibition Training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 72,
                "end": 114,
                "text": "Obsessive-Compulsive and Related Disorders",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 135,
                "text": "Trichotillomania",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 167,
                "text": "Obsessive-compulsive disorder",
                "type": "CONDITION"
            },
            {
                "start": 169,
                "end": 172,
                "text": "OCD",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 223,
                "text": "trichotillomania",
                "type": "CONDITION"
            },
            {
                "start": 409,
                "end": 412,
                "text": "OCD",
                "type": "CONDITION"
            },
            {
                "start": 528,
                "end": 548,
                "text": "cognitive deficiency",
                "type": "CONDITION"
            },
            {
                "start": 616,
                "end": 655,
                "text": "computerized cognitive training program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 729,
                "end": 732,
                "text": "OCD",
                "type": "CONDITION"
            },
            {
                "start": 736,
                "end": 752,
                "text": "trichotillomania",
                "type": "CONDITION"
            },
            {
                "start": 782,
                "end": 824,
                "text": "systematic practice of response inhibition",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 842,
                "end": 864,
                "text": "40-level computer game",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 947,
                "end": 988,
                "text": "computerized response inhibition training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 990,
                "end": 993,
                "text": "RIT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1002,
                "end": 1027,
                "text": "placebo computer training",
                "type": "CONTROL"
            },
            {
                "start": 1029,
                "end": 1032,
                "text": "PLT",
                "type": "CONTROL"
            },
            {
                "start": 1055,
                "end": 1058,
                "text": "RIT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1075,
                "end": 1078,
                "text": "PLT",
                "type": "CONTROL"
            },
            {
                "start": 1521,
                "end": 1524,
                "text": "OCD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01590745",
        "study_official_title": "A Randomised Controlled Double Blind Trial Of Therapeutic Ultrasound in Carpal Tunnel Syndrome (CTS) ",
        "study_brief_summary": " Carpal Tunnel Syndrome (CTS) is a recognisable pattern of symptoms and signs, which are caused by compression of the median (middle) nerve as it passes through the carpal tunnel at the wrist.\n\nThis condition affects individuals by causing pain, numbness, tingling sensations and sometimes weakness in the fingers and may extend to shoulder and neck areas. The cause for most cases is unknown (idiopathic) though some common conditions are associated with an increased incidence, including obesity, pregnancy, hypothyroidism, arthritis, diabetes, and trauma.\n\nDiagnosis is primarily clinical and the condition is easily recognised from the characteristic symptoms in straightforward cases but diagnostic support is provided by investigations such as nerve conduction studies and ultrasound imaging.\n\nTreatment may include splinting, local steroid injection at wrist, activity modification,physical or occupational therapy (controversial), medications, and surgery. Treatment with local therapeutic ultrasound has been suggested to be effective but existing trials are inconclusive.\n\nWrist splinting is only partially effective with a success rate of 34%, Steroid injection is followed by frequent relapses and there remains uncertainty about the safety of serial injections. Surgery is effective but has a small but significant incidence of permanent complications. Any demonstrably effective and safe addition to the therapeutic options would be a significant advance in treatment. Therapeutic ultrasound at present appears a promising option, having a very good safety record but so far uncertain evidence of efficacy.\n\nIn our trial patients, with mild carpal tunnel syndrome, confirmed by nerve conduction studies, will all be given wrist splints so that no patients will be left untreated. They will be randomly allocated to either therapeutic or sham ultrasound therapy (20 sessions over 7 weeks) and followed up for 1year. The patients, operators of the ultrasound equipment and assessors will all be blind to treatment allocation.\n\nThe effect of treatment on symptoms will be assessed using a validated questionnaire and nerve conduction studies will be repeated at completion of the ultrasound treatment, 6 and 12 months.\n\nThis study is designed to find out to whether therapeutic ultrasound is an effective treatment for carpal tunnel syndrome (CTS).",
        "text": "A Randomised Controlled Double Blind Trial Of Therapeutic Ultrasound in Carpal Tunnel Syndrome (CTS) | Carpal Tunnel Syndrome (CTS) is a recognisable pattern of symptoms and signs, which are caused by compression of the median (middle) nerve as it passes through the carpal tunnel at the wrist.\n\nThis condition affects individuals by causing pain, numbness, tingling sensations and sometimes weakness in the fingers and may extend to shoulder and neck areas. The cause for most cases is unknown (idiopathic) though some common conditions are associated with an increased incidence, including obesity, pregnancy, hypothyroidism, arthritis, diabetes, and trauma.\n\nDiagnosis is primarily clinical and the condition is easily recognised from the characteristic symptoms in straightforward cases but diagnostic support is provided by investigations such as nerve conduction studies and ultrasound imaging.\n\nTreatment may include splinting, local steroid injection at wrist, activity modification,physical or occupational therapy (controversial), medications, and surgery. Treatment with local therapeutic ultrasound has been suggested to be effective but existing trials are inconclusive.\n\nWrist splinting is only partially effective with a success rate of 34%, Steroid injection is followed by frequent relapses and there remains uncertainty about the safety of serial injections. Surgery is effective but has a small but significant incidence of permanent complications. Any demonstrably effective and safe addition to the therapeutic options would be a significant advance in treatment. Therapeutic ultrasound at present appears a promising option, having a very good safety record but so far uncertain evidence of efficacy.\n\nIn our trial patients, with mild carpal tunnel syndrome, confirmed by nerve conduction studies, will all be given wrist splints so that no patients will be left untreated. They will be randomly allocated to either therapeutic or sham ultrasound therapy (20 sessions over 7 weeks) and followed up for 1year. The patients, operators of the ultrasound equipment and assessors will all be blind to treatment allocation.\n\nThe effect of treatment on symptoms will be assessed using a validated questionnaire and nerve conduction studies will be repeated at completion of the ultrasound treatment, 6 and 12 months.\n\nThis study is designed to find out to whether therapeutic ultrasound is an effective treatment for carpal tunnel syndrome (CTS).",
        "tokens": "['A', 'Randomised', 'Controlled', 'Double', 'Blind', 'Trial', 'Of', 'Therapeutic', 'Ultrasound', 'in', 'Carpal', 'Tunnel', 'Syndrome', '(', 'CTS', ')', '|', 'Carpal', 'Tunnel', 'Syndrome', '(', 'CTS', ')', 'is', 'a', 'recognisable', 'pattern', 'of', 'symptoms', 'and', 'signs', ',', 'which', 'are', 'caused', 'by', 'compression', 'of', 'the', 'median', '(', 'middle', ')', 'nerve', 'as', 'it', 'passes', 'through', 'the', 'carpal', 'tunnel', 'at', 'the', 'wrist', '.', '\\n\\n', 'This', 'condition', 'affects', 'individuals', 'by', 'causing', 'pain', ',', 'numbness', ',', 'tingling', 'sensations', 'and', 'sometimes', 'weakness', 'in', 'the', 'fingers', 'and', 'may', 'extend', 'to', 'shoulder', 'and', 'neck', 'areas', '.', 'The', 'cause', 'for', 'most', 'cases', 'is', 'unknown', '(', 'idiopathic', ')', 'though', 'some', 'common', 'conditions', 'are', 'associated', 'with', 'an', 'increased', 'incidence', ',', 'including', 'obesity', ',', 'pregnancy', ',', 'hypothyroidism', ',', 'arthritis', ',', 'diabetes', ',', 'and', 'trauma', '.', '\\n\\n', 'Diagnosis', 'is', 'primarily', 'clinical', 'and', 'the', 'condition', 'is', 'easily', 'recognised', 'from', 'the', 'characteristic', 'symptoms', 'in', 'straightforward', 'cases', 'but', 'diagnostic', 'support', 'is', 'provided', 'by', 'investigations', 'such', 'as', 'nerve', 'conduction', 'studies', 'and', 'ultrasound', 'imaging', '.', '\\n\\n', 'Treatment', 'may', 'include', 'splinting', ',', 'local', 'steroid', 'injection', 'at', 'wrist', ',', 'activity', 'modification', ',', 'physical', 'or', 'occupational', 'therapy', '(', 'controversial', ')', ',', 'medications', ',', 'and', 'surgery', '.', 'Treatment', 'with', 'local', 'therapeutic', 'ultrasound', 'has', 'been', 'suggested', 'to', 'be', 'effective', 'but', 'existing', 'trials', 'are', 'inconclusive', '.', '\\n\\n', 'Wrist', 'splinting', 'is', 'only', 'partially', 'effective', 'with', 'a', 'success', 'rate', 'of', '34', '%', ',', 'Steroid', 'injection', 'is', 'followed', 'by', 'frequent', 'relapses', 'and', 'there', 'remains', 'uncertainty', 'about', 'the', 'safety', 'of', 'serial', 'injections', '.', 'Surgery', 'is', 'effective', 'but', 'has', 'a', 'small', 'but', 'significant', 'incidence', 'of', 'permanent', 'complications', '.', 'Any', 'demonstrably', 'effective', 'and', 'safe', 'addition', 'to', 'the', 'therapeutic', 'options', 'would', 'be', 'a', 'significant', 'advance', 'in', 'treatment', '.', 'Therapeutic', 'ultrasound', 'at', 'present', 'appears', 'a', 'promising', 'option', ',', 'having', 'a', 'very', 'good', 'safety', 'record', 'but', 'so', 'far', 'uncertain', 'evidence', 'of', 'efficacy', '.', '\\n\\n', 'In', 'our', 'trial', 'patients', ',', 'with', 'mild', 'carpal', 'tunnel', 'syndrome', ',', 'confirmed', 'by', 'nerve', 'conduction', 'studies', ',', 'will', 'all', 'be', 'given', 'wrist', 'splints', 'so', 'that', 'no', 'patients', 'will', 'be', 'left', 'untreated', '.', 'They', 'will', 'be', 'randomly', 'allocated', 'to', 'either', 'therapeutic', 'or', 'sham', 'ultrasound', 'therapy', '(', '20', 'sessions', 'over', '7', 'weeks', ')', 'and', 'followed', 'up', 'for', '1year', '.', 'The', 'patients', ',', 'operators', 'of', 'the', 'ultrasound', 'equipment', 'and', 'assessors', 'will', 'all', 'be', 'blind', 'to', 'treatment', 'allocation', '.', '\\n\\n', 'The', 'effect', 'of', 'treatment', 'on', 'symptoms', 'will', 'be', 'assessed', 'using', 'a', 'validated', 'questionnaire', 'and', 'nerve', 'conduction', 'studies', 'will', 'be', 'repeated', 'at', 'completion', 'of', 'the', 'ultrasound', 'treatment', ',', '6', 'and', '12', 'months', '.', '\\n\\n', 'This', 'study', 'is', 'designed', 'to', 'find', 'out', 'to', 'whether', 'therapeutic', 'ultrasound', 'is', 'an', 'effective', 'treatment', 'for', 'carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 46,
                "end": 68,
                "text": "Therapeutic Ultrasound",
                "type": "OTHER"
            },
            {
                "start": 72,
                "end": 94,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 99,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 125,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 127,
                "end": 130,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 1088,
                "end": 1110,
                "text": "therapeutic ultrasound",
                "type": "OTHER"
            },
            {
                "start": 1585,
                "end": 1607,
                "text": "Therapeutic ultrasound",
                "type": "OTHER"
            },
            {
                "start": 1757,
                "end": 1779,
                "text": "carpal tunnel syndrome",
                "type": "CONDITION"
            },
            {
                "start": 1953,
                "end": 1976,
                "text": "sham ultrasound therapy",
                "type": "CONTROL"
            },
            {
                "start": 2293,
                "end": 2313,
                "text": "ultrasound treatment",
                "type": "OTHER"
            },
            {
                "start": 2379,
                "end": 2401,
                "text": "therapeutic ultrasound",
                "type": "OTHER"
            },
            {
                "start": 2432,
                "end": 2454,
                "text": "carpal tunnel syndrome",
                "type": "CONDITION"
            },
            {
                "start": 2456,
                "end": 2459,
                "text": "CTS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05217628",
        "study_official_title": "A Phase II/III, Multicentre, 8-week run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, With a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 mg Basimglurant in Patients With Pain Associated With Trigeminal Neuralgia With Suboptimal Response to Their Current Anti-pain Therapy. ",
        "study_brief_summary": " Trigeminal neuralgia (TN), also called \"tic douloureux\", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice.\n\nThis study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.",
        "text": "A Phase II/III, Multicentre, 8-week run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, With a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 mg Basimglurant in Patients With Pain Associated With Trigeminal Neuralgia With Suboptimal Response to Their Current Anti-pain Therapy. | Trigeminal neuralgia (TN), also called \"tic douloureux\", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice.\n\nThis study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.",
        "tokens": "['A', 'Phase', 'II', '/', 'III', ',', 'Multicentre', ',', '8', '-', 'week', 'run', '-', 'in', 'Phase', 'Followed', 'by', 'a', '12', '-', 'week', ',', 'Prospective', ',', 'Parallel', '-', 'group', ',', 'Double', '-', 'blind', ',', 'Randomized', 'Withdrawal', ',', 'Placebo', '-', 'controlled', 'Study', ',', 'With', 'a', '52', 'Week', 'Open', 'Label', 'Extension', ',', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Daily', '1.5', 'to', '3.5', 'mg', 'Basimglurant', 'in', 'Patients', 'With', 'Pain', 'Associated', 'With', 'Trigeminal', 'Neuralgia', 'With', 'Suboptimal', 'Response', 'to', 'Their', 'Current', 'Anti', '-', 'pain', 'Therapy', '.', '|', 'Trigeminal', 'neuralgia', '(', 'TN', ')', ',', 'also', 'called', '\"', 'tic', 'douloureux', '\"', ',', 'is', 'the', 'most', 'common', 'form', 'of', 'craniofacial', 'neuropathic', 'pain', 'and', 'is', 'considered', 'the', 'cause', 'of', 'one', 'of', 'the', 'most', 'painful', 'afflictions', 'known', 'in', 'medical', 'practice', '.', '\\n\\n', 'This', 'study', 'is', 'designed', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', '1.5', 'mg', '-', '3.5', 'mg', 'basimglurant', 'in', 'adults', 'with', 'TN', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 138,
                "end": 145,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 260,
                "end": 272,
                "text": "Basimglurant",
                "type": "DRUG"
            },
            {
                "start": 290,
                "end": 294,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 311,
                "end": 331,
                "text": "Trigeminal Neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 395,
                "end": 415,
                "text": "Trigeminal neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 417,
                "end": 419,
                "text": "TN",
                "type": "CONDITION"
            },
            {
                "start": 435,
                "end": 449,
                "text": "tic douloureux",
                "type": "CONDITION"
            },
            {
                "start": 479,
                "end": 508,
                "text": "craniofacial neuropathic pain",
                "type": "CONDITION"
            },
            {
                "start": 680,
                "end": 692,
                "text": "basimglurant",
                "type": "DRUG"
            },
            {
                "start": 708,
                "end": 710,
                "text": "TN",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04678115",
        "study_official_title": "A Randomized Cross-Over Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis ",
        "study_brief_summary": " This clinical trial will evaluate two non-surgical devices designed to improve eye lid opening for patients with severe Blepharoptosis (incomplete opening of the eyelids).",
        "text": "A Randomized Cross-Over Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis | This clinical trial will evaluate two non-surgical devices designed to improve eye lid opening for patients with severe Blepharoptosis (incomplete opening of the eyelids).",
        "tokens": "['A', 'Randomized', 'Cross', '-', 'Over', 'Clinical', 'Trial', 'Comparing', 'Two', 'Non', '-', 'Surgical', 'Treatments', 'for', 'Severe', 'Blepharoptosis', '|', 'This', 'clinical', 'trial', 'will', 'evaluate', 'two', 'non', '-', 'surgical', 'devices', 'designed', 'to', 'improve', 'eye', 'lid', 'opening', 'for', 'patients', 'with', 'severe', 'Blepharoptosis', '(', 'incomplete', 'opening', 'of', 'the', 'eyelids', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 53,
                "end": 76,
                "text": "Non-Surgical Treatments",
                "type": "OTHER"
            },
            {
                "start": 81,
                "end": 102,
                "text": "Severe Blepharoptosis",
                "type": "CONDITION"
            },
            {
                "start": 143,
                "end": 212,
                "text": "non-surgical devices designed to improve eye lid opening for patients",
                "type": "OTHER"
            },
            {
                "start": 218,
                "end": 239,
                "text": "severe Blepharoptosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00573612",
        "study_official_title": "Exercise-based Motivational Interviewing for Fibromyalgia ",
        "study_brief_summary": " Fibromyalgia (FMS), defined as the presence of both chronic widespread pain and the finding of 11/18 tender points on examination, affects 2% of the general population. Drug therapy for FMS is largely symptomatic as there is not yet a complete understanding of the pathogenesis of the disease. In the past 17 years, supervised aerobic exercise has emerged as an important treatment modality to improve pain, aerobic capacity, function, and well-being. Individuals who are able to adhere to exercise almost always maintain the symptomatic benefits of exercise. Unfortunately, the rate of exercise adherence six months after the completion of a well-structured supervised exercise program is disappointingly low. Furthermore, although the efficacy of supervised aerobic exercise in the research setting is well documented, the applicability of such intervention in the clinic setting is doubtful. Therefore, we propose to conduct the Research to Encourage Exercise for Fibromyalgia (REEF), a randomized attention-controlled trial whose primary aim is to evaluate the efficacy of telephone-delivered motivational interviewing (MI) to encourage exercise, in improving exercise adherence and self-report physical function (co-primary outcome measures) for FMS patients. REEF will enroll 200 FMS patients, randomizing them to either the MI group or the attention-control (AC) group. Participants from each group will receive a total of 6 telephone calls within a 12-week period. Prior to the phone calls, participants from both groups will receive an individualized exercise prescription and 2 supervised exercise training sessions to get them started on an exercise program. All subjects will undergo comprehensive outcome assessment at baseline, week 12, week 24, and week 36. The secondary aim of this proposal is to determine the mediators between MI and improvement in self-report physical function. The proposed research is significant because our focus is the promotion of adherence to an exercise program, of adequate intensity, in order to maximize functioning and well-being for patients with FMS. The use of a predominantly home-based exercise program and telephone-delivered MI by a trained licensed practice nurse (LPN) could potentially make the proposed intervention more accessible to the greater majority of FMS patients. Furthermore, if proven efficacious, MI could readily be applied to other chronically painful conditions (e.g. chronic back pain).",
        "text": "Exercise-based Motivational Interviewing for Fibromyalgia | Fibromyalgia (FMS), defined as the presence of both chronic widespread pain and the finding of 11/18 tender points on examination, affects 2% of the general population. Drug therapy for FMS is largely symptomatic as there is not yet a complete understanding of the pathogenesis of the disease. In the past 17 years, supervised aerobic exercise has emerged as an important treatment modality to improve pain, aerobic capacity, function, and well-being. Individuals who are able to adhere to exercise almost always maintain the symptomatic benefits of exercise. Unfortunately, the rate of exercise adherence six months after the completion of a well-structured supervised exercise program is disappointingly low. Furthermore, although the efficacy of supervised aerobic exercise in the research setting is well documented, the applicability of such intervention in the clinic setting is doubtful. Therefore, we propose to conduct the Research to Encourage Exercise for Fibromyalgia (REEF), a randomized attention-controlled trial whose primary aim is to evaluate the efficacy of telephone-delivered motivational interviewing (MI) to encourage exercise, in improving exercise adherence and self-report physical function (co-primary outcome measures) for FMS patients. REEF will enroll 200 FMS patients, randomizing them to either the MI group or the attention-control (AC) group. Participants from each group will receive a total of 6 telephone calls within a 12-week period. Prior to the phone calls, participants from both groups will receive an individualized exercise prescription and 2 supervised exercise training sessions to get them started on an exercise program. All subjects will undergo comprehensive outcome assessment at baseline, week 12, week 24, and week 36. The secondary aim of this proposal is to determine the mediators between MI and improvement in self-report physical function. The proposed research is significant because our focus is the promotion of adherence to an exercise program, of adequate intensity, in order to maximize functioning and well-being for patients with FMS. The use of a predominantly home-based exercise program and telephone-delivered MI by a trained licensed practice nurse (LPN) could potentially make the proposed intervention more accessible to the greater majority of FMS patients. Furthermore, if proven efficacious, MI could readily be applied to other chronically painful conditions (e.g. chronic back pain).",
        "tokens": "['Exercise', '-', 'based', 'Motivational', 'Interviewing', 'for', 'Fibromyalgia', '|', 'Fibromyalgia', '(', 'FMS', ')', ',', 'defined', 'as', 'the', 'presence', 'of', 'both', 'chronic', 'widespread', 'pain', 'and', 'the', 'finding', 'of', '11/18', 'tender', 'points', 'on', 'examination', ',', 'affects', '2', '%', 'of', 'the', 'general', 'population', '.', 'Drug', 'therapy', 'for', 'FMS', 'is', 'largely', 'symptomatic', 'as', 'there', 'is', 'not', 'yet', 'a', 'complete', 'understanding', 'of', 'the', 'pathogenesis', 'of', 'the', 'disease', '.', 'In', 'the', 'past', '17', 'years', ',', 'supervised', 'aerobic', 'exercise', 'has', 'emerged', 'as', 'an', 'important', 'treatment', 'modality', 'to', 'improve', 'pain', ',', 'aerobic', 'capacity', ',', 'function', ',', 'and', 'well', '-', 'being', '.', 'Individuals', 'who', 'are', 'able', 'to', 'adhere', 'to', 'exercise', 'almost', 'always', 'maintain', 'the', 'symptomatic', 'benefits', 'of', 'exercise', '.', 'Unfortunately', ',', 'the', 'rate', 'of', 'exercise', 'adherence', 'six', 'months', 'after', 'the', 'completion', 'of', 'a', 'well', '-', 'structured', 'supervised', 'exercise', 'program', 'is', 'disappointingly', 'low', '.', 'Furthermore', ',', 'although', 'the', 'efficacy', 'of', 'supervised', 'aerobic', 'exercise', 'in', 'the', 'research', 'setting', 'is', 'well', 'documented', ',', 'the', 'applicability', 'of', 'such', 'intervention', 'in', 'the', 'clinic', 'setting', 'is', 'doubtful', '.', 'Therefore', ',', 'we', 'propose', 'to', 'conduct', 'the', 'Research', 'to', 'Encourage', 'Exercise', 'for', 'Fibromyalgia', '(', 'REEF', ')', ',', 'a', 'randomized', 'attention', '-', 'controlled', 'trial', 'whose', 'primary', 'aim', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'telephone', '-', 'delivered', 'motivational', 'interviewing', '(', 'MI', ')', 'to', 'encourage', 'exercise', ',', 'in', 'improving', 'exercise', 'adherence', 'and', 'self', '-', 'report', 'physical', 'function', '(', 'co', '-', 'primary', 'outcome', 'measures', ')', 'for', 'FMS', 'patients', '.', 'REEF', 'will', 'enroll', '200', 'FMS', 'patients', ',', 'randomizing', 'them', 'to', 'either', 'the', 'MI', 'group', 'or', 'the', 'attention', '-', 'control', '(', 'AC', ')', 'group', '.', 'Participants', 'from', 'each', 'group', 'will', 'receive', 'a', 'total', 'of', '6', 'telephone', 'calls', 'within', 'a', '12', '-', 'week', 'period', '.', 'Prior', 'to', 'the', 'phone', 'calls', ',', 'participants', 'from', 'both', 'groups', 'will', 'receive', 'an', 'individualized', 'exercise', 'prescription', 'and', '2', 'supervised', 'exercise', 'training', 'sessions', 'to', 'get', 'them', 'started', 'on', 'an', 'exercise', 'program', '.', 'All', 'subjects', 'will', 'undergo', 'comprehensive', 'outcome', 'assessment', 'at', 'baseline', ',', 'week', '12', ',', 'week', '24', ',', 'and', 'week', '36', '.', 'The', 'secondary', 'aim', 'of', 'this', 'proposal', 'is', 'to', 'determine', 'the', 'mediators', 'between', 'MI', 'and', 'improvement', 'in', 'self', '-', 'report', 'physical', 'function', '.', 'The', 'proposed', 'research', 'is', 'significant', 'because', 'our', 'focus', 'is', 'the', 'promotion', 'of', 'adherence', 'to', 'an', 'exercise', 'program', ',', 'of', 'adequate', 'intensity', ',', 'in', 'order', 'to', 'maximize', 'functioning', 'and', 'well', '-', 'being', 'for', 'patients', 'with', 'FMS', '.', 'The', 'use', 'of', 'a', 'predominantly', 'home', '-', 'based', 'exercise', 'program', 'and', 'telephone', '-', 'delivered', 'MI', 'by', 'a', 'trained', 'licensed', 'practice', 'nurse', '(', 'LPN', ')', 'could', 'potentially', 'make', 'the', 'proposed', 'intervention', 'more', 'accessible', 'to', 'the', 'greater', 'majority', 'of', 'FMS', 'patients', '.', 'Furthermore', ',', 'if', 'proven', 'efficacious', ',', 'MI', 'could', 'readily', 'be', 'applied', 'to', 'other', 'chronically', 'painful', 'conditions', '(', 'e.g.', 'chronic', 'back', 'pain', ')', '.']",
        "token_bio_labels": "['B-PHYS', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 15,
                "end": 40,
                "text": "Motivational Interviewing",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 45,
                "end": 57,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 60,
                "end": 72,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 74,
                "end": 77,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 135,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 246,
                "end": 249,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 387,
                "end": 403,
                "text": "aerobic exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 462,
                "end": 466,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 550,
                "end": 558,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 610,
                "end": 618,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 647,
                "end": 655,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 730,
                "end": 738,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 820,
                "end": 836,
                "text": "aerobic exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1157,
                "end": 1182,
                "text": "motivational interviewing",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1184,
                "end": 1186,
                "text": "MI",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1201,
                "end": 1209,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1224,
                "end": 1232,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1311,
                "end": 1314,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 1346,
                "end": 1349,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 1391,
                "end": 1393,
                "text": "MI",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1407,
                "end": 1424,
                "text": "attention-control",
                "type": "CONTROL"
            },
            {
                "start": 1426,
                "end": 1428,
                "text": "AC",
                "type": "CONTROL"
            },
            {
                "start": 1605,
                "end": 1628,
                "text": "individualized exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1648,
                "end": 1667,
                "text": "supervised exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1712,
                "end": 1720,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1906,
                "end": 1908,
                "text": "MI",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 2050,
                "end": 2058,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 2157,
                "end": 2160,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 2200,
                "end": 2208,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 2241,
                "end": 2243,
                "text": "MI",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 2379,
                "end": 2382,
                "text": "FMS",
                "type": "CONDITION"
            },
            {
                "start": 2429,
                "end": 2431,
                "text": "MI",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT03911609",
        "study_official_title": "The Influence of Cardiovascular Autonomic Function on Endogenous Pain Modulation Before and After Exercise and Cognitive Task in Fibromyalgia ",
        "study_brief_summary": " The study has three aims:\n\nTo investigate the influence of cardiovascular autonomic function on pain sensitivity at rest in patients with fibromyalgia and age- and sex-matched controls\nTo investigate the influence of cardiovascular autonomic function at baseline and during exercise on the pain response following submaximal isometric exercise\nTo study the relation between the pain response following physical and cognitive tasks (exercise and mental math, respectively).",
        "text": "The Influence of Cardiovascular Autonomic Function on Endogenous Pain Modulation Before and After Exercise and Cognitive Task in Fibromyalgia | The study has three aims:\n\nTo investigate the influence of cardiovascular autonomic function on pain sensitivity at rest in patients with fibromyalgia and age- and sex-matched controls\nTo investigate the influence of cardiovascular autonomic function at baseline and during exercise on the pain response following submaximal isometric exercise\nTo study the relation between the pain response following physical and cognitive tasks (exercise and mental math, respectively).",
        "tokens": "['The', 'Influence', 'of', 'Cardiovascular', 'Autonomic', 'Function', 'on', 'Endogenous', 'Pain', 'Modulation', 'Before', 'and', 'After', 'Exercise', 'and', 'Cognitive', 'Task', 'in', 'Fibromyalgia', '|', 'The', 'study', 'has', 'three', 'aims', ':', '\\n\\n', 'To', 'investigate', 'the', 'influence', 'of', 'cardiovascular', 'autonomic', 'function', 'on', 'pain', 'sensitivity', 'at', 'rest', 'in', 'patients', 'with', 'fibromyalgia', 'and', 'age-', 'and', 'sex', '-', 'matched', 'controls', '\\n', 'To', 'investigate', 'the', 'influence', 'of', 'cardiovascular', 'autonomic', 'function', 'at', 'baseline', 'and', 'during', 'exercise', 'on', 'the', 'pain', 'response', 'following', 'submaximal', 'isometric', 'exercise', '\\n', 'To', 'study', 'the', 'relation', 'between', 'the', 'pain', 'response', 'following', 'physical', 'and', 'cognitive', 'tasks', '(', 'exercise', 'and', 'mental', 'math', ',', 'respectively', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 65,
                "end": 69,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 106,
                "text": "Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 111,
                "end": 125,
                "text": "Cognitive Task",
                "type": "OTHER"
            },
            {
                "start": 129,
                "end": 141,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 240,
                "end": 244,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 282,
                "end": 294,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 418,
                "end": 426,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 434,
                "end": 438,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 458,
                "end": 487,
                "text": "submaximal isometric exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 522,
                "end": 526,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 546,
                "end": 574,
                "text": "physical and cognitive tasks",
                "type": "OTHER"
            },
            {
                "start": 576,
                "end": 584,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 589,
                "end": 600,
                "text": "mental math",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05000476",
        "study_official_title": "Effect of Eye Mask and Earplugs on Prevention of Delirium in Intensive Care Patients ",
        "study_brief_summary": " This research is planned as a randomized controlled experimental study to examine the effect of using eye mask and earplugs in preventing delirium with evidence-based nonpharmacological nursing interventions in intensive care units.",
        "text": "Effect of Eye Mask and Earplugs on Prevention of Delirium in Intensive Care Patients | This research is planned as a randomized controlled experimental study to examine the effect of using eye mask and earplugs in preventing delirium with evidence-based nonpharmacological nursing interventions in intensive care units.",
        "tokens": "['Effect', 'of', 'Eye', 'Mask', 'and', 'Earplugs', 'on', 'Prevention', 'of', 'Delirium', 'in', 'Intensive', 'Care', 'Patients', '|', 'This', 'research', 'is', 'planned', 'as', 'a', 'randomized', 'controlled', 'experimental', 'study', 'to', 'examine', 'the', 'effect', 'of', 'using', 'eye', 'mask', 'and', 'earplugs', 'in', 'preventing', 'delirium', 'with', 'evidence', '-', 'based', 'nonpharmacological', 'nursing', 'interventions', 'in', 'intensive', 'care', 'units', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 18,
                "text": "Eye Mask",
                "type": "OTHER"
            },
            {
                "start": 23,
                "end": 31,
                "text": "Earplugs",
                "type": "OTHER"
            },
            {
                "start": 49,
                "end": 57,
                "text": "Delirium",
                "type": "CONDITION"
            },
            {
                "start": 61,
                "end": 75,
                "text": "Intensive Care",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 197,
                "text": "eye mask",
                "type": "OTHER"
            },
            {
                "start": 202,
                "end": 210,
                "text": "earplugs",
                "type": "OTHER"
            },
            {
                "start": 225,
                "end": 233,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 312,
                "text": "intensive care",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04242797",
        "study_official_title": "Central Mechanisms of Calmare: an fMRI Trial ",
        "study_brief_summary": " Pilot one-treatment and extended 10-treatment studies are carried out on participants with peripheral neuropathy comparing traditional TENS and Calmare stimulation protocols using a double-blind apparatus. Resting fMRI scans are obtained before and after the treatment, as well as after most of the pain has returned.",
        "text": "Central Mechanisms of Calmare: an fMRI Trial | Pilot one-treatment and extended 10-treatment studies are carried out on participants with peripheral neuropathy comparing traditional TENS and Calmare stimulation protocols using a double-blind apparatus. Resting fMRI scans are obtained before and after the treatment, as well as after most of the pain has returned.",
        "tokens": "['Central', 'Mechanisms', 'of', 'Calmare', ':', 'an', 'fMRI', 'Trial', '|', 'Pilot', 'one', '-', 'treatment', 'and', 'extended', '10', '-', 'treatment', 'studies', 'are', 'carried', 'out', 'on', 'participants', 'with', 'peripheral', 'neuropathy', 'comparing', 'traditional', 'TENS', 'and', 'Calmare', 'stimulation', 'protocols', 'using', 'a', 'double', '-', 'blind', 'apparatus', '.', 'Resting', 'fMRI', 'scans', 'are', 'obtained', 'before', 'and', 'after', 'the', 'treatment', ',', 'as', 'well', 'as', 'after', 'most', 'of', 'the', 'pain', 'has', 'returned', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 29,
                "text": "Calmare",
                "type": "OTHER"
            },
            {
                "start": 138,
                "end": 159,
                "text": "peripheral neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 186,
                "text": "TENS",
                "type": "CONTROL"
            },
            {
                "start": 191,
                "end": 198,
                "text": "Calmare",
                "type": "OTHER"
            },
            {
                "start": 346,
                "end": 350,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02396082",
        "study_official_title": "MIND: An RCT of Care Coordination for Community-living Person With Dementia ",
        "study_brief_summary": " This is a 24-month, prospective, single- blind, randomized controlled trial evaluating the MIND at Home-streamlined dementia care coordination intervention (called MIND-S) in a cohort of 300 community-living persons with dementia and their family caregivers in the Greater Baltimore area. Participants receiving MIND-S will get 18 months of care coordination by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (persons with dementia (PWD) and care giver (CG) needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.Participants in the comparison group will receive an initial in-home needs assessment and will be given the written results along with any recommendations for care that are indicated.",
        "text": "MIND: An RCT of Care Coordination for Community-living Person With Dementia | This is a 24-month, prospective, single- blind, randomized controlled trial evaluating the MIND at Home-streamlined dementia care coordination intervention (called MIND-S) in a cohort of 300 community-living persons with dementia and their family caregivers in the Greater Baltimore area. Participants receiving MIND-S will get 18 months of care coordination by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (persons with dementia (PWD) and care giver (CG) needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.Participants in the comparison group will receive an initial in-home needs assessment and will be given the written results along with any recommendations for care that are indicated.",
        "tokens": "['MIND', ':', 'An', 'RCT', 'of', 'Care', 'Coordination', 'for', 'Community', '-', 'living', 'Person', 'With', 'Dementia', '|', 'This', 'is', 'a', '24', '-', 'month', ',', 'prospective', ',', 'single-', 'blind', ',', 'randomized', 'controlled', 'trial', 'evaluating', 'the', 'MIND', 'at', 'Home', '-', 'streamlined', 'dementia', 'care', 'coordination', 'intervention', '(', 'called', 'MIND', '-', 'S', ')', 'in', 'a', 'cohort', 'of', '300', 'community', '-', 'living', 'persons', 'with', 'dementia', 'and', 'their', 'family', 'caregivers', 'in', 'the', 'Greater', 'Baltimore', 'area', '.', 'Participants', 'receiving', 'MIND', '-', 'S', 'will', 'get', '18', 'months', 'of', 'care', 'coordination', 'by', 'an', 'interdisciplinary', 'team', 'comprised', 'of', 'trained', 'memory', 'care', 'coordinators', '(', 'non', '-', 'clinical', ')', ',', 'a', 'psychiatric', 'nurse', ',', 'and', 'geriatric', 'psychiatrist', '.', 'The', 'intervention', 'involves', '4', 'key', 'components', ':', 'identification', 'of', 'needs', 'and', 'individualized', 'care', 'planning', '(', 'persons', 'with', 'dementia', '(', 'PWD', ')', 'and', 'care', 'giver', '(', 'CG', ')', 'needs', ')', ';', 'dementia', 'education', 'and', 'skill', 'building', ';', 'coordination', ',', 'referral', 'and', 'linkage', 'of', 'services', ';', 'and', 'care', 'monitoring', '.', 'Participants', 'in', 'the', 'comparison', 'group', 'will', 'receive', 'an', 'initial', 'in', '-', 'home', 'needs', 'assessment', 'and', 'will', 'be', 'given', 'the', 'written', 'results', 'along', 'with', 'any', 'recommendations', 'for', 'care', 'that', 'are', 'indicated', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 67,
                "end": 75,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 169,
                "end": 233,
                "text": "MIND at Home-streamlined dementia care coordination intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 242,
                "end": 248,
                "text": "MIND-S",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 299,
                "end": 307,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 396,
                "text": "MIND-S",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 419,
                "end": 436,
                "text": "care coordination",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 621,
                "end": 677,
                "text": "identification of needs and individualized care planning",
                "type": "OTHER"
            },
            {
                "start": 692,
                "end": 700,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 735,
                "end": 772,
                "text": "dementia education and skill building",
                "type": "OTHER"
            },
            {
                "start": 774,
                "end": 820,
                "text": "coordination, referral and linkage of services",
                "type": "OTHER"
            },
            {
                "start": 895,
                "end": 927,
                "text": "initial in-home needs assessment",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00210912",
        "study_official_title": "A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine ",
        "study_brief_summary": " The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo for the prevention of headaches in patients with chronic migraine. Topiramate has been approved to prevent migraine headaches as well as in the treatment of epilepsy.",
        "text": "A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine | The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo for the prevention of headaches in patients with chronic migraine. Topiramate has been approved to prevent migraine headaches as well as in the treatment of epilepsy.",
        "tokens": "['A', 'Comparison', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Topiramate', 'Versus', 'Placebo', 'for', 'the', 'Prophylaxis', 'of', 'Chronic', 'Migraine', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'effectiveness', 'of', 'topiramate', 'as', 'compared', 'to', 'placebo', 'for', 'the', 'prevention', 'of', 'headaches', 'in', 'patients', 'with', 'chronic', 'migraine', '.', 'Topiramate', 'has', 'been', 'approved', 'to', 'prevent', 'migraine', 'headaches', 'as', 'well', 'as', 'in', 'the', 'treatment', 'of', 'epilepsy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 53,
                "text": "Topiramate",
                "type": "DRUG"
            },
            {
                "start": 61,
                "end": 68,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 92,
                "end": 108,
                "text": "Chronic Migraine",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 192,
                "text": "topiramate",
                "type": "DRUG"
            },
            {
                "start": 208,
                "end": 215,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 238,
                "end": 247,
                "text": "headaches",
                "type": "CONDITION"
            },
            {
                "start": 265,
                "end": 281,
                "text": "chronic migraine",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 293,
                "text": "Topiramate",
                "type": "DRUG"
            },
            {
                "start": 323,
                "end": 341,
                "text": "migraine headaches",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00298532",
        "study_official_title": "The Ontario Prehospital Advanced Life Support (OPALS) Study for Critically Ill and Injured Pediatric Patients ",
        "study_brief_summary": " The OPALS Pediatric Study will examine the incremental impact of introducing a prehospital full advanced life support in pediatric patients.",
        "text": "The Ontario Prehospital Advanced Life Support (OPALS) Study for Critically Ill and Injured Pediatric Patients | The OPALS Pediatric Study will examine the incremental impact of introducing a prehospital full advanced life support in pediatric patients.",
        "tokens": "['The', 'Ontario', 'Prehospital', 'Advanced', 'Life', 'Support', '(', 'OPALS', ')', 'Study', 'for', 'Critically', 'Ill', 'and', 'Injured', 'Pediatric', 'Patients', '|', 'The', 'OPALS', 'Pediatric', 'Study', 'will', 'examine', 'the', 'incremental', 'impact', 'of', 'introducing', 'a', 'prehospital', 'full', 'advanced', 'life', 'support', 'in', 'pediatric', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 64,
                "end": 78,
                "text": "Critically Ill",
                "type": "CONDITION"
            },
            {
                "start": 191,
                "end": 229,
                "text": "prehospital full advanced life support",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01465087",
        "study_official_title": "Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis, In Comparison to Other Autoimmune and Neurological Diseases by Exhalation Samples ",
        "study_brief_summary": " Multiple Sclerosis (MS) is a complex multi-factorial disease, with underlying both genetic and environmental factors. Different populations have different susceptibility to MS. The disease is characterized by 2 main phenotypes: relapsing-remitting or progressive course. Clinical disability is due to distraction of the central nervous system (CNS) myelin.\n\nRepair processes are mainly noted after the acute relapse - and recovery of function can be spontaneous. However, in severe relapses sometimes there is need for STEROID TREATMENT.\n\nFor the long term prophylaxis - following the increased understanding of the disease, in the last 10-15 years, there are new immunotherapies available (COPAXON / TEVA; Interferon -beta). However these can attenuate the disease (reduce the number of relapses per year) but cannot cure it. Also, they are beneficial in only ~40 % of the Relapsing -Remitting patients.\n\nCurrently there are no biomarkers available for MS (other than oligoclonal Immunoglobulin G (IgG) in the cervical spine fluid (CSF) - which helps confirm diagnosis but require an invasive procedure and are not correlated with disease activity nor response to therapy) and monitoring of MS and its treatment is by magnetic resonance Imaging (MRI) - which is an expensive procedure.\n\nDr Hossam Haick from the Technion developed an electronic nose based on nanomaterials for diagnosis of diseases (e.g., cancer, kidney failure, etc.) via breath samples.The research hypothesis is that Biomarkers of CNS inflammation and/or neurodegeneration and/or CNS repair in persons with MS can be detected by the \"electronic nose\".",
        "text": "Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis, In Comparison to Other Autoimmune and Neurological Diseases by Exhalation Samples | Multiple Sclerosis (MS) is a complex multi-factorial disease, with underlying both genetic and environmental factors. Different populations have different susceptibility to MS. The disease is characterized by 2 main phenotypes: relapsing-remitting or progressive course. Clinical disability is due to distraction of the central nervous system (CNS) myelin.\n\nRepair processes are mainly noted after the acute relapse - and recovery of function can be spontaneous. However, in severe relapses sometimes there is need for STEROID TREATMENT.\n\nFor the long term prophylaxis - following the increased understanding of the disease, in the last 10-15 years, there are new immunotherapies available (COPAXON / TEVA; Interferon -beta). However these can attenuate the disease (reduce the number of relapses per year) but cannot cure it. Also, they are beneficial in only ~40 % of the Relapsing -Remitting patients.\n\nCurrently there are no biomarkers available for MS (other than oligoclonal Immunoglobulin G (IgG) in the cervical spine fluid (CSF) - which helps confirm diagnosis but require an invasive procedure and are not correlated with disease activity nor response to therapy) and monitoring of MS and its treatment is by magnetic resonance Imaging (MRI) - which is an expensive procedure.\n\nDr Hossam Haick from the Technion developed an electronic nose based on nanomaterials for diagnosis of diseases (e.g., cancer, kidney failure, etc.) via breath samples.The research hypothesis is that Biomarkers of CNS inflammation and/or neurodegeneration and/or CNS repair in persons with MS can be detected by the \"electronic nose\".",
        "tokens": "['Applications', 'of', 'Nanotechnology', 'and', 'Chemical', 'Sensors', 'for', 'the', 'Detection', 'and', 'Identification', 'of', 'Multiple', 'Sclerosis', ',', 'In', 'Comparison', 'to', 'Other', 'Autoimmune', 'and', 'Neurological', 'Diseases', 'by', 'Exhalation', 'Samples', '|', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'is', 'a', 'complex', 'multi', '-', 'factorial', 'disease', ',', 'with', 'underlying', 'both', 'genetic', 'and', 'environmental', 'factors', '.', 'Different', 'populations', 'have', 'different', 'susceptibility', 'to', 'MS', '.', 'The', 'disease', 'is', 'characterized', 'by', '2', 'main', 'phenotypes', ':', 'relapsing', '-', 'remitting', 'or', 'progressive', 'course', '.', 'Clinical', 'disability', 'is', 'due', 'to', 'distraction', 'of', 'the', 'central', 'nervous', 'system', '(', 'CNS', ')', 'myelin', '.', '\\n\\n', 'Repair', 'processes', 'are', 'mainly', 'noted', 'after', 'the', 'acute', 'relapse', '-', 'and', 'recovery', 'of', 'function', 'can', 'be', 'spontaneous', '.', 'However', ',', 'in', 'severe', 'relapses', 'sometimes', 'there', 'is', 'need', 'for', 'STEROID', 'TREATMENT', '.', '\\n\\n', 'For', 'the', 'long', 'term', 'prophylaxis', '-', 'following', 'the', 'increased', 'understanding', 'of', 'the', 'disease', ',', 'in', 'the', 'last', '10', '-', '15', 'years', ',', 'there', 'are', 'new', 'immunotherapies', 'available', '(', 'COPAXON', '/', 'TEVA', ';', 'Interferon', '-beta', ')', '.', 'However', 'these', 'can', 'attenuate', 'the', 'disease', '(', 'reduce', 'the', 'number', 'of', 'relapses', 'per', 'year', ')', 'but', 'can', 'not', 'cure', 'it', '.', 'Also', ',', 'they', 'are', 'beneficial', 'in', 'only', '~40', '%', 'of', 'the', 'Relapsing', '-Remitting', 'patients', '.', '\\n\\n', 'Currently', 'there', 'are', 'no', 'biomarkers', 'available', 'for', 'MS', '(', 'other', 'than', 'oligoclonal', 'Immunoglobulin', 'G', '(', 'IgG', ')', 'in', 'the', 'cervical', 'spine', 'fluid', '(', 'CSF', ')', '-', 'which', 'helps', 'confirm', 'diagnosis', 'but', 'require', 'an', 'invasive', 'procedure', 'and', 'are', 'not', 'correlated', 'with', 'disease', 'activity', 'nor', 'response', 'to', 'therapy', ')', 'and', 'monitoring', 'of', 'MS', 'and', 'its', 'treatment', 'is', 'by', 'magnetic', 'resonance', 'Imaging', '(', 'MRI', ')', '-', 'which', 'is', 'an', 'expensive', 'procedure', '.', '\\n\\n', 'Dr', 'Hossam', 'Haick', 'from', 'the', 'Technion', 'developed', 'an', 'electronic', 'nose', 'based', 'on', 'nanomaterials', 'for', 'diagnosis', 'of', 'diseases', '(', 'e.g.', ',', 'cancer', ',', 'kidney', 'failure', ',', 'etc', '.', ')', 'via', 'breath', 'samples', '.', 'The', 'research', 'hypothesis', 'is', 'that', 'Biomarkers', 'of', 'CNS', 'inflammation', 'and/or', 'neurodegeneration', 'and/or', 'CNS', 'repair', 'in', 'persons', 'with', 'MS', 'can', 'be', 'detected', 'by', 'the', '\"', 'electronic', 'nose', '\"', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 92,
                "end": 110,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 196,
                "end": 214,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 216,
                "end": 218,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 369,
                "end": 371,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1150,
                "end": 1152,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1388,
                "end": 1390,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1774,
                "end": 1776,
                "text": "MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02829801",
        "study_official_title": "Evaluation of the Animal Intervention Used as Therapy. Impact of Animal-assisted Therapy on the Well-being in Patients With Alzheimer's Disease ",
        "study_brief_summary": " The animal-assisted therapy (AAT) is now considered a non-drug care and is often used in geriatrics. Many studies have shown a link between the presence of the animal and the psycho-behavioral symptoms decrease in dementia (PBSD) such as depression, anxiety or irritability that affects their quality of life and improved cognitive abilities. However, many methodological flaws in these researches exist.\n\nThe aim of the study is to evaluate the effectiveness of AAT on the well-being of patients with Alzheimer disease (AD) at the stage of Major Neuro Cognitive Disorder (NCD) at short and medium term (before care, during care (at the beginning and end of each session), 1 week after, 2 weeks and 1 month after the last session) compared to a group receiving the same stimulation without the dog's response.\n\nPatients will be seen in groups of 4 to 6 people at 8 workshops. 2 groups will be formed: AAT group versus control group. The only difference between these two groups is the intervention of the dog at each workshop in the AAT group.\n\nEach workshop will consist of three identical times. It will begin with a 15 minute introductory activity, the first goal will be to establish a relationship with patients (patients-patients and patients-caregivers) and a 40 minute cognitive stimulation, identical in the 2 groups, will be proposed and finally 5 minutes will be devoted to the closing of the session This study should highlight a positive effect of animal assisted therapy on the well-being, PBSD, depression, anxiety and cognitive abilities and a long-term retention of these positive effects.",
        "text": "Evaluation of the Animal Intervention Used as Therapy. Impact of Animal-assisted Therapy on the Well-being in Patients With Alzheimer's Disease | The animal-assisted therapy (AAT) is now considered a non-drug care and is often used in geriatrics. Many studies have shown a link between the presence of the animal and the psycho-behavioral symptoms decrease in dementia (PBSD) such as depression, anxiety or irritability that affects their quality of life and improved cognitive abilities. However, many methodological flaws in these researches exist.\n\nThe aim of the study is to evaluate the effectiveness of AAT on the well-being of patients with Alzheimer disease (AD) at the stage of Major Neuro Cognitive Disorder (NCD) at short and medium term (before care, during care (at the beginning and end of each session), 1 week after, 2 weeks and 1 month after the last session) compared to a group receiving the same stimulation without the dog's response.\n\nPatients will be seen in groups of 4 to 6 people at 8 workshops. 2 groups will be formed: AAT group versus control group. The only difference between these two groups is the intervention of the dog at each workshop in the AAT group.\n\nEach workshop will consist of three identical times. It will begin with a 15 minute introductory activity, the first goal will be to establish a relationship with patients (patients-patients and patients-caregivers) and a 40 minute cognitive stimulation, identical in the 2 groups, will be proposed and finally 5 minutes will be devoted to the closing of the session This study should highlight a positive effect of animal assisted therapy on the well-being, PBSD, depression, anxiety and cognitive abilities and a long-term retention of these positive effects.",
        "tokens": "['Evaluation', 'of', 'the', 'Animal', 'Intervention', 'Used', 'as', 'Therapy', '.', 'Impact', 'of', 'Animal', '-', 'assisted', 'Therapy', 'on', 'the', 'Well', '-', 'being', 'in', 'Patients', 'With', 'Alzheimer', \"'s\", 'Disease', '|', 'The', 'animal', '-', 'assisted', 'therapy', '(', 'AAT', ')', 'is', 'now', 'considered', 'a', 'non', '-', 'drug', 'care', 'and', 'is', 'often', 'used', 'in', 'geriatrics', '.', 'Many', 'studies', 'have', 'shown', 'a', 'link', 'between', 'the', 'presence', 'of', 'the', 'animal', 'and', 'the', 'psycho', '-', 'behavioral', 'symptoms', 'decrease', 'in', 'dementia', '(', 'PBSD', ')', 'such', 'as', 'depression', ',', 'anxiety', 'or', 'irritability', 'that', 'affects', 'their', 'quality', 'of', 'life', 'and', 'improved', 'cognitive', 'abilities', '.', 'However', ',', 'many', 'methodological', 'flaws', 'in', 'these', 'researches', 'exist', '.', '\\n\\n', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'AAT', 'on', 'the', 'well', '-', 'being', 'of', 'patients', 'with', 'Alzheimer', 'disease', '(', 'AD', ')', 'at', 'the', 'stage', 'of', 'Major', 'Neuro', 'Cognitive', 'Disorder', '(', 'NCD', ')', 'at', 'short', 'and', 'medium', 'term', '(', 'before', 'care', ',', 'during', 'care', '(', 'at', 'the', 'beginning', 'and', 'end', 'of', 'each', 'session', ')', ',', '1', 'week', 'after', ',', '2', 'weeks', 'and', '1', 'month', 'after', 'the', 'last', 'session', ')', 'compared', 'to', 'a', 'group', 'receiving', 'the', 'same', 'stimulation', 'without', 'the', 'dog', \"'s\", 'response', '.', '\\n\\n', 'Patients', 'will', 'be', 'seen', 'in', 'groups', 'of', '4', 'to', '6', 'people', 'at', '8', 'workshops', '.', '2', 'groups', 'will', 'be', 'formed', ':', 'AAT', 'group', 'versus', 'control', 'group', '.', 'The', 'only', 'difference', 'between', 'these', 'two', 'groups', 'is', 'the', 'intervention', 'of', 'the', 'dog', 'at', 'each', 'workshop', 'in', 'the', 'AAT', 'group', '.', '\\n\\n', 'Each', 'workshop', 'will', 'consist', 'of', 'three', 'identical', 'times', '.', 'It', 'will', 'begin', 'with', 'a', '15', 'minute', 'introductory', 'activity', ',', 'the', 'first', 'goal', 'will', 'be', 'to', 'establish', 'a', 'relationship', 'with', 'patients', '(', 'patients', '-', 'patients', 'and', 'patients', '-', 'caregivers', ')', 'and', 'a', '40', 'minute', 'cognitive', 'stimulation', ',', 'identical', 'in', 'the', '2', 'groups', ',', 'will', 'be', 'proposed', 'and', 'finally', '5', 'minutes', 'will', 'be', 'devoted', 'to', 'the', 'closing', 'of', 'the', 'session', 'This', 'study', 'should', 'highlight', 'a', 'positive', 'effect', 'of', 'animal', 'assisted', 'therapy', 'on', 'the', 'well', '-', 'being', ',', 'PBSD', ',', 'depression', ',', 'anxiety', 'and', 'cognitive', 'abilities', 'and', 'a', 'long', '-', 'term', 'retention', 'of', 'these', 'positive', 'effects', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 37,
                "text": "Animal Intervention",
                "type": "OTHER"
            },
            {
                "start": 65,
                "end": 88,
                "text": "Animal-assisted Therapy",
                "type": "OTHER"
            },
            {
                "start": 124,
                "end": 143,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 150,
                "end": 173,
                "text": "animal-assisted therapy",
                "type": "OTHER"
            },
            {
                "start": 175,
                "end": 178,
                "text": "AAT",
                "type": "OTHER"
            },
            {
                "start": 290,
                "end": 312,
                "text": "presence of the animal",
                "type": "OTHER"
            },
            {
                "start": 360,
                "end": 368,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 384,
                "end": 394,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 396,
                "end": 403,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 609,
                "end": 612,
                "text": "AAT",
                "type": "OTHER"
            },
            {
                "start": 648,
                "end": 665,
                "text": "Alzheimer disease",
                "type": "CONDITION"
            },
            {
                "start": 667,
                "end": 669,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 687,
                "end": 717,
                "text": "Major Neuro Cognitive Disorder",
                "type": "CONDITION"
            },
            {
                "start": 719,
                "end": 722,
                "text": "NCD",
                "type": "CONDITION"
            },
            {
                "start": 911,
                "end": 954,
                "text": "same stimulation without the dog's response",
                "type": "CONTROL"
            },
            {
                "start": 1011,
                "end": 1020,
                "text": "workshops",
                "type": "OTHER"
            },
            {
                "start": 1047,
                "end": 1050,
                "text": "AAT",
                "type": "OTHER"
            },
            {
                "start": 1131,
                "end": 1154,
                "text": "intervention of the dog",
                "type": "OTHER"
            },
            {
                "start": 1179,
                "end": 1182,
                "text": "AAT",
                "type": "OTHER"
            },
            {
                "start": 1423,
                "end": 1444,
                "text": "cognitive stimulation",
                "type": "OTHER"
            },
            {
                "start": 1607,
                "end": 1630,
                "text": "animal assisted therapy",
                "type": "OTHER"
            },
            {
                "start": 1656,
                "end": 1666,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 1668,
                "end": 1675,
                "text": "anxiety",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04518540",
        "study_official_title": "Randomized, Parallel Safety and Efficacy Study of Lipoic Acid in Patients With Amyotrophic Lateral Sclerosis ",
        "study_brief_summary": " In this proposed study, the investigators will evaluate the safety and efficacy of lipoic acid in treatment of Amyotrophic lateral sclerosis (ALS). The study will recruit 150 AD patients, and then these patients will be randomized to lipoic acid group or control group (75 patients per arm) for 6 courses for about 5 months. Clinical assessment will be done at screen/baseline, 3th course and 6th course. The specific aims are to compare lipoic acid versus control on: motor function and disease progression. During the study period, clinical effect index will be recorded, including bulbar function, motor function, respiratory function, and safety index including blood and urine routine, liver and kidney function, coagulation function.",
        "text": "Randomized, Parallel Safety and Efficacy Study of Lipoic Acid in Patients With Amyotrophic Lateral Sclerosis | In this proposed study, the investigators will evaluate the safety and efficacy of lipoic acid in treatment of Amyotrophic lateral sclerosis (ALS). The study will recruit 150 AD patients, and then these patients will be randomized to lipoic acid group or control group (75 patients per arm) for 6 courses for about 5 months. Clinical assessment will be done at screen/baseline, 3th course and 6th course. The specific aims are to compare lipoic acid versus control on: motor function and disease progression. During the study period, clinical effect index will be recorded, including bulbar function, motor function, respiratory function, and safety index including blood and urine routine, liver and kidney function, coagulation function.",
        "tokens": "['Randomized', ',', 'Parallel', 'Safety', 'and', 'Efficacy', 'Study', 'of', 'Lipoic', 'Acid', 'in', 'Patients', 'With', 'Amyotrophic', 'Lateral', 'Sclerosis', '|', 'In', 'this', 'proposed', 'study', ',', 'the', 'investigators', 'will', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'lipoic', 'acid', 'in', 'treatment', 'of', 'Amyotrophic', 'lateral', 'sclerosis', '(', 'ALS', ')', '.', 'The', 'study', 'will', 'recruit', '150', 'AD', 'patients', ',', 'and', 'then', 'these', 'patients', 'will', 'be', 'randomized', 'to', 'lipoic', 'acid', 'group', 'or', 'control', 'group', '(', '75', 'patients', 'per', 'arm', ')', 'for', '6', 'courses', 'for', 'about', '5', 'months', '.', 'Clinical', 'assessment', 'will', 'be', 'done', 'at', 'screen', '/', 'baseline', ',', '3th', 'course', 'and', '6th', 'course', '.', 'The', 'specific', 'aims', 'are', 'to', 'compare', 'lipoic', 'acid', 'versus', 'control', 'on', ':', 'motor', 'function', 'and', 'disease', 'progression', '.', 'During', 'the', 'study', 'period', ',', 'clinical', 'effect', 'index', 'will', 'be', 'recorded', ',', 'including', 'bulbar', 'function', ',', 'motor', 'function', ',', 'respiratory', 'function', ',', 'and', 'safety', 'index', 'including', 'blood', 'and', 'urine', 'routine', ',', 'liver', 'and', 'kidney', 'function', ',', 'coagulation', 'function', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 61,
                "text": "Lipoic Acid",
                "type": "DRUG"
            },
            {
                "start": 79,
                "end": 108,
                "text": "Amyotrophic Lateral Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 194,
                "end": 205,
                "text": "lipoic acid",
                "type": "DRUG"
            },
            {
                "start": 222,
                "end": 251,
                "text": "Amyotrophic lateral sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 253,
                "end": 256,
                "text": "ALS",
                "type": "CONDITION"
            },
            {
                "start": 345,
                "end": 356,
                "text": "lipoic acid",
                "type": "DRUG"
            },
            {
                "start": 366,
                "end": 373,
                "text": "control",
                "type": "CONTROL"
            },
            {
                "start": 549,
                "end": 560,
                "text": "lipoic acid",
                "type": "DRUG"
            },
            {
                "start": 568,
                "end": 575,
                "text": "control",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00291148",
        "study_official_title": "A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine ",
        "study_brief_summary": " This is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.",
        "text": "A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine | This is a comparative drug trial involving patients with clinically definite Multiple Sclerosis and documented neuropathic pain. Patients will be randomized to receive treatment with either paroxetine or pregabalin. After dose titration, participants will complete various pain scale assessments at several points during the study in order to determine the effectiveness of their assigned pain medication.",
        "tokens": "['A', 'Comparative', 'Single', 'Center', ',', 'Randomized', 'Neuropathic', 'Pain', 'Assessment', 'Study', 'Involving', 'Patients', 'With', 'Clinically', 'Definite', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'Receiving', 'Treatment', 'With', 'Either', 'Pregabalin', 'or', 'Paroxetine', '|', 'This', 'is', 'a', 'comparative', 'drug', 'trial', 'involving', 'patients', 'with', 'clinically', 'definite', 'Multiple', 'Sclerosis', 'and', 'documented', 'neuropathic', 'pain', '.', 'Patients', 'will', 'be', 'randomized', 'to', 'receive', 'treatment', 'with', 'either', 'paroxetine', 'or', 'pregabalin', '.', 'After', 'dose', 'titration', ',', 'participants', 'will', 'complete', 'various', 'pain', 'scale', 'assessments', 'at', 'several', 'points', 'during', 'the', 'study', 'in', 'order', 'to', 'determine', 'the', 'effectiveness', 'of', 'their', 'assigned', 'pain', 'medication', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 40,
                "end": 56,
                "text": "Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 136,
                "text": "Clinically Definite Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 140,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 174,
                "end": 184,
                "text": "Pregabalin",
                "type": "DRUG"
            },
            {
                "start": 188,
                "end": 198,
                "text": "Paroxetine",
                "type": "DRUG"
            },
            {
                "start": 258,
                "end": 296,
                "text": "clinically definite Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 312,
                "end": 328,
                "text": "neuropathic pain",
                "type": "CONDITION"
            },
            {
                "start": 391,
                "end": 401,
                "text": "paroxetine",
                "type": "DRUG"
            },
            {
                "start": 405,
                "end": 415,
                "text": "pregabalin",
                "type": "DRUG"
            },
            {
                "start": 474,
                "end": 478,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 590,
                "end": 594,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01225614",
        "study_official_title": "Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1) ",
        "study_brief_summary": " This is a multicenter randomized controlled open labeled study testing efficacy and tolerance of early launching of night non invasive ventilation in patients with myotonic dystrophy type 1(DM1). The object of this project is to estimate the effects of the early introduction of non invasive ventilation on the arisen of complication (non expected hospitalization, tracheostomy even death) with regard to a simple respiratory follow-up in patients affected by myotonic dystrophy.",
        "text": "Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1) | This is a multicenter randomized controlled open labeled study testing efficacy and tolerance of early launching of night non invasive ventilation in patients with myotonic dystrophy type 1(DM1). The object of this project is to estimate the effects of the early introduction of non invasive ventilation on the arisen of complication (non expected hospitalization, tracheostomy even death) with regard to a simple respiratory follow-up in patients affected by myotonic dystrophy.",
        "tokens": "['Study', 'of', 'Efficacy', 'and', 'Tolerance', 'of', 'Early', 'Launching', 'of', 'Nocturnal', 'Non', 'Invasive', 'Ventilation', 'in', 'Adults', 'With', 'Myotonic', 'Dystrophy', 'Type', '1(DM1', ')', '|', 'This', 'is', 'a', 'multicenter', 'randomized', 'controlled', 'open', 'labeled', 'study', 'testing', 'efficacy', 'and', 'tolerance', 'of', 'early', 'launching', 'of', 'night', 'non', 'invasive', 'ventilation', 'in', 'patients', 'with', 'myotonic', 'dystrophy', 'type', '1(DM1', ')', '.', 'The', 'object', 'of', 'this', 'project', 'is', 'to', 'estimate', 'the', 'effects', 'of', 'the', 'early', 'introduction', 'of', 'non', 'invasive', 'ventilation', 'on', 'the', 'arisen', 'of', 'complication', '(', 'non', 'expected', 'hospitalization', ',', 'tracheostomy', 'even', 'death', ')', 'with', 'regard', 'to', 'a', 'simple', 'respiratory', 'follow', '-', 'up', 'in', 'patients', 'affected', 'by', 'myotonic', 'dystrophy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 88,
                "text": "Early Launching of Nocturnal Non Invasive Ventilation",
                "type": "OTHER"
            },
            {
                "start": 104,
                "end": 134,
                "text": "Myotonic Dystrophy Type 1(DM1)",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 283,
                "text": "early launching of night non invasive ventilation",
                "type": "OTHER"
            },
            {
                "start": 301,
                "end": 331,
                "text": "myotonic dystrophy type 1(DM1)",
                "type": "CONDITION"
            },
            {
                "start": 394,
                "end": 440,
                "text": "early introduction of non invasive ventilation",
                "type": "OTHER"
            },
            {
                "start": 597,
                "end": 615,
                "text": "myotonic dystrophy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02588300",
        "study_official_title": "Evaluation of the Upper Airway Collapse in Patients With Obstructive Sleep Apnea Syndrome by Drug Induced Sleep Endoscopy According to the Munich Sleep Video Protocol ",
        "study_brief_summary": " This is a prospective, interventional cohort study of drug-induced sleep endoscopy (DISE). The goal is to evaluate the upper airway in a cohort of patients with obstructive sleep apnea hypopnea syndrome (OSAHS) diagnosed in a prior polysomnography.\n\nThis study correlates the sedation level measured by entropy during DISE using propofol via a TCI pump with the local obstruction patterns of the upper airway according to the VOTE classification.\n\nAs OSAHS is a widespread disease and the DISE procedure has become a common tool for diagnosis and evaluation of further treatment, a growing number of research articles deal with this topic. These articles are available through pubmed.",
        "text": "Evaluation of the Upper Airway Collapse in Patients With Obstructive Sleep Apnea Syndrome by Drug Induced Sleep Endoscopy According to the Munich Sleep Video Protocol | This is a prospective, interventional cohort study of drug-induced sleep endoscopy (DISE). The goal is to evaluate the upper airway in a cohort of patients with obstructive sleep apnea hypopnea syndrome (OSAHS) diagnosed in a prior polysomnography.\n\nThis study correlates the sedation level measured by entropy during DISE using propofol via a TCI pump with the local obstruction patterns of the upper airway according to the VOTE classification.\n\nAs OSAHS is a widespread disease and the DISE procedure has become a common tool for diagnosis and evaluation of further treatment, a growing number of research articles deal with this topic. These articles are available through pubmed.",
        "tokens": "['Evaluation', 'of', 'the', 'Upper', 'Airway', 'Collapse', 'in', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', 'by', 'Drug', 'Induced', 'Sleep', 'Endoscopy', 'According', 'to', 'the', 'Munich', 'Sleep', 'Video', 'Protocol', '|', 'This', 'is', 'a', 'prospective', ',', 'interventional', 'cohort', 'study', 'of', 'drug', '-', 'induced', 'sleep', 'endoscopy', '(', 'DISE', ')', '.', 'The', 'goal', 'is', 'to', 'evaluate', 'the', 'upper', 'airway', 'in', 'a', 'cohort', 'of', 'patients', 'with', 'obstructive', 'sleep', 'apnea', 'hypopnea', 'syndrome', '(', 'OSAHS', ')', 'diagnosed', 'in', 'a', 'prior', 'polysomnography', '.', '\\n\\n', 'This', 'study', 'correlates', 'the', 'sedation', 'level', 'measured', 'by', 'entropy', 'during', 'DISE', 'using', 'propofol', 'via', 'a', 'TCI', 'pump', 'with', 'the', 'local', 'obstruction', 'patterns', 'of', 'the', 'upper', 'airway', 'according', 'to', 'the', 'VOTE', 'classification', '.', '\\n\\n', 'As', 'OSAHS', 'is', 'a', 'widespread', 'disease', 'and', 'the', 'DISE', 'procedure', 'has', 'become', 'a', 'common', 'tool', 'for', 'diagnosis', 'and', 'evaluation', 'of', 'further', 'treatment', ',', 'a', 'growing', 'number', 'of', 'research', 'articles', 'deal', 'with', 'this', 'topic', '.', 'These', 'articles', 'are', 'available', 'through', 'pubmed', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 57,
                "end": 89,
                "text": "Obstructive Sleep Apnea Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 330,
                "end": 371,
                "text": "obstructive sleep apnea hypopnea syndrome",
                "type": "CONDITION"
            },
            {
                "start": 373,
                "end": 378,
                "text": "OSAHS",
                "type": "CONDITION"
            },
            {
                "start": 620,
                "end": 625,
                "text": "OSAHS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01714011",
        "study_official_title": "Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. ",
        "study_brief_summary": " Introduction:\n\nSchizophrenia is a serious mental illness. For majority of patients it is a lifetime condition,characterized by intermittent episodes of hospitalization due to relapse or acute symptom exacerbation. The nature and course of the disorder impose significant social and economic burden. Relapse is costly, with hospitalization accounting for a substantial portion of healthcare expenses. Second generation antipsychotic side effect such as metabolic syndrome and diabetes mellitus will contribute additional costs to the treatment.\n\nMany studies have since then provided convincing evidence for a high risk of diabetes and other glucose abnormalities, metabolic syndrome and mortality due to elevated cardiovascular risk in patients with schizophrenia.\n\nHowever many studies has shown the effectiveness and safety of aripiprazole and ziprazidone.In one of the study, aripiprazole showed improvement of negative schizophrenic symptoms by 25% and 50% of functioning level from baseline. In term of safety, antipsychotics considered to have a safer metabolic profile were amisulpride, ziprasidone and aripiprazole.\n\nStudy objectives:\n\nTo investigate the safety and efficacy of ziprazidone versus aripiprazole in the treatment of schizophrenia patients with metabolic syndrome and diabetes mellitus.\nTo investigate the reversibility of metabolic syndrome and diabetes parameters following the treatment with ziprazidone versus aripiprazole.\n\nHypotheses:\n\n* The proportion of reversibility of metabolic syndrome and diabetes parameters is higher following the treatment of ziprazidone than aripiprazole.",
        "text": "Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. | Introduction:\n\nSchizophrenia is a serious mental illness. For majority of patients it is a lifetime condition,characterized by intermittent episodes of hospitalization due to relapse or acute symptom exacerbation. The nature and course of the disorder impose significant social and economic burden. Relapse is costly, with hospitalization accounting for a substantial portion of healthcare expenses. Second generation antipsychotic side effect such as metabolic syndrome and diabetes mellitus will contribute additional costs to the treatment.\n\nMany studies have since then provided convincing evidence for a high risk of diabetes and other glucose abnormalities, metabolic syndrome and mortality due to elevated cardiovascular risk in patients with schizophrenia.\n\nHowever many studies has shown the effectiveness and safety of aripiprazole and ziprazidone.In one of the study, aripiprazole showed improvement of negative schizophrenic symptoms by 25% and 50% of functioning level from baseline. In term of safety, antipsychotics considered to have a safer metabolic profile were amisulpride, ziprasidone and aripiprazole.\n\nStudy objectives:\n\nTo investigate the safety and efficacy of ziprazidone versus aripiprazole in the treatment of schizophrenia patients with metabolic syndrome and diabetes mellitus.\nTo investigate the reversibility of metabolic syndrome and diabetes parameters following the treatment with ziprazidone versus aripiprazole.\n\nHypotheses:\n\n* The proportion of reversibility of metabolic syndrome and diabetes parameters is higher following the treatment of ziprazidone than aripiprazole.",
        "tokens": "['Randomized', 'Controlled', 'Trial', 'of', 'The', 'Safety', 'and', 'Efficacy', 'of', 'Aripiprazole', 'VS', 'Ziprasidone', 'in', 'Schizophrenic', 'Patients', 'With', 'Metabolic', 'Syndrome', 'and', 'Diabetes', 'Mellitus', '.', '|', 'Introduction', ':', '\\n\\n', 'Schizophrenia', 'is', 'a', 'serious', 'mental', 'illness', '.', 'For', 'majority', 'of', 'patients', 'it', 'is', 'a', 'lifetime', 'condition', ',', 'characterized', 'by', 'intermittent', 'episodes', 'of', 'hospitalization', 'due', 'to', 'relapse', 'or', 'acute', 'symptom', 'exacerbation', '.', 'The', 'nature', 'and', 'course', 'of', 'the', 'disorder', 'impose', 'significant', 'social', 'and', 'economic', 'burden', '.', 'Relapse', 'is', 'costly', ',', 'with', 'hospitalization', 'accounting', 'for', 'a', 'substantial', 'portion', 'of', 'healthcare', 'expenses', '.', 'Second', 'generation', 'antipsychotic', 'side', 'effect', 'such', 'as', 'metabolic', 'syndrome', 'and', 'diabetes', 'mellitus', 'will', 'contribute', 'additional', 'costs', 'to', 'the', 'treatment', '.', '\\n\\n', 'Many', 'studies', 'have', 'since', 'then', 'provided', 'convincing', 'evidence', 'for', 'a', 'high', 'risk', 'of', 'diabetes', 'and', 'other', 'glucose', 'abnormalities', ',', 'metabolic', 'syndrome', 'and', 'mortality', 'due', 'to', 'elevated', 'cardiovascular', 'risk', 'in', 'patients', 'with', 'schizophrenia', '.', '\\n\\n', 'However', 'many', 'studies', 'has', 'shown', 'the', 'effectiveness', 'and', 'safety', 'of', 'aripiprazole', 'and', 'ziprazidone', '.', 'In', 'one', 'of', 'the', 'study', ',', 'aripiprazole', 'showed', 'improvement', 'of', 'negative', 'schizophrenic', 'symptoms', 'by', '25', '%', 'and', '50', '%', 'of', 'functioning', 'level', 'from', 'baseline', '.', 'In', 'term', 'of', 'safety', ',', 'antipsychotics', 'considered', 'to', 'have', 'a', 'safer', 'metabolic', 'profile', 'were', 'amisulpride', ',', 'ziprasidone', 'and', 'aripiprazole', '.', '\\n\\n', 'Study', 'objectives', ':', '\\n\\n', 'To', 'investigate', 'the', 'safety', 'and', 'efficacy', 'of', 'ziprazidone', 'versus', 'aripiprazole', 'in', 'the', 'treatment', 'of', 'schizophrenia', 'patients', 'with', 'metabolic', 'syndrome', 'and', 'diabetes', 'mellitus', '.', '\\n', 'To', 'investigate', 'the', 'reversibility', 'of', 'metabolic', 'syndrome', 'and', 'diabetes', 'parameters', 'following', 'the', 'treatment', 'with', 'ziprazidone', 'versus', 'aripiprazole', '.', '\\n\\n', 'Hypotheses', ':', '\\n\\n', '*', 'The', 'proportion', 'of', 'reversibility', 'of', 'metabolic', 'syndrome', 'and', 'diabetes', 'parameters', 'is', 'higher', 'following', 'the', 'treatment', 'of', 'ziprazidone', 'than', 'aripiprazole', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 58,
                "end": 70,
                "text": "Aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 74,
                "end": 85,
                "text": "Ziprasidone",
                "type": "DRUG"
            },
            {
                "start": 89,
                "end": 102,
                "text": "Schizophrenic",
                "type": "CONDITION"
            },
            {
                "start": 117,
                "end": 135,
                "text": "Metabolic Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 140,
                "end": 157,
                "text": "Diabetes Mellitus",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 189,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 613,
                "end": 631,
                "text": "metabolic syndrome",
                "type": "CONDITION"
            },
            {
                "start": 636,
                "end": 653,
                "text": "diabetes mellitus",
                "type": "CONDITION"
            },
            {
                "start": 783,
                "end": 791,
                "text": "diabetes",
                "type": "CONDITION"
            },
            {
                "start": 825,
                "end": 843,
                "text": "metabolic syndrome",
                "type": "CONDITION"
            },
            {
                "start": 911,
                "end": 924,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 990,
                "end": 1002,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 1007,
                "end": 1018,
                "text": "ziprazidone",
                "type": "DRUG"
            },
            {
                "start": 1040,
                "end": 1052,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 1084,
                "end": 1097,
                "text": "schizophrenic",
                "type": "CONDITION"
            },
            {
                "start": 1177,
                "end": 1191,
                "text": "antipsychotics",
                "type": "DRUG"
            },
            {
                "start": 1242,
                "end": 1253,
                "text": "amisulpride",
                "type": "DRUG"
            },
            {
                "start": 1255,
                "end": 1266,
                "text": "ziprasidone",
                "type": "DRUG"
            },
            {
                "start": 1271,
                "end": 1283,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 1347,
                "end": 1358,
                "text": "ziprazidone",
                "type": "DRUG"
            },
            {
                "start": 1366,
                "end": 1378,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 1399,
                "end": 1412,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 1427,
                "end": 1445,
                "text": "metabolic syndrome",
                "type": "CONDITION"
            },
            {
                "start": 1450,
                "end": 1467,
                "text": "diabetes mellitus",
                "type": "CONDITION"
            },
            {
                "start": 1505,
                "end": 1523,
                "text": "metabolic syndrome",
                "type": "CONDITION"
            },
            {
                "start": 1528,
                "end": 1536,
                "text": "diabetes",
                "type": "CONDITION"
            },
            {
                "start": 1577,
                "end": 1588,
                "text": "ziprazidone",
                "type": "DRUG"
            },
            {
                "start": 1596,
                "end": 1608,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 1661,
                "end": 1679,
                "text": "metabolic syndrome",
                "type": "CONDITION"
            },
            {
                "start": 1684,
                "end": 1692,
                "text": "diabetes",
                "type": "CONDITION"
            },
            {
                "start": 1741,
                "end": 1752,
                "text": "ziprazidone",
                "type": "DRUG"
            },
            {
                "start": 1758,
                "end": 1770,
                "text": "aripiprazole",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT01608516",
        "study_official_title": "Multimodal Assessment of the Inflammatory Atheromatous Plaque : Comparison Between 68Ga-NODAGA-RGD PET/CT, 18F-FDG PET/CT, MRI AND US ",
        "study_brief_summary": " The present study aims at assessing the ability of 68Ga-NODAGA-RGD PET/CT for the detection of inflammatory atheromatous plaques in the carotid arteries, compared to 18F-FDG PET/CT, MRI and US and to determine the contribution of each imaging technique. Current gold standard for inflammation is histopathology.\n\nHypothesis : 68Ga-NODAGA-RGD might give a better initial evaluation of patients with atheromatous plaques in the carotid artery eligible for endarterectomy.",
        "text": "Multimodal Assessment of the Inflammatory Atheromatous Plaque : Comparison Between 68Ga-NODAGA-RGD PET/CT, 18F-FDG PET/CT, MRI AND US | The present study aims at assessing the ability of 68Ga-NODAGA-RGD PET/CT for the detection of inflammatory atheromatous plaques in the carotid arteries, compared to 18F-FDG PET/CT, MRI and US and to determine the contribution of each imaging technique. Current gold standard for inflammation is histopathology.\n\nHypothesis : 68Ga-NODAGA-RGD might give a better initial evaluation of patients with atheromatous plaques in the carotid artery eligible for endarterectomy.",
        "tokens": "['Multimodal', 'Assessment', 'of', 'the', 'Inflammatory', 'Atheromatous', 'Plaque', ':', 'Comparison', 'Between', '68Ga', '-', 'NODAGA', '-', 'RGD', 'PET', '/', 'CT', ',', '18F', '-', 'FDG', 'PET', '/', 'CT', ',', 'MRI', 'AND', 'US', '|', 'The', 'present', 'study', 'aims', 'at', 'assessing', 'the', 'ability', 'of', '68Ga', '-', 'NODAGA', '-', 'RGD', 'PET', '/', 'CT', 'for', 'the', 'detection', 'of', 'inflammatory', 'atheromatous', 'plaques', 'in', 'the', 'carotid', 'arteries', ',', 'compared', 'to', '18F', '-', 'FDG', 'PET', '/', 'CT', ',', 'MRI', 'and', 'US', 'and', 'to', 'determine', 'the', 'contribution', 'of', 'each', 'imaging', 'technique', '.', 'Current', 'gold', 'standard', 'for', 'inflammation', 'is', 'histopathology', '.', '\\n\\n', 'Hypothesis', ':', '68Ga', '-', 'NODAGA', '-', 'RGD', 'might', 'give', 'a', 'better', 'initial', 'evaluation', 'of', 'patients', 'with', 'atheromatous', 'plaques', 'in', 'the', 'carotid', 'artery', 'eligible', 'for', 'endarterectomy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 61,
                "text": "Inflammatory Atheromatous Plaque",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 264,
                "text": "inflammatory atheromatous plaques",
                "type": "CONDITION"
            },
            {
                "start": 534,
                "end": 554,
                "text": "atheromatous plaques",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02274558",
        "study_official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia ",
        "study_brief_summary": " The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.",
        "text": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia | The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.",
        "tokens": "['A', 'Phase', '3', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', ',', 'Fixed', '-', 'Dose', 'Study', 'to', 'Assess', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'NBI-98854', 'for', 'the', 'Treatment', 'of', 'Tardive', 'Dyskinesia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', ',', 'safety', ',', 'and', 'tolerability', 'of', 'NBI-98854', 'administered', 'once', 'daily', 'for', 'the', 'treatment', 'of', 'Tardive', 'Dyskinesia', '(', 'TD', ')', 'symptoms', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 44,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 136,
                "end": 145,
                "text": "NBI-98854",
                "type": "DRUG"
            },
            {
                "start": 167,
                "end": 185,
                "text": "Tardive Dyskinesia",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 280,
                "text": "NBI-98854",
                "type": "DRUG"
            },
            {
                "start": 326,
                "end": 344,
                "text": "Tardive Dyskinesia",
                "type": "CONDITION"
            },
            {
                "start": 346,
                "end": 348,
                "text": "TD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01283152",
        "study_official_title": "Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY\u00ae) in Patients With Hepatic Encephalopathy. ",
        "study_brief_summary": " This study is being done to find out if the laxative polyethylene glycol (also known as GoLYTELY\u00ae or Miralax\u00ae) can treat your hepatic encephalopathy (confusion due to your liver disease and/or cirrhosis) better and/or more safely than lactulose (another laxative). In this study, the investigators will evaluate if polyethylene glycol (GoLYTELY\u00ae) is more effective than lactulose on neurocognition (memory and thinking skills) and determine if it decreases the hospital stay.",
        "text": "Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY\u00ae) in Patients With Hepatic Encephalopathy. | This study is being done to find out if the laxative polyethylene glycol (also known as GoLYTELY\u00ae or Miralax\u00ae) can treat your hepatic encephalopathy (confusion due to your liver disease and/or cirrhosis) better and/or more safely than lactulose (another laxative). In this study, the investigators will evaluate if polyethylene glycol (GoLYTELY\u00ae) is more effective than lactulose on neurocognition (memory and thinking skills) and determine if it decreases the hospital stay.",
        "tokens": "['Randomized', 'Controlled', 'Trial', 'Evaluating', 'the', 'Efficacy', 'of', 'Polyethylene', 'Glycol', '3350', '-', 'electrolyte', 'Solution', '(', 'GoLYTELY', '\u00ae', ')', 'in', 'Patients', 'With', 'Hepatic', 'Encephalopathy', '.', '|', 'This', 'study', 'is', 'being', 'done', 'to', 'find', 'out', 'if', 'the', 'laxative', 'polyethylene', 'glycol', '(', 'also', 'known', 'as', 'GoLYTELY', '\u00ae', 'or', 'Miralax', '\u00ae', ')', 'can', 'treat', 'your', 'hepatic', 'encephalopathy', '(', 'confusion', 'due', 'to', 'your', 'liver', 'disease', 'and/or', 'cirrhosis', ')', 'better', 'and/or', 'more', 'safely', 'than', 'lactulose', '(', 'another', 'laxative', ')', '.', 'In', 'this', 'study', ',', 'the', 'investigators', 'will', 'evaluate', 'if', 'polyethylene', 'glycol', '(', 'GoLYTELY', '\u00ae', ')', 'is', 'more', 'effective', 'than', 'lactulose', 'on', 'neurocognition', '(', 'memory', 'and', 'thinking', 'skills', ')', 'and', 'determine', 'if', 'it', 'decreases', 'the', 'hospital', 'stay', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 55,
                "end": 100,
                "text": "Polyethylene Glycol 3350-electrolyte Solution",
                "type": "DRUG"
            },
            {
                "start": 102,
                "end": 110,
                "text": "GoLYTELY",
                "type": "DRUG"
            },
            {
                "start": 130,
                "end": 152,
                "text": "Hepatic Encephalopathy",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 228,
                "text": "polyethylene glycol",
                "type": "DRUG"
            },
            {
                "start": 244,
                "end": 252,
                "text": "GoLYTELY",
                "type": "DRUG"
            },
            {
                "start": 257,
                "end": 264,
                "text": "Miralax",
                "type": "DRUG"
            },
            {
                "start": 282,
                "end": 304,
                "text": "hepatic encephalopathy",
                "type": "CONDITION"
            },
            {
                "start": 391,
                "end": 400,
                "text": "lactulose",
                "type": "DRUG"
            },
            {
                "start": 471,
                "end": 490,
                "text": "polyethylene glycol",
                "type": "DRUG"
            },
            {
                "start": 492,
                "end": 500,
                "text": "GoLYTELY",
                "type": "DRUG"
            },
            {
                "start": 526,
                "end": 535,
                "text": "lactulose",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02304913",
        "study_official_title": "Hypoglossal Acupuncture for Dysgeusia in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial ",
        "study_brief_summary": " This randomized controlled trial aims to investigate hypoglossal acupuncture in comparison to sham acupuncture and standard medical treatment (dietary recommendations) in the treatment of dysgeusia in cancer patients undergoing chemotherapy.",
        "text": "Hypoglossal Acupuncture for Dysgeusia in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial | This randomized controlled trial aims to investigate hypoglossal acupuncture in comparison to sham acupuncture and standard medical treatment (dietary recommendations) in the treatment of dysgeusia in cancer patients undergoing chemotherapy.",
        "tokens": "['Hypoglossal', 'Acupuncture', 'for', 'Dysgeusia', 'in', 'Gynecologic', 'Cancer', 'Patients', 'Undergoing', 'Chemotherapy', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'randomized', 'controlled', 'trial', 'aims', 'to', 'investigate', 'hypoglossal', 'acupuncture', 'in', 'comparison', 'to', 'sham', 'acupuncture', 'and', 'standard', 'medical', 'treatment', '(', 'dietary', 'recommendations', ')', 'in', 'the', 'treatment', 'of', 'dysgeusia', 'in', 'cancer', 'patients', 'undergoing', 'chemotherapy', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 23,
                "text": "Hypoglossal Acupuncture",
                "type": "OTHER"
            },
            {
                "start": 28,
                "end": 37,
                "text": "Dysgeusia",
                "type": "CONDITION"
            },
            {
                "start": 41,
                "end": 59,
                "text": "Gynecologic Cancer",
                "type": "CONDITION"
            },
            {
                "start": 80,
                "end": 92,
                "text": "Chemotherapy",
                "type": "CONDITION"
            },
            {
                "start": 179,
                "end": 202,
                "text": "hypoglossal acupuncture",
                "type": "OTHER"
            },
            {
                "start": 220,
                "end": 236,
                "text": "sham acupuncture",
                "type": "CONTROL"
            },
            {
                "start": 269,
                "end": 292,
                "text": "dietary recommendations",
                "type": "CONTROL"
            },
            {
                "start": 314,
                "end": 323,
                "text": "dysgeusia",
                "type": "CONDITION"
            },
            {
                "start": 327,
                "end": 333,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 366,
                "text": "chemotherapy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00701701",
        "study_official_title": "An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients With Pompe Disease Who Have Previously Received Myozyme ",
        "study_brief_summary": " An exploratory, open-labeled study of participants with Pompe disease, who had previously received Myozyme\u00ae (alglucosidase alfa) treatment, to evaluate the efficacy, safety and clinical benefit of 2 Immune Tolerance Induction (ITI) regimens in combination with Myozyme\u00ae. Eligible participants who were then receiving Myozyme\u00ae therapy were enrolled into the study, and were followed for a minimum of 18 months on-study (a 6-month ITI treatment module and a 12-month follow-up module on Myozyme\u00ae alone). Eligible participants were followed for a minimum of 18 months on treatment or, if a participant was <6 months of age at the time of enrollment, until the participant was 2 years of age. Both cross-reacting immunologic material (CRIM)-negative and CRIM-positive participants were eligible for Regimen A depending if they met the required criteria. Regimen B, however, was limited to CRIM-negative participants.",
        "text": "An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients With Pompe Disease Who Have Previously Received Myozyme | An exploratory, open-labeled study of participants with Pompe disease, who had previously received Myozyme\u00ae (alglucosidase alfa) treatment, to evaluate the efficacy, safety and clinical benefit of 2 Immune Tolerance Induction (ITI) regimens in combination with Myozyme\u00ae. Eligible participants who were then receiving Myozyme\u00ae therapy were enrolled into the study, and were followed for a minimum of 18 months on-study (a 6-month ITI treatment module and a 12-month follow-up module on Myozyme\u00ae alone). Eligible participants were followed for a minimum of 18 months on treatment or, if a participant was <6 months of age at the time of enrollment, until the participant was 2 years of age. Both cross-reacting immunologic material (CRIM)-negative and CRIM-positive participants were eligible for Regimen A depending if they met the required criteria. Regimen B, however, was limited to CRIM-negative participants.",
        "tokens": "['An', 'Exploratory', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Immune', 'Tolerance', 'Induction', '(', 'ITI', ')', 'in', 'Patients', 'With', 'Pompe', 'Disease', 'Who', 'Have', 'Previously', 'Received', 'Myozyme', '|', 'An', 'exploratory', ',', 'open', '-', 'labeled', 'study', 'of', 'participants', 'with', 'Pompe', 'disease', ',', 'who', 'had', 'previously', 'received', 'Myozyme', '\u00ae', '(', 'alglucosidase', 'alfa', ')', 'treatment', ',', 'to', 'evaluate', 'the', 'efficacy', ',', 'safety', 'and', 'clinical', 'benefit', 'of', '2', 'Immune', 'Tolerance', 'Induction', '(', 'ITI', ')', 'regimens', 'in', 'combination', 'with', 'Myozyme', '\u00ae', '.', 'Eligible', 'participants', 'who', 'were', 'then', 'receiving', 'Myozyme', '\u00ae', 'therapy', 'were', 'enrolled', 'into', 'the', 'study', ',', 'and', 'were', 'followed', 'for', 'a', 'minimum', 'of', '18', 'months', 'on', '-', 'study', '(', 'a', '6', '-', 'month', 'ITI', 'treatment', 'module', 'and', 'a', '12', '-', 'month', 'follow', '-', 'up', 'module', 'on', 'Myozyme', '\u00ae', 'alone', ')', '.', 'Eligible', 'participants', 'were', 'followed', 'for', 'a', 'minimum', 'of', '18', 'months', 'on', 'treatment', 'or', ',', 'if', 'a', 'participant', 'was', '<', '6', 'months', 'of', 'age', 'at', 'the', 'time', 'of', 'enrollment', ',', 'until', 'the', 'participant', 'was', '2', 'years', 'of', 'age', '.', 'Both', 'cross', '-', 'reacting', 'immunologic', 'material', '(', 'CRIM)-negative', 'and', 'CRIM', '-', 'positive', 'participants', 'were', 'eligible', 'for', 'Regimen', 'A', 'depending', 'if', 'they', 'met', 'the', 'required', 'criteria', '.', 'Regimen', 'B', ',', 'however', ',', 'was', 'limited', 'to', 'CRIM', '-', 'negative', 'participants', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 51,
                "end": 77,
                "text": "Immune Tolerance Induction",
                "type": "OTHER"
            },
            {
                "start": 79,
                "end": 82,
                "text": "ITI",
                "type": "OTHER"
            },
            {
                "start": 101,
                "end": 114,
                "text": "Pompe Disease",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 151,
                "text": "Myozyme",
                "type": "DRUG"
            },
            {
                "start": 210,
                "end": 223,
                "text": "Pompe disease",
                "type": "CONDITION"
            },
            {
                "start": 253,
                "end": 260,
                "text": "Myozyme",
                "type": "DRUG"
            },
            {
                "start": 263,
                "end": 281,
                "text": "alglucosidase alfa",
                "type": "DRUG"
            },
            {
                "start": 353,
                "end": 379,
                "text": "Immune Tolerance Induction",
                "type": "OTHER"
            },
            {
                "start": 381,
                "end": 384,
                "text": "ITI",
                "type": "OTHER"
            },
            {
                "start": 415,
                "end": 422,
                "text": "Myozyme",
                "type": "DRUG"
            },
            {
                "start": 471,
                "end": 478,
                "text": "Myozyme",
                "type": "DRUG"
            },
            {
                "start": 583,
                "end": 586,
                "text": "ITI",
                "type": "OTHER"
            },
            {
                "start": 639,
                "end": 646,
                "text": "Myozyme",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02068391",
        "study_official_title": "Achieving Brain Benefits in Covert Stroke Through Aerobic Exercise ",
        "study_brief_summary": " Silent ischemic, also known as \"covert stroke vascular disease\" (CSVD), contributes to neurological deficits that are caused by damage to small blood vessels in the brain. CSVD occurs six to ten times more often that an acute stroke. It is misleading to think, however, that CSVD is an inevitable part of \"getting old\" because people with CSVD are at high risk of developing an acute stroke or dementia. In fact, people with more CSVD lesion volume are more likely to develop day to day problems in planning, decision-making and speed of thinking. Unfortunately, there are no proven therapies designed to address CSVD. We propose to test whether aerobic exercise is an intervention that can combat CSVD because the disease is fundamentally a blood flow problem that may be improved by aerobic exercise. We will recruit CSVD adults with moderate to severe lesion burden and use magnetic resonance imaging (MRI) to study the brain in terms of structure, perfusion and function. Participants will be randomly assigned to either our established aerobic exercise program or a control stretching program. Both groups will take part in lab exercise sessions, which are designed to monitor progress and assess adherence to the program. The duration and intensity of their exercise will increase as participants progress. We will use activity log books, phone calls and extra \"booster\" exercise sessions, as needed, to maximize retention and adherence. We aim to show that aerobic exercise increases cerebral blood flow (CBF) in frontal-subcortical grey matter, supports regional tissue growth, and improves cognitive function in CSVD adults with substantial risk of acute stroke and dementia. A positive outcome of this research will provide strong support for additional clinical trials aimed at sustaining cognition and maintaining independent living.",
        "text": "Achieving Brain Benefits in Covert Stroke Through Aerobic Exercise | Silent ischemic, also known as \"covert stroke vascular disease\" (CSVD), contributes to neurological deficits that are caused by damage to small blood vessels in the brain. CSVD occurs six to ten times more often that an acute stroke. It is misleading to think, however, that CSVD is an inevitable part of \"getting old\" because people with CSVD are at high risk of developing an acute stroke or dementia. In fact, people with more CSVD lesion volume are more likely to develop day to day problems in planning, decision-making and speed of thinking. Unfortunately, there are no proven therapies designed to address CSVD. We propose to test whether aerobic exercise is an intervention that can combat CSVD because the disease is fundamentally a blood flow problem that may be improved by aerobic exercise. We will recruit CSVD adults with moderate to severe lesion burden and use magnetic resonance imaging (MRI) to study the brain in terms of structure, perfusion and function. Participants will be randomly assigned to either our established aerobic exercise program or a control stretching program. Both groups will take part in lab exercise sessions, which are designed to monitor progress and assess adherence to the program. The duration and intensity of their exercise will increase as participants progress. We will use activity log books, phone calls and extra \"booster\" exercise sessions, as needed, to maximize retention and adherence. We aim to show that aerobic exercise increases cerebral blood flow (CBF) in frontal-subcortical grey matter, supports regional tissue growth, and improves cognitive function in CSVD adults with substantial risk of acute stroke and dementia. A positive outcome of this research will provide strong support for additional clinical trials aimed at sustaining cognition and maintaining independent living.",
        "tokens": "['Achieving', 'Brain', 'Benefits', 'in', 'Covert', 'Stroke', 'Through', 'Aerobic', 'Exercise', '|', 'Silent', 'ischemic', ',', 'also', 'known', 'as', '\"', 'covert', 'stroke', 'vascular', 'disease', '\"', '(', 'CSVD', ')', ',', 'contributes', 'to', 'neurological', 'deficits', 'that', 'are', 'caused', 'by', 'damage', 'to', 'small', 'blood', 'vessels', 'in', 'the', 'brain', '.', 'CSVD', 'occurs', 'six', 'to', 'ten', 'times', 'more', 'often', 'that', 'an', 'acute', 'stroke', '.', 'It', 'is', 'misleading', 'to', 'think', ',', 'however', ',', 'that', 'CSVD', 'is', 'an', 'inevitable', 'part', 'of', '\"', 'getting', 'old', '\"', 'because', 'people', 'with', 'CSVD', 'are', 'at', 'high', 'risk', 'of', 'developing', 'an', 'acute', 'stroke', 'or', 'dementia', '.', 'In', 'fact', ',', 'people', 'with', 'more', 'CSVD', 'lesion', 'volume', 'are', 'more', 'likely', 'to', 'develop', 'day', 'to', 'day', 'problems', 'in', 'planning', ',', 'decision', '-', 'making', 'and', 'speed', 'of', 'thinking', '.', 'Unfortunately', ',', 'there', 'are', 'no', 'proven', 'therapies', 'designed', 'to', 'address', 'CSVD', '.', 'We', 'propose', 'to', 'test', 'whether', 'aerobic', 'exercise', 'is', 'an', 'intervention', 'that', 'can', 'combat', 'CSVD', 'because', 'the', 'disease', 'is', 'fundamentally', 'a', 'blood', 'flow', 'problem', 'that', 'may', 'be', 'improved', 'by', 'aerobic', 'exercise', '.', 'We', 'will', 'recruit', 'CSVD', 'adults', 'with', 'moderate', 'to', 'severe', 'lesion', 'burden', 'and', 'use', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'to', 'study', 'the', 'brain', 'in', 'terms', 'of', 'structure', ',', 'perfusion', 'and', 'function', '.', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'either', 'our', 'established', 'aerobic', 'exercise', 'program', 'or', 'a', 'control', 'stretching', 'program', '.', 'Both', 'groups', 'will', 'take', 'part', 'in', 'lab', 'exercise', 'sessions', ',', 'which', 'are', 'designed', 'to', 'monitor', 'progress', 'and', 'assess', 'adherence', 'to', 'the', 'program', '.', 'The', 'duration', 'and', 'intensity', 'of', 'their', 'exercise', 'will', 'increase', 'as', 'participants', 'progress', '.', 'We', 'will', 'use', 'activity', 'log', 'books', ',', 'phone', 'calls', 'and', 'extra', '\"', 'booster', '\"', 'exercise', 'sessions', ',', 'as', 'needed', ',', 'to', 'maximize', 'retention', 'and', 'adherence', '.', 'We', 'aim', 'to', 'show', 'that', 'aerobic', 'exercise', 'increases', 'cerebral', 'blood', 'flow', '(', 'CBF', ')', 'in', 'frontal', '-', 'subcortical', 'grey', 'matter', ',', 'supports', 'regional', 'tissue', 'growth', ',', 'and', 'improves', 'cognitive', 'function', 'in', 'CSVD', 'adults', 'with', 'substantial', 'risk', 'of', 'acute', 'stroke', 'and', 'dementia', '.', 'A', 'positive', 'outcome', 'of', 'this', 'research', 'will', 'provide', 'strong', 'support', 'for', 'additional', 'clinical', 'trials', 'aimed', 'at', 'sustaining', 'cognition', 'and', 'maintaining', 'independent', 'living', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 41,
                "text": "Covert Stroke",
                "type": "CONDITION"
            },
            {
                "start": 50,
                "end": 66,
                "text": "Aerobic Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 101,
                "end": 131,
                "text": "covert stroke vascular disease",
                "type": "CONDITION"
            },
            {
                "start": 134,
                "end": 138,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 241,
                "end": 245,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 289,
                "end": 301,
                "text": "acute stroke",
                "type": "CONDITION"
            },
            {
                "start": 344,
                "end": 348,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 408,
                "end": 412,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 447,
                "end": 459,
                "text": "acute stroke",
                "type": "CONDITION"
            },
            {
                "start": 499,
                "end": 503,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 682,
                "end": 686,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 715,
                "end": 731,
                "text": "aerobic exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 767,
                "end": 771,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 854,
                "end": 870,
                "text": "aerobic exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 888,
                "end": 892,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 1110,
                "end": 1134,
                "text": "aerobic exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 1140,
                "end": 1166,
                "text": "control stretching program",
                "type": "CONTROL"
            },
            {
                "start": 1333,
                "end": 1341,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1430,
                "end": 1463,
                "text": "extra \"booster\" exercise sessions",
                "type": "PHYSICAL"
            },
            {
                "start": 1533,
                "end": 1549,
                "text": "aerobic exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1690,
                "end": 1694,
                "text": "CSVD",
                "type": "CONDITION"
            },
            {
                "start": 1727,
                "end": 1739,
                "text": "acute stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00163878",
        "study_official_title": "A Randomised Control Trial to Determine the Effectiveness of Sensory Stimulation Program in Reducing the Length of Time Spent by Severely Brain Injured Patients in a Vegetative State in the Acute Hospital Environment ",
        "study_brief_summary": " A randomised control trial of patients who have a severe brain injury to determine if patients who receive a standardised sensory stimulation program emerge earlier from a vegetative state. The experimental group would receive, in addition to their normal occuaptional therapy, sensory stimulation which would involve the daily application of stimulation to all five senses using the Sensory Modalities Assessment and Rehabilitation Technique (SMART).",
        "text": "A Randomised Control Trial to Determine the Effectiveness of Sensory Stimulation Program in Reducing the Length of Time Spent by Severely Brain Injured Patients in a Vegetative State in the Acute Hospital Environment | A randomised control trial of patients who have a severe brain injury to determine if patients who receive a standardised sensory stimulation program emerge earlier from a vegetative state. The experimental group would receive, in addition to their normal occuaptional therapy, sensory stimulation which would involve the daily application of stimulation to all five senses using the Sensory Modalities Assessment and Rehabilitation Technique (SMART).",
        "tokens": "['A', 'Randomised', 'Control', 'Trial', 'to', 'Determine', 'the', 'Effectiveness', 'of', 'Sensory', 'Stimulation', 'Program', 'in', 'Reducing', 'the', 'Length', 'of', 'Time', 'Spent', 'by', 'Severely', 'Brain', 'Injured', 'Patients', 'in', 'a', 'Vegetative', 'State', 'in', 'the', 'Acute', 'Hospital', 'Environment', '|', 'A', 'randomised', 'control', 'trial', 'of', 'patients', 'who', 'have', 'a', 'severe', 'brain', 'injury', 'to', 'determine', 'if', 'patients', 'who', 'receive', 'a', 'standardised', 'sensory', 'stimulation', 'program', 'emerge', 'earlier', 'from', 'a', 'vegetative', 'state', '.', 'The', 'experimental', 'group', 'would', 'receive', ',', 'in', 'addition', 'to', 'their', 'normal', 'occuaptional', 'therapy', ',', 'sensory', 'stimulation', 'which', 'would', 'involve', 'the', 'daily', 'application', 'of', 'stimulation', 'to', 'all', 'five', 'senses', 'using', 'the', 'Sensory', 'Modalities', 'Assessment', 'and', 'Rehabilitation', 'Technique', '(', 'SMART', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O']",
        "entities": [
            {
                "start": 61,
                "end": 88,
                "text": "Sensory Stimulation Program",
                "type": "OTHER"
            },
            {
                "start": 129,
                "end": 151,
                "text": "Severely Brain Injured",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 182,
                "text": "Vegetative State",
                "type": "CONDITION"
            },
            {
                "start": 269,
                "end": 288,
                "text": "severe brain injury",
                "type": "CONDITION"
            },
            {
                "start": 328,
                "end": 360,
                "text": "standardised sensory stimulation",
                "type": "OTHER"
            },
            {
                "start": 391,
                "end": 407,
                "text": "vegetative state",
                "type": "CONDITION"
            },
            {
                "start": 475,
                "end": 495,
                "text": "occuaptional therapy",
                "type": "OTHER"
            },
            {
                "start": 497,
                "end": 516,
                "text": "sensory stimulation",
                "type": "OTHER"
            },
            {
                "start": 603,
                "end": 661,
                "text": "Sensory Modalities Assessment and Rehabilitation Technique",
                "type": "OTHER"
            },
            {
                "start": 663,
                "end": 668,
                "text": "SMART",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02080806",
        "study_official_title": "Effects of Mechanical Insufflation-exsufflation in Stroke Patients With Dysphagia - Pilot Study ",
        "study_brief_summary": " Stroke patients with dysphagia have restrictive lung dysfunction and impaired cough response. This pilot study was performed to determine if Mechanical Insufflation Exsufflation (MIE) therapy can help recover impaired cough function.",
        "text": "Effects of Mechanical Insufflation-exsufflation in Stroke Patients With Dysphagia - Pilot Study | Stroke patients with dysphagia have restrictive lung dysfunction and impaired cough response. This pilot study was performed to determine if Mechanical Insufflation Exsufflation (MIE) therapy can help recover impaired cough function.",
        "tokens": "['Effects', 'of', 'Mechanical', 'Insufflation', '-', 'exsufflation', 'in', 'Stroke', 'Patients', 'With', 'Dysphagia', '-', 'Pilot', 'Study', '|', 'Stroke', 'patients', 'with', 'dysphagia', 'have', 'restrictive', 'lung', 'dysfunction', 'and', 'impaired', 'cough', 'response', '.', 'This', 'pilot', 'study', 'was', 'performed', 'to', 'determine', 'if', 'Mechanical', 'Insufflation', 'Exsufflation', '(', 'MIE', ')', 'therapy', 'can', 'help', 'recover', 'impaired', 'cough', 'function', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 47,
                "text": "Mechanical Insufflation-exsufflation",
                "type": "OTHER"
            },
            {
                "start": 51,
                "end": 57,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 72,
                "end": 81,
                "text": "Dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 104,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 128,
                "text": "dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 162,
                "text": "lung dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 167,
                "end": 190,
                "text": "impaired cough response",
                "type": "CONDITION"
            },
            {
                "start": 239,
                "end": 275,
                "text": "Mechanical Insufflation Exsufflation",
                "type": "OTHER"
            },
            {
                "start": 277,
                "end": 280,
                "text": "MIE",
                "type": "OTHER"
            },
            {
                "start": 307,
                "end": 330,
                "text": "impaired cough function",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01841840",
        "study_official_title": "The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke ",
        "study_brief_summary": " Stroke is the third leading cause of death in the United States. Of those who are affected by stroke, a third becomes permanently disabled. Risk factors for stroke include, but are not limited to, advancing age, physical inactivity, arterial stiffness, and most commonly, high blood pressure. Stroke is a major form of a much boarder problem, cardiovascular disease (CVD). CVD is considered the primary cause of death in the US. Interestingly, increased arterial stiffness of elastic arteries (carotid and aorta) has been shown to be strongly correlated to CVD and stroke. Increased arterial stiffness is considered an independent risk for the development of CVD and stroke. Hence, arterial stiffness has been suggested as a potential therapeutic target for CVD and more specifically stroke.\n\nRecently, whole-body vibration (WBV) exercise has been proposed as a new and effective method to improve muscle mass and muscle strength in younger and older individuals. It is known that systemic arterial stiffness decreased 40 min after a single WBV session in healthy men. In our laboratory, we have shown that leg arterial stiffness decreases after a session of WBV. Taken together, this data seems to suggest WBV may be used as a viable way to decrease arterial stiffness. Special populations, such as post-stroke patients, may be unwilling or unable to perform WBV exercise so an inactive form of exercise (vibration) therapy is needed.\n\nPassive vibration (PV), allows patients to lie in an inactive, supine position, with their legs placed onto the vibration plate. This exposes the lower limbs to continuous vibration without performing voluntary muscle contraction. PV has been shown to increase skin blood flow on the vibrated extremity through vasodilation in healthy individuals and type 2 diabetics. Previous work in our laboratory has demonstrated that a 10-min session of PV on the legs decreases augmentation index (AIx) , a marker of pressure wave reflection, as well as leg and systemic PWV through decreases in local peripheral resistance in young men. However, the effects of PV on arterial function in post-stroke patients are unknown.\n\nIt is hypothesized that post-stroke patients will demonstrate a decrease in leg PWV and central AIx. However, greater responses are expected with the lower vibration frequency.",
        "text": "The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke | Stroke is the third leading cause of death in the United States. Of those who are affected by stroke, a third becomes permanently disabled. Risk factors for stroke include, but are not limited to, advancing age, physical inactivity, arterial stiffness, and most commonly, high blood pressure. Stroke is a major form of a much boarder problem, cardiovascular disease (CVD). CVD is considered the primary cause of death in the US. Interestingly, increased arterial stiffness of elastic arteries (carotid and aorta) has been shown to be strongly correlated to CVD and stroke. Increased arterial stiffness is considered an independent risk for the development of CVD and stroke. Hence, arterial stiffness has been suggested as a potential therapeutic target for CVD and more specifically stroke.\n\nRecently, whole-body vibration (WBV) exercise has been proposed as a new and effective method to improve muscle mass and muscle strength in younger and older individuals. It is known that systemic arterial stiffness decreased 40 min after a single WBV session in healthy men. In our laboratory, we have shown that leg arterial stiffness decreases after a session of WBV. Taken together, this data seems to suggest WBV may be used as a viable way to decrease arterial stiffness. Special populations, such as post-stroke patients, may be unwilling or unable to perform WBV exercise so an inactive form of exercise (vibration) therapy is needed.\n\nPassive vibration (PV), allows patients to lie in an inactive, supine position, with their legs placed onto the vibration plate. This exposes the lower limbs to continuous vibration without performing voluntary muscle contraction. PV has been shown to increase skin blood flow on the vibrated extremity through vasodilation in healthy individuals and type 2 diabetics. Previous work in our laboratory has demonstrated that a 10-min session of PV on the legs decreases augmentation index (AIx) , a marker of pressure wave reflection, as well as leg and systemic PWV through decreases in local peripheral resistance in young men. However, the effects of PV on arterial function in post-stroke patients are unknown.\n\nIt is hypothesized that post-stroke patients will demonstrate a decrease in leg PWV and central AIx. However, greater responses are expected with the lower vibration frequency.",
        "tokens": "['The', 'Acute', 'Effects', 'of', 'Passive', 'Vibration', 'on', 'Cardiovascular', 'Function', 'in', 'Individuals', 'With', 'Stroke', '|', 'Stroke', 'is', 'the', 'third', 'leading', 'cause', 'of', 'death', 'in', 'the', 'United', 'States', '.', 'Of', 'those', 'who', 'are', 'affected', 'by', 'stroke', ',', 'a', 'third', 'becomes', 'permanently', 'disabled', '.', 'Risk', 'factors', 'for', 'stroke', 'include', ',', 'but', 'are', 'not', 'limited', 'to', ',', 'advancing', 'age', ',', 'physical', 'inactivity', ',', 'arterial', 'stiffness', ',', 'and', 'most', 'commonly', ',', 'high', 'blood', 'pressure', '.', 'Stroke', 'is', 'a', 'major', 'form', 'of', 'a', 'much', 'boarder', 'problem', ',', 'cardiovascular', 'disease', '(', 'CVD', ')', '.', 'CVD', 'is', 'considered', 'the', 'primary', 'cause', 'of', 'death', 'in', 'the', 'US', '.', 'Interestingly', ',', 'increased', 'arterial', 'stiffness', 'of', 'elastic', 'arteries', '(', 'carotid', 'and', 'aorta', ')', 'has', 'been', 'shown', 'to', 'be', 'strongly', 'correlated', 'to', 'CVD', 'and', 'stroke', '.', 'Increased', 'arterial', 'stiffness', 'is', 'considered', 'an', 'independent', 'risk', 'for', 'the', 'development', 'of', 'CVD', 'and', 'stroke', '.', 'Hence', ',', 'arterial', 'stiffness', 'has', 'been', 'suggested', 'as', 'a', 'potential', 'therapeutic', 'target', 'for', 'CVD', 'and', 'more', 'specifically', 'stroke', '.', '\\n\\n', 'Recently', ',', 'whole', '-', 'body', 'vibration', '(', 'WBV', ')', 'exercise', 'has', 'been', 'proposed', 'as', 'a', 'new', 'and', 'effective', 'method', 'to', 'improve', 'muscle', 'mass', 'and', 'muscle', 'strength', 'in', 'younger', 'and', 'older', 'individuals', '.', 'It', 'is', 'known', 'that', 'systemic', 'arterial', 'stiffness', 'decreased', '40', 'min', 'after', 'a', 'single', 'WBV', 'session', 'in', 'healthy', 'men', '.', 'In', 'our', 'laboratory', ',', 'we', 'have', 'shown', 'that', 'leg', 'arterial', 'stiffness', 'decreases', 'after', 'a', 'session', 'of', 'WBV', '.', 'Taken', 'together', ',', 'this', 'data', 'seems', 'to', 'suggest', 'WBV', 'may', 'be', 'used', 'as', 'a', 'viable', 'way', 'to', 'decrease', 'arterial', 'stiffness', '.', 'Special', 'populations', ',', 'such', 'as', 'post', '-', 'stroke', 'patients', ',', 'may', 'be', 'unwilling', 'or', 'unable', 'to', 'perform', 'WBV', 'exercise', 'so', 'an', 'inactive', 'form', 'of', 'exercise', '(', 'vibration', ')', 'therapy', 'is', 'needed', '.', '\\n\\n', 'Passive', 'vibration', '(', 'PV', ')', ',', 'allows', 'patients', 'to', 'lie', 'in', 'an', 'inactive', ',', 'supine', 'position', ',', 'with', 'their', 'legs', 'placed', 'onto', 'the', 'vibration', 'plate', '.', 'This', 'exposes', 'the', 'lower', 'limbs', 'to', 'continuous', 'vibration', 'without', 'performing', 'voluntary', 'muscle', 'contraction', '.', 'PV', 'has', 'been', 'shown', 'to', 'increase', 'skin', 'blood', 'flow', 'on', 'the', 'vibrated', 'extremity', 'through', 'vasodilation', 'in', 'healthy', 'individuals', 'and', 'type', '2', 'diabetics', '.', 'Previous', 'work', 'in', 'our', 'laboratory', 'has', 'demonstrated', 'that', 'a', '10', '-', 'min', 'session', 'of', 'PV', 'on', 'the', 'legs', 'decreases', 'augmentation', 'index', '(', 'AIx', ')', ',', 'a', 'marker', 'of', 'pressure', 'wave', 'reflection', ',', 'as', 'well', 'as', 'leg', 'and', 'systemic', 'PWV', 'through', 'decreases', 'in', 'local', 'peripheral', 'resistance', 'in', 'young', 'men', '.', 'However', ',', 'the', 'effects', 'of', 'PV', 'on', 'arterial', 'function', 'in', 'post', '-', 'stroke', 'patients', 'are', 'unknown', '.', '\\n\\n', 'It', 'is', 'hypothesized', 'that', 'post', '-', 'stroke', 'patients', 'will', 'demonstrate', 'a', 'decrease', 'in', 'leg', 'PWV', 'and', 'central', 'AIx', '.', 'However', ',', 'greater', 'responses', 'are', 'expected', 'with', 'the', 'lower', 'vibration', 'frequency', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 38,
                "text": "Passive Vibration",
                "type": "OTHER"
            },
            {
                "start": 86,
                "end": 92,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 95,
                "end": 101,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 195,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 252,
                "end": 258,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 388,
                "end": 394,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 438,
                "end": 460,
                "text": "cardiovascular disease",
                "type": "CONDITION"
            },
            {
                "start": 462,
                "end": 465,
                "text": "CVD",
                "type": "CONDITION"
            },
            {
                "start": 468,
                "end": 471,
                "text": "CVD",
                "type": "CONDITION"
            },
            {
                "start": 539,
                "end": 587,
                "text": "increased arterial stiffness of elastic arteries",
                "type": "CONDITION"
            },
            {
                "start": 652,
                "end": 655,
                "text": "CVD",
                "type": "CONDITION"
            },
            {
                "start": 660,
                "end": 666,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 668,
                "end": 696,
                "text": "Increased arterial stiffness",
                "type": "CONDITION"
            },
            {
                "start": 754,
                "end": 757,
                "text": "CVD",
                "type": "CONDITION"
            },
            {
                "start": 762,
                "end": 768,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 777,
                "end": 795,
                "text": "arterial stiffness",
                "type": "CONDITION"
            },
            {
                "start": 853,
                "end": 856,
                "text": "CVD",
                "type": "CONDITION"
            },
            {
                "start": 879,
                "end": 885,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1076,
                "end": 1103,
                "text": "systemic arterial stiffness",
                "type": "CONDITION"
            },
            {
                "start": 1206,
                "end": 1224,
                "text": "arterial stiffness",
                "type": "CONDITION"
            },
            {
                "start": 1346,
                "end": 1364,
                "text": "arterial stiffness",
                "type": "CONDITION"
            },
            {
                "start": 1400,
                "end": 1406,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1532,
                "end": 1549,
                "text": "Passive vibration",
                "type": "PHYSICAL"
            },
            {
                "start": 1551,
                "end": 1553,
                "text": "PV",
                "type": "PHYSICAL"
            },
            {
                "start": 1693,
                "end": 1713,
                "text": "continuous vibration",
                "type": "PHYSICAL"
            },
            {
                "start": 1763,
                "end": 1765,
                "text": "PV",
                "type": "PHYSICAL"
            },
            {
                "start": 1975,
                "end": 1977,
                "text": "PV",
                "type": "PHYSICAL"
            },
            {
                "start": 2076,
                "end": 2096,
                "text": "leg and systemic PWV",
                "type": "PHYSICAL"
            },
            {
                "start": 2184,
                "end": 2186,
                "text": "PV",
                "type": "PHYSICAL"
            },
            {
                "start": 2216,
                "end": 2222,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 2275,
                "end": 2281,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 2322,
                "end": 2329,
                "text": "leg PWV",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT01165008",
        "study_official_title": "Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies ",
        "study_brief_summary": " To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.\n\nPatients and methods: Fifteen patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 100 mg anakinra subcutaneously per day during 12 months. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS) and for muscle performance the functional index of myositis (FI). In addition repeat muscle biopsies were performed",
        "text": "Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies | To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.\n\nPatients and methods: Fifteen patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 100 mg anakinra subcutaneously per day during 12 months. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS) and for muscle performance the functional index of myositis (FI). In addition repeat muscle biopsies were performed",
        "tokens": "['Anakinra', 'in', 'Patients', 'With', 'Refractory', 'Idiopathic', 'Inflammatory', 'Myopathies', '|', 'To', 'investigate', 'the', 'effect', 'of', 'the', 'interleukin-1', '(', 'IL-1', ')', 'blocking', 'agent', ',', 'anakinra', ',', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'inflammatory', 'myopathies', '.', '\\n\\n', 'Patients', 'and', 'methods', ':', 'Fifteen', 'patients', 'with', 'refractory', 'polymyositis', '(', 'PM', ')', ',', 'dermatomyositis', '(', 'DM', ')', ',', 'or', 'inclusion', 'body', 'myositis', '(', 'IBM', ')', 'were', 'treated', 'with', '100', 'mg', 'anakinra', 'subcutaneously', 'per', 'day', 'during', '12', 'months', '.', 'Outcome', 'measures', 'included', 'myositis', 'disease', 'activity', 'score', 'with', 'improvement', 'defined', 'according', 'to', 'The', 'International', 'Myositis', 'Assessment', 'and', 'Clinical', 'Studies', 'Group', '(', 'IMACS', ')', 'and', 'for', 'muscle', 'performance', 'the', 'functional', 'index', 'of', 'myositis', '(', 'FI', ')', '.', 'In', 'addition', 'repeat', 'muscle', 'biopsies', 'were', 'performed']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "Anakinra",
                "type": "DRUG"
            },
            {
                "start": 26,
                "end": 71,
                "text": "Refractory Idiopathic Inflammatory Myopathies",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 142,
                "text": "interleukin-1 (IL-1) blocking agent",
                "type": "DRUG"
            },
            {
                "start": 144,
                "end": 152,
                "text": "anakinra",
                "type": "DRUG"
            },
            {
                "start": 171,
                "end": 214,
                "text": "treatment-resistant inflammatory myopathies",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 284,
                "text": "refractory polymyositis",
                "type": "CONDITION"
            },
            {
                "start": 286,
                "end": 288,
                "text": "PM",
                "type": "CONDITION"
            },
            {
                "start": 291,
                "end": 306,
                "text": "dermatomyositis",
                "type": "CONDITION"
            },
            {
                "start": 308,
                "end": 310,
                "text": "DM",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 339,
                "text": "inclusion body myositis",
                "type": "CONDITION"
            },
            {
                "start": 341,
                "end": 344,
                "text": "IBM",
                "type": "CONDITION"
            },
            {
                "start": 371,
                "end": 379,
                "text": "anakinra",
                "type": "DRUG"
            },
            {
                "start": 447,
                "end": 455,
                "text": "myositis",
                "type": "CONDITION"
            },
            {
                "start": 641,
                "end": 649,
                "text": "myositis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02019667",
        "study_official_title": "Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency ",
        "study_brief_summary": " Objective:\n\nTo perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency.\n\nStudy Population:\n\nTwenty-two children and adults with SSADH deficiency.\n\nDesign:\n\nDouble-blind, cross-over, phase II clinical trial.\n\nOutcome Measures:\n\nThe primary outcome measures for drug efficacy will be performance on neuropsychological testing and responses to parent questionnaire. The secondary outcome measure will be TMS parameters of cortical excitation and inhibition. The outcome measures for safety will include clinical examination and neuropsychological tests.",
        "text": "Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency | Objective:\n\nTo perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency.\n\nStudy Population:\n\nTwenty-two children and adults with SSADH deficiency.\n\nDesign:\n\nDouble-blind, cross-over, phase II clinical trial.\n\nOutcome Measures:\n\nThe primary outcome measures for drug efficacy will be performance on neuropsychological testing and responses to parent questionnaire. The secondary outcome measure will be TMS parameters of cortical excitation and inhibition. The outcome measures for safety will include clinical examination and neuropsychological tests.",
        "tokens": "['Phase', '2', 'Clinical', 'Trial', 'of', 'SGS-742', 'Therapy', 'in', 'Succinic', 'Semialdehyde', 'Dehydrogenase', 'Deficiency', '|', 'Objective', ':', '\\n\\n', 'To', 'perform', 'a', 'clinical', 'trial', 'assessing', 'the', 'safety', ',', 'tolerability', 'and', 'efficacy', 'of', 'the', 'GABA(B', ')', 'receptor', 'antagonist', 'SGS-742', 'in', 'patients', 'with', 'SSADH', 'deficiency', '.', '\\n\\n', 'Study', 'Population', ':', '\\n\\n', 'Twenty', '-', 'two', 'children', 'and', 'adults', 'with', 'SSADH', 'deficiency', '.', '\\n\\n', 'Design', ':', '\\n\\n', 'Double', '-', 'blind', ',', 'cross', '-', 'over', ',', 'phase', 'II', 'clinical', 'trial', '.', '\\n\\n', 'Outcome', 'Measures', ':', '\\n\\n', 'The', 'primary', 'outcome', 'measures', 'for', 'drug', 'efficacy', 'will', 'be', 'performance', 'on', 'neuropsychological', 'testing', 'and', 'responses', 'to', 'parent', 'questionnaire', '.', 'The', 'secondary', 'outcome', 'measure', 'will', 'be', 'TMS', 'parameters', 'of', 'cortical', 'excitation', 'and', 'inhibition', '.', 'The', 'outcome', 'measures', 'for', 'safety', 'will', 'include', 'clinical', 'examination', 'and', 'neuropsychological', 'tests', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 33,
                "text": "SGS-742",
                "type": "DRUG"
            },
            {
                "start": 45,
                "end": 91,
                "text": "Succinic Semialdehyde Dehydrogenase Deficiency",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 216,
                "text": "GABA(B) receptor antagonist",
                "type": "DRUG"
            },
            {
                "start": 217,
                "end": 224,
                "text": "SGS-742",
                "type": "DRUG"
            },
            {
                "start": 242,
                "end": 258,
                "text": "SSADH deficiency",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 332,
                "text": "SSADH deficiency",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00466323",
        "study_official_title": "The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness ",
        "study_brief_summary": " The purpose of this study is to learn how to help veterans play a stronger role in shaping their mental health care. Specifically we want to see if we can help veterans improve their mental health treatment by helping them decide if they want to involve family in their mental health treatment, and if so, how. The study will compare a \"family member provider\" program to an \"enhanced treatment as usual approach\" in achieving these goals.",
        "text": "The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness | The purpose of this study is to learn how to help veterans play a stronger role in shaping their mental health care. Specifically we want to see if we can help veterans improve their mental health treatment by helping them decide if they want to involve family in their mental health treatment, and if so, how. The study will compare a \"family member provider\" program to an \"enhanced treatment as usual approach\" in achieving these goals.",
        "tokens": "['The', 'Effectiveness', 'of', 'FMPO', 'in', 'Improving', 'the', 'Quality', 'of', 'Care', 'for', 'Persons', 'With', 'Severe', 'Mental', 'Illness', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'learn', 'how', 'to', 'help', 'veterans', 'play', 'a', 'stronger', 'role', 'in', 'shaping', 'their', 'mental', 'health', 'care', '.', 'Specifically', 'we', 'want', 'to', 'see', 'if', 'we', 'can', 'help', 'veterans', 'improve', 'their', 'mental', 'health', 'treatment', 'by', 'helping', 'them', 'decide', 'if', 'they', 'want', 'to', 'involve', 'family', 'in', 'their', 'mental', 'health', 'treatment', ',', 'and', 'if', 'so', ',', 'how', '.', 'The', 'study', 'will', 'compare', 'a', '\"', 'family', 'member', 'provider', '\"', 'program', 'to', 'an', '\"', 'enhanced', 'treatment', 'as', 'usual', 'approach', '\"', 'in', 'achieving', 'these', 'goals', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 25,
                "text": "FMPO",
                "type": "OTHER"
            },
            {
                "start": 76,
                "end": 97,
                "text": "Severe Mental Illness",
                "type": "CONDITION"
            },
            {
                "start": 437,
                "end": 459,
                "text": "family member provider",
                "type": "OTHER"
            },
            {
                "start": 476,
                "end": 512,
                "text": "enhanced treatment as usual approach",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04652921",
        "study_official_title": "The Effects of 6-month Supplementation With Creatine and Guanidinoacetic Acid on Biomarkers of Sarcopenia in Elderly ",
        "study_brief_summary": " Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.",
        "text": "The Effects of 6-month Supplementation With Creatine and Guanidinoacetic Acid on Biomarkers of Sarcopenia in Elderly | Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.",
        "tokens": "['The', 'Effects', 'of', '6', '-', 'month', 'Supplementation', 'With', 'Creatine', 'and', 'Guanidinoacetic', 'Acid', 'on', 'Biomarkers', 'of', 'Sarcopenia', 'in', 'Elderly', '|', 'Sarcopenia', '-', 'driven', 'brain', 'and', 'muscle', 'creatine', 'deficit', 'could', 'be', 'seen', 'as', 'a', 'distinctive', 'pathological', 'facet', 'of', 'this', 'condition', ',', 'and', 'this', 'might', 'be', 'approached', 'with', 'targeted', 'therapies', 'in', 'aim', 'to', 'restore', 'creatine', 'homeostasis', 'in', 'target', 'tissues', '.', 'Among', 'potential', 'therapeutic', 'candidates', ',', 'guanidinoacetate', '(', 'GAA', ')', 'appears', 'recently', 'as', 'a', 'direct', 'precursor', 'of', 'creatine', 'that', 'may', 'favorably', 'upregulate', 'muscle', 'and', 'brain', 'creatine', 'concentration', '.', 'Interestingly', ',', 'GAA', '-', 'creatine', 'mixture', 'was', 'found', 'to', 'be', 'superior', 'than', 'creatine', 'itself', 'to', 'effectively', 'improves', 'bioenergetics', 'in', 'the', 'human', 'brain', 'and', 'muscle', 'in', 'healthy', 'humans', ',', 'perhaps', 'due', 'to', 'the', 'unique', 'transportability', 'features', 'of', 'this', 'combination', '.', 'Here', ',', 'we', 'plan', 'to', 'evaluate', 'does', 'creatine', '-', 'GAA', 'supplementation', 'affects', 'various', 'biomarkers', 'of', 'sarcopenia', 'in', 'elderly', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 44,
                "end": 52,
                "text": "Creatine",
                "type": "DRUG"
            },
            {
                "start": 57,
                "end": 77,
                "text": "Guanidinoacetic Acid",
                "type": "DRUG"
            },
            {
                "start": 95,
                "end": 105,
                "text": "Sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 129,
                "text": "Sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 154,
                "end": 170,
                "text": "creatine deficit",
                "type": "CONDITION"
            },
            {
                "start": 311,
                "end": 319,
                "text": "creatine",
                "type": "DRUG"
            },
            {
                "start": 391,
                "end": 407,
                "text": "guanidinoacetate",
                "type": "DRUG"
            },
            {
                "start": 409,
                "end": 412,
                "text": "GAA",
                "type": "DRUG"
            },
            {
                "start": 456,
                "end": 464,
                "text": "creatine",
                "type": "DRUG"
            },
            {
                "start": 512,
                "end": 520,
                "text": "creatine",
                "type": "DRUG"
            },
            {
                "start": 551,
                "end": 554,
                "text": "GAA",
                "type": "DRUG"
            },
            {
                "start": 555,
                "end": 563,
                "text": "creatine",
                "type": "DRUG"
            },
            {
                "start": 809,
                "end": 817,
                "text": "creatine",
                "type": "DRUG"
            },
            {
                "start": 818,
                "end": 821,
                "text": "GAA",
                "type": "DRUG"
            },
            {
                "start": 868,
                "end": 878,
                "text": "sarcopenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04269577",
        "study_official_title": "Motor Learning in Parkinson's Disease: Underlying Effective Connectivity and Influential Factors ",
        "study_brief_summary": " Parkinson's disease (PD) is characterized by severe motor symptoms that can only be partially alleviated by medication. It was shown previously that rehabilitation is an important therapeutic supplement for micrographia in early disease. However, what is unknown is how motor learning impacts on the underlying neural networks in patients with different disease progression and how this interacts with dopaminergic medication. Furthermore, difficulties with upper limb motor control has a severe impact on the daily lives of PD patients since fine motor skills become increasingly important for the use of smartphones and tablets. Therefore, the current project will include a newly developed Swipe-Slide Pattern test, resembling the pattern codes used to unlock smartphones and tablets. This task will be used to determine learning-induced neuroplasticity of cortico-striatal effective connectivity across disease stages in PD. Using a combination of behavioral assessment and functional magnetic resonance imaging, the investigators aim to contribute to the understanding of upper limb motor learning in patients with PD for the development of individualized rehabilitation programs.",
        "text": "Motor Learning in Parkinson's Disease: Underlying Effective Connectivity and Influential Factors | Parkinson's disease (PD) is characterized by severe motor symptoms that can only be partially alleviated by medication. It was shown previously that rehabilitation is an important therapeutic supplement for micrographia in early disease. However, what is unknown is how motor learning impacts on the underlying neural networks in patients with different disease progression and how this interacts with dopaminergic medication. Furthermore, difficulties with upper limb motor control has a severe impact on the daily lives of PD patients since fine motor skills become increasingly important for the use of smartphones and tablets. Therefore, the current project will include a newly developed Swipe-Slide Pattern test, resembling the pattern codes used to unlock smartphones and tablets. This task will be used to determine learning-induced neuroplasticity of cortico-striatal effective connectivity across disease stages in PD. Using a combination of behavioral assessment and functional magnetic resonance imaging, the investigators aim to contribute to the understanding of upper limb motor learning in patients with PD for the development of individualized rehabilitation programs.",
        "tokens": "['Motor', 'Learning', 'in', 'Parkinson', \"'s\", 'Disease', ':', 'Underlying', 'Effective', 'Connectivity', 'and', 'Influential', 'Factors', '|', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'is', 'characterized', 'by', 'severe', 'motor', 'symptoms', 'that', 'can', 'only', 'be', 'partially', 'alleviated', 'by', 'medication', '.', 'It', 'was', 'shown', 'previously', 'that', 'rehabilitation', 'is', 'an', 'important', 'therapeutic', 'supplement', 'for', 'micrographia', 'in', 'early', 'disease', '.', 'However', ',', 'what', 'is', 'unknown', 'is', 'how', 'motor', 'learning', 'impacts', 'on', 'the', 'underlying', 'neural', 'networks', 'in', 'patients', 'with', 'different', 'disease', 'progression', 'and', 'how', 'this', 'interacts', 'with', 'dopaminergic', 'medication', '.', 'Furthermore', ',', 'difficulties', 'with', 'upper', 'limb', 'motor', 'control', 'has', 'a', 'severe', 'impact', 'on', 'the', 'daily', 'lives', 'of', 'PD', 'patients', 'since', 'fine', 'motor', 'skills', 'become', 'increasingly', 'important', 'for', 'the', 'use', 'of', 'smartphones', 'and', 'tablets', '.', 'Therefore', ',', 'the', 'current', 'project', 'will', 'include', 'a', 'newly', 'developed', 'Swipe', '-', 'Slide', 'Pattern', 'test', ',', 'resembling', 'the', 'pattern', 'codes', 'used', 'to', 'unlock', 'smartphones', 'and', 'tablets', '.', 'This', 'task', 'will', 'be', 'used', 'to', 'determine', 'learning', '-', 'induced', 'neuroplasticity', 'of', 'cortico', '-', 'striatal', 'effective', 'connectivity', 'across', 'disease', 'stages', 'in', 'PD', '.', 'Using', 'a', 'combination', 'of', 'behavioral', 'assessment', 'and', 'functional', 'magnetic', 'resonance', 'imaging', ',', 'the', 'investigators', 'aim', 'to', 'contribute', 'to', 'the', 'understanding', 'of', 'upper', 'limb', 'motor', 'learning', 'in', 'patients', 'with', 'PD', 'for', 'the', 'development', 'of', 'individualized', 'rehabilitation', 'programs', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 37,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 99,
                "end": 118,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 122,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 624,
                "end": 626,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1024,
                "end": 1026,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1219,
                "end": 1221,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04555616",
        "study_official_title": "Environmental Design for Behavioral Regulation in People With Dementia ",
        "study_brief_summary": " Individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. Environmental features may be influential in behavioral regulation. The purpose of this study is to assess the feasibility of environmental design protocols in older adults with dementia and their caregivers. Thirty subjects with moderate to severe Alzheimer's disease as primary dementia type, and their caregivers, will be randomly assigned to one of three arms: standard care; standard environmental design protocol; or personalized environmental design protocol.",
        "text": "Environmental Design for Behavioral Regulation in People With Dementia | Individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. Environmental features may be influential in behavioral regulation. The purpose of this study is to assess the feasibility of environmental design protocols in older adults with dementia and their caregivers. Thirty subjects with moderate to severe Alzheimer's disease as primary dementia type, and their caregivers, will be randomly assigned to one of three arms: standard care; standard environmental design protocol; or personalized environmental design protocol.",
        "tokens": "['Environmental', 'Design', 'for', 'Behavioral', 'Regulation', 'in', 'People', 'With', 'Dementia', '|', 'Individuals', 'with', 'dementia', 'present', 'with', 'changes', 'in', 'behaviors', 'throughout', 'the', 'continuum', 'of', 'cognitive', 'decline', '.', 'Environmental', 'features', 'may', 'be', 'influential', 'in', 'behavioral', 'regulation', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'feasibility', 'of', 'environmental', 'design', 'protocols', 'in', 'older', 'adults', 'with', 'dementia', 'and', 'their', 'caregivers', '.', 'Thirty', 'subjects', 'with', 'moderate', 'to', 'severe', 'Alzheimer', \"'s\", 'disease', 'as', 'primary', 'dementia', 'type', ',', 'and', 'their', 'caregivers', ',', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'three', 'arms', ':', 'standard', 'care', ';', 'standard', 'environmental', 'design', 'protocol', ';', 'or', 'personalized', 'environmental', 'design', 'protocol', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 20,
                "text": "Environmental Design",
                "type": "OTHER"
            },
            {
                "start": 25,
                "end": 46,
                "text": "Behavioral Regulation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 62,
                "end": 70,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 90,
                "end": 98,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 178,
                "text": "cognitive decline",
                "type": "CONDITION"
            },
            {
                "start": 225,
                "end": 246,
                "text": "behavioral regulation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 306,
                "end": 326,
                "text": "environmental design",
                "type": "OTHER"
            },
            {
                "start": 358,
                "end": 366,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 410,
                "end": 448,
                "text": "moderate to severe Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 460,
                "end": 468,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 545,
                "end": 558,
                "text": "standard care",
                "type": "CONTROL"
            },
            {
                "start": 560,
                "end": 589,
                "text": "standard environmental design",
                "type": "OTHER"
            },
            {
                "start": 603,
                "end": 636,
                "text": "personalized environmental design",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01605357",
        "study_official_title": "A Randomized, Open Label Clinical Trial of Sustained Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury ",
        "study_brief_summary": " Cerebral edema is seen heterogenous group of neurological disease states that mainly fall under the categories of metabolic, infectious, neoplasia, cerebrovascular, and traumatic brain injury disease states. Regardless of the driving force, cerebral edema is defined as the accumulation of fluid in the brain's intracellular and extracellular spaces. This occurs secondary to alterations in the complex interplay between four distinct fluid compartments within the cranium. In any human cranium; fluid is contained in the blood, the cerebrospinal fluid, interstitial fluid of the brain parenchyma, and the intracellular fluid of the neurons and glia. Fluid movement occurs normally between these compartments and depends on specific concentrations of solutes (such as sodium) and water. In brain-injured states, the normal regulation of this process is disturbed and cerebral edema can develop. Cerebral edema leads to increased intracranial pressure and mortality secondary to brain tissue compression, given the confines of the fixed-volume cranium. Additionally, secondary neuronal dysfunction or death can occur at the cellular level secondary to the disruption of ion gradients that control metabolism and function.\n\nWhile studies utilizing bolus dosing of hyperosmolar therapy to target signs or symptoms of increased intracranial pressure secondary to cerebral edema are numerous, there is a paucity of studies relating to continuous infusion of hyperosmolar therapy for targeted sustained hypernatremia for the prevention and treatment of cerebral edema. The investigators hypothesize that induced, sustained hypernatremia following traumatic brain injury will decrease the rate of cerebral edema formation and improve patient outcomes.",
        "text": "A Randomized, Open Label Clinical Trial of Sustained Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury | Cerebral edema is seen heterogenous group of neurological disease states that mainly fall under the categories of metabolic, infectious, neoplasia, cerebrovascular, and traumatic brain injury disease states. Regardless of the driving force, cerebral edema is defined as the accumulation of fluid in the brain's intracellular and extracellular spaces. This occurs secondary to alterations in the complex interplay between four distinct fluid compartments within the cranium. In any human cranium; fluid is contained in the blood, the cerebrospinal fluid, interstitial fluid of the brain parenchyma, and the intracellular fluid of the neurons and glia. Fluid movement occurs normally between these compartments and depends on specific concentrations of solutes (such as sodium) and water. In brain-injured states, the normal regulation of this process is disturbed and cerebral edema can develop. Cerebral edema leads to increased intracranial pressure and mortality secondary to brain tissue compression, given the confines of the fixed-volume cranium. Additionally, secondary neuronal dysfunction or death can occur at the cellular level secondary to the disruption of ion gradients that control metabolism and function.\n\nWhile studies utilizing bolus dosing of hyperosmolar therapy to target signs or symptoms of increased intracranial pressure secondary to cerebral edema are numerous, there is a paucity of studies relating to continuous infusion of hyperosmolar therapy for targeted sustained hypernatremia for the prevention and treatment of cerebral edema. The investigators hypothesize that induced, sustained hypernatremia following traumatic brain injury will decrease the rate of cerebral edema formation and improve patient outcomes.",
        "tokens": "['A', 'Randomized', ',', 'Open', 'Label', 'Clinical', 'Trial', 'of', 'Sustained', 'Hypernatremia', 'for', 'the', 'Prevention', 'and', 'Treatment', 'of', 'Cerebral', 'Edema', 'in', 'Traumatic', 'Brain', 'Injury', '|', 'Cerebral', 'edema', 'is', 'seen', 'heterogenous', 'group', 'of', 'neurological', 'disease', 'states', 'that', 'mainly', 'fall', 'under', 'the', 'categories', 'of', 'metabolic', ',', 'infectious', ',', 'neoplasia', ',', 'cerebrovascular', ',', 'and', 'traumatic', 'brain', 'injury', 'disease', 'states', '.', 'Regardless', 'of', 'the', 'driving', 'force', ',', 'cerebral', 'edema', 'is', 'defined', 'as', 'the', 'accumulation', 'of', 'fluid', 'in', 'the', 'brain', \"'s\", 'intracellular', 'and', 'extracellular', 'spaces', '.', 'This', 'occurs', 'secondary', 'to', 'alterations', 'in', 'the', 'complex', 'interplay', 'between', 'four', 'distinct', 'fluid', 'compartments', 'within', 'the', 'cranium', '.', 'In', 'any', 'human', 'cranium', ';', 'fluid', 'is', 'contained', 'in', 'the', 'blood', ',', 'the', 'cerebrospinal', 'fluid', ',', 'interstitial', 'fluid', 'of', 'the', 'brain', 'parenchyma', ',', 'and', 'the', 'intracellular', 'fluid', 'of', 'the', 'neurons', 'and', 'glia', '.', 'Fluid', 'movement', 'occurs', 'normally', 'between', 'these', 'compartments', 'and', 'depends', 'on', 'specific', 'concentrations', 'of', 'solutes', '(', 'such', 'as', 'sodium', ')', 'and', 'water', '.', 'In', 'brain', '-', 'injured', 'states', ',', 'the', 'normal', 'regulation', 'of', 'this', 'process', 'is', 'disturbed', 'and', 'cerebral', 'edema', 'can', 'develop', '.', 'Cerebral', 'edema', 'leads', 'to', 'increased', 'intracranial', 'pressure', 'and', 'mortality', 'secondary', 'to', 'brain', 'tissue', 'compression', ',', 'given', 'the', 'confines', 'of', 'the', 'fixed', '-', 'volume', 'cranium', '.', 'Additionally', ',', 'secondary', 'neuronal', 'dysfunction', 'or', 'death', 'can', 'occur', 'at', 'the', 'cellular', 'level', 'secondary', 'to', 'the', 'disruption', 'of', 'ion', 'gradients', 'that', 'control', 'metabolism', 'and', 'function', '.', '\\n\\n', 'While', 'studies', 'utilizing', 'bolus', 'dosing', 'of', 'hyperosmolar', 'therapy', 'to', 'target', 'signs', 'or', 'symptoms', 'of', 'increased', 'intracranial', 'pressure', 'secondary', 'to', 'cerebral', 'edema', 'are', 'numerous', ',', 'there', 'is', 'a', 'paucity', 'of', 'studies', 'relating', 'to', 'continuous', 'infusion', 'of', 'hyperosmolar', 'therapy', 'for', 'targeted', 'sustained', 'hypernatremia', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'cerebral', 'edema', '.', 'The', 'investigators', 'hypothesize', 'that', 'induced', ',', 'sustained', 'hypernatremia', 'following', 'traumatic', 'brain', 'injury', 'will', 'decrease', 'the', 'rate', 'of', 'cerebral', 'edema', 'formation', 'and', 'improve', 'patient', 'outcomes', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 66,
                "text": "Sustained Hypernatremia",
                "type": "OTHER"
            },
            {
                "start": 103,
                "end": 117,
                "text": "Cerebral Edema",
                "type": "CONDITION"
            },
            {
                "start": 121,
                "end": 143,
                "text": "Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 160,
                "text": "Cerebral edema",
                "type": "CONDITION"
            },
            {
                "start": 315,
                "end": 337,
                "text": "traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 387,
                "end": 401,
                "text": "cerebral edema",
                "type": "CONDITION"
            },
            {
                "start": 936,
                "end": 949,
                "text": "brain-injured",
                "type": "CONDITION"
            },
            {
                "start": 1013,
                "end": 1027,
                "text": "cerebral edema",
                "type": "CONDITION"
            },
            {
                "start": 1041,
                "end": 1055,
                "text": "Cerebral edema",
                "type": "CONDITION"
            },
            {
                "start": 1505,
                "end": 1519,
                "text": "cerebral edema",
                "type": "CONDITION"
            },
            {
                "start": 1599,
                "end": 1619,
                "text": "hyperosmolar therapy",
                "type": "OTHER"
            },
            {
                "start": 1633,
                "end": 1656,
                "text": "sustained hypernatremia",
                "type": "OTHER"
            },
            {
                "start": 1693,
                "end": 1707,
                "text": "cerebral edema",
                "type": "CONDITION"
            },
            {
                "start": 1753,
                "end": 1776,
                "text": "sustained hypernatremia",
                "type": "OTHER"
            },
            {
                "start": 1787,
                "end": 1809,
                "text": "traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 1836,
                "end": 1850,
                "text": "cerebral edema",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01090453",
        "study_official_title": "Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 4 and 12 Months of Age ",
        "study_brief_summary": " This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13\u00ae at 2, 4 and 12 months of age and with Rotarix\u2122 at 2 and 4 months of age.",
        "text": "Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 4 and 12 Months of Age | This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13\u00ae at 2, 4 and 12 months of age and with Rotarix\u2122 at 2 and 4 months of age.",
        "tokens": "['Feasibility', 'Study', 'of', 'GlaxoSmithKline', 'Biologicals', \"'\", 'GSK2202083A', 'Vaccine', 'in', 'Healthy', 'Infants', 'at', '2', ',', '4', 'and', '12', 'Months', 'of', 'Age', '|', 'This', 'study', 'will', 'evaluate', 'the', 'safety', 'and', 'immunogenicity', 'of', 'GSK', 'Biologicals', \"'\", 'GSK2202083', 'vaccine', 'co', '-', 'administered', 'with', 'Prevenar', '13', '\u00ae', 'at', '2', ',', '4', 'and', '12', 'months', 'of', 'age', 'and', 'with', 'Rotarix', '\u2122', 'at', '2', 'and', '4', 'months', 'of', 'age', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 69,
                "text": "GSK2202083A Vaccine",
                "type": "DRUG"
            },
            {
                "start": 195,
                "end": 213,
                "text": "GSK2202083 vaccine",
                "type": "DRUG"
            },
            {
                "start": 235,
                "end": 243,
                "text": "Prevenar",
                "type": "DRUG"
            },
            {
                "start": 286,
                "end": 293,
                "text": "Rotarix",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04507490",
        "study_official_title": "Acute Effect of Whole Body Vibration of Different Frequencies on Balance and Functional Mobility of Patients With Parkinson: Crossover-type Controlled Clinical Trial ",
        "study_brief_summary": " Parkinson's disease has innumerous motor symptoms that impacting on the functional level of the patient, such as impairment in functional mobility and balance . Previous studies have already aimed to evaluate the effectiveness of whole body vibration, but without methodological criteria. The use of whole body vibration may be an alternative for the treatment of Parkinson's disease. Therefore, the objective of the study is to verify which frequency of vibration is able to improve the balance and mobility of patients with Parkinson's disease.",
        "text": "Acute Effect of Whole Body Vibration of Different Frequencies on Balance and Functional Mobility of Patients With Parkinson: Crossover-type Controlled Clinical Trial | Parkinson's disease has innumerous motor symptoms that impacting on the functional level of the patient, such as impairment in functional mobility and balance . Previous studies have already aimed to evaluate the effectiveness of whole body vibration, but without methodological criteria. The use of whole body vibration may be an alternative for the treatment of Parkinson's disease. Therefore, the objective of the study is to verify which frequency of vibration is able to improve the balance and mobility of patients with Parkinson's disease.",
        "tokens": "['Acute', 'Effect', 'of', 'Whole', 'Body', 'Vibration', 'of', 'Different', 'Frequencies', 'on', 'Balance', 'and', 'Functional', 'Mobility', 'of', 'Patients', 'With', 'Parkinson', ':', 'Crossover', '-', 'type', 'Controlled', 'Clinical', 'Trial', '|', 'Parkinson', \"'s\", 'disease', 'has', 'innumerous', 'motor', 'symptoms', 'that', 'impacting', 'on', 'the', 'functional', 'level', 'of', 'the', 'patient', ',', 'such', 'as', 'impairment', 'in', 'functional', 'mobility', 'and', 'balance', '.', 'Previous', 'studies', 'have', 'already', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'whole', 'body', 'vibration', ',', 'but', 'without', 'methodological', 'criteria', '.', 'The', 'use', 'of', 'whole', 'body', 'vibration', 'may', 'be', 'an', 'alternative', 'for', 'the', 'treatment', 'of', 'Parkinson', \"'s\", 'disease', '.', 'Therefore', ',', 'the', 'objective', 'of', 'the', 'study', 'is', 'to', 'verify', 'which', 'frequency', 'of', 'vibration', 'is', 'able', 'to', 'improve', 'the', 'balance', 'and', 'mobility', 'of', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 36,
                "text": "Whole Body Vibration",
                "type": "OTHER"
            },
            {
                "start": 114,
                "end": 123,
                "text": "Parkinson",
                "type": "CONDITION"
            },
            {
                "start": 168,
                "end": 187,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 398,
                "end": 418,
                "text": "whole body vibration",
                "type": "OTHER"
            },
            {
                "start": 468,
                "end": 488,
                "text": "whole body vibration",
                "type": "OTHER"
            },
            {
                "start": 532,
                "end": 551,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 694,
                "end": 713,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05182437",
        "study_official_title": "Precision Radiation Treatment for Epilepsy (PRECISION) ",
        "study_brief_summary": " The PRECISION-study offers a non-invasive, curative intervention for drug-resistant localised epilepsy patients who are not eligible for surgery. The intervention will consist of a single LINAC based SRT treatment and is given by the radiation-oncologist after detailed localisation of the epileptogenic zone with the neurologist, radiologist and neurosurgeon. This intervention will make curative-intent treatment possible where this could otherwise not be given and is a non-invasive and non-competitive alternative to epilepsy surgery. It is expected that the health costs for this curative treatment will not exceed standard treatment, such as lifelong medication and neuromodulation.",
        "text": "Precision Radiation Treatment for Epilepsy (PRECISION) | The PRECISION-study offers a non-invasive, curative intervention for drug-resistant localised epilepsy patients who are not eligible for surgery. The intervention will consist of a single LINAC based SRT treatment and is given by the radiation-oncologist after detailed localisation of the epileptogenic zone with the neurologist, radiologist and neurosurgeon. This intervention will make curative-intent treatment possible where this could otherwise not be given and is a non-invasive and non-competitive alternative to epilepsy surgery. It is expected that the health costs for this curative treatment will not exceed standard treatment, such as lifelong medication and neuromodulation.",
        "tokens": "['Precision', 'Radiation', 'Treatment', 'for', 'Epilepsy', '(', 'PRECISION', ')', '|', 'The', 'PRECISION', '-', 'study', 'offers', 'a', 'non', '-', 'invasive', ',', 'curative', 'intervention', 'for', 'drug', '-', 'resistant', 'localised', 'epilepsy', 'patients', 'who', 'are', 'not', 'eligible', 'for', 'surgery', '.', 'The', 'intervention', 'will', 'consist', 'of', 'a', 'single', 'LINAC', 'based', 'SRT', 'treatment', 'and', 'is', 'given', 'by', 'the', 'radiation', '-', 'oncologist', 'after', 'detailed', 'localisation', 'of', 'the', 'epileptogenic', 'zone', 'with', 'the', 'neurologist', ',', 'radiologist', 'and', 'neurosurgeon', '.', 'This', 'intervention', 'will', 'make', 'curative', '-', 'intent', 'treatment', 'possible', 'where', 'this', 'could', 'otherwise', 'not', 'be', 'given', 'and', 'is', 'a', 'non', '-', 'invasive', 'and', 'non', '-', 'competitive', 'alternative', 'to', 'epilepsy', 'surgery', '.', 'It', 'is', 'expected', 'that', 'the', 'health', 'costs', 'for', 'this', 'curative', 'treatment', 'will', 'not', 'exceed', 'standard', 'treatment', ',', 'such', 'as', 'lifelong', 'medication', 'and', 'neuromodulation', '.']",
        "token_bio_labels": "['B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 29,
                "text": "Precision Radiation Treatment",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 34,
                "end": 42,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 159,
                "text": "drug-resistant localised epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 270,
                "text": "LINAC based SRT treatment",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 578,
                "end": 586,
                "text": "epilepsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00191906",
        "study_official_title": "A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder. ",
        "study_brief_summary": " To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with combined type ADHD and Reading Disorder.",
        "text": "A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder. | To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with combined type ADHD and Reading Disorder.",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Crossover', 'Comparison', 'of', 'Atomoxetine', 'and', 'Placebo', 'in', 'Child', 'Outpatients', 'With', 'Attention', '-', 'Deficit', '/', 'Hyperactivity', 'Disorder', ',', 'Reading', 'Disorder', ',', 'or', 'Comorbid', 'Attention', '-', 'Deficit', '/', 'Hyperactivity', 'Disorder', 'and', 'Reading', 'Disorder', '.', '|', 'To', 'test', 'the', 'hypothesis', 'that', 'a', '4', 'week', 'treatment', 'with', 'atomoxetine', 'is', 'more', 'effective', 'than', 'placebo', 'in', 'patients', 'with', 'combined', 'type', 'Attention', 'Deficit', '/', 'Hyperactivity', 'Disorder', '(', 'ADHD', ')', ',', 'patients', 'with', 'only', 'Reading', 'Disorder', ',', 'and', 'patients', 'with', 'combined', 'type', 'ADHD', 'and', 'Reading', 'Disorder', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 52,
                "end": 63,
                "text": "Atomoxetine",
                "type": "DRUG"
            },
            {
                "start": 68,
                "end": 75,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 102,
                "end": 119,
                "text": "Attention-Deficit",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 142,
                "text": "Hyperactivity Disorder",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 160,
                "text": "Reading Disorder",
                "type": "CONDITION"
            },
            {
                "start": 165,
                "end": 191,
                "text": "Comorbid Attention-Deficit",
                "type": "CONDITION"
            },
            {
                "start": 192,
                "end": 214,
                "text": "Hyperactivity Disorder",
                "type": "CONDITION"
            },
            {
                "start": 219,
                "end": 235,
                "text": "Reading Disorder",
                "type": "CONDITION"
            },
            {
                "start": 291,
                "end": 302,
                "text": "atomoxetine",
                "type": "DRUG"
            },
            {
                "start": 326,
                "end": 333,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 351,
                "end": 382,
                "text": "combined type Attention Deficit",
                "type": "CONDITION"
            },
            {
                "start": 383,
                "end": 405,
                "text": "Hyperactivity Disorder",
                "type": "CONDITION"
            },
            {
                "start": 407,
                "end": 411,
                "text": "ADHD",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 449,
                "text": "Reading Disorder",
                "type": "CONDITION"
            },
            {
                "start": 483,
                "end": 487,
                "text": "ADHD",
                "type": "CONDITION"
            },
            {
                "start": 492,
                "end": 508,
                "text": "Reading Disorder",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04570085",
        "study_official_title": "Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Effect of a 30-week Caffeine Treatment on Cognition in Alzheimer's Disease at Beginning to Moderate Stages ",
        "study_brief_summary": " Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available.\n\nCoffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which Alzheimer's patients might be more vulnerable.\n\nThe main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage (MMSE 16-24).",
        "text": "Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Effect of a 30-week Caffeine Treatment on Cognition in Alzheimer's Disease at Beginning to Moderate Stages | Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available.\n\nCoffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which Alzheimer's patients might be more vulnerable.\n\nThe main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage (MMSE 16-24).",
        "tokens": "['Multicentre', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', 'Evaluating', 'the', 'Effect', 'of', 'a', '30', '-', 'week', 'Caffeine', 'Treatment', 'on', 'Cognition', 'in', 'Alzheimer', \"'s\", 'Disease', 'at', 'Beginning', 'to', 'Moderate', 'Stages', '|', 'Sporadic', 'Alzheimer', \"'s\", 'disease', 'is', 'a', 'multifactorial', 'illness', 'arising', 'a', 'major', 'medico', '-', 'economic', 'stakes', 'for', 'our', 'aging', 'societies', '.', 'There', 'is', 'currently', 'no', 'curative', 'treatment', 'available', '.', '\\n\\n', 'Coffee', 'is', 'a', 'complex', 'beverage', 'with', 'psychostimulant', 'properties', 'whose', 'main', 'effective', 'element', ',', 'caffeine', ',', 'has', 'a', 'pleiotropic', 'effect', 'on', 'the', 'central', 'nervous', 'system', '.', 'Caffeine', 'pharmacological', 'properties', 'enable', 'its', 'use', 'like', 'an', 'Alzheimer', \"'s\", 'disease', 'symptomatic', 'treatment', '.', 'Its', 'supposed', 'benefits', 'must', \"n't\", 'obscure', 'anxiety', 'and', 'insomnia', 'caffeine', 'effect', 'at', 'large', 'dose', ',', 'which', 'Alzheimer', \"'s\", 'patients', 'might', 'be', 'more', 'vulnerable', '.', '\\n\\n', 'The', 'main', 'study', 'objective', 'is', 'to', 'evaluate', 'placebo', '-', 'controlled', 'caffeine', 'efficacy', '(', '30', 'treatments', 'weeks', ')', 'on', 'cognitive', 'decline', 'in', 'Alzheimer', \"'s\", 'disease', 'dementia', 'at', 'beginning', 'to', 'moderate', 'stage', '(', 'MMSE', '16', '-', '24', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 46,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 99,
                "end": 107,
                "text": "Caffeine",
                "type": "DRUG"
            },
            {
                "start": 134,
                "end": 185,
                "text": "Alzheimer's Disease at Beginning to Moderate Stages",
                "type": "CONDITION"
            },
            {
                "start": 188,
                "end": 216,
                "text": "Sporadic Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 453,
                "end": 461,
                "text": "caffeine",
                "type": "DRUG"
            },
            {
                "start": 519,
                "end": 527,
                "text": "Caffeine",
                "type": "DRUG"
            },
            {
                "start": 578,
                "end": 597,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 680,
                "end": 688,
                "text": "caffeine",
                "type": "DRUG"
            },
            {
                "start": 717,
                "end": 728,
                "text": "Alzheimer's",
                "type": "CONDITION"
            },
            {
                "start": 805,
                "end": 812,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 824,
                "end": 832,
                "text": "caffeine",
                "type": "DRUG"
            },
            {
                "start": 888,
                "end": 947,
                "text": "Alzheimer's disease dementia at beginning to moderate stage",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00257842",
        "study_official_title": "Constipation is a common disorder and current treatments are unsatisfactory. Biofeedback may help patients with constipation and dyssynergic defecation, but its efficacy is unproven and whether this is due to behavioral modification or excessive attention is unknown. Methods: In a prospective randomized trial, the investigators investigated the efficacy of Biofeedback (manometric- assisted anal relaxation, muscle coordination and simulated defecation training), with either sham feedback therapy (Sham) or standard therapy (diet, exercise, laxatives; Standard) in 77 subjects (69 women) with dyssynergic defecation. Primary outcome measures included presence of dyssynergia, balloon expulsion time, number of complete spontaneous bowel movements (CSBM), and global bowel satisfaction. Data analyzed per protocol.",
        "study_brief_summary": null,
        "text": "Constipation is a common disorder and current treatments are unsatisfactory. Biofeedback may help patients with constipation and dyssynergic defecation, but its efficacy is unproven and whether this is due to behavioral modification or excessive attention is unknown. Methods: In a prospective randomized trial, the investigators investigated the efficacy of Biofeedback (manometric- assisted anal relaxation, muscle coordination and simulated defecation training), with either sham feedback therapy (Sham) or standard therapy (diet, exercise, laxatives; Standard) in 77 subjects (69 women) with dyssynergic defecation. Primary outcome measures included presence of dyssynergia, balloon expulsion time, number of complete spontaneous bowel movements (CSBM), and global bowel satisfaction. Data analyzed per protocol.",
        "tokens": "['Constipation', 'is', 'a', 'common', 'disorder', 'and', 'current', 'treatments', 'are', 'unsatisfactory', '.', 'Biofeedback', 'may', 'help', 'patients', 'with', 'constipation', 'and', 'dyssynergic', 'defecation', ',', 'but', 'its', 'efficacy', 'is', 'unproven', 'and', 'whether', 'this', 'is', 'due', 'to', 'behavioral', 'modification', 'or', 'excessive', 'attention', 'is', 'unknown', '.', 'Methods', ':', 'In', 'a', 'prospective', 'randomized', 'trial', ',', 'the', 'investigators', 'investigated', 'the', 'efficacy', 'of', 'Biofeedback', '(', 'manometric-', 'assisted', 'anal', 'relaxation', ',', 'muscle', 'coordination', 'and', 'simulated', 'defecation', 'training', ')', ',', 'with', 'either', 'sham', 'feedback', 'therapy', '(', 'Sham', ')', 'or', 'standard', 'therapy', '(', 'diet', ',', 'exercise', ',', 'laxatives', ';', 'Standard', ')', 'in', '77', 'subjects', '(', '69', 'women', ')', 'with', 'dyssynergic', 'defecation', '.', 'Primary', 'outcome', 'measures', 'included', 'presence', 'of', 'dyssynergia', ',', 'balloon', 'expulsion', 'time', ',', 'number', 'of', 'complete', 'spontaneous', 'bowel', 'movements', '(', 'CSBM', ')', ',', 'and', 'global', 'bowel', 'satisfaction', '.', 'Data', 'analyzed', 'per', 'protocol', '.']",
        "token_bio_labels": "['B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 12,
                "text": "Constipation",
                "type": "CONDITION"
            },
            {
                "start": 77,
                "end": 88,
                "text": "Biofeedback",
                "type": "PHYSICAL"
            },
            {
                "start": 112,
                "end": 124,
                "text": "constipation",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 151,
                "text": "dyssynergic defecation",
                "type": "CONDITION"
            },
            {
                "start": 359,
                "end": 370,
                "text": "Biofeedback",
                "type": "PHYSICAL"
            },
            {
                "start": 372,
                "end": 463,
                "text": "manometric- assisted anal relaxation, muscle coordination and simulated defecation training",
                "type": "PHYSICAL"
            },
            {
                "start": 478,
                "end": 499,
                "text": "sham feedback therapy",
                "type": "CONTROL"
            },
            {
                "start": 528,
                "end": 532,
                "text": "diet",
                "type": "CONTROL"
            },
            {
                "start": 534,
                "end": 542,
                "text": "exercise",
                "type": "CONTROL"
            },
            {
                "start": 544,
                "end": 553,
                "text": "laxatives",
                "type": "CONTROL"
            },
            {
                "start": 596,
                "end": 618,
                "text": "dyssynergic defecation",
                "type": "CONDITION"
            },
            {
                "start": 666,
                "end": 677,
                "text": "dyssynergia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00001929",
        "study_official_title": "NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease ",
        "study_brief_summary": " Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Patients with the disease experience, rigid muscles, stooped posture, and a shuffling-type walk (gait).\n\nIn this study researchers plan to evaluate the effectiveness of the drug eliprodil for the treatment of Parkinson's Disease. Eliprodil works by blocking special receptors (NMDA) that are associated with the symptoms of Parkinson's Disease.",
        "text": "NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease | Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Patients with the disease experience, rigid muscles, stooped posture, and a shuffling-type walk (gait).\n\nIn this study researchers plan to evaluate the effectiveness of the drug eliprodil for the treatment of Parkinson's Disease. Eliprodil works by blocking special receptors (NMDA) that are associated with the symptoms of Parkinson's Disease.",
        "tokens": "['NMDA', '-', 'Receptor', 'Blockade', 'With', 'Eliprodil', 'in', 'Parkinson', \"'s\", 'Disease', '|', 'Patients', 'with', 'Parkinson', \"'s\", 'disease', 'are', 'missing', 'the', 'chemical', 'neurotransmitter', 'dopamine', '.', 'This', 'occurs', 'as', 'a', 'result', 'of', 'destructive', 'changes', 'in', 'an', 'area', 'of', 'the', 'brain', 'responsible', 'for', 'making', 'dopamine', ',', 'the', 'basal', 'ganglia', '.', 'Patients', 'with', 'the', 'disease', 'experience', ',', 'rigid', 'muscles', ',', 'stooped', 'posture', ',', 'and', 'a', 'shuffling', '-', 'type', 'walk', '(', 'gait', ')', '.', '\\n\\n', 'In', 'this', 'study', 'researchers', 'plan', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'the', 'drug', 'eliprodil', 'for', 'the', 'treatment', 'of', 'Parkinson', \"'s\", 'Disease', '.', 'Eliprodil', 'works', 'by', 'blocking', 'special', 'receptors', '(', 'NMDA', ')', 'that', 'are', 'associated', 'with', 'the', 'symptoms', 'of', 'Parkinson', \"'s\", 'Disease', '.']",
        "token_bio_labels": "['B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "NMDA-Receptor Blockade",
                "type": "DRUG"
            },
            {
                "start": 28,
                "end": 37,
                "text": "Eliprodil",
                "type": "DRUG"
            },
            {
                "start": 41,
                "end": 60,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 77,
                "end": 96,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 450,
                "end": 459,
                "text": "eliprodil",
                "type": "DRUG"
            },
            {
                "start": 481,
                "end": 500,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 502,
                "end": 511,
                "text": "Eliprodil",
                "type": "DRUG"
            },
            {
                "start": 596,
                "end": 615,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03227783",
        "study_official_title": "The Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in Parkinson's Disease ",
        "study_brief_summary": " Depression is common in Parkinson's disease (PD), but the effective treatment is not established yet. tDCS is a non-invasive brain stimulation to modulate brain function. The tDCS on the depression in general population were already conducted, but not in PD. This study is to know whether transcranial direct current stimulation (tDCS) is effective for the treatment of depression in PD. Participant will be asked to visit three consecutive days for the non-invasive stimulation.",
        "text": "The Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in Parkinson's Disease | Depression is common in Parkinson's disease (PD), but the effective treatment is not established yet. tDCS is a non-invasive brain stimulation to modulate brain function. The tDCS on the depression in general population were already conducted, but not in PD. This study is to know whether transcranial direct current stimulation (tDCS) is effective for the treatment of depression in PD. Participant will be asked to visit three consecutive days for the non-invasive stimulation.",
        "tokens": "['The', 'Effect', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', 'on', 'Depression', 'in', 'Parkinson', \"'s\", 'Disease', '|', 'Depression', 'is', 'common', 'in', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', ',', 'but', 'the', 'effective', 'treatment', 'is', 'not', 'established', 'yet', '.', 'tDCS', 'is', 'a', 'non', '-', 'invasive', 'brain', 'stimulation', 'to', 'modulate', 'brain', 'function', '.', 'The', 'tDCS', 'on', 'the', 'depression', 'in', 'general', 'population', 'were', 'already', 'conducted', ',', 'but', 'not', 'in', 'PD', '.', 'This', 'study', 'is', 'to', 'know', 'whether', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'is', 'effective', 'for', 'the', 'treatment', 'of', 'depression', 'in', 'PD', '.', 'Participant', 'will', 'be', 'asked', 'to', 'visit', 'three', 'consecutive', 'days', 'for', 'the', 'non', '-', 'invasive', 'stimulation', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 53,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 55,
                "end": 59,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 64,
                "end": 74,
                "text": "Depression",
                "type": "CONDITION"
            },
            {
                "start": 78,
                "end": 97,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 100,
                "end": 110,
                "text": "Depression",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 143,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 147,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 202,
                "end": 206,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 275,
                "end": 279,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 287,
                "end": 297,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 355,
                "end": 357,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 389,
                "end": 428,
                "text": "transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 430,
                "end": 434,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 470,
                "end": 480,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 484,
                "end": 486,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01445613",
        "study_official_title": "CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy ",
        "study_brief_summary": " The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.",
        "text": "CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy | The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.",
        "tokens": "['CANOPY', ':', 'Carotid', 'Artery', 'Stenting', 'Outcomes', 'in', 'the', 'Standard', 'Risk', 'Population', 'for', 'Carotid', 'Endarterectomy', '|', 'The', 'objective', 'of', 'the', 'CANOPY', 'trial', 'is', 'to', 'assess', 'the', 'continued', 'safety', 'and', 'effectiveness', 'of', 'the', 'RX', 'Acculink', 'Carotid', 'Stent', 'System', 'under', 'commercial', 'use', 'in', 'subjects', 'at', 'standard', 'risk', 'for', 'adverse', 'events', 'from', 'Carotid', 'Endarterectomy', '(', 'CEA', ')', 'enrolled', 'by', 'physicians', 'with', 'a', 'range', 'of', 'carotid', 'stenting', 'experience', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 77,
                "end": 99,
                "text": "Carotid Endarterectomy",
                "type": "SURGICAL"
            },
            {
                "start": 195,
                "end": 227,
                "text": "RX Acculink Carotid Stent System",
                "type": "SURGICAL"
            },
            {
                "start": 302,
                "end": 324,
                "text": "Carotid Endarterectomy",
                "type": "SURGICAL"
            },
            {
                "start": 326,
                "end": 329,
                "text": "CEA",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT05776706",
        "study_official_title": "Clinical Trial for the Evaluation of the Accuracy of Augmented Reality Based Neuronavigation System ",
        "study_brief_summary": " The goal of this clinical trial is to test augmented reality (AR) based neuronavigation system in surgeries for patients of brain neoplasm or cerebral vascular disease. The main questions it aims to answer are:\n\n\u2022 AR based neuronavigation system can achieve accuracy that is not inferior to conventional intraoperative navigation system.\n\nParticipants will participate the study after informed consent. When participants undergo surgery for their brain tumor, we will set up 2 types of neuronavigation, conventional navigation system and developed AR based neuronavigation system. Surgeon will plan and conduct surgery based on only conventional navigation system, but 3D errors at several selected points between two types of navigation will be measured and analyzed.",
        "text": "Clinical Trial for the Evaluation of the Accuracy of Augmented Reality Based Neuronavigation System | The goal of this clinical trial is to test augmented reality (AR) based neuronavigation system in surgeries for patients of brain neoplasm or cerebral vascular disease. The main questions it aims to answer are:\n\n\u2022 AR based neuronavigation system can achieve accuracy that is not inferior to conventional intraoperative navigation system.\n\nParticipants will participate the study after informed consent. When participants undergo surgery for their brain tumor, we will set up 2 types of neuronavigation, conventional navigation system and developed AR based neuronavigation system. Surgeon will plan and conduct surgery based on only conventional navigation system, but 3D errors at several selected points between two types of navigation will be measured and analyzed.",
        "tokens": "['Clinical', 'Trial', 'for', 'the', 'Evaluation', 'of', 'the', 'Accuracy', 'of', 'Augmented', 'Reality', 'Based', 'Neuronavigation', 'System', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'test', 'augmented', 'reality', '(', 'AR', ')', 'based', 'neuronavigation', 'system', 'in', 'surgeries', 'for', 'patients', 'of', 'brain', 'neoplasm', 'or', 'cerebral', 'vascular', 'disease', '.', 'The', 'main', 'questions', 'it', 'aims', 'to', 'answer', 'are', ':', '\\n\\n', '\u2022', 'AR', 'based', 'neuronavigation', 'system', 'can', 'achieve', 'accuracy', 'that', 'is', 'not', 'inferior', 'to', 'conventional', 'intraoperative', 'navigation', 'system', '.', '\\n\\n', 'Participants', 'will', 'participate', 'the', 'study', 'after', 'informed', 'consent', '.', 'When', 'participants', 'undergo', 'surgery', 'for', 'their', 'brain', 'tumor', ',', 'we', 'will', 'set', 'up', '2', 'types', 'of', 'neuronavigation', ',', 'conventional', 'navigation', 'system', 'and', 'developed', 'AR', 'based', 'neuronavigation', 'system', '.', 'Surgeon', 'will', 'plan', 'and', 'conduct', 'surgery', 'based', 'on', 'only', 'conventional', 'navigation', 'system', ',', 'but', '3D', 'errors', 'at', 'several', 'selected', 'points', 'between', 'two', 'types', 'of', 'navigation', 'will', 'be', 'measured', 'and', 'analyzed', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 53,
                "end": 99,
                "text": "Augmented Reality Based Neuronavigation System",
                "type": "OTHER"
            },
            {
                "start": 145,
                "end": 196,
                "text": "augmented reality (AR) based neuronavigation system",
                "type": "OTHER"
            },
            {
                "start": 226,
                "end": 240,
                "text": "brain neoplasm",
                "type": "CONDITION"
            },
            {
                "start": 244,
                "end": 269,
                "text": "cerebral vascular disease",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 347,
                "text": "AR based neuronavigation system",
                "type": "OTHER"
            },
            {
                "start": 393,
                "end": 438,
                "text": "conventional intraoperative navigation system",
                "type": "CONTROL"
            },
            {
                "start": 549,
                "end": 560,
                "text": "brain tumor",
                "type": "CONDITION"
            },
            {
                "start": 605,
                "end": 635,
                "text": "conventional navigation system",
                "type": "CONTROL"
            },
            {
                "start": 650,
                "end": 681,
                "text": "AR based neuronavigation system",
                "type": "OTHER"
            },
            {
                "start": 735,
                "end": 765,
                "text": "conventional navigation system",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05148247",
        "study_official_title": "Evaluation of The Perceive, Recall, Plan and Perform Intervention for Persons With Cognitive Impairments After Brain Injuries in Community Rehabilitation: Single Case Experimental Study ",
        "study_brief_summary": " Background: There is a need for standardized interventions in community rehabilitation that can improve everyday task performance for older adults with cognitive challenges after acquired brain injury. Older adults are often excluded from research due to strict inclusion criteria. It is critical for a sustainable health service system that these patients are empowered and reach their maximum level of independence. The Perceive, Recall, Plan and Perform System (PRPP) of Intervention can be applied by Occupational Therapists (OT) for clients with cognitive challenges to enhance mastery of needed or desired everyday tasks. There is no current evidence for the effectiveness of this intervention for this population.\n\nPurpose: A clinical trial to investigate the effectiveness of the PRPP intervention for older persons with cognitive impairments after brain injury in the context of community-based rehabilitation.\n\nMethod: In PRPP intervention the OT uses systematically instructions in task training to support a client to use cognitive strategies efficiently. The everyday tasks used for training should be valued by the participant and useful in their rehabilitation. The tasks could include different parts of morning routines, simple or complex meal planning or preparation, use of cell phone, leisure activities, or other household and community activities. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as participants internalize the strategies. The participants receive PRPP intervention 3 times a week for 3 weeks, every session last for 45-60 minutes.\n\nThe participants' task mastery and cognitive strategy use will be measured at least 5 times in each phase: baseline, intervention, after the intervention, and 4 weeks after the discharge from rehabilitation. The measurement scores at baseline act controls and are therefore compared with the other phases for the same participant. The same procedure will be repeated for the other participants, but then with a staggered intervention phase. A staggered intervention phase acts as a control between participants and allows to see if changes occur only when the intervention is introduced.\n\nImplications for practice: The investigators assume that this systematic intervention will improve everyday task performance, and will in turn contribute to empowerment and independence of older adults with cognitive challenges after brain injuries.",
        "text": "Evaluation of The Perceive, Recall, Plan and Perform Intervention for Persons With Cognitive Impairments After Brain Injuries in Community Rehabilitation: Single Case Experimental Study | Background: There is a need for standardized interventions in community rehabilitation that can improve everyday task performance for older adults with cognitive challenges after acquired brain injury. Older adults are often excluded from research due to strict inclusion criteria. It is critical for a sustainable health service system that these patients are empowered and reach their maximum level of independence. The Perceive, Recall, Plan and Perform System (PRPP) of Intervention can be applied by Occupational Therapists (OT) for clients with cognitive challenges to enhance mastery of needed or desired everyday tasks. There is no current evidence for the effectiveness of this intervention for this population.\n\nPurpose: A clinical trial to investigate the effectiveness of the PRPP intervention for older persons with cognitive impairments after brain injury in the context of community-based rehabilitation.\n\nMethod: In PRPP intervention the OT uses systematically instructions in task training to support a client to use cognitive strategies efficiently. The everyday tasks used for training should be valued by the participant and useful in their rehabilitation. The tasks could include different parts of morning routines, simple or complex meal planning or preparation, use of cell phone, leisure activities, or other household and community activities. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as participants internalize the strategies. The participants receive PRPP intervention 3 times a week for 3 weeks, every session last for 45-60 minutes.\n\nThe participants' task mastery and cognitive strategy use will be measured at least 5 times in each phase: baseline, intervention, after the intervention, and 4 weeks after the discharge from rehabilitation. The measurement scores at baseline act controls and are therefore compared with the other phases for the same participant. The same procedure will be repeated for the other participants, but then with a staggered intervention phase. A staggered intervention phase acts as a control between participants and allows to see if changes occur only when the intervention is introduced.\n\nImplications for practice: The investigators assume that this systematic intervention will improve everyday task performance, and will in turn contribute to empowerment and independence of older adults with cognitive challenges after brain injuries.",
        "tokens": "['Evaluation', 'of', 'The', 'Perceive', ',', 'Recall', ',', 'Plan', 'and', 'Perform', 'Intervention', 'for', 'Persons', 'With', 'Cognitive', 'Impairments', 'After', 'Brain', 'Injuries', 'in', 'Community', 'Rehabilitation', ':', 'Single', 'Case', 'Experimental', 'Study', '|', 'Background', ':', 'There', 'is', 'a', 'need', 'for', 'standardized', 'interventions', 'in', 'community', 'rehabilitation', 'that', 'can', 'improve', 'everyday', 'task', 'performance', 'for', 'older', 'adults', 'with', 'cognitive', 'challenges', 'after', 'acquired', 'brain', 'injury', '.', 'Older', 'adults', 'are', 'often', 'excluded', 'from', 'research', 'due', 'to', 'strict', 'inclusion', 'criteria', '.', 'It', 'is', 'critical', 'for', 'a', 'sustainable', 'health', 'service', 'system', 'that', 'these', 'patients', 'are', 'empowered', 'and', 'reach', 'their', 'maximum', 'level', 'of', 'independence', '.', 'The', 'Perceive', ',', 'Recall', ',', 'Plan', 'and', 'Perform', 'System', '(', 'PRPP', ')', 'of', 'Intervention', 'can', 'be', 'applied', 'by', 'Occupational', 'Therapists', '(', 'OT', ')', 'for', 'clients', 'with', 'cognitive', 'challenges', 'to', 'enhance', 'mastery', 'of', 'needed', 'or', 'desired', 'everyday', 'tasks', '.', 'There', 'is', 'no', 'current', 'evidence', 'for', 'the', 'effectiveness', 'of', 'this', 'intervention', 'for', 'this', 'population', '.', '\\n\\n', 'Purpose', ':', 'A', 'clinical', 'trial', 'to', 'investigate', 'the', 'effectiveness', 'of', 'the', 'PRPP', 'intervention', 'for', 'older', 'persons', 'with', 'cognitive', 'impairments', 'after', 'brain', 'injury', 'in', 'the', 'context', 'of', 'community', '-', 'based', 'rehabilitation', '.', '\\n\\n', 'Method', ':', 'In', 'PRPP', 'intervention', 'the', 'OT', 'uses', 'systematically', 'instructions', 'in', 'task', 'training', 'to', 'support', 'a', 'client', 'to', 'use', 'cognitive', 'strategies', 'efficiently', '.', 'The', 'everyday', 'tasks', 'used', 'for', 'training', 'should', 'be', 'valued', 'by', 'the', 'participant', 'and', 'useful', 'in', 'their', 'rehabilitation', '.', 'The', 'tasks', 'could', 'include', 'different', 'parts', 'of', 'morning', 'routines', ',', 'simple', 'or', 'complex', 'meal', 'planning', 'or', 'preparation', ',', 'use', 'of', 'cell', 'phone', ',', 'leisure', 'activities', ',', 'or', 'other', 'household', 'and', 'community', 'activities', '.', 'At', 'best', 'the', 'skills', 'are', 'generalized', 'throughout', 'all', 'everyday', 'activities', ',', 'and', 'the', 'OTs', \"'\", 'role', 'as', 'a', 'cognitive', 'mediator', 'fades', 'as', 'participants', 'internalize', 'the', 'strategies', '.', 'The', 'participants', 'receive', 'PRPP', 'intervention', '3', 'times', 'a', 'week', 'for', '3', 'weeks', ',', 'every', 'session', 'last', 'for', '45', '-', '60', 'minutes', '.', '\\n\\n', 'The', 'participants', \"'\", 'task', 'mastery', 'and', 'cognitive', 'strategy', 'use', 'will', 'be', 'measured', 'at', 'least', '5', 'times', 'in', 'each', 'phase', ':', 'baseline', ',', 'intervention', ',', 'after', 'the', 'intervention', ',', 'and', '4', 'weeks', 'after', 'the', 'discharge', 'from', 'rehabilitation', '.', 'The', 'measurement', 'scores', 'at', 'baseline', 'act', 'controls', 'and', 'are', 'therefore', 'compared', 'with', 'the', 'other', 'phases', 'for', 'the', 'same', 'participant', '.', 'The', 'same', 'procedure', 'will', 'be', 'repeated', 'for', 'the', 'other', 'participants', ',', 'but', 'then', 'with', 'a', 'staggered', 'intervention', 'phase', '.', 'A', 'staggered', 'intervention', 'phase', 'acts', 'as', 'a', 'control', 'between', 'participants', 'and', 'allows', 'to', 'see', 'if', 'changes', 'occur', 'only', 'when', 'the', 'intervention', 'is', 'introduced', '.', '\\n\\n', 'Implications', 'for', 'practice', ':', 'The', 'investigators', 'assume', 'that', 'this', 'systematic', 'intervention', 'will', 'improve', 'everyday', 'task', 'performance', ',', 'and', 'will', 'in', 'turn', 'contribute', 'to', 'empowerment', 'and', 'independence', 'of', 'older', 'adults', 'with', 'cognitive', 'challenges', 'after', 'brain', 'injuries', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 65,
                "text": "Perceive, Recall, Plan and Perform Intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 83,
                "end": 104,
                "text": "Cognitive Impairments",
                "type": "CONDITION"
            },
            {
                "start": 111,
                "end": 125,
                "text": "Brain Injuries",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 153,
                "text": "Community Rehabilitation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 250,
                "end": 274,
                "text": "community rehabilitation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 340,
                "end": 360,
                "text": "cognitive challenges",
                "type": "CONDITION"
            },
            {
                "start": 376,
                "end": 388,
                "text": "brain injury",
                "type": "CONDITION"
            },
            {
                "start": 610,
                "end": 651,
                "text": "Perceive, Recall, Plan and Perform System",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 653,
                "end": 657,
                "text": "PRPP",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 739,
                "end": 759,
                "text": "cognitive challenges",
                "type": "CONDITION"
            },
            {
                "start": 976,
                "end": 980,
                "text": "PRPP",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1017,
                "end": 1038,
                "text": "cognitive impairments",
                "type": "CONDITION"
            },
            {
                "start": 1045,
                "end": 1057,
                "text": "brain injury",
                "type": "CONDITION"
            },
            {
                "start": 1076,
                "end": 1106,
                "text": "community-based rehabilitation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1120,
                "end": 1124,
                "text": "PRPP",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1746,
                "end": 1750,
                "text": "PRPP",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 2242,
                "end": 2264,
                "text": "staggered intervention",
                "type": "CONTROL"
            },
            {
                "start": 2274,
                "end": 2296,
                "text": "staggered intervention",
                "type": "CONTROL"
            },
            {
                "start": 2627,
                "end": 2647,
                "text": "cognitive challenges",
                "type": "CONDITION"
            },
            {
                "start": 2654,
                "end": 2668,
                "text": "brain injuries",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03243214",
        "study_official_title": "Effect of Excitatory Theta-Burst Transcranial Magnetic Stimulation on Cognition in Patients With Both Parkinson's Disease and Mild Cognitive Impairment and Analysis of Functional and Structural Brain Changes After Stimulation ",
        "study_brief_summary": " Parkinson's disease (PD) affects more than 100,000 Canadians and results in symptoms affecting both motor and cognitive (thinking and memory) functions. Parkinson's disease with Mild Cognitive Impairment (MCI) frequently results in development of dementia for which few treatment options exist. Transcranial Magnetic Stimulation (TMS) is used to alter activity in the outer regions of the brain and has been shown in previous studies to increase cognitive performance in patients with different disorders. This study will investigate the effectiveness of TMS as a clinical treatment for the cognitive deficits associated with Parkinson's disease. 64 male and female participants between the ages of 50 and 90 will attend eight study visits over a period of 63 to 66 days. This study is a double-blind randomized clinical trial meaning the participant will be assigned by chance to either the TMS-treatment group or the Sham-treatment group. Additionally, a combination of memory and thinking tests and Magnetic Resonance Imaging (MRI) will be used to see if there are structural and functional changes within the brain. Genotyping and blood analysis before and after treatment for different biomarkers will also be performed and these data will be compared to the TMS data. Initially, this research will increase knowledge about the effects of TMS on various brain regions. Ultimately, we will be able to determine if TMS can be used as a complementary therapy for PD to improve cognitive performance and to reduce progression into dementia.",
        "text": "Effect of Excitatory Theta-Burst Transcranial Magnetic Stimulation on Cognition in Patients With Both Parkinson's Disease and Mild Cognitive Impairment and Analysis of Functional and Structural Brain Changes After Stimulation | Parkinson's disease (PD) affects more than 100,000 Canadians and results in symptoms affecting both motor and cognitive (thinking and memory) functions. Parkinson's disease with Mild Cognitive Impairment (MCI) frequently results in development of dementia for which few treatment options exist. Transcranial Magnetic Stimulation (TMS) is used to alter activity in the outer regions of the brain and has been shown in previous studies to increase cognitive performance in patients with different disorders. This study will investigate the effectiveness of TMS as a clinical treatment for the cognitive deficits associated with Parkinson's disease. 64 male and female participants between the ages of 50 and 90 will attend eight study visits over a period of 63 to 66 days. This study is a double-blind randomized clinical trial meaning the participant will be assigned by chance to either the TMS-treatment group or the Sham-treatment group. Additionally, a combination of memory and thinking tests and Magnetic Resonance Imaging (MRI) will be used to see if there are structural and functional changes within the brain. Genotyping and blood analysis before and after treatment for different biomarkers will also be performed and these data will be compared to the TMS data. Initially, this research will increase knowledge about the effects of TMS on various brain regions. Ultimately, we will be able to determine if TMS can be used as a complementary therapy for PD to improve cognitive performance and to reduce progression into dementia.",
        "tokens": "['Effect', 'of', 'Excitatory', 'Theta', '-', 'Burst', 'Transcranial', 'Magnetic', 'Stimulation', 'on', 'Cognition', 'in', 'Patients', 'With', 'Both', 'Parkinson', \"'s\", 'Disease', 'and', 'Mild', 'Cognitive', 'Impairment', 'and', 'Analysis', 'of', 'Functional', 'and', 'Structural', 'Brain', 'Changes', 'After', 'Stimulation', '|', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'affects', 'more', 'than', '100,000', 'Canadians', 'and', 'results', 'in', 'symptoms', 'affecting', 'both', 'motor', 'and', 'cognitive', '(', 'thinking', 'and', 'memory', ')', 'functions', '.', 'Parkinson', \"'s\", 'disease', 'with', 'Mild', 'Cognitive', 'Impairment', '(', 'MCI', ')', 'frequently', 'results', 'in', 'development', 'of', 'dementia', 'for', 'which', 'few', 'treatment', 'options', 'exist', '.', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'TMS', ')', 'is', 'used', 'to', 'alter', 'activity', 'in', 'the', 'outer', 'regions', 'of', 'the', 'brain', 'and', 'has', 'been', 'shown', 'in', 'previous', 'studies', 'to', 'increase', 'cognitive', 'performance', 'in', 'patients', 'with', 'different', 'disorders', '.', 'This', 'study', 'will', 'investigate', 'the', 'effectiveness', 'of', 'TMS', 'as', 'a', 'clinical', 'treatment', 'for', 'the', 'cognitive', 'deficits', 'associated', 'with', 'Parkinson', \"'s\", 'disease', '.', '64', 'male', 'and', 'female', 'participants', 'between', 'the', 'ages', 'of', '50', 'and', '90', 'will', 'attend', 'eight', 'study', 'visits', 'over', 'a', 'period', 'of', '63', 'to', '66', 'days', '.', 'This', 'study', 'is', 'a', 'double', '-', 'blind', 'randomized', 'clinical', 'trial', 'meaning', 'the', 'participant', 'will', 'be', 'assigned', 'by', 'chance', 'to', 'either', 'the', 'TMS', '-', 'treatment', 'group', 'or', 'the', 'Sham', '-', 'treatment', 'group', '.', 'Additionally', ',', 'a', 'combination', 'of', 'memory', 'and', 'thinking', 'tests', 'and', 'Magnetic', 'Resonance', 'Imaging', '(', 'MRI', ')', 'will', 'be', 'used', 'to', 'see', 'if', 'there', 'are', 'structural', 'and', 'functional', 'changes', 'within', 'the', 'brain', '.', 'Genotyping', 'and', 'blood', 'analysis', 'before', 'and', 'after', 'treatment', 'for', 'different', 'biomarkers', 'will', 'also', 'be', 'performed', 'and', 'these', 'data', 'will', 'be', 'compared', 'to', 'the', 'TMS', 'data', '.', 'Initially', ',', 'this', 'research', 'will', 'increase', 'knowledge', 'about', 'the', 'effects', 'of', 'TMS', 'on', 'various', 'brain', 'regions', '.', 'Ultimately', ',', 'we', 'will', 'be', 'able', 'to', 'determine', 'if', 'TMS', 'can', 'be', 'used', 'as', 'a', 'complementary', 'therapy', 'for', 'PD', 'to', 'improve', 'cognitive', 'performance', 'and', 'to', 'reduce', 'progression', 'into', 'dementia', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 66,
                "text": "Excitatory Theta-Burst Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 102,
                "end": 121,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 151,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 228,
                "end": 247,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 249,
                "end": 251,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 381,
                "end": 400,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 406,
                "end": 431,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 436,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 475,
                "end": 483,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 523,
                "end": 556,
                "text": "Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 558,
                "end": 561,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 783,
                "end": 786,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 854,
                "end": 873,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 1120,
                "end": 1123,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 1147,
                "end": 1151,
                "text": "Sham",
                "type": "CONTROL"
            },
            {
                "start": 1492,
                "end": 1495,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 1572,
                "end": 1575,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 1646,
                "end": 1649,
                "text": "TMS",
                "type": "OTHER"
            },
            {
                "start": 1693,
                "end": 1695,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1760,
                "end": 1768,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04789499",
        "study_official_title": "Smell in Covid-19 and Efficacy of Nasal Theophylline ",
        "study_brief_summary": " Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily.\n\nCurrently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even higher.\n\nWe propose a phase II single-site, double-blinded, placebo-controlled randomized clinical trial to determine the efficacy and safety of intranasal theophylline, a known phosphodiesterase inhibitor in the treatment of asthma, as a possible treatment for COVID-19 related OD. Theophylline has shown benefit in similar clinical trials for post-viral OD.",
        "text": "Smell in Covid-19 and Efficacy of Nasal Theophylline | Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily.\n\nCurrently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even higher.\n\nWe propose a phase II single-site, double-blinded, placebo-controlled randomized clinical trial to determine the efficacy and safety of intranasal theophylline, a known phosphodiesterase inhibitor in the treatment of asthma, as a possible treatment for COVID-19 related OD. Theophylline has shown benefit in similar clinical trials for post-viral OD.",
        "tokens": "['Smell', 'in', 'Covid-19', 'and', 'Efficacy', 'of', 'Nasal', 'Theophylline', '|', 'Evidence', 'of', 'COVID-19', 'related', 'anosmia', 'and', 'dysgeusia', 'continues', 'to', 'accumulate', 'daily', '.', '\\n\\n', 'Currently', ',', 'up', 'to', '80', '%', 'of', 'patients', 'report', 'subjective', 'olfactory', 'dysfunction', '(', 'OD', ')', ',', 'and', 'prevalence', 'using', 'objective', 'olfactory', 'testing', 'could', 'be', 'even', 'higher', '.', '\\n\\n', 'We', 'propose', 'a', 'phase', 'II', 'single', '-', 'site', ',', 'double', '-', 'blinded', ',', 'placebo', '-', 'controlled', 'randomized', 'clinical', 'trial', 'to', 'determine', 'the', 'efficacy', 'and', 'safety', 'of', 'intranasal', 'theophylline', ',', 'a', 'known', 'phosphodiesterase', 'inhibitor', 'in', 'the', 'treatment', 'of', 'asthma', ',', 'as', 'a', 'possible', 'treatment', 'for', 'COVID-19', 'related', 'OD', '.', 'Theophylline', 'has', 'shown', 'benefit', 'in', 'similar', 'clinical', 'trials', 'for', 'post', '-', 'viral', 'OD', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 9,
                "end": 17,
                "text": "Covid-19",
                "type": "CONDITION"
            },
            {
                "start": 40,
                "end": 52,
                "text": "Theophylline",
                "type": "DRUG"
            },
            {
                "start": 67,
                "end": 75,
                "text": "COVID-19",
                "type": "CONDITION"
            },
            {
                "start": 84,
                "end": 91,
                "text": "anosmia",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 105,
                "text": "dysgeusia",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 210,
                "text": "olfactory dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 214,
                "text": "OD",
                "type": "CONDITION"
            },
            {
                "start": 340,
                "end": 347,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 436,
                "end": 448,
                "text": "theophylline",
                "type": "DRUG"
            },
            {
                "start": 542,
                "end": 550,
                "text": "COVID-19",
                "type": "CONDITION"
            },
            {
                "start": 559,
                "end": 561,
                "text": "OD",
                "type": "CONDITION"
            },
            {
                "start": 563,
                "end": 575,
                "text": "Theophylline",
                "type": "DRUG"
            },
            {
                "start": 625,
                "end": 638,
                "text": "post-viral OD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01420796",
        "study_official_title": "Effect of Oral Motor Exercises and Breathing Exercises for Dysphagia in Parkinson Disease: Randomized Clinical Trial ",
        "study_brief_summary": " Parkinson's disease (PD) is a chronic, degenerative disease described by motors and non-motors symptoms. Changes in swallowing and respiratory dynamics increase risk of tracheal aspiration largely responsible for increased morbidity and mortality in this population. Thus, interdisciplinary rehabilitation strategies can reduce the complications of dysphagia, with consequent improvement of the prognosis of individuals with PD. Objective: To determine the impact of combined oral motor exercises and breathing exercises on swallowing disorders in individuals with PD. Method: Clinical trial, randomized and blinded for the examinator. For all subjects will be given the stage of PD and applied quality of life questionnaire. The swallowing complaints will be investigated through structured questionnaire and functional aspects of swallowing with videofluoroscopy. The Manovacuometry Spirometry will determine measures of respiratory function. The assessment of vocal and speech disorders will be done with perceptive, acoustic, aerodynamic and electroglottographic measures as well as analysis of intelligibility. Three groups of intervention will be defined: one of them doing oral motor exercises for swallowing, one doing breathing exercises and another must do this two interventions combined. Effect of intervention will be assessed through measures of swallowing, breathing, voice and speech. The groups will be compared, according to the principle of \"intention to treat\" by appropriate statistical tests, according to the distribution of the dependent variables.",
        "text": "Effect of Oral Motor Exercises and Breathing Exercises for Dysphagia in Parkinson Disease: Randomized Clinical Trial | Parkinson's disease (PD) is a chronic, degenerative disease described by motors and non-motors symptoms. Changes in swallowing and respiratory dynamics increase risk of tracheal aspiration largely responsible for increased morbidity and mortality in this population. Thus, interdisciplinary rehabilitation strategies can reduce the complications of dysphagia, with consequent improvement of the prognosis of individuals with PD. Objective: To determine the impact of combined oral motor exercises and breathing exercises on swallowing disorders in individuals with PD. Method: Clinical trial, randomized and blinded for the examinator. For all subjects will be given the stage of PD and applied quality of life questionnaire. The swallowing complaints will be investigated through structured questionnaire and functional aspects of swallowing with videofluoroscopy. The Manovacuometry Spirometry will determine measures of respiratory function. The assessment of vocal and speech disorders will be done with perceptive, acoustic, aerodynamic and electroglottographic measures as well as analysis of intelligibility. Three groups of intervention will be defined: one of them doing oral motor exercises for swallowing, one doing breathing exercises and another must do this two interventions combined. Effect of intervention will be assessed through measures of swallowing, breathing, voice and speech. The groups will be compared, according to the principle of \"intention to treat\" by appropriate statistical tests, according to the distribution of the dependent variables.",
        "tokens": "['Effect', 'of', 'Oral', 'Motor', 'Exercises', 'and', 'Breathing', 'Exercises', 'for', 'Dysphagia', 'in', 'Parkinson', 'Disease', ':', 'Randomized', 'Clinical', 'Trial', '|', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'is', 'a', 'chronic', ',', 'degenerative', 'disease', 'described', 'by', 'motors', 'and', 'non', '-', 'motors', 'symptoms', '.', 'Changes', 'in', 'swallowing', 'and', 'respiratory', 'dynamics', 'increase', 'risk', 'of', 'tracheal', 'aspiration', 'largely', 'responsible', 'for', 'increased', 'morbidity', 'and', 'mortality', 'in', 'this', 'population', '.', 'Thus', ',', 'interdisciplinary', 'rehabilitation', 'strategies', 'can', 'reduce', 'the', 'complications', 'of', 'dysphagia', ',', 'with', 'consequent', 'improvement', 'of', 'the', 'prognosis', 'of', 'individuals', 'with', 'PD', '.', 'Objective', ':', 'To', 'determine', 'the', 'impact', 'of', 'combined', 'oral', 'motor', 'exercises', 'and', 'breathing', 'exercises', 'on', 'swallowing', 'disorders', 'in', 'individuals', 'with', 'PD', '.', 'Method', ':', 'Clinical', 'trial', ',', 'randomized', 'and', 'blinded', 'for', 'the', 'examinator', '.', 'For', 'all', 'subjects', 'will', 'be', 'given', 'the', 'stage', 'of', 'PD', 'and', 'applied', 'quality', 'of', 'life', 'questionnaire', '.', 'The', 'swallowing', 'complaints', 'will', 'be', 'investigated', 'through', 'structured', 'questionnaire', 'and', 'functional', 'aspects', 'of', 'swallowing', 'with', 'videofluoroscopy', '.', 'The', 'Manovacuometry', 'Spirometry', 'will', 'determine', 'measures', 'of', 'respiratory', 'function', '.', 'The', 'assessment', 'of', 'vocal', 'and', 'speech', 'disorders', 'will', 'be', 'done', 'with', 'perceptive', ',', 'acoustic', ',', 'aerodynamic', 'and', 'electroglottographic', 'measures', 'as', 'well', 'as', 'analysis', 'of', 'intelligibility', '.', 'Three', 'groups', 'of', 'intervention', 'will', 'be', 'defined', ':', 'one', 'of', 'them', 'doing', 'oral', 'motor', 'exercises', 'for', 'swallowing', ',', 'one', 'doing', 'breathing', 'exercises', 'and', 'another', 'must', 'do', 'this', 'two', 'interventions', 'combined', '.', 'Effect', 'of', 'intervention', 'will', 'be', 'assessed', 'through', 'measures', 'of', 'swallowing', ',', 'breathing', ',', 'voice', 'and', 'speech', '.', 'The', 'groups', 'will', 'be', 'compared', ',', 'according', 'to', 'the', 'principle', 'of', '\"', 'intention', 'to', 'treat', '\"', 'by', 'appropriate', 'statistical', 'tests', ',', 'according', 'to', 'the', 'distribution', 'of', 'the', 'dependent', 'variables', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 30,
                "text": "Oral Motor Exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 35,
                "end": 54,
                "text": "Breathing Exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 59,
                "end": 68,
                "text": "Dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 72,
                "end": 89,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 138,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 140,
                "end": 142,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 392,
                "end": 435,
                "text": "interdisciplinary rehabilitation strategies",
                "type": "OTHER"
            },
            {
                "start": 468,
                "end": 477,
                "text": "dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 544,
                "end": 546,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 595,
                "end": 615,
                "text": "oral motor exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 620,
                "end": 639,
                "text": "breathing exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 643,
                "end": 663,
                "text": "swallowing disorders",
                "type": "CONDITION"
            },
            {
                "start": 684,
                "end": 686,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 799,
                "end": 801,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 849,
                "end": 870,
                "text": "swallowing complaints",
                "type": "CONDITION"
            },
            {
                "start": 1082,
                "end": 1108,
                "text": "vocal and speech disorders",
                "type": "CONDITION"
            },
            {
                "start": 1299,
                "end": 1319,
                "text": "oral motor exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 1346,
                "end": 1365,
                "text": "breathing exercises",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT00632736",
        "study_official_title": "An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169 ",
        "study_brief_summary": " To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease",
        "text": "An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169 | To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease",
        "tokens": "['An', 'Open', '-', 'Label', 'Extension', 'Study', 'With', 'REQUIP', '(', 'Ropinirole', ')', 'CR', 'for', 'Subjects', 'From', 'Studies', '101468/165', ',', '101468/168', 'and', '101468/169', '|', 'To', 'evaluate', 'the', 'safety', 'profile', 'of', 'ropinirole', 'XL', 'during', 'long', '-', 'term', 'treatment', 'in', 'subjects', 'with', 'early', 'and', 'advanced', 'Parkinson', \"'s\", 'disease']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 35,
                "end": 41,
                "text": "REQUIP",
                "type": "DRUG"
            },
            {
                "start": 43,
                "end": 53,
                "text": "Ropinirole",
                "type": "DRUG"
            },
            {
                "start": 158,
                "end": 168,
                "text": "ropinirole",
                "type": "DRUG"
            },
            {
                "start": 216,
                "end": 254,
                "text": "early and advanced Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03973203",
        "study_official_title": "The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients ",
        "study_brief_summary": " The most frequent form of adult-onset mitochondrial disorders is mitochondrial myopathy, often manifesting with progressive external ophthalmoplegia (PEO), progressive muscle weakness and exercise intolerance. Mitochondrial myopathy is often caused by single heteroplasmic mitochondrial DNA (mtDNA) deletions or multiple mtDNA deletions, the former being sporadic and latter caused by mutations in nuclear-encoded proteins of mtDNA maintenance. Currently, no curative treatment exists for this disease. The investigators have previously observed that supplementation with an NAD+ precursor vitamin B3, nicotinamide riboside, prevented and delayed disease symptoms by increasing mitochondrial biogenesis in a mouse model for mitochondrial myopathy. Vitamin B3 exists in several forms: nicotinic acid (niacin), nicotinamide, and nicotinamide riboside, and it has been demonstrated to give power to diseased mitochondria in animal studies by increasing intracellular levels of NAD+, the important cofactor required for the cellular energy metabolism.\n\nIn this study, the form of vitamin B3, niacin, was used to activate dysfunctional mitochondria and to rescue signs of mitochondrial myopathy. Of the vitamin B3 forms, niacin, is employed, because it has been used in large doses to treat hypercholesterolemia patients, and has a proven safety record in humans. Phenotypically similar mitochondrial myopathy patients are studied, as the investigator's previous expertise indicates that similar presenting phenotypes predict uniform physiological and clinical responses to interventions, despite varying genetic backgrounds. Patients either with sporadic single mtDNA deletions or a mutation in a Twinkle gene causing multiple mtDNA deletions were recruited. In addition, for every patient, two gender- and age-matched healthy controls are recruited. Clinical examinations and collection of muscle biopsies are performed at the time points 0, 4 and 10 months (patients) or at 0 and 4 months (controls). Fasting blood samples are collected every second week until 4 months and thereafter every six weeks until the end of the study. The effects of niacin on disease markers, muscle mitochondrial biogenesis, muscle strength and the metabolism of the whole body are studied in patients and healthy controls.\n\nThe hypothesis is that an NAD+ precursor, niacin, will increase intracellular NAD+ levels, improve mitochondrial biogenesis and alleviate the symptoms of mitochondrial myopathy in humans.",
        "text": "The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients | The most frequent form of adult-onset mitochondrial disorders is mitochondrial myopathy, often manifesting with progressive external ophthalmoplegia (PEO), progressive muscle weakness and exercise intolerance. Mitochondrial myopathy is often caused by single heteroplasmic mitochondrial DNA (mtDNA) deletions or multiple mtDNA deletions, the former being sporadic and latter caused by mutations in nuclear-encoded proteins of mtDNA maintenance. Currently, no curative treatment exists for this disease. The investigators have previously observed that supplementation with an NAD+ precursor vitamin B3, nicotinamide riboside, prevented and delayed disease symptoms by increasing mitochondrial biogenesis in a mouse model for mitochondrial myopathy. Vitamin B3 exists in several forms: nicotinic acid (niacin), nicotinamide, and nicotinamide riboside, and it has been demonstrated to give power to diseased mitochondria in animal studies by increasing intracellular levels of NAD+, the important cofactor required for the cellular energy metabolism.\n\nIn this study, the form of vitamin B3, niacin, was used to activate dysfunctional mitochondria and to rescue signs of mitochondrial myopathy. Of the vitamin B3 forms, niacin, is employed, because it has been used in large doses to treat hypercholesterolemia patients, and has a proven safety record in humans. Phenotypically similar mitochondrial myopathy patients are studied, as the investigator's previous expertise indicates that similar presenting phenotypes predict uniform physiological and clinical responses to interventions, despite varying genetic backgrounds. Patients either with sporadic single mtDNA deletions or a mutation in a Twinkle gene causing multiple mtDNA deletions were recruited. In addition, for every patient, two gender- and age-matched healthy controls are recruited. Clinical examinations and collection of muscle biopsies are performed at the time points 0, 4 and 10 months (patients) or at 0 and 4 months (controls). Fasting blood samples are collected every second week until 4 months and thereafter every six weeks until the end of the study. The effects of niacin on disease markers, muscle mitochondrial biogenesis, muscle strength and the metabolism of the whole body are studied in patients and healthy controls.\n\nThe hypothesis is that an NAD+ precursor, niacin, will increase intracellular NAD+ levels, improve mitochondrial biogenesis and alleviate the symptoms of mitochondrial myopathy in humans.",
        "tokens": "['The', 'Effect', 'of', 'Niacin', 'Supplementation', 'on', 'Systemic', 'Nicotinamide', 'Adenine', 'Dinucleotide', '(', 'NAD+', ')', 'Metabolism', ',', 'Physiology', 'and', 'Muscle', 'Performance', 'in', 'Healthy', 'Controls', 'and', 'Mitochondrial', 'Myopathy', 'Patients', '|', 'The', 'most', 'frequent', 'form', 'of', 'adult', '-', 'onset', 'mitochondrial', 'disorders', 'is', 'mitochondrial', 'myopathy', ',', 'often', 'manifesting', 'with', 'progressive', 'external', 'ophthalmoplegia', '(', 'PEO', ')', ',', 'progressive', 'muscle', 'weakness', 'and', 'exercise', 'intolerance', '.', 'Mitochondrial', 'myopathy', 'is', 'often', 'caused', 'by', 'single', 'heteroplasmic', 'mitochondrial', 'DNA', '(', 'mtDNA', ')', 'deletions', 'or', 'multiple', 'mtDNA', 'deletions', ',', 'the', 'former', 'being', 'sporadic', 'and', 'latter', 'caused', 'by', 'mutations', 'in', 'nuclear', '-', 'encoded', 'proteins', 'of', 'mtDNA', 'maintenance', '.', 'Currently', ',', 'no', 'curative', 'treatment', 'exists', 'for', 'this', 'disease', '.', 'The', 'investigators', 'have', 'previously', 'observed', 'that', 'supplementation', 'with', 'an', 'NAD+', 'precursor', 'vitamin', 'B3', ',', 'nicotinamide', 'riboside', ',', 'prevented', 'and', 'delayed', 'disease', 'symptoms', 'by', 'increasing', 'mitochondrial', 'biogenesis', 'in', 'a', 'mouse', 'model', 'for', 'mitochondrial', 'myopathy', '.', 'Vitamin', 'B3', 'exists', 'in', 'several', 'forms', ':', 'nicotinic', 'acid', '(', 'niacin', ')', ',', 'nicotinamide', ',', 'and', 'nicotinamide', 'riboside', ',', 'and', 'it', 'has', 'been', 'demonstrated', 'to', 'give', 'power', 'to', 'diseased', 'mitochondria', 'in', 'animal', 'studies', 'by', 'increasing', 'intracellular', 'levels', 'of', 'NAD+', ',', 'the', 'important', 'cofactor', 'required', 'for', 'the', 'cellular', 'energy', 'metabolism', '.', '\\n\\n', 'In', 'this', 'study', ',', 'the', 'form', 'of', 'vitamin', 'B3', ',', 'niacin', ',', 'was', 'used', 'to', 'activate', 'dysfunctional', 'mitochondria', 'and', 'to', 'rescue', 'signs', 'of', 'mitochondrial', 'myopathy', '.', 'Of', 'the', 'vitamin', 'B3', 'forms', ',', 'niacin', ',', 'is', 'employed', ',', 'because', 'it', 'has', 'been', 'used', 'in', 'large', 'doses', 'to', 'treat', 'hypercholesterolemia', 'patients', ',', 'and', 'has', 'a', 'proven', 'safety', 'record', 'in', 'humans', '.', 'Phenotypically', 'similar', 'mitochondrial', 'myopathy', 'patients', 'are', 'studied', ',', 'as', 'the', 'investigator', \"'s\", 'previous', 'expertise', 'indicates', 'that', 'similar', 'presenting', 'phenotypes', 'predict', 'uniform', 'physiological', 'and', 'clinical', 'responses', 'to', 'interventions', ',', 'despite', 'varying', 'genetic', 'backgrounds', '.', 'Patients', 'either', 'with', 'sporadic', 'single', 'mtDNA', 'deletions', 'or', 'a', 'mutation', 'in', 'a', 'Twinkle', 'gene', 'causing', 'multiple', 'mtDNA', 'deletions', 'were', 'recruited', '.', 'In', 'addition', ',', 'for', 'every', 'patient', ',', 'two', 'gender-', 'and', 'age', '-', 'matched', 'healthy', 'controls', 'are', 'recruited', '.', 'Clinical', 'examinations', 'and', 'collection', 'of', 'muscle', 'biopsies', 'are', 'performed', 'at', 'the', 'time', 'points', '0', ',', '4', 'and', '10', 'months', '(', 'patients', ')', 'or', 'at', '0', 'and', '4', 'months', '(', 'controls', ')', '.', 'Fasting', 'blood', 'samples', 'are', 'collected', 'every', 'second', 'week', 'until', '4', 'months', 'and', 'thereafter', 'every', 'six', 'weeks', 'until', 'the', 'end', 'of', 'the', 'study', '.', 'The', 'effects', 'of', 'niacin', 'on', 'disease', 'markers', ',', 'muscle', 'mitochondrial', 'biogenesis', ',', 'muscle', 'strength', 'and', 'the', 'metabolism', 'of', 'the', 'whole', 'body', 'are', 'studied', 'in', 'patients', 'and', 'healthy', 'controls', '.', '\\n\\n', 'The', 'hypothesis', 'is', 'that', 'an', 'NAD+', 'precursor', ',', 'niacin', ',', 'will', 'increase', 'intracellular', 'NAD+', 'levels', ',', 'improve', 'mitochondrial', 'biogenesis', 'and', 'alleviate', 'the', 'symptoms', 'of', 'mitochondrial', 'myopathy', 'in', 'humans', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 20,
                "text": "Niacin",
                "type": "DRUG"
            },
            {
                "start": 160,
                "end": 182,
                "text": "Mitochondrial Myopathy",
                "type": "CONDITION"
            },
            {
                "start": 259,
                "end": 281,
                "text": "mitochondrial myopathy",
                "type": "CONDITION"
            },
            {
                "start": 404,
                "end": 426,
                "text": "Mitochondrial myopathy",
                "type": "CONDITION"
            },
            {
                "start": 918,
                "end": 940,
                "text": "mitochondrial myopathy",
                "type": "CONDITION"
            },
            {
                "start": 978,
                "end": 992,
                "text": "nicotinic acid",
                "type": "DRUG"
            },
            {
                "start": 994,
                "end": 1000,
                "text": "niacin",
                "type": "DRUG"
            },
            {
                "start": 1282,
                "end": 1288,
                "text": "niacin",
                "type": "DRUG"
            },
            {
                "start": 1361,
                "end": 1383,
                "text": "mitochondrial myopathy",
                "type": "CONDITION"
            },
            {
                "start": 1410,
                "end": 1416,
                "text": "niacin",
                "type": "DRUG"
            },
            {
                "start": 1576,
                "end": 1598,
                "text": "mitochondrial myopathy",
                "type": "CONDITION"
            },
            {
                "start": 2336,
                "end": 2342,
                "text": "niacin",
                "type": "DRUG"
            },
            {
                "start": 2538,
                "end": 2544,
                "text": "niacin",
                "type": "DRUG"
            },
            {
                "start": 2650,
                "end": 2672,
                "text": "mitochondrial myopathy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02034188",
        "study_official_title": "Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis ",
        "study_brief_summary": " Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 7 days is a safe and will induce a therapeutic effect in multiple sclerosis (MS) patients.",
        "text": "Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 7 days is a safe and will induce a therapeutic effect in multiple sclerosis (MS) patients.",
        "tokens": "['Feasibility', 'Study', 'of', 'Human', 'Umbilical', 'Cord', 'Tissue', '-', 'Derived', 'Mesenchymal', 'Stem', 'Cells', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '|', 'Allogeneic', 'human', 'umbilical', 'cord', 'tissue', '-', 'derived', 'stem', 'cells', 'injected', 'intravenously', '(', 'IV', ')', 'once', 'per', 'day', 'for', '7', 'days', 'is', 'a', 'safe', 'and', 'will', 'induce', 'a', 'therapeutic', 'effect', 'in', 'multiple', 'sclerosis', '(', 'MS', ')', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 79,
                "text": "Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells",
                "type": "SURGICAL"
            },
            {
                "start": 97,
                "end": 115,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 118,
                "end": 175,
                "text": "Allogeneic human umbilical cord tissue-derived stem cells",
                "type": "SURGICAL"
            },
            {
                "start": 278,
                "end": 296,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 300,
                "text": "MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05730049",
        "study_official_title": "Assessing the Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation as an Anti-inflammatory Treatment Following Spinal Cord Injury ",
        "study_brief_summary": " The goal of this single-blinded randomized, controlled trial is to assess the impact of 1-hour of active transcutaneous auricular vagus nerve stimulation (taVNS) vs sham taVNS on serum biomarkers of the inflammatory reflex and inflammation in individuals with spinal cord injury.\n\nThe main question it aims to answer is: whether taVNS is a safe and effective anti-inflammatory intervention for individuals with SCI. Participants will perform a single 1-hour bout of the respective taVNS treatment with blood draws prior to treatment, immediately following treatment, and 24 hours following treatment. Changes in biomarkers between the active and sham taVNS conditions will be compared.",
        "text": "Assessing the Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation as an Anti-inflammatory Treatment Following Spinal Cord Injury | The goal of this single-blinded randomized, controlled trial is to assess the impact of 1-hour of active transcutaneous auricular vagus nerve stimulation (taVNS) vs sham taVNS on serum biomarkers of the inflammatory reflex and inflammation in individuals with spinal cord injury.\n\nThe main question it aims to answer is: whether taVNS is a safe and effective anti-inflammatory intervention for individuals with SCI. Participants will perform a single 1-hour bout of the respective taVNS treatment with blood draws prior to treatment, immediately following treatment, and 24 hours following treatment. Changes in biomarkers between the active and sham taVNS conditions will be compared.",
        "tokens": "['Assessing', 'the', 'Efficacy', 'of', 'Transcutaneous', 'Auricular', 'Vagus', 'Nerve', 'Stimulation', 'as', 'an', 'Anti', '-', 'inflammatory', 'Treatment', 'Following', 'Spinal', 'Cord', 'Injury', '|', 'The', 'goal', 'of', 'this', 'single', '-', 'blinded', 'randomized', ',', 'controlled', 'trial', 'is', 'to', 'assess', 'the', 'impact', 'of', '1', '-', 'hour', 'of', 'active', 'transcutaneous', 'auricular', 'vagus', 'nerve', 'stimulation', '(', 'taVNS', ')', 'vs', 'sham', 'taVNS', 'on', 'serum', 'biomarkers', 'of', 'the', 'inflammatory', 'reflex', 'and', 'inflammation', 'in', 'individuals', 'with', 'spinal', 'cord', 'injury', '.', '\\n\\n', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'is', ':', 'whether', 'taVNS', 'is', 'a', 'safe', 'and', 'effective', 'anti', '-', 'inflammatory', 'intervention', 'for', 'individuals', 'with', 'SCI', '.', 'Participants', 'will', 'perform', 'a', 'single', '1', '-', 'hour', 'bout', 'of', 'the', 'respective', 'taVNS', 'treatment', 'with', 'blood', 'draws', 'prior', 'to', 'treatment', ',', 'immediately', 'following', 'treatment', ',', 'and', '24', 'hours', 'following', 'treatment', '.', 'Changes', 'in', 'biomarkers', 'between', 'the', 'active', 'and', 'sham', 'taVNS', 'conditions', 'will', 'be', 'compared', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 74,
                "text": "Transcutaneous Auricular Vagus Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 119,
                "end": 137,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 238,
                "end": 293,
                "text": "active transcutaneous auricular vagus nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 295,
                "end": 300,
                "text": "taVNS",
                "type": "OTHER"
            },
            {
                "start": 305,
                "end": 315,
                "text": "sham taVNS",
                "type": "CONTROL"
            },
            {
                "start": 367,
                "end": 379,
                "text": "inflammation",
                "type": "CONDITION"
            },
            {
                "start": 400,
                "end": 418,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 469,
                "end": 474,
                "text": "taVNS",
                "type": "OTHER"
            },
            {
                "start": 551,
                "end": 554,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 621,
                "end": 626,
                "text": "taVNS",
                "type": "OTHER"
            },
            {
                "start": 786,
                "end": 796,
                "text": "sham taVNS",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04705246",
        "study_official_title": "Effect of Psychoeducation Upon Exposure to Sounds and Hyperacusis Severity ",
        "study_brief_summary": " This study focuses on patients with a primary complaint of hyperacusis. Hyperacusis has been defined as 'abnormally reduced tolerance to sound'. It shows a high comorbidity with tinnitus, the perception of sound in the absence of a sound source. For the period of one month, hyperacusis and tinnitus severity and exposure to sounds will be evaluated by use of Ecological Momentary Assessment (EMA) in all participants. A novel approach to assessments, EMA prompts participants during their daily life to answer short questionnaires, increasing ecological validity and minimizing the risk for recall and memory biases. At a randomized time point during the one-month period, participants will individually receive a single psychoeducation session (1h) delivered by an experienced audiologist. The goal of the study is to investigate if the psychoeducation session leads to an increase in exposure to sound and a decrease in hyperacusis severity.",
        "text": "Effect of Psychoeducation Upon Exposure to Sounds and Hyperacusis Severity | This study focuses on patients with a primary complaint of hyperacusis. Hyperacusis has been defined as 'abnormally reduced tolerance to sound'. It shows a high comorbidity with tinnitus, the perception of sound in the absence of a sound source. For the period of one month, hyperacusis and tinnitus severity and exposure to sounds will be evaluated by use of Ecological Momentary Assessment (EMA) in all participants. A novel approach to assessments, EMA prompts participants during their daily life to answer short questionnaires, increasing ecological validity and minimizing the risk for recall and memory biases. At a randomized time point during the one-month period, participants will individually receive a single psychoeducation session (1h) delivered by an experienced audiologist. The goal of the study is to investigate if the psychoeducation session leads to an increase in exposure to sound and a decrease in hyperacusis severity.",
        "tokens": "['Effect', 'of', 'Psychoeducation', 'Upon', 'Exposure', 'to', 'Sounds', 'and', 'Hyperacusis', 'Severity', '|', 'This', 'study', 'focuses', 'on', 'patients', 'with', 'a', 'primary', 'complaint', 'of', 'hyperacusis', '.', 'Hyperacusis', 'has', 'been', 'defined', 'as', \"'\", 'abnormally', 'reduced', 'tolerance', 'to', 'sound', \"'\", '.', 'It', 'shows', 'a', 'high', 'comorbidity', 'with', 'tinnitus', ',', 'the', 'perception', 'of', 'sound', 'in', 'the', 'absence', 'of', 'a', 'sound', 'source', '.', 'For', 'the', 'period', 'of', 'one', 'month', ',', 'hyperacusis', 'and', 'tinnitus', 'severity', 'and', 'exposure', 'to', 'sounds', 'will', 'be', 'evaluated', 'by', 'use', 'of', 'Ecological', 'Momentary', 'Assessment', '(', 'EMA', ')', 'in', 'all', 'participants', '.', 'A', 'novel', 'approach', 'to', 'assessments', ',', 'EMA', 'prompts', 'participants', 'during', 'their', 'daily', 'life', 'to', 'answer', 'short', 'questionnaires', ',', 'increasing', 'ecological', 'validity', 'and', 'minimizing', 'the', 'risk', 'for', 'recall', 'and', 'memory', 'biases', '.', 'At', 'a', 'randomized', 'time', 'point', 'during', 'the', 'one', '-', 'month', 'period', ',', 'participants', 'will', 'individually', 'receive', 'a', 'single', 'psychoeducation', 'session', '(', '1h', ')', 'delivered', 'by', 'an', 'experienced', 'audiologist', '.', 'The', 'goal', 'of', 'the', 'study', 'is', 'to', 'investigate', 'if', 'the', 'psychoeducation', 'session', 'leads', 'to', 'an', 'increase', 'in', 'exposure', 'to', 'sound', 'and', 'a', 'decrease', 'in', 'hyperacusis', 'severity', '.']",
        "token_bio_labels": "['O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 25,
                "text": "Psychoeducation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 54,
                "end": 65,
                "text": "Hyperacusis",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 147,
                "text": "hyperacusis",
                "type": "CONDITION"
            },
            {
                "start": 149,
                "end": 160,
                "text": "Hyperacusis",
                "type": "CONDITION"
            },
            {
                "start": 255,
                "end": 263,
                "text": "tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 352,
                "end": 363,
                "text": "hyperacusis",
                "type": "CONDITION"
            },
            {
                "start": 368,
                "end": 376,
                "text": "tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 799,
                "end": 822,
                "text": "psychoeducation session",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 916,
                "end": 939,
                "text": "psychoeducation session",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1000,
                "end": 1011,
                "text": "hyperacusis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00705783",
        "study_official_title": "A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia ",
        "study_brief_summary": " The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.\n\nThe trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient to be converted from their current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2, they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was stabilized, they were eligible to be randomized into the double-blind IM depot maintenance phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic symptoms and/or impending relapse for up to 52 weeks.",
        "text": "A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia | The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.\n\nThe trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient to be converted from their current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2, they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was stabilized, they were eligible to be randomized into the double-blind IM depot maintenance phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic symptoms and/or impending relapse for up to 52 weeks.",
        "tokens": "['A', '52', '-', 'week', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'an', 'Intramuscular', 'Depot', 'Formulation', 'of', 'Aripiprazole', 'as', 'Maintenance', 'Treatment', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'the', 'trial', 'was', 'to', 'evaluate', 'the', 'efficacy', ',', 'safety', ',', 'and', 'tolerability', 'of', 'an', 'intramuscular', 'depot', 'formulation', 'of', 'aripiprazole', 'as', 'maintenance', 'treatment', 'in', 'patients', 'with', 'schizophrenia', '.', '\\n\\n', 'The', 'trial', 'was', 'designed', 'into', '4', 'treatment', 'phases', '.', 'Phase', '1', 'was', 'designed', 'to', 'allow', 'for', 'a', 'patient', 'to', 'be', 'converted', 'from', 'their', 'current', 'antipsychotic', 'treatment', 'to', 'oral', 'non', '-', 'generic', 'aripiprazole', 'monotherapy', '(', 'oral', 'conversion', 'phase', 'from', '4', 'to', '6', 'weeks', ')', '.', 'During', 'Phase', '2', ',', 'the', 'patient', 'was', 'stabilized', 'on', 'oral', 'non', '-', 'generic', 'aripiprazole', 'monotherapy', '(', 'oral', 'stabilization', 'phase', 'from', 'a', 'minimum', 'of', '4', 'weeks', 'to', 'a', 'maximum', 'of', '12', 'weeks', ')', '.', 'Once', 'the', 'patient', 'was', 'stabilized', 'in', 'Phase', '2', ',', 'they', 'entered', 'Phase', '3', ',', 'the', 'single', '-', 'blind', 'intramuscular', '(', 'IM', ')', 'depot', 'aripiprazole', 'stabilization', 'phase', '.', 'The', 'goal', 'of', 'the', 'phase', 'was', 'to', 'stabilize', 'the', 'patient', 'on', 'the', 'IM', 'depot', 'aripiprazole', 'formulation', 'for', 'a', 'minimum', 'of', '12', 'weeks', 'to', 'a', 'maximum', 'of', '36', 'weeks', '.', 'When', 'the', 'patient', 'was', 'stabilized', ',', 'they', 'were', 'eligible', 'to', 'be', 'randomized', 'into', 'the', 'double', '-', 'blind', 'IM', 'depot', 'maintenance', 'phase', '(', 'Phase', '4', ')', '.', 'During', 'Phase', '4', ',', 'the', 'patient', 'was', 'assessed', 'for', 'exacerbation', 'of', 'psychotic', 'symptoms', 'and/or', 'impending', 'relapse', 'for', 'up', 'to', '52', 'weeks', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 57,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 167,
                "end": 179,
                "text": "Aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 222,
                "end": 235,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 359,
                "end": 371,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 414,
                "end": 427,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 601,
                "end": 613,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 732,
                "end": 744,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 944,
                "end": 956,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 1045,
                "end": 1057,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 1312,
                "end": 1321,
                "text": "psychotic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00950196",
        "study_official_title": "The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia ",
        "study_brief_summary": " Ataxia-Telangiectasia A-T is a neurodegenerative disorder of the cerebellum, manifesting with ataxia, as well as extrapyramidal features. Treatment of A-T is discouraging, since no treatment seems to change the course of disease, but improvement can be achieved by symptomatic treatment of the bothersome movement disorder . While various dopaminergic agents are occasionally used, reports of benefit are rather sparse and anecdotal. Amantadine, a well known drug used in influenza as well as movement disorder of Parkinson, has been proved to improve various other types of movement disorder as ataxia, chorea, dystonia, akinesia and attention span. The purpose of this study is to investigate weather amantadine sulphate improves ataxia and the movement disorder (bradykinesia, parkinsonism, dystonia, chorea), as well as the general well being in patients with A-T.",
        "text": "The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia | Ataxia-Telangiectasia A-T is a neurodegenerative disorder of the cerebellum, manifesting with ataxia, as well as extrapyramidal features. Treatment of A-T is discouraging, since no treatment seems to change the course of disease, but improvement can be achieved by symptomatic treatment of the bothersome movement disorder . While various dopaminergic agents are occasionally used, reports of benefit are rather sparse and anecdotal. Amantadine, a well known drug used in influenza as well as movement disorder of Parkinson, has been proved to improve various other types of movement disorder as ataxia, chorea, dystonia, akinesia and attention span. The purpose of this study is to investigate weather amantadine sulphate improves ataxia and the movement disorder (bradykinesia, parkinsonism, dystonia, chorea), as well as the general well being in patients with A-T.",
        "tokens": "['The', 'Effect', 'of', 'Amantadine', 'on', 'Movement', 'Disorder', 'in', 'Ataxia', '-', 'Telangiectasia', '|', 'Ataxia', '-', 'Telangiectasia', 'A', '-', 'T', 'is', 'a', 'neurodegenerative', 'disorder', 'of', 'the', 'cerebellum', ',', 'manifesting', 'with', 'ataxia', ',', 'as', 'well', 'as', 'extrapyramidal', 'features', '.', 'Treatment', 'of', 'A', '-', 'T', 'is', 'discouraging', ',', 'since', 'no', 'treatment', 'seems', 'to', 'change', 'the', 'course', 'of', 'disease', ',', 'but', 'improvement', 'can', 'be', 'achieved', 'by', 'symptomatic', 'treatment', 'of', 'the', 'bothersome', 'movement', 'disorder', '.', 'While', 'various', 'dopaminergic', 'agents', 'are', 'occasionally', 'used', ',', 'reports', 'of', 'benefit', 'are', 'rather', 'sparse', 'and', 'anecdotal', '.', 'Amantadine', ',', 'a', 'well', 'known', 'drug', 'used', 'in', 'influenza', 'as', 'well', 'as', 'movement', 'disorder', 'of', 'Parkinson', ',', 'has', 'been', 'proved', 'to', 'improve', 'various', 'other', 'types', 'of', 'movement', 'disorder', 'as', 'ataxia', ',', 'chorea', ',', 'dystonia', ',', 'akinesia', 'and', 'attention', 'span', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'weather', 'amantadine', 'sulphate', 'improves', 'ataxia', 'and', 'the', 'movement', 'disorder', '(', 'bradykinesia', ',', 'parkinsonism', ',', 'dystonia', ',', 'chorea', ')', ',', 'as', 'well', 'as', 'the', 'general', 'well', 'being', 'in', 'patients', 'with', 'A', '-', 'T.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 14,
                "end": 24,
                "text": "Amantadine",
                "type": "DRUG"
            },
            {
                "start": 28,
                "end": 45,
                "text": "Movement Disorder",
                "type": "CONDITION"
            },
            {
                "start": 49,
                "end": 70,
                "text": "Ataxia-Telangiectasia",
                "type": "CONDITION"
            },
            {
                "start": 73,
                "end": 94,
                "text": "Ataxia-Telangiectasia",
                "type": "CONDITION"
            },
            {
                "start": 95,
                "end": 98,
                "text": "A-T",
                "type": "CONDITION"
            },
            {
                "start": 167,
                "end": 173,
                "text": "ataxia",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 227,
                "text": "A-T",
                "type": "CONDITION"
            },
            {
                "start": 507,
                "end": 517,
                "text": "Amantadine",
                "type": "DRUG"
            },
            {
                "start": 587,
                "end": 596,
                "text": "Parkinson",
                "type": "CONDITION"
            },
            {
                "start": 669,
                "end": 675,
                "text": "ataxia",
                "type": "CONDITION"
            },
            {
                "start": 677,
                "end": 683,
                "text": "chorea",
                "type": "CONDITION"
            },
            {
                "start": 685,
                "end": 693,
                "text": "dystonia",
                "type": "CONDITION"
            },
            {
                "start": 695,
                "end": 703,
                "text": "akinesia",
                "type": "CONDITION"
            },
            {
                "start": 776,
                "end": 795,
                "text": "amantadine sulphate",
                "type": "DRUG"
            },
            {
                "start": 805,
                "end": 811,
                "text": "ataxia",
                "type": "CONDITION"
            },
            {
                "start": 820,
                "end": 837,
                "text": "movement disorder",
                "type": "CONDITION"
            },
            {
                "start": 839,
                "end": 851,
                "text": "bradykinesia",
                "type": "CONDITION"
            },
            {
                "start": 853,
                "end": 865,
                "text": "parkinsonism",
                "type": "CONDITION"
            },
            {
                "start": 867,
                "end": 875,
                "text": "dystonia",
                "type": "CONDITION"
            },
            {
                "start": 877,
                "end": 883,
                "text": "chorea",
                "type": "CONDITION"
            },
            {
                "start": 937,
                "end": 941,
                "text": "A-T.",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01369225",
        "study_official_title": "A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001 ",
        "study_brief_summary": " This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.",
        "text": "A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001 | This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.",
        "tokens": "['A', 'Multicenter', ',', 'Open', '-', 'label', 'Extension', ',', 'Multiple', 'Dose', ',', 'Parallel', 'Group', 'Study', 'To', 'Investigate', 'The', 'Long', '-', 'term', 'Safety', 'And', 'Tolerability', 'Of', 'Aab-003', '(', 'Pf-05236812', ')', 'Administered', 'Intravenously', 'In', 'Subjects', 'With', 'Mild', 'To', 'Moderate', 'Alzheimer', \"'s\", 'Disease', 'Previously', 'Treated', 'With', 'Aab-003', 'Or', 'Placebo', 'In', 'Protocol', 'B2601001', '|', 'This', 'is', 'a', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'multiple', 'doses', 'of', 'AAB-003', '(', 'PF-05236812', ')', 'in', 'patients', 'with', 'mild', 'to', 'moderate', 'Alzheimer', \"'s\", 'Disease', '.', 'Patients', 'who', 'complete', 'study', 'B2601001', 'may', 'participate', 'in', 'this', 'trial', 'and', 'receive', 'AAB-003', '(', 'PF-05236812', ')', '.', 'Each', 'patient', \"'s\", 'participation', 'will', 'last', 'approximately', '52', 'weeks', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 129,
                "end": 136,
                "text": "Aab-003",
                "type": "DRUG"
            },
            {
                "start": 138,
                "end": 149,
                "text": "Pf-05236812",
                "type": "DRUG"
            },
            {
                "start": 195,
                "end": 231,
                "text": "Mild To Moderate Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 256,
                "end": 263,
                "text": "Aab-003",
                "type": "DRUG"
            },
            {
                "start": 267,
                "end": 274,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 375,
                "end": 382,
                "text": "AAB-003",
                "type": "DRUG"
            },
            {
                "start": 384,
                "end": 395,
                "text": "PF-05236812",
                "type": "DRUG"
            },
            {
                "start": 414,
                "end": 450,
                "text": "mild to moderate Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 531,
                "end": 538,
                "text": "AAB-003",
                "type": "DRUG"
            },
            {
                "start": 540,
                "end": 551,
                "text": "PF-05236812",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05022147",
        "study_official_title": "ENGAGE-PD: Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease ",
        "study_brief_summary": " The purpose of this study is to assess how alternating-frequency Deep Brain Stimulation (DBS) works to improve postural instability and gait, while also treating other motor symptoms of Parkinson Disease (PD).",
        "text": "ENGAGE-PD: Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease | The purpose of this study is to assess how alternating-frequency Deep Brain Stimulation (DBS) works to improve postural instability and gait, while also treating other motor symptoms of Parkinson Disease (PD).",
        "tokens": "['ENGAGE', '-', 'PD', ':', 'Enhancing', 'Gait', 'Using', 'Alternating', '-', 'Frequency', 'DBS', 'in', 'Parkinson', 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'how', 'alternating', '-', 'frequency', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'works', 'to', 'improve', 'postural', 'instability', 'and', 'gait', ',', 'while', 'also', 'treating', 'other', 'motor', 'symptoms', 'of', 'Parkinson', 'Disease', '(', 'PD', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 57,
                "text": "Alternating-Frequency DBS",
                "type": "OTHER"
            },
            {
                "start": 61,
                "end": 78,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 168,
                "text": "alternating-frequency Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 170,
                "end": 173,
                "text": "DBS",
                "type": "OTHER"
            },
            {
                "start": 267,
                "end": 284,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 286,
                "end": 288,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03937700",
        "study_official_title": "Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker ",
        "study_brief_summary": " This trial is being conducted to determine if the CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy",
        "text": "Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker | This trial is being conducted to determine if the CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy",
        "tokens": "['Robot', 'Based', 'Gait', 'Training', 'Therapy', 'for', 'Pediatric', 'Population', 'With', 'Cerebral', 'Palsy', 'Using', 'the', 'CPWalker', '|', 'This', 'trial', 'is', 'being', 'conducted', 'to', 'determine', 'if', 'the', 'CPWalker', 'can', 'be', 'used', 'as', 'a', 'gait', 'training', 'intervention', 'for', 'pediatric', 'patients', 'with', 'gait', 'impairments', 'due', 'to', 'cerebral', 'palsy']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",
        "entities": [
            {
                "start": 0,
                "end": 25,
                "text": "Robot Based Gait Training",
                "type": "PHYSICAL"
            },
            {
                "start": 64,
                "end": 78,
                "text": "Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 89,
                "end": 97,
                "text": "CPWalker",
                "type": "PHYSICAL"
            },
            {
                "start": 150,
                "end": 158,
                "text": "CPWalker",
                "type": "PHYSICAL"
            },
            {
                "start": 176,
                "end": 189,
                "text": "gait training",
                "type": "PHYSICAL"
            },
            {
                "start": 255,
                "end": 269,
                "text": "cerebral palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00483028",
        "study_official_title": "A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil (5 mg QD for 6 Weeks) After Single Dose and Steady State Therapy (2 Weeks and 6 Weeks) in Subjects With Mild Cognitive Impairment ",
        "study_brief_summary": " To purpose of this study is to estimate the effect of donepezil on Neuropsychological Testing (NPT) and brain Proton Magnetic Resonance Spectroscopy.",
        "text": "A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil (5 mg QD for 6 Weeks) After Single Dose and Steady State Therapy (2 Weeks and 6 Weeks) in Subjects With Mild Cognitive Impairment | To purpose of this study is to estimate the effect of donepezil on Neuropsychological Testing (NPT) and brain Proton Magnetic Resonance Spectroscopy.",
        "tokens": "['A', 'Randomized', 'Double', '-', 'Blind', ',', 'Parallel', ',', 'Placebo', '-', 'Controlled', 'Trial', 'to', 'Examine', 'the', 'Efficacy', 'of', 'Oral', 'Donepezil', '(', '5', 'mg', 'QD', 'for', '6', 'Weeks', ')', 'After', 'Single', 'Dose', 'and', 'Steady', 'State', 'Therapy', '(', '2', 'Weeks', 'and', '6', 'Weeks', ')', 'in', 'Subjects', 'With', 'Mild', 'Cognitive', 'Impairment', '|', 'To', 'purpose', 'of', 'this', 'study', 'is', 'to', 'estimate', 'the', 'effect', 'of', 'donepezil', 'on', 'Neuropsychological', 'Testing', '(', 'NPT', ')', 'and', 'brain', 'Proton', 'Magnetic', 'Resonance', 'Spectroscopy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 44,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 94,
                "end": 103,
                "text": "Donepezil",
                "type": "DRUG"
            },
            {
                "start": 208,
                "end": 233,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 290,
                "end": 299,
                "text": "donepezil",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05220072",
        "study_official_title": "An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male Subjects ",
        "study_brief_summary": " The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into blood cells, provide additional safety and tolerability information and collect samples for metabolite profiling and structural identification.",
        "text": "An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of Carbon-14 BIA 28-6156 in Healthy Male Subjects | The study is designed to determine the absorption, distribution, metabolism and elimination (ADME) of BIA 28-6156 in humans, further explore the PK of BIA 28-6156, evaluate the extent of distribution of total radioactivity into blood cells, provide additional safety and tolerability information and collect samples for metabolite profiling and structural identification.",
        "tokens": "['An', 'Open', 'Label', ',', 'Single', '-', 'dose', ',', 'Single', '-', 'period', 'Study', 'Designed', 'to', 'Assess', 'the', 'Mass', 'Balance', 'Recovery', ',', 'Metabolite', 'Profile', 'and', 'Metabolite', 'Identification', 'of', 'Carbon-14', 'BIA', '28', '-', '6156', 'in', 'Healthy', 'Male', 'Subjects', '|', 'The', 'study', 'is', 'designed', 'to', 'determine', 'the', 'absorption', ',', 'distribution', ',', 'metabolism', 'and', 'elimination', '(', 'ADME', ')', 'of', 'BIA', '28', '-', '6156', 'in', 'humans', ',', 'further', 'explore', 'the', 'PK', 'of', 'BIA', '28', '-', '6156', ',', 'evaluate', 'the', 'extent', 'of', 'distribution', 'of', 'total', 'radioactivity', 'into', 'blood', 'cells', ',', 'provide', 'additional', 'safety', 'and', 'tolerability', 'information', 'and', 'collect', 'samples', 'for', 'metabolite', 'profiling', 'and', 'structural', 'identification', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 146,
                "end": 167,
                "text": "Carbon-14 BIA 28-6156",
                "type": "DRUG"
            },
            {
                "start": 297,
                "end": 308,
                "text": "BIA 28-6156",
                "type": "DRUG"
            },
            {
                "start": 346,
                "end": 357,
                "text": "BIA 28-6156",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04412447",
        "study_official_title": "Training of Persons With Complete Spinal Cord Injury for Pedaling on a Tricycle, Induced by Electrical Stimulation of the Paralysed Muscles: a Case Series ",
        "study_brief_summary": " The main objective of this study is to validate the effectivity of a simple home-based training for cycling with functional electrical stimulation (FES). The training is designed to progressively increase strength and endurance of the paralysed muscles of a person with complete spinal cord injury. After a limited period of only several months, performance will be assessed during FES-assisted cycling on a recumbent tricycle over flat ground. The outcomes of this study should provide evidence for the effectivity of FES-cycling as potential rehabilitation method.",
        "text": "Training of Persons With Complete Spinal Cord Injury for Pedaling on a Tricycle, Induced by Electrical Stimulation of the Paralysed Muscles: a Case Series | The main objective of this study is to validate the effectivity of a simple home-based training for cycling with functional electrical stimulation (FES). The training is designed to progressively increase strength and endurance of the paralysed muscles of a person with complete spinal cord injury. After a limited period of only several months, performance will be assessed during FES-assisted cycling on a recumbent tricycle over flat ground. The outcomes of this study should provide evidence for the effectivity of FES-cycling as potential rehabilitation method.",
        "tokens": "['Training', 'of', 'Persons', 'With', 'Complete', 'Spinal', 'Cord', 'Injury', 'for', 'Pedaling', 'on', 'a', 'Tricycle', ',', 'Induced', 'by', 'Electrical', 'Stimulation', 'of', 'the', 'Paralysed', 'Muscles', ':', 'a', 'Case', 'Series', '|', 'The', 'main', 'objective', 'of', 'this', 'study', 'is', 'to', 'validate', 'the', 'effectivity', 'of', 'a', 'simple', 'home', '-', 'based', 'training', 'for', 'cycling', 'with', 'functional', 'electrical', 'stimulation', '(', 'FES', ')', '.', 'The', 'training', 'is', 'designed', 'to', 'progressively', 'increase', 'strength', 'and', 'endurance', 'of', 'the', 'paralysed', 'muscles', 'of', 'a', 'person', 'with', 'complete', 'spinal', 'cord', 'injury', '.', 'After', 'a', 'limited', 'period', 'of', 'only', 'several', 'months', ',', 'performance', 'will', 'be', 'assessed', 'during', 'FES', '-', 'assisted', 'cycling', 'on', 'a', 'recumbent', 'tricycle', 'over', 'flat', 'ground', '.', 'The', 'outcomes', 'of', 'this', 'study', 'should', 'provide', 'evidence', 'for', 'the', 'effectivity', 'of', 'FES', '-', 'cycling', 'as', 'potential', 'rehabilitation', 'method', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 52,
                "text": "Complete Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 57,
                "end": 139,
                "text": "Pedaling on a Tricycle, Induced by Electrical Stimulation of the Paralysed Muscles",
                "type": "PHYSICAL"
            },
            {
                "start": 233,
                "end": 303,
                "text": "home-based training for cycling with functional electrical stimulation",
                "type": "PHYSICAL"
            },
            {
                "start": 305,
                "end": 308,
                "text": "FES",
                "type": "PHYSICAL"
            },
            {
                "start": 427,
                "end": 454,
                "text": "complete spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 539,
                "end": 559,
                "text": "FES-assisted cycling",
                "type": "PHYSICAL"
            },
            {
                "start": 676,
                "end": 687,
                "text": "FES-cycling",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT04956874",
        "study_official_title": "The Florida REACH Translation Project ",
        "study_brief_summary": " The primary aim of this study is to test feasibility of a modified REACH II intervention in an outpatient clinic.",
        "text": "The Florida REACH Translation Project | The primary aim of this study is to test feasibility of a modified REACH II intervention in an outpatient clinic.",
        "tokens": "['The', 'Florida', 'REACH', 'Translation', 'Project', '|', 'The', 'primary', 'aim', 'of', 'this', 'study', 'is', 'to', 'test', 'feasibility', 'of', 'a', 'modified', 'REACH', 'II', 'intervention', 'in', 'an', 'outpatient', 'clinic', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT02038608",
        "study_official_title": "Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET ",
        "study_brief_summary": " Parkinson's disease is characterized by a large number of non motor, especially neuropsychiatric, signs. Their pathophysiology is complex but the role of dopaminergic and serotoninergic systems dysfunction is suggested by several studies. In addition, the serotoninergic system is involved in the pathophysiology of dyskinesias. Very few studies have analyzed the abnormalities of these two neurotransmission systems at disease onset, in de novo PD patients. Furthermore, the parallel evolution of the degeneration of the dopaminergic and serotoninergic systems with disease progression remains unknown. Thus the present study aims at determining, by using PET and 11C-PE2I and 11C-DASB the respective role of the serotoninergic and dopaminergic systems dysfunction in motor and non motor manifestations in PD, at different evolution stages.",
        "text": "Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET | Parkinson's disease is characterized by a large number of non motor, especially neuropsychiatric, signs. Their pathophysiology is complex but the role of dopaminergic and serotoninergic systems dysfunction is suggested by several studies. In addition, the serotoninergic system is involved in the pathophysiology of dyskinesias. Very few studies have analyzed the abnormalities of these two neurotransmission systems at disease onset, in de novo PD patients. Furthermore, the parallel evolution of the degeneration of the dopaminergic and serotoninergic systems with disease progression remains unknown. Thus the present study aims at determining, by using PET and 11C-PE2I and 11C-DASB the respective role of the serotoninergic and dopaminergic systems dysfunction in motor and non motor manifestations in PD, at different evolution stages.",
        "tokens": "['Pathophysiology', 'of', 'Non', 'Motor', 'Signs', 'and', 'Compensatory', 'Mechanisms', 'in', 'Parkinson', \"'s\", 'Disease', ':', 'Role', 'of', 'the', 'Serotoninergic', 'and', 'Dopaminergic', 'Lesions', 'Studied', 'by', 'PET', '|', 'Parkinson', \"'s\", 'disease', 'is', 'characterized', 'by', 'a', 'large', 'number', 'of', 'non', 'motor', ',', 'especially', 'neuropsychiatric', ',', 'signs', '.', 'Their', 'pathophysiology', 'is', 'complex', 'but', 'the', 'role', 'of', 'dopaminergic', 'and', 'serotoninergic', 'systems', 'dysfunction', 'is', 'suggested', 'by', 'several', 'studies', '.', 'In', 'addition', ',', 'the', 'serotoninergic', 'system', 'is', 'involved', 'in', 'the', 'pathophysiology', 'of', 'dyskinesias', '.', 'Very', 'few', 'studies', 'have', 'analyzed', 'the', 'abnormalities', 'of', 'these', 'two', 'neurotransmission', 'systems', 'at', 'disease', 'onset', ',', 'in', 'de', 'novo', 'PD', 'patients', '.', 'Furthermore', ',', 'the', 'parallel', 'evolution', 'of', 'the', 'degeneration', 'of', 'the', 'dopaminergic', 'and', 'serotoninergic', 'systems', 'with', 'disease', 'progression', 'remains', 'unknown', '.', 'Thus', 'the', 'present', 'study', 'aims', 'at', 'determining', ',', 'by', 'using', 'PET', 'and', '11C', '-', 'PE2I', 'and', '11C', '-', 'DASB', 'the', 'respective', 'role', 'of', 'the', 'serotoninergic', 'and', 'dopaminergic', 'systems', 'dysfunction', 'in', 'motor', 'and', 'non', 'motor', 'manifestations', 'in', 'PD', ',', 'at', 'different', 'evolution', 'stages', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 66,
                "end": 85,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 175,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 602,
                "end": 604,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 963,
                "end": 965,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02840643",
        "study_official_title": "Combined Constraint Therapy and Bimanual Therapy for Children With Unilateral Brain Injury ",
        "study_brief_summary": " To examine efficacy of combined unimanual and bimanual intensive therapy in children with unilateral brain injury. A key question in hemiplegia therapy is whether the affected hand should be trained alone or in tandem with the other hand. In constraint-induced movement therapy (CIMT), a participant's less-affected upper extremity is restricted with a sling, cast, or mitt, while the participant actively uses the affected arm and hand in skill-based therapeutic activities. Bimanual therapy, in contrast, engages both hands in therapeutic movement. Since constraint and bimanual therapy target different aspects of hand use, they could have synergistic effects on hand function when given in combination.",
        "text": "Combined Constraint Therapy and Bimanual Therapy for Children With Unilateral Brain Injury | To examine efficacy of combined unimanual and bimanual intensive therapy in children with unilateral brain injury. A key question in hemiplegia therapy is whether the affected hand should be trained alone or in tandem with the other hand. In constraint-induced movement therapy (CIMT), a participant's less-affected upper extremity is restricted with a sling, cast, or mitt, while the participant actively uses the affected arm and hand in skill-based therapeutic activities. Bimanual therapy, in contrast, engages both hands in therapeutic movement. Since constraint and bimanual therapy target different aspects of hand use, they could have synergistic effects on hand function when given in combination.",
        "tokens": "['Combined', 'Constraint', 'Therapy', 'and', 'Bimanual', 'Therapy', 'for', 'Children', 'With', 'Unilateral', 'Brain', 'Injury', '|', 'To', 'examine', 'efficacy', 'of', 'combined', 'unimanual', 'and', 'bimanual', 'intensive', 'therapy', 'in', 'children', 'with', 'unilateral', 'brain', 'injury', '.', 'A', 'key', 'question', 'in', 'hemiplegia', 'therapy', 'is', 'whether', 'the', 'affected', 'hand', 'should', 'be', 'trained', 'alone', 'or', 'in', 'tandem', 'with', 'the', 'other', 'hand', '.', 'In', 'constraint', '-', 'induced', 'movement', 'therapy', '(', 'CIMT', ')', ',', 'a', 'participant', \"'s\", 'less', '-', 'affected', 'upper', 'extremity', 'is', 'restricted', 'with', 'a', 'sling', ',', 'cast', ',', 'or', 'mitt', ',', 'while', 'the', 'participant', 'actively', 'uses', 'the', 'affected', 'arm', 'and', 'hand', 'in', 'skill', '-', 'based', 'therapeutic', 'activities', '.', 'Bimanual', 'therapy', ',', 'in', 'contrast', ',', 'engages', 'both', 'hands', 'in', 'therapeutic', 'movement', '.', 'Since', 'constraint', 'and', 'bimanual', 'therapy', 'target', 'different', 'aspects', 'of', 'hand', 'use', ',', 'they', 'could', 'have', 'synergistic', 'effects', 'on', 'hand', 'function', 'when', 'given', 'in', 'combination', '.']",
        "token_bio_labels": "['O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 9,
                "end": 27,
                "text": "Constraint Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 32,
                "end": 48,
                "text": "Bimanual Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 67,
                "end": 90,
                "text": "Unilateral Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 116,
                "end": 165,
                "text": "combined unimanual and bimanual intensive therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 183,
                "end": 206,
                "text": "unilateral brain injury",
                "type": "CONDITION"
            },
            {
                "start": 226,
                "end": 236,
                "text": "hemiplegia",
                "type": "CONDITION"
            },
            {
                "start": 335,
                "end": 370,
                "text": "constraint-induced movement therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 372,
                "end": 376,
                "text": "CIMT",
                "type": "PHYSICAL"
            },
            {
                "start": 569,
                "end": 585,
                "text": "Bimanual therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 650,
                "end": 681,
                "text": "constraint and bimanual therapy",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT03928496",
        "study_official_title": "Abobotulinumtoxina Efficacy in Post-Traumatic Headache ",
        "study_brief_summary": " This study will evaluate the efficacy of abobotulinumtoxina on Veterans with post-traumatic headache",
        "text": "Abobotulinumtoxina Efficacy in Post-Traumatic Headache | This study will evaluate the efficacy of abobotulinumtoxina on Veterans with post-traumatic headache",
        "tokens": "['Abobotulinumtoxina', 'Efficacy', 'in', 'Post', '-', 'Traumatic', 'Headache', '|', 'This', 'study', 'will', 'evaluate', 'the', 'efficacy', 'of', 'abobotulinumtoxina', 'on', 'Veterans', 'with', 'post', '-', 'traumatic', 'headache']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 0,
                "end": 18,
                "text": "Abobotulinumtoxina",
                "type": "DRUG"
            },
            {
                "start": 31,
                "end": 54,
                "text": "Post-Traumatic Headache",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 116,
                "text": "abobotulinumtoxina",
                "type": "DRUG"
            },
            {
                "start": 134,
                "end": 157,
                "text": "post-traumatic headache",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03766113",
        "study_official_title": "Effect of Unimodal (EEG) and Bimodal (EEG-fMRI) Neurofeedback on Upper Limb Recovery After Stroke ",
        "study_brief_summary": " Interventional study with minimal risks and constraints, prospective, monocentric.",
        "text": "Effect of Unimodal (EEG) and Bimodal (EEG-fMRI) Neurofeedback on Upper Limb Recovery After Stroke | Interventional study with minimal risks and constraints, prospective, monocentric.",
        "tokens": "['Effect', 'of', 'Unimodal', '(', 'EEG', ')', 'and', 'Bimodal', '(', 'EEG', '-', 'fMRI', ')', 'Neurofeedback', 'on', 'Upper', 'Limb', 'Recovery', 'After', 'Stroke', '|', 'Interventional', 'study', 'with', 'minimal', 'risks', 'and', 'constraints', ',', 'prospective', ',', 'monocentric', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 61,
                "text": "Unimodal (EEG) and Bimodal (EEG-fMRI) Neurofeedback",
                "type": "OTHER"
            },
            {
                "start": 85,
                "end": 97,
                "text": "After Stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03098732",
        "study_official_title": "A Prospective International Multicentre Randomised Controlled Single Blind Clinical Investigation of Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) ",
        "study_brief_summary": " The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation 30-90 minutes after the completion of tPA infusion than subjects treated with IV tPA (plus sham device). Safety of the MED System Procedure will be evaluated by the incidence of symptomatic PH-2 haemorrhagic transformation within 24 hours following the procedure. Lastly, a health economics study will be conducted to estimate health care costs for each treatment.",
        "text": "A Prospective International Multicentre Randomised Controlled Single Blind Clinical Investigation of Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) | The objective of the MEDIS study is to determine if subjects experiencing an Acute Ischaemic Stroke due to large vessel occlusion, treated with IV tPA combined with the MED procedure have a greater likelihood of recanalisation 30-90 minutes after the completion of tPA infusion than subjects treated with IV tPA (plus sham device). Safety of the MED System Procedure will be evaluated by the incidence of symptomatic PH-2 haemorrhagic transformation within 24 hours following the procedure. Lastly, a health economics study will be conducted to estimate health care costs for each treatment.",
        "tokens": "['A', 'Prospective', 'International', 'Multicentre', 'Randomised', 'Controlled', 'Single', 'Blind', 'Clinical', 'Investigation', 'of', 'Magnetically', 'Enhanced', 'Diffusion', 'for', 'Acute', 'Ischaemic', 'Stroke', '(', 'MEDIS', ')', '|', 'The', 'objective', 'of', 'the', 'MEDIS', 'study', 'is', 'to', 'determine', 'if', 'subjects', 'experiencing', 'an', 'Acute', 'Ischaemic', 'Stroke', 'due', 'to', 'large', 'vessel', 'occlusion', ',', 'treated', 'with', 'IV', 'tPA', 'combined', 'with', 'the', 'MED', 'procedure', 'have', 'a', 'greater', 'likelihood', 'of', 'recanalisation', '30', '-', '90', 'minutes', 'after', 'the', 'completion', 'of', 'tPA', 'infusion', 'than', 'subjects', 'treated', 'with', 'IV', 'tPA', '(', 'plus', 'sham', 'device', ')', '.', 'Safety', 'of', 'the', 'MED', 'System', 'Procedure', 'will', 'be', 'evaluated', 'by', 'the', 'incidence', 'of', 'symptomatic', 'PH-2', 'haemorrhagic', 'transformation', 'within', '24', 'hours', 'following', 'the', 'procedure', '.', 'Lastly', ',', 'a', 'health', 'economics', 'study', 'will', 'be', 'conducted', 'to', 'estimate', 'health', 'care', 'costs', 'for', 'each', 'treatment', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 101,
                "end": 132,
                "text": "Magnetically Enhanced Diffusion",
                "type": "OTHER"
            },
            {
                "start": 137,
                "end": 159,
                "text": "Acute Ischaemic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 247,
                "end": 269,
                "text": "Acute Ischaemic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 277,
                "end": 299,
                "text": "large vessel occlusion",
                "type": "CONDITION"
            },
            {
                "start": 317,
                "end": 320,
                "text": "tPA",
                "type": "DRUG"
            },
            {
                "start": 339,
                "end": 342,
                "text": "MED",
                "type": "OTHER"
            },
            {
                "start": 435,
                "end": 438,
                "text": "tPA",
                "type": "DRUG"
            },
            {
                "start": 478,
                "end": 481,
                "text": "tPA",
                "type": "DRUG"
            },
            {
                "start": 488,
                "end": 499,
                "text": "sham device",
                "type": "CONTROL"
            },
            {
                "start": 516,
                "end": 519,
                "text": "MED",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03592420",
        "study_official_title": "Efficacy of a Multifactorial and Personalized Program for Fall Prevention in Community-dwelling Elderly in Comparison to the Usual Care: a Randomized Controlled Trial ",
        "study_brief_summary": " Randomized Controlled Trial (RCT) aiming at assessing the efficacy of an interdisciplinary multi-component and personalized multi-factorial intervention for reducing falls at one year post-enrolment in comparison to the usual care in a sample of community dwelling elderly (age \u226565 years), with or without Parkinson's Disease and/or previous Stroke.",
        "text": "Efficacy of a Multifactorial and Personalized Program for Fall Prevention in Community-dwelling Elderly in Comparison to the Usual Care: a Randomized Controlled Trial | Randomized Controlled Trial (RCT) aiming at assessing the efficacy of an interdisciplinary multi-component and personalized multi-factorial intervention for reducing falls at one year post-enrolment in comparison to the usual care in a sample of community dwelling elderly (age \u226565 years), with or without Parkinson's Disease and/or previous Stroke.",
        "tokens": "['Efficacy', 'of', 'a', 'Multifactorial', 'and', 'Personalized', 'Program', 'for', 'Fall', 'Prevention', 'in', 'Community', '-', 'dwelling', 'Elderly', 'in', 'Comparison', 'to', 'the', 'Usual', 'Care', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Randomized', 'Controlled', 'Trial', '(', 'RCT', ')', 'aiming', 'at', 'assessing', 'the', 'efficacy', 'of', 'an', 'interdisciplinary', 'multi', '-', 'component', 'and', 'personalized', 'multi', '-', 'factorial', 'intervention', 'for', 'reducing', 'falls', 'at', 'one', 'year', 'post', '-', 'enrolment', 'in', 'comparison', 'to', 'the', 'usual', 'care', 'in', 'a', 'sample', 'of', 'community', 'dwelling', 'elderly', '(', 'age', '\u226565', 'years', ')', ',', 'with', 'or', 'without', 'Parkinson', \"'s\", 'Disease', 'and/or', 'previous', 'Stroke', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 73,
                "text": "Multifactorial and Personalized Program for Fall Prevention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 242,
                "end": 321,
                "text": "interdisciplinary multi-component and personalized multi-factorial intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 475,
                "end": 494,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 511,
                "end": 517,
                "text": "Stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03167697",
        "study_official_title": "Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia ",
        "study_brief_summary": " This study centres around a new one-a-day phenylalanine-free protein substitute for phenylketonuria patients. Fifty eligible adults (\u2265 16 years) with proven phenylketonuria or hyperphenylalaninemia will be recruited and randomly allocated to one of two intervention arms (n = 25 per arm). Following a 3-day baseline period, and in addition to routine nutritional management, patients will receive either one sachet of the new protein substitute daily (intervention) or continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.",
        "text": "Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia | This study centres around a new one-a-day phenylalanine-free protein substitute for phenylketonuria patients. Fifty eligible adults (\u2265 16 years) with proven phenylketonuria or hyperphenylalaninemia will be recruited and randomly allocated to one of two intervention arms (n = 25 per arm). Following a 3-day baseline period, and in addition to routine nutritional management, patients will receive either one sachet of the new protein substitute daily (intervention) or continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.",
        "tokens": "['Evaluating', 'the', 'Efficacy', 'of', 'PKU', 'Synergy', 'in', 'Patients', 'Expressing', 'Phenylketonuria', 'or', 'Hyperphenylalaninemia', '|', 'This', 'study', 'centres', 'around', 'a', 'new', 'one', '-', 'a', '-', 'day', 'phenylalanine', '-', 'free', 'protein', 'substitute', 'for', 'phenylketonuria', 'patients', '.', 'Fifty', 'eligible', 'adults', '(', '\u2265', '16', 'years', ')', 'with', 'proven', 'phenylketonuria', 'or', 'hyperphenylalaninemia', 'will', 'be', 'recruited', 'and', 'randomly', 'allocated', 'to', 'one', 'of', 'two', 'intervention', 'arms', '(', 'n', '=', '25', 'per', 'arm', ')', '.', 'Following', 'a', '3', '-', 'day', 'baseline', 'period', ',', 'and', 'in', 'addition', 'to', 'routine', 'nutritional', 'management', ',', 'patients', 'will', 'receive', 'either', 'one', 'sachet', 'of', 'the', 'new', 'protein', 'substitute', 'daily', '(', 'intervention', ')', 'or', 'continue', 'their', 'usual', 'dietary', 'and/or', 'protein', 'substitute', 'regimen', '(', 'maximum', 'of', '1', 'protein', 'substitute', 'per', 'day', '(', 'equal', 'to', '20', 'g', 'protein', 'equivalent', ')', 'control', ')', 'for', '28', 'days', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 27,
                "end": 38,
                "text": "PKU Synergy",
                "type": "OTHER"
            },
            {
                "start": 62,
                "end": 77,
                "text": "Phenylketonuria",
                "type": "CONDITION"
            },
            {
                "start": 81,
                "end": 102,
                "text": "Hyperphenylalaninemia",
                "type": "CONDITION"
            },
            {
                "start": 147,
                "end": 184,
                "text": "phenylalanine-free protein substitute",
                "type": "OTHER"
            },
            {
                "start": 189,
                "end": 204,
                "text": "phenylketonuria",
                "type": "CONDITION"
            },
            {
                "start": 262,
                "end": 277,
                "text": "phenylketonuria",
                "type": "CONDITION"
            },
            {
                "start": 281,
                "end": 302,
                "text": "hyperphenylalaninemia",
                "type": "CONDITION"
            },
            {
                "start": 448,
                "end": 478,
                "text": "routine nutritional management",
                "type": "OTHER"
            },
            {
                "start": 531,
                "end": 549,
                "text": "protein substitute",
                "type": "OTHER"
            },
            {
                "start": 589,
                "end": 636,
                "text": "usual dietary and/or protein substitute regimen",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00101933",
        "study_official_title": "SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy ",
        "study_brief_summary": " The purpose of this research is to study the safety and effectiveness of bilateral stimulation of the anterior nucleus of the thalamus as adjunctive therapy for reducing the frequency of seizures in adults diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to antiepileptic medications.",
        "text": "SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy | The purpose of this research is to study the safety and effectiveness of bilateral stimulation of the anterior nucleus of the thalamus as adjunctive therapy for reducing the frequency of seizures in adults diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to antiepileptic medications.",
        "tokens": "['SANTE', '-', 'Stimulation', 'of', 'the', 'Anterior', 'Nucleus', 'of', 'the', 'Thalamus', 'for', 'Epilepsy', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'study', 'the', 'safety', 'and', 'effectiveness', 'of', 'bilateral', 'stimulation', 'of', 'the', 'anterior', 'nucleus', 'of', 'the', 'thalamus', 'as', 'adjunctive', 'therapy', 'for', 'reducing', 'the', 'frequency', 'of', 'seizures', 'in', 'adults', 'diagnosed', 'with', 'epilepsy', 'characterized', 'by', 'partial', '-', 'onset', 'seizures', ',', 'with', 'or', 'without', 'secondary', 'generalization', ',', 'that', 'are', 'refractory', 'to', 'antiepileptic', 'medications', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 8,
                "end": 59,
                "text": "Stimulation of the Anterior Nucleus of the Thalamus",
                "type": "OTHER"
            },
            {
                "start": 64,
                "end": 72,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 209,
                "text": "bilateral stimulation of the anterior nucleus of the thalamus",
                "type": "OTHER"
            },
            {
                "start": 262,
                "end": 270,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 296,
                "end": 304,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 344,
                "text": "partial-onset seizures",
                "type": "CONDITION"
            },
            {
                "start": 362,
                "end": 386,
                "text": "secondary generalization",
                "type": "CONDITION"
            },
            {
                "start": 397,
                "end": 436,
                "text": "refractory to antiepileptic medications",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04524182",
        "study_official_title": "The Acute Effect of Lumbo-sacral Mobilization on Functional Activities, Balance and Gait in Patients With Idiopathic Parkinson's Disease ",
        "study_brief_summary": " Parkinson's disease is a neurodegenerative disease including resting tremor, bradykinesia, rigidity and postural instability. In addition, postural disorders, motor freezing, gait disturbances, decreased arm swing and axial rotation loss accompany the disease. There is an important relationship between axial rotation and turning, which is one of many activities in daily life. Parkinson's patients with loss of axial rotation have a difficulty gait, daily living activities and is associated with falls.\n\nClassical physiotherapy methods for Parkinson's patients such as stretching, strengthening and posture exercises, balance, coordination and gait training, and different methods such as motor imagery, sensory stimuli and neurophysiological approaches can be used in the treatment of Parkinson's patients. Although there are applications that can increase axial rotation in physiotherapy programs, all programs may be able to focus adequately on the treatment of this symptom. In addition, according to the literature, the effects of all physiotherapy approaches emerge as a result of long-term training.\n\nMobilization techniques are applications that are included in physiotherapy programs and have a wide area of use. It is divided into three subtitles according to its severity and degree: Grade A (mobilization), grade B (mobilization) and grade C (manipulation).\n\nConsidering the effects of mobilization on muscle activation and balance, grade A and grade B mobilization applications are likely to increase the mobility of this area when applied on the lumbosacral region. Therefore, these practices can affect balance, gait and functional activities by regulating muscle tone (rigidity) and muscle activation and reducing axial symptoms in Parkinson's patients. Based on this information, the aim of our study is to investigate the acute effect of lumbosacral mobilization on balance, gait and functional activities in patients with Parkinson's disease.",
        "text": "The Acute Effect of Lumbo-sacral Mobilization on Functional Activities, Balance and Gait in Patients With Idiopathic Parkinson's Disease | Parkinson's disease is a neurodegenerative disease including resting tremor, bradykinesia, rigidity and postural instability. In addition, postural disorders, motor freezing, gait disturbances, decreased arm swing and axial rotation loss accompany the disease. There is an important relationship between axial rotation and turning, which is one of many activities in daily life. Parkinson's patients with loss of axial rotation have a difficulty gait, daily living activities and is associated with falls.\n\nClassical physiotherapy methods for Parkinson's patients such as stretching, strengthening and posture exercises, balance, coordination and gait training, and different methods such as motor imagery, sensory stimuli and neurophysiological approaches can be used in the treatment of Parkinson's patients. Although there are applications that can increase axial rotation in physiotherapy programs, all programs may be able to focus adequately on the treatment of this symptom. In addition, according to the literature, the effects of all physiotherapy approaches emerge as a result of long-term training.\n\nMobilization techniques are applications that are included in physiotherapy programs and have a wide area of use. It is divided into three subtitles according to its severity and degree: Grade A (mobilization), grade B (mobilization) and grade C (manipulation).\n\nConsidering the effects of mobilization on muscle activation and balance, grade A and grade B mobilization applications are likely to increase the mobility of this area when applied on the lumbosacral region. Therefore, these practices can affect balance, gait and functional activities by regulating muscle tone (rigidity) and muscle activation and reducing axial symptoms in Parkinson's patients. Based on this information, the aim of our study is to investigate the acute effect of lumbosacral mobilization on balance, gait and functional activities in patients with Parkinson's disease.",
        "tokens": "['The', 'Acute', 'Effect', 'of', 'Lumbo', '-', 'sacral', 'Mobilization', 'on', 'Functional', 'Activities', ',', 'Balance', 'and', 'Gait', 'in', 'Patients', 'With', 'Idiopathic', 'Parkinson', \"'s\", 'Disease', '|', 'Parkinson', \"'s\", 'disease', 'is', 'a', 'neurodegenerative', 'disease', 'including', 'resting', 'tremor', ',', 'bradykinesia', ',', 'rigidity', 'and', 'postural', 'instability', '.', 'In', 'addition', ',', 'postural', 'disorders', ',', 'motor', 'freezing', ',', 'gait', 'disturbances', ',', 'decreased', 'arm', 'swing', 'and', 'axial', 'rotation', 'loss', 'accompany', 'the', 'disease', '.', 'There', 'is', 'an', 'important', 'relationship', 'between', 'axial', 'rotation', 'and', 'turning', ',', 'which', 'is', 'one', 'of', 'many', 'activities', 'in', 'daily', 'life', '.', 'Parkinson', \"'s\", 'patients', 'with', 'loss', 'of', 'axial', 'rotation', 'have', 'a', 'difficulty', 'gait', ',', 'daily', 'living', 'activities', 'and', 'is', 'associated', 'with', 'falls', '.', '\\n\\n', 'Classical', 'physiotherapy', 'methods', 'for', 'Parkinson', \"'s\", 'patients', 'such', 'as', 'stretching', ',', 'strengthening', 'and', 'posture', 'exercises', ',', 'balance', ',', 'coordination', 'and', 'gait', 'training', ',', 'and', 'different', 'methods', 'such', 'as', 'motor', 'imagery', ',', 'sensory', 'stimuli', 'and', 'neurophysiological', 'approaches', 'can', 'be', 'used', 'in', 'the', 'treatment', 'of', 'Parkinson', \"'s\", 'patients', '.', 'Although', 'there', 'are', 'applications', 'that', 'can', 'increase', 'axial', 'rotation', 'in', 'physiotherapy', 'programs', ',', 'all', 'programs', 'may', 'be', 'able', 'to', 'focus', 'adequately', 'on', 'the', 'treatment', 'of', 'this', 'symptom', '.', 'In', 'addition', ',', 'according', 'to', 'the', 'literature', ',', 'the', 'effects', 'of', 'all', 'physiotherapy', 'approaches', 'emerge', 'as', 'a', 'result', 'of', 'long', '-', 'term', 'training', '.', '\\n\\n', 'Mobilization', 'techniques', 'are', 'applications', 'that', 'are', 'included', 'in', 'physiotherapy', 'programs', 'and', 'have', 'a', 'wide', 'area', 'of', 'use', '.', 'It', 'is', 'divided', 'into', 'three', 'subtitles', 'according', 'to', 'its', 'severity', 'and', 'degree', ':', 'Grade', 'A', '(', 'mobilization', ')', ',', 'grade', 'B', '(', 'mobilization', ')', 'and', 'grade', 'C', '(', 'manipulation', ')', '.', '\\n\\n', 'Considering', 'the', 'effects', 'of', 'mobilization', 'on', 'muscle', 'activation', 'and', 'balance', ',', 'grade', 'A', 'and', 'grade', 'B', 'mobilization', 'applications', 'are', 'likely', 'to', 'increase', 'the', 'mobility', 'of', 'this', 'area', 'when', 'applied', 'on', 'the', 'lumbosacral', 'region', '.', 'Therefore', ',', 'these', 'practices', 'can', 'affect', 'balance', ',', 'gait', 'and', 'functional', 'activities', 'by', 'regulating', 'muscle', 'tone', '(', 'rigidity', ')', 'and', 'muscle', 'activation', 'and', 'reducing', 'axial', 'symptoms', 'in', 'Parkinson', \"'s\", 'patients', '.', 'Based', 'on', 'this', 'information', ',', 'the', 'aim', 'of', 'our', 'study', 'is', 'to', 'investigate', 'the', 'acute', 'effect', 'of', 'lumbosacral', 'mobilization', 'on', 'balance', ',', 'gait', 'and', 'functional', 'activities', 'in', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 45,
                "text": "Lumbo-sacral Mobilization",
                "type": "OTHER"
            },
            {
                "start": 106,
                "end": 136,
                "text": "Idiopathic Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 158,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 518,
                "end": 529,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 544,
                "end": 566,
                "text": "loss of axial rotation",
                "type": "CONDITION"
            },
            {
                "start": 682,
                "end": 693,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 928,
                "end": 939,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 1250,
                "end": 1273,
                "text": "Mobilization techniques",
                "type": "OTHER"
            },
            {
                "start": 1446,
                "end": 1458,
                "text": "mobilization",
                "type": "OTHER"
            },
            {
                "start": 1470,
                "end": 1482,
                "text": "mobilization",
                "type": "OTHER"
            },
            {
                "start": 1497,
                "end": 1509,
                "text": "manipulation",
                "type": "OTHER"
            },
            {
                "start": 1587,
                "end": 1632,
                "text": "grade A and grade B mobilization applications",
                "type": "OTHER"
            },
            {
                "start": 1890,
                "end": 1901,
                "text": "Parkinson's",
                "type": "CONDITION"
            },
            {
                "start": 1998,
                "end": 2022,
                "text": "lumbosacral mobilization",
                "type": "OTHER"
            },
            {
                "start": 2083,
                "end": 2102,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03506906",
        "study_official_title": "The Debated Role of Sleep Studies in Patients Under Established Home Mechanical Ventilation ",
        "study_brief_summary": " Patients suffering chronic hypercapnic respiratory insufficiency (e.g. in chronic obstructive pulmonary disease, obesity hypoventilation syndrome) benefit from home mechanical ventilation. These patients are complex; and the ventilator\u00b4s parameters should be set-up according to the underlying disease and particular patient's characteristics. The non-invasive ventilation therapy is mostly titrated while the patient is awake, hence Problems, such as Patient-Ventilator asynchrony, arising while sleeping on the ventilator therapy would remain undetected.\n\nSleep studies, such as polysomnography or polygraphy and transcutaneous carbon dioxide monitoring could be valuable tools to fine-tune the ventilator's settings. This could foster the ventilator\u00b4s effectivity and patient satisfaction, thus therapy's adherence. Nevertheless the sleep studies are expensive, time-consuming and not widely available.\n\nThe aim of this study is to learn the findings of sleep studies when they are performed on stable patients on home mechanical ventilation as part of their routine check-ups. In this context, it will be assessed whether the sleep studies' findings lead to a change (adjustment) of the ventilator\u00b4s therapy. Moreover, this study aims to investigate whether the absence of sleep studies would result in missing important events that require an adjustment of therapy. The results of this study could provide information that lead to a more standardized protocol of follow-up checks of patients on home mechanical ventilation in a cost-effective manner.",
        "text": "The Debated Role of Sleep Studies in Patients Under Established Home Mechanical Ventilation | Patients suffering chronic hypercapnic respiratory insufficiency (e.g. in chronic obstructive pulmonary disease, obesity hypoventilation syndrome) benefit from home mechanical ventilation. These patients are complex; and the ventilator\u00b4s parameters should be set-up according to the underlying disease and particular patient's characteristics. The non-invasive ventilation therapy is mostly titrated while the patient is awake, hence Problems, such as Patient-Ventilator asynchrony, arising while sleeping on the ventilator therapy would remain undetected.\n\nSleep studies, such as polysomnography or polygraphy and transcutaneous carbon dioxide monitoring could be valuable tools to fine-tune the ventilator's settings. This could foster the ventilator\u00b4s effectivity and patient satisfaction, thus therapy's adherence. Nevertheless the sleep studies are expensive, time-consuming and not widely available.\n\nThe aim of this study is to learn the findings of sleep studies when they are performed on stable patients on home mechanical ventilation as part of their routine check-ups. In this context, it will be assessed whether the sleep studies' findings lead to a change (adjustment) of the ventilator\u00b4s therapy. Moreover, this study aims to investigate whether the absence of sleep studies would result in missing important events that require an adjustment of therapy. The results of this study could provide information that lead to a more standardized protocol of follow-up checks of patients on home mechanical ventilation in a cost-effective manner.",
        "tokens": "['The', 'Debated', 'Role', 'of', 'Sleep', 'Studies', 'in', 'Patients', 'Under', 'Established', 'Home', 'Mechanical', 'Ventilation', '|', 'Patients', 'suffering', 'chronic', 'hypercapnic', 'respiratory', 'insufficiency', '(', 'e.g.', 'in', 'chronic', 'obstructive', 'pulmonary', 'disease', ',', 'obesity', 'hypoventilation', 'syndrome', ')', 'benefit', 'from', 'home', 'mechanical', 'ventilation', '.', 'These', 'patients', 'are', 'complex', ';', 'and', 'the', 'ventilator\u00b4s', 'parameters', 'should', 'be', 'set', '-', 'up', 'according', 'to', 'the', 'underlying', 'disease', 'and', 'particular', 'patient', \"'s\", 'characteristics', '.', 'The', 'non', '-', 'invasive', 'ventilation', 'therapy', 'is', 'mostly', 'titrated', 'while', 'the', 'patient', 'is', 'awake', ',', 'hence', 'Problems', ',', 'such', 'as', 'Patient', '-', 'Ventilator', 'asynchrony', ',', 'arising', 'while', 'sleeping', 'on', 'the', 'ventilator', 'therapy', 'would', 'remain', 'undetected', '.', '\\n\\n', 'Sleep', 'studies', ',', 'such', 'as', 'polysomnography', 'or', 'polygraphy', 'and', 'transcutaneous', 'carbon', 'dioxide', 'monitoring', 'could', 'be', 'valuable', 'tools', 'to', 'fine', '-', 'tune', 'the', 'ventilator', \"'s\", 'settings', '.', 'This', 'could', 'foster', 'the', 'ventilator\u00b4s', 'effectivity', 'and', 'patient', 'satisfaction', ',', 'thus', 'therapy', \"'s\", 'adherence', '.', 'Nevertheless', 'the', 'sleep', 'studies', 'are', 'expensive', ',', 'time', '-', 'consuming', 'and', 'not', 'widely', 'available', '.', '\\n\\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'learn', 'the', 'findings', 'of', 'sleep', 'studies', 'when', 'they', 'are', 'performed', 'on', 'stable', 'patients', 'on', 'home', 'mechanical', 'ventilation', 'as', 'part', 'of', 'their', 'routine', 'check', '-', 'ups', '.', 'In', 'this', 'context', ',', 'it', 'will', 'be', 'assessed', 'whether', 'the', 'sleep', 'studies', \"'\", 'findings', 'lead', 'to', 'a', 'change', '(', 'adjustment', ')', 'of', 'the', 'ventilator\u00b4s', 'therapy', '.', 'Moreover', ',', 'this', 'study', 'aims', 'to', 'investigate', 'whether', 'the', 'absence', 'of', 'sleep', 'studies', 'would', 'result', 'in', 'missing', 'important', 'events', 'that', 'require', 'an', 'adjustment', 'of', 'therapy', '.', 'The', 'results', 'of', 'this', 'study', 'could', 'provide', 'information', 'that', 'lead', 'to', 'a', 'more', 'standardized', 'protocol', 'of', 'follow', '-', 'up', 'checks', 'of', 'patients', 'on', 'home', 'mechanical', 'ventilation', 'in', 'a', 'cost', '-', 'effective', 'manner', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 64,
                "end": 91,
                "text": "Home Mechanical Ventilation",
                "type": "OTHER"
            },
            {
                "start": 113,
                "end": 158,
                "text": "chronic hypercapnic respiratory insufficiency",
                "type": "CONDITION"
            },
            {
                "start": 168,
                "end": 205,
                "text": "chronic obstructive pulmonary disease",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 239,
                "text": "obesity hypoventilation syndrome",
                "type": "CONDITION"
            },
            {
                "start": 254,
                "end": 281,
                "text": "home mechanical ventilation",
                "type": "OTHER"
            },
            {
                "start": 442,
                "end": 474,
                "text": "non-invasive ventilation therapy",
                "type": "OTHER"
            },
            {
                "start": 607,
                "end": 625,
                "text": "ventilator therapy",
                "type": "OTHER"
            },
            {
                "start": 1111,
                "end": 1138,
                "text": "home mechanical ventilation",
                "type": "OTHER"
            },
            {
                "start": 1285,
                "end": 1305,
                "text": "ventilator\u00b4s therapy",
                "type": "OTHER"
            },
            {
                "start": 1599,
                "end": 1621,
                "text": "mechanical ventilation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02499900",
        "study_official_title": "CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily ",
        "study_brief_summary": " The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.",
        "text": "CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily | The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.",
        "tokens": "['CONFIDENCE', ':', 'A', 'Multinational', ',', 'Multicenter', ',', 'Randomized', ',', 'Parallel', 'Group', ',', 'Open', '-', 'Label', 'Study', 'to', 'Assess', 'Medication', 'Satisfaction', 'in', 'Patients', 'With', 'Relapsing', 'Remitting', 'Multiple', 'Sclerosis', '(', 'RRMS', ')', 'Treated', 'With', 'Subcutaneous', 'Injections', 'of', 'Copaxone(R', ')', '(', 'Glatiramer', 'Acetate', ')', '40', 'mg', '/', 'mL', 'Three', 'Times', 'a', 'Week', 'Compared', 'to', '20', 'mg', '/', 'mL', 'Daily', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'patient', 'medication', 'satisfaction', 'as', 'measured', 'by', 'the', 'Medication', 'Satisfaction', 'Questionnaire', '(', 'MSQ', ')', 'scores', 'between', 'the', 'Copaxone', '40', 'mg', '/', 'mL', 'three', 'time', 'a', 'week', '(', 'TIW', ')', 'group', 'and', 'the', 'Copaxone', '20', 'mg', '/', 'mL', 'once', 'daily', '(', 'QD', ')', 'group', 'over', '6', 'months', 'of', 'treatment', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 138,
                "end": 176,
                "text": "Relapsing Remitting Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 182,
                "text": "RRMS",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 235,
                "text": "Copaxone(R)",
                "type": "DRUG"
            },
            {
                "start": 237,
                "end": 255,
                "text": "Glatiramer Acetate",
                "type": "DRUG"
            },
            {
                "start": 478,
                "end": 486,
                "text": "Copaxone",
                "type": "DRUG"
            },
            {
                "start": 534,
                "end": 542,
                "text": "Copaxone",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04855825",
        "study_official_title": "Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS ",
        "study_brief_summary": " The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. The study will evaluate the mobility, learning and memory, and walking abilities of individuals with multiple sclerosis who went through the traditional as compared to others who used the robotic exoskeleton as part of their therapy.",
        "text": "Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS | The purpose of this research study is to evaluate the usefulness of a wearable robotic exoskeleton device (Ekso-GT), to improve learning and memory, and gait therapy in persons with walking disability due to Multiple Sclerosis. The study will evaluate the mobility, learning and memory, and walking abilities of individuals with multiple sclerosis who went through the traditional as compared to others who used the robotic exoskeleton as part of their therapy.",
        "tokens": "['Investigating', 'the', 'Effects', 'of', 'Wearable', 'Robotic', 'Exoskeleton', 'for', 'Improving', 'Mobility', 'and', 'Cognition', 'in', 'Persons', 'With', 'MS', '|', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'evaluate', 'the', 'usefulness', 'of', 'a', 'wearable', 'robotic', 'exoskeleton', 'device', '(', 'Ekso', '-', 'GT', ')', ',', 'to', 'improve', 'learning', 'and', 'memory', ',', 'and', 'gait', 'therapy', 'in', 'persons', 'with', 'walking', 'disability', 'due', 'to', 'Multiple', 'Sclerosis', '.', 'The', 'study', 'will', 'evaluate', 'the', 'mobility', ',', 'learning', 'and', 'memory', ',', 'and', 'walking', 'abilities', 'of', 'individuals', 'with', 'multiple', 'sclerosis', 'who', 'went', 'through', 'the', 'traditional', 'as', 'compared', 'to', 'others', 'who', 'used', 'the', 'robotic', 'exoskeleton', 'as', 'part', 'of', 'their', 'therapy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 57,
                "text": "Wearable Robotic Exoskeleton",
                "type": "PHYSICAL"
            },
            {
                "start": 111,
                "end": 113,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 221,
                "text": "robotic exoskeleton device",
                "type": "PHYSICAL"
            },
            {
                "start": 223,
                "end": 230,
                "text": "Ekso-GT",
                "type": "PHYSICAL"
            },
            {
                "start": 298,
                "end": 316,
                "text": "walking disability",
                "type": "CONDITION"
            },
            {
                "start": 324,
                "end": 342,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 445,
                "end": 463,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 485,
                "end": 496,
                "text": "traditional",
                "type": "CONTROL"
            },
            {
                "start": 532,
                "end": 551,
                "text": "robotic exoskeleton",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT02368366",
        "study_official_title": "Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI ",
        "study_brief_summary": " Traumatic brain injury (TBI) is the most common cause of acquired disability in youth and a source of significant morbidity and family burden. Novel behavior problems are among the most common and problematic consequences, yet many youth fail to receive needed psychological services due to lack of identification and access. Linking youth with TBI to effective treatments could improve functional outcomes, reduce family burden, and increase treatment satisfaction. The investigators overarching aim is to compare the effectiveness, feasibility, and acceptability of three formats of family problem solving therapy (F-PST) for improving functional outcomes of complicated mild to severe adolescent TBI: therapist-guided, face-to-face; therapist-guided online; and self-guided, online F-PST.",
        "text": "Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI | Traumatic brain injury (TBI) is the most common cause of acquired disability in youth and a source of significant morbidity and family burden. Novel behavior problems are among the most common and problematic consequences, yet many youth fail to receive needed psychological services due to lack of identification and access. Linking youth with TBI to effective treatments could improve functional outcomes, reduce family burden, and increase treatment satisfaction. The investigators overarching aim is to compare the effectiveness, feasibility, and acceptability of three formats of family problem solving therapy (F-PST) for improving functional outcomes of complicated mild to severe adolescent TBI: therapist-guided, face-to-face; therapist-guided online; and self-guided, online F-PST.",
        "tokens": "['Comparative', 'Effectiveness', 'of', 'Family', 'Problem', '-', 'Solving', 'Therapy', '(', 'F', '-', 'PST', ')', 'for', 'Adolescent', 'TBI', '|', 'Traumatic', 'brain', 'injury', '(', 'TBI', ')', 'is', 'the', 'most', 'common', 'cause', 'of', 'acquired', 'disability', 'in', 'youth', 'and', 'a', 'source', 'of', 'significant', 'morbidity', 'and', 'family', 'burden', '.', 'Novel', 'behavior', 'problems', 'are', 'among', 'the', 'most', 'common', 'and', 'problematic', 'consequences', ',', 'yet', 'many', 'youth', 'fail', 'to', 'receive', 'needed', 'psychological', 'services', 'due', 'to', 'lack', 'of', 'identification', 'and', 'access', '.', 'Linking', 'youth', 'with', 'TBI', 'to', 'effective', 'treatments', 'could', 'improve', 'functional', 'outcomes', ',', 'reduce', 'family', 'burden', ',', 'and', 'increase', 'treatment', 'satisfaction', '.', 'The', 'investigators', 'overarching', 'aim', 'is', 'to', 'compare', 'the', 'effectiveness', ',', 'feasibility', ',', 'and', 'acceptability', 'of', 'three', 'formats', 'of', 'family', 'problem', 'solving', 'therapy', '(', 'F', '-', 'PST', ')', 'for', 'improving', 'functional', 'outcomes', 'of', 'complicated', 'mild', 'to', 'severe', 'adolescent', 'TBI', ':', 'therapist', '-', 'guided', ',', 'face', '-', 'to', '-', 'face', ';', 'therapist', '-', 'guided', 'online', ';', 'and', 'self', '-', 'guided', ',', 'online', 'F', '-', 'PST', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'B-BEH', 'I-BEH', 'I-BEH', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 59,
                "text": "Family Problem-Solving Therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 61,
                "end": 66,
                "text": "F-PST",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 83,
                "end": 86,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 89,
                "end": 111,
                "text": "Traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 116,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 434,
                "end": 437,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 674,
                "end": 704,
                "text": "family problem solving therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 706,
                "end": 711,
                "text": "F-PST",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 762,
                "end": 791,
                "text": "mild to severe adolescent TBI",
                "type": "CONDITION"
            },
            {
                "start": 793,
                "end": 823,
                "text": "therapist-guided, face-to-face",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 825,
                "end": 848,
                "text": "therapist-guided online",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 854,
                "end": 873,
                "text": "self-guided, online",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 874,
                "end": 879,
                "text": "F-PST",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT03333720",
        "study_official_title": "Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria ",
        "study_brief_summary": " Thirty eligible PKU patients (\u2265 8 years), identified as tablet protein substitute users, will be recruited. Patients will firstly observe a 7-day baseline period, in which participants will continue with their existing diet, protein substitute and multi vitamin prescription. Patients will then receive the phaenylalanine-free protein substitute tablets daily for 28 days in addition to appropriate nutritional management. The aim of this prospective, single arm trial is to evaluate the acceptability (compliance, tolerance and palatability) of the phenylalanine-free protein substitute tablets in patients with proven PKU. The primary outcome measure is compliance, with secondary outcome measures of gastrointestinal tolerance, acceptability, blood amino acids, dietary intake, anthropometry and safety.",
        "text": "Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria | Thirty eligible PKU patients (\u2265 8 years), identified as tablet protein substitute users, will be recruited. Patients will firstly observe a 7-day baseline period, in which participants will continue with their existing diet, protein substitute and multi vitamin prescription. Patients will then receive the phaenylalanine-free protein substitute tablets daily for 28 days in addition to appropriate nutritional management. The aim of this prospective, single arm trial is to evaluate the acceptability (compliance, tolerance and palatability) of the phenylalanine-free protein substitute tablets in patients with proven PKU. The primary outcome measure is compliance, with secondary outcome measures of gastrointestinal tolerance, acceptability, blood amino acids, dietary intake, anthropometry and safety.",
        "tokens": "['Compliance', ',', 'Tolerance', 'and', 'Acceptability', 'of', 'a', 'Tablet', 'Protein', 'Substitute', 'for', 'the', 'Dietary', 'Management', 'of', 'Phenylketonuria', '|', 'Thirty', 'eligible', 'PKU', 'patients', '(', '\u2265', '8', 'years', ')', ',', 'identified', 'as', 'tablet', 'protein', 'substitute', 'users', ',', 'will', 'be', 'recruited', '.', 'Patients', 'will', 'firstly', 'observe', 'a', '7', '-', 'day', 'baseline', 'period', ',', 'in', 'which', 'participants', 'will', 'continue', 'with', 'their', 'existing', 'diet', ',', 'protein', 'substitute', 'and', 'multi', 'vitamin', 'prescription', '.', 'Patients', 'will', 'then', 'receive', 'the', 'phaenylalanine', '-', 'free', 'protein', 'substitute', 'tablets', 'daily', 'for', '28', 'days', 'in', 'addition', 'to', 'appropriate', 'nutritional', 'management', '.', 'The', 'aim', 'of', 'this', 'prospective', ',', 'single', 'arm', 'trial', 'is', 'to', 'evaluate', 'the', 'acceptability', '(', 'compliance', ',', 'tolerance', 'and', 'palatability', ')', 'of', 'the', 'phenylalanine', '-', 'free', 'protein', 'substitute', 'tablets', 'in', 'patients', 'with', 'proven', 'PKU', '.', 'The', 'primary', 'outcome', 'measure', 'is', 'compliance', ',', 'with', 'secondary', 'outcome', 'measures', 'of', 'gastrointestinal', 'tolerance', ',', 'acceptability', ',', 'blood', 'amino', 'acids', ',', 'dietary', 'intake', ',', 'anthropometry', 'and', 'safety', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 52,
                "end": 70,
                "text": "Protein Substitute",
                "type": "OTHER"
            },
            {
                "start": 101,
                "end": 116,
                "text": "Phenylketonuria",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 138,
                "text": "PKU",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 200,
                "text": "protein substitute",
                "type": "OTHER"
            },
            {
                "start": 426,
                "end": 464,
                "text": "phaenylalanine-free protein substitute",
                "type": "OTHER"
            },
            {
                "start": 669,
                "end": 706,
                "text": "phenylalanine-free protein substitute",
                "type": "OTHER"
            },
            {
                "start": 739,
                "end": 742,
                "text": "PKU",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02644473",
        "study_official_title": "To evaluate whether there is a difference in symptomatic thromboembolism events in the subset of patients with a history of, or risk factors for thromboembolic disease for topically applied tranexamic acid in total joint arthroplasty.",
        "study_brief_summary": null,
        "text": "To evaluate whether there is a difference in symptomatic thromboembolism events in the subset of patients with a history of, or risk factors for thromboembolic disease for topically applied tranexamic acid in total joint arthroplasty.",
        "tokens": "['To', 'evaluate', 'whether', 'there', 'is', 'a', 'difference', 'in', 'symptomatic', 'thromboembolism', 'events', 'in', 'the', 'subset', 'of', 'patients', 'with', 'a', 'history', 'of', ',', 'or', 'risk', 'factors', 'for', 'thromboembolic', 'disease', 'for', 'topically', 'applied', 'tranexamic', 'acid', 'in', 'total', 'joint', 'arthroplasty', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 45,
                "end": 72,
                "text": "symptomatic thromboembolism",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 167,
                "text": "thromboembolic disease",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 205,
                "text": "tranexamic acid",
                "type": "DRUG"
            },
            {
                "start": 209,
                "end": 233,
                "text": "total joint arthroplasty",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05811494",
        "study_official_title": "Effectiveness of Multiple Robotic Gait-Devices for Improving Walking Ability in Subacute Stroke Patients: A Randomized Controlled Trial ",
        "study_brief_summary": " The purpose of this study is to know the effectiveness of different robotic devices for gait rehabilitation in stroke patients",
        "text": "Effectiveness of Multiple Robotic Gait-Devices for Improving Walking Ability in Subacute Stroke Patients: A Randomized Controlled Trial | The purpose of this study is to know the effectiveness of different robotic devices for gait rehabilitation in stroke patients",
        "tokens": "['Effectiveness', 'of', 'Multiple', 'Robotic', 'Gait', '-', 'Devices', 'for', 'Improving', 'Walking', 'Ability', 'in', 'Subacute', 'Stroke', 'Patients', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'know', 'the', 'effectiveness', 'of', 'different', 'robotic', 'devices', 'for', 'gait', 'rehabilitation', 'in', 'stroke', 'patients']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 46,
                "text": "Robotic Gait-Devices",
                "type": "OTHER"
            },
            {
                "start": 80,
                "end": 95,
                "text": "Subacute Stroke",
                "type": "CONDITION"
            },
            {
                "start": 206,
                "end": 221,
                "text": "robotic devices",
                "type": "OTHER"
            },
            {
                "start": 226,
                "end": 245,
                "text": "gait rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 249,
                "end": 255,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03306875",
        "study_official_title": "Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis ",
        "study_brief_summary": " This study aims to apply baseline MRI and neuropsychological measures to predict patient responses to behavioral cognitive rehabilitation. Training will take place over 12 weeks, 1 hour per day, 5 days per week.\n\nThe investigator hypothesizes the following:\n\n[1a] The investigator expects that individuals with low baseline Conscientiousness will experience a lower magnitude of overall cognitive improvement following rehabilitation\n\nb] The investigator expects the impact of Conscientiousness on fidelity of rehabilitation will in part be moderated by individual differences in program adherence and executive function\na] The investigator expects that individual differences in structural and functional connectome disturbances will in part explain differences in participant responses to cognitive rehabilitation.\n\nThis study will also serve to supplement the sample of participants for the current IRB approved study ((IRB: 603069, Title: A case-control, 5-year follow-up study of cardiovascular, environmental and genetic risk factors for disease progression in patients with multiple sclerosis.",
        "text": "Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis | This study aims to apply baseline MRI and neuropsychological measures to predict patient responses to behavioral cognitive rehabilitation. Training will take place over 12 weeks, 1 hour per day, 5 days per week.\n\nThe investigator hypothesizes the following:\n\n[1a] The investigator expects that individuals with low baseline Conscientiousness will experience a lower magnitude of overall cognitive improvement following rehabilitation\n\nb] The investigator expects the impact of Conscientiousness on fidelity of rehabilitation will in part be moderated by individual differences in program adherence and executive function\na] The investigator expects that individual differences in structural and functional connectome disturbances will in part explain differences in participant responses to cognitive rehabilitation.\n\nThis study will also serve to supplement the sample of participants for the current IRB approved study ((IRB: 603069, Title: A case-control, 5-year follow-up study of cardiovascular, environmental and genetic risk factors for disease progression in patients with multiple sclerosis.",
        "tokens": "['Impact', 'of', 'Brain', 'Connectome', 'and', 'Personality', 'on', 'Cognitive', 'Rehabilitation', 'in', 'Multiple', 'Sclerosis', '|', 'This', 'study', 'aims', 'to', 'apply', 'baseline', 'MRI', 'and', 'neuropsychological', 'measures', 'to', 'predict', 'patient', 'responses', 'to', 'behavioral', 'cognitive', 'rehabilitation', '.', 'Training', 'will', 'take', 'place', 'over', '12', 'weeks', ',', '1', 'hour', 'per', 'day', ',', '5', 'days', 'per', 'week', '.', '\\n\\n', 'The', 'investigator', 'hypothesizes', 'the', 'following', ':', '\\n\\n', '[', '1a', ']', 'The', 'investigator', 'expects', 'that', 'individuals', 'with', 'low', 'baseline', 'Conscientiousness', 'will', 'experience', 'a', 'lower', 'magnitude', 'of', 'overall', 'cognitive', 'improvement', 'following', 'rehabilitation', '\\n\\n', 'b', ']', 'The', 'investigator', 'expects', 'the', 'impact', 'of', 'Conscientiousness', 'on', 'fidelity', 'of', 'rehabilitation', 'will', 'in', 'part', 'be', 'moderated', 'by', 'individual', 'differences', 'in', 'program', 'adherence', 'and', 'executive', 'function', '\\n', 'a', ']', 'The', 'investigator', 'expects', 'that', 'individual', 'differences', 'in', 'structural', 'and', 'functional', 'connectome', 'disturbances', 'will', 'in', 'part', 'explain', 'differences', 'in', 'participant', 'responses', 'to', 'cognitive', 'rehabilitation', '.', '\\n\\n', 'This', 'study', 'will', 'also', 'serve', 'to', 'supplement', 'the', 'sample', 'of', 'participants', 'for', 'the', 'current', 'IRB', 'approved', 'study', '(', '(', 'IRB', ':', '603069', ',', 'Title', ':', 'A', 'case', '-', 'control', ',', '5', '-', 'year', 'follow', '-', 'up', 'study', 'of', 'cardiovascular', ',', 'environmental', 'and', 'genetic', 'risk', 'factors', 'for', 'disease', 'progression', 'in', 'patients', 'with', 'multiple', 'sclerosis', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 46,
                "end": 70,
                "text": "Cognitive Rehabilitation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 74,
                "end": 92,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 197,
                "end": 232,
                "text": "behavioral cognitive rehabilitation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 886,
                "end": 910,
                "text": "cognitive rehabilitation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1176,
                "end": 1194,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02910024",
        "study_official_title": "Theta-Burst-Stimulation in Der fr\u00fchen Rehabilitation Von Schlaganfallpatienten ",
        "study_brief_summary": " The present prospective, randomized, controlled, double-blinded trial investigates the effects of intermittent theta-burst stimulation (iTBS) during the early rehabilitation after stroke. Patients with hemipresis will receive either sham or real iTBS over their affected hemispheres before occupational therapy for 8 days. Motor recovery is assessed one day after the intervention phase and three months after enrollment.",
        "text": "Theta-Burst-Stimulation in Der fr\u00fchen Rehabilitation Von Schlaganfallpatienten | The present prospective, randomized, controlled, double-blinded trial investigates the effects of intermittent theta-burst stimulation (iTBS) during the early rehabilitation after stroke. Patients with hemipresis will receive either sham or real iTBS over their affected hemispheres before occupational therapy for 8 days. Motor recovery is assessed one day after the intervention phase and three months after enrollment.",
        "tokens": "['Theta', '-', 'Burst', '-', 'Stimulation', 'in', 'Der', 'fr\u00fchen', 'Rehabilitation', 'Von', 'Schlaganfallpatienten', '|', 'The', 'present', 'prospective', ',', 'randomized', ',', 'controlled', ',', 'double', '-', 'blinded', 'trial', 'investigates', 'the', 'effects', 'of', 'intermittent', 'theta', '-', 'burst', 'stimulation', '(', 'iTBS', ')', 'during', 'the', 'early', 'rehabilitation', 'after', 'stroke', '.', 'Patients', 'with', 'hemipresis', 'will', 'receive', 'either', 'sham', 'or', 'real', 'iTBS', 'over', 'their', 'affected', 'hemispheres', 'before', 'occupational', 'therapy', 'for', '8', 'days', '.', 'Motor', 'recovery', 'is', 'assessed', 'one', 'day', 'after', 'the', 'intervention', 'phase', 'and', 'three', 'months', 'after', 'enrollment', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 23,
                "text": "Theta-Burst-Stimulation",
                "type": "OTHER"
            },
            {
                "start": 179,
                "end": 215,
                "text": "intermittent theta-burst stimulation",
                "type": "OTHER"
            },
            {
                "start": 217,
                "end": 221,
                "text": "iTBS",
                "type": "OTHER"
            },
            {
                "start": 261,
                "end": 267,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 293,
                "text": "hemipresis",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 318,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 327,
                "end": 331,
                "text": "iTBS",
                "type": "OTHER"
            },
            {
                "start": 371,
                "end": 391,
                "text": "occupational therapy",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02255929",
        "study_official_title": "Gamma Knife Thalamotomy for Treatment of Essential Tremor ",
        "study_brief_summary": " The purpose of this study is to examine effects (good and bad) of gamma knife radiosurgery for essential tremor. The gamma knife places a small lesion in the brain to suppress tremors.",
        "text": "Gamma Knife Thalamotomy for Treatment of Essential Tremor | The purpose of this study is to examine effects (good and bad) of gamma knife radiosurgery for essential tremor. The gamma knife places a small lesion in the brain to suppress tremors.",
        "tokens": "['Gamma', 'Knife', 'Thalamotomy', 'for', 'Treatment', 'of', 'Essential', 'Tremor', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'effects', '(', 'good', 'and', 'bad', ')', 'of', 'gamma', 'knife', 'radiosurgery', 'for', 'essential', 'tremor', '.', 'The', 'gamma', 'knife', 'places', 'a', 'small', 'lesion', 'in', 'the', 'brain', 'to', 'suppress', 'tremors', '.']",
        "token_bio_labels": "['B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 23,
                "text": "Gamma Knife Thalamotomy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 41,
                "end": 57,
                "text": "Essential Tremor",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 150,
                "text": "gamma knife radiosurgery",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 155,
                "end": 171,
                "text": "essential tremor",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 188,
                "text": "gamma knife",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 236,
                "end": 243,
                "text": "tremors",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01313819",
        "study_official_title": "A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy ",
        "study_brief_summary": " Tp determine the effect of IV amantadine on dopaminergic-drug-resistant freezing of gait(FOG)in patients with Parkinson's disease",
        "text": "A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy | Tp determine the effect of IV amantadine on dopaminergic-drug-resistant freezing of gait(FOG)in patients with Parkinson's disease",
        "tokens": "['A', 'Double', 'Blind', ',', 'Placebo', '-', 'controlled', 'Study', 'for', 'the', 'Effect', 'of', 'IV', 'Amantadine', 'on', 'Freezing', 'of', 'Gait', '(', 'FOG', ')', 'Resistant', 'to', 'Dopaminergic', 'Therapy', '|', 'Tp', 'determine', 'the', 'effect', 'of', 'IV', 'amantadine', 'on', 'dopaminergic', '-', 'drug', '-', 'resistant', 'freezing', 'of', 'gait(FOG)in', 'patients', 'with', 'Parkinson', \"'s\", 'disease']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 16,
                "end": 23,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 59,
                "end": 72,
                "text": "IV Amantadine",
                "type": "DRUG"
            },
            {
                "start": 76,
                "end": 92,
                "text": "Freezing of Gait",
                "type": "CONDITION"
            },
            {
                "start": 94,
                "end": 97,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 99,
                "end": 132,
                "text": "Resistant to Dopaminergic Therapy",
                "type": "CONDITION"
            },
            {
                "start": 162,
                "end": 175,
                "text": "IV amantadine",
                "type": "DRUG"
            },
            {
                "start": 245,
                "end": 264,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00364429",
        "study_official_title": "Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study ",
        "study_brief_summary": " This study was designed to compare the [123]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients. Investigation of the potential influence of antipsychotic and concomitant medication on [123I] CNS 1261 binding is also relevant.Fifteen healthy subjects (male and female of non-child bearing potential) will be recruited and 40 schizophrenic patients divided in 3 subgroups as indicated before: Subgroup a) treatment-naive, (n=10); Subgroup b) on stable treatment with risperidone (without criteria of deficit syndrome on the SDS scale, (n=15);Subgroup c) on stable treatment with risperidone fitting criteria of deficit syndrome on the SDS scale, (n=15).",
        "text": "Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study | This study was designed to compare the [123]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients. Investigation of the potential influence of antipsychotic and concomitant medication on [123I] CNS 1261 binding is also relevant.Fifteen healthy subjects (male and female of non-child bearing potential) will be recruited and 40 schizophrenic patients divided in 3 subgroups as indicated before: Subgroup a) treatment-naive, (n=10); Subgroup b) on stable treatment with risperidone (without criteria of deficit syndrome on the SDS scale, (n=15);Subgroup c) on stable treatment with risperidone fitting criteria of deficit syndrome on the SDS scale, (n=15).",
        "tokens": "['Investigation', 'of', 'the', 'NMDA', 'Receptor', 'System', 'in', 'Man', 'as', 'a', 'Potential', 'Surrogate', 'Marker', 'for', 'Deficit', 'Syndrome', 'in', 'Schizophrenia', ':', 'a', '[', '123]I', '-', 'CNS', '1261', 'Single', 'Photon', 'Emission', 'Tomography', '(', 'SPET', ')', 'Study', '|', 'This', 'study', 'was', 'designed', 'to', 'compare', 'the', '[', '123]I', '-', 'CNS', '1261', 'binding', 'to', 'NMDA', 'receptor', 'between', 'healthy', 'volunteers', 'and', 'different', 'subgroups', 'of', 'schizophrenic', 'patients', '.', 'Investigation', 'of', 'the', 'potential', 'influence', 'of', 'antipsychotic', 'and', 'concomitant', 'medication', 'on', '[', '123I', ']', 'CNS', '1261', 'binding', 'is', 'also', 'relevant', '.', 'Fifteen', 'healthy', 'subjects', '(', 'male', 'and', 'female', 'of', 'non', '-', 'child', 'bearing', 'potential', ')', 'will', 'be', 'recruited', 'and', '40', 'schizophrenic', 'patients', 'divided', 'in', '3', 'subgroups', 'as', 'indicated', 'before', ':', 'Subgroup', 'a', ')', 'treatment', '-', 'naive', ',', '(', 'n=10', ')', ';', 'Subgroup', 'b', ')', 'on', 'stable', 'treatment', 'with', 'risperidone', '(', 'without', 'criteria', 'of', 'deficit', 'syndrome', 'on', 'the', 'SDS', 'scale', ',', '(', 'n=15);Subgroup', 'c', ')', 'on', 'stable', 'treatment', 'with', 'risperidone', 'fitting', 'criteria', 'of', 'deficit', 'syndrome', 'on', 'the', 'SDS', 'scale', ',', '(', 'n=15', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 85,
                "end": 101,
                "text": "Deficit Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 105,
                "end": 118,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 321,
                "end": 334,
                "text": "schizophrenic",
                "type": "CONDITION"
            },
            {
                "start": 389,
                "end": 402,
                "text": "antipsychotic",
                "type": "DRUG"
            },
            {
                "start": 573,
                "end": 586,
                "text": "schizophrenic",
                "type": "CONDITION"
            },
            {
                "start": 714,
                "end": 725,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 747,
                "end": 763,
                "text": "deficit syndrome",
                "type": "CONDITION"
            },
            {
                "start": 826,
                "end": 837,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 858,
                "end": 874,
                "text": "deficit syndrome",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00217763",
        "study_official_title": "A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimer's Disease ",
        "study_brief_summary": " The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.",
        "text": "A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimer's Disease | The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.",
        "tokens": "['A', 'Phase', 'III', 'Study', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', '3APS', 'as', 'Add', '-', 'on', 'Therapy', 'in', 'Mild', 'to', 'Moderate', 'Alzheimer', \"'s\", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'Phase', '3', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', '3APS', 'as', 'an', 'add', '-', 'on', 'therapy', 'to', 'most', 'standard', 'medication', 'for', 'Alzheimer', \"'s\", 'disease', 'compared', 'to', 'placebo', '(', 'inactive', 'substance', 'pill', ')', 'in', 'patients', 'with', 'mild', 'to', 'moderate', 'Alzheimer', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 48,
                "end": 52,
                "text": "3APS",
                "type": "DRUG"
            },
            {
                "start": 74,
                "end": 110,
                "text": "Mild to Moderate Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 193,
                "text": "3APS",
                "type": "DRUG"
            },
            {
                "start": 247,
                "end": 266,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 288,
                "end": 311,
                "text": "inactive substance pill",
                "type": "CONTROL"
            },
            {
                "start": 330,
                "end": 366,
                "text": "mild to moderate Alzheimer's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03900000",
        "study_official_title": "Improved Orthostatic Tolerance = Better Cognitive Function in Parkinson's Disease: Does a Successful Treatment of Orthostatic Hypotension Measurably Enhance Attention and Memory Functions in Parkinson's Disease ",
        "study_brief_summary": " Study on orthostatic Hypotension in Parkinson's disease",
        "text": "Improved Orthostatic Tolerance = Better Cognitive Function in Parkinson's Disease: Does a Successful Treatment of Orthostatic Hypotension Measurably Enhance Attention and Memory Functions in Parkinson's Disease | Study on orthostatic Hypotension in Parkinson's disease",
        "tokens": "['Improved', 'Orthostatic', 'Tolerance', '=', 'Better', 'Cognitive', 'Function', 'in', 'Parkinson', \"'s\", 'Disease', ':', 'Does', 'a', 'Successful', 'Treatment', 'of', 'Orthostatic', 'Hypotension', 'Measurably', 'Enhance', 'Attention', 'and', 'Memory', 'Functions', 'in', 'Parkinson', \"'s\", 'Disease', '|', 'Study', 'on', 'orthostatic', 'Hypotension', 'in', 'Parkinson', \"'s\", 'disease']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 62,
                "end": 81,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 101,
                "end": 137,
                "text": "Treatment of Orthostatic Hypotension",
                "type": "OTHER"
            },
            {
                "start": 191,
                "end": 210,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 249,
                "end": 268,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02582138",
        "study_official_title": "Sarcopenia and Physical fRailty IN Older People: Multi-componenT Treatment Strategies (SPRINTT) ",
        "study_brief_summary": " The SPRINTT study will evaluate the efficacy of a multicomponent intervention programme (physical activity, nutritional counselling/dietary intervention, and information and communications technology intervention) compared with a healthy aging lifestyle education programme on mobility disability, in non-disabled older people with physical frailty and sarcopenia.",
        "text": "Sarcopenia and Physical fRailty IN Older People: Multi-componenT Treatment Strategies (SPRINTT) | The SPRINTT study will evaluate the efficacy of a multicomponent intervention programme (physical activity, nutritional counselling/dietary intervention, and information and communications technology intervention) compared with a healthy aging lifestyle education programme on mobility disability, in non-disabled older people with physical frailty and sarcopenia.",
        "tokens": "['Sarcopenia', 'and', 'Physical', 'fRailty', 'IN', 'Older', 'People', ':', 'Multi', '-', 'componenT', 'Treatment', 'Strategies', '(', 'SPRINTT', ')', '|', 'The', 'SPRINTT', 'study', 'will', 'evaluate', 'the', 'efficacy', 'of', 'a', 'multicomponent', 'intervention', 'programme', '(', 'physical', 'activity', ',', 'nutritional', 'counselling', '/', 'dietary', 'intervention', ',', 'and', 'information', 'and', 'communications', 'technology', 'intervention', ')', 'compared', 'with', 'a', 'healthy', 'aging', 'lifestyle', 'education', 'programme', 'on', 'mobility', 'disability', ',', 'in', 'non', '-', 'disabled', 'older', 'people', 'with', 'physical', 'frailty', 'and', 'sarcopenia', '.']",
        "token_bio_labels": "['B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 10,
                "text": "Sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 15,
                "end": 31,
                "text": "Physical fRailty",
                "type": "CONDITION"
            },
            {
                "start": 49,
                "end": 85,
                "text": "Multi-componenT Treatment Strategies",
                "type": "OTHER"
            },
            {
                "start": 148,
                "end": 185,
                "text": "multicomponent intervention programme",
                "type": "OTHER"
            },
            {
                "start": 187,
                "end": 204,
                "text": "physical activity",
                "type": "OTHER"
            },
            {
                "start": 206,
                "end": 250,
                "text": "nutritional counselling/dietary intervention",
                "type": "OTHER"
            },
            {
                "start": 256,
                "end": 310,
                "text": "information and communications technology intervention",
                "type": "OTHER"
            },
            {
                "start": 328,
                "end": 371,
                "text": "healthy aging lifestyle education programme",
                "type": "CONTROL"
            },
            {
                "start": 375,
                "end": 394,
                "text": "mobility disability",
                "type": "CONDITION"
            },
            {
                "start": 430,
                "end": 446,
                "text": "physical frailty",
                "type": "CONDITION"
            },
            {
                "start": 451,
                "end": 461,
                "text": "sarcopenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04728295",
        "study_official_title": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD) ",
        "study_brief_summary": " Evaluate the Safety and Effectiveness of Staged Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD).",
        "text": "Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD) | Evaluate the Safety and Effectiveness of Staged Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD).",
        "tokens": "['Evaluation', 'of', 'the', 'Safety', 'and', 'Effectiveness', 'of', 'Bilateral', 'Exablate', 'Ablation', 'of', 'the', 'Pallidothalamic', 'Tract', '(', 'PTT', ')', 'for', 'the', 'Treatment', 'of', 'the', 'Motor', 'Complications', 'of', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', '|', 'Evaluate', 'the', 'Safety', 'and', 'Effectiveness', 'of', 'Staged', 'Bilateral', 'Exablate', 'Ablation', 'of', 'the', 'Pallidothalamic', 'Tract', '(', 'PTT', ')', 'for', 'the', 'Treatment', 'of', 'the', 'Motor', 'Complications', 'of', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 46,
                "end": 102,
                "text": "Bilateral Exablate Ablation of the Pallidothalamic Tract",
                "type": "OTHER"
            },
            {
                "start": 104,
                "end": 107,
                "text": "PTT",
                "type": "OTHER"
            },
            {
                "start": 134,
                "end": 153,
                "text": "Motor Complications",
                "type": "CONDITION"
            },
            {
                "start": 157,
                "end": 176,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 180,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 232,
                "end": 288,
                "text": "Bilateral Exablate Ablation of the Pallidothalamic Tract",
                "type": "OTHER"
            },
            {
                "start": 290,
                "end": 293,
                "text": "PTT",
                "type": "OTHER"
            },
            {
                "start": 320,
                "end": 339,
                "text": "Motor Complications",
                "type": "CONDITION"
            },
            {
                "start": 343,
                "end": 362,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 364,
                "end": 366,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03716206",
        "study_official_title": "Effects of Exergames on Post-stroke Shoulder Pain and Motor Function ",
        "study_brief_summary": " This study is to investigate the effects of exergame on shoulder pain and motor function of upper extremity in individuals with stroke.",
        "text": "Effects of Exergames on Post-stroke Shoulder Pain and Motor Function | This study is to investigate the effects of exergame on shoulder pain and motor function of upper extremity in individuals with stroke.",
        "tokens": "['Effects', 'of', 'Exergames', 'on', 'Post', '-', 'stroke', 'Shoulder', 'Pain', 'and', 'Motor', 'Function', '|', 'This', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'exergame', 'on', 'shoulder', 'pain', 'and', 'motor', 'function', 'of', 'upper', 'extremity', 'in', 'individuals', 'with', 'stroke', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 20,
                "text": "Exergames",
                "type": "PHYSICAL"
            },
            {
                "start": 29,
                "end": 35,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 36,
                "end": 49,
                "text": "Shoulder Pain",
                "type": "CONDITION"
            },
            {
                "start": 115,
                "end": 123,
                "text": "exergame",
                "type": "PHYSICAL"
            },
            {
                "start": 127,
                "end": 140,
                "text": "shoulder pain",
                "type": "CONDITION"
            },
            {
                "start": 199,
                "end": 205,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05301335",
        "study_official_title": "Transformation of Dormant Spinal Networks to Mitigate Symptoms of Neurogenic Bladder ",
        "study_brief_summary": " The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction",
        "text": "Transformation of Dormant Spinal Networks to Mitigate Symptoms of Neurogenic Bladder | The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction",
        "tokens": "['Transformation', 'of', 'Dormant', 'Spinal', 'Networks', 'to', 'Mitigate', 'Symptoms', 'of', 'Neurogenic', 'Bladder', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'SCONE', 'neuromodulation', 'therapy', 'after', '12', 'weeks', 'of', 'therapy', 'in', 'comparison', 'to', 'inactive', 'sham', 'control', 'in', 'improving', 'symptoms', 'of', 'Neurogenic', 'Lower', 'Urinary', 'Tract', 'Dysfunction']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 0,
                "end": 41,
                "text": "Transformation of Dormant Spinal Networks",
                "type": "OTHER"
            },
            {
                "start": 66,
                "end": 84,
                "text": "Neurogenic Bladder",
                "type": "CONDITION"
            },
            {
                "start": 160,
                "end": 189,
                "text": "SCONE neuromodulation therapy",
                "type": "OTHER"
            },
            {
                "start": 233,
                "end": 246,
                "text": "inactive sham",
                "type": "CONTROL"
            },
            {
                "start": 280,
                "end": 322,
                "text": "Neurogenic Lower Urinary Tract Dysfunction",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05637957",
        "study_official_title": "The Feasibility of Transcranial Direct Current Stimulation as an Adjunct to Outpatient Physiotherapy in Children With Acquired Brain Injury ",
        "study_brief_summary": " This study will evaluate the feasibility of transcranial direct current stimulation (tDCS) as an adjunct to an outpatient motor skills-based physiotherapy intervention for children and youth with acquired brain injury. Up to 10 children (age 5-18 years) with childhood onset stroke or traumatic brain injury will be randomly allocated to receive active or sham anodal tDCS immediately prior to the physiotherapy session. These sessions will occur twice weekly for a total of 10 sessions. Assessment of gross motor outcome measures will occur immediately before and after the combined tDCS and physiotherapy treatment protocol. The preliminary treatment effect between the two treatment groups will be compared and other feasibility indicators will be evaluated.",
        "text": "The Feasibility of Transcranial Direct Current Stimulation as an Adjunct to Outpatient Physiotherapy in Children With Acquired Brain Injury | This study will evaluate the feasibility of transcranial direct current stimulation (tDCS) as an adjunct to an outpatient motor skills-based physiotherapy intervention for children and youth with acquired brain injury. Up to 10 children (age 5-18 years) with childhood onset stroke or traumatic brain injury will be randomly allocated to receive active or sham anodal tDCS immediately prior to the physiotherapy session. These sessions will occur twice weekly for a total of 10 sessions. Assessment of gross motor outcome measures will occur immediately before and after the combined tDCS and physiotherapy treatment protocol. The preliminary treatment effect between the two treatment groups will be compared and other feasibility indicators will be evaluated.",
        "tokens": "['The', 'Feasibility', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'as', 'an', 'Adjunct', 'to', 'Outpatient', 'Physiotherapy', 'in', 'Children', 'With', 'Acquired', 'Brain', 'Injury', '|', 'This', 'study', 'will', 'evaluate', 'the', 'feasibility', 'of', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'as', 'an', 'adjunct', 'to', 'an', 'outpatient', 'motor', 'skills', '-', 'based', 'physiotherapy', 'intervention', 'for', 'children', 'and', 'youth', 'with', 'acquired', 'brain', 'injury', '.', 'Up', 'to', '10', 'children', '(', 'age', '5', '-', '18', 'years', ')', 'with', 'childhood', 'onset', 'stroke', 'or', 'traumatic', 'brain', 'injury', 'will', 'be', 'randomly', 'allocated', 'to', 'receive', 'active', 'or', 'sham', 'anodal', 'tDCS', 'immediately', 'prior', 'to', 'the', 'physiotherapy', 'session', '.', 'These', 'sessions', 'will', 'occur', 'twice', 'weekly', 'for', 'a', 'total', 'of', '10', 'sessions', '.', 'Assessment', 'of', 'gross', 'motor', 'outcome', 'measures', 'will', 'occur', 'immediately', 'before', 'and', 'after', 'the', 'combined', 'tDCS', 'and', 'physiotherapy', 'treatment', 'protocol', '.', 'The', 'preliminary', 'treatment', 'effect', 'between', 'the', 'two', 'treatment', 'groups', 'will', 'be', 'compared', 'and', 'other', 'feasibility', 'indicators', 'will', 'be', 'evaluated', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 19,
                "end": 58,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 76,
                "end": 100,
                "text": "Outpatient Physiotherapy",
                "type": "PHYSICAL"
            },
            {
                "start": 118,
                "end": 139,
                "text": "Acquired Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 186,
                "end": 225,
                "text": "transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 227,
                "end": 231,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 253,
                "end": 309,
                "text": "outpatient motor skills-based physiotherapy intervention",
                "type": "PHYSICAL"
            },
            {
                "start": 338,
                "end": 359,
                "text": "acquired brain injury",
                "type": "CONDITION"
            },
            {
                "start": 417,
                "end": 423,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 427,
                "end": 449,
                "text": "traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 498,
                "end": 514,
                "text": "sham anodal tDCS",
                "type": "CONTROL"
            },
            {
                "start": 540,
                "end": 561,
                "text": "physiotherapy session",
                "type": "OTHER"
            },
            {
                "start": 726,
                "end": 730,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 735,
                "end": 767,
                "text": "physiotherapy treatment protocol",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03865953",
        "study_official_title": "A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain ",
        "study_brief_summary": " This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.",
        "text": "A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain | This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.",
        "tokens": "['A', 'Phase', 'IIa', 'Study', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Oral', 'LAT8881', 'in', 'Neuropathic', 'Pain', '|', 'This', 'is', 'a', 'randomised', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blind', ',', 'crossover', ',', 'phase', 'IIa', 'study', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'oral', 'LAT8881', 'in', 'neuropathic', 'pain', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 53,
                "end": 60,
                "text": "LAT8881",
                "type": "DRUG"
            },
            {
                "start": 64,
                "end": 80,
                "text": "Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 105,
                "end": 112,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 213,
                "end": 220,
                "text": "LAT8881",
                "type": "DRUG"
            },
            {
                "start": 224,
                "end": 240,
                "text": "neuropathic pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01942590",
        "study_official_title": "A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy ",
        "study_brief_summary": " Funding Source- FDA OOPD\n\nThe purpose of this study is to investigate the safety and efficacy of clenbuterol on motor function in individuals with late-onset Pompe disease (LOPD) who are treated with enzyme replacement therapy (ERT).",
        "text": "A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy | Funding Source- FDA OOPD\n\nThe purpose of this study is to investigate the safety and efficacy of clenbuterol on motor function in individuals with late-onset Pompe disease (LOPD) who are treated with enzyme replacement therapy (ERT).",
        "tokens": "['A', 'Clinical', 'Investigation', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Clenbuterol', 'on', 'Motor', 'Function', 'in', 'Individuals', 'With', 'Late', '-', 'onset', 'Pompe', 'Disease', 'and', 'Receiving', 'Enzyme', 'Replacement', 'Therapy', '|', 'Funding', 'Source-', 'FDA', 'OOPD', '\\n\\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'safety', 'and', 'efficacy', 'of', 'clenbuterol', 'on', 'motor', 'function', 'in', 'individuals', 'with', 'late', '-', 'onset', 'Pompe', 'disease', '(', 'LOPD', ')', 'who', 'are', 'treated', 'with', 'enzyme', 'replacement', 'therapy', '(', 'ERT', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 55,
                "end": 66,
                "text": "Clenbuterol",
                "type": "DRUG"
            },
            {
                "start": 105,
                "end": 170,
                "text": "Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy",
                "type": "CONDITION"
            },
            {
                "start": 270,
                "end": 281,
                "text": "clenbuterol",
                "type": "DRUG"
            },
            {
                "start": 320,
                "end": 399,
                "text": "late-onset Pompe disease (LOPD) who are treated with enzyme replacement therapy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00909012",
        "study_official_title": "Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria ",
        "study_brief_summary": " Patients with phenylketonuria (PKU) have an inborn error in the metabolism of the amino acid phenylalanine (Phe) and thus must follow a strictly controlled protein-restricted diet from early infancy. This protein-restricted diet is devoid of natural dietary sources of n-3 long chain polyunsaturated fatty acids (LC-PUFA), such as eggs, meat, milk or fish. Therefore, blood concentrations of n-3 LC-PUFA, especially of docosahexaenoic acid (DHA) are reduced in PKU children compared to healthy controls. DHA availability is considered important for optimal neurological function. Previous studies have shown that neural function of PKU children is improved by high dose supplementation of fish oil providing DHA, as shown by significant improvements of both visual evoked potential latencies and of fine motor skills and coordination, but no dose response relationship has been established so far.\n\nThis multicentric double-blind randomized trial aims at determining quantitative DHA requirements for optimal neural function in PKU children. Patients with classical PKU from several major treatment centers in Europe will be randomized to receive between 0 and 8 mg of DHA per kg body weight daily for a duration of 6 months. Biochemical (fatty acid composition of plasma phospholipids, lipoprotein metabolism and metabolic profiles), and functional testing (visual evoked potentials, fine motor skills, cognitive function and markers of immune function) will be performed at baseline and after 6 months. Intake per kg body weight will be related to outcome parameters and thus a possible dose response relationship will be defined. The results from this study are expected to contribute to the improvement of the diet of PKU patients, but they also have the potential to help defining quantitative DHA needs of healthy children.\n\nThe primary hypothesis is that supplementation with DHA improves visual function in children with PKU.",
        "text": "Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria | Patients with phenylketonuria (PKU) have an inborn error in the metabolism of the amino acid phenylalanine (Phe) and thus must follow a strictly controlled protein-restricted diet from early infancy. This protein-restricted diet is devoid of natural dietary sources of n-3 long chain polyunsaturated fatty acids (LC-PUFA), such as eggs, meat, milk or fish. Therefore, blood concentrations of n-3 LC-PUFA, especially of docosahexaenoic acid (DHA) are reduced in PKU children compared to healthy controls. DHA availability is considered important for optimal neurological function. Previous studies have shown that neural function of PKU children is improved by high dose supplementation of fish oil providing DHA, as shown by significant improvements of both visual evoked potential latencies and of fine motor skills and coordination, but no dose response relationship has been established so far.\n\nThis multicentric double-blind randomized trial aims at determining quantitative DHA requirements for optimal neural function in PKU children. Patients with classical PKU from several major treatment centers in Europe will be randomized to receive between 0 and 8 mg of DHA per kg body weight daily for a duration of 6 months. Biochemical (fatty acid composition of plasma phospholipids, lipoprotein metabolism and metabolic profiles), and functional testing (visual evoked potentials, fine motor skills, cognitive function and markers of immune function) will be performed at baseline and after 6 months. Intake per kg body weight will be related to outcome parameters and thus a possible dose response relationship will be defined. The results from this study are expected to contribute to the improvement of the diet of PKU patients, but they also have the potential to help defining quantitative DHA needs of healthy children.\n\nThe primary hypothesis is that supplementation with DHA improves visual function in children with PKU.",
        "tokens": "['Quantitative', 'Requirements', 'of', 'Docosahexaenoic', 'Acid', 'for', 'Neural', 'Function', 'in', 'Children', 'With', 'Phenylketonuria', '|', 'Patients', 'with', 'phenylketonuria', '(', 'PKU', ')', 'have', 'an', 'inborn', 'error', 'in', 'the', 'metabolism', 'of', 'the', 'amino', 'acid', 'phenylalanine', '(', 'Phe', ')', 'and', 'thus', 'must', 'follow', 'a', 'strictly', 'controlled', 'protein', '-', 'restricted', 'diet', 'from', 'early', 'infancy', '.', 'This', 'protein', '-', 'restricted', 'diet', 'is', 'devoid', 'of', 'natural', 'dietary', 'sources', 'of', 'n-3', 'long', 'chain', 'polyunsaturated', 'fatty', 'acids', '(', 'LC', '-', 'PUFA', ')', ',', 'such', 'as', 'eggs', ',', 'meat', ',', 'milk', 'or', 'fish', '.', 'Therefore', ',', 'blood', 'concentrations', 'of', 'n-3', 'LC', '-', 'PUFA', ',', 'especially', 'of', 'docosahexaenoic', 'acid', '(', 'DHA', ')', 'are', 'reduced', 'in', 'PKU', 'children', 'compared', 'to', 'healthy', 'controls', '.', 'DHA', 'availability', 'is', 'considered', 'important', 'for', 'optimal', 'neurological', 'function', '.', 'Previous', 'studies', 'have', 'shown', 'that', 'neural', 'function', 'of', 'PKU', 'children', 'is', 'improved', 'by', 'high', 'dose', 'supplementation', 'of', 'fish', 'oil', 'providing', 'DHA', ',', 'as', 'shown', 'by', 'significant', 'improvements', 'of', 'both', 'visual', 'evoked', 'potential', 'latencies', 'and', 'of', 'fine', 'motor', 'skills', 'and', 'coordination', ',', 'but', 'no', 'dose', 'response', 'relationship', 'has', 'been', 'established', 'so', 'far', '.', '\\n\\n', 'This', 'multicentric', 'double', '-', 'blind', 'randomized', 'trial', 'aims', 'at', 'determining', 'quantitative', 'DHA', 'requirements', 'for', 'optimal', 'neural', 'function', 'in', 'PKU', 'children', '.', 'Patients', 'with', 'classical', 'PKU', 'from', 'several', 'major', 'treatment', 'centers', 'in', 'Europe', 'will', 'be', 'randomized', 'to', 'receive', 'between', '0', 'and', '8', 'mg', 'of', 'DHA', 'per', 'kg', 'body', 'weight', 'daily', 'for', 'a', 'duration', 'of', '6', 'months', '.', 'Biochemical', '(', 'fatty', 'acid', 'composition', 'of', 'plasma', 'phospholipids', ',', 'lipoprotein', 'metabolism', 'and', 'metabolic', 'profiles', ')', ',', 'and', 'functional', 'testing', '(', 'visual', 'evoked', 'potentials', ',', 'fine', 'motor', 'skills', ',', 'cognitive', 'function', 'and', 'markers', 'of', 'immune', 'function', ')', 'will', 'be', 'performed', 'at', 'baseline', 'and', 'after', '6', 'months', '.', 'Intake', 'per', 'kg', 'body', 'weight', 'will', 'be', 'related', 'to', 'outcome', 'parameters', 'and', 'thus', 'a', 'possible', 'dose', 'response', 'relationship', 'will', 'be', 'defined', '.', 'The', 'results', 'from', 'this', 'study', 'are', 'expected', 'to', 'contribute', 'to', 'the', 'improvement', 'of', 'the', 'diet', 'of', 'PKU', 'patients', ',', 'but', 'they', 'also', 'have', 'the', 'potential', 'to', 'help', 'defining', 'quantitative', 'DHA', 'needs', 'of', 'healthy', 'children', '.', '\\n\\n', 'The', 'primary', 'hypothesis', 'is', 'that', 'supplementation', 'with', 'DHA', 'improves', 'visual', 'function', 'in', 'children', 'with', 'PKU', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 49,
                "text": "Docosahexaenoic Acid",
                "type": "DRUG"
            },
            {
                "start": 87,
                "end": 102,
                "text": "Phenylketonuria",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 134,
                "text": "phenylketonuria",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 139,
                "text": "PKU",
                "type": "CONDITION"
            },
            {
                "start": 524,
                "end": 544,
                "text": "docosahexaenoic acid",
                "type": "DRUG"
            },
            {
                "start": 546,
                "end": 549,
                "text": "DHA",
                "type": "DRUG"
            },
            {
                "start": 566,
                "end": 569,
                "text": "PKU",
                "type": "CONDITION"
            },
            {
                "start": 609,
                "end": 612,
                "text": "DHA",
                "type": "DRUG"
            },
            {
                "start": 737,
                "end": 740,
                "text": "PKU",
                "type": "CONDITION"
            },
            {
                "start": 813,
                "end": 816,
                "text": "DHA",
                "type": "DRUG"
            },
            {
                "start": 1085,
                "end": 1088,
                "text": "DHA",
                "type": "DRUG"
            },
            {
                "start": 1133,
                "end": 1136,
                "text": "PKU",
                "type": "CONDITION"
            },
            {
                "start": 1171,
                "end": 1174,
                "text": "PKU",
                "type": "CONDITION"
            },
            {
                "start": 1274,
                "end": 1277,
                "text": "DHA",
                "type": "DRUG"
            },
            {
                "start": 1827,
                "end": 1830,
                "text": "PKU",
                "type": "CONDITION"
            },
            {
                "start": 1904,
                "end": 1907,
                "text": "DHA",
                "type": "DRUG"
            },
            {
                "start": 1988,
                "end": 1991,
                "text": "DHA",
                "type": "DRUG"
            },
            {
                "start": 2034,
                "end": 2037,
                "text": "PKU",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01876667",
        "study_official_title": "An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke ",
        "study_brief_summary": " Clinical pharmacy specialists are in an ideal position to assist medical teams in the management of patients with ischemic stroke. Given their extensive and specialized knowledge regarding medication efficacy, safety, and cost-effective use as well as their ability to critically review, interpret and apply the results from clinical studies to patient care, clinical pharmacy specialists have the potential to have a significant impact on stroke care delivery. There are numerous opportunities for clinical pharmacy specialists to become more extensively involved in the delivery of care to these high-risk patients. However, to-date there are few studies demonstrating the impact of clinical pharmacy specialists on outcomes of patients with stroke Stroke is the third leading cause of death in the United States (U.S.) and the most common life-threatening neurologic disorder.1 Stroke is a leading cause of long-term disability and results in significant individual and societal financial burdens. In 2006, stroke accounted for 1 of every 18 deaths and ischemic stroke accounted for 87% of all strokes.1 In the U.S., out of the approximately 795,000 people who develop a stroke each year, approximately 185,000 (23%) are recurrent events.1 After the first year, the average annual risk for recurrent stroke is 4%.2 Patients who survive at least 30 days after a first-ever stroke, have an average annual risk of death of 9.1%, much of the risk due to nonstroke cardiovascular disease.\n\nDespite the evidence supporting the use of various therapeutic interventions within the ischemic stroke population, a significant proportion of patients continue to have uncontrolled risk factors and remain undertreated.26-30 A recent prospective study of more than 4933 high-risk patients reported that, as compared to patients with coronary artery disease, patients with cerebrovascular disease are undertreated and thus less likely to achieve blood pressure (45.3% vs. 57.3%; p<0.001) and lipid (19.4% vs. 30.5%; p<0.001) targets.28 Although the reasons for the so-called \"treatment gap\" have not been explored specifically within this population, data from studies within the coronary artery disease population suggest that provider, patient and health care system factors likely all contribute.\n\nThis will be the first, prospective, randomized study to evaluate the impact of a clinical pharmacist disease management program on both surrogate and clinical outcomes for patients with non-cardioembolic ischemic stroke.\n\nThis will be a randomized, controlled study comparing a clinical pharmacist-led disease management intervention by the Clinical Pharmacy Cardiac Risk Service (CPCRS) to usual care (UC).",
        "text": "An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke | Clinical pharmacy specialists are in an ideal position to assist medical teams in the management of patients with ischemic stroke. Given their extensive and specialized knowledge regarding medication efficacy, safety, and cost-effective use as well as their ability to critically review, interpret and apply the results from clinical studies to patient care, clinical pharmacy specialists have the potential to have a significant impact on stroke care delivery. There are numerous opportunities for clinical pharmacy specialists to become more extensively involved in the delivery of care to these high-risk patients. However, to-date there are few studies demonstrating the impact of clinical pharmacy specialists on outcomes of patients with stroke Stroke is the third leading cause of death in the United States (U.S.) and the most common life-threatening neurologic disorder.1 Stroke is a leading cause of long-term disability and results in significant individual and societal financial burdens. In 2006, stroke accounted for 1 of every 18 deaths and ischemic stroke accounted for 87% of all strokes.1 In the U.S., out of the approximately 795,000 people who develop a stroke each year, approximately 185,000 (23%) are recurrent events.1 After the first year, the average annual risk for recurrent stroke is 4%.2 Patients who survive at least 30 days after a first-ever stroke, have an average annual risk of death of 9.1%, much of the risk due to nonstroke cardiovascular disease.\n\nDespite the evidence supporting the use of various therapeutic interventions within the ischemic stroke population, a significant proportion of patients continue to have uncontrolled risk factors and remain undertreated.26-30 A recent prospective study of more than 4933 high-risk patients reported that, as compared to patients with coronary artery disease, patients with cerebrovascular disease are undertreated and thus less likely to achieve blood pressure (45.3% vs. 57.3%; p<0.001) and lipid (19.4% vs. 30.5%; p<0.001) targets.28 Although the reasons for the so-called \"treatment gap\" have not been explored specifically within this population, data from studies within the coronary artery disease population suggest that provider, patient and health care system factors likely all contribute.\n\nThis will be the first, prospective, randomized study to evaluate the impact of a clinical pharmacist disease management program on both surrogate and clinical outcomes for patients with non-cardioembolic ischemic stroke.\n\nThis will be a randomized, controlled study comparing a clinical pharmacist-led disease management intervention by the Clinical Pharmacy Cardiac Risk Service (CPCRS) to usual care (UC).",
        "tokens": "['An', 'Evaluation', 'of', 'Clinical', 'Pharmacist', '-', 'led', 'Intervention', 'on', 'Clinical', 'Outcomes', 'in', 'Patients', 'With', 'Ischemic', 'Stroke', '|', 'Clinical', 'pharmacy', 'specialists', 'are', 'in', 'an', 'ideal', 'position', 'to', 'assist', 'medical', 'teams', 'in', 'the', 'management', 'of', 'patients', 'with', 'ischemic', 'stroke', '.', 'Given', 'their', 'extensive', 'and', 'specialized', 'knowledge', 'regarding', 'medication', 'efficacy', ',', 'safety', ',', 'and', 'cost', '-', 'effective', 'use', 'as', 'well', 'as', 'their', 'ability', 'to', 'critically', 'review', ',', 'interpret', 'and', 'apply', 'the', 'results', 'from', 'clinical', 'studies', 'to', 'patient', 'care', ',', 'clinical', 'pharmacy', 'specialists', 'have', 'the', 'potential', 'to', 'have', 'a', 'significant', 'impact', 'on', 'stroke', 'care', 'delivery', '.', 'There', 'are', 'numerous', 'opportunities', 'for', 'clinical', 'pharmacy', 'specialists', 'to', 'become', 'more', 'extensively', 'involved', 'in', 'the', 'delivery', 'of', 'care', 'to', 'these', 'high', '-', 'risk', 'patients', '.', 'However', ',', 'to', '-', 'date', 'there', 'are', 'few', 'studies', 'demonstrating', 'the', 'impact', 'of', 'clinical', 'pharmacy', 'specialists', 'on', 'outcomes', 'of', 'patients', 'with', 'stroke', 'Stroke', 'is', 'the', 'third', 'leading', 'cause', 'of', 'death', 'in', 'the', 'United', 'States', '(', 'U.S.', ')', 'and', 'the', 'most', 'common', 'life', '-', 'threatening', 'neurologic', 'disorder.1', 'Stroke', 'is', 'a', 'leading', 'cause', 'of', 'long', '-', 'term', 'disability', 'and', 'results', 'in', 'significant', 'individual', 'and', 'societal', 'financial', 'burdens', '.', 'In', '2006', ',', 'stroke', 'accounted', 'for', '1', 'of', 'every', '18', 'deaths', 'and', 'ischemic', 'stroke', 'accounted', 'for', '87', '%', 'of', 'all', 'strokes.1', 'In', 'the', 'U.S.', ',', 'out', 'of', 'the', 'approximately', '795,000', 'people', 'who', 'develop', 'a', 'stroke', 'each', 'year', ',', 'approximately', '185,000', '(', '23', '%', ')', 'are', 'recurrent', 'events.1', 'After', 'the', 'first', 'year', ',', 'the', 'average', 'annual', 'risk', 'for', 'recurrent', 'stroke', 'is', '4%.2', 'Patients', 'who', 'survive', 'at', 'least', '30', 'days', 'after', 'a', 'first', '-', 'ever', 'stroke', ',', 'have', 'an', 'average', 'annual', 'risk', 'of', 'death', 'of', '9.1', '%', ',', 'much', 'of', 'the', 'risk', 'due', 'to', 'nonstroke', 'cardiovascular', 'disease', '.', '\\n\\n', 'Despite', 'the', 'evidence', 'supporting', 'the', 'use', 'of', 'various', 'therapeutic', 'interventions', 'within', 'the', 'ischemic', 'stroke', 'population', ',', 'a', 'significant', 'proportion', 'of', 'patients', 'continue', 'to', 'have', 'uncontrolled', 'risk', 'factors', 'and', 'remain', 'undertreated.26', '-', '30', 'A', 'recent', 'prospective', 'study', 'of', 'more', 'than', '4933', 'high', '-', 'risk', 'patients', 'reported', 'that', ',', 'as', 'compared', 'to', 'patients', 'with', 'coronary', 'artery', 'disease', ',', 'patients', 'with', 'cerebrovascular', 'disease', 'are', 'undertreated', 'and', 'thus', 'less', 'likely', 'to', 'achieve', 'blood', 'pressure', '(', '45.3', '%', 'vs.', '57.3', '%', ';', 'p<0.001', ')', 'and', 'lipid', '(', '19.4', '%', 'vs.', '30.5', '%', ';', 'p<0.001', ')', 'targets.28', 'Although', 'the', 'reasons', 'for', 'the', 'so', '-', 'called', '\"', 'treatment', 'gap', '\"', 'have', 'not', 'been', 'explored', 'specifically', 'within', 'this', 'population', ',', 'data', 'from', 'studies', 'within', 'the', 'coronary', 'artery', 'disease', 'population', 'suggest', 'that', 'provider', ',', 'patient', 'and', 'health', 'care', 'system', 'factors', 'likely', 'all', 'contribute', '.', '\\n\\n', 'This', 'will', 'be', 'the', 'first', ',', 'prospective', ',', 'randomized', 'study', 'to', 'evaluate', 'the', 'impact', 'of', 'a', 'clinical', 'pharmacist', 'disease', 'management', 'program', 'on', 'both', 'surrogate', 'and', 'clinical', 'outcomes', 'for', 'patients', 'with', 'non', '-', 'cardioembolic', 'ischemic', 'stroke', '.', '\\n\\n', 'This', 'will', 'be', 'a', 'randomized', ',', 'controlled', 'study', 'comparing', 'a', 'clinical', 'pharmacist', '-', 'led', 'disease', 'management', 'intervention', 'by', 'the', 'Clinical', 'Pharmacy', 'Cardiac', 'Risk', 'Service', '(', 'CPCRS', ')', 'to', 'usual', 'care', '(', 'UC', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 53,
                "text": "Clinical Pharmacist-led Intervention",
                "type": "OTHER"
            },
            {
                "start": 92,
                "end": 107,
                "text": "Ischemic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 110,
                "end": 139,
                "text": "Clinical pharmacy specialists",
                "type": "OTHER"
            },
            {
                "start": 224,
                "end": 239,
                "text": "ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 469,
                "end": 498,
                "text": "clinical pharmacy specialists",
                "type": "OTHER"
            },
            {
                "start": 550,
                "end": 556,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 609,
                "end": 638,
                "text": "clinical pharmacy specialists",
                "type": "OTHER"
            },
            {
                "start": 795,
                "end": 824,
                "text": "clinical pharmacy specialists",
                "type": "OTHER"
            },
            {
                "start": 854,
                "end": 860,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 861,
                "end": 867,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 991,
                "end": 997,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 1120,
                "end": 1126,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1166,
                "end": 1181,
                "text": "ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 1284,
                "end": 1290,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1413,
                "end": 1419,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1485,
                "end": 1491,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1686,
                "end": 1701,
                "text": "ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 1971,
                "end": 1994,
                "text": "cerebrovascular disease",
                "type": "CONDITION"
            },
            {
                "start": 2481,
                "end": 2527,
                "text": "clinical pharmacist disease management program",
                "type": "OTHER"
            },
            {
                "start": 2586,
                "end": 2619,
                "text": "non-cardioembolic ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 2678,
                "end": 2733,
                "text": "clinical pharmacist-led disease management intervention",
                "type": "OTHER"
            },
            {
                "start": 2741,
                "end": 2779,
                "text": "Clinical Pharmacy Cardiac Risk Service",
                "type": "OTHER"
            },
            {
                "start": 2781,
                "end": 2786,
                "text": "CPCRS",
                "type": "OTHER"
            },
            {
                "start": 2791,
                "end": 2801,
                "text": "usual care",
                "type": "CONTROL"
            },
            {
                "start": 2803,
                "end": 2805,
                "text": "UC",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03759678",
        "study_official_title": "Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study ",
        "study_brief_summary": " This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T).\n\nThere are two phases to this study: the Parent Study, and the Extension Phase.\n\nThe Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the symptomatic treatment of A-T.\n\nThe Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of A-T.",
        "text": "Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study | This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T).\n\nThere are two phases to this study: the Parent Study, and the Extension Phase.\n\nThe Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the symptomatic treatment of A-T.\n\nThe Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of A-T.",
        "tokens": "['Effects', 'of', 'N', '-', 'Acetyl', '-', 'L', '-', 'Leucine', 'on', 'Ataxia', '-', 'Telangiectasia', '(', 'A', '-', 'T', '):', 'A', 'Multinational', ',', 'Multicenter', ',', 'Open', '-', 'label', ',', 'Rater', '-', 'blinded', 'Phase', 'II', 'Study', '|', 'This', 'is', 'a', 'multinational', ',', 'multicenter', ',', 'open', '-', 'label', ',', 'rater', '-', 'blinded', 'prospective', 'Phase', 'II', 'study', 'which', 'will', 'assess', 'the', 'safety', 'and', 'efficacy', 'of', 'N', '-', 'Acetyl', '-', 'L', '-', 'Leucine', '(', 'IB1001', ')', 'for', 'the', 'treatment', 'of', 'Ataxia', '-', 'Telangiectasia', '(', 'A', '-', 'T', ')', '.', '\\n\\n', 'There', 'are', 'two', 'phases', 'to', 'this', 'study', ':', 'the', 'Parent', 'Study', ',', 'and', 'the', 'Extension', 'Phase', '.', '\\n\\n', 'The', 'Parent', 'Study', 'evaluates', 'the', 'safety', 'and', 'efficacy', 'of', 'N', '-', 'Acetyl', '-', 'L', '-', 'Leucine', '(', 'IB1001', ')', 'for', 'the', 'symptomatic', 'treatment', 'of', 'A', '-', 'T.', '\\n\\n', 'The', 'Extension', 'Phase', 'evaluates', 'the', 'long', '-', 'term', 'safety', 'and', 'efficacy', 'of', 'IB1001', 'for', 'the', 'neuroprotective', ',', 'disease', '-', 'modifying', 'treatment', 'of', 'A', '-', 'T.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 11,
                "end": 29,
                "text": "N-Acetyl-L-Leucine",
                "type": "DRUG"
            },
            {
                "start": 33,
                "end": 54,
                "text": "Ataxia-Telangiectasia",
                "type": "CONDITION"
            },
            {
                "start": 56,
                "end": 59,
                "text": "A-T",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 289,
                "text": "N-Acetyl-L-Leucine",
                "type": "DRUG"
            },
            {
                "start": 291,
                "end": 297,
                "text": "IB1001",
                "type": "DRUG"
            },
            {
                "start": 320,
                "end": 341,
                "text": "Ataxia-Telangiectasia",
                "type": "CONDITION"
            },
            {
                "start": 343,
                "end": 346,
                "text": "A-T",
                "type": "CONDITION"
            },
            {
                "start": 484,
                "end": 502,
                "text": "N-Acetyl-L-Leucine",
                "type": "DRUG"
            },
            {
                "start": 504,
                "end": 510,
                "text": "IB1001",
                "type": "DRUG"
            },
            {
                "start": 545,
                "end": 549,
                "text": "A-T.",
                "type": "CONDITION"
            },
            {
                "start": 618,
                "end": 624,
                "text": "IB1001",
                "type": "DRUG"
            },
            {
                "start": 681,
                "end": 685,
                "text": "A-T.",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01751347",
        "study_official_title": "Bupivacaine Versus Lidocaine Local Anesthesia in Elective Outpatient Hand Surgery: A Randomized Controlled Trial ",
        "study_brief_summary": " The use of local anesthetics has become an important aspect of pain management in surgical settings and is currently recommended in pain management guidelines.\n\nElective outpatient hand surgeries, such as carpal tunnel or trigger finger release, cause minimum tissue disruption and are short in duration. As a result, these local anesthetic agents are a major component in post-operative pain control. The most commonly used local anesthetic agents are Lidocaine and Bupivacaine. Lidocaine acts faster (within 2-5 minutes of injection) and for this reason is often favored in outpatient setting for pre-incisional injection. However its effects only last up to 2 hours, without epinephrine, and 3 hours, with epinephrine. On the other hand, Bupivacaine, has a slower onset of action (about 5-10 minutes after injection) but its effects last much longer, for about 4-8 hours. The delay in onset of action makes it a less popular option as a primary source of local anesthesia in outpatient hand surgery.\n\nGiven the longer duration of anesthesia offered by Bupivacaine, the investigators believe that by giving it pre-operatively in elective outpatient hand surgeries will offer more effective post operative pain control compared to using Lidocaine only. There is limited published data confirming the effectiveness of use of pre-operative Bupivicaine in improved postoperative pain control and decreased consumption of narcotics. Therefore, the aim in this study is to compare the postoperative pain experienced by patients undergoing either elective carpal tunnel release or trigger finger release as well as their use of pain medications when the incision site is infiltrated preemptively with Lidocaine versus Bupivacaine.\n\nThe investigators believe that adequate post surgical pain control is essential for patients' full functional recovery. Poorly controlled post surgical pain increases incidence of surgery related complications and thus increased health care costs. It can also reduce patients' mobility, delay their return to full function,. If poorly controlled, post surgical pain may progress to chronic pain and rarely complex regional pain syndromes may ensue.",
        "text": "Bupivacaine Versus Lidocaine Local Anesthesia in Elective Outpatient Hand Surgery: A Randomized Controlled Trial | The use of local anesthetics has become an important aspect of pain management in surgical settings and is currently recommended in pain management guidelines.\n\nElective outpatient hand surgeries, such as carpal tunnel or trigger finger release, cause minimum tissue disruption and are short in duration. As a result, these local anesthetic agents are a major component in post-operative pain control. The most commonly used local anesthetic agents are Lidocaine and Bupivacaine. Lidocaine acts faster (within 2-5 minutes of injection) and for this reason is often favored in outpatient setting for pre-incisional injection. However its effects only last up to 2 hours, without epinephrine, and 3 hours, with epinephrine. On the other hand, Bupivacaine, has a slower onset of action (about 5-10 minutes after injection) but its effects last much longer, for about 4-8 hours. The delay in onset of action makes it a less popular option as a primary source of local anesthesia in outpatient hand surgery.\n\nGiven the longer duration of anesthesia offered by Bupivacaine, the investigators believe that by giving it pre-operatively in elective outpatient hand surgeries will offer more effective post operative pain control compared to using Lidocaine only. There is limited published data confirming the effectiveness of use of pre-operative Bupivicaine in improved postoperative pain control and decreased consumption of narcotics. Therefore, the aim in this study is to compare the postoperative pain experienced by patients undergoing either elective carpal tunnel release or trigger finger release as well as their use of pain medications when the incision site is infiltrated preemptively with Lidocaine versus Bupivacaine.\n\nThe investigators believe that adequate post surgical pain control is essential for patients' full functional recovery. Poorly controlled post surgical pain increases incidence of surgery related complications and thus increased health care costs. It can also reduce patients' mobility, delay their return to full function,. If poorly controlled, post surgical pain may progress to chronic pain and rarely complex regional pain syndromes may ensue.",
        "tokens": "['Bupivacaine', 'Versus', 'Lidocaine', 'Local', 'Anesthesia', 'in', 'Elective', 'Outpatient', 'Hand', 'Surgery', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'use', 'of', 'local', 'anesthetics', 'has', 'become', 'an', 'important', 'aspect', 'of', 'pain', 'management', 'in', 'surgical', 'settings', 'and', 'is', 'currently', 'recommended', 'in', 'pain', 'management', 'guidelines', '.', '\\n\\n', 'Elective', 'outpatient', 'hand', 'surgeries', ',', 'such', 'as', 'carpal', 'tunnel', 'or', 'trigger', 'finger', 'release', ',', 'cause', 'minimum', 'tissue', 'disruption', 'and', 'are', 'short', 'in', 'duration', '.', 'As', 'a', 'result', ',', 'these', 'local', 'anesthetic', 'agents', 'are', 'a', 'major', 'component', 'in', 'post', '-', 'operative', 'pain', 'control', '.', 'The', 'most', 'commonly', 'used', 'local', 'anesthetic', 'agents', 'are', 'Lidocaine', 'and', 'Bupivacaine', '.', 'Lidocaine', 'acts', 'faster', '(', 'within', '2', '-', '5', 'minutes', 'of', 'injection', ')', 'and', 'for', 'this', 'reason', 'is', 'often', 'favored', 'in', 'outpatient', 'setting', 'for', 'pre', '-', 'incisional', 'injection', '.', 'However', 'its', 'effects', 'only', 'last', 'up', 'to', '2', 'hours', ',', 'without', 'epinephrine', ',', 'and', '3', 'hours', ',', 'with', 'epinephrine', '.', 'On', 'the', 'other', 'hand', ',', 'Bupivacaine', ',', 'has', 'a', 'slower', 'onset', 'of', 'action', '(', 'about', '5', '-', '10', 'minutes', 'after', 'injection', ')', 'but', 'its', 'effects', 'last', 'much', 'longer', ',', 'for', 'about', '4', '-', '8', 'hours', '.', 'The', 'delay', 'in', 'onset', 'of', 'action', 'makes', 'it', 'a', 'less', 'popular', 'option', 'as', 'a', 'primary', 'source', 'of', 'local', 'anesthesia', 'in', 'outpatient', 'hand', 'surgery', '.', '\\n\\n', 'Given', 'the', 'longer', 'duration', 'of', 'anesthesia', 'offered', 'by', 'Bupivacaine', ',', 'the', 'investigators', 'believe', 'that', 'by', 'giving', 'it', 'pre', '-', 'operatively', 'in', 'elective', 'outpatient', 'hand', 'surgeries', 'will', 'offer', 'more', 'effective', 'post', 'operative', 'pain', 'control', 'compared', 'to', 'using', 'Lidocaine', 'only', '.', 'There', 'is', 'limited', 'published', 'data', 'confirming', 'the', 'effectiveness', 'of', 'use', 'of', 'pre', '-', 'operative', 'Bupivicaine', 'in', 'improved', 'postoperative', 'pain', 'control', 'and', 'decreased', 'consumption', 'of', 'narcotics', '.', 'Therefore', ',', 'the', 'aim', 'in', 'this', 'study', 'is', 'to', 'compare', 'the', 'postoperative', 'pain', 'experienced', 'by', 'patients', 'undergoing', 'either', 'elective', 'carpal', 'tunnel', 'release', 'or', 'trigger', 'finger', 'release', 'as', 'well', 'as', 'their', 'use', 'of', 'pain', 'medications', 'when', 'the', 'incision', 'site', 'is', 'infiltrated', 'preemptively', 'with', 'Lidocaine', 'versus', 'Bupivacaine', '.', '\\n\\n', 'The', 'investigators', 'believe', 'that', 'adequate', 'post', 'surgical', 'pain', 'control', 'is', 'essential', 'for', 'patients', \"'\", 'full', 'functional', 'recovery', '.', 'Poorly', 'controlled', 'post', 'surgical', 'pain', 'increases', 'incidence', 'of', 'surgery', 'related', 'complications', 'and', 'thus', 'increased', 'health', 'care', 'costs', '.', 'It', 'can', 'also', 'reduce', 'patients', \"'\", 'mobility', ',', 'delay', 'their', 'return', 'to', 'full', 'function', ',', '.', 'If', 'poorly', 'controlled', ',', 'post', 'surgical', 'pain', 'may', 'progress', 'to', 'chronic', 'pain', 'and', 'rarely', 'complex', 'regional', 'pain', 'syndromes', 'may', 'ensue', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 11,
                "text": "Bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 19,
                "end": 28,
                "text": "Lidocaine",
                "type": "DRUG"
            },
            {
                "start": 69,
                "end": 81,
                "text": "Hand Surgery",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 182,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 247,
                "end": 251,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 296,
                "end": 310,
                "text": "hand surgeries",
                "type": "CONDITION"
            },
            {
                "start": 337,
                "end": 359,
                "text": "trigger finger release",
                "type": "CONDITION"
            },
            {
                "start": 488,
                "end": 507,
                "text": "post-operative pain",
                "type": "CONDITION"
            },
            {
                "start": 568,
                "end": 577,
                "text": "Lidocaine",
                "type": "DRUG"
            },
            {
                "start": 582,
                "end": 593,
                "text": "Bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 595,
                "end": 604,
                "text": "Lidocaine",
                "type": "DRUG"
            },
            {
                "start": 793,
                "end": 804,
                "text": "epinephrine",
                "type": "DRUG"
            },
            {
                "start": 824,
                "end": 835,
                "text": "epinephrine",
                "type": "DRUG"
            },
            {
                "start": 856,
                "end": 867,
                "text": "Bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 1104,
                "end": 1116,
                "text": "hand surgery",
                "type": "CONDITION"
            },
            {
                "start": 1170,
                "end": 1181,
                "text": "Bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 1307,
                "end": 1326,
                "text": "post operative pain",
                "type": "CONDITION"
            },
            {
                "start": 1353,
                "end": 1362,
                "text": "Lidocaine",
                "type": "DRUG"
            },
            {
                "start": 1454,
                "end": 1465,
                "text": "Bupivicaine",
                "type": "DRUG"
            },
            {
                "start": 1478,
                "end": 1496,
                "text": "postoperative pain",
                "type": "CONDITION"
            },
            {
                "start": 1596,
                "end": 1614,
                "text": "postoperative pain",
                "type": "CONDITION"
            },
            {
                "start": 1691,
                "end": 1713,
                "text": "trigger finger release",
                "type": "CONDITION"
            },
            {
                "start": 1738,
                "end": 1742,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1811,
                "end": 1820,
                "text": "Lidocaine",
                "type": "DRUG"
            },
            {
                "start": 1828,
                "end": 1839,
                "text": "Bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 1882,
                "end": 1900,
                "text": "post surgical pain",
                "type": "CONDITION"
            },
            {
                "start": 1980,
                "end": 1998,
                "text": "post surgical pain",
                "type": "CONDITION"
            },
            {
                "start": 2189,
                "end": 2207,
                "text": "post surgical pain",
                "type": "CONDITION"
            },
            {
                "start": 2224,
                "end": 2236,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 2256,
                "end": 2279,
                "text": "regional pain syndromes",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03272906",
        "study_official_title": "Clinical Feasibility of Transcranial Direct Current Stimulation [tDCS] With Standard Aphasia Therapy ",
        "study_brief_summary": " Study Design: This is a within-subjects crossover design. Subjects will participate in the procedures twice, once under each condition (active vs. sham stimulation). The order of conditions will be counter-balanced across subjects. Stimulation will target ventral inferior frontal gyrus (IFG) and will be paired with standard speech-language therapy. Outcome measures will be acquired at the beginning and end of a semester of standard speech-language therapy, and at follow-up.",
        "text": "Clinical Feasibility of Transcranial Direct Current Stimulation [tDCS] With Standard Aphasia Therapy | Study Design: This is a within-subjects crossover design. Subjects will participate in the procedures twice, once under each condition (active vs. sham stimulation). The order of conditions will be counter-balanced across subjects. Stimulation will target ventral inferior frontal gyrus (IFG) and will be paired with standard speech-language therapy. Outcome measures will be acquired at the beginning and end of a semester of standard speech-language therapy, and at follow-up.",
        "tokens": "['Clinical', 'Feasibility', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', '[', 'tDCS', ']', 'With', 'Standard', 'Aphasia', 'Therapy', '|', 'Study', 'Design', ':', 'This', 'is', 'a', 'within', '-', 'subjects', 'crossover', 'design', '.', 'Subjects', 'will', 'participate', 'in', 'the', 'procedures', 'twice', ',', 'once', 'under', 'each', 'condition', '(', 'active', 'vs.', 'sham', 'stimulation', ')', '.', 'The', 'order', 'of', 'conditions', 'will', 'be', 'counter', '-', 'balanced', 'across', 'subjects', '.', 'Stimulation', 'will', 'target', 'ventral', 'inferior', 'frontal', 'gyrus', '(', 'IFG', ')', 'and', 'will', 'be', 'paired', 'with', 'standard', 'speech', '-', 'language', 'therapy', '.', 'Outcome', 'measures', 'will', 'be', 'acquired', 'at', 'the', 'beginning', 'and', 'end', 'of', 'a', 'semester', 'of', 'standard', 'speech', '-', 'language', 'therapy', ',', 'and', 'at', 'follow', '-', 'up', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 63,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 65,
                "end": 69,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 85,
                "end": 92,
                "text": "Aphasia",
                "type": "CONDITION"
            },
            {
                "start": 250,
                "end": 266,
                "text": "sham stimulation",
                "type": "CONTROL"
            },
            {
                "start": 429,
                "end": 452,
                "text": "speech-language therapy",
                "type": "OTHER"
            },
            {
                "start": 539,
                "end": 562,
                "text": "speech-language therapy",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02843906",
        "study_official_title": "Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection? ",
        "study_brief_summary": " The purpose of this study is to identify association between cerebrospinal fluid Alzheimer's Disease's neurodegenerescence biomarkers (tau, ptau, A\u00df40 and A\u00df1-42) and occurrence of cognitive deficits in older patients with bipolar disorders.",
        "text": "Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection? | The purpose of this study is to identify association between cerebrospinal fluid Alzheimer's Disease's neurodegenerescence biomarkers (tau, ptau, A\u00df40 and A\u00df1-42) and occurrence of cognitive deficits in older patients with bipolar disorders.",
        "tokens": "['Cognitive', ',', 'Morphological', 'and', 'Neurobiological', 'Progressive', 'Aspects', 'in', 'Bipolar', 'Disorders', 'in', 'the', 'Elderly', ':', 'Toward', 'to', 'a', 'Neurodegenerescence', 'Detection', '?', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'identify', 'association', 'between', 'cerebrospinal', 'fluid', 'Alzheimer', \"'s\", 'Disease', \"'s\", 'neurodegenerescence', 'biomarkers', '(', 'tau', ',', 'ptau', ',', 'A\u00df40', 'and', 'A\u00df1', '-', '42', ')', 'and', 'occurrence', 'of', 'cognitive', 'deficits', 'in', 'older', 'patients', 'with', 'bipolar', 'disorders', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 68,
                "end": 85,
                "text": "Bipolar Disorders",
                "type": "CONDITION"
            },
            {
                "start": 228,
                "end": 247,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 328,
                "end": 346,
                "text": "cognitive deficits",
                "type": "CONDITION"
            },
            {
                "start": 370,
                "end": 387,
                "text": "bipolar disorders",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03538522",
        "study_official_title": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment ",
        "study_brief_summary": " This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease",
        "text": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment | This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'NA-831', 'in', 'Alzheimer', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', '|', 'This', 'study', 'seeks', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'NA-83', 'in', 'subjects', 'with', 'mild', 'cognitive', 'impairment', 'due', 'to', 'Alzheimer', \"'s\", 'Disease']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 105,
                "end": 111,
                "text": "NA-831",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 124,
                "text": "Alzheimer",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 164,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 228,
                "text": "NA-83",
                "type": "DRUG"
            },
            {
                "start": 246,
                "end": 271,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 298,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00423943",
        "study_official_title": "Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia ",
        "study_brief_summary": " Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This appears to be responsible for their difficulties in social and occupational functioning. One particular cognitive function that may be important for schizophrenia is called context processing. This refers to the ability to properly use information in the environment to guide thinking and behavior so that it is appropriate to the present circumstance. Problems with this function may explain why patients with schizophrenia think and act in unusual ways, and often have problems managing aspects of their lives that healthy adults take for granted. This cognitive function depends on a region of the brain called the prefrontal cortex, which shows impaired function in schizophrenia as well. Unfortunately, the biochemical aspects of this dysfunction are presently unknown, and it is not clear whether current psychiatric medications can improve this function. A recent FDA-approved medication that may improve this function is modafinil. Studies in animals and healthy adults show that this medication can improve cognitive functions which are related to context processing. We plan to study the effects of modafinil on context processing and the brain activity that underlies this function. We will use functional MRI and electrophysiology to examine the effects of modafinil, both after a single dose and after sustained (4 week) treatment. We predict that when patients receive modafinil they will perform better on cognitive tests and have improved activity in the regions of the brain that are responsible for these cognitive processes.",
        "text": "Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia | Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This appears to be responsible for their difficulties in social and occupational functioning. One particular cognitive function that may be important for schizophrenia is called context processing. This refers to the ability to properly use information in the environment to guide thinking and behavior so that it is appropriate to the present circumstance. Problems with this function may explain why patients with schizophrenia think and act in unusual ways, and often have problems managing aspects of their lives that healthy adults take for granted. This cognitive function depends on a region of the brain called the prefrontal cortex, which shows impaired function in schizophrenia as well. Unfortunately, the biochemical aspects of this dysfunction are presently unknown, and it is not clear whether current psychiatric medications can improve this function. A recent FDA-approved medication that may improve this function is modafinil. Studies in animals and healthy adults show that this medication can improve cognitive functions which are related to context processing. We plan to study the effects of modafinil on context processing and the brain activity that underlies this function. We will use functional MRI and electrophysiology to examine the effects of modafinil, both after a single dose and after sustained (4 week) treatment. We predict that when patients receive modafinil they will perform better on cognitive tests and have improved activity in the regions of the brain that are responsible for these cognitive processes.",
        "tokens": "['Modafinil', 'for', 'Treatment', 'of', 'Cognitive', 'Dysfunction', 'in', 'Schizophrenia', '|', 'Patients', 'with', 'schizophrenia', 'have', 'problems', 'in', 'thinking', ',', 'known', 'as', 'cognitive', 'dysfunction', '.', 'This', 'appears', 'to', 'be', 'responsible', 'for', 'their', 'difficulties', 'in', 'social', 'and', 'occupational', 'functioning', '.', 'One', 'particular', 'cognitive', 'function', 'that', 'may', 'be', 'important', 'for', 'schizophrenia', 'is', 'called', 'context', 'processing', '.', 'This', 'refers', 'to', 'the', 'ability', 'to', 'properly', 'use', 'information', 'in', 'the', 'environment', 'to', 'guide', 'thinking', 'and', 'behavior', 'so', 'that', 'it', 'is', 'appropriate', 'to', 'the', 'present', 'circumstance', '.', 'Problems', 'with', 'this', 'function', 'may', 'explain', 'why', 'patients', 'with', 'schizophrenia', 'think', 'and', 'act', 'in', 'unusual', 'ways', ',', 'and', 'often', 'have', 'problems', 'managing', 'aspects', 'of', 'their', 'lives', 'that', 'healthy', 'adults', 'take', 'for', 'granted', '.', 'This', 'cognitive', 'function', 'depends', 'on', 'a', 'region', 'of', 'the', 'brain', 'called', 'the', 'prefrontal', 'cortex', ',', 'which', 'shows', 'impaired', 'function', 'in', 'schizophrenia', 'as', 'well', '.', 'Unfortunately', ',', 'the', 'biochemical', 'aspects', 'of', 'this', 'dysfunction', 'are', 'presently', 'unknown', ',', 'and', 'it', 'is', 'not', 'clear', 'whether', 'current', 'psychiatric', 'medications', 'can', 'improve', 'this', 'function', '.', 'A', 'recent', 'FDA', '-', 'approved', 'medication', 'that', 'may', 'improve', 'this', 'function', 'is', 'modafinil', '.', 'Studies', 'in', 'animals', 'and', 'healthy', 'adults', 'show', 'that', 'this', 'medication', 'can', 'improve', 'cognitive', 'functions', 'which', 'are', 'related', 'to', 'context', 'processing', '.', 'We', 'plan', 'to', 'study', 'the', 'effects', 'of', 'modafinil', 'on', 'context', 'processing', 'and', 'the', 'brain', 'activity', 'that', 'underlies', 'this', 'function', '.', 'We', 'will', 'use', 'functional', 'MRI', 'and', 'electrophysiology', 'to', 'examine', 'the', 'effects', 'of', 'modafinil', ',', 'both', 'after', 'a', 'single', 'dose', 'and', 'after', 'sustained', '(', '4', 'week', ')', 'treatment', '.', 'We', 'predict', 'that', 'when', 'patients', 'receive', 'modafinil', 'they', 'will', 'perform', 'better', 'on', 'cognitive', 'tests', 'and', 'have', 'improved', 'activity', 'in', 'the', 'regions', 'of', 'the', 'brain', 'that', 'are', 'responsible', 'for', 'these', 'cognitive', 'processes', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 9,
                "text": "Modafinil",
                "type": "DRUG"
            },
            {
                "start": 27,
                "end": 48,
                "text": "Cognitive Dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 52,
                "end": 65,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 82,
                "end": 95,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 153,
                "text": "cognitive dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 309,
                "end": 322,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 571,
                "end": 584,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 1089,
                "end": 1098,
                "text": "modafinil",
                "type": "DRUG"
            },
            {
                "start": 1269,
                "end": 1278,
                "text": "modafinil",
                "type": "DRUG"
            },
            {
                "start": 1429,
                "end": 1438,
                "text": "modafinil",
                "type": "DRUG"
            },
            {
                "start": 1543,
                "end": 1552,
                "text": "modafinil",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02560597",
        "study_official_title": "Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy - Case Study in Patients With Epilepsia Partialis Continua (EPC) and Refractory Status Epilepticus (SE) ",
        "study_brief_summary": " The purpose of this study is to assess the effects of repetitive transcranial magnetic stimulation (rTMS) as a treatment for Epilepsia Partialis Continua (EPC) or refractory Status Epilepticus (SE), when standard clinical treatments have failed.",
        "text": "Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy - Case Study in Patients With Epilepsia Partialis Continua (EPC) and Refractory Status Epilepticus (SE) | The purpose of this study is to assess the effects of repetitive transcranial magnetic stimulation (rTMS) as a treatment for Epilepsia Partialis Continua (EPC) or refractory Status Epilepticus (SE), when standard clinical treatments have failed.",
        "tokens": "['Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'rTMS', ')', 'for', 'the', 'Treatment', 'of', 'Epilepsy', '-', 'Case', 'Study', 'in', 'Patients', 'With', 'Epilepsia', 'Partialis', 'Continua', '(', 'EPC', ')', 'and', 'Refractory', 'Status', 'Epilepticus', '(', 'SE', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effects', 'of', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'as', 'a', 'treatment', 'for', 'Epilepsia', 'Partialis', 'Continua', '(', 'EPC', ')', 'or', 'refractory', 'Status', 'Epilepticus', '(', 'SE', ')', ',', 'when', 'standard', 'clinical', 'treatments', 'have', 'failed', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 44,
                "text": "Repetitive Transcranial Magnetic Stimulation",
                "type": "OTHER"
            },
            {
                "start": 46,
                "end": 50,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 73,
                "end": 81,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 112,
                "end": 140,
                "text": "Epilepsia Partialis Continua",
                "type": "CONDITION"
            },
            {
                "start": 142,
                "end": 145,
                "text": "EPC",
                "type": "CONDITION"
            },
            {
                "start": 151,
                "end": 180,
                "text": "Refractory Status Epilepticus",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 184,
                "text": "SE",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 286,
                "text": "repetitive transcranial magnetic stimulation",
                "type": "OTHER"
            },
            {
                "start": 288,
                "end": 292,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 313,
                "end": 341,
                "text": "Epilepsia Partialis Continua",
                "type": "CONDITION"
            },
            {
                "start": 343,
                "end": 346,
                "text": "EPC",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 380,
                "text": "refractory Status Epilepticus",
                "type": "CONDITION"
            },
            {
                "start": 382,
                "end": 384,
                "text": "SE",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05749393",
        "study_official_title": "Effect of Heparinization on Intracranial Aneurysm ",
        "study_brief_summary": " The goal of this clinical trial is to compare intracranial aneurysm patients. The main question it aims to answer are: Which heparinization regimen is most beneficial to patients during surgery for intracranial aneurysms. Participants will be randomized to different intraoperative heparinization regimens: (i) 50 U/kg intravenous (IV) at 1-h intervals reduced by half to a minimum of 1000 u/h; (ii) 60 U/kg IV at 1-h intervals reduced by half to a minimum of 1000 u/h; (iii) 70 U/kg IV at 1-h intervals reduced by half to a minimum of 1000 u/h. MRI will be performed within 72 h after surgery, and the DWI sequence of MRI will be analyzed. If there is a comparison group: Researchers will compare different intraoperative heparinization protocol groups to see which dose of intraoperative heparin has the best prognosis for use.",
        "text": "Effect of Heparinization on Intracranial Aneurysm | The goal of this clinical trial is to compare intracranial aneurysm patients. The main question it aims to answer are: Which heparinization regimen is most beneficial to patients during surgery for intracranial aneurysms. Participants will be randomized to different intraoperative heparinization regimens: (i) 50 U/kg intravenous (IV) at 1-h intervals reduced by half to a minimum of 1000 u/h; (ii) 60 U/kg IV at 1-h intervals reduced by half to a minimum of 1000 u/h; (iii) 70 U/kg IV at 1-h intervals reduced by half to a minimum of 1000 u/h. MRI will be performed within 72 h after surgery, and the DWI sequence of MRI will be analyzed. If there is a comparison group: Researchers will compare different intraoperative heparinization protocol groups to see which dose of intraoperative heparin has the best prognosis for use.",
        "tokens": "['Effect', 'of', 'Heparinization', 'on', 'Intracranial', 'Aneurysm', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'compare', 'intracranial', 'aneurysm', 'patients', '.', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'are', ':', 'Which', 'heparinization', 'regimen', 'is', 'most', 'beneficial', 'to', 'patients', 'during', 'surgery', 'for', 'intracranial', 'aneurysms', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'different', 'intraoperative', 'heparinization', 'regimens', ':', '(', 'i', ')', '50', 'U', '/', 'kg', 'intravenous', '(', 'IV', ')', 'at', '1', '-', 'h', 'intervals', 'reduced', 'by', 'half', 'to', 'a', 'minimum', 'of', '1000', 'u', '/', 'h', ';', '(', 'ii', ')', '60', 'U', '/', 'kg', 'IV', 'at', '1', '-', 'h', 'intervals', 'reduced', 'by', 'half', 'to', 'a', 'minimum', 'of', '1000', 'u', '/', 'h', ';', '(', 'iii', ')', '70', 'U', '/', 'kg', 'IV', 'at', '1', '-', 'h', 'intervals', 'reduced', 'by', 'half', 'to', 'a', 'minimum', 'of', '1000', 'u', '/', 'h.', 'MRI', 'will', 'be', 'performed', 'within', '72', 'h', 'after', 'surgery', ',', 'and', 'the', 'DWI', 'sequence', 'of', 'MRI', 'will', 'be', 'analyzed', '.', 'If', 'there', 'is', 'a', 'comparison', 'group', ':', 'Researchers', 'will', 'compare', 'different', 'intraoperative', 'heparinization', 'protocol', 'groups', 'to', 'see', 'which', 'dose', 'of', 'intraoperative', 'heparin', 'has', 'the', 'best', 'prognosis', 'for', 'use', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 24,
                "text": "Heparinization",
                "type": "DRUG"
            },
            {
                "start": 28,
                "end": 49,
                "text": "Intracranial Aneurysm",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 119,
                "text": "intracranial aneurysm",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 191,
                "text": "heparinization",
                "type": "DRUG"
            },
            {
                "start": 238,
                "end": 245,
                "text": "surgery",
                "type": "CONDITION"
            },
            {
                "start": 250,
                "end": 272,
                "text": "intracranial aneurysms",
                "type": "CONDITION"
            },
            {
                "start": 334,
                "end": 348,
                "text": "heparinization",
                "type": "DRUG"
            },
            {
                "start": 775,
                "end": 789,
                "text": "heparinization",
                "type": "DRUG"
            },
            {
                "start": 842,
                "end": 849,
                "text": "heparin",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00195013",
        "study_official_title": "A Randomized Placebo-controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients With a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy ",
        "study_brief_summary": " Patients with breast cancer receiving paclitaxel chemotherapy who have mild symptoms of peripheral neuropathy will receive glutamine or placebo to try and improve symptoms.",
        "text": "A Randomized Placebo-controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients With a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy | Patients with breast cancer receiving paclitaxel chemotherapy who have mild symptoms of peripheral neuropathy will receive glutamine or placebo to try and improve symptoms.",
        "tokens": "['A', 'Randomized', 'Placebo', '-', 'controlled', 'Trial', 'of', 'Glutamine', 'to', 'Reduce', 'the', 'Signs', 'and', 'Symptoms', 'of', 'Peripheral', 'Neuropathy', 'in', 'Breast', 'Cancer', 'Patients', 'With', 'a', 'Mild', 'Peripheral', 'Neuropathy', 'Receiving', 'Paclitaxel', 'Chemotherapy', '|', 'Patients', 'with', 'breast', 'cancer', 'receiving', 'paclitaxel', 'chemotherapy', 'who', 'have', 'mild', 'symptoms', 'of', 'peripheral', 'neuropathy', 'will', 'receive', 'glutamine', 'or', 'placebo', 'to', 'try', 'and', 'improve', 'symptoms', '.']",
        "token_bio_labels": "['O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 20,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 41,
                "end": 50,
                "text": "Glutamine",
                "type": "DRUG"
            },
            {
                "start": 87,
                "end": 108,
                "text": "Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 112,
                "end": 125,
                "text": "Breast Cancer",
                "type": "CONDITION"
            },
            {
                "start": 142,
                "end": 168,
                "text": "Mild Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 179,
                "end": 189,
                "text": "Paclitaxel",
                "type": "DRUG"
            },
            {
                "start": 219,
                "end": 232,
                "text": "breast cancer",
                "type": "CONDITION"
            },
            {
                "start": 243,
                "end": 253,
                "text": "paclitaxel",
                "type": "DRUG"
            },
            {
                "start": 293,
                "end": 314,
                "text": "peripheral neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 328,
                "end": 337,
                "text": "glutamine",
                "type": "DRUG"
            },
            {
                "start": 341,
                "end": 348,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05025917",
        "study_official_title": "Assessing the Effect of Shatavari Supplementation on Bone and Skeletal Muscle Health in Healthy Postmenopausal Women: A Randomised Double Blind Clinical Trial ",
        "study_brief_summary": " Shatavari is a plant that grows in Nepal, Sri Lanka, India and the Himalayas and its root has long been used in Ayurvedic medicine. Its traditional uses include supporting women's health, particularly during breastfeeding and during the perimenopausal period. Shatavari has been found to contain substances that have similar chemical properties to estrogen. A decrease in the amount of ovarian estrogen production causes the menopause and this reduction in circulating estrogen has widespread effects, including promoting a decrease in bone density. This increases the risk of bone fractures. Having less oestrogen is also thought to contribute to a loss of muscle strength in postmenopausal women.\n\nAs shatavari may act on the body's tissues in a similar way to estrogen, shatavari supplementation may represent one way of preventing postmenopausal bone and muscle loss. This study will investigate these questions. 24 healthy postmenopausal women aged 60 years or older will be recruited. The participants will be randomly assigned to consume shatavari (1000 mg per day, equivalent to 26,500 mg per day fresh weight shatavari) or placebo (1000 mg per day magnesium stearate) for 6 weeks. Handgrip and knee extensor strength will be measured at baseline and at 6 weeks. Vastus lateralis (VL) muscle biopsy samples will be obtained at baseline and at 6 weeks and analysed for markers of muscle function and protein turnover. Plasma and serum samples will be collected via venepuncture and markers of bone turnover (P1NP, \u03b2-CTX) will be measured at baseline and at 6 weeks. Primary human osteoblasts (not obtained from these participants) will be stimulated with pooled sera from the placebo and shatavari supplementation conditions to assess markers of osteoblast (bone-building) activity.",
        "text": "Assessing the Effect of Shatavari Supplementation on Bone and Skeletal Muscle Health in Healthy Postmenopausal Women: A Randomised Double Blind Clinical Trial | Shatavari is a plant that grows in Nepal, Sri Lanka, India and the Himalayas and its root has long been used in Ayurvedic medicine. Its traditional uses include supporting women's health, particularly during breastfeeding and during the perimenopausal period. Shatavari has been found to contain substances that have similar chemical properties to estrogen. A decrease in the amount of ovarian estrogen production causes the menopause and this reduction in circulating estrogen has widespread effects, including promoting a decrease in bone density. This increases the risk of bone fractures. Having less oestrogen is also thought to contribute to a loss of muscle strength in postmenopausal women.\n\nAs shatavari may act on the body's tissues in a similar way to estrogen, shatavari supplementation may represent one way of preventing postmenopausal bone and muscle loss. This study will investigate these questions. 24 healthy postmenopausal women aged 60 years or older will be recruited. The participants will be randomly assigned to consume shatavari (1000 mg per day, equivalent to 26,500 mg per day fresh weight shatavari) or placebo (1000 mg per day magnesium stearate) for 6 weeks. Handgrip and knee extensor strength will be measured at baseline and at 6 weeks. Vastus lateralis (VL) muscle biopsy samples will be obtained at baseline and at 6 weeks and analysed for markers of muscle function and protein turnover. Plasma and serum samples will be collected via venepuncture and markers of bone turnover (P1NP, \u03b2-CTX) will be measured at baseline and at 6 weeks. Primary human osteoblasts (not obtained from these participants) will be stimulated with pooled sera from the placebo and shatavari supplementation conditions to assess markers of osteoblast (bone-building) activity.",
        "tokens": "['Assessing', 'the', 'Effect', 'of', 'Shatavari', 'Supplementation', 'on', 'Bone', 'and', 'Skeletal', 'Muscle', 'Health', 'in', 'Healthy', 'Postmenopausal', 'Women', ':', 'A', 'Randomised', 'Double', 'Blind', 'Clinical', 'Trial', '|', 'Shatavari', 'is', 'a', 'plant', 'that', 'grows', 'in', 'Nepal', ',', 'Sri', 'Lanka', ',', 'India', 'and', 'the', 'Himalayas', 'and', 'its', 'root', 'has', 'long', 'been', 'used', 'in', 'Ayurvedic', 'medicine', '.', 'Its', 'traditional', 'uses', 'include', 'supporting', 'women', \"'s\", 'health', ',', 'particularly', 'during', 'breastfeeding', 'and', 'during', 'the', 'perimenopausal', 'period', '.', 'Shatavari', 'has', 'been', 'found', 'to', 'contain', 'substances', 'that', 'have', 'similar', 'chemical', 'properties', 'to', 'estrogen', '.', 'A', 'decrease', 'in', 'the', 'amount', 'of', 'ovarian', 'estrogen', 'production', 'causes', 'the', 'menopause', 'and', 'this', 'reduction', 'in', 'circulating', 'estrogen', 'has', 'widespread', 'effects', ',', 'including', 'promoting', 'a', 'decrease', 'in', 'bone', 'density', '.', 'This', 'increases', 'the', 'risk', 'of', 'bone', 'fractures', '.', 'Having', 'less', 'oestrogen', 'is', 'also', 'thought', 'to', 'contribute', 'to', 'a', 'loss', 'of', 'muscle', 'strength', 'in', 'postmenopausal', 'women', '.', '\\n\\n', 'As', 'shatavari', 'may', 'act', 'on', 'the', 'body', \"'s\", 'tissues', 'in', 'a', 'similar', 'way', 'to', 'estrogen', ',', 'shatavari', 'supplementation', 'may', 'represent', 'one', 'way', 'of', 'preventing', 'postmenopausal', 'bone', 'and', 'muscle', 'loss', '.', 'This', 'study', 'will', 'investigate', 'these', 'questions', '.', '24', 'healthy', 'postmenopausal', 'women', 'aged', '60', 'years', 'or', 'older', 'will', 'be', 'recruited', '.', 'The', 'participants', 'will', 'be', 'randomly', 'assigned', 'to', 'consume', 'shatavari', '(', '1000', 'mg', 'per', 'day', ',', 'equivalent', 'to', '26,500', 'mg', 'per', 'day', 'fresh', 'weight', 'shatavari', ')', 'or', 'placebo', '(', '1000', 'mg', 'per', 'day', 'magnesium', 'stearate', ')', 'for', '6', 'weeks', '.', 'Handgrip', 'and', 'knee', 'extensor', 'strength', 'will', 'be', 'measured', 'at', 'baseline', 'and', 'at', '6', 'weeks', '.', 'Vastus', 'lateralis', '(', 'VL', ')', 'muscle', 'biopsy', 'samples', 'will', 'be', 'obtained', 'at', 'baseline', 'and', 'at', '6', 'weeks', 'and', 'analysed', 'for', 'markers', 'of', 'muscle', 'function', 'and', 'protein', 'turnover', '.', 'Plasma', 'and', 'serum', 'samples', 'will', 'be', 'collected', 'via', 'venepuncture', 'and', 'markers', 'of', 'bone', 'turnover', '(', 'P1NP', ',', '\u03b2', '-', 'CTX', ')', 'will', 'be', 'measured', 'at', 'baseline', 'and', 'at', '6', 'weeks', '.', 'Primary', 'human', 'osteoblasts', '(', 'not', 'obtained', 'from', 'these', 'participants', ')', 'will', 'be', 'stimulated', 'with', 'pooled', 'sera', 'from', 'the', 'placebo', 'and', 'shatavari', 'supplementation', 'conditions', 'to', 'assess', 'markers', 'of', 'osteoblast', '(', 'bone', '-', 'building', ')', 'activity', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 49,
                "text": "Shatavari Supplementation",
                "type": "OTHER"
            },
            {
                "start": 96,
                "end": 110,
                "text": "Postmenopausal",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 170,
                "text": "Shatavari",
                "type": "OTHER"
            },
            {
                "start": 421,
                "end": 430,
                "text": "Shatavari",
                "type": "OTHER"
            },
            {
                "start": 838,
                "end": 852,
                "text": "postmenopausal",
                "type": "CONDITION"
            },
            {
                "start": 864,
                "end": 873,
                "text": "shatavari",
                "type": "OTHER"
            },
            {
                "start": 934,
                "end": 959,
                "text": "shatavari supplementation",
                "type": "OTHER"
            },
            {
                "start": 1089,
                "end": 1103,
                "text": "postmenopausal",
                "type": "CONDITION"
            },
            {
                "start": 1206,
                "end": 1215,
                "text": "shatavari",
                "type": "OTHER"
            },
            {
                "start": 1279,
                "end": 1288,
                "text": "shatavari",
                "type": "OTHER"
            },
            {
                "start": 1318,
                "end": 1336,
                "text": "magnesium stearate",
                "type": "DRUG"
            },
            {
                "start": 1856,
                "end": 1881,
                "text": "shatavari supplementation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00549718",
        "study_official_title": "A Phase 3 Randomized, Placebo-Controlled, CLinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia ",
        "study_brief_summary": " Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.",
        "text": "A Phase 3 Randomized, Placebo-Controlled, CLinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia | Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.",
        "tokens": "['A', 'Phase', '3', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'CLinical', 'Trial', 'to', 'Study', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Three', 'Doses', 'of', 'Lurasidone', 'HCl', 'in', 'Acutely', 'Psychotic', 'Patients', 'With', 'Schizophrenia', '|', 'Lurasidone', 'HCl', 'is', 'a', 'compound', 'being', 'developed', 'for', 'the', 'treatment', 'of', 'schizophrenia', '.', 'This', 'clinical', 'study', 'is', 'designed', 'to', 'test', 'the', 'hypothesis', 'that', 'lurasidone', 'is', 'more', 'efficacious', 'than', 'placebo', '.', 'The', 'study', 'will', 'also', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'lurasidone', 'as', 'compared', 'to', 'placebo', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 29,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 108,
                "end": 122,
                "text": "Lurasidone HCl",
                "type": "DRUG"
            },
            {
                "start": 126,
                "end": 143,
                "text": "Acutely Psychotic",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 171,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 174,
                "end": 188,
                "text": "Lurasidone HCl",
                "type": "DRUG"
            },
            {
                "start": 240,
                "end": 253,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 315,
                "end": 325,
                "text": "lurasidone",
                "type": "DRUG"
            },
            {
                "start": 351,
                "end": 358,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 420,
                "end": 430,
                "text": "lurasidone",
                "type": "DRUG"
            },
            {
                "start": 446,
                "end": 453,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02924194",
        "study_official_title": "Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (nbM) to Treat Parkinson's Patients With Mild Cognitive Impairment, Amnestic Subtype ",
        "study_brief_summary": " The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation of the nucleus basalis of Meynert (also called the \"nbM\") at improving memory in Parkinson's disease patients with mild cognitive impairments and memory difficulties. Patients with Parkinson's disease (PD) that are eligible for Deep Brain Stimulation (DBS) therapy for improvement of their motor symptoms and with evidence of mild cognitive impairments and memory difficulties will be enrolled.",
        "text": "Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (nbM) to Treat Parkinson's Patients With Mild Cognitive Impairment, Amnestic Subtype | The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation of the nucleus basalis of Meynert (also called the \"nbM\") at improving memory in Parkinson's disease patients with mild cognitive impairments and memory difficulties. Patients with Parkinson's disease (PD) that are eligible for Deep Brain Stimulation (DBS) therapy for improvement of their motor symptoms and with evidence of mild cognitive impairments and memory difficulties will be enrolled.",
        "tokens": "['Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'of', 'the', 'Nucleus', 'Basalis', 'of', 'Meynert', '(', 'nbM', ')', 'to', 'Treat', 'Parkinson', \"'s\", 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', ',', 'Amnestic', 'Subtype', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'effectiveness', 'of', 'deep', 'brain', 'stimulation', 'of', 'the', 'nucleus', 'basalis', 'of', 'Meynert', '(', 'also', 'called', 'the', '\"', 'nbM', '\"', ')', 'at', 'improving', 'memory', 'in', 'Parkinson', \"'s\", 'disease', 'patients', 'with', 'mild', 'cognitive', 'impairments', 'and', 'memory', 'difficulties', '.', 'Patients', 'with', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'that', 'are', 'eligible', 'for', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'therapy', 'for', 'improvement', 'of', 'their', 'motor', 'symptoms', 'and', 'with', 'evidence', 'of', 'mild', 'cognitive', 'impairments', 'and', 'memory', 'difficulties', 'will', 'be', 'enrolled', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 62,
                "text": "Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert",
                "type": "OTHER"
            },
            {
                "start": 78,
                "end": 98,
                "text": "Parkinson's Patients",
                "type": "CONDITION"
            },
            {
                "start": 104,
                "end": 147,
                "text": "Mild Cognitive Impairment, Amnestic Subtype",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 279,
                "text": "deep brain stimulation of the nucleus basalis of Meynert",
                "type": "OTHER"
            },
            {
                "start": 327,
                "end": 346,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 361,
                "end": 387,
                "text": "mild cognitive impairments",
                "type": "CONDITION"
            },
            {
                "start": 392,
                "end": 411,
                "text": "memory difficulties",
                "type": "CONDITION"
            },
            {
                "start": 427,
                "end": 446,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 448,
                "end": 450,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 474,
                "end": 496,
                "text": "Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 498,
                "end": 501,
                "text": "DBS",
                "type": "OTHER"
            },
            {
                "start": 572,
                "end": 598,
                "text": "mild cognitive impairments",
                "type": "CONDITION"
            },
            {
                "start": 603,
                "end": 622,
                "text": "memory difficulties",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00000514",
        "study_official_title": "The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.",
        "study_brief_summary": null,
        "text": "The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.",
        "tokens": "['The', 'primary', 'objective', 'was', 'to', 'assess', 'whether', 'long', '-', 'term', 'administration', 'of', 'antihypertensive', 'therapy', 'to', 'elderly', 'subjects', 'with', 'isolated', 'systolic', 'hypertension', 'reduced', 'the', 'combined', 'incidence', 'of', 'fatal', 'and', 'non', '-', 'fatal', 'stroke', '.', 'The', 'secondary', 'objectives', 'were', 'to', 'evaluate', ':', 'the', 'effect', 'of', 'long', '-', 'term', 'antihypertensive', 'therapy', 'on', 'mortality', 'from', 'any', 'cause', 'in', 'elderly', 'people', 'with', 'isolated', 'systolic', 'hypertension', ';', 'possible', 'adverse', 'effects', 'of', 'chronic', 'use', 'of', 'antihypertensive', 'drug', 'treatment', 'in', 'this', 'population', ';', 'the', 'effect', 'of', 'therapy', 'on', 'indices', 'of', 'quality', '-', 'of', '-', 'life', ';', 'the', 'natural', 'history', 'of', 'isolated', 'systolic', 'hypertension', 'in', 'the', 'placebo', 'population', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'O', 'O']",
        "entities": [
            {
                "start": 72,
                "end": 96,
                "text": "antihypertensive therapy",
                "type": "DRUG"
            },
            {
                "start": 122,
                "end": 152,
                "text": "isolated systolic hypertension",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 213,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 282,
                "end": 306,
                "text": "antihypertensive therapy",
                "type": "DRUG"
            },
            {
                "start": 358,
                "end": 388,
                "text": "isolated systolic hypertension",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 464,
                "text": "antihypertensive drug treatment",
                "type": "DRUG"
            },
            {
                "start": 561,
                "end": 591,
                "text": "isolated systolic hypertension",
                "type": "CONDITION"
            },
            {
                "start": 599,
                "end": 606,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03626727",
        "study_official_title": "Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem\u00ae) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia ",
        "study_brief_summary": " The study evaluates whether the use of Sodium Oxybate (Xyrem\u00ae) in TBI patients will be effective in reducing symptoms of post traumatic narcolepsy and post traumatic hypersomnia.",
        "text": "Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem\u00ae) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia | The study evaluates whether the use of Sodium Oxybate (Xyrem\u00ae) in TBI patients will be effective in reducing symptoms of post traumatic narcolepsy and post traumatic hypersomnia.",
        "tokens": "['Open', '-', 'label', 'Clinical', 'Trial', 'to', 'Evaluate', 'the', 'Efficacy', 'of', 'Sodium', 'Oxybate', '(', 'Xyrem', '\u00ae', ')', 'in', 'the', 'Treatment', 'of', 'Two', 'Under', '-', 'recognized', 'Clinical', 'Conditions', ':', 'Post', '-', 'traumatic', 'Narcolepsy', 'and', 'Post', '-', 'traumatic', 'Hypersomnia', '|', 'The', 'study', 'evaluates', 'whether', 'the', 'use', 'of', 'Sodium', 'Oxybate', '(', 'Xyrem', '\u00ae', ')', 'in', 'TBI', 'patients', 'will', 'be', 'effective', 'in', 'reducing', 'symptoms', 'of', 'post', 'traumatic', 'narcolepsy', 'and', 'post', 'traumatic', 'hypersomnia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 54,
                "end": 68,
                "text": "Sodium Oxybate",
                "type": "DRUG"
            },
            {
                "start": 70,
                "end": 75,
                "text": "Xyrem",
                "type": "DRUG"
            },
            {
                "start": 140,
                "end": 165,
                "text": "Post-traumatic Narcolepsy",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 196,
                "text": "Post-traumatic Hypersomnia",
                "type": "CONDITION"
            },
            {
                "start": 238,
                "end": 252,
                "text": "Sodium Oxybate",
                "type": "DRUG"
            },
            {
                "start": 254,
                "end": 259,
                "text": "Xyrem",
                "type": "DRUG"
            },
            {
                "start": 265,
                "end": 268,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 325,
                "end": 345,
                "text": "traumatic narcolepsy",
                "type": "CONDITION"
            },
            {
                "start": 350,
                "end": 376,
                "text": "post traumatic hypersomnia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00809679",
        "study_official_title": "A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled, Pilot Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia ",
        "study_brief_summary": " The purpose of this study is to evaluate the safety and efficacy of T-62 in subjects with postherpetic neuralgia.",
        "text": "A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled, Pilot Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia | The purpose of this study is to evaluate the safety and efficacy of T-62 in subjects with postherpetic neuralgia.",
        "tokens": "['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Parallel', ',', 'Placebo', '-', 'Controlled', ',', 'Pilot', 'Analgesic', 'Efficacy', 'and', 'Safety', 'Study', 'of', 'T-62', 'in', 'Subjects', 'With', 'Postherpetic', 'Neuralgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'T-62', 'in', 'subjects', 'with', 'postherpetic', 'neuralgia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 116,
                "end": 120,
                "text": "T-62",
                "type": "DRUG"
            },
            {
                "start": 138,
                "end": 160,
                "text": "Postherpetic Neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 235,
                "text": "T-62",
                "type": "DRUG"
            },
            {
                "start": 253,
                "end": 275,
                "text": "postherpetic neuralgia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05314348",
        "study_official_title": "Exploring the Electro-mechanical Coupling of Fasciculations in Motor Neuron Disease Using Surface Electromyography and Ultrasound: a Feasibility Study ",
        "study_brief_summary": " Patients with motor neurone disease typically experience relentless motor decline and die within three years of symptom onset from respiratory muscle weakness. There are currently no effective therapies and the discovery of novel therapies is hampered by the lack of a sensitive disease biomarker. Consequently, there is a huge drive to discover novel biomarkers, which can reliably track disease progression over time. These can then be incorporated into clinical drug trials to expedite effective drug discovery.\n\nMuscle fasciculations represent the hyperexcitability of diseased motor neurons and are almost universally present from the early stages of MND. We predict that the site, frequency and shape of fasciculations might provide a sensitive measure of disease progression in an individual.\n\nWe have been conducting a 12-month longitudinal study of 25 patients, performing high-density surface EMG every two months. We have validated an automated technique to process these large data sets. Ultrasound is widely used in clinical medicine to assess anatomical structure in a safe and non-invasive way. Dr Emma Hodson-Tole (Manchester Metropolitan University) and her group have been applying this to the analysis of fasciculations in healthy individuals and patients with MND.\n\nThis collaborative project will explore combining these two techniques simultaneously in patients with motor neuron disease and control subjects. The goal is to explore the nature of electro-mechanical coupling related to fasciculations and to determine whether any of these properties are pathophysiological. This would complement other studies from our two groups, investigating the natural history and potential utility of fasciculations as a biomarker of motor neuron health in MND.",
        "text": "Exploring the Electro-mechanical Coupling of Fasciculations in Motor Neuron Disease Using Surface Electromyography and Ultrasound: a Feasibility Study | Patients with motor neurone disease typically experience relentless motor decline and die within three years of symptom onset from respiratory muscle weakness. There are currently no effective therapies and the discovery of novel therapies is hampered by the lack of a sensitive disease biomarker. Consequently, there is a huge drive to discover novel biomarkers, which can reliably track disease progression over time. These can then be incorporated into clinical drug trials to expedite effective drug discovery.\n\nMuscle fasciculations represent the hyperexcitability of diseased motor neurons and are almost universally present from the early stages of MND. We predict that the site, frequency and shape of fasciculations might provide a sensitive measure of disease progression in an individual.\n\nWe have been conducting a 12-month longitudinal study of 25 patients, performing high-density surface EMG every two months. We have validated an automated technique to process these large data sets. Ultrasound is widely used in clinical medicine to assess anatomical structure in a safe and non-invasive way. Dr Emma Hodson-Tole (Manchester Metropolitan University) and her group have been applying this to the analysis of fasciculations in healthy individuals and patients with MND.\n\nThis collaborative project will explore combining these two techniques simultaneously in patients with motor neuron disease and control subjects. The goal is to explore the nature of electro-mechanical coupling related to fasciculations and to determine whether any of these properties are pathophysiological. This would complement other studies from our two groups, investigating the natural history and potential utility of fasciculations as a biomarker of motor neuron health in MND.",
        "tokens": "['Exploring', 'the', 'Electro', '-', 'mechanical', 'Coupling', 'of', 'Fasciculations', 'in', 'Motor', 'Neuron', 'Disease', 'Using', 'Surface', 'Electromyography', 'and', 'Ultrasound', ':', 'a', 'Feasibility', 'Study', '|', 'Patients', 'with', 'motor', 'neurone', 'disease', 'typically', 'experience', 'relentless', 'motor', 'decline', 'and', 'die', 'within', 'three', 'years', 'of', 'symptom', 'onset', 'from', 'respiratory', 'muscle', 'weakness', '.', 'There', 'are', 'currently', 'no', 'effective', 'therapies', 'and', 'the', 'discovery', 'of', 'novel', 'therapies', 'is', 'hampered', 'by', 'the', 'lack', 'of', 'a', 'sensitive', 'disease', 'biomarker', '.', 'Consequently', ',', 'there', 'is', 'a', 'huge', 'drive', 'to', 'discover', 'novel', 'biomarkers', ',', 'which', 'can', 'reliably', 'track', 'disease', 'progression', 'over', 'time', '.', 'These', 'can', 'then', 'be', 'incorporated', 'into', 'clinical', 'drug', 'trials', 'to', 'expedite', 'effective', 'drug', 'discovery', '.', '\\n\\n', 'Muscle', 'fasciculations', 'represent', 'the', 'hyperexcitability', 'of', 'diseased', 'motor', 'neurons', 'and', 'are', 'almost', 'universally', 'present', 'from', 'the', 'early', 'stages', 'of', 'MND', '.', 'We', 'predict', 'that', 'the', 'site', ',', 'frequency', 'and', 'shape', 'of', 'fasciculations', 'might', 'provide', 'a', 'sensitive', 'measure', 'of', 'disease', 'progression', 'in', 'an', 'individual', '.', '\\n\\n', 'We', 'have', 'been', 'conducting', 'a', '12', '-', 'month', 'longitudinal', 'study', 'of', '25', 'patients', ',', 'performing', 'high', '-', 'density', 'surface', 'EMG', 'every', 'two', 'months', '.', 'We', 'have', 'validated', 'an', 'automated', 'technique', 'to', 'process', 'these', 'large', 'data', 'sets', '.', 'Ultrasound', 'is', 'widely', 'used', 'in', 'clinical', 'medicine', 'to', 'assess', 'anatomical', 'structure', 'in', 'a', 'safe', 'and', 'non', '-', 'invasive', 'way', '.', 'Dr', 'Emma', 'Hodson', '-', 'Tole', '(', 'Manchester', 'Metropolitan', 'University', ')', 'and', 'her', 'group', 'have', 'been', 'applying', 'this', 'to', 'the', 'analysis', 'of', 'fasciculations', 'in', 'healthy', 'individuals', 'and', 'patients', 'with', 'MND', '.', '\\n\\n', 'This', 'collaborative', 'project', 'will', 'explore', 'combining', 'these', 'two', 'techniques', 'simultaneously', 'in', 'patients', 'with', 'motor', 'neuron', 'disease', 'and', 'control', 'subjects', '.', 'The', 'goal', 'is', 'to', 'explore', 'the', 'nature', 'of', 'electro', '-', 'mechanical', 'coupling', 'related', 'to', 'fasciculations', 'and', 'to', 'determine', 'whether', 'any', 'of', 'these', 'properties', 'are', 'pathophysiological', '.', 'This', 'would', 'complement', 'other', 'studies', 'from', 'our', 'two', 'groups', ',', 'investigating', 'the', 'natural', 'history', 'and', 'potential', 'utility', 'of', 'fasciculations', 'as', 'a', 'biomarker', 'of', 'motor', 'neuron', 'health', 'in', 'MND', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 63,
                "end": 83,
                "text": "Motor Neuron Disease",
                "type": "CONDITION"
            },
            {
                "start": 167,
                "end": 188,
                "text": "motor neurone disease",
                "type": "CONDITION"
            },
            {
                "start": 809,
                "end": 812,
                "text": "MND",
                "type": "CONDITION"
            },
            {
                "start": 1433,
                "end": 1436,
                "text": "MND",
                "type": "CONDITION"
            },
            {
                "start": 1542,
                "end": 1562,
                "text": "motor neuron disease",
                "type": "CONDITION"
            },
            {
                "start": 1921,
                "end": 1924,
                "text": "MND",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05254964",
        "study_official_title": "Effect of Intensive Cognitive Rehabilitation on Cognitive, Motor, and Language Functional Networks in Subacute Stroke Patient ",
        "study_brief_summary": " Altered brain networks, including cognitive, motor, and language networks, are investigated by intensive cognitive rehabilitation in subacute stroke patients.",
        "text": "Effect of Intensive Cognitive Rehabilitation on Cognitive, Motor, and Language Functional Networks in Subacute Stroke Patient | Altered brain networks, including cognitive, motor, and language networks, are investigated by intensive cognitive rehabilitation in subacute stroke patients.",
        "tokens": "['Effect', 'of', 'Intensive', 'Cognitive', 'Rehabilitation', 'on', 'Cognitive', ',', 'Motor', ',', 'and', 'Language', 'Functional', 'Networks', 'in', 'Subacute', 'Stroke', 'Patient', '|', 'Altered', 'brain', 'networks', ',', 'including', 'cognitive', ',', 'motor', ',', 'and', 'language', 'networks', ',', 'are', 'investigated', 'by', 'intensive', 'cognitive', 'rehabilitation', 'in', 'subacute', 'stroke', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 44,
                "text": "Intensive Cognitive Rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 102,
                "end": 117,
                "text": "Subacute Stroke",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 257,
                "text": "intensive cognitive rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 261,
                "end": 276,
                "text": "subacute stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03682081",
        "study_official_title": "Impact of Novel Rehabilitative Approaches for Dysphagia in Patients With Alzheimer's Disease and Related Dementias ",
        "study_brief_summary": " The overall purpose of this project is to develop effective dysphagia rehabilitative interventions for patients with Alzheimer's Disease and related dementias at risk for pneumonia development.",
        "text": "Impact of Novel Rehabilitative Approaches for Dysphagia in Patients With Alzheimer's Disease and Related Dementias | The overall purpose of this project is to develop effective dysphagia rehabilitative interventions for patients with Alzheimer's Disease and related dementias at risk for pneumonia development.",
        "tokens": "['Impact', 'of', 'Novel', 'Rehabilitative', 'Approaches', 'for', 'Dysphagia', 'in', 'Patients', 'With', 'Alzheimer', \"'s\", 'Disease', 'and', 'Related', 'Dementias', '|', 'The', 'overall', 'purpose', 'of', 'this', 'project', 'is', 'to', 'develop', 'effective', 'dysphagia', 'rehabilitative', 'interventions', 'for', 'patients', 'with', 'Alzheimer', \"'s\", 'Disease', 'and', 'related', 'dementias', 'at', 'risk', 'for', 'pneumonia', 'development', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 41,
                "text": "Rehabilitative Approaches",
                "type": "OTHER"
            },
            {
                "start": 46,
                "end": 55,
                "text": "Dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 73,
                "end": 92,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 105,
                "end": 114,
                "text": "Dementias",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 215,
                "text": "dysphagia rehabilitative interventions",
                "type": "OTHER"
            },
            {
                "start": 234,
                "end": 253,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 275,
                "text": "dementias",
                "type": "CONDITION"
            },
            {
                "start": 288,
                "end": 297,
                "text": "pneumonia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02099383",
        "study_official_title": "A Phase III Trial of BUN/Cr-based Hydration Therapy to Reduce Stroke-in-evolution and Improve Short-term Functional Outcomes for Dehydrated Patients With Acute Ischemic Stroke ",
        "study_brief_summary": " The investigators' preliminary findings suggest that providing patients with acute ischemic stroke hydration therapy on the basis of their presenting BUN/Cr ratio may help reduce the occurrence of stroke-in-evolution(SIE) and therefore improve prognosis.\n\nThe trial will be carried out in two parts. Part 1 assesses the rate of stroke-in-evolution 72 hours after the onset of stroke as a measure of the activity of BUN/Cr ratio based hydration therapy. Part 2, The investigators use two outcome measures, including Barthel index, and modified Rankin scale for neurological evaluation to assess whether BUN/Cr ratio based hydration therapy results in sustained clinical benefit at three months.",
        "text": "A Phase III Trial of BUN/Cr-based Hydration Therapy to Reduce Stroke-in-evolution and Improve Short-term Functional Outcomes for Dehydrated Patients With Acute Ischemic Stroke | The investigators' preliminary findings suggest that providing patients with acute ischemic stroke hydration therapy on the basis of their presenting BUN/Cr ratio may help reduce the occurrence of stroke-in-evolution(SIE) and therefore improve prognosis.\n\nThe trial will be carried out in two parts. Part 1 assesses the rate of stroke-in-evolution 72 hours after the onset of stroke as a measure of the activity of BUN/Cr ratio based hydration therapy. Part 2, The investigators use two outcome measures, including Barthel index, and modified Rankin scale for neurological evaluation to assess whether BUN/Cr ratio based hydration therapy results in sustained clinical benefit at three months.",
        "tokens": "['A', 'Phase', 'III', 'Trial', 'of', 'BUN', '/', 'Cr', '-', 'based', 'Hydration', 'Therapy', 'to', 'Reduce', 'Stroke', '-', 'in', '-', 'evolution', 'and', 'Improve', 'Short', '-', 'term', 'Functional', 'Outcomes', 'for', 'Dehydrated', 'Patients', 'With', 'Acute', 'Ischemic', 'Stroke', '|', 'The', 'investigators', \"'\", 'preliminary', 'findings', 'suggest', 'that', 'providing', 'patients', 'with', 'acute', 'ischemic', 'stroke', 'hydration', 'therapy', 'on', 'the', 'basis', 'of', 'their', 'presenting', 'BUN', '/', 'Cr', 'ratio', 'may', 'help', 'reduce', 'the', 'occurrence', 'of', 'stroke', '-', 'in', '-', 'evolution(SIE', ')', 'and', 'therefore', 'improve', 'prognosis', '.', '\\n\\n', 'The', 'trial', 'will', 'be', 'carried', 'out', 'in', 'two', 'parts', '.', 'Part', '1', 'assesses', 'the', 'rate', 'of', 'stroke', '-', 'in', '-', 'evolution', '72', 'hours', 'after', 'the', 'onset', 'of', 'stroke', 'as', 'a', 'measure', 'of', 'the', 'activity', 'of', 'BUN', '/', 'Cr', 'ratio', 'based', 'hydration', 'therapy', '.', 'Part', '2', ',', 'The', 'investigators', 'use', 'two', 'outcome', 'measures', ',', 'including', 'Barthel', 'index', ',', 'and', 'modified', 'Rankin', 'scale', 'for', 'neurological', 'evaluation', 'to', 'assess', 'whether', 'BUN', '/', 'Cr', 'ratio', 'based', 'hydration', 'therapy', 'results', 'in', 'sustained', 'clinical', 'benefit', 'at', 'three', 'months', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 51,
                "text": "BUN/Cr-based Hydration Therapy",
                "type": "OTHER"
            },
            {
                "start": 62,
                "end": 81,
                "text": "Stroke-in-evolution",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 139,
                "text": "Dehydrated",
                "type": "CONDITION"
            },
            {
                "start": 154,
                "end": 175,
                "text": "Acute Ischemic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 255,
                "end": 276,
                "text": "acute ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 277,
                "end": 340,
                "text": "hydration therapy on the basis of their presenting BUN/Cr ratio",
                "type": "OTHER"
            },
            {
                "start": 375,
                "end": 398,
                "text": "stroke-in-evolution(SIE",
                "type": "CONDITION"
            },
            {
                "start": 506,
                "end": 525,
                "text": "stroke-in-evolution",
                "type": "CONDITION"
            },
            {
                "start": 554,
                "end": 560,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 593,
                "end": 629,
                "text": "BUN/Cr ratio based hydration therapy",
                "type": "OTHER"
            },
            {
                "start": 780,
                "end": 816,
                "text": "BUN/Cr ratio based hydration therapy",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03488381",
        "study_official_title": "Effects of Repetitive Subconcussive Head Impacts on Ocular-motor Function and Brain-derived Blood Biomarker ",
        "study_brief_summary": " Repetitive head impacts in sports and military may cause deleterious effects in the nervous system. Investigators' previous works in football players have shown promising results in prediction of concussion and prevention of long-term defect using eye-movement paradigm (ocular-motor system) and blood biomarker. However, acute head impact effects on aforementioned parameters remain unknown. Thus, to answer a critical research question that whether or not ocular-motor system and brain-derived blood biomarker may be acutely altered following 10 successions of controlled soccer heading. To answer the question, investigators hypothesized that acute bout of soccer heading will not elicit noticeable change in subject's symptoms but to induce a transient defect in the ocular-motor system and increase plasma expression of brain-derived biomarker.",
        "text": "Effects of Repetitive Subconcussive Head Impacts on Ocular-motor Function and Brain-derived Blood Biomarker | Repetitive head impacts in sports and military may cause deleterious effects in the nervous system. Investigators' previous works in football players have shown promising results in prediction of concussion and prevention of long-term defect using eye-movement paradigm (ocular-motor system) and blood biomarker. However, acute head impact effects on aforementioned parameters remain unknown. Thus, to answer a critical research question that whether or not ocular-motor system and brain-derived blood biomarker may be acutely altered following 10 successions of controlled soccer heading. To answer the question, investigators hypothesized that acute bout of soccer heading will not elicit noticeable change in subject's symptoms but to induce a transient defect in the ocular-motor system and increase plasma expression of brain-derived biomarker.",
        "tokens": "['Effects', 'of', 'Repetitive', 'Subconcussive', 'Head', 'Impacts', 'on', 'Ocular', '-', 'motor', 'Function', 'and', 'Brain', '-', 'derived', 'Blood', 'Biomarker', '|', 'Repetitive', 'head', 'impacts', 'in', 'sports', 'and', 'military', 'may', 'cause', 'deleterious', 'effects', 'in', 'the', 'nervous', 'system', '.', 'Investigators', \"'\", 'previous', 'works', 'in', 'football', 'players', 'have', 'shown', 'promising', 'results', 'in', 'prediction', 'of', 'concussion', 'and', 'prevention', 'of', 'long', '-', 'term', 'defect', 'using', 'eye', '-', 'movement', 'paradigm', '(', 'ocular', '-', 'motor', 'system', ')', 'and', 'blood', 'biomarker', '.', 'However', ',', 'acute', 'head', 'impact', 'effects', 'on', 'aforementioned', 'parameters', 'remain', 'unknown', '.', 'Thus', ',', 'to', 'answer', 'a', 'critical', 'research', 'question', 'that', 'whether', 'or', 'not', 'ocular', '-', 'motor', 'system', 'and', 'brain', '-', 'derived', 'blood', 'biomarker', 'may', 'be', 'acutely', 'altered', 'following', '10', 'successions', 'of', 'controlled', 'soccer', 'heading', '.', 'To', 'answer', 'the', 'question', ',', 'investigators', 'hypothesized', 'that', 'acute', 'bout', 'of', 'soccer', 'heading', 'will', 'not', 'elicit', 'noticeable', 'change', 'in', 'subject', \"'s\", 'symptoms', 'but', 'to', 'induce', 'a', 'transient', 'defect', 'in', 'the', 'ocular', '-', 'motor', 'system', 'and', 'increase', 'plasma', 'expression', 'of', 'brain', '-', 'derived', 'biomarker', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 48,
                "text": "Repetitive Subconcussive Head Impacts",
                "type": "CONDITION"
            },
            {
                "start": 110,
                "end": 133,
                "text": "Repetitive head impacts",
                "type": "CONDITION"
            },
            {
                "start": 306,
                "end": 316,
                "text": "concussion",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02034357",
        "study_official_title": "Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease ",
        "study_brief_summary": " The purpose of this study is to determine the impact of sleep and breathing problems during sleep on memory, attention, and general well being (quality of life) in people with Parkinson Disease.",
        "text": "Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease | The purpose of this study is to determine the impact of sleep and breathing problems during sleep on memory, attention, and general well being (quality of life) in people with Parkinson Disease.",
        "tokens": "['Sleep', 'Disordered', 'Breathing', 'and', 'Its', 'Impact', 'on', 'Neuro', '-', 'cognitive', 'Performance', 'and', 'Quality', 'of', 'Life', 'in', 'Parkinson', 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'impact', 'of', 'sleep', 'and', 'breathing', 'problems', 'during', 'sleep', 'on', 'memory', ',', 'attention', ',', 'and', 'general', 'well', 'being', '(', 'quality', 'of', 'life', ')', 'in', 'people', 'with', 'Parkinson', 'Disease', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 26,
                "text": "Sleep Disordered Breathing",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 113,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 172,
                "end": 200,
                "text": "sleep and breathing problems",
                "type": "CONDITION"
            },
            {
                "start": 292,
                "end": 309,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01800786",
        "study_official_title": "Memory Consolidation in Obstructive Sleep Apnea ",
        "study_brief_summary": " The overarching goal of the research proposed here is to test the hypothesis (i) that the pathophysiological mechanisms of OSA lead to deterioration in sleep-dependent memory consolidation across memory systems, with the genetic marker APO\u03b54 as a modulator, and (ii) that CPAP can reverse some or all of these measured memory deficits.\n\nIn addition, we are exploring which aspects of OSA (e.g., changes in sleep architecture, measures of hypoxemia, or the EEG power spectrum) most likely impact sleep-dependent memory processing.To this end, we are using specific cognitive tasks for which sleep-dependent memory consolidation processes have previously been demonstrated by our group and others. In addition, we are carrying out quantitative EEG power spectral analyses, to delineate abnormal functioning of brain regions with more precision.",
        "text": "Memory Consolidation in Obstructive Sleep Apnea | The overarching goal of the research proposed here is to test the hypothesis (i) that the pathophysiological mechanisms of OSA lead to deterioration in sleep-dependent memory consolidation across memory systems, with the genetic marker APO\u03b54 as a modulator, and (ii) that CPAP can reverse some or all of these measured memory deficits.\n\nIn addition, we are exploring which aspects of OSA (e.g., changes in sleep architecture, measures of hypoxemia, or the EEG power spectrum) most likely impact sleep-dependent memory processing.To this end, we are using specific cognitive tasks for which sleep-dependent memory consolidation processes have previously been demonstrated by our group and others. In addition, we are carrying out quantitative EEG power spectral analyses, to delineate abnormal functioning of brain regions with more precision.",
        "tokens": "['Memory', 'Consolidation', 'in', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'overarching', 'goal', 'of', 'the', 'research', 'proposed', 'here', 'is', 'to', 'test', 'the', 'hypothesis', '(', 'i', ')', 'that', 'the', 'pathophysiological', 'mechanisms', 'of', 'OSA', 'lead', 'to', 'deterioration', 'in', 'sleep', '-', 'dependent', 'memory', 'consolidation', 'across', 'memory', 'systems', ',', 'with', 'the', 'genetic', 'marker', 'APO\u03b54', 'as', 'a', 'modulator', ',', 'and', '(', 'ii', ')', 'that', 'CPAP', 'can', 'reverse', 'some', 'or', 'all', 'of', 'these', 'measured', 'memory', 'deficits', '.', '\\n\\n', 'In', 'addition', ',', 'we', 'are', 'exploring', 'which', 'aspects', 'of', 'OSA', '(', 'e.g.', ',', 'changes', 'in', 'sleep', 'architecture', ',', 'measures', 'of', 'hypoxemia', ',', 'or', 'the', 'EEG', 'power', 'spectrum', ')', 'most', 'likely', 'impact', 'sleep', '-', 'dependent', 'memory', 'processing', '.', 'To', 'this', 'end', ',', 'we', 'are', 'using', 'specific', 'cognitive', 'tasks', 'for', 'which', 'sleep', '-', 'dependent', 'memory', 'consolidation', 'processes', 'have', 'previously', 'been', 'demonstrated', 'by', 'our', 'group', 'and', 'others', '.', 'In', 'addition', ',', 'we', 'are', 'carrying', 'out', 'quantitative', 'EEG', 'power', 'spectral', 'analyses', ',', 'to', 'delineate', 'abnormal', 'functioning', 'of', 'brain', 'regions', 'with', 'more', 'precision', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 47,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 176,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 326,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 434,
                "end": 437,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02848898",
        "study_official_title": "The Effects of Focal Vibration on Central and Peripheral Spasticity in Multiple Sclerosis Patients. A Randomized, Multicenter, Double Blinded vs Placebo Study ",
        "study_brief_summary": " This trial consists of application of little devices (named Equistasi\u00ae) generating focal vibrations to treat spasticity in neurological patients, affected by multiple sclerosis. The expected effects are on gait and postural instability.",
        "text": "The Effects of Focal Vibration on Central and Peripheral Spasticity in Multiple Sclerosis Patients. A Randomized, Multicenter, Double Blinded vs Placebo Study | This trial consists of application of little devices (named Equistasi\u00ae) generating focal vibrations to treat spasticity in neurological patients, affected by multiple sclerosis. The expected effects are on gait and postural instability.",
        "tokens": "['The', 'Effects', 'of', 'Focal', 'Vibration', 'on', 'Central', 'and', 'Peripheral', 'Spasticity', 'in', 'Multiple', 'Sclerosis', 'Patients', '.', 'A', 'Randomized', ',', 'Multicenter', ',', 'Double', 'Blinded', 'vs', 'Placebo', 'Study', '|', 'This', 'trial', 'consists', 'of', 'application', 'of', 'little', 'devices', '(', 'named', 'Equistasi', '\u00ae', ')', 'generating', 'focal', 'vibrations', 'to', 'treat', 'spasticity', 'in', 'neurological', 'patients', ',', 'affected', 'by', 'multiple', 'sclerosis', '.', 'The', 'expected', 'effects', 'are', 'on', 'gait', 'and', 'postural', 'instability', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 30,
                "text": "Focal Vibration",
                "type": "OTHER"
            },
            {
                "start": 34,
                "end": 67,
                "text": "Central and Peripheral Spasticity",
                "type": "CONDITION"
            },
            {
                "start": 71,
                "end": 89,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 152,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 221,
                "end": 230,
                "text": "Equistasi",
                "type": "OTHER"
            },
            {
                "start": 244,
                "end": 260,
                "text": "focal vibrations",
                "type": "OTHER"
            },
            {
                "start": 270,
                "end": 280,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 319,
                "end": 337,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01475383",
        "study_official_title": "A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Of The Safety And Efficacy Of PF-03654746 In Adults With Tourette's Syndrome ",
        "study_brief_summary": " The purpose of this study is to evaluate the safety and efficacy of an investigational compound designated PF-03654746 compared to placebo in the treatment of adults with Tourette's Syndrome. The study will also explore the pharmacokinetics of PF-03654746 in adults with Tourette's Syndrome.",
        "text": "A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Of The Safety And Efficacy Of PF-03654746 In Adults With Tourette's Syndrome | The purpose of this study is to evaluate the safety and efficacy of an investigational compound designated PF-03654746 compared to placebo in the treatment of adults with Tourette's Syndrome. The study will also explore the pharmacokinetics of PF-03654746 in adults with Tourette's Syndrome.",
        "tokens": "['A', 'Phase', '2', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Cross', '-', 'Over', 'Study', 'Of', 'The', 'Safety', 'And', 'Efficacy', 'Of', 'PF-03654746', 'In', 'Adults', 'With', 'Tourette', \"'s\", 'Syndrome', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'an', 'investigational', 'compound', 'designated', 'PF-03654746', 'compared', 'to', 'placebo', 'in', 'the', 'treatment', 'of', 'adults', 'with', 'Tourette', \"'s\", 'Syndrome', '.', 'The', 'study', 'will', 'also', 'explore', 'the', 'pharmacokinetics', 'of', 'PF-03654746', 'in', 'adults', 'with', 'Tourette', \"'s\", 'Syndrome', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 49,
                "end": 56,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 116,
                "end": 127,
                "text": "PF-03654746",
                "type": "DRUG"
            },
            {
                "start": 143,
                "end": 162,
                "text": "Tourette's Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 272,
                "end": 283,
                "text": "PF-03654746",
                "type": "DRUG"
            },
            {
                "start": 296,
                "end": 303,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 336,
                "end": 355,
                "text": "Tourette's Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 409,
                "end": 420,
                "text": "PF-03654746",
                "type": "DRUG"
            },
            {
                "start": 436,
                "end": 455,
                "text": "Tourette's Syndrome",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00850421",
        "study_official_title": "A Single-Center Pharmacoeconomic Pilot Study of BOTOX\u00ae (Botulinum Toxin Type A) for the Prophylactic Treatment of Migraine Headaches ",
        "study_brief_summary": " The purposes of this study are to assess whether subjects treated with BOTOX will:\n\nhave a decrease in the frequency and intensity of migraine headaches\nexperience improvements in quality of life\nexperience a reduction in the frequency of health care services obtained.",
        "text": "A Single-Center Pharmacoeconomic Pilot Study of BOTOX\u00ae (Botulinum Toxin Type A) for the Prophylactic Treatment of Migraine Headaches | The purposes of this study are to assess whether subjects treated with BOTOX will:\n\nhave a decrease in the frequency and intensity of migraine headaches\nexperience improvements in quality of life\nexperience a reduction in the frequency of health care services obtained.",
        "tokens": "['A', 'Single', '-', 'Center', 'Pharmacoeconomic', 'Pilot', 'Study', 'of', 'BOTOX', '\u00ae', '(', 'Botulinum', 'Toxin', 'Type', 'A', ')', 'for', 'the', 'Prophylactic', 'Treatment', 'of', 'Migraine', 'Headaches', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', 'to', 'assess', 'whether', 'subjects', 'treated', 'with', 'BOTOX', 'will', ':', '\\n\\n', 'have', 'a', 'decrease', 'in', 'the', 'frequency', 'and', 'intensity', 'of', 'migraine', 'headaches', '\\n', 'experience', 'improvements', 'in', 'quality', 'of', 'life', '\\n', 'experience', 'a', 'reduction', 'in', 'the', 'frequency', 'of', 'health', 'care', 'services', 'obtained', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 48,
                "end": 53,
                "text": "BOTOX",
                "type": "DRUG"
            },
            {
                "start": 56,
                "end": 78,
                "text": "Botulinum Toxin Type A",
                "type": "DRUG"
            },
            {
                "start": 114,
                "end": 132,
                "text": "Migraine Headaches",
                "type": "CONDITION"
            },
            {
                "start": 206,
                "end": 211,
                "text": "BOTOX",
                "type": "DRUG"
            },
            {
                "start": 269,
                "end": 287,
                "text": "migraine headaches",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00829361",
        "study_official_title": "Stroke Telemedicine for Arizona Rural Residents Trial ",
        "study_brief_summary": " The STARR network registry consists of a 4 spoke 1 hub system. Which will consist of prospective collection, recording, and regular analysis of telestroke patient consultation and care data for the purpose of quality measure assessment and improvement and benchmarking against other national and international telestroke programs.",
        "text": "Stroke Telemedicine for Arizona Rural Residents Trial | The STARR network registry consists of a 4 spoke 1 hub system. Which will consist of prospective collection, recording, and regular analysis of telestroke patient consultation and care data for the purpose of quality measure assessment and improvement and benchmarking against other national and international telestroke programs.",
        "tokens": "['Stroke', 'Telemedicine', 'for', 'Arizona', 'Rural', 'Residents', 'Trial', '|', 'The', 'STARR', 'network', 'registry', 'consists', 'of', 'a', '4', 'spoke', '1', 'hub', 'system', '.', 'Which', 'will', 'consist', 'of', 'prospective', 'collection', ',', 'recording', ',', 'and', 'regular', 'analysis', 'of', 'telestroke', 'patient', 'consultation', 'and', 'care', 'data', 'for', 'the', 'purpose', 'of', 'quality', 'measure', 'assessment', 'and', 'improvement', 'and', 'benchmarking', 'against', 'other', 'national', 'and', 'international', 'telestroke', 'programs', '.']",
        "token_bio_labels": "['B-COND', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 6,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 7,
                "end": 19,
                "text": "Telemedicine",
                "type": "OTHER"
            },
            {
                "start": 200,
                "end": 231,
                "text": "telestroke patient consultation",
                "type": "OTHER"
            },
            {
                "start": 333,
                "end": 385,
                "text": "other national and international telestroke programs",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04983368",
        "study_official_title": "XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem\u00ae in Healthy Elderly Volunteers ",
        "study_brief_summary": " Xanamem\u00ae is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Mild Cognitive Impairment in Alzheimer's disease.\n\nThe purpose of this study in older volunteers is to investigate the smallest dose of Xanamem\u00ae (5 mg or 10 mg) which works and to investigate which dose in this study will be used in the upcoming clinical trials in patients.",
        "text": "XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem\u00ae in Healthy Elderly Volunteers | Xanamem\u00ae is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Mild Cognitive Impairment in Alzheimer's disease.\n\nThe purpose of this study in older volunteers is to investigate the smallest dose of Xanamem\u00ae (5 mg or 10 mg) which works and to investigate which dose in this study will be used in the upcoming clinical trials in patients.",
        "tokens": "['XanaMIA', '-', 'DR', 'A', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Dose', 'Ranging', 'Study', 'to', 'Assess', 'the', 'Efficacy', ',', 'Pharmacodynamics', 'and', 'Safety', 'of', 'Xanamem', '\u00ae', 'in', 'Healthy', 'Elderly', 'Volunteers', '|', 'Xanamem', '\u00ae', 'is', 'being', 'developed', 'as', 'a', 'potential', 'drug', 'for', 'Mild', 'Cognitive', 'Impairment', 'in', 'Alzheimer', \"'s\", 'disease', '.', 'This', 'study', 'drug', 'has', 'been', 'designed', 'to', 'change', 'the', 'cortisol', 'levels', 'in', 'the', 'brain', '.', 'Cortisol', 'is', 'a', 'naturally', 'occurring', 'hormone', 'in', 'the', 'body', '.', 'It', 'is', 'believed', 'that', 'reducing', 'the', 'level', 'of', 'cortisol', 'will', 'be', 'a', 'benefit', 'in', 'the', 'treatment', 'of', 'Mild', 'Cognitive', 'Impairment', 'in', 'Alzheimer', \"'s\", 'disease', '.', '\\n\\n', 'The', 'purpose', 'of', 'this', 'study', 'in', 'older', 'volunteers', 'is', 'to', 'investigate', 'the', 'smallest', 'dose', 'of', 'Xanamem', '\u00ae', '(', '5', 'mg', 'or', '10', 'mg', ')', 'which', 'works', 'and', 'to', 'investigate', 'which', 'dose', 'in', 'this', 'study', 'will', 'be', 'used', 'in', 'the', 'upcoming', 'clinical', 'trials', 'in', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 27,
                "end": 34,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 121,
                "end": 128,
                "text": "Xanamem",
                "type": "DRUG"
            },
            {
                "start": 162,
                "end": 169,
                "text": "Xanamem",
                "type": "DRUG"
            },
            {
                "start": 622,
                "end": 629,
                "text": "Xanamem",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03484936",
        "study_official_title": "Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage ",
        "study_brief_summary": " The purpose of this study is to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.",
        "text": "Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage | The purpose of this study is to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.",
        "tokens": "['Safety', 'and', 'Efficacy', 'of', 'Remote', 'Ischemic', 'Conditioning', 'in', 'Patients', 'With', 'Spontaneous', 'Intracerebral', 'Hemorrhage', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'treatment', 'with', 'remote', 'ischemic', 'conditioning', 'is', 'of', 'sufficient', 'promise', 'to', 'improve', 'outcome', 'before', 'conducting', 'a', 'larger', 'clinical', 'trial', 'to', 'examine', 'its', 'effectiveness', 'as', 'a', 'treatment', 'for', 'intracerebral', 'hemorrhage', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 23,
                "end": 51,
                "text": "Remote Ischemic Conditioning",
                "type": "OTHER"
            },
            {
                "start": 69,
                "end": 105,
                "text": "Spontaneous Intracerebral Hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 201,
                "text": "remote ischemic conditioning",
                "type": "OTHER"
            },
            {
                "start": 336,
                "end": 360,
                "text": "intracerebral hemorrhage",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03071224",
        "study_official_title": "Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers ",
        "study_brief_summary": " The overall goal of this protocol is to evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.",
        "text": "Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers | The overall goal of this protocol is to evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.",
        "tokens": "['Phase', '1', 'Evaluation', 'of', '[', '18F]MK-6240', 'PET', 'as', 'an', 'Imaging', 'Marker', 'for', 'Tau', 'Protein', 'in', 'the', 'Brain', 'of', 'Patients', 'With', 'Alzheimer', \"'s\", 'Disease', 'Compared', 'to', 'Healthy', 'Volunteers', '|', 'The', 'overall', 'goal', 'of', 'this', 'protocol', 'is', 'to', 'evaluate', '[', '18F]MK-6240', '(', 'also', 'known', 'as', '[', '18F]MNI-946', ')', 'a', 'tau', 'targeted', 'radiopharmaceutical', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 106,
                "end": 125,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04994054",
        "study_official_title": "Effect of Silkworms (Bombyx Mori L.) Pupae Extracts on Musculoskeletal Biomarkers in Adults With With Relatively Low Muscle Mass: a Randomized, Double-blinded, Placebo-controlled Trial ",
        "study_brief_summary": " The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of silkworms (Bombyx mori L.) pupae extracts on muscle strength, muscle mass, and muscle function in adults with relative sarcopenia for 12 weeks.",
        "text": "Effect of Silkworms (Bombyx Mori L.) Pupae Extracts on Musculoskeletal Biomarkers in Adults With With Relatively Low Muscle Mass: a Randomized, Double-blinded, Placebo-controlled Trial | The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of silkworms (Bombyx mori L.) pupae extracts on muscle strength, muscle mass, and muscle function in adults with relative sarcopenia for 12 weeks.",
        "tokens": "['Effect', 'of', 'Silkworms', '(', 'Bombyx', 'Mori', 'L.', ')', 'Pupae', 'Extracts', 'on', 'Musculoskeletal', 'Biomarkers', 'in', 'Adults', 'With', 'With', 'Relatively', 'Low', 'Muscle', 'Mass', ':', 'a', 'Randomized', ',', 'Double', '-', 'blinded', ',', 'Placebo', '-', 'controlled', 'Trial', '|', 'The', 'investigators', 'conduct', 'a', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'study', 'to', 'investigate', 'the', 'effects', 'of', 'silkworms', '(', 'Bombyx', 'mori', 'L.', ')', 'pupae', 'extracts', 'on', 'muscle', 'strength', ',', 'muscle', 'mass', ',', 'and', 'muscle', 'function', 'in', 'adults', 'with', 'relative', 'sarcopenia', 'for', '12', 'weeks', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 51,
                "text": "Silkworms (Bombyx Mori L.) Pupae Extracts",
                "type": "OTHER"
            },
            {
                "start": 113,
                "end": 128,
                "text": "Low Muscle Mass",
                "type": "CONDITION"
            },
            {
                "start": 160,
                "end": 167,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 241,
                "end": 248,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 296,
                "end": 337,
                "text": "silkworms (Bombyx mori L.) pupae extracts",
                "type": "OTHER"
            },
            {
                "start": 406,
                "end": 425,
                "text": "relative sarcopenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03840265",
        "study_official_title": "Evaluation of Cerebrovascular Events in Patients With Occlusive Carotid Artery Disorders Based on Morphological and Hemodynamical Features ",
        "study_brief_summary": " As of today, no suitable multiparametric predictive method is available to properly estimate stroke risk in patients with carotid artery stenosis. Carotid artery stenosis is one of the proven risk factors of stroke incidence, but the indication of its intervention is merely the grade of stenosis itself. The current international guidelines suggest intervention for asymptomatic patients only with potentially high risk plaques but pharmacological treatment is advised to low risk patients. Unfortunately there is no proven and widely accepted system to distinguish these two categories of patients with carotid artery stenosis.\n\nIn this project the following parameters will be assessed both in asymptomatic and symptomatic patients: 1, preoperative stroke risk prediction based on comparative analysis of CT angiography (CTA) results of plaque morphology and ultrasound (US) based plaque elastography analysis, 2) intracranial bloodflow will be measured by transcranial Doppler sonography(TCD), 3) presence recent of silent brain ischemia on diffusion weighted imaging (DWI) MR (magnetic resonance), 4) retinal perfusion measurement by optical coherence tomography angiography (OCT). The investigators aim to establish a clinically meaningful and more accurate (than stenosis grade) stroke risk prediction algorithm for asymptomatic carotid stenosis patients based on these parameters.",
        "text": "Evaluation of Cerebrovascular Events in Patients With Occlusive Carotid Artery Disorders Based on Morphological and Hemodynamical Features | As of today, no suitable multiparametric predictive method is available to properly estimate stroke risk in patients with carotid artery stenosis. Carotid artery stenosis is one of the proven risk factors of stroke incidence, but the indication of its intervention is merely the grade of stenosis itself. The current international guidelines suggest intervention for asymptomatic patients only with potentially high risk plaques but pharmacological treatment is advised to low risk patients. Unfortunately there is no proven and widely accepted system to distinguish these two categories of patients with carotid artery stenosis.\n\nIn this project the following parameters will be assessed both in asymptomatic and symptomatic patients: 1, preoperative stroke risk prediction based on comparative analysis of CT angiography (CTA) results of plaque morphology and ultrasound (US) based plaque elastography analysis, 2) intracranial bloodflow will be measured by transcranial Doppler sonography(TCD), 3) presence recent of silent brain ischemia on diffusion weighted imaging (DWI) MR (magnetic resonance), 4) retinal perfusion measurement by optical coherence tomography angiography (OCT). The investigators aim to establish a clinically meaningful and more accurate (than stenosis grade) stroke risk prediction algorithm for asymptomatic carotid stenosis patients based on these parameters.",
        "tokens": "['Evaluation', 'of', 'Cerebrovascular', 'Events', 'in', 'Patients', 'With', 'Occlusive', 'Carotid', 'Artery', 'Disorders', 'Based', 'on', 'Morphological', 'and', 'Hemodynamical', 'Features', '|', 'As', 'of', 'today', ',', 'no', 'suitable', 'multiparametric', 'predictive', 'method', 'is', 'available', 'to', 'properly', 'estimate', 'stroke', 'risk', 'in', 'patients', 'with', 'carotid', 'artery', 'stenosis', '.', 'Carotid', 'artery', 'stenosis', 'is', 'one', 'of', 'the', 'proven', 'risk', 'factors', 'of', 'stroke', 'incidence', ',', 'but', 'the', 'indication', 'of', 'its', 'intervention', 'is', 'merely', 'the', 'grade', 'of', 'stenosis', 'itself', '.', 'The', 'current', 'international', 'guidelines', 'suggest', 'intervention', 'for', 'asymptomatic', 'patients', 'only', 'with', 'potentially', 'high', 'risk', 'plaques', 'but', 'pharmacological', 'treatment', 'is', 'advised', 'to', 'low', 'risk', 'patients', '.', 'Unfortunately', 'there', 'is', 'no', 'proven', 'and', 'widely', 'accepted', 'system', 'to', 'distinguish', 'these', 'two', 'categories', 'of', 'patients', 'with', 'carotid', 'artery', 'stenosis', '.', '\\n\\n', 'In', 'this', 'project', 'the', 'following', 'parameters', 'will', 'be', 'assessed', 'both', 'in', 'asymptomatic', 'and', 'symptomatic', 'patients', ':', '1', ',', 'preoperative', 'stroke', 'risk', 'prediction', 'based', 'on', 'comparative', 'analysis', 'of', 'CT', 'angiography', '(', 'CTA', ')', 'results', 'of', 'plaque', 'morphology', 'and', 'ultrasound', '(', 'US', ')', 'based', 'plaque', 'elastography', 'analysis', ',', '2', ')', 'intracranial', 'bloodflow', 'will', 'be', 'measured', 'by', 'transcranial', 'Doppler', 'sonography(TCD', ')', ',', '3', ')', 'presence', 'recent', 'of', 'silent', 'brain', 'ischemia', 'on', 'diffusion', 'weighted', 'imaging', '(', 'DWI', ')', 'MR', '(', 'magnetic', 'resonance', ')', ',', '4', ')', 'retinal', 'perfusion', 'measurement', 'by', 'optical', 'coherence', 'tomography', 'angiography', '(', 'OCT', ')', '.', 'The', 'investigators', 'aim', 'to', 'establish', 'a', 'clinically', 'meaningful', 'and', 'more', 'accurate', '(', 'than', 'stenosis', 'grade', ')', 'stroke', 'risk', 'prediction', 'algorithm', 'for', 'asymptomatic', 'carotid', 'stenosis', 'patients', 'based', 'on', 'these', 'parameters', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 36,
                "text": "Cerebrovascular Events",
                "type": "CONDITION"
            },
            {
                "start": 54,
                "end": 88,
                "text": "Occlusive Carotid Artery Disorders",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 240,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 263,
                "end": 286,
                "text": "carotid artery stenosis",
                "type": "CONDITION"
            },
            {
                "start": 288,
                "end": 311,
                "text": "Carotid artery stenosis",
                "type": "CONDITION"
            },
            {
                "start": 349,
                "end": 355,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 746,
                "end": 769,
                "text": "carotid artery stenosis",
                "type": "CONDITION"
            },
            {
                "start": 893,
                "end": 899,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1161,
                "end": 1182,
                "text": "silent brain ischemia",
                "type": "CONDITION"
            },
            {
                "start": 1427,
                "end": 1433,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1464,
                "end": 1493,
                "text": "asymptomatic carotid stenosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05590455",
        "study_official_title": "ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical Trial ",
        "study_brief_summary": " Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis meningitis in 3 countries (Brazil, Mozambique, and Zambia).",
        "text": "ANRS 12404 TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis: a Phase II, Multicenter, Randomized Clinical Trial | Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and corticosteroids) in HIV patients with tuberculosis meningitis in 3 countries (Brazil, Mozambique, and Zambia).",
        "tokens": "['ANRS', '12404', 'TIMPANI', ':', 'Tnf', 'Inhibitors', 'to', 'Reduce', 'Mortality', 'in', 'HIV-1', 'Infected', 'PAtients', 'With', 'Tuberculosis', 'meNIngitis', ':', 'a', 'Phase', 'II', ',', 'Multicenter', ',', 'Randomized', 'Clinical', 'Trial', '|', 'Randomized', 'phase', 'II', 'clinical', 'trial', 'which', 'aims', 'to', 'assess', 'the', 'impact', 'on', '3', '-', 'month', 'mortality', 'and', 'safety', 'of', 'adding', 'adalimumab', 'to', 'standard', 'treatment', '(', 'anti', '-', 'tuberculosis', 'drugs', 'and', 'corticosteroids', ')', 'in', 'HIV', 'patients', 'with', 'tuberculosis', 'meningitis', 'in', '3', 'countries', '(', 'Brazil', ',', 'Mozambique', ',', 'and', 'Zambia', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 34,
                "text": "Tnf Inhibitors",
                "type": "DRUG"
            },
            {
                "start": 58,
                "end": 63,
                "text": "HIV-1",
                "type": "CONDITION"
            },
            {
                "start": 87,
                "end": 110,
                "text": "Tuberculosis meNIngitis",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 284,
                "text": "adalimumab",
                "type": "DRUG"
            },
            {
                "start": 356,
                "end": 359,
                "text": "HIV",
                "type": "CONDITION"
            },
            {
                "start": 374,
                "end": 397,
                "text": "tuberculosis meningitis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00506415",
        "study_official_title": "A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon\u00ae 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline ",
        "study_brief_summary": " The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm^2.",
        "text": "A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon\u00ae 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline | The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm^2.",
        "tokens": "['A', '48', '-', 'Week', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Parallel', '-', 'Group', 'Evaluation', 'of', 'the', 'Comparative', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'Exelon', '\u00ae', '10', 'and', '15', 'cm^2', 'Patch', 'in', 'Patients', 'With', 'Mild', 'to', 'Moderate', 'Alzheimer', \"'s\", 'Disease', '(', 'AD', ')', 'Showing', 'Functional', 'and', 'Cognitive', 'Decline', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'support', 'the', 'optimal', 'use', 'of', 'rivastigmine', 'patch', 'in', 'long', '-', 'term', 'treatment', 'of', 'Alzheimer', \"'s\", 'Disease', 'in', 'patients', 'demonstrating', 'functional', 'and', 'cognitive', 'decline', 'at', 'the', 'target', 'maintenance', 'dose', 'of', 'rivastigmine', 'patch', '10', 'cm^2', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 133,
                "end": 139,
                "text": "Exelon",
                "type": "DRUG"
            },
            {
                "start": 179,
                "end": 215,
                "text": "Mild to Moderate Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 217,
                "end": 219,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 229,
                "end": 261,
                "text": "Functional and Cognitive Decline",
                "type": "CONDITION"
            },
            {
                "start": 324,
                "end": 336,
                "text": "rivastigmine",
                "type": "DRUG"
            },
            {
                "start": 369,
                "end": 388,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 415,
                "end": 447,
                "text": "functional and cognitive decline",
                "type": "CONDITION"
            },
            {
                "start": 482,
                "end": 494,
                "text": "rivastigmine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05239390",
        "study_official_title": "Phase IIA Open-Label, to Evaluate the Safety, Tolerability, and Efficacy Trend of SCI -110 in Patients With AD and Agitation ",
        "study_brief_summary": " As of today, there is no FDA-approved treatment for agitation in AD. Hence, it is still considered an unmet need.\n\nSporadic observation in healthy or diagnosed individuals indicated that cannabis products, in particular, THC have calming and anti-anxiety effects. These observations are supported by basic science data as well as animal experiments.\n\nSCI -110 is a combination of (1) dronabinol, the active ingredient in an FDA-approved synthetic analog of tetrahydrocannabinol, the psychoactive molecule in the cannabis plant, and (2) palmitoylethanolamide.\n\nIn the present study, the starting daily dose for all subjects is 2.5 mg dronabinol and 800 mg PEA and will be gradually increased (every 3 days an addition of 2.5 mg dronabinol per day, with no change in the PEA dose) to a maximum of 12.5 mg Dronebinol and 800 mg PEA per day. The study product will be given orally, twice daily, to add-on the medical treatment.\n\nStudy Duration per patient is up to 64 days: a. screening (3-21 days); b. treatment phase: (1) titration (15-23 days) of dronabinol from 2.5 to 12.5 mg or up to the maximal subject's tolerated dose (2) Stabilization phase (10 days) until end of treatment on the highest subject's daily tolerated dose. c. follow-up phase (7 days) - until the end-of-study.\n\nDuring the study, the tolerability of the drug, its safety (vital signs, physical examinations, blood, and urine tests and side effects follow-up) as well as changes in subject's condition (using CMAI, MMSE, SIB-8 questionnaires), appetite and sleep quality (SDI) will be followed.",
        "text": "Phase IIA Open-Label, to Evaluate the Safety, Tolerability, and Efficacy Trend of SCI -110 in Patients With AD and Agitation | As of today, there is no FDA-approved treatment for agitation in AD. Hence, it is still considered an unmet need.\n\nSporadic observation in healthy or diagnosed individuals indicated that cannabis products, in particular, THC have calming and anti-anxiety effects. These observations are supported by basic science data as well as animal experiments.\n\nSCI -110 is a combination of (1) dronabinol, the active ingredient in an FDA-approved synthetic analog of tetrahydrocannabinol, the psychoactive molecule in the cannabis plant, and (2) palmitoylethanolamide.\n\nIn the present study, the starting daily dose for all subjects is 2.5 mg dronabinol and 800 mg PEA and will be gradually increased (every 3 days an addition of 2.5 mg dronabinol per day, with no change in the PEA dose) to a maximum of 12.5 mg Dronebinol and 800 mg PEA per day. The study product will be given orally, twice daily, to add-on the medical treatment.\n\nStudy Duration per patient is up to 64 days: a. screening (3-21 days); b. treatment phase: (1) titration (15-23 days) of dronabinol from 2.5 to 12.5 mg or up to the maximal subject's tolerated dose (2) Stabilization phase (10 days) until end of treatment on the highest subject's daily tolerated dose. c. follow-up phase (7 days) - until the end-of-study.\n\nDuring the study, the tolerability of the drug, its safety (vital signs, physical examinations, blood, and urine tests and side effects follow-up) as well as changes in subject's condition (using CMAI, MMSE, SIB-8 questionnaires), appetite and sleep quality (SDI) will be followed.",
        "tokens": "['Phase', 'IIA', 'Open', '-', 'Label', ',', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'Trend', 'of', 'SCI', '-110', 'in', 'Patients', 'With', 'AD', 'and', 'Agitation', '|', 'As', 'of', 'today', ',', 'there', 'is', 'no', 'FDA', '-', 'approved', 'treatment', 'for', 'agitation', 'in', 'AD', '.', 'Hence', ',', 'it', 'is', 'still', 'considered', 'an', 'unmet', 'need', '.', '\\n\\n', 'Sporadic', 'observation', 'in', 'healthy', 'or', 'diagnosed', 'individuals', 'indicated', 'that', 'cannabis', 'products', ',', 'in', 'particular', ',', 'THC', 'have', 'calming', 'and', 'anti', '-', 'anxiety', 'effects', '.', 'These', 'observations', 'are', 'supported', 'by', 'basic', 'science', 'data', 'as', 'well', 'as', 'animal', 'experiments', '.', '\\n\\n', 'SCI', '-110', 'is', 'a', 'combination', 'of', '(', '1', ')', 'dronabinol', ',', 'the', 'active', 'ingredient', 'in', 'an', 'FDA', '-', 'approved', 'synthetic', 'analog', 'of', 'tetrahydrocannabinol', ',', 'the', 'psychoactive', 'molecule', 'in', 'the', 'cannabis', 'plant', ',', 'and', '(', '2', ')', 'palmitoylethanolamide', '.', '\\n\\n', 'In', 'the', 'present', 'study', ',', 'the', 'starting', 'daily', 'dose', 'for', 'all', 'subjects', 'is', '2.5', 'mg', 'dronabinol', 'and', '800', 'mg', 'PEA', 'and', 'will', 'be', 'gradually', 'increased', '(', 'every', '3', 'days', 'an', 'addition', 'of', '2.5', 'mg', 'dronabinol', 'per', 'day', ',', 'with', 'no', 'change', 'in', 'the', 'PEA', 'dose', ')', 'to', 'a', 'maximum', 'of', '12.5', 'mg', 'Dronebinol', 'and', '800', 'mg', 'PEA', 'per', 'day', '.', 'The', 'study', 'product', 'will', 'be', 'given', 'orally', ',', 'twice', 'daily', ',', 'to', 'add', '-', 'on', 'the', 'medical', 'treatment', '.', '\\n\\n', 'Study', 'Duration', 'per', 'patient', 'is', 'up', 'to', '64', 'days', ':', 'a.', 'screening', '(', '3', '-', '21', 'days', ')', ';', 'b.', 'treatment', 'phase', ':', '(', '1', ')', 'titration', '(', '15', '-', '23', 'days', ')', 'of', 'dronabinol', 'from', '2.5', 'to', '12.5', 'mg', 'or', 'up', 'to', 'the', 'maximal', 'subject', \"'s\", 'tolerated', 'dose', '(', '2', ')', 'Stabilization', 'phase', '(', '10', 'days', ')', 'until', 'end', 'of', 'treatment', 'on', 'the', 'highest', 'subject', \"'s\", 'daily', 'tolerated', 'dose', '.', 'c.', 'follow', '-', 'up', 'phase', '(', '7', 'days', ')', '-', 'until', 'the', 'end', '-', 'of', '-', 'study', '.', '\\n\\n', 'During', 'the', 'study', ',', 'the', 'tolerability', 'of', 'the', 'drug', ',', 'its', 'safety', '(', 'vital', 'signs', ',', 'physical', 'examinations', ',', 'blood', ',', 'and', 'urine', 'tests', 'and', 'side', 'effects', 'follow', '-', 'up', ')', 'as', 'well', 'as', 'changes', 'in', 'subject', \"'s\", 'condition', '(', 'using', 'CMAI', ',', 'MMSE', ',', 'SIB-8', 'questionnaires', ')', ',', 'appetite', 'and', 'sleep', 'quality', '(', 'SDI', ')', 'will', 'be', 'followed', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 82,
                "end": 90,
                "text": "SCI -110",
                "type": "DRUG"
            },
            {
                "start": 108,
                "end": 110,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 115,
                "end": 124,
                "text": "Agitation",
                "type": "CONDITION"
            },
            {
                "start": 179,
                "end": 188,
                "text": "agitation",
                "type": "CONDITION"
            },
            {
                "start": 192,
                "end": 194,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 322,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 348,
                "end": 351,
                "text": "THC",
                "type": "DRUG"
            },
            {
                "start": 478,
                "end": 486,
                "text": "SCI -110",
                "type": "DRUG"
            },
            {
                "start": 511,
                "end": 521,
                "text": "dronabinol",
                "type": "DRUG"
            },
            {
                "start": 584,
                "end": 604,
                "text": "tetrahydrocannabinol",
                "type": "DRUG"
            },
            {
                "start": 639,
                "end": 647,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 663,
                "end": 684,
                "text": "palmitoylethanolamide",
                "type": "DRUG"
            },
            {
                "start": 760,
                "end": 770,
                "text": "dronabinol",
                "type": "DRUG"
            },
            {
                "start": 782,
                "end": 785,
                "text": "PEA",
                "type": "DRUG"
            },
            {
                "start": 854,
                "end": 864,
                "text": "dronabinol",
                "type": "DRUG"
            },
            {
                "start": 896,
                "end": 899,
                "text": "PEA",
                "type": "DRUG"
            },
            {
                "start": 930,
                "end": 940,
                "text": "Dronebinol",
                "type": "DRUG"
            },
            {
                "start": 952,
                "end": 955,
                "text": "PEA",
                "type": "DRUG"
            },
            {
                "start": 1173,
                "end": 1183,
                "text": "dronabinol",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04849026",
        "study_official_title": "A Randomized, Open Label, Multiple-dose, 2-way Crossover, Phase I Study to Compare the Safety and Pharmacokinetics Profile of WID-CLZ18 and Clozaril 100 mg Tablet (Clozapine) After Oral Administration in Schizophrenia Patients ",
        "study_brief_summary": " This clinical study is a randomized, open label, multiple-dose, 2-way crossover, phase I (Bioequivalence) study to compare the safety and pharmacokinetics profile of WID-CLZ18 and Clozaril 100 mg tablet (Clozapine) after oral administration in schizophrenia patients.",
        "text": "A Randomized, Open Label, Multiple-dose, 2-way Crossover, Phase I Study to Compare the Safety and Pharmacokinetics Profile of WID-CLZ18 and Clozaril 100 mg Tablet (Clozapine) After Oral Administration in Schizophrenia Patients | This clinical study is a randomized, open label, multiple-dose, 2-way crossover, phase I (Bioequivalence) study to compare the safety and pharmacokinetics profile of WID-CLZ18 and Clozaril 100 mg tablet (Clozapine) after oral administration in schizophrenia patients.",
        "tokens": "['A', 'Randomized', ',', 'Open', 'Label', ',', 'Multiple', '-', 'dose', ',', '2', '-', 'way', 'Crossover', ',', 'Phase', 'I', 'Study', 'to', 'Compare', 'the', 'Safety', 'and', 'Pharmacokinetics', 'Profile', 'of', 'WID', '-', 'CLZ18', 'and', 'Clozaril', '100', 'mg', 'Tablet', '(', 'Clozapine', ')', 'After', 'Oral', 'Administration', 'in', 'Schizophrenia', 'Patients', '|', 'This', 'clinical', 'study', 'is', 'a', 'randomized', ',', 'open', 'label', ',', 'multiple', '-', 'dose', ',', '2', '-', 'way', 'crossover', ',', 'phase', 'I', '(', 'Bioequivalence', ')', 'study', 'to', 'compare', 'the', 'safety', 'and', 'pharmacokinetics', 'profile', 'of', 'WID', '-', 'CLZ18', 'and', 'Clozaril', '100', 'mg', 'tablet', '(', 'Clozapine', ')', 'after', 'oral', 'administration', 'in', 'schizophrenia', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 126,
                "end": 135,
                "text": "WID-CLZ18",
                "type": "DRUG"
            },
            {
                "start": 140,
                "end": 148,
                "text": "Clozaril",
                "type": "DRUG"
            },
            {
                "start": 164,
                "end": 173,
                "text": "Clozapine",
                "type": "DRUG"
            },
            {
                "start": 204,
                "end": 217,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 395,
                "end": 404,
                "text": "WID-CLZ18",
                "type": "DRUG"
            },
            {
                "start": 409,
                "end": 417,
                "text": "Clozaril",
                "type": "DRUG"
            },
            {
                "start": 433,
                "end": 442,
                "text": "Clozapine",
                "type": "DRUG"
            },
            {
                "start": 473,
                "end": 486,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05520359",
        "study_official_title": "Transcutaneous Stimulation and Mobility Device Use for Individuals With Neurologic Conditions ",
        "study_brief_summary": " This research study will combine non-invasive spinal stimulation with mobility devices to examine the acute impact of the individual and combined effects of these innovative techniques on mobility in children with cerebral palsy.",
        "text": "Transcutaneous Stimulation and Mobility Device Use for Individuals With Neurologic Conditions | This research study will combine non-invasive spinal stimulation with mobility devices to examine the acute impact of the individual and combined effects of these innovative techniques on mobility in children with cerebral palsy.",
        "tokens": "['Transcutaneous', 'Stimulation', 'and', 'Mobility', 'Device', 'Use', 'for', 'Individuals', 'With', 'Neurologic', 'Conditions', '|', 'This', 'research', 'study', 'will', 'combine', 'non', '-', 'invasive', 'spinal', 'stimulation', 'with', 'mobility', 'devices', 'to', 'examine', 'the', 'acute', 'impact', 'of', 'the', 'individual', 'and', 'combined', 'effects', 'of', 'these', 'innovative', 'techniques', 'on', 'mobility', 'in', 'children', 'with', 'cerebral', 'palsy', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 26,
                "text": "Transcutaneous Stimulation",
                "type": "OTHER"
            },
            {
                "start": 31,
                "end": 50,
                "text": "Mobility Device Use",
                "type": "OTHER"
            },
            {
                "start": 129,
                "end": 160,
                "text": "non-invasive spinal stimulation",
                "type": "OTHER"
            },
            {
                "start": 166,
                "end": 182,
                "text": "mobility devices",
                "type": "OTHER"
            },
            {
                "start": 310,
                "end": 324,
                "text": "cerebral palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01205906",
        "study_official_title": "Comparison of the Efficacy of an Internet-based Self-help Training and a Well-established Outpatient Group Therapy for the Treatment of Chronic Tinnitus: A Randomized Controlled Trial ",
        "study_brief_summary": " The aim of this study is to compare the efficacy of an internet-based guided self-help training for chronic tinnitus with a well-established outpatient group therapy and a discussion forum group.",
        "text": "Comparison of the Efficacy of an Internet-based Self-help Training and a Well-established Outpatient Group Therapy for the Treatment of Chronic Tinnitus: A Randomized Controlled Trial | The aim of this study is to compare the efficacy of an internet-based guided self-help training for chronic tinnitus with a well-established outpatient group therapy and a discussion forum group.",
        "tokens": "['Comparison', 'of', 'the', 'Efficacy', 'of', 'an', 'Internet', '-', 'based', 'Self', '-', 'help', 'Training', 'and', 'a', 'Well', '-', 'established', 'Outpatient', 'Group', 'Therapy', 'for', 'the', 'Treatment', 'of', 'Chronic', 'Tinnitus', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'an', 'internet', '-', 'based', 'guided', 'self', '-', 'help', 'training', 'for', 'chronic', 'tinnitus', 'with', 'a', 'well', '-', 'established', 'outpatient', 'group', 'therapy', 'and', 'a', 'discussion', 'forum', 'group', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 66,
                "text": "Internet-based Self-help Training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 73,
                "end": 114,
                "text": "Well-established Outpatient Group Therapy",
                "type": "CONTROL"
            },
            {
                "start": 136,
                "end": 152,
                "text": "Chronic Tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 241,
                "end": 281,
                "text": "internet-based guided self-help training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 286,
                "end": 302,
                "text": "chronic tinnitus",
                "type": "CONDITION"
            },
            {
                "start": 310,
                "end": 351,
                "text": "well-established outpatient group therapy",
                "type": "CONTROL"
            },
            {
                "start": 358,
                "end": 380,
                "text": "discussion forum group",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01482351",
        "study_official_title": "Mild Cognitive Impairment and Obstructive Sleep Apnea ",
        "study_brief_summary": " Obstructive sleep apnea (OSA) has been linked to increased risk for Alzheimer's disease (AD), but little prospective evidence exists on the effects of OSA treatment in preclinical AD. The objective was to determine if CPAP treatment adherence, controlling for baseline differences, predicts cognitive and everyday function after 1 year in older adults with MCI and to determine effect sizes for a larger trial. The aim of the Mild Cognitive Impairment and Obstructive Sleep Apnea (Memories 1) trial was to determine whether CPAP treatment adherence, controlling for any baseline differences in OSA severity, ApoE4, and other previously identified demographic and patient factors, might predict cognitive and everyday function after 1 year in older adults with amnestic MCI.",
        "text": "Mild Cognitive Impairment and Obstructive Sleep Apnea | Obstructive sleep apnea (OSA) has been linked to increased risk for Alzheimer's disease (AD), but little prospective evidence exists on the effects of OSA treatment in preclinical AD. The objective was to determine if CPAP treatment adherence, controlling for baseline differences, predicts cognitive and everyday function after 1 year in older adults with MCI and to determine effect sizes for a larger trial. The aim of the Mild Cognitive Impairment and Obstructive Sleep Apnea (Memories 1) trial was to determine whether CPAP treatment adherence, controlling for any baseline differences in OSA severity, ApoE4, and other previously identified demographic and patient factors, might predict cognitive and everyday function after 1 year in older adults with amnestic MCI.",
        "tokens": "['Mild', 'Cognitive', 'Impairment', 'and', 'Obstructive', 'Sleep', 'Apnea', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'has', 'been', 'linked', 'to', 'increased', 'risk', 'for', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', ',', 'but', 'little', 'prospective', 'evidence', 'exists', 'on', 'the', 'effects', 'of', 'OSA', 'treatment', 'in', 'preclinical', 'AD', '.', 'The', 'objective', 'was', 'to', 'determine', 'if', 'CPAP', 'treatment', 'adherence', ',', 'controlling', 'for', 'baseline', 'differences', ',', 'predicts', 'cognitive', 'and', 'everyday', 'function', 'after', '1', 'year', 'in', 'older', 'adults', 'with', 'MCI', 'and', 'to', 'determine', 'effect', 'sizes', 'for', 'a', 'larger', 'trial', '.', 'The', 'aim', 'of', 'the', 'Mild', 'Cognitive', 'Impairment', 'and', 'Obstructive', 'Sleep', 'Apnea', '(', 'Memories', '1', ')', 'trial', 'was', 'to', 'determine', 'whether', 'CPAP', 'treatment', 'adherence', ',', 'controlling', 'for', 'any', 'baseline', 'differences', 'in', 'OSA', 'severity', ',', 'ApoE4', ',', 'and', 'other', 'previously', 'identified', 'demographic', 'and', 'patient', 'factors', ',', 'might', 'predict', 'cognitive', 'and', 'everyday', 'function', 'after', '1', 'year', 'in', 'older', 'adults', 'with', 'amnestic', 'MCI', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 25,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 30,
                "end": 53,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 56,
                "end": 79,
                "text": "Obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 81,
                "end": 84,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 143,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 147,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 210,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 238,
                "text": "preclinical AD",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 278,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 413,
                "end": 416,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 482,
                "end": 507,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 512,
                "end": 535,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 580,
                "end": 584,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 650,
                "end": 653,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 825,
                "end": 828,
                "text": "MCI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04787718",
        "study_official_title": "Roles of Almonds in Physical Performance ",
        "study_brief_summary": " Investigators specific aims are to compare the effects of consuming daily snacks of raw, shelled, unsalted almonds (2.0 ounces) versus an isocaloric amount of another commonly consumed snack food (pretzels) on energy (vigor) perception and physical activity, exercise performance (VO2max and measures of strength), strength and power performance as well as muscle soreness recovery after strenuous eccentrically-biased exercise.",
        "text": "Roles of Almonds in Physical Performance | Investigators specific aims are to compare the effects of consuming daily snacks of raw, shelled, unsalted almonds (2.0 ounces) versus an isocaloric amount of another commonly consumed snack food (pretzels) on energy (vigor) perception and physical activity, exercise performance (VO2max and measures of strength), strength and power performance as well as muscle soreness recovery after strenuous eccentrically-biased exercise.",
        "tokens": "['Roles', 'of', 'Almonds', 'in', 'Physical', 'Performance', '|', 'Investigators', 'specific', 'aims', 'are', 'to', 'compare', 'the', 'effects', 'of', 'consuming', 'daily', 'snacks', 'of', 'raw', ',', 'shelled', ',', 'unsalted', 'almonds', '(', '2.0', 'ounces', ')', 'versus', 'an', 'isocaloric', 'amount', 'of', 'another', 'commonly', 'consumed', 'snack', 'food', '(', 'pretzels', ')', 'on', 'energy', '(', 'vigor', ')', 'perception', 'and', 'physical', 'activity', ',', 'exercise', 'performance', '(', 'VO2max', 'and', 'measures', 'of', 'strength', ')', ',', 'strength', 'and', 'power', 'performance', 'as', 'well', 'as', 'muscle', 'soreness', 'recovery', 'after', 'strenuous', 'eccentrically', '-', 'biased', 'exercise', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 9,
                "end": 16,
                "text": "Almonds",
                "type": "OTHER"
            },
            {
                "start": 127,
                "end": 157,
                "text": "raw, shelled, unsalted almonds",
                "type": "OTHER"
            },
            {
                "start": 240,
                "end": 248,
                "text": "pretzels",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00723983",
        "study_official_title": "A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex\u00ae (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period ",
        "study_brief_summary": " To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex\u00ae (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.",
        "text": "A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex\u00ae (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period | To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex\u00ae (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.",
        "tokens": "['A', 'Phase', 'I', ',', 'Open', 'Label', ',', 'Single', '-', 'Dose', ',', 'Four', '-', 'Way', 'Crossover', 'Study', 'Comparing', 'the', 'Pharmacokinetics', 'of', 'NP101', '(', 'Sumatriptan', 'Iontophoretic', 'Transdermal', 'Patch', ')', 'With', 'an', 'Oral', 'Formulation', 'of', 'Imitrex', '\u00ae', '(', '50', 'mg', ')', 'in', 'Migraine', 'Subjects', 'During', 'an', 'Acute', 'Migraine', 'Attack', 'and', 'During', 'a', 'Non', '-', 'Migraine', 'Period', '|', 'To', 'compare', 'the', 'pharmacokinetics', 'of', 'NP101', 'with', 'a', 'currently', 'approved', 'oral', 'formulation', 'of', 'Imitrex', '\u00ae', '(', '50', 'mg', ')', 'in', 'migraine', 'subjects', 'both', 'during', 'an', 'acute', 'migraine', 'attack', 'and', 'during', 'a', 'non', '-', 'migraine', 'period', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 95,
                "end": 100,
                "text": "NP101",
                "type": "DRUG"
            },
            {
                "start": 102,
                "end": 113,
                "text": "Sumatriptan",
                "type": "DRUG"
            },
            {
                "start": 175,
                "end": 182,
                "text": "Imitrex",
                "type": "DRUG"
            },
            {
                "start": 194,
                "end": 202,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 222,
                "end": 243,
                "text": "Acute Migraine Attack",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 319,
                "text": "NP101",
                "type": "DRUG"
            },
            {
                "start": 366,
                "end": 373,
                "text": "Imitrex",
                "type": "DRUG"
            },
            {
                "start": 386,
                "end": 394,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 419,
                "end": 440,
                "text": "acute migraine attack",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03298672",
        "study_official_title": "A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects ",
        "study_brief_summary": " This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with amnestic mild cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).",
        "text": "A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects | This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with amnestic mild cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).",
        "tokens": "['A', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'Double', '-', 'Blinded', ',', 'First', '-', 'in', '-', 'Human', 'Study', 'to', 'Evaluate', 'Safety', ',', 'Tolerability', ',', 'and', 'Pharmacokinetics', 'of', 'Single', 'Ascending', 'Doses', '(', 'Part', 'A', ')', 'and', 'Multiple', 'Ascending', 'Doses', '(', 'Part', 'B', ')', 'of', 'NDX-1017', 'in', 'Healthy', 'Young', 'and', 'Elderly', 'Subjects', '|', 'This', 'Phase', '1', 'randomized', ',', 'placebo', '-', 'controlled', ',', 'double', '-', 'blinded', ',', 'first', '-', 'in', '-', 'human', 'study', 'will', 'evaluate', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'single', 'and', 'multiple', 'ascending', 'doses', 'of', 'NDX-1017', 'in', 'healthy', 'young', 'and', 'elderly', 'subjects', ',', 'and', 'elderly', 'subjects', 'with', 'amnestic', 'mild', 'cognitive', 'impairment', '(', 'MCI', ')', ',', 'Alzheimer', \"'s\", 'disease', '(', 'mild', ',', 'mild', '-', 'to', '-', 'moderate', ',', 'or', 'moderate', ')', ',', 'or', 'mixed', 'dementia', 'with', 'Alzheimer', \"'s\", 'and', 'vascular', 'components', '(', 'mild', ',', 'mild', '-', 'to', '-', 'moderate', ',', 'or', 'moderate', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 21,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 202,
                "end": 210,
                "text": "NDX-1017",
                "type": "DRUG"
            },
            {
                "start": 276,
                "end": 283,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 432,
                "end": 440,
                "text": "NDX-1017",
                "type": "DRUG"
            },
            {
                "start": 515,
                "end": 540,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 542,
                "end": 545,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 548,
                "end": 567,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 610,
                "end": 665,
                "text": "mixed dementia with Alzheimer's and vascular components",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03621046",
        "study_official_title": "A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's ",
        "study_brief_summary": " This study will evaluate the motor and cognitive benefits of low-dose zolpidem in Parkinson's.",
        "text": "A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's | This study will evaluate the motor and cognitive benefits of low-dose zolpidem in Parkinson's.",
        "tokens": "['A', 'Placebo', 'Controlled', 'Double', 'Blind', 'Randomised', 'Controlled', 'Proof', 'of', 'Concept', 'Study', 'of', 'Zolpidem', 'for', 'the', 'Treatment', 'of', 'Motor', 'and', 'Cognitive', 'Deficits', 'in', 'Late', '-', 'stage', 'Parkinson', \"'s\", '|', 'This', 'study', 'will', 'evaluate', 'the', 'motor', 'and', 'cognitive', 'benefits', 'of', 'low', '-', 'dose', 'zolpidem', 'in', 'Parkinson', \"'s\", '.']",
        "token_bio_labels": "['O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 2,
                "end": 9,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 82,
                "end": 90,
                "text": "Zolpidem",
                "type": "DRUG"
            },
            {
                "start": 112,
                "end": 140,
                "text": "Motor and Cognitive Deficits",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 164,
                "text": "Late-stage Parkinson",
                "type": "CONDITION"
            },
            {
                "start": 239,
                "end": 247,
                "text": "zolpidem",
                "type": "DRUG"
            },
            {
                "start": 251,
                "end": 262,
                "text": "Parkinson's",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00626912",
        "study_official_title": "PRET: Patients Prone to Recurrence After Endovascular Treatment. A Randomized Trial Comparing Platinum and Hydrogel-coated Coils ",
        "study_brief_summary": " The PRET study aims at comparing two types of coils used in the endovascular treatment of intracranial aneurysms. The first type made of platinum has been used for more than 15 years. The other, referred to as hydrocoil, containing in addition to platinum a polymer layer that expands when in contact with blood, has been in use since 2002. The hypothesis of the PRET study is that the newer hydrocoil will be more effective and yet as safe as the older platinum coil.",
        "text": "PRET: Patients Prone to Recurrence After Endovascular Treatment. A Randomized Trial Comparing Platinum and Hydrogel-coated Coils | The PRET study aims at comparing two types of coils used in the endovascular treatment of intracranial aneurysms. The first type made of platinum has been used for more than 15 years. The other, referred to as hydrocoil, containing in addition to platinum a polymer layer that expands when in contact with blood, has been in use since 2002. The hypothesis of the PRET study is that the newer hydrocoil will be more effective and yet as safe as the older platinum coil.",
        "tokens": "['PRET', ':', 'Patients', 'Prone', 'to', 'Recurrence', 'After', 'Endovascular', 'Treatment', '.', 'A', 'Randomized', 'Trial', 'Comparing', 'Platinum', 'and', 'Hydrogel', '-', 'coated', 'Coils', '|', 'The', 'PRET', 'study', 'aims', 'at', 'comparing', 'two', 'types', 'of', 'coils', 'used', 'in', 'the', 'endovascular', 'treatment', 'of', 'intracranial', 'aneurysms', '.', 'The', 'first', 'type', 'made', 'of', 'platinum', 'has', 'been', 'used', 'for', 'more', 'than', '15', 'years', '.', 'The', 'other', ',', 'referred', 'to', 'as', 'hydrocoil', ',', 'containing', 'in', 'addition', 'to', 'platinum', 'a', 'polymer', 'layer', 'that', 'expands', 'when', 'in', 'contact', 'with', 'blood', ',', 'has', 'been', 'in', 'use', 'since', '2002', '.', 'The', 'hypothesis', 'of', 'the', 'PRET', 'study', 'is', 'that', 'the', 'newer', 'hydrocoil', 'will', 'be', 'more', 'effective', 'and', 'yet', 'as', 'safe', 'as', 'the', 'older', 'platinum', 'coil', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 63,
                "text": "Endovascular Treatment",
                "type": "CONDITION"
            },
            {
                "start": 94,
                "end": 128,
                "text": "Platinum and Hydrogel-coated Coils",
                "type": "OTHER"
            },
            {
                "start": 195,
                "end": 217,
                "text": "endovascular treatment",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 243,
                "text": "intracranial aneurysms",
                "type": "CONDITION"
            },
            {
                "start": 341,
                "end": 350,
                "text": "hydrocoil",
                "type": "OTHER"
            },
            {
                "start": 523,
                "end": 532,
                "text": "hydrocoil",
                "type": "OTHER"
            },
            {
                "start": 585,
                "end": 598,
                "text": "platinum coil",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03010540",
        "study_official_title": "Emergence Delirium and Recovery Profile in Patients Undergoing Cleft Lip and Palate Repair: Comparison of Combination of Morphine and Fentanyl With Fentanyl Alone ",
        "study_brief_summary": " Emergence Delirium And Recovery Profile In Patients Undergoing Cleft Lip And Cleft Palate Repair With Either Combination Of Morphine Plus Fentanyl Or Fentanyl Alone",
        "text": "Emergence Delirium and Recovery Profile in Patients Undergoing Cleft Lip and Palate Repair: Comparison of Combination of Morphine and Fentanyl With Fentanyl Alone | Emergence Delirium And Recovery Profile In Patients Undergoing Cleft Lip And Cleft Palate Repair With Either Combination Of Morphine Plus Fentanyl Or Fentanyl Alone",
        "tokens": "['Emergence', 'Delirium', 'and', 'Recovery', 'Profile', 'in', 'Patients', 'Undergoing', 'Cleft', 'Lip', 'and', 'Palate', 'Repair', ':', 'Comparison', 'of', 'Combination', 'of', 'Morphine', 'and', 'Fentanyl', 'With', 'Fentanyl', 'Alone', '|', 'Emergence', 'Delirium', 'And', 'Recovery', 'Profile', 'In', 'Patients', 'Undergoing', 'Cleft', 'Lip', 'And', 'Cleft', 'Palate', 'Repair', 'With', 'Either', 'Combination', 'Of', 'Morphine', 'Plus', 'Fentanyl', 'Or', 'Fentanyl', 'Alone']",
        "token_bio_labels": "['O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 18,
                "text": "Delirium",
                "type": "CONDITION"
            },
            {
                "start": 63,
                "end": 72,
                "text": "Cleft Lip",
                "type": "CONDITION"
            },
            {
                "start": 77,
                "end": 90,
                "text": "Palate Repair",
                "type": "CONDITION"
            },
            {
                "start": 121,
                "end": 129,
                "text": "Morphine",
                "type": "DRUG"
            },
            {
                "start": 134,
                "end": 142,
                "text": "Fentanyl",
                "type": "DRUG"
            },
            {
                "start": 148,
                "end": 156,
                "text": "Fentanyl",
                "type": "DRUG"
            },
            {
                "start": 228,
                "end": 237,
                "text": "Cleft Lip",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 261,
                "text": "Cleft Palate Repair",
                "type": "CONDITION"
            },
            {
                "start": 289,
                "end": 297,
                "text": "Morphine",
                "type": "DRUG"
            },
            {
                "start": 303,
                "end": 311,
                "text": "Fentanyl",
                "type": "DRUG"
            },
            {
                "start": 315,
                "end": 323,
                "text": "Fentanyl",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00069550",
        "study_official_title": "Pathogenesis of Rett Syndrome: Natural History and Treatment ",
        "study_brief_summary": " Rett syndrome (RTT) is a disorder in which the nervous system does not develop properly. RTT generally affects girls, but there are some boys who have been diagnosed with RTT. Symptoms of RTT include small brain size, poor language skills, repetitive hand movements, and seizures. This study will evaluate the effectiveness of two drugs in treating the symptoms of RTT.",
        "text": "Pathogenesis of Rett Syndrome: Natural History and Treatment | Rett syndrome (RTT) is a disorder in which the nervous system does not develop properly. RTT generally affects girls, but there are some boys who have been diagnosed with RTT. Symptoms of RTT include small brain size, poor language skills, repetitive hand movements, and seizures. This study will evaluate the effectiveness of two drugs in treating the symptoms of RTT.",
        "tokens": "['Pathogenesis', 'of', 'Rett', 'Syndrome', ':', 'Natural', 'History', 'and', 'Treatment', '|', 'Rett', 'syndrome', '(', 'RTT', ')', 'is', 'a', 'disorder', 'in', 'which', 'the', 'nervous', 'system', 'does', 'not', 'develop', 'properly', '.', 'RTT', 'generally', 'affects', 'girls', ',', 'but', 'there', 'are', 'some', 'boys', 'who', 'have', 'been', 'diagnosed', 'with', 'RTT', '.', 'Symptoms', 'of', 'RTT', 'include', 'small', 'brain', 'size', ',', 'poor', 'language', 'skills', ',', 'repetitive', 'hand', 'movements', ',', 'and', 'seizures', '.', 'This', 'study', 'will', 'evaluate', 'the', 'effectiveness', 'of', 'two', 'drugs', 'in', 'treating', 'the', 'symptoms', 'of', 'RTT', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 29,
                "text": "Rett Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 63,
                "end": 76,
                "text": "Rett syndrome",
                "type": "CONDITION"
            },
            {
                "start": 78,
                "end": 81,
                "text": "RTT",
                "type": "CONDITION"
            },
            {
                "start": 152,
                "end": 155,
                "text": "RTT",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 237,
                "text": "RTT",
                "type": "CONDITION"
            },
            {
                "start": 251,
                "end": 254,
                "text": "RTT",
                "type": "CONDITION"
            },
            {
                "start": 428,
                "end": 431,
                "text": "RTT",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03656796",
        "study_official_title": "Effects of Rhythmic Auditory Cueing With Locomotion Training on Cortical Excitability and Behavior in Patients With Parkinson's Disease ",
        "study_brief_summary": " In this study, 51 subjects include 17 freezers,17 non-freezers and 17 aged-matched healthy subjects will be recruited. We will compare the cortical excitability, gait performance, and stepping-in-place performance before and after intervention of auditory cues combined with gait training. The cortical excitability will be assessed by transcranial magnetic stimulation (TMS). The purpose in this study is to investigate the effects of auditory cues with gait training on cortical excitability and rhythmic movements in patients with Parkinson's disease.",
        "text": "Effects of Rhythmic Auditory Cueing With Locomotion Training on Cortical Excitability and Behavior in Patients With Parkinson's Disease | In this study, 51 subjects include 17 freezers,17 non-freezers and 17 aged-matched healthy subjects will be recruited. We will compare the cortical excitability, gait performance, and stepping-in-place performance before and after intervention of auditory cues combined with gait training. The cortical excitability will be assessed by transcranial magnetic stimulation (TMS). The purpose in this study is to investigate the effects of auditory cues with gait training on cortical excitability and rhythmic movements in patients with Parkinson's disease.",
        "tokens": "['Effects', 'of', 'Rhythmic', 'Auditory', 'Cueing', 'With', 'Locomotion', 'Training', 'on', 'Cortical', 'Excitability', 'and', 'Behavior', 'in', 'Patients', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'In', 'this', 'study', ',', '51', 'subjects', 'include', '17', 'freezers,17', 'non', '-', 'freezers', 'and', '17', 'aged', '-', 'matched', 'healthy', 'subjects', 'will', 'be', 'recruited', '.', 'We', 'will', 'compare', 'the', 'cortical', 'excitability', ',', 'gait', 'performance', ',', 'and', 'stepping', '-', 'in', '-', 'place', 'performance', 'before', 'and', 'after', 'intervention', 'of', 'auditory', 'cues', 'combined', 'with', 'gait', 'training', '.', 'The', 'cortical', 'excitability', 'will', 'be', 'assessed', 'by', 'transcranial', 'magnetic', 'stimulation', '(', 'TMS', ')', '.', 'The', 'purpose', 'in', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'auditory', 'cues', 'with', 'gait', 'training', 'on', 'cortical', 'excitability', 'and', 'rhythmic', 'movements', 'in', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 35,
                "text": "Rhythmic Auditory Cueing",
                "type": "OTHER"
            },
            {
                "start": 41,
                "end": 60,
                "text": "Locomotion Training",
                "type": "PHYSICAL"
            },
            {
                "start": 116,
                "end": 135,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 398,
                "text": "auditory cues",
                "type": "OTHER"
            },
            {
                "start": 413,
                "end": 426,
                "text": "gait training",
                "type": "PHYSICAL"
            },
            {
                "start": 574,
                "end": 587,
                "text": "auditory cues",
                "type": "OTHER"
            },
            {
                "start": 593,
                "end": 606,
                "text": "gait training",
                "type": "PHYSICAL"
            },
            {
                "start": 672,
                "end": 691,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05265377",
        "study_official_title": "Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury ",
        "study_brief_summary": " Gait impairment in people with acquired brain injury (ABI) and spinal cord injury (SCI) can be very heterogeneous. For this reason, STELO has been developed: a new concept of exoskeleton based on modular technology for gait assistance. It allows a personalised configuration according to the functional capacity of each patient, as the therapist can choose which robotic joints to use depending on the therapeutic goal and on the patient recovery phase. The objective is to analyse the usability of the STELO modular exoskeleton in people with ABI and SCI.",
        "text": "Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury | Gait impairment in people with acquired brain injury (ABI) and spinal cord injury (SCI) can be very heterogeneous. For this reason, STELO has been developed: a new concept of exoskeleton based on modular technology for gait assistance. It allows a personalised configuration according to the functional capacity of each patient, as the therapist can choose which robotic joints to use depending on the therapeutic goal and on the patient recovery phase. The objective is to analyse the usability of the STELO modular exoskeleton in people with ABI and SCI.",
        "tokens": "['Safety', 'and', 'Usability', 'of', 'the', 'STELO', 'Exoskeleton', 'in', 'People', 'With', 'Acquired', 'Brain', 'Injury', 'and', 'Spinal', 'Cord', 'Injury', '|', 'Gait', 'impairment', 'in', 'people', 'with', 'acquired', 'brain', 'injury', '(', 'ABI', ')', 'and', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'can', 'be', 'very', 'heterogeneous', '.', 'For', 'this', 'reason', ',', 'STELO', 'has', 'been', 'developed', ':', 'a', 'new', 'concept', 'of', 'exoskeleton', 'based', 'on', 'modular', 'technology', 'for', 'gait', 'assistance', '.', 'It', 'allows', 'a', 'personalised', 'configuration', 'according', 'to', 'the', 'functional', 'capacity', 'of', 'each', 'patient', ',', 'as', 'the', 'therapist', 'can', 'choose', 'which', 'robotic', 'joints', 'to', 'use', 'depending', 'on', 'the', 'therapeutic', 'goal', 'and', 'on', 'the', 'patient', 'recovery', 'phase', '.', 'The', 'objective', 'is', 'to', 'analyse', 'the', 'usability', 'of', 'the', 'STELO', 'modular', 'exoskeleton', 'in', 'people', 'with', 'ABI', 'and', 'SCI', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 45,
                "text": "STELO Exoskeleton",
                "type": "OTHER"
            },
            {
                "start": 61,
                "end": 82,
                "text": "Acquired Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 87,
                "end": 105,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 108,
                "end": 123,
                "text": "Gait impairment",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 160,
                "text": "acquired brain injury",
                "type": "CONDITION"
            },
            {
                "start": 162,
                "end": 165,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 171,
                "end": 189,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 191,
                "end": 194,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 240,
                "end": 245,
                "text": "STELO",
                "type": "OTHER"
            },
            {
                "start": 283,
                "end": 322,
                "text": "exoskeleton based on modular technology",
                "type": "OTHER"
            },
            {
                "start": 611,
                "end": 636,
                "text": "STELO modular exoskeleton",
                "type": "OTHER"
            },
            {
                "start": 652,
                "end": 655,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 660,
                "end": 663,
                "text": "SCI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05389657",
        "study_official_title": "Dissemination and Implementation of Family-Based Treatment in Publicly-Funded Clinics: Optimizing Provider Training in Eating Disorders (OPTED) ",
        "study_brief_summary": " This is a randomized controlled trial for mental health clinicians comparing two methods of training in family-based treatment (FBT) for restrictive eating disorders.",
        "text": "Dissemination and Implementation of Family-Based Treatment in Publicly-Funded Clinics: Optimizing Provider Training in Eating Disorders (OPTED) | This is a randomized controlled trial for mental health clinicians comparing two methods of training in family-based treatment (FBT) for restrictive eating disorders.",
        "tokens": "['Dissemination', 'and', 'Implementation', 'of', 'Family', '-', 'Based', 'Treatment', 'in', 'Publicly', '-', 'Funded', 'Clinics', ':', 'Optimizing', 'Provider', 'Training', 'in', 'Eating', 'Disorders', '(', 'OPTED', ')', '|', 'This', 'is', 'a', 'randomized', 'controlled', 'trial', 'for', 'mental', 'health', 'clinicians', 'comparing', 'two', 'methods', 'of', 'training', 'in', 'family', '-', 'based', 'treatment', '(', 'FBT', ')', 'for', 'restrictive', 'eating', 'disorders', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 36,
                "end": 58,
                "text": "Family-Based Treatment",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 119,
                "end": 135,
                "text": "Eating Disorders",
                "type": "CONDITION"
            },
            {
                "start": 250,
                "end": 272,
                "text": "family-based treatment",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 274,
                "end": 277,
                "text": "FBT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 283,
                "end": 311,
                "text": "restrictive eating disorders",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00607893",
        "study_official_title": "Oxidative Stress in Sleep Apnea and Cardiac Disease ",
        "study_brief_summary": " Sleep-disordered breathing (SDB) is a condition in which a person experiences frequent breathing pauses during sleep, also known as sleep apnea. There is evidence that the recurrent sleep arousal and associated shortage of oxygen in the body may increase risk for cardiovascular disease (CVD). It is believed that treatment with continuous positive airway pressure (CPAP) may reduce certain risk factors for heart disease, including markers of inflammation and oxidative stress. This study will evaluate the effectiveness of CPAP in reducing CVD risk factors in people with SDB.",
        "text": "Oxidative Stress in Sleep Apnea and Cardiac Disease | Sleep-disordered breathing (SDB) is a condition in which a person experiences frequent breathing pauses during sleep, also known as sleep apnea. There is evidence that the recurrent sleep arousal and associated shortage of oxygen in the body may increase risk for cardiovascular disease (CVD). It is believed that treatment with continuous positive airway pressure (CPAP) may reduce certain risk factors for heart disease, including markers of inflammation and oxidative stress. This study will evaluate the effectiveness of CPAP in reducing CVD risk factors in people with SDB.",
        "tokens": "['Oxidative', 'Stress', 'in', 'Sleep', 'Apnea', 'and', 'Cardiac', 'Disease', '|', 'Sleep', '-', 'disordered', 'breathing', '(', 'SDB', ')', 'is', 'a', 'condition', 'in', 'which', 'a', 'person', 'experiences', 'frequent', 'breathing', 'pauses', 'during', 'sleep', ',', 'also', 'known', 'as', 'sleep', 'apnea', '.', 'There', 'is', 'evidence', 'that', 'the', 'recurrent', 'sleep', 'arousal', 'and', 'associated', 'shortage', 'of', 'oxygen', 'in', 'the', 'body', 'may', 'increase', 'risk', 'for', 'cardiovascular', 'disease', '(', 'CVD', ')', '.', 'It', 'is', 'believed', 'that', 'treatment', 'with', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'may', 'reduce', 'certain', 'risk', 'factors', 'for', 'heart', 'disease', ',', 'including', 'markers', 'of', 'inflammation', 'and', 'oxidative', 'stress', '.', 'This', 'study', 'will', 'evaluate', 'the', 'effectiveness', 'of', 'CPAP', 'in', 'reducing', 'CVD', 'risk', 'factors', 'in', 'people', 'with', 'SDB', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 31,
                "text": "Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 36,
                "end": 51,
                "text": "Cardiac Disease",
                "type": "CONDITION"
            },
            {
                "start": 54,
                "end": 80,
                "text": "Sleep-disordered breathing",
                "type": "CONDITION"
            },
            {
                "start": 82,
                "end": 85,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 186,
                "end": 197,
                "text": "sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 318,
                "end": 340,
                "text": "cardiovascular disease",
                "type": "CONDITION"
            },
            {
                "start": 342,
                "end": 345,
                "text": "CVD",
                "type": "CONDITION"
            },
            {
                "start": 383,
                "end": 418,
                "text": "continuous positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 420,
                "end": 424,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 462,
                "end": 475,
                "text": "heart disease",
                "type": "CONDITION"
            },
            {
                "start": 579,
                "end": 583,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 596,
                "end": 599,
                "text": "CVD",
                "type": "CONDITION"
            },
            {
                "start": 628,
                "end": 631,
                "text": "SDB",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00299702",
        "study_official_title": "A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal\u00ae Consta\u00ae and Abilify\u00ae (Aripiprazole) in Adults With Schizophrenia ",
        "study_brief_summary": " The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal\u00c2\u00ae Consta\u00c2\u00ae versus Abilify\u00c2\u00ae, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.",
        "text": "A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal\u00ae Consta\u00ae and Abilify\u00ae (Aripiprazole) in Adults With Schizophrenia | The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal\u00c2\u00ae Consta\u00c2\u00ae versus Abilify\u00c2\u00ae, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.",
        "tokens": "['A', '2', '-', 'year', ',', 'Prospective', ',', 'Blinded', '-', 'rater', ',', 'Open', '-', 'label', ',', 'Active', '-', 'controlled', ',', 'Multicenter', ',', 'Randomized', 'Study', 'of', 'Long', '-', 'term', 'Efficacy', 'and', 'Effectiveness', 'Comparing', 'Risperdal', '\u00ae', 'Consta', '\u00ae', 'and', 'Abilify', '\u00ae', '(', 'Aripiprazole', ')', 'in', 'Adults', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'two', 'antipsychotic', 'medications', ',', 'Risperdal\u00c2', '\u00ae', 'Consta\u00c2', '\u00ae', 'versus', 'Abilify\u00c2', '\u00ae', ',', 'over', 'a', '2', '-', 'year', 'treatment', 'period', 'in', 'the', 'long', '-', 'term', 'maintenance', 'of', 'patients', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 149,
                "end": 158,
                "text": "Risperdal",
                "type": "DRUG"
            },
            {
                "start": 160,
                "end": 166,
                "text": "Consta",
                "type": "DRUG"
            },
            {
                "start": 172,
                "end": 179,
                "text": "Abilify",
                "type": "DRUG"
            },
            {
                "start": 182,
                "end": 194,
                "text": "Aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 211,
                "end": 224,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 319,
                "end": 329,
                "text": "Risperdal\u00c2",
                "type": "DRUG"
            },
            {
                "start": 331,
                "end": 338,
                "text": "Consta\u00c2",
                "type": "DRUG"
            },
            {
                "start": 347,
                "end": 355,
                "text": "Abilify\u00c2",
                "type": "DRUG"
            },
            {
                "start": 435,
                "end": 448,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00797277",
        "study_official_title": "An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia ",
        "study_brief_summary": " The aim of this study was to compare the efficacy and safety of intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg in the treatment of acute agitated schizophrenic patients of Taiwanese populations.",
        "text": "An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia | The aim of this study was to compare the efficacy and safety of intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg in the treatment of acute agitated schizophrenic patients of Taiwanese populations.",
        "tokens": "['An', 'Open', '-', 'label', ',', 'Randomized', 'Trial', 'of', 'Intramuscular', '(', 'IM', ')', 'Olanzapine', 'Versus', 'Intramuscular', 'Combination', 'of', 'Haloperidol', 'and', 'Lorazepam', 'in', 'the', 'Treatment', 'of', 'Acute', 'Agitation', 'in', 'Schizophrenia', '|', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'and', 'safety', 'of', 'intramuscular', '10', 'mg', 'olanzapine', 'versus', 'intramuscular', '5', 'mg', 'haloperidol', 'plus', 'lorazepam', '2', 'mg', 'in', 'the', 'treatment', 'of', 'acute', 'agitated', 'schizophrenic', 'patients', 'of', 'Taiwanese', 'populations', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 54,
                "end": 64,
                "text": "Olanzapine",
                "type": "DRUG"
            },
            {
                "start": 101,
                "end": 112,
                "text": "Haloperidol",
                "type": "DRUG"
            },
            {
                "start": 117,
                "end": 126,
                "text": "Lorazepam",
                "type": "DRUG"
            },
            {
                "start": 147,
                "end": 162,
                "text": "Acute Agitation",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 179,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 276,
                "text": "olanzapine",
                "type": "DRUG"
            },
            {
                "start": 303,
                "end": 314,
                "text": "haloperidol",
                "type": "DRUG"
            },
            {
                "start": 320,
                "end": 329,
                "text": "lorazepam",
                "type": "DRUG"
            },
            {
                "start": 355,
                "end": 369,
                "text": "acute agitated",
                "type": "CONDITION"
            },
            {
                "start": 370,
                "end": 383,
                "text": "schizophrenic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04872452",
        "study_official_title": "Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders ",
        "study_brief_summary": " This study is being done to evaluate cutaneous nerve biopsies from patients with refractory gastrointestinal motility disorders. The purpose of the study is to evaluate skin biopsies for signs of small fiber neuropathy in GI dysmotility patients, which may provide a better understanding of the underlying pathology of their condition. Specifically, identifying any small fiber neuropathy that may exist in the peripheral nervous system may help us to better understand the mechanism of presumed enteric neuropathy that may be involved in causing GI dysmotility.",
        "text": "Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders | This study is being done to evaluate cutaneous nerve biopsies from patients with refractory gastrointestinal motility disorders. The purpose of the study is to evaluate skin biopsies for signs of small fiber neuropathy in GI dysmotility patients, which may provide a better understanding of the underlying pathology of their condition. Specifically, identifying any small fiber neuropathy that may exist in the peripheral nervous system may help us to better understand the mechanism of presumed enteric neuropathy that may be involved in causing GI dysmotility.",
        "tokens": "['Analysis', 'of', 'Cutaneous', 'Nerve', 'Biopsies', 'in', 'Gastrointestinal', 'Motility', 'Disorders', '|', 'This', 'study', 'is', 'being', 'done', 'to', 'evaluate', 'cutaneous', 'nerve', 'biopsies', 'from', 'patients', 'with', 'refractory', 'gastrointestinal', 'motility', 'disorders', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'skin', 'biopsies', 'for', 'signs', 'of', 'small', 'fiber', 'neuropathy', 'in', 'GI', 'dysmotility', 'patients', ',', 'which', 'may', 'provide', 'a', 'better', 'understanding', 'of', 'the', 'underlying', 'pathology', 'of', 'their', 'condition', '.', 'Specifically', ',', 'identifying', 'any', 'small', 'fiber', 'neuropathy', 'that', 'may', 'exist', 'in', 'the', 'peripheral', 'nervous', 'system', 'may', 'help', 'us', 'to', 'better', 'understand', 'the', 'mechanism', 'of', 'presumed', 'enteric', 'neuropathy', 'that', 'may', 'be', 'involved', 'in', 'causing', 'GI', 'dysmotility', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 40,
                "end": 75,
                "text": "Gastrointestinal Motility Disorders",
                "type": "CONDITION"
            },
            {
                "start": 159,
                "end": 205,
                "text": "refractory gastrointestinal motility disorders",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 296,
                "text": "small fiber neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 300,
                "end": 314,
                "text": "GI dysmotility",
                "type": "CONDITION"
            },
            {
                "start": 444,
                "end": 466,
                "text": "small fiber neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 574,
                "end": 592,
                "text": "enteric neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 625,
                "end": 639,
                "text": "GI dysmotility",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04967274",
        "study_official_title": "Contributions of the Reticulospinal System to Movement Control and Functional Recovery in Patients With Spinal Cord Injury ",
        "study_brief_summary": " Accurate movement execution is a result of a complex interplay between various muscle groups whose activity is controlled by different areas of the central nervous system. Besides the corticospinal system, the phylogenetically old reticulospinal system is a key motor system controlling different elementary movements including posture, locomotion and reaching across all mammals. In contrast to the extensively investigated corticospinal system, there is only sparse knowledge on the motor physiology of the functionally important reticulospinal system in humans. Reticulospinal motor control can be assessed with the StartReact paradigm which is based on the activation of reticulospinal motor circuitries by startling acoustic stimuli. The StartReact phenomenon is characterized by a shortening in movement reaction time which is mediated by a startle-triggered, early release of a planned motor program by the reticulospinal system. Thus, StartReact is a unique tool to examine reticulospinal involvement on human motor control under physiological and pathological conditions. StartReact assessments will be supplemented by comprehensive 3-D kinematic analysis and muscle activity recordings (i.e. electromyography) to gain quantitative insights into reticulospinal movement control.\n\nThe first objective of this clinical study is to gain more insights into the mechanisms underlying StartReact and to advance the knowledge on reticulo-spinal motor physiology regarding different movement tasks (i.e. simple single-joint movements, complex multi-joint movements and bilateral hand movements) in healthy subjects. The findings of these experiments will provide new insights into proximal-distal, flexor-extensor and upper-lower extremity gradients in reticulospinal motor control of healthy subjects. Moreover, the results will expand the StartReact paradigm to complex, functionally more relevant movements (i.e. reaching and stepping tasks requiring endpoint accuracy; co-operative, bilateral hand movements) for which the involvement of the reticulo-spinal system is not yet understood.\n\nThe second goal of this project is to use the StartReact paradigm to shed more light onto the role of reticulospinal plasticity in functional recovery of patients with spinal cord injury (SCI). Whereas preclinical findings emphasize a remarkable potential of the reticulospinal system for neuroplastic adaptations underlying functional recovery, there is only little evidence from clinical trials in the field of SCI. First, the study aims at monitoring StartReact effects in hand and leg muscles of patients with acute SCI over a period of 6 months. Simultaneous tracking of StartReact effects and motor recovery will allow to closely relate processes of reticulospinal plasticity to functional recovery in patients with acute SCI. Second, the focus will be on the re-weighting of descending motor control (i.e. cortico- vs. reticulospinal system) in response to SCI and investigate the distinct contributions of the cortico- and reticulospinal system to motor recovery in patients with chronic SCI.\n\nThe findings of this project will advance the mechanistic understanding on the motor physiology and neurorestorative capacity of the reticulospinal system in humans. New insights from these projects will hopefully translate into a better exploitation of this important motor system in clinical trials that aim to improve motor recovery in patients with SCI.",
        "text": "Contributions of the Reticulospinal System to Movement Control and Functional Recovery in Patients With Spinal Cord Injury | Accurate movement execution is a result of a complex interplay between various muscle groups whose activity is controlled by different areas of the central nervous system. Besides the corticospinal system, the phylogenetically old reticulospinal system is a key motor system controlling different elementary movements including posture, locomotion and reaching across all mammals. In contrast to the extensively investigated corticospinal system, there is only sparse knowledge on the motor physiology of the functionally important reticulospinal system in humans. Reticulospinal motor control can be assessed with the StartReact paradigm which is based on the activation of reticulospinal motor circuitries by startling acoustic stimuli. The StartReact phenomenon is characterized by a shortening in movement reaction time which is mediated by a startle-triggered, early release of a planned motor program by the reticulospinal system. Thus, StartReact is a unique tool to examine reticulospinal involvement on human motor control under physiological and pathological conditions. StartReact assessments will be supplemented by comprehensive 3-D kinematic analysis and muscle activity recordings (i.e. electromyography) to gain quantitative insights into reticulospinal movement control.\n\nThe first objective of this clinical study is to gain more insights into the mechanisms underlying StartReact and to advance the knowledge on reticulo-spinal motor physiology regarding different movement tasks (i.e. simple single-joint movements, complex multi-joint movements and bilateral hand movements) in healthy subjects. The findings of these experiments will provide new insights into proximal-distal, flexor-extensor and upper-lower extremity gradients in reticulospinal motor control of healthy subjects. Moreover, the results will expand the StartReact paradigm to complex, functionally more relevant movements (i.e. reaching and stepping tasks requiring endpoint accuracy; co-operative, bilateral hand movements) for which the involvement of the reticulo-spinal system is not yet understood.\n\nThe second goal of this project is to use the StartReact paradigm to shed more light onto the role of reticulospinal plasticity in functional recovery of patients with spinal cord injury (SCI). Whereas preclinical findings emphasize a remarkable potential of the reticulospinal system for neuroplastic adaptations underlying functional recovery, there is only little evidence from clinical trials in the field of SCI. First, the study aims at monitoring StartReact effects in hand and leg muscles of patients with acute SCI over a period of 6 months. Simultaneous tracking of StartReact effects and motor recovery will allow to closely relate processes of reticulospinal plasticity to functional recovery in patients with acute SCI. Second, the focus will be on the re-weighting of descending motor control (i.e. cortico- vs. reticulospinal system) in response to SCI and investigate the distinct contributions of the cortico- and reticulospinal system to motor recovery in patients with chronic SCI.\n\nThe findings of this project will advance the mechanistic understanding on the motor physiology and neurorestorative capacity of the reticulospinal system in humans. New insights from these projects will hopefully translate into a better exploitation of this important motor system in clinical trials that aim to improve motor recovery in patients with SCI.",
        "tokens": "['Contributions', 'of', 'the', 'Reticulospinal', 'System', 'to', 'Movement', 'Control', 'and', 'Functional', 'Recovery', 'in', 'Patients', 'With', 'Spinal', 'Cord', 'Injury', '|', 'Accurate', 'movement', 'execution', 'is', 'a', 'result', 'of', 'a', 'complex', 'interplay', 'between', 'various', 'muscle', 'groups', 'whose', 'activity', 'is', 'controlled', 'by', 'different', 'areas', 'of', 'the', 'central', 'nervous', 'system', '.', 'Besides', 'the', 'corticospinal', 'system', ',', 'the', 'phylogenetically', 'old', 'reticulospinal', 'system', 'is', 'a', 'key', 'motor', 'system', 'controlling', 'different', 'elementary', 'movements', 'including', 'posture', ',', 'locomotion', 'and', 'reaching', 'across', 'all', 'mammals', '.', 'In', 'contrast', 'to', 'the', 'extensively', 'investigated', 'corticospinal', 'system', ',', 'there', 'is', 'only', 'sparse', 'knowledge', 'on', 'the', 'motor', 'physiology', 'of', 'the', 'functionally', 'important', 'reticulospinal', 'system', 'in', 'humans', '.', 'Reticulospinal', 'motor', 'control', 'can', 'be', 'assessed', 'with', 'the', 'StartReact', 'paradigm', 'which', 'is', 'based', 'on', 'the', 'activation', 'of', 'reticulospinal', 'motor', 'circuitries', 'by', 'startling', 'acoustic', 'stimuli', '.', 'The', 'StartReact', 'phenomenon', 'is', 'characterized', 'by', 'a', 'shortening', 'in', 'movement', 'reaction', 'time', 'which', 'is', 'mediated', 'by', 'a', 'startle', '-', 'triggered', ',', 'early', 'release', 'of', 'a', 'planned', 'motor', 'program', 'by', 'the', 'reticulospinal', 'system', '.', 'Thus', ',', 'StartReact', 'is', 'a', 'unique', 'tool', 'to', 'examine', 'reticulospinal', 'involvement', 'on', 'human', 'motor', 'control', 'under', 'physiological', 'and', 'pathological', 'conditions', '.', 'StartReact', 'assessments', 'will', 'be', 'supplemented', 'by', 'comprehensive', '3', '-', 'D', 'kinematic', 'analysis', 'and', 'muscle', 'activity', 'recordings', '(', 'i.e.', 'electromyography', ')', 'to', 'gain', 'quantitative', 'insights', 'into', 'reticulospinal', 'movement', 'control', '.', '\\n\\n', 'The', 'first', 'objective', 'of', 'this', 'clinical', 'study', 'is', 'to', 'gain', 'more', 'insights', 'into', 'the', 'mechanisms', 'underlying', 'StartReact', 'and', 'to', 'advance', 'the', 'knowledge', 'on', 'reticulo', '-', 'spinal', 'motor', 'physiology', 'regarding', 'different', 'movement', 'tasks', '(', 'i.e.', 'simple', 'single', '-', 'joint', 'movements', ',', 'complex', 'multi', '-', 'joint', 'movements', 'and', 'bilateral', 'hand', 'movements', ')', 'in', 'healthy', 'subjects', '.', 'The', 'findings', 'of', 'these', 'experiments', 'will', 'provide', 'new', 'insights', 'into', 'proximal', '-', 'distal', ',', 'flexor', '-', 'extensor', 'and', 'upper', '-', 'lower', 'extremity', 'gradients', 'in', 'reticulospinal', 'motor', 'control', 'of', 'healthy', 'subjects', '.', 'Moreover', ',', 'the', 'results', 'will', 'expand', 'the', 'StartReact', 'paradigm', 'to', 'complex', ',', 'functionally', 'more', 'relevant', 'movements', '(', 'i.e.', 'reaching', 'and', 'stepping', 'tasks', 'requiring', 'endpoint', 'accuracy', ';', 'co', '-', 'operative', ',', 'bilateral', 'hand', 'movements', ')', 'for', 'which', 'the', 'involvement', 'of', 'the', 'reticulo', '-', 'spinal', 'system', 'is', 'not', 'yet', 'understood', '.', '\\n\\n', 'The', 'second', 'goal', 'of', 'this', 'project', 'is', 'to', 'use', 'the', 'StartReact', 'paradigm', 'to', 'shed', 'more', 'light', 'onto', 'the', 'role', 'of', 'reticulospinal', 'plasticity', 'in', 'functional', 'recovery', 'of', 'patients', 'with', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'Whereas', 'preclinical', 'findings', 'emphasize', 'a', 'remarkable', 'potential', 'of', 'the', 'reticulospinal', 'system', 'for', 'neuroplastic', 'adaptations', 'underlying', 'functional', 'recovery', ',', 'there', 'is', 'only', 'little', 'evidence', 'from', 'clinical', 'trials', 'in', 'the', 'field', 'of', 'SCI', '.', 'First', ',', 'the', 'study', 'aims', 'at', 'monitoring', 'StartReact', 'effects', 'in', 'hand', 'and', 'leg', 'muscles', 'of', 'patients', 'with', 'acute', 'SCI', 'over', 'a', 'period', 'of', '6', 'months', '.', 'Simultaneous', 'tracking', 'of', 'StartReact', 'effects', 'and', 'motor', 'recovery', 'will', 'allow', 'to', 'closely', 'relate', 'processes', 'of', 'reticulospinal', 'plasticity', 'to', 'functional', 'recovery', 'in', 'patients', 'with', 'acute', 'SCI', '.', 'Second', ',', 'the', 'focus', 'will', 'be', 'on', 'the', 're', '-', 'weighting', 'of', 'descending', 'motor', 'control', '(', 'i.e.', 'cortico-', 'vs.', 'reticulospinal', 'system', ')', 'in', 'response', 'to', 'SCI', 'and', 'investigate', 'the', 'distinct', 'contributions', 'of', 'the', 'cortico-', 'and', 'reticulospinal', 'system', 'to', 'motor', 'recovery', 'in', 'patients', 'with', 'chronic', 'SCI', '.', '\\n\\n', 'The', 'findings', 'of', 'this', 'project', 'will', 'advance', 'the', 'mechanistic', 'understanding', 'on', 'the', 'motor', 'physiology', 'and', 'neurorestorative', 'capacity', 'of', 'the', 'reticulospinal', 'system', 'in', 'humans', '.', 'New', 'insights', 'from', 'these', 'projects', 'will', 'hopefully', 'translate', 'into', 'a', 'better', 'exploitation', 'of', 'this', 'important', 'motor', 'system', 'in', 'clinical', 'trials', 'that', 'aim', 'to', 'improve', 'motor', 'recovery', 'in', 'patients', 'with', 'SCI', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 104,
                "end": 122,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 2387,
                "end": 2405,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 2407,
                "end": 2410,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 2632,
                "end": 2635,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 2733,
                "end": 2742,
                "text": "acute SCI",
                "type": "CONDITION"
            },
            {
                "start": 2941,
                "end": 2950,
                "text": "acute SCI",
                "type": "CONDITION"
            },
            {
                "start": 3083,
                "end": 3086,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 3207,
                "end": 3218,
                "text": "chronic SCI",
                "type": "CONDITION"
            },
            {
                "start": 3574,
                "end": 3577,
                "text": "SCI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02757053",
        "study_official_title": "Screening Brain MRI in High School Football: What is the Risk of Traumatic Brain Injury and Does the Guardian Cap Reduce the Incidence of Injury as Determined by Fluid-attenuated Inversion Recovery (FLAIR) and Susceptibility Weighted Imaging (SWI) Magnetic Resonance Imaging (MRI) Sequences ",
        "study_brief_summary": " Screening Brain magnetic resonance imaging (MRI) with Fluid-attenuated Inversion Recovery (FLAIR) and Susceptibility Weighted Imaging (SWI) sequences will be performed pre and post season on high school football players. One set of players will wear the Guardian Cap on their five star rated helmets and the other will wear five star rated helmets only. The investigators will compare outcomes of ImPACT scores and MRI findings between the two groups to see if there is a statistical difference in reduction of injury and to establish what the baseline level of MRI findings related to injury from high school football is as well as what the baseline level of injury is prior to the start of the season.",
        "text": "Screening Brain MRI in High School Football: What is the Risk of Traumatic Brain Injury and Does the Guardian Cap Reduce the Incidence of Injury as Determined by Fluid-attenuated Inversion Recovery (FLAIR) and Susceptibility Weighted Imaging (SWI) Magnetic Resonance Imaging (MRI) Sequences | Screening Brain magnetic resonance imaging (MRI) with Fluid-attenuated Inversion Recovery (FLAIR) and Susceptibility Weighted Imaging (SWI) sequences will be performed pre and post season on high school football players. One set of players will wear the Guardian Cap on their five star rated helmets and the other will wear five star rated helmets only. The investigators will compare outcomes of ImPACT scores and MRI findings between the two groups to see if there is a statistical difference in reduction of injury and to establish what the baseline level of MRI findings related to injury from high school football is as well as what the baseline level of injury is prior to the start of the season.",
        "tokens": "['Screening', 'Brain', 'MRI', 'in', 'High', 'School', 'Football', ':', 'What', 'is', 'the', 'Risk', 'of', 'Traumatic', 'Brain', 'Injury', 'and', 'Does', 'the', 'Guardian', 'Cap', 'Reduce', 'the', 'Incidence', 'of', 'Injury', 'as', 'Determined', 'by', 'Fluid', '-', 'attenuated', 'Inversion', 'Recovery', '(', 'FLAIR', ')', 'and', 'Susceptibility', 'Weighted', 'Imaging', '(', 'SWI', ')', 'Magnetic', 'Resonance', 'Imaging', '(', 'MRI', ')', 'Sequences', '|', 'Screening', 'Brain', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'with', 'Fluid', '-', 'attenuated', 'Inversion', 'Recovery', '(', 'FLAIR', ')', 'and', 'Susceptibility', 'Weighted', 'Imaging', '(', 'SWI', ')', 'sequences', 'will', 'be', 'performed', 'pre', 'and', 'post', 'season', 'on', 'high', 'school', 'football', 'players', '.', 'One', 'set', 'of', 'players', 'will', 'wear', 'the', 'Guardian', 'Cap', 'on', 'their', 'five', 'star', 'rated', 'helmets', 'and', 'the', 'other', 'will', 'wear', 'five', 'star', 'rated', 'helmets', 'only', '.', 'The', 'investigators', 'will', 'compare', 'outcomes', 'of', 'ImPACT', 'scores', 'and', 'MRI', 'findings', 'between', 'the', 'two', 'groups', 'to', 'see', 'if', 'there', 'is', 'a', 'statistical', 'difference', 'in', 'reduction', 'of', 'injury', 'and', 'to', 'establish', 'what', 'the', 'baseline', 'level', 'of', 'MRI', 'findings', 'related', 'to', 'injury', 'from', 'high', 'school', 'football', 'is', 'as', 'well', 'as', 'what', 'the', 'baseline', 'level', 'of', 'injury', 'is', 'prior', 'to', 'the', 'start', 'of', 'the', 'season', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 65,
                "end": 87,
                "text": "Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 101,
                "end": 113,
                "text": "Guardian Cap",
                "type": "OTHER"
            },
            {
                "start": 547,
                "end": 559,
                "text": "Guardian Cap",
                "type": "OTHER"
            },
            {
                "start": 617,
                "end": 645,
                "text": "five star rated helmets only",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03562286",
        "study_official_title": "Open Spina Bifida Fetoscopic Repair Project ",
        "study_brief_summary": " The aim of the study is to assess a new fetal surgery approach to repair open spina bifida. The fetal group hypothesis is to perform a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair. This approach will allow investigators to make the closure of the defect and avoid the use of an hysterotomy, reducing the risk of maternal complications as uterine dehiscence (rupture), hemorrhage and preterm premature rupture of membranes (PPROM), the patient also will be able to have a vaginal delivery.",
        "text": "Open Spina Bifida Fetoscopic Repair Project | The aim of the study is to assess a new fetal surgery approach to repair open spina bifida. The fetal group hypothesis is to perform a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair. This approach will allow investigators to make the closure of the defect and avoid the use of an hysterotomy, reducing the risk of maternal complications as uterine dehiscence (rupture), hemorrhage and preterm premature rupture of membranes (PPROM), the patient also will be able to have a vaginal delivery.",
        "tokens": "['Open', 'Spina', 'Bifida', 'Fetoscopic', 'Repair', 'Project', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'assess', 'a', 'new', 'fetal', 'surgery', 'approach', 'to', 'repair', 'open', 'spina', 'bifida', '.', 'The', 'fetal', 'group', 'hypothesis', 'is', 'to', 'perform', 'a', 'minimally', 'invasive', 'procedure', 'using', 'a', 'fetoscopic', 'technique', 'in', 'order', 'to', 'access', 'to', 'amniotic', 'cavity', 'and', 'make', 'the', 'endoscopic', 'repair', '.', 'This', 'approach', 'will', 'allow', 'investigators', 'to', 'make', 'the', 'closure', 'of', 'the', 'defect', 'and', 'avoid', 'the', 'use', 'of', 'an', 'hysterotomy', ',', 'reducing', 'the', 'risk', 'of', 'maternal', 'complications', 'as', 'uterine', 'dehiscence', '(', 'rupture', ')', ',', 'hemorrhage', 'and', 'preterm', 'premature', 'rupture', 'of', 'membranes', '(', 'PPROM', ')', ',', 'the', 'patient', 'also', 'will', 'be', 'able', 'to', 'have', 'a', 'vaginal', 'delivery', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'I-COND', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 17,
                "text": "Open Spina Bifida",
                "type": "CONDITION"
            },
            {
                "start": 18,
                "end": 35,
                "text": "Fetoscopic Repair",
                "type": "SURGICAL"
            },
            {
                "start": 86,
                "end": 99,
                "text": "fetal surgery",
                "type": "SURGICAL"
            },
            {
                "start": 119,
                "end": 136,
                "text": "open spina bifida",
                "type": "CONDITION"
            },
            {
                "start": 218,
                "end": 238,
                "text": "fetoscopic technique",
                "type": "SURGICAL"
            },
            {
                "start": 290,
                "end": 307,
                "text": "endoscopic repair",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT01475578",
        "study_official_title": "A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) ",
        "study_brief_summary": " The objectives of this phase II study of STA-1 capsule was to make preliminary evaluation on clinical efficacy and safety of STA-1 capsule in order that based on the dosage and study structure planned in this project, the dosage and study structure of phase III study can be confirmed.",
        "text": "A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) | The objectives of this phase II study of STA-1 capsule was to make preliminary evaluation on clinical efficacy and safety of STA-1 capsule in order that based on the dosage and study structure planned in this project, the dosage and study structure of phase III study can be confirmed.",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Double', '-', 'Dummy', ',', 'Active', '-', 'Controlled', ',', 'Parallel', ',', 'Comparative', ',', 'Multicenter', ',', 'Phase', 'II', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'STA-1', 'Capsule', 'in', 'Patients', 'With', 'Vascular', 'Dementia', '(', 'Marrow', '-', 'Sea', 'Deficiency', ')', '|', 'The', 'objectives', 'of', 'this', 'phase', 'II', 'study', 'of', 'STA-1', 'capsule', 'was', 'to', 'make', 'preliminary', 'evaluation', 'on', 'clinical', 'efficacy', 'and', 'safety', 'of', 'STA-1', 'capsule', 'in', 'order', 'that', 'based', 'on', 'the', 'dosage', 'and', 'study', 'structure', 'planned', 'in', 'this', 'project', ',', 'the', 'dosage', 'and', 'study', 'structure', 'of', 'phase', 'III', 'study', 'can', 'be', 'confirmed', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 151,
                "end": 164,
                "text": "STA-1 Capsule",
                "type": "OTHER"
            },
            {
                "start": 182,
                "end": 199,
                "text": "Vascular Dementia",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 222,
                "text": "Marrow-Sea Deficiency",
                "type": "CONDITION"
            },
            {
                "start": 267,
                "end": 280,
                "text": "STA-1 capsule",
                "type": "OTHER"
            },
            {
                "start": 351,
                "end": 364,
                "text": "STA-1 capsule",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05658731",
        "study_official_title": "Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients ",
        "study_brief_summary": " The goal of this trial is to see if it is possible to better plan how radiation therapy is delivered to different parts of the brain in children who require radiation to treat their tumor, and if this will help reduce neurocognitive (thinking and learning) impairments in these patients.\n\nPatients with newly diagnosed brain or head and neck tumors who are having radiation therapy will have neurocognitive testing and MRI imaging (both research and for regular care) done as part of their participation in the study.\n\nSurvivors of childhood brain tumors who completed radiation therapy at least two years before joining the study, and have not had a recurrence, will have neurocognitive testing and research MRIs completed.\n\nHealthy children will also be enrolled and have research MRIs done.\n\nThe researchers will use the radiation plan to determine how much radiation was delivered to different parts of the brain. The investigators will use the MRIs to determine how the normal brain is changing after treatment; and how this compares to patients who had standard radiation treatment or who never had a brain tumor. The neurocognitive testing will be compared among different groups to see how different treatment plans affect performance on neurocognitive tests.",
        "text": "Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients | The goal of this trial is to see if it is possible to better plan how radiation therapy is delivered to different parts of the brain in children who require radiation to treat their tumor, and if this will help reduce neurocognitive (thinking and learning) impairments in these patients.\n\nPatients with newly diagnosed brain or head and neck tumors who are having radiation therapy will have neurocognitive testing and MRI imaging (both research and for regular care) done as part of their participation in the study.\n\nSurvivors of childhood brain tumors who completed radiation therapy at least two years before joining the study, and have not had a recurrence, will have neurocognitive testing and research MRIs completed.\n\nHealthy children will also be enrolled and have research MRIs done.\n\nThe researchers will use the radiation plan to determine how much radiation was delivered to different parts of the brain. The investigators will use the MRIs to determine how the normal brain is changing after treatment; and how this compares to patients who had standard radiation treatment or who never had a brain tumor. The neurocognitive testing will be compared among different groups to see how different treatment plans affect performance on neurocognitive tests.",
        "tokens": "['Cognitive', 'Outcomes', 'After', 'Brain', 'Substructure', '-', 'informed', 'Radiation', 'Planning', 'in', 'Pediatric', 'Patients', '|', 'The', 'goal', 'of', 'this', 'trial', 'is', 'to', 'see', 'if', 'it', 'is', 'possible', 'to', 'better', 'plan', 'how', 'radiation', 'therapy', 'is', 'delivered', 'to', 'different', 'parts', 'of', 'the', 'brain', 'in', 'children', 'who', 'require', 'radiation', 'to', 'treat', 'their', 'tumor', ',', 'and', 'if', 'this', 'will', 'help', 'reduce', 'neurocognitive', '(', 'thinking', 'and', 'learning', ')', 'impairments', 'in', 'these', 'patients', '.', '\\n\\n', 'Patients', 'with', 'newly', 'diagnosed', 'brain', 'or', 'head', 'and', 'neck', 'tumors', 'who', 'are', 'having', 'radiation', 'therapy', 'will', 'have', 'neurocognitive', 'testing', 'and', 'MRI', 'imaging', '(', 'both', 'research', 'and', 'for', 'regular', 'care', ')', 'done', 'as', 'part', 'of', 'their', 'participation', 'in', 'the', 'study', '.', '\\n\\n', 'Survivors', 'of', 'childhood', 'brain', 'tumors', 'who', 'completed', 'radiation', 'therapy', 'at', 'least', 'two', 'years', 'before', 'joining', 'the', 'study', ',', 'and', 'have', 'not', 'had', 'a', 'recurrence', ',', 'will', 'have', 'neurocognitive', 'testing', 'and', 'research', 'MRIs', 'completed', '.', '\\n\\n', 'Healthy', 'children', 'will', 'also', 'be', 'enrolled', 'and', 'have', 'research', 'MRIs', 'done', '.', '\\n\\n', 'The', 'researchers', 'will', 'use', 'the', 'radiation', 'plan', 'to', 'determine', 'how', 'much', 'radiation', 'was', 'delivered', 'to', 'different', 'parts', 'of', 'the', 'brain', '.', 'The', 'investigators', 'will', 'use', 'the', 'MRIs', 'to', 'determine', 'how', 'the', 'normal', 'brain', 'is', 'changing', 'after', 'treatment', ';', 'and', 'how', 'this', 'compares', 'to', 'patients', 'who', 'had', 'standard', 'radiation', 'treatment', 'or', 'who', 'never', 'had', 'a', 'brain', 'tumor', '.', 'The', 'neurocognitive', 'testing', 'will', 'be', 'compared', 'among', 'different', 'groups', 'to', 'see', 'how', 'different', 'treatment', 'plans', 'affect', 'performance', 'on', 'neurocognitive', 'tests', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 71,
                "text": "Brain Substructure-informed Radiation Planning",
                "type": "OTHER"
            },
            {
                "start": 166,
                "end": 183,
                "text": "radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 253,
                "end": 262,
                "text": "radiation",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 278,
                "end": 283,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 399,
                "end": 444,
                "text": "newly diagnosed brain or head and neck tumors",
                "type": "CONDITION"
            },
            {
                "start": 460,
                "end": 477,
                "text": "radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 638,
                "end": 650,
                "text": "brain tumors",
                "type": "CONDITION"
            },
            {
                "start": 665,
                "end": 682,
                "text": "radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 920,
                "end": 934,
                "text": "radiation plan",
                "type": "OTHER"
            },
            {
                "start": 957,
                "end": 966,
                "text": "radiation",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 1155,
                "end": 1183,
                "text": "standard radiation treatment",
                "type": "CONTROL"
            },
            {
                "start": 1203,
                "end": 1214,
                "text": "brain tumor",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02719483",
        "study_official_title": "Applied Research in Children With Spastic Cerebral Palsy in the Extracorporeal Shock Wave Therapy ",
        "study_brief_summary": " The purpose of this study is to determine whether radial extracorporeal shock wave therapy in combination with traditional physical therapy is safe and effective for the management of spastic plantar flexor muscles in patients with cerebral palsy younger than averaged three years of age.",
        "text": "Applied Research in Children With Spastic Cerebral Palsy in the Extracorporeal Shock Wave Therapy | The purpose of this study is to determine whether radial extracorporeal shock wave therapy in combination with traditional physical therapy is safe and effective for the management of spastic plantar flexor muscles in patients with cerebral palsy younger than averaged three years of age.",
        "tokens": "['Applied', 'Research', 'in', 'Children', 'With', 'Spastic', 'Cerebral', 'Palsy', 'in', 'the', 'Extracorporeal', 'Shock', 'Wave', 'Therapy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'radial', 'extracorporeal', 'shock', 'wave', 'therapy', 'in', 'combination', 'with', 'traditional', 'physical', 'therapy', 'is', 'safe', 'and', 'effective', 'for', 'the', 'management', 'of', 'spastic', 'plantar', 'flexor', 'muscles', 'in', 'patients', 'with', 'cerebral', 'palsy', 'younger', 'than', 'averaged', 'three', 'years', 'of', 'age', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 34,
                "end": 56,
                "text": "Spastic Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 64,
                "end": 97,
                "text": "Extracorporeal Shock Wave Therapy",
                "type": "OTHER"
            },
            {
                "start": 150,
                "end": 190,
                "text": "radial extracorporeal shock wave therapy",
                "type": "OTHER"
            },
            {
                "start": 223,
                "end": 239,
                "text": "physical therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 284,
                "end": 291,
                "text": "spastic",
                "type": "CONDITION"
            },
            {
                "start": 332,
                "end": 346,
                "text": "cerebral palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05168384",
        "study_official_title": "Randomized, Controlled, Open-label Study Evaluating the Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis ",
        "study_brief_summary": " PHOMS Study is a randomized, controlled, open-label, prospective, and multicentric clinical trial involving outpatients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Relapsing-Remitting Multiple Sclerosis (RRMS). The primary objective is the safety profile assessment of the investigational intervention (Extracorporeal Photopheresis -ECP) and its preliminary efficacy evaluation, while the secondary objective is the assessment of the immune response profile in MS patients.",
        "text": "Randomized, Controlled, Open-label Study Evaluating the Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis | PHOMS Study is a randomized, controlled, open-label, prospective, and multicentric clinical trial involving outpatients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Relapsing-Remitting Multiple Sclerosis (RRMS). The primary objective is the safety profile assessment of the investigational intervention (Extracorporeal Photopheresis -ECP) and its preliminary efficacy evaluation, while the secondary objective is the assessment of the immune response profile in MS patients.",
        "tokens": "['Randomized', ',', 'Controlled', ',', 'Open', '-', 'label', 'Study', 'Evaluating', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Extracorporeal', 'Photopheresis', '(', 'ECP', ')', 'in', 'the', 'Treatment', 'of', 'Multiple', 'Sclerosis', '|', 'PHOMS', 'Study', 'is', 'a', 'randomized', ',', 'controlled', ',', 'open', '-', 'label', ',', 'prospective', ',', 'and', 'multicentric', 'clinical', 'trial', 'involving', 'outpatients', 'diagnosed', 'with', 'Secondary', 'Progressive', 'Multiple', 'Sclerosis', '(', 'SPMS', ')', 'or', 'Relapsing', '-', 'Remitting', 'Multiple', 'Sclerosis', '(', 'RRMS', ')', '.', 'The', 'primary', 'objective', 'is', 'the', 'safety', 'profile', 'assessment', 'of', 'the', 'investigational', 'intervention', '(', 'Extracorporeal', 'Photopheresis', '-ECP', ')', 'and', 'its', 'preliminary', 'efficacy', 'evaluation', ',', 'while', 'the', 'secondary', 'objective', 'is', 'the', 'assessment', 'of', 'the', 'immune', 'response', 'profile', 'in', 'MS', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 79,
                "end": 107,
                "text": "Extracorporeal Photopheresis",
                "type": "OTHER"
            },
            {
                "start": 109,
                "end": 112,
                "text": "ECP",
                "type": "OTHER"
            },
            {
                "start": 134,
                "end": 152,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 290,
                "end": 330,
                "text": "Secondary Progressive Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 332,
                "end": 336,
                "text": "SPMS",
                "type": "CONDITION"
            },
            {
                "start": 341,
                "end": 379,
                "text": "Relapsing-Remitting Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 381,
                "end": 385,
                "text": "RRMS",
                "type": "CONDITION"
            },
            {
                "start": 480,
                "end": 508,
                "text": "Extracorporeal Photopheresis",
                "type": "OTHER"
            },
            {
                "start": 509,
                "end": 513,
                "text": "-ECP",
                "type": "OTHER"
            },
            {
                "start": 638,
                "end": 640,
                "text": "MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02522351",
        "study_official_title": "Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia Due to Ischemic/Hemorrhagic Cerebral Cause (Stroke) ",
        "study_brief_summary": " The aim of the trial is to identify any systematic effect of cohesiveness on the efficacy of swallowing in patients having dysphagia problems.",
        "text": "Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia Due to Ischemic/Hemorrhagic Cerebral Cause (Stroke) | The aim of the trial is to identify any systematic effect of cohesiveness on the efficacy of swallowing in patients having dysphagia problems.",
        "tokens": "['Reduction', 'of', 'Aspiration', 'Through', 'Cohesive', 'Thin', 'Liquids', '(', 'CTL', ')', 'in', 'Patients', 'With', 'Mild', 'Oropharyngeal', 'Dysphagia', 'Due', 'to', 'Ischemic', '/', 'Hemorrhagic', 'Cerebral', 'Cause', '(', 'Stroke', ')', '|', 'The', 'aim', 'of', 'the', 'trial', 'is', 'to', 'identify', 'any', 'systematic', 'effect', 'of', 'cohesiveness', 'on', 'the', 'efficacy', 'of', 'swallowing', 'in', 'patients', 'having', 'dysphagia', 'problems', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 53,
                "text": "Cohesive Thin Liquids",
                "type": "OTHER"
            },
            {
                "start": 55,
                "end": 58,
                "text": "CTL",
                "type": "OTHER"
            },
            {
                "start": 77,
                "end": 105,
                "text": "Mild Oropharyngeal Dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 148,
                "text": "Ischemic/Hemorrhagic Cerebral Cause",
                "type": "CONDITION"
            },
            {
                "start": 150,
                "end": 156,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 292,
                "text": "dysphagia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02633709",
        "study_official_title": "A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending-Dose(SAD), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food and the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of RO7034067), and Pharmacodynamics of RO7034067 Following Oral Administration in Healthy Subjects ",
        "study_brief_summary": " The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body. Risdiplam (RO7034067) will be given by mouth in gradually increasing doses. The data from this study will help to define the dose to further explore Risdiplam (RO7034067) in patients with Spinal Muscular Atrophy.",
        "text": "A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending-Dose(SAD), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food and the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of RO7034067), and Pharmacodynamics of RO7034067 Following Oral Administration in Healthy Subjects | The objective of this study is to assess the safety and tolerability of Risdiplam (RO7034067) in healthy people. The study will assess what the body does to Risdiplam (RO7034067) and what Risdiplam (RO7034067) does to the body. Risdiplam (RO7034067) will be given by mouth in gradually increasing doses. The data from this study will help to define the dose to further explore Risdiplam (RO7034067) in patients with Spinal Muscular Atrophy.",
        "tokens": "['A', 'Single', '-', 'Center', ',', 'Randomized', ',', 'Investigator', '/', 'Subject', '-', 'Blind', ',', 'Adaptive', 'Single', '-', 'Ascending', '-', 'Dose(SAD', ')', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', 'Study', 'to', 'Investigate', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', '(', 'Including', 'the', 'Effect', 'of', 'Food', 'and', 'the', 'Effect', 'of', 'Itraconazole', 'on', 'the', 'Pharmacokinetics', 'of', 'a', 'Single', 'Oral', 'Dose', 'of', 'RO7034067', ')', ',', 'and', 'Pharmacodynamics', 'of', 'RO7034067', 'Following', 'Oral', 'Administration', 'in', 'Healthy', 'Subjects', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'tolerability', 'of', 'Risdiplam', '(', 'RO7034067', ')', 'in', 'healthy', 'people', '.', 'The', 'study', 'will', 'assess', 'what', 'the', 'body', 'does', 'to', 'Risdiplam', '(', 'RO7034067', ')', 'and', 'what', 'Risdiplam', '(', 'RO7034067', ')', 'does', 'to', 'the', 'body', '.', 'Risdiplam', '(', 'RO7034067', ')', 'will', 'be', 'given', 'by', 'mouth', 'in', 'gradually', 'increasing', 'doses', '.', 'The', 'data', 'from', 'this', 'study', 'will', 'help', 'to', 'define', 'the', 'dose', 'to', 'further', 'explore', 'Risdiplam', '(', 'RO7034067', ')', 'in', 'patients', 'with', 'Spinal', 'Muscular', 'Atrophy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 94,
                "end": 101,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 235,
                "end": 247,
                "text": "Itraconazole",
                "type": "DRUG"
            },
            {
                "start": 297,
                "end": 306,
                "text": "RO7034067",
                "type": "DRUG"
            },
            {
                "start": 333,
                "end": 342,
                "text": "RO7034067",
                "type": "DRUG"
            },
            {
                "start": 467,
                "end": 476,
                "text": "Risdiplam",
                "type": "DRUG"
            },
            {
                "start": 478,
                "end": 487,
                "text": "RO7034067",
                "type": "DRUG"
            },
            {
                "start": 552,
                "end": 561,
                "text": "Risdiplam",
                "type": "DRUG"
            },
            {
                "start": 563,
                "end": 572,
                "text": "RO7034067",
                "type": "DRUG"
            },
            {
                "start": 583,
                "end": 592,
                "text": "Risdiplam",
                "type": "DRUG"
            },
            {
                "start": 594,
                "end": 603,
                "text": "RO7034067",
                "type": "DRUG"
            },
            {
                "start": 623,
                "end": 632,
                "text": "Risdiplam",
                "type": "DRUG"
            },
            {
                "start": 634,
                "end": 643,
                "text": "RO7034067",
                "type": "DRUG"
            },
            {
                "start": 772,
                "end": 781,
                "text": "Risdiplam",
                "type": "DRUG"
            },
            {
                "start": 783,
                "end": 792,
                "text": "RO7034067",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00505167",
        "study_official_title": "Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy. ",
        "study_brief_summary": " It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.",
        "text": "Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy. | It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.",
        "tokens": "['Memantine', 'Versus', 'Donepezil', 'in', 'Mild', 'to', 'Moderate', 'Alzheimer', \"'s\", 'Disease', '.', 'A', 'Randomized', 'Trial', 'With', 'Magnetic', 'Resonance', 'Spectroscopy', '.', '|', 'It', 'is', 'well', 'known', 'that', 'in', 'the', 'brain', 'of', 'the', 'patients', 'with', 'Alzheimer', \"'s\", 'disease', 'there', 'is', 'a', 'glutamatergic', 'hyperstimulation', 'leading', 'to', 'neuronal', 'death', '.', 'Memantine', 'is', 'a', 'low', 'affinity', 'antagonist', 'of', 'NMDA', 'glutamate', 'receptors', '.', 'The', 'use', 'of', 'this', 'drug', 'in', 'the', 'early', 'phases', 'of', 'the', 'disease', 'could', 'provide', 'neuroprotective', 'effects', 'and', 'delay', 'of', 'progression', '.', 'The', 'effects', 'of', 'memantine', 'should', 'be', 'compared', 'to', 'those', 'of', 'donepezil', ',', 'which', 'is', 'the', 'most', 'prescribed', 'anticholinesterase', 'drug', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 9,
                "text": "Memantine",
                "type": "DRUG"
            },
            {
                "start": 17,
                "end": 26,
                "text": "Donepezil",
                "type": "DRUG"
            },
            {
                "start": 30,
                "end": 67,
                "text": "Mild to Moderate Alzheimer's Disease.",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 202,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 272,
                "end": 281,
                "text": "Memantine",
                "type": "DRUG"
            },
            {
                "start": 475,
                "end": 484,
                "text": "memantine",
                "type": "DRUG"
            },
            {
                "start": 516,
                "end": 525,
                "text": "donepezil",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00661869",
        "study_official_title": "Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness ",
        "study_brief_summary": " Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics. In order to address the weight and metabolic syndrome issues, Manhattan Psychiatric Center (MPC) has implemented the Solutions for Wellness and Team Solutions Program. This program is designed to create a supportive, educational and monitoring environment to stabilize both the psychiatric and medical conditions and to prepare patients for independent management of their psychiatric and physical health condition in the community.",
        "text": "Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness | Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics. In order to address the weight and metabolic syndrome issues, Manhattan Psychiatric Center (MPC) has implemented the Solutions for Wellness and Team Solutions Program. This program is designed to create a supportive, educational and monitoring environment to stabilize both the psychiatric and medical conditions and to prepare patients for independent management of their psychiatric and physical health condition in the community.",
        "tokens": "['Outcome', 'Evaluation', 'of', 'Solutions', 'for', 'Wellness', 'and', 'Team', 'Solutions', 'Program', 'in', 'Patients', 'With', 'Severe', 'Mental', 'Illness', '|', 'Obesity', 'is', 'increasing', 'at', 'an', 'alarming', 'rate', 'in', 'patients', 'with', 'schizophrenia', ',', 'possibly', 'in', 'association', 'with', 'the', 'increased', 'use', 'of', 'atypical', 'antipsychotics', '.', 'In', 'order', 'to', 'address', 'the', 'weight', 'and', 'metabolic', 'syndrome', 'issues', ',', 'Manhattan', 'Psychiatric', 'Center', '(', 'MPC', ')', 'has', 'implemented', 'the', 'Solutions', 'for', 'Wellness', 'and', 'Team', 'Solutions', 'Program', '.', 'This', 'program', 'is', 'designed', 'to', 'create', 'a', 'supportive', ',', 'educational', 'and', 'monitoring', 'environment', 'to', 'stabilize', 'both', 'the', 'psychiatric', 'and', 'medical', 'conditions', 'and', 'to', 'prepare', 'patients', 'for', 'independent', 'management', 'of', 'their', 'psychiatric', 'and', 'physical', 'health', 'condition', 'in', 'the', 'community', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 36,
                "end": 71,
                "text": "Wellness and Team Solutions Program",
                "type": "OTHER"
            },
            {
                "start": 89,
                "end": 110,
                "text": "Severe Mental Illness",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 120,
                "text": "Obesity",
                "type": "CONDITION"
            },
            {
                "start": 172,
                "end": 185,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 297,
                "end": 315,
                "text": "metabolic syndrome",
                "type": "CONDITION"
            },
            {
                "start": 393,
                "end": 428,
                "text": "Wellness and Team Solutions Program",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00123136",
        "study_official_title": "Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial ",
        "study_brief_summary": " The researchers will study the application of a commercial pulsed magnetic stimulating device to the feet of patients with moderate-severe foot pain secondary to diabetic peripheral neuropathy (DPN).",
        "text": "Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial | The researchers will study the application of a commercial pulsed magnetic stimulating device to the feet of patients with moderate-severe foot pain secondary to diabetic peripheral neuropathy (DPN).",
        "tokens": "['Bi', '-', 'Axial', 'Rotating', 'Magnetic', 'Field', 'Therapy', 'in', 'Refractory', 'Neuropathic', 'Foot', 'Pain', 'Secondary', 'to', 'Diabetic', 'Peripheral', 'Neuropathy', '.', 'Multi', '-', 'Center', ',', 'Randomized', 'Placebo', 'Controlled', 'Trial', '|', 'The', 'researchers', 'will', 'study', 'the', 'application', 'of', 'a', 'commercial', 'pulsed', 'magnetic', 'stimulating', 'device', 'to', 'the', 'feet', 'of', 'patients', 'with', 'moderate', '-', 'severe', 'foot', 'pain', 'secondary', 'to', 'diabetic', 'peripheral', 'neuropathy', '(', 'DPN', ')', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 40,
                "text": "Bi-Axial Rotating Magnetic Field Therapy",
                "type": "OTHER"
            },
            {
                "start": 44,
                "end": 76,
                "text": "Refractory Neuropathic Foot Pain",
                "type": "CONDITION"
            },
            {
                "start": 90,
                "end": 120,
                "text": "Diabetic Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 147,
                "end": 154,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 233,
                "end": 260,
                "text": "pulsed magnetic stimulating",
                "type": "OTHER"
            },
            {
                "start": 297,
                "end": 322,
                "text": "moderate-severe foot pain",
                "type": "CONDITION"
            },
            {
                "start": 336,
                "end": 366,
                "text": "diabetic peripheral neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 368,
                "end": 371,
                "text": "DPN",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00996983",
        "study_official_title": "Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer ",
        "study_brief_summary": " Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.",
        "text": "Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer | Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.",
        "tokens": "['Phase', 'II', 'Study', 'of', 'Intrathecal', 'Ziconotide', 'for', 'the', 'Treatment', 'of', 'Neuropathic', 'Pain', 'in', 'Patients', 'With', 'Cancer', '|', 'Neuropathic', 'pain', 'is', 'difficult', 'to', 'control', 'because', 'it', 'is', 'only', 'partially', 'sensitive', 'to', 'opioid', 'analgesics', ',', 'and', 'requires', 'the', 'addition', 'of', 'other', 'therapies', 'such', 'as', 'antidepressants', 'and', 'epileptics', '.', 'Ziconotide', 'is', 'a', 'drug', 'that', 'is', 'used', 'to', 'treat', 'neuropathic', 'pain', 'in', 'patients', 'who', 'have', 'had', 'inadequate', 'pain', 'control', 'with', 'prior', 'combination', 'of', 'medicines', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 40,
                "text": "Ziconotide",
                "type": "DRUG"
            },
            {
                "start": 62,
                "end": 78,
                "text": "Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 102,
                "text": "Cancer",
                "type": "CONDITION"
            },
            {
                "start": 105,
                "end": 121,
                "text": "Neuropathic pain",
                "type": "CONDITION"
            },
            {
                "start": 292,
                "end": 302,
                "text": "Ziconotide",
                "type": "DRUG"
            },
            {
                "start": 335,
                "end": 351,
                "text": "neuropathic pain",
                "type": "CONDITION"
            },
            {
                "start": 388,
                "end": 392,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01626885",
        "study_official_title": "A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia ",
        "study_brief_summary": " The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.",
        "text": "A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia | The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.",
        "tokens": "['A', 'Long', '-', 'Term', 'Study', 'of', 'MP-214', 'in', 'Patients', 'With', 'Receiving', 'Multiple', 'Drugs', 'Schizophrenia', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', ',', 'tolerability', ',', 'and', 'efficacy', 'of', 'MP-214', 'in', 'patients', 'with', 'receiving', 'multiple', 'drugs', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 27,
                "text": "MP-214",
                "type": "DRUG"
            },
            {
                "start": 45,
                "end": 83,
                "text": "Receiving Multiple Drugs Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 181,
                "end": 187,
                "text": "MP-214",
                "type": "DRUG"
            },
            {
                "start": 205,
                "end": 243,
                "text": "receiving multiple drugs schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03550495",
        "study_official_title": "A Multidisciplinary Delirium Prevention Strategy Involving Psychiatry in the Intensive Care Unit (ICU): Effects on Delirium Incidence and Outcomes ",
        "study_brief_summary": " Delirium affects up to 80% of intensive care unit (ICU) patients and is associated with longer hospital stays, increased morbidity and mortality, and increased costs. There is no FDA-approved treatment for delirium; the most effective strategy is prevention by nonpharmacological methods. The investigators propose to study a comprehensive delirium prevention bundle that has been effective against delirium in preliminary studies in elderly in-hospital patients and elderly ICU patients. This delirium prevention bundle includes the novel addition of psychiatrists to daily ICU rounds, as these professionals are specially trained to screen for latent mental illness and provide treatment for these illnesses. The effects of daily psychiatric evaluation of ICU patients has never been systematically studied, as ICU professionals are well-equipped to manage ICU delirium. Psychiatric consultation is reserved for severe and/or refractory cases of delirium. The investigators hypothesize that a multidisciplinary rounding approach including psychiatry within the ICU team will help diagnose psychiatric components that may contribute to delirium at an earlier time point, and thus can reduce the incidence and duration of delirium. The investigators also hypothesize that the proposed multidisciplinary approach will shorten hospital and ICU lengths of stay, duration of mechanical ventilation, and decrease in-hospital mortality.",
        "text": "A Multidisciplinary Delirium Prevention Strategy Involving Psychiatry in the Intensive Care Unit (ICU): Effects on Delirium Incidence and Outcomes | Delirium affects up to 80% of intensive care unit (ICU) patients and is associated with longer hospital stays, increased morbidity and mortality, and increased costs. There is no FDA-approved treatment for delirium; the most effective strategy is prevention by nonpharmacological methods. The investigators propose to study a comprehensive delirium prevention bundle that has been effective against delirium in preliminary studies in elderly in-hospital patients and elderly ICU patients. This delirium prevention bundle includes the novel addition of psychiatrists to daily ICU rounds, as these professionals are specially trained to screen for latent mental illness and provide treatment for these illnesses. The effects of daily psychiatric evaluation of ICU patients has never been systematically studied, as ICU professionals are well-equipped to manage ICU delirium. Psychiatric consultation is reserved for severe and/or refractory cases of delirium. The investigators hypothesize that a multidisciplinary rounding approach including psychiatry within the ICU team will help diagnose psychiatric components that may contribute to delirium at an earlier time point, and thus can reduce the incidence and duration of delirium. The investigators also hypothesize that the proposed multidisciplinary approach will shorten hospital and ICU lengths of stay, duration of mechanical ventilation, and decrease in-hospital mortality.",
        "tokens": "['A', 'Multidisciplinary', 'Delirium', 'Prevention', 'Strategy', 'Involving', 'Psychiatry', 'in', 'the', 'Intensive', 'Care', 'Unit', '(', 'ICU', '):', 'Effects', 'on', 'Delirium', 'Incidence', 'and', 'Outcomes', '|', 'Delirium', 'affects', 'up', 'to', '80', '%', 'of', 'intensive', 'care', 'unit', '(', 'ICU', ')', 'patients', 'and', 'is', 'associated', 'with', 'longer', 'hospital', 'stays', ',', 'increased', 'morbidity', 'and', 'mortality', ',', 'and', 'increased', 'costs', '.', 'There', 'is', 'no', 'FDA', '-', 'approved', 'treatment', 'for', 'delirium', ';', 'the', 'most', 'effective', 'strategy', 'is', 'prevention', 'by', 'nonpharmacological', 'methods', '.', 'The', 'investigators', 'propose', 'to', 'study', 'a', 'comprehensive', 'delirium', 'prevention', 'bundle', 'that', 'has', 'been', 'effective', 'against', 'delirium', 'in', 'preliminary', 'studies', 'in', 'elderly', 'in', '-', 'hospital', 'patients', 'and', 'elderly', 'ICU', 'patients', '.', 'This', 'delirium', 'prevention', 'bundle', 'includes', 'the', 'novel', 'addition', 'of', 'psychiatrists', 'to', 'daily', 'ICU', 'rounds', ',', 'as', 'these', 'professionals', 'are', 'specially', 'trained', 'to', 'screen', 'for', 'latent', 'mental', 'illness', 'and', 'provide', 'treatment', 'for', 'these', 'illnesses', '.', 'The', 'effects', 'of', 'daily', 'psychiatric', 'evaluation', 'of', 'ICU', 'patients', 'has', 'never', 'been', 'systematically', 'studied', ',', 'as', 'ICU', 'professionals', 'are', 'well', '-', 'equipped', 'to', 'manage', 'ICU', 'delirium', '.', 'Psychiatric', 'consultation', 'is', 'reserved', 'for', 'severe', 'and/or', 'refractory', 'cases', 'of', 'delirium', '.', 'The', 'investigators', 'hypothesize', 'that', 'a', 'multidisciplinary', 'rounding', 'approach', 'including', 'psychiatry', 'within', 'the', 'ICU', 'team', 'will', 'help', 'diagnose', 'psychiatric', 'components', 'that', 'may', 'contribute', 'to', 'delirium', 'at', 'an', 'earlier', 'time', 'point', ',', 'and', 'thus', 'can', 'reduce', 'the', 'incidence', 'and', 'duration', 'of', 'delirium', '.', 'The', 'investigators', 'also', 'hypothesize', 'that', 'the', 'proposed', 'multidisciplinary', 'approach', 'will', 'shorten', 'hospital', 'and', 'ICU', 'lengths', 'of', 'stay', ',', 'duration', 'of', 'mechanical', 'ventilation', ',', 'and', 'decrease', 'in', '-', 'hospital', 'mortality', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 2,
                "end": 48,
                "text": "Multidisciplinary Delirium Prevention Strategy",
                "type": "OTHER"
            },
            {
                "start": 59,
                "end": 69,
                "text": "Psychiatry",
                "type": "OTHER"
            },
            {
                "start": 77,
                "end": 96,
                "text": "Intensive Care Unit",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 101,
                "text": "ICU",
                "type": "CONDITION"
            },
            {
                "start": 115,
                "end": 123,
                "text": "Delirium",
                "type": "CONDITION"
            },
            {
                "start": 149,
                "end": 157,
                "text": "Delirium",
                "type": "CONDITION"
            },
            {
                "start": 179,
                "end": 198,
                "text": "intensive care unit",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 203,
                "text": "ICU",
                "type": "CONDITION"
            },
            {
                "start": 355,
                "end": 363,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 489,
                "end": 515,
                "text": "delirium prevention bundle",
                "type": "OTHER"
            },
            {
                "start": 548,
                "end": 556,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 624,
                "end": 627,
                "text": "ICU",
                "type": "CONDITION"
            },
            {
                "start": 643,
                "end": 669,
                "text": "delirium prevention bundle",
                "type": "OTHER"
            },
            {
                "start": 689,
                "end": 734,
                "text": "addition of psychiatrists to daily ICU rounds",
                "type": "OTHER"
            },
            {
                "start": 881,
                "end": 903,
                "text": "psychiatric evaluation",
                "type": "OTHER"
            },
            {
                "start": 907,
                "end": 910,
                "text": "ICU",
                "type": "CONDITION"
            },
            {
                "start": 962,
                "end": 965,
                "text": "ICU",
                "type": "CONDITION"
            },
            {
                "start": 1008,
                "end": 1011,
                "text": "ICU",
                "type": "CONDITION"
            },
            {
                "start": 1012,
                "end": 1020,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 1022,
                "end": 1046,
                "text": "Psychiatric consultation",
                "type": "OTHER"
            },
            {
                "start": 1097,
                "end": 1105,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 1144,
                "end": 1220,
                "text": "multidisciplinary rounding approach including psychiatry within the ICU team",
                "type": "OTHER"
            },
            {
                "start": 1286,
                "end": 1294,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 1371,
                "end": 1379,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 1434,
                "end": 1460,
                "text": "multidisciplinary approach",
                "type": "OTHER"
            },
            {
                "start": 1487,
                "end": 1490,
                "text": "ICU",
                "type": "CONDITION"
            },
            {
                "start": 1520,
                "end": 1542,
                "text": "mechanical ventilation",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03049033",
        "study_official_title": "Neurologic Music Therapy for Enhancing Fine Motor Control in Parkinson's Disease ",
        "study_brief_summary": " Parkinson's Disease (PD) is defined by characteristic motor symptoms including slow movements, small movements, difficulty with movement initiation and disruptions in timing. Besides gross motor symptoms, fine motor impairments in PD cause difficulties with everyday tasks such as writing, self-care, and fine object manipulation. These activity limitations can lead to disability, social isolation, and a reduced quality of life. In a series of breakthrough studies Michael Thaut and colleagues developed Neurologic Music Therapy (NMT) and found it can address many gross motor impairments and improve gait and balance. Other music therapies such as Music-supported Therapy (MST) have proven motor benefits in stroke patients through movement exercises with musical instruments. However, the pathological basal ganglia (BG) in PD brains leads to a reduced supply of those internally generated movements. In contrast, externally cued movements (eg. via a beat or a rhythm) during NMT sessions are instantaneously entrained to the period of a rhythmic stimulus possibly without involvement of the BG. The underlying idea is that rhythm is the essential component relating music specifically to motor behavior. The mechanism of action is called \"rhythmic entrainment\" where one system's motion or signal frequency entrains the frequency of another system. The effect of NMT on fine motor function has not been investigated yet. Music activities are important in the lives of many older adults. Notably, the use of music has been associated with increased well-being for older adults, as it fosters social connection and mood regulation. Furthermore, many musical activities have limited physical demands, making them attainable for individuals who are living with mobility impairments or other physical restrictions. Based on the literature and the investigators preliminary studies, the investigators propose to test the efficacy of Neurologic Music Therapy in comparison to Music Supported Therapy and Occupational Therapy (OT) as standard of care on adults in the Parkinson's spectrum. The investigators have defined a working plan using different musical instruments and growing tempo to specifically improve fine motor movements.",
        "text": "Neurologic Music Therapy for Enhancing Fine Motor Control in Parkinson's Disease | Parkinson's Disease (PD) is defined by characteristic motor symptoms including slow movements, small movements, difficulty with movement initiation and disruptions in timing. Besides gross motor symptoms, fine motor impairments in PD cause difficulties with everyday tasks such as writing, self-care, and fine object manipulation. These activity limitations can lead to disability, social isolation, and a reduced quality of life. In a series of breakthrough studies Michael Thaut and colleagues developed Neurologic Music Therapy (NMT) and found it can address many gross motor impairments and improve gait and balance. Other music therapies such as Music-supported Therapy (MST) have proven motor benefits in stroke patients through movement exercises with musical instruments. However, the pathological basal ganglia (BG) in PD brains leads to a reduced supply of those internally generated movements. In contrast, externally cued movements (eg. via a beat or a rhythm) during NMT sessions are instantaneously entrained to the period of a rhythmic stimulus possibly without involvement of the BG. The underlying idea is that rhythm is the essential component relating music specifically to motor behavior. The mechanism of action is called \"rhythmic entrainment\" where one system's motion or signal frequency entrains the frequency of another system. The effect of NMT on fine motor function has not been investigated yet. Music activities are important in the lives of many older adults. Notably, the use of music has been associated with increased well-being for older adults, as it fosters social connection and mood regulation. Furthermore, many musical activities have limited physical demands, making them attainable for individuals who are living with mobility impairments or other physical restrictions. Based on the literature and the investigators preliminary studies, the investigators propose to test the efficacy of Neurologic Music Therapy in comparison to Music Supported Therapy and Occupational Therapy (OT) as standard of care on adults in the Parkinson's spectrum. The investigators have defined a working plan using different musical instruments and growing tempo to specifically improve fine motor movements.",
        "tokens": "['Neurologic', 'Music', 'Therapy', 'for', 'Enhancing', 'Fine', 'Motor', 'Control', 'in', 'Parkinson', \"'s\", 'Disease', '|', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', 'is', 'defined', 'by', 'characteristic', 'motor', 'symptoms', 'including', 'slow', 'movements', ',', 'small', 'movements', ',', 'difficulty', 'with', 'movement', 'initiation', 'and', 'disruptions', 'in', 'timing', '.', 'Besides', 'gross', 'motor', 'symptoms', ',', 'fine', 'motor', 'impairments', 'in', 'PD', 'cause', 'difficulties', 'with', 'everyday', 'tasks', 'such', 'as', 'writing', ',', 'self', '-', 'care', ',', 'and', 'fine', 'object', 'manipulation', '.', 'These', 'activity', 'limitations', 'can', 'lead', 'to', 'disability', ',', 'social', 'isolation', ',', 'and', 'a', 'reduced', 'quality', 'of', 'life', '.', 'In', 'a', 'series', 'of', 'breakthrough', 'studies', 'Michael', 'Thaut', 'and', 'colleagues', 'developed', 'Neurologic', 'Music', 'Therapy', '(', 'NMT', ')', 'and', 'found', 'it', 'can', 'address', 'many', 'gross', 'motor', 'impairments', 'and', 'improve', 'gait', 'and', 'balance', '.', 'Other', 'music', 'therapies', 'such', 'as', 'Music', '-', 'supported', 'Therapy', '(', 'MST', ')', 'have', 'proven', 'motor', 'benefits', 'in', 'stroke', 'patients', 'through', 'movement', 'exercises', 'with', 'musical', 'instruments', '.', 'However', ',', 'the', 'pathological', 'basal', 'ganglia', '(', 'BG', ')', 'in', 'PD', 'brains', 'leads', 'to', 'a', 'reduced', 'supply', 'of', 'those', 'internally', 'generated', 'movements', '.', 'In', 'contrast', ',', 'externally', 'cued', 'movements', '(', 'eg', '.', 'via', 'a', 'beat', 'or', 'a', 'rhythm', ')', 'during', 'NMT', 'sessions', 'are', 'instantaneously', 'entrained', 'to', 'the', 'period', 'of', 'a', 'rhythmic', 'stimulus', 'possibly', 'without', 'involvement', 'of', 'the', 'BG', '.', 'The', 'underlying', 'idea', 'is', 'that', 'rhythm', 'is', 'the', 'essential', 'component', 'relating', 'music', 'specifically', 'to', 'motor', 'behavior', '.', 'The', 'mechanism', 'of', 'action', 'is', 'called', '\"', 'rhythmic', 'entrainment', '\"', 'where', 'one', 'system', \"'s\", 'motion', 'or', 'signal', 'frequency', 'entrains', 'the', 'frequency', 'of', 'another', 'system', '.', 'The', 'effect', 'of', 'NMT', 'on', 'fine', 'motor', 'function', 'has', 'not', 'been', 'investigated', 'yet', '.', 'Music', 'activities', 'are', 'important', 'in', 'the', 'lives', 'of', 'many', 'older', 'adults', '.', 'Notably', ',', 'the', 'use', 'of', 'music', 'has', 'been', 'associated', 'with', 'increased', 'well', '-', 'being', 'for', 'older', 'adults', ',', 'as', 'it', 'fosters', 'social', 'connection', 'and', 'mood', 'regulation', '.', 'Furthermore', ',', 'many', 'musical', 'activities', 'have', 'limited', 'physical', 'demands', ',', 'making', 'them', 'attainable', 'for', 'individuals', 'who', 'are', 'living', 'with', 'mobility', 'impairments', 'or', 'other', 'physical', 'restrictions', '.', 'Based', 'on', 'the', 'literature', 'and', 'the', 'investigators', 'preliminary', 'studies', ',', 'the', 'investigators', 'propose', 'to', 'test', 'the', 'efficacy', 'of', 'Neurologic', 'Music', 'Therapy', 'in', 'comparison', 'to', 'Music', 'Supported', 'Therapy', 'and', 'Occupational', 'Therapy', '(', 'OT', ')', 'as', 'standard', 'of', 'care', 'on', 'adults', 'in', 'the', 'Parkinson', \"'s\", 'spectrum', '.', 'The', 'investigators', 'have', 'defined', 'a', 'working', 'plan', 'using', 'different', 'musical', 'instruments', 'and', 'growing', 'tempo', 'to', 'specifically', 'improve', 'fine', 'motor', 'movements', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 24,
                "text": "Neurologic Music Therapy",
                "type": "OTHER"
            },
            {
                "start": 61,
                "end": 80,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 83,
                "end": 102,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 104,
                "end": 106,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 316,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 589,
                "end": 613,
                "text": "Neurologic Music Therapy",
                "type": "OTHER"
            },
            {
                "start": 615,
                "end": 618,
                "text": "NMT",
                "type": "OTHER"
            },
            {
                "start": 734,
                "end": 757,
                "text": "Music-supported Therapy",
                "type": "CONTROL"
            },
            {
                "start": 759,
                "end": 762,
                "text": "MST",
                "type": "CONTROL"
            },
            {
                "start": 911,
                "end": 913,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1063,
                "end": 1066,
                "text": "NMT",
                "type": "OTHER"
            },
            {
                "start": 1451,
                "end": 1454,
                "text": "NMT",
                "type": "OTHER"
            },
            {
                "start": 2015,
                "end": 2039,
                "text": "Neurologic Music Therapy",
                "type": "OTHER"
            },
            {
                "start": 2057,
                "end": 2080,
                "text": "Music Supported Therapy",
                "type": "CONTROL"
            },
            {
                "start": 2085,
                "end": 2105,
                "text": "Occupational Therapy",
                "type": "CONTROL"
            },
            {
                "start": 2107,
                "end": 2109,
                "text": "OT",
                "type": "CONTROL"
            },
            {
                "start": 2148,
                "end": 2168,
                "text": "Parkinson's spectrum",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02914951",
        "study_official_title": "Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents (An Open Pilot Study in Autism Spectrum Disorder) ",
        "study_brief_summary": " In addition to the core symptoms, children and adolescents with Autism Spectrum Disorder (ASD) often exhibit disruptive behavior problems including irritability, tantrums, noncompliance, and aggression. The purpose of this study is to investigate cognitive-behavioral therapy (CBT) for disruptive behavior in children with autism spectrum disorders and intellectual disability. This pilot study will include children with ASD and IQ between 55 and 85 in an open study of CBT. CBT is modified in this study to reduce complexity of activities during therapy sessions but retains all key elements and principles of CBT. Assessments of irritability and disruptive behavior will include clinical interviews, parent ratings and child self-report measures. Study participants will be asked to complete functional magnetic resonance imaging (fMRI) to evaluate biomarkers of social perception and emotion regulation before and after CBT.",
        "text": "Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents (An Open Pilot Study in Autism Spectrum Disorder) | In addition to the core symptoms, children and adolescents with Autism Spectrum Disorder (ASD) often exhibit disruptive behavior problems including irritability, tantrums, noncompliance, and aggression. The purpose of this study is to investigate cognitive-behavioral therapy (CBT) for disruptive behavior in children with autism spectrum disorders and intellectual disability. This pilot study will include children with ASD and IQ between 55 and 85 in an open study of CBT. CBT is modified in this study to reduce complexity of activities during therapy sessions but retains all key elements and principles of CBT. Assessments of irritability and disruptive behavior will include clinical interviews, parent ratings and child self-report measures. Study participants will be asked to complete functional magnetic resonance imaging (fMRI) to evaluate biomarkers of social perception and emotion regulation before and after CBT.",
        "tokens": "['Cognitive', '-', 'Behavioral', 'Therapy', 'for', 'Disruptive', 'Behavior', 'in', 'Children', 'and', 'Adolescents', '(', 'An', 'Open', 'Pilot', 'Study', 'in', 'Autism', 'Spectrum', 'Disorder', ')', '|', 'In', 'addition', 'to', 'the', 'core', 'symptoms', ',', 'children', 'and', 'adolescents', 'with', 'Autism', 'Spectrum', 'Disorder', '(', 'ASD', ')', 'often', 'exhibit', 'disruptive', 'behavior', 'problems', 'including', 'irritability', ',', 'tantrums', ',', 'noncompliance', ',', 'and', 'aggression', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'cognitive', '-', 'behavioral', 'therapy', '(', 'CBT', ')', 'for', 'disruptive', 'behavior', 'in', 'children', 'with', 'autism', 'spectrum', 'disorders', 'and', 'intellectual', 'disability', '.', 'This', 'pilot', 'study', 'will', 'include', 'children', 'with', 'ASD', 'and', 'IQ', 'between', '55', 'and', '85', 'in', 'an', 'open', 'study', 'of', 'CBT', '.', 'CBT', 'is', 'modified', 'in', 'this', 'study', 'to', 'reduce', 'complexity', 'of', 'activities', 'during', 'therapy', 'sessions', 'but', 'retains', 'all', 'key', 'elements', 'and', 'principles', 'of', 'CBT', '.', 'Assessments', 'of', 'irritability', 'and', 'disruptive', 'behavior', 'will', 'include', 'clinical', 'interviews', ',', 'parent', 'ratings', 'and', 'child', 'self', '-', 'report', 'measures', '.', 'Study', 'participants', 'will', 'be', 'asked', 'to', 'complete', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'fMRI', ')', 'to', 'evaluate', 'biomarkers', 'of', 'social', 'perception', 'and', 'emotion', 'regulation', 'before', 'and', 'after', 'CBT', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 28,
                "text": "Cognitive-Behavioral Therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 33,
                "end": 52,
                "text": "Disruptive Behavior",
                "type": "CONDITION"
            },
            {
                "start": 105,
                "end": 129,
                "text": "Autism Spectrum Disorder",
                "type": "CONDITION"
            },
            {
                "start": 197,
                "end": 221,
                "text": "Autism Spectrum Disorder",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 226,
                "text": "ASD",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 261,
                "text": "disruptive behavior",
                "type": "CONDITION"
            },
            {
                "start": 380,
                "end": 408,
                "text": "cognitive-behavioral therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 410,
                "end": 413,
                "text": "CBT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 419,
                "end": 438,
                "text": "disruptive behavior",
                "type": "CONDITION"
            },
            {
                "start": 456,
                "end": 481,
                "text": "autism spectrum disorders",
                "type": "CONDITION"
            },
            {
                "start": 486,
                "end": 509,
                "text": "intellectual disability",
                "type": "CONDITION"
            },
            {
                "start": 555,
                "end": 558,
                "text": "ASD",
                "type": "CONDITION"
            },
            {
                "start": 604,
                "end": 607,
                "text": "CBT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 609,
                "end": 612,
                "text": "CBT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 745,
                "end": 748,
                "text": "CBT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 782,
                "end": 801,
                "text": "disruptive behavior",
                "type": "CONDITION"
            },
            {
                "start": 1057,
                "end": 1060,
                "text": "CBT",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT05473676",
        "study_official_title": "Robotic Walking for Children Who Cannot Walk ",
        "study_brief_summary": " A common problem among children with nervous system disorders is difficulty walking on their own. This has impacts beyond mobility including short and long-term health conditions associated with physical inactivity and different developmental experiences as a result of the mobility impairments. A robotic trainer can both provide rehabilitation and be an assistive device to help compensate for difficulties. Figuring out how to prescribe it is critical to improve daily life for children with significant disabilities. Preliminary use of robotic trainers have shown many benefits, such as better head control and improved independence in transfers, which greatly increases ability to live independently. Additionally, vital functions that are frequently impaired in those with less physical activity, such as sleep and bowel habits, seem to improve. Finally, these children enjoy using them.\n\nThis project aims to determine who is most likely to benefit from training with a robotic trainer and investigate key details about the dose of training that is needed. Families that are already using or hope to use robotic training need this data to help improve their access to the intervention. Clinicians need this systematic approach to building evidence to ensure a future multi-centre randomized control trial is well designed. This study is needed to help improve the lives of those who live with significant disabilities. The objective is to evaluate the feasibility and impacts of delivering robotic gait training at home. Integral in this study is capturing the user perspectives. This will both provide preliminary evidence-based advice to potential users, their families, and clinicians as well as provide key metrics to design a definitive multi-centre randomized control trial.\n\nThe investigators will provide robotic gait trainers, specifically Trexo robotic gait trainers, to participants and their families to use in their home communities for 12 weeks to evaluate the feasibility and impacts of intensive robotic gait training in people who cannot walk independently. Assessments will be completed throughout the duration of study, including before, during, and after the training intervention, with the goal of evaluating a wide range of feasibility considerations and impacts from robotic training.",
        "text": "Robotic Walking for Children Who Cannot Walk | A common problem among children with nervous system disorders is difficulty walking on their own. This has impacts beyond mobility including short and long-term health conditions associated with physical inactivity and different developmental experiences as a result of the mobility impairments. A robotic trainer can both provide rehabilitation and be an assistive device to help compensate for difficulties. Figuring out how to prescribe it is critical to improve daily life for children with significant disabilities. Preliminary use of robotic trainers have shown many benefits, such as better head control and improved independence in transfers, which greatly increases ability to live independently. Additionally, vital functions that are frequently impaired in those with less physical activity, such as sleep and bowel habits, seem to improve. Finally, these children enjoy using them.\n\nThis project aims to determine who is most likely to benefit from training with a robotic trainer and investigate key details about the dose of training that is needed. Families that are already using or hope to use robotic training need this data to help improve their access to the intervention. Clinicians need this systematic approach to building evidence to ensure a future multi-centre randomized control trial is well designed. This study is needed to help improve the lives of those who live with significant disabilities. The objective is to evaluate the feasibility and impacts of delivering robotic gait training at home. Integral in this study is capturing the user perspectives. This will both provide preliminary evidence-based advice to potential users, their families, and clinicians as well as provide key metrics to design a definitive multi-centre randomized control trial.\n\nThe investigators will provide robotic gait trainers, specifically Trexo robotic gait trainers, to participants and their families to use in their home communities for 12 weeks to evaluate the feasibility and impacts of intensive robotic gait training in people who cannot walk independently. Assessments will be completed throughout the duration of study, including before, during, and after the training intervention, with the goal of evaluating a wide range of feasibility considerations and impacts from robotic training.",
        "tokens": "['Robotic', 'Walking', 'for', 'Children', 'Who', 'Can', 'not', 'Walk', '|', 'A', 'common', 'problem', 'among', 'children', 'with', 'nervous', 'system', 'disorders', 'is', 'difficulty', 'walking', 'on', 'their', 'own', '.', 'This', 'has', 'impacts', 'beyond', 'mobility', 'including', 'short', 'and', 'long', '-', 'term', 'health', 'conditions', 'associated', 'with', 'physical', 'inactivity', 'and', 'different', 'developmental', 'experiences', 'as', 'a', 'result', 'of', 'the', 'mobility', 'impairments', '.', 'A', 'robotic', 'trainer', 'can', 'both', 'provide', 'rehabilitation', 'and', 'be', 'an', 'assistive', 'device', 'to', 'help', 'compensate', 'for', 'difficulties', '.', 'Figuring', 'out', 'how', 'to', 'prescribe', 'it', 'is', 'critical', 'to', 'improve', 'daily', 'life', 'for', 'children', 'with', 'significant', 'disabilities', '.', 'Preliminary', 'use', 'of', 'robotic', 'trainers', 'have', 'shown', 'many', 'benefits', ',', 'such', 'as', 'better', 'head', 'control', 'and', 'improved', 'independence', 'in', 'transfers', ',', 'which', 'greatly', 'increases', 'ability', 'to', 'live', 'independently', '.', 'Additionally', ',', 'vital', 'functions', 'that', 'are', 'frequently', 'impaired', 'in', 'those', 'with', 'less', 'physical', 'activity', ',', 'such', 'as', 'sleep', 'and', 'bowel', 'habits', ',', 'seem', 'to', 'improve', '.', 'Finally', ',', 'these', 'children', 'enjoy', 'using', 'them', '.', '\\n\\n', 'This', 'project', 'aims', 'to', 'determine', 'who', 'is', 'most', 'likely', 'to', 'benefit', 'from', 'training', 'with', 'a', 'robotic', 'trainer', 'and', 'investigate', 'key', 'details', 'about', 'the', 'dose', 'of', 'training', 'that', 'is', 'needed', '.', 'Families', 'that', 'are', 'already', 'using', 'or', 'hope', 'to', 'use', 'robotic', 'training', 'need', 'this', 'data', 'to', 'help', 'improve', 'their', 'access', 'to', 'the', 'intervention', '.', 'Clinicians', 'need', 'this', 'systematic', 'approach', 'to', 'building', 'evidence', 'to', 'ensure', 'a', 'future', 'multi', '-', 'centre', 'randomized', 'control', 'trial', 'is', 'well', 'designed', '.', 'This', 'study', 'is', 'needed', 'to', 'help', 'improve', 'the', 'lives', 'of', 'those', 'who', 'live', 'with', 'significant', 'disabilities', '.', 'The', 'objective', 'is', 'to', 'evaluate', 'the', 'feasibility', 'and', 'impacts', 'of', 'delivering', 'robotic', 'gait', 'training', 'at', 'home', '.', 'Integral', 'in', 'this', 'study', 'is', 'capturing', 'the', 'user', 'perspectives', '.', 'This', 'will', 'both', 'provide', 'preliminary', 'evidence', '-', 'based', 'advice', 'to', 'potential', 'users', ',', 'their', 'families', ',', 'and', 'clinicians', 'as', 'well', 'as', 'provide', 'key', 'metrics', 'to', 'design', 'a', 'definitive', 'multi', '-', 'centre', 'randomized', 'control', 'trial', '.', '\\n\\n', 'The', 'investigators', 'will', 'provide', 'robotic', 'gait', 'trainers', ',', 'specifically', 'Trexo', 'robotic', 'gait', 'trainers', ',', 'to', 'participants', 'and', 'their', 'families', 'to', 'use', 'in', 'their', 'home', 'communities', 'for', '12', 'weeks', 'to', 'evaluate', 'the', 'feasibility', 'and', 'impacts', 'of', 'intensive', 'robotic', 'gait', 'training', 'in', 'people', 'who', 'can', 'not', 'walk', 'independently', '.', 'Assessments', 'will', 'be', 'completed', 'throughout', 'the', 'duration', 'of', 'study', ',', 'including', 'before', ',', 'during', ',', 'and', 'after', 'the', 'training', 'intervention', ',', 'with', 'the', 'goal', 'of', 'evaluating', 'a', 'wide', 'range', 'of', 'feasibility', 'considerations', 'and', 'impacts', 'from', 'robotic', 'training', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 15,
                "text": "Robotic Walking",
                "type": "PHYSICAL"
            },
            {
                "start": 321,
                "end": 341,
                "text": "mobility impairments",
                "type": "CONDITION"
            },
            {
                "start": 345,
                "end": 360,
                "text": "robotic trainer",
                "type": "PHYSICAL"
            },
            {
                "start": 587,
                "end": 603,
                "text": "robotic trainers",
                "type": "PHYSICAL"
            },
            {
                "start": 1024,
                "end": 1039,
                "text": "robotic trainer",
                "type": "PHYSICAL"
            },
            {
                "start": 1158,
                "end": 1174,
                "text": "robotic training",
                "type": "PHYSICAL"
            },
            {
                "start": 1544,
                "end": 1565,
                "text": "robotic gait training",
                "type": "PHYSICAL"
            },
            {
                "start": 1867,
                "end": 1888,
                "text": "robotic gait trainers",
                "type": "PHYSICAL"
            },
            {
                "start": 1903,
                "end": 1930,
                "text": "Trexo robotic gait trainers",
                "type": "PHYSICAL"
            },
            {
                "start": 2066,
                "end": 2087,
                "text": "robotic gait training",
                "type": "PHYSICAL"
            },
            {
                "start": 2344,
                "end": 2360,
                "text": "robotic training",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT02554734",
        "study_official_title": "Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females ",
        "study_brief_summary": " Phase I open, randomized cross-over pharmacokinetic study.",
        "text": "Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females | Phase I open, randomized cross-over pharmacokinetic study.",
        "tokens": "['Pharmacokinetics', 'of', 'Levodopa', 'After', 'Repeated', 'Doses', 'of', 'Carbidopa', ',', 'ODM-104', 'and', 'Levodopa', ':', 'an', 'Open', ',', 'Randomised', 'Study', 'With', 'Crossover', 'Design', 'in', 'Healthy', 'Males', 'and', 'Females', '|', 'Phase', 'I', 'open', ',', 'randomized', 'cross', '-', 'over', 'pharmacokinetic', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 28,
                "text": "Levodopa",
                "type": "DRUG"
            },
            {
                "start": 53,
                "end": 62,
                "text": "Carbidopa",
                "type": "DRUG"
            },
            {
                "start": 64,
                "end": 71,
                "text": "ODM-104",
                "type": "DRUG"
            },
            {
                "start": 76,
                "end": 84,
                "text": "Levodopa",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04246216",
        "study_official_title": "Ultrasound-Guided Percutaneous Electrical Nerve Stimulation of the Median Nerve for Carpal Tunnel Syndrome ",
        "study_brief_summary": " There is evidence supporting that physical therapy interventions can be effective for the management of patients with CTS. No consensus on the best approach exist. It seems clear that the median nerve is affected in several ways (compression, inflammation, excursion) in carpal tunnel syndrome. Percutaneous Electrical Nerve Stimulation is a treatment approach consisting of the application of an electrical current throughout needling filaments placed close to the nerve, in this case the median nerve. The purpose of this clinical trial is to compare changes in function, symptom severity and the intensity of pain after the application of Percutaneous Electrical Nerve Stimulation vs. endoscopic surgery in women with CTS at short- and long-term follow-up periods.",
        "text": "Ultrasound-Guided Percutaneous Electrical Nerve Stimulation of the Median Nerve for Carpal Tunnel Syndrome | There is evidence supporting that physical therapy interventions can be effective for the management of patients with CTS. No consensus on the best approach exist. It seems clear that the median nerve is affected in several ways (compression, inflammation, excursion) in carpal tunnel syndrome. Percutaneous Electrical Nerve Stimulation is a treatment approach consisting of the application of an electrical current throughout needling filaments placed close to the nerve, in this case the median nerve. The purpose of this clinical trial is to compare changes in function, symptom severity and the intensity of pain after the application of Percutaneous Electrical Nerve Stimulation vs. endoscopic surgery in women with CTS at short- and long-term follow-up periods.",
        "tokens": "['Ultrasound', '-', 'Guided', 'Percutaneous', 'Electrical', 'Nerve', 'Stimulation', 'of', 'the', 'Median', 'Nerve', 'for', 'Carpal', 'Tunnel', 'Syndrome', '|', 'There', 'is', 'evidence', 'supporting', 'that', 'physical', 'therapy', 'interventions', 'can', 'be', 'effective', 'for', 'the', 'management', 'of', 'patients', 'with', 'CTS', '.', 'No', 'consensus', 'on', 'the', 'best', 'approach', 'exist', '.', 'It', 'seems', 'clear', 'that', 'the', 'median', 'nerve', 'is', 'affected', 'in', 'several', 'ways', '(', 'compression', ',', 'inflammation', ',', 'excursion', ')', 'in', 'carpal', 'tunnel', 'syndrome', '.', 'Percutaneous', 'Electrical', 'Nerve', 'Stimulation', 'is', 'a', 'treatment', 'approach', 'consisting', 'of', 'the', 'application', 'of', 'an', 'electrical', 'current', 'throughout', 'needling', 'filaments', 'placed', 'close', 'to', 'the', 'nerve', ',', 'in', 'this', 'case', 'the', 'median', 'nerve', '.', 'The', 'purpose', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'compare', 'changes', 'in', 'function', ',', 'symptom', 'severity', 'and', 'the', 'intensity', 'of', 'pain', 'after', 'the', 'application', 'of', 'Percutaneous', 'Electrical', 'Nerve', 'Stimulation', 'vs.', 'endoscopic', 'surgery', 'in', 'women', 'with', 'CTS', 'at', 'short-', 'and', 'long', '-', 'term', 'follow', '-', 'up', 'periods', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 59,
                "text": "Ultrasound-Guided Percutaneous Electrical Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 84,
                "end": 106,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 227,
                "end": 230,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 380,
                "end": 402,
                "text": "carpal tunnel syndrome",
                "type": "CONDITION"
            },
            {
                "start": 404,
                "end": 445,
                "text": "Percutaneous Electrical Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 721,
                "end": 725,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 751,
                "end": 792,
                "text": "Percutaneous Electrical Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 797,
                "end": 815,
                "text": "endoscopic surgery",
                "type": "CONTROL"
            },
            {
                "start": 830,
                "end": 833,
                "text": "CTS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01554527",
        "study_official_title": "Sleep-Disordered Breathing and CPAP After Adenotonsillectomy in Children ",
        "study_brief_summary": " Obstructive sleep-disordered breathing (SDB) affects 2-3% of children and may lead to problems with nighttime sleep and daytime behavior, learning, sleepiness, and mood. Adenotonsillectomy (AT) is the second most common surgical procedure in children. It is now performed more often for suspected SDB than for any other indication. However, recent studies indicate that many if not most children still have SDB after AT, and many still have learning or behavioral problems associated with SDB. The goals of this study are: (1) to assess the extent that behavior, cognition, and sleepiness in children can improve with Continuous positive airway pressure (CPAP) treatment after AT, and (2) to identify which patients stand to gain most from post-operative assessment and treatment.",
        "text": "Sleep-Disordered Breathing and CPAP After Adenotonsillectomy in Children | Obstructive sleep-disordered breathing (SDB) affects 2-3% of children and may lead to problems with nighttime sleep and daytime behavior, learning, sleepiness, and mood. Adenotonsillectomy (AT) is the second most common surgical procedure in children. It is now performed more often for suspected SDB than for any other indication. However, recent studies indicate that many if not most children still have SDB after AT, and many still have learning or behavioral problems associated with SDB. The goals of this study are: (1) to assess the extent that behavior, cognition, and sleepiness in children can improve with Continuous positive airway pressure (CPAP) treatment after AT, and (2) to identify which patients stand to gain most from post-operative assessment and treatment.",
        "tokens": "['Sleep', '-', 'Disordered', 'Breathing', 'and', 'CPAP', 'After', 'Adenotonsillectomy', 'in', 'Children', '|', 'Obstructive', 'sleep', '-', 'disordered', 'breathing', '(', 'SDB', ')', 'affects', '2', '-', '3', '%', 'of', 'children', 'and', 'may', 'lead', 'to', 'problems', 'with', 'nighttime', 'sleep', 'and', 'daytime', 'behavior', ',', 'learning', ',', 'sleepiness', ',', 'and', 'mood', '.', 'Adenotonsillectomy', '(', 'AT', ')', 'is', 'the', 'second', 'most', 'common', 'surgical', 'procedure', 'in', 'children', '.', 'It', 'is', 'now', 'performed', 'more', 'often', 'for', 'suspected', 'SDB', 'than', 'for', 'any', 'other', 'indication', '.', 'However', ',', 'recent', 'studies', 'indicate', 'that', 'many', 'if', 'not', 'most', 'children', 'still', 'have', 'SDB', 'after', 'AT', ',', 'and', 'many', 'still', 'have', 'learning', 'or', 'behavioral', 'problems', 'associated', 'with', 'SDB', '.', 'The', 'goals', 'of', 'this', 'study', 'are', ':', '(', '1', ')', 'to', 'assess', 'the', 'extent', 'that', 'behavior', ',', 'cognition', ',', 'and', 'sleepiness', 'in', 'children', 'can', 'improve', 'with', 'Continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'treatment', 'after', 'AT', ',', 'and', '(', '2', ')', 'to', 'identify', 'which', 'patients', 'stand', 'to', 'gain', 'most', 'from', 'post', '-', 'operative', 'assessment', 'and', 'treatment', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 26,
                "text": "Sleep-Disordered Breathing",
                "type": "CONDITION"
            },
            {
                "start": 42,
                "end": 60,
                "text": "Adenotonsillectomy",
                "type": "SURGICAL"
            },
            {
                "start": 75,
                "end": 113,
                "text": "Obstructive sleep-disordered breathing",
                "type": "CONDITION"
            },
            {
                "start": 115,
                "end": 118,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 263,
                "text": "Adenotonsillectomy",
                "type": "SURGICAL"
            },
            {
                "start": 265,
                "end": 267,
                "text": "AT",
                "type": "SURGICAL"
            },
            {
                "start": 372,
                "end": 375,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 482,
                "end": 485,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 492,
                "end": 494,
                "text": "AT",
                "type": "SURGICAL"
            },
            {
                "start": 564,
                "end": 567,
                "text": "SDB",
                "type": "CONDITION"
            },
            {
                "start": 693,
                "end": 728,
                "text": "Continuous positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 730,
                "end": 734,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 752,
                "end": 754,
                "text": "AT",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT00826345",
        "study_official_title": "Patient-Oriented TCM Intervention for DSP in HIV: A Pilot Study ",
        "study_brief_summary": " This preliminary study will investigate the use of Acupuncture and Moxibustion (Acu/Moxa) for distal symmetric peripheral neuropathy (DSP) associated with HIV applying traditional Chinese medicine (TCM) evaluations conducted by a diagnostic acupuncturist. The investigators will evaluate the role of Acu/Moxa in reducing the symptoms of DSP related to HIV/AIDS and treatment side effects. The effects of symptom reduction on quality of life will also be examined. This application will establish a proof of principle for the role of Acu/Moxa in the treatment of DSP and provide data that will serve as a foundation for establishing a future larger clinical trial.",
        "text": "Patient-Oriented TCM Intervention for DSP in HIV: A Pilot Study | This preliminary study will investigate the use of Acupuncture and Moxibustion (Acu/Moxa) for distal symmetric peripheral neuropathy (DSP) associated with HIV applying traditional Chinese medicine (TCM) evaluations conducted by a diagnostic acupuncturist. The investigators will evaluate the role of Acu/Moxa in reducing the symptoms of DSP related to HIV/AIDS and treatment side effects. The effects of symptom reduction on quality of life will also be examined. This application will establish a proof of principle for the role of Acu/Moxa in the treatment of DSP and provide data that will serve as a foundation for establishing a future larger clinical trial.",
        "tokens": "['Patient', '-', 'Oriented', 'TCM', 'Intervention', 'for', 'DSP', 'in', 'HIV', ':', 'A', 'Pilot', 'Study', '|', 'This', 'preliminary', 'study', 'will', 'investigate', 'the', 'use', 'of', 'Acupuncture', 'and', 'Moxibustion', '(', 'Acu', '/', 'Moxa', ')', 'for', 'distal', 'symmetric', 'peripheral', 'neuropathy', '(', 'DSP', ')', 'associated', 'with', 'HIV', 'applying', 'traditional', 'Chinese', 'medicine', '(', 'TCM', ')', 'evaluations', 'conducted', 'by', 'a', 'diagnostic', 'acupuncturist', '.', 'The', 'investigators', 'will', 'evaluate', 'the', 'role', 'of', 'Acu', '/', 'Moxa', 'in', 'reducing', 'the', 'symptoms', 'of', 'DSP', 'related', 'to', 'HIV', '/', 'AIDS', 'and', 'treatment', 'side', 'effects', '.', 'The', 'effects', 'of', 'symptom', 'reduction', 'on', 'quality', 'of', 'life', 'will', 'also', 'be', 'examined', '.', 'This', 'application', 'will', 'establish', 'a', 'proof', 'of', 'principle', 'for', 'the', 'role', 'of', 'Acu', '/', 'Moxa', 'in', 'the', 'treatment', 'of', 'DSP', 'and', 'provide', 'data', 'that', 'will', 'serve', 'as', 'a', 'foundation', 'for', 'establishing', 'a', 'future', 'larger', 'clinical', 'trial', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 33,
                "text": "TCM Intervention",
                "type": "OTHER"
            },
            {
                "start": 38,
                "end": 41,
                "text": "DSP",
                "type": "CONDITION"
            },
            {
                "start": 45,
                "end": 48,
                "text": "HIV",
                "type": "CONDITION"
            },
            {
                "start": 117,
                "end": 128,
                "text": "Acupuncture",
                "type": "OTHER"
            },
            {
                "start": 133,
                "end": 144,
                "text": "Moxibustion",
                "type": "OTHER"
            },
            {
                "start": 146,
                "end": 149,
                "text": "Acu",
                "type": "OTHER"
            },
            {
                "start": 150,
                "end": 154,
                "text": "Moxa",
                "type": "OTHER"
            },
            {
                "start": 160,
                "end": 198,
                "text": "distal symmetric peripheral neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 203,
                "text": "DSP",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 224,
                "text": "HIV",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 262,
                "text": "traditional Chinese medicine",
                "type": "OTHER"
            },
            {
                "start": 264,
                "end": 267,
                "text": "TCM",
                "type": "OTHER"
            },
            {
                "start": 366,
                "end": 369,
                "text": "Acu",
                "type": "OTHER"
            },
            {
                "start": 370,
                "end": 374,
                "text": "Moxa",
                "type": "OTHER"
            },
            {
                "start": 403,
                "end": 406,
                "text": "DSP",
                "type": "CONDITION"
            },
            {
                "start": 418,
                "end": 421,
                "text": "HIV",
                "type": "CONDITION"
            },
            {
                "start": 422,
                "end": 426,
                "text": "AIDS",
                "type": "CONDITION"
            },
            {
                "start": 599,
                "end": 602,
                "text": "Acu",
                "type": "OTHER"
            },
            {
                "start": 603,
                "end": 607,
                "text": "Moxa",
                "type": "OTHER"
            },
            {
                "start": 628,
                "end": 631,
                "text": "DSP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00422994",
        "study_official_title": "An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628) ",
        "study_brief_summary": " This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.",
        "text": "An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628) | This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Parallel', '-', 'Group', ',', 'Repeat', '-', 'Dose', 'Study', 'to', 'Investigate', 'the', 'Effects', 'of', 'End', 'Stage', 'Renal', 'Disease', 'and', 'Haemodialysis', 'on', 'the', 'Pharmacokinetics', 'of', 'Ropinirole', '(', 'Study', 'RRL103628', ')', '|', 'This', 'study', 'will', 'investigate', 'the', 'effects', 'of', 'severe', 'renal', 'impairment', 'and', 'hemodialysis', 'on', 'the', 'characteristics', 'of', 'the', 'drug', ',', 'ropinirole', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 79,
                "end": 102,
                "text": "End Stage Renal Disease",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 120,
                "text": "Haemodialysis",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 158,
                "text": "Ropinirole",
                "type": "DRUG"
            },
            {
                "start": 222,
                "end": 245,
                "text": "severe renal impairment",
                "type": "CONDITION"
            },
            {
                "start": 250,
                "end": 262,
                "text": "hemodialysis",
                "type": "CONDITION"
            },
            {
                "start": 299,
                "end": 309,
                "text": "ropinirole",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03351452",
        "study_official_title": "Effects of Transcranial Electric Stimulation on Associative Memory Formation in Healthy Elderly Participants as Well as in Individuals With Memory Impairment ",
        "study_brief_summary": " Previous studies showed that transcranial electric stimulation (tES) applied over the prefrontal cortex improves cognitive performance in healthy elderly adults as well as in patients suffering from mild cognitive impairment or early Alzheimer's disease. Therefore, tES methods might be a useful intervention tool for patients suffering from memory impairment in early terms of the disease.\n\nThe present study aims at establishing a connection between the stimulation-induced changes on associative memory performance and its underlying neurophysiological parameters. tES effects and their underlying mechanisms will be compared between healthy elderly controls and clinical study populations receiving either real or sham tES over the left ventrolateral prefrontal cortex during an associative memory task.",
        "text": "Effects of Transcranial Electric Stimulation on Associative Memory Formation in Healthy Elderly Participants as Well as in Individuals With Memory Impairment | Previous studies showed that transcranial electric stimulation (tES) applied over the prefrontal cortex improves cognitive performance in healthy elderly adults as well as in patients suffering from mild cognitive impairment or early Alzheimer's disease. Therefore, tES methods might be a useful intervention tool for patients suffering from memory impairment in early terms of the disease.\n\nThe present study aims at establishing a connection between the stimulation-induced changes on associative memory performance and its underlying neurophysiological parameters. tES effects and their underlying mechanisms will be compared between healthy elderly controls and clinical study populations receiving either real or sham tES over the left ventrolateral prefrontal cortex during an associative memory task.",
        "tokens": "['Effects', 'of', 'Transcranial', 'Electric', 'Stimulation', 'on', 'Associative', 'Memory', 'Formation', 'in', 'Healthy', 'Elderly', 'Participants', 'as', 'Well', 'as', 'in', 'Individuals', 'With', 'Memory', 'Impairment', '|', 'Previous', 'studies', 'showed', 'that', 'transcranial', 'electric', 'stimulation', '(', 'tES', ')', 'applied', 'over', 'the', 'prefrontal', 'cortex', 'improves', 'cognitive', 'performance', 'in', 'healthy', 'elderly', 'adults', 'as', 'well', 'as', 'in', 'patients', 'suffering', 'from', 'mild', 'cognitive', 'impairment', 'or', 'early', 'Alzheimer', \"'s\", 'disease', '.', 'Therefore', ',', 'tES', 'methods', 'might', 'be', 'a', 'useful', 'intervention', 'tool', 'for', 'patients', 'suffering', 'from', 'memory', 'impairment', 'in', 'early', 'terms', 'of', 'the', 'disease', '.', '\\n\\n', 'The', 'present', 'study', 'aims', 'at', 'establishing', 'a', 'connection', 'between', 'the', 'stimulation', '-', 'induced', 'changes', 'on', 'associative', 'memory', 'performance', 'and', 'its', 'underlying', 'neurophysiological', 'parameters', '.', 'tES', 'effects', 'and', 'their', 'underlying', 'mechanisms', 'will', 'be', 'compared', 'between', 'healthy', 'elderly', 'controls', 'and', 'clinical', 'study', 'populations', 'receiving', 'either', 'real', 'or', 'sham', 'tES', 'over', 'the', 'left', 'ventrolateral', 'prefrontal', 'cortex', 'during', 'an', 'associative', 'memory', 'task', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 44,
                "text": "Transcranial Electric Stimulation",
                "type": "OTHER"
            },
            {
                "start": 140,
                "end": 157,
                "text": "Memory Impairment",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 222,
                "text": "transcranial electric stimulation",
                "type": "OTHER"
            },
            {
                "start": 224,
                "end": 227,
                "text": "tES",
                "type": "OTHER"
            },
            {
                "start": 359,
                "end": 384,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 388,
                "end": 413,
                "text": "early Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 426,
                "end": 429,
                "text": "tES",
                "type": "OTHER"
            },
            {
                "start": 502,
                "end": 519,
                "text": "memory impairment",
                "type": "CONDITION"
            },
            {
                "start": 728,
                "end": 731,
                "text": "tES",
                "type": "OTHER"
            },
            {
                "start": 878,
                "end": 886,
                "text": "sham tES",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02066558",
        "study_official_title": "Basic Research on Carbon Monoxide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model ",
        "study_brief_summary": " In this study the investigators will research the hypothesis that the gas carbon monoxide induces headache and increases the blood flow velocity in the middle cerebral artery.",
        "text": "Basic Research on Carbon Monoxide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model | In this study the investigators will research the hypothesis that the gas carbon monoxide induces headache and increases the blood flow velocity in the middle cerebral artery.",
        "tokens": "['Basic', 'Research', 'on', 'Carbon', 'Monoxide', \"'s\", 'Headache', 'Inducing', 'Characteristics', 'and', 'Effects', 'on', 'the', 'Cerebral', 'Arteries', 'and', 'Blood', 'Flow', 'in', 'a', 'Humane', 'Experimental', 'Headache', 'Model', '|', 'In', 'this', 'study', 'the', 'investigators', 'will', 'research', 'the', 'hypothesis', 'that', 'the', 'gas', 'carbon', 'monoxide', 'induces', 'headache', 'and', 'increases', 'the', 'blood', 'flow', 'velocity', 'in', 'the', 'middle', 'cerebral', 'artery', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 44,
                "text": "Carbon Monoxide's Headache",
                "type": "CONDITION"
            },
            {
                "start": 147,
                "end": 155,
                "text": "Headache",
                "type": "CONDITION"
            },
            {
                "start": 262,
                "end": 270,
                "text": "headache",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04154579",
        "study_official_title": "A Randomized Controlled Trial Utilizing the Arts to Improve Health, Resilience, and Well-Being in Individuals With Chronic Health Conditions in Underserved Neighborhoods ",
        "study_brief_summary": " This is an 8-week randomized controlled trial to help address health, resilience, and well-being. Participants are randomized into either a health education group or an arts-based health education group. Both groups will attend for 8 weeks and various study assessments will be conducted in order to measure the experience and impact of the program. Anyone 18 years and older with a chronic health condition (for example, diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disorder, asthma, weight, anxiety, depression, cardiac, arthritis, multiple sclerosis, and many more) are eligible to participate.",
        "text": "A Randomized Controlled Trial Utilizing the Arts to Improve Health, Resilience, and Well-Being in Individuals With Chronic Health Conditions in Underserved Neighborhoods | This is an 8-week randomized controlled trial to help address health, resilience, and well-being. Participants are randomized into either a health education group or an arts-based health education group. Both groups will attend for 8 weeks and various study assessments will be conducted in order to measure the experience and impact of the program. Anyone 18 years and older with a chronic health condition (for example, diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disorder, asthma, weight, anxiety, depression, cardiac, arthritis, multiple sclerosis, and many more) are eligible to participate.",
        "tokens": "['A', 'Randomized', 'Controlled', 'Trial', 'Utilizing', 'the', 'Arts', 'to', 'Improve', 'Health', ',', 'Resilience', ',', 'and', 'Well', '-', 'Being', 'in', 'Individuals', 'With', 'Chronic', 'Health', 'Conditions', 'in', 'Underserved', 'Neighborhoods', '|', 'This', 'is', 'an', '8', '-', 'week', 'randomized', 'controlled', 'trial', 'to', 'help', 'address', 'health', ',', 'resilience', ',', 'and', 'well', '-', 'being', '.', 'Participants', 'are', 'randomized', 'into', 'either', 'a', 'health', 'education', 'group', 'or', 'an', 'arts', '-', 'based', 'health', 'education', 'group', '.', 'Both', 'groups', 'will', 'attend', 'for', '8', 'weeks', 'and', 'various', 'study', 'assessments', 'will', 'be', 'conducted', 'in', 'order', 'to', 'measure', 'the', 'experience', 'and', 'impact', 'of', 'the', 'program', '.', 'Anyone', '18', 'years', 'and', 'older', 'with', 'a', 'chronic', 'health', 'condition', '(', 'for', 'example', ',', 'diabetes', ',', 'hypertension', ',', 'congestive', 'heart', 'failure', ',', 'chronic', 'obstructive', 'pulmonary', 'disorder', ',', 'asthma', ',', 'weight', ',', 'anxiety', ',', 'depression', ',', 'cardiac', ',', 'arthritis', ',', 'multiple', 'sclerosis', ',', 'and', 'many', 'more', ')', 'are', 'eligible', 'to', 'participate', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 44,
                "end": 48,
                "text": "Arts",
                "type": "OTHER"
            },
            {
                "start": 312,
                "end": 328,
                "text": "health education",
                "type": "CONTROL"
            },
            {
                "start": 341,
                "end": 368,
                "text": "arts-based health education",
                "type": "OTHER"
            },
            {
                "start": 594,
                "end": 602,
                "text": "diabetes",
                "type": "CONDITION"
            },
            {
                "start": 604,
                "end": 616,
                "text": "hypertension",
                "type": "CONDITION"
            },
            {
                "start": 618,
                "end": 642,
                "text": "congestive heart failure",
                "type": "CONDITION"
            },
            {
                "start": 644,
                "end": 682,
                "text": "chronic obstructive pulmonary disorder",
                "type": "CONDITION"
            },
            {
                "start": 684,
                "end": 690,
                "text": "asthma",
                "type": "CONDITION"
            },
            {
                "start": 692,
                "end": 698,
                "text": "weight",
                "type": "CONDITION"
            },
            {
                "start": 700,
                "end": 707,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 709,
                "end": 719,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 721,
                "end": 728,
                "text": "cardiac",
                "type": "CONDITION"
            },
            {
                "start": 730,
                "end": 739,
                "text": "arthritis",
                "type": "CONDITION"
            },
            {
                "start": 741,
                "end": 759,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04103138",
        "study_official_title": "EEG Monitoring Under Anaesthesia in Children: Towards Personalized Anaesthesia Care ",
        "study_brief_summary": " Electroencephalographic recordings (EEG) present an opportunity to monitor changes in human brain electrical activity during changing states of consciousness during general anesthesia.\n\nThe investigators aim to determine if EEG-guided anaesthesia using the Masimo Sedline Root monitor will result in different anaesthetic requirements, different anaesthetic depth, and emergence characteristics in children under 16 years of age.\n\n200 children under 16 years undergoing routine general anaesthesia under sevoflurane will be randomized to either EEG monitoring or routine care. We will compare the anaesthetic requirements, the patient state index, number of episodes of burst suppression and the incidence and severity of emergence delrium between the two groups.",
        "text": "EEG Monitoring Under Anaesthesia in Children: Towards Personalized Anaesthesia Care | Electroencephalographic recordings (EEG) present an opportunity to monitor changes in human brain electrical activity during changing states of consciousness during general anesthesia.\n\nThe investigators aim to determine if EEG-guided anaesthesia using the Masimo Sedline Root monitor will result in different anaesthetic requirements, different anaesthetic depth, and emergence characteristics in children under 16 years of age.\n\n200 children under 16 years undergoing routine general anaesthesia under sevoflurane will be randomized to either EEG monitoring or routine care. We will compare the anaesthetic requirements, the patient state index, number of episodes of burst suppression and the incidence and severity of emergence delrium between the two groups.",
        "tokens": "['EEG', 'Monitoring', 'Under', 'Anaesthesia', 'in', 'Children', ':', 'Towards', 'Personalized', 'Anaesthesia', 'Care', '|', 'Electroencephalographic', 'recordings', '(', 'EEG', ')', 'present', 'an', 'opportunity', 'to', 'monitor', 'changes', 'in', 'human', 'brain', 'electrical', 'activity', 'during', 'changing', 'states', 'of', 'consciousness', 'during', 'general', 'anesthesia', '.', '\\n\\n', 'The', 'investigators', 'aim', 'to', 'determine', 'if', 'EEG', '-', 'guided', 'anaesthesia', 'using', 'the', 'Masimo', 'Sedline', 'Root', 'monitor', 'will', 'result', 'in', 'different', 'anaesthetic', 'requirements', ',', 'different', 'anaesthetic', 'depth', ',', 'and', 'emergence', 'characteristics', 'in', 'children', 'under', '16', 'years', 'of', 'age', '.', '\\n\\n', '200', 'children', 'under', '16', 'years', 'undergoing', 'routine', 'general', 'anaesthesia', 'under', 'sevoflurane', 'will', 'be', 'randomized', 'to', 'either', 'EEG', 'monitoring', 'or', 'routine', 'care', '.', 'We', 'will', 'compare', 'the', 'anaesthetic', 'requirements', ',', 'the', 'patient', 'state', 'index', ',', 'number', 'of', 'episodes', 'of', 'burst', 'suppression', 'and', 'the', 'incidence', 'and', 'severity', 'of', 'emergence', 'delrium', 'between', 'the', 'two', 'groups', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 808,
                "end": 825,
                "text": "emergence delrium",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04239469",
        "study_official_title": "Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment. ",
        "study_brief_summary": " A double blind randomized placebo controlled trial in 44 women with fibromyalgia and persistent symptoms in spite of use of conventional pharmacotherapy, will be performed in the city of Valparaiso. Patients will be randomized to either placebo or active principle and be followed for 3 months. Assesment of efficacy and safety will be done by measurement of changes in their Fibromyalgia Impact Questionnaire (FIQ) score, Insomnia Severity Index (ISI) score, pain Visual Analogue Scale (VAS) score, plasma cytokine levels and detection of adverse effects.\n\nThe active principle will be a standardized extract of cannabis sativa containing 1 milligram of tetrahydrocannabinol (THC) and 0.45 milligrams cannabidiol (CBD) per drop.",
        "text": "Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment. | A double blind randomized placebo controlled trial in 44 women with fibromyalgia and persistent symptoms in spite of use of conventional pharmacotherapy, will be performed in the city of Valparaiso. Patients will be randomized to either placebo or active principle and be followed for 3 months. Assesment of efficacy and safety will be done by measurement of changes in their Fibromyalgia Impact Questionnaire (FIQ) score, Insomnia Severity Index (ISI) score, pain Visual Analogue Scale (VAS) score, plasma cytokine levels and detection of adverse effects.\n\nThe active principle will be a standardized extract of cannabis sativa containing 1 milligram of tetrahydrocannabinol (THC) and 0.45 milligrams cannabidiol (CBD) per drop.",
        "tokens": "['Phase', 'II', 'Clinical', 'Trial', ',', 'Use', 'of', 'KL16', '-', '012', 'in', 'Women', 'With', 'Fibromyalgia', 'Refractary', 'to', 'Conventional', 'Treatment', '.', '|', 'A', 'double', 'blind', 'randomized', 'placebo', 'controlled', 'trial', 'in', '44', 'women', 'with', 'fibromyalgia', 'and', 'persistent', 'symptoms', 'in', 'spite', 'of', 'use', 'of', 'conventional', 'pharmacotherapy', ',', 'will', 'be', 'performed', 'in', 'the', 'city', 'of', 'Valparaiso', '.', 'Patients', 'will', 'be', 'randomized', 'to', 'either', 'placebo', 'or', 'active', 'principle', 'and', 'be', 'followed', 'for', '3', 'months', '.', 'Assesment', 'of', 'efficacy', 'and', 'safety', 'will', 'be', 'done', 'by', 'measurement', 'of', 'changes', 'in', 'their', 'Fibromyalgia', 'Impact', 'Questionnaire', '(', 'FIQ', ')', 'score', ',', 'Insomnia', 'Severity', 'Index', '(', 'ISI', ')', 'score', ',', 'pain', 'Visual', 'Analogue', 'Scale', '(', 'VAS', ')', 'score', ',', 'plasma', 'cytokine', 'levels', 'and', 'detection', 'of', 'adverse', 'effects', '.', '\\n\\n', 'The', 'active', 'principle', 'will', 'be', 'a', 'standardized', 'extract', 'of', 'cannabis', 'sativa', 'containing', '1', 'milligram', 'of', 'tetrahydrocannabinol', '(', 'THC', ')', 'and', '0.45', 'milligrams', 'cannabidiol', '(', 'CBD', ')', 'per', 'drop', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 40,
                "text": "KL16-012",
                "type": "DRUG"
            },
            {
                "start": 55,
                "end": 104,
                "text": "Fibromyalgia Refractary to Conventional Treatment",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 188,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 345,
                "end": 352,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 484,
                "end": 496,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 710,
                "end": 736,
                "text": "extract of cannabis sativa",
                "type": "OTHER"
            },
            {
                "start": 763,
                "end": 783,
                "text": "tetrahydrocannabinol",
                "type": "DRUG"
            },
            {
                "start": 785,
                "end": 788,
                "text": "THC",
                "type": "DRUG"
            },
            {
                "start": 810,
                "end": 821,
                "text": "cannabidiol",
                "type": "DRUG"
            },
            {
                "start": 823,
                "end": 826,
                "text": "CBD",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00053417",
        "study_official_title": "Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis ",
        "study_brief_summary": " Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the Central Nervous System (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called \"myelin\") deteriorates, causing nerve impulses to be slowed or stopped. As a result patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR (Sustained Release, SR) is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will evaluate the effects of Fampridine-SR on the walking ability of subjects with MS, as well as to examine the effects on muscle strength and spasticity. The study will also examine the possible risks of taking Fampridine-SR.",
        "text": "Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis | Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the Central Nervous System (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called \"myelin\") deteriorates, causing nerve impulses to be slowed or stopped. As a result patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR (Sustained Release, SR) is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will evaluate the effects of Fampridine-SR on the walking ability of subjects with MS, as well as to examine the effects on muscle strength and spasticity. The study will also examine the possible risks of taking Fampridine-SR.",
        "tokens": "['Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', '20', '-', 'Week', ',', 'Parallel', 'Group', 'Study', 'to', 'Evaluate', 'Safety', ',', 'Tolerability', 'and', 'Activity', 'of', 'Oral', 'Fampridine', '-', 'SR', 'in', 'Subjects', 'With', 'Multiple', 'Sclerosis', '|', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'is', 'a', 'disorder', 'of', 'the', 'body', \"'s\", 'immune', 'system', 'that', 'affects', 'the', 'Central', 'Nervous', 'System', '(', 'CNS', ')', '.', 'Normally', ',', 'nerve', 'fibers', 'carry', 'electrical', 'impulses', 'through', 'the', 'spinal', 'cord', ',', 'providing', 'communication', 'between', 'the', 'brain', 'and', 'the', 'arms', 'and', 'legs', '.', 'In', 'people', 'with', 'MS', ',', 'the', 'fatty', 'sheath', 'that', 'surrounds', 'and', 'insulates', 'the', 'nerve', 'fibers', '(', 'called', '\"', 'myelin', '\"', ')', 'deteriorates', ',', 'causing', 'nerve', 'impulses', 'to', 'be', 'slowed', 'or', 'stopped', '.', 'As', 'a', 'result', 'patients', 'with', 'MS', 'may', 'experience', 'periods', 'of', 'muscle', 'weakness', 'and', 'other', 'symptoms', 'such', 'as', 'numbness', ',', 'loss', 'of', 'vision', ',', 'loss', 'of', 'coordination', ',', 'paralysis', ',', 'spasticity', ',', 'mental', 'and', 'physical', 'fatigue', 'and', 'a', 'decrease', 'in', 'the', 'ability', 'to', 'think', 'and/or', 'remember', '.', 'These', 'periods', 'of', 'illness', 'may', 'come', '(', 'exacerbations', ')', 'and', 'go', '(', 'remissions', ')', '.', 'Fampridine', '-', 'SR', '(', 'Sustained', 'Release', ',', 'SR', ')', 'is', 'an', 'experimental', 'drug', 'that', 'increases', 'the', 'ability', 'of', 'the', 'nerve', 'to', 'conduct', 'electrical', 'impulses', '.', 'This', 'study', 'will', 'evaluate', 'the', 'effects', 'of', 'Fampridine', '-', 'SR', 'on', 'the', 'walking', 'ability', 'of', 'subjects', 'with', 'MS', ',', 'as', 'well', 'as', 'to', 'examine', 'the', 'effects', 'on', 'muscle', 'strength', 'and', 'spasticity', '.', 'The', 'study', 'will', 'also', 'examine', 'the', 'possible', 'risks', 'of', 'taking', 'Fampridine', '-', 'SR', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 21,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 118,
                "end": 128,
                "text": "Fampridine",
                "type": "DRUG"
            },
            {
                "start": 149,
                "end": 167,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 188,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 192,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 437,
                "end": 439,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 610,
                "end": 612,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 741,
                "end": 751,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 908,
                "end": 918,
                "text": "Fampridine",
                "type": "DRUG"
            },
            {
                "start": 1082,
                "end": 1092,
                "text": "Fampridine",
                "type": "DRUG"
            },
            {
                "start": 1136,
                "end": 1138,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1197,
                "end": 1207,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 1266,
                "end": 1276,
                "text": "Fampridine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02536911",
        "study_official_title": "An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function ",
        "study_brief_summary": " Primary Objective:\n\nTo study the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of eliglustat.\n\nSecondary Objective:\n\nTo assess the tolerability of eliglustat tartrate given as a single dose in subjects with mild and moderate hepatic impairment in comparison with matched subjects with normal hepatic function.",
        "text": "An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function | Primary Objective:\n\nTo study the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of eliglustat.\n\nSecondary Objective:\n\nTo assess the tolerability of eliglustat tartrate given as a single dose in subjects with mild and moderate hepatic impairment in comparison with matched subjects with normal hepatic function.",
        "tokens": "['An', 'Open', '-', 'label', 'Pharmacokinetic', 'and', 'Tolerability', 'Study', 'of', 'Eliglustat', 'Tartrate', 'Given', 'as', 'a', 'Single', 'Dose', 'in', 'Subjects', 'With', 'Mild', 'and', 'Moderate', 'Hepatic', 'Impairment', ',', 'and', 'in', 'Matched', 'Subjects', 'With', 'Normal', 'Hepatic', 'Function', '|', 'Primary', 'Objective', ':', '\\n\\n', 'To', 'study', 'the', 'effect', 'of', 'mild', 'and', 'moderate', 'hepatic', 'impairment', 'on', 'the', 'pharmacokinetics', '(', 'PK', ')', 'of', 'eliglustat', '.', '\\n\\n', 'Secondary', 'Objective', ':', '\\n\\n', 'To', 'assess', 'the', 'tolerability', 'of', 'eliglustat', 'tartrate', 'given', 'as', 'a', 'single', 'dose', 'in', 'subjects', 'with', 'mild', 'and', 'moderate', 'hepatic', 'impairment', 'in', 'comparison', 'with', 'matched', 'subjects', 'with', 'normal', 'hepatic', 'function', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 56,
                "end": 75,
                "text": "Eliglustat Tartrate",
                "type": "DRUG"
            },
            {
                "start": 116,
                "end": 152,
                "text": "Mild and Moderate Hepatic Impairment",
                "type": "CONDITION"
            },
            {
                "start": 252,
                "end": 288,
                "text": "mild and moderate hepatic impairment",
                "type": "CONDITION"
            },
            {
                "start": 321,
                "end": 331,
                "text": "eliglustat",
                "type": "DRUG"
            },
            {
                "start": 386,
                "end": 405,
                "text": "eliglustat tartrate",
                "type": "DRUG"
            },
            {
                "start": 446,
                "end": 482,
                "text": "mild and moderate hepatic impairment",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00871884",
        "study_official_title": "The Role of Anxiety Sensitivity in the Maintenance of Chronic Post Concussion Symptoms ",
        "study_brief_summary": " This study is designed to investigate factors that are associated with prolonged recovery from mild head injury. The investigators are particularly interested in defining the impact of anxiety related variables, such as health anxiety and anxiety sensitivity in the maintenance of symptoms.\n\nA further goal of the study is the evaluation of two treatment methods that have been proposed to be effective in reducing the impact of post concussion symptoms. The investigators hypothesize that a treatment which is directly focused on changing these anxiety related variables will be more effective than one that does not.",
        "text": "The Role of Anxiety Sensitivity in the Maintenance of Chronic Post Concussion Symptoms | This study is designed to investigate factors that are associated with prolonged recovery from mild head injury. The investigators are particularly interested in defining the impact of anxiety related variables, such as health anxiety and anxiety sensitivity in the maintenance of symptoms.\n\nA further goal of the study is the evaluation of two treatment methods that have been proposed to be effective in reducing the impact of post concussion symptoms. The investigators hypothesize that a treatment which is directly focused on changing these anxiety related variables will be more effective than one that does not.",
        "tokens": "['The', 'Role', 'of', 'Anxiety', 'Sensitivity', 'in', 'the', 'Maintenance', 'of', 'Chronic', 'Post', 'Concussion', 'Symptoms', '|', 'This', 'study', 'is', 'designed', 'to', 'investigate', 'factors', 'that', 'are', 'associated', 'with', 'prolonged', 'recovery', 'from', 'mild', 'head', 'injury', '.', 'The', 'investigators', 'are', 'particularly', 'interested', 'in', 'defining', 'the', 'impact', 'of', 'anxiety', 'related', 'variables', ',', 'such', 'as', 'health', 'anxiety', 'and', 'anxiety', 'sensitivity', 'in', 'the', 'maintenance', 'of', 'symptoms', '.', '\\n\\n', 'A', 'further', 'goal', 'of', 'the', 'study', 'is', 'the', 'evaluation', 'of', 'two', 'treatment', 'methods', 'that', 'have', 'been', 'proposed', 'to', 'be', 'effective', 'in', 'reducing', 'the', 'impact', 'of', 'post', 'concussion', 'symptoms', '.', 'The', 'investigators', 'hypothesize', 'that', 'a', 'treatment', 'which', 'is', 'directly', 'focused', 'on', 'changing', 'these', 'anxiety', 'related', 'variables', 'will', 'be', 'more', 'effective', 'than', 'one', 'that', 'does', 'not', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 19,
                "text": "Anxiety",
                "type": "CONDITION"
            },
            {
                "start": 54,
                "end": 77,
                "text": "Chronic Post Concussion",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 200,
                "text": "mild head injury",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 281,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 323,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 328,
                "end": 335,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 518,
                "end": 533,
                "text": "post concussion",
                "type": "CONDITION"
            },
            {
                "start": 635,
                "end": 642,
                "text": "anxiety",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02422173",
        "study_official_title": "Effects of Different Montages of Transcranial Direct Current Stimulation on the Risk of Falls and Lower Limb Function for Acute Stroke Patients: a Randomized Controlled Trial ",
        "study_brief_summary": " Transcranial direct current stimulation (tDCS) has shown promising results in the modulation of cortical excitability and the promotion of neuronal plasticity after stroke. The purpose of this study was to compare the effectiveness of three different montages of tDCS (anodal, cathodal and bilateral) in reducing the risk of falls and recovery of lower limb function in acute stroke patients.",
        "text": "Effects of Different Montages of Transcranial Direct Current Stimulation on the Risk of Falls and Lower Limb Function for Acute Stroke Patients: a Randomized Controlled Trial | Transcranial direct current stimulation (tDCS) has shown promising results in the modulation of cortical excitability and the promotion of neuronal plasticity after stroke. The purpose of this study was to compare the effectiveness of three different montages of tDCS (anodal, cathodal and bilateral) in reducing the risk of falls and recovery of lower limb function in acute stroke patients.",
        "tokens": "['Effects', 'of', 'Different', 'Montages', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'on', 'the', 'Risk', 'of', 'Falls', 'and', 'Lower', 'Limb', 'Function', 'for', 'Acute', 'Stroke', 'Patients', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'has', 'shown', 'promising', 'results', 'in', 'the', 'modulation', 'of', 'cortical', 'excitability', 'and', 'the', 'promotion', 'of', 'neuronal', 'plasticity', 'after', 'stroke', '.', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'effectiveness', 'of', 'three', 'different', 'montages', 'of', 'tDCS', '(', 'anodal', ',', 'cathodal', 'and', 'bilateral', ')', 'in', 'reducing', 'the', 'risk', 'of', 'falls', 'and', 'recovery', 'of', 'lower', 'limb', 'function', 'in', 'acute', 'stroke', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 72,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 80,
                "end": 93,
                "text": "Risk of Falls",
                "type": "CONDITION"
            },
            {
                "start": 122,
                "end": 134,
                "text": "Acute Stroke",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 216,
                "text": "Transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 218,
                "end": 222,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 342,
                "end": 348,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 440,
                "end": 444,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 494,
                "end": 507,
                "text": "risk of falls",
                "type": "CONDITION"
            },
            {
                "start": 547,
                "end": 559,
                "text": "acute stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02337114",
        "study_official_title": "REACT - Recovery Enhancement From TBI Using ACT. A Pilot Study. ",
        "study_brief_summary": " Is Acceptance and Commitment Therapy (ACT) feasible and acceptable for adults with severe Traumatic Brain Injury (sTBI) in inpatient services? sTBI is associated with depression, anxiety and low self awareness. A key factor in recovery is adjustment to the effects of injury. Psychological intervention may facilitate this change\u037e however what works is unclear. ACT seeks to improve psychological flexibility\u037e the ability to be present with difficult thoughts and emotions, rather than fighting them, and to accept ourselves as we are, not what we believe we should be. Current research is limited, but what is published suggests it may be useful for this group.\n\nDue to the limited research this pilot study aims to conduct preliminary analysis on the acceptability and feasibility of ACT for people with sTBI whilst also examining the suitability of the study protocol in order to make recommendations for future studies. Clients and staff from three Brain Injury Rehabilitation Trust (BIRT) centres will be recruited, one of which will serve as the intervention centre.\n\nClients in the intervention group will be asked to complete questionnaires a week before and after participation in the 6 week ACT programme. Clients in the comparison group will be asked to complete questionnaires a week before and after receiving 6 weeks of treatment as usual (TAU). The treatment group will also receive TAU. All participants will be invited to participate in a focus group at the end of this 8 week period to discuss their involvement in the study.\n\nStaff will be asked to complete a parallel version of one of the client questionnaires within a similar timeframe. In addition staff at the intervention centre will be invited to attend a focus group and complete an additional questionnaire after the eight week period.",
        "text": "REACT - Recovery Enhancement From TBI Using ACT. A Pilot Study. | Is Acceptance and Commitment Therapy (ACT) feasible and acceptable for adults with severe Traumatic Brain Injury (sTBI) in inpatient services? sTBI is associated with depression, anxiety and low self awareness. A key factor in recovery is adjustment to the effects of injury. Psychological intervention may facilitate this change\u037e however what works is unclear. ACT seeks to improve psychological flexibility\u037e the ability to be present with difficult thoughts and emotions, rather than fighting them, and to accept ourselves as we are, not what we believe we should be. Current research is limited, but what is published suggests it may be useful for this group.\n\nDue to the limited research this pilot study aims to conduct preliminary analysis on the acceptability and feasibility of ACT for people with sTBI whilst also examining the suitability of the study protocol in order to make recommendations for future studies. Clients and staff from three Brain Injury Rehabilitation Trust (BIRT) centres will be recruited, one of which will serve as the intervention centre.\n\nClients in the intervention group will be asked to complete questionnaires a week before and after participation in the 6 week ACT programme. Clients in the comparison group will be asked to complete questionnaires a week before and after receiving 6 weeks of treatment as usual (TAU). The treatment group will also receive TAU. All participants will be invited to participate in a focus group at the end of this 8 week period to discuss their involvement in the study.\n\nStaff will be asked to complete a parallel version of one of the client questionnaires within a similar timeframe. In addition staff at the intervention centre will be invited to attend a focus group and complete an additional questionnaire after the eight week period.",
        "tokens": "['REACT', '-', 'Recovery', 'Enhancement', 'From', 'TBI', 'Using', 'ACT', '.', 'A', 'Pilot', 'Study', '.', '|', 'Is', 'Acceptance', 'and', 'Commitment', 'Therapy', '(', 'ACT', ')', 'feasible', 'and', 'acceptable', 'for', 'adults', 'with', 'severe', 'Traumatic', 'Brain', 'Injury', '(', 'sTBI', ')', 'in', 'inpatient', 'services', '?', 'sTBI', 'is', 'associated', 'with', 'depression', ',', 'anxiety', 'and', 'low', 'self', 'awareness', '.', 'A', 'key', 'factor', 'in', 'recovery', 'is', 'adjustment', 'to', 'the', 'effects', 'of', 'injury', '.', 'Psychological', 'intervention', 'may', 'facilitate', 'this', 'change\u037e', 'however', 'what', 'works', 'is', 'unclear', '.', 'ACT', 'seeks', 'to', 'improve', 'psychological', 'flexibility\u037e', 'the', 'ability', 'to', 'be', 'present', 'with', 'difficult', 'thoughts', 'and', 'emotions', ',', 'rather', 'than', 'fighting', 'them', ',', 'and', 'to', 'accept', 'ourselves', 'as', 'we', 'are', ',', 'not', 'what', 'we', 'believe', 'we', 'should', 'be', '.', 'Current', 'research', 'is', 'limited', ',', 'but', 'what', 'is', 'published', 'suggests', 'it', 'may', 'be', 'useful', 'for', 'this', 'group', '.', '\\n\\n', 'Due', 'to', 'the', 'limited', 'research', 'this', 'pilot', 'study', 'aims', 'to', 'conduct', 'preliminary', 'analysis', 'on', 'the', 'acceptability', 'and', 'feasibility', 'of', 'ACT', 'for', 'people', 'with', 'sTBI', 'whilst', 'also', 'examining', 'the', 'suitability', 'of', 'the', 'study', 'protocol', 'in', 'order', 'to', 'make', 'recommendations', 'for', 'future', 'studies', '.', 'Clients', 'and', 'staff', 'from', 'three', 'Brain', 'Injury', 'Rehabilitation', 'Trust', '(', 'BIRT', ')', 'centres', 'will', 'be', 'recruited', ',', 'one', 'of', 'which', 'will', 'serve', 'as', 'the', 'intervention', 'centre', '.', '\\n\\n', 'Clients', 'in', 'the', 'intervention', 'group', 'will', 'be', 'asked', 'to', 'complete', 'questionnaires', 'a', 'week', 'before', 'and', 'after', 'participation', 'in', 'the', '6', 'week', 'ACT', 'programme', '.', 'Clients', 'in', 'the', 'comparison', 'group', 'will', 'be', 'asked', 'to', 'complete', 'questionnaires', 'a', 'week', 'before', 'and', 'after', 'receiving', '6', 'weeks', 'of', 'treatment', 'as', 'usual', '(', 'TAU', ')', '.', 'The', 'treatment', 'group', 'will', 'also', 'receive', 'TAU', '.', 'All', 'participants', 'will', 'be', 'invited', 'to', 'participate', 'in', 'a', 'focus', 'group', 'at', 'the', 'end', 'of', 'this', '8', 'week', 'period', 'to', 'discuss', 'their', 'involvement', 'in', 'the', 'study', '.', '\\n\\n', 'Staff', 'will', 'be', 'asked', 'to', 'complete', 'a', 'parallel', 'version', 'of', 'one', 'of', 'the', 'client', 'questionnaires', 'within', 'a', 'similar', 'timeframe', '.', 'In', 'addition', 'staff', 'at', 'the', 'intervention', 'centre', 'will', 'be', 'invited', 'to', 'attend', 'a', 'focus', 'group', 'and', 'complete', 'an', 'additional', 'questionnaire', 'after', 'the', 'eight', 'week', 'period', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 34,
                "end": 37,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 44,
                "end": 47,
                "text": "ACT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 69,
                "end": 102,
                "text": "Acceptance and Commitment Therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 104,
                "end": 107,
                "text": "ACT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 149,
                "end": 178,
                "text": "severe Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 180,
                "end": 184,
                "text": "sTBI",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 213,
                "text": "sTBI",
                "type": "CONDITION"
            },
            {
                "start": 233,
                "end": 243,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 252,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 428,
                "end": 431,
                "text": "ACT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 852,
                "end": 855,
                "text": "ACT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 872,
                "end": 876,
                "text": "sTBI",
                "type": "CONDITION"
            },
            {
                "start": 1267,
                "end": 1270,
                "text": "ACT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1400,
                "end": 1418,
                "text": "treatment as usual",
                "type": "CONTROL"
            },
            {
                "start": 1420,
                "end": 1423,
                "text": "TAU",
                "type": "CONTROL"
            },
            {
                "start": 1464,
                "end": 1467,
                "text": "TAU",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04550507",
        "study_official_title": "Mind-Body Interventions to Mitigate Effects of Media Use on Sleep (Sleepazoid Study) ",
        "study_brief_summary": " Eliminating media use is neither feasible at a public health level nor perhaps even desirable given the role it plays in the lives of youth and adults, but mind-body interventions have the potential to mitigate state arousal effects and thus reduce negative impacts on sleep. Given emerging literature on links between intensive media use, sensory and interoceptive awareness, and self-regulation, this study will examine two related mind-body approaches -- a mindfulness sensory awareness exercises and mindful body awareness check-ins -- in a randomized clinical trial of early adolescents with evening media use and sleep problems.",
        "text": "Mind-Body Interventions to Mitigate Effects of Media Use on Sleep (Sleepazoid Study) | Eliminating media use is neither feasible at a public health level nor perhaps even desirable given the role it plays in the lives of youth and adults, but mind-body interventions have the potential to mitigate state arousal effects and thus reduce negative impacts on sleep. Given emerging literature on links between intensive media use, sensory and interoceptive awareness, and self-regulation, this study will examine two related mind-body approaches -- a mindfulness sensory awareness exercises and mindful body awareness check-ins -- in a randomized clinical trial of early adolescents with evening media use and sleep problems.",
        "tokens": "['Mind', '-', 'Body', 'Interventions', 'to', 'Mitigate', 'Effects', 'of', 'Media', 'Use', 'on', 'Sleep', '(', 'Sleepazoid', 'Study', ')', '|', 'Eliminating', 'media', 'use', 'is', 'neither', 'feasible', 'at', 'a', 'public', 'health', 'level', 'nor', 'perhaps', 'even', 'desirable', 'given', 'the', 'role', 'it', 'plays', 'in', 'the', 'lives', 'of', 'youth', 'and', 'adults', ',', 'but', 'mind', '-', 'body', 'interventions', 'have', 'the', 'potential', 'to', 'mitigate', 'state', 'arousal', 'effects', 'and', 'thus', 'reduce', 'negative', 'impacts', 'on', 'sleep', '.', 'Given', 'emerging', 'literature', 'on', 'links', 'between', 'intensive', 'media', 'use', ',', 'sensory', 'and', 'interoceptive', 'awareness', ',', 'and', 'self', '-', 'regulation', ',', 'this', 'study', 'will', 'examine', 'two', 'related', 'mind', '-', 'body', 'approaches', '--', 'a', 'mindfulness', 'sensory', 'awareness', 'exercises', 'and', 'mindful', 'body', 'awareness', 'check', '-', 'ins', '--', 'in', 'a', 'randomized', 'clinical', 'trial', 'of', 'early', 'adolescents', 'with', 'evening', 'media', 'use', 'and', 'sleep', 'problems', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 23,
                "text": "Mind-Body Interventions",
                "type": "OTHER"
            },
            {
                "start": 243,
                "end": 266,
                "text": "mind-body interventions",
                "type": "OTHER"
            },
            {
                "start": 521,
                "end": 541,
                "text": "mind-body approaches",
                "type": "OTHER"
            },
            {
                "start": 547,
                "end": 586,
                "text": "mindfulness sensory awareness exercises",
                "type": "OTHER"
            },
            {
                "start": 591,
                "end": 623,
                "text": "mindful body awareness check-ins",
                "type": "OTHER"
            },
            {
                "start": 706,
                "end": 720,
                "text": "sleep problems",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05016765",
        "study_official_title": "Open Trial of Median Nerve Stimulation for Treatment of Tourette Syndrome ",
        "study_brief_summary": " A recent report (Morera Maiquez et al 2020) described reduced tic severity in people with Tourette syndrome during 1-minute epochs of median nerve stimulation (MNS) at 10 Hz. Among the various questions still to be answered is the question of whether a device to administer MNS is practical for use in a chronic, real-world setting. This study will recruit participants who complete the clinic-based, blinded, randomized controlled trial, https://clinicaltrials.gov/ct2/show/NCT04731714, to determine the real-world usage and apparent utility of median nerve stimulation in people with chronic tics.",
        "text": "Open Trial of Median Nerve Stimulation for Treatment of Tourette Syndrome | A recent report (Morera Maiquez et al 2020) described reduced tic severity in people with Tourette syndrome during 1-minute epochs of median nerve stimulation (MNS) at 10 Hz. Among the various questions still to be answered is the question of whether a device to administer MNS is practical for use in a chronic, real-world setting. This study will recruit participants who complete the clinic-based, blinded, randomized controlled trial, https://clinicaltrials.gov/ct2/show/NCT04731714, to determine the real-world usage and apparent utility of median nerve stimulation in people with chronic tics.",
        "tokens": "['Open', 'Trial', 'of', 'Median', 'Nerve', 'Stimulation', 'for', 'Treatment', 'of', 'Tourette', 'Syndrome', '|', 'A', 'recent', 'report', '(', 'Morera', 'Maiquez', 'et', 'al', '2020', ')', 'described', 'reduced', 'tic', 'severity', 'in', 'people', 'with', 'Tourette', 'syndrome', 'during', '1', '-', 'minute', 'epochs', 'of', 'median', 'nerve', 'stimulation', '(', 'MNS', ')', 'at', '10', 'Hz', '.', 'Among', 'the', 'various', 'questions', 'still', 'to', 'be', 'answered', 'is', 'the', 'question', 'of', 'whether', 'a', 'device', 'to', 'administer', 'MNS', 'is', 'practical', 'for', 'use', 'in', 'a', 'chronic', ',', 'real', '-', 'world', 'setting', '.', 'This', 'study', 'will', 'recruit', 'participants', 'who', 'complete', 'the', 'clinic', '-', 'based', ',', 'blinded', ',', 'randomized', 'controlled', 'trial', ',', 'https://clinicaltrials.gov/ct2/show/NCT04731714', ',', 'to', 'determine', 'the', 'real', '-', 'world', 'usage', 'and', 'apparent', 'utility', 'of', 'median', 'nerve', 'stimulation', 'in', 'people', 'with', 'chronic', 'tics', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 38,
                "text": "Median Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 73,
                "text": "Tourette Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 183,
                "text": "Tourette syndrome",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 234,
                "text": "median nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 236,
                "end": 239,
                "text": "MNS",
                "type": "OTHER"
            },
            {
                "start": 350,
                "end": 353,
                "text": "MNS",
                "type": "OTHER"
            },
            {
                "start": 622,
                "end": 646,
                "text": "median nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 662,
                "end": 674,
                "text": "chronic tics",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02481232",
        "study_official_title": "A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine ",
        "study_brief_summary": " Safety Evaluation of freeze-dried Group ACYW135 Meningococcal conjugate vaccine in healthy people above 2-months-old",
        "text": "A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine | Safety Evaluation of freeze-dried Group ACYW135 Meningococcal conjugate vaccine in healthy people above 2-months-old",
        "tokens": "['A', 'Single', '-', 'center', ',', 'Open', 'Trials', 'to', 'Evaluate', 'the', 'Safety', 'of', 'Freeze', '-', 'dried', 'Group', 'ACYW135', 'Meningococcal', 'Conjugate', 'Vaccine', '|', 'Safety', 'Evaluation', 'of', 'freeze', '-', 'dried', 'Group', 'ACYW135', 'Meningococcal', 'conjugate', 'vaccine', 'in', 'healthy', 'people', 'above', '2', '-', 'months', '-', 'old']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 68,
                "end": 105,
                "text": "Group ACYW135 Meningococcal Conjugate",
                "type": "DRUG"
            },
            {
                "start": 150,
                "end": 187,
                "text": "Group ACYW135 Meningococcal conjugate",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05273320",
        "study_official_title": "Phase I Pre-pilot Open-label Clinical Trial of Nabilone for Severe Behavioural Problems (Aggression) in Adults With Intellectual and Developmental Disabilities ",
        "study_brief_summary": " Innovative treatments are urgently needed for severe behavioural problems (SBPs) in adults with intellectual and developmental disabilities (IDD). Although a synthetic cannabinoid, nabilone may be a plausible and safe alternative to treat SBP, safety and efficacy of nabilone in people with IDD has never been evaluated. The investigators propose to conduct this first-ever Phase I pre-pilot open-label clinical trial to collect data on the tolerability and safety profile of nabilone in adults with IDD, and explore changes in SBP pre- and post-treatment. The results will inform a next-stage pilot randomized controlled trial, followed by a fully powered trial eventually.",
        "text": "Phase I Pre-pilot Open-label Clinical Trial of Nabilone for Severe Behavioural Problems (Aggression) in Adults With Intellectual and Developmental Disabilities | Innovative treatments are urgently needed for severe behavioural problems (SBPs) in adults with intellectual and developmental disabilities (IDD). Although a synthetic cannabinoid, nabilone may be a plausible and safe alternative to treat SBP, safety and efficacy of nabilone in people with IDD has never been evaluated. The investigators propose to conduct this first-ever Phase I pre-pilot open-label clinical trial to collect data on the tolerability and safety profile of nabilone in adults with IDD, and explore changes in SBP pre- and post-treatment. The results will inform a next-stage pilot randomized controlled trial, followed by a fully powered trial eventually.",
        "tokens": "['Phase', 'I', 'Pre', '-', 'pilot', 'Open', '-', 'label', 'Clinical', 'Trial', 'of', 'Nabilone', 'for', 'Severe', 'Behavioural', 'Problems', '(', 'Aggression', ')', 'in', 'Adults', 'With', 'Intellectual', 'and', 'Developmental', 'Disabilities', '|', 'Innovative', 'treatments', 'are', 'urgently', 'needed', 'for', 'severe', 'behavioural', 'problems', '(', 'SBPs', ')', 'in', 'adults', 'with', 'intellectual', 'and', 'developmental', 'disabilities', '(', 'IDD', ')', '.', 'Although', 'a', 'synthetic', 'cannabinoid', ',', 'nabilone', 'may', 'be', 'a', 'plausible', 'and', 'safe', 'alternative', 'to', 'treat', 'SBP', ',', 'safety', 'and', 'efficacy', 'of', 'nabilone', 'in', 'people', 'with', 'IDD', 'has', 'never', 'been', 'evaluated', '.', 'The', 'investigators', 'propose', 'to', 'conduct', 'this', 'first', '-', 'ever', 'Phase', 'I', 'pre', '-', 'pilot', 'open', '-', 'label', 'clinical', 'trial', 'to', 'collect', 'data', 'on', 'the', 'tolerability', 'and', 'safety', 'profile', 'of', 'nabilone', 'in', 'adults', 'with', 'IDD', ',', 'and', 'explore', 'changes', 'in', 'SBP', 'pre-', 'and', 'post', '-', 'treatment', '.', 'The', 'results', 'will', 'inform', 'a', 'next', '-', 'stage', 'pilot', 'randomized', 'controlled', 'trial', ',', 'followed', 'by', 'a', 'fully', 'powered', 'trial', 'eventually', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 47,
                "end": 55,
                "text": "Nabilone",
                "type": "DRUG"
            },
            {
                "start": 60,
                "end": 87,
                "text": "Severe Behavioural Problems",
                "type": "CONDITION"
            },
            {
                "start": 89,
                "end": 99,
                "text": "Aggression",
                "type": "CONDITION"
            },
            {
                "start": 116,
                "end": 159,
                "text": "Intellectual and Developmental Disabilities",
                "type": "CONDITION"
            },
            {
                "start": 208,
                "end": 235,
                "text": "severe behavioural problems",
                "type": "CONDITION"
            },
            {
                "start": 237,
                "end": 241,
                "text": "SBPs",
                "type": "CONDITION"
            },
            {
                "start": 258,
                "end": 301,
                "text": "intellectual and developmental disabilities",
                "type": "CONDITION"
            },
            {
                "start": 303,
                "end": 306,
                "text": "IDD",
                "type": "CONDITION"
            },
            {
                "start": 330,
                "end": 341,
                "text": "cannabinoid",
                "type": "DRUG"
            },
            {
                "start": 343,
                "end": 351,
                "text": "nabilone",
                "type": "DRUG"
            },
            {
                "start": 401,
                "end": 404,
                "text": "SBP",
                "type": "CONDITION"
            },
            {
                "start": 429,
                "end": 437,
                "text": "nabilone",
                "type": "DRUG"
            },
            {
                "start": 453,
                "end": 456,
                "text": "IDD",
                "type": "CONDITION"
            },
            {
                "start": 638,
                "end": 646,
                "text": "nabilone",
                "type": "DRUG"
            },
            {
                "start": 662,
                "end": 665,
                "text": "IDD",
                "type": "CONDITION"
            },
            {
                "start": 690,
                "end": 693,
                "text": "SBP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01399606",
        "study_official_title": "An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) ",
        "study_brief_summary": " This is a multicentric International Phase III,Long term open label study(12 months)assessing the long-term safety and efficacy of BF2.649 (Pitolisant)in the treatment of Excessive Daytime Sleepiness (EDS) in narcoleptic patients with or without cataplexy.",
        "text": "An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) | This is a multicentric International Phase III,Long term open label study(12 months)assessing the long-term safety and efficacy of BF2.649 (Pitolisant)in the treatment of Excessive Daytime Sleepiness (EDS) in narcoleptic patients with or without cataplexy.",
        "tokens": "['An', 'Open', '-', 'label', 'Naturalistic', 'Pragmatic', 'Study', 'to', 'Assess', 'the', 'Long', 'Term', 'Safety', 'of', 'BF2.649', '(', 'Pitolisant', ')', 'in', 'the', 'Treatment', 'of', 'Excessive', 'Daytime', 'Sleepiness', '(', 'EDS', ')', 'in', 'Narcolepsy', '(', '12', 'Months', 'Follow', '-', 'up', ',', 'Followed', 'by', 'a', 'Prolonged', 'Follow', 'up', ')', '|', 'This', 'is', 'a', 'multicentric', 'International', 'Phase', 'III', ',', 'Long', 'term', 'open', 'label', 'study(12', 'months)assessing', 'the', 'long', '-', 'term', 'safety', 'and', 'efficacy', 'of', 'BF2.649', '(', 'Pitolisant)in', 'the', 'treatment', 'of', 'Excessive', 'Daytime', 'Sleepiness', '(', 'EDS', ')', 'in', 'narcoleptic', 'patients', 'with', 'or', 'without', 'cataplexy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 77,
                "end": 84,
                "text": "BF2.649",
                "type": "DRUG"
            },
            {
                "start": 86,
                "end": 96,
                "text": "Pitolisant",
                "type": "DRUG"
            },
            {
                "start": 118,
                "end": 146,
                "text": "Excessive Daytime Sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 151,
                "text": "EDS",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 166,
                "text": "Narcolepsy",
                "type": "CONDITION"
            },
            {
                "start": 357,
                "end": 364,
                "text": "BF2.649",
                "type": "DRUG"
            },
            {
                "start": 397,
                "end": 425,
                "text": "Excessive Daytime Sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 427,
                "end": 430,
                "text": "EDS",
                "type": "CONDITION"
            },
            {
                "start": 435,
                "end": 446,
                "text": "narcoleptic",
                "type": "CONDITION"
            },
            {
                "start": 472,
                "end": 481,
                "text": "cataplexy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02938520",
        "study_official_title": "A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants ",
        "study_brief_summary": " The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, anti-retroviral therapy (ART)-na\u00efve adult participants. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4 weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B*5701 positive at Screening may enroll into the study and receive DTG plus a non-abacavir containing dual nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week [-20] to Day 1). Participants who have an HIV 1 ribose nucleic acid (RNA) <50 copies per milliliter (c/mL) at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from visit Week 4b until study completion or withdrawal. Participants who successfully complete Week 100 (without meeting study defined withdrawal criteria and who remain virologically suppressed through Week 96: HIV-1 RNA <50 c/mL) will be given the option to switch to the LA arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn from the study. Participants will continue to receive injections every 4 weeks during the Extension Phase until CAB LA and RPV LA are either locally approved and commercially available, the participant no longer derives clinical benefit, the participant meets a protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA is terminated.",
        "text": "A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants | The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, anti-retroviral therapy (ART)-na\u00efve adult participants. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4 weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B*5701 positive at Screening may enroll into the study and receive DTG plus a non-abacavir containing dual nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week [-20] to Day 1). Participants who have an HIV 1 ribose nucleic acid (RNA) <50 copies per milliliter (c/mL) at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from visit Week 4b until study completion or withdrawal. Participants who successfully complete Week 100 (without meeting study defined withdrawal criteria and who remain virologically suppressed through Week 96: HIV-1 RNA <50 c/mL) will be given the option to switch to the LA arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn from the study. Participants will continue to receive injections every 4 weeks during the Extension Phase until CAB LA and RPV LA are either locally approved and commercially available, the participant no longer derives clinical benefit, the participant meets a protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA is terminated.",
        "tokens": "['A', 'Phase', 'III', ',', 'Randomized', ',', 'Multicenter', ',', 'Parallel', '-', 'group', ',', 'Open', '-', 'Label', 'Study', 'Evaluating', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'Long', '-', 'Acting', 'Intramuscular', 'Cabotegravir', 'and', 'Rilpivirine', 'for', 'Maintenance', 'of', 'Virologic', 'Suppression', 'Following', 'Switch', 'From', 'an', 'Integrase', 'Inhibitor', 'Single', 'Tablet', 'Regimen', 'in', 'HIV-1', 'Infected', 'Antiretroviral', 'Therapy', 'Naive', 'Adult', 'Participants', '|', 'The', 'First', 'Long', '-', 'Acting', 'Injectable', 'Regimen', '(', 'FLAIR', ')', 'study', 'is', 'being', 'conducted', 'to', 'establish', 'if', 'human', 'immunodeficiency', 'virus', 'type-1', '(', 'HIV-1', ')', 'infected', 'adult', 'participants', 'whose', 'virus', 'is', 'virologically', 'suppressed', 'on', 'an', 'integrase', 'inhibitor', 'single', 'tablet', 'regimen', '(', 'INI', 'STR', ')', 'will', 'remain', 'suppressed', 'after', 'switching', 'to', 'a', 'two', '-', 'drug', 'intramuscular', '(', 'IM', ')', 'long', '-', 'acting', '(', 'LA', ')', 'regimen', 'of', 'cabotegravir', '(', 'CAB', ')', 'and', 'rilpivirine', '(', 'RPV', ')', '.', 'In', 'this', 'study', ',', 'the', 'INI', 'STR', 'will', 'be', 'limited', 'to', 'abacavir', '/', 'dolutegravir', '/', 'lamivudine', '(', 'ABC', '/', 'DTG/3TC', ')', '.', 'FLAIR', 'is', 'a', 'Phase', '3', ',', 'multi', '-', 'phase', ',', 'randomized', ',', 'open', 'label', ',', 'active', '-', 'controlled', ',', 'multicenter', ',', 'parallel', '-', 'group', ',', 'non', '-', 'inferiority', 'study', 'in', 'HIV-1', ',', 'anti', '-', 'retroviral', 'therapy', '(', 'ART)-na\u00efve', 'adult', 'participants', '.', 'This', 'study', 'is', 'designed', 'to', 'demonstrate', 'the', 'non', '-', 'inferior', 'antiviral', 'activity', 'of', 'switching', 'to', 'a', 'two', 'drug', 'CAB', 'LA', '400', 'mg', '+', 'RPV', 'LA', '600', 'mg', 'regimen', 'every', '4', 'weeks', '(', 'Q4W', ':', 'monthly', ')', 'compared', 'to', 'remaining', 'on', 'ABC', '/', 'DTG/3TC', 'over', '48', 'weeks', '(', '4', 'weeks', 'oral', 'CAB', '+', 'RPV', ',', '44', 'weeks', 'LA', 'therapy', ')', '.', 'Participants', 'who', 'are', 'HLA', '-', 'B*5701', 'positive', 'at', 'Screening', 'may', 'enroll', 'into', 'the', 'study', 'and', 'receive', 'DTG', 'plus', 'a', 'non', '-', 'abacavir', 'containing', 'dual', 'nucleoside', 'reverse', 'transcriptase', 'inhibitor', '(', 'NRTI', ')', 'regimen', '.', 'Eligible', 'participants', 'will', 'enroll', 'into', 'the', 'Induction', 'Phase', 'of', 'the', 'study', 'and', 'receive', 'ABC', '/', 'DTG/3TC', 'for', '20', 'weeks', '(', 'Week', '[', '-20', ']', 'to', 'Day', '1', ')', '.', 'Participants', 'who', 'have', 'an', 'HIV', '1', 'ribose', 'nucleic', 'acid', '(', 'RNA', ')', '<', '50', 'copies', 'per', 'milliliter', '(', 'c', '/', 'mL', ')', 'at', 'Week', '(', '-4', ')', 'will', 'be', 'randomized', '(', '1:1', ')', 'into', 'the', 'Maintenance', 'Phase', 'at', 'Day', '1', 'to', 'either', 'continue', 'ABC', '/', 'DTG/3TC', 'or', 'to', 'discontinue', 'ABC', '/', 'DTG/3TC', 'and', 'begin', 'oral', 'therapy', 'with', 'CAB', '30', 'mg', '+', 'RPV', '25', 'mg', 'once', 'daily', 'for', 'approximately', '4', 'Weeks', ',', 'followed', 'by', 'monthly', 'CAB', 'LA', '+', 'RPV', 'LA', 'injections', 'from', 'visit', 'Week', '4b', 'until', 'study', 'completion', 'or', 'withdrawal', '.', 'Participants', 'who', 'successfully', 'complete', 'Week', '100', '(', 'without', 'meeting', 'study', 'defined', 'withdrawal', 'criteria', 'and', 'who', 'remain', 'virologically', 'suppressed', 'through', 'Week', '96', ':', 'HIV-1', 'RNA', '<', '50', 'c', '/', 'mL', ')', 'will', 'be', 'given', 'the', 'option', 'to', 'switch', 'to', 'the', 'LA', 'arm', 'in', 'the', 'Extension', 'Phase', '(', 'using', 'an', 'optional', 'oral', 'lead', '-', 'in', 'with', 'CAB', '+', 'RPV', ')', 'or', 'be', 'withdrawn', 'from', 'the', 'study', '.', 'Participants', 'will', 'continue', 'to', 'receive', 'injections', 'every', '4', 'weeks', 'during', 'the', 'Extension', 'Phase', 'until', 'CAB', 'LA', 'and', 'RPV', 'LA', 'are', 'either', 'locally', 'approved', 'and', 'commercially', 'available', ',', 'the', 'participant', 'no', 'longer', 'derives', 'clinical', 'benefit', ',', 'the', 'participant', 'meets', 'a', 'protocol', '-', 'defined', 'reason', 'for', 'discontinuation', ',', 'or', 'until', 'development', 'of', 'either', 'CAB', 'LA', 'or', 'RPV', 'LA', 'is', 'terminated', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 150,
                "end": 162,
                "text": "Cabotegravir",
                "type": "DRUG"
            },
            {
                "start": 167,
                "end": 178,
                "text": "Rilpivirine",
                "type": "DRUG"
            },
            {
                "start": 245,
                "end": 264,
                "text": "Integrase Inhibitor",
                "type": "DRUG"
            },
            {
                "start": 290,
                "end": 295,
                "text": "HIV-1",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 333,
                "text": "Antiretroviral Therapy Naive",
                "type": "CONDITION"
            },
            {
                "start": 445,
                "end": 480,
                "text": "human immunodeficiency virus type-1",
                "type": "CONDITION"
            },
            {
                "start": 482,
                "end": 487,
                "text": "HIV-1",
                "type": "CONDITION"
            },
            {
                "start": 563,
                "end": 582,
                "text": "integrase inhibitor",
                "type": "DRUG"
            },
            {
                "start": 715,
                "end": 727,
                "text": "cabotegravir",
                "type": "DRUG"
            },
            {
                "start": 729,
                "end": 732,
                "text": "CAB",
                "type": "DRUG"
            },
            {
                "start": 738,
                "end": 749,
                "text": "rilpivirine",
                "type": "DRUG"
            },
            {
                "start": 751,
                "end": 754,
                "text": "RPV",
                "type": "DRUG"
            },
            {
                "start": 803,
                "end": 811,
                "text": "abacavir",
                "type": "DRUG"
            },
            {
                "start": 812,
                "end": 824,
                "text": "dolutegravir",
                "type": "DRUG"
            },
            {
                "start": 825,
                "end": 835,
                "text": "lamivudine",
                "type": "DRUG"
            },
            {
                "start": 837,
                "end": 840,
                "text": "ABC",
                "type": "DRUG"
            },
            {
                "start": 841,
                "end": 848,
                "text": "DTG/3TC",
                "type": "DRUG"
            },
            {
                "start": 981,
                "end": 986,
                "text": "HIV-1",
                "type": "CONDITION"
            },
            {
                "start": 1145,
                "end": 1148,
                "text": "CAB",
                "type": "DRUG"
            },
            {
                "start": 1161,
                "end": 1164,
                "text": "RPV",
                "type": "DRUG"
            },
            {
                "start": 1237,
                "end": 1240,
                "text": "ABC",
                "type": "DRUG"
            },
            {
                "start": 1241,
                "end": 1248,
                "text": "DTG/3TC",
                "type": "DRUG"
            },
            {
                "start": 1277,
                "end": 1280,
                "text": "CAB",
                "type": "DRUG"
            },
            {
                "start": 1283,
                "end": 1286,
                "text": "RPV",
                "type": "DRUG"
            },
            {
                "start": 1331,
                "end": 1350,
                "text": "HLA-B*5701 positive",
                "type": "CONDITION"
            },
            {
                "start": 1402,
                "end": 1405,
                "text": "DTG",
                "type": "DRUG"
            },
            {
                "start": 1437,
                "end": 1484,
                "text": "dual nucleoside reverse transcriptase inhibitor",
                "type": "DRUG"
            },
            {
                "start": 1486,
                "end": 1490,
                "text": "NRTI",
                "type": "DRUG"
            },
            {
                "start": 1585,
                "end": 1588,
                "text": "ABC",
                "type": "DRUG"
            },
            {
                "start": 1589,
                "end": 1596,
                "text": "DTG/3TC",
                "type": "DRUG"
            },
            {
                "start": 1658,
                "end": 1663,
                "text": "HIV 1",
                "type": "CONDITION"
            },
            {
                "start": 1816,
                "end": 1819,
                "text": "ABC",
                "type": "DRUG"
            },
            {
                "start": 1820,
                "end": 1827,
                "text": "DTG/3TC",
                "type": "DRUG"
            },
            {
                "start": 1846,
                "end": 1849,
                "text": "ABC",
                "type": "DRUG"
            },
            {
                "start": 1850,
                "end": 1857,
                "text": "DTG/3TC",
                "type": "DRUG"
            },
            {
                "start": 1886,
                "end": 1889,
                "text": "CAB",
                "type": "DRUG"
            },
            {
                "start": 1898,
                "end": 1901,
                "text": "RPV",
                "type": "DRUG"
            },
            {
                "start": 1966,
                "end": 1969,
                "text": "CAB",
                "type": "DRUG"
            },
            {
                "start": 1975,
                "end": 1978,
                "text": "RPV",
                "type": "DRUG"
            },
            {
                "start": 2206,
                "end": 2211,
                "text": "HIV-1",
                "type": "CONDITION"
            },
            {
                "start": 2335,
                "end": 2338,
                "text": "CAB",
                "type": "DRUG"
            },
            {
                "start": 2341,
                "end": 2344,
                "text": "RPV",
                "type": "DRUG"
            },
            {
                "start": 2474,
                "end": 2477,
                "text": "CAB",
                "type": "DRUG"
            },
            {
                "start": 2485,
                "end": 2488,
                "text": "RPV",
                "type": "DRUG"
            },
            {
                "start": 2700,
                "end": 2703,
                "text": "CAB",
                "type": "DRUG"
            },
            {
                "start": 2710,
                "end": 2713,
                "text": "RPV",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00455507",
        "study_official_title": "Placebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study) ",
        "study_brief_summary": " The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa.",
        "text": "Placebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study) | The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa.",
        "tokens": "['Placebo', '-', 'controlled', ',', 'Double', '-', 'blind', ',', 'Parallel', 'Group', ',', 'Fixed', 'Dose', 'Study', 'of', 'KW-6002', '(', 'Istradefylline', ')', 'in', 'the', 'Treatment', 'of', 'Parkinson', \"'s\", 'Disease', '(', 'Phase', '2', 'Study', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'establish', 'the', 'efficacy', 'of', '20', 'mg', '/', 'day', 'and', '40', 'mg', '/', 'day', 'doses', 'of', 'istradefylline', 'for', 'reducing', 'the', 'mean', 'total', 'hours', 'of', 'awake', 'time', 'per', 'day', 'spent', 'in', 'the', 'OFF', 'state', 'in', 'patients', 'with', 'advanced', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'treated', 'with', 'levodopa', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 70,
                "end": 77,
                "text": "KW-6002",
                "type": "DRUG"
            },
            {
                "start": 79,
                "end": 93,
                "text": "Istradefylline",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 134,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 244,
                "end": 258,
                "text": "istradefylline",
                "type": "DRUG"
            },
            {
                "start": 355,
                "end": 383,
                "text": "advanced Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 387,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 402,
                "end": 410,
                "text": "levodopa",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05589805",
        "study_official_title": "Comparison of the Effectiveness of Low-intensity Laser and ESWT Treatments in Carpal Tunnel Syndrome ",
        "study_brief_summary": " Carpal tunnel syndrome is the most common neuropathy of the median nerve. Conservative methods are used in mild and moderate CTS in the treatment. In this study, we aimed to compare the effectiveness of low-intensity laser and ESWT treatments in patients with mild and moderate carpal tunnel syndrome diagnosed with EMG.",
        "text": "Comparison of the Effectiveness of Low-intensity Laser and ESWT Treatments in Carpal Tunnel Syndrome | Carpal tunnel syndrome is the most common neuropathy of the median nerve. Conservative methods are used in mild and moderate CTS in the treatment. In this study, we aimed to compare the effectiveness of low-intensity laser and ESWT treatments in patients with mild and moderate carpal tunnel syndrome diagnosed with EMG.",
        "tokens": "['Comparison', 'of', 'the', 'Effectiveness', 'of', 'Low', '-', 'intensity', 'Laser', 'and', 'ESWT', 'Treatments', 'in', 'Carpal', 'Tunnel', 'Syndrome', '|', 'Carpal', 'tunnel', 'syndrome', 'is', 'the', 'most', 'common', 'neuropathy', 'of', 'the', 'median', 'nerve', '.', 'Conservative', 'methods', 'are', 'used', 'in', 'mild', 'and', 'moderate', 'CTS', 'in', 'the', 'treatment', '.', 'In', 'this', 'study', ',', 'we', 'aimed', 'to', 'compare', 'the', 'effectiveness', 'of', 'low', '-', 'intensity', 'laser', 'and', 'ESWT', 'treatments', 'in', 'patients', 'with', 'mild', 'and', 'moderate', 'carpal', 'tunnel', 'syndrome', 'diagnosed', 'with', 'EMG', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 54,
                "text": "Low-intensity Laser",
                "type": "OTHER"
            },
            {
                "start": 59,
                "end": 63,
                "text": "ESWT",
                "type": "OTHER"
            },
            {
                "start": 78,
                "end": 100,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 125,
                "text": "Carpal tunnel syndrome",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 231,
                "text": "mild and moderate CTS",
                "type": "CONDITION"
            },
            {
                "start": 306,
                "end": 325,
                "text": "low-intensity laser",
                "type": "OTHER"
            },
            {
                "start": 330,
                "end": 334,
                "text": "ESWT",
                "type": "OTHER"
            },
            {
                "start": 363,
                "end": 403,
                "text": "mild and moderate carpal tunnel syndrome",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03696381",
        "study_official_title": "Clinical Trial of The Boosting Effect of Transcranial Random Noise Stimulation (tRNS) in Cognitive Rehabilitation of Patients With Traumatic Brain Injury ",
        "study_brief_summary": " The main objective of this study is to evaluate the effects of tRNS while undergoing computerized cognitive rehabilitation therapy to conclude if this combination of therapies would be effective for the cognitive rehabilitation of patients with acquired brain damage, such as traumatic brain injury. We want to study the therapeutic potential of tRNS to enhance the therapeutic outcome of cognitive training, studying its global effect over the rehabilitation of attention, memory and executive functions, compared to sham tRNS.",
        "text": "Clinical Trial of The Boosting Effect of Transcranial Random Noise Stimulation (tRNS) in Cognitive Rehabilitation of Patients With Traumatic Brain Injury | The main objective of this study is to evaluate the effects of tRNS while undergoing computerized cognitive rehabilitation therapy to conclude if this combination of therapies would be effective for the cognitive rehabilitation of patients with acquired brain damage, such as traumatic brain injury. We want to study the therapeutic potential of tRNS to enhance the therapeutic outcome of cognitive training, studying its global effect over the rehabilitation of attention, memory and executive functions, compared to sham tRNS.",
        "tokens": "['Clinical', 'Trial', 'of', 'The', 'Boosting', 'Effect', 'of', 'Transcranial', 'Random', 'Noise', 'Stimulation', '(', 'tRNS', ')', 'in', 'Cognitive', 'Rehabilitation', 'of', 'Patients', 'With', 'Traumatic', 'Brain', 'Injury', '|', 'The', 'main', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'of', 'tRNS', 'while', 'undergoing', 'computerized', 'cognitive', 'rehabilitation', 'therapy', 'to', 'conclude', 'if', 'this', 'combination', 'of', 'therapies', 'would', 'be', 'effective', 'for', 'the', 'cognitive', 'rehabilitation', 'of', 'patients', 'with', 'acquired', 'brain', 'damage', ',', 'such', 'as', 'traumatic', 'brain', 'injury', '.', 'We', 'want', 'to', 'study', 'the', 'therapeutic', 'potential', 'of', 'tRNS', 'to', 'enhance', 'the', 'therapeutic', 'outcome', 'of', 'cognitive', 'training', ',', 'studying', 'its', 'global', 'effect', 'over', 'the', 'rehabilitation', 'of', 'attention', ',', 'memory', 'and', 'executive', 'functions', ',', 'compared', 'to', 'sham', 'tRNS', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 78,
                "text": "Transcranial Random Noise Stimulation",
                "type": "OTHER"
            },
            {
                "start": 80,
                "end": 84,
                "text": "tRNS",
                "type": "OTHER"
            },
            {
                "start": 89,
                "end": 113,
                "text": "Cognitive Rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 131,
                "end": 153,
                "text": "Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 219,
                "end": 223,
                "text": "tRNS",
                "type": "OTHER"
            },
            {
                "start": 241,
                "end": 286,
                "text": "computerized cognitive rehabilitation therapy",
                "type": "OTHER"
            },
            {
                "start": 359,
                "end": 383,
                "text": "cognitive rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 401,
                "end": 422,
                "text": "acquired brain damage",
                "type": "CONDITION"
            },
            {
                "start": 432,
                "end": 454,
                "text": "traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 502,
                "end": 506,
                "text": "tRNS",
                "type": "OTHER"
            },
            {
                "start": 545,
                "end": 563,
                "text": "cognitive training",
                "type": "OTHER"
            },
            {
                "start": 674,
                "end": 683,
                "text": "sham tRNS",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04424810",
        "study_official_title": "Effect of High-quality Pre-operative Videos on Patient Anxiety Levels Prior to Ambulatory Hand Surgery ",
        "study_brief_summary": " Previous research has shown that YouTube is a poor source of high-quality medical information. This is likely because there is no regulation of the content on YouTube and relatively little of the content is posted by qualified medical professionals. It is known that up to 30% of patients use the internet to research the procedure they will be having and given the increasing popularity of YouTube we suspect many patients are using YouTube or similar sites as a source of information prior to elective surgery. There are likely a number of patient factors that contribute to patients seeking out videos as a source of pre-operative medical information. Patient age, which is generally inversely correlated to computer literacy, may have a role. Patient anxiety and pre-operative worrying may cause a patient to turn to the internet to search for information, and the poor overall quality of the content available may worsen pre-operative anxiety.\n\nThe primary objective of this study is to determine if providing patients with a reliable, high-quality video about their condition and operation prior to surgery reduces pre-operative anxiety. Secondary aims are to determine the percentage of patients that independently seek out videos online as a source of medical information prior to elective hand surgery, identify patient attributes that are associated with this behavior, and understand if introducing high quality pre-surgical videos has an impact on post-operative patient outcomes and/or patient engagement. The investigators hypothesize that providing patients with high-quality pre-operative videos will reduce pre-operative anxiety. Its is also expected that patients who seek out videos on their own for pre-operative medical information will be younger and have higher anxiety levels and pain catastrophizing scores. Additionally, the investigators hypothesize that patients who watch high-quality pre-operative videos may have better short term post-operative outcomes and greater engagement in their care than their counterparts that did not watch videos or who sought out videos on their own.",
        "text": "Effect of High-quality Pre-operative Videos on Patient Anxiety Levels Prior to Ambulatory Hand Surgery | Previous research has shown that YouTube is a poor source of high-quality medical information. This is likely because there is no regulation of the content on YouTube and relatively little of the content is posted by qualified medical professionals. It is known that up to 30% of patients use the internet to research the procedure they will be having and given the increasing popularity of YouTube we suspect many patients are using YouTube or similar sites as a source of information prior to elective surgery. There are likely a number of patient factors that contribute to patients seeking out videos as a source of pre-operative medical information. Patient age, which is generally inversely correlated to computer literacy, may have a role. Patient anxiety and pre-operative worrying may cause a patient to turn to the internet to search for information, and the poor overall quality of the content available may worsen pre-operative anxiety.\n\nThe primary objective of this study is to determine if providing patients with a reliable, high-quality video about their condition and operation prior to surgery reduces pre-operative anxiety. Secondary aims are to determine the percentage of patients that independently seek out videos online as a source of medical information prior to elective hand surgery, identify patient attributes that are associated with this behavior, and understand if introducing high quality pre-surgical videos has an impact on post-operative patient outcomes and/or patient engagement. The investigators hypothesize that providing patients with high-quality pre-operative videos will reduce pre-operative anxiety. Its is also expected that patients who seek out videos on their own for pre-operative medical information will be younger and have higher anxiety levels and pain catastrophizing scores. Additionally, the investigators hypothesize that patients who watch high-quality pre-operative videos may have better short term post-operative outcomes and greater engagement in their care than their counterparts that did not watch videos or who sought out videos on their own.",
        "tokens": "['Effect', 'of', 'High', '-', 'quality', 'Pre', '-', 'operative', 'Videos', 'on', 'Patient', 'Anxiety', 'Levels', 'Prior', 'to', 'Ambulatory', 'Hand', 'Surgery', '|', 'Previous', 'research', 'has', 'shown', 'that', 'YouTube', 'is', 'a', 'poor', 'source', 'of', 'high', '-', 'quality', 'medical', 'information', '.', 'This', 'is', 'likely', 'because', 'there', 'is', 'no', 'regulation', 'of', 'the', 'content', 'on', 'YouTube', 'and', 'relatively', 'little', 'of', 'the', 'content', 'is', 'posted', 'by', 'qualified', 'medical', 'professionals', '.', 'It', 'is', 'known', 'that', 'up', 'to', '30', '%', 'of', 'patients', 'use', 'the', 'internet', 'to', 'research', 'the', 'procedure', 'they', 'will', 'be', 'having', 'and', 'given', 'the', 'increasing', 'popularity', 'of', 'YouTube', 'we', 'suspect', 'many', 'patients', 'are', 'using', 'YouTube', 'or', 'similar', 'sites', 'as', 'a', 'source', 'of', 'information', 'prior', 'to', 'elective', 'surgery', '.', 'There', 'are', 'likely', 'a', 'number', 'of', 'patient', 'factors', 'that', 'contribute', 'to', 'patients', 'seeking', 'out', 'videos', 'as', 'a', 'source', 'of', 'pre', '-', 'operative', 'medical', 'information', '.', 'Patient', 'age', ',', 'which', 'is', 'generally', 'inversely', 'correlated', 'to', 'computer', 'literacy', ',', 'may', 'have', 'a', 'role', '.', 'Patient', 'anxiety', 'and', 'pre', '-', 'operative', 'worrying', 'may', 'cause', 'a', 'patient', 'to', 'turn', 'to', 'the', 'internet', 'to', 'search', 'for', 'information', ',', 'and', 'the', 'poor', 'overall', 'quality', 'of', 'the', 'content', 'available', 'may', 'worsen', 'pre', '-', 'operative', 'anxiety', '.', '\\n\\n', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'providing', 'patients', 'with', 'a', 'reliable', ',', 'high', '-', 'quality', 'video', 'about', 'their', 'condition', 'and', 'operation', 'prior', 'to', 'surgery', 'reduces', 'pre', '-', 'operative', 'anxiety', '.', 'Secondary', 'aims', 'are', 'to', 'determine', 'the', 'percentage', 'of', 'patients', 'that', 'independently', 'seek', 'out', 'videos', 'online', 'as', 'a', 'source', 'of', 'medical', 'information', 'prior', 'to', 'elective', 'hand', 'surgery', ',', 'identify', 'patient', 'attributes', 'that', 'are', 'associated', 'with', 'this', 'behavior', ',', 'and', 'understand', 'if', 'introducing', 'high', 'quality', 'pre', '-', 'surgical', 'videos', 'has', 'an', 'impact', 'on', 'post', '-', 'operative', 'patient', 'outcomes', 'and/or', 'patient', 'engagement', '.', 'The', 'investigators', 'hypothesize', 'that', 'providing', 'patients', 'with', 'high', '-', 'quality', 'pre', '-', 'operative', 'videos', 'will', 'reduce', 'pre', '-', 'operative', 'anxiety', '.', 'Its', 'is', 'also', 'expected', 'that', 'patients', 'who', 'seek', 'out', 'videos', 'on', 'their', 'own', 'for', 'pre', '-', 'operative', 'medical', 'information', 'will', 'be', 'younger', 'and', 'have', 'higher', 'anxiety', 'levels', 'and', 'pain', 'catastrophizing', 'scores', '.', 'Additionally', ',', 'the', 'investigators', 'hypothesize', 'that', 'patients', 'who', 'watch', 'high', '-', 'quality', 'pre', '-', 'operative', 'videos', 'may', 'have', 'better', 'short', 'term', 'post', '-', 'operative', 'outcomes', 'and', 'greater', 'engagement', 'in', 'their', 'care', 'than', 'their', 'counterparts', 'that', 'did', 'not', 'watch', 'videos', 'or', 'who', 'sought', 'out', 'videos', 'on', 'their', 'own', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 43,
                "text": "High-quality Pre-operative Videos",
                "type": "OTHER"
            },
            {
                "start": 55,
                "end": 62,
                "text": "Anxiety",
                "type": "CONDITION"
            },
            {
                "start": 90,
                "end": 102,
                "text": "Hand Surgery",
                "type": "CONDITION"
            },
            {
                "start": 860,
                "end": 867,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 1045,
                "end": 1052,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 1136,
                "end": 1164,
                "text": "reliable, high-quality video",
                "type": "OTHER"
            },
            {
                "start": 1240,
                "end": 1247,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 1515,
                "end": 1547,
                "text": "high quality pre-surgical videos",
                "type": "OTHER"
            },
            {
                "start": 1683,
                "end": 1716,
                "text": "high-quality pre-operative videos",
                "type": "OTHER"
            },
            {
                "start": 1743,
                "end": 1750,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 1890,
                "end": 1897,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 2006,
                "end": 2039,
                "text": "high-quality pre-operative videos",
                "type": "OTHER"
            },
            {
                "start": 2161,
                "end": 2177,
                "text": "not watch videos",
                "type": "CONTROL"
            },
            {
                "start": 2196,
                "end": 2215,
                "text": "videos on their own",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03916029",
        "study_official_title": "The Hearing for Learning Initiative - a Service-enhancement Model of Ear Health Facilitators to Address the Crisis in Ear and Hearing Health of Aboriginal Children in the Northern Territory: a Stepped-wedge Cluster Randomised Trial ",
        "study_brief_summary": " The Hearing for Learning Initiative is a stepped-wedge cluster randomised controlled trial. The HfLI will implement and rigorously evaluate an innovative community-based service-enhancement model of ear and hearing health, in partnership with participating communities and health and education services.\n\nThis initiative will address the following research question: In urban, rural and remote Aboriginal communities in the Northern Territory, does employment, training and integration of local Ear and Hearing Clinical and Education Support Officers into health and education services (the Hearing for Learning initiative), compared to current practice, increase the proportion of children who receive an ear assessment, reduce the prevalence of ear and hearing problems and improve education outcomes of Aboriginal and Torres Strait Islander children, during a four year trial period?",
        "text": "The Hearing for Learning Initiative - a Service-enhancement Model of Ear Health Facilitators to Address the Crisis in Ear and Hearing Health of Aboriginal Children in the Northern Territory: a Stepped-wedge Cluster Randomised Trial | The Hearing for Learning Initiative is a stepped-wedge cluster randomised controlled trial. The HfLI will implement and rigorously evaluate an innovative community-based service-enhancement model of ear and hearing health, in partnership with participating communities and health and education services.\n\nThis initiative will address the following research question: In urban, rural and remote Aboriginal communities in the Northern Territory, does employment, training and integration of local Ear and Hearing Clinical and Education Support Officers into health and education services (the Hearing for Learning initiative), compared to current practice, increase the proportion of children who receive an ear assessment, reduce the prevalence of ear and hearing problems and improve education outcomes of Aboriginal and Torres Strait Islander children, during a four year trial period?",
        "tokens": "['The', 'Hearing', 'for', 'Learning', 'Initiative', '-', 'a', 'Service', '-', 'enhancement', 'Model', 'of', 'Ear', 'Health', 'Facilitators', 'to', 'Address', 'the', 'Crisis', 'in', 'Ear', 'and', 'Hearing', 'Health', 'of', 'Aboriginal', 'Children', 'in', 'the', 'Northern', 'Territory', ':', 'a', 'Stepped', '-', 'wedge', 'Cluster', 'Randomised', 'Trial', '|', 'The', 'Hearing', 'for', 'Learning', 'Initiative', 'is', 'a', 'stepped', '-', 'wedge', 'cluster', 'randomised', 'controlled', 'trial', '.', 'The', 'HfLI', 'will', 'implement', 'and', 'rigorously', 'evaluate', 'an', 'innovative', 'community', '-', 'based', 'service', '-', 'enhancement', 'model', 'of', 'ear', 'and', 'hearing', 'health', ',', 'in', 'partnership', 'with', 'participating', 'communities', 'and', 'health', 'and', 'education', 'services', '.', '\\n\\n', 'This', 'initiative', 'will', 'address', 'the', 'following', 'research', 'question', ':', 'In', 'urban', ',', 'rural', 'and', 'remote', 'Aboriginal', 'communities', 'in', 'the', 'Northern', 'Territory', ',', 'does', 'employment', ',', 'training', 'and', 'integration', 'of', 'local', 'Ear', 'and', 'Hearing', 'Clinical', 'and', 'Education', 'Support', 'Officers', 'into', 'health', 'and', 'education', 'services', '(', 'the', 'Hearing', 'for', 'Learning', 'initiative', ')', ',', 'compared', 'to', 'current', 'practice', ',', 'increase', 'the', 'proportion', 'of', 'children', 'who', 'receive', 'an', 'ear', 'assessment', ',', 'reduce', 'the', 'prevalence', 'of', 'ear', 'and', 'hearing', 'problems', 'and', 'improve', 'education', 'outcomes', 'of', 'Aboriginal', 'and', 'Torres', 'Strait', 'Islander', 'children', ',', 'during', 'a', 'four', 'year', 'trial', 'period', '?']",
        "token_bio_labels": "['O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 4,
                "end": 35,
                "text": "Hearing for Learning Initiative",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 40,
                "end": 92,
                "text": "Service-enhancement Model of Ear Health Facilitators",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 238,
                "end": 269,
                "text": "Hearing for Learning Initiative",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 330,
                "end": 334,
                "text": "HfLI",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 388,
                "end": 455,
                "text": "community-based service-enhancement model of ear and hearing health",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 729,
                "end": 784,
                "text": "Ear and Hearing Clinical and Education Support Officers",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 871,
                "end": 887,
                "text": "current practice",
                "type": "CONTROL"
            },
            {
                "start": 981,
                "end": 1005,
                "text": "ear and hearing problems",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04329247",
        "study_official_title": "Physical Therapy Versus Control in the Treatment of Carpal Tunnel Syndrome ",
        "study_brief_summary": " In the present investigation the pain reduction effects of a physical therapy technique will be compared to those produced by the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.",
        "text": "Physical Therapy Versus Control in the Treatment of Carpal Tunnel Syndrome | In the present investigation the pain reduction effects of a physical therapy technique will be compared to those produced by the absence of treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.",
        "tokens": "['Physical', 'Therapy', 'Versus', 'Control', 'in', 'the', 'Treatment', 'of', 'Carpal', 'Tunnel', 'Syndrome', '|', 'In', 'the', 'present', 'investigation', 'the', 'pain', 'reduction', 'effects', 'of', 'a', 'physical', 'therapy', 'technique', 'will', 'be', 'compared', 'to', 'those', 'produced', 'by', 'the', 'absence', 'of', 'treatment', ',', 'in', 'subjects', 'who', 'suffer', 'the', 'signs', 'and', 'symptoms', 'of', 'carpal', 'tunnel', 'syndrome', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 16,
                "text": "Physical Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 52,
                "end": 74,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 110,
                "end": 114,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 154,
                "text": "physical therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 207,
                "end": 227,
                "text": "absence of treatment",
                "type": "CONTROL"
            },
            {
                "start": 278,
                "end": 300,
                "text": "carpal tunnel syndrome",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01990313",
        "study_official_title": "Neural Signatures of Tremor, Bradykinesia and Freezing in the Subthalamic Region on Parkinson's Disease and Their Acute and Long-Term Modulation by Subthalamic Deep Brain Stimulation. ",
        "study_brief_summary": " The purpose of this study is to provide objective measurements of abnormal movements of the body in correlation with neural activity of the brain and track how these change over time. This may allow for the development of objective evaluation of the neural activity causing abnormal movements, which may lead to the ability of the DBS system to stimulate the brain by sensing the abnormal neural activity that is causing abnormal movements.",
        "text": "Neural Signatures of Tremor, Bradykinesia and Freezing in the Subthalamic Region on Parkinson's Disease and Their Acute and Long-Term Modulation by Subthalamic Deep Brain Stimulation. | The purpose of this study is to provide objective measurements of abnormal movements of the body in correlation with neural activity of the brain and track how these change over time. This may allow for the development of objective evaluation of the neural activity causing abnormal movements, which may lead to the ability of the DBS system to stimulate the brain by sensing the abnormal neural activity that is causing abnormal movements.",
        "tokens": "['Neural', 'Signatures', 'of', 'Tremor', ',', 'Bradykinesia', 'and', 'Freezing', 'in', 'the', 'Subthalamic', 'Region', 'on', 'Parkinson', \"'s\", 'Disease', 'and', 'Their', 'Acute', 'and', 'Long', '-', 'Term', 'Modulation', 'by', 'Subthalamic', 'Deep', 'Brain', 'Stimulation', '.', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'provide', 'objective', 'measurements', 'of', 'abnormal', 'movements', 'of', 'the', 'body', 'in', 'correlation', 'with', 'neural', 'activity', 'of', 'the', 'brain', 'and', 'track', 'how', 'these', 'change', 'over', 'time', '.', 'This', 'may', 'allow', 'for', 'the', 'development', 'of', 'objective', 'evaluation', 'of', 'the', 'neural', 'activity', 'causing', 'abnormal', 'movements', ',', 'which', 'may', 'lead', 'to', 'the', 'ability', 'of', 'the', 'DBS', 'system', 'to', 'stimulate', 'the', 'brain', 'by', 'sensing', 'the', 'abnormal', 'neural', 'activity', 'that', 'is', 'causing', 'abnormal', 'movements', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 27,
                "text": "Tremor",
                "type": "CONDITION"
            },
            {
                "start": 29,
                "end": 41,
                "text": "Bradykinesia",
                "type": "CONDITION"
            },
            {
                "start": 46,
                "end": 80,
                "text": "Freezing in the Subthalamic Region",
                "type": "CONDITION"
            },
            {
                "start": 84,
                "end": 103,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 160,
                "end": 182,
                "text": "Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 517,
                "end": 520,
                "text": "DBS",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00506259",
        "study_official_title": "A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS) ",
        "study_brief_summary": " This study will examine the effect of bright light or melatonin treatment on sleep in children with Smith-Magenis syndrome (SMS), a genetic disorder characterized by certain physical, behavioral and developmental features. Patients have a disrupted sleep cycle involving early waking, frequent daytime napping and frequent nighttime awakenings. Melatonin is a hormone normally produced at night in healthy people. People with SMS produce high levels of melatonin during the daytime and very low levels at night. This may affect their behavior, mood, attention span and sleep patterns.\n\nHealthy volunteers between 18 and 45 years of age and children with SMS who are between 3 and 16 years of age may be eligible for this study.\n\nHealthy subjects are admitted to the NIH Clinical Center overnight. In the morning they take one dose of time-release melatonin and have blood and saliva samples collected hourly from 7:00 AM to 6:00 PM.\n\nChildren with SMS participate in a 2-part study, as follows:\n\nPart 1 Inpatient Trial\n\nPre-trial at-home phase: During the month before NIH inpatient admission, participants do the following:\n\nWear an actiwatch device or keep a daily sleep diary to monitor daytime alertness, mood shifts and sleep patterns.\nComplete a behavior assessment survey related to the child s behaviors and sleep patterns.\nObtain frequent body temperature measurements.\nCollect several saliva samples over a 24-hour period.\n\nNIH admission phase:\n\nChildren are admitted to the NIH Clinical Center for 2-3 nights for bright light treatment. They remain in their rooms for alternating periods of exposure to standard dim room light and bright light, using a light box placed within 3 to 5 feet of the child. An electroencephalogram (EEG) with additional electrodes to track eye movements is used to monitor the child s attention. Between 8AM and 6PM serial blood samples are collected to measure melatonin levels. A parent rates the child s mood and behavior during the 2-day test period.\nChildren are admitted to the NIH Clinical Center for 2-3 nights for melatonin treatment. They take a single dose of melatonin or placebo tablet at bedtime. During the daytime, EEG electrodes are placed to track eye movements. Between 7 PM and 7 AM serial blood samples are collected to measure melatonin levels. A parent rates the child s behavior and mood as described for the bright light study.\nChildren may receive either or both of the bright light and melatonin treatments.\n\nPart 2 Outpatient Trial\n\nChildren participate in a combined bright light with melatonin trial at home. They undergo the same procedures outlined in the pre-trial at-home phase of Part 1 (actiwatch, behavior assessments, body temperature measurements, saliva samples) over an 11-week period. If saliva samples cannot be collected for melatonin testing, 24-hour urine samples may be collected instead.",
        "text": "A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS) | This study will examine the effect of bright light or melatonin treatment on sleep in children with Smith-Magenis syndrome (SMS), a genetic disorder characterized by certain physical, behavioral and developmental features. Patients have a disrupted sleep cycle involving early waking, frequent daytime napping and frequent nighttime awakenings. Melatonin is a hormone normally produced at night in healthy people. People with SMS produce high levels of melatonin during the daytime and very low levels at night. This may affect their behavior, mood, attention span and sleep patterns.\n\nHealthy volunteers between 18 and 45 years of age and children with SMS who are between 3 and 16 years of age may be eligible for this study.\n\nHealthy subjects are admitted to the NIH Clinical Center overnight. In the morning they take one dose of time-release melatonin and have blood and saliva samples collected hourly from 7:00 AM to 6:00 PM.\n\nChildren with SMS participate in a 2-part study, as follows:\n\nPart 1 Inpatient Trial\n\nPre-trial at-home phase: During the month before NIH inpatient admission, participants do the following:\n\nWear an actiwatch device or keep a daily sleep diary to monitor daytime alertness, mood shifts and sleep patterns.\nComplete a behavior assessment survey related to the child s behaviors and sleep patterns.\nObtain frequent body temperature measurements.\nCollect several saliva samples over a 24-hour period.\n\nNIH admission phase:\n\nChildren are admitted to the NIH Clinical Center for 2-3 nights for bright light treatment. They remain in their rooms for alternating periods of exposure to standard dim room light and bright light, using a light box placed within 3 to 5 feet of the child. An electroencephalogram (EEG) with additional electrodes to track eye movements is used to monitor the child s attention. Between 8AM and 6PM serial blood samples are collected to measure melatonin levels. A parent rates the child s mood and behavior during the 2-day test period.\nChildren are admitted to the NIH Clinical Center for 2-3 nights for melatonin treatment. They take a single dose of melatonin or placebo tablet at bedtime. During the daytime, EEG electrodes are placed to track eye movements. Between 7 PM and 7 AM serial blood samples are collected to measure melatonin levels. A parent rates the child s behavior and mood as described for the bright light study.\nChildren may receive either or both of the bright light and melatonin treatments.\n\nPart 2 Outpatient Trial\n\nChildren participate in a combined bright light with melatonin trial at home. They undergo the same procedures outlined in the pre-trial at-home phase of Part 1 (actiwatch, behavior assessments, body temperature measurements, saliva samples) over an 11-week period. If saliva samples cannot be collected for melatonin testing, 24-hour urine samples may be collected instead.",
        "tokens": "['A', 'Phase', 'One', 'Treatment', 'Trial', 'of', 'the', 'Circadian', 'Sleep', 'Disturbance', 'in', 'Smith', '-', 'Magenis', 'Syndrome', '(', 'SMS', ')', '|', 'This', 'study', 'will', 'examine', 'the', 'effect', 'of', 'bright', 'light', 'or', 'melatonin', 'treatment', 'on', 'sleep', 'in', 'children', 'with', 'Smith', '-', 'Magenis', 'syndrome', '(', 'SMS', ')', ',', 'a', 'genetic', 'disorder', 'characterized', 'by', 'certain', 'physical', ',', 'behavioral', 'and', 'developmental', 'features', '.', 'Patients', 'have', 'a', 'disrupted', 'sleep', 'cycle', 'involving', 'early', 'waking', ',', 'frequent', 'daytime', 'napping', 'and', 'frequent', 'nighttime', 'awakenings', '.', 'Melatonin', 'is', 'a', 'hormone', 'normally', 'produced', 'at', 'night', 'in', 'healthy', 'people', '.', 'People', 'with', 'SMS', 'produce', 'high', 'levels', 'of', 'melatonin', 'during', 'the', 'daytime', 'and', 'very', 'low', 'levels', 'at', 'night', '.', 'This', 'may', 'affect', 'their', 'behavior', ',', 'mood', ',', 'attention', 'span', 'and', 'sleep', 'patterns', '.', '\\n\\n', 'Healthy', 'volunteers', 'between', '18', 'and', '45', 'years', 'of', 'age', 'and', 'children', 'with', 'SMS', 'who', 'are', 'between', '3', 'and', '16', 'years', 'of', 'age', 'may', 'be', 'eligible', 'for', 'this', 'study', '.', '\\n\\n', 'Healthy', 'subjects', 'are', 'admitted', 'to', 'the', 'NIH', 'Clinical', 'Center', 'overnight', '.', 'In', 'the', 'morning', 'they', 'take', 'one', 'dose', 'of', 'time', '-', 'release', 'melatonin', 'and', 'have', 'blood', 'and', 'saliva', 'samples', 'collected', 'hourly', 'from', '7:00', 'AM', 'to', '6:00', 'PM', '.', '\\n\\n', 'Children', 'with', 'SMS', 'participate', 'in', 'a', '2', '-', 'part', 'study', ',', 'as', 'follows', ':', '\\n\\n', 'Part', '1', 'Inpatient', 'Trial', '\\n\\n', 'Pre', '-', 'trial', 'at', '-', 'home', 'phase', ':', 'During', 'the', 'month', 'before', 'NIH', 'inpatient', 'admission', ',', 'participants', 'do', 'the', 'following', ':', '\\n\\n', 'Wear', 'an', 'actiwatch', 'device', 'or', 'keep', 'a', 'daily', 'sleep', 'diary', 'to', 'monitor', 'daytime', 'alertness', ',', 'mood', 'shifts', 'and', 'sleep', 'patterns', '.', '\\n', 'Complete', 'a', 'behavior', 'assessment', 'survey', 'related', 'to', 'the', 'child', 's', 'behaviors', 'and', 'sleep', 'patterns', '.', '\\n', 'Obtain', 'frequent', 'body', 'temperature', 'measurements', '.', '\\n', 'Collect', 'several', 'saliva', 'samples', 'over', 'a', '24', '-', 'hour', 'period', '.', '\\n\\n', 'NIH', 'admission', 'phase', ':', '\\n\\n', 'Children', 'are', 'admitted', 'to', 'the', 'NIH', 'Clinical', 'Center', 'for', '2', '-', '3', 'nights', 'for', 'bright', 'light', 'treatment', '.', 'They', 'remain', 'in', 'their', 'rooms', 'for', 'alternating', 'periods', 'of', 'exposure', 'to', 'standard', 'dim', 'room', 'light', 'and', 'bright', 'light', ',', 'using', 'a', 'light', 'box', 'placed', 'within', '3', 'to', '5', 'feet', 'of', 'the', 'child', '.', 'An', 'electroencephalogram', '(', 'EEG', ')', 'with', 'additional', 'electrodes', 'to', 'track', 'eye', 'movements', 'is', 'used', 'to', 'monitor', 'the', 'child', 's', 'attention', '.', 'Between', '8AM', 'and', '6PM', 'serial', 'blood', 'samples', 'are', 'collected', 'to', 'measure', 'melatonin', 'levels', '.', 'A', 'parent', 'rates', 'the', 'child', 's', 'mood', 'and', 'behavior', 'during', 'the', '2', '-', 'day', 'test', 'period', '.', '\\n', 'Children', 'are', 'admitted', 'to', 'the', 'NIH', 'Clinical', 'Center', 'for', '2', '-', '3', 'nights', 'for', 'melatonin', 'treatment', '.', 'They', 'take', 'a', 'single', 'dose', 'of', 'melatonin', 'or', 'placebo', 'tablet', 'at', 'bedtime', '.', 'During', 'the', 'daytime', ',', 'EEG', 'electrodes', 'are', 'placed', 'to', 'track', 'eye', 'movements', '.', 'Between', '7', 'PM', 'and', '7', 'AM', 'serial', 'blood', 'samples', 'are', 'collected', 'to', 'measure', 'melatonin', 'levels', '.', 'A', 'parent', 'rates', 'the', 'child', 's', 'behavior', 'and', 'mood', 'as', 'described', 'for', 'the', 'bright', 'light', 'study', '.', '\\n', 'Children', 'may', 'receive', 'either', 'or', 'both', 'of', 'the', 'bright', 'light', 'and', 'melatonin', 'treatments', '.', '\\n\\n', 'Part', '2', 'Outpatient', 'Trial', '\\n\\n', 'Children', 'participate', 'in', 'a', 'combined', 'bright', 'light', 'with', 'melatonin', 'trial', 'at', 'home', '.', 'They', 'undergo', 'the', 'same', 'procedures', 'outlined', 'in', 'the', 'pre', '-', 'trial', 'at', '-', 'home', 'phase', 'of', 'Part', '1', '(', 'actiwatch', ',', 'behavior', 'assessments', ',', 'body', 'temperature', 'measurements', ',', 'saliva', 'samples', ')', 'over', 'an', '11', '-', 'week', 'period', '.', 'If', 'saliva', 'samples', 'can', 'not', 'be', 'collected', 'for', 'melatonin', 'testing', ',', '24', '-', 'hour', 'urine', 'samples', 'may', 'be', 'collected', 'instead', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 62,
                "text": "Circadian Sleep Disturbance",
                "type": "CONDITION"
            },
            {
                "start": 66,
                "end": 88,
                "text": "Smith-Magenis Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 90,
                "end": 93,
                "text": "SMS",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 147,
                "text": "bright light",
                "type": "OTHER"
            },
            {
                "start": 151,
                "end": 160,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 197,
                "end": 219,
                "text": "Smith-Magenis syndrome",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 224,
                "text": "SMS",
                "type": "CONDITION"
            },
            {
                "start": 336,
                "end": 357,
                "text": "disrupted sleep cycle",
                "type": "CONDITION"
            },
            {
                "start": 442,
                "end": 451,
                "text": "Melatonin",
                "type": "DRUG"
            },
            {
                "start": 523,
                "end": 526,
                "text": "SMS",
                "type": "CONDITION"
            },
            {
                "start": 550,
                "end": 559,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 751,
                "end": 754,
                "text": "SMS",
                "type": "CONDITION"
            },
            {
                "start": 944,
                "end": 953,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 1045,
                "end": 1048,
                "text": "SMS",
                "type": "CONDITION"
            },
            {
                "start": 1621,
                "end": 1643,
                "text": "bright light treatment",
                "type": "OTHER"
            },
            {
                "start": 1739,
                "end": 1751,
                "text": "bright light",
                "type": "OTHER"
            },
            {
                "start": 1999,
                "end": 2008,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 2160,
                "end": 2169,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 2208,
                "end": 2217,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 2221,
                "end": 2228,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 2386,
                "end": 2395,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 2533,
                "end": 2545,
                "text": "bright light",
                "type": "OTHER"
            },
            {
                "start": 2550,
                "end": 2559,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 2633,
                "end": 2645,
                "text": "bright light",
                "type": "OTHER"
            },
            {
                "start": 2651,
                "end": 2660,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 2906,
                "end": 2915,
                "text": "melatonin",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00053937",
        "study_official_title": "Phase I Trial Of Pirfenidone In Children With Neurofibromatosis Type 1 And Plexiform Neurofibromas ",
        "study_brief_summary": " RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Pirfenidone may slow the growth or prevent further development of plexiform neurofibromas.\n\nPURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young patients who have neurofibromatosis type 1 and plexiform neurofibroma.",
        "text": "Phase I Trial Of Pirfenidone In Children With Neurofibromatosis Type 1 And Plexiform Neurofibromas | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Pirfenidone may slow the growth or prevent further development of plexiform neurofibromas.\n\nPURPOSE: Phase I trial to study the effectiveness of pirfenidone in treating young patients who have neurofibromatosis type 1 and plexiform neurofibroma.",
        "tokens": "['Phase', 'I', 'Trial', 'Of', 'Pirfenidone', 'In', 'Children', 'With', 'Neurofibromatosis', 'Type', '1', 'And', 'Plexiform', 'Neurofibromas', '|', 'RATIONALE', ':', 'Chemoprevention', 'therapy', 'is', 'the', 'use', 'of', 'certain', 'drugs', 'to', 'try', 'to', 'prevent', 'the', 'development', 'or', 'recurrence', 'of', 'cancer', '.', 'Pirfenidone', 'may', 'slow', 'the', 'growth', 'or', 'prevent', 'further', 'development', 'of', 'plexiform', 'neurofibromas', '.', '\\n\\n', 'PURPOSE', ':', 'Phase', 'I', 'trial', 'to', 'study', 'the', 'effectiveness', 'of', 'pirfenidone', 'in', 'treating', 'young', 'patients', 'who', 'have', 'neurofibromatosis', 'type', '1', 'and', 'plexiform', 'neurofibroma', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 28,
                "text": "Pirfenidone",
                "type": "DRUG"
            },
            {
                "start": 46,
                "end": 70,
                "text": "Neurofibromatosis Type 1",
                "type": "CONDITION"
            },
            {
                "start": 75,
                "end": 98,
                "text": "Plexiform Neurofibromas",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 234,
                "text": "Pirfenidone",
                "type": "DRUG"
            },
            {
                "start": 289,
                "end": 312,
                "text": "plexiform neurofibromas",
                "type": "CONDITION"
            },
            {
                "start": 368,
                "end": 379,
                "text": "pirfenidone",
                "type": "DRUG"
            },
            {
                "start": 416,
                "end": 440,
                "text": "neurofibromatosis type 1",
                "type": "CONDITION"
            },
            {
                "start": 445,
                "end": 467,
                "text": "plexiform neurofibroma",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02971462",
        "study_official_title": "The purpose of this study is to investigate whether remote ischemic conditioning(RIC) would reduce the stroke risk of patients with symptomatic vertebrobasilar lesion of atherosclerosis,then we would observe the haemodynamics and plasma biomarkers changes.",
        "study_brief_summary": null,
        "text": "The purpose of this study is to investigate whether remote ischemic conditioning(RIC) would reduce the stroke risk of patients with symptomatic vertebrobasilar lesion of atherosclerosis,then we would observe the haemodynamics and plasma biomarkers changes.",
        "tokens": "['The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'whether', 'remote', 'ischemic', 'conditioning(RIC', ')', 'would', 'reduce', 'the', 'stroke', 'risk', 'of', 'patients', 'with', 'symptomatic', 'vertebrobasilar', 'lesion', 'of', 'atherosclerosis', ',', 'then', 'we', 'would', 'observe', 'the', 'haemodynamics', 'and', 'plasma', 'biomarkers', 'changes', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 52,
                "end": 84,
                "text": "remote ischemic conditioning(RIC",
                "type": "OTHER"
            },
            {
                "start": 103,
                "end": 109,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 185,
                "text": "symptomatic vertebrobasilar lesion of atherosclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03195049",
        "study_official_title": "Complications of Exchange Transfusion in Neonates ",
        "study_brief_summary": " Exchange transfusion is effective and considered to be safe procedure ; however, it is not without risks. Complications have been reported and mortality rates vary from 0.5 to 3.3%. therefore ,the current recommendation for performing exchange transfusion are based on balance between the risks of encephalopathy and complications related to the procedure .",
        "text": "Complications of Exchange Transfusion in Neonates | Exchange transfusion is effective and considered to be safe procedure ; however, it is not without risks. Complications have been reported and mortality rates vary from 0.5 to 3.3%. therefore ,the current recommendation for performing exchange transfusion are based on balance between the risks of encephalopathy and complications related to the procedure .",
        "tokens": "['Complications', 'of', 'Exchange', 'Transfusion', 'in', 'Neonates', '|', 'Exchange', 'transfusion', 'is', 'effective', 'and', 'considered', 'to', 'be', 'safe', 'procedure', ';', 'however', ',', 'it', 'is', 'not', 'without', 'risks', '.', 'Complications', 'have', 'been', 'reported', 'and', 'mortality', 'rates', 'vary', 'from', '0.5', 'to', '3.3', '%', '.', 'therefore', ',', 'the', 'current', 'recommendation', 'for', 'performing', 'exchange', 'transfusion', 'are', 'based', 'on', 'balance', 'between', 'the', 'risks', 'of', 'encephalopathy', 'and', 'complications', 'related', 'to', 'the', 'procedure', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 37,
                "text": "Exchange Transfusion",
                "type": "OTHER"
            },
            {
                "start": 52,
                "end": 72,
                "text": "Exchange transfusion",
                "type": "OTHER"
            },
            {
                "start": 287,
                "end": 307,
                "text": "exchange transfusion",
                "type": "OTHER"
            },
            {
                "start": 350,
                "end": 364,
                "text": "encephalopathy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03729375",
        "study_official_title": "The Effect Of An Anesthetic Procedure On Post Operative Pain Management In Carpal Tunnel Release ",
        "study_brief_summary": " Carpal Tunnel Syndrome patients undergoing carpal tunnel release surgery performed by the PI will receive intra-operative injections of bupivacaine (Marcaine). Two groups of patients will be randomly selected and will receive either 10cc or 20cc of injection. Their post-operative pain scores and usage of post-operative pain medication will be recorded and analyzed.",
        "text": "The Effect Of An Anesthetic Procedure On Post Operative Pain Management In Carpal Tunnel Release | Carpal Tunnel Syndrome patients undergoing carpal tunnel release surgery performed by the PI will receive intra-operative injections of bupivacaine (Marcaine). Two groups of patients will be randomly selected and will receive either 10cc or 20cc of injection. Their post-operative pain scores and usage of post-operative pain medication will be recorded and analyzed.",
        "tokens": "['The', 'Effect', 'Of', 'An', 'Anesthetic', 'Procedure', 'On', 'Post', 'Operative', 'Pain', 'Management', 'In', 'Carpal', 'Tunnel', 'Release', '|', 'Carpal', 'Tunnel', 'Syndrome', 'patients', 'undergoing', 'carpal', 'tunnel', 'release', 'surgery', 'performed', 'by', 'the', 'PI', 'will', 'receive', 'intra', '-', 'operative', 'injections', 'of', 'bupivacaine', '(', 'Marcaine', ')', '.', 'Two', 'groups', 'of', 'patients', 'will', 'be', 'randomly', 'selected', 'and', 'will', 'receive', 'either', '10cc', 'or', '20cc', 'of', 'injection', '.', 'Their', 'post', '-', 'operative', 'pain', 'scores', 'and', 'usage', 'of', 'post', '-', 'operative', 'pain', 'medication', 'will', 'be', 'recorded', 'and', 'analyzed', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 60,
                "text": "Post Operative Pain",
                "type": "CONDITION"
            },
            {
                "start": 75,
                "end": 96,
                "text": "Carpal Tunnel Release",
                "type": "CONDITION"
            },
            {
                "start": 99,
                "end": 121,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 142,
                "end": 171,
                "text": "carpal tunnel release surgery",
                "type": "CONDITION"
            },
            {
                "start": 235,
                "end": 246,
                "text": "bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 248,
                "end": 256,
                "text": "Marcaine",
                "type": "DRUG"
            },
            {
                "start": 365,
                "end": 384,
                "text": "post-operative pain",
                "type": "CONDITION"
            },
            {
                "start": 405,
                "end": 424,
                "text": "post-operative pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02265029",
        "study_official_title": "Evaluation of Spa Therapy in the Treatment of Fibromyalgia : a Randomized, Controlled, Open Multicenter Study ",
        "study_brief_summary": " Fibromyalgia is a common health problem that causes widespread pain and tenderness (sensitive to touch). The pain and tenderness tend to come and go, and move about the body. There is no cure for fibromyalgia. Complementary and alternative therapy such as acupuncture, chiropractic and massage therapy, can be useful to manage fibromyalgia symptoms. Many of these treatments have not been well tested in patients with fibromyalgia. Fibromyalgia affect 3 to 4% of the general population and 14 % of patients with rheumatologic disease. Fibromyalgia is most common in women 90 % in many studies. It most often starts in middle adulthood. A chronic evolution occured for Fibromyalgic patients with a major alteration of quality of life.\n\nThermalgi is a randomized, multicentre, open label trial wich aims to evaluate the effects of spa therapy in rheumatologia on evolution of disability in daily life of patients with fibromyalgia.",
        "text": "Evaluation of Spa Therapy in the Treatment of Fibromyalgia : a Randomized, Controlled, Open Multicenter Study | Fibromyalgia is a common health problem that causes widespread pain and tenderness (sensitive to touch). The pain and tenderness tend to come and go, and move about the body. There is no cure for fibromyalgia. Complementary and alternative therapy such as acupuncture, chiropractic and massage therapy, can be useful to manage fibromyalgia symptoms. Many of these treatments have not been well tested in patients with fibromyalgia. Fibromyalgia affect 3 to 4% of the general population and 14 % of patients with rheumatologic disease. Fibromyalgia is most common in women 90 % in many studies. It most often starts in middle adulthood. A chronic evolution occured for Fibromyalgic patients with a major alteration of quality of life.\n\nThermalgi is a randomized, multicentre, open label trial wich aims to evaluate the effects of spa therapy in rheumatologia on evolution of disability in daily life of patients with fibromyalgia.",
        "tokens": "['Evaluation', 'of', 'Spa', 'Therapy', 'in', 'the', 'Treatment', 'of', 'Fibromyalgia', ':', 'a', 'Randomized', ',', 'Controlled', ',', 'Open', 'Multicenter', 'Study', '|', 'Fibromyalgia', 'is', 'a', 'common', 'health', 'problem', 'that', 'causes', 'widespread', 'pain', 'and', 'tenderness', '(', 'sensitive', 'to', 'touch', ')', '.', 'The', 'pain', 'and', 'tenderness', 'tend', 'to', 'come', 'and', 'go', ',', 'and', 'move', 'about', 'the', 'body', '.', 'There', 'is', 'no', 'cure', 'for', 'fibromyalgia', '.', 'Complementary', 'and', 'alternative', 'therapy', 'such', 'as', 'acupuncture', ',', 'chiropractic', 'and', 'massage', 'therapy', ',', 'can', 'be', 'useful', 'to', 'manage', 'fibromyalgia', 'symptoms', '.', 'Many', 'of', 'these', 'treatments', 'have', 'not', 'been', 'well', 'tested', 'in', 'patients', 'with', 'fibromyalgia', '.', 'Fibromyalgia', 'affect', '3', 'to', '4', '%', 'of', 'the', 'general', 'population', 'and', '14', '%', 'of', 'patients', 'with', 'rheumatologic', 'disease', '.', 'Fibromyalgia', 'is', 'most', 'common', 'in', 'women', '90', '%', 'in', 'many', 'studies', '.', 'It', 'most', 'often', 'starts', 'in', 'middle', 'adulthood', '.', 'A', 'chronic', 'evolution', 'occured', 'for', 'Fibromyalgic', 'patients', 'with', 'a', 'major', 'alteration', 'of', 'quality', 'of', 'life', '.', '\\n\\n', 'Thermalgi', 'is', 'a', 'randomized', ',', 'multicentre', ',', 'open', 'label', 'trial', 'wich', 'aims', 'to', 'evaluate', 'the', 'effects', 'of', 'spa', 'therapy', 'in', 'rheumatologia', 'on', 'evolution', 'of', 'disability', 'in', 'daily', 'life', 'of', 'patients', 'with', 'fibromyalgia', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 25,
                "text": "Spa Therapy",
                "type": "OTHER"
            },
            {
                "start": 46,
                "end": 58,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 112,
                "end": 124,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 179,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 194,
                "text": "tenderness",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 225,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 230,
                "end": 240,
                "text": "tenderness",
                "type": "CONDITION"
            },
            {
                "start": 308,
                "end": 320,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 368,
                "end": 379,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 381,
                "end": 393,
                "text": "chiropractic",
                "type": "OTHER"
            },
            {
                "start": 398,
                "end": 413,
                "text": "massage therapy",
                "type": "OTHER"
            },
            {
                "start": 439,
                "end": 451,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 530,
                "end": 542,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 544,
                "end": 556,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 624,
                "end": 645,
                "text": "rheumatologic disease",
                "type": "CONDITION"
            },
            {
                "start": 647,
                "end": 659,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 780,
                "end": 792,
                "text": "Fibromyalgic",
                "type": "CONDITION"
            },
            {
                "start": 941,
                "end": 952,
                "text": "spa therapy",
                "type": "OTHER"
            },
            {
                "start": 1028,
                "end": 1040,
                "text": "fibromyalgia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02408627",
        "study_official_title": "The goal of this project is the development of an EEG-cap (min. 21 electrodes) with user-friendly active dry electrodes that meets the expectations of the users regarding comfort and esthetics, without losing sight of the functional and technical demands for recording high quality EEG signals. The purpose is to use the EEG-cap to investigate clinical neurological disorders (e.g. epilepsy). The EEG-cap could also be used at home so that hospital admission in the EMU can be avoided for some patients and an increasing number of patients can be examined.\n\nPhase 3 of the Project will be divided into a Phase 3a and Phase 3b.\n\nPhase 3a of the project will comprise of an EEG-registration with the different types of electrodes in epilepsy patients with prominent interictal epileptiform discharges (IEDs) on EEG. For each epilepsy patient the EEG-recording with dry electrodes will be compared to the EEG-recordings with conventionally used wet electrodes (bridge and cup electrodes). Each EEG-recording will take approximately 10 minutes.\n\nMinimum 2 - maximum 10 epilepsy patients will be included.\n\nThere will be an visual and clinical evaluation of the EEG-signals (blinded) and a technical evaluation of the EEG-signals. User experience will also be collected.",
        "study_brief_summary": null,
        "text": "The goal of this project is the development of an EEG-cap (min. 21 electrodes) with user-friendly active dry electrodes that meets the expectations of the users regarding comfort and esthetics, without losing sight of the functional and technical demands for recording high quality EEG signals. The purpose is to use the EEG-cap to investigate clinical neurological disorders (e.g. epilepsy). The EEG-cap could also be used at home so that hospital admission in the EMU can be avoided for some patients and an increasing number of patients can be examined.\n\nPhase 3 of the Project will be divided into a Phase 3a and Phase 3b.\n\nPhase 3a of the project will comprise of an EEG-registration with the different types of electrodes in epilepsy patients with prominent interictal epileptiform discharges (IEDs) on EEG. For each epilepsy patient the EEG-recording with dry electrodes will be compared to the EEG-recordings with conventionally used wet electrodes (bridge and cup electrodes). Each EEG-recording will take approximately 10 minutes.\n\nMinimum 2 - maximum 10 epilepsy patients will be included.\n\nThere will be an visual and clinical evaluation of the EEG-signals (blinded) and a technical evaluation of the EEG-signals. User experience will also be collected.",
        "tokens": "['The', 'goal', 'of', 'this', 'project', 'is', 'the', 'development', 'of', 'an', 'EEG', '-', 'cap', '(', 'min', '.', '21', 'electrodes', ')', 'with', 'user', '-', 'friendly', 'active', 'dry', 'electrodes', 'that', 'meets', 'the', 'expectations', 'of', 'the', 'users', 'regarding', 'comfort', 'and', 'esthetics', ',', 'without', 'losing', 'sight', 'of', 'the', 'functional', 'and', 'technical', 'demands', 'for', 'recording', 'high', 'quality', 'EEG', 'signals', '.', 'The', 'purpose', 'is', 'to', 'use', 'the', 'EEG', '-', 'cap', 'to', 'investigate', 'clinical', 'neurological', 'disorders', '(', 'e.g.', 'epilepsy', ')', '.', 'The', 'EEG', '-', 'cap', 'could', 'also', 'be', 'used', 'at', 'home', 'so', 'that', 'hospital', 'admission', 'in', 'the', 'EMU', 'can', 'be', 'avoided', 'for', 'some', 'patients', 'and', 'an', 'increasing', 'number', 'of', 'patients', 'can', 'be', 'examined', '.', '\\n\\n', 'Phase', '3', 'of', 'the', 'Project', 'will', 'be', 'divided', 'into', 'a', 'Phase', '3a', 'and', 'Phase', '3b', '.', '\\n\\n', 'Phase', '3a', 'of', 'the', 'project', 'will', 'comprise', 'of', 'an', 'EEG', '-', 'registration', 'with', 'the', 'different', 'types', 'of', 'electrodes', 'in', 'epilepsy', 'patients', 'with', 'prominent', 'interictal', 'epileptiform', 'discharges', '(', 'IEDs', ')', 'on', 'EEG', '.', 'For', 'each', 'epilepsy', 'patient', 'the', 'EEG', '-', 'recording', 'with', 'dry', 'electrodes', 'will', 'be', 'compared', 'to', 'the', 'EEG', '-', 'recordings', 'with', 'conventionally', 'used', 'wet', 'electrodes', '(', 'bridge', 'and', 'cup', 'electrodes', ')', '.', 'Each', 'EEG', '-', 'recording', 'will', 'take', 'approximately', '10', 'minutes', '.', '\\n\\n', 'Minimum', '2', '-', 'maximum', '10', 'epilepsy', 'patients', 'will', 'be', 'included', '.', '\\n\\n', 'There', 'will', 'be', 'an', 'visual', 'and', 'clinical', 'evaluation', 'of', 'the', 'EEG', '-', 'signals', '(', 'blinded', ')', 'and', 'a', 'technical', 'evaluation', 'of', 'the', 'EEG', '-', 'signals', '.', 'User', 'experience', 'will', 'also', 'be', 'collected', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 382,
                "end": 390,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 731,
                "end": 739,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 823,
                "end": 831,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 1065,
                "end": 1073,
                "text": "epilepsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00727467",
        "study_official_title": "A Randomised Controlled Trial Evaluating the Effect of an Individual Auditory Cueing Device on Freezing and Gait Speed in People With Parkinson's Disease ",
        "study_brief_summary": " The primary aim of the study is to evaluate the effect of an IACD i.e. Apple iPod-shuffle, on freezing and gait speed in people with a diagnosis of PD through the implementation of a randomised controlled trial. A secondary aim of the study is to evaluate the impact of such a device on the quality of life of people with stroke through the administration of a self-report questionnaire. The IACD will be pre-loaded with an individualised auditory cueing frequency (metronome sound) matched to the walking speed of the individual with PD.",
        "text": "A Randomised Controlled Trial Evaluating the Effect of an Individual Auditory Cueing Device on Freezing and Gait Speed in People With Parkinson's Disease | The primary aim of the study is to evaluate the effect of an IACD i.e. Apple iPod-shuffle, on freezing and gait speed in people with a diagnosis of PD through the implementation of a randomised controlled trial. A secondary aim of the study is to evaluate the impact of such a device on the quality of life of people with stroke through the administration of a self-report questionnaire. The IACD will be pre-loaded with an individualised auditory cueing frequency (metronome sound) matched to the walking speed of the individual with PD.",
        "tokens": "['A', 'Randomised', 'Controlled', 'Trial', 'Evaluating', 'the', 'Effect', 'of', 'an', 'Individual', 'Auditory', 'Cueing', 'Device', 'on', 'Freezing', 'and', 'Gait', 'Speed', 'in', 'People', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'The', 'primary', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'an', 'IACD', 'i.e.', 'Apple', 'iPod', '-', 'shuffle', ',', 'on', 'freezing', 'and', 'gait', 'speed', 'in', 'people', 'with', 'a', 'diagnosis', 'of', 'PD', 'through', 'the', 'implementation', 'of', 'a', 'randomised', 'controlled', 'trial', '.', 'A', 'secondary', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'impact', 'of', 'such', 'a', 'device', 'on', 'the', 'quality', 'of', 'life', 'of', 'people', 'with', 'stroke', 'through', 'the', 'administration', 'of', 'a', 'self', '-', 'report', 'questionnaire', '.', 'The', 'IACD', 'will', 'be', 'pre', '-', 'loaded', 'with', 'an', 'individualised', 'auditory', 'cueing', 'frequency', '(', 'metronome', 'sound', ')', 'matched', 'to', 'the', 'walking', 'speed', 'of', 'the', 'individual', 'with', 'PD', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 58,
                "end": 91,
                "text": "Individual Auditory Cueing Device",
                "type": "OTHER"
            },
            {
                "start": 134,
                "end": 153,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 217,
                "end": 221,
                "text": "IACD",
                "type": "OTHER"
            },
            {
                "start": 227,
                "end": 245,
                "text": "Apple iPod-shuffle",
                "type": "OTHER"
            },
            {
                "start": 304,
                "end": 306,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 478,
                "end": 484,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 548,
                "end": 552,
                "text": "IACD",
                "type": "OTHER"
            },
            {
                "start": 580,
                "end": 610,
                "text": "individualised auditory cueing",
                "type": "OTHER"
            },
            {
                "start": 691,
                "end": 693,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01555983",
        "study_official_title": "The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury ",
        "study_brief_summary": " This study will demonstrate that vaporized marijuana results in antinociception when compared to placebo in subjects with spinal cord injury. To further evaluate potential benefits and side effects, the effect of different strengths of cannabis on mood, cognition, and psychomotor performance will also be measured.",
        "text": "The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury | This study will demonstrate that vaporized marijuana results in antinociception when compared to placebo in subjects with spinal cord injury. To further evaluate potential benefits and side effects, the effect of different strengths of cannabis on mood, cognition, and psychomotor performance will also be measured.",
        "tokens": "['The', 'Effect', 'of', 'Vaporized', 'Cannabis', 'on', 'Neuropathic', 'Pain', 'in', 'Spinal', 'Cord', 'Injury', '|', 'This', 'study', 'will', 'demonstrate', 'that', 'vaporized', 'marijuana', 'results', 'in', 'antinociception', 'when', 'compared', 'to', 'placebo', 'in', 'subjects', 'with', 'spinal', 'cord', 'injury', '.', 'To', 'further', 'evaluate', 'potential', 'benefits', 'and', 'side', 'effects', ',', 'the', 'effect', 'of', 'different', 'strengths', 'of', 'cannabis', 'on', 'mood', ',', 'cognition', ',', 'and', 'psychomotor', 'performance', 'will', 'also', 'be', 'measured', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 32,
                "text": "Cannabis",
                "type": "OTHER"
            },
            {
                "start": 36,
                "end": 52,
                "text": "Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 56,
                "end": 74,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 129,
                "text": "marijuana",
                "type": "OTHER"
            },
            {
                "start": 174,
                "end": 181,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 199,
                "end": 217,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 313,
                "end": 321,
                "text": "cannabis",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03712917",
        "study_official_title": "Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine: A Randomised Parallel Group Study ",
        "study_brief_summary": " Background: Preventive drug therapy in migraine aims to reduce the attack frequency, severity and duration of headache. Flunarizine and topiramate are widely used in the prevention of migraine attacks. Greater occipital nerve block (GONB) is an alternative treatment option for the prophylactic treatment of migraine. In this study, investigators compared the effectiveness of GONB, topiramate, and flunarizine in terms of reduction in post-treatment VAS scores and attack frequencies in patients with episodic migraine in a four-week period.\n\nMaterial and Methods: At least one hundred and twenty migraine patients are aimed to be randomly divided into three treatment groups, namely flunarizine (n=40, estimated), topiramate (n=40, estimated) and GONB (n=40, estimated). The patients will be followed up for four weeks and the attack frequencies and VAS scores will be recorded weekly. At the end of the fourth week, the response rates based on 50% and 75% or more reduction in the VAS scores and attack frequencies will be calculated. Group-wise comparisons will be assessed statistically.",
        "text": "Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine: A Randomised Parallel Group Study | Background: Preventive drug therapy in migraine aims to reduce the attack frequency, severity and duration of headache. Flunarizine and topiramate are widely used in the prevention of migraine attacks. Greater occipital nerve block (GONB) is an alternative treatment option for the prophylactic treatment of migraine. In this study, investigators compared the effectiveness of GONB, topiramate, and flunarizine in terms of reduction in post-treatment VAS scores and attack frequencies in patients with episodic migraine in a four-week period.\n\nMaterial and Methods: At least one hundred and twenty migraine patients are aimed to be randomly divided into three treatment groups, namely flunarizine (n=40, estimated), topiramate (n=40, estimated) and GONB (n=40, estimated). The patients will be followed up for four weeks and the attack frequencies and VAS scores will be recorded weekly. At the end of the fourth week, the response rates based on 50% and 75% or more reduction in the VAS scores and attack frequencies will be calculated. Group-wise comparisons will be assessed statistically.",
        "tokens": "['Comparison', 'of', 'Therapeutic', 'Effects', 'of', 'Greater', 'Occipital', 'Nerve', 'Block', ',', 'Topiramate', ',', 'and', 'Flunarizine', 'on', 'Episodic', 'Migraine', ':', 'A', 'Randomised', 'Parallel', 'Group', 'Study', '|', 'Background', ':', 'Preventive', 'drug', 'therapy', 'in', 'migraine', 'aims', 'to', 'reduce', 'the', 'attack', 'frequency', ',', 'severity', 'and', 'duration', 'of', 'headache', '.', 'Flunarizine', 'and', 'topiramate', 'are', 'widely', 'used', 'in', 'the', 'prevention', 'of', 'migraine', 'attacks', '.', 'Greater', 'occipital', 'nerve', 'block', '(', 'GONB', ')', 'is', 'an', 'alternative', 'treatment', 'option', 'for', 'the', 'prophylactic', 'treatment', 'of', 'migraine', '.', 'In', 'this', 'study', ',', 'investigators', 'compared', 'the', 'effectiveness', 'of', 'GONB', ',', 'topiramate', ',', 'and', 'flunarizine', 'in', 'terms', 'of', 'reduction', 'in', 'post', '-', 'treatment', 'VAS', 'scores', 'and', 'attack', 'frequencies', 'in', 'patients', 'with', 'episodic', 'migraine', 'in', 'a', 'four', '-', 'week', 'period', '.', '\\n\\n', 'Material', 'and', 'Methods', ':', 'At', 'least', 'one', 'hundred', 'and', 'twenty', 'migraine', 'patients', 'are', 'aimed', 'to', 'be', 'randomly', 'divided', 'into', 'three', 'treatment', 'groups', ',', 'namely', 'flunarizine', '(', 'n=40', ',', 'estimated', ')', ',', 'topiramate', '(', 'n=40', ',', 'estimated', ')', 'and', 'GONB', '(', 'n=40', ',', 'estimated', ')', '.', 'The', 'patients', 'will', 'be', 'followed', 'up', 'for', 'four', 'weeks', 'and', 'the', 'attack', 'frequencies', 'and', 'VAS', 'scores', 'will', 'be', 'recorded', 'weekly', '.', 'At', 'the', 'end', 'of', 'the', 'fourth', 'week', ',', 'the', 'response', 'rates', 'based', 'on', '50', '%', 'and', '75', '%', 'or', 'more', 'reduction', 'in', 'the', 'VAS', 'scores', 'and', 'attack', 'frequencies', 'will', 'be', 'calculated', '.', 'Group', '-', 'wise', 'comparisons', 'will', 'be', 'assessed', 'statistically', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 66,
                "text": "Greater Occipital Nerve Block",
                "type": "SURGICAL"
            },
            {
                "start": 68,
                "end": 78,
                "text": "Topiramate",
                "type": "DRUG"
            },
            {
                "start": 84,
                "end": 95,
                "text": "Flunarizine",
                "type": "DRUG"
            },
            {
                "start": 99,
                "end": 116,
                "text": "Episodic Migraine",
                "type": "CONDITION"
            },
            {
                "start": 193,
                "end": 201,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 264,
                "end": 272,
                "text": "headache",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 285,
                "text": "Flunarizine",
                "type": "DRUG"
            },
            {
                "start": 290,
                "end": 300,
                "text": "topiramate",
                "type": "DRUG"
            },
            {
                "start": 338,
                "end": 354,
                "text": "migraine attacks",
                "type": "CONDITION"
            },
            {
                "start": 356,
                "end": 385,
                "text": "Greater occipital nerve block",
                "type": "SURGICAL"
            },
            {
                "start": 387,
                "end": 391,
                "text": "GONB",
                "type": "SURGICAL"
            },
            {
                "start": 462,
                "end": 470,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 531,
                "end": 535,
                "text": "GONB",
                "type": "SURGICAL"
            },
            {
                "start": 537,
                "end": 547,
                "text": "topiramate",
                "type": "DRUG"
            },
            {
                "start": 553,
                "end": 564,
                "text": "flunarizine",
                "type": "DRUG"
            },
            {
                "start": 656,
                "end": 673,
                "text": "episodic migraine",
                "type": "CONDITION"
            },
            {
                "start": 752,
                "end": 760,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 839,
                "end": 850,
                "text": "flunarizine",
                "type": "DRUG"
            },
            {
                "start": 870,
                "end": 880,
                "text": "topiramate",
                "type": "DRUG"
            },
            {
                "start": 903,
                "end": 907,
                "text": "GONB",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT02541032",
        "study_official_title": "PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke ",
        "study_brief_summary": " The PREMIERS study is a proposal for conducting an adequately powered two center phase III randomized controlled trial to test whether intensive periodontal treatment reduces the risk of recurrent vascular events among ischemic stroke and TIA survivors. The study uses the resources in both states including established dental centers, Joint Commission Certified Stroke Centers, the Schools of Public Health, and the Institute for Partnerships to Eliminate Health Disparities. The proposal addresses specific issues with regards to recruitment of African-American and rural stroke/TIA patients advocating the use of culturally appropriate strategies to educate the study subjects regarding stroke, periodontal disease and the periodontal stroke link.\n\nThe study proposes to utilize economic evaluation of the periodontal intervention from the budgetary perspective. The focus will be on the financial sustainability of providing aggressive periodontal therapy (with certain, although relatively low expenditures) in exchange for a reduction of uncertain recurrent vascular events that may require high cost emergency department utilization and/or inpatient care. The sustainability of the proposed intervention after the completion of the project is integrally linked to the health economic assessment to show the health care cost savings. By integration with a rural primary care center, with an African American majority and households with average incomes below the state average, the study ensures that the proposed intervention to reduce stroke disparity is applicable to this target population.",
        "text": "PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke | The PREMIERS study is a proposal for conducting an adequately powered two center phase III randomized controlled trial to test whether intensive periodontal treatment reduces the risk of recurrent vascular events among ischemic stroke and TIA survivors. The study uses the resources in both states including established dental centers, Joint Commission Certified Stroke Centers, the Schools of Public Health, and the Institute for Partnerships to Eliminate Health Disparities. The proposal addresses specific issues with regards to recruitment of African-American and rural stroke/TIA patients advocating the use of culturally appropriate strategies to educate the study subjects regarding stroke, periodontal disease and the periodontal stroke link.\n\nThe study proposes to utilize economic evaluation of the periodontal intervention from the budgetary perspective. The focus will be on the financial sustainability of providing aggressive periodontal therapy (with certain, although relatively low expenditures) in exchange for a reduction of uncertain recurrent vascular events that may require high cost emergency department utilization and/or inpatient care. The sustainability of the proposed intervention after the completion of the project is integrally linked to the health economic assessment to show the health care cost savings. By integration with a rural primary care center, with an African American majority and households with average incomes below the state average, the study ensures that the proposed intervention to reduce stroke disparity is applicable to this target population.",
        "tokens": "['PeRiodontal', 'Treatment', 'to', 'Eliminate', 'Minority', 'InEquality', 'and', 'Rural', 'Disparities', 'in', 'Stroke', '|', 'The', 'PREMIERS', 'study', 'is', 'a', 'proposal', 'for', 'conducting', 'an', 'adequately', 'powered', 'two', 'center', 'phase', 'III', 'randomized', 'controlled', 'trial', 'to', 'test', 'whether', 'intensive', 'periodontal', 'treatment', 'reduces', 'the', 'risk', 'of', 'recurrent', 'vascular', 'events', 'among', 'ischemic', 'stroke', 'and', 'TIA', 'survivors', '.', 'The', 'study', 'uses', 'the', 'resources', 'in', 'both', 'states', 'including', 'established', 'dental', 'centers', ',', 'Joint', 'Commission', 'Certified', 'Stroke', 'Centers', ',', 'the', 'Schools', 'of', 'Public', 'Health', ',', 'and', 'the', 'Institute', 'for', 'Partnerships', 'to', 'Eliminate', 'Health', 'Disparities', '.', 'The', 'proposal', 'addresses', 'specific', 'issues', 'with', 'regards', 'to', 'recruitment', 'of', 'African', '-', 'American', 'and', 'rural', 'stroke', '/', 'TIA', 'patients', 'advocating', 'the', 'use', 'of', 'culturally', 'appropriate', 'strategies', 'to', 'educate', 'the', 'study', 'subjects', 'regarding', 'stroke', ',', 'periodontal', 'disease', 'and', 'the', 'periodontal', 'stroke', 'link', '.', '\\n\\n', 'The', 'study', 'proposes', 'to', 'utilize', 'economic', 'evaluation', 'of', 'the', 'periodontal', 'intervention', 'from', 'the', 'budgetary', 'perspective', '.', 'The', 'focus', 'will', 'be', 'on', 'the', 'financial', 'sustainability', 'of', 'providing', 'aggressive', 'periodontal', 'therapy', '(', 'with', 'certain', ',', 'although', 'relatively', 'low', 'expenditures', ')', 'in', 'exchange', 'for', 'a', 'reduction', 'of', 'uncertain', 'recurrent', 'vascular', 'events', 'that', 'may', 'require', 'high', 'cost', 'emergency', 'department', 'utilization', 'and/or', 'inpatient', 'care', '.', 'The', 'sustainability', 'of', 'the', 'proposed', 'intervention', 'after', 'the', 'completion', 'of', 'the', 'project', 'is', 'integrally', 'linked', 'to', 'the', 'health', 'economic', 'assessment', 'to', 'show', 'the', 'health', 'care', 'cost', 'savings', '.', 'By', 'integration', 'with', 'a', 'rural', 'primary', 'care', 'center', ',', 'with', 'an', 'African', 'American', 'majority', 'and', 'households', 'with', 'average', 'incomes', 'below', 'the', 'state', 'average', ',', 'the', 'study', 'ensures', 'that', 'the', 'proposed', 'intervention', 'to', 'reduce', 'stroke', 'disparity', 'is', 'applicable', 'to', 'this', 'target', 'population', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 21,
                "text": "PeRiodontal Treatment",
                "type": "OTHER"
            },
            {
                "start": 80,
                "end": 86,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 255,
                "text": "intensive periodontal treatment",
                "type": "OTHER"
            },
            {
                "start": 308,
                "end": 323,
                "text": "ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 328,
                "end": 331,
                "text": "TIA",
                "type": "CONDITION"
            },
            {
                "start": 663,
                "end": 669,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 670,
                "end": 673,
                "text": "TIA",
                "type": "CONDITION"
            },
            {
                "start": 779,
                "end": 785,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 787,
                "end": 806,
                "text": "periodontal disease",
                "type": "CONDITION"
            },
            {
                "start": 815,
                "end": 833,
                "text": "periodontal stroke",
                "type": "CONDITION"
            },
            {
                "start": 898,
                "end": 922,
                "text": "periodontal intervention",
                "type": "OTHER"
            },
            {
                "start": 1018,
                "end": 1048,
                "text": "aggressive periodontal therapy",
                "type": "OTHER"
            },
            {
                "start": 1632,
                "end": 1638,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03620279",
        "study_official_title": "Magic Camp for Children With Hemiplegic Cerebral Palsy ",
        "study_brief_summary": " The proposed study will test the feasibility and effectiveness of a \"Magic Camp\" in children with spastic hemiplegic cerebral palsy (CP). A single group pretest-posttest design (n=10) will be used to investigate the immediate (2 weeks) and longer-term effect (3 months) of a \"Magic Camp\" on improving upper limb motor function and health-related quality of life (HRQoL) in children with hemiplegic CP.",
        "text": "Magic Camp for Children With Hemiplegic Cerebral Palsy | The proposed study will test the feasibility and effectiveness of a \"Magic Camp\" in children with spastic hemiplegic cerebral palsy (CP). A single group pretest-posttest design (n=10) will be used to investigate the immediate (2 weeks) and longer-term effect (3 months) of a \"Magic Camp\" on improving upper limb motor function and health-related quality of life (HRQoL) in children with hemiplegic CP.",
        "tokens": "['Magic', 'Camp', 'for', 'Children', 'With', 'Hemiplegic', 'Cerebral', 'Palsy', '|', 'The', 'proposed', 'study', 'will', 'test', 'the', 'feasibility', 'and', 'effectiveness', 'of', 'a', '\"', 'Magic', 'Camp', '\"', 'in', 'children', 'with', 'spastic', 'hemiplegic', 'cerebral', 'palsy', '(', 'CP', ')', '.', 'A', 'single', 'group', 'pretest', '-', 'posttest', 'design', '(', 'n=10', ')', 'will', 'be', 'used', 'to', 'investigate', 'the', 'immediate', '(', '2', 'weeks', ')', 'and', 'longer', '-', 'term', 'effect', '(', '3', 'months', ')', 'of', 'a', '\"', 'Magic', 'Camp', '\"', 'on', 'improving', 'upper', 'limb', 'motor', 'function', 'and', 'health', '-', 'related', 'quality', 'of', 'life', '(', 'HRQoL', ')', 'in', 'children', 'with', 'hemiplegic', 'CP', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 10,
                "text": "Magic Camp",
                "type": "OTHER"
            },
            {
                "start": 29,
                "end": 54,
                "text": "Hemiplegic Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 136,
                "text": "Magic Camp",
                "type": "OTHER"
            },
            {
                "start": 155,
                "end": 188,
                "text": "spastic hemiplegic cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 192,
                "text": "CP",
                "type": "CONDITION"
            },
            {
                "start": 333,
                "end": 343,
                "text": "Magic Camp",
                "type": "OTHER"
            },
            {
                "start": 444,
                "end": 457,
                "text": "hemiplegic CP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04881318",
        "study_official_title": "Compression Garments in the Community With POTS ",
        "study_brief_summary": " Compression Garments are a commonly prescribed treatment in Postural Orthostatic Tachycardia Syndrome (POTS). The effectiveness of a proof-of-concept compression garment has been demonstrated in an acute laboratory setting. It is not known if commercially available compression garments that participants wear in their every day lives are effective at improving heart rate and reducing symptoms in POTS. This trial will evaluate the use of commercially available waist-high and abdominal compression garments in adults diagnosed with POTS in a community setting.",
        "text": "Compression Garments in the Community With POTS | Compression Garments are a commonly prescribed treatment in Postural Orthostatic Tachycardia Syndrome (POTS). The effectiveness of a proof-of-concept compression garment has been demonstrated in an acute laboratory setting. It is not known if commercially available compression garments that participants wear in their every day lives are effective at improving heart rate and reducing symptoms in POTS. This trial will evaluate the use of commercially available waist-high and abdominal compression garments in adults diagnosed with POTS in a community setting.",
        "tokens": "['Compression', 'Garments', 'in', 'the', 'Community', 'With', 'POTS', '|', 'Compression', 'Garments', 'are', 'a', 'commonly', 'prescribed', 'treatment', 'in', 'Postural', 'Orthostatic', 'Tachycardia', 'Syndrome', '(', 'POTS', ')', '.', 'The', 'effectiveness', 'of', 'a', 'proof', '-', 'of', '-', 'concept', 'compression', 'garment', 'has', 'been', 'demonstrated', 'in', 'an', 'acute', 'laboratory', 'setting', '.', 'It', 'is', 'not', 'known', 'if', 'commercially', 'available', 'compression', 'garments', 'that', 'participants', 'wear', 'in', 'their', 'every', 'day', 'lives', 'are', 'effective', 'at', 'improving', 'heart', 'rate', 'and', 'reducing', 'symptoms', 'in', 'POTS', '.', 'This', 'trial', 'will', 'evaluate', 'the', 'use', 'of', 'commercially', 'available', 'waist', '-', 'high', 'and', 'abdominal', 'compression', 'garments', 'in', 'adults', 'diagnosed', 'with', 'POTS', 'in', 'a', 'community', 'setting', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 20,
                "text": "Compression Garments",
                "type": "OTHER"
            },
            {
                "start": 43,
                "end": 47,
                "text": "POTS",
                "type": "CONDITION"
            },
            {
                "start": 50,
                "end": 70,
                "text": "Compression Garments",
                "type": "OTHER"
            },
            {
                "start": 110,
                "end": 151,
                "text": "Postural Orthostatic Tachycardia Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 157,
                "text": "POTS",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 219,
                "text": "compression garment",
                "type": "OTHER"
            },
            {
                "start": 316,
                "end": 336,
                "text": "compression garments",
                "type": "OTHER"
            },
            {
                "start": 448,
                "end": 452,
                "text": "POTS",
                "type": "CONDITION"
            },
            {
                "start": 490,
                "end": 558,
                "text": "commercially available waist-high and abdominal compression garments",
                "type": "OTHER"
            },
            {
                "start": 584,
                "end": 588,
                "text": "POTS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01780116",
        "study_official_title": "An Evaluation of the Effectiveness of Adherence Therapy for Schizophrenia: A Randomized Controlled Trial ",
        "study_brief_summary": " When compared with those in the control (usual care) group, participants in the AT group are expected to demonstrate significant improvements immediately and at three, six and 12 months after completion of the intervention in: level of medication adherence, readmission rate, mental status, insight into treatment, and level of functioning.",
        "text": "An Evaluation of the Effectiveness of Adherence Therapy for Schizophrenia: A Randomized Controlled Trial | When compared with those in the control (usual care) group, participants in the AT group are expected to demonstrate significant improvements immediately and at three, six and 12 months after completion of the intervention in: level of medication adherence, readmission rate, mental status, insight into treatment, and level of functioning.",
        "tokens": "['An', 'Evaluation', 'of', 'the', 'Effectiveness', 'of', 'Adherence', 'Therapy', 'for', 'Schizophrenia', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'When', 'compared', 'with', 'those', 'in', 'the', 'control', '(', 'usual', 'care', ')', 'group', ',', 'participants', 'in', 'the', 'AT', 'group', 'are', 'expected', 'to', 'demonstrate', 'significant', 'improvements', 'immediately', 'and', 'at', 'three', ',', 'six', 'and', '12', 'months', 'after', 'completion', 'of', 'the', 'intervention', 'in', ':', 'level', 'of', 'medication', 'adherence', ',', 'readmission', 'rate', ',', 'mental', 'status', ',', 'insight', 'into', 'treatment', ',', 'and', 'level', 'of', 'functioning', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 38,
                "end": 55,
                "text": "Adherence Therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 60,
                "end": 73,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 158,
                "text": "usual care",
                "type": "CONTROL"
            },
            {
                "start": 187,
                "end": 189,
                "text": "AT",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT04176991",
        "study_official_title": "A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia ",
        "study_brief_summary": " To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants with Friedreich's ataxia",
        "text": "A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants with Friedreich's ataxia",
        "tokens": "['A', 'Phase', '1', 'Single', 'Ascending', 'Dose', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', ',', 'and', 'Pharmacodynamics', 'of', 'Subcutaneous', 'CTI-1601', 'Versus', 'Placebo', 'in', 'Subjects', 'With', 'Friedreich', \"'s\", 'Ataxia', '|', 'To', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'single', 'ascending', 'doses', 'of', 'CTI-1601', 'in', 'participants', 'with', 'Friedreich', \"'s\", 'ataxia']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 129,
                "end": 137,
                "text": "CTI-1601",
                "type": "DRUG"
            },
            {
                "start": 145,
                "end": 152,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 170,
                "end": 189,
                "text": "Friedreich's Ataxia",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 269,
                "text": "CTI-1601",
                "type": "DRUG"
            },
            {
                "start": 291,
                "end": 310,
                "text": "Friedreich's ataxia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04550975",
        "study_official_title": "Feasibility Randomised Controlled Trial (RCT) of Advanced Cognitive Stimulation Therapy (ACST) for People With Moderate to Severe Dementia ",
        "study_brief_summary": " This study is a feasibility randomised controlled trial (RCT) for an evidence-based intervention for people with moderate to severe dementia. The psychosocial intervention is adapted from Cognitive Stimulation Therapy (CST) and developed within the Medical Research Council (MRC) framework.",
        "text": "Feasibility Randomised Controlled Trial (RCT) of Advanced Cognitive Stimulation Therapy (ACST) for People With Moderate to Severe Dementia | This study is a feasibility randomised controlled trial (RCT) for an evidence-based intervention for people with moderate to severe dementia. The psychosocial intervention is adapted from Cognitive Stimulation Therapy (CST) and developed within the Medical Research Council (MRC) framework.",
        "tokens": "['Feasibility', 'Randomised', 'Controlled', 'Trial', '(', 'RCT', ')', 'of', 'Advanced', 'Cognitive', 'Stimulation', 'Therapy', '(', 'ACST', ')', 'for', 'People', 'With', 'Moderate', 'to', 'Severe', 'Dementia', '|', 'This', 'study', 'is', 'a', 'feasibility', 'randomised', 'controlled', 'trial', '(', 'RCT', ')', 'for', 'an', 'evidence', '-', 'based', 'intervention', 'for', 'people', 'with', 'moderate', 'to', 'severe', 'dementia', '.', 'The', 'psychosocial', 'intervention', 'is', 'adapted', 'from', 'Cognitive', 'Stimulation', 'Therapy', '(', 'CST', ')', 'and', 'developed', 'within', 'the', 'Medical', 'Research', 'Council', '(', 'MRC', ')', 'framework', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 49,
                "end": 87,
                "text": "Advanced Cognitive Stimulation Therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 89,
                "end": 93,
                "text": "ACST",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 111,
                "end": 138,
                "text": "Moderate to Severe Dementia",
                "type": "CONDITION"
            },
            {
                "start": 254,
                "end": 281,
                "text": "moderate to severe dementia",
                "type": "CONDITION"
            },
            {
                "start": 329,
                "end": 358,
                "text": "Cognitive Stimulation Therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 360,
                "end": 363,
                "text": "CST",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT01438697",
        "study_official_title": "An Internet Intervention for Insomnia: Efficacy and Dissemination ",
        "study_brief_summary": " This study will compare the efficacy of an interactive Internet intervention for adult insomnia (Sleep Healthy Using the Internet; SHUTi) to that of a static educational website to improve sleep, mood related symptoms, perceived health status, and overall quality of life.",
        "text": "An Internet Intervention for Insomnia: Efficacy and Dissemination | This study will compare the efficacy of an interactive Internet intervention for adult insomnia (Sleep Healthy Using the Internet; SHUTi) to that of a static educational website to improve sleep, mood related symptoms, perceived health status, and overall quality of life.",
        "tokens": "['An', 'Internet', 'Intervention', 'for', 'Insomnia', ':', 'Efficacy', 'and', 'Dissemination', '|', 'This', 'study', 'will', 'compare', 'the', 'efficacy', 'of', 'an', 'interactive', 'Internet', 'intervention', 'for', 'adult', 'insomnia', '(', 'Sleep', 'Healthy', 'Using', 'the', 'Internet', ';', 'SHUTi', ')', 'to', 'that', 'of', 'a', 'static', 'educational', 'website', 'to', 'improve', 'sleep', ',', 'mood', 'related', 'symptoms', ',', 'perceived', 'health', 'status', ',', 'and', 'overall', 'quality', 'of', 'life', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 3,
                "end": 24,
                "text": "Internet Intervention",
                "type": "OTHER"
            },
            {
                "start": 29,
                "end": 37,
                "text": "Insomnia",
                "type": "CONDITION"
            },
            {
                "start": 111,
                "end": 144,
                "text": "interactive Internet intervention",
                "type": "OTHER"
            },
            {
                "start": 155,
                "end": 163,
                "text": "insomnia",
                "type": "CONDITION"
            },
            {
                "start": 219,
                "end": 245,
                "text": "static educational website",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03385993",
        "study_official_title": "Digital Rehabilitation Environment Augmenting Medical System ",
        "study_brief_summary": " D.R.E.A.M.S. will assess an immersive digital reality-augmenting system in reducing the occurrence of cognitive, behavioral, and emotional consequences of critical illness and environmental exposures that are risk factors for the development of delirium.",
        "text": "Digital Rehabilitation Environment Augmenting Medical System | D.R.E.A.M.S. will assess an immersive digital reality-augmenting system in reducing the occurrence of cognitive, behavioral, and emotional consequences of critical illness and environmental exposures that are risk factors for the development of delirium.",
        "tokens": "['Digital', 'Rehabilitation', 'Environment', 'Augmenting', 'Medical', 'System', '|', 'D.R.E.A.M.S.', 'will', 'assess', 'an', 'immersive', 'digital', 'reality', '-', 'augmenting', 'system', 'in', 'reducing', 'the', 'occurrence', 'of', 'cognitive', ',', 'behavioral', ',', 'and', 'emotional', 'consequences', 'of', 'critical', 'illness', 'and', 'environmental', 'exposures', 'that', 'are', 'risk', 'factors', 'for', 'the', 'development', 'of', 'delirium', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 91,
                "end": 134,
                "text": "immersive digital reality-augmenting system",
                "type": "OTHER"
            },
            {
                "start": 218,
                "end": 234,
                "text": "critical illness",
                "type": "CONDITION"
            },
            {
                "start": 308,
                "end": 316,
                "text": "delirium",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01515839",
        "study_official_title": "Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study ",
        "study_brief_summary": " The investigators primary objective is to acquire preliminary data on one-hundred former NFL veterans with at least one full year of professional service using brain SPECT imaging in order to assess the degree to which NFL football puts players at risk for traumatic brain injury (TBI). TBI severity shall be gauged via visual inspection by a clinician trained in neuroanatomy, and also by a statistical comparison of subjects' brains to an in-house proprietary database comprised of the brains of healthy subjects.\n\nThe investigators secondary objective is to acquire additional data on these players such that investigators may establish causative factors and risks associated with said TBI.\n\nThe investigators tertiary objective is to acquire data on subjects using various mental health metrics in order to determine the effects of TBI.",
        "text": "Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study | The investigators primary objective is to acquire preliminary data on one-hundred former NFL veterans with at least one full year of professional service using brain SPECT imaging in order to assess the degree to which NFL football puts players at risk for traumatic brain injury (TBI). TBI severity shall be gauged via visual inspection by a clinician trained in neuroanatomy, and also by a statistical comparison of subjects' brains to an in-house proprietary database comprised of the brains of healthy subjects.\n\nThe investigators secondary objective is to acquire additional data on these players such that investigators may establish causative factors and risks associated with said TBI.\n\nThe investigators tertiary objective is to acquire data on subjects using various mental health metrics in order to determine the effects of TBI.",
        "tokens": "['Brain', 'Single', 'Photon', 'Emission', 'Computed', 'Tomography', 'and', 'Quantitative', 'Electroencephalography', 'In', 'Former', 'NFL', 'Players', ':', 'A', 'Single', '-', 'Site', 'Exploratory', 'Pilot', 'Study', '|', 'The', 'investigators', 'primary', 'objective', 'is', 'to', 'acquire', 'preliminary', 'data', 'on', 'one', '-', 'hundred', 'former', 'NFL', 'veterans', 'with', 'at', 'least', 'one', 'full', 'year', 'of', 'professional', 'service', 'using', 'brain', 'SPECT', 'imaging', 'in', 'order', 'to', 'assess', 'the', 'degree', 'to', 'which', 'NFL', 'football', 'puts', 'players', 'at', 'risk', 'for', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', '.', 'TBI', 'severity', 'shall', 'be', 'gauged', 'via', 'visual', 'inspection', 'by', 'a', 'clinician', 'trained', 'in', 'neuroanatomy', ',', 'and', 'also', 'by', 'a', 'statistical', 'comparison', 'of', 'subjects', \"'\", 'brains', 'to', 'an', 'in', '-', 'house', 'proprietary', 'database', 'comprised', 'of', 'the', 'brains', 'of', 'healthy', 'subjects', '.', '\\n\\n', 'The', 'investigators', 'secondary', 'objective', 'is', 'to', 'acquire', 'additional', 'data', 'on', 'these', 'players', 'such', 'that', 'investigators', 'may', 'establish', 'causative', 'factors', 'and', 'risks', 'associated', 'with', 'said', 'TBI', '.', '\\n\\n', 'The', 'investigators', 'tertiary', 'objective', 'is', 'to', 'acquire', 'data', 'on', 'subjects', 'using', 'various', 'mental', 'health', 'metrics', 'in', 'order', 'to', 'determine', 'the', 'effects', 'of', 'TBI', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 409,
                "end": 431,
                "text": "traumatic brain injury",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 436,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 439,
                "end": 442,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 841,
                "end": 844,
                "text": "TBI",
                "type": "CONDITION"
            },
            {
                "start": 988,
                "end": 991,
                "text": "TBI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01090934",
        "study_official_title": "Etude de la Performance Diagnostique de l'EEG-Haute R\u00e9solution Sur la Localisation de la Zone \u00e9pileptog\u00e8ne Pour le Traitement Chirurgical Des \u00e9pilepsies Partielles Pharmaco-r\u00e9sistantes ",
        "study_brief_summary": " Multicenter prospective study comparing the diagnosis value of high-resolution EEG and depth-EEG to localize the epileptogenic zone in drug resistant partial epilepsies.",
        "text": "Etude de la Performance Diagnostique de l'EEG-Haute R\u00e9solution Sur la Localisation de la Zone \u00e9pileptog\u00e8ne Pour le Traitement Chirurgical Des \u00e9pilepsies Partielles Pharmaco-r\u00e9sistantes | Multicenter prospective study comparing the diagnosis value of high-resolution EEG and depth-EEG to localize the epileptogenic zone in drug resistant partial epilepsies.",
        "tokens": "['Etude', 'de', 'la', 'Performance', 'Diagnostique', 'de', \"l'EEG\", '-', 'Haute', 'R\u00e9solution', 'Sur', 'la', 'Localisation', 'de', 'la', 'Zone', '\u00e9pileptog\u00e8ne', 'Pour', 'le', 'Traitement', 'Chirurgical', 'Des', '\u00e9pilepsies', 'Partielles', 'Pharmaco', '-', 'r\u00e9sistantes', '|', 'Multicenter', 'prospective', 'study', 'comparing', 'the', 'diagnosis', 'value', 'of', 'high', '-', 'resolution', 'EEG', 'and', 'depth', '-', 'EEG', 'to', 'localize', 'the', 'epileptogenic', 'zone', 'in', 'drug', 'resistant', 'partial', 'epilepsies', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 300,
                "end": 313,
                "text": "epileptogenic",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 355,
                "text": "drug resistant partial epilepsies",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00366535",
        "study_official_title": "Neurotropin Treatment of Fibromyalgia ",
        "study_brief_summary": " This study will examine the safety and effectiveness of the experimental drug, neurotropin, for preventing or easing pain associated with fibromyalgia. A disorder that primarily affects women, fibromyalgia causes widespread aching and stiffness in muscles. Neurotropin has been used in Japan for many years to treat various chronic painful conditions, including fibromyalgia.\n\nWomen with fibromyalgia who have been treated unsuccessfully with standard therapy may be eligible for this study. Patients must have a history of widespread pain for more than half of the days in each of the three months before they enter the study. Candidates are screened with a medical history, physical examination, blood and urine tests, questionnaires and an electrocardiogram (EKG).\n\nParticipants take their usual medications for fibromyalgia in addition to either neurotropin or a placebo (look-alike medicine with no active ingredient). At 6 weeks and 12 weeks into the study, they return to the NIH Clinical Center for evaluation of their sensitivity to pain and level of physical capability. After 12 weeks, study subjects \"cross-over\" their medication; that is, patients who took neurotropin for the first 12 weeks of the study take placebo for the next 12 weeks, and vice-versa. Again, after 6 and 12 weeks, patients return for evaluation.\n\nParticipants have blood and urine tests six times during the study and complete questionnaires each week about their pain, symptoms, and activities.",
        "text": "Neurotropin Treatment of Fibromyalgia | This study will examine the safety and effectiveness of the experimental drug, neurotropin, for preventing or easing pain associated with fibromyalgia. A disorder that primarily affects women, fibromyalgia causes widespread aching and stiffness in muscles. Neurotropin has been used in Japan for many years to treat various chronic painful conditions, including fibromyalgia.\n\nWomen with fibromyalgia who have been treated unsuccessfully with standard therapy may be eligible for this study. Patients must have a history of widespread pain for more than half of the days in each of the three months before they enter the study. Candidates are screened with a medical history, physical examination, blood and urine tests, questionnaires and an electrocardiogram (EKG).\n\nParticipants take their usual medications for fibromyalgia in addition to either neurotropin or a placebo (look-alike medicine with no active ingredient). At 6 weeks and 12 weeks into the study, they return to the NIH Clinical Center for evaluation of their sensitivity to pain and level of physical capability. After 12 weeks, study subjects \"cross-over\" their medication; that is, patients who took neurotropin for the first 12 weeks of the study take placebo for the next 12 weeks, and vice-versa. Again, after 6 and 12 weeks, patients return for evaluation.\n\nParticipants have blood and urine tests six times during the study and complete questionnaires each week about their pain, symptoms, and activities.",
        "tokens": "['Neurotropin', 'Treatment', 'of', 'Fibromyalgia', '|', 'This', 'study', 'will', 'examine', 'the', 'safety', 'and', 'effectiveness', 'of', 'the', 'experimental', 'drug', ',', 'neurotropin', ',', 'for', 'preventing', 'or', 'easing', 'pain', 'associated', 'with', 'fibromyalgia', '.', 'A', 'disorder', 'that', 'primarily', 'affects', 'women', ',', 'fibromyalgia', 'causes', 'widespread', 'aching', 'and', 'stiffness', 'in', 'muscles', '.', 'Neurotropin', 'has', 'been', 'used', 'in', 'Japan', 'for', 'many', 'years', 'to', 'treat', 'various', 'chronic', 'painful', 'conditions', ',', 'including', 'fibromyalgia', '.', '\\n\\n', 'Women', 'with', 'fibromyalgia', 'who', 'have', 'been', 'treated', 'unsuccessfully', 'with', 'standard', 'therapy', 'may', 'be', 'eligible', 'for', 'this', 'study', '.', 'Patients', 'must', 'have', 'a', 'history', 'of', 'widespread', 'pain', 'for', 'more', 'than', 'half', 'of', 'the', 'days', 'in', 'each', 'of', 'the', 'three', 'months', 'before', 'they', 'enter', 'the', 'study', '.', 'Candidates', 'are', 'screened', 'with', 'a', 'medical', 'history', ',', 'physical', 'examination', ',', 'blood', 'and', 'urine', 'tests', ',', 'questionnaires', 'and', 'an', 'electrocardiogram', '(', 'EKG', ')', '.', '\\n\\n', 'Participants', 'take', 'their', 'usual', 'medications', 'for', 'fibromyalgia', 'in', 'addition', 'to', 'either', 'neurotropin', 'or', 'a', 'placebo', '(', 'look', '-', 'alike', 'medicine', 'with', 'no', 'active', 'ingredient', ')', '.', 'At', '6', 'weeks', 'and', '12', 'weeks', 'into', 'the', 'study', ',', 'they', 'return', 'to', 'the', 'NIH', 'Clinical', 'Center', 'for', 'evaluation', 'of', 'their', 'sensitivity', 'to', 'pain', 'and', 'level', 'of', 'physical', 'capability', '.', 'After', '12', 'weeks', ',', 'study', 'subjects', '\"', 'cross', '-', 'over', '\"', 'their', 'medication', ';', 'that', 'is', ',', 'patients', 'who', 'took', 'neurotropin', 'for', 'the', 'first', '12', 'weeks', 'of', 'the', 'study', 'take', 'placebo', 'for', 'the', 'next', '12', 'weeks', ',', 'and', 'vice', '-', 'versa', '.', 'Again', ',', 'after', '6', 'and', '12', 'weeks', ',', 'patients', 'return', 'for', 'evaluation', '.', '\\n\\n', 'Participants', 'have', 'blood', 'and', 'urine', 'tests', 'six', 'times', 'during', 'the', 'study', 'and', 'complete', 'questionnaires', 'each', 'week', 'about', 'their', 'pain', ',', 'symptoms', ',', 'and', 'activities', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 11,
                "text": "Neurotropin",
                "type": "DRUG"
            },
            {
                "start": 25,
                "end": 37,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 130,
                "text": "neurotropin",
                "type": "DRUG"
            },
            {
                "start": 157,
                "end": 161,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 190,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 233,
                "end": 245,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 297,
                "end": 308,
                "text": "Neurotropin",
                "type": "DRUG"
            },
            {
                "start": 402,
                "end": 414,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 428,
                "end": 440,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 575,
                "end": 579,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 855,
                "end": 867,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 890,
                "end": 901,
                "text": "neurotropin",
                "type": "DRUG"
            },
            {
                "start": 907,
                "end": 914,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1082,
                "end": 1086,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1210,
                "end": 1221,
                "text": "neurotropin",
                "type": "DRUG"
            },
            {
                "start": 1263,
                "end": 1270,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1489,
                "end": 1493,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02573402",
        "study_official_title": "The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury ",
        "study_brief_summary": " The purpose of this research study is to evaluate the effects upon the bladder of electric stimulation of the leg's tibial nerve in people with acute spinal cord injury with an intervention called transcutaneous tibial nerve stimulation (TTNS).",
        "text": "The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury | The purpose of this research study is to evaluate the effects upon the bladder of electric stimulation of the leg's tibial nerve in people with acute spinal cord injury with an intervention called transcutaneous tibial nerve stimulation (TTNS).",
        "tokens": "['The', 'Effects', 'Upon', 'the', 'Bladder', 'of', 'Transcutaneous', 'Tibial', 'Nerve', 'Stimulation', 'in', 'Acute', 'Traumatic', 'Spinal', 'Cord', 'Injury', '|', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'upon', 'the', 'bladder', 'of', 'electric', 'stimulation', 'of', 'the', 'leg', \"'s\", 'tibial', 'nerve', 'in', 'people', 'with', 'acute', 'spinal', 'cord', 'injury', 'with', 'an', 'intervention', 'called', 'transcutaneous', 'tibial', 'nerve', 'stimulation', '(', 'TTNS', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 71,
                "text": "Transcutaneous Tibial Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 75,
                "end": 109,
                "text": "Acute Traumatic Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 194,
                "end": 240,
                "text": "electric stimulation of the leg's tibial nerve",
                "type": "OTHER"
            },
            {
                "start": 256,
                "end": 280,
                "text": "acute spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 309,
                "end": 348,
                "text": "transcutaneous tibial nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 350,
                "end": 354,
                "text": "TTNS",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00480818",
        "study_official_title": "An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Young and Elderly Subjects ",
        "study_brief_summary": " To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy young adult and elderly subjects.To assess the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy young adult and elderly subjects.",
        "text": "An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Young and Elderly Subjects | To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy young adult and elderly subjects.To assess the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy young adult and elderly subjects.",
        "tokens": "['An', 'Ascending', 'Multiple', 'Dose', 'Study', 'of', 'the', 'Safety', ',', 'Pharmacokinetics', '(', 'PK', ')', ',', 'and', 'Pharmacodynamics', '(', 'PD', ')', 'of', 'SAM-531', 'Administered', 'Orally', 'to', 'Healthy', 'Young', 'and', 'Elderly', 'Subjects', '|', 'To', 'assess', 'the', 'safety', 'and', 'tolerability', 'of', 'ascending', 'multiple', 'oral', 'doses', 'of', 'SAM-531', ',', 'an', 'investigational', 'drug', ',', 'in', 'healthy', 'young', 'adult', 'and', 'elderly', 'subjects', '.', 'To', 'assess', 'the', 'pharmacokinetics', '(', 'PK', ')', 'and', 'pharmacodynamics', '(', 'PD', ')', 'profiles', 'of', 'multiple', 'oral', 'doses', 'of', 'SAM-531', 'in', 'healthy', 'young', 'adult', 'and', 'elderly', 'subjects', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 100,
                "end": 107,
                "text": "SAM-531",
                "type": "DRUG"
            },
            {
                "start": 242,
                "end": 249,
                "text": "SAM-531",
                "type": "DRUG"
            },
            {
                "start": 417,
                "end": 424,
                "text": "SAM-531",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03953131",
        "study_official_title": "A Pilot Study of 68Ga-Dotatate PET CT for Radiation Treatment Response Assessment in Meningiomas ",
        "study_brief_summary": " This phase I trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in predicting tumor growth in patients with meningiomas. Giving Gallium Ga 68-DOTATATE before PET/CT scan may work better in predicting tumor growth in patients with meningiomas.",
        "text": "A Pilot Study of 68Ga-Dotatate PET CT for Radiation Treatment Response Assessment in Meningiomas | This phase I trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in predicting tumor growth in patients with meningiomas. Giving Gallium Ga 68-DOTATATE before PET/CT scan may work better in predicting tumor growth in patients with meningiomas.",
        "tokens": "['A', 'Pilot', 'Study', 'of', '68Ga', '-', 'Dotatate', 'PET', 'CT', 'for', 'Radiation', 'Treatment', 'Response', 'Assessment', 'in', 'Meningiomas', '|', 'This', 'phase', 'I', 'trial', 'studies', 'how', 'well', 'gallium', 'Ga', '68', '-', 'DOTATATE', 'positron', 'emission', 'tomography', '(', 'PET)/computed', 'tomography', '(', 'CT', ')', 'works', 'in', 'predicting', 'tumor', 'growth', 'in', 'patients', 'with', 'meningiomas', '.', 'Giving', 'Gallium', 'Ga', '68', '-', 'DOTATATE', 'before', 'PET', '/', 'CT', 'scan', 'may', 'work', 'better', 'in', 'predicting', 'tumor', 'growth', 'in', 'patients', 'with', 'meningiomas', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 85,
                "end": 96,
                "text": "Meningiomas",
                "type": "CONDITION"
            },
            {
                "start": 268,
                "end": 279,
                "text": "meningiomas",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 401,
                "text": "meningiomas",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00363753",
        "study_official_title": "Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack ",
        "study_brief_summary": " Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.",
        "text": "Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack | Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.",
        "tokens": "['Pilot', 'Study', 'of', 'Continuing', 'Aspirin', 'Versus', 'Switching', 'to', 'Clopidogrel', 'After', 'Stroke', 'or', 'Transient', 'Ischemic', 'Attack', '|', 'Pilot', 'study', 'of', 'continuing', 'aspirin', 'versus', 'switching', 'to', 'clopidogrel', 'after', 'stroke', 'or', 'transient', 'ischemic', 'attack', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 33,
                "text": "Aspirin",
                "type": "DRUG"
            },
            {
                "start": 54,
                "end": 65,
                "text": "Clopidogrel",
                "type": "DRUG"
            },
            {
                "start": 72,
                "end": 78,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 82,
                "end": 107,
                "text": "Transient Ischemic Attack",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 143,
                "text": "aspirin",
                "type": "DRUG"
            },
            {
                "start": 164,
                "end": 175,
                "text": "clopidogrel",
                "type": "DRUG"
            },
            {
                "start": 182,
                "end": 188,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 192,
                "end": 217,
                "text": "transient ischemic attack",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04859673",
        "study_official_title": "Influence of Radial Extracorpeal Shock Wave Therapy on Sonographic Findings in Patients With Hemiplegic Shoulder Pain ",
        "study_brief_summary": " The purposes of this study are to examine sonographic structural changes pre and post the radial extracorporeal shock wave intervention in hemiplegic shoulder pain, and to assess the relationships between sonographic structural changes and hemiplegic shoulder pain.",
        "text": "Influence of Radial Extracorpeal Shock Wave Therapy on Sonographic Findings in Patients With Hemiplegic Shoulder Pain | The purposes of this study are to examine sonographic structural changes pre and post the radial extracorporeal shock wave intervention in hemiplegic shoulder pain, and to assess the relationships between sonographic structural changes and hemiplegic shoulder pain.",
        "tokens": "['Influence', 'of', 'Radial', 'Extracorpeal', 'Shock', 'Wave', 'Therapy', 'on', 'Sonographic', 'Findings', 'in', 'Patients', 'With', 'Hemiplegic', 'Shoulder', 'Pain', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', 'to', 'examine', 'sonographic', 'structural', 'changes', 'pre', 'and', 'post', 'the', 'radial', 'extracorporeal', 'shock', 'wave', 'intervention', 'in', 'hemiplegic', 'shoulder', 'pain', ',', 'and', 'to', 'assess', 'the', 'relationships', 'between', 'sonographic', 'structural', 'changes', 'and', 'hemiplegic', 'shoulder', 'pain', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 51,
                "text": "Radial Extracorpeal Shock Wave Therapy",
                "type": "OTHER"
            },
            {
                "start": 93,
                "end": 103,
                "text": "Hemiplegic",
                "type": "CONDITION"
            },
            {
                "start": 104,
                "end": 117,
                "text": "Shoulder Pain",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 255,
                "text": "radial extracorporeal shock wave intervention",
                "type": "OTHER"
            },
            {
                "start": 259,
                "end": 269,
                "text": "hemiplegic",
                "type": "CONDITION"
            },
            {
                "start": 270,
                "end": 283,
                "text": "shoulder pain",
                "type": "CONDITION"
            },
            {
                "start": 360,
                "end": 370,
                "text": "hemiplegic",
                "type": "CONDITION"
            },
            {
                "start": 371,
                "end": 384,
                "text": "shoulder pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02728752",
        "study_official_title": "Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (\"ProDERM Study\") ",
        "study_brief_summary": " Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (\"ProDERM study\")",
        "text": "Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (\"ProDERM Study\") | Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (\"ProDERM study\")",
        "tokens": "['Prospective', ',', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Phase', 'III', 'Study', 'Evaluating', 'Efficacy', 'and', 'Safety', 'of', 'Octagam', '10', '%', 'in', 'Patients', 'With', 'Dermatomyositis', '(', '\"', 'ProDERM', 'Study', '\"', ')', '|', 'Prospective', ',', 'Double', '-', 'blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', 'Phase', 'III', 'Study', 'Evaluating', 'Efficacy', 'and', 'Safety', 'of', 'Octagam', '10', '%', 'in', 'Patients', 'With', 'Dermatomyositis', '(', '\"', 'ProDERM', 'study', '\"', ')']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 46,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 108,
                "end": 115,
                "text": "Octagam",
                "type": "DRUG"
            },
            {
                "start": 137,
                "end": 152,
                "text": "Dermatomyositis",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 219,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 281,
                "end": 288,
                "text": "Octagam",
                "type": "DRUG"
            },
            {
                "start": 310,
                "end": 325,
                "text": "Dermatomyositis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04913506",
        "study_official_title": "Evaluation of the Effects of Neuromuscular Electrical Stimulation and Mirror Therapy in Hemiplegia Rehabilitation; Prospective, Randomized, Controlled, Single-Blinded Study ",
        "study_brief_summary": " In this study, it was aimed to evaluate whether or not NMES in front of the mirror brings an additional benefit to mirror therapy alone or NMES alone on upper extremity motor and functional development, spasticity, anxiety, depression, cognitive function and activities of daily living, and neuropathic pain.",
        "text": "Evaluation of the Effects of Neuromuscular Electrical Stimulation and Mirror Therapy in Hemiplegia Rehabilitation; Prospective, Randomized, Controlled, Single-Blinded Study | In this study, it was aimed to evaluate whether or not NMES in front of the mirror brings an additional benefit to mirror therapy alone or NMES alone on upper extremity motor and functional development, spasticity, anxiety, depression, cognitive function and activities of daily living, and neuropathic pain.",
        "tokens": "['Evaluation', 'of', 'the', 'Effects', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'and', 'Mirror', 'Therapy', 'in', 'Hemiplegia', 'Rehabilitation', ';', 'Prospective', ',', 'Randomized', ',', 'Controlled', ',', 'Single', '-', 'Blinded', 'Study', '|', 'In', 'this', 'study', ',', 'it', 'was', 'aimed', 'to', 'evaluate', 'whether', 'or', 'not', 'NMES', 'in', 'front', 'of', 'the', 'mirror', 'brings', 'an', 'additional', 'benefit', 'to', 'mirror', 'therapy', 'alone', 'or', 'NMES', 'alone', 'on', 'upper', 'extremity', 'motor', 'and', 'functional', 'development', ',', 'spasticity', ',', 'anxiety', ',', 'depression', ',', 'cognitive', 'function', 'and', 'activities', 'of', 'daily', 'living', ',', 'and', 'neuropathic', 'pain', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 65,
                "text": "Neuromuscular Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 70,
                "end": 84,
                "text": "Mirror Therapy",
                "type": "OTHER"
            },
            {
                "start": 88,
                "end": 98,
                "text": "Hemiplegia",
                "type": "CONDITION"
            },
            {
                "start": 230,
                "end": 257,
                "text": "NMES in front of the mirror",
                "type": "OTHER"
            },
            {
                "start": 290,
                "end": 310,
                "text": "mirror therapy alone",
                "type": "CONTROL"
            },
            {
                "start": 314,
                "end": 324,
                "text": "NMES alone",
                "type": "CONTROL"
            },
            {
                "start": 378,
                "end": 388,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 397,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 399,
                "end": 409,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 466,
                "end": 482,
                "text": "neuropathic pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02938000",
        "study_official_title": "E-Rehabilitation: Aerobic Resistance Training for Stroke Survivors ",
        "study_brief_summary": " This pilot study intends to evaluate an online exercise video rehabilitation program for stroke survivors with moderate disability compared to usual care. The intervention videos combine aerobic and resistance training using a latex resistance band, Thera band\u00ae elastic band, specifically designed for rehabilitation. This study will aim to show that for patients suffering acute ischemic stroke resulting in disability, at-home physical therapy with aerobic exercise videos will improve depression level and aerobic capacity more than usual care.",
        "text": "E-Rehabilitation: Aerobic Resistance Training for Stroke Survivors | This pilot study intends to evaluate an online exercise video rehabilitation program for stroke survivors with moderate disability compared to usual care. The intervention videos combine aerobic and resistance training using a latex resistance band, Thera band\u00ae elastic band, specifically designed for rehabilitation. This study will aim to show that for patients suffering acute ischemic stroke resulting in disability, at-home physical therapy with aerobic exercise videos will improve depression level and aerobic capacity more than usual care.",
        "tokens": "['E', '-', 'Rehabilitation', ':', 'Aerobic', 'Resistance', 'Training', 'for', 'Stroke', 'Survivors', '|', 'This', 'pilot', 'study', 'intends', 'to', 'evaluate', 'an', 'online', 'exercise', 'video', 'rehabilitation', 'program', 'for', 'stroke', 'survivors', 'with', 'moderate', 'disability', 'compared', 'to', 'usual', 'care', '.', 'The', 'intervention', 'videos', 'combine', 'aerobic', 'and', 'resistance', 'training', 'using', 'a', 'latex', 'resistance', 'band', ',', 'Thera', 'band', '\u00ae', 'elastic', 'band', ',', 'specifically', 'designed', 'for', 'rehabilitation', '.', 'This', 'study', 'will', 'aim', 'to', 'show', 'that', 'for', 'patients', 'suffering', 'acute', 'ischemic', 'stroke', 'resulting', 'in', 'disability', ',', 'at', '-', 'home', 'physical', 'therapy', 'with', 'aerobic', 'exercise', 'videos', 'will', 'improve', 'depression', 'level', 'and', 'aerobic', 'capacity', 'more', 'than', 'usual', 'care', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 45,
                "text": "Aerobic Resistance Training",
                "type": "PHYSICAL"
            },
            {
                "start": 50,
                "end": 56,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 109,
                "end": 153,
                "text": "online exercise video rehabilitation program",
                "type": "PHYSICAL"
            },
            {
                "start": 158,
                "end": 164,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 222,
                "text": "usual care",
                "type": "CONTROL"
            },
            {
                "start": 256,
                "end": 317,
                "text": "aerobic and resistance training using a latex resistance band",
                "type": "PHYSICAL"
            },
            {
                "start": 319,
                "end": 343,
                "text": "Thera band\u00ae elastic band",
                "type": "PHYSICAL"
            },
            {
                "start": 443,
                "end": 464,
                "text": "acute ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 520,
                "end": 543,
                "text": "aerobic exercise videos",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT05150093",
        "study_official_title": "Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor ",
        "study_brief_summary": " The goals of this project are 1) to determine the incidence of neurological voice disorders in patients with dystonia and essential tremor undergoing deep brain stimulation (DBS), 2) investigate the neuroimaging and intracranial neurophysiology correlates of voice dysfunction in these subjects, and subsequently 3) determine the effects of DBS on voice function.",
        "text": "Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor | The goals of this project are 1) to determine the incidence of neurological voice disorders in patients with dystonia and essential tremor undergoing deep brain stimulation (DBS), 2) investigate the neuroimaging and intracranial neurophysiology correlates of voice dysfunction in these subjects, and subsequently 3) determine the effects of DBS on voice function.",
        "tokens": "['Deep', 'Brain', 'Stimulation', 'in', 'Laryngeal', 'Dystonia', 'and', 'Voice', 'Tremor', '|', 'The', 'goals', 'of', 'this', 'project', 'are', '1', ')', 'to', 'determine', 'the', 'incidence', 'of', 'neurological', 'voice', 'disorders', 'in', 'patients', 'with', 'dystonia', 'and', 'essential', 'tremor', 'undergoing', 'deep', 'brain', 'stimulation', '(', 'DBS', ')', ',', '2', ')', 'investigate', 'the', 'neuroimaging', 'and', 'intracranial', 'neurophysiology', 'correlates', 'of', 'voice', 'dysfunction', 'in', 'these', 'subjects', ',', 'and', 'subsequently', '3', ')', 'determine', 'the', 'effects', 'of', 'DBS', 'on', 'voice', 'function', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 26,
                "end": 44,
                "text": "Laryngeal Dystonia",
                "type": "CONDITION"
            },
            {
                "start": 49,
                "end": 61,
                "text": "Voice Tremor",
                "type": "CONDITION"
            },
            {
                "start": 127,
                "end": 155,
                "text": "neurological voice disorders",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 181,
                "text": "dystonia",
                "type": "CONDITION"
            },
            {
                "start": 186,
                "end": 202,
                "text": "essential tremor",
                "type": "CONDITION"
            },
            {
                "start": 214,
                "end": 236,
                "text": "deep brain stimulation",
                "type": "OTHER"
            },
            {
                "start": 238,
                "end": 241,
                "text": "DBS",
                "type": "OTHER"
            },
            {
                "start": 323,
                "end": 340,
                "text": "voice dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 405,
                "end": 408,
                "text": "DBS",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03317171",
        "study_official_title": "Studio Monocentrico in Doppio Cieco Randomizzato Dell'Effetto di Una Miscela di Flavonoidi ed Acidi Grassi Naturali in Pazienti Affetti da Distrofia Muscolare ",
        "study_brief_summary": " The study aimed to assess the safety and, partially, the efficacy of dietary supplementation of a flavonoids-, DHA- and EPA-based natural supplement in non-ambulant DMD boys and in a cohort of LGMD and FSHD patients to compare its effect in MDs of different aetiology and to eventually highlight any differences in inflammatory involved pathways. To assess safety, patient's laboratory parameters were monitored and adverse events recorded, while efficacy was evaluated through performance scale questionnaire and strength measurement (6 minute walking test and Biodex System 4 Dynamometer parameter evaluation). This study was conceived as proof of principle for the safe use of flavonoids/omega3s-based compound as an adjuvant in the management of neuromuscular disorders; besides, its efficacy in alleviating symptoms linked to secondary effects of genetic mutation as inflammation, muscular pain and weakness was assessed.",
        "text": "Studio Monocentrico in Doppio Cieco Randomizzato Dell'Effetto di Una Miscela di Flavonoidi ed Acidi Grassi Naturali in Pazienti Affetti da Distrofia Muscolare | The study aimed to assess the safety and, partially, the efficacy of dietary supplementation of a flavonoids-, DHA- and EPA-based natural supplement in non-ambulant DMD boys and in a cohort of LGMD and FSHD patients to compare its effect in MDs of different aetiology and to eventually highlight any differences in inflammatory involved pathways. To assess safety, patient's laboratory parameters were monitored and adverse events recorded, while efficacy was evaluated through performance scale questionnaire and strength measurement (6 minute walking test and Biodex System 4 Dynamometer parameter evaluation). This study was conceived as proof of principle for the safe use of flavonoids/omega3s-based compound as an adjuvant in the management of neuromuscular disorders; besides, its efficacy in alleviating symptoms linked to secondary effects of genetic mutation as inflammation, muscular pain and weakness was assessed.",
        "tokens": "['Studio', 'Monocentrico', 'in', 'Doppio', 'Cieco', 'Randomizzato', \"Dell'Effetto\", 'di', 'Una', 'Miscela', 'di', 'Flavonoidi', 'ed', 'Acidi', 'Grassi', 'Naturali', 'in', 'Pazienti', 'Affetti', 'da', 'Distrofia', 'Muscolare', '|', 'The', 'study', 'aimed', 'to', 'assess', 'the', 'safety', 'and', ',', 'partially', ',', 'the', 'efficacy', 'of', 'dietary', 'supplementation', 'of', 'a', 'flavonoids-', ',', 'DHA-', 'and', 'EPA', '-', 'based', 'natural', 'supplement', 'in', 'non', '-', 'ambulant', 'DMD', 'boys', 'and', 'in', 'a', 'cohort', 'of', 'LGMD', 'and', 'FSHD', 'patients', 'to', 'compare', 'its', 'effect', 'in', 'MDs', 'of', 'different', 'aetiology', 'and', 'to', 'eventually', 'highlight', 'any', 'differences', 'in', 'inflammatory', 'involved', 'pathways', '.', 'To', 'assess', 'safety', ',', 'patient', \"'s\", 'laboratory', 'parameters', 'were', 'monitored', 'and', 'adverse', 'events', 'recorded', ',', 'while', 'efficacy', 'was', 'evaluated', 'through', 'performance', 'scale', 'questionnaire', 'and', 'strength', 'measurement', '(', '6', 'minute', 'walking', 'test', 'and', 'Biodex', 'System', '4', 'Dynamometer', 'parameter', 'evaluation', ')', '.', 'This', 'study', 'was', 'conceived', 'as', 'proof', 'of', 'principle', 'for', 'the', 'safe', 'use', 'of', 'flavonoids', '/', 'omega3s', '-', 'based', 'compound', 'as', 'an', 'adjuvant', 'in', 'the', 'management', 'of', 'neuromuscular', 'disorders', ';', 'besides', ',', 'its', 'efficacy', 'in', 'alleviating', 'symptoms', 'linked', 'to', 'secondary', 'effects', 'of', 'genetic', 'mutation', 'as', 'inflammation', ',', 'muscular', 'pain', 'and', 'weakness', 'was', 'assessed', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 259,
                "end": 270,
                "text": "flavonoids-",
                "type": "DRUG"
            },
            {
                "start": 272,
                "end": 276,
                "text": "DHA-",
                "type": "DRUG"
            },
            {
                "start": 281,
                "end": 284,
                "text": "EPA",
                "type": "DRUG"
            },
            {
                "start": 326,
                "end": 329,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 358,
                "text": "LGMD",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 367,
                "text": "FSHD",
                "type": "CONDITION"
            },
            {
                "start": 402,
                "end": 405,
                "text": "MDs",
                "type": "CONDITION"
            },
            {
                "start": 841,
                "end": 851,
                "text": "flavonoids",
                "type": "DRUG"
            },
            {
                "start": 852,
                "end": 859,
                "text": "omega3s",
                "type": "DRUG"
            },
            {
                "start": 1033,
                "end": 1045,
                "text": "inflammation",
                "type": "CONDITION"
            },
            {
                "start": 1047,
                "end": 1060,
                "text": "muscular pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00314041",
        "study_official_title": "A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age. ",
        "study_brief_summary": " Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines.\n\nBooster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory",
        "text": "A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age. | Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines.\n\nBooster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Controlled', ',', 'Active', 'Comparator', ',', 'Phase', 'II', 'Study', 'to', 'Assess', 'the', 'Tolerance', 'and', 'Immunogenicity', 'of', 'Conjugate', 'Meningococcal', 'C', '(', 'MnCC', ')', 'Vaccine', 'in', 'Infants', 'When', 'Administered', 'in', 'Conjunction', 'With', 'Primary', 'DTP', '/', 'Hib', 'Vaccination', 'at', '2', ',', '3', ',', 'and', '4', 'Months', 'of', 'Age', '.', '|', 'Infant', 'phase', ':', 'To', 'determine', 'the', 'safety', 'of', 'and', 'production', 'of', 'antibodies', 'by', 'a', 'group', 'C', 'meningococcal', 'conjugate', 'vaccine', '(', 'MnCC', ')', ',', 'when', 'given', 'at', '2', ',', '3', ',', 'and', '4', 'months', 'of', 'age', 'with', 'routine', 'vaccines', '.', '\\n\\n', 'Booster', 'phase', ':', 'To', 'compare', 'the', 'safety', 'of', 'and', 'production', 'of', 'antibodies', 'by', 'MnCC', 'with', 'and', 'without', 'MMR', 'and', 'to', 'compare', 'the', 'antibody', 'response', 'to', 'that', 'produced', 'by', 'a', 'low', 'dose', 'of', 'plain', 'polysaccharide', 'vaccine', 'as', 'a', 'way', 'of', 'investigating', 'immune', 'memory']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 120,
                "end": 160,
                "text": "Conjugate Meningococcal C (MnCC) Vaccine",
                "type": "DRUG"
            },
            {
                "start": 210,
                "end": 237,
                "text": "Primary DTP/Hib Vaccination",
                "type": "DRUG"
            },
            {
                "start": 345,
                "end": 384,
                "text": "group C meningococcal conjugate vaccine",
                "type": "DRUG"
            },
            {
                "start": 386,
                "end": 390,
                "text": "MnCC",
                "type": "DRUG"
            },
            {
                "start": 529,
                "end": 533,
                "text": "MnCC",
                "type": "DRUG"
            },
            {
                "start": 551,
                "end": 554,
                "text": "MMR",
                "type": "DRUG"
            },
            {
                "start": 626,
                "end": 654,
                "text": "plain polysaccharide vaccine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT01565395",
        "study_official_title": "Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin\u00ae) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) ",
        "study_brief_summary": " The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A (Xeomin\u00ae) injections into the parotid and submandibular glands in patients with Parkinson's Disease/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) with troublesome sialorrhea.",
        "text": "Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin\u00ae) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) | The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A (Xeomin\u00ae) injections into the parotid and submandibular glands in patients with Parkinson's Disease/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) with troublesome sialorrhea.",
        "tokens": "['Randomized', 'Double', 'Blind', 'Placebo', 'Controlled', 'Cross', '-', 'Over', 'Study', 'of', 'Incobotulinum', 'Toxin', 'A', '(', 'Xeomin', '\u00ae', ')', 'for', 'Troublesome', 'Sialorrhea', 'in', 'Parkinson', \"'s\", 'Disease', '(', 'PD)/Parkinsonism', 'and', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'Incobotulinum', 'Toxin', 'A', '(', 'Xeomin', '\u00ae', ')', 'injections', 'into', 'the', 'parotid', 'and', 'submandibular', 'glands', 'in', 'patients', 'with', 'Parkinson', \"'s\", 'Disease', '/', 'Parkinsonism', 'and', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', 'with', 'troublesome', 'sialorrhea', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 31,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 63,
                "end": 84,
                "text": "Incobotulinum Toxin A",
                "type": "DRUG"
            },
            {
                "start": 86,
                "end": 92,
                "text": "Xeomin",
                "type": "DRUG"
            },
            {
                "start": 111,
                "end": 121,
                "text": "Sialorrhea",
                "type": "CONDITION"
            },
            {
                "start": 125,
                "end": 144,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 167,
                "end": 196,
                "text": "Amyotrophic Lateral Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 198,
                "end": 201,
                "text": "ALS",
                "type": "CONDITION"
            },
            {
                "start": 273,
                "end": 294,
                "text": "Incobotulinum Toxin A",
                "type": "DRUG"
            },
            {
                "start": 296,
                "end": 302,
                "text": "Xeomin",
                "type": "DRUG"
            },
            {
                "start": 375,
                "end": 394,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 395,
                "end": 407,
                "text": "Parkinsonism",
                "type": "CONDITION"
            },
            {
                "start": 412,
                "end": 441,
                "text": "Amyotrophic Lateral Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 443,
                "end": 446,
                "text": "ALS",
                "type": "CONDITION"
            },
            {
                "start": 465,
                "end": 475,
                "text": "sialorrhea",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01995825",
        "study_official_title": "Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients ",
        "study_brief_summary": " In this study, brand name lamotrigine (LAMICTAL) and generic lamotrigine will be compared in patients with epilepsy. Both the brand name and generic lamotrigine are approved by the Food and Drug Administration (FDA) and are commonly used to treat epilepsy. Some physicians and patients with epilepsy have believed that brand and generic lamotrigine have had clinically significant differences in efficacy and tolerability. The brand name and generic tablets have been shown to be the same when blood levels were measured in healthy volunteers without epilepsy, but these drugs have not yet been compared in patients with epilepsy. This study will do this comparison, by switching patients between brand and generic in a very structured manner, and seeing if the drugs are the same, primarily in terms of blood levels. Other comparisons will also be made secondarily, looking for any differences in adverse effects and seizure control.",
        "text": "Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients | In this study, brand name lamotrigine (LAMICTAL) and generic lamotrigine will be compared in patients with epilepsy. Both the brand name and generic lamotrigine are approved by the Food and Drug Administration (FDA) and are commonly used to treat epilepsy. Some physicians and patients with epilepsy have believed that brand and generic lamotrigine have had clinically significant differences in efficacy and tolerability. The brand name and generic tablets have been shown to be the same when blood levels were measured in healthy volunteers without epilepsy, but these drugs have not yet been compared in patients with epilepsy. This study will do this comparison, by switching patients between brand and generic in a very structured manner, and seeing if the drugs are the same, primarily in terms of blood levels. Other comparisons will also be made secondarily, looking for any differences in adverse effects and seizure control.",
        "tokens": "['Evaluation', 'of', 'Bioequivalence', 'of', 'Lamotrigine', 'Tablets', 'in', 'Epileptic', 'Patients', '|', 'In', 'this', 'study', ',', 'brand', 'name', 'lamotrigine', '(', 'LAMICTAL', ')', 'and', 'generic', 'lamotrigine', 'will', 'be', 'compared', 'in', 'patients', 'with', 'epilepsy', '.', 'Both', 'the', 'brand', 'name', 'and', 'generic', 'lamotrigine', 'are', 'approved', 'by', 'the', 'Food', 'and', 'Drug', 'Administration', '(', 'FDA', ')', 'and', 'are', 'commonly', 'used', 'to', 'treat', 'epilepsy', '.', 'Some', 'physicians', 'and', 'patients', 'with', 'epilepsy', 'have', 'believed', 'that', 'brand', 'and', 'generic', 'lamotrigine', 'have', 'had', 'clinically', 'significant', 'differences', 'in', 'efficacy', 'and', 'tolerability', '.', 'The', 'brand', 'name', 'and', 'generic', 'tablets', 'have', 'been', 'shown', 'to', 'be', 'the', 'same', 'when', 'blood', 'levels', 'were', 'measured', 'in', 'healthy', 'volunteers', 'without', 'epilepsy', ',', 'but', 'these', 'drugs', 'have', 'not', 'yet', 'been', 'compared', 'in', 'patients', 'with', 'epilepsy', '.', 'This', 'study', 'will', 'do', 'this', 'comparison', ',', 'by', 'switching', 'patients', 'between', 'brand', 'and', 'generic', 'in', 'a', 'very', 'structured', 'manner', ',', 'and', 'seeing', 'if', 'the', 'drugs', 'are', 'the', 'same', ',', 'primarily', 'in', 'terms', 'of', 'blood', 'levels', '.', 'Other', 'comparisons', 'will', 'also', 'be', 'made', 'secondarily', ',', 'looking', 'for', 'any', 'differences', 'in', 'adverse', 'effects', 'and', 'seizure', 'control', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 43,
                "text": "Lamotrigine",
                "type": "DRUG"
            },
            {
                "start": 55,
                "end": 64,
                "text": "Epileptic",
                "type": "CONDITION"
            },
            {
                "start": 102,
                "end": 113,
                "text": "lamotrigine",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 123,
                "text": "LAMICTAL",
                "type": "DRUG"
            },
            {
                "start": 137,
                "end": 148,
                "text": "lamotrigine",
                "type": "DRUG"
            },
            {
                "start": 183,
                "end": 191,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 225,
                "end": 236,
                "text": "lamotrigine",
                "type": "DRUG"
            },
            {
                "start": 323,
                "end": 331,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 367,
                "end": 375,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 413,
                "end": 424,
                "text": "lamotrigine",
                "type": "DRUG"
            },
            {
                "start": 627,
                "end": 635,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 697,
                "end": 705,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 994,
                "end": 1001,
                "text": "seizure",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02713464",
        "study_official_title": "Effect of Education on Prevalence of Kernicterus in Five Regions in Nigeria ",
        "study_brief_summary": " This study examines (a) whether introduction of public, health provider, and maternal education about risks of jaundice will decrease the occurrence of ABE compared with baseline prevalence (before-after design) or (b) whether antenatal or postpartum instruction to mothers will decrease the incidence of ABE compared with those who did not received instruction (concurrent opportunistic controls in phase 2).",
        "text": "Effect of Education on Prevalence of Kernicterus in Five Regions in Nigeria | This study examines (a) whether introduction of public, health provider, and maternal education about risks of jaundice will decrease the occurrence of ABE compared with baseline prevalence (before-after design) or (b) whether antenatal or postpartum instruction to mothers will decrease the incidence of ABE compared with those who did not received instruction (concurrent opportunistic controls in phase 2).",
        "tokens": "['Effect', 'of', 'Education', 'on', 'Prevalence', 'of', 'Kernicterus', 'in', 'Five', 'Regions', 'in', 'Nigeria', '|', 'This', 'study', 'examines', '(', 'a', ')', 'whether', 'introduction', 'of', 'public', ',', 'health', 'provider', ',', 'and', 'maternal', 'education', 'about', 'risks', 'of', 'jaundice', 'will', 'decrease', 'the', 'occurrence', 'of', 'ABE', 'compared', 'with', 'baseline', 'prevalence', '(', 'before', '-', 'after', 'design', ')', 'or', '(', 'b', ')', 'whether', 'antenatal', 'or', 'postpartum', 'instruction', 'to', 'mothers', 'will', 'decrease', 'the', 'incidence', 'of', 'ABE', 'compared', 'with', 'those', 'who', 'did', 'not', 'received', 'instruction', '(', 'concurrent', 'opportunistic', 'controls', 'in', 'phase', '2', ')', '.']",
        "token_bio_labels": "['O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 19,
                "text": "Education",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 37,
                "end": 48,
                "text": "Kernicterus",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 173,
                "text": "public, health provider, and maternal education",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 189,
                "end": 197,
                "text": "jaundice",
                "type": "CONDITION"
            },
            {
                "start": 230,
                "end": 233,
                "text": "ABE",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 340,
                "text": "antenatal or postpartum instruction",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 383,
                "end": 386,
                "text": "ABE",
                "type": "CONDITION"
            },
            {
                "start": 415,
                "end": 439,
                "text": "not received instruction",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01329770",
        "study_official_title": "Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome ",
        "study_brief_summary": " The Fragile X syndrome (FXS) was first described by Dr. Martin and Dr. Bell in 1943, in families with several patients affected by sex-linked mental disability. This disorder is the most common cause of inherited mental disability. The prevalence of the Fragile X syndrome has been established at 1 in 2,500 males and 1 in 4000 females.\n\nDespite moderate to severe mental retardation, fragile X patients exhibit macroorchidism, an elongated face, long ears, connective tissue dysplasia, hyperactivity, autistic-like and stereotypical behaviours, speech delay and increased sensory sensitivity.\n\nObjective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.\n\nHypothesis: It is proposed that part of the pathophysiology of the central nervous system in the animal model of the fragile X syndrome may be determined by oxidative stress. In addition, Fragile X patients showed a significantly low level of ascorbic acid in plasma. The biochemical characteristics of oxidative stress may be reversed in the FMR1-KO mice, by a chronic treatment with antioxidant compounds such as tocopherol or melatonin, it may also normalize several hallmarks of the Syndrome such as hyperactivity, anxiety and cognitive deficits. The normalization of the oxidative stress is proposed as a new therapeutic pathway to alleviate conditions caused by an excess of free radicals that are crucial in neurodevelopmental diseases such as autism, down syndrome and other diseases of the central nervous system.",
        "text": "Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome | The Fragile X syndrome (FXS) was first described by Dr. Martin and Dr. Bell in 1943, in families with several patients affected by sex-linked mental disability. This disorder is the most common cause of inherited mental disability. The prevalence of the Fragile X syndrome has been established at 1 in 2,500 males and 1 in 4000 females.\n\nDespite moderate to severe mental retardation, fragile X patients exhibit macroorchidism, an elongated face, long ears, connective tissue dysplasia, hyperactivity, autistic-like and stereotypical behaviours, speech delay and increased sensory sensitivity.\n\nObjective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.\n\nHypothesis: It is proposed that part of the pathophysiology of the central nervous system in the animal model of the fragile X syndrome may be determined by oxidative stress. In addition, Fragile X patients showed a significantly low level of ascorbic acid in plasma. The biochemical characteristics of oxidative stress may be reversed in the FMR1-KO mice, by a chronic treatment with antioxidant compounds such as tocopherol or melatonin, it may also normalize several hallmarks of the Syndrome such as hyperactivity, anxiety and cognitive deficits. The normalization of the oxidative stress is proposed as a new therapeutic pathway to alleviate conditions caused by an excess of free radicals that are crucial in neurodevelopmental diseases such as autism, down syndrome and other diseases of the central nervous system.",
        "tokens": "['Phase', 'II', 'Double', '-', 'blind', 'Randomized', 'Placebo', '-', 'controlled', '1', '-', 'way', 'Crossover', 'Trial', 'to', 'Investigate', 'Safety', 'and', 'Efficacy', 'of', 'the', 'Ascorbic', 'Acid', 'and', 'Tocopherol', 'for', 'the', 'Treatment', 'of', 'the', 'Fragile', 'X', 'Syndrome', '|', 'The', 'Fragile', 'X', 'syndrome', '(', 'FXS', ')', 'was', 'first', 'described', 'by', 'Dr.', 'Martin', 'and', 'Dr.', 'Bell', 'in', '1943', ',', 'in', 'families', 'with', 'several', 'patients', 'affected', 'by', 'sex', '-', 'linked', 'mental', 'disability', '.', 'This', 'disorder', 'is', 'the', 'most', 'common', 'cause', 'of', 'inherited', 'mental', 'disability', '.', 'The', 'prevalence', 'of', 'the', 'Fragile', 'X', 'syndrome', 'has', 'been', 'established', 'at', '1', 'in', '2,500', 'males', 'and', '1', 'in', '4000', 'females', '.', '\\n\\n', 'Despite', 'moderate', 'to', 'severe', 'mental', 'retardation', ',', 'fragile', 'X', 'patients', 'exhibit', 'macroorchidism', ',', 'an', 'elongated', 'face', ',', 'long', 'ears', ',', 'connective', 'tissue', 'dysplasia', ',', 'hyperactivity', ',', 'autistic', '-', 'like', 'and', 'stereotypical', 'behaviours', ',', 'speech', 'delay', 'and', 'increased', 'sensory', 'sensitivity', '.', '\\n\\n', 'Objective', ':', 'To', 'evaluate', 'the', 'effect', 'of', 'the', 'combination', 'of', 'the', 'antioxidant', 'Ascorbic', 'acid', 'and', 'tocopherol', ',', 'as', 'therapy', 'of', 'the', 'Fragile', 'X', 'Syndrome', 'in', 'young', 'males', '.', '\\n\\n', 'Hypothesis', ':', 'It', 'is', 'proposed', 'that', 'part', 'of', 'the', 'pathophysiology', 'of', 'the', 'central', 'nervous', 'system', 'in', 'the', 'animal', 'model', 'of', 'the', 'fragile', 'X', 'syndrome', 'may', 'be', 'determined', 'by', 'oxidative', 'stress', '.', 'In', 'addition', ',', 'Fragile', 'X', 'patients', 'showed', 'a', 'significantly', 'low', 'level', 'of', 'ascorbic', 'acid', 'in', 'plasma', '.', 'The', 'biochemical', 'characteristics', 'of', 'oxidative', 'stress', 'may', 'be', 'reversed', 'in', 'the', 'FMR1', '-', 'KO', 'mice', ',', 'by', 'a', 'chronic', 'treatment', 'with', 'antioxidant', 'compounds', 'such', 'as', 'tocopherol', 'or', 'melatonin', ',', 'it', 'may', 'also', 'normalize', 'several', 'hallmarks', 'of', 'the', 'Syndrome', 'such', 'as', 'hyperactivity', ',', 'anxiety', 'and', 'cognitive', 'deficits', '.', 'The', 'normalization', 'of', 'the', 'oxidative', 'stress', 'is', 'proposed', 'as', 'a', 'new', 'therapeutic', 'pathway', 'to', 'alleviate', 'conditions', 'caused', 'by', 'an', 'excess', 'of', 'free', 'radicals', 'that', 'are', 'crucial', 'in', 'neurodevelopmental', 'diseases', 'such', 'as', 'autism', ',', 'down', 'syndrome', 'and', 'other', 'diseases', 'of', 'the', 'central', 'nervous', 'system', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 40,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 116,
                "end": 129,
                "text": "Ascorbic Acid",
                "type": "DRUG"
            },
            {
                "start": 134,
                "end": 144,
                "text": "Tocopherol",
                "type": "DRUG"
            },
            {
                "start": 170,
                "end": 188,
                "text": "Fragile X Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 213,
                "text": "Fragile X syndrome",
                "type": "CONDITION"
            },
            {
                "start": 215,
                "end": 218,
                "text": "FXS",
                "type": "CONDITION"
            },
            {
                "start": 445,
                "end": 463,
                "text": "Fragile X syndrome",
                "type": "CONDITION"
            },
            {
                "start": 576,
                "end": 585,
                "text": "fragile X",
                "type": "CONDITION"
            },
            {
                "start": 846,
                "end": 857,
                "text": "antioxidant",
                "type": "DRUG"
            },
            {
                "start": 858,
                "end": 871,
                "text": "Ascorbic acid",
                "type": "DRUG"
            },
            {
                "start": 876,
                "end": 886,
                "text": "tocopherol",
                "type": "DRUG"
            },
            {
                "start": 906,
                "end": 924,
                "text": "Fragile X Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 1059,
                "end": 1068,
                "text": "fragile X",
                "type": "CONDITION"
            },
            {
                "start": 1099,
                "end": 1115,
                "text": "oxidative stress",
                "type": "CONDITION"
            },
            {
                "start": 1130,
                "end": 1139,
                "text": "Fragile X",
                "type": "CONDITION"
            },
            {
                "start": 1245,
                "end": 1261,
                "text": "oxidative stress",
                "type": "CONDITION"
            },
            {
                "start": 1327,
                "end": 1338,
                "text": "antioxidant",
                "type": "DRUG"
            },
            {
                "start": 1446,
                "end": 1459,
                "text": "hyperactivity",
                "type": "CONDITION"
            },
            {
                "start": 1461,
                "end": 1468,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 1473,
                "end": 1491,
                "text": "cognitive deficits",
                "type": "CONDITION"
            },
            {
                "start": 1518,
                "end": 1534,
                "text": "oxidative stress",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01537757",
        "study_official_title": "An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (Protocol No. MK-8931-009 [P08535]) ",
        "study_brief_summary": " This study will assess the pharmacokinetics of MK-8931, a \u00df-secretase inhibitor, in participants with renal insufficiency. In Part 1 of the study, pharmacokinetics of MK-8931 in participants with severe renal disease and in healthy matched control participants will be studied. If data from Part 1 confirms that severe renal impairment does not alter the pharmacokinetics of MK-8931 to the extent requiring dosage adjustment, then no further study will be required and Part 2 will be optional. If the data does not support this conclusion, then Part 2 will be conducted to study the pharmacokinetics of MK-8931 in participants with moderate and mild renal impairment compared to healthy matched controls.",
        "text": "An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (Protocol No. MK-8931-009 [P08535]) | This study will assess the pharmacokinetics of MK-8931, a \u00df-secretase inhibitor, in participants with renal insufficiency. In Part 1 of the study, pharmacokinetics of MK-8931 in participants with severe renal disease and in healthy matched control participants will be studied. If data from Part 1 confirms that severe renal impairment does not alter the pharmacokinetics of MK-8931 to the extent requiring dosage adjustment, then no further study will be required and Part 2 will be optional. If the data does not support this conclusion, then Part 2 will be conducted to study the pharmacokinetics of MK-8931 in participants with moderate and mild renal impairment compared to healthy matched controls.",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Two', '-', 'Part', ',', 'Single', '-', 'Dose', 'Study', 'to', 'Investigate', 'the', 'Pharmacokinetics', 'of', 'MK-8931', 'in', 'Subjects', 'With', 'Renal', 'Insufficiency', '(', 'Protocol', 'No', '.', 'MK-8931', '-', '009', '[', 'P08535', ']', ')', '|', 'This', 'study', 'will', 'assess', 'the', 'pharmacokinetics', 'of', 'MK-8931', ',', 'a', '\u00df', '-', 'secretase', 'inhibitor', ',', 'in', 'participants', 'with', 'renal', 'insufficiency', '.', 'In', 'Part', '1', 'of', 'the', 'study', ',', 'pharmacokinetics', 'of', 'MK-8931', 'in', 'participants', 'with', 'severe', 'renal', 'disease', 'and', 'in', 'healthy', 'matched', 'control', 'participants', 'will', 'be', 'studied', '.', 'If', 'data', 'from', 'Part', '1', 'confirms', 'that', 'severe', 'renal', 'impairment', 'does', 'not', 'alter', 'the', 'pharmacokinetics', 'of', 'MK-8931', 'to', 'the', 'extent', 'requiring', 'dosage', 'adjustment', ',', 'then', 'no', 'further', 'study', 'will', 'be', 'required', 'and', 'Part', '2', 'will', 'be', 'optional', '.', 'If', 'the', 'data', 'does', 'not', 'support', 'this', 'conclusion', ',', 'then', 'Part', '2', 'will', 'be', 'conducted', 'to', 'study', 'the', 'pharmacokinetics', 'of', 'MK-8931', 'in', 'participants', 'with', 'moderate', 'and', 'mild', 'renal', 'impairment', 'compared', 'to', 'healthy', 'matched', 'controls', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 82,
                "end": 89,
                "text": "MK-8931",
                "type": "DRUG"
            },
            {
                "start": 107,
                "end": 126,
                "text": "Renal Insufficiency",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 219,
                "text": "MK-8931",
                "type": "DRUG"
            },
            {
                "start": 223,
                "end": 244,
                "text": "\u00df-secretase inhibitor",
                "type": "DRUG"
            },
            {
                "start": 267,
                "end": 286,
                "text": "renal insufficiency",
                "type": "CONDITION"
            },
            {
                "start": 332,
                "end": 339,
                "text": "MK-8931",
                "type": "DRUG"
            },
            {
                "start": 361,
                "end": 381,
                "text": "severe renal disease",
                "type": "CONDITION"
            },
            {
                "start": 540,
                "end": 547,
                "text": "MK-8931",
                "type": "DRUG"
            },
            {
                "start": 768,
                "end": 775,
                "text": "MK-8931",
                "type": "DRUG"
            },
            {
                "start": 797,
                "end": 831,
                "text": "moderate and mild renal impairment",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05357469",
        "study_official_title": "Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study ",
        "study_brief_summary": " To evaluate the efficacy and safety of Scrambler therapy (ST) for chemotherapy-induced painful peripheral neuropathy (CIPN), and the impact of ST on physical functioning and quality of life (QoL) in adolescents and young adults (AYA) cancer patients.\n\nIn this proposed study, we will conduct a two-arm prospective, randomized wait-list controlled clinical trial to investigate the effectiveness of ST on pain and CIPN in AYAs with cancer.",
        "text": "Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study | To evaluate the efficacy and safety of Scrambler therapy (ST) for chemotherapy-induced painful peripheral neuropathy (CIPN), and the impact of ST on physical functioning and quality of life (QoL) in adolescents and young adults (AYA) cancer patients.\n\nIn this proposed study, we will conduct a two-arm prospective, randomized wait-list controlled clinical trial to investigate the effectiveness of ST on pain and CIPN in AYAs with cancer.",
        "tokens": "['Innovative', 'Treatment', 'of', 'Chemotherapy', '-', 'Induced', 'Painful', 'Peripheral', 'Neuropathy', 'in', 'Adolescents', 'and', 'Young', 'Adults', 'With', 'Cancer', ':', 'A', 'Two', 'Arm', 'Pilot', 'Study', '|', 'To', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'Scrambler', 'therapy', '(', 'ST', ')', 'for', 'chemotherapy', '-', 'induced', 'painful', 'peripheral', 'neuropathy', '(', 'CIPN', ')', ',', 'and', 'the', 'impact', 'of', 'ST', 'on', 'physical', 'functioning', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', 'in', 'adolescents', 'and', 'young', 'adults', '(', 'AYA', ')', 'cancer', 'patients', '.', '\\n\\n', 'In', 'this', 'proposed', 'study', ',', 'we', 'will', 'conduct', 'a', 'two', '-', 'arm', 'prospective', ',', 'randomized', 'wait', '-', 'list', 'controlled', 'clinical', 'trial', 'to', 'investigate', 'the', 'effectiveness', 'of', 'ST', 'on', 'pain', 'and', 'CIPN', 'in', 'AYAs', 'with', 'cancer', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 74,
                "text": "Chemotherapy-Induced Painful Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 112,
                "end": 118,
                "text": "Cancer",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 200,
                "text": "Scrambler therapy",
                "type": "OTHER"
            },
            {
                "start": 202,
                "end": 204,
                "text": "ST",
                "type": "OTHER"
            },
            {
                "start": 210,
                "end": 260,
                "text": "chemotherapy-induced painful peripheral neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 262,
                "end": 266,
                "text": "CIPN",
                "type": "CONDITION"
            },
            {
                "start": 287,
                "end": 289,
                "text": "ST",
                "type": "OTHER"
            },
            {
                "start": 378,
                "end": 384,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 542,
                "end": 544,
                "text": "ST",
                "type": "OTHER"
            },
            {
                "start": 548,
                "end": 552,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 557,
                "end": 561,
                "text": "CIPN",
                "type": "CONDITION"
            },
            {
                "start": 575,
                "end": 581,
                "text": "cancer",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02926976",
        "study_official_title": "The Optimal Treatment for Treatment-resistant Schizophrenia ",
        "study_brief_summary": " The Optimal Treatment for Treatment-resistant Schizophrenia",
        "text": "The Optimal Treatment for Treatment-resistant Schizophrenia | The Optimal Treatment for Treatment-resistant Schizophrenia",
        "tokens": "['The', 'Optimal', 'Treatment', 'for', 'Treatment', '-', 'resistant', 'Schizophrenia', '|', 'The', 'Optimal', 'Treatment', 'for', 'Treatment', '-', 'resistant', 'Schizophrenia']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 26,
                "end": 59,
                "text": "Treatment-resistant Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 88,
                "end": 121,
                "text": "Treatment-resistant Schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01607151",
        "study_official_title": "Safety and Feasibility of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage ",
        "study_brief_summary": " Though TTM is ubiquitously used in the neuro-intensive care unit, there is limited experience with the use of TTM after intracerebral hemorrhage (ICH), the most devastating type of stroke. TTM may be a an intervention to improve patient outcomes. This trial addresses the safety and tolerability of a protocol of ultra-early TTM after ICH/IPH and may be the basis for future larger clinical trials.",
        "text": "Safety and Feasibility of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage | Though TTM is ubiquitously used in the neuro-intensive care unit, there is limited experience with the use of TTM after intracerebral hemorrhage (ICH), the most devastating type of stroke. TTM may be a an intervention to improve patient outcomes. This trial addresses the safety and tolerability of a protocol of ultra-early TTM after ICH/IPH and may be the basis for future larger clinical trials.",
        "tokens": "['Safety', 'and', 'Feasibility', 'of', 'a', 'Protocol', 'of', 'Targeted', 'Temperature', 'Management', 'After', 'Intracerebral', 'Hemorrhage', '|', 'Though', 'TTM', 'is', 'ubiquitously', 'used', 'in', 'the', 'neuro', '-', 'intensive', 'care', 'unit', ',', 'there', 'is', 'limited', 'experience', 'with', 'the', 'use', 'of', 'TTM', 'after', 'intracerebral', 'hemorrhage', '(', 'ICH', ')', ',', 'the', 'most', 'devastating', 'type', 'of', 'stroke', '.', 'TTM', 'may', 'be', 'a', 'an', 'intervention', 'to', 'improve', 'patient', 'outcomes', '.', 'This', 'trial', 'addresses', 'the', 'safety', 'and', 'tolerability', 'of', 'a', 'protocol', 'of', 'ultra', '-', 'early', 'TTM', 'after', 'ICH', '/', 'IPH', 'and', 'may', 'be', 'the', 'basis', 'for', 'future', 'larger', 'clinical', 'trials', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 40,
                "end": 71,
                "text": "Targeted Temperature Management",
                "type": "OTHER"
            },
            {
                "start": 78,
                "end": 102,
                "text": "Intracerebral Hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 112,
                "end": 115,
                "text": "TTM",
                "type": "OTHER"
            },
            {
                "start": 215,
                "end": 218,
                "text": "TTM",
                "type": "OTHER"
            },
            {
                "start": 225,
                "end": 249,
                "text": "intracerebral hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 251,
                "end": 254,
                "text": "ICH",
                "type": "CONDITION"
            },
            {
                "start": 286,
                "end": 292,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 294,
                "end": 297,
                "text": "TTM",
                "type": "OTHER"
            },
            {
                "start": 418,
                "end": 433,
                "text": "ultra-early TTM",
                "type": "OTHER"
            },
            {
                "start": 440,
                "end": 443,
                "text": "ICH",
                "type": "CONDITION"
            },
            {
                "start": 444,
                "end": 447,
                "text": "IPH",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00275275",
        "study_official_title": "An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease. ",
        "study_brief_summary": " A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.",
        "text": "An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease. | A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.",
        "tokens": "['An', 'Open', 'Label', 'Conversion', 'Study', 'of', 'Pramipexole', 'to', 'Ropinirole', 'Controlled', 'Release', '(', 'CR', ')', 'in', 'Patients', 'With', 'Parkinson', \"'s\", 'Disease', '.', '|', 'A', 'conversion', 'study', 'of', 'Mirapex', '(', 'pramipexole', ')', 'to', 'Requip', '(', 'ropinirole', ')', 'controlled', 'release', '(', 'CR', ')', 'in', 'patients', 'with', 'Parkinson', \"'s\", 'disease', 'to', 'determine', 'the', 'appropriate', 'conversion', 'ratio', 'and', 'side', 'effects', 'related', 'to', 'the', 'drug', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 34,
                "end": 45,
                "text": "Pramipexole",
                "type": "DRUG"
            },
            {
                "start": 49,
                "end": 59,
                "text": "Ropinirole",
                "type": "DRUG"
            },
            {
                "start": 101,
                "end": 120,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 153,
                "text": "Mirapex",
                "type": "DRUG"
            },
            {
                "start": 155,
                "end": 166,
                "text": "pramipexole",
                "type": "DRUG"
            },
            {
                "start": 171,
                "end": 177,
                "text": "Requip",
                "type": "DRUG"
            },
            {
                "start": 179,
                "end": 189,
                "text": "ropinirole",
                "type": "DRUG"
            },
            {
                "start": 232,
                "end": 251,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03857243",
        "study_official_title": "Dual Transcranial Direct Current Stimulation (dTDCS)-Enhanced Therapy After Hemorrhagic Strokes and VEGF ",
        "study_brief_summary": " This study will evaluate the feasibility of dual tDCS to improve arm motor function in chronic stroke patients. In addition it will collect pilot data on the blood biomarkers associated with treatment effect.",
        "text": "Dual Transcranial Direct Current Stimulation (dTDCS)-Enhanced Therapy After Hemorrhagic Strokes and VEGF | This study will evaluate the feasibility of dual tDCS to improve arm motor function in chronic stroke patients. In addition it will collect pilot data on the blood biomarkers associated with treatment effect.",
        "tokens": "['Dual', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'dTDCS)-Enhanced', 'Therapy', 'After', 'Hemorrhagic', 'Strokes', 'and', 'VEGF', '|', 'This', 'study', 'will', 'evaluate', 'the', 'feasibility', 'of', 'dual', 'tDCS', 'to', 'improve', 'arm', 'motor', 'function', 'in', 'chronic', 'stroke', 'patients', '.', 'In', 'addition', 'it', 'will', 'collect', 'pilot', 'data', 'on', 'the', 'blood', 'biomarkers', 'associated', 'with', 'treatment', 'effect', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 69,
                "text": "Dual Transcranial Direct Current Stimulation (dTDCS)-Enhanced Therapy",
                "type": "OTHER"
            },
            {
                "start": 76,
                "end": 95,
                "text": "Hemorrhagic Strokes",
                "type": "CONDITION"
            },
            {
                "start": 100,
                "end": 104,
                "text": "VEGF",
                "type": "DRUG"
            },
            {
                "start": 151,
                "end": 160,
                "text": "dual tDCS",
                "type": "OTHER"
            },
            {
                "start": 194,
                "end": 208,
                "text": "chronic stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05527652",
        "study_official_title": "Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia ",
        "study_brief_summary": " The researchers are investigating if the Self-Supporting Nasopharyngeal Airway (ssNPA) device can be used in the treatment of obstructive sleep apnea in children with Hypotonic Upper Airway Obstruction (HUAO).",
        "text": "Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia | The researchers are investigating if the Self-Supporting Nasopharyngeal Airway (ssNPA) device can be used in the treatment of obstructive sleep apnea in children with Hypotonic Upper Airway Obstruction (HUAO).",
        "tokens": "['Self', '-', 'Supporting', 'Nasopharyngeal', 'Airway', '(', 'ssNPA', ')', 'Treating', 'Upper', 'Airway', 'Obstruction', 'in', 'Hypotonia', '|', 'The', 'researchers', 'are', 'investigating', 'if', 'the', 'Self', '-', 'Supporting', 'Nasopharyngeal', 'Airway', '(', 'ssNPA', ')', 'device', 'can', 'be', 'used', 'in', 'the', 'treatment', 'of', 'obstructive', 'sleep', 'apnea', 'in', 'children', 'with', 'Hypotonic', 'Upper', 'Airway', 'Obstruction', '(', 'HUAO', ')', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 37,
                "text": "Self-Supporting Nasopharyngeal Airway",
                "type": "OTHER"
            },
            {
                "start": 39,
                "end": 44,
                "text": "ssNPA",
                "type": "OTHER"
            },
            {
                "start": 55,
                "end": 79,
                "text": "Upper Airway Obstruction",
                "type": "CONDITION"
            },
            {
                "start": 83,
                "end": 92,
                "text": "Hypotonia",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 173,
                "text": "Self-Supporting Nasopharyngeal Airway",
                "type": "OTHER"
            },
            {
                "start": 175,
                "end": 180,
                "text": "ssNPA",
                "type": "OTHER"
            },
            {
                "start": 221,
                "end": 244,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 262,
                "end": 296,
                "text": "Hypotonic Upper Airway Obstruction",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 302,
                "text": "HUAO",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01865721",
        "study_official_title": "Optimizing the Use of Entonox\u00ae During Screening Colonoscopy: an Open Randomised Controlled Trial ",
        "study_brief_summary": " This study will randomise patients undergoing screening colonoscopy to receive Entonox either continuously or as required.\n\nBoth these methods are used in the published studies of Entonox and in clinical practice.\n\nNull hypothesis There will be no difference in pain levels between these two methods of Entonox administration",
        "text": "Optimizing the Use of Entonox\u00ae During Screening Colonoscopy: an Open Randomised Controlled Trial | This study will randomise patients undergoing screening colonoscopy to receive Entonox either continuously or as required.\n\nBoth these methods are used in the published studies of Entonox and in clinical practice.\n\nNull hypothesis There will be no difference in pain levels between these two methods of Entonox administration",
        "tokens": "['Optimizing', 'the', 'Use', 'of', 'Entonox', '\u00ae', 'During', 'Screening', 'Colonoscopy', ':', 'an', 'Open', 'Randomised', 'Controlled', 'Trial', '|', 'This', 'study', 'will', 'randomise', 'patients', 'undergoing', 'screening', 'colonoscopy', 'to', 'receive', 'Entonox', 'either', 'continuously', 'or', 'as', 'required', '.', '\\n\\n', 'Both', 'these', 'methods', 'are', 'used', 'in', 'the', 'published', 'studies', 'of', 'Entonox', 'and', 'in', 'clinical', 'practice', '.', '\\n\\n', 'Null', 'hypothesis', 'There', 'will', 'be', 'no', 'difference', 'in', 'pain', 'levels', 'between', 'these', 'two', 'methods', 'of', 'Entonox', 'administration']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 29,
                "text": "Entonox",
                "type": "DRUG"
            },
            {
                "start": 38,
                "end": 59,
                "text": "Screening Colonoscopy",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 166,
                "text": "screening colonoscopy",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 185,
                "text": "Entonox",
                "type": "DRUG"
            },
            {
                "start": 279,
                "end": 286,
                "text": "Entonox",
                "type": "DRUG"
            },
            {
                "start": 361,
                "end": 365,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 402,
                "end": 409,
                "text": "Entonox",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03196739",
        "study_official_title": "Feasibility of Virtual Reality Games Using Head-mounted Display on Patients With Brain Disorders ",
        "study_brief_summary": " Because virtual reality can provide more enriched environment, repetitive goal-oriented tasks, and increased patients' interest and motivation, it is expected to stimulate neuroplasticity of injured brain and promote recovery in patients with brain disorders. On the other hand, immersive virtual reality using a head-mounted display has not yet been attempted in the rehabilitation of patients with brain disorders. In addition to the benefits of existing virtual reality or game rehabilitation, immersive virtual reality can further enhance brain plasticity, such as the effect of mirror therapy or action observation, through self-awareness of the body in the virtual space. The purpose of this study is to investigate the feasibility of applying the immersive virtual reality using a head-mounted display in patients with upper extremity dysfunction due to brain disorders.",
        "text": "Feasibility of Virtual Reality Games Using Head-mounted Display on Patients With Brain Disorders | Because virtual reality can provide more enriched environment, repetitive goal-oriented tasks, and increased patients' interest and motivation, it is expected to stimulate neuroplasticity of injured brain and promote recovery in patients with brain disorders. On the other hand, immersive virtual reality using a head-mounted display has not yet been attempted in the rehabilitation of patients with brain disorders. In addition to the benefits of existing virtual reality or game rehabilitation, immersive virtual reality can further enhance brain plasticity, such as the effect of mirror therapy or action observation, through self-awareness of the body in the virtual space. The purpose of this study is to investigate the feasibility of applying the immersive virtual reality using a head-mounted display in patients with upper extremity dysfunction due to brain disorders.",
        "tokens": "['Feasibility', 'of', 'Virtual', 'Reality', 'Games', 'Using', 'Head', '-', 'mounted', 'Display', 'on', 'Patients', 'With', 'Brain', 'Disorders', '|', 'Because', 'virtual', 'reality', 'can', 'provide', 'more', 'enriched', 'environment', ',', 'repetitive', 'goal', '-', 'oriented', 'tasks', ',', 'and', 'increased', 'patients', \"'\", 'interest', 'and', 'motivation', ',', 'it', 'is', 'expected', 'to', 'stimulate', 'neuroplasticity', 'of', 'injured', 'brain', 'and', 'promote', 'recovery', 'in', 'patients', 'with', 'brain', 'disorders', '.', 'On', 'the', 'other', 'hand', ',', 'immersive', 'virtual', 'reality', 'using', 'a', 'head', '-', 'mounted', 'display', 'has', 'not', 'yet', 'been', 'attempted', 'in', 'the', 'rehabilitation', 'of', 'patients', 'with', 'brain', 'disorders', '.', 'In', 'addition', 'to', 'the', 'benefits', 'of', 'existing', 'virtual', 'reality', 'or', 'game', 'rehabilitation', ',', 'immersive', 'virtual', 'reality', 'can', 'further', 'enhance', 'brain', 'plasticity', ',', 'such', 'as', 'the', 'effect', 'of', 'mirror', 'therapy', 'or', 'action', 'observation', ',', 'through', 'self', '-', 'awareness', 'of', 'the', 'body', 'in', 'the', 'virtual', 'space', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'feasibility', 'of', 'applying', 'the', 'immersive', 'virtual', 'reality', 'using', 'a', 'head', '-', 'mounted', 'display', 'in', 'patients', 'with', 'upper', 'extremity', 'dysfunction', 'due', 'to', 'brain', 'disorders', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 36,
                "text": "Virtual Reality Games",
                "type": "OTHER"
            },
            {
                "start": 43,
                "end": 63,
                "text": "Head-mounted Display",
                "type": "OTHER"
            },
            {
                "start": 107,
                "end": 122,
                "text": "virtual reality",
                "type": "OTHER"
            },
            {
                "start": 378,
                "end": 403,
                "text": "immersive virtual reality",
                "type": "OTHER"
            },
            {
                "start": 412,
                "end": 432,
                "text": "head-mounted display",
                "type": "OTHER"
            },
            {
                "start": 556,
                "end": 571,
                "text": "virtual reality",
                "type": "OTHER"
            },
            {
                "start": 575,
                "end": 594,
                "text": "game rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 596,
                "end": 621,
                "text": "immersive virtual reality",
                "type": "OTHER"
            },
            {
                "start": 853,
                "end": 878,
                "text": "immersive virtual reality",
                "type": "OTHER"
            },
            {
                "start": 887,
                "end": 907,
                "text": "head-mounted display",
                "type": "OTHER"
            },
            {
                "start": 925,
                "end": 952,
                "text": "upper extremity dysfunction",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00285402",
        "study_official_title": "Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study ",
        "study_brief_summary": " The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a reduction in the number of migraine days.",
        "text": "Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study | The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a reduction in the number of migraine days.",
        "tokens": "['Intranasal', 'AST-726', 'Treatment', 'for', 'Prophylaxis', 'of', 'Migraine', ':', 'A', 'Placebo', '-', 'Controlled', 'Clinical', 'Study', '|', 'The', 'purpose', 'of', 'this', 'migraine', 'prevention', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'AST-726', 'in', 'moderate', 'to', 'severe', 'migraine', 'patients', 'at', 'one', 'of', 'two', 'doses', 'compared', 'to', 'placebo', 'and', 'compared', 'to', 'a', 'baseline', 'period', 'as', 'measured', 'by', 'a', 'reduction', 'in', 'the', 'number', 'of', 'migraine', 'days', '.']",
        "token_bio_labels": "['O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 18,
                "text": "AST-726",
                "type": "DRUG"
            },
            {
                "start": 48,
                "end": 56,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 60,
                "end": 67,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 116,
                "end": 124,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 191,
                "text": "AST-726",
                "type": "DRUG"
            },
            {
                "start": 195,
                "end": 222,
                "text": "moderate to severe migraine",
                "type": "CONDITION"
            },
            {
                "start": 264,
                "end": 271,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 350,
                "end": 358,
                "text": "migraine",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01500707",
        "study_official_title": "A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease ",
        "study_brief_summary": " This study is being done to assess the pharmacokinetics of SCH 900800 in participants with moderate to severe Parkinson's Disease (PD) being treated with L-DOPA.",
        "text": "A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease | This study is being done to assess the pharmacokinetics of SCH 900800 in participants with moderate to severe Parkinson's Disease (PD) being treated with L-DOPA.",
        "tokens": "['A', 'Single', 'Dose', 'Study', 'to', 'Assess', 'the', 'Pharmacokinetics', 'of', 'SCH', '900800', 'Administered', 'as', 'Oral', 'Tablets', 'in', 'L', '-', 'DOPA', '-', 'treated', 'Subjects', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'This', 'study', 'is', 'being', 'done', 'to', 'assess', 'the', 'pharmacokinetics', 'of', 'SCH', '900800', 'in', 'participants', 'with', 'moderate', 'to', 'severe', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', 'being', 'treated', 'with', 'L', '-', 'DOPA', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O']",
        "entities": [
            {
                "start": 54,
                "end": 64,
                "text": "SCH 900800",
                "type": "DRUG"
            },
            {
                "start": 97,
                "end": 103,
                "text": "L-DOPA",
                "type": "DRUG"
            },
            {
                "start": 126,
                "end": 145,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 217,
                "text": "SCH 900800",
                "type": "DRUG"
            },
            {
                "start": 239,
                "end": 277,
                "text": "moderate to severe Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 281,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 302,
                "end": 308,
                "text": "L-DOPA",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03270592",
        "study_official_title": "Assessment of Service and Hearing Dogs ",
        "study_brief_summary": " For persons with impairments and certain illnesses the use of service dogs may have positive effect. The effects of using these dogs to assist in every day life need to be studied further.The aim of the study was to assess how health care consumption was effected by using certified service dogs and to study the cost-effectiveness of having a certified service dog.",
        "text": "Assessment of Service and Hearing Dogs | For persons with impairments and certain illnesses the use of service dogs may have positive effect. The effects of using these dogs to assist in every day life need to be studied further.The aim of the study was to assess how health care consumption was effected by using certified service dogs and to study the cost-effectiveness of having a certified service dog.",
        "tokens": "['Assessment', 'of', 'Service', 'and', 'Hearing', 'Dogs', '|', 'For', 'persons', 'with', 'impairments', 'and', 'certain', 'illnesses', 'the', 'use', 'of', 'service', 'dogs', 'may', 'have', 'positive', 'effect', '.', 'The', 'effects', 'of', 'using', 'these', 'dogs', 'to', 'assist', 'in', 'every', 'day', 'life', 'need', 'to', 'be', 'studied', 'further', '.', 'The', 'aim', 'of', 'the', 'study', 'was', 'to', 'assess', 'how', 'health', 'care', 'consumption', 'was', 'effected', 'by', 'using', 'certified', 'service', 'dogs', 'and', 'to', 'study', 'the', 'cost', '-', 'effectiveness', 'of', 'having', 'a', 'certified', 'service', 'dog', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 38,
                "text": "Service and Hearing Dogs",
                "type": "OTHER"
            },
            {
                "start": 58,
                "end": 69,
                "text": "impairments",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 115,
                "text": "service dogs",
                "type": "OTHER"
            },
            {
                "start": 324,
                "end": 336,
                "text": "service dogs",
                "type": "OTHER"
            },
            {
                "start": 395,
                "end": 406,
                "text": "service dog",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05124522",
        "study_official_title": "Developing A Person-centered Internet-based Health Action Process Approach to Promoting Physical Activity in People With Multiple Sclerosis ",
        "study_brief_summary": " The purpose of this study is to implement the person-centered internet-based Health Action Process Approach to promoting physical activity in people with Multiple Sclerosis (i.e., eHAPA-MS online intervention) and assess the intervention's effectiveness and adherence.",
        "text": "Developing A Person-centered Internet-based Health Action Process Approach to Promoting Physical Activity in People With Multiple Sclerosis | The purpose of this study is to implement the person-centered internet-based Health Action Process Approach to promoting physical activity in people with Multiple Sclerosis (i.e., eHAPA-MS online intervention) and assess the intervention's effectiveness and adherence.",
        "tokens": "['Developing', 'A', 'Person', '-', 'centered', 'Internet', '-', 'based', 'Health', 'Action', 'Process', 'Approach', 'to', 'Promoting', 'Physical', 'Activity', 'in', 'People', 'With', 'Multiple', 'Sclerosis', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'implement', 'the', 'person', '-', 'centered', 'internet', '-', 'based', 'Health', 'Action', 'Process', 'Approach', 'to', 'promoting', 'physical', 'activity', 'in', 'people', 'with', 'Multiple', 'Sclerosis', '(', 'i.e.', ',', 'eHAPA', '-', 'MS', 'online', 'intervention', ')', 'and', 'assess', 'the', 'intervention', \"'s\", 'effectiveness', 'and', 'adherence', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 65,
                "text": "Person-centered Internet-based Health Action Process",
                "type": "OTHER"
            },
            {
                "start": 88,
                "end": 105,
                "text": "Physical Activity",
                "type": "PHYSICAL"
            },
            {
                "start": 121,
                "end": 139,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 188,
                "end": 240,
                "text": "person-centered internet-based Health Action Process",
                "type": "OTHER"
            },
            {
                "start": 263,
                "end": 280,
                "text": "physical activity",
                "type": "PHYSICAL"
            },
            {
                "start": 296,
                "end": 314,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 350,
                "text": "eHAPA-MS online intervention",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05614713",
        "study_official_title": "Effect of Sensory Integration Therapy on Balance and Functional Mobility in Children With Spastic Cerebral Palsy ",
        "study_brief_summary": " Purpose: to investigate the effect of sensory integration therapy on balance and functional mobility in children with spastic diplegic cerebral palsy. Methods: children with spastic cerebral palsy, the children were assigned to a control group and a study group. Balance was assessed using the Biodex balance system and functional mobility was assessed using the Timed Up and Go test.",
        "text": "Effect of Sensory Integration Therapy on Balance and Functional Mobility in Children With Spastic Cerebral Palsy | Purpose: to investigate the effect of sensory integration therapy on balance and functional mobility in children with spastic diplegic cerebral palsy. Methods: children with spastic cerebral palsy, the children were assigned to a control group and a study group. Balance was assessed using the Biodex balance system and functional mobility was assessed using the Timed Up and Go test.",
        "tokens": "['Effect', 'of', 'Sensory', 'Integration', 'Therapy', 'on', 'Balance', 'and', 'Functional', 'Mobility', 'in', 'Children', 'With', 'Spastic', 'Cerebral', 'Palsy', '|', 'Purpose', ':', 'to', 'investigate', 'the', 'effect', 'of', 'sensory', 'integration', 'therapy', 'on', 'balance', 'and', 'functional', 'mobility', 'in', 'children', 'with', 'spastic', 'diplegic', 'cerebral', 'palsy', '.', 'Methods', ':', 'children', 'with', 'spastic', 'cerebral', 'palsy', ',', 'the', 'children', 'were', 'assigned', 'to', 'a', 'control', 'group', 'and', 'a', 'study', 'group', '.', 'Balance', 'was', 'assessed', 'using', 'the', 'Biodex', 'balance', 'system', 'and', 'functional', 'mobility', 'was', 'assessed', 'using', 'the', 'Timed', 'Up', 'and', 'Go', 'test', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 72,
                "text": "Sensory Integration Therapy on Balance and Functional Mobility",
                "type": "PHYSICAL"
            },
            {
                "start": 90,
                "end": 112,
                "text": "Spastic Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 215,
                "text": "sensory integration therapy on balance and functional mobility",
                "type": "PHYSICAL"
            },
            {
                "start": 233,
                "end": 264,
                "text": "spastic diplegic cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 289,
                "end": 311,
                "text": "spastic cerebral palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01826487",
        "study_official_title": "A Phase 3 Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Dystrophinopathy ",
        "study_brief_summary": " Dystrophinopathy is a disease continuum that includes Duchenne muscular dystrophy, which develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability. A specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of dystrophinopathy in approximately 10-15 percent (%) of boys with the disease. Ataluren is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. The main goal of this Phase 3 study is to evaluate the effect of ataluren on walking ability. The effect of ataluren on physical function, quality of life, and activities of daily living will be evaluated. This study will also provide additional information on the long-term safety of ataluren.",
        "text": "A Phase 3 Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Dystrophinopathy | Dystrophinopathy is a disease continuum that includes Duchenne muscular dystrophy, which develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability. A specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of dystrophinopathy in approximately 10-15 percent (%) of boys with the disease. Ataluren is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. The main goal of this Phase 3 study is to evaluate the effect of ataluren on walking ability. The effect of ataluren on physical function, quality of life, and activities of daily living will be evaluated. This study will also provide additional information on the long-term safety of ataluren.",
        "tokens": "['A', 'Phase', '3', 'Efficacy', 'and', 'Safety', 'Study', 'of', 'Ataluren', 'in', 'Patients', 'With', 'Nonsense', 'Mutation', 'Dystrophinopathy', '|', 'Dystrophinopathy', 'is', 'a', 'disease', 'continuum', 'that', 'includes', 'Duchenne', 'muscular', 'dystrophy', ',', 'which', 'develops', 'in', 'boys', '.', 'It', 'is', 'caused', 'by', 'a', 'mutation', 'in', 'the', 'gene', 'for', 'dystrophin', ',', 'a', 'protein', 'that', 'is', 'important', 'for', 'maintaining', 'normal', 'muscle', 'structure', 'and', 'function', '.', 'Loss', 'of', 'dystrophin', 'causes', 'muscle', 'fragility', 'that', 'leads', 'to', 'weakness', 'and', 'loss', 'of', 'walking', 'ability', '.', 'A', 'specific', 'type', 'of', 'mutation', ',', 'called', 'a', 'nonsense', '(', 'premature', 'stop', 'codon', ')', 'mutation', 'is', 'the', 'cause', 'of', 'dystrophinopathy', 'in', 'approximately', '10', '-', '15', 'percent', '(', '%', ')', 'of', 'boys', 'with', 'the', 'disease', '.', 'Ataluren', 'is', 'an', 'orally', 'delivered', ',', 'investigational', 'drug', 'that', 'has', 'the', 'potential', 'to', 'overcome', 'the', 'effects', 'of', 'the', 'nonsense', 'mutation', '.', 'The', 'main', 'goal', 'of', 'this', 'Phase', '3', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'ataluren', 'on', 'walking', 'ability', '.', 'The', 'effect', 'of', 'ataluren', 'on', 'physical', 'function', ',', 'quality', 'of', 'life', ',', 'and', 'activities', 'of', 'daily', 'living', 'will', 'be', 'evaluated', '.', 'This', 'study', 'will', 'also', 'provide', 'additional', 'information', 'on', 'the', 'long', '-', 'term', 'safety', 'of', 'ataluren', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 47,
                "text": "Ataluren",
                "type": "DRUG"
            },
            {
                "start": 65,
                "end": 99,
                "text": "Nonsense Mutation Dystrophinopathy",
                "type": "CONDITION"
            },
            {
                "start": 102,
                "end": 118,
                "text": "Dystrophinopathy",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 183,
                "text": "Duchenne muscular dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 479,
                "end": 519,
                "text": "nonsense (premature stop codon) mutation",
                "type": "CONDITION"
            },
            {
                "start": 536,
                "end": 552,
                "text": "dystrophinopathy",
                "type": "CONDITION"
            },
            {
                "start": 614,
                "end": 622,
                "text": "Ataluren",
                "type": "DRUG"
            },
            {
                "start": 722,
                "end": 739,
                "text": "nonsense mutation",
                "type": "CONDITION"
            },
            {
                "start": 806,
                "end": 814,
                "text": "ataluren",
                "type": "DRUG"
            },
            {
                "start": 849,
                "end": 857,
                "text": "ataluren",
                "type": "DRUG"
            },
            {
                "start": 1026,
                "end": 1034,
                "text": "ataluren",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05173051",
        "study_official_title": "Medication Intake of Solid Dosage Forms: A Risk Factor for Patients With Stroke-induced Dysphagia? ",
        "study_brief_summary": " In a prospective, quantitative explorative study, the risk of aspiration and penetration when swallowing solid pills (placebo) compared to a crushed placebo pill will be evaluated during a routine Fiberoptic Endoscopic Evaluation of Swallowing (FEES). The study design is thus a quasi-experimental study design with repeated measurements in the sense of a pre-posttest. Each patient undergoes a baseline examination (routine procedure) followed by the intervention (administration of three different solid pills and a crushed pill).",
        "text": "Medication Intake of Solid Dosage Forms: A Risk Factor for Patients With Stroke-induced Dysphagia? | In a prospective, quantitative explorative study, the risk of aspiration and penetration when swallowing solid pills (placebo) compared to a crushed placebo pill will be evaluated during a routine Fiberoptic Endoscopic Evaluation of Swallowing (FEES). The study design is thus a quasi-experimental study design with repeated measurements in the sense of a pre-posttest. Each patient undergoes a baseline examination (routine procedure) followed by the intervention (administration of three different solid pills and a crushed pill).",
        "tokens": "['Medication', 'Intake', 'of', 'Solid', 'Dosage', 'Forms', ':', 'A', 'Risk', 'Factor', 'for', 'Patients', 'With', 'Stroke', '-', 'induced', 'Dysphagia', '?', '|', 'In', 'a', 'prospective', ',', 'quantitative', 'explorative', 'study', ',', 'the', 'risk', 'of', 'aspiration', 'and', 'penetration', 'when', 'swallowing', 'solid', 'pills', '(', 'placebo', ')', 'compared', 'to', 'a', 'crushed', 'placebo', 'pill', 'will', 'be', 'evaluated', 'during', 'a', 'routine', 'Fiberoptic', 'Endoscopic', 'Evaluation', 'of', 'Swallowing', '(', 'FEES', ')', '.', 'The', 'study', 'design', 'is', 'thus', 'a', 'quasi', '-', 'experimental', 'study', 'design', 'with', 'repeated', 'measurements', 'in', 'the', 'sense', 'of', 'a', 'pre', '-', 'posttest', '.', 'Each', 'patient', 'undergoes', 'a', 'baseline', 'examination', '(', 'routine', 'procedure', ')', 'followed', 'by', 'the', 'intervention', '(', 'administration', 'of', 'three', 'different', 'solid', 'pills', 'and', 'a', 'crushed', 'pill', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 73,
                "end": 79,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 88,
                "end": 97,
                "text": "Dysphagia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05531500",
        "study_official_title": "Patient Reported Outcomes Following Interventional Procedures in Pelvic Pain ",
        "study_brief_summary": " The investigators aim from this study, to determine the safety and efficacy of pulsed radiofrequency in the management of pudendal neuralgia, compared to current a standard intervention, which is corticosteroid injection for PN, as part of multidisciplinary pain management.",
        "text": "Patient Reported Outcomes Following Interventional Procedures in Pelvic Pain | The investigators aim from this study, to determine the safety and efficacy of pulsed radiofrequency in the management of pudendal neuralgia, compared to current a standard intervention, which is corticosteroid injection for PN, as part of multidisciplinary pain management.",
        "tokens": "['Patient', 'Reported', 'Outcomes', 'Following', 'Interventional', 'Procedures', 'in', 'Pelvic', 'Pain', '|', 'The', 'investigators', 'aim', 'from', 'this', 'study', ',', 'to', 'determine', 'the', 'safety', 'and', 'efficacy', 'of', 'pulsed', 'radiofrequency', 'in', 'the', 'management', 'of', 'pudendal', 'neuralgia', ',', 'compared', 'to', 'current', 'a', 'standard', 'intervention', ',', 'which', 'is', 'corticosteroid', 'injection', 'for', 'PN', ',', 'as', 'part', 'of', 'multidisciplinary', 'pain', 'management', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 65,
                "end": 76,
                "text": "Pelvic Pain",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 179,
                "text": "pulsed radiofrequency",
                "type": "OTHER"
            },
            {
                "start": 201,
                "end": 219,
                "text": "pudendal neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 275,
                "end": 289,
                "text": "corticosteroid",
                "type": "DRUG"
            },
            {
                "start": 304,
                "end": 306,
                "text": "PN",
                "type": "CONDITION"
            },
            {
                "start": 337,
                "end": 341,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02503098",
        "study_official_title": "Optimizing a Smartphone Application for Individuals With Eating Disorders ",
        "study_brief_summary": " This study will augment an existing mobile application for individuals with eating disorders by developing adaptive, tailored content targeting remediation of cognitive distortions. The adaptive application will be deployed and assessed for efficacy relative to the standard product in a randomized controlled trial.",
        "text": "Optimizing a Smartphone Application for Individuals With Eating Disorders | This study will augment an existing mobile application for individuals with eating disorders by developing adaptive, tailored content targeting remediation of cognitive distortions. The adaptive application will be deployed and assessed for efficacy relative to the standard product in a randomized controlled trial.",
        "tokens": "['Optimizing', 'a', 'Smartphone', 'Application', 'for', 'Individuals', 'With', 'Eating', 'Disorders', '|', 'This', 'study', 'will', 'augment', 'an', 'existing', 'mobile', 'application', 'for', 'individuals', 'with', 'eating', 'disorders', 'by', 'developing', 'adaptive', ',', 'tailored', 'content', 'targeting', 'remediation', 'of', 'cognitive', 'distortions', '.', 'The', 'adaptive', 'application', 'will', 'be', 'deployed', 'and', 'assessed', 'for', 'efficacy', 'relative', 'to', 'the', 'standard', 'product', 'in', 'a', 'randomized', 'controlled', 'trial', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 35,
                "text": "Smartphone Application",
                "type": "OTHER"
            },
            {
                "start": 57,
                "end": 73,
                "text": "Eating Disorders",
                "type": "CONDITION"
            },
            {
                "start": 112,
                "end": 130,
                "text": "mobile application",
                "type": "OTHER"
            },
            {
                "start": 152,
                "end": 168,
                "text": "eating disorders",
                "type": "CONDITION"
            },
            {
                "start": 183,
                "end": 256,
                "text": "adaptive, tailored content targeting remediation of cognitive distortions",
                "type": "OTHER"
            },
            {
                "start": 262,
                "end": 282,
                "text": "adaptive application",
                "type": "OTHER"
            },
            {
                "start": 342,
                "end": 358,
                "text": "standard product",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01815905",
        "study_official_title": "U-Health Service Using Mobile Device for Improvement of Post-Stroke Upper Limb Function and Aphasia ",
        "study_brief_summary": " Provides mobile programs for occupational and speech therapy to patients with stroke.",
        "text": "U-Health Service Using Mobile Device for Improvement of Post-Stroke Upper Limb Function and Aphasia | Provides mobile programs for occupational and speech therapy to patients with stroke.",
        "tokens": "['U', '-', 'Health', 'Service', 'Using', 'Mobile', 'Device', 'for', 'Improvement', 'of', 'Post', '-', 'Stroke', 'Upper', 'Limb', 'Function', 'and', 'Aphasia', '|', 'Provides', 'mobile', 'programs', 'for', 'occupational', 'and', 'speech', 'therapy', 'to', 'patients', 'with', 'stroke', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 36,
                "text": "U-Health Service Using Mobile Device",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 67,
                "text": "Post-Stroke",
                "type": "CONDITION"
            },
            {
                "start": 92,
                "end": 99,
                "text": "Aphasia",
                "type": "CONDITION"
            },
            {
                "start": 111,
                "end": 126,
                "text": "mobile programs",
                "type": "OTHER"
            },
            {
                "start": 131,
                "end": 162,
                "text": "occupational and speech therapy",
                "type": "OTHER"
            },
            {
                "start": 180,
                "end": 186,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02972281",
        "study_official_title": "Systematic Search for Primary Immunodeficiency in Adults With Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria ",
        "study_brief_summary": " Antibody deficiencies and complement deficiencies are the most frequent Primary immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility to recurrent and/or severe bacterial infections - especially upper and lower respiratory tract infections and meningitis. The literature data suggest that PIDs are under-diagnosed in adults. The current European and US guidelines advocate screening adults for PIDs if they present recurrent benign especially upper and lower respiratory tract infections, or if they have experienced at least two severe bacterial infections and/or have a recurrent need for intravenous antibiotics. The objective of the demonstrate the interest of PIDs screening in adult patients who present such recurrent infections and/or after the first severe bacterial infection, especially when the patients do not present with known, etiologically relevant comorbidities.",
        "text": "Systematic Search for Primary Immunodeficiency in Adults With Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria | Antibody deficiencies and complement deficiencies are the most frequent Primary immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility to recurrent and/or severe bacterial infections - especially upper and lower respiratory tract infections and meningitis. The literature data suggest that PIDs are under-diagnosed in adults. The current European and US guidelines advocate screening adults for PIDs if they present recurrent benign especially upper and lower respiratory tract infections, or if they have experienced at least two severe bacterial infections and/or have a recurrent need for intravenous antibiotics. The objective of the demonstrate the interest of PIDs screening in adult patients who present such recurrent infections and/or after the first severe bacterial infection, especially when the patients do not present with known, etiologically relevant comorbidities.",
        "tokens": "['Systematic', 'Search', 'for', 'Primary', 'Immunodeficiency', 'in', 'Adults', 'With', 'Unexplained', 'Recurrent', 'and/or', 'Severe', 'Infections', 'With', 'Encapsulated', 'Bacteria', '|', 'Antibody', 'deficiencies', 'and', 'complement', 'deficiencies', 'are', 'the', 'most', 'frequent', 'Primary', 'immunodeficiencies', '(', 'PIDs', ')', 'in', 'adults', ',', 'and', 'are', 'associated', 'with', 'greatly', 'increased', 'susceptibility', 'to', 'recurrent', 'and/or', 'severe', 'bacterial', 'infections', '-', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'infections', 'and', 'meningitis', '.', 'The', 'literature', 'data', 'suggest', 'that', 'PIDs', 'are', 'under', '-', 'diagnosed', 'in', 'adults', '.', 'The', 'current', 'European', 'and', 'US', 'guidelines', 'advocate', 'screening', 'adults', 'for', 'PIDs', 'if', 'they', 'present', 'recurrent', 'benign', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'infections', ',', 'or', 'if', 'they', 'have', 'experienced', 'at', 'least', 'two', 'severe', 'bacterial', 'infections', 'and/or', 'have', 'a', 'recurrent', 'need', 'for', 'intravenous', 'antibiotics', '.', 'The', 'objective', 'of', 'the', 'demonstrate', 'the', 'interest', 'of', 'PIDs', 'screening', 'in', 'adult', 'patients', 'who', 'present', 'such', 'recurrent', 'infections', 'and/or', 'after', 'the', 'first', 'severe', 'bacterial', 'infection', ',', 'especially', 'when', 'the', 'patients', 'do', 'not', 'present', 'with', 'known', ',', 'etiologically', 'relevant', 'comorbidities', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 46,
                "text": "Primary Immunodeficiency",
                "type": "CONDITION"
            },
            {
                "start": 62,
                "end": 135,
                "text": "Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 159,
                "text": "Antibody deficiencies",
                "type": "CONDITION"
            },
            {
                "start": 164,
                "end": 187,
                "text": "complement deficiencies",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 236,
                "text": "Primary immunodeficiencies",
                "type": "CONDITION"
            },
            {
                "start": 238,
                "end": 242,
                "text": "PIDs",
                "type": "CONDITION"
            },
            {
                "start": 315,
                "end": 359,
                "text": "recurrent and/or severe bacterial infections",
                "type": "CONDITION"
            },
            {
                "start": 467,
                "end": 471,
                "text": "PIDs",
                "type": "CONDITION"
            },
            {
                "start": 572,
                "end": 576,
                "text": "PIDs",
                "type": "CONDITION"
            },
            {
                "start": 621,
                "end": 665,
                "text": "upper and lower respiratory tract infections",
                "type": "CONDITION"
            },
            {
                "start": 715,
                "end": 735,
                "text": "bacterial infections",
                "type": "CONDITION"
            },
            {
                "start": 843,
                "end": 847,
                "text": "PIDs",
                "type": "CONDITION"
            },
            {
                "start": 893,
                "end": 913,
                "text": "recurrent infections",
                "type": "CONDITION"
            },
            {
                "start": 937,
                "end": 963,
                "text": "severe bacterial infection",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03981744",
        "study_official_title": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments ",
        "study_brief_summary": " The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active polymyositis (PM)/dermatomyositis (DM) despite receiving 1 or more standard-of-care treatments (for example, glucocorticoids and/or immunomodulators).",
        "text": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments | The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active polymyositis (PM)/dermatomyositis (DM) despite receiving 1 or more standard-of-care treatments (for example, glucocorticoids and/or immunomodulators).",
        "tokens": "['A', 'Phase', '3', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', '-', 'group', 'Study', 'of', 'Ustekinumab', 'in', 'Participants', 'With', 'Active', 'Polymyositis', 'and', 'Dermatomyositis', 'Who', 'Have', 'Not', 'Adequately', 'Responded', 'to', 'One', 'or', 'More', 'Standard', '-', 'of', '-', 'care', 'Treatments', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'ustekinumab', 'in', 'participants', 'with', 'active', 'polymyositis', '(', 'PM)/dermatomyositis', '(', 'DM', ')', 'despite', 'receiving', '1', 'or', 'more', 'standard', '-', 'of', '-', 'care', 'treatments', '(', 'for', 'example', ',', 'glucocorticoids', 'and/or', 'immunomodulators', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 57,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 94,
                "end": 105,
                "text": "Ustekinumab",
                "type": "DRUG"
            },
            {
                "start": 127,
                "end": 146,
                "text": "Active Polymyositis",
                "type": "CONDITION"
            },
            {
                "start": 151,
                "end": 166,
                "text": "Dermatomyositis",
                "type": "CONDITION"
            },
            {
                "start": 303,
                "end": 314,
                "text": "ustekinumab",
                "type": "DRUG"
            },
            {
                "start": 336,
                "end": 381,
                "text": "active polymyositis (PM)/dermatomyositis (DM)",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05516342",
        "study_official_title": "LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers ",
        "study_brief_summary": " The proposed Phase 2 project will involve the further development and evaluation of LEAD IT!, which is a tablet-based app designed to enable persons with dementia to lead activities for their peers (i.e., other persons with dementia). The study will examine the clinical outcomes of long-term use of the app by both Resident Leaders (RLs) and Resident Players (RPs).\n\nThe Specific Aims of the proposed Phase 2 project are to:\n\nDevelop improved Beta 1 and Beta 2 Versions of LEAD IT! with sufficient content to facilitate six activities twice per week for 4.5 months.\nExamine the extent to which RLs are able to serve as leaders while using LEAD IT!\nExamine the effects of resident-led LEAD IT! programming on RPs.\nExamine PWD and staff satisfaction with LEAD IT!",
        "text": "LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers | The proposed Phase 2 project will involve the further development and evaluation of LEAD IT!, which is a tablet-based app designed to enable persons with dementia to lead activities for their peers (i.e., other persons with dementia). The study will examine the clinical outcomes of long-term use of the app by both Resident Leaders (RLs) and Resident Players (RPs).\n\nThe Specific Aims of the proposed Phase 2 project are to:\n\nDevelop improved Beta 1 and Beta 2 Versions of LEAD IT! with sufficient content to facilitate six activities twice per week for 4.5 months.\nExamine the extent to which RLs are able to serve as leaders while using LEAD IT!\nExamine the effects of resident-led LEAD IT! programming on RPs.\nExamine PWD and staff satisfaction with LEAD IT!",
        "tokens": "['LEAD', 'IT', '!', 'An', 'App', 'to', 'Enable', 'Persons', 'With', 'Early', 'Stage', 'Dementia', 'to', 'Lead', 'Group', 'Activities', 'for', 'Their', 'Peers', '|', 'The', 'proposed', 'Phase', '2', 'project', 'will', 'involve', 'the', 'further', 'development', 'and', 'evaluation', 'of', 'LEAD', 'IT', '!', ',', 'which', 'is', 'a', 'tablet', '-', 'based', 'app', 'designed', 'to', 'enable', 'persons', 'with', 'dementia', 'to', 'lead', 'activities', 'for', 'their', 'peers', '(', 'i.e.', ',', 'other', 'persons', 'with', 'dementia', ')', '.', 'The', 'study', 'will', 'examine', 'the', 'clinical', 'outcomes', 'of', 'long', '-', 'term', 'use', 'of', 'the', 'app', 'by', 'both', 'Resident', 'Leaders', '(', 'RLs', ')', 'and', 'Resident', 'Players', '(', 'RPs', ')', '.', '\\n\\n', 'The', 'Specific', 'Aims', 'of', 'the', 'proposed', 'Phase', '2', 'project', 'are', 'to', ':', '\\n\\n', 'Develop', 'improved', 'Beta', '1', 'and', 'Beta', '2', 'Versions', 'of', 'LEAD', 'IT', '!', 'with', 'sufficient', 'content', 'to', 'facilitate', 'six', 'activities', 'twice', 'per', 'week', 'for', '4.5', 'months', '.', '\\n', 'Examine', 'the', 'extent', 'to', 'which', 'RLs', 'are', 'able', 'to', 'serve', 'as', 'leaders', 'while', 'using', 'LEAD', 'IT', '!', '\\n', 'Examine', 'the', 'effects', 'of', 'resident', '-', 'led', 'LEAD', 'IT', '!', 'programming', 'on', 'RPs', '.', '\\n', 'Examine', 'PWD', 'and', 'staff', 'satisfaction', 'with', 'LEAD', 'IT', '!']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "LEAD IT!",
                "type": "OTHER"
            },
            {
                "start": 12,
                "end": 15,
                "text": "App",
                "type": "OTHER"
            },
            {
                "start": 39,
                "end": 59,
                "text": "Early Stage Dementia",
                "type": "CONDITION"
            },
            {
                "start": 187,
                "end": 195,
                "text": "LEAD IT!",
                "type": "OTHER"
            },
            {
                "start": 208,
                "end": 224,
                "text": "tablet-based app",
                "type": "OTHER"
            },
            {
                "start": 257,
                "end": 265,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 327,
                "end": 335,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 407,
                "end": 410,
                "text": "app",
                "type": "OTHER"
            },
            {
                "start": 577,
                "end": 585,
                "text": "LEAD IT!",
                "type": "OTHER"
            },
            {
                "start": 743,
                "end": 751,
                "text": "LEAD IT!",
                "type": "OTHER"
            },
            {
                "start": 788,
                "end": 796,
                "text": "LEAD IT!",
                "type": "OTHER"
            },
            {
                "start": 857,
                "end": 865,
                "text": "LEAD IT!",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01788696",
        "study_official_title": "Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection) ",
        "study_brief_summary": " The purpose of this study is to evaluate the impact of imaging the brain as a diagnostic tool in the management of early Parkinson's disease (PD).",
        "text": "Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection) | The purpose of this study is to evaluate the impact of imaging the brain as a diagnostic tool in the management of early Parkinson's disease (PD).",
        "tokens": "['Assessment', 'of', 'the', 'Effect', 'of', 'Treatment', 'Pathways', ',', 'Adherence', ',', 'and', 'Treatment', 'Efficacy', 'in', 'Parkinson', \"'s\", 'Disease', 'Subjects', 'Randomized', 'to', 'SPECT', 'Imaging', 'of', 'the', 'Dopamine', 'Transporter', '(', 'Ioflupane', 'I123', 'Injection', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'impact', 'of', 'imaging', 'the', 'brain', 'as', 'a', 'diagnostic', 'tool', 'in', 'the', 'management', 'of', 'early', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 85,
                "end": 104,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 339,
                "text": "early Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 341,
                "end": 343,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05199207",
        "study_official_title": "Sarcopenia Physical Activity and Metabolomic ",
        "study_brief_summary": " Muscle failure (sarcopenia or dynapenia) is a factor of frailty and therefore, ultimately, of loss of autonomy in the elderly. Currently, no biomarker of muscle failure has a high sensitivity, specificity and positive predictive value. Several results, although preliminary, suggest that metabolomics could facilitate the early identification of frail patients, allowing the implementation of primary prevention strategies. Untargeted high-resolution metabolomics analysis would identify discriminative biomarkers and biological mechanisms associated with frailty. Finally, the hypothesis that metabolic signatures can be identified as risk factors for the development of age-related dynapenia should be tested in a longitudinal design.",
        "text": "Sarcopenia Physical Activity and Metabolomic | Muscle failure (sarcopenia or dynapenia) is a factor of frailty and therefore, ultimately, of loss of autonomy in the elderly. Currently, no biomarker of muscle failure has a high sensitivity, specificity and positive predictive value. Several results, although preliminary, suggest that metabolomics could facilitate the early identification of frail patients, allowing the implementation of primary prevention strategies. Untargeted high-resolution metabolomics analysis would identify discriminative biomarkers and biological mechanisms associated with frailty. Finally, the hypothesis that metabolic signatures can be identified as risk factors for the development of age-related dynapenia should be tested in a longitudinal design.",
        "tokens": "['Sarcopenia', 'Physical', 'Activity', 'and', 'Metabolomic', '|', 'Muscle', 'failure', '(', 'sarcopenia', 'or', 'dynapenia', ')', 'is', 'a', 'factor', 'of', 'frailty', 'and', 'therefore', ',', 'ultimately', ',', 'of', 'loss', 'of', 'autonomy', 'in', 'the', 'elderly', '.', 'Currently', ',', 'no', 'biomarker', 'of', 'muscle', 'failure', 'has', 'a', 'high', 'sensitivity', ',', 'specificity', 'and', 'positive', 'predictive', 'value', '.', 'Several', 'results', ',', 'although', 'preliminary', ',', 'suggest', 'that', 'metabolomics', 'could', 'facilitate', 'the', 'early', 'identification', 'of', 'frail', 'patients', ',', 'allowing', 'the', 'implementation', 'of', 'primary', 'prevention', 'strategies', '.', 'Untargeted', 'high', '-', 'resolution', 'metabolomics', 'analysis', 'would', 'identify', 'discriminative', 'biomarkers', 'and', 'biological', 'mechanisms', 'associated', 'with', 'frailty', '.', 'Finally', ',', 'the', 'hypothesis', 'that', 'metabolic', 'signatures', 'can', 'be', 'identified', 'as', 'risk', 'factors', 'for', 'the', 'development', 'of', 'age', '-', 'related', 'dynapenia', 'should', 'be', 'tested', 'in', 'a', 'longitudinal', 'design', '.']",
        "token_bio_labels": "['B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 10,
                "text": "Sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 47,
                "end": 61,
                "text": "Muscle failure",
                "type": "CONDITION"
            },
            {
                "start": 63,
                "end": 73,
                "text": "sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 77,
                "end": 86,
                "text": "dynapenia",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 215,
                "text": "muscle failure",
                "type": "CONDITION"
            },
            {
                "start": 731,
                "end": 740,
                "text": "dynapenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04492696",
        "study_official_title": "Comparison of Concussion Education Programs and Intent to Report Concussion in High School Football Athletes ",
        "study_brief_summary": " Importance: Concussion underreporting leads to delays in diagnosis and treatment, resulting in prolonged recovery. Athletes' report of concussion symptoms is therefore an important component of risk reduction. Numerous educational interventions to improve concussion knowledge and reporting exist.\n\nObjective: Evaluate the comparative efficacy of three concussion education programs in improving concussion-reporting intention.\n\nDesign: Randomized clinical trial conducted from August 2018 to October 2018, with assessment before, immediately after, and one-month after educational intervention.",
        "text": "Comparison of Concussion Education Programs and Intent to Report Concussion in High School Football Athletes | Importance: Concussion underreporting leads to delays in diagnosis and treatment, resulting in prolonged recovery. Athletes' report of concussion symptoms is therefore an important component of risk reduction. Numerous educational interventions to improve concussion knowledge and reporting exist.\n\nObjective: Evaluate the comparative efficacy of three concussion education programs in improving concussion-reporting intention.\n\nDesign: Randomized clinical trial conducted from August 2018 to October 2018, with assessment before, immediately after, and one-month after educational intervention.",
        "tokens": "['Comparison', 'of', 'Concussion', 'Education', 'Programs', 'and', 'Intent', 'to', 'Report', 'Concussion', 'in', 'High', 'School', 'Football', 'Athletes', '|', 'Importance', ':', 'Concussion', 'underreporting', 'leads', 'to', 'delays', 'in', 'diagnosis', 'and', 'treatment', ',', 'resulting', 'in', 'prolonged', 'recovery', '.', 'Athletes', \"'\", 'report', 'of', 'concussion', 'symptoms', 'is', 'therefore', 'an', 'important', 'component', 'of', 'risk', 'reduction', '.', 'Numerous', 'educational', 'interventions', 'to', 'improve', 'concussion', 'knowledge', 'and', 'reporting', 'exist', '.', '\\n\\n', 'Objective', ':', 'Evaluate', 'the', 'comparative', 'efficacy', 'of', 'three', 'concussion', 'education', 'programs', 'in', 'improving', 'concussion', '-', 'reporting', 'intention', '.', '\\n\\n', 'Design', ':', 'Randomized', 'clinical', 'trial', 'conducted', 'from', 'August', '2018', 'to', 'October', '2018', ',', 'with', 'assessment', 'before', ',', 'immediately', 'after', ',', 'and', 'one', '-', 'month', 'after', 'educational', 'intervention', '.']",
        "token_bio_labels": "['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 43,
                "text": "Concussion Education Programs",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 65,
                "end": 75,
                "text": "Concussion",
                "type": "CONDITION"
            },
            {
                "start": 123,
                "end": 133,
                "text": "Concussion",
                "type": "CONDITION"
            },
            {
                "start": 246,
                "end": 256,
                "text": "concussion",
                "type": "CONDITION"
            },
            {
                "start": 367,
                "end": 377,
                "text": "concussion",
                "type": "CONDITION"
            },
            {
                "start": 464,
                "end": 493,
                "text": "concussion education programs",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 507,
                "end": 517,
                "text": "concussion",
                "type": "CONDITION"
            },
            {
                "start": 681,
                "end": 705,
                "text": "educational intervention",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT03548779",
        "study_official_title": "North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 ",
        "study_brief_summary": " The \"North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)\" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and medical outcomes. A clinical trial will be implemented to compare (1) first-line exome sequencing to usual care and (2) participant pre-visit preparation to no pre-visit preparation. The study will use a randomized controlled design, with 2x2 factorial design, coupled with patient-reported outcomes and comprehensive clinical data collection addressing key outcomes, to determine the net impact of diagnostic results and secondary findings.",
        "text": "North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 | The \"North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)\" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and medical outcomes. A clinical trial will be implemented to compare (1) first-line exome sequencing to usual care and (2) participant pre-visit preparation to no pre-visit preparation. The study will use a randomized controlled design, with 2x2 factorial design, coupled with patient-reported outcomes and comprehensive clinical data collection addressing key outcomes, to determine the net impact of diagnostic results and secondary findings.",
        "tokens": "['North', 'Carolina', 'Genomic', 'Evaluation', 'by', 'Next', '-', 'generation', 'Exome', 'Sequencing', ',', '2', '|', 'The', '\"', 'North', 'Carolina', 'Clinical', 'Genomic', 'Evaluation', 'by', 'Next', '-', 'gen', 'Exome', 'Sequencing', ',', '2', '(', 'NCGENES', '2', ')', '\"', 'study', 'is', 'part', 'of', 'a', 'larger', 'consortium', 'project', 'investigating', 'the', 'clinical', 'utility', ',', 'or', 'net', 'benefit', 'of', 'an', 'intervention', 'on', 'patient', 'and', 'family', 'well', '-', 'being', 'as', 'well', 'as', 'diagnostic', 'efficacy', ',', 'management', 'planning', ',', 'and', 'medical', 'outcomes', '.', 'A', 'clinical', 'trial', 'will', 'be', 'implemented', 'to', 'compare', '(', '1', ')', 'first', '-', 'line', 'exome', 'sequencing', 'to', 'usual', 'care', 'and', '(', '2', ')', 'participant', 'pre', '-', 'visit', 'preparation', 'to', 'no', 'pre', '-', 'visit', 'preparation', '.', 'The', 'study', 'will', 'use', 'a', 'randomized', 'controlled', 'design', ',', 'with', '2x2', 'factorial', 'design', ',', 'coupled', 'with', 'patient', '-', 'reported', 'outcomes', 'and', 'comprehensive', 'clinical', 'data', 'collection', 'addressing', 'key', 'outcomes', ',', 'to', 'determine', 'the', 'net', 'impact', 'of', 'diagnostic', 'results', 'and', 'secondary', 'findings', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT05479981",
        "study_official_title": "A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients ",
        "study_brief_summary": " AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients",
        "text": "A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients | AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients",
        "tokens": "['A', 'Phase', '2', 'Extension', 'Study', 'to', 'Evaluate', 'the', 'Long', '-', 'Term', 'Safety', ',', 'Tolerability', ',', 'Efficacy', ',', 'Pharmacokinetics', ',', 'and', 'Pharmacodynamics', 'of', 'AOC', '1001', 'Administered', 'Intravenously', 'to', 'Adult', 'Myotonic', 'Dystrophy', 'Type', '1', '(', 'DM1', ')', 'Patients', '|', 'AOC', '1001', '-', 'CS2', '(', 'MARINA', '-', 'OLE', ')', 'is', 'a', 'Phase', '2', 'extension', 'of', 'the', 'AOC', '1001', '-', 'CS1', '(', 'MARINA', ')', 'study', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'efficacy', ',', 'pharmacokinetics', 'and', 'pharmacodynamics', 'of', 'multiple', '-', 'doses', 'of', 'AOC', '1001', 'Administered', 'Intravenously', 'to', 'Adult', 'Myotonic', 'Dystrophy', 'Type', '1', '(', 'DM1', ')', 'patients']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 126,
                "end": 134,
                "text": "AOC 1001",
                "type": "DRUG"
            },
            {
                "start": 171,
                "end": 196,
                "text": "Myotonic Dystrophy Type 1",
                "type": "CONDITION"
            },
            {
                "start": 198,
                "end": 201,
                "text": "DM1",
                "type": "CONDITION"
            },
            {
                "start": 405,
                "end": 413,
                "text": "AOC 1001",
                "type": "DRUG"
            },
            {
                "start": 450,
                "end": 475,
                "text": "Myotonic Dystrophy Type 1",
                "type": "CONDITION"
            },
            {
                "start": 477,
                "end": 480,
                "text": "DM1",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04610879",
        "study_official_title": "Randomised Factorial Design Controlled Trial Comparing Carbamazepine, Levetiracetam or Active Monitoring Combined With or Without Sleep Behaviour Intervention in Treatment Naive Children With Rolandic Epilepsy ",
        "study_brief_summary": " Rolandic epilepsy (RE) is the most common type of epilepsy. Children with RE have seizures and can often find that their learning, sleep, behaviour, self-esteem and mood are affected.\n\nAs part of standard NHS care, children diagnosed with RE may be treated with standard anti-epileptic medicines, like carbamazepine, or no medicine at all. The medicines used to treat epilepsy often slow down a child's thinking and learning. In the past, doctors believed this was an acceptable price to pay to reduce seizures. However, with RE, where the seizures usually stop in teenage years, investigators do not know if it is better to treat these children with medicines or not, especially if the medicines might have a negative effect on their learning.\n\nA newer medicine called levetiracetam has also been found to work in children with RE and has shown less problems with thinking and learning in adults. However, it is still no known if this is also the case for children and it has not been proven which of the three options (carbamazepine, levetiracetam or no treatment) would be best for RE patients. The CASTLE study aims to find this out.\n\nIn addition, it has been found that seizures often happen when a child has had poor sleep and they often come at night or early in the morning. It has been shown that sleep can be improved through practice without the need of medicines. There are established guidelines to help toddlers go to sleep, but nothing available that helps young people with epilepsy and their parents improve their sleep quality. In the CASTLE study, a sleep training plan has been developed for children with epilepsy and the trial aims to find out whether following this sleep training plan results in less seizures than using no sleep training at all.",
        "text": "Randomised Factorial Design Controlled Trial Comparing Carbamazepine, Levetiracetam or Active Monitoring Combined With or Without Sleep Behaviour Intervention in Treatment Naive Children With Rolandic Epilepsy | Rolandic epilepsy (RE) is the most common type of epilepsy. Children with RE have seizures and can often find that their learning, sleep, behaviour, self-esteem and mood are affected.\n\nAs part of standard NHS care, children diagnosed with RE may be treated with standard anti-epileptic medicines, like carbamazepine, or no medicine at all. The medicines used to treat epilepsy often slow down a child's thinking and learning. In the past, doctors believed this was an acceptable price to pay to reduce seizures. However, with RE, where the seizures usually stop in teenage years, investigators do not know if it is better to treat these children with medicines or not, especially if the medicines might have a negative effect on their learning.\n\nA newer medicine called levetiracetam has also been found to work in children with RE and has shown less problems with thinking and learning in adults. However, it is still no known if this is also the case for children and it has not been proven which of the three options (carbamazepine, levetiracetam or no treatment) would be best for RE patients. The CASTLE study aims to find this out.\n\nIn addition, it has been found that seizures often happen when a child has had poor sleep and they often come at night or early in the morning. It has been shown that sleep can be improved through practice without the need of medicines. There are established guidelines to help toddlers go to sleep, but nothing available that helps young people with epilepsy and their parents improve their sleep quality. In the CASTLE study, a sleep training plan has been developed for children with epilepsy and the trial aims to find out whether following this sleep training plan results in less seizures than using no sleep training at all.",
        "tokens": "['Randomised', 'Factorial', 'Design', 'Controlled', 'Trial', 'Comparing', 'Carbamazepine', ',', 'Levetiracetam', 'or', 'Active', 'Monitoring', 'Combined', 'With', 'or', 'Without', 'Sleep', 'Behaviour', 'Intervention', 'in', 'Treatment', 'Naive', 'Children', 'With', 'Rolandic', 'Epilepsy', '|', 'Rolandic', 'epilepsy', '(', 'RE', ')', 'is', 'the', 'most', 'common', 'type', 'of', 'epilepsy', '.', 'Children', 'with', 'RE', 'have', 'seizures', 'and', 'can', 'often', 'find', 'that', 'their', 'learning', ',', 'sleep', ',', 'behaviour', ',', 'self', '-', 'esteem', 'and', 'mood', 'are', 'affected', '.', '\\n\\n', 'As', 'part', 'of', 'standard', 'NHS', 'care', ',', 'children', 'diagnosed', 'with', 'RE', 'may', 'be', 'treated', 'with', 'standard', 'anti', '-', 'epileptic', 'medicines', ',', 'like', 'carbamazepine', ',', 'or', 'no', 'medicine', 'at', 'all', '.', 'The', 'medicines', 'used', 'to', 'treat', 'epilepsy', 'often', 'slow', 'down', 'a', 'child', \"'s\", 'thinking', 'and', 'learning', '.', 'In', 'the', 'past', ',', 'doctors', 'believed', 'this', 'was', 'an', 'acceptable', 'price', 'to', 'pay', 'to', 'reduce', 'seizures', '.', 'However', ',', 'with', 'RE', ',', 'where', 'the', 'seizures', 'usually', 'stop', 'in', 'teenage', 'years', ',', 'investigators', 'do', 'not', 'know', 'if', 'it', 'is', 'better', 'to', 'treat', 'these', 'children', 'with', 'medicines', 'or', 'not', ',', 'especially', 'if', 'the', 'medicines', 'might', 'have', 'a', 'negative', 'effect', 'on', 'their', 'learning', '.', '\\n\\n', 'A', 'newer', 'medicine', 'called', 'levetiracetam', 'has', 'also', 'been', 'found', 'to', 'work', 'in', 'children', 'with', 'RE', 'and', 'has', 'shown', 'less', 'problems', 'with', 'thinking', 'and', 'learning', 'in', 'adults', '.', 'However', ',', 'it', 'is', 'still', 'no', 'known', 'if', 'this', 'is', 'also', 'the', 'case', 'for', 'children', 'and', 'it', 'has', 'not', 'been', 'proven', 'which', 'of', 'the', 'three', 'options', '(', 'carbamazepine', ',', 'levetiracetam', 'or', 'no', 'treatment', ')', 'would', 'be', 'best', 'for', 'RE', 'patients', '.', 'The', 'CASTLE', 'study', 'aims', 'to', 'find', 'this', 'out', '.', '\\n\\n', 'In', 'addition', ',', 'it', 'has', 'been', 'found', 'that', 'seizures', 'often', 'happen', 'when', 'a', 'child', 'has', 'had', 'poor', 'sleep', 'and', 'they', 'often', 'come', 'at', 'night', 'or', 'early', 'in', 'the', 'morning', '.', 'It', 'has', 'been', 'shown', 'that', 'sleep', 'can', 'be', 'improved', 'through', 'practice', 'without', 'the', 'need', 'of', 'medicines', '.', 'There', 'are', 'established', 'guidelines', 'to', 'help', 'toddlers', 'go', 'to', 'sleep', ',', 'but', 'nothing', 'available', 'that', 'helps', 'young', 'people', 'with', 'epilepsy', 'and', 'their', 'parents', 'improve', 'their', 'sleep', 'quality', '.', 'In', 'the', 'CASTLE', 'study', ',', 'a', 'sleep', 'training', 'plan', 'has', 'been', 'developed', 'for', 'children', 'with', 'epilepsy', 'and', 'the', 'trial', 'aims', 'to', 'find', 'out', 'whether', 'following', 'this', 'sleep', 'training', 'plan', 'results', 'in', 'less', 'seizures', 'than', 'using', 'no', 'sleep', 'training', 'at', 'all', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 55,
                "end": 68,
                "text": "Carbamazepine",
                "type": "DRUG"
            },
            {
                "start": 70,
                "end": 83,
                "text": "Levetiracetam",
                "type": "DRUG"
            },
            {
                "start": 130,
                "end": 158,
                "text": "Sleep Behaviour Intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 192,
                "end": 209,
                "text": "Rolandic Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 229,
                "text": "Rolandic epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 233,
                "text": "RE",
                "type": "CONDITION"
            },
            {
                "start": 262,
                "end": 270,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 286,
                "end": 288,
                "text": "RE",
                "type": "CONDITION"
            },
            {
                "start": 294,
                "end": 302,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 451,
                "end": 453,
                "text": "RE",
                "type": "CONDITION"
            },
            {
                "start": 514,
                "end": 527,
                "text": "carbamazepine",
                "type": "DRUG"
            },
            {
                "start": 580,
                "end": 588,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 714,
                "end": 722,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 738,
                "end": 740,
                "text": "RE",
                "type": "CONDITION"
            },
            {
                "start": 752,
                "end": 760,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 982,
                "end": 995,
                "text": "levetiracetam",
                "type": "DRUG"
            },
            {
                "start": 1041,
                "end": 1043,
                "text": "RE",
                "type": "CONDITION"
            },
            {
                "start": 1233,
                "end": 1246,
                "text": "carbamazepine",
                "type": "DRUG"
            },
            {
                "start": 1248,
                "end": 1261,
                "text": "levetiracetam",
                "type": "DRUG"
            },
            {
                "start": 1265,
                "end": 1277,
                "text": "no treatment",
                "type": "CONTROL"
            },
            {
                "start": 1297,
                "end": 1299,
                "text": "RE",
                "type": "CONDITION"
            },
            {
                "start": 1387,
                "end": 1395,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 1702,
                "end": 1710,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 1781,
                "end": 1795,
                "text": "sleep training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1838,
                "end": 1846,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 1901,
                "end": 1915,
                "text": "sleep training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1937,
                "end": 1945,
                "text": "seizures",
                "type": "CONDITION"
            },
            {
                "start": 1957,
                "end": 1974,
                "text": "no sleep training",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05730465",
        "study_official_title": "Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor ",
        "study_brief_summary": " The goal of this clinical trial is to learn whether providing teaching with a low-cost device can help to improve blood pressure, health outcomes, patient self-efficacy without exacerbating inequity between advantaged and disadvantaged patients.\n\nThe main question[s] it aims to answer are:\n\nDoes providing a free home blood pressure cuff improve control of hypertension?\nDoes providing a free home blood pressure cuff have a greater impact on control of hypertension in disadvantaged populations?\nDoes improved control of home blood pressure decrease adverse patient outcomes?\n\nParticipants will be asked to\n\nTake their blood pressure at home and records the results\nParticipate in follow-up phone calls from investigators at at 3 and 6 months\n\nResearchers will compare patients provided with home blood pressure monitors to those who are provided with routine education",
        "text": "Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor | The goal of this clinical trial is to learn whether providing teaching with a low-cost device can help to improve blood pressure, health outcomes, patient self-efficacy without exacerbating inequity between advantaged and disadvantaged patients.\n\nThe main question[s] it aims to answer are:\n\nDoes providing a free home blood pressure cuff improve control of hypertension?\nDoes providing a free home blood pressure cuff have a greater impact on control of hypertension in disadvantaged populations?\nDoes improved control of home blood pressure decrease adverse patient outcomes?\n\nParticipants will be asked to\n\nTake their blood pressure at home and records the results\nParticipate in follow-up phone calls from investigators at at 3 and 6 months\n\nResearchers will compare patients provided with home blood pressure monitors to those who are provided with routine education",
        "tokens": "['Improving', 'Blood', 'Pressure', 'Control', 'in', 'Stroke', 'Patients', 'by', 'Increasing', 'Access', 'to', 'a', 'Home', 'Blood', 'Pressure', 'Monitor', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'learn', 'whether', 'providing', 'teaching', 'with', 'a', 'low', '-', 'cost', 'device', 'can', 'help', 'to', 'improve', 'blood', 'pressure', ',', 'health', 'outcomes', ',', 'patient', 'self', '-', 'efficacy', 'without', 'exacerbating', 'inequity', 'between', 'advantaged', 'and', 'disadvantaged', 'patients', '.', '\\n\\n', 'The', 'main', 'question[s', ']', 'it', 'aims', 'to', 'answer', 'are', ':', '\\n\\n', 'Does', 'providing', 'a', 'free', 'home', 'blood', 'pressure', 'cuff', 'improve', 'control', 'of', 'hypertension', '?', '\\n', 'Does', 'providing', 'a', 'free', 'home', 'blood', 'pressure', 'cuff', 'have', 'a', 'greater', 'impact', 'on', 'control', 'of', 'hypertension', 'in', 'disadvantaged', 'populations', '?', '\\n', 'Does', 'improved', 'control', 'of', 'home', 'blood', 'pressure', 'decrease', 'adverse', 'patient', 'outcomes', '?', '\\n\\n', 'Participants', 'will', 'be', 'asked', 'to', '\\n\\n', 'Take', 'their', 'blood', 'pressure', 'at', 'home', 'and', 'records', 'the', 'results', '\\n', 'Participate', 'in', 'follow', '-', 'up', 'phone', 'calls', 'from', 'investigators', 'at', 'at', '3', 'and', '6', 'months', '\\n\\n', 'Researchers', 'will', 'compare', 'patients', 'provided', 'with', 'home', 'blood', 'pressure', 'monitors', 'to', 'those', 'who', 'are', 'provided', 'with', 'routine', 'education']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 36,
                "end": 42,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 78,
                "end": 105,
                "text": "Home Blood Pressure Monitor",
                "type": "OTHER"
            },
            {
                "start": 422,
                "end": 446,
                "text": "home blood pressure cuff",
                "type": "OTHER"
            },
            {
                "start": 466,
                "end": 478,
                "text": "hypertension",
                "type": "CONDITION"
            },
            {
                "start": 502,
                "end": 526,
                "text": "home blood pressure cuff",
                "type": "OTHER"
            },
            {
                "start": 563,
                "end": 575,
                "text": "hypertension",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04421937",
        "study_official_title": "The Effects of Neuromuscular Electrical Stimulation on Swallowing Functions in Stroke Patients With Dysphagia: Randomized Controlled Trial ",
        "study_brief_summary": " In our study, our aim is to evaluate the effect of neuromuscular electrical stimulation added to traditional dysphagia therapy in stroke patients with dysphagia, on functional oral intake status, dysphagia-related symptoms, quality of life, and complications related to dysphagia.",
        "text": "The Effects of Neuromuscular Electrical Stimulation on Swallowing Functions in Stroke Patients With Dysphagia: Randomized Controlled Trial | In our study, our aim is to evaluate the effect of neuromuscular electrical stimulation added to traditional dysphagia therapy in stroke patients with dysphagia, on functional oral intake status, dysphagia-related symptoms, quality of life, and complications related to dysphagia.",
        "tokens": "['The', 'Effects', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'on', 'Swallowing', 'Functions', 'in', 'Stroke', 'Patients', 'With', 'Dysphagia', ':', 'Randomized', 'Controlled', 'Trial', '|', 'In', 'our', 'study', ',', 'our', 'aim', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'neuromuscular', 'electrical', 'stimulation', 'added', 'to', 'traditional', 'dysphagia', 'therapy', 'in', 'stroke', 'patients', 'with', 'dysphagia', ',', 'on', 'functional', 'oral', 'intake', 'status', ',', 'dysphagia', '-', 'related', 'symptoms', ',', 'quality', 'of', 'life', ',', 'and', 'complications', 'related', 'to', 'dysphagia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 51,
                "text": "Neuromuscular Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 79,
                "end": 85,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 100,
                "end": 109,
                "text": "Dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 192,
                "end": 228,
                "text": "neuromuscular electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 238,
                "end": 267,
                "text": "traditional dysphagia therapy",
                "type": "OTHER"
            },
            {
                "start": 271,
                "end": 277,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 292,
                "end": 301,
                "text": "dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 337,
                "end": 346,
                "text": "dysphagia",
                "type": "CONDITION"
            },
            {
                "start": 411,
                "end": 420,
                "text": "dysphagia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01466543",
        "study_official_title": "Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects ",
        "study_brief_summary": " The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.",
        "text": "Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects | The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.",
        "tokens": "['Effect', 'of', 'Zydena', '(', 'Udenafil', ')', 'on', 'Cerebral', 'Blood', 'Flow', 'and', 'Peripheral', 'Blood', 'Viscosity', 'in', 'Normal', 'and', 'Subcortical', 'Vascular', 'Cognitive', 'Impairment', 'Subjects', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'Zydena', '(', 'Udenafil', ')', 'has', 'effect', 'on', 'cerebral', 'blood', 'flow', 'and', 'peripheral', 'blood', 'viscosity', 'in', 'normal', 'and', 'subcortical', 'vascular', 'cognitive', 'impairment', 'subjects', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 16,
                "text": "Zydena",
                "type": "DRUG"
            },
            {
                "start": 18,
                "end": 26,
                "text": "Udenafil",
                "type": "DRUG"
            },
            {
                "start": 85,
                "end": 137,
                "text": "Normal and Subcortical Vascular Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 199,
                "end": 205,
                "text": "Zydena",
                "type": "DRUG"
            },
            {
                "start": 207,
                "end": 215,
                "text": "Udenafil",
                "type": "DRUG"
            },
            {
                "start": 285,
                "end": 337,
                "text": "normal and subcortical vascular cognitive impairment",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04546399",
        "study_official_title": "A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse ",
        "study_brief_summary": " This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.",
        "text": "A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse | This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.",
        "tokens": "['A', 'Phase', '2', 'Study', 'of', 'Blinatumomab', '(', 'NSC', '#', '765986', ')', 'in', 'Combination', 'With', 'Nivolumab', '(', 'NSC', '#', '748726', ')', ',', 'a', 'Checkpoint', 'Inhibitor', 'of', 'PD-1', ',', 'in', 'B', '-', 'ALL', 'Patients', 'Aged', '>', '/=', '1', 'to', '<', '31', 'Years', 'Old', 'With', 'First', 'Relapse', '|', 'This', 'phase', 'II', 'trial', 'studies', 'the', 'effect', 'of', 'nivolumab', 'in', 'combination', 'with', 'blinatumomab', 'compared', 'to', 'blinatumomab', 'alone', 'in', 'treating', 'patients', 'with', 'B', '-', 'cell', 'acute', 'lymphoblastic', 'leukemia', '(', 'B', '-', 'ALL', ')', 'that', 'has', 'come', 'back', '(', 'relapsed', ')', '.', 'Down', 'syndrome', 'patients', 'with', 'relapsed', 'B', '-', 'ALL', 'are', 'included', 'in', 'this', 'study', '.', 'Blinatumomab', 'is', 'an', 'antibody', ',', 'which', 'is', 'a', 'protein', 'that', 'identifies', 'and', 'targets', 'specific', 'molecules', 'in', 'the', 'body', '.', 'Blinatumomab', 'searches', 'for', 'and', 'attaches', 'itself', 'to', 'the', 'cancer', 'cell', '.', 'Once', 'attached', ',', 'an', 'immune', 'response', 'occurs', 'which', 'may', 'kill', 'the', 'cancer', 'cell', '.', 'Nivolumab', 'is', 'a', 'medicine', 'that', 'may', 'boost', 'a', 'patient', \"'s\", 'immune', 'system', '.', 'Giving', 'nivolumab', 'in', 'combination', 'with', 'blinatumomab', 'may', 'cause', 'the', 'cancer', 'to', 'stop', 'growing', 'for', 'a', 'period', 'of', 'time', ',', 'and', 'for', 'some', 'patients', ',', 'it', 'may', 'lessen', 'the', 'symptoms', ',', 'such', 'as', 'pain', ',', 'that', 'are', 'caused', 'by', 'the', 'cancer', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 19,
                "end": 31,
                "text": "Blinatumomab",
                "type": "DRUG"
            },
            {
                "start": 66,
                "end": 75,
                "text": "Nivolumab",
                "type": "DRUG"
            },
            {
                "start": 94,
                "end": 122,
                "text": "Checkpoint Inhibitor of PD-1",
                "type": "DRUG"
            },
            {
                "start": 127,
                "end": 132,
                "text": "B-ALL",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 189,
                "text": "First Relapse",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 243,
                "text": "nivolumab",
                "type": "DRUG"
            },
            {
                "start": 264,
                "end": 276,
                "text": "blinatumomab",
                "type": "DRUG"
            },
            {
                "start": 289,
                "end": 301,
                "text": "blinatumomab",
                "type": "DRUG"
            },
            {
                "start": 334,
                "end": 369,
                "text": "B-cell acute lymphoblastic leukemia",
                "type": "CONDITION"
            },
            {
                "start": 371,
                "end": 376,
                "text": "B-ALL",
                "type": "CONDITION"
            },
            {
                "start": 398,
                "end": 406,
                "text": "relapsed",
                "type": "CONDITION"
            },
            {
                "start": 409,
                "end": 422,
                "text": "Down syndrome",
                "type": "CONDITION"
            },
            {
                "start": 437,
                "end": 451,
                "text": "relapsed B-ALL",
                "type": "CONDITION"
            },
            {
                "start": 480,
                "end": 492,
                "text": "Blinatumomab",
                "type": "DRUG"
            },
            {
                "start": 588,
                "end": 600,
                "text": "Blinatumomab",
                "type": "DRUG"
            },
            {
                "start": 641,
                "end": 647,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 714,
                "end": 720,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 727,
                "end": 736,
                "text": "Nivolumab",
                "type": "DRUG"
            },
            {
                "start": 800,
                "end": 809,
                "text": "nivolumab",
                "type": "DRUG"
            },
            {
                "start": 830,
                "end": 842,
                "text": "blinatumomab",
                "type": "DRUG"
            },
            {
                "start": 857,
                "end": 863,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 961,
                "end": 965,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 990,
                "end": 996,
                "text": "cancer",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05287750",
        "study_official_title": "Brain Diseases on 7.0T Magnetic Resonance Imaging ",
        "study_brief_summary": " This clinical trial studies the use of 7-Tesla (7T)and 3T magnetic resonance imaging (MRI) in detecting brain diseases. 7T MRI has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. Diagnostic procedures such as 7T MRI may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3T MRI.",
        "text": "Brain Diseases on 7.0T Magnetic Resonance Imaging | This clinical trial studies the use of 7-Tesla (7T)and 3T magnetic resonance imaging (MRI) in detecting brain diseases. 7T MRI has increased detection sensitivity, including more accurate lesion delineation, higher inter-rater agreement. Diagnostic procedures such as 7T MRI may help ultimately improved diagnostic and therapies confidence to inform decision making than standard 3T MRI.",
        "tokens": "['Brain', 'Diseases', 'on', '7.0', 'T', 'Magnetic', 'Resonance', 'Imaging', '|', 'This', 'clinical', 'trial', 'studies', 'the', 'use', 'of', '7', '-', 'Tesla', '(', '7T)and', '3', 'T', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'in', 'detecting', 'brain', 'diseases', '.', '7', 'T', 'MRI', 'has', 'increased', 'detection', 'sensitivity', ',', 'including', 'more', 'accurate', 'lesion', 'delineation', ',', 'higher', 'inter', '-', 'rater', 'agreement', '.', 'Diagnostic', 'procedures', 'such', 'as', '7', 'T', 'MRI', 'may', 'help', 'ultimately', 'improved', 'diagnostic', 'and', 'therapies', 'confidence', 'to', 'inform', 'decision', 'making', 'than', 'standard', '3', 'T', 'MRI', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT05061758",
        "study_official_title": "A Phase 2 Double Blind, Randomized, Placebo Controlled Trial inVEstigating the Effect and Safety of Several Dosing Regimens of LY3056480 in Patients With STAble Sensorineural Hearing Loss ",
        "study_brief_summary": " A phase 2 trial with LY3056480 in patients with stable SNHL",
        "text": "A Phase 2 Double Blind, Randomized, Placebo Controlled Trial inVEstigating the Effect and Safety of Several Dosing Regimens of LY3056480 in Patients With STAble Sensorineural Hearing Loss | A phase 2 trial with LY3056480 in patients with stable SNHL",
        "tokens": "['A', 'Phase', '2', 'Double', 'Blind', ',', 'Randomized', ',', 'Placebo', 'Controlled', 'Trial', 'inVEstigating', 'the', 'Effect', 'and', 'Safety', 'of', 'Several', 'Dosing', 'Regimens', 'of', 'LY3056480', 'in', 'Patients', 'With', 'STAble', 'Sensorineural', 'Hearing', 'Loss', '|', 'A', 'phase', '2', 'trial', 'with', 'LY3056480', 'in', 'patients', 'with', 'stable', 'SNHL']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND']",
        "entities": [
            {
                "start": 36,
                "end": 43,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 127,
                "end": 136,
                "text": "LY3056480",
                "type": "DRUG"
            },
            {
                "start": 154,
                "end": 187,
                "text": "STAble Sensorineural Hearing Loss",
                "type": "CONDITION"
            },
            {
                "start": 211,
                "end": 220,
                "text": "LY3056480",
                "type": "DRUG"
            },
            {
                "start": 238,
                "end": 249,
                "text": "stable SNHL",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02579655",
        "study_official_title": "Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study ",
        "study_brief_summary": " The purpose of this study is to determine the effect of two novel interventions; (1) a value-based formulary which eliminates copayment for selected high-value medications (proven to prevent heart attacks, stroke, and hospitalizations); and (2) a comprehensive patient education program aimed at lifestyle modification and optimal drug use, combined with relay of information on medication use, on the risk of adverse clinical outcomes (mortality, heart attack, stroke, need for coronary revascularization, and chronic disease related hospitalizations) in low-income seniors with chronic conditions over three years of follow-up or until March 31, 2021 (whichever comes first).",
        "text": "Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study | The purpose of this study is to determine the effect of two novel interventions; (1) a value-based formulary which eliminates copayment for selected high-value medications (proven to prevent heart attacks, stroke, and hospitalizations); and (2) a comprehensive patient education program aimed at lifestyle modification and optimal drug use, combined with relay of information on medication use, on the risk of adverse clinical outcomes (mortality, heart attack, stroke, need for coronary revascularization, and chronic disease related hospitalizations) in low-income seniors with chronic conditions over three years of follow-up or until March 31, 2021 (whichever comes first).",
        "tokens": "['Assessing', 'Outcomes', 'of', 'Enhanced', 'Chronic', 'Disease', 'Care', 'Through', 'Patient', 'Education', 'and', 'a', 'Value', '-', 'based', 'Formulary', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'two', 'novel', 'interventions', ';', '(', '1', ')', 'a', 'value', '-', 'based', 'formulary', 'which', 'eliminates', 'copayment', 'for', 'selected', 'high', '-', 'value', 'medications', '(', 'proven', 'to', 'prevent', 'heart', 'attacks', ',', 'stroke', ',', 'and', 'hospitalizations', ')', ';', 'and', '(', '2', ')', 'a', 'comprehensive', 'patient', 'education', 'program', 'aimed', 'at', 'lifestyle', 'modification', 'and', 'optimal', 'drug', 'use', ',', 'combined', 'with', 'relay', 'of', 'information', 'on', 'medication', 'use', ',', 'on', 'the', 'risk', 'of', 'adverse', 'clinical', 'outcomes', '(', 'mortality', ',', 'heart', 'attack', ',', 'stroke', ',', 'need', 'for', 'coronary', 'revascularization', ',', 'and', 'chronic', 'disease', 'related', 'hospitalizations', ')', 'in', 'low', '-', 'income', 'seniors', 'with', 'chronic', 'conditions', 'over', 'three', 'years', 'of', 'follow', '-', 'up', 'or', 'until', 'March', '31', ',', '2021', '(', 'whichever', 'comes', 'first', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 60,
                "end": 77,
                "text": "Patient Education",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 84,
                "end": 105,
                "text": "Value-based Formulary",
                "type": "OTHER"
            },
            {
                "start": 201,
                "end": 222,
                "text": "value-based formulary",
                "type": "OTHER"
            },
            {
                "start": 375,
                "end": 392,
                "text": "patient education",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 562,
                "end": 574,
                "text": "heart attack",
                "type": "CONDITION"
            },
            {
                "start": 576,
                "end": 582,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02214550",
        "study_official_title": "Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain ",
        "study_brief_summary": " The purpose of this study is to determine if some women with dysmenorrhea (painful periods) are at higher future risk of developing chronic pelvic pain (CPP) and if oral contraceptives (OC) can be used to reverse this chronic pain risk.\n\nInvestigators will examine whether dysmenorrhea produces CPP via repetitive cross organ sensitization (COS) episodes. The use of cyclical OCs to eliminate dysmenorrhea is expected to reduce COS and decrease the risk of developing CPP.",
        "text": "Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain | The purpose of this study is to determine if some women with dysmenorrhea (painful periods) are at higher future risk of developing chronic pelvic pain (CPP) and if oral contraceptives (OC) can be used to reverse this chronic pain risk.\n\nInvestigators will examine whether dysmenorrhea produces CPP via repetitive cross organ sensitization (COS) episodes. The use of cyclical OCs to eliminate dysmenorrhea is expected to reduce COS and decrease the risk of developing CPP.",
        "tokens": "['Deciphering', 'the', 'Hormonal', 'and', 'Nociceptive', 'Mechanisms', 'Underlying', 'Bladder', 'Pain', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'some', 'women', 'with', 'dysmenorrhea', '(', 'painful', 'periods', ')', 'are', 'at', 'higher', 'future', 'risk', 'of', 'developing', 'chronic', 'pelvic', 'pain', '(', 'CPP', ')', 'and', 'if', 'oral', 'contraceptives', '(', 'OC', ')', 'can', 'be', 'used', 'to', 'reverse', 'this', 'chronic', 'pain', 'risk', '.', '\\n\\n', 'Investigators', 'will', 'examine', 'whether', 'dysmenorrhea', 'produces', 'CPP', 'via', 'repetitive', 'cross', 'organ', 'sensitization', '(', 'COS', ')', 'episodes', '.', 'The', 'use', 'of', 'cyclical', 'OCs', 'to', 'eliminate', 'dysmenorrhea', 'is', 'expected', 'to', 'reduce', 'COS', 'and', 'decrease', 'the', 'risk', 'of', 'developing', 'CPP', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 63,
                "end": 75,
                "text": "Bladder Pain",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 151,
                "text": "dysmenorrhea",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 229,
                "text": "chronic pelvic pain",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 234,
                "text": "CPP",
                "type": "CONDITION"
            },
            {
                "start": 243,
                "end": 262,
                "text": "oral contraceptives",
                "type": "DRUG"
            },
            {
                "start": 264,
                "end": 266,
                "text": "OC",
                "type": "DRUG"
            },
            {
                "start": 296,
                "end": 308,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 363,
                "text": "dysmenorrhea",
                "type": "CONDITION"
            },
            {
                "start": 373,
                "end": 376,
                "text": "CPP",
                "type": "CONDITION"
            },
            {
                "start": 445,
                "end": 457,
                "text": "cyclical OCs",
                "type": "DRUG"
            },
            {
                "start": 471,
                "end": 483,
                "text": "dysmenorrhea",
                "type": "CONDITION"
            },
            {
                "start": 506,
                "end": 509,
                "text": "COS",
                "type": "CONDITION"
            },
            {
                "start": 546,
                "end": 549,
                "text": "CPP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00642369",
        "study_official_title": "Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia ",
        "study_brief_summary": " This study will apply polysomnography (PSG) to evaluate the effect of quetiapine fumarate on sleep architecture. Most of previous studies evaluated sleep by self-reported questionnaires during the antipsychotic treatment (clozapine, risperidone, olanzapine, et al), while only a few studies with PSG evaluation had some limitation, such as: small sample size, respective or cross-sectional, potential sleep disorders, et al. In this study, we will investigate both subjective and objective effect of quetiapine fumarate in improving sleep quality in schizophrenic patients by PSG as well as psychiatric scales. The control drug in this study is the typical antipsychotic - haloperidol. It could increase sleep duration and efficiency by mostly increasing the S2 without effect on rapid eye movement (REM) sleep and slow wave sleep (SWS). The patients will be randomised into two groups as a parallel design. This study is designed as rater blinded to reduce the bias in evaluation. It is suggested that the sedative effect of quetiapine fumarate could diminish in 2 weeks, therefore, we use 4 weeks to ensure the change of sleep quality in this study, which could be helpful for the evaluation of relative short and middle term effect of quetiapine fumarate on sleep quality.",
        "text": "Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia | This study will apply polysomnography (PSG) to evaluate the effect of quetiapine fumarate on sleep architecture. Most of previous studies evaluated sleep by self-reported questionnaires during the antipsychotic treatment (clozapine, risperidone, olanzapine, et al), while only a few studies with PSG evaluation had some limitation, such as: small sample size, respective or cross-sectional, potential sleep disorders, et al. In this study, we will investigate both subjective and objective effect of quetiapine fumarate in improving sleep quality in schizophrenic patients by PSG as well as psychiatric scales. The control drug in this study is the typical antipsychotic - haloperidol. It could increase sleep duration and efficiency by mostly increasing the S2 without effect on rapid eye movement (REM) sleep and slow wave sleep (SWS). The patients will be randomised into two groups as a parallel design. This study is designed as rater blinded to reduce the bias in evaluation. It is suggested that the sedative effect of quetiapine fumarate could diminish in 2 weeks, therefore, we use 4 weeks to ensure the change of sleep quality in this study, which could be helpful for the evaluation of relative short and middle term effect of quetiapine fumarate on sleep quality.",
        "tokens": "['Study', 'of', 'Evaluating', 'Quetiapine', 'in', 'Improving', 'Sleep', 'Quality', 'of', 'Schizophrenia', '|', 'This', 'study', 'will', 'apply', 'polysomnography', '(', 'PSG', ')', 'to', 'evaluate', 'the', 'effect', 'of', 'quetiapine', 'fumarate', 'on', 'sleep', 'architecture', '.', 'Most', 'of', 'previous', 'studies', 'evaluated', 'sleep', 'by', 'self', '-', 'reported', 'questionnaires', 'during', 'the', 'antipsychotic', 'treatment', '(', 'clozapine', ',', 'risperidone', ',', 'olanzapine', ',', 'et', 'al', ')', ',', 'while', 'only', 'a', 'few', 'studies', 'with', 'PSG', 'evaluation', 'had', 'some', 'limitation', ',', 'such', 'as', ':', 'small', 'sample', 'size', ',', 'respective', 'or', 'cross', '-', 'sectional', ',', 'potential', 'sleep', 'disorders', ',', 'et', 'al', '.', 'In', 'this', 'study', ',', 'we', 'will', 'investigate', 'both', 'subjective', 'and', 'objective', 'effect', 'of', 'quetiapine', 'fumarate', 'in', 'improving', 'sleep', 'quality', 'in', 'schizophrenic', 'patients', 'by', 'PSG', 'as', 'well', 'as', 'psychiatric', 'scales', '.', 'The', 'control', 'drug', 'in', 'this', 'study', 'is', 'the', 'typical', 'antipsychotic', '-', 'haloperidol', '.', 'It', 'could', 'increase', 'sleep', 'duration', 'and', 'efficiency', 'by', 'mostly', 'increasing', 'the', 'S2', 'without', 'effect', 'on', 'rapid', 'eye', 'movement', '(', 'REM', ')', 'sleep', 'and', 'slow', 'wave', 'sleep', '(', 'SWS', ')', '.', 'The', 'patients', 'will', 'be', 'randomised', 'into', 'two', 'groups', 'as', 'a', 'parallel', 'design', '.', 'This', 'study', 'is', 'designed', 'as', 'rater', 'blinded', 'to', 'reduce', 'the', 'bias', 'in', 'evaluation', '.', 'It', 'is', 'suggested', 'that', 'the', 'sedative', 'effect', 'of', 'quetiapine', 'fumarate', 'could', 'diminish', 'in', '2', 'weeks', ',', 'therefore', ',', 'we', 'use', '4', 'weeks', 'to', 'ensure', 'the', 'change', 'of', 'sleep', 'quality', 'in', 'this', 'study', ',', 'which', 'could', 'be', 'helpful', 'for', 'the', 'evaluation', 'of', 'relative', 'short', 'and', 'middle', 'term', 'effect', 'of', 'quetiapine', 'fumarate', 'on', 'sleep', 'quality', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 30,
                "text": "Quetiapine",
                "type": "DRUG"
            },
            {
                "start": 61,
                "end": 74,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 147,
                "end": 166,
                "text": "quetiapine fumarate",
                "type": "DRUG"
            },
            {
                "start": 577,
                "end": 596,
                "text": "quetiapine fumarate",
                "type": "DRUG"
            },
            {
                "start": 627,
                "end": 640,
                "text": "schizophrenic",
                "type": "CONDITION"
            },
            {
                "start": 750,
                "end": 761,
                "text": "haloperidol",
                "type": "DRUG"
            },
            {
                "start": 1103,
                "end": 1122,
                "text": "quetiapine fumarate",
                "type": "DRUG"
            },
            {
                "start": 1315,
                "end": 1334,
                "text": "quetiapine fumarate",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02427607",
        "study_official_title": "An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects ",
        "study_brief_summary": " To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.",
        "text": "An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects | To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.",
        "tokens": "['An', 'Open', '-', 'label', 'Extension', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Perampanel', '(', 'E2007', ')', 'Administered', 'as', 'an', 'Adjunctive', 'Therapy', 'in', 'Epilepsy', 'Subjects', '|', 'To', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'perampanel', 'given', 'as', 'an', 'adjunctive', 'therapy', 'in', 'participants', 'with', 'epilepsy', '.', 'This', 'study', 'will', 'be', 'continued', 'until', 'perampanel', 'is', 'commercially', 'available', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 73,
                "end": 83,
                "text": "Perampanel",
                "type": "DRUG"
            },
            {
                "start": 85,
                "end": 90,
                "text": "E2007",
                "type": "DRUG"
            },
            {
                "start": 133,
                "end": 141,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 196,
                "end": 206,
                "text": "perampanel",
                "type": "DRUG"
            },
            {
                "start": 259,
                "end": 267,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 304,
                "end": 314,
                "text": "perampanel",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02058940",
        "study_official_title": "Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury ",
        "study_brief_summary": " The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.",
        "text": "Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury | The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.",
        "tokens": "['Intravenous', 'Exenatide', 'Infusion', 'in', 'Critically', 'Ill', 'Patients', 'With', 'Acute', 'Brain', 'Injury', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'feasibility', 'of', 'exenatide', 'infusion', 'for', 'the', 'treatment', 'of', 'high', 'blood', 'sugars', 'following', 'acute', 'brain', 'injury', '.']",
        "token_bio_labels": "['O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 21,
                "text": "Exenatide",
                "type": "DRUG"
            },
            {
                "start": 34,
                "end": 48,
                "text": "Critically Ill",
                "type": "CONDITION"
            },
            {
                "start": 63,
                "end": 81,
                "text": "Acute Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 142,
                "end": 151,
                "text": "exenatide",
                "type": "DRUG"
            },
            {
                "start": 182,
                "end": 199,
                "text": "high blood sugars",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 228,
                "text": "acute brain injury",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03704272",
        "study_official_title": "Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral (SunBrite) ",
        "study_brief_summary": " The Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral (SunBrite) protocol is a family-empowered, risk mitigation strategy that targets families with young children who present to the ED with intracranial trauma. Based on the widely utilized screening, brief intervention, and referral to treatment (SBIRT) protocol, SunBrite has 3 core components: screening, brief motivational interview, and referral for treatment. PCH will: 1) engage community partnerships to support SunBrite development; 2) utilize participatory action research approach for design, implementation, process evaluation, and dissemination of the pilot program; and 3) evaluate intervention implementation and pilot outcomes. Over a 2-year period, this study will encompass a pilot intervention and implementation assessment and a randomized trial to evaluate outcomes. Implementation of SunBrite will yield rigorous scientific evidence for a sustainable, evidenced-based, widely-needed non-accidental (NAT) screening and intervention for families with young children.",
        "text": "Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral (SunBrite) | The Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral (SunBrite) protocol is a family-empowered, risk mitigation strategy that targets families with young children who present to the ED with intracranial trauma. Based on the widely utilized screening, brief intervention, and referral to treatment (SBIRT) protocol, SunBrite has 3 core components: screening, brief motivational interview, and referral for treatment. PCH will: 1) engage community partnerships to support SunBrite development; 2) utilize participatory action research approach for design, implementation, process evaluation, and dissemination of the pilot program; and 3) evaluate intervention implementation and pilot outcomes. Over a 2-year period, this study will encompass a pilot intervention and implementation assessment and a randomized trial to evaluate outcomes. Implementation of SunBrite will yield rigorous scientific evidence for a sustainable, evidenced-based, widely-needed non-accidental (NAT) screening and intervention for families with young children.",
        "tokens": "['Supervisory', 'Neglect', ',', 'Non', '-', 'Accidental', 'Trauma', ',', 'Brief', 'Intervention', ',', 'and', 'Treatment', 'Referral', '(', 'SunBrite', ')', '|', 'The', 'Supervisory', 'Neglect', ',', 'Non', '-', 'Accidental', 'Trauma', ',', 'Brief', 'Intervention', ',', 'and', 'Treatment', 'Referral', '(', 'SunBrite', ')', 'protocol', 'is', 'a', 'family', '-', 'empowered', ',', 'risk', 'mitigation', 'strategy', 'that', 'targets', 'families', 'with', 'young', 'children', 'who', 'present', 'to', 'the', 'ED', 'with', 'intracranial', 'trauma', '.', 'Based', 'on', 'the', 'widely', 'utilized', 'screening', ',', 'brief', 'intervention', ',', 'and', 'referral', 'to', 'treatment', '(', 'SBIRT', ')', 'protocol', ',', 'SunBrite', 'has', '3', 'core', 'components', ':', 'screening', ',', 'brief', 'motivational', 'interview', ',', 'and', 'referral', 'for', 'treatment', '.', 'PCH', 'will', ':', '1', ')', 'engage', 'community', 'partnerships', 'to', 'support', 'SunBrite', 'development', ';', '2', ')', 'utilize', 'participatory', 'action', 'research', 'approach', 'for', 'design', ',', 'implementation', ',', 'process', 'evaluation', ',', 'and', 'dissemination', 'of', 'the', 'pilot', 'program', ';', 'and', '3', ')', 'evaluate', 'intervention', 'implementation', 'and', 'pilot', 'outcomes', '.', 'Over', 'a', '2', '-', 'year', 'period', ',', 'this', 'study', 'will', 'encompass', 'a', 'pilot', 'intervention', 'and', 'implementation', 'assessment', 'and', 'a', 'randomized', 'trial', 'to', 'evaluate', 'outcomes', '.', 'Implementation', 'of', 'SunBrite', 'will', 'yield', 'rigorous', 'scientific', 'evidence', 'for', 'a', 'sustainable', ',', 'evidenced', '-', 'based', ',', 'widely', '-', 'needed', 'non', '-', 'accidental', '(', 'NAT', ')', 'screening', 'and', 'intervention', 'for', 'families', 'with', 'young', 'children', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 86,
                "text": "Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 88,
                "end": 96,
                "text": "SunBrite",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 104,
                "end": 190,
                "text": "Supervisory Neglect, Non-Accidental Trauma, Brief Intervention, and Treatment Referral",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 192,
                "end": 200,
                "text": "SunBrite",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 328,
                "end": 347,
                "text": "intracranial trauma",
                "type": "CONDITION"
            },
            {
                "start": 453,
                "end": 461,
                "text": "SunBrite",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 485,
                "end": 494,
                "text": "screening",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 496,
                "end": 524,
                "text": "brief motivational interview",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 530,
                "end": 552,
                "text": "referral for treatment",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 608,
                "end": 616,
                "text": "SunBrite",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 994,
                "end": 1002,
                "text": "SunBrite",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT02274649",
        "study_official_title": "A Patient Centered Approach to Successful Community Transition After Catastrophic Injury: Clinical Trial to Evaluate One-to-one Peer Mentoring ",
        "study_brief_summary": " The research will examine the effects of enhanced peer mentor interactions on facilitating a successful transition to community living following traumatic spinal cord injury (SCI). Participants in the research will be assigned to either (1) the control group that will receive traditional peer mentor types of interactions or (2) to the intervention group that will receive an enhanced peer mentor program called the One-on-One Initiative. Assignment to one of these two groups will occur randomly on admission to Shepherd Center; the only stratifying criteria is injury level - C6 and above vs. C7 and below.",
        "text": "A Patient Centered Approach to Successful Community Transition After Catastrophic Injury: Clinical Trial to Evaluate One-to-one Peer Mentoring | The research will examine the effects of enhanced peer mentor interactions on facilitating a successful transition to community living following traumatic spinal cord injury (SCI). Participants in the research will be assigned to either (1) the control group that will receive traditional peer mentor types of interactions or (2) to the intervention group that will receive an enhanced peer mentor program called the One-on-One Initiative. Assignment to one of these two groups will occur randomly on admission to Shepherd Center; the only stratifying criteria is injury level - C6 and above vs. C7 and below.",
        "tokens": "['A', 'Patient', 'Centered', 'Approach', 'to', 'Successful', 'Community', 'Transition', 'After', 'Catastrophic', 'Injury', ':', 'Clinical', 'Trial', 'to', 'Evaluate', 'One', '-', 'to', '-', 'one', 'Peer', 'Mentoring', '|', 'The', 'research', 'will', 'examine', 'the', 'effects', 'of', 'enhanced', 'peer', 'mentor', 'interactions', 'on', 'facilitating', 'a', 'successful', 'transition', 'to', 'community', 'living', 'following', 'traumatic', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'Participants', 'in', 'the', 'research', 'will', 'be', 'assigned', 'to', 'either', '(', '1', ')', 'the', 'control', 'group', 'that', 'will', 'receive', 'traditional', 'peer', 'mentor', 'types', 'of', 'interactions', 'or', '(', '2', ')', 'to', 'the', 'intervention', 'group', 'that', 'will', 'receive', 'an', 'enhanced', 'peer', 'mentor', 'program', 'called', 'the', 'One', '-', 'on', '-', 'One', 'Initiative', '.', 'Assignment', 'to', 'one', 'of', 'these', 'two', 'groups', 'will', 'occur', 'randomly', 'on', 'admission', 'to', 'Shepherd', 'Center', ';', 'the', 'only', 'stratifying', 'criteria', 'is', 'injury', 'level', '-', 'C6', 'and', 'above', 'vs.', 'C7', 'and', 'below', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 69,
                "end": 88,
                "text": "Catastrophic Injury",
                "type": "CONDITION"
            },
            {
                "start": 117,
                "end": 142,
                "text": "One-to-one Peer Mentoring",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 186,
                "end": 219,
                "text": "enhanced peer mentor interactions",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 290,
                "end": 318,
                "text": "traumatic spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 320,
                "end": 323,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 422,
                "end": 467,
                "text": "traditional peer mentor types of interactions",
                "type": "CONTROL"
            },
            {
                "start": 522,
                "end": 550,
                "text": "enhanced peer mentor program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 562,
                "end": 583,
                "text": "One-on-One Initiative",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT00233922",
        "study_official_title": "Reconstruction of the Orbit With a Bioresorbable Polycaprolactone Implant ",
        "study_brief_summary": " Patients with orbital injuries are entered into the trial. Age: 20 - 70. After obtaining appropriate consent, they are entered into either a control arm where reconstruction of the orbit is done with a titanium mesh (established practice) or the experimental arm where reconstruction is by a bioresorbable implant made of polycaprolactone. Patients are followuped at 1 week, 1 month, 3 months, 6 months & 12 months. CT scan of the orbits are performed preop, 6 months & 12 months. End point is the 12 month follow-up appointment. Visual acuity, range of motion, enophthalmos & diplopia are assessed in follow-up.",
        "text": "Reconstruction of the Orbit With a Bioresorbable Polycaprolactone Implant | Patients with orbital injuries are entered into the trial. Age: 20 - 70. After obtaining appropriate consent, they are entered into either a control arm where reconstruction of the orbit is done with a titanium mesh (established practice) or the experimental arm where reconstruction is by a bioresorbable implant made of polycaprolactone. Patients are followuped at 1 week, 1 month, 3 months, 6 months & 12 months. CT scan of the orbits are performed preop, 6 months & 12 months. End point is the 12 month follow-up appointment. Visual acuity, range of motion, enophthalmos & diplopia are assessed in follow-up.",
        "tokens": "['Reconstruction', 'of', 'the', 'Orbit', 'With', 'a', 'Bioresorbable', 'Polycaprolactone', 'Implant', '|', 'Patients', 'with', 'orbital', 'injuries', 'are', 'entered', 'into', 'the', 'trial', '.', 'Age', ':', '20', '-', '70', '.', 'After', 'obtaining', 'appropriate', 'consent', ',', 'they', 'are', 'entered', 'into', 'either', 'a', 'control', 'arm', 'where', 'reconstruction', 'of', 'the', 'orbit', 'is', 'done', 'with', 'a', 'titanium', 'mesh', '(', 'established', 'practice', ')', 'or', 'the', 'experimental', 'arm', 'where', 'reconstruction', 'is', 'by', 'a', 'bioresorbable', 'implant', 'made', 'of', 'polycaprolactone', '.', 'Patients', 'are', 'followuped', 'at', '1', 'week', ',', '1', 'month', ',', '3', 'months', ',', '6', 'months', '&', '12', 'months', '.', 'CT', 'scan', 'of', 'the', 'orbits', 'are', 'performed', 'preop', ',', '6', 'months', '&', '12', 'months', '.', 'End', 'point', 'is', 'the', '12', 'month', 'follow', '-', 'up', 'appointment', '.', 'Visual', 'acuity', ',', 'range', 'of', 'motion', ',', 'enophthalmos', '&', 'diplopia', 'are', 'assessed', 'in', 'follow', '-', 'up', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 73,
                "text": "Bioresorbable Polycaprolactone Implant",
                "type": "OTHER"
            },
            {
                "start": 90,
                "end": 106,
                "text": "orbital injuries",
                "type": "CONDITION"
            },
            {
                "start": 278,
                "end": 291,
                "text": "titanium mesh",
                "type": "CONTROL"
            },
            {
                "start": 368,
                "end": 414,
                "text": "bioresorbable implant made of polycaprolactone",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01966172",
        "study_official_title": "Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial ",
        "study_brief_summary": " To test if multimodal analgesia with different analgesic medication offer better pain relief, lesser side effects and is safe compared to conventionel opiod analgesia after cardiac surgery.",
        "text": "Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial | To test if multimodal analgesia with different analgesic medication offer better pain relief, lesser side effects and is safe compared to conventionel opiod analgesia after cardiac surgery.",
        "tokens": "['Multimodal', 'Opiate', '-', 'sparing', 'Analgesia', 'Versus', 'Traditional', 'Opiate', 'Based', 'Analgesia', 'After', 'Cardiac', 'Surgery', ',', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'To', 'test', 'if', 'multimodal', 'analgesia', 'with', 'different', 'analgesic', 'medication', 'offer', 'better', 'pain', 'relief', ',', 'lesser', 'side', 'effects', 'and', 'is', 'safe', 'compared', 'to', 'conventionel', 'opiod', 'analgesia', 'after', 'cardiac', 'surgery', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 35,
                "text": "Multimodal Opiate-sparing Analgesia",
                "type": "OTHER"
            },
            {
                "start": 43,
                "end": 77,
                "text": "Traditional Opiate Based Analgesia",
                "type": "OTHER"
            },
            {
                "start": 84,
                "end": 99,
                "text": "Cardiac Surgery",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 164,
                "text": "multimodal analgesia",
                "type": "OTHER"
            },
            {
                "start": 271,
                "end": 299,
                "text": "conventionel opiod analgesia",
                "type": "OTHER"
            },
            {
                "start": 306,
                "end": 321,
                "text": "cardiac surgery",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05563909",
        "study_official_title": "Investigation of the Efficacy of Virtual Reality Mediated Neurodynamic Exercises in Carpal Tunnel Syndrome: A Prospective Randomized Controlled Clinical Study ",
        "study_brief_summary": " Carpal tunnel syndrome (CTS) is the most common nerve entrapment syndrome. It occurs as a result of compression of the median nerve as it passes through a restricted osteofibrous canal in the wrist. Known as the carpal tunnel, this canal contains the wrist bones, transverse carpal ligament, median nerve, and digital flexor tendons. Edema, tendon inflammation, hormonal changes, and manual activity can contribute to increased nerve compression and sometimes cause pain.\n\nIn this research, the investigators aim to present the virtual reality-mediated exercise program to patients non-immersive. It is planned to use the Leap Motion motion sensor to detect hand and wrist movements and to monitor the gamified setup on the computer screen.\n\nIn the system that will be presented via computer and hand motion sensor, the patient will be asked to perform therapeutic exercises for the diagnosis of CTS in a scenario developed through virtual reality. The investigators predict that patients will actively participate in virtual reality-mediated therapeutic exercise program with high motivation and their functional results will be better than classical exercise programs.\n\nIn our research, the investigators aim to present the tendon and nerve gliding exercises with proven effectiveness in patients with CTS, with non-immersive virtual reality systems, and to compare their effectiveness with the classical exercise program.",
        "text": "Investigation of the Efficacy of Virtual Reality Mediated Neurodynamic Exercises in Carpal Tunnel Syndrome: A Prospective Randomized Controlled Clinical Study | Carpal tunnel syndrome (CTS) is the most common nerve entrapment syndrome. It occurs as a result of compression of the median nerve as it passes through a restricted osteofibrous canal in the wrist. Known as the carpal tunnel, this canal contains the wrist bones, transverse carpal ligament, median nerve, and digital flexor tendons. Edema, tendon inflammation, hormonal changes, and manual activity can contribute to increased nerve compression and sometimes cause pain.\n\nIn this research, the investigators aim to present the virtual reality-mediated exercise program to patients non-immersive. It is planned to use the Leap Motion motion sensor to detect hand and wrist movements and to monitor the gamified setup on the computer screen.\n\nIn the system that will be presented via computer and hand motion sensor, the patient will be asked to perform therapeutic exercises for the diagnosis of CTS in a scenario developed through virtual reality. The investigators predict that patients will actively participate in virtual reality-mediated therapeutic exercise program with high motivation and their functional results will be better than classical exercise programs.\n\nIn our research, the investigators aim to present the tendon and nerve gliding exercises with proven effectiveness in patients with CTS, with non-immersive virtual reality systems, and to compare their effectiveness with the classical exercise program.",
        "tokens": "['Investigation', 'of', 'the', 'Efficacy', 'of', 'Virtual', 'Reality', 'Mediated', 'Neurodynamic', 'Exercises', 'in', 'Carpal', 'Tunnel', 'Syndrome', ':', 'A', 'Prospective', 'Randomized', 'Controlled', 'Clinical', 'Study', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'the', 'most', 'common', 'nerve', 'entrapment', 'syndrome', '.', 'It', 'occurs', 'as', 'a', 'result', 'of', 'compression', 'of', 'the', 'median', 'nerve', 'as', 'it', 'passes', 'through', 'a', 'restricted', 'osteofibrous', 'canal', 'in', 'the', 'wrist', '.', 'Known', 'as', 'the', 'carpal', 'tunnel', ',', 'this', 'canal', 'contains', 'the', 'wrist', 'bones', ',', 'transverse', 'carpal', 'ligament', ',', 'median', 'nerve', ',', 'and', 'digital', 'flexor', 'tendons', '.', 'Edema', ',', 'tendon', 'inflammation', ',', 'hormonal', 'changes', ',', 'and', 'manual', 'activity', 'can', 'contribute', 'to', 'increased', 'nerve', 'compression', 'and', 'sometimes', 'cause', 'pain', '.', '\\n\\n', 'In', 'this', 'research', ',', 'the', 'investigators', 'aim', 'to', 'present', 'the', 'virtual', 'reality', '-', 'mediated', 'exercise', 'program', 'to', 'patients', 'non', '-', 'immersive', '.', 'It', 'is', 'planned', 'to', 'use', 'the', 'Leap', 'Motion', 'motion', 'sensor', 'to', 'detect', 'hand', 'and', 'wrist', 'movements', 'and', 'to', 'monitor', 'the', 'gamified', 'setup', 'on', 'the', 'computer', 'screen', '.', '\\n\\n', 'In', 'the', 'system', 'that', 'will', 'be', 'presented', 'via', 'computer', 'and', 'hand', 'motion', 'sensor', ',', 'the', 'patient', 'will', 'be', 'asked', 'to', 'perform', 'therapeutic', 'exercises', 'for', 'the', 'diagnosis', 'of', 'CTS', 'in', 'a', 'scenario', 'developed', 'through', 'virtual', 'reality', '.', 'The', 'investigators', 'predict', 'that', 'patients', 'will', 'actively', 'participate', 'in', 'virtual', 'reality', '-', 'mediated', 'therapeutic', 'exercise', 'program', 'with', 'high', 'motivation', 'and', 'their', 'functional', 'results', 'will', 'be', 'better', 'than', 'classical', 'exercise', 'programs', '.', '\\n\\n', 'In', 'our', 'research', ',', 'the', 'investigators', 'aim', 'to', 'present', 'the', 'tendon', 'and', 'nerve', 'gliding', 'exercises', 'with', 'proven', 'effectiveness', 'in', 'patients', 'with', 'CTS', ',', 'with', 'non', '-', 'immersive', 'virtual', 'reality', 'systems', ',', 'and', 'to', 'compare', 'their', 'effectiveness', 'with', 'the', 'classical', 'exercise', 'program', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 80,
                "text": "Virtual Reality Mediated Neurodynamic Exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 84,
                "end": 106,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 183,
                "text": "Carpal tunnel syndrome",
                "type": "CONDITION"
            },
            {
                "start": 185,
                "end": 188,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 689,
                "end": 730,
                "text": "virtual reality-mediated exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 1057,
                "end": 1060,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 1093,
                "end": 1108,
                "text": "virtual reality",
                "type": "PHYSICAL"
            },
            {
                "start": 1179,
                "end": 1232,
                "text": "virtual reality-mediated therapeutic exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 1303,
                "end": 1330,
                "text": "classical exercise programs",
                "type": "CONTROL"
            },
            {
                "start": 1387,
                "end": 1421,
                "text": "tendon and nerve gliding exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 1465,
                "end": 1468,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 1475,
                "end": 1512,
                "text": "non-immersive virtual reality systems",
                "type": "OTHER"
            },
            {
                "start": 1558,
                "end": 1584,
                "text": "classical exercise program",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04569435",
        "study_official_title": "A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS) ",
        "study_brief_summary": " This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.",
        "text": "A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.",
        "tokens": "['A', 'Phase', '2a', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetic', '(', 'PK', ')', ',', 'and', 'Pharmacodynamic', '(', 'PD', ')', 'Study', 'of', 'Intravenous', 'ANX005', 'in', 'Subjects', 'With', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'This', 'study', 'is', 'a', 'multi', '-', 'center', ',', 'open', '-', 'label', 'study', 'of', 'intravenous', '(', 'IV', ')', 'ANX005', 'in', 'participants', 'with', 'ALS', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 101,
                "end": 107,
                "text": "ANX005",
                "type": "DRUG"
            },
            {
                "start": 125,
                "end": 154,
                "text": "Amyotrophic Lateral Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 159,
                "text": "ALS",
                "type": "CONDITION"
            },
            {
                "start": 230,
                "end": 236,
                "text": "ANX005",
                "type": "DRUG"
            },
            {
                "start": 258,
                "end": 261,
                "text": "ALS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02098759",
        "study_official_title": "Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex ",
        "study_brief_summary": " The primary objective of clinical part of EPISTOP project is to identify the clinical and molecular biomarkers of epileptogenesis in a prospective clinical study of patients with TSC.\n\nSecondary objective of the clinical part of EPISTOP is to compare the effects of standard antiepileptic treatment in patients diagnosed as having epilepsy after clinical seizures vs after electroencephalographic epileptiform discharges, in a randomized trial in TSC patients.",
        "text": "Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex | The primary objective of clinical part of EPISTOP project is to identify the clinical and molecular biomarkers of epileptogenesis in a prospective clinical study of patients with TSC.\n\nSecondary objective of the clinical part of EPISTOP is to compare the effects of standard antiepileptic treatment in patients diagnosed as having epilepsy after clinical seizures vs after electroencephalographic epileptiform discharges, in a randomized trial in TSC patients.",
        "tokens": "['Long', '-', 'term', ',', 'Prospective', 'Study', 'Evaluating', 'Clinical', 'and', 'Molecular', 'Biomarkers', 'of', 'Epileptogenesis', 'in', 'a', 'Genetic', 'Model', 'of', 'Epilepsy', '-', 'Tuberous', 'Sclerosis', 'Complex', '|', 'The', 'primary', 'objective', 'of', 'clinical', 'part', 'of', 'EPISTOP', 'project', 'is', 'to', 'identify', 'the', 'clinical', 'and', 'molecular', 'biomarkers', 'of', 'epileptogenesis', 'in', 'a', 'prospective', 'clinical', 'study', 'of', 'patients', 'with', 'TSC', '.', '\\n\\n', 'Secondary', 'objective', 'of', 'the', 'clinical', 'part', 'of', 'EPISTOP', 'is', 'to', 'compare', 'the', 'effects', 'of', 'standard', 'antiepileptic', 'treatment', 'in', 'patients', 'diagnosed', 'as', 'having', 'epilepsy', 'after', 'clinical', 'seizures', 'vs', 'after', 'electroencephalographic', 'epileptiform', 'discharges', ',', 'in', 'a', 'randomized', 'trial', 'in', 'TSC', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 115,
                "end": 123,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 152,
                "text": "Tuberous Sclerosis Complex",
                "type": "CONDITION"
            },
            {
                "start": 334,
                "end": 337,
                "text": "TSC",
                "type": "CONDITION"
            },
            {
                "start": 421,
                "end": 453,
                "text": "standard antiepileptic treatment",
                "type": "OTHER"
            },
            {
                "start": 486,
                "end": 494,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 602,
                "end": 605,
                "text": "TSC",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04172376",
        "study_official_title": "Stereotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation II (SOITBE II) ",
        "study_brief_summary": " Spontaneous cerebral hemorrhage is one of the main causes of death and disability all over the world, accounting for 20%-30% of all cerebrovascular diseases. Minimally invasive surgery of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term neurological recovery in patients with cerebral hemorrhage. Until now, no standardized practice for minimally invasive surgery of spontaneous cerebral hemorrhage has been established. Hematoma puncture and drainage based on CT scans without precise localization and personalized approach design, which may lead to poor efficacy and high risk of complications. The investigators' hospital has much experience in treating cerebral hemorrhage with stereotactic puncture and aspiration. So the investigators conduct a prospective multicenter randomized controlled clinical trial across the country to determine the therapeutic effects of puncture aspiration plus thrombolysis treatment for the perioperative and long-term recovery of patients with small hematoma in deep basal ganglia via computerized precision coordinates and personalized approach design.",
        "text": "Stereotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation II (SOITBE II) | Spontaneous cerebral hemorrhage is one of the main causes of death and disability all over the world, accounting for 20%-30% of all cerebrovascular diseases. Minimally invasive surgery of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term neurological recovery in patients with cerebral hemorrhage. Until now, no standardized practice for minimally invasive surgery of spontaneous cerebral hemorrhage has been established. Hematoma puncture and drainage based on CT scans without precise localization and personalized approach design, which may lead to poor efficacy and high risk of complications. The investigators' hospital has much experience in treating cerebral hemorrhage with stereotactic puncture and aspiration. So the investigators conduct a prospective multicenter randomized controlled clinical trial across the country to determine the therapeutic effects of puncture aspiration plus thrombolysis treatment for the perioperative and long-term recovery of patients with small hematoma in deep basal ganglia via computerized precision coordinates and personalized approach design.",
        "tokens": "['Stereotactic', 'Operation', 'Integrating', 'With', 'Thrombolysis', 'in', 'Basal', 'Ganglion', 'Hemorrhage', 'Evacuation', 'II', '(', 'SOITBE', 'II', ')', '|', 'Spontaneous', 'cerebral', 'hemorrhage', 'is', 'one', 'of', 'the', 'main', 'causes', 'of', 'death', 'and', 'disability', 'all', 'over', 'the', 'world', ',', 'accounting', 'for', '20%-30', '%', 'of', 'all', 'cerebrovascular', 'diseases', '.', 'Minimally', 'invasive', 'surgery', 'of', 'cerebral', 'hemorrhage', ',', 'especially', 'puncture', 'aspiration', ',', 'can', 'improve', 'early', 'and', 'long', '-', 'term', 'neurological', 'recovery', 'in', 'patients', 'with', 'cerebral', 'hemorrhage', '.', 'Until', 'now', ',', 'no', 'standardized', 'practice', 'for', 'minimally', 'invasive', 'surgery', 'of', 'spontaneous', 'cerebral', 'hemorrhage', 'has', 'been', 'established', '.', 'Hematoma', 'puncture', 'and', 'drainage', 'based', 'on', 'CT', 'scans', 'without', 'precise', 'localization', 'and', 'personalized', 'approach', 'design', ',', 'which', 'may', 'lead', 'to', 'poor', 'efficacy', 'and', 'high', 'risk', 'of', 'complications', '.', 'The', 'investigators', \"'\", 'hospital', 'has', 'much', 'experience', 'in', 'treating', 'cerebral', 'hemorrhage', 'with', 'stereotactic', 'puncture', 'and', 'aspiration', '.', 'So', 'the', 'investigators', 'conduct', 'a', 'prospective', 'multicenter', 'randomized', 'controlled', 'clinical', 'trial', 'across', 'the', 'country', 'to', 'determine', 'the', 'therapeutic', 'effects', 'of', 'puncture', 'aspiration', 'plus', 'thrombolysis', 'treatment', 'for', 'the', 'perioperative', 'and', 'long', '-', 'term', 'recovery', 'of', 'patients', 'with', 'small', 'hematoma', 'in', 'deep', 'basal', 'ganglia', 'via', 'computerized', 'precision', 'coordinates', 'and', 'personalized', 'approach', 'design', '.']",
        "token_bio_labels": "['B-SURG', 'I-SURG', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "Stereotactic Operation",
                "type": "SURGICAL"
            },
            {
                "start": 40,
                "end": 52,
                "text": "Thrombolysis",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 81,
                "text": "Basal Ganglion Hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 110,
                "end": 141,
                "text": "Spontaneous cerebral hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 330,
                "end": 349,
                "text": "puncture aspiration",
                "type": "SURGICAL"
            },
            {
                "start": 422,
                "end": 441,
                "text": "cerebral hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 513,
                "end": 544,
                "text": "spontaneous cerebral hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 803,
                "end": 822,
                "text": "cerebral hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 828,
                "end": 849,
                "text": "stereotactic puncture",
                "type": "SURGICAL"
            },
            {
                "start": 854,
                "end": 864,
                "text": "aspiration",
                "type": "SURGICAL"
            },
            {
                "start": 1017,
                "end": 1036,
                "text": "puncture aspiration",
                "type": "SURGICAL"
            },
            {
                "start": 1042,
                "end": 1054,
                "text": "thrombolysis",
                "type": "OTHER"
            },
            {
                "start": 1127,
                "end": 1163,
                "text": "small hematoma in deep basal ganglia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05394610",
        "study_official_title": "A Confirmatory Investigation of the Effectiveness of Sana Treatment in Fibromyalgia ",
        "study_brief_summary": " This is study designed to confirm the effectiveness of the Sana Device in patients with pain due to fibromyalgia on quality of life as measured by the Fibromyalgia Impact Questionnaire Revised (FIQR). It is a two arm study in which subjects will be randomly assigned to either active device group or sham-controlled group.",
        "text": "A Confirmatory Investigation of the Effectiveness of Sana Treatment in Fibromyalgia | This is study designed to confirm the effectiveness of the Sana Device in patients with pain due to fibromyalgia on quality of life as measured by the Fibromyalgia Impact Questionnaire Revised (FIQR). It is a two arm study in which subjects will be randomly assigned to either active device group or sham-controlled group.",
        "tokens": "['A', 'Confirmatory', 'Investigation', 'of', 'the', 'Effectiveness', 'of', 'Sana', 'Treatment', 'in', 'Fibromyalgia', '|', 'This', 'is', 'study', 'designed', 'to', 'confirm', 'the', 'effectiveness', 'of', 'the', 'Sana', 'Device', 'in', 'patients', 'with', 'pain', 'due', 'to', 'fibromyalgia', 'on', 'quality', 'of', 'life', 'as', 'measured', 'by', 'the', 'Fibromyalgia', 'Impact', 'Questionnaire', 'Revised', '(', 'FIQR', ')', '.', 'It', 'is', 'a', 'two', 'arm', 'study', 'in', 'which', 'subjects', 'will', 'be', 'randomly', 'assigned', 'to', 'either', 'active', 'device', 'group', 'or', 'sham', '-', 'controlled', 'group', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 53,
                "end": 67,
                "text": "Sana Treatment",
                "type": "OTHER"
            },
            {
                "start": 71,
                "end": 83,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 156,
                "text": "Sana Device",
                "type": "OTHER"
            },
            {
                "start": 174,
                "end": 178,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 186,
                "end": 198,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 376,
                "text": "active device",
                "type": "OTHER"
            },
            {
                "start": 386,
                "end": 390,
                "text": "sham",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01641900",
        "study_official_title": "Sleep-dependent Memory Processing in Schizophrenia ",
        "study_brief_summary": " The investigators will test the hypothesis that the sleep medication, eszopiclone, can normalize brain activity during sleep and improve memory in patients with schizophrenia. The investigators will do this by measuring sleep and memory performance on two conditions separated by one week: taking 3 mg of eszopiclone and taking placebo. The investigators will study healthy subjects and chronic, medicated outpatients with schizophrenia.",
        "text": "Sleep-dependent Memory Processing in Schizophrenia | The investigators will test the hypothesis that the sleep medication, eszopiclone, can normalize brain activity during sleep and improve memory in patients with schizophrenia. The investigators will do this by measuring sleep and memory performance on two conditions separated by one week: taking 3 mg of eszopiclone and taking placebo. The investigators will study healthy subjects and chronic, medicated outpatients with schizophrenia.",
        "tokens": "['Sleep', '-', 'dependent', 'Memory', 'Processing', 'in', 'Schizophrenia', '|', 'The', 'investigators', 'will', 'test', 'the', 'hypothesis', 'that', 'the', 'sleep', 'medication', ',', 'eszopiclone', ',', 'can', 'normalize', 'brain', 'activity', 'during', 'sleep', 'and', 'improve', 'memory', 'in', 'patients', 'with', 'schizophrenia', '.', 'The', 'investigators', 'will', 'do', 'this', 'by', 'measuring', 'sleep', 'and', 'memory', 'performance', 'on', 'two', 'conditions', 'separated', 'by', 'one', 'week', ':', 'taking', '3', 'mg', 'of', 'eszopiclone', 'and', 'taking', 'placebo', '.', 'The', 'investigators', 'will', 'study', 'healthy', 'subjects', 'and', 'chronic', ',', 'medicated', 'outpatients', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 50,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 123,
                "end": 134,
                "text": "eszopiclone",
                "type": "DRUG"
            },
            {
                "start": 214,
                "end": 227,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 358,
                "end": 369,
                "text": "eszopiclone",
                "type": "DRUG"
            },
            {
                "start": 381,
                "end": 388,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 476,
                "end": 489,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03721887",
        "study_official_title": "Exploit the Neural Source and the Feasibility of Transcranial Direct Current Stimulation for Freezing of Gait in Parkinson's Disease and Multiple System Atrophy ",
        "study_brief_summary": " In this project, the investigators will deliver a 5-day session of transcranial direct current stimulation (tDCS) to the leg motor cortex of the FOG patients to examine whether the intervention will benefit the patients in a double blind randomized design. Six assessments with different combinations of clinical scaling, gait analysis, electrophysiological investigation and fMRI examinations before and after tDCS will be conducted. The treatment and placebo groups will be crossed over after one-month washout. The investigators will investigate whether the possible tDCS beneficial effect will be different or similar in patients with different electric sources. In addition, how long the possible beneficial effect of tDCS can be consolidated after the 5-day course of stimulation is also crucial. The investigators aim to peep the myth of FOG in PD and MSA by the multi-modality approach and hope the study will benefit the long suffering patients.",
        "text": "Exploit the Neural Source and the Feasibility of Transcranial Direct Current Stimulation for Freezing of Gait in Parkinson's Disease and Multiple System Atrophy | In this project, the investigators will deliver a 5-day session of transcranial direct current stimulation (tDCS) to the leg motor cortex of the FOG patients to examine whether the intervention will benefit the patients in a double blind randomized design. Six assessments with different combinations of clinical scaling, gait analysis, electrophysiological investigation and fMRI examinations before and after tDCS will be conducted. The treatment and placebo groups will be crossed over after one-month washout. The investigators will investigate whether the possible tDCS beneficial effect will be different or similar in patients with different electric sources. In addition, how long the possible beneficial effect of tDCS can be consolidated after the 5-day course of stimulation is also crucial. The investigators aim to peep the myth of FOG in PD and MSA by the multi-modality approach and hope the study will benefit the long suffering patients.",
        "tokens": "['Exploit', 'the', 'Neural', 'Source', 'and', 'the', 'Feasibility', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'for', 'Freezing', 'of', 'Gait', 'in', 'Parkinson', \"'s\", 'Disease', 'and', 'Multiple', 'System', 'Atrophy', '|', 'In', 'this', 'project', ',', 'the', 'investigators', 'will', 'deliver', 'a', '5', '-', 'day', 'session', 'of', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'to', 'the', 'leg', 'motor', 'cortex', 'of', 'the', 'FOG', 'patients', 'to', 'examine', 'whether', 'the', 'intervention', 'will', 'benefit', 'the', 'patients', 'in', 'a', 'double', 'blind', 'randomized', 'design', '.', 'Six', 'assessments', 'with', 'different', 'combinations', 'of', 'clinical', 'scaling', ',', 'gait', 'analysis', ',', 'electrophysiological', 'investigation', 'and', 'fMRI', 'examinations', 'before', 'and', 'after', 'tDCS', 'will', 'be', 'conducted', '.', 'The', 'treatment', 'and', 'placebo', 'groups', 'will', 'be', 'crossed', 'over', 'after', 'one', '-', 'month', 'washout', '.', 'The', 'investigators', 'will', 'investigate', 'whether', 'the', 'possible', 'tDCS', 'beneficial', 'effect', 'will', 'be', 'different', 'or', 'similar', 'in', 'patients', 'with', 'different', 'electric', 'sources', '.', 'In', 'addition', ',', 'how', 'long', 'the', 'possible', 'beneficial', 'effect', 'of', 'tDCS', 'can', 'be', 'consolidated', 'after', 'the', '5', '-', 'day', 'course', 'of', 'stimulation', 'is', 'also', 'crucial', '.', 'The', 'investigators', 'aim', 'to', 'peep', 'the', 'myth', 'of', 'FOG', 'in', 'PD', 'and', 'MSA', 'by', 'the', 'multi', '-', 'modality', 'approach', 'and', 'hope', 'the', 'study', 'will', 'benefit', 'the', 'long', 'suffering', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 49,
                "end": 88,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 93,
                "end": 109,
                "text": "Freezing of Gait",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 132,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 137,
                "end": 160,
                "text": "Multiple System Atrophy",
                "type": "CONDITION"
            },
            {
                "start": 230,
                "end": 269,
                "text": "transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 271,
                "end": 275,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 308,
                "end": 311,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 574,
                "end": 578,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 616,
                "end": 623,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 733,
                "end": 737,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 886,
                "end": 890,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 1008,
                "end": 1011,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 1015,
                "end": 1017,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1022,
                "end": 1025,
                "text": "MSA",
                "type": "CONDITION"
            },
            {
                "start": 1033,
                "end": 1056,
                "text": "multi-modality approach",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00747253",
        "study_official_title": "AutoLITT\u2122 FIM Trial - A Prospective First-In-Man (FIM) Safety Trial of the AutoLITT Laser Treatment of Recurrent/Progressive Brain Tumors ",
        "study_brief_summary": " The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).",
        "text": "AutoLITT\u2122 FIM Trial - A Prospective First-In-Man (FIM) Safety Trial of the AutoLITT Laser Treatment of Recurrent/Progressive Brain Tumors | The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).",
        "tokens": "['AutoLITT', '\u2122', 'FIM', 'Trial', '-', 'A', 'Prospective', 'First', '-', 'In', '-', 'Man', '(', 'FIM', ')', 'Safety', 'Trial', 'of', 'the', 'AutoLITT', 'Laser', 'Treatment', 'of', 'Recurrent', '/', 'Progressive', 'Brain', 'Tumors', '|', 'The', 'main', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'performance', 'of', 'the', 'AutoLITT', 'system', 'for', 'the', 'treatment', 'of', 'recurrent', '/', 'progressive', 'glioblastoma', 'multiforme', 'tumors', '(', 'GBM', ')', '.']",
        "token_bio_labels": "['B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "AutoLITT",
                "type": "OTHER"
            },
            {
                "start": 75,
                "end": 99,
                "text": "AutoLITT Laser Treatment",
                "type": "OTHER"
            },
            {
                "start": 103,
                "end": 137,
                "text": "Recurrent/Progressive Brain Tumors",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 235,
                "text": "AutoLITT system",
                "type": "OTHER"
            },
            {
                "start": 257,
                "end": 309,
                "text": "recurrent/progressive glioblastoma multiforme tumors",
                "type": "CONDITION"
            },
            {
                "start": 311,
                "end": 314,
                "text": "GBM",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01237587",
        "study_official_title": "Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome ",
        "study_brief_summary": " The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS).\n\nThis trial consists of two distinct study periods. A blinded treatment period of 13 weeks and an open label extension period of 26 weeks.",
        "text": "Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome | The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS).\n\nThis trial consists of two distinct study periods. A blinded treatment period of 13 weeks and an open label extension period of 26 weeks.",
        "tokens": "['Effect', 'of', 'Duloxetine', '30/60', 'mg', 'Once', 'Daily', 'Versus', 'Placebo', 'in', 'Adolescents', 'With', 'Juvenile', 'Primary', 'Fibromyalgia', 'Syndrome', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'duloxetine', 'is', 'safe', 'and', 'effective', 'in', 'the', 'treatment', 'of', 'adolescents', 'with', 'Juvenile', 'Primary', 'Fibromyalgia', 'Syndrome', '(', 'JPFS', ')', '.', '\\n\\n', 'This', 'trial', 'consists', 'of', 'two', 'distinct', 'study', 'periods', '.', 'A', 'blinded', 'treatment', 'period', 'of', '13', 'weeks', 'and', 'an', 'open', 'label', 'extension', 'period', 'of', '26', 'weeks', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 20,
                "text": "Duloxetine",
                "type": "DRUG"
            },
            {
                "start": 48,
                "end": 55,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 76,
                "end": 114,
                "text": "Juvenile Primary Fibromyalgia Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 167,
                "end": 177,
                "text": "duloxetine",
                "type": "DRUG"
            },
            {
                "start": 237,
                "end": 275,
                "text": "Juvenile Primary Fibromyalgia Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 277,
                "end": 281,
                "text": "JPFS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01490502",
        "study_official_title": "A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis ",
        "study_brief_summary": " Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks. However, it is not known if giving supplemental vitamin D to those with MS reduces the risk of attacks, and some research suggests that vitamin D could even be harmful to people with MS.\n\nIn this clinical trial, patients with relapsing-remitting MS will receive high-dose or low-dose oral vitamin D in addition to an approved therapy for MS, glatiramer acetate. Patients will be evaluated for two years, and the effect of high-dose vitamin D supplementation on the rate of MS attacks and on the number of new lesions and change in brain volume on MRI will be determined. Establishing this association will have major implications for the treatment of individuals with MS throughout the world.",
        "text": "A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis | Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks. However, it is not known if giving supplemental vitamin D to those with MS reduces the risk of attacks, and some research suggests that vitamin D could even be harmful to people with MS.\n\nIn this clinical trial, patients with relapsing-remitting MS will receive high-dose or low-dose oral vitamin D in addition to an approved therapy for MS, glatiramer acetate. Patients will be evaluated for two years, and the effect of high-dose vitamin D supplementation on the rate of MS attacks and on the number of new lesions and change in brain volume on MRI will be determined. Establishing this association will have major implications for the treatment of individuals with MS throughout the world.",
        "tokens": "['A', 'Randomized', 'Controlled', 'Trial', 'of', 'Vitamin', 'D', 'Supplementation', 'in', 'Multiple', 'Sclerosis', '|', 'Low', 'vitamin', 'D', 'levels', 'have', 'been', 'shown', 'to', 'increase', 'a', 'person', \"'s\", 'risk', 'of', 'developing', 'multiple', 'sclerosis', '(', 'MS', ')', ',', 'and', 'patients', 'with', 'MS', 'who', 'have', 'lower', 'vitamin', 'D', 'levels', 'are', 'at', 'increased', 'risk', 'of', 'having', 'attacks', '.', 'However', ',', 'it', 'is', 'not', 'known', 'if', 'giving', 'supplemental', 'vitamin', 'D', 'to', 'those', 'with', 'MS', 'reduces', 'the', 'risk', 'of', 'attacks', ',', 'and', 'some', 'research', 'suggests', 'that', 'vitamin', 'D', 'could', 'even', 'be', 'harmful', 'to', 'people', 'with', 'MS', '.', '\\n\\n', 'In', 'this', 'clinical', 'trial', ',', 'patients', 'with', 'relapsing', '-', 'remitting', 'MS', 'will', 'receive', 'high', '-', 'dose', 'or', 'low', '-', 'dose', 'oral', 'vitamin', 'D', 'in', 'addition', 'to', 'an', 'approved', 'therapy', 'for', 'MS', ',', 'glatiramer', 'acetate', '.', 'Patients', 'will', 'be', 'evaluated', 'for', 'two', 'years', ',', 'and', 'the', 'effect', 'of', 'high', '-', 'dose', 'vitamin', 'D', 'supplementation', 'on', 'the', 'rate', 'of', 'MS', 'attacks', 'and', 'on', 'the', 'number', 'of', 'new', 'lesions', 'and', 'change', 'in', 'brain', 'volume', 'on', 'MRI', 'will', 'be', 'determined', '.', 'Establishing', 'this', 'association', 'will', 'have', 'major', 'implications', 'for', 'the', 'treatment', 'of', 'individuals', 'with', 'MS', 'throughout', 'the', 'world', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 42,
                "text": "Vitamin D",
                "type": "DRUG"
            },
            {
                "start": 62,
                "end": 80,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 87,
                "end": 96,
                "text": "vitamin D",
                "type": "DRUG"
            },
            {
                "start": 162,
                "end": 180,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 184,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 205,
                "end": 207,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 232,
                "text": "vitamin D",
                "type": "DRUG"
            },
            {
                "start": 329,
                "end": 338,
                "text": "vitamin D",
                "type": "DRUG"
            },
            {
                "start": 353,
                "end": 355,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 417,
                "end": 426,
                "text": "vitamin D",
                "type": "DRUG"
            },
            {
                "start": 464,
                "end": 466,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 507,
                "end": 529,
                "text": "relapsing-remitting MS",
                "type": "CONDITION"
            },
            {
                "start": 570,
                "end": 579,
                "text": "vitamin D",
                "type": "DRUG"
            },
            {
                "start": 619,
                "end": 621,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 623,
                "end": 641,
                "text": "glatiramer acetate",
                "type": "DRUG"
            },
            {
                "start": 713,
                "end": 722,
                "text": "vitamin D",
                "type": "DRUG"
            },
            {
                "start": 754,
                "end": 756,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 949,
                "end": 951,
                "text": "MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04180098",
        "study_official_title": "Improving Gait Adaptability in Hereditary Spastic Paraplegia During Task-specific Training on the C-Mill: Towards Evidence-Based and Individually Tailored Rehabilitation ",
        "study_brief_summary": " This study evaluates the effects of ten hours C-mill training on gait adaptability in participants with hereditary spastic paraplegia (HSP). Half of the participants start with five weeks of C-mill training (ten 1-hour sessions). The other participants are placed on a waiting list, which is followed by the same five weeks of C-mill training (ten 1-hour sessions). It is hypothesized that ten hours of context specific C-mill training is effective in improving gait adaptability in participants with pure HSP.",
        "text": "Improving Gait Adaptability in Hereditary Spastic Paraplegia During Task-specific Training on the C-Mill: Towards Evidence-Based and Individually Tailored Rehabilitation | This study evaluates the effects of ten hours C-mill training on gait adaptability in participants with hereditary spastic paraplegia (HSP). Half of the participants start with five weeks of C-mill training (ten 1-hour sessions). The other participants are placed on a waiting list, which is followed by the same five weeks of C-mill training (ten 1-hour sessions). It is hypothesized that ten hours of context specific C-mill training is effective in improving gait adaptability in participants with pure HSP.",
        "tokens": "['Improving', 'Gait', 'Adaptability', 'in', 'Hereditary', 'Spastic', 'Paraplegia', 'During', 'Task', '-', 'specific', 'Training', 'on', 'the', 'C', '-', 'Mill', ':', 'Towards', 'Evidence', '-', 'Based', 'and', 'Individually', 'Tailored', 'Rehabilitation', '|', 'This', 'study', 'evaluates', 'the', 'effects', 'of', 'ten', 'hours', 'C', '-', 'mill', 'training', 'on', 'gait', 'adaptability', 'in', 'participants', 'with', 'hereditary', 'spastic', 'paraplegia', '(', 'HSP', ')', '.', 'Half', 'of', 'the', 'participants', 'start', 'with', 'five', 'weeks', 'of', 'C', '-', 'mill', 'training', '(', 'ten', '1', '-', 'hour', 'sessions', ')', '.', 'The', 'other', 'participants', 'are', 'placed', 'on', 'a', 'waiting', 'list', ',', 'which', 'is', 'followed', 'by', 'the', 'same', 'five', 'weeks', 'of', 'C', '-', 'mill', 'training', '(', 'ten', '1', '-', 'hour', 'sessions', ')', '.', 'It', 'is', 'hypothesized', 'that', 'ten', 'hours', 'of', 'context', 'specific', 'C', '-', 'mill', 'training', 'is', 'effective', 'in', 'improving', 'gait', 'adaptability', 'in', 'participants', 'with', 'pure', 'HSP', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 60,
                "text": "Hereditary Spastic Paraplegia",
                "type": "CONDITION"
            },
            {
                "start": 68,
                "end": 104,
                "text": "Task-specific Training on the C-Mill",
                "type": "PHYSICAL"
            },
            {
                "start": 218,
                "end": 233,
                "text": "C-mill training",
                "type": "PHYSICAL"
            },
            {
                "start": 276,
                "end": 305,
                "text": "hereditary spastic paraplegia",
                "type": "CONDITION"
            },
            {
                "start": 307,
                "end": 310,
                "text": "HSP",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 378,
                "text": "C-mill training",
                "type": "PHYSICAL"
            },
            {
                "start": 441,
                "end": 453,
                "text": "waiting list",
                "type": "CONTROL"
            },
            {
                "start": 499,
                "end": 514,
                "text": "C-mill training",
                "type": "PHYSICAL"
            },
            {
                "start": 592,
                "end": 607,
                "text": "C-mill training",
                "type": "PHYSICAL"
            },
            {
                "start": 678,
                "end": 681,
                "text": "HSP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05635968",
        "study_official_title": "The Multicenter Phase II Clinical Trial for Evaluation of Safety and Efficacy Using Low Dose Irradiation With Alzheimer's Disease ",
        "study_brief_summary": " This is a phase II, multicenter, prospective, randomized controlled trial to treat patients with Alzheimer's disease (AD) using low-dose irradiation (LDIR). This study aims to evaluate the safety and efficacy of LDIR to whole brain in patients with AD and to determine the potentially applicable radiation dose.",
        "text": "The Multicenter Phase II Clinical Trial for Evaluation of Safety and Efficacy Using Low Dose Irradiation With Alzheimer's Disease | This is a phase II, multicenter, prospective, randomized controlled trial to treat patients with Alzheimer's disease (AD) using low-dose irradiation (LDIR). This study aims to evaluate the safety and efficacy of LDIR to whole brain in patients with AD and to determine the potentially applicable radiation dose.",
        "tokens": "['The', 'Multicenter', 'Phase', 'II', 'Clinical', 'Trial', 'for', 'Evaluation', 'of', 'Safety', 'and', 'Efficacy', 'Using', 'Low', 'Dose', 'Irradiation', 'With', 'Alzheimer', \"'s\", 'Disease', '|', 'This', 'is', 'a', 'phase', 'II', ',', 'multicenter', ',', 'prospective', ',', 'randomized', 'controlled', 'trial', 'to', 'treat', 'patients', 'with', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', 'using', 'low', '-', 'dose', 'irradiation', '(', 'LDIR', ')', '.', 'This', 'study', 'aims', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'LDIR', 'to', 'whole', 'brain', 'in', 'patients', 'with', 'AD', 'and', 'to', 'determine', 'the', 'potentially', 'applicable', 'radiation', 'dose', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O']",
        "entities": [
            {
                "start": 84,
                "end": 104,
                "text": "Low Dose Irradiation",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 110,
                "end": 129,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 229,
                "end": 248,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 250,
                "end": 252,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 260,
                "end": 280,
                "text": "low-dose irradiation",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 282,
                "end": 286,
                "text": "LDIR",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 344,
                "end": 348,
                "text": "LDIR",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 381,
                "end": 383,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 428,
                "end": 437,
                "text": "radiation",
                "type": "RADIOTHERAPY"
            }
        ]
    },
    {
        "nctid": "NCT05331027",
        "study_official_title": "The Effect of Desflurane Versus Sevoflurane on Postoperative Recovery in Patients Undergoing Minor- to Moderate-risk Noncardiac Surgery - a Prospective Double-blinded Randomized Clinical Trial ",
        "study_brief_summary": " Patients over the age of 65 years are at increased risk for developing delirium and cognitive complications in the immediate postoperative period after noncardiac surgeries, resulting in increased morbidity and mortality. Previous small studies have shown beneficial effects of desflurane on postoperative cognitive recovery, which has been explained by the more rapid onset and offset of anesthesia as compared to sevoflurane. However, there are very limited data on the effect of desflurane on postoperative recovery and time until criteria for discharge from post-anesthesia care unit (PACU) are fulfilled in elderly patients undergoing minor-to moderate-risk noncardiac surgery. Therefore, the investigators will test the primary hypothesis that general anesthesia with desflurane significantly reduces the time between discontinuation of volatile anesthetics after the end of surgery and reaching ready for discharge from PACU criteria, which are defined as reaching a modified Aldrete score \u2265 12, as compared to sevoflurane in patients \u2265 65 years of age undergoing minor-to moderate-risk noncardiac surgery.",
        "text": "The Effect of Desflurane Versus Sevoflurane on Postoperative Recovery in Patients Undergoing Minor- to Moderate-risk Noncardiac Surgery - a Prospective Double-blinded Randomized Clinical Trial | Patients over the age of 65 years are at increased risk for developing delirium and cognitive complications in the immediate postoperative period after noncardiac surgeries, resulting in increased morbidity and mortality. Previous small studies have shown beneficial effects of desflurane on postoperative cognitive recovery, which has been explained by the more rapid onset and offset of anesthesia as compared to sevoflurane. However, there are very limited data on the effect of desflurane on postoperative recovery and time until criteria for discharge from post-anesthesia care unit (PACU) are fulfilled in elderly patients undergoing minor-to moderate-risk noncardiac surgery. Therefore, the investigators will test the primary hypothesis that general anesthesia with desflurane significantly reduces the time between discontinuation of volatile anesthetics after the end of surgery and reaching ready for discharge from PACU criteria, which are defined as reaching a modified Aldrete score \u2265 12, as compared to sevoflurane in patients \u2265 65 years of age undergoing minor-to moderate-risk noncardiac surgery.",
        "tokens": "['The', 'Effect', 'of', 'Desflurane', 'Versus', 'Sevoflurane', 'on', 'Postoperative', 'Recovery', 'in', 'Patients', 'Undergoing', 'Minor-', 'to', 'Moderate', '-', 'risk', 'Noncardiac', 'Surgery', '-', 'a', 'Prospective', 'Double', '-', 'blinded', 'Randomized', 'Clinical', 'Trial', '|', 'Patients', 'over', 'the', 'age', 'of', '65', 'years', 'are', 'at', 'increased', 'risk', 'for', 'developing', 'delirium', 'and', 'cognitive', 'complications', 'in', 'the', 'immediate', 'postoperative', 'period', 'after', 'noncardiac', 'surgeries', ',', 'resulting', 'in', 'increased', 'morbidity', 'and', 'mortality', '.', 'Previous', 'small', 'studies', 'have', 'shown', 'beneficial', 'effects', 'of', 'desflurane', 'on', 'postoperative', 'cognitive', 'recovery', ',', 'which', 'has', 'been', 'explained', 'by', 'the', 'more', 'rapid', 'onset', 'and', 'offset', 'of', 'anesthesia', 'as', 'compared', 'to', 'sevoflurane', '.', 'However', ',', 'there', 'are', 'very', 'limited', 'data', 'on', 'the', 'effect', 'of', 'desflurane', 'on', 'postoperative', 'recovery', 'and', 'time', 'until', 'criteria', 'for', 'discharge', 'from', 'post', '-', 'anesthesia', 'care', 'unit', '(', 'PACU', ')', 'are', 'fulfilled', 'in', 'elderly', 'patients', 'undergoing', 'minor', '-', 'to', 'moderate', '-', 'risk', 'noncardiac', 'surgery', '.', 'Therefore', ',', 'the', 'investigators', 'will', 'test', 'the', 'primary', 'hypothesis', 'that', 'general', 'anesthesia', 'with', 'desflurane', 'significantly', 'reduces', 'the', 'time', 'between', 'discontinuation', 'of', 'volatile', 'anesthetics', 'after', 'the', 'end', 'of', 'surgery', 'and', 'reaching', 'ready', 'for', 'discharge', 'from', 'PACU', 'criteria', ',', 'which', 'are', 'defined', 'as', 'reaching', 'a', 'modified', 'Aldrete', 'score', '\u2265', '12', ',', 'as', 'compared', 'to', 'sevoflurane', 'in', 'patients', '\u2265', '65', 'years', 'of', 'age', 'undergoing', 'minor', '-', 'to', 'moderate', '-', 'risk', 'noncardiac', 'surgery', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 24,
                "text": "Desflurane",
                "type": "DRUG"
            },
            {
                "start": 32,
                "end": 43,
                "text": "Sevoflurane",
                "type": "DRUG"
            },
            {
                "start": 93,
                "end": 135,
                "text": "Minor- to Moderate-risk Noncardiac Surgery",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 274,
                "text": "delirium",
                "type": "CONDITION"
            },
            {
                "start": 347,
                "end": 367,
                "text": "noncardiac surgeries",
                "type": "CONDITION"
            },
            {
                "start": 473,
                "end": 483,
                "text": "desflurane",
                "type": "DRUG"
            },
            {
                "start": 610,
                "end": 621,
                "text": "sevoflurane",
                "type": "DRUG"
            },
            {
                "start": 677,
                "end": 687,
                "text": "desflurane",
                "type": "DRUG"
            },
            {
                "start": 835,
                "end": 876,
                "text": "minor-to moderate-risk noncardiac surgery",
                "type": "CONDITION"
            },
            {
                "start": 969,
                "end": 979,
                "text": "desflurane",
                "type": "DRUG"
            },
            {
                "start": 1213,
                "end": 1224,
                "text": "sevoflurane",
                "type": "DRUG"
            },
            {
                "start": 1266,
                "end": 1307,
                "text": "minor-to moderate-risk noncardiac surgery",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03120013",
        "study_official_title": "Rehabilitative Trial With Cerebello-Spinal tDCS for the Treatment of Neurodegenerative Ataxia ",
        "study_brief_summary": " Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.",
        "text": "Rehabilitative Trial With Cerebello-Spinal tDCS for the Treatment of Neurodegenerative Ataxia | Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.",
        "tokens": "['Rehabilitative', 'Trial', 'With', 'Cerebello', '-', 'Spinal', 'tDCS', 'for', 'the', 'Treatment', 'of', 'Neurodegenerative', 'Ataxia', '|', 'Neurodegenerative', 'cerebellar', 'ataxias', 'represent', 'a', 'group', 'of', 'disabling', 'disorders', 'for', 'which', 'we', 'currently', 'lack', 'effective', 'therapies', '.', 'Cerebellar', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'is', 'a', 'non', '-', 'invasive', 'technique', ',', 'which', 'has', 'been', 'demonstrated', 'to', 'modulate', 'cerebellar', 'excitability', 'and', 'improve', 'symptoms', 'in', 'patients', 'with', 'cerebellar', 'ataxias', '.', 'In', 'this', 'randomized', ',', 'double', '-', 'blind', ',', 'sham', '-', 'controlled', 'study', ',', 'the', 'investigators', 'will', 'evaluate', 'whether', 'a', 'two', '-', 'weeks', \"'\", 'treatment', 'with', 'cerebellar', 'anodal', 'tDCS', 'and', 'spinal', 'cathodal', 'tDCS', 'can', 'improve', 'symptoms', 'in', 'patients', 'with', 'neurodegenerative', 'cerebellar', 'ataxia', 'and', 'can', 'modulate', 'cerebello', '-', 'motor', 'connectivity', ',', 'at', 'short', 'and', 'long', 'term', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 47,
                "text": "Cerebello-Spinal tDCS",
                "type": "OTHER"
            },
            {
                "start": 69,
                "end": 93,
                "text": "Neurodegenerative Ataxia",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 132,
                "text": "Neurodegenerative cerebellar ataxias",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 273,
                "text": "Cerebellar transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 275,
                "end": 279,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 412,
                "end": 430,
                "text": "cerebellar ataxias",
                "type": "CONDITION"
            },
            {
                "start": 466,
                "end": 470,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 557,
                "end": 579,
                "text": "cerebellar anodal tDCS",
                "type": "OTHER"
            },
            {
                "start": 584,
                "end": 604,
                "text": "spinal cathodal tDCS",
                "type": "OTHER"
            },
            {
                "start": 643,
                "end": 678,
                "text": "neurodegenerative cerebellar ataxia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00603265",
        "study_official_title": "A Phase 2a, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100 mg BID in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy ",
        "study_brief_summary": " The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of painful DPN). The pain symptoms of DPN are thought to be due to damage to nerves caused by the diabetes.",
        "text": "A Phase 2a, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100 mg BID in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of painful DPN). The pain symptoms of DPN are thought to be due to damage to nerves caused by the diabetes.",
        "tokens": "['A', 'Phase', '2a', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo-', 'and', 'Active', '-', 'Controlled', ',', 'Parallel', '-', 'Group', ',', 'Multicenter', 'Study', 'to', 'Assess', 'the', 'Safety', 'and', 'Efficacy', 'of', 'ADL5859', '100', 'mg', 'BID', 'in', 'Subjects', 'With', 'Neuropathic', 'Pain', 'Associated', 'With', 'Diabetic', 'Peripheral', 'Neuropathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'ADL5859', 'in', 'relieving', 'the', 'pain', 'associated', 'with', 'diabetic', 'peripheral', 'neuropathy', '(', 'DPN', ')', 'compared', 'with', 'placebo', 'and', 'duloxetine', '(', 'a', 'marketed', 'drug', 'approved', 'for', 'the', 'treatment', 'of', 'painful', 'DPN', ')', '.', 'The', 'pain', 'symptoms', 'of', 'DPN', 'are', 'thought', 'to', 'be', 'due', 'to', 'damage', 'to', 'nerves', 'caused', 'by', 'the', 'diabetes', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 38,
                "end": 46,
                "text": "Placebo-",
                "type": "CONTROL"
            },
            {
                "start": 141,
                "end": 148,
                "text": "ADL5859",
                "type": "DRUG"
            },
            {
                "start": 177,
                "end": 193,
                "text": "Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 240,
                "text": "Diabetic Peripheral Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 312,
                "text": "ADL5859",
                "type": "DRUG"
            },
            {
                "start": 330,
                "end": 334,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 381,
                "text": "diabetic peripheral neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 383,
                "end": 386,
                "text": "DPN",
                "type": "CONDITION"
            },
            {
                "start": 402,
                "end": 409,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 414,
                "end": 424,
                "text": "duloxetine",
                "type": "DRUG"
            },
            {
                "start": 480,
                "end": 483,
                "text": "DPN",
                "type": "CONDITION"
            },
            {
                "start": 490,
                "end": 494,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 507,
                "end": 510,
                "text": "DPN",
                "type": "CONDITION"
            },
            {
                "start": 567,
                "end": 575,
                "text": "diabetes",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03766711",
        "study_official_title": "FEATHERS 2.0: Functional Engagement in Assistive Therapy Through Exercise Robotics v2.0 ",
        "study_brief_summary": " This project is a continuing study from the FEATHERS project (NCT02290353) which focuses on developing novel home therapy program for persons with hemiparesis. This study will focus on examining motor behaviour and adaptation in neurodevelopmental hemiparesis (cerebral palsy, acquired brain injury (ABI)). New algorithms for motion control involved in encouraging active movement are developed and will be tested, but the study has the same therapeutic goal and focus as the original FEATHERS project of creating an engaging at-home bimanual upper limb training program. By incorporating existing gaming technology, we hope to discover novel ways to adapt commercial motion tracking controllers and visual feedback into engaging rehabilitative learning tools. This study will focus on a basic science aspect of human bimanual movements that can be incorporated into future applications of the full FEATHERS project devices. We believe that together these approaches will yield interventions that significantly improve functional ability and lead to improved quality of life.",
        "text": "FEATHERS 2.0: Functional Engagement in Assistive Therapy Through Exercise Robotics v2.0 | This project is a continuing study from the FEATHERS project (NCT02290353) which focuses on developing novel home therapy program for persons with hemiparesis. This study will focus on examining motor behaviour and adaptation in neurodevelopmental hemiparesis (cerebral palsy, acquired brain injury (ABI)). New algorithms for motion control involved in encouraging active movement are developed and will be tested, but the study has the same therapeutic goal and focus as the original FEATHERS project of creating an engaging at-home bimanual upper limb training program. By incorporating existing gaming technology, we hope to discover novel ways to adapt commercial motion tracking controllers and visual feedback into engaging rehabilitative learning tools. This study will focus on a basic science aspect of human bimanual movements that can be incorporated into future applications of the full FEATHERS project devices. We believe that together these approaches will yield interventions that significantly improve functional ability and lead to improved quality of life.",
        "tokens": "['FEATHERS', '2.0', ':', 'Functional', 'Engagement', 'in', 'Assistive', 'Therapy', 'Through', 'Exercise', 'Robotics', 'v2.0', '|', 'This', 'project', 'is', 'a', 'continuing', 'study', 'from', 'the', 'FEATHERS', 'project', '(', 'NCT02290353', ')', 'which', 'focuses', 'on', 'developing', 'novel', 'home', 'therapy', 'program', 'for', 'persons', 'with', 'hemiparesis', '.', 'This', 'study', 'will', 'focus', 'on', 'examining', 'motor', 'behaviour', 'and', 'adaptation', 'in', 'neurodevelopmental', 'hemiparesis', '(', 'cerebral', 'palsy', ',', 'acquired', 'brain', 'injury', '(', 'ABI', ')', ')', '.', 'New', 'algorithms', 'for', 'motion', 'control', 'involved', 'in', 'encouraging', 'active', 'movement', 'are', 'developed', 'and', 'will', 'be', 'tested', ',', 'but', 'the', 'study', 'has', 'the', 'same', 'therapeutic', 'goal', 'and', 'focus', 'as', 'the', 'original', 'FEATHERS', 'project', 'of', 'creating', 'an', 'engaging', 'at', '-', 'home', 'bimanual', 'upper', 'limb', 'training', 'program', '.', 'By', 'incorporating', 'existing', 'gaming', 'technology', ',', 'we', 'hope', 'to', 'discover', 'novel', 'ways', 'to', 'adapt', 'commercial', 'motion', 'tracking', 'controllers', 'and', 'visual', 'feedback', 'into', 'engaging', 'rehabilitative', 'learning', 'tools', '.', 'This', 'study', 'will', 'focus', 'on', 'a', 'basic', 'science', 'aspect', 'of', 'human', 'bimanual', 'movements', 'that', 'can', 'be', 'incorporated', 'into', 'future', 'applications', 'of', 'the', 'full', 'FEATHERS', 'project', 'devices', '.', 'We', 'believe', 'that', 'together', 'these', 'approaches', 'will', 'yield', 'interventions', 'that', 'significantly', 'improve', 'functional', 'ability', 'and', 'lead', 'to', 'improved', 'quality', 'of', 'life', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 56,
                "text": "Assistive Therapy",
                "type": "OTHER"
            },
            {
                "start": 65,
                "end": 82,
                "text": "Exercise Robotics",
                "type": "PHYSICAL"
            },
            {
                "start": 237,
                "end": 248,
                "text": "hemiparesis",
                "type": "CONDITION"
            },
            {
                "start": 319,
                "end": 349,
                "text": "neurodevelopmental hemiparesis",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 365,
                "text": "cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 367,
                "end": 388,
                "text": "acquired brain injury",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 393,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 624,
                "end": 660,
                "text": "bimanual upper limb training program",
                "type": "PHYSICAL"
            },
            {
                "start": 688,
                "end": 705,
                "text": "gaming technology",
                "type": "OTHER"
            },
            {
                "start": 758,
                "end": 785,
                "text": "motion tracking controllers",
                "type": "OTHER"
            },
            {
                "start": 790,
                "end": 805,
                "text": "visual feedback",
                "type": "OTHER"
            },
            {
                "start": 820,
                "end": 849,
                "text": "rehabilitative learning tools",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT03755362",
        "study_official_title": "Treatment of Periodontitis to Prevent Dementia in Older Adults With Asymptomatic Carotid Artery Stenosis and Mild Cognitive Impairment ",
        "study_brief_summary": " Periodontal Disease (PD) is present in 60+% of adults >65 years and is associated with tobacco smoking, diabetes, and atherosclerosis that worsen inflammation, comorbidities common in older people with mild to moderate cognitive impairment (MCI). Older MCI patients are prone to poor oral hygiene and dental health, which if untreated worsens inflammation-mediated brain and nervous system function, and accelerates progression to dementia. Asymptomatic carotid artery stenosis (ACAS) is often a silent disease detected in only ~10% of older adults, and may have a strong association with MCI. This study examines the effects of intensive therapy for periodontitis on cognition in high-risk older people with ACAS. Results could highlight PD as a readily modifiable risk factor for dementia.",
        "text": "Treatment of Periodontitis to Prevent Dementia in Older Adults With Asymptomatic Carotid Artery Stenosis and Mild Cognitive Impairment | Periodontal Disease (PD) is present in 60+% of adults >65 years and is associated with tobacco smoking, diabetes, and atherosclerosis that worsen inflammation, comorbidities common in older people with mild to moderate cognitive impairment (MCI). Older MCI patients are prone to poor oral hygiene and dental health, which if untreated worsens inflammation-mediated brain and nervous system function, and accelerates progression to dementia. Asymptomatic carotid artery stenosis (ACAS) is often a silent disease detected in only ~10% of older adults, and may have a strong association with MCI. This study examines the effects of intensive therapy for periodontitis on cognition in high-risk older people with ACAS. Results could highlight PD as a readily modifiable risk factor for dementia.",
        "tokens": "['Treatment', 'of', 'Periodontitis', 'to', 'Prevent', 'Dementia', 'in', 'Older', 'Adults', 'With', 'Asymptomatic', 'Carotid', 'Artery', 'Stenosis', 'and', 'Mild', 'Cognitive', 'Impairment', '|', 'Periodontal', 'Disease', '(', 'PD', ')', 'is', 'present', 'in', '60+%', 'of', 'adults', '>', '65', 'years', 'and', 'is', 'associated', 'with', 'tobacco', 'smoking', ',', 'diabetes', ',', 'and', 'atherosclerosis', 'that', 'worsen', 'inflammation', ',', 'comorbidities', 'common', 'in', 'older', 'people', 'with', 'mild', 'to', 'moderate', 'cognitive', 'impairment', '(', 'MCI', ')', '.', 'Older', 'MCI', 'patients', 'are', 'prone', 'to', 'poor', 'oral', 'hygiene', 'and', 'dental', 'health', ',', 'which', 'if', 'untreated', 'worsens', 'inflammation', '-', 'mediated', 'brain', 'and', 'nervous', 'system', 'function', ',', 'and', 'accelerates', 'progression', 'to', 'dementia', '.', 'Asymptomatic', 'carotid', 'artery', 'stenosis', '(', 'ACAS', ')', 'is', 'often', 'a', 'silent', 'disease', 'detected', 'in', 'only', '~10', '%', 'of', 'older', 'adults', ',', 'and', 'may', 'have', 'a', 'strong', 'association', 'with', 'MCI', '.', 'This', 'study', 'examines', 'the', 'effects', 'of', 'intensive', 'therapy', 'for', 'periodontitis', 'on', 'cognition', 'in', 'high', '-', 'risk', 'older', 'people', 'with', 'ACAS', '.', 'Results', 'could', 'highlight', 'PD', 'as', 'a', 'readily', 'modifiable', 'risk', 'factor', 'for', 'dementia', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 26,
                "text": "Treatment of Periodontitis",
                "type": "OTHER"
            },
            {
                "start": 38,
                "end": 46,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 68,
                "end": 104,
                "text": "Asymptomatic Carotid Artery Stenosis",
                "type": "CONDITION"
            },
            {
                "start": 109,
                "end": 134,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 137,
                "end": 156,
                "text": "Periodontal Disease",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 160,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 339,
                "end": 376,
                "text": "mild to moderate cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 378,
                "end": 381,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 393,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 568,
                "end": 576,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 578,
                "end": 614,
                "text": "Asymptomatic carotid artery stenosis",
                "type": "CONDITION"
            },
            {
                "start": 616,
                "end": 620,
                "text": "ACAS",
                "type": "CONDITION"
            },
            {
                "start": 726,
                "end": 729,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 766,
                "end": 801,
                "text": "intensive therapy for periodontitis",
                "type": "OTHER"
            },
            {
                "start": 846,
                "end": 850,
                "text": "ACAS",
                "type": "CONDITION"
            },
            {
                "start": 876,
                "end": 878,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 919,
                "end": 927,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01025245",
        "study_official_title": "The purpose of this study is to study the effect of intraoperative magnesium on remifentanil-induced postoperative hyperalgesia after thyroidectomy",
        "study_brief_summary": null,
        "text": "The purpose of this study is to study the effect of intraoperative magnesium on remifentanil-induced postoperative hyperalgesia after thyroidectomy",
        "tokens": "['The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'study', 'the', 'effect', 'of', 'intraoperative', 'magnesium', 'on', 'remifentanil', '-', 'induced', 'postoperative', 'hyperalgesia', 'after', 'thyroidectomy']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND']",
        "entities": [
            {
                "start": 67,
                "end": 76,
                "text": "magnesium",
                "type": "DRUG"
            },
            {
                "start": 80,
                "end": 92,
                "text": "remifentanil",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 127,
                "text": "hyperalgesia",
                "type": "CONDITION"
            },
            {
                "start": 134,
                "end": 147,
                "text": "thyroidectomy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00608660",
        "study_official_title": "Studying of Acupuncture for Bell's Palsy According to Different Stages ",
        "study_brief_summary": " The purpose of this trial will certify the efficacy of using staging acupuncture and moxibustion to treat Bell's Palsy",
        "text": "Studying of Acupuncture for Bell's Palsy According to Different Stages | The purpose of this trial will certify the efficacy of using staging acupuncture and moxibustion to treat Bell's Palsy",
        "tokens": "['Studying', 'of', 'Acupuncture', 'for', 'Bell', \"'s\", 'Palsy', 'According', 'to', 'Different', 'Stages', '|', 'The', 'purpose', 'of', 'this', 'trial', 'will', 'certify', 'the', 'efficacy', 'of', 'using', 'staging', 'acupuncture', 'and', 'moxibustion', 'to', 'treat', 'Bell', \"'s\", 'Palsy']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 12,
                "end": 23,
                "text": "Acupuncture",
                "type": "OTHER"
            },
            {
                "start": 28,
                "end": 40,
                "text": "Bell's Palsy",
                "type": "CONDITION"
            },
            {
                "start": 142,
                "end": 153,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 158,
                "end": 169,
                "text": "moxibustion",
                "type": "OTHER"
            },
            {
                "start": 179,
                "end": 191,
                "text": "Bell's Palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04405427",
        "study_official_title": "A Comparison of the Therapeutic Effect Between Head-point Acupuncture and Conventional Body Acupuncture on Insomnia: A Randomized Controlled Case Study ",
        "study_brief_summary": " The investigators will conduct a single-center, and randomized controlled cases study. A total of 120 participants with insomnia will be enrolled. The aim of the study is to compare the therapeutic effect between head-acupoints acupuncture and body-acupoints acupuncture on Insomnia.",
        "text": "A Comparison of the Therapeutic Effect Between Head-point Acupuncture and Conventional Body Acupuncture on Insomnia: A Randomized Controlled Case Study | The investigators will conduct a single-center, and randomized controlled cases study. A total of 120 participants with insomnia will be enrolled. The aim of the study is to compare the therapeutic effect between head-acupoints acupuncture and body-acupoints acupuncture on Insomnia.",
        "tokens": "['A', 'Comparison', 'of', 'the', 'Therapeutic', 'Effect', 'Between', 'Head', '-', 'point', 'Acupuncture', 'and', 'Conventional', 'Body', 'Acupuncture', 'on', 'Insomnia', ':', 'A', 'Randomized', 'Controlled', 'Case', 'Study', '|', 'The', 'investigators', 'will', 'conduct', 'a', 'single', '-', 'center', ',', 'and', 'randomized', 'controlled', 'cases', 'study', '.', 'A', 'total', 'of', '120', 'participants', 'with', 'insomnia', 'will', 'be', 'enrolled', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'therapeutic', 'effect', 'between', 'head', '-', 'acupoints', 'acupuncture', 'and', 'body', '-', 'acupoints', 'acupuncture', 'on', 'Insomnia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 47,
                "end": 69,
                "text": "Head-point Acupuncture",
                "type": "PHYSICAL"
            },
            {
                "start": 74,
                "end": 103,
                "text": "Conventional Body Acupuncture",
                "type": "CONTROL"
            },
            {
                "start": 107,
                "end": 115,
                "text": "Insomnia",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 282,
                "text": "insomnia",
                "type": "CONDITION"
            },
            {
                "start": 367,
                "end": 393,
                "text": "head-acupoints acupuncture",
                "type": "PHYSICAL"
            },
            {
                "start": 398,
                "end": 424,
                "text": "body-acupoints acupuncture",
                "type": "CONTROL"
            },
            {
                "start": 428,
                "end": 436,
                "text": "Insomnia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02571335",
        "study_official_title": "Intensity-dependent Impacts of Training on Growth Factors BDNF and Cognitive Functions in Persons With Multiple Sclerosis - a Single-center Randomized Controlled Trial ",
        "study_brief_summary": " Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system, accompanied by varying inflammatory manifestations, demyelinization and axonal loss. With chronic progressive or relapsing-remitting disease onsets persons with MS (pwMS) progressively develop impaired functional capacity and show reduced physical activity and cognitive decline compared to healthy controls. The primary aims of rehabilitation in pwMS are therefore to increase levels of activity and participation leading to increase independence of the participants. In general exercise ranges from passive physiotherapy-based interventions to submaximal endurance training sessions. Current recommendations advise pwMS that exercise should be matched with the individual performance capacities. Exercise training in pwMS then has the potential to target and improve many components outlined in the ICF-model.\n\nCytokines and neurotrophic factors have received increased attention in MS research and addressed the brain-derived neurotrophic factor (BDNF) as an important mediator of neuronal regeneration linking the effects of exercise with MS pathogenesis. Data show positive connections between elevated neurotrophin concentrations, induction of neuroplasticity, recovery of the motor and cognitive functions and the applied training intensities. Similarly, intensive and progressive exercise bouts seem to have greater benefits on cardiorespiratory fitness and maximum voluntary strength in elderly and seniors with dementia. Therefore, specific exercise prescriptions may be necessary for targeting the specific impairments also in pwMS.\n\nThis study aims to evaluate two different training modalities (intensive versus normal) in pwMS. It is expected that both modalities will improve cardiorespiratory fitness and cognitive functions in pwMS. Based on the findings that higher training intensities facilitate greater benefits, it is expected that pwMS will tolerate the intensive training intensities and show positive connections to elevated neurotrophin concentrations.\n\nThe results will to help to clearer understand the benefits of each type of exercise conveyed for pwMS and will assist in the development of patient-specific exercise prescriptions.",
        "text": "Intensity-dependent Impacts of Training on Growth Factors BDNF and Cognitive Functions in Persons With Multiple Sclerosis - a Single-center Randomized Controlled Trial | Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system, accompanied by varying inflammatory manifestations, demyelinization and axonal loss. With chronic progressive or relapsing-remitting disease onsets persons with MS (pwMS) progressively develop impaired functional capacity and show reduced physical activity and cognitive decline compared to healthy controls. The primary aims of rehabilitation in pwMS are therefore to increase levels of activity and participation leading to increase independence of the participants. In general exercise ranges from passive physiotherapy-based interventions to submaximal endurance training sessions. Current recommendations advise pwMS that exercise should be matched with the individual performance capacities. Exercise training in pwMS then has the potential to target and improve many components outlined in the ICF-model.\n\nCytokines and neurotrophic factors have received increased attention in MS research and addressed the brain-derived neurotrophic factor (BDNF) as an important mediator of neuronal regeneration linking the effects of exercise with MS pathogenesis. Data show positive connections between elevated neurotrophin concentrations, induction of neuroplasticity, recovery of the motor and cognitive functions and the applied training intensities. Similarly, intensive and progressive exercise bouts seem to have greater benefits on cardiorespiratory fitness and maximum voluntary strength in elderly and seniors with dementia. Therefore, specific exercise prescriptions may be necessary for targeting the specific impairments also in pwMS.\n\nThis study aims to evaluate two different training modalities (intensive versus normal) in pwMS. It is expected that both modalities will improve cardiorespiratory fitness and cognitive functions in pwMS. Based on the findings that higher training intensities facilitate greater benefits, it is expected that pwMS will tolerate the intensive training intensities and show positive connections to elevated neurotrophin concentrations.\n\nThe results will to help to clearer understand the benefits of each type of exercise conveyed for pwMS and will assist in the development of patient-specific exercise prescriptions.",
        "tokens": "['Intensity', '-', 'dependent', 'Impacts', 'of', 'Training', 'on', 'Growth', 'Factors', 'BDNF', 'and', 'Cognitive', 'Functions', 'in', 'Persons', 'With', 'Multiple', 'Sclerosis', '-', 'a', 'Single', '-', 'center', 'Randomized', 'Controlled', 'Trial', '|', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'is', 'a', 'chronic', 'immune', '-', 'mediated', 'disease', 'of', 'the', 'central', 'nervous', 'system', ',', 'accompanied', 'by', 'varying', 'inflammatory', 'manifestations', ',', 'demyelinization', 'and', 'axonal', 'loss', '.', 'With', 'chronic', 'progressive', 'or', 'relapsing', '-', 'remitting', 'disease', 'onsets', 'persons', 'with', 'MS', '(', 'pwMS', ')', 'progressively', 'develop', 'impaired', 'functional', 'capacity', 'and', 'show', 'reduced', 'physical', 'activity', 'and', 'cognitive', 'decline', 'compared', 'to', 'healthy', 'controls', '.', 'The', 'primary', 'aims', 'of', 'rehabilitation', 'in', 'pwMS', 'are', 'therefore', 'to', 'increase', 'levels', 'of', 'activity', 'and', 'participation', 'leading', 'to', 'increase', 'independence', 'of', 'the', 'participants', '.', 'In', 'general', 'exercise', 'ranges', 'from', 'passive', 'physiotherapy', '-', 'based', 'interventions', 'to', 'submaximal', 'endurance', 'training', 'sessions', '.', 'Current', 'recommendations', 'advise', 'pwMS', 'that', 'exercise', 'should', 'be', 'matched', 'with', 'the', 'individual', 'performance', 'capacities', '.', 'Exercise', 'training', 'in', 'pwMS', 'then', 'has', 'the', 'potential', 'to', 'target', 'and', 'improve', 'many', 'components', 'outlined', 'in', 'the', 'ICF', '-', 'model', '.', '\\n\\n', 'Cytokines', 'and', 'neurotrophic', 'factors', 'have', 'received', 'increased', 'attention', 'in', 'MS', 'research', 'and', 'addressed', 'the', 'brain', '-', 'derived', 'neurotrophic', 'factor', '(', 'BDNF', ')', 'as', 'an', 'important', 'mediator', 'of', 'neuronal', 'regeneration', 'linking', 'the', 'effects', 'of', 'exercise', 'with', 'MS', 'pathogenesis', '.', 'Data', 'show', 'positive', 'connections', 'between', 'elevated', 'neurotrophin', 'concentrations', ',', 'induction', 'of', 'neuroplasticity', ',', 'recovery', 'of', 'the', 'motor', 'and', 'cognitive', 'functions', 'and', 'the', 'applied', 'training', 'intensities', '.', 'Similarly', ',', 'intensive', 'and', 'progressive', 'exercise', 'bouts', 'seem', 'to', 'have', 'greater', 'benefits', 'on', 'cardiorespiratory', 'fitness', 'and', 'maximum', 'voluntary', 'strength', 'in', 'elderly', 'and', 'seniors', 'with', 'dementia', '.', 'Therefore', ',', 'specific', 'exercise', 'prescriptions', 'may', 'be', 'necessary', 'for', 'targeting', 'the', 'specific', 'impairments', 'also', 'in', 'pwMS', '.', '\\n\\n', 'This', 'study', 'aims', 'to', 'evaluate', 'two', 'different', 'training', 'modalities', '(', 'intensive', 'versus', 'normal', ')', 'in', 'pwMS', '.', 'It', 'is', 'expected', 'that', 'both', 'modalities', 'will', 'improve', 'cardiorespiratory', 'fitness', 'and', 'cognitive', 'functions', 'in', 'pwMS', '.', 'Based', 'on', 'the', 'findings', 'that', 'higher', 'training', 'intensities', 'facilitate', 'greater', 'benefits', ',', 'it', 'is', 'expected', 'that', 'pwMS', 'will', 'tolerate', 'the', 'intensive', 'training', 'intensities', 'and', 'show', 'positive', 'connections', 'to', 'elevated', 'neurotrophin', 'concentrations', '.', '\\n\\n', 'The', 'results', 'will', 'to', 'help', 'to', 'clearer', 'understand', 'the', 'benefits', 'of', 'each', 'type', 'of', 'exercise', 'conveyed', 'for', 'pwMS', 'and', 'will', 'assist', 'in', 'the', 'development', 'of', 'patient', '-', 'specific', 'exercise', 'prescriptions', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O']",
        "entities": [
            {
                "start": 103,
                "end": 121,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 188,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 192,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 423,
                "end": 425,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 455,
                "end": 483,
                "text": "impaired functional capacity",
                "type": "CONDITION"
            },
            {
                "start": 493,
                "end": 518,
                "text": "reduced physical activity",
                "type": "CONDITION"
            },
            {
                "start": 523,
                "end": 540,
                "text": "cognitive decline",
                "type": "CONDITION"
            },
            {
                "start": 889,
                "end": 897,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 960,
                "end": 977,
                "text": "Exercise training",
                "type": "PHYSICAL"
            },
            {
                "start": 1147,
                "end": 1149,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1291,
                "end": 1299,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1305,
                "end": 1307,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1524,
                "end": 1564,
                "text": "intensive and progressive exercise bouts",
                "type": "PHYSICAL"
            },
            {
                "start": 1713,
                "end": 1721,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1849,
                "end": 1868,
                "text": "training modalities",
                "type": "PHYSICAL"
            },
            {
                "start": 1870,
                "end": 1879,
                "text": "intensive",
                "type": "PHYSICAL"
            },
            {
                "start": 1887,
                "end": 1893,
                "text": "normal",
                "type": "CONTROL"
            },
            {
                "start": 2039,
                "end": 2066,
                "text": "higher training intensities",
                "type": "PHYSICAL"
            },
            {
                "start": 2139,
                "end": 2169,
                "text": "intensive training intensities",
                "type": "PHYSICAL"
            },
            {
                "start": 2318,
                "end": 2326,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 2400,
                "end": 2408,
                "text": "exercise",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT04291469",
        "study_official_title": "A Prospective, Randomized, Controlled Multicenter Trial of Probiotics and Prebiotics to Improve the Efficacy of Antipsychotics in Patients With Schizophrenia ",
        "study_brief_summary": " In this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment, gastrointestinal function, and metabolic disorders in schizophrenia patients, through genotype identification, psychopathology, neuropsychology, biochemical evaluation and other methods.",
        "text": "A Prospective, Randomized, Controlled Multicenter Trial of Probiotics and Prebiotics to Improve the Efficacy of Antipsychotics in Patients With Schizophrenia | In this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment, gastrointestinal function, and metabolic disorders in schizophrenia patients, through genotype identification, psychopathology, neuropsychology, biochemical evaluation and other methods.",
        "tokens": "['A', 'Prospective', ',', 'Randomized', ',', 'Controlled', 'Multicenter', 'Trial', 'of', 'Probiotics', 'and', 'Prebiotics', 'to', 'Improve', 'the', 'Efficacy', 'of', 'Antipsychotics', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'In', 'this', 'study', ',', 'investigators', 'will', 'evaluate', 'the', 'efficacy', 'and', 'related', 'mechanism', 'of', 'probiotics', 'and', 'prebiotics', 'as', 'an', 'add', '-', 'on', 'treatment', 'in', 'improving', 'the', 'antipsychotic', 'induced', 'psychotic', 'syndrome', ',', 'the', 'cognitive', 'impairment', ',', 'gastrointestinal', 'function', ',', 'and', 'metabolic', 'disorders', 'in', 'schizophrenia', 'patients', ',', 'through', 'genotype', 'identification', ',', 'psychopathology', ',', 'neuropsychology', ',', 'biochemical', 'evaluation', 'and', 'other', 'methods', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 59,
                "end": 69,
                "text": "Probiotics",
                "type": "OTHER"
            },
            {
                "start": 74,
                "end": 84,
                "text": "Prebiotics",
                "type": "OTHER"
            },
            {
                "start": 144,
                "end": 157,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 241,
                "end": 251,
                "text": "probiotics",
                "type": "OTHER"
            },
            {
                "start": 256,
                "end": 266,
                "text": "prebiotics",
                "type": "OTHER"
            },
            {
                "start": 307,
                "end": 347,
                "text": "antipsychotic induced psychotic syndrome",
                "type": "CONDITION"
            },
            {
                "start": 429,
                "end": 442,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02761096",
        "study_official_title": "Effect of Acupuncture on Inflammation and Immune Function After Craniotomy ",
        "study_brief_summary": " The aim of this study is to evaluate the effect of acupuncture on inflammation and immune function after craniotomy. This study will be a single-center, parallel group clinical trial that will be conducted at Kyung Hee University Hospital at Gangdong, Seoul, Korea.",
        "text": "Effect of Acupuncture on Inflammation and Immune Function After Craniotomy | The aim of this study is to evaluate the effect of acupuncture on inflammation and immune function after craniotomy. This study will be a single-center, parallel group clinical trial that will be conducted at Kyung Hee University Hospital at Gangdong, Seoul, Korea.",
        "tokens": "['Effect', 'of', 'Acupuncture', 'on', 'Inflammation', 'and', 'Immune', 'Function', 'After', 'Craniotomy', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'acupuncture', 'on', 'inflammation', 'and', 'immune', 'function', 'after', 'craniotomy', '.', 'This', 'study', 'will', 'be', 'a', 'single', '-', 'center', ',', 'parallel', 'group', 'clinical', 'trial', 'that', 'will', 'be', 'conducted', 'at', 'Kyung', 'Hee', 'University', 'Hospital', 'at', 'Gangdong', ',', 'Seoul', ',', 'Korea', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 21,
                "text": "Acupuncture",
                "type": "OTHER"
            },
            {
                "start": 25,
                "end": 37,
                "text": "Inflammation",
                "type": "CONDITION"
            },
            {
                "start": 64,
                "end": 74,
                "text": "Craniotomy",
                "type": "CONDITION"
            },
            {
                "start": 128,
                "end": 139,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 143,
                "end": 155,
                "text": "inflammation",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 192,
                "text": "craniotomy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01553149",
        "study_official_title": "A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas ",
        "study_brief_summary": " This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment (refractory), or are growing, spreading, or getting worse (progressive). Lenalidomide is classified as an immunomodulatory drug as it boosts the immune system. It has other potential anti-tumor effects, for example, it may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether low-dose lenalidomide is more or less effective than high-dose lenalidomide in treating patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas.",
        "text": "A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas | This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment (refractory), or are growing, spreading, or getting worse (progressive). Lenalidomide is classified as an immunomodulatory drug as it boosts the immune system. It has other potential anti-tumor effects, for example, it may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether low-dose lenalidomide is more or less effective than high-dose lenalidomide in treating patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas.",
        "tokens": "['A', 'Phase', 'II', 'Randomized', 'Trial', 'of', 'Lenalidomide', '(', 'NSC', '#', '703813', ')', 'in', 'Pediatric', 'Patients', 'With', 'Recurrent', ',', 'Refractory', 'or', 'Progressive', 'Juvenile', 'Pilocytic', 'Astrocytomas', 'and', 'Optic', 'Pathway', 'Gliomas', '|', 'This', 'randomized', 'phase', 'II', 'trial', 'studies', 'how', 'well', 'low', '-', 'dose', 'lenalidomide', 'works', 'compared', 'with', 'high', '-', 'dose', 'lenalidomide', 'in', 'treating', 'younger', 'patients', 'with', 'juvenile', 'pilocytic', 'astrocytomas', 'or', 'optic', 'nerve', 'pathway', 'gliomas', 'that', 'have', 'come', 'back', '(', 'recurrent', ')', ',', 'have', 'not', 'responded', 'to', 'treatment', '(', 'refractory', ')', ',', 'or', 'are', 'growing', ',', 'spreading', ',', 'or', 'getting', 'worse', '(', 'progressive', ')', '.', 'Lenalidomide', 'is', 'classified', 'as', 'an', 'immunomodulatory', 'drug', 'as', 'it', 'boosts', 'the', 'immune', 'system', '.', 'It', 'has', 'other', 'potential', 'anti', '-', 'tumor', 'effects', ',', 'for', 'example', ',', 'it', 'may', 'stop', 'the', 'growth', 'of', 'tumor', 'cells', 'by', 'blocking', 'blood', 'flow', 'to', 'the', 'tumor', '.', 'It', 'is', 'not', 'yet', 'known', 'whether', 'low', '-', 'dose', 'lenalidomide', 'is', 'more', 'or', 'less', 'effective', 'than', 'high', '-', 'dose', 'lenalidomide', 'in', 'treating', 'patients', 'with', 'juvenile', 'pilocytic', 'astrocytomas', 'or', 'optic', 'nerve', 'pathway', 'gliomas', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 43,
                "text": "Lenalidomide",
                "type": "DRUG"
            },
            {
                "start": 86,
                "end": 154,
                "text": "Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas",
                "type": "CONDITION"
            },
            {
                "start": 159,
                "end": 180,
                "text": "Optic Pathway Gliomas",
                "type": "CONDITION"
            },
            {
                "start": 240,
                "end": 252,
                "text": "lenalidomide",
                "type": "DRUG"
            },
            {
                "start": 283,
                "end": 295,
                "text": "lenalidomide",
                "type": "DRUG"
            },
            {
                "start": 330,
                "end": 361,
                "text": "juvenile pilocytic astrocytomas",
                "type": "CONDITION"
            },
            {
                "start": 365,
                "end": 392,
                "text": "optic nerve pathway gliomas",
                "type": "CONDITION"
            },
            {
                "start": 531,
                "end": 543,
                "text": "Lenalidomide",
                "type": "DRUG"
            },
            {
                "start": 700,
                "end": 705,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 742,
                "end": 747,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 786,
                "end": 798,
                "text": "lenalidomide",
                "type": "DRUG"
            },
            {
                "start": 840,
                "end": 852,
                "text": "lenalidomide",
                "type": "DRUG"
            },
            {
                "start": 879,
                "end": 910,
                "text": "juvenile pilocytic astrocytomas",
                "type": "CONDITION"
            },
            {
                "start": 914,
                "end": 941,
                "text": "optic nerve pathway gliomas",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03859063",
        "study_official_title": "A Multimodal Individualized Intervention to Prevent Functional Decline After Stroke. A Randomized Controlled Trial on Long-term Follow-up After Stroke (The LAST-long Trial) ",
        "study_brief_summary": " Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. These are also regarded as barriers to achieve optimal adherence to the guidelines regarding secondary prevention. The primary aim of this project is to evaluate the effectiveness of a multimodal individualized intervention to prevent functional decline in the long term after stroke.",
        "text": "A Multimodal Individualized Intervention to Prevent Functional Decline After Stroke. A Randomized Controlled Trial on Long-term Follow-up After Stroke (The LAST-long Trial) | Despite the improved treatment of acute stroke over the past decades, those suffering from stroke still are at an increased risk of functional and cognitive decline in the long term. The most common consequences of stroke are functional impairments, cognitive impairments, depression and fatigue. These are also regarded as barriers to achieve optimal adherence to the guidelines regarding secondary prevention. The primary aim of this project is to evaluate the effectiveness of a multimodal individualized intervention to prevent functional decline in the long term after stroke.",
        "tokens": "['A', 'Multimodal', 'Individualized', 'Intervention', 'to', 'Prevent', 'Functional', 'Decline', 'After', 'Stroke', '.', 'A', 'Randomized', 'Controlled', 'Trial', 'on', 'Long', '-', 'term', 'Follow', '-', 'up', 'After', 'Stroke', '(', 'The', 'LAST', '-', 'long', 'Trial', ')', '|', 'Despite', 'the', 'improved', 'treatment', 'of', 'acute', 'stroke', 'over', 'the', 'past', 'decades', ',', 'those', 'suffering', 'from', 'stroke', 'still', 'are', 'at', 'an', 'increased', 'risk', 'of', 'functional', 'and', 'cognitive', 'decline', 'in', 'the', 'long', 'term', '.', 'The', 'most', 'common', 'consequences', 'of', 'stroke', 'are', 'functional', 'impairments', ',', 'cognitive', 'impairments', ',', 'depression', 'and', 'fatigue', '.', 'These', 'are', 'also', 'regarded', 'as', 'barriers', 'to', 'achieve', 'optimal', 'adherence', 'to', 'the', 'guidelines', 'regarding', 'secondary', 'prevention', '.', 'The', 'primary', 'aim', 'of', 'this', 'project', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'a', 'multimodal', 'individualized', 'intervention', 'to', 'prevent', 'functional', 'decline', 'in', 'the', 'long', 'term', 'after', 'stroke', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 2,
                "end": 40,
                "text": "Multimodal Individualized Intervention",
                "type": "OTHER"
            },
            {
                "start": 52,
                "end": 70,
                "text": "Functional Decline",
                "type": "CONDITION"
            },
            {
                "start": 77,
                "end": 83,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 150,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 221,
                "text": "acute stroke",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 272,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 307,
                "end": 339,
                "text": "functional and cognitive decline",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 396,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 401,
                "end": 423,
                "text": "functional impairments",
                "type": "CONDITION"
            },
            {
                "start": 425,
                "end": 446,
                "text": "cognitive impairments",
                "type": "CONDITION"
            },
            {
                "start": 448,
                "end": 458,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 463,
                "end": 470,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 657,
                "end": 695,
                "text": "multimodal individualized intervention",
                "type": "OTHER"
            },
            {
                "start": 749,
                "end": 755,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03883217",
        "study_official_title": "Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease ",
        "study_brief_summary": " The purpose of this research study is to test the safety, tolerability, and the effect of vibration (delivered by an experimental device called PDVibe2) on freezing of gait (FOG) in persons with Parkinson's disease (PD). The PDVibe2 was developed by Resonate Forward, LLC (RF). This PDVibe2 was designed to administer vibration therapy to the wearer to improve gait and balance in persons with PD while wearing the device.",
        "text": "Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease | The purpose of this research study is to test the safety, tolerability, and the effect of vibration (delivered by an experimental device called PDVibe2) on freezing of gait (FOG) in persons with Parkinson's disease (PD). The PDVibe2 was developed by Resonate Forward, LLC (RF). This PDVibe2 was designed to administer vibration therapy to the wearer to improve gait and balance in persons with PD while wearing the device.",
        "tokens": "['Optimizing', 'Vibrational', 'Therapy', 'to', 'Improve', 'Gait', 'and', 'Balance', 'in', 'Parkinson', \"'s\", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'test', 'the', 'safety', ',', 'tolerability', ',', 'and', 'the', 'effect', 'of', 'vibration', '(', 'delivered', 'by', 'an', 'experimental', 'device', 'called', 'PDVibe2', ')', 'on', 'freezing', 'of', 'gait', '(', 'FOG', ')', 'in', 'persons', 'with', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', '.', 'The', 'PDVibe2', 'was', 'developed', 'by', 'Resonate', 'Forward', ',', 'LLC', '(', 'RF', ')', '.', 'This', 'PDVibe2', 'was', 'designed', 'to', 'administer', 'vibration', 'therapy', 'to', 'the', 'wearer', 'to', 'improve', 'gait', 'and', 'balance', 'in', 'persons', 'with', 'PD', 'while', 'wearing', 'the', 'device', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 30,
                "text": "Vibrational Therapy",
                "type": "OTHER"
            },
            {
                "start": 62,
                "end": 81,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 174,
                "end": 183,
                "text": "vibration",
                "type": "OTHER"
            },
            {
                "start": 228,
                "end": 235,
                "text": "PDVibe2",
                "type": "OTHER"
            },
            {
                "start": 240,
                "end": 256,
                "text": "freezing of gait",
                "type": "CONDITION"
            },
            {
                "start": 258,
                "end": 261,
                "text": "FOG",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 298,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 300,
                "end": 302,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 309,
                "end": 316,
                "text": "PDVibe2",
                "type": "OTHER"
            },
            {
                "start": 367,
                "end": 374,
                "text": "PDVibe2",
                "type": "OTHER"
            },
            {
                "start": 402,
                "end": 419,
                "text": "vibration therapy",
                "type": "OTHER"
            },
            {
                "start": 478,
                "end": 480,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02331407",
        "study_official_title": "Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke ",
        "study_brief_summary": " Stroke is a leading cause of neurological disability worldwide, often causing significant weakening and paresis of the affected arm. National spending on post-stroke rehabilitation is project to expand 20% to 35% through 2010. As a new tool for therapists, robotic stroke therapy devices have the potential to be a cost-effective device aid to physical therapy and enable novel modes of exercise not currently available. While recent studies have shown chronic patients benefit from repetitive practice, it is not clear whether they improved via a reduction in impairment or increased functional compensation because there is a lack of standard treatment and scales to assess rehabilitation efficacy in chronic stroke patients. This study aims to reconcile difference performance measurements in robotic rehabilitation to assess the outcome of robotic rehabilitation training.",
        "text": "Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke | Stroke is a leading cause of neurological disability worldwide, often causing significant weakening and paresis of the affected arm. National spending on post-stroke rehabilitation is project to expand 20% to 35% through 2010. As a new tool for therapists, robotic stroke therapy devices have the potential to be a cost-effective device aid to physical therapy and enable novel modes of exercise not currently available. While recent studies have shown chronic patients benefit from repetitive practice, it is not clear whether they improved via a reduction in impairment or increased functional compensation because there is a lack of standard treatment and scales to assess rehabilitation efficacy in chronic stroke patients. This study aims to reconcile difference performance measurements in robotic rehabilitation to assess the outcome of robotic rehabilitation training.",
        "tokens": "['Effect', 'of', 'Robot', 'Rehabilitation', 'Exercise', 'Training', 'on', 'Motor', 'Control', 'After', 'Stroke', '|', 'Stroke', 'is', 'a', 'leading', 'cause', 'of', 'neurological', 'disability', 'worldwide', ',', 'often', 'causing', 'significant', 'weakening', 'and', 'paresis', 'of', 'the', 'affected', 'arm', '.', 'National', 'spending', 'on', 'post', '-', 'stroke', 'rehabilitation', 'is', 'project', 'to', 'expand', '20', '%', 'to', '35', '%', 'through', '2010', '.', 'As', 'a', 'new', 'tool', 'for', 'therapists', ',', 'robotic', 'stroke', 'therapy', 'devices', 'have', 'the', 'potential', 'to', 'be', 'a', 'cost', '-', 'effective', 'device', 'aid', 'to', 'physical', 'therapy', 'and', 'enable', 'novel', 'modes', 'of', 'exercise', 'not', 'currently', 'available', '.', 'While', 'recent', 'studies', 'have', 'shown', 'chronic', 'patients', 'benefit', 'from', 'repetitive', 'practice', ',', 'it', 'is', 'not', 'clear', 'whether', 'they', 'improved', 'via', 'a', 'reduction', 'in', 'impairment', 'or', 'increased', 'functional', 'compensation', 'because', 'there', 'is', 'a', 'lack', 'of', 'standard', 'treatment', 'and', 'scales', 'to', 'assess', 'rehabilitation', 'efficacy', 'in', 'chronic', 'stroke', 'patients', '.', 'This', 'study', 'aims', 'to', 'reconcile', 'difference', 'performance', 'measurements', 'in', 'robotic', 'rehabilitation', 'to', 'assess', 'the', 'outcome', 'of', 'robotic', 'rehabilitation', 'training', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 48,
                "text": "Robot Rehabilitation Exercise Training",
                "type": "PHYSICAL"
            },
            {
                "start": 72,
                "end": 78,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 81,
                "end": 87,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 235,
                "end": 246,
                "text": "post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 338,
                "end": 360,
                "text": "robotic stroke therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 784,
                "end": 798,
                "text": "chronic stroke",
                "type": "CONDITION"
            },
            {
                "start": 877,
                "end": 899,
                "text": "robotic rehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 925,
                "end": 956,
                "text": "robotic rehabilitation training",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT05398575",
        "study_official_title": "Music Listening for Cardiorespiratory Exercise in Inpatient Stroke Rehabilitation ",
        "study_brief_summary": " Stroke survivors struggle to meet clinical recommendations for physical exercise duration and intensity. During the past two decades, music interventions have increasingly shown effectiveness in several motor tasks in stroke rehabilitation. Additionally, music has been found effective in increasing exercise performance in athletes and other clinical populations. Based on a meta-theoretical review paper by Clark, Baker & Taylor (2016), it was hypothesized that the therapeutic effects of music in physical exercise is modulated by the preference and task-specificity of the music. We will test this hypothesis using a three-armed randomized cross-over design comprised of the following auditory conditions: 1) a group-tailored playlist 2) radio as active control and 3) a non-music control condition during cycle ergometry cardiorespiratory exercise sessions. Participants are inpatient stroke survivors undergoing rehabilitation between 2-12 weeks post infarct.",
        "text": "Music Listening for Cardiorespiratory Exercise in Inpatient Stroke Rehabilitation | Stroke survivors struggle to meet clinical recommendations for physical exercise duration and intensity. During the past two decades, music interventions have increasingly shown effectiveness in several motor tasks in stroke rehabilitation. Additionally, music has been found effective in increasing exercise performance in athletes and other clinical populations. Based on a meta-theoretical review paper by Clark, Baker & Taylor (2016), it was hypothesized that the therapeutic effects of music in physical exercise is modulated by the preference and task-specificity of the music. We will test this hypothesis using a three-armed randomized cross-over design comprised of the following auditory conditions: 1) a group-tailored playlist 2) radio as active control and 3) a non-music control condition during cycle ergometry cardiorespiratory exercise sessions. Participants are inpatient stroke survivors undergoing rehabilitation between 2-12 weeks post infarct.",
        "tokens": "['Music', 'Listening', 'for', 'Cardiorespiratory', 'Exercise', 'in', 'Inpatient', 'Stroke', 'Rehabilitation', '|', 'Stroke', 'survivors', 'struggle', 'to', 'meet', 'clinical', 'recommendations', 'for', 'physical', 'exercise', 'duration', 'and', 'intensity', '.', 'During', 'the', 'past', 'two', 'decades', ',', 'music', 'interventions', 'have', 'increasingly', 'shown', 'effectiveness', 'in', 'several', 'motor', 'tasks', 'in', 'stroke', 'rehabilitation', '.', 'Additionally', ',', 'music', 'has', 'been', 'found', 'effective', 'in', 'increasing', 'exercise', 'performance', 'in', 'athletes', 'and', 'other', 'clinical', 'populations', '.', 'Based', 'on', 'a', 'meta', '-', 'theoretical', 'review', 'paper', 'by', 'Clark', ',', 'Baker', '&', 'Taylor', '(', '2016', ')', ',', 'it', 'was', 'hypothesized', 'that', 'the', 'therapeutic', 'effects', 'of', 'music', 'in', 'physical', 'exercise', 'is', 'modulated', 'by', 'the', 'preference', 'and', 'task', '-', 'specificity', 'of', 'the', 'music', '.', 'We', 'will', 'test', 'this', 'hypothesis', 'using', 'a', 'three', '-', 'armed', 'randomized', 'cross', '-', 'over', 'design', 'comprised', 'of', 'the', 'following', 'auditory', 'conditions', ':', '1', ')', 'a', 'group', '-', 'tailored', 'playlist', '2', ')', 'radio', 'as', 'active', 'control', 'and', '3', ')', 'a', 'non', '-', 'music', 'control', 'condition', 'during', 'cycle', 'ergometry', 'cardiorespiratory', 'exercise', 'sessions', '.', 'Participants', 'are', 'inpatient', 'stroke', 'survivors', 'undergoing', 'rehabilitation', 'between', '2', '-', '12', 'weeks', 'post', 'infarct', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 15,
                "text": "Music Listening",
                "type": "OTHER"
            },
            {
                "start": 20,
                "end": 46,
                "text": "Cardiorespiratory Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 60,
                "end": 66,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 84,
                "end": 90,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 218,
                "end": 237,
                "text": "music interventions",
                "type": "OTHER"
            },
            {
                "start": 302,
                "end": 308,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 799,
                "end": 822,
                "text": "group-tailored playlist",
                "type": "OTHER"
            },
            {
                "start": 826,
                "end": 831,
                "text": "radio",
                "type": "CONTROL"
            },
            {
                "start": 859,
                "end": 868,
                "text": "non-music",
                "type": "CONTROL"
            },
            {
                "start": 910,
                "end": 936,
                "text": "cardiorespiratory exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 974,
                "end": 980,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1036,
                "end": 1048,
                "text": "post infarct",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01603446",
        "study_official_title": "Pilot Study to Investigate the Efficacy of L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome. ",
        "study_brief_summary": " MELAS patients suffer from exercise intolerance, weakness, poor vision or blindness, poor growth, developmental delay, and deafness. They also have unique 'stroke-like' episodes (SLEs) which are not due to blockages of large or medium arteries. These 'strokes' are thought to be due to energy failure of very small brain blood vessels combined with energy failure in the mitochondria (cell battery) of the brain cells, especially in the back region of the brain in the vision centre. This leads to visual loss and paralysis. The overall goal of this study is to better understand the mechanism of these SLEs at the level of the brain cells and small blood vessels.",
        "text": "Pilot Study to Investigate the Efficacy of L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome. | MELAS patients suffer from exercise intolerance, weakness, poor vision or blindness, poor growth, developmental delay, and deafness. They also have unique 'stroke-like' episodes (SLEs) which are not due to blockages of large or medium arteries. These 'strokes' are thought to be due to energy failure of very small brain blood vessels combined with energy failure in the mitochondria (cell battery) of the brain cells, especially in the back region of the brain in the vision centre. This leads to visual loss and paralysis. The overall goal of this study is to better understand the mechanism of these SLEs at the level of the brain cells and small blood vessels.",
        "tokens": "['Pilot', 'Study', 'to', 'Investigate', 'the', 'Efficacy', 'of', 'L', '-', 'arginine', 'Therapy', 'on', 'Endothelium', '-', 'dependent', 'Vasodilation', '&', 'Mitochondrial', 'Metabolism', 'in', 'MELAS', 'Syndrome', '.', '|', 'MELAS', 'patients', 'suffer', 'from', 'exercise', 'intolerance', ',', 'weakness', ',', 'poor', 'vision', 'or', 'blindness', ',', 'poor', 'growth', ',', 'developmental', 'delay', ',', 'and', 'deafness', '.', 'They', 'also', 'have', 'unique', \"'\", 'stroke', '-', 'like', \"'\", 'episodes', '(', 'SLEs', ')', 'which', 'are', 'not', 'due', 'to', 'blockages', 'of', 'large', 'or', 'medium', 'arteries', '.', 'These', \"'\", 'strokes', \"'\", 'are', 'thought', 'to', 'be', 'due', 'to', 'energy', 'failure', 'of', 'very', 'small', 'brain', 'blood', 'vessels', 'combined', 'with', 'energy', 'failure', 'in', 'the', 'mitochondria', '(', 'cell', 'battery', ')', 'of', 'the', 'brain', 'cells', ',', 'especially', 'in', 'the', 'back', 'region', 'of', 'the', 'brain', 'in', 'the', 'vision', 'centre', '.', 'This', 'leads', 'to', 'visual', 'loss', 'and', 'paralysis', '.', 'The', 'overall', 'goal', 'of', 'this', 'study', 'is', 'to', 'better', 'understand', 'the', 'mechanism', 'of', 'these', 'SLEs', 'at', 'the', 'level', 'of', 'the', 'brain', 'cells', 'and', 'small', 'blood', 'vessels', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 53,
                "text": "L-arginine",
                "type": "DRUG"
            },
            {
                "start": 130,
                "end": 144,
                "text": "MELAS Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 153,
                "text": "MELAS",
                "type": "CONDITION"
            },
            {
                "start": 303,
                "end": 325,
                "text": "'stroke-like' episodes",
                "type": "CONDITION"
            },
            {
                "start": 327,
                "end": 331,
                "text": "SLEs",
                "type": "CONDITION"
            },
            {
                "start": 400,
                "end": 407,
                "text": "strokes",
                "type": "CONDITION"
            },
            {
                "start": 751,
                "end": 755,
                "text": "SLEs",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01429077",
        "study_official_title": "Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy ",
        "study_brief_summary": " The purpose of this study is to evaluate the effectiveness of the medication levodopa, in combination with speech-language treatment, on the language outcome of study subjects with nonfluent aphasia (i.e. difficulty with the comprehension and expression of spoken and written language) following a stroke.",
        "text": "Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy | The purpose of this study is to evaluate the effectiveness of the medication levodopa, in combination with speech-language treatment, on the language outcome of study subjects with nonfluent aphasia (i.e. difficulty with the comprehension and expression of spoken and written language) following a stroke.",
        "tokens": "['Augmenting', 'Language', 'Therapy', 'for', 'Aphasia', ':', 'A', 'Randomized', 'Double', '-', 'Blind', 'Placebo', '-', 'Controlled', 'Trial', 'of', 'Levodopa', 'in', 'Combination', 'With', 'Speech', '-', 'Language', 'Therapy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'the', 'medication', 'levodopa', ',', 'in', 'combination', 'with', 'speech', '-', 'language', 'treatment', ',', 'on', 'the', 'language', 'outcome', 'of', 'study', 'subjects', 'with', 'nonfluent', 'aphasia', '(', 'i.e.', 'difficulty', 'with', 'the', 'comprehension', 'and', 'expression', 'of', 'spoken', 'and', 'written', 'language', ')', 'following', 'a', 'stroke', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 27,
                "text": "Language Therapy",
                "type": "OTHER"
            },
            {
                "start": 32,
                "end": 39,
                "text": "Aphasia",
                "type": "CONDITION"
            },
            {
                "start": 67,
                "end": 74,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 95,
                "end": 103,
                "text": "Levodopa",
                "type": "DRUG"
            },
            {
                "start": 124,
                "end": 147,
                "text": "Speech-Language Therapy",
                "type": "OTHER"
            },
            {
                "start": 227,
                "end": 235,
                "text": "levodopa",
                "type": "DRUG"
            },
            {
                "start": 257,
                "end": 283,
                "text": "speech-language treatment,",
                "type": "OTHER"
            },
            {
                "start": 331,
                "end": 348,
                "text": "nonfluent aphasia",
                "type": "CONDITION"
            },
            {
                "start": 448,
                "end": 454,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04899284",
        "study_official_title": "Impact of Early and Intensive Bimanual Stimulation on the Evolution of Bimanual Function in Infants With Clinical Findings Suggesting Unilateral Cerebral Palsy (BB-BIM) ",
        "study_brief_summary": " The aim of this study is to measure the impact of early bimanual stimulation in babies with clinical signs of underuse of one hand. The observation focuses on the developmental curve of hands use. The intervention is provided by the family environment and takes place in the child's familiar surroundings.",
        "text": "Impact of Early and Intensive Bimanual Stimulation on the Evolution of Bimanual Function in Infants With Clinical Findings Suggesting Unilateral Cerebral Palsy (BB-BIM) | The aim of this study is to measure the impact of early bimanual stimulation in babies with clinical signs of underuse of one hand. The observation focuses on the developmental curve of hands use. The intervention is provided by the family environment and takes place in the child's familiar surroundings.",
        "tokens": "['Impact', 'of', 'Early', 'and', 'Intensive', 'Bimanual', 'Stimulation', 'on', 'the', 'Evolution', 'of', 'Bimanual', 'Function', 'in', 'Infants', 'With', 'Clinical', 'Findings', 'Suggesting', 'Unilateral', 'Cerebral', 'Palsy', '(', 'BB', '-', 'BIM', ')', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'measure', 'the', 'impact', 'of', 'early', 'bimanual', 'stimulation', 'in', 'babies', 'with', 'clinical', 'signs', 'of', 'underuse', 'of', 'one', 'hand', '.', 'The', 'observation', 'focuses', 'on', 'the', 'developmental', 'curve', 'of', 'hands', 'use', '.', 'The', 'intervention', 'is', 'provided', 'by', 'the', 'family', 'environment', 'and', 'takes', 'place', 'in', 'the', 'child', \"'s\", 'familiar', 'surroundings', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 50,
                "text": "Early and Intensive Bimanual Stimulation",
                "type": "OTHER"
            },
            {
                "start": 134,
                "end": 159,
                "text": "Unilateral Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 247,
                "text": "early bimanual stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04426123",
        "study_official_title": "Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A: A Randomized Double-blind Controlled Multicenter Pilot Study ",
        "study_brief_summary": " Investigating the effect of a single intramuscular injection with botulinum toxin (BTX) compared to NaCl in patients with jaw muscle myalgia.\n\nThis investigation is designed as an double blind multicenter pilot study for hypothesis generation on 48 patients with chronic jaw muscle myalgia at four specialist dental clinics. The subjects visit the clinic on 3 predefined occasions, one telephone call and one scheduled evaluation by mail.\n\nThe objective is primarily to evaluate the change in number of days with pain at two months following one session of BTX injections of the masseter and temporalis muscles in subjects with jaw muscle myalgia pain.\n\nThe outcome of this study will serve as a basis for a later randomized controlled trial",
        "text": "Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A: A Randomized Double-blind Controlled Multicenter Pilot Study | Investigating the effect of a single intramuscular injection with botulinum toxin (BTX) compared to NaCl in patients with jaw muscle myalgia.\n\nThis investigation is designed as an double blind multicenter pilot study for hypothesis generation on 48 patients with chronic jaw muscle myalgia at four specialist dental clinics. The subjects visit the clinic on 3 predefined occasions, one telephone call and one scheduled evaluation by mail.\n\nThe objective is primarily to evaluate the change in number of days with pain at two months following one session of BTX injections of the masseter and temporalis muscles in subjects with jaw muscle myalgia pain.\n\nThe outcome of this study will serve as a basis for a later randomized controlled trial",
        "tokens": "['Masseter', 'Myofascial', 'Pain', 'Relief', 'Following', 'an', 'Intra', '-', 'muscular', 'Injection', 'With', 'Botulinum', 'Toxin', 'Type', 'A', ':', 'A', 'Randomized', 'Double', '-', 'blind', 'Controlled', 'Multicenter', 'Pilot', 'Study', '|', 'Investigating', 'the', 'effect', 'of', 'a', 'single', 'intramuscular', 'injection', 'with', 'botulinum', 'toxin', '(', 'BTX', ')', 'compared', 'to', 'NaCl', 'in', 'patients', 'with', 'jaw', 'muscle', 'myalgia', '.', '\\n\\n', 'This', 'investigation', 'is', 'designed', 'as', 'an', 'double', 'blind', 'multicenter', 'pilot', 'study', 'for', 'hypothesis', 'generation', 'on', '48', 'patients', 'with', 'chronic', 'jaw', 'muscle', 'myalgia', 'at', 'four', 'specialist', 'dental', 'clinics', '.', 'The', 'subjects', 'visit', 'the', 'clinic', 'on', '3', 'predefined', 'occasions', ',', 'one', 'telephone', 'call', 'and', 'one', 'scheduled', 'evaluation', 'by', 'mail', '.', '\\n\\n', 'The', 'objective', 'is', 'primarily', 'to', 'evaluate', 'the', 'change', 'in', 'number', 'of', 'days', 'with', 'pain', 'at', 'two', 'months', 'following', 'one', 'session', 'of', 'BTX', 'injections', 'of', 'the', 'masseter', 'and', 'temporalis', 'muscles', 'in', 'subjects', 'with', 'jaw', 'muscle', 'myalgia', 'pain', '.', '\\n\\n', 'The', 'outcome', 'of', 'this', 'study', 'will', 'serve', 'as', 'a', 'basis', 'for', 'a', 'later', 'randomized', 'controlled', 'trial']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 75,
                "end": 97,
                "text": "Botulinum Toxin Type A",
                "type": "DRUG"
            },
            {
                "start": 228,
                "end": 243,
                "text": "botulinum toxin",
                "type": "DRUG"
            },
            {
                "start": 245,
                "end": 248,
                "text": "BTX",
                "type": "DRUG"
            },
            {
                "start": 262,
                "end": 266,
                "text": "NaCl",
                "type": "DRUG"
            },
            {
                "start": 284,
                "end": 302,
                "text": "jaw muscle myalgia",
                "type": "CONDITION"
            },
            {
                "start": 425,
                "end": 451,
                "text": "chronic jaw muscle myalgia",
                "type": "CONDITION"
            },
            {
                "start": 719,
                "end": 722,
                "text": "BTX",
                "type": "DRUG"
            },
            {
                "start": 790,
                "end": 808,
                "text": "jaw muscle myalgia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02281097",
        "study_official_title": "Transdermal Vagal Stimulation for the Treatment of Postural Tachycardia Syndrome ",
        "study_brief_summary": " Some patients experience high heart rates and symptoms of light-headedness, fatigue, headache during standing despite well maintained blood pressure.\n\nThese patient are disabled and can't be in upright position for a longer time. The purpose of this study is to test whether electrical stimulation of a nerve through a skin of the ear may improve heart rate response and reduce disabling symptoms.",
        "text": "Transdermal Vagal Stimulation for the Treatment of Postural Tachycardia Syndrome | Some patients experience high heart rates and symptoms of light-headedness, fatigue, headache during standing despite well maintained blood pressure.\n\nThese patient are disabled and can't be in upright position for a longer time. The purpose of this study is to test whether electrical stimulation of a nerve through a skin of the ear may improve heart rate response and reduce disabling symptoms.",
        "tokens": "['Transdermal', 'Vagal', 'Stimulation', 'for', 'the', 'Treatment', 'of', 'Postural', 'Tachycardia', 'Syndrome', '|', 'Some', 'patients', 'experience', 'high', 'heart', 'rates', 'and', 'symptoms', 'of', 'light', '-', 'headedness', ',', 'fatigue', ',', 'headache', 'during', 'standing', 'despite', 'well', 'maintained', 'blood', 'pressure', '.', '\\n\\n', 'These', 'patient', 'are', 'disabled', 'and', 'ca', \"n't\", 'be', 'in', 'upright', 'position', 'for', 'a', 'longer', 'time', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'whether', 'electrical', 'stimulation', 'of', 'a', 'nerve', 'through', 'a', 'skin', 'of', 'the', 'ear', 'may', 'improve', 'heart', 'rate', 'response', 'and', 'reduce', 'disabling', 'symptoms', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 29,
                "text": "Transdermal Vagal Stimulation",
                "type": "OTHER"
            },
            {
                "start": 51,
                "end": 80,
                "text": "Postural Tachycardia Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 141,
                "end": 157,
                "text": "light-headedness",
                "type": "CONDITION"
            },
            {
                "start": 159,
                "end": 166,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 168,
                "end": 176,
                "text": "headache",
                "type": "CONDITION"
            },
            {
                "start": 358,
                "end": 417,
                "text": "electrical stimulation of a nerve through a skin of the ear",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01546467",
        "study_official_title": "Cognitive Remediation in Early Phase Psychosis ",
        "study_brief_summary": " The purpose of the study is to investigate the effect of a 30 hour cognitive remediation program for young patients with early phase schizophrenia spectrum disorders on cognitive, clinical and functional outcome measures. The remediation program is integrated with whatever active rehabilitation the participant is currently attending (school, work, day program etc).",
        "text": "Cognitive Remediation in Early Phase Psychosis | The purpose of the study is to investigate the effect of a 30 hour cognitive remediation program for young patients with early phase schizophrenia spectrum disorders on cognitive, clinical and functional outcome measures. The remediation program is integrated with whatever active rehabilitation the participant is currently attending (school, work, day program etc).",
        "tokens": "['Cognitive', 'Remediation', 'in', 'Early', 'Phase', 'Psychosis', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'investigate', 'the', 'effect', 'of', 'a', '30', 'hour', 'cognitive', 'remediation', 'program', 'for', 'young', 'patients', 'with', 'early', 'phase', 'schizophrenia', 'spectrum', 'disorders', 'on', 'cognitive', ',', 'clinical', 'and', 'functional', 'outcome', 'measures', '.', 'The', 'remediation', 'program', 'is', 'integrated', 'with', 'whatever', 'active', 'rehabilitation', 'the', 'participant', 'is', 'currently', 'attending', '(', 'school', ',', 'work', ',', 'day', 'program', 'etc', ')', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 21,
                "text": "Cognitive Remediation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 25,
                "end": 46,
                "text": "Early Phase Psychosis",
                "type": "CONDITION"
            },
            {
                "start": 116,
                "end": 145,
                "text": "cognitive remediation program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 170,
                "end": 214,
                "text": "early phase schizophrenia spectrum disorders",
                "type": "CONDITION"
            },
            {
                "start": 275,
                "end": 294,
                "text": "remediation program",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT03319771",
        "study_official_title": "Effects of Exercise Training on Learning and Memory Outcomes in Multiple Sclerosis ",
        "study_brief_summary": " The two primary study objectives involve examining the effects of treadmill walking exercise training versus stretching-and-toning activities on the primary and secondary outcomes.\n\nSpecific Aim 1: The first specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on learning and memory outcomes in fully-ambulatory persons with MS who have impairment in learning new information. We hypothesize that those who undergo treadmill walking exercise training will demonstrate improvements in learning and memory relative to those who undergo stretching-and-toning activities.\n\nSpecific Aim 2: The second specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on hippocampal volume, hippocampal resting-state functional connectivity, and cardiorespiratory fitness in those persons with MS. We hypothesize that those who are randomly assigned to the treadmill walking exercise condition will demonstrate increases in hippocampal volume and resting-state functional connectivity (i.e., adaptive increases) and improved cardiorespiratory fitness relative to those in the stretching-and-toning condition.",
        "text": "Effects of Exercise Training on Learning and Memory Outcomes in Multiple Sclerosis | The two primary study objectives involve examining the effects of treadmill walking exercise training versus stretching-and-toning activities on the primary and secondary outcomes.\n\nSpecific Aim 1: The first specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on learning and memory outcomes in fully-ambulatory persons with MS who have impairment in learning new information. We hypothesize that those who undergo treadmill walking exercise training will demonstrate improvements in learning and memory relative to those who undergo stretching-and-toning activities.\n\nSpecific Aim 2: The second specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on hippocampal volume, hippocampal resting-state functional connectivity, and cardiorespiratory fitness in those persons with MS. We hypothesize that those who are randomly assigned to the treadmill walking exercise condition will demonstrate increases in hippocampal volume and resting-state functional connectivity (i.e., adaptive increases) and improved cardiorespiratory fitness relative to those in the stretching-and-toning condition.",
        "tokens": "['Effects', 'of', 'Exercise', 'Training', 'on', 'Learning', 'and', 'Memory', 'Outcomes', 'in', 'Multiple', 'Sclerosis', '|', 'The', 'two', 'primary', 'study', 'objectives', 'involve', 'examining', 'the', 'effects', 'of', 'treadmill', 'walking', 'exercise', 'training', 'versus', 'stretching', '-', 'and', '-', 'toning', 'activities', 'on', 'the', 'primary', 'and', 'secondary', 'outcomes', '.', '\\n\\n', 'Specific', 'Aim', '1', ':', 'The', 'first', 'specific', 'aim', 'is', 'to', 'examine', 'the', 'effects', 'of', '3', '-', 'months', 'of', 'treadmill', 'walking', 'exercise', 'training', 'compared', 'with', 'an', 'active', 'control', 'condition', 'on', 'learning', 'and', 'memory', 'outcomes', 'in', 'fully', '-', 'ambulatory', 'persons', 'with', 'MS', 'who', 'have', 'impairment', 'in', 'learning', 'new', 'information', '.', 'We', 'hypothesize', 'that', 'those', 'who', 'undergo', 'treadmill', 'walking', 'exercise', 'training', 'will', 'demonstrate', 'improvements', 'in', 'learning', 'and', 'memory', 'relative', 'to', 'those', 'who', 'undergo', 'stretching', '-', 'and', '-', 'toning', 'activities', '.', '\\n\\n', 'Specific', 'Aim', '2', ':', 'The', 'second', 'specific', 'aim', 'is', 'to', 'examine', 'the', 'effects', 'of', '3', '-', 'months', 'of', 'treadmill', 'walking', 'exercise', 'training', 'compared', 'with', 'an', 'active', 'control', 'condition', 'on', 'hippocampal', 'volume', ',', 'hippocampal', 'resting', '-', 'state', 'functional', 'connectivity', ',', 'and', 'cardiorespiratory', 'fitness', 'in', 'those', 'persons', 'with', 'MS', '.', 'We', 'hypothesize', 'that', 'those', 'who', 'are', 'randomly', 'assigned', 'to', 'the', 'treadmill', 'walking', 'exercise', 'condition', 'will', 'demonstrate', 'increases', 'in', 'hippocampal', 'volume', 'and', 'resting', '-', 'state', 'functional', 'connectivity', '(', 'i.e.', ',', 'adaptive', 'increases', ')', 'and', 'improved', 'cardiorespiratory', 'fitness', 'relative', 'to', 'those', 'in', 'the', 'stretching', '-', 'and', '-', 'toning', 'condition', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 28,
                "text": "Exercise Training",
                "type": "PHYSICAL"
            },
            {
                "start": 64,
                "end": 82,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 151,
                "end": 177,
                "text": "treadmill walking exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 194,
                "end": 226,
                "text": "stretching-and-toning activities",
                "type": "CONTROL"
            },
            {
                "start": 347,
                "end": 373,
                "text": "treadmill walking exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 400,
                "end": 414,
                "text": "active control",
                "type": "CONTROL"
            },
            {
                "start": 490,
                "end": 492,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 580,
                "end": 606,
                "text": "treadmill walking exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 699,
                "end": 731,
                "text": "stretching-and-toning activities",
                "type": "CONTROL"
            },
            {
                "start": 815,
                "end": 841,
                "text": "treadmill walking exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 868,
                "end": 882,
                "text": "active control",
                "type": "CONTROL"
            },
            {
                "start": 1019,
                "end": 1021,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1082,
                "end": 1108,
                "text": "treadmill walking exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1301,
                "end": 1322,
                "text": "stretching-and-toning",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03482310",
        "study_official_title": "Restoring High Dimensional Hand Function to Persons With Chronic High Tetraplegia ",
        "study_brief_summary": " This study is for people who have a paralyzed arm and hand from a spinal cord injury, who have also received a recording electrode array in the brain as part of the BrainGate study. The study will look at the ability of these participants to control different grasping patterns of the hand, both in virtual reality and in his/her actual hand. Movement of the participant's hand is controlled by a functional electrical stimulation (FES) system, which involves small electrodes implanted in the arm, shoulder and hand that use small electrical currents to activate the appropriate muscles.",
        "text": "Restoring High Dimensional Hand Function to Persons With Chronic High Tetraplegia | This study is for people who have a paralyzed arm and hand from a spinal cord injury, who have also received a recording electrode array in the brain as part of the BrainGate study. The study will look at the ability of these participants to control different grasping patterns of the hand, both in virtual reality and in his/her actual hand. Movement of the participant's hand is controlled by a functional electrical stimulation (FES) system, which involves small electrodes implanted in the arm, shoulder and hand that use small electrical currents to activate the appropriate muscles.",
        "tokens": "['Restoring', 'High', 'Dimensional', 'Hand', 'Function', 'to', 'Persons', 'With', 'Chronic', 'High', 'Tetraplegia', '|', 'This', 'study', 'is', 'for', 'people', 'who', 'have', 'a', 'paralyzed', 'arm', 'and', 'hand', 'from', 'a', 'spinal', 'cord', 'injury', ',', 'who', 'have', 'also', 'received', 'a', 'recording', 'electrode', 'array', 'in', 'the', 'brain', 'as', 'part', 'of', 'the', 'BrainGate', 'study', '.', 'The', 'study', 'will', 'look', 'at', 'the', 'ability', 'of', 'these', 'participants', 'to', 'control', 'different', 'grasping', 'patterns', 'of', 'the', 'hand', ',', 'both', 'in', 'virtual', 'reality', 'and', 'in', 'his', '/', 'her', 'actual', 'hand', '.', 'Movement', 'of', 'the', 'participant', \"'s\", 'hand', 'is', 'controlled', 'by', 'a', 'functional', 'electrical', 'stimulation', '(', 'FES', ')', 'system', ',', 'which', 'involves', 'small', 'electrodes', 'implanted', 'in', 'the', 'arm', ',', 'shoulder', 'and', 'hand', 'that', 'use', 'small', 'electrical', 'currents', 'to', 'activate', 'the', 'appropriate', 'muscles', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 57,
                "end": 81,
                "text": "Chronic High Tetraplegia",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 129,
                "text": "paralyzed",
                "type": "CONDITION"
            },
            {
                "start": 150,
                "end": 168,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 481,
                "end": 514,
                "text": "functional electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 516,
                "end": 519,
                "text": "FES",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02751268",
        "study_official_title": "Effect of Infraorbital and Infratrochlear Nerve Block on Emergence Agitation in Patients Undergoing Septorhinoplasty: A Randomized Controlled Trial ",
        "study_brief_summary": " The purpose of this study is to determine whether bilateral infraorbital and infratrochlear nerve block in patients undergoing septorhinoplasty are effective in preventing emergence agitation.",
        "text": "Effect of Infraorbital and Infratrochlear Nerve Block on Emergence Agitation in Patients Undergoing Septorhinoplasty: A Randomized Controlled Trial | The purpose of this study is to determine whether bilateral infraorbital and infratrochlear nerve block in patients undergoing septorhinoplasty are effective in preventing emergence agitation.",
        "tokens": "['Effect', 'of', 'Infraorbital', 'and', 'Infratrochlear', 'Nerve', 'Block', 'on', 'Emergence', 'Agitation', 'in', 'Patients', 'Undergoing', 'Septorhinoplasty', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'bilateral', 'infraorbital', 'and', 'infratrochlear', 'nerve', 'block', 'in', 'patients', 'undergoing', 'septorhinoplasty', 'are', 'effective', 'in', 'preventing', 'emergence', 'agitation', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 53,
                "text": "Infraorbital and Infratrochlear Nerve Block",
                "type": "OTHER"
            },
            {
                "start": 57,
                "end": 76,
                "text": "Emergence Agitation",
                "type": "CONDITION"
            },
            {
                "start": 100,
                "end": 116,
                "text": "Septorhinoplasty",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 253,
                "text": "bilateral infraorbital and infratrochlear nerve block",
                "type": "OTHER"
            },
            {
                "start": 277,
                "end": 293,
                "text": "septorhinoplasty",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 341,
                "text": "emergence agitation",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04123223",
        "study_official_title": "Comparing Cognitive Remediation Approaches for Schizophrenia ",
        "study_brief_summary": " This research compares the relative efficacy of two empirically-supported, standardized programs of cognitive remediation for treatment of cognitive deficits and community function in schizophrenia to help inform best practices. The proposed study advances public health by developing and evaluating new behavioral techniques for improving psychosocial outcome in individuals diagnosed with schizophrenia.",
        "text": "Comparing Cognitive Remediation Approaches for Schizophrenia | This research compares the relative efficacy of two empirically-supported, standardized programs of cognitive remediation for treatment of cognitive deficits and community function in schizophrenia to help inform best practices. The proposed study advances public health by developing and evaluating new behavioral techniques for improving psychosocial outcome in individuals diagnosed with schizophrenia.",
        "tokens": "['Comparing', 'Cognitive', 'Remediation', 'Approaches', 'for', 'Schizophrenia', '|', 'This', 'research', 'compares', 'the', 'relative', 'efficacy', 'of', 'two', 'empirically', '-', 'supported', ',', 'standardized', 'programs', 'of', 'cognitive', 'remediation', 'for', 'treatment', 'of', 'cognitive', 'deficits', 'and', 'community', 'function', 'in', 'schizophrenia', 'to', 'help', 'inform', 'best', 'practices', '.', 'The', 'proposed', 'study', 'advances', 'public', 'health', 'by', 'developing', 'and', 'evaluating', 'new', 'behavioral', 'techniques', 'for', 'improving', 'psychosocial', 'outcome', 'in', 'individuals', 'diagnosed', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'B-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 31,
                "text": "Cognitive Remediation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 47,
                "end": 60,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 163,
                "end": 184,
                "text": "cognitive remediation",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 202,
                "end": 220,
                "text": "cognitive deficits",
                "type": "CONDITION"
            },
            {
                "start": 247,
                "end": 260,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 367,
                "end": 388,
                "text": "behavioral techniques",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 454,
                "end": 467,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03174249",
        "study_official_title": "Leaving the Wheelchair Behind - Treating CRPS-II With Exposure Therapy Combined With Cortical Interventions: a Series of Case Reports ",
        "study_brief_summary": " Consecutive patients with long-standing complex regional pain syndrome II in a lower limb are treated with graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.",
        "text": "Leaving the Wheelchair Behind - Treating CRPS-II With Exposure Therapy Combined With Cortical Interventions: a Series of Case Reports | Consecutive patients with long-standing complex regional pain syndrome II in a lower limb are treated with graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.",
        "tokens": "['Leaving', 'the', 'Wheelchair', 'Behind', '-', 'Treating', 'CRPS', '-', 'II', 'With', 'Exposure', 'Therapy', 'Combined', 'With', 'Cortical', 'Interventions', ':', 'a', 'Series', 'of', 'Case', 'Reports', '|', 'Consecutive', 'patients', 'with', 'long', '-', 'standing', 'complex', 'regional', 'pain', 'syndrome', 'II', 'in', 'a', 'lower', 'limb', 'are', 'treated', 'with', 'graded', 'exposure', 'therapy', 'in', 'vivo', 'in', 'combination', 'with', 'methods', 'targeting', 'cortical', 'reorganisation', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 48,
                "text": "CRPS-II",
                "type": "CONDITION"
            },
            {
                "start": 54,
                "end": 70,
                "text": "Exposure Therapy",
                "type": "OTHER"
            },
            {
                "start": 85,
                "end": 107,
                "text": "Cortical Interventions",
                "type": "OTHER"
            },
            {
                "start": 176,
                "end": 209,
                "text": "complex regional pain syndrome II",
                "type": "CONDITION"
            },
            {
                "start": 243,
                "end": 266,
                "text": "graded exposure therapy",
                "type": "OTHER"
            },
            {
                "start": 295,
                "end": 336,
                "text": "methods targeting cortical reorganisation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04032626",
        "study_official_title": "MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease ",
        "study_brief_summary": " Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing on the experience from a previous clinical trial with thalidomide, here, the investigators hypothesize that modulating both systemic and CNS inflammation via the pleiotropic immunomodulator lenalidomide is a putative therapeutic intervention for AD if administered at a proper time window during the course of the disease.",
        "text": "MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease | Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients. These data suggest that systemic inflammation plays a crucial role in the cause and effects of AD neuropathology. Capitalizing on the experience from a previous clinical trial with thalidomide, here, the investigators hypothesize that modulating both systemic and CNS inflammation via the pleiotropic immunomodulator lenalidomide is a putative therapeutic intervention for AD if administered at a proper time window during the course of the disease.",
        "tokens": "['MCLENA-1', ':', 'A', 'Phase', 'II', 'Clinical', 'Trial', 'for', 'the', 'Assessment', 'of', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'Lenalidomide', 'in', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', 'Due', 'to', 'Alzheimer', \"'s\", 'Disease', '|', 'Accumulating', 'evidence', 'indicates', 'that', 'inflammation', 'is', 'prominent', 'both', 'in', 'the', 'blood', 'and', 'central', 'nervous', 'system', '(', 'CNS', ')', 'of', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', 'patients', '.', 'These', 'data', 'suggest', 'that', 'systemic', 'inflammation', 'plays', 'a', 'crucial', 'role', 'in', 'the', 'cause', 'and', 'effects', 'of', 'AD', 'neuropathology', '.', 'Capitalizing', 'on', 'the', 'experience', 'from', 'a', 'previous', 'clinical', 'trial', 'with', 'thalidomide', ',', 'here', ',', 'the', 'investigators', 'hypothesize', 'that', 'modulating', 'both', 'systemic', 'and', 'CNS', 'inflammation', 'via', 'the', 'pleiotropic', 'immunomodulator', 'lenalidomide', 'is', 'a', 'putative', 'therapeutic', 'intervention', 'for', 'AD', 'if', 'administered', 'at', 'a', 'proper', 'time', 'window', 'during', 'the', 'course', 'of', 'the', 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 96,
                "end": 108,
                "text": "Lenalidomide",
                "type": "DRUG"
            },
            {
                "start": 126,
                "end": 151,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 159,
                "end": 178,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 317,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 319,
                "end": 321,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 428,
                "end": 430,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 514,
                "end": 525,
                "text": "thalidomide",
                "type": "DRUG"
            },
            {
                "start": 650,
                "end": 662,
                "text": "lenalidomide",
                "type": "DRUG"
            },
            {
                "start": 706,
                "end": 708,
                "text": "AD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00225602",
        "study_official_title": "Quasi-Experimental Trial of the Effect of Assertive Community Treatment Among Those With Severe Mental Disorder ",
        "study_brief_summary": " The aim of the study is to evaluate the effect of assertive community treatment in Copenhagen in two regions compared with two regions where this treatment was not implemented. The effect on user satisfaction, use of bed days, social network, global assessment of functioning, substance misuse will be evaluated.",
        "text": "Quasi-Experimental Trial of the Effect of Assertive Community Treatment Among Those With Severe Mental Disorder | The aim of the study is to evaluate the effect of assertive community treatment in Copenhagen in two regions compared with two regions where this treatment was not implemented. The effect on user satisfaction, use of bed days, social network, global assessment of functioning, substance misuse will be evaluated.",
        "tokens": "['Quasi', '-', 'Experimental', 'Trial', 'of', 'the', 'Effect', 'of', 'Assertive', 'Community', 'Treatment', 'Among', 'Those', 'With', 'Severe', 'Mental', 'Disorder', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'assertive', 'community', 'treatment', 'in', 'Copenhagen', 'in', 'two', 'regions', 'compared', 'with', 'two', 'regions', 'where', 'this', 'treatment', 'was', 'not', 'implemented', '.', 'The', 'effect', 'on', 'user', 'satisfaction', ',', 'use', 'of', 'bed', 'days', ',', 'social', 'network', ',', 'global', 'assessment', 'of', 'functioning', ',', 'substance', 'misuse', 'will', 'be', 'evaluated', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 71,
                "text": "Assertive Community Treatment",
                "type": "OTHER"
            },
            {
                "start": 89,
                "end": 111,
                "text": "Severe Mental Disorder",
                "type": "CONDITION"
            },
            {
                "start": 164,
                "end": 193,
                "text": "assertive community treatment",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04891107",
        "study_official_title": "Feasibility and Preliminary Effects of Using a Music-based, Rhythm-modulating Wearable Sensor System in the Community in Persons With Parkinson Disease ",
        "study_brief_summary": " The purpose of this clinical study is to evaluate the effects of music, tailored to the participant's cadence, on adherence, quality of life, gait speed, functional mobility, and walking activity in individuals with Parkinson disease when used in the home and community environment.",
        "text": "Feasibility and Preliminary Effects of Using a Music-based, Rhythm-modulating Wearable Sensor System in the Community in Persons With Parkinson Disease | The purpose of this clinical study is to evaluate the effects of music, tailored to the participant's cadence, on adherence, quality of life, gait speed, functional mobility, and walking activity in individuals with Parkinson disease when used in the home and community environment.",
        "tokens": "['Feasibility', 'and', 'Preliminary', 'Effects', 'of', 'Using', 'a', 'Music', '-', 'based', ',', 'Rhythm', '-', 'modulating', 'Wearable', 'Sensor', 'System', 'in', 'the', 'Community', 'in', 'Persons', 'With', 'Parkinson', 'Disease', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'of', 'music', ',', 'tailored', 'to', 'the', 'participant', \"'s\", 'cadence', ',', 'on', 'adherence', ',', 'quality', 'of', 'life', ',', 'gait', 'speed', ',', 'functional', 'mobility', ',', 'and', 'walking', 'activity', 'in', 'individuals', 'with', 'Parkinson', 'disease', 'when', 'used', 'in', 'the', 'home', 'and', 'community', 'environment', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 47,
                "end": 100,
                "text": "Music-based, Rhythm-modulating Wearable Sensor System",
                "type": "OTHER"
            },
            {
                "start": 134,
                "end": 151,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 219,
                "end": 263,
                "text": "music, tailored to the participant's cadence",
                "type": "OTHER"
            },
            {
                "start": 370,
                "end": 387,
                "text": "Parkinson disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00880165",
        "study_official_title": "Cost Effective Strategy to Evaluate Veterans With Sleep Apnea ",
        "study_brief_summary": " This research study is comparing home and in-laboratory testing of veterans with suspected obstructive sleep apnea, a common breathing disorder during sleep. It is hoped that home testing will be equally effective in improving quality of life but have lower cost than in-lab testing. These findings will allow veterans to have greater access to diagnosis and treatment of their sleep apnea.",
        "text": "Cost Effective Strategy to Evaluate Veterans With Sleep Apnea | This research study is comparing home and in-laboratory testing of veterans with suspected obstructive sleep apnea, a common breathing disorder during sleep. It is hoped that home testing will be equally effective in improving quality of life but have lower cost than in-lab testing. These findings will allow veterans to have greater access to diagnosis and treatment of their sleep apnea.",
        "tokens": "['Cost', 'Effective', 'Strategy', 'to', 'Evaluate', 'Veterans', 'With', 'Sleep', 'Apnea', '|', 'This', 'research', 'study', 'is', 'comparing', 'home', 'and', 'in', '-', 'laboratory', 'testing', 'of', 'veterans', 'with', 'suspected', 'obstructive', 'sleep', 'apnea', ',', 'a', 'common', 'breathing', 'disorder', 'during', 'sleep', '.', 'It', 'is', 'hoped', 'that', 'home', 'testing', 'will', 'be', 'equally', 'effective', 'in', 'improving', 'quality', 'of', 'life', 'but', 'have', 'lower', 'cost', 'than', 'in', '-', 'lab', 'testing', '.', 'These', 'findings', 'will', 'allow', 'veterans', 'to', 'have', 'greater', 'access', 'to', 'diagnosis', 'and', 'treatment', 'of', 'their', 'sleep', 'apnea', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 61,
                "text": "Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 97,
                "end": 127,
                "text": "home and in-laboratory testing",
                "type": "OTHER"
            },
            {
                "start": 155,
                "end": 178,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 239,
                "end": 251,
                "text": "home testing",
                "type": "OTHER"
            },
            {
                "start": 332,
                "end": 346,
                "text": "in-lab testing",
                "type": "OTHER"
            },
            {
                "start": 442,
                "end": 453,
                "text": "sleep apnea",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02484599",
        "study_official_title": "Evaluation of a Computerized Attention Training (CAT) to Modify Attention Bias for Food Cues in Anorexia Nervosa Patients ",
        "study_brief_summary": " The purpose of this study is to test the therapeutic effects of a computerized attention training for patients with Anorexia Nervosa (AN). The primary aim is to determine if a computerized attention training can modify attention towards food and ameliorate eating disorder symptoms and related difficulties, such as anxiety. The secondary aim is to explore underlying mechanisms that contribute to these improvements. The stability of potentially observed effects over a one-month period will also be determined.",
        "text": "Evaluation of a Computerized Attention Training (CAT) to Modify Attention Bias for Food Cues in Anorexia Nervosa Patients | The purpose of this study is to test the therapeutic effects of a computerized attention training for patients with Anorexia Nervosa (AN). The primary aim is to determine if a computerized attention training can modify attention towards food and ameliorate eating disorder symptoms and related difficulties, such as anxiety. The secondary aim is to explore underlying mechanisms that contribute to these improvements. The stability of potentially observed effects over a one-month period will also be determined.",
        "tokens": "['Evaluation', 'of', 'a', 'Computerized', 'Attention', 'Training', '(', 'CAT', ')', 'to', 'Modify', 'Attention', 'Bias', 'for', 'Food', 'Cues', 'in', 'Anorexia', 'Nervosa', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'therapeutic', 'effects', 'of', 'a', 'computerized', 'attention', 'training', 'for', 'patients', 'with', 'Anorexia', 'Nervosa', '(', 'AN', ')', '.', 'The', 'primary', 'aim', 'is', 'to', 'determine', 'if', 'a', 'computerized', 'attention', 'training', 'can', 'modify', 'attention', 'towards', 'food', 'and', 'ameliorate', 'eating', 'disorder', 'symptoms', 'and', 'related', 'difficulties', ',', 'such', 'as', 'anxiety', '.', 'The', 'secondary', 'aim', 'is', 'to', 'explore', 'underlying', 'mechanisms', 'that', 'contribute', 'to', 'these', 'improvements', '.', 'The', 'stability', 'of', 'potentially', 'observed', 'effects', 'over', 'a', 'one', '-', 'month', 'period', 'will', 'also', 'be', 'determined', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 47,
                "text": "Computerized Attention Training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 49,
                "end": 52,
                "text": "CAT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 96,
                "end": 112,
                "text": "Anorexia Nervosa",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 221,
                "text": "computerized attention training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 240,
                "end": 256,
                "text": "Anorexia Nervosa",
                "type": "CONDITION"
            },
            {
                "start": 258,
                "end": 260,
                "text": "AN",
                "type": "CONDITION"
            },
            {
                "start": 300,
                "end": 331,
                "text": "computerized attention training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 381,
                "end": 396,
                "text": "eating disorder",
                "type": "CONDITION"
            },
            {
                "start": 440,
                "end": 447,
                "text": "anxiety",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03922425",
        "study_official_title": "Large Scale Implementation of Community Based Mental Health Care for People With Severe and Enduring Mental Ill Health in Europe ",
        "study_brief_summary": " A single-blinded hybrid effectiveness-implementation trial (Type II), that both evaluates the intervention outcomes (clinical and service use outcomes) through patient-randomization in the implementation sites, as well as evaluates the implementation strategy chosen for the intervention and its impact on implementation outcomes (e.g. adoption, fidelity, acceptability and maintenance (continued implementation) of the intervention).",
        "text": "Large Scale Implementation of Community Based Mental Health Care for People With Severe and Enduring Mental Ill Health in Europe | A single-blinded hybrid effectiveness-implementation trial (Type II), that both evaluates the intervention outcomes (clinical and service use outcomes) through patient-randomization in the implementation sites, as well as evaluates the implementation strategy chosen for the intervention and its impact on implementation outcomes (e.g. adoption, fidelity, acceptability and maintenance (continued implementation) of the intervention).",
        "tokens": "['Large', 'Scale', 'Implementation', 'of', 'Community', 'Based', 'Mental', 'Health', 'Care', 'for', 'People', 'With', 'Severe', 'and', 'Enduring', 'Mental', 'Ill', 'Health', 'in', 'Europe', '|', 'A', 'single', '-', 'blinded', 'hybrid', 'effectiveness', '-', 'implementation', 'trial', '(', 'Type', 'II', ')', ',', 'that', 'both', 'evaluates', 'the', 'intervention', 'outcomes', '(', 'clinical', 'and', 'service', 'use', 'outcomes', ')', 'through', 'patient', '-', 'randomization', 'in', 'the', 'implementation', 'sites', ',', 'as', 'well', 'as', 'evaluates', 'the', 'implementation', 'strategy', 'chosen', 'for', 'the', 'intervention', 'and', 'its', 'impact', 'on', 'implementation', 'outcomes', '(', 'e.g.', 'adoption', ',', 'fidelity', ',', 'acceptability', 'and', 'maintenance', '(', 'continued', 'implementation', ')', 'of', 'the', 'intervention', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 64,
                "text": "Community Based Mental Health Care",
                "type": "OTHER"
            },
            {
                "start": 81,
                "end": 118,
                "text": "Severe and Enduring Mental Ill Health",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00499200",
        "study_official_title": "A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease ",
        "study_brief_summary": " The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease (AD) subjects.",
        "text": "A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease | The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease (AD) subjects.",
        "tokens": "['A', 'Positron', 'Emission', 'Tomography', 'Study', 'to', 'Assess', 'the', 'Level', 'and', 'Duration', 'of', 'Occupancy', 'of', 'Serotonin-1A', 'Receptors', 'Produced', 'by', 'Single', 'Oral', 'Doses', 'of', 'SRA-444', 'in', 'Healthy', 'Elderly', 'Subjects', 'and', 'in', 'Subjects', 'With', 'Alzheimer', 'Disease', '|', 'The', 'study', 'will', 'include', 'a', 'preliminary', 'pharmacokinetics', '(', 'PK', ')', '/', 'safety', '/', 'tolerability', 'evaluation', 'in', 'healthy', 'elderly', 'subjects', 'followed', 'by', 'the', 'Receptor', 'Occupancy', '(', 'RO', ')', 'evaluations', 'in', 'healthy', 'elderly', 'subjects', 'and', 'in', 'Alzheimer', \"'s\", 'Disease', '(', 'AD', ')', 'subjects', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 142,
                "end": 149,
                "text": "SRA-444",
                "type": "DRUG"
            },
            {
                "start": 199,
                "end": 216,
                "text": "Alzheimer Disease",
                "type": "CONDITION"
            },
            {
                "start": 428,
                "end": 447,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 449,
                "end": 451,
                "text": "AD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05104593",
        "study_official_title": "An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients With Mild Cognitive Impairment or Mild Dementia (CAREPATH) ",
        "study_brief_summary": " The CAREPATH will conduct Technical Validation and Usability (TVU) study by involving \u2265 45 target end users (16 patients with MCI or mild dementia with their informal caregivers and 16 healthcare professionals from various disciplines) and Clinical Investigation (CI) study involving \u2265 200 patients (\u2265 100 users to pilot the CAREPATH platform and \u2265 100 patients as reference cases). Both of these pilot studies will be coordinated in four European countries (Spain, Romania, Germany and UK) with diverse health and social care systems, ICT landscape/digital maturity of healthcare provision and dementia national programs, which will allow for strengthening the evidence base on health outcomes and efficiency gains.\n\nThe CAREPATH outcomes can be summarized as:\n\nAn Integrated Care Platform that jointly addresses multimorbidity, dementia and diminished intrinsic capacity and optimally manages healthcare interventions for its users (patients, informal caregiver, healthcare providers, etc).\nTechnical Validation and Usability (TVU) study involving over 45 users and Clinical Investigation (CI) involving over 200 patients that will be conducted in four European countries (Spain, Romania, Germany and UK) during two years and mobilizing the other necessary actors, such as caregivers and healthcare professionals, for the validation of healthcare interventions.\nDementia / Multimorbidity Guidelines that will be conceived for best healthcare delivery.\nHealth Economics Impact Assessment for healthcare cost effectiveness and care provision equalities. The incremental cost-effectiveness and the incremental cost-utility ratio would allow revealing the incremental cost (or the potential savings) per unit of benefit of switching from usual care to CAREPATH-an integrated patient-centred approach- in multimorbid elderly patients with dementia, and therefore, to determinate whether the CAREPATH approach would be considered as a cost-effective alternative.",
        "text": "An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients With Mild Cognitive Impairment or Mild Dementia (CAREPATH) | The CAREPATH will conduct Technical Validation and Usability (TVU) study by involving \u2265 45 target end users (16 patients with MCI or mild dementia with their informal caregivers and 16 healthcare professionals from various disciplines) and Clinical Investigation (CI) study involving \u2265 200 patients (\u2265 100 users to pilot the CAREPATH platform and \u2265 100 patients as reference cases). Both of these pilot studies will be coordinated in four European countries (Spain, Romania, Germany and UK) with diverse health and social care systems, ICT landscape/digital maturity of healthcare provision and dementia national programs, which will allow for strengthening the evidence base on health outcomes and efficiency gains.\n\nThe CAREPATH outcomes can be summarized as:\n\nAn Integrated Care Platform that jointly addresses multimorbidity, dementia and diminished intrinsic capacity and optimally manages healthcare interventions for its users (patients, informal caregiver, healthcare providers, etc).\nTechnical Validation and Usability (TVU) study involving over 45 users and Clinical Investigation (CI) involving over 200 patients that will be conducted in four European countries (Spain, Romania, Germany and UK) during two years and mobilizing the other necessary actors, such as caregivers and healthcare professionals, for the validation of healthcare interventions.\nDementia / Multimorbidity Guidelines that will be conceived for best healthcare delivery.\nHealth Economics Impact Assessment for healthcare cost effectiveness and care provision equalities. The incremental cost-effectiveness and the incremental cost-utility ratio would allow revealing the incremental cost (or the potential savings) per unit of benefit of switching from usual care to CAREPATH-an integrated patient-centred approach- in multimorbid elderly patients with dementia, and therefore, to determinate whether the CAREPATH approach would be considered as a cost-effective alternative.",
        "tokens": "['An', 'Integrated', 'Solution', 'for', 'Sustainable', 'Care', 'for', 'Multimorbid', 'Elderly', 'Patients', 'With', 'Mild', 'Cognitive', 'Impairment', 'or', 'Mild', 'Dementia', '(', 'CAREPATH', ')', '|', 'The', 'CAREPATH', 'will', 'conduct', 'Technical', 'Validation', 'and', 'Usability', '(', 'TVU', ')', 'study', 'by', 'involving', '\u2265', '45', 'target', 'end', 'users', '(', '16', 'patients', 'with', 'MCI', 'or', 'mild', 'dementia', 'with', 'their', 'informal', 'caregivers', 'and', '16', 'healthcare', 'professionals', 'from', 'various', 'disciplines', ')', 'and', 'Clinical', 'Investigation', '(', 'CI', ')', 'study', 'involving', '\u2265', '200', 'patients', '(', '\u2265', '100', 'users', 'to', 'pilot', 'the', 'CAREPATH', 'platform', 'and', '\u2265', '100', 'patients', 'as', 'reference', 'cases', ')', '.', 'Both', 'of', 'these', 'pilot', 'studies', 'will', 'be', 'coordinated', 'in', 'four', 'European', 'countries', '(', 'Spain', ',', 'Romania', ',', 'Germany', 'and', 'UK', ')', 'with', 'diverse', 'health', 'and', 'social', 'care', 'systems', ',', 'ICT', 'landscape', '/', 'digital', 'maturity', 'of', 'healthcare', 'provision', 'and', 'dementia', 'national', 'programs', ',', 'which', 'will', 'allow', 'for', 'strengthening', 'the', 'evidence', 'base', 'on', 'health', 'outcomes', 'and', 'efficiency', 'gains', '.', '\\n\\n', 'The', 'CAREPATH', 'outcomes', 'can', 'be', 'summarized', 'as', ':', '\\n\\n', 'An', 'Integrated', 'Care', 'Platform', 'that', 'jointly', 'addresses', 'multimorbidity', ',', 'dementia', 'and', 'diminished', 'intrinsic', 'capacity', 'and', 'optimally', 'manages', 'healthcare', 'interventions', 'for', 'its', 'users', '(', 'patients', ',', 'informal', 'caregiver', ',', 'healthcare', 'providers', ',', 'etc', ')', '.', '\\n', 'Technical', 'Validation', 'and', 'Usability', '(', 'TVU', ')', 'study', 'involving', 'over', '45', 'users', 'and', 'Clinical', 'Investigation', '(', 'CI', ')', 'involving', 'over', '200', 'patients', 'that', 'will', 'be', 'conducted', 'in', 'four', 'European', 'countries', '(', 'Spain', ',', 'Romania', ',', 'Germany', 'and', 'UK', ')', 'during', 'two', 'years', 'and', 'mobilizing', 'the', 'other', 'necessary', 'actors', ',', 'such', 'as', 'caregivers', 'and', 'healthcare', 'professionals', ',', 'for', 'the', 'validation', 'of', 'healthcare', 'interventions', '.', '\\n', 'Dementia', '/', 'Multimorbidity', 'Guidelines', 'that', 'will', 'be', 'conceived', 'for', 'best', 'healthcare', 'delivery', '.', '\\n', 'Health', 'Economics', 'Impact', 'Assessment', 'for', 'healthcare', 'cost', 'effectiveness', 'and', 'care', 'provision', 'equalities', '.', 'The', 'incremental', 'cost', '-', 'effectiveness', 'and', 'the', 'incremental', 'cost', '-', 'utility', 'ratio', 'would', 'allow', 'revealing', 'the', 'incremental', 'cost', '(', 'or', 'the', 'potential', 'savings', ')', 'per', 'unit', 'of', 'benefit', 'of', 'switching', 'from', 'usual', 'care', 'to', 'CAREPATH', '-', 'an', 'integrated', 'patient', '-', 'centred', 'approach-', 'in', 'multimorbid', 'elderly', 'patients', 'with', 'dementia', ',', 'and', 'therefore', ',', 'to', 'determinate', 'whether', 'the', 'CAREPATH', 'approach', 'would', 'be', 'considered', 'as', 'a', 'cost', '-', 'effective', 'alternative', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 3,
                "end": 43,
                "text": "Integrated Solution for Sustainable Care",
                "type": "OTHER"
            },
            {
                "start": 48,
                "end": 59,
                "text": "Multimorbid",
                "type": "CONDITION"
            },
            {
                "start": 82,
                "end": 107,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 111,
                "end": 124,
                "text": "Mild Dementia",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 134,
                "text": "CAREPATH",
                "type": "OTHER"
            },
            {
                "start": 142,
                "end": 150,
                "text": "CAREPATH",
                "type": "OTHER"
            },
            {
                "start": 264,
                "end": 267,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 284,
                "text": "mild dementia",
                "type": "CONDITION"
            },
            {
                "start": 463,
                "end": 471,
                "text": "CAREPATH",
                "type": "OTHER"
            },
            {
                "start": 860,
                "end": 868,
                "text": "CAREPATH",
                "type": "OTHER"
            },
            {
                "start": 904,
                "end": 928,
                "text": "Integrated Care Platform",
                "type": "OTHER"
            },
            {
                "start": 952,
                "end": 966,
                "text": "multimorbidity",
                "type": "CONDITION"
            },
            {
                "start": 968,
                "end": 976,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 981,
                "end": 1010,
                "text": "diminished intrinsic capacity",
                "type": "CONDITION"
            },
            {
                "start": 1888,
                "end": 1896,
                "text": "CAREPATH",
                "type": "OTHER"
            },
            {
                "start": 1900,
                "end": 1936,
                "text": "integrated patient-centred approach-",
                "type": "OTHER"
            },
            {
                "start": 1940,
                "end": 1951,
                "text": "multimorbid",
                "type": "CONDITION"
            },
            {
                "start": 1974,
                "end": 1982,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 2026,
                "end": 2034,
                "text": "CAREPATH",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04096014",
        "study_official_title": "Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy ",
        "study_brief_summary": " Readmission rates for patients with hepatic encephalopathy due to end stage liver disease are high. Hyperammonemia contributes significantly to encephalopathy and occurs because of impaired hepatic ureagenesis and increased skeletal muscle proteolysis. We propose a randomized, 6-month nutritional intervention in cirrhotic patients who have had at least 1 admission for hepatic encephalopathy within the last 6 months. We hypothesize that a combination of late evening and early morning protein supplement (Ensure Enlive) will decrease recurrent hepatic encephalopathy and consequent readmission rates by lowering skeletal muscle proteolysis and improved lean body mass.",
        "text": "Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy | Readmission rates for patients with hepatic encephalopathy due to end stage liver disease are high. Hyperammonemia contributes significantly to encephalopathy and occurs because of impaired hepatic ureagenesis and increased skeletal muscle proteolysis. We propose a randomized, 6-month nutritional intervention in cirrhotic patients who have had at least 1 admission for hepatic encephalopathy within the last 6 months. We hypothesize that a combination of late evening and early morning protein supplement (Ensure Enlive) will decrease recurrent hepatic encephalopathy and consequent readmission rates by lowering skeletal muscle proteolysis and improved lean body mass.",
        "tokens": "['Late', 'Evening', 'and', 'Early', 'Morning', 'Protein', 'Supplement', 'to', 'Reduce', 'Readmissions', 'for', 'Hepatic', 'Encephalopathy', '|', 'Readmission', 'rates', 'for', 'patients', 'with', 'hepatic', 'encephalopathy', 'due', 'to', 'end', 'stage', 'liver', 'disease', 'are', 'high', '.', 'Hyperammonemia', 'contributes', 'significantly', 'to', 'encephalopathy', 'and', 'occurs', 'because', 'of', 'impaired', 'hepatic', 'ureagenesis', 'and', 'increased', 'skeletal', 'muscle', 'proteolysis', '.', 'We', 'propose', 'a', 'randomized', ',', '6', '-', 'month', 'nutritional', 'intervention', 'in', 'cirrhotic', 'patients', 'who', 'have', 'had', 'at', 'least', '1', 'admission', 'for', 'hepatic', 'encephalopathy', 'within', 'the', 'last', '6', 'months', '.', 'We', 'hypothesize', 'that', 'a', 'combination', 'of', 'late', 'evening', 'and', 'early', 'morning', 'protein', 'supplement', '(', 'Ensure', 'Enlive', ')', 'will', 'decrease', 'recurrent', 'hepatic', 'encephalopathy', 'and', 'consequent', 'readmission', 'rates', 'by', 'lowering', 'skeletal', 'muscle', 'proteolysis', 'and', 'improved', 'lean', 'body', 'mass', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 49,
                "text": "Protein Supplement",
                "type": "OTHER"
            },
            {
                "start": 77,
                "end": 99,
                "text": "Hepatic Encephalopathy",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 160,
                "text": "hepatic encephalopathy",
                "type": "CONDITION"
            },
            {
                "start": 202,
                "end": 216,
                "text": "Hyperammonemia",
                "type": "CONDITION"
            },
            {
                "start": 246,
                "end": 260,
                "text": "encephalopathy",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 311,
                "text": "impaired hepatic ureagenesis",
                "type": "CONDITION"
            },
            {
                "start": 326,
                "end": 353,
                "text": "skeletal muscle proteolysis",
                "type": "CONDITION"
            },
            {
                "start": 388,
                "end": 412,
                "text": "nutritional intervention",
                "type": "OTHER"
            },
            {
                "start": 473,
                "end": 495,
                "text": "hepatic encephalopathy",
                "type": "CONDITION"
            },
            {
                "start": 590,
                "end": 608,
                "text": "protein supplement",
                "type": "OTHER"
            },
            {
                "start": 610,
                "end": 623,
                "text": "Ensure Enlive",
                "type": "OTHER"
            },
            {
                "start": 649,
                "end": 671,
                "text": "hepatic encephalopathy",
                "type": "CONDITION"
            },
            {
                "start": 717,
                "end": 744,
                "text": "skeletal muscle proteolysis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01207908",
        "study_official_title": "IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy ",
        "study_brief_summary": " The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).",
        "text": "IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy | The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).",
        "tokens": "['IGF-1', 'Therapy', 'and', 'Muscle', 'Function', 'in', 'Duchenne', 'Muscular', 'Dystrophy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'IGF-1', 'therapy', 'improves', 'or', 'preserves', 'muscle', 'function', 'in', 'Duchenne', 'Muscular', 'Dystrophy', '(', 'DMD', ')', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 5,
                "text": "IGF-1",
                "type": "DRUG"
            },
            {
                "start": 37,
                "end": 64,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 117,
                "end": 122,
                "text": "IGF-1",
                "type": "DRUG"
            },
            {
                "start": 172,
                "end": 199,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 204,
                "text": "DMD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04177485",
        "study_official_title": "Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda-a Randomized Controlled Trial ",
        "study_brief_summary": " Faced with high rates of immunization drop-out, Uganda's immunization program requires innovative approaches to address this weakness. Building upon Uganda's growing mHealth infrastructure to pilot a scalable short message service (SMS) system to remind caregivers of their children's upcoming vaccination visits, it was hypothesized that the SMS intervention will increase immunization coverage in a cost-effective and affordable manner that would make it scalable. The study design was an investigator-blinded, multi-center, parallel groups randomized controlled trial with randomization occurring at the caregiver level in select health facilities of Arua District in Uganda. Enrollment took place at the time of Pentavalent 1 vaccination, and both arms included standard of care provided by the health worker. However, in the intervention arm, caregivers also received SMS text messages reminding them to return for their children's second and third doses of Pentavalent vaccine (four and eight weeks after the first dose of Pentavalent vaccine) and measles-containing vaccine (9 months of age). The primary outcome of interest is vaccination coverage at 12 months of age among children enrolled in the study and will be measured by comparing Penta3 and MCV coverage between arms. The study will also examine the SMS impact on timeliness of vaccine receipt, as it is hypothesized that those children receiving the SMS intervention will be more likely to have timely vaccination than those in the control group. The study will also assess caregiver acceptability and cost-effectiveness of the SMS intervention. In addition to assessing its impact on strengthening the immunization program, this intervention has implications for strengthening other programs of the health system through similar health messaging directed toward caregivers.",
        "text": "Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda-a Randomized Controlled Trial | Faced with high rates of immunization drop-out, Uganda's immunization program requires innovative approaches to address this weakness. Building upon Uganda's growing mHealth infrastructure to pilot a scalable short message service (SMS) system to remind caregivers of their children's upcoming vaccination visits, it was hypothesized that the SMS intervention will increase immunization coverage in a cost-effective and affordable manner that would make it scalable. The study design was an investigator-blinded, multi-center, parallel groups randomized controlled trial with randomization occurring at the caregiver level in select health facilities of Arua District in Uganda. Enrollment took place at the time of Pentavalent 1 vaccination, and both arms included standard of care provided by the health worker. However, in the intervention arm, caregivers also received SMS text messages reminding them to return for their children's second and third doses of Pentavalent vaccine (four and eight weeks after the first dose of Pentavalent vaccine) and measles-containing vaccine (9 months of age). The primary outcome of interest is vaccination coverage at 12 months of age among children enrolled in the study and will be measured by comparing Penta3 and MCV coverage between arms. The study will also examine the SMS impact on timeliness of vaccine receipt, as it is hypothesized that those children receiving the SMS intervention will be more likely to have timely vaccination than those in the control group. The study will also assess caregiver acceptability and cost-effectiveness of the SMS intervention. In addition to assessing its impact on strengthening the immunization program, this intervention has implications for strengthening other programs of the health system through similar health messaging directed toward caregivers.",
        "tokens": "['Evaluating', 'a', 'Caregiver', 'SMS', 'Reminder', 'Intervention', 'to', 'Reduce', 'Immunization', 'Drop', '-', 'out', 'in', 'Arua', ',', 'Uganda', '-', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Faced', 'with', 'high', 'rates', 'of', 'immunization', 'drop', '-', 'out', ',', 'Uganda', \"'s\", 'immunization', 'program', 'requires', 'innovative', 'approaches', 'to', 'address', 'this', 'weakness', '.', 'Building', 'upon', 'Uganda', \"'s\", 'growing', 'mHealth', 'infrastructure', 'to', 'pilot', 'a', 'scalable', 'short', 'message', 'service', '(', 'SMS', ')', 'system', 'to', 'remind', 'caregivers', 'of', 'their', 'children', \"'s\", 'upcoming', 'vaccination', 'visits', ',', 'it', 'was', 'hypothesized', 'that', 'the', 'SMS', 'intervention', 'will', 'increase', 'immunization', 'coverage', 'in', 'a', 'cost', '-', 'effective', 'and', 'affordable', 'manner', 'that', 'would', 'make', 'it', 'scalable', '.', 'The', 'study', 'design', 'was', 'an', 'investigator', '-', 'blinded', ',', 'multi', '-', 'center', ',', 'parallel', 'groups', 'randomized', 'controlled', 'trial', 'with', 'randomization', 'occurring', 'at', 'the', 'caregiver', 'level', 'in', 'select', 'health', 'facilities', 'of', 'Arua', 'District', 'in', 'Uganda', '.', 'Enrollment', 'took', 'place', 'at', 'the', 'time', 'of', 'Pentavalent', '1', 'vaccination', ',', 'and', 'both', 'arms', 'included', 'standard', 'of', 'care', 'provided', 'by', 'the', 'health', 'worker', '.', 'However', ',', 'in', 'the', 'intervention', 'arm', ',', 'caregivers', 'also', 'received', 'SMS', 'text', 'messages', 'reminding', 'them', 'to', 'return', 'for', 'their', 'children', \"'s\", 'second', 'and', 'third', 'doses', 'of', 'Pentavalent', 'vaccine', '(', 'four', 'and', 'eight', 'weeks', 'after', 'the', 'first', 'dose', 'of', 'Pentavalent', 'vaccine', ')', 'and', 'measles', '-', 'containing', 'vaccine', '(', '9', 'months', 'of', 'age', ')', '.', 'The', 'primary', 'outcome', 'of', 'interest', 'is', 'vaccination', 'coverage', 'at', '12', 'months', 'of', 'age', 'among', 'children', 'enrolled', 'in', 'the', 'study', 'and', 'will', 'be', 'measured', 'by', 'comparing', 'Penta3', 'and', 'MCV', 'coverage', 'between', 'arms', '.', 'The', 'study', 'will', 'also', 'examine', 'the', 'SMS', 'impact', 'on', 'timeliness', 'of', 'vaccine', 'receipt', ',', 'as', 'it', 'is', 'hypothesized', 'that', 'those', 'children', 'receiving', 'the', 'SMS', 'intervention', 'will', 'be', 'more', 'likely', 'to', 'have', 'timely', 'vaccination', 'than', 'those', 'in', 'the', 'control', 'group', '.', 'The', 'study', 'will', 'also', 'assess', 'caregiver', 'acceptability', 'and', 'cost', '-', 'effectiveness', 'of', 'the', 'SMS', 'intervention', '.', 'In', 'addition', 'to', 'assessing', 'its', 'impact', 'on', 'strengthening', 'the', 'immunization', 'program', ',', 'this', 'intervention', 'has', 'implications', 'for', 'strengthening', 'other', 'programs', 'of', 'the', 'health', 'system', 'through', 'similar', 'health', 'messaging', 'directed', 'toward', 'caregivers', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 35,
                "text": "Caregiver SMS Reminder",
                "type": "OTHER"
            },
            {
                "start": 329,
                "end": 372,
                "text": "scalable short message service (SMS) system",
                "type": "OTHER"
            },
            {
                "start": 472,
                "end": 488,
                "text": "SMS intervention",
                "type": "OTHER"
            },
            {
                "start": 1002,
                "end": 1019,
                "text": "SMS text messages",
                "type": "OTHER"
            },
            {
                "start": 1446,
                "end": 1449,
                "text": "SMS",
                "type": "OTHER"
            },
            {
                "start": 1547,
                "end": 1563,
                "text": "SMS intervention",
                "type": "OTHER"
            },
            {
                "start": 1725,
                "end": 1741,
                "text": "SMS intervention",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04159987",
        "study_official_title": "A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA\u00ae ",
        "study_brief_summary": " SPINRAZA\u00ae (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA\u00ae (Nusinersen).",
        "text": "A Multicenter, Interventional, Open-label Study to Monitor the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA\u00ae | SPINRAZA\u00ae (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA\u00ae (Nusinersen).",
        "tokens": "['A', 'Multicenter', ',', 'Interventional', ',', 'Open', '-', 'label', 'Study', 'to', 'Monitor', 'the', 'Evolution', 'of', 'Motor', 'Function', 'in', 'SMA', 'Type', 'II', 'Adults', 'Patients', 'Treated', 'With', 'SPINRAZA', '\u00ae', '|', 'SPINRAZA', '\u00ae', '(', 'Nusinersen', ')', 'is', 'the', 'first', 'intrathecal', 'administered', 'drug', 'which', 'was', 'approved', 'by', 'the', 'FDA', 'to', 'treat', 'SMA', 'children', 'and', 'adults', '(', '2016', ')', '.', 'The', 'aim', 'is', 'to', 'monitor', 'the', 'evolution', 'of', 'the', 'Motor', 'Function', 'Measure-32', 'for', 'SMA', 'type', 'II', 'adult', 'patients', 'treated', 'with', 'SPINRAZA', '\u00ae', '(', 'Nusinersen', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O']",
        "entities": [
            {
                "start": 94,
                "end": 105,
                "text": "SMA Type II",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 143,
                "text": "SPINRAZA",
                "type": "DRUG"
            },
            {
                "start": 147,
                "end": 155,
                "text": "SPINRAZA",
                "type": "DRUG"
            },
            {
                "start": 158,
                "end": 168,
                "text": "Nusinersen",
                "type": "DRUG"
            },
            {
                "start": 252,
                "end": 255,
                "text": "SMA",
                "type": "CONDITION"
            },
            {
                "start": 357,
                "end": 368,
                "text": "SMA type II",
                "type": "CONDITION"
            },
            {
                "start": 397,
                "end": 405,
                "text": "SPINRAZA",
                "type": "DRUG"
            },
            {
                "start": 408,
                "end": 418,
                "text": "Nusinersen",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05195606",
        "study_official_title": "The Effect of Auditory and Tactile Stimulus on Consciousness, Oxygen Saturation, and Mean Arterial Pressure in Traumatic Coma Patients: A Randomized Controlled Single-Blind Study ",
        "study_brief_summary": " This study focused on examining the effects of auditory and tactile stimuli to reduce sensory deprivation on consciousness, oxygen saturation and mean arterial pressure in traumatic coma patients.",
        "text": "The Effect of Auditory and Tactile Stimulus on Consciousness, Oxygen Saturation, and Mean Arterial Pressure in Traumatic Coma Patients: A Randomized Controlled Single-Blind Study | This study focused on examining the effects of auditory and tactile stimuli to reduce sensory deprivation on consciousness, oxygen saturation and mean arterial pressure in traumatic coma patients.",
        "tokens": "['The', 'Effect', 'of', 'Auditory', 'and', 'Tactile', 'Stimulus', 'on', 'Consciousness', ',', 'Oxygen', 'Saturation', ',', 'and', 'Mean', 'Arterial', 'Pressure', 'in', 'Traumatic', 'Coma', 'Patients', ':', 'A', 'Randomized', 'Controlled', 'Single', '-', 'Blind', 'Study', '|', 'This', 'study', 'focused', 'on', 'examining', 'the', 'effects', 'of', 'auditory', 'and', 'tactile', 'stimuli', 'to', 'reduce', 'sensory', 'deprivation', 'on', 'consciousness', ',', 'oxygen', 'saturation', 'and', 'mean', 'arterial', 'pressure', 'in', 'traumatic', 'coma', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 43,
                "text": "Auditory and Tactile Stimulus",
                "type": "OTHER"
            },
            {
                "start": 111,
                "end": 125,
                "text": "Traumatic Coma",
                "type": "CONDITION"
            },
            {
                "start": 228,
                "end": 256,
                "text": "auditory and tactile stimuli",
                "type": "OTHER"
            },
            {
                "start": 353,
                "end": 367,
                "text": "traumatic coma",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01279655",
        "study_official_title": "The Influence of a tDCS Combined Long-term Motor Training Program on Structural White Matter Changes in the Brain, Functionality and Psychological Outcome Measures in Multiple Sclerosis. ",
        "study_brief_summary": " In the current study the researchers will firstly investigate whether a bimanual coordination training protocol (20 min/day, for 8 consecutive weeks) correlates with changes in white matter architecture and improved upper-limb functionality in patients with multiple sclerosis. Secondly, the researchers predict that motor learning is more efficient when it is combined with anodal transcranial direct current (tDCS) stimulation on the left primary motor cortex.",
        "text": "The Influence of a tDCS Combined Long-term Motor Training Program on Structural White Matter Changes in the Brain, Functionality and Psychological Outcome Measures in Multiple Sclerosis. | In the current study the researchers will firstly investigate whether a bimanual coordination training protocol (20 min/day, for 8 consecutive weeks) correlates with changes in white matter architecture and improved upper-limb functionality in patients with multiple sclerosis. Secondly, the researchers predict that motor learning is more efficient when it is combined with anodal transcranial direct current (tDCS) stimulation on the left primary motor cortex.",
        "tokens": "['The', 'Influence', 'of', 'a', 'tDCS', 'Combined', 'Long', '-', 'term', 'Motor', 'Training', 'Program', 'on', 'Structural', 'White', 'Matter', 'Changes', 'in', 'the', 'Brain', ',', 'Functionality', 'and', 'Psychological', 'Outcome', 'Measures', 'in', 'Multiple', 'Sclerosis', '.', '|', 'In', 'the', 'current', 'study', 'the', 'researchers', 'will', 'firstly', 'investigate', 'whether', 'a', 'bimanual', 'coordination', 'training', 'protocol', '(', '20', 'min', '/', 'day', ',', 'for', '8', 'consecutive', 'weeks', ')', 'correlates', 'with', 'changes', 'in', 'white', 'matter', 'architecture', 'and', 'improved', 'upper', '-', 'limb', 'functionality', 'in', 'patients', 'with', 'multiple', 'sclerosis', '.', 'Secondly', ',', 'the', 'researchers', 'predict', 'that', 'motor', 'learning', 'is', 'more', 'efficient', 'when', 'it', 'is', 'combined', 'with', 'anodal', 'transcranial', 'direct', 'current', '(', 'tDCS', ')', 'stimulation', 'on', 'the', 'left', 'primary', 'motor', 'cortex', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 19,
                "end": 23,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 33,
                "end": 57,
                "text": "Long-term Motor Training",
                "type": "PHYSICAL"
            },
            {
                "start": 167,
                "end": 185,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 291,
                "text": "bimanual coordination training",
                "type": "PHYSICAL"
            },
            {
                "start": 447,
                "end": 465,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 564,
                "end": 598,
                "text": "anodal transcranial direct current",
                "type": "OTHER"
            },
            {
                "start": 600,
                "end": 604,
                "text": "tDCS",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05468801",
        "study_official_title": "Randomized, Triple-blind, Placebo Controlled Study to Evaluate the Efficacy of Individualized Homeopathic Remedies With High Grade of Pathological Similarity vs Conventional Standardized Pharmacological Treatment in Patients With Migraine. ",
        "study_brief_summary": " Migraine, a chronic and often lifelong neurological disorder, is the second leading cause of years lived with disability worldwide. To reduce this global burden, concerted efforts are needed to implement and improve migraine health-care policies. Several observational studies showed significant improvement of different headaches types with homeopathy. The purpose of this study is the assessment of the efficacy of Individualized Homeopathic Remedies (specific remedies for each patient) versus Conventional pharmacological treatment in patients with migraine.",
        "text": "Randomized, Triple-blind, Placebo Controlled Study to Evaluate the Efficacy of Individualized Homeopathic Remedies With High Grade of Pathological Similarity vs Conventional Standardized Pharmacological Treatment in Patients With Migraine. | Migraine, a chronic and often lifelong neurological disorder, is the second leading cause of years lived with disability worldwide. To reduce this global burden, concerted efforts are needed to implement and improve migraine health-care policies. Several observational studies showed significant improvement of different headaches types with homeopathy. The purpose of this study is the assessment of the efficacy of Individualized Homeopathic Remedies (specific remedies for each patient) versus Conventional pharmacological treatment in patients with migraine.",
        "tokens": "['Randomized', ',', 'Triple', '-', 'blind', ',', 'Placebo', 'Controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'of', 'Individualized', 'Homeopathic', 'Remedies', 'With', 'High', 'Grade', 'of', 'Pathological', 'Similarity', 'vs', 'Conventional', 'Standardized', 'Pharmacological', 'Treatment', 'in', 'Patients', 'With', 'Migraine', '.', '|', 'Migraine', ',', 'a', 'chronic', 'and', 'often', 'lifelong', 'neurological', 'disorder', ',', 'is', 'the', 'second', 'leading', 'cause', 'of', 'years', 'lived', 'with', 'disability', 'worldwide', '.', 'To', 'reduce', 'this', 'global', 'burden', ',', 'concerted', 'efforts', 'are', 'needed', 'to', 'implement', 'and', 'improve', 'migraine', 'health', '-', 'care', 'policies', '.', 'Several', 'observational', 'studies', 'showed', 'significant', 'improvement', 'of', 'different', 'headaches', 'types', 'with', 'homeopathy', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'the', 'assessment', 'of', 'the', 'efficacy', 'of', 'Individualized', 'Homeopathic', 'Remedies', '(', 'specific', 'remedies', 'for', 'each', 'patient', ')', 'versus', 'Conventional', 'pharmacological', 'treatment', 'in', 'patients', 'with', 'migraine', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 33,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 79,
                "end": 157,
                "text": "Individualized Homeopathic Remedies With High Grade of Pathological Similarity",
                "type": "OTHER"
            },
            {
                "start": 161,
                "end": 212,
                "text": "Conventional Standardized Pharmacological Treatment",
                "type": "CONTROL"
            },
            {
                "start": 230,
                "end": 238,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 250,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 458,
                "end": 466,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 563,
                "end": 572,
                "text": "headaches",
                "type": "CONDITION"
            },
            {
                "start": 584,
                "end": 594,
                "text": "homeopathy",
                "type": "OTHER"
            },
            {
                "start": 659,
                "end": 694,
                "text": "Individualized Homeopathic Remedies",
                "type": "OTHER"
            },
            {
                "start": 739,
                "end": 777,
                "text": "Conventional pharmacological treatment",
                "type": "CONTROL"
            },
            {
                "start": 795,
                "end": 803,
                "text": "migraine",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03598322",
        "study_official_title": "The Volume Effect of Hydrodissection for Injection Therapies in Patients With Carpal Tunnel Syndrome - Evaluation Model by Shear Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis ",
        "study_brief_summary": " The investigators investigated the volume effect of hydrodissection for Injection therapies in patients with Carpal Tunnel Syndrome. The investigators evaluated participants by Shear Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis",
        "text": "The Volume Effect of Hydrodissection for Injection Therapies in Patients With Carpal Tunnel Syndrome - Evaluation Model by Shear Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis | The investigators investigated the volume effect of hydrodissection for Injection therapies in patients with Carpal Tunnel Syndrome. The investigators evaluated participants by Shear Wave Ultrasound Elastography and Artificial Intelligence Imaging Analysis",
        "tokens": "['The', 'Volume', 'Effect', 'of', 'Hydrodissection', 'for', 'Injection', 'Therapies', 'in', 'Patients', 'With', 'Carpal', 'Tunnel', 'Syndrome', '-', 'Evaluation', 'Model', 'by', 'Shear', 'Wave', 'Ultrasound', 'Elastography', 'and', 'Artificial', 'Intelligence', 'Imaging', 'Analysis', '|', 'The', 'investigators', 'investigated', 'the', 'volume', 'effect', 'of', 'hydrodissection', 'for', 'Injection', 'therapies', 'in', 'patients', 'with', 'Carpal', 'Tunnel', 'Syndrome', '.', 'The', 'investigators', 'evaluated', 'participants', 'by', 'Shear', 'Wave', 'Ultrasound', 'Elastography', 'and', 'Artificial', 'Intelligence', 'Imaging', 'Analysis']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 36,
                "text": "Hydrodissection",
                "type": "OTHER"
            },
            {
                "start": 78,
                "end": 100,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 257,
                "end": 272,
                "text": "hydrodissection",
                "type": "OTHER"
            },
            {
                "start": 314,
                "end": 336,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02566720",
        "study_official_title": "Mechanism of Amantadine and Functional Improvement Following Acquired Brain Injury as Measured by MRI Tractography; A Pilot Study ",
        "study_brief_summary": " This is a pilot study. The objective is to further understand the mechanism by which amantadine improves function in patients with persistent vegetative state and minimally conscious state. Specifically, the investigators will measure the size of the nerve fibers that mediate arousal (reticular activating system, or RAS) pre and post treatment on MRI tractography. MRI findings will be correlated with the Disability Rating Scale (DRS) score. The information gathered from this study will be used to formulate a larger clinical trial.",
        "text": "Mechanism of Amantadine and Functional Improvement Following Acquired Brain Injury as Measured by MRI Tractography; A Pilot Study | This is a pilot study. The objective is to further understand the mechanism by which amantadine improves function in patients with persistent vegetative state and minimally conscious state. Specifically, the investigators will measure the size of the nerve fibers that mediate arousal (reticular activating system, or RAS) pre and post treatment on MRI tractography. MRI findings will be correlated with the Disability Rating Scale (DRS) score. The information gathered from this study will be used to formulate a larger clinical trial.",
        "tokens": "['Mechanism', 'of', 'Amantadine', 'and', 'Functional', 'Improvement', 'Following', 'Acquired', 'Brain', 'Injury', 'as', 'Measured', 'by', 'MRI', 'Tractography', ';', 'A', 'Pilot', 'Study', '|', 'This', 'is', 'a', 'pilot', 'study', '.', 'The', 'objective', 'is', 'to', 'further', 'understand', 'the', 'mechanism', 'by', 'which', 'amantadine', 'improves', 'function', 'in', 'patients', 'with', 'persistent', 'vegetative', 'state', 'and', 'minimally', 'conscious', 'state', '.', 'Specifically', ',', 'the', 'investigators', 'will', 'measure', 'the', 'size', 'of', 'the', 'nerve', 'fibers', 'that', 'mediate', 'arousal', '(', 'reticular', 'activating', 'system', ',', 'or', 'RAS', ')', 'pre', 'and', 'post', 'treatment', 'on', 'MRI', 'tractography', '.', 'MRI', 'findings', 'will', 'be', 'correlated', 'with', 'the', 'Disability', 'Rating', 'Scale', '(', 'DRS', ')', 'score', '.', 'The', 'information', 'gathered', 'from', 'this', 'study', 'will', 'be', 'used', 'to', 'formulate', 'a', 'larger', 'clinical', 'trial', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 23,
                "text": "Amantadine",
                "type": "DRUG"
            },
            {
                "start": 61,
                "end": 82,
                "text": "Acquired Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 217,
                "end": 227,
                "text": "amantadine",
                "type": "DRUG"
            },
            {
                "start": 263,
                "end": 290,
                "text": "persistent vegetative state",
                "type": "CONDITION"
            },
            {
                "start": 295,
                "end": 320,
                "text": "minimally conscious state",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05541276",
        "study_official_title": "MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children. The MELA-PAED Trial: a Randomized, Double-blind, Placebo-controlled Trial. ",
        "study_brief_summary": " Postoperative agitation and emergence delirium describe a spectrum of symptoms of early postoperative negative behavior, in which the child experiences a variety of behavioral disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. The symptoms are common with a reported incidence of approximately 25%. Some clinical trials have studied the effect of prophylactic oral melatonin for reducing the risk of emergence agitation in children, some finding a considerable dose-response effect. Melatonin has a low bio-availability of approximately 15 %. The safety of exogenous melatonin for pediatric patients has been studied with no apparent serious adverse effects, even at repeated short-term use of high doses of intravenous melatonin. The aim of this clinical trial is to investigate the prophylactic effects and safety of intravenous melatonin administered intraoperatively for prevention of postopreative agitation and emergence delirium in children after an elective surgical procedure. The study is designed as a randomised, double-blind, placebo-controlled clinical trial.",
        "text": "MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children. The MELA-PAED Trial: a Randomized, Double-blind, Placebo-controlled Trial. | Postoperative agitation and emergence delirium describe a spectrum of symptoms of early postoperative negative behavior, in which the child experiences a variety of behavioral disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. The symptoms are common with a reported incidence of approximately 25%. Some clinical trials have studied the effect of prophylactic oral melatonin for reducing the risk of emergence agitation in children, some finding a considerable dose-response effect. Melatonin has a low bio-availability of approximately 15 %. The safety of exogenous melatonin for pediatric patients has been studied with no apparent serious adverse effects, even at repeated short-term use of high doses of intravenous melatonin. The aim of this clinical trial is to investigate the prophylactic effects and safety of intravenous melatonin administered intraoperatively for prevention of postopreative agitation and emergence delirium in children after an elective surgical procedure. The study is designed as a randomised, double-blind, placebo-controlled clinical trial.",
        "tokens": "['MELAtonin', 'for', 'Prevention', 'of', 'Postoperative', 'Agitation', 'and', 'Emergence', 'Delirium', 'in', 'Children', '.', 'The', 'MELA', '-', 'PAED', 'Trial', ':', 'a', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', '.', '|', 'Postoperative', 'agitation', 'and', 'emergence', 'delirium', 'describe', 'a', 'spectrum', 'of', 'symptoms', 'of', 'early', 'postoperative', 'negative', 'behavior', ',', 'in', 'which', 'the', 'child', 'experiences', 'a', 'variety', 'of', 'behavioral', 'disturbances', 'including', 'crying', ',', 'thrashing', ',', 'and', 'disorientation', 'during', 'early', 'awakening', 'from', 'anaesthesia', '.', 'The', 'symptoms', 'are', 'common', 'with', 'a', 'reported', 'incidence', 'of', 'approximately', '25', '%', '.', 'Some', 'clinical', 'trials', 'have', 'studied', 'the', 'effect', 'of', 'prophylactic', 'oral', 'melatonin', 'for', 'reducing', 'the', 'risk', 'of', 'emergence', 'agitation', 'in', 'children', ',', 'some', 'finding', 'a', 'considerable', 'dose', '-', 'response', 'effect', '.', 'Melatonin', 'has', 'a', 'low', 'bio', '-', 'availability', 'of', 'approximately', '15', '%', '.', 'The', 'safety', 'of', 'exogenous', 'melatonin', 'for', 'pediatric', 'patients', 'has', 'been', 'studied', 'with', 'no', 'apparent', 'serious', 'adverse', 'effects', ',', 'even', 'at', 'repeated', 'short', '-', 'term', 'use', 'of', 'high', 'doses', 'of', 'intravenous', 'melatonin', '.', 'The', 'aim', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'investigate', 'the', 'prophylactic', 'effects', 'and', 'safety', 'of', 'intravenous', 'melatonin', 'administered', 'intraoperatively', 'for', 'prevention', 'of', 'postopreative', 'agitation', 'and', 'emergence', 'delirium', 'in', 'children', 'after', 'an', 'elective', 'surgical', 'procedure', '.', 'The', 'study', 'is', 'designed', 'as', 'a', 'randomised', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'clinical', 'trial', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 9,
                "text": "MELAtonin",
                "type": "DRUG"
            },
            {
                "start": 28,
                "end": 51,
                "text": "Postoperative Agitation",
                "type": "CONDITION"
            },
            {
                "start": 56,
                "end": 74,
                "text": "Emergence Delirium",
                "type": "CONDITION"
            },
            {
                "start": 137,
                "end": 144,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 165,
                "end": 188,
                "text": "Postoperative agitation",
                "type": "CONDITION"
            },
            {
                "start": 193,
                "end": 211,
                "text": "emergence delirium",
                "type": "CONDITION"
            },
            {
                "start": 581,
                "end": 590,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 616,
                "end": 635,
                "text": "emergence agitation",
                "type": "CONDITION"
            },
            {
                "start": 699,
                "end": 708,
                "text": "Melatonin",
                "type": "DRUG"
            },
            {
                "start": 783,
                "end": 792,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 936,
                "end": 945,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 1047,
                "end": 1056,
                "text": "melatonin",
                "type": "DRUG"
            },
            {
                "start": 1105,
                "end": 1128,
                "text": "postopreative agitation",
                "type": "CONDITION"
            },
            {
                "start": 1133,
                "end": 1151,
                "text": "emergence delirium",
                "type": "CONDITION"
            },
            {
                "start": 1255,
                "end": 1262,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03774407",
        "study_official_title": "Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS) ",
        "study_brief_summary": " Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.",
        "text": "Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS) | Study to evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS. The secondary objective is to evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.",
        "tokens": "['Dual', 'Benefits', 'of', 'Vaginal', 'Estriol', ':', 'Improved', 'Urogenital', 'Health', 'and', 'Re', '-', 'myelination', 'in', 'Relapsing', 'Remitting', 'Multiple', 'Sclerosis', '(', 'RRMS', ')', '|', 'Study', 'to', 'evaluate', 'the', 'efficiency', 'of', 'vaginal', 'estriol', ',', 'as', 'a', 'treatment', 'for', 'urogenital', 'symptoms', 'in', 'female', 'patients', 'with', 'RRMS', '.', 'The', 'secondary', 'objective', 'is', 'to', 'evaluate', 'the', 'potential', 'role', 'of', 'vaginal', 'estriol', 'in', 're', '-', 'myelination', 'in', 'RRMS', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 32,
                "text": "Estriol",
                "type": "DRUG"
            },
            {
                "start": 83,
                "end": 121,
                "text": "Relapsing Remitting Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 123,
                "end": 127,
                "text": "RRMS",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 182,
                "text": "estriol",
                "type": "DRUG"
            },
            {
                "start": 247,
                "end": 251,
                "text": "RRMS",
                "type": "CONDITION"
            },
            {
                "start": 322,
                "end": 329,
                "text": "estriol",
                "type": "DRUG"
            },
            {
                "start": 351,
                "end": 355,
                "text": "RRMS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00911261",
        "study_official_title": "An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain ",
        "study_brief_summary": " The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.",
        "text": "An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain | The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.",
        "tokens": "['An', 'Open', '-', 'Label', 'Long', 'Term', 'Effectiveness', 'and', 'Safety', 'Study', 'of', 'Oxymorphone', 'Extended', 'Release', 'Tablets', 'in', 'Patients', 'With', 'Cancer', 'or', 'Neuropathic', 'Pain', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'Oxymorphone', 'Extended', 'Release', 'is', 'effective', 'and', 'safe', 'in', 'treating', 'chronic', 'pain', 'in', 'patients', 'with', 'cancer', 'or', 'neuropathic', 'pain', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 58,
                "end": 69,
                "text": "Oxymorphone",
                "type": "DRUG"
            },
            {
                "start": 112,
                "end": 118,
                "text": "Cancer",
                "type": "CONDITION"
            },
            {
                "start": 122,
                "end": 138,
                "text": "Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 186,
                "end": 197,
                "text": "Oxymorphone",
                "type": "DRUG"
            },
            {
                "start": 249,
                "end": 261,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 285,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 289,
                "end": 305,
                "text": "neuropathic pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02563288",
        "study_official_title": "Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures ",
        "study_brief_summary": " Patients undergoing intracranial procedures may experience severe hypertension and tachycardia due to intracranial hypertension and to increased release of adrenaline. Preventing perioperative sympathetic activity is of great importance. A common technique is using b-blockers like esmolol, which effectively block perioperative hemodynamic changes during intracranial surgery. A2 agonists, like Dexmedetomidine-Dex are now being used as a component of a balanced anesthesia during neurosurgical procedures. This study aimed to evaluate whether esmolol or dex attenuates perioperative changes in patients undergoing elective craniotomy with fast track neuroanesthesia.",
        "text": "Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures | Patients undergoing intracranial procedures may experience severe hypertension and tachycardia due to intracranial hypertension and to increased release of adrenaline. Preventing perioperative sympathetic activity is of great importance. A common technique is using b-blockers like esmolol, which effectively block perioperative hemodynamic changes during intracranial surgery. A2 agonists, like Dexmedetomidine-Dex are now being used as a component of a balanced anesthesia during neurosurgical procedures. This study aimed to evaluate whether esmolol or dex attenuates perioperative changes in patients undergoing elective craniotomy with fast track neuroanesthesia.",
        "tokens": "['Comparison', 'of', 'Esmolol', 'and', 'Dexmedetomidine', 'on', 'Sympathetic', 'Control', 'During', 'Intracranial', 'Procedures', '|', 'Patients', 'undergoing', 'intracranial', 'procedures', 'may', 'experience', 'severe', 'hypertension', 'and', 'tachycardia', 'due', 'to', 'intracranial', 'hypertension', 'and', 'to', 'increased', 'release', 'of', 'adrenaline', '.', 'Preventing', 'perioperative', 'sympathetic', 'activity', 'is', 'of', 'great', 'importance', '.', 'A', 'common', 'technique', 'is', 'using', 'b', '-', 'blockers', 'like', 'esmolol', ',', 'which', 'effectively', 'block', 'perioperative', 'hemodynamic', 'changes', 'during', 'intracranial', 'surgery', '.', 'A2', 'agonists', ',', 'like', 'Dexmedetomidine', '-', 'Dex', 'are', 'now', 'being', 'used', 'as', 'a', 'component', 'of', 'a', 'balanced', 'anesthesia', 'during', 'neurosurgical', 'procedures', '.', 'This', 'study', 'aimed', 'to', 'evaluate', 'whether', 'esmolol', 'or', 'dex', 'attenuates', 'perioperative', 'changes', 'in', 'patients', 'undergoing', 'elective', 'craniotomy', 'with', 'fast', 'track', 'neuroanesthesia', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 21,
                "text": "Esmolol",
                "type": "DRUG"
            },
            {
                "start": 26,
                "end": 41,
                "text": "Dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 72,
                "end": 95,
                "text": "Intracranial Procedures",
                "type": "CONDITION"
            },
            {
                "start": 118,
                "end": 141,
                "text": "intracranial procedures",
                "type": "CONDITION"
            },
            {
                "start": 164,
                "end": 176,
                "text": "hypertension",
                "type": "CONDITION"
            },
            {
                "start": 181,
                "end": 192,
                "text": "tachycardia",
                "type": "CONDITION"
            },
            {
                "start": 200,
                "end": 225,
                "text": "intracranial hypertension",
                "type": "CONDITION"
            },
            {
                "start": 364,
                "end": 374,
                "text": "b-blockers",
                "type": "DRUG"
            },
            {
                "start": 380,
                "end": 387,
                "text": "esmolol",
                "type": "DRUG"
            },
            {
                "start": 476,
                "end": 487,
                "text": "A2 agonists",
                "type": "DRUG"
            },
            {
                "start": 494,
                "end": 509,
                "text": "Dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 510,
                "end": 513,
                "text": "Dex",
                "type": "DRUG"
            },
            {
                "start": 643,
                "end": 650,
                "text": "esmolol",
                "type": "DRUG"
            },
            {
                "start": 654,
                "end": 657,
                "text": "dex",
                "type": "DRUG"
            },
            {
                "start": 714,
                "end": 733,
                "text": "elective craniotomy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01418352",
        "study_official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder ",
        "study_brief_summary": " The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.",
        "text": "A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder | The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.",
        "tokens": "['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'Evaluating', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Fixed', '-', 'Dose', 'Once', '-', 'weekly', 'Oral', 'Aripiprazole', 'in', 'Children', 'and', 'Adolescents', 'With', 'Tourette', \"'s\", 'Disorder', '|', 'The', 'goal', 'of', 'the', 'current', 'trial', 'is', 'to', 'determine', 'efficacy', 'and', 'safety', 'of', 'once', '-', 'weekly', 'aripiprazole', 'in', 'reducing', 'Total', 'Tic', 'Severity', '(', 'TTS', ')', 'score', 'in', 'children', 'and', 'adolescents', 'with', 'Tourette', \"'s\", 'Disorder', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 48,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 132,
                "end": 144,
                "text": "Aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 178,
                "end": 197,
                "text": "Tourette's Disorder",
                "type": "CONDITION"
            },
            {
                "start": 281,
                "end": 293,
                "text": "aripiprazole",
                "type": "DRUG"
            },
            {
                "start": 370,
                "end": 389,
                "text": "Tourette's Disorder",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01059877",
        "study_official_title": "Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial. ",
        "study_brief_summary": " This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.",
        "text": "Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial. | This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.",
        "tokens": "['Assessing', 'the', 'Effect', 'of', '1072', 'nm', 'Infrared', '(', 'IR', ')', 'Phototherapy', 'on', 'the', 'Behavioral', 'and', 'Cognitive', 'Symptoms', 'Associated', 'With', 'Early', 'and', 'Mid', '-', 'stage', 'Dementia', ':', 'a', 'Randomized', 'Placebo', '-', 'controlled', 'Clinical', 'Trial', '.', '|', 'This', 'study', 'will', 'employ', 'a', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'approach', 'to', 'assess', 'the', 'effect', 'of', '1072', 'nm', 'infrared', '(', 'IR', ')', 'phototherapy', 'on', 'the', 'behavioral', 'and', 'cognitive', 'symptoms', 'associated', 'with', 'early', 'and', 'mid', '-', 'stage', 'dementia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 57,
                "text": "1072nm Infrared (IR) Phototherapy",
                "type": "OTHER"
            },
            {
                "start": 115,
                "end": 144,
                "text": "Early and Mid-stage Dementia:",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 241,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 286,
                "end": 319,
                "text": "1072nm infrared (IR) phototherapy",
                "type": "OTHER"
            },
            {
                "start": 377,
                "end": 405,
                "text": "early and mid-stage dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04897347",
        "study_official_title": "Postural Control Intervention With the Robotic Trunk-Support-Trainer (TruST) in Children With Cerebral Palsy: A Randomized Controlled Trial ",
        "study_brief_summary": " The purpose of this study is to test the efficacy of a motor learning-based postural and reaching control intervention delivered with the robotic Trunk-Support-Trainer (TruST) compared to the same motor learning-based intervention delivered with Static Trunk Support Equipment in children with cerebral palsy (CP) classified as III and IV with the Gross Motor Function Classification System (GMFCS).",
        "text": "Postural Control Intervention With the Robotic Trunk-Support-Trainer (TruST) in Children With Cerebral Palsy: A Randomized Controlled Trial | The purpose of this study is to test the efficacy of a motor learning-based postural and reaching control intervention delivered with the robotic Trunk-Support-Trainer (TruST) compared to the same motor learning-based intervention delivered with Static Trunk Support Equipment in children with cerebral palsy (CP) classified as III and IV with the Gross Motor Function Classification System (GMFCS).",
        "tokens": "['Postural', 'Control', 'Intervention', 'With', 'the', 'Robotic', 'Trunk', '-', 'Support', '-', 'Trainer', '(', 'TruST', ')', 'in', 'Children', 'With', 'Cerebral', 'Palsy', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'efficacy', 'of', 'a', 'motor', 'learning', '-', 'based', 'postural', 'and', 'reaching', 'control', 'intervention', 'delivered', 'with', 'the', 'robotic', 'Trunk', '-', 'Support', '-', 'Trainer', '(', 'TruST', ')', 'compared', 'to', 'the', 'same', 'motor', 'learning', '-', 'based', 'intervention', 'delivered', 'with', 'Static', 'Trunk', 'Support', 'Equipment', 'in', 'children', 'with', 'cerebral', 'palsy', '(', 'CP', ')', 'classified', 'as', 'III', 'and', 'IV', 'with', 'the', 'Gross', 'Motor', 'Function', 'Classification', 'System', '(', 'GMFCS', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 39,
                "end": 68,
                "text": "Robotic Trunk-Support-Trainer",
                "type": "PHYSICAL"
            },
            {
                "start": 70,
                "end": 75,
                "text": "TruST",
                "type": "PHYSICAL"
            },
            {
                "start": 94,
                "end": 108,
                "text": "Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 197,
                "end": 260,
                "text": "motor learning-based postural and reaching control intervention",
                "type": "PHYSICAL"
            },
            {
                "start": 288,
                "end": 309,
                "text": "Trunk-Support-Trainer",
                "type": "PHYSICAL"
            },
            {
                "start": 311,
                "end": 316,
                "text": "TruST",
                "type": "PHYSICAL"
            },
            {
                "start": 339,
                "end": 372,
                "text": "motor learning-based intervention",
                "type": "PHYSICAL"
            },
            {
                "start": 388,
                "end": 418,
                "text": "Static Trunk Support Equipment",
                "type": "PHYSICAL"
            },
            {
                "start": 436,
                "end": 450,
                "text": "cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 452,
                "end": 454,
                "text": "CP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02029547",
        "study_official_title": "Evaluation of Computer-Based Training to Educate Japanese Physicians in the Methods of Interpreting Florbetapir (18F) PET Scans ",
        "study_brief_summary": " This study is designed to validate the Japanese electronic florbetapir (18F) interpretation training program intended for post-approval implementation in Japan.",
        "text": "Evaluation of Computer-Based Training to Educate Japanese Physicians in the Methods of Interpreting Florbetapir (18F) PET Scans | This study is designed to validate the Japanese electronic florbetapir (18F) interpretation training program intended for post-approval implementation in Japan.",
        "tokens": "['Evaluation', 'of', 'Computer', '-', 'Based', 'Training', 'to', 'Educate', 'Japanese', 'Physicians', 'in', 'the', 'Methods', 'of', 'Interpreting', 'Florbetapir', '(', '18F', ')', 'PET', 'Scans', '|', 'This', 'study', 'is', 'designed', 'to', 'validate', 'the', 'Japanese', 'electronic', 'florbetapir', '(', '18F', ')', 'interpretation', 'training', 'program', 'intended', 'for', 'post', '-', 'approval', 'implementation', 'in', 'Japan', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 37,
                "text": "Computer-Based Training",
                "type": "OTHER"
            },
            {
                "start": 76,
                "end": 127,
                "text": "Methods of Interpreting Florbetapir (18F) PET Scans",
                "type": "OTHER"
            },
            {
                "start": 178,
                "end": 238,
                "text": "electronic florbetapir (18F) interpretation training program",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01148810",
        "study_official_title": "A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis ",
        "study_brief_summary": " This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or corticosteroid therapy. The study consisted of a 12 week, randomized, placebo controlled period, followed by another 12 weeks where all subjects received BAF312 treatment.",
        "text": "A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis | This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or corticosteroid therapy. The study consisted of a 12 week, randomized, placebo controlled period, followed by another 12 weeks where all subjects received BAF312 treatment.",
        "tokens": "['A', 'Multi', '-', 'centre', ',', 'Double', '-', 'blind', ',', 'Placebo', 'Controlled', ',', 'Proof', 'of', 'Concept', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Tolerability', 'of', 'BAF312', 'in', 'Patients', 'With', 'Polymyositis', 'and', 'Dermatomyositis', '|', 'This', 'study', 'determined', 'the', 'efficacy', ',', 'safety', ',', 'tolerability', 'and', 'the', 'PK', 'profile', 'of', 'BAF312', ',', 'a', 'novel', 'immunomodulator', ',', 'in', 'polymyositis', 'and', 'dermatomyositis', 'patients', 'who', 'were', 'not', 'responsive', 'to', 'traditional', 'immunosuppressive', 'and/or', 'corticosteroid', 'therapy', '.', 'The', 'study', 'consisted', 'of', 'a', '12', 'week', ',', 'randomized', ',', 'placebo', 'controlled', 'period', ',', 'followed', 'by', 'another', '12', 'weeks', 'where', 'all', 'subjects', 'received', 'BAF312', 'treatment', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 37,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 118,
                "end": 124,
                "text": "BAF312",
                "type": "DRUG"
            },
            {
                "start": 142,
                "end": 154,
                "text": "Polymyositis",
                "type": "CONDITION"
            },
            {
                "start": 159,
                "end": 174,
                "text": "Dermatomyositis",
                "type": "CONDITION"
            },
            {
                "start": 256,
                "end": 262,
                "text": "BAF312",
                "type": "DRUG"
            },
            {
                "start": 292,
                "end": 304,
                "text": "polymyositis",
                "type": "CONDITION"
            },
            {
                "start": 309,
                "end": 324,
                "text": "dermatomyositis",
                "type": "CONDITION"
            },
            {
                "start": 468,
                "end": 475,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 552,
                "end": 558,
                "text": "BAF312",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02729766",
        "study_official_title": "Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study ",
        "study_brief_summary": " Empagliflozin (Jardiance)\u00ae is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2. The SGLT2 is expressed in the proximal tubule and reabsorbs approximately 90 percent of the filtered glucose. The inhibition of SGLT2 results in renal excretion of glucose with subsequent osmotic diuresis. This mechanism could result in a therapeutic effect in patients with hypotonic hyponatremia as in the syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIAD). Because patients with SIAD usually have several comorbidities and different medications, studies investigating the physiological effects are difficult to interpret. Therefore a model to study the possible physiological effect of SGLT2-inhibitors in hypotonic hyponatremia as in SIAD is needed.\n\nThe aim of this study is to evaluate whether empagliflozin (Jardiance)\u00ae has an effect on serum sodium levels of healthy volunteers with induced hypotonic hyponatremia.",
        "text": "Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study | Empagliflozin (Jardiance)\u00ae is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2. The SGLT2 is expressed in the proximal tubule and reabsorbs approximately 90 percent of the filtered glucose. The inhibition of SGLT2 results in renal excretion of glucose with subsequent osmotic diuresis. This mechanism could result in a therapeutic effect in patients with hypotonic hyponatremia as in the syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIAD). Because patients with SIAD usually have several comorbidities and different medications, studies investigating the physiological effects are difficult to interpret. Therefore a model to study the possible physiological effect of SGLT2-inhibitors in hypotonic hyponatremia as in SIAD is needed.\n\nThe aim of this study is to evaluate whether empagliflozin (Jardiance)\u00ae has an effect on serum sodium levels of healthy volunteers with induced hypotonic hyponatremia.",
        "tokens": "['Effects', 'of', 'Empagliflozin', 'an', 'SGLT2', '-', 'Inhibitor', 'on', 'Healthy', 'Volunteers', 'With', 'Induced', 'Hypotonic', 'Hyponatremia', '-', 'the', 'DIVE', 'Study', '|', 'Empagliflozin', '(', 'Jardiance', ')', '\u00ae', 'is', 'a', 'sodium', 'glucose', 'co', '-', 'transporter', '2', '(', 'SGLT2)-Inhibitor', ',', 'which', 'is', 'a', 'new', 'treatment', 'option', 'developed', 'for', 'patients', 'with', 'diabetes', 'mellitus', 'type', '2', '.', 'The', 'SGLT2', 'is', 'expressed', 'in', 'the', 'proximal', 'tubule', 'and', 'reabsorbs', 'approximately', '90', 'percent', 'of', 'the', 'filtered', 'glucose', '.', 'The', 'inhibition', 'of', 'SGLT2', 'results', 'in', 'renal', 'excretion', 'of', 'glucose', 'with', 'subsequent', 'osmotic', 'diuresis', '.', 'This', 'mechanism', 'could', 'result', 'in', 'a', 'therapeutic', 'effect', 'in', 'patients', 'with', 'hypotonic', 'hyponatremia', 'as', 'in', 'the', 'syndrome', 'of', 'inappropriate', 'antidiuretic', 'hormone', '(', 'ADH', ')', 'secretion', '(', 'SIAD', ')', '.', 'Because', 'patients', 'with', 'SIAD', 'usually', 'have', 'several', 'comorbidities', 'and', 'different', 'medications', ',', 'studies', 'investigating', 'the', 'physiological', 'effects', 'are', 'difficult', 'to', 'interpret', '.', 'Therefore', 'a', 'model', 'to', 'study', 'the', 'possible', 'physiological', 'effect', 'of', 'SGLT2', '-', 'inhibitors', 'in', 'hypotonic', 'hyponatremia', 'as', 'in', 'SIAD', 'is', 'needed', '.', '\\n\\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'empagliflozin', '(', 'Jardiance', ')', '\u00ae', 'has', 'an', 'effect', 'on', 'serum', 'sodium', 'levels', 'of', 'healthy', 'volunteers', 'with', 'induced', 'hypotonic', 'hyponatremia', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 24,
                "text": "Empagliflozin",
                "type": "DRUG"
            },
            {
                "start": 28,
                "end": 43,
                "text": "SGLT2-Inhibitor",
                "type": "DRUG"
            },
            {
                "start": 79,
                "end": 101,
                "text": "Hypotonic Hyponatremia",
                "type": "CONDITION"
            },
            {
                "start": 121,
                "end": 134,
                "text": "Empagliflozin",
                "type": "DRUG"
            },
            {
                "start": 136,
                "end": 145,
                "text": "Jardiance",
                "type": "DRUG"
            },
            {
                "start": 153,
                "end": 202,
                "text": "sodium glucose co-transporter 2 (SGLT2)-Inhibitor",
                "type": "DRUG"
            },
            {
                "start": 565,
                "end": 587,
                "text": "hypotonic hyponatremia",
                "type": "CONDITION"
            },
            {
                "start": 898,
                "end": 914,
                "text": "SGLT2-inhibitors",
                "type": "DRUG"
            },
            {
                "start": 918,
                "end": 940,
                "text": "hypotonic hyponatremia",
                "type": "CONDITION"
            },
            {
                "start": 1009,
                "end": 1022,
                "text": "empagliflozin",
                "type": "DRUG"
            },
            {
                "start": 1024,
                "end": 1033,
                "text": "Jardiance",
                "type": "DRUG"
            },
            {
                "start": 1108,
                "end": 1130,
                "text": "hypotonic hyponatremia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00780806",
        "study_official_title": "An Open-Label Safety And Blood Collection Study In Mnb Rlp2086 Vaccinated Healthy Adult Volunteers For Immunological Assay Development ",
        "study_brief_summary": " The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.",
        "text": "An Open-Label Safety And Blood Collection Study In Mnb Rlp2086 Vaccinated Healthy Adult Volunteers For Immunological Assay Development | The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.",
        "tokens": "['An', 'Open', '-', 'Label', 'Safety', 'And', 'Blood', 'Collection', 'Study', 'In', 'Mnb', 'Rlp2086', 'Vaccinated', 'Healthy', 'Adult', 'Volunteers', 'For', 'Immunological', 'Assay', 'Development', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'of', 'an', 'investigational', 'meningococcal', 'B', 'rLP2086', 'vaccine', 'in', 'adults', 'and', 'to', 'obtain', 'blood', 'samples', 'from', 'immunized', 'subjects', 'for', 'use', 'in', 'assay', 'development', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 51,
                "end": 62,
                "text": "Mnb Rlp2086",
                "type": "DRUG"
            },
            {
                "start": 211,
                "end": 242,
                "text": "meningococcal B rLP2086 vaccine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00120588",
        "study_official_title": "Effect of Magnesium Sulfate on the Incidence of Periventricular Leukomalacia in the Very Preterm Neonate ",
        "study_brief_summary": " Magnesium is neuroprotective in neonatal animal models of acquired hypoxic-ischemic and/or inflammatory cerebral lesions. It is associated with a significant reduction of perinatal death and cerebral palsy in some observational studies.\n\nThe objective of the study is to assess if prenatal magnesium sulfate given to women at risk of preterm birth before 33 week's gestation is neuroprotective.",
        "text": "Effect of Magnesium Sulfate on the Incidence of Periventricular Leukomalacia in the Very Preterm Neonate | Magnesium is neuroprotective in neonatal animal models of acquired hypoxic-ischemic and/or inflammatory cerebral lesions. It is associated with a significant reduction of perinatal death and cerebral palsy in some observational studies.\n\nThe objective of the study is to assess if prenatal magnesium sulfate given to women at risk of preterm birth before 33 week's gestation is neuroprotective.",
        "tokens": "['Effect', 'of', 'Magnesium', 'Sulfate', 'on', 'the', 'Incidence', 'of', 'Periventricular', 'Leukomalacia', 'in', 'the', 'Very', 'Preterm', 'Neonate', '|', 'Magnesium', 'is', 'neuroprotective', 'in', 'neonatal', 'animal', 'models', 'of', 'acquired', 'hypoxic', '-', 'ischemic', 'and/or', 'inflammatory', 'cerebral', 'lesions', '.', 'It', 'is', 'associated', 'with', 'a', 'significant', 'reduction', 'of', 'perinatal', 'death', 'and', 'cerebral', 'palsy', 'in', 'some', 'observational', 'studies', '.', '\\n\\n', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'assess', 'if', 'prenatal', 'magnesium', 'sulfate', 'given', 'to', 'women', 'at', 'risk', 'of', 'preterm', 'birth', 'before', '33', 'week', \"'s\", 'gestation', 'is', 'neuroprotective', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 27,
                "text": "Magnesium Sulfate",
                "type": "DRUG"
            },
            {
                "start": 48,
                "end": 76,
                "text": "Periventricular Leukomalacia",
                "type": "CONDITION"
            },
            {
                "start": 89,
                "end": 96,
                "text": "Preterm",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 116,
                "text": "Magnesium",
                "type": "DRUG"
            },
            {
                "start": 397,
                "end": 414,
                "text": "magnesium sulfate",
                "type": "DRUG"
            },
            {
                "start": 441,
                "end": 454,
                "text": "preterm birth",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00197509",
        "study_official_title": "Task Specific Training for Stroke Patients ",
        "study_brief_summary": " The purpose of this study is to see if providing training using a Sit-to-Stand protocol for residents of Long-Term Care Facilities who have had a stroke will increase their independence in performing Sit-to-Stand.",
        "text": "Task Specific Training for Stroke Patients | The purpose of this study is to see if providing training using a Sit-to-Stand protocol for residents of Long-Term Care Facilities who have had a stroke will increase their independence in performing Sit-to-Stand.",
        "tokens": "['Task', 'Specific', 'Training', 'for', 'Stroke', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'see', 'if', 'providing', 'training', 'using', 'a', 'Sit', '-', 'to', '-', 'Stand', 'protocol', 'for', 'residents', 'of', 'Long', '-', 'Term', 'Care', 'Facilities', 'who', 'have', 'had', 'a', 'stroke', 'will', 'increase', 'their', 'independence', 'in', 'performing', 'Sit', '-', 'to', '-', 'Stand', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "Task Specific Training",
                "type": "PHYSICAL"
            },
            {
                "start": 27,
                "end": 33,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 111,
                "end": 132,
                "text": "Sit-to-Stand protocol",
                "type": "PHYSICAL"
            },
            {
                "start": 191,
                "end": 197,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 257,
                "text": "Sit-to-Stand",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT01866384",
        "study_official_title": "Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage ",
        "study_brief_summary": " Early hematoma growth (HG) after spontaneous intra-cerebral/intra-parenchymal hemorrhage (IPH) is common and associated with neurological deterioration and poor clinical outcome. Temperature modulation to hypothermia (Temperature, 32-34\u00b0C) has been associated with reduction or improvement of physiopathologic processes associated with inflammatory activation and degradation of blood-brain barrier after all types of brain injury. In this sense, we believe that the initiation of an ultra-early protocol of active temperature modulation or Targeted Temperature Management (TTM) to mild induced hypothermia (MIH, 32-34\u00b0C) may be associated with good safety and tolerability profile, less HG and cerebral edema after IPH by modulation of systemic and local inflammatory responses, so we hypothesize that TTM to MIH will be a safe/tolerable and effective therapy to limit HG and cerebral edema after IPH.",
        "text": "Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage | Early hematoma growth (HG) after spontaneous intra-cerebral/intra-parenchymal hemorrhage (IPH) is common and associated with neurological deterioration and poor clinical outcome. Temperature modulation to hypothermia (Temperature, 32-34\u00b0C) has been associated with reduction or improvement of physiopathologic processes associated with inflammatory activation and degradation of blood-brain barrier after all types of brain injury. In this sense, we believe that the initiation of an ultra-early protocol of active temperature modulation or Targeted Temperature Management (TTM) to mild induced hypothermia (MIH, 32-34\u00b0C) may be associated with good safety and tolerability profile, less HG and cerebral edema after IPH by modulation of systemic and local inflammatory responses, so we hypothesize that TTM to MIH will be a safe/tolerable and effective therapy to limit HG and cerebral edema after IPH.",
        "tokens": "['Safety', 'and', 'Tolerability', 'of', 'a', 'Protocol', 'of', 'Targeted', 'Temperature', 'Management', 'After', 'Intracerebral', 'Hemorrhage', '|', 'Early', 'hematoma', 'growth', '(', 'HG', ')', 'after', 'spontaneous', 'intra', '-', 'cerebral', '/', 'intra', '-', 'parenchymal', 'hemorrhage', '(', 'IPH', ')', 'is', 'common', 'and', 'associated', 'with', 'neurological', 'deterioration', 'and', 'poor', 'clinical', 'outcome', '.', 'Temperature', 'modulation', 'to', 'hypothermia', '(', 'Temperature', ',', '32', '-', '34', '\u00b0', 'C', ')', 'has', 'been', 'associated', 'with', 'reduction', 'or', 'improvement', 'of', 'physiopathologic', 'processes', 'associated', 'with', 'inflammatory', 'activation', 'and', 'degradation', 'of', 'blood', '-', 'brain', 'barrier', 'after', 'all', 'types', 'of', 'brain', 'injury', '.', 'In', 'this', 'sense', ',', 'we', 'believe', 'that', 'the', 'initiation', 'of', 'an', 'ultra', '-', 'early', 'protocol', 'of', 'active', 'temperature', 'modulation', 'or', 'Targeted', 'Temperature', 'Management', '(', 'TTM', ')', 'to', 'mild', 'induced', 'hypothermia', '(', 'MIH', ',', '32', '-', '34', '\u00b0', 'C', ')', 'may', 'be', 'associated', 'with', 'good', 'safety', 'and', 'tolerability', 'profile', ',', 'less', 'HG', 'and', 'cerebral', 'edema', 'after', 'IPH', 'by', 'modulation', 'of', 'systemic', 'and', 'local', 'inflammatory', 'responses', ',', 'so', 'we', 'hypothesize', 'that', 'TTM', 'to', 'MIH', 'will', 'be', 'a', 'safe', '/', 'tolerable', 'and', 'effective', 'therapy', 'to', 'limit', 'HG', 'and', 'cerebral', 'edema', 'after', 'IPH', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 72,
                "text": "Targeted Temperature Management",
                "type": "OTHER"
            },
            {
                "start": 79,
                "end": 103,
                "text": "Intracerebral Hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 106,
                "end": 127,
                "text": "Early hematoma growth",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 131,
                "text": "HG",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 194,
                "text": "spontaneous intra-cerebral/intra-parenchymal hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 196,
                "end": 199,
                "text": "IPH",
                "type": "CONDITION"
            },
            {
                "start": 285,
                "end": 307,
                "text": "Temperature modulation",
                "type": "OTHER"
            },
            {
                "start": 311,
                "end": 322,
                "text": "hypothermia",
                "type": "OTHER"
            },
            {
                "start": 647,
                "end": 678,
                "text": "Targeted Temperature Management",
                "type": "OTHER"
            },
            {
                "start": 680,
                "end": 683,
                "text": "TTM",
                "type": "OTHER"
            },
            {
                "start": 688,
                "end": 712,
                "text": "mild induced hypothermia",
                "type": "OTHER"
            },
            {
                "start": 714,
                "end": 717,
                "text": "MIH",
                "type": "OTHER"
            },
            {
                "start": 794,
                "end": 796,
                "text": "HG",
                "type": "CONDITION"
            },
            {
                "start": 801,
                "end": 815,
                "text": "cerebral edema",
                "type": "CONDITION"
            },
            {
                "start": 822,
                "end": 825,
                "text": "IPH",
                "type": "CONDITION"
            },
            {
                "start": 909,
                "end": 912,
                "text": "TTM",
                "type": "OTHER"
            },
            {
                "start": 916,
                "end": 919,
                "text": "MIH",
                "type": "OTHER"
            },
            {
                "start": 976,
                "end": 978,
                "text": "HG",
                "type": "CONDITION"
            },
            {
                "start": 983,
                "end": 997,
                "text": "cerebral edema",
                "type": "CONDITION"
            },
            {
                "start": 1004,
                "end": 1007,
                "text": "IPH",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02798601",
        "study_official_title": "Early Induced Hypernatremia for the Prevention and Management of Brain Edema in Patients With Severe Traumatic Brain Injury in a University Hospital ",
        "study_brief_summary": " The purpose of this study is to estimate the effect of an early induced hypernatremia protocol (150-155 milliequivalent/L) versus normonatremia plus mannitol (135 - 145 milliequivalent/L) in terms of neurologic outcome in patients with severe traumatic brain injury managed at critical care unit.",
        "text": "Early Induced Hypernatremia for the Prevention and Management of Brain Edema in Patients With Severe Traumatic Brain Injury in a University Hospital | The purpose of this study is to estimate the effect of an early induced hypernatremia protocol (150-155 milliequivalent/L) versus normonatremia plus mannitol (135 - 145 milliequivalent/L) in terms of neurologic outcome in patients with severe traumatic brain injury managed at critical care unit.",
        "tokens": "['Early', 'Induced', 'Hypernatremia', 'for', 'the', 'Prevention', 'and', 'Management', 'of', 'Brain', 'Edema', 'in', 'Patients', 'With', 'Severe', 'Traumatic', 'Brain', 'Injury', 'in', 'a', 'University', 'Hospital', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'estimate', 'the', 'effect', 'of', 'an', 'early', 'induced', 'hypernatremia', 'protocol', '(', '150', '-', '155', 'milliequivalent', '/', 'L', ')', 'versus', 'normonatremia', 'plus', 'mannitol', '(', '135', '-', '145', 'milliequivalent', '/', 'L', ')', 'in', 'terms', 'of', 'neurologic', 'outcome', 'in', 'patients', 'with', 'severe', 'traumatic', 'brain', 'injury', 'managed', 'at', 'critical', 'care', 'unit', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 27,
                "text": "Early Induced Hypernatremia",
                "type": "OTHER"
            },
            {
                "start": 65,
                "end": 76,
                "text": "Brain Edema",
                "type": "CONDITION"
            },
            {
                "start": 94,
                "end": 123,
                "text": "Severe Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 236,
                "text": "early induced hypernatremia",
                "type": "OTHER"
            },
            {
                "start": 281,
                "end": 294,
                "text": "normonatremia",
                "type": "OTHER"
            },
            {
                "start": 300,
                "end": 308,
                "text": "mannitol",
                "type": "DRUG"
            },
            {
                "start": 387,
                "end": 416,
                "text": "severe traumatic brain injury",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04842955",
        "study_official_title": "Interventional Cross-over Study to Evaluate the Modulators of Efficacy of Alternating Current Brain Stimulation (tACS) in Patients With Alzheimer's Disease ",
        "study_brief_summary": " Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as \"oscillopathies\". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.\n\nTranscranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory. On the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.\n\nIn this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate the modulators of response on cognitive measure to a single stimulation with gamma tACS on the posterior parietal cortex in patients with Mild Cognitive Impairment due to Alzheimer's disease.",
        "text": "Interventional Cross-over Study to Evaluate the Modulators of Efficacy of Alternating Current Brain Stimulation (tACS) in Patients With Alzheimer's Disease | Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as \"oscillopathies\". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.\n\nTranscranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory. On the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.\n\nIn this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate the modulators of response on cognitive measure to a single stimulation with gamma tACS on the posterior parietal cortex in patients with Mild Cognitive Impairment due to Alzheimer's disease.",
        "tokens": "['Interventional', 'Cross', '-', 'over', 'Study', 'to', 'Evaluate', 'the', 'Modulators', 'of', 'Efficacy', 'of', 'Alternating', 'Current', 'Brain', 'Stimulation', '(', 'tACS', ')', 'in', 'Patients', 'With', 'Alzheimer', \"'s\", 'Disease', '|', 'Brain', 'oscillations', 'are', 'ubiquitous', 'in', 'the', 'human', 'brain', 'and', 'have', 'been', 'implicated', 'in', 'cognitive', 'and', 'behavioral', 'states', 'defined', 'in', 'precisely', 'tuned', 'neural', 'networks', '.', 'In', 'neurodegenerative', 'disorders', ',', 'neurodegeneration', 'is', 'accompanied', 'by', 'changes', 'in', 'oscillatory', 'activity', 'leading', 'to', 'the', 'emerging', 'concept', 'of', 'neurological', 'and', 'psychiatric', 'disorders', 'as', '\"', 'oscillopathies', '\"', '.', 'Alzheimer', \"'s\", 'disease', ',', 'which', 'accounts', 'for', 'the', 'vast', 'majority', 'of', 'age', '-', 'related', 'dementias', ',', 'is', 'characterised', 'by', 'a', 'prominent', 'disruption', 'of', 'oscillations', 'in', 'the', 'gamma', 'frequency', 'band', '.', 'The', 'restoration', 'of', 'gamma', 'oscillations', 'by', 'neural', 'entrainment', 'in', 'animal', 'models', 'of', 'Alzheimer', \"'s\", 'disease', 'have', 'shown', 'a', 'remarkable', 'decrease', 'in', 'the', 'pathological', 'burden', 'of', 'amyloid', 'and', 'tau', 'via', 'increased', 'microglial', 'activity', ',', 'resulting', 'in', 'a', 'significant', 'increase', 'of', 'cognitive', 'performances', '.', '\\n\\n', 'Transcranial', 'alternating', 'current', 'brain', 'stimulation', '(', 'tACS', ')', ',', 'is', 'a', 'neurophysiological', 'method', 'of', 'non', '-', 'invasive', 'modulation', 'of', 'the', 'excitability', 'of', 'the', 'central', 'nervous', 'system', 'that', 'is', 'having', 'an', 'increasingly', 'numerous', 'spectrum', 'of', 'potential', 'therapeutic', 'applications', '.', 'Recent', 'studies', 'have', 'demonstrated', 'the', 'effectiveness', 'of', 'this', 'method', 'in', 'modulating', 'the', 'natural', 'frequencies', 'of', 'cerebral', 'oscillation', ',', 'underlying', 'multiple', 'cognitive', 'processes', 'such', 'as', 'verbal', 'memory', ',', 'perception', 'and', 'working', 'memory', '.', 'On', 'the', 'basis', 'of', 'these', 'premises', ',', 'the', 'treatment', 'with', 'gamma', 'tACS', 'is', 'proposed', 'in', 'patients', 'affected', 'by', 'Alzheimer', \"'s\", 'disease', '.', '\\n\\n', 'In', 'this', 'randomized', ',', 'double', '-', 'blind', ',', 'sham', '-', 'controlled', ',', 'cross', '-', 'over', 'study', ',', 'the', 'investigators', 'will', 'evaluate', 'the', 'modulators', 'of', 'response', 'on', 'cognitive', 'measure', 'to', 'a', 'single', 'stimulation', 'with', 'gamma', 'tACS', 'on', 'the', 'posterior', 'parietal', 'cortex', 'in', 'patients', 'with', 'Mild', 'Cognitive', 'Impairment', 'due', 'to', 'Alzheimer', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 74,
                "end": 111,
                "text": "Alternating Current Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 113,
                "end": 117,
                "text": "tACS",
                "type": "OTHER"
            },
            {
                "start": 136,
                "end": 155,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 510,
                "end": 529,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 583,
                "end": 592,
                "text": "dementias",
                "type": "CONDITION"
            },
            {
                "start": 762,
                "end": 781,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 960,
                "end": 1010,
                "text": "Transcranial alternating current brain stimulation",
                "type": "OTHER"
            },
            {
                "start": 1012,
                "end": 1016,
                "text": "tACS",
                "type": "OTHER"
            },
            {
                "start": 1495,
                "end": 1499,
                "text": "tACS",
                "type": "OTHER"
            },
            {
                "start": 1536,
                "end": 1555,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 1592,
                "end": 1596,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 1736,
                "end": 1779,
                "text": "gamma tACS on the posterior parietal cortex",
                "type": "OTHER"
            },
            {
                "start": 1797,
                "end": 1822,
                "text": "Mild Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 1830,
                "end": 1849,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03299335",
        "study_official_title": "Molecular Profile of the Evolution of Inclusion Body Myositis ",
        "study_brief_summary": " This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of control subject. The investigators use the RNA-seq technique to analyze the gene expression levels and potential alternate transcripts, including long non-coding RNAs (lncRNAs), in muscle tissue samples. The gene expression profiles will point to the genes of interest that can then become the object of future studies, in which epigenetic changes of these genes will be explored further. The value of those possible biomarkers will be assessed. The investigators will also evaluate the correlation between the gene expression profile, the degree of functional impairment, the histological picture and the presence or absence of autoantibodies.",
        "text": "Molecular Profile of the Evolution of Inclusion Body Myositis | This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of control subject. The investigators use the RNA-seq technique to analyze the gene expression levels and potential alternate transcripts, including long non-coding RNAs (lncRNAs), in muscle tissue samples. The gene expression profiles will point to the genes of interest that can then become the object of future studies, in which epigenetic changes of these genes will be explored further. The value of those possible biomarkers will be assessed. The investigators will also evaluate the correlation between the gene expression profile, the degree of functional impairment, the histological picture and the presence or absence of autoantibodies.",
        "tokens": "['Molecular', 'Profile', 'of', 'the', 'Evolution', 'of', 'Inclusion', 'Body', 'Myositis', '|', 'This', 'study', 'aims', 'at', 'assessing', 'the', 'gene', 'expression', 'in', 'the', 'muscles', 'of', 'patients', 'suffering', 'from', 'sporadic', 'Inclusion', 'Body', 'Myositis', '(', 'sIBM', ')', 'at', 'various', 'stages', 'of', 'the', 'disease', ',', 'by', 'comparison', 'with', 'muscles', 'of', 'control', 'subject', '.', 'The', 'investigators', 'use', 'the', 'RNA', '-', 'seq', 'technique', 'to', 'analyze', 'the', 'gene', 'expression', 'levels', 'and', 'potential', 'alternate', 'transcripts', ',', 'including', 'long', 'non', '-', 'coding', 'RNAs', '(', 'lncRNAs', ')', ',', 'in', 'muscle', 'tissue', 'samples', '.', 'The', 'gene', 'expression', 'profiles', 'will', 'point', 'to', 'the', 'genes', 'of', 'interest', 'that', 'can', 'then', 'become', 'the', 'object', 'of', 'future', 'studies', ',', 'in', 'which', 'epigenetic', 'changes', 'of', 'these', 'genes', 'will', 'be', 'explored', 'further', '.', 'The', 'value', 'of', 'those', 'possible', 'biomarkers', 'will', 'be', 'assessed', '.', 'The', 'investigators', 'will', 'also', 'evaluate', 'the', 'correlation', 'between', 'the', 'gene', 'expression', 'profile', ',', 'the', 'degree', 'of', 'functional', 'impairment', ',', 'the', 'histological', 'picture', 'and', 'the', 'presence', 'or', 'absence', 'of', 'autoantibodies', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 38,
                "end": 61,
                "text": "Inclusion Body Myositis",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 187,
                "text": "sporadic Inclusion Body Myositis",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 193,
                "text": "sIBM",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04446416",
        "study_official_title": "An Open Label, Prospective, Pilot Study to Evaluate the Efficacy and Safety of Best Physician's Choice of Standard of Care Combined With NaviFUS System in Patients With Recurrent Glioblastoma Multiforme ",
        "study_brief_summary": " This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients. The BEV is the best physician's choice of standard of care for rGBM after prior radiotherapy and temozolomide chemotherapy in the LinKou Chang Gung Memorial Hospital. Eligible patients will be enrolled through the process of informed consent.",
        "text": "An Open Label, Prospective, Pilot Study to Evaluate the Efficacy and Safety of Best Physician's Choice of Standard of Care Combined With NaviFUS System in Patients With Recurrent Glioblastoma Multiforme | This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients. The BEV is the best physician's choice of standard of care for rGBM after prior radiotherapy and temozolomide chemotherapy in the LinKou Chang Gung Memorial Hospital. Eligible patients will be enrolled through the process of informed consent.",
        "tokens": "['An', 'Open', 'Label', ',', 'Prospective', ',', 'Pilot', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Best', 'Physician', \"'s\", 'Choice', 'of', 'Standard', 'of', 'Care', 'Combined', 'With', 'NaviFUS', 'System', 'in', 'Patients', 'With', 'Recurrent', 'Glioblastoma', 'Multiforme', '|', 'This', 'is', 'a', 'prospective', ',', 'single', '-', 'arm', ',', 'two', 'stages', ',', 'open', '-', 'label', ',', 'pilot', 'study', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'FUS', 'add', '-', 'on', 'bevacizumab', '(', 'BEV', ')', 'in', 'rGBM', 'patients', '.', 'The', 'BEV', 'is', 'the', 'best', 'physician', \"'s\", 'choice', 'of', 'standard', 'of', 'care', 'for', 'rGBM', 'after', 'prior', 'radiotherapy', 'and', 'temozolomide', 'chemotherapy', 'in', 'the', 'LinKou', 'Chang', 'Gung', 'Memorial', 'Hospital', '.', 'Eligible', 'patients', 'will', 'be', 'enrolled', 'through', 'the', 'process', 'of', 'informed', 'consent', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-RADIO', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 137,
                "end": 151,
                "text": "NaviFUS System",
                "type": "OTHER"
            },
            {
                "start": 169,
                "end": 202,
                "text": "Recurrent Glioblastoma Multiforme",
                "type": "CONDITION"
            },
            {
                "start": 318,
                "end": 328,
                "text": "FUS add-on",
                "type": "OTHER"
            },
            {
                "start": 329,
                "end": 340,
                "text": "bevacizumab",
                "type": "DRUG"
            },
            {
                "start": 342,
                "end": 345,
                "text": "BEV",
                "type": "DRUG"
            },
            {
                "start": 350,
                "end": 354,
                "text": "rGBM",
                "type": "CONDITION"
            },
            {
                "start": 369,
                "end": 372,
                "text": "BEV",
                "type": "DRUG"
            },
            {
                "start": 428,
                "end": 432,
                "text": "rGBM",
                "type": "CONDITION"
            },
            {
                "start": 445,
                "end": 457,
                "text": "radiotherapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 462,
                "end": 474,
                "text": "temozolomide",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT01621737",
        "study_official_title": "Antipsychotic Effects of Oxytocin ",
        "study_brief_summary": " The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with antipsychotic medication.",
        "text": "Antipsychotic Effects of Oxytocin | The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with antipsychotic medication.",
        "tokens": "['Antipsychotic', 'Effects', 'of', 'Oxytocin', '|', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'intranasal', 'oxytocin', 'versus', 'intranasal', 'placebo', 'to', 'improve', 'symptoms', 'in', 'schizophrenia', 'patients', 'who', 'have', 'residual', 'symptoms', 'despite', 'being', 'on', 'adequate', 'treatment', 'with', 'antipsychotic', 'medication', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 33,
                "text": "Oxytocin",
                "type": "DRUG"
            },
            {
                "start": 104,
                "end": 112,
                "text": "oxytocin",
                "type": "DRUG"
            },
            {
                "start": 131,
                "end": 138,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 162,
                "end": 175,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05269017",
        "study_official_title": "The Potential Therapeutic Effect of Vitamin D Nasal Drops in the Treatment of Post COVID-19 Parosmia ",
        "study_brief_summary": " The current study will be a pilot study for a randomized controlled trial conducted on patients recruited from the outpatient clinic of the Otorhinolaryngology Department, Menoufia Faculty of Medicine To evaluate the effect of vitamin D nasal drops in the treatment of post COVID 19 parosmia",
        "text": "The Potential Therapeutic Effect of Vitamin D Nasal Drops in the Treatment of Post COVID-19 Parosmia | The current study will be a pilot study for a randomized controlled trial conducted on patients recruited from the outpatient clinic of the Otorhinolaryngology Department, Menoufia Faculty of Medicine To evaluate the effect of vitamin D nasal drops in the treatment of post COVID 19 parosmia",
        "tokens": "['The', 'Potential', 'Therapeutic', 'Effect', 'of', 'Vitamin', 'D', 'Nasal', 'Drops', 'in', 'the', 'Treatment', 'of', 'Post', 'COVID-19', 'Parosmia', '|', 'The', 'current', 'study', 'will', 'be', 'a', 'pilot', 'study', 'for', 'a', 'randomized', 'controlled', 'trial', 'conducted', 'on', 'patients', 'recruited', 'from', 'the', 'outpatient', 'clinic', 'of', 'the', 'Otorhinolaryngology', 'Department', ',', 'Menoufia', 'Faculty', 'of', 'Medicine', 'To', 'evaluate', 'the', 'effect', 'of', 'vitamin', 'D', 'nasal', 'drops', 'in', 'the', 'treatment', 'of', 'post', 'COVID', '19', 'parosmia']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 36,
                "end": 45,
                "text": "Vitamin D",
                "type": "DRUG"
            },
            {
                "start": 78,
                "end": 100,
                "text": "Post COVID-19 Parosmia",
                "type": "CONDITION"
            },
            {
                "start": 330,
                "end": 339,
                "text": "vitamin D",
                "type": "DRUG"
            },
            {
                "start": 372,
                "end": 394,
                "text": "post COVID 19 parosmia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00537940",
        "study_official_title": "A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures. ",
        "study_brief_summary": " To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.",
        "text": "A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures. | To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Parallel', '-', 'group', 'Multi', '-', 'center', 'Comparative', 'Flexible', '-', 'dose', 'Trial', 'Of', 'Pregabalin', 'Versus', 'Gabapentin', 'As', 'Adjunctive', 'Therapy', 'In', 'Subjects', 'With', 'Partial', 'Seizures', '.', '|', 'To', 'compare', 'the', 'efficacy', 'of', 'pregabalin', 'and', 'gabapentin', ',', 'as', 'adjunctive', 'therapy', 'in', 'subjects', 'with', 'partial', 'seizures', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 91,
                "end": 101,
                "text": "Pregabalin",
                "type": "DRUG"
            },
            {
                "start": 109,
                "end": 119,
                "text": "Gabapentin",
                "type": "DRUG"
            },
            {
                "start": 159,
                "end": 175,
                "text": "Partial Seizures",
                "type": "CONDITION"
            },
            {
                "start": 206,
                "end": 216,
                "text": "pregabalin",
                "type": "DRUG"
            },
            {
                "start": 221,
                "end": 231,
                "text": "gabapentin",
                "type": "DRUG"
            },
            {
                "start": 272,
                "end": 288,
                "text": "partial seizures",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05352373",
        "study_official_title": "The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome ",
        "study_brief_summary": " Randomized, placebo-controlled trial of oral calcium supplementation for osteopenia in girls and women with Rett syndrome",
        "text": "The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome | Randomized, placebo-controlled trial of oral calcium supplementation for osteopenia in girls and women with Rett syndrome",
        "tokens": "['The', 'Role', 'of', 'Dietary', 'Calcium', 'for', 'the', 'Treatment', 'of', 'Osteopenia', 'in', 'Girls', 'With', 'Rett', 'Syndrome', '|', 'Randomized', ',', 'placebo', '-', 'controlled', 'trial', 'of', 'oral', 'calcium', 'supplementation', 'for', 'osteopenia', 'in', 'girls', 'and', 'women', 'with', 'Rett', 'syndrome']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",
        "entities": [
            {
                "start": 20,
                "end": 27,
                "text": "Calcium",
                "type": "DRUG"
            },
            {
                "start": 49,
                "end": 59,
                "text": "Osteopenia",
                "type": "CONDITION"
            },
            {
                "start": 74,
                "end": 87,
                "text": "Rett Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 102,
                "end": 109,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 135,
                "end": 142,
                "text": "calcium",
                "type": "DRUG"
            },
            {
                "start": 163,
                "end": 173,
                "text": "osteopenia",
                "type": "CONDITION"
            },
            {
                "start": 198,
                "end": 211,
                "text": "Rett syndrome",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05596799",
        "study_official_title": "Facing Eating Disorder Fears for Anorexia Nervosa: A Virtual Relapse Prevention Program Targeted at Approach and Avoidance Behaviors ",
        "study_brief_summary": " FED-F is a modular treatment that enhances exposure therapy with psychoeducation and cognitive skills teaching how to face fears of (a) food, (b) weight gain, (c) interoception/body, and (d) social situations. The study goals are to (1) refine and test the acceptability and feasibility of FED-F treatment (Phase I), (2) test if this treatment outperforms treatment as usual (TAU) delivered post-acute treatment as adjunctive to stepdown specialty care (Phase II), and (3) to examine if treatment targets the hypothesized mechanism of action: approach behaviors (Phase II). These goals will lead to a highly deployable and accessible virtual treatment targeted at core AN mechanisms that predict relapse. Specific aims are to (1) refine FED-F into a fully virtual format with input from patients and stakeholders and collect preliminary data (N=10) on its feasibility and acceptability (Phase I), (2) conduct a small pilot RCT (randomized controlled trial) of FED-F (n=30) as compared to TAU (n=30; Phase II), and (3) examine if FED-F targets approach/avoidance behaviors and test if this mechanism is associated with clinical outcomes (Phase II).",
        "text": "Facing Eating Disorder Fears for Anorexia Nervosa: A Virtual Relapse Prevention Program Targeted at Approach and Avoidance Behaviors | FED-F is a modular treatment that enhances exposure therapy with psychoeducation and cognitive skills teaching how to face fears of (a) food, (b) weight gain, (c) interoception/body, and (d) social situations. The study goals are to (1) refine and test the acceptability and feasibility of FED-F treatment (Phase I), (2) test if this treatment outperforms treatment as usual (TAU) delivered post-acute treatment as adjunctive to stepdown specialty care (Phase II), and (3) to examine if treatment targets the hypothesized mechanism of action: approach behaviors (Phase II). These goals will lead to a highly deployable and accessible virtual treatment targeted at core AN mechanisms that predict relapse. Specific aims are to (1) refine FED-F into a fully virtual format with input from patients and stakeholders and collect preliminary data (N=10) on its feasibility and acceptability (Phase I), (2) conduct a small pilot RCT (randomized controlled trial) of FED-F (n=30) as compared to TAU (n=30; Phase II), and (3) examine if FED-F targets approach/avoidance behaviors and test if this mechanism is associated with clinical outcomes (Phase II).",
        "tokens": "['Facing', 'Eating', 'Disorder', 'Fears', 'for', 'Anorexia', 'Nervosa', ':', 'A', 'Virtual', 'Relapse', 'Prevention', 'Program', 'Targeted', 'at', 'Approach', 'and', 'Avoidance', 'Behaviors', '|', 'FED', '-', 'F', 'is', 'a', 'modular', 'treatment', 'that', 'enhances', 'exposure', 'therapy', 'with', 'psychoeducation', 'and', 'cognitive', 'skills', 'teaching', 'how', 'to', 'face', 'fears', 'of', '(', 'a', ')', 'food', ',', '(', 'b', ')', 'weight', 'gain', ',', '(', 'c', ')', 'interoception', '/', 'body', ',', 'and', '(', 'd', ')', 'social', 'situations', '.', 'The', 'study', 'goals', 'are', 'to', '(', '1', ')', 'refine', 'and', 'test', 'the', 'acceptability', 'and', 'feasibility', 'of', 'FED', '-', 'F', 'treatment', '(', 'Phase', 'I', ')', ',', '(', '2', ')', 'test', 'if', 'this', 'treatment', 'outperforms', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'delivered', 'post', '-', 'acute', 'treatment', 'as', 'adjunctive', 'to', 'stepdown', 'specialty', 'care', '(', 'Phase', 'II', ')', ',', 'and', '(', '3', ')', 'to', 'examine', 'if', 'treatment', 'targets', 'the', 'hypothesized', 'mechanism', 'of', 'action', ':', 'approach', 'behaviors', '(', 'Phase', 'II', ')', '.', 'These', 'goals', 'will', 'lead', 'to', 'a', 'highly', 'deployable', 'and', 'accessible', 'virtual', 'treatment', 'targeted', 'at', 'core', 'AN', 'mechanisms', 'that', 'predict', 'relapse', '.', 'Specific', 'aims', 'are', 'to', '(', '1', ')', 'refine', 'FED', '-', 'F', 'into', 'a', 'fully', 'virtual', 'format', 'with', 'input', 'from', 'patients', 'and', 'stakeholders', 'and', 'collect', 'preliminary', 'data', '(', 'N=10', ')', 'on', 'its', 'feasibility', 'and', 'acceptability', '(', 'Phase', 'I', ')', ',', '(', '2', ')', 'conduct', 'a', 'small', 'pilot', 'RCT', '(', 'randomized', 'controlled', 'trial', ')', 'of', 'FED', '-', 'F', '(', 'n=30', ')', 'as', 'compared', 'to', 'TAU', '(', 'n=30', ';', 'Phase', 'II', ')', ',', 'and', '(', '3', ')', 'examine', 'if', 'FED', '-', 'F', 'targets', 'approach', '/', 'avoidance', 'behaviors', 'and', 'test', 'if', 'this', 'mechanism', 'is', 'associated', 'with', 'clinical', 'outcomes', '(', 'Phase', 'II', ')', '.']",
        "token_bio_labels": "['O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 7,
                "end": 28,
                "text": "Eating Disorder Fears",
                "type": "CONDITION"
            },
            {
                "start": 33,
                "end": 49,
                "text": "Anorexia Nervosa",
                "type": "CONDITION"
            },
            {
                "start": 53,
                "end": 87,
                "text": "Virtual Relapse Prevention Program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 135,
                "end": 140,
                "text": "FED-F",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 258,
                "end": 263,
                "text": "fears",
                "type": "CONDITION"
            },
            {
                "start": 425,
                "end": 440,
                "text": "FED-F treatment",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 491,
                "end": 509,
                "text": "treatment as usual",
                "type": "CONTROL"
            },
            {
                "start": 511,
                "end": 514,
                "text": "TAU",
                "type": "CONTROL"
            },
            {
                "start": 804,
                "end": 806,
                "text": "AN",
                "type": "CONDITION"
            },
            {
                "start": 872,
                "end": 877,
                "text": "FED-F",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1095,
                "end": 1100,
                "text": "FED-F",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1123,
                "end": 1126,
                "text": "TAU",
                "type": "CONTROL"
            },
            {
                "start": 1164,
                "end": 1169,
                "text": "FED-F",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT02572206",
        "study_official_title": "Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers ",
        "study_brief_summary": " The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related /mTOR kinase pathway dysregulation.",
        "text": "Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers | The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related /mTOR kinase pathway dysregulation.",
        "tokens": "['Demonstration', 'of', 'mGluR5', 'Overexpression', 'in', 'Amish', 'and', 'Mennonite', 'CNTNAP2', 'Mutation', 'Carriers', '|', 'The', 'primary', 'goal', 'of', 'the', 'present', 'study', 'is', 'to', 'evaluate', 'the', 'utility', 'of', 'mGluR5', 'binding', 'as', 'measured', 'by', 'PET', 'as', 'a', 'biomarker', 'of', 'the', 'CNTNAP2', 'mutation', 'and', 'related', '/mTOR', 'kinase', 'pathway', 'dysregulation', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 62,
                "end": 78,
                "text": "CNTNAP2 Mutation",
                "type": "CONDITION"
            },
            {
                "start": 214,
                "end": 230,
                "text": "CNTNAP2 mutation",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04202770",
        "study_official_title": "Focused Ultrasound Delivery of Exosomes for Treatment of Refractory Depression, Anxiety, and Neurodegenerative Dementias ",
        "study_brief_summary": " This study is designed to evaluate the safety and efficacy of exosome deployment with concurrent transcranial ultrasound in patients with refractory, treatment resistant depression, anxiety, and neurodegenerative dementia.",
        "text": "Focused Ultrasound Delivery of Exosomes for Treatment of Refractory Depression, Anxiety, and Neurodegenerative Dementias | This study is designed to evaluate the safety and efficacy of exosome deployment with concurrent transcranial ultrasound in patients with refractory, treatment resistant depression, anxiety, and neurodegenerative dementia.",
        "tokens": "['Focused', 'Ultrasound', 'Delivery', 'of', 'Exosomes', 'for', 'Treatment', 'of', 'Refractory', 'Depression', ',', 'Anxiety', ',', 'and', 'Neurodegenerative', 'Dementias', '|', 'This', 'study', 'is', 'designed', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'exosome', 'deployment', 'with', 'concurrent', 'transcranial', 'ultrasound', 'in', 'patients', 'with', 'refractory', ',', 'treatment', 'resistant', 'depression', ',', 'anxiety', ',', 'and', 'neurodegenerative', 'dementia', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 39,
                "text": "Focused Ultrasound Delivery of Exosomes",
                "type": "OTHER"
            },
            {
                "start": 57,
                "end": 78,
                "text": "Refractory Depression",
                "type": "CONDITION"
            },
            {
                "start": 80,
                "end": 87,
                "text": "Anxiety",
                "type": "CONDITION"
            },
            {
                "start": 93,
                "end": 120,
                "text": "Neurodegenerative Dementias",
                "type": "CONDITION"
            },
            {
                "start": 185,
                "end": 192,
                "text": "exosome",
                "type": "OTHER"
            },
            {
                "start": 220,
                "end": 243,
                "text": "transcranial ultrasound",
                "type": "OTHER"
            },
            {
                "start": 261,
                "end": 303,
                "text": "refractory, treatment resistant depression",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 312,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 318,
                "end": 344,
                "text": "neurodegenerative dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00468897",
        "study_official_title": "An Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg Manufactured at Two Different Sites in Healthy Volunteers in Fasting Conditions ",
        "study_brief_summary": " The present pharmacokinetic study is designed to compare bioavailability and assess bioequivalence of two Rosiglitazone XR formulations produced at two different sites.Both formulations will be tested in fasting healthy volunteers",
        "text": "An Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg Manufactured at Two Different Sites in Healthy Volunteers in Fasting Conditions | The present pharmacokinetic study is designed to compare bioavailability and assess bioequivalence of two Rosiglitazone XR formulations produced at two different sites.Both formulations will be tested in fasting healthy volunteers",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Randomized', ',', 'Two', '-', 'Period', 'Crossover', 'Study', 'to', 'Demonstrate', 'the', 'Bioequivalence', 'of', 'a', 'Tablet', 'Formulation', 'of', 'Rosiglitazone', 'XR', '(', 'BRL-049653', ')', '8', 'mg', 'Manufactured', 'at', 'Two', 'Different', 'Sites', 'in', 'Healthy', 'Volunteers', 'in', 'Fasting', 'Conditions', '|', 'The', 'present', 'pharmacokinetic', 'study', 'is', 'designed', 'to', 'compare', 'bioavailability', 'and', 'assess', 'bioequivalence', 'of', 'two', 'Rosiglitazone', 'XR', 'formulations', 'produced', 'at', 'two', 'different', 'sites', '.', 'Both', 'formulations', 'will', 'be', 'tested', 'in', 'fasting', 'healthy', 'volunteers']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 115,
                "end": 128,
                "text": "Rosiglitazone",
                "type": "DRUG"
            },
            {
                "start": 133,
                "end": 143,
                "text": "BRL-049653",
                "type": "DRUG"
            },
            {
                "start": 337,
                "end": 350,
                "text": "Rosiglitazone",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00755521",
        "study_official_title": "Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures ",
        "study_brief_summary": " The main of the proposed study is to assess whether the use of the Cox-2 inhibitor Etoricoxib is beneficial for the use in fibromyalgia. We intend to seek whether this medication may improve psychiatric and rheumatologic parameters of the disease.",
        "text": "Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures | The main of the proposed study is to assess whether the use of the Cox-2 inhibitor Etoricoxib is beneficial for the use in fibromyalgia. We intend to seek whether this medication may improve psychiatric and rheumatologic parameters of the disease.",
        "tokens": "['Study', 'Proposal', '-', 'A', 'Randomized', 'Double', '-', 'blinded', 'Study', 'Comparing', 'Adding', 'Etoricoxib', 'Versus', 'Placebo', 'to', 'Female', 'Patients', 'With', 'Fibromyalgia', '-', 'analysis', 'of', 'Organic', 'and', 'Psychiatric', 'Measures', '|', 'The', 'main', 'of', 'the', 'proposed', 'study', 'is', 'to', 'assess', 'whether', 'the', 'use', 'of', 'the', 'Cox-2', 'inhibitor', 'Etoricoxib', 'is', 'beneficial', 'for', 'the', 'use', 'in', 'fibromyalgia', '.', 'We', 'intend', 'to', 'seek', 'whether', 'this', 'medication', 'may', 'improve', 'psychiatric', 'and', 'rheumatologic', 'parameters', 'of', 'the', 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 68,
                "end": 78,
                "text": "Etoricoxib",
                "type": "DRUG"
            },
            {
                "start": 86,
                "end": 93,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 118,
                "end": 130,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 271,
                "text": "Etoricoxib",
                "type": "DRUG"
            },
            {
                "start": 301,
                "end": 313,
                "text": "fibromyalgia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00252239",
        "study_official_title": "Phase 2B Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B) ",
        "study_brief_summary": " The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA).",
        "text": "Phase 2B Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B) | The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA).",
        "tokens": "['Phase', '2B', 'Study', 'of', 'Tenecteplase', '(', 'TNK', ')', 'in', 'Acute', 'Ischemic', 'Stroke', '(', 'TNK', '-', 'S2B', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'which', 'of', '3', 'different', 'doses', 'of', 'tenecteplase', '(', 'TNK', ')', 'is', 'better', 'for', 'treating', 'stroke', 'patients', 'and', 'if', 'TNK', 'offers', 'an', 'advantage', 'over', 'currently', 'available', 'treatment', 'with', 'tissue', 'plasminogen', 'activator', '(', 'tPA', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 30,
                "text": "Tenecteplase",
                "type": "DRUG"
            },
            {
                "start": 32,
                "end": 35,
                "text": "TNK",
                "type": "DRUG"
            },
            {
                "start": 40,
                "end": 61,
                "text": "Acute Ischemic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 158,
                "text": "tenecteplase",
                "type": "DRUG"
            },
            {
                "start": 160,
                "end": 163,
                "text": "TNK",
                "type": "DRUG"
            },
            {
                "start": 188,
                "end": 194,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 211,
                "end": 214,
                "text": "TNK",
                "type": "DRUG"
            },
            {
                "start": 275,
                "end": 303,
                "text": "tissue plasminogen activator",
                "type": "CONTROL"
            },
            {
                "start": 305,
                "end": 308,
                "text": "tPA",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04328142",
        "study_official_title": "Effectiveness of Qigong vs. Physiotherapy to Improve Quality of Life of Women With Fibromyalgia: A Randomized Controlled Trial ",
        "study_brief_summary": " This study analyze the effectiveness of a Physiotherapy treatment versus a Qigong exercise programme improving quality of life of subjects with Fibromyalgia.",
        "text": "Effectiveness of Qigong vs. Physiotherapy to Improve Quality of Life of Women With Fibromyalgia: A Randomized Controlled Trial | This study analyze the effectiveness of a Physiotherapy treatment versus a Qigong exercise programme improving quality of life of subjects with Fibromyalgia.",
        "tokens": "['Effectiveness', 'of', 'Qigong', 'vs.', 'Physiotherapy', 'to', 'Improve', 'Quality', 'of', 'Life', 'of', 'Women', 'With', 'Fibromyalgia', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'analyze', 'the', 'effectiveness', 'of', 'a', 'Physiotherapy', 'treatment', 'versus', 'a', 'Qigong', 'exercise', 'programme', 'improving', 'quality', 'of', 'life', 'of', 'subjects', 'with', 'Fibromyalgia', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 23,
                "text": "Qigong",
                "type": "PHYSICAL"
            },
            {
                "start": 28,
                "end": 41,
                "text": "Physiotherapy",
                "type": "PHYSICAL"
            },
            {
                "start": 83,
                "end": 95,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 171,
                "end": 184,
                "text": "Physiotherapy",
                "type": "PHYSICAL"
            },
            {
                "start": 204,
                "end": 210,
                "text": "Qigong",
                "type": "PHYSICAL"
            },
            {
                "start": 273,
                "end": 285,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05823857",
        "study_official_title": "Effect of Aquatic Exercise on Paraspinal and Gluteal Morphology and Function in Patients With Chronic Low Back Pain ",
        "study_brief_summary": " The goal of this pilot randomized controlled trial is to compare the effects of aquatic therapy versus standard care on paraspinal and gluteal morphology and function in individuals with chronic low back pain.The main questions it aims to answer are:\n\nWhat are the effects of aquatic therapy versus standard care on a) paraspinal and gluteal muscle size, composition (e.g., fatty infiltration) and b) lumbar and gluteal muscle strength in individuals with chronic LBP?\nIs aquatic therapy more effective than standard care to improve pain, function and psychological factors (e.g., kinesiophobia, catastrophizing, anxiety, and depression)?\nIs using a digital application \"play the pain\" feasible to monitor pain levels and the activities that participants used to cope with pain?\n\nParticipants will be assigned to either the aquatic therapy group or standard care group where they will undergo a 10-week intervention including two 60-minute session per week.",
        "text": "Effect of Aquatic Exercise on Paraspinal and Gluteal Morphology and Function in Patients With Chronic Low Back Pain | The goal of this pilot randomized controlled trial is to compare the effects of aquatic therapy versus standard care on paraspinal and gluteal morphology and function in individuals with chronic low back pain.The main questions it aims to answer are:\n\nWhat are the effects of aquatic therapy versus standard care on a) paraspinal and gluteal muscle size, composition (e.g., fatty infiltration) and b) lumbar and gluteal muscle strength in individuals with chronic LBP?\nIs aquatic therapy more effective than standard care to improve pain, function and psychological factors (e.g., kinesiophobia, catastrophizing, anxiety, and depression)?\nIs using a digital application \"play the pain\" feasible to monitor pain levels and the activities that participants used to cope with pain?\n\nParticipants will be assigned to either the aquatic therapy group or standard care group where they will undergo a 10-week intervention including two 60-minute session per week.",
        "tokens": "['Effect', 'of', 'Aquatic', 'Exercise', 'on', 'Paraspinal', 'and', 'Gluteal', 'Morphology', 'and', 'Function', 'in', 'Patients', 'With', 'Chronic', 'Low', 'Back', 'Pain', '|', 'The', 'goal', 'of', 'this', 'pilot', 'randomized', 'controlled', 'trial', 'is', 'to', 'compare', 'the', 'effects', 'of', 'aquatic', 'therapy', 'versus', 'standard', 'care', 'on', 'paraspinal', 'and', 'gluteal', 'morphology', 'and', 'function', 'in', 'individuals', 'with', 'chronic', 'low', 'back', 'pain', '.', 'The', 'main', 'questions', 'it', 'aims', 'to', 'answer', 'are', ':', '\\n\\n', 'What', 'are', 'the', 'effects', 'of', 'aquatic', 'therapy', 'versus', 'standard', 'care', 'on', 'a', ')', 'paraspinal', 'and', 'gluteal', 'muscle', 'size', ',', 'composition', '(', 'e.g.', ',', 'fatty', 'infiltration', ')', 'and', 'b', ')', 'lumbar', 'and', 'gluteal', 'muscle', 'strength', 'in', 'individuals', 'with', 'chronic', 'LBP', '?', '\\n', 'Is', 'aquatic', 'therapy', 'more', 'effective', 'than', 'standard', 'care', 'to', 'improve', 'pain', ',', 'function', 'and', 'psychological', 'factors', '(', 'e.g.', ',', 'kinesiophobia', ',', 'catastrophizing', ',', 'anxiety', ',', 'and', 'depression', ')', '?', '\\n', 'Is', 'using', 'a', 'digital', 'application', '\"', 'play', 'the', 'pain', '\"', 'feasible', 'to', 'monitor', 'pain', 'levels', 'and', 'the', 'activities', 'that', 'participants', 'used', 'to', 'cope', 'with', 'pain', '?', '\\n\\n', 'Participants', 'will', 'be', 'assigned', 'to', 'either', 'the', 'aquatic', 'therapy', 'group', 'or', 'standard', 'care', 'group', 'where', 'they', 'will', 'undergo', 'a', '10', '-', 'week', 'intervention', 'including', 'two', '60', '-', 'minute', 'session', 'per', 'week', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 26,
                "text": "Aquatic Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 94,
                "end": 115,
                "text": "Chronic Low Back Pain",
                "type": "CONDITION"
            },
            {
                "start": 198,
                "end": 213,
                "text": "aquatic therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 221,
                "end": 234,
                "text": "standard care",
                "type": "CONTROL"
            },
            {
                "start": 305,
                "end": 326,
                "text": "chronic low back pain",
                "type": "CONDITION"
            },
            {
                "start": 394,
                "end": 409,
                "text": "aquatic therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 574,
                "end": 585,
                "text": "chronic LBP",
                "type": "CONDITION"
            },
            {
                "start": 590,
                "end": 605,
                "text": "aquatic therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 626,
                "end": 639,
                "text": "standard care",
                "type": "CONTROL"
            },
            {
                "start": 651,
                "end": 655,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 699,
                "end": 712,
                "text": "kinesiophobia",
                "type": "CONDITION"
            },
            {
                "start": 714,
                "end": 729,
                "text": "catastrophizing",
                "type": "CONDITION"
            },
            {
                "start": 731,
                "end": 738,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 744,
                "end": 754,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 768,
                "end": 803,
                "text": "digital application \"play the pain\"",
                "type": "OTHER"
            },
            {
                "start": 824,
                "end": 828,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 891,
                "end": 895,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 942,
                "end": 957,
                "text": "aquatic therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 967,
                "end": 980,
                "text": "standard care",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00413946",
        "study_official_title": "Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants ",
        "study_brief_summary": " The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age.\n\nThis study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.",
        "text": "Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants | The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age.\n\nThis study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.",
        "tokens": "['Neuroprotective', 'Effect', 'of', 'High', 'Dose', 'Erythropoietin', 'in', 'Very', 'Preterm', 'Infants', '|', 'The', 'main', 'goal', 'of', 'this', 'trial', 'is', 'to', 'investigate', 'whether', 'early', 'administration', 'of', 'human', 'erythropoietin', '(', 'EPO', ')', 'in', 'very', 'preterm', 'infants', 'improves', 'neurodevelopmental', 'outcome', 'at', '24', 'months', 'corrected', 'age', '.', '\\n\\n', 'This', 'study', 'is', 'designed', 'as', 'randomized', ',', 'double', '-', 'masked', ',', 'placebo', 'controlled', 'multicenter', 'study', 'involving', 'at', 'least', '420', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 36,
                "end": 50,
                "text": "Erythropoietin",
                "type": "DRUG"
            },
            {
                "start": 59,
                "end": 66,
                "text": "Preterm",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 175,
                "text": "erythropoietin",
                "type": "DRUG"
            },
            {
                "start": 177,
                "end": 180,
                "text": "EPO",
                "type": "DRUG"
            },
            {
                "start": 190,
                "end": 197,
                "text": "preterm",
                "type": "CONDITION"
            },
            {
                "start": 324,
                "end": 331,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03242148",
        "study_official_title": "The Evaluation of the Toffee Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea ",
        "study_brief_summary": " This investigation is a prospective, non-randomized, non-blinded study. This investigation is designed to evaluate the performance, comfort and ease of use of the F&P Toffee nasal pillows mask amongst obstructive sleep apnea (OSA) patients. Up to 45 OSA patients will be recruited from the Ohio Sleep Medical Institute (OSMI)",
        "text": "The Evaluation of the Toffee Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea | This investigation is a prospective, non-randomized, non-blinded study. This investigation is designed to evaluate the performance, comfort and ease of use of the F&P Toffee nasal pillows mask amongst obstructive sleep apnea (OSA) patients. Up to 45 OSA patients will be recruited from the Ohio Sleep Medical Institute (OSMI)",
        "tokens": "['The', 'Evaluation', 'of', 'the', 'Toffee', 'Nasal', 'Pillows', 'Mask', 'for', 'the', 'Treatment', 'of', 'Obstructive', 'Sleep', 'Apnea', '|', 'This', 'investigation', 'is', 'a', 'prospective', ',', 'non', '-', 'randomized', ',', 'non', '-', 'blinded', 'study', '.', 'This', 'investigation', 'is', 'designed', 'to', 'evaluate', 'the', 'performance', ',', 'comfort', 'and', 'ease', 'of', 'use', 'of', 'the', 'F&P', 'Toffee', 'nasal', 'pillows', 'mask', 'amongst', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'patients', '.', 'Up', 'to', '45', 'OSA', 'patients', 'will', 'be', 'recruited', 'from', 'the', 'Ohio', 'Sleep', 'Medical', 'Institute', '(', 'OSMI', ')']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 47,
                "text": "Toffee Nasal Pillows Mask",
                "type": "OTHER"
            },
            {
                "start": 69,
                "end": 92,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 258,
                "end": 287,
                "text": "F&P Toffee nasal pillows mask",
                "type": "OTHER"
            },
            {
                "start": 296,
                "end": 319,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 321,
                "end": 324,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 345,
                "end": 348,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01286935",
        "study_official_title": "A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic ",
        "study_brief_summary": " The purpose of this study is to determine the long-term efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations, who are currently receiving a stable dose of levodopa.",
        "text": "A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic | The purpose of this study is to determine the long-term efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations, who are currently receiving a stable dose of levodopa.",
        "tokens": "['A', 'Phase', 'III', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', '18', '-', 'mon', 'Ext', 'Study', 'Long', '-', 'term', 'Efficacy', '&', 'Safety', 'of', '50', '&', '100mg', '/', 'Day', 'Doses', 'of', 'Safinamide', ',', 'as', 'add', '-', 'on', 'Therapy', ',', 'in', 'Idiopathic', 'PD', 'Pts', 'With', 'Motor', 'Fluctuations', ',', 'Treated', 'With', 'Levodopa', ',', 'Who', 'May', 'be', 'Receiving', 'DA', ',', 'and/or', 'Anticholinergic', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'long', '-', 'term', 'efficacy', 'and', 'safety', 'of', 'two', 'doses', 'of', 'safinamide', '(', '50', 'and', '100', 'mg', '/', 'day', ',', 'p.o', ')', ',', 'compared', 'to', 'placebo', ',', 'as', 'add', '-', 'on', 'therapy', 'in', 'patients', 'with', 'idiopathic', 'Parkinson', \"'s\", 'disease', 'with', 'motor', 'fluctuations', ',', 'who', 'are', 'currently', 'receiving', 'a', 'stable', 'dose', 'of', 'levodopa', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 27,
                "end": 34,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 119,
                "end": 129,
                "text": "Safinamide",
                "type": "DRUG"
            },
            {
                "start": 153,
                "end": 166,
                "text": "Idiopathic PD",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 194,
                "text": "Motor Fluctuations",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 217,
                "text": "Levodopa",
                "type": "DRUG"
            },
            {
                "start": 361,
                "end": 371,
                "text": "safinamide",
                "type": "DRUG"
            },
            {
                "start": 410,
                "end": 417,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 454,
                "end": 484,
                "text": "idiopathic Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 490,
                "end": 508,
                "text": "motor fluctuations",
                "type": "CONDITION"
            },
            {
                "start": 555,
                "end": 563,
                "text": "levodopa",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03166046",
        "study_official_title": "Migraine Prevention Using Pulsed Shortwave Therapy ",
        "study_brief_summary": " Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception, since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attach. There is early evidence that ActiPatch can help mitigate this sensitization, so this study is being conducted to determine the efficacy of ActiPatch in preventing chronic, episodic migraines.",
        "text": "Migraine Prevention Using Pulsed Shortwave Therapy | Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception. Migraine is no exception, since it is well known that sensitization of the trigeminovascular pain pathway can occur during a migraine attach. There is early evidence that ActiPatch can help mitigate this sensitization, so this study is being conducted to determine the efficacy of ActiPatch in preventing chronic, episodic migraines.",
        "tokens": "['Migraine', 'Prevention', 'Using', 'Pulsed', 'Shortwave', 'Therapy', '|', 'Chronic', 'pain', 'is', 'now', 'widely', 'understood', 'to', 'be', 'due', 'to', 'central', 'sensitization', ',', 'which', 'leads', 'to', 'exaggerated', 'pain', 'perception', '.', 'Migraine', 'is', 'no', 'exception', ',', 'since', 'it', 'is', 'well', 'known', 'that', 'sensitization', 'of', 'the', 'trigeminovascular', 'pain', 'pathway', 'can', 'occur', 'during', 'a', 'migraine', 'attach', '.', 'There', 'is', 'early', 'evidence', 'that', 'ActiPatch', 'can', 'help', 'mitigate', 'this', 'sensitization', ',', 'so', 'this', 'study', 'is', 'being', 'conducted', 'to', 'determine', 'the', 'efficacy', 'of', 'ActiPatch', 'in', 'preventing', 'chronic', ',', 'episodic', 'migraines', '.']",
        "token_bio_labels": "['B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 26,
                "end": 50,
                "text": "Pulsed Shortwave Therapy",
                "type": "OTHER"
            },
            {
                "start": 53,
                "end": 65,
                "text": "Chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 154,
                "end": 158,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 171,
                "end": 179,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 296,
                "end": 311,
                "text": "migraine attach",
                "type": "CONDITION"
            },
            {
                "start": 342,
                "end": 351,
                "text": "ActiPatch",
                "type": "OTHER"
            },
            {
                "start": 452,
                "end": 461,
                "text": "ActiPatch",
                "type": "OTHER"
            },
            {
                "start": 476,
                "end": 503,
                "text": "chronic, episodic migraines",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03940872",
        "study_official_title": "Development and Validation of a Diagnosis Questionnaire of Primary Parkinsonian Pain: the 3 PDQ Primary Parkinsonian Pain Diagnostic Questionnaire ",
        "study_brief_summary": " Development and validation of a diagnosis questionnaire of parkinsonian primary pain: the \"Primary Parkinsonian Pain Diagnostic Questionnaire\" (3PDQ)",
        "text": "Development and Validation of a Diagnosis Questionnaire of Primary Parkinsonian Pain: the 3 PDQ Primary Parkinsonian Pain Diagnostic Questionnaire | Development and validation of a diagnosis questionnaire of parkinsonian primary pain: the \"Primary Parkinsonian Pain Diagnostic Questionnaire\" (3PDQ)",
        "tokens": "['Development', 'and', 'Validation', 'of', 'a', 'Diagnosis', 'Questionnaire', 'of', 'Primary', 'Parkinsonian', 'Pain', ':', 'the', '3', 'PDQ', 'Primary', 'Parkinsonian', 'Pain', 'Diagnostic', 'Questionnaire', '|', 'Development', 'and', 'validation', 'of', 'a', 'diagnosis', 'questionnaire', 'of', 'parkinsonian', 'primary', 'pain', ':', 'the', '\"', 'Primary', 'Parkinsonian', 'Pain', 'Diagnostic', 'Questionnaire', '\"', '(', '3PDQ', ')']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 59,
                "end": 84,
                "text": "Primary Parkinsonian Pain",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 121,
                "text": "Primary Parkinsonian Pain",
                "type": "CONDITION"
            },
            {
                "start": 208,
                "end": 233,
                "text": "parkinsonian primary pain",
                "type": "CONDITION"
            },
            {
                "start": 240,
                "end": 265,
                "text": "Primary Parkinsonian Pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02472028",
        "study_official_title": "LEukoaraiosis and blOod Pressure Reduction in OLD People ",
        "study_brief_summary": " The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.",
        "text": "LEukoaraiosis and blOod Pressure Reduction in OLD People | The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.",
        "tokens": "['LEukoaraiosis', 'and', 'blOod', 'Pressure', 'Reduction', 'in', 'OLD', 'People', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'test', 'the', 'hypothesis', 'of', 'slowing', 'the', 'progression', 'of', 'White', 'Matter', 'Lesions', '(', 'WML', ')', 'by', 'lowering', 'blood', 'pressure', '(', 'BP', ')', 'in', 'patients', 'with', 'cognitive', 'complaints', 'and', 'a', 'moderate', 'to', 'high', 'grade', 'of', 'WML', 'on', 'brain', 'MRI', '.']",
        "token_bio_labels": "['B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 13,
                "text": "LEukoaraiosis",
                "type": "CONDITION"
            },
            {
                "start": 18,
                "end": 42,
                "text": "blOod Pressure Reduction",
                "type": "OTHER"
            },
            {
                "start": 140,
                "end": 160,
                "text": "White Matter Lesions",
                "type": "CONDITION"
            },
            {
                "start": 162,
                "end": 165,
                "text": "WML",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 193,
                "text": "lowering blood pressure",
                "type": "OTHER"
            },
            {
                "start": 269,
                "end": 272,
                "text": "WML",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05513794",
        "study_official_title": "Prospective Data Collect Study for Development of Neurimelanin Image Analysis System ",
        "study_brief_summary": " In order to develop an image analysis system that automatically detects and quantifies neuromelanin, this study aims to construct a database of a wide sample by collecting brain MRI neuromelanin images prospectively.",
        "text": "Prospective Data Collect Study for Development of Neurimelanin Image Analysis System | In order to develop an image analysis system that automatically detects and quantifies neuromelanin, this study aims to construct a database of a wide sample by collecting brain MRI neuromelanin images prospectively.",
        "tokens": "['Prospective', 'Data', 'Collect', 'Study', 'for', 'Development', 'of', 'Neurimelanin', 'Image', 'Analysis', 'System', '|', 'In', 'order', 'to', 'develop', 'an', 'image', 'analysis', 'system', 'that', 'automatically', 'detects', 'and', 'quantifies', 'neuromelanin', ',', 'this', 'study', 'aims', 'to', 'construct', 'a', 'database', 'of', 'a', 'wide', 'sample', 'by', 'collecting', 'brain', 'MRI', 'neuromelanin', 'images', 'prospectively', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT04124471",
        "study_official_title": "Positive Airway Pressure for the Treatment of the Obstructive Sleep Apnea Syndrome in Children With Down Syndrome (Stage 1) ",
        "study_brief_summary": " To identify the perceptions, beliefs, and family-relevant outcomes regarding the treatment of obstructive sleep apnea syndrome (OSAS) with positive airway pressure (PAP) in children with Down's Syndrome (DS).",
        "text": "Positive Airway Pressure for the Treatment of the Obstructive Sleep Apnea Syndrome in Children With Down Syndrome (Stage 1) | To identify the perceptions, beliefs, and family-relevant outcomes regarding the treatment of obstructive sleep apnea syndrome (OSAS) with positive airway pressure (PAP) in children with Down's Syndrome (DS).",
        "tokens": "['Positive', 'Airway', 'Pressure', 'for', 'the', 'Treatment', 'of', 'the', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', 'in', 'Children', 'With', 'Down', 'Syndrome', '(', 'Stage', '1', ')', '|', 'To', 'identify', 'the', 'perceptions', ',', 'beliefs', ',', 'and', 'family', '-', 'relevant', 'outcomes', 'regarding', 'the', 'treatment', 'of', 'obstructive', 'sleep', 'apnea', 'syndrome', '(', 'OSAS', ')', 'with', 'positive', 'airway', 'pressure', '(', 'PAP', ')', 'in', 'children', 'with', 'Down', \"'s\", 'Syndrome', '(', 'DS', ')', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 24,
                "text": "Positive Airway Pressure",
                "type": "OTHER"
            },
            {
                "start": 50,
                "end": 82,
                "text": "Obstructive Sleep Apnea Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 100,
                "end": 113,
                "text": "Down Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 252,
                "text": "obstructive sleep apnea syndrome",
                "type": "CONDITION"
            },
            {
                "start": 254,
                "end": 258,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 265,
                "end": 289,
                "text": "positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 291,
                "end": 294,
                "text": "PAP",
                "type": "OTHER"
            },
            {
                "start": 313,
                "end": 328,
                "text": "Down's Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 330,
                "end": 332,
                "text": "DS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04184206",
        "study_official_title": "Effects of Attention Training Interventions on Depression ",
        "study_brief_summary": " The purpose of this study is to study the effects of attention training interventions on symptoms and brain function in major depressive disorder.",
        "text": "Effects of Attention Training Interventions on Depression | The purpose of this study is to study the effects of attention training interventions on symptoms and brain function in major depressive disorder.",
        "tokens": "['Effects', 'of', 'Attention', 'Training', 'Interventions', 'on', 'Depression', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'study', 'the', 'effects', 'of', 'attention', 'training', 'interventions', 'on', 'symptoms', 'and', 'brain', 'function', 'in', 'major', 'depressive', 'disorder', '.']",
        "token_bio_labels": "['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 43,
                "text": "Attention Training Interventions",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 47,
                "end": 57,
                "text": "Depression",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 145,
                "text": "attention training interventions",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 180,
                "end": 205,
                "text": "major depressive disorder",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02704195",
        "study_official_title": "Subthalamic Nucleus Stimulation Effect on Gait Symmetry and Freezing of Gait ",
        "study_brief_summary": " Impact of unilateral modulation of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease",
        "text": "Subthalamic Nucleus Stimulation Effect on Gait Symmetry and Freezing of Gait | Impact of unilateral modulation of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease",
        "tokens": "['Subthalamic', 'Nucleus', 'Stimulation', 'Effect', 'on', 'Gait', 'Symmetry', 'and', 'Freezing', 'of', 'Gait', '|', 'Impact', 'of', 'unilateral', 'modulation', 'of', 'deep', 'brain', 'stimulation', 'of', 'the', 'subthalamic', 'nucleus', 'on', 'freezing', 'of', 'gait', 'in', 'Parkinson', \"'s\", 'disease']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 0,
                "end": 31,
                "text": "Subthalamic Nucleus Stimulation",
                "type": "OTHER"
            },
            {
                "start": 60,
                "end": 76,
                "text": "Freezing of Gait",
                "type": "CONDITION"
            },
            {
                "start": 114,
                "end": 163,
                "text": "deep brain stimulation of the subthalamic nucleus",
                "type": "OTHER"
            },
            {
                "start": 167,
                "end": 183,
                "text": "freezing of gait",
                "type": "CONDITION"
            },
            {
                "start": 187,
                "end": 206,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02618941",
        "study_official_title": "Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE\u00ae PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program ",
        "study_brief_summary": " This is a follow-up study to assess safety and clinical activity of continued AFFITOPE\u00ae PD01A vaccinations in patients with Parkinson's disease. Patients, who have already participated in the AFF008 program will be involved and will receive a second boost immunization with AFFITOPE\u00ae PD01A. One study site in Vienna (Austria) will be involved.\n\nIn addition, up to 6 patients will be offered participation within an untreated control Group.",
        "text": "Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE\u00ae PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program | This is a follow-up study to assess safety and clinical activity of continued AFFITOPE\u00ae PD01A vaccinations in patients with Parkinson's disease. Patients, who have already participated in the AFF008 program will be involved and will receive a second boost immunization with AFFITOPE\u00ae PD01A. One study site in Vienna (Austria) will be involved.\n\nIn addition, up to 6 patients will be offered participation within an untreated control Group.",
        "tokens": "['Phase', 'IB', 'Follow', '-', 'up', ',', 'Controlled', ',', 'Parallel', 'Group', ',', 'Single', '-', 'center', 'Study', 'to', 'Assess', 'a', 'Second', 'Boost', 'Immunization', 'With', 'AFFITOPE', '\u00ae', 'PD01A', 'With', 'Regard', 'to', 'Safety', '/', 'Tolerability', ',', 'Immunological', 'and', 'Clinical', 'Activity', 'in', 'Patients', 'Who', 'Have', 'Participated', 'in', 'the', 'AFF008', 'Program', '|', 'This', 'is', 'a', 'follow', '-', 'up', 'study', 'to', 'assess', 'safety', 'and', 'clinical', 'activity', 'of', 'continued', 'AFFITOPE', '\u00ae', 'PD01A', 'vaccinations', 'in', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '.', 'Patients', ',', 'who', 'have', 'already', 'participated', 'in', 'the', 'AFF008', 'program', 'will', 'be', 'involved', 'and', 'will', 'receive', 'a', 'second', 'boost', 'immunization', 'with', 'AFFITOPE', '\u00ae', 'PD01A.', 'One', 'study', 'site', 'in', 'Vienna', '(', 'Austria', ')', 'will', 'be', 'involved', '.', '\\n\\n', 'In', 'addition', ',', 'up', 'to', '6', 'patients', 'will', 'be', 'offered', 'participation', 'within', 'an', 'untreated', 'control', 'Group', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O']",
        "entities": [
            {
                "start": 111,
                "end": 126,
                "text": "AFFITOPE\u00ae PD01A",
                "type": "DRUG"
            },
            {
                "start": 335,
                "end": 350,
                "text": "AFFITOPE\u00ae PD01A",
                "type": "DRUG"
            },
            {
                "start": 381,
                "end": 400,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 531,
                "end": 547,
                "text": "AFFITOPE\u00ae PD01A.",
                "type": "DRUG"
            },
            {
                "start": 672,
                "end": 689,
                "text": "untreated control",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03532373",
        "study_official_title": "Testing of a Tool to Elicit Patient Preferences for CTS ",
        "study_brief_summary": " This study will complete a randomized controlled trial to quantitatively measure patient decisional conflict (Decisional Conflict Scale) in 150 patients treated for CTS with the tool compared to 150 patients treated with standard care. The investigators hypothesize patients treated for CTS will have lower decisional conflict with the tool.",
        "text": "Testing of a Tool to Elicit Patient Preferences for CTS | This study will complete a randomized controlled trial to quantitatively measure patient decisional conflict (Decisional Conflict Scale) in 150 patients treated for CTS with the tool compared to 150 patients treated with standard care. The investigators hypothesize patients treated for CTS will have lower decisional conflict with the tool.",
        "tokens": "['Testing', 'of', 'a', 'Tool', 'to', 'Elicit', 'Patient', 'Preferences', 'for', 'CTS', '|', 'This', 'study', 'will', 'complete', 'a', 'randomized', 'controlled', 'trial', 'to', 'quantitatively', 'measure', 'patient', 'decisional', 'conflict', '(', 'Decisional', 'Conflict', 'Scale', ')', 'in', '150', 'patients', 'treated', 'for', 'CTS', 'with', 'the', 'tool', 'compared', 'to', '150', 'patients', 'treated', 'with', 'standard', 'care', '.', 'The', 'investigators', 'hypothesize', 'patients', 'treated', 'for', 'CTS', 'will', 'have', 'lower', 'decisional', 'conflict', 'with', 'the', 'tool', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": []
    },
    {
        "nctid": "NCT05353413",
        "study_official_title": "Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy. ",
        "study_brief_summary": " The aim of the project is to create a new, non-invasive and safe protocol for the early diagnosis of various types of optic neuropathies with the use of diffusion magnetic resonance imaging",
        "text": "Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy. | The aim of the project is to create a new, non-invasive and safe protocol for the early diagnosis of various types of optic neuropathies with the use of diffusion magnetic resonance imaging",
        "tokens": "['Diffusion', 'Weighted', 'Magnetic', 'Resonance', 'Imaging', 'and', 'the', 'Optic', 'Nerve', 'Neuropathy', '.', '|', 'The', 'aim', 'of', 'the', 'project', 'is', 'to', 'create', 'a', 'new', ',', 'non', '-', 'invasive', 'and', 'safe', 'protocol', 'for', 'the', 'early', 'diagnosis', 'of', 'various', 'types', 'of', 'optic', 'neuropathies', 'with', 'the', 'use', 'of', 'diffusion', 'magnetic', 'resonance', 'imaging']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 54,
                "end": 76,
                "text": "Optic Nerve Neuropathy",
                "type": "CONDITION"
            },
            {
                "start": 198,
                "end": 216,
                "text": "optic neuropathies",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00772278",
        "study_official_title": "A Randomized Evaluation of Short Term and Long Term Outcome After Endovascular Repair by Stenting of Carotid Artery Stenosis in Patients With Severe (70% and Higher) Asymptomatic Carotid Stenosis ",
        "study_brief_summary": " Purpose of this study:\n\nPrimary:\n\n\u2022 Comparison of cardiovascular mortality and morbidity which includes cardiac and neurological morbidity (TIA and CVA) in the two invasive treatments of asymptomatic carotid artery stenosis\n\nSecondary:\n\nComparison of non cardiovascular morbidity caused by the two invasive techniques\n\nmorbidity at the site of incision (infection or local hematoma)\ndamage to cranial nerves (hypoglossus, vagus)\nbrain hyperperfusion which is defined as severe headache which is not responsive to analgesics with or without nausea and vomiting.\nevents of bradycardia within the first 24 hours, clinically evident and/or silent\nmicroembolic brain events immediately after the procedure and their relationship with morbidity and/or mortality due to TIA's or CVA's\nthe change in the stenotic carotid artery at the time of follow up with duplex of neck arteries\nthe comparison of the affect of the two procedures on patient life style",
        "text": "A Randomized Evaluation of Short Term and Long Term Outcome After Endovascular Repair by Stenting of Carotid Artery Stenosis in Patients With Severe (70% and Higher) Asymptomatic Carotid Stenosis | Purpose of this study:\n\nPrimary:\n\n\u2022 Comparison of cardiovascular mortality and morbidity which includes cardiac and neurological morbidity (TIA and CVA) in the two invasive treatments of asymptomatic carotid artery stenosis\n\nSecondary:\n\nComparison of non cardiovascular morbidity caused by the two invasive techniques\n\nmorbidity at the site of incision (infection or local hematoma)\ndamage to cranial nerves (hypoglossus, vagus)\nbrain hyperperfusion which is defined as severe headache which is not responsive to analgesics with or without nausea and vomiting.\nevents of bradycardia within the first 24 hours, clinically evident and/or silent\nmicroembolic brain events immediately after the procedure and their relationship with morbidity and/or mortality due to TIA's or CVA's\nthe change in the stenotic carotid artery at the time of follow up with duplex of neck arteries\nthe comparison of the affect of the two procedures on patient life style",
        "tokens": "['A', 'Randomized', 'Evaluation', 'of', 'Short', 'Term', 'and', 'Long', 'Term', 'Outcome', 'After', 'Endovascular', 'Repair', 'by', 'Stenting', 'of', 'Carotid', 'Artery', 'Stenosis', 'in', 'Patients', 'With', 'Severe', '(', '70', '%', 'and', 'Higher', ')', 'Asymptomatic', 'Carotid', 'Stenosis', '|', 'Purpose', 'of', 'this', 'study', ':', '\\n\\n', 'Primary', ':', '\\n\\n', '\u2022', 'Comparison', 'of', 'cardiovascular', 'mortality', 'and', 'morbidity', 'which', 'includes', 'cardiac', 'and', 'neurological', 'morbidity', '(', 'TIA', 'and', 'CVA', ')', 'in', 'the', 'two', 'invasive', 'treatments', 'of', 'asymptomatic', 'carotid', 'artery', 'stenosis', '\\n\\n', 'Secondary', ':', '\\n\\n', 'Comparison', 'of', 'non', 'cardiovascular', 'morbidity', 'caused', 'by', 'the', 'two', 'invasive', 'techniques', '\\n\\n', 'morbidity', 'at', 'the', 'site', 'of', 'incision', '(', 'infection', 'or', 'local', 'hematoma', ')', '\\n', 'damage', 'to', 'cranial', 'nerves', '(', 'hypoglossus', ',', 'vagus', ')', '\\n', 'brain', 'hyperperfusion', 'which', 'is', 'defined', 'as', 'severe', 'headache', 'which', 'is', 'not', 'responsive', 'to', 'analgesics', 'with', 'or', 'without', 'nausea', 'and', 'vomiting', '.', '\\n', 'events', 'of', 'bradycardia', 'within', 'the', 'first', '24', 'hours', ',', 'clinically', 'evident', 'and/or', 'silent', '\\n', 'microembolic', 'brain', 'events', 'immediately', 'after', 'the', 'procedure', 'and', 'their', 'relationship', 'with', 'morbidity', 'and/or', 'mortality', 'due', 'to', 'TIA', \"'s\", 'or', 'CVA', \"'s\", '\\n', 'the', 'change', 'in', 'the', 'stenotic', 'carotid', 'artery', 'at', 'the', 'time', 'of', 'follow', 'up', 'with', 'duplex', 'of', 'neck', 'arteries', '\\n', 'the', 'comparison', 'of', 'the', 'affect', 'of', 'the', 'two', 'procedures', 'on', 'patient', 'life', 'style']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 66,
                "end": 97,
                "text": "Endovascular Repair by Stenting",
                "type": "SURGICAL"
            },
            {
                "start": 101,
                "end": 124,
                "text": "Carotid Artery Stenosis",
                "type": "CONDITION"
            },
            {
                "start": 142,
                "end": 195,
                "text": "Severe (70% and Higher) Asymptomatic Carotid Stenosis",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 421,
                "text": "asymptomatic carotid artery stenosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05327114",
        "study_official_title": "Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ",
        "study_brief_summary": " The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.",
        "text": "Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.",
        "tokens": "['Phase', '2/3', ',', 'Multistage', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Parallel', 'Group', 'Withdrawal', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Nipocalimab', 'Administered', 'to', 'Adults', 'With', 'Chronic', 'Inflammatory', 'Demyelinating', 'Polyneuropathy', '(', 'CIDP', ')', '|', 'The', 'main', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'nipocalimab', 'compared', 'to', 'placebo', 'in', 'delaying', 'relapse', 'in', 'adults', 'with', 'chronic', 'inflammatory', 'demyelinating', 'polyneuropathy', '(', 'CIDP', ')', 'who', 'initially', 'respond', 'to', 'nipocalimab', 'in', 'Stage', 'A.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 62,
                "end": 69,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 152,
                "end": 163,
                "text": "Nipocalimab",
                "type": "DRUG"
            },
            {
                "start": 192,
                "end": 241,
                "text": "Chronic Inflammatory Demyelinating Polyneuropathy",
                "type": "CONDITION"
            },
            {
                "start": 243,
                "end": 247,
                "text": "CIDP",
                "type": "CONDITION"
            },
            {
                "start": 324,
                "end": 335,
                "text": "nipocalimab",
                "type": "DRUG"
            },
            {
                "start": 348,
                "end": 355,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 391,
                "end": 440,
                "text": "chronic inflammatory demyelinating polyneuropathy",
                "type": "CONDITION"
            },
            {
                "start": 442,
                "end": 446,
                "text": "CIDP",
                "type": "CONDITION"
            },
            {
                "start": 473,
                "end": 484,
                "text": "nipocalimab",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT01294137",
        "study_official_title": "Accuracy of Pulse Oximetry to Detect Sleep Apnea in Frail Hospitalized Patients ",
        "study_brief_summary": " Sleep apnea syndrome is common and increases with age. In the elderly, symptoms might be different than in the youngest people, and its consequences might be severe and atypical (falls, functional and cognitive decline).\n\nToday, there is no specific tool to detect sleep apnea in the elderly. The goal of this study is to evaluate the accuracy of oximetry for detection of respiratory disturbances in sleep apnea in the hospitalized elderly.",
        "text": "Accuracy of Pulse Oximetry to Detect Sleep Apnea in Frail Hospitalized Patients | Sleep apnea syndrome is common and increases with age. In the elderly, symptoms might be different than in the youngest people, and its consequences might be severe and atypical (falls, functional and cognitive decline).\n\nToday, there is no specific tool to detect sleep apnea in the elderly. The goal of this study is to evaluate the accuracy of oximetry for detection of respiratory disturbances in sleep apnea in the hospitalized elderly.",
        "tokens": "['Accuracy', 'of', 'Pulse', 'Oximetry', 'to', 'Detect', 'Sleep', 'Apnea', 'in', 'Frail', 'Hospitalized', 'Patients', '|', 'Sleep', 'apnea', 'syndrome', 'is', 'common', 'and', 'increases', 'with', 'age', '.', 'In', 'the', 'elderly', ',', 'symptoms', 'might', 'be', 'different', 'than', 'in', 'the', 'youngest', 'people', ',', 'and', 'its', 'consequences', 'might', 'be', 'severe', 'and', 'atypical', '(', 'falls', ',', 'functional', 'and', 'cognitive', 'decline', ')', '.', '\\n\\n', 'Today', ',', 'there', 'is', 'no', 'specific', 'tool', 'to', 'detect', 'sleep', 'apnea', 'in', 'the', 'elderly', '.', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'accuracy', 'of', 'oximetry', 'for', 'detection', 'of', 'respiratory', 'disturbances', 'in', 'sleep', 'apnea', 'in', 'the', 'hospitalized', 'elderly', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 48,
                "text": "Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 82,
                "end": 102,
                "text": "Sleep apnea syndrome",
                "type": "CONDITION"
            },
            {
                "start": 347,
                "end": 358,
                "text": "sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 455,
                "end": 479,
                "text": "respiratory disturbances",
                "type": "CONDITION"
            },
            {
                "start": 483,
                "end": 494,
                "text": "sleep apnea",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00252850",
        "study_official_title": "A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease ",
        "study_brief_summary": " This is a Phase I dose escalating open-label study designed to assess the safety, tolerability and biologic activity of an in vivo AAV2 mediated delivery of the gene encoding NTN (CERE-120).\n\nTwelve (up to 18) subjects will receive one of two open-label doses of CERE-120 via bilateral stereotactic injections targeting the putaminal region of the brain. Subjects will be enrolled in one of two cohorts, a low-dose cohort of six subjects followed by a high dose cohort of six subjects.\n\nThe design of this study is such that the primary objective, the evaluation of safety and tolerability, will be assessed by frequent observations for adverse events, clinical laboratory test results, imaging (MRI), neuropsychometric testing, and evaluations of disease status.",
        "text": "A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease | This is a Phase I dose escalating open-label study designed to assess the safety, tolerability and biologic activity of an in vivo AAV2 mediated delivery of the gene encoding NTN (CERE-120).\n\nTwelve (up to 18) subjects will receive one of two open-label doses of CERE-120 via bilateral stereotactic injections targeting the putaminal region of the brain. Subjects will be enrolled in one of two cohorts, a low-dose cohort of six subjects followed by a high dose cohort of six subjects.\n\nThe design of this study is such that the primary objective, the evaluation of safety and tolerability, will be assessed by frequent observations for adverse events, clinical laboratory test results, imaging (MRI), neuropsychometric testing, and evaluations of disease status.",
        "tokens": "['A', 'Phase', 'I', ',', 'Open', '-', 'Label', 'Study', 'of', 'CERE-120', '(', 'Adeno', '-', 'Associated', 'Virus', 'Serotype', '2', '[', 'AAV2]-Neurturin[NTN', ']', 'to', 'Assess', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Intrastriatal', 'Delivery', 'to', 'Subjects', 'With', 'Idiopathic', 'Parkinson', \"'s\", 'Disease', '|', 'This', 'is', 'a', 'Phase', 'I', 'dose', 'escalating', 'open', '-', 'label', 'study', 'designed', 'to', 'assess', 'the', 'safety', ',', 'tolerability', 'and', 'biologic', 'activity', 'of', 'an', 'in', 'vivo', 'AAV2', 'mediated', 'delivery', 'of', 'the', 'gene', 'encoding', 'NTN', '(', 'CERE-120', ')', '.', '\\n\\n', 'Twelve', '(', 'up', 'to', '18', ')', 'subjects', 'will', 'receive', 'one', 'of', 'two', 'open', '-', 'label', 'doses', 'of', 'CERE-120', 'via', 'bilateral', 'stereotactic', 'injections', 'targeting', 'the', 'putaminal', 'region', 'of', 'the', 'brain', '.', 'Subjects', 'will', 'be', 'enrolled', 'in', 'one', 'of', 'two', 'cohorts', ',', 'a', 'low', '-', 'dose', 'cohort', 'of', 'six', 'subjects', 'followed', 'by', 'a', 'high', 'dose', 'cohort', 'of', 'six', 'subjects', '.', '\\n\\n', 'The', 'design', 'of', 'this', 'study', 'is', 'such', 'that', 'the', 'primary', 'objective', ',', 'the', 'evaluation', 'of', 'safety', 'and', 'tolerability', ',', 'will', 'be', 'assessed', 'by', 'frequent', 'observations', 'for', 'adverse', 'events', ',', 'clinical', 'laboratory', 'test', 'results', ',', 'imaging', '(', 'MRI', ')', ',', 'neuropsychometric', 'testing', ',', 'and', 'evaluations', 'of', 'disease', 'status', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 39,
                "text": "CERE-120",
                "type": "OTHER"
            },
            {
                "start": 41,
                "end": 96,
                "text": "Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN]",
                "type": "OTHER"
            },
            {
                "start": 178,
                "end": 208,
                "text": "Idiopathic Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 334,
                "end": 389,
                "text": "in vivo AAV2 mediated delivery of the gene encoding NTN",
                "type": "OTHER"
            },
            {
                "start": 391,
                "end": 399,
                "text": "CERE-120",
                "type": "OTHER"
            },
            {
                "start": 474,
                "end": 482,
                "text": "CERE-120",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01244269",
        "study_official_title": "Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease. ",
        "study_brief_summary": " This project aims to determine if methylphenidate can improve deficits in attention and symptoms of orthostatic hypotension, two common non-motor symptoms, in patients with Parkinson's Disease. This project also seeks to evaluate the effect of methylphenidate on postural control in these patients, a debilitating motor symptom that places patients at an increased risk of falling. This study will build on existing data to support a new indication for the use of methylphenidate in Parkinson's Disease. Using standard and objective evaluations, this study will quantify the effect of methylphenidate at two doses on attention levels, orthostatic hypotension, and measures of postural control. Phase I of the study will compare methylphenidate 10mg three times daily to placebo and Phase II of the study, for those tolerating the lower dose in Phase I, will compare methylphenidate 20mg three times daily to placebo. By incorporating two different doses, the study also seeks to determine if any improvements are dose-related. Secondary endpoints will include safety assessments (adverse event monitoring and vital signs) performed every 30 minutes following supervised drug administration. Visual analog scales will be presented to each participant before treatment and following the final dose of each treatment to assess changes in fatigue. A secondary task will be added to postural tests to assess the influence of cognitive processes. It is hypothesized that methylphenidate will demonstrate a significant beneficial effect on all outcomes. It is projected that objective improvements will be observed following treatment with methylphenidate at both doses (10 and 20mg three time daily) when compared to placebo. It is further hypothesized that the effects will be dose-related and therefore more profound with higher doses.",
        "text": "Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease. | This project aims to determine if methylphenidate can improve deficits in attention and symptoms of orthostatic hypotension, two common non-motor symptoms, in patients with Parkinson's Disease. This project also seeks to evaluate the effect of methylphenidate on postural control in these patients, a debilitating motor symptom that places patients at an increased risk of falling. This study will build on existing data to support a new indication for the use of methylphenidate in Parkinson's Disease. Using standard and objective evaluations, this study will quantify the effect of methylphenidate at two doses on attention levels, orthostatic hypotension, and measures of postural control. Phase I of the study will compare methylphenidate 10mg three times daily to placebo and Phase II of the study, for those tolerating the lower dose in Phase I, will compare methylphenidate 20mg three times daily to placebo. By incorporating two different doses, the study also seeks to determine if any improvements are dose-related. Secondary endpoints will include safety assessments (adverse event monitoring and vital signs) performed every 30 minutes following supervised drug administration. Visual analog scales will be presented to each participant before treatment and following the final dose of each treatment to assess changes in fatigue. A secondary task will be added to postural tests to assess the influence of cognitive processes. It is hypothesized that methylphenidate will demonstrate a significant beneficial effect on all outcomes. It is projected that objective improvements will be observed following treatment with methylphenidate at both doses (10 and 20mg three time daily) when compared to placebo. It is further hypothesized that the effects will be dose-related and therefore more profound with higher doses.",
        "tokens": "['Two', '-', 'phase', 'Randomized', 'Controlled', 'Trial', 'of', 'Low', 'and', 'Moderate', 'Dose', 'Methylphenidate', 'for', 'Non', '-', 'motor', 'and', 'Postural', 'Symptoms', 'in', 'Parkinson', \"'s\", 'Disease', '.', '|', 'This', 'project', 'aims', 'to', 'determine', 'if', 'methylphenidate', 'can', 'improve', 'deficits', 'in', 'attention', 'and', 'symptoms', 'of', 'orthostatic', 'hypotension', ',', 'two', 'common', 'non', '-', 'motor', 'symptoms', ',', 'in', 'patients', 'with', 'Parkinson', \"'s\", 'Disease', '.', 'This', 'project', 'also', 'seeks', 'to', 'evaluate', 'the', 'effect', 'of', 'methylphenidate', 'on', 'postural', 'control', 'in', 'these', 'patients', ',', 'a', 'debilitating', 'motor', 'symptom', 'that', 'places', 'patients', 'at', 'an', 'increased', 'risk', 'of', 'falling', '.', 'This', 'study', 'will', 'build', 'on', 'existing', 'data', 'to', 'support', 'a', 'new', 'indication', 'for', 'the', 'use', 'of', 'methylphenidate', 'in', 'Parkinson', \"'s\", 'Disease', '.', 'Using', 'standard', 'and', 'objective', 'evaluations', ',', 'this', 'study', 'will', 'quantify', 'the', 'effect', 'of', 'methylphenidate', 'at', 'two', 'doses', 'on', 'attention', 'levels', ',', 'orthostatic', 'hypotension', ',', 'and', 'measures', 'of', 'postural', 'control', '.', 'Phase', 'I', 'of', 'the', 'study', 'will', 'compare', 'methylphenidate', '10', 'mg', 'three', 'times', 'daily', 'to', 'placebo', 'and', 'Phase', 'II', 'of', 'the', 'study', ',', 'for', 'those', 'tolerating', 'the', 'lower', 'dose', 'in', 'Phase', 'I', ',', 'will', 'compare', 'methylphenidate', '20', 'mg', 'three', 'times', 'daily', 'to', 'placebo', '.', 'By', 'incorporating', 'two', 'different', 'doses', ',', 'the', 'study', 'also', 'seeks', 'to', 'determine', 'if', 'any', 'improvements', 'are', 'dose', '-', 'related', '.', 'Secondary', 'endpoints', 'will', 'include', 'safety', 'assessments', '(', 'adverse', 'event', 'monitoring', 'and', 'vital', 'signs', ')', 'performed', 'every', '30', 'minutes', 'following', 'supervised', 'drug', 'administration', '.', 'Visual', 'analog', 'scales', 'will', 'be', 'presented', 'to', 'each', 'participant', 'before', 'treatment', 'and', 'following', 'the', 'final', 'dose', 'of', 'each', 'treatment', 'to', 'assess', 'changes', 'in', 'fatigue', '.', 'A', 'secondary', 'task', 'will', 'be', 'added', 'to', 'postural', 'tests', 'to', 'assess', 'the', 'influence', 'of', 'cognitive', 'processes', '.', 'It', 'is', 'hypothesized', 'that', 'methylphenidate', 'will', 'demonstrate', 'a', 'significant', 'beneficial', 'effect', 'on', 'all', 'outcomes', '.', 'It', 'is', 'projected', 'that', 'objective', 'improvements', 'will', 'be', 'observed', 'following', 'treatment', 'with', 'methylphenidate', 'at', 'both', 'doses', '(', '10', 'and', '20', 'mg', 'three', 'time', 'daily', ')', 'when', 'compared', 'to', 'placebo', '.', 'It', 'is', 'further', 'hypothesized', 'that', 'the', 'effects', 'will', 'be', 'dose', '-', 'related', 'and', 'therefore', 'more', 'profound', 'with', 'higher', 'doses', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 63,
                "end": 78,
                "text": "Methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 97,
                "end": 114,
                "text": "Postural Symptoms",
                "type": "CONDITION"
            },
            {
                "start": 118,
                "end": 137,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 190,
                "text": "methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 203,
                "end": 224,
                "text": "deficits in attention",
                "type": "CONDITION"
            },
            {
                "start": 241,
                "end": 264,
                "text": "orthostatic hypotension",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 333,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 400,
                "text": "methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 605,
                "end": 620,
                "text": "methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 624,
                "end": 643,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 726,
                "end": 741,
                "text": "methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 776,
                "end": 799,
                "text": "orthostatic hypotension",
                "type": "CONDITION"
            },
            {
                "start": 869,
                "end": 884,
                "text": "methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 911,
                "end": 918,
                "text": "placebo",
                "type": "OTHER"
            },
            {
                "start": 1007,
                "end": 1022,
                "text": "methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 1049,
                "end": 1056,
                "text": "placebo",
                "type": "OTHER"
            },
            {
                "start": 1606,
                "end": 1621,
                "text": "methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 1774,
                "end": 1789,
                "text": "methylphenidate",
                "type": "DRUG"
            },
            {
                "start": 1852,
                "end": 1859,
                "text": "placebo",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04428775",
        "study_official_title": "A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS) ",
        "study_brief_summary": " This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild to moderate ALS.",
        "text": "A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS) | This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild to moderate ALS.",
        "tokens": "['A', 'Phase', 'IIa', ',', 'Randomized', ',', 'Open', '-', 'label', ',', 'Multi', '-', 'Center', ',', 'Multi', '-', 'Dose', 'Study', 'to', 'Evaluate', 'the', 'Effects', 'of', 'ALZT', '-', 'OP1a', 'in', 'Subjects', 'With', 'Mild', '-', 'Moderate', 'Stage', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'This', 'is', 'a', 'Phase', 'IIa', ',', 'randomized', ',', 'open', '-', 'label', ',', 'multi', '-', 'center', ',', 'multi', '-', 'dose', 'study', 'for', 'subjects', 'with', 'mild', 'to', 'moderate', 'ALS', '.', 'The', 'protocol', 'is', 'designed', 'to', 'determine', 'whether', 'ALZT', '-', 'OP1a', 'treatment', 'will', 'positively', 'impact', 'neuro', '-', 'inflammatory', 'biomarkers', 'and', 'slow', 'down', 'or', 'arrest', 'functional', 'decline', 'in', 'subjects', 'with', 'mild', 'to', 'moderate', 'ALS', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 95,
                "end": 104,
                "text": "ALZT-OP1a",
                "type": "DRUG"
            },
            {
                "start": 122,
                "end": 171,
                "text": "Mild-Moderate Stage Amyotrophic Lateral Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 176,
                "text": "ALS",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 294,
                "text": "mild to moderate ALS",
                "type": "CONDITION"
            },
            {
                "start": 342,
                "end": 351,
                "text": "ALZT-OP1a",
                "type": "DRUG"
            },
            {
                "start": 475,
                "end": 495,
                "text": "mild to moderate ALS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00440323",
        "study_official_title": "A Double-blind, Double-dummy, Randomised, Placebo-controlled,Four-way Crossover Study to Investigate the Effect of Single Oral Doses of SB-649868 and of Zolpidem in a Model of Noise Induced Situational Insomnia in Healthy Male Volunteers. ",
        "study_brief_summary": " Subjects will be screened within 28 days. Each treatment session will consist of 2 PSG nights, study drug administration and noise model is conducted on second night.",
        "text": "A Double-blind, Double-dummy, Randomised, Placebo-controlled,Four-way Crossover Study to Investigate the Effect of Single Oral Doses of SB-649868 and of Zolpidem in a Model of Noise Induced Situational Insomnia in Healthy Male Volunteers. | Subjects will be screened within 28 days. Each treatment session will consist of 2 PSG nights, study drug administration and noise model is conducted on second night.",
        "tokens": "['A', 'Double', '-', 'blind', ',', 'Double', '-', 'dummy', ',', 'Randomised', ',', 'Placebo', '-', 'controlled', ',', 'Four', '-', 'way', 'Crossover', 'Study', 'to', 'Investigate', 'the', 'Effect', 'of', 'Single', 'Oral', 'Doses', 'of', 'SB-649868', 'and', 'of', 'Zolpidem', 'in', 'a', 'Model', 'of', 'Noise', 'Induced', 'Situational', 'Insomnia', 'in', 'Healthy', 'Male', 'Volunteers', '.', '|', 'Subjects', 'will', 'be', 'screened', 'within', '28', 'days', '.', 'Each', 'treatment', 'session', 'will', 'consist', 'of', '2', 'PSG', 'nights', ',', 'study', 'drug', 'administration', 'and', 'noise', 'model', 'is', 'conducted', 'on', 'second', 'night', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 49,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 136,
                "end": 145,
                "text": "SB-649868",
                "type": "DRUG"
            },
            {
                "start": 153,
                "end": 161,
                "text": "Zolpidem",
                "type": "DRUG"
            },
            {
                "start": 176,
                "end": 210,
                "text": "Noise Induced Situational Insomnia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00952211",
        "study_official_title": "Burden of Obstructive Sleep Apnea in Stroke (BOSAST) ",
        "study_brief_summary": " There are two purposes of this study. The first purpose is to define the frequency of obstructive sleep apnea in stroke survivors as well as its association with fatigue and quality of life. The second purpose is to determine if continuous positive airways pressure (CPAP) treatment can have a beneficial effect on these patients' fatigue and quality of life.",
        "text": "Burden of Obstructive Sleep Apnea in Stroke (BOSAST) | There are two purposes of this study. The first purpose is to define the frequency of obstructive sleep apnea in stroke survivors as well as its association with fatigue and quality of life. The second purpose is to determine if continuous positive airways pressure (CPAP) treatment can have a beneficial effect on these patients' fatigue and quality of life.",
        "tokens": "['Burden', 'of', 'Obstructive', 'Sleep', 'Apnea', 'in', 'Stroke', '(', 'BOSAST', ')', '|', 'There', 'are', 'two', 'purposes', 'of', 'this', 'study', '.', 'The', 'first', 'purpose', 'is', 'to', 'define', 'the', 'frequency', 'of', 'obstructive', 'sleep', 'apnea', 'in', 'stroke', 'survivors', 'as', 'well', 'as', 'its', 'association', 'with', 'fatigue', 'and', 'quality', 'of', 'life', '.', 'The', 'second', 'purpose', 'is', 'to', 'determine', 'if', 'continuous', 'positive', 'airways', 'pressure', '(', 'CPAP', ')', 'treatment', 'can', 'have', 'a', 'beneficial', 'effect', 'on', 'these', 'patients', \"'\", 'fatigue', 'and', 'quality', 'of', 'life', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 33,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 37,
                "end": 43,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 141,
                "end": 164,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 168,
                "end": 174,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 217,
                "end": 224,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 284,
                "end": 320,
                "text": "continuous positive airways pressure",
                "type": "OTHER"
            },
            {
                "start": 322,
                "end": 326,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 386,
                "end": 393,
                "text": "fatigue",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01185743",
        "study_official_title": "Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study ",
        "study_brief_summary": " Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.\n\nAim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.",
        "text": "Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study | Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.\n\nAim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.",
        "tokens": "['Effect', 'of', 'Atypical', 'Antipsychotics', 'on', 'Gene', 'Expression', 'in', 'Soft', 'Tissues', 'of', 'Healthy', 'Subjects', '-', 'A', 'Placebo', 'Controlled', 'Randomised', 'Pilot', 'Study', '|', 'Schizophrenia', 'is', 'a', 'severe', 'chronic', 'and', 'disabling', 'mental', 'disorder', 'and', 'is', 'associated', 'with', 'a', 'significant', 'reduction', 'in', 'life', 'expectancy', '.', 'Atypical', 'antipsychotic', 'treatment', 'compliance', 'may', 'be', 'jeopardized', 'because', 'of', 'drug', 'induced', 'weight', 'gain', 'and', 'abnormalities', 'in', 'carbohydrate', 'and', 'lipid', 'metabolism', '.', '\\n\\n', 'Aim', ':', 'to', 'gain', 'data', 'on', 'drug', 'related', 'effects', 'on', 'gene', 'expression', 'and', 'regulation', 'with', 'special', 'regard', 'to', 'glucose', 'metabolism', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 33,
                "text": "Atypical Antipsychotics",
                "type": "DRUG"
            },
            {
                "start": 93,
                "end": 100,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 137,
                "end": 150,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 268,
                "end": 290,
                "text": "Atypical antipsychotic",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02120820",
        "study_official_title": "An Evaluation of the Clinical Efficacy of Massage Therapy in a Multisensory Environment for Residents With Severe and Profound Intellectual Disabilities ",
        "study_brief_summary": " The aim of this study is to evaluate the effectiveness of multisensory environment (MSE) and/or massage therapy (MT) in residents with severe and profound intellectual disabilities (ID) who received massage therapy in MSE, activities in MSE alone, massage therapy in usual care environment, or usual care with attention.\n\nSince there has not yet been any conclusive evidence to show the clinical efficacy of MT and MSE on relaxation and reducing challenging behaviours, the following null hypotheses are suggested:\n\nThere will not be any differences on reducing heart and respiration rates between MT-MSE, MT, MSE, and usual care only over the 10-week intervention period and a 2-week follow-up.\nThere will not be any differences on adaptive behaviours and levels of alertness between MT-MSE, MT, MSE, and control group over the 10-week intervention period and a 2-week follow-up.\nThere will not be any differences on frequency and severity of challenging behaviours between MT-MSE, MT, MSE, and control group over the 10-week intervention period and a 2-week follow-up.",
        "text": "An Evaluation of the Clinical Efficacy of Massage Therapy in a Multisensory Environment for Residents With Severe and Profound Intellectual Disabilities | The aim of this study is to evaluate the effectiveness of multisensory environment (MSE) and/or massage therapy (MT) in residents with severe and profound intellectual disabilities (ID) who received massage therapy in MSE, activities in MSE alone, massage therapy in usual care environment, or usual care with attention.\n\nSince there has not yet been any conclusive evidence to show the clinical efficacy of MT and MSE on relaxation and reducing challenging behaviours, the following null hypotheses are suggested:\n\nThere will not be any differences on reducing heart and respiration rates between MT-MSE, MT, MSE, and usual care only over the 10-week intervention period and a 2-week follow-up.\nThere will not be any differences on adaptive behaviours and levels of alertness between MT-MSE, MT, MSE, and control group over the 10-week intervention period and a 2-week follow-up.\nThere will not be any differences on frequency and severity of challenging behaviours between MT-MSE, MT, MSE, and control group over the 10-week intervention period and a 2-week follow-up.",
        "tokens": "['An', 'Evaluation', 'of', 'the', 'Clinical', 'Efficacy', 'of', 'Massage', 'Therapy', 'in', 'a', 'Multisensory', 'Environment', 'for', 'Residents', 'With', 'Severe', 'and', 'Profound', 'Intellectual', 'Disabilities', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'multisensory', 'environment', '(', 'MSE', ')', 'and/or', 'massage', 'therapy', '(', 'MT', ')', 'in', 'residents', 'with', 'severe', 'and', 'profound', 'intellectual', 'disabilities', '(', 'ID', ')', 'who', 'received', 'massage', 'therapy', 'in', 'MSE', ',', 'activities', 'in', 'MSE', 'alone', ',', 'massage', 'therapy', 'in', 'usual', 'care', 'environment', ',', 'or', 'usual', 'care', 'with', 'attention', '.', '\\n\\n', 'Since', 'there', 'has', 'not', 'yet', 'been', 'any', 'conclusive', 'evidence', 'to', 'show', 'the', 'clinical', 'efficacy', 'of', 'MT', 'and', 'MSE', 'on', 'relaxation', 'and', 'reducing', 'challenging', 'behaviours', ',', 'the', 'following', 'null', 'hypotheses', 'are', 'suggested', ':', '\\n\\n', 'There', 'will', 'not', 'be', 'any', 'differences', 'on', 'reducing', 'heart', 'and', 'respiration', 'rates', 'between', 'MT', '-', 'MSE', ',', 'MT', ',', 'MSE', ',', 'and', 'usual', 'care', 'only', 'over', 'the', '10', '-', 'week', 'intervention', 'period', 'and', 'a', '2', '-', 'week', 'follow', '-', 'up', '.', '\\n', 'There', 'will', 'not', 'be', 'any', 'differences', 'on', 'adaptive', 'behaviours', 'and', 'levels', 'of', 'alertness', 'between', 'MT', '-', 'MSE', ',', 'MT', ',', 'MSE', ',', 'and', 'control', 'group', 'over', 'the', '10', '-', 'week', 'intervention', 'period', 'and', 'a', '2', '-', 'week', 'follow', '-', 'up', '.', '\\n', 'There', 'will', 'not', 'be', 'any', 'differences', 'on', 'frequency', 'and', 'severity', 'of', 'challenging', 'behaviours', 'between', 'MT', '-', 'MSE', ',', 'MT', ',', 'MSE', ',', 'and', 'control', 'group', 'over', 'the', '10', '-', 'week', 'intervention', 'period', 'and', 'a', '2', '-', 'week', 'follow', '-', 'up', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 57,
                "text": "Massage Therapy",
                "type": "OTHER"
            },
            {
                "start": 63,
                "end": 87,
                "text": "Multisensory Environment",
                "type": "OTHER"
            },
            {
                "start": 107,
                "end": 152,
                "text": "Severe and Profound Intellectual Disabilities",
                "type": "CONDITION"
            },
            {
                "start": 213,
                "end": 237,
                "text": "multisensory environment",
                "type": "OTHER"
            },
            {
                "start": 239,
                "end": 242,
                "text": "MSE",
                "type": "OTHER"
            },
            {
                "start": 251,
                "end": 266,
                "text": "massage therapy",
                "type": "OTHER"
            },
            {
                "start": 268,
                "end": 270,
                "text": "MT",
                "type": "OTHER"
            },
            {
                "start": 290,
                "end": 335,
                "text": "severe and profound intellectual disabilities",
                "type": "CONDITION"
            },
            {
                "start": 337,
                "end": 339,
                "text": "ID",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 369,
                "text": "massage therapy",
                "type": "OTHER"
            },
            {
                "start": 373,
                "end": 376,
                "text": "MSE",
                "type": "OTHER"
            },
            {
                "start": 378,
                "end": 401,
                "text": "activities in MSE alone",
                "type": "OTHER"
            },
            {
                "start": 403,
                "end": 444,
                "text": "massage therapy in usual care environment",
                "type": "OTHER"
            },
            {
                "start": 449,
                "end": 474,
                "text": "usual care with attention",
                "type": "CONTROL"
            },
            {
                "start": 563,
                "end": 565,
                "text": "MT",
                "type": "OTHER"
            },
            {
                "start": 570,
                "end": 573,
                "text": "MSE",
                "type": "OTHER"
            },
            {
                "start": 753,
                "end": 759,
                "text": "MT-MSE",
                "type": "OTHER"
            },
            {
                "start": 761,
                "end": 763,
                "text": "MT",
                "type": "OTHER"
            },
            {
                "start": 765,
                "end": 768,
                "text": "MSE",
                "type": "OTHER"
            },
            {
                "start": 774,
                "end": 789,
                "text": "usual care only",
                "type": "CONTROL"
            },
            {
                "start": 940,
                "end": 946,
                "text": "MT-MSE",
                "type": "OTHER"
            },
            {
                "start": 948,
                "end": 950,
                "text": "MT",
                "type": "OTHER"
            },
            {
                "start": 952,
                "end": 955,
                "text": "MSE",
                "type": "OTHER"
            },
            {
                "start": 961,
                "end": 968,
                "text": "control",
                "type": "CONTROL"
            },
            {
                "start": 1130,
                "end": 1136,
                "text": "MT-MSE",
                "type": "OTHER"
            },
            {
                "start": 1138,
                "end": 1140,
                "text": "MT",
                "type": "OTHER"
            },
            {
                "start": 1142,
                "end": 1145,
                "text": "MSE",
                "type": "OTHER"
            },
            {
                "start": 1151,
                "end": 1158,
                "text": "control",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03244527",
        "study_official_title": "Use of BCAA-rich Protein Supplements for Chronic Stroke Patients to Improve the Functional Performance ",
        "study_brief_summary": " In the past few years, Branched Chain Amino Acid (BCAA) supplements have gradually used on different groups. From training athletes, maintaining functions of healthy elders to preventing disabilities of people that can't do intense exercises. BCAAs are now considered to be able to prevent muscle atrophy and strength loss, also possible to increase strength and muscle mass if combined with resistance exercises. Stroke patients have difficulties with moving, which led to multiple disabilities, are more likely to have sarcopenia and strength loss. Furthermore, reducing the will of moving or walking. Recently, studies showed that combined BCAAs with resistance exercises can effectively increase muscle mass, thus commonly used on training athletes.\n\nAlthough aerobic exercises are proven to be more likely to improve walking ability of chronic stroke patients than traditional rehabilitation, BCAAs' effects are yet to be proven. Therefore, the aim of this study is to explore if BCAAs combined with moderate intensity exercises can prevent muscle atrophy, loss of strength and cardiopulmonary function.\n\nThis is a randomized control trial. Participants are randomly assigned to either experiment or control groups. Both group received aerobic exercise (30 min in a session, 3 days a week, and for 8 weeks). Experiment group received BCAA supplement immediately after the exercise while the control group receive sham product (vitamins). The outcome measurements (including muscle mass, functional measures, and quality of life) are performed before (0-wk) and after (8-wk) the interventions, also after interventions in 3 months and 6 months for follow up.",
        "text": "Use of BCAA-rich Protein Supplements for Chronic Stroke Patients to Improve the Functional Performance | In the past few years, Branched Chain Amino Acid (BCAA) supplements have gradually used on different groups. From training athletes, maintaining functions of healthy elders to preventing disabilities of people that can't do intense exercises. BCAAs are now considered to be able to prevent muscle atrophy and strength loss, also possible to increase strength and muscle mass if combined with resistance exercises. Stroke patients have difficulties with moving, which led to multiple disabilities, are more likely to have sarcopenia and strength loss. Furthermore, reducing the will of moving or walking. Recently, studies showed that combined BCAAs with resistance exercises can effectively increase muscle mass, thus commonly used on training athletes.\n\nAlthough aerobic exercises are proven to be more likely to improve walking ability of chronic stroke patients than traditional rehabilitation, BCAAs' effects are yet to be proven. Therefore, the aim of this study is to explore if BCAAs combined with moderate intensity exercises can prevent muscle atrophy, loss of strength and cardiopulmonary function.\n\nThis is a randomized control trial. Participants are randomly assigned to either experiment or control groups. Both group received aerobic exercise (30 min in a session, 3 days a week, and for 8 weeks). Experiment group received BCAA supplement immediately after the exercise while the control group receive sham product (vitamins). The outcome measurements (including muscle mass, functional measures, and quality of life) are performed before (0-wk) and after (8-wk) the interventions, also after interventions in 3 months and 6 months for follow up.",
        "tokens": "['Use', 'of', 'BCAA', '-', 'rich', 'Protein', 'Supplements', 'for', 'Chronic', 'Stroke', 'Patients', 'to', 'Improve', 'the', 'Functional', 'Performance', '|', 'In', 'the', 'past', 'few', 'years', ',', 'Branched', 'Chain', 'Amino', 'Acid', '(', 'BCAA', ')', 'supplements', 'have', 'gradually', 'used', 'on', 'different', 'groups', '.', 'From', 'training', 'athletes', ',', 'maintaining', 'functions', 'of', 'healthy', 'elders', 'to', 'preventing', 'disabilities', 'of', 'people', 'that', 'ca', \"n't\", 'do', 'intense', 'exercises', '.', 'BCAAs', 'are', 'now', 'considered', 'to', 'be', 'able', 'to', 'prevent', 'muscle', 'atrophy', 'and', 'strength', 'loss', ',', 'also', 'possible', 'to', 'increase', 'strength', 'and', 'muscle', 'mass', 'if', 'combined', 'with', 'resistance', 'exercises', '.', 'Stroke', 'patients', 'have', 'difficulties', 'with', 'moving', ',', 'which', 'led', 'to', 'multiple', 'disabilities', ',', 'are', 'more', 'likely', 'to', 'have', 'sarcopenia', 'and', 'strength', 'loss', '.', 'Furthermore', ',', 'reducing', 'the', 'will', 'of', 'moving', 'or', 'walking', '.', 'Recently', ',', 'studies', 'showed', 'that', 'combined', 'BCAAs', 'with', 'resistance', 'exercises', 'can', 'effectively', 'increase', 'muscle', 'mass', ',', 'thus', 'commonly', 'used', 'on', 'training', 'athletes', '.', '\\n\\n', 'Although', 'aerobic', 'exercises', 'are', 'proven', 'to', 'be', 'more', 'likely', 'to', 'improve', 'walking', 'ability', 'of', 'chronic', 'stroke', 'patients', 'than', 'traditional', 'rehabilitation', ',', 'BCAAs', \"'\", 'effects', 'are', 'yet', 'to', 'be', 'proven', '.', 'Therefore', ',', 'the', 'aim', 'of', 'this', 'study', 'is', 'to', 'explore', 'if', 'BCAAs', 'combined', 'with', 'moderate', 'intensity', 'exercises', 'can', 'prevent', 'muscle', 'atrophy', ',', 'loss', 'of', 'strength', 'and', 'cardiopulmonary', 'function', '.', '\\n\\n', 'This', 'is', 'a', 'randomized', 'control', 'trial', '.', 'Participants', 'are', 'randomly', 'assigned', 'to', 'either', 'experiment', 'or', 'control', 'groups', '.', 'Both', 'group', 'received', 'aerobic', 'exercise', '(', '30', 'min', 'in', 'a', 'session', ',', '3', 'days', 'a', 'week', ',', 'and', 'for', '8', 'weeks', ')', '.', 'Experiment', 'group', 'received', 'BCAA', 'supplement', 'immediately', 'after', 'the', 'exercise', 'while', 'the', 'control', 'group', 'receive', 'sham', 'product', '(', 'vitamins', ')', '.', 'The', 'outcome', 'measurements', '(', 'including', 'muscle', 'mass', ',', 'functional', 'measures', ',', 'and', 'quality', 'of', 'life', ')', 'are', 'performed', 'before', '(', '0', '-', 'wk', ')', 'and', 'after', '(', '8', '-', 'wk', ')', 'the', 'interventions', ',', 'also', 'after', 'interventions', 'in', '3', 'months', 'and', '6', 'months', 'for', 'follow', 'up', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 7,
                "end": 11,
                "text": "BCAA",
                "type": "DRUG"
            },
            {
                "start": 41,
                "end": 55,
                "text": "Chronic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 128,
                "end": 153,
                "text": "Branched Chain Amino Acid",
                "type": "DRUG"
            },
            {
                "start": 155,
                "end": 159,
                "text": "BCAA",
                "type": "DRUG"
            },
            {
                "start": 348,
                "end": 353,
                "text": "BCAAs",
                "type": "DRUG"
            },
            {
                "start": 519,
                "end": 525,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 748,
                "end": 753,
                "text": "BCAAs",
                "type": "DRUG"
            },
            {
                "start": 946,
                "end": 960,
                "text": "chronic stroke",
                "type": "CONDITION"
            },
            {
                "start": 1003,
                "end": 1008,
                "text": "BCAAs",
                "type": "DRUG"
            },
            {
                "start": 1090,
                "end": 1095,
                "text": "BCAAs",
                "type": "DRUG"
            },
            {
                "start": 1110,
                "end": 1138,
                "text": "moderate intensity exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 1346,
                "end": 1362,
                "text": "aerobic exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1444,
                "end": 1448,
                "text": "BCAA",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04671381",
        "study_official_title": "Improving Access and Affordability of Adult Hearing Healthcare: Effectiveness of Community-based Interventions in West Central and South Alabama ",
        "study_brief_summary": " This project will address quality of care issues associated with hearing loss in adults who have mild-to-moderate hearing loss and who have no access to hearing healthcare. Through the use of three different interventions involving personal sound amplification products (PSAPs), it will lead to options that will increase access and affordability of hearing healthcare for adults with mild-to-moderate hearing loss.",
        "text": "Improving Access and Affordability of Adult Hearing Healthcare: Effectiveness of Community-based Interventions in West Central and South Alabama | This project will address quality of care issues associated with hearing loss in adults who have mild-to-moderate hearing loss and who have no access to hearing healthcare. Through the use of three different interventions involving personal sound amplification products (PSAPs), it will lead to options that will increase access and affordability of hearing healthcare for adults with mild-to-moderate hearing loss.",
        "tokens": "['Improving', 'Access', 'and', 'Affordability', 'of', 'Adult', 'Hearing', 'Healthcare', ':', 'Effectiveness', 'of', 'Community', '-', 'based', 'Interventions', 'in', 'West', 'Central', 'and', 'South', 'Alabama', '|', 'This', 'project', 'will', 'address', 'quality', 'of', 'care', 'issues', 'associated', 'with', 'hearing', 'loss', 'in', 'adults', 'who', 'have', 'mild', '-', 'to', '-', 'moderate', 'hearing', 'loss', 'and', 'who', 'have', 'no', 'access', 'to', 'hearing', 'healthcare', '.', 'Through', 'the', 'use', 'of', 'three', 'different', 'interventions', 'involving', 'personal', 'sound', 'amplification', 'products', '(', 'PSAPs', ')', ',', 'it', 'will', 'lead', 'to', 'options', 'that', 'will', 'increase', 'access', 'and', 'affordability', 'of', 'hearing', 'healthcare', 'for', 'adults', 'with', 'mild', '-', 'to', '-', 'moderate', 'hearing', 'loss', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 212,
                "end": 224,
                "text": "hearing loss",
                "type": "CONDITION"
            },
            {
                "start": 244,
                "end": 273,
                "text": "mild-to-moderate hearing loss",
                "type": "CONDITION"
            },
            {
                "start": 379,
                "end": 416,
                "text": "personal sound amplification products",
                "type": "OTHER"
            },
            {
                "start": 418,
                "end": 423,
                "text": "PSAPs",
                "type": "OTHER"
            },
            {
                "start": 532,
                "end": 561,
                "text": "mild-to-moderate hearing loss",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04141150",
        "study_official_title": "A Phase 2, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects ",
        "study_brief_summary": " The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.",
        "text": "A Phase 2, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects | The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and healthy subjects.",
        "tokens": "['A', 'Phase', '2', ',', 'Multicenter', 'Study', 'of', '[', '18F]APN-1607', 'Positron', 'Emission', 'Tomography', 'in', 'Subjects', 'With', 'Alzheimer', \"'s\", 'Disease', 'Compared', 'to', 'Healthy', 'Subjects', '|', 'The', 'overall', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'overall', 'pattern', 'of', '[', '18F]APN-1607', 'uptake', 'in', 'subjects', 'with', 'MDAD', ',', 'subjects', 'with', 'AD', 'dementia', ',', 'and', 'healthy', 'subjects', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 92,
                "end": 111,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 285,
                "text": "AD dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00827268",
        "study_official_title": "Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes ",
        "study_brief_summary": " This study offers 90-120 hours of 1:1 training to improve reading skills in adults who have poor reading skills following a stroke. Specifically, this study is designed to improve skill in sounding out words for reading and spelling. The overall time commitment for participation in this study is approximately 11-30 weeks.",
        "text": "Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes | This study offers 90-120 hours of 1:1 training to improve reading skills in adults who have poor reading skills following a stroke. Specifically, this study is designed to improve skill in sounding out words for reading and spelling. The overall time commitment for participation in this study is approximately 11-30 weeks.",
        "tokens": "['Multimodal', 'Treatment', 'of', 'Phonological', 'Alexia', ':', 'Behavioral', '&', 'fMRI', 'Outcomes', '|', 'This', 'study', 'offers', '90', '-', '120', 'hours', 'of', '1:1', 'training', 'to', 'improve', 'reading', 'skills', 'in', 'adults', 'who', 'have', 'poor', 'reading', 'skills', 'following', 'a', 'stroke', '.', 'Specifically', ',', 'this', 'study', 'is', 'designed', 'to', 'improve', 'skill', 'in', 'sounding', 'out', 'words', 'for', 'reading', 'and', 'spelling', '.', 'The', 'overall', 'time', 'commitment', 'for', 'participation', 'in', 'this', 'study', 'is', 'approximately', '11', '-', '30', 'weeks', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 43,
                "text": "Phonological Alexia",
                "type": "CONDITION"
            },
            {
                "start": 108,
                "end": 146,
                "text": "1:1 training to improve reading skills",
                "type": "OTHER"
            },
            {
                "start": 198,
                "end": 204,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04212260",
        "study_official_title": "Strengthening Oropharyngeal Muscles as a Novel Approach to Treat Obstructive Sleep Apnea After Stroke: A Randomized Feasibility Study ",
        "study_brief_summary": " This study evaluates the feasibility and effectiveness of an oropharyngeal exercise (O-PE) regimen in treating post-stroke obstructive sleep apnea, as an alternative therapy to continuous positive airway pressure (CPAP). Eligible patients will be randomized (1:1) to treatment using a pre-specified schedule of O-PEs vs. a sham control arm.",
        "text": "Strengthening Oropharyngeal Muscles as a Novel Approach to Treat Obstructive Sleep Apnea After Stroke: A Randomized Feasibility Study | This study evaluates the feasibility and effectiveness of an oropharyngeal exercise (O-PE) regimen in treating post-stroke obstructive sleep apnea, as an alternative therapy to continuous positive airway pressure (CPAP). Eligible patients will be randomized (1:1) to treatment using a pre-specified schedule of O-PEs vs. a sham control arm.",
        "tokens": "['Strengthening', 'Oropharyngeal', 'Muscles', 'as', 'a', 'Novel', 'Approach', 'to', 'Treat', 'Obstructive', 'Sleep', 'Apnea', 'After', 'Stroke', ':', 'A', 'Randomized', 'Feasibility', 'Study', '|', 'This', 'study', 'evaluates', 'the', 'feasibility', 'and', 'effectiveness', 'of', 'an', 'oropharyngeal', 'exercise', '(', 'O', '-', 'PE', ')', 'regimen', 'in', 'treating', 'post', '-', 'stroke', 'obstructive', 'sleep', 'apnea', ',', 'as', 'an', 'alternative', 'therapy', 'to', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', '.', 'Eligible', 'patients', 'will', 'be', 'randomized', '(', '1:1', ')', 'to', 'treatment', 'using', 'a', 'pre', '-', 'specified', 'schedule', 'of', 'O', '-', 'PEs', 'vs.', 'a', 'sham', 'control', 'arm', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 35,
                "text": "Strengthening Oropharyngeal Muscles",
                "type": "PHYSICAL"
            },
            {
                "start": 65,
                "end": 88,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 95,
                "end": 101,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 197,
                "end": 219,
                "text": "oropharyngeal exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 221,
                "end": 225,
                "text": "O-PE",
                "type": "PHYSICAL"
            },
            {
                "start": 247,
                "end": 258,
                "text": "post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 259,
                "end": 282,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 313,
                "end": 348,
                "text": "continuous positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 350,
                "end": 354,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 447,
                "end": 452,
                "text": "O-PEs",
                "type": "PHYSICAL"
            },
            {
                "start": 459,
                "end": 471,
                "text": "sham control",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00778323",
        "study_official_title": "Effects of Remote Ischemic Preconditioning on Biochemical Markers and Neurological Outcomes in Patients Undergoing Elective Cervical Decompression Surgery ",
        "study_brief_summary": " The purpose of this study is to assess whether a large clinical trial testing the effect of RIPC on neurologic outcome in patients undergoing elective cervical decompression surge is warranted.",
        "text": "Effects of Remote Ischemic Preconditioning on Biochemical Markers and Neurological Outcomes in Patients Undergoing Elective Cervical Decompression Surgery | The purpose of this study is to assess whether a large clinical trial testing the effect of RIPC on neurologic outcome in patients undergoing elective cervical decompression surge is warranted.",
        "tokens": "['Effects', 'of', 'Remote', 'Ischemic', 'Preconditioning', 'on', 'Biochemical', 'Markers', 'and', 'Neurological', 'Outcomes', 'in', 'Patients', 'Undergoing', 'Elective', 'Cervical', 'Decompression', 'Surgery', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'whether', 'a', 'large', 'clinical', 'trial', 'testing', 'the', 'effect', 'of', 'RIPC', 'on', 'neurologic', 'outcome', 'in', 'patients', 'undergoing', 'elective', 'cervical', 'decompression', 'surge', 'is', 'warranted', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 42,
                "text": "Remote Ischemic Preconditioning",
                "type": "OTHER"
            },
            {
                "start": 124,
                "end": 154,
                "text": "Cervical Decompression Surgery",
                "type": "CONDITION"
            },
            {
                "start": 249,
                "end": 253,
                "text": "RIPC",
                "type": "OTHER"
            },
            {
                "start": 308,
                "end": 336,
                "text": "cervical decompression surge",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03607994",
        "study_official_title": "Randomized Controlled Pilot Trial of HIRREM-SOP for Insomnia ",
        "study_brief_summary": " Prior research studies have shown benefit for use of a technique called High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM\u00ae), to reduce symptoms of moderate to severe insomnia. HIRREM uses scalp sensors to monitor brain electrical activity, and software algorithms translate selected brain frequencies into audible tones in real time. Those tones (acoustic stimulation) are reflected back to participants via ear buds in as little as four milliseconds, providing the brain an opportunity to self-adjust and balance its electrical pattern.\n\nThe purpose of this research study is to determine the effects of HIRREM-SOP, an updated version of this technology that is based on the HIRREM approach, but now includes new hardware and software, a standardized series of HIRREM protocols, and a fixed number of sessions. Adults over the age of 18 who have documented sleep trouble that place them in the category of subthreshold (mild), moderate, or severe clinical insomnia as defined by the Insomnia Severity Index, are eligible to participate in the study.",
        "text": "Randomized Controlled Pilot Trial of HIRREM-SOP for Insomnia | Prior research studies have shown benefit for use of a technique called High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM\u00ae), to reduce symptoms of moderate to severe insomnia. HIRREM uses scalp sensors to monitor brain electrical activity, and software algorithms translate selected brain frequencies into audible tones in real time. Those tones (acoustic stimulation) are reflected back to participants via ear buds in as little as four milliseconds, providing the brain an opportunity to self-adjust and balance its electrical pattern.\n\nThe purpose of this research study is to determine the effects of HIRREM-SOP, an updated version of this technology that is based on the HIRREM approach, but now includes new hardware and software, a standardized series of HIRREM protocols, and a fixed number of sessions. Adults over the age of 18 who have documented sleep trouble that place them in the category of subthreshold (mild), moderate, or severe clinical insomnia as defined by the Insomnia Severity Index, are eligible to participate in the study.",
        "tokens": "['Randomized', 'Controlled', 'Pilot', 'Trial', 'of', 'HIRREM', '-', 'SOP', 'for', 'Insomnia', '|', 'Prior', 'research', 'studies', 'have', 'shown', 'benefit', 'for', 'use', 'of', 'a', 'technique', 'called', 'High', '-', 'resolution', ',', 'relational', ',', 'resonance', '-', 'based', ',', 'electroencephalic', 'mirroring', '(', 'HIRREM', '\u00ae', ')', ',', 'to', 'reduce', 'symptoms', 'of', 'moderate', 'to', 'severe', 'insomnia', '.', 'HIRREM', 'uses', 'scalp', 'sensors', 'to', 'monitor', 'brain', 'electrical', 'activity', ',', 'and', 'software', 'algorithms', 'translate', 'selected', 'brain', 'frequencies', 'into', 'audible', 'tones', 'in', 'real', 'time', '.', 'Those', 'tones', '(', 'acoustic', 'stimulation', ')', 'are', 'reflected', 'back', 'to', 'participants', 'via', 'ear', 'buds', 'in', 'as', 'little', 'as', 'four', 'milliseconds', ',', 'providing', 'the', 'brain', 'an', 'opportunity', 'to', 'self', '-', 'adjust', 'and', 'balance', 'its', 'electrical', 'pattern', '.', '\\n\\n', 'The', 'purpose', 'of', 'this', 'research', 'study', 'is', 'to', 'determine', 'the', 'effects', 'of', 'HIRREM', '-', 'SOP', ',', 'an', 'updated', 'version', 'of', 'this', 'technology', 'that', 'is', 'based', 'on', 'the', 'HIRREM', 'approach', ',', 'but', 'now', 'includes', 'new', 'hardware', 'and', 'software', ',', 'a', 'standardized', 'series', 'of', 'HIRREM', 'protocols', ',', 'and', 'a', 'fixed', 'number', 'of', 'sessions', '.', 'Adults', 'over', 'the', 'age', 'of', '18', 'who', 'have', 'documented', 'sleep', 'trouble', 'that', 'place', 'them', 'in', 'the', 'category', 'of', 'subthreshold', '(', 'mild', ')', ',', 'moderate', ',', 'or', 'severe', 'clinical', 'insomnia', 'as', 'defined', 'by', 'the', 'Insomnia', 'Severity', 'Index', ',', 'are', 'eligible', 'to', 'participate', 'in', 'the', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 47,
                "text": "HIRREM-SOP",
                "type": "OTHER"
            },
            {
                "start": 52,
                "end": 60,
                "text": "Insomnia",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 208,
                "text": "High-resolution, relational, resonance-based, electroencephalic mirroring",
                "type": "OTHER"
            },
            {
                "start": 210,
                "end": 216,
                "text": "HIRREM",
                "type": "OTHER"
            },
            {
                "start": 242,
                "end": 269,
                "text": "moderate to severe insomnia",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 277,
                "text": "HIRREM",
                "type": "OTHER"
            },
            {
                "start": 700,
                "end": 710,
                "text": "HIRREM-SOP",
                "type": "OTHER"
            },
            {
                "start": 771,
                "end": 777,
                "text": "HIRREM",
                "type": "OTHER"
            },
            {
                "start": 857,
                "end": 863,
                "text": "HIRREM",
                "type": "OTHER"
            },
            {
                "start": 953,
                "end": 966,
                "text": "sleep trouble",
                "type": "CONDITION"
            },
            {
                "start": 1002,
                "end": 1060,
                "text": "subthreshold (mild), moderate, or severe clinical insomnia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03024125",
        "study_official_title": "Effect of Normal and High Protein Diets in Lean Mass, Adiposity, and Strength in Postmenopausal Women Practitioners of Resistance Exercise ",
        "study_brief_summary": " This study evaluates the effect of different types of diets (high and normal protein) on lean and fat mass, and strength in postmenopausal women practitioners of resistance exercise. Two groups will be created: high protein (1.2 protein g/body mass/day) and normal protein (0.8 protein g/body mass/day). The same training will be performed for both groups.",
        "text": "Effect of Normal and High Protein Diets in Lean Mass, Adiposity, and Strength in Postmenopausal Women Practitioners of Resistance Exercise | This study evaluates the effect of different types of diets (high and normal protein) on lean and fat mass, and strength in postmenopausal women practitioners of resistance exercise. Two groups will be created: high protein (1.2 protein g/body mass/day) and normal protein (0.8 protein g/body mass/day). The same training will be performed for both groups.",
        "tokens": "['Effect', 'of', 'Normal', 'and', 'High', 'Protein', 'Diets', 'in', 'Lean', 'Mass', ',', 'Adiposity', ',', 'and', 'Strength', 'in', 'Postmenopausal', 'Women', 'Practitioners', 'of', 'Resistance', 'Exercise', '|', 'This', 'study', 'evaluates', 'the', 'effect', 'of', 'different', 'types', 'of', 'diets', '(', 'high', 'and', 'normal', 'protein', ')', 'on', 'lean', 'and', 'fat', 'mass', ',', 'and', 'strength', 'in', 'postmenopausal', 'women', 'practitioners', 'of', 'resistance', 'exercise', '.', 'Two', 'groups', 'will', 'be', 'created', ':', 'high', 'protein', '(', '1.2', 'protein', 'g', '/', 'body', 'mass', '/', 'day', ')', 'and', 'normal', 'protein', '(', '0.8', 'protein', 'g', '/', 'body', 'mass', '/', 'day', ')', '.', 'The', 'same', 'training', 'will', 'be', 'performed', 'for', 'both', 'groups', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 39,
                "text": "Normal and High Protein Diets",
                "type": "OTHER"
            },
            {
                "start": 54,
                "end": 63,
                "text": "Adiposity",
                "type": "CONDITION"
            },
            {
                "start": 81,
                "end": 95,
                "text": "Postmenopausal",
                "type": "CONDITION"
            },
            {
                "start": 202,
                "end": 225,
                "text": "high and normal protein",
                "type": "OTHER"
            },
            {
                "start": 265,
                "end": 279,
                "text": "postmenopausal",
                "type": "CONDITION"
            },
            {
                "start": 352,
                "end": 364,
                "text": "high protein",
                "type": "OTHER"
            },
            {
                "start": 399,
                "end": 413,
                "text": "normal protein",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01282268",
        "study_official_title": "A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome ",
        "study_brief_summary": " To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in adolescents and adults with fragile X syndrome (FXS)",
        "text": "A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome | To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in adolescents and adults with fragile X syndrome (FXS)",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Study', 'of', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'STX209', '(', 'Arbaclofen', ')', 'Administered', 'for', 'the', 'Treatment', 'of', 'Social', 'Function', 'in', 'Adolescents', 'and', 'Adults', 'With', 'Fragile', 'X', 'Syndrome', '|', 'To', 'explore', 'the', 'efficacy', ',', 'safety', 'and', 'tolerability', 'of', 'STX209', '(', 'arbaclofen', ')', 'administered', 'for', 'the', 'treatment', 'of', 'social', 'withdrawal', 'in', 'adolescents', 'and', 'adults', 'with', 'fragile', 'X', 'syndrome', '(', 'FXS', ')']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 98,
                "end": 104,
                "text": "STX209",
                "type": "DRUG"
            },
            {
                "start": 106,
                "end": 116,
                "text": "Arbaclofen",
                "type": "DRUG"
            },
            {
                "start": 199,
                "end": 217,
                "text": "Fragile X Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 272,
                "end": 278,
                "text": "STX209",
                "type": "DRUG"
            },
            {
                "start": 280,
                "end": 290,
                "text": "arbaclofen",
                "type": "DRUG"
            },
            {
                "start": 326,
                "end": 343,
                "text": "social withdrawal",
                "type": "CONDITION"
            },
            {
                "start": 375,
                "end": 393,
                "text": "fragile X syndrome",
                "type": "CONDITION"
            },
            {
                "start": 395,
                "end": 398,
                "text": "FXS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03047408",
        "study_official_title": "Evolution of REM Sleep Behavior Disorder in Parkinson's Disease Patients RBD Diagnosed Three Years Earlier ",
        "study_brief_summary": " About 60% of Parkinson's Disease (PD) patients have REM sleep Behavior Disorder (RBD), a parasomnia characterized by partial or complete loss of REM sleep muscle atonia and dream-enacting behaviors, usually associated to vivid dreams. The REM Sleep without atonia is the polysomnographic hallmark of RBD, and its quantification is necessary for the diagnosis.\n\nRBD in PD is believed to be a marker of a more widespread degenerative process and a marker of malignant phenotype. Therefore, PD patients with RBD (PD-RBD) are more severely impaired in both motor and non-motor domains, compared to those without RBD, with an increased risk of dementia. However, little is know about the relationship between the evolution of RBD, clinic and video-polysomnographic, and the progression of PD. Besides, an improvement of RBD symptoms is anecdotally reported in PD patients over time. Longitudinal evaluation of RBD in PD, assessed by questionnaires, led to controversial results, but so far, no longitudinal vPSG study has been performed in PD-RBD population.\n\nThus, the main objective of this study is to longitudinally evaluate clinical and video-polysomnographic features of RBD, including measure of REM Sleep without atonia, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.",
        "text": "Evolution of REM Sleep Behavior Disorder in Parkinson's Disease Patients RBD Diagnosed Three Years Earlier | About 60% of Parkinson's Disease (PD) patients have REM sleep Behavior Disorder (RBD), a parasomnia characterized by partial or complete loss of REM sleep muscle atonia and dream-enacting behaviors, usually associated to vivid dreams. The REM Sleep without atonia is the polysomnographic hallmark of RBD, and its quantification is necessary for the diagnosis.\n\nRBD in PD is believed to be a marker of a more widespread degenerative process and a marker of malignant phenotype. Therefore, PD patients with RBD (PD-RBD) are more severely impaired in both motor and non-motor domains, compared to those without RBD, with an increased risk of dementia. However, little is know about the relationship between the evolution of RBD, clinic and video-polysomnographic, and the progression of PD. Besides, an improvement of RBD symptoms is anecdotally reported in PD patients over time. Longitudinal evaluation of RBD in PD, assessed by questionnaires, led to controversial results, but so far, no longitudinal vPSG study has been performed in PD-RBD population.\n\nThus, the main objective of this study is to longitudinally evaluate clinical and video-polysomnographic features of RBD, including measure of REM Sleep without atonia, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.",
        "tokens": "['Evolution', 'of', 'REM', 'Sleep', 'Behavior', 'Disorder', 'in', 'Parkinson', \"'s\", 'Disease', 'Patients', 'RBD', 'Diagnosed', 'Three', 'Years', 'Earlier', '|', 'About', '60', '%', 'of', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', 'patients', 'have', 'REM', 'sleep', 'Behavior', 'Disorder', '(', 'RBD', ')', ',', 'a', 'parasomnia', 'characterized', 'by', 'partial', 'or', 'complete', 'loss', 'of', 'REM', 'sleep', 'muscle', 'atonia', 'and', 'dream', '-', 'enacting', 'behaviors', ',', 'usually', 'associated', 'to', 'vivid', 'dreams', '.', 'The', 'REM', 'Sleep', 'without', 'atonia', 'is', 'the', 'polysomnographic', 'hallmark', 'of', 'RBD', ',', 'and', 'its', 'quantification', 'is', 'necessary', 'for', 'the', 'diagnosis', '.', '\\n\\n', 'RBD', 'in', 'PD', 'is', 'believed', 'to', 'be', 'a', 'marker', 'of', 'a', 'more', 'widespread', 'degenerative', 'process', 'and', 'a', 'marker', 'of', 'malignant', 'phenotype', '.', 'Therefore', ',', 'PD', 'patients', 'with', 'RBD', '(', 'PD', '-', 'RBD', ')', 'are', 'more', 'severely', 'impaired', 'in', 'both', 'motor', 'and', 'non', '-', 'motor', 'domains', ',', 'compared', 'to', 'those', 'without', 'RBD', ',', 'with', 'an', 'increased', 'risk', 'of', 'dementia', '.', 'However', ',', 'little', 'is', 'know', 'about', 'the', 'relationship', 'between', 'the', 'evolution', 'of', 'RBD', ',', 'clinic', 'and', 'video', '-', 'polysomnographic', ',', 'and', 'the', 'progression', 'of', 'PD', '.', 'Besides', ',', 'an', 'improvement', 'of', 'RBD', 'symptoms', 'is', 'anecdotally', 'reported', 'in', 'PD', 'patients', 'over', 'time', '.', 'Longitudinal', 'evaluation', 'of', 'RBD', 'in', 'PD', ',', 'assessed', 'by', 'questionnaires', ',', 'led', 'to', 'controversial', 'results', ',', 'but', 'so', 'far', ',', 'no', 'longitudinal', 'vPSG', 'study', 'has', 'been', 'performed', 'in', 'PD', '-', 'RBD', 'population', '.', '\\n\\n', 'Thus', ',', 'the', 'main', 'objective', 'of', 'this', 'study', 'is', 'to', 'longitudinally', 'evaluate', 'clinical', 'and', 'video', '-', 'polysomnographic', 'features', 'of', 'RBD', ',', 'including', 'measure', 'of', 'REM', 'Sleep', 'without', 'atonia', ',', 'in', 'patients', 'with', 'PD', '-', 'RBD', ',', 'after', 'three', 'years', 'from', 'the', 'diagnosis', 'of', 'RBD', ',', 'in', 'order', 'to', 'ascertain', 'whether', 'RBD', 'features', 'remain', 'stable', 'over', 'time', '.', 'The', 'possible', 'remission', 'of', 'RBD', 'with', 'the', 'progression', 'of', 'PD', 'would', 'question', 'indeed', 'its', 'reliability', 'as', 'prognostic', 'bio', '-', 'marker', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 40,
                "text": "REM Sleep Behavior Disorder",
                "type": "CONDITION"
            },
            {
                "start": 44,
                "end": 63,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 73,
                "end": 76,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 122,
                "end": 141,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 143,
                "end": 145,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 188,
                "text": "REM sleep Behavior Disorder",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 193,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 409,
                "end": 412,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 470,
                "end": 473,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 477,
                "end": 479,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 597,
                "end": 599,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 614,
                "end": 617,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 619,
                "end": 625,
                "text": "PD-RBD",
                "type": "CONDITION"
            },
            {
                "start": 717,
                "end": 720,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 830,
                "end": 833,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 893,
                "end": 895,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 924,
                "end": 927,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 964,
                "end": 966,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1014,
                "end": 1017,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 1021,
                "end": 1023,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1144,
                "end": 1146,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1147,
                "end": 1150,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 1281,
                "end": 1284,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 1350,
                "end": 1352,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1353,
                "end": 1356,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 1398,
                "end": 1401,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 1433,
                "end": 1436,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 1497,
                "end": 1500,
                "text": "RBD",
                "type": "CONDITION"
            },
            {
                "start": 1525,
                "end": 1527,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04389762",
        "study_official_title": "Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study ",
        "study_brief_summary": " The purpose of this study is to investigate the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.",
        "text": "Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study | The purpose of this study is to investigate the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.",
        "tokens": "['Lactobacillus', 'Plantarum', 'PS128', 'May', 'Improve', 'Off', 'Duration', 'in', 'Parkinson', \"'s\", 'Disease', ':', 'a', 'Pilot', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'short', 'term', 'effects', '(', '12', 'Weeks', ')', 'of', 'Lactobacillus', 'plantarum', 'PS128', '(', 'PS128', ')', 'on', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'symptoms', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 29,
                "text": "Lactobacillus Plantarum PS128",
                "type": "OTHER"
            },
            {
                "start": 58,
                "end": 77,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 176,
                "end": 205,
                "text": "Lactobacillus plantarum PS128",
                "type": "OTHER"
            },
            {
                "start": 207,
                "end": 212,
                "text": "PS128",
                "type": "OTHER"
            },
            {
                "start": 217,
                "end": 236,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 238,
                "end": 240,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02453893",
        "study_official_title": "Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia ",
        "study_brief_summary": " This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.",
        "text": "Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia | This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.",
        "tokens": "['Double', '-', 'blind', ',', 'Double', '-', 'simulation', ',', 'Risperidone', '-', 'controlled', ',', 'Multicentre', 'Clinical', 'Trial', 'of', 'Iloperidone', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'This', 'research', 'is', 'a', 'Randomized', ',', 'double', '-', 'blind', ',', 'risperidone', '-', 'controlled', ',', 'multicenter', 'clinical', 'study', '.', 'Chinese', 'subjects', 'with', 'Ischemic', 'Schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 42,
                "text": "Risperidone",
                "type": "DRUG"
            },
            {
                "start": 84,
                "end": 95,
                "text": "Iloperidone",
                "type": "DRUG"
            },
            {
                "start": 113,
                "end": 126,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 174,
                "end": 185,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 248,
                "end": 270,
                "text": "Ischemic Schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00315081",
        "study_official_title": "Therapy With Bromocriptine in Patients With Symptomatic Risperidone-Induced Hyperprolactinemia ",
        "study_brief_summary": " Antipsychotic drugs can cause a clinically relevant hyperprolactinemia due to blocking the dopamine receptors in the pituitary.Schizophrenic patients suffering from a neuroleptic-induced hyperprolactinemia will be examined endocrinologically. Adverse drug effects and diagnoses will be confirmed by measuring hormones.",
        "text": "Therapy With Bromocriptine in Patients With Symptomatic Risperidone-Induced Hyperprolactinemia | Antipsychotic drugs can cause a clinically relevant hyperprolactinemia due to blocking the dopamine receptors in the pituitary.Schizophrenic patients suffering from a neuroleptic-induced hyperprolactinemia will be examined endocrinologically. Adverse drug effects and diagnoses will be confirmed by measuring hormones.",
        "tokens": "['Therapy', 'With', 'Bromocriptine', 'in', 'Patients', 'With', 'Symptomatic', 'Risperidone', '-', 'Induced', 'Hyperprolactinemia', '|', 'Antipsychotic', 'drugs', 'can', 'cause', 'a', 'clinically', 'relevant', 'hyperprolactinemia', 'due', 'to', 'blocking', 'the', 'dopamine', 'receptors', 'in', 'the', 'pituitary', '.', 'Schizophrenic', 'patients', 'suffering', 'from', 'a', 'neuroleptic', '-', 'induced', 'hyperprolactinemia', 'will', 'be', 'examined', 'endocrinologically', '.', 'Adverse', 'drug', 'effects', 'and', 'diagnoses', 'will', 'be', 'confirmed', 'by', 'measuring', 'hormones', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 26,
                "text": "Bromocriptine",
                "type": "DRUG"
            },
            {
                "start": 56,
                "end": 67,
                "text": "Risperidone",
                "type": "DRUG"
            },
            {
                "start": 76,
                "end": 94,
                "text": "Hyperprolactinemia",
                "type": "CONDITION"
            },
            {
                "start": 97,
                "end": 110,
                "text": "Antipsychotic",
                "type": "DRUG"
            },
            {
                "start": 149,
                "end": 167,
                "text": "hyperprolactinemia",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 237,
                "text": "Schizophrenic",
                "type": "CONDITION"
            },
            {
                "start": 264,
                "end": 302,
                "text": "neuroleptic-induced hyperprolactinemia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00680303",
        "study_official_title": "The Effect of Spacing of Lidcombe Program Clinic Visits ",
        "study_brief_summary": " The purpose of this study is to evaluate the efficiency of the Lidcombe Program for early stuttering by varying the time between clinic visits during the first stage of the program.",
        "text": "The Effect of Spacing of Lidcombe Program Clinic Visits | The purpose of this study is to evaluate the efficiency of the Lidcombe Program for early stuttering by varying the time between clinic visits during the first stage of the program.",
        "tokens": "['The', 'Effect', 'of', 'Spacing', 'of', 'Lidcombe', 'Program', 'Clinic', 'Visits', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficiency', 'of', 'the', 'Lidcombe', 'Program', 'for', 'early', 'stuttering', 'by', 'varying', 'the', 'time', 'between', 'clinic', 'visits', 'during', 'the', 'first', 'stage', 'of', 'the', 'program', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 41,
                "text": "Lidcombe Program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 121,
                "end": 137,
                "text": "Lidcombe Program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 142,
                "end": 158,
                "text": "early stuttering",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05245955",
        "study_official_title": "Feasibility and Validity of Robotic Assessments With the ReHapticKnob to Characterize Kinaesthesia and Haptic Perception of the Hand in Patients With Parkinson's Disease: an Exploratory Study ",
        "study_brief_summary": " It has been shown that patients with Parkinson's disease (PD) have impaired kinaesthesia and haptic perception of the upper limbs. In PD patients, these impairments might be involved in the development of hypometria or bradykinesia and may play a role in postural deficits, thereby significantly contributing to the overall disability level.\n\nDedicated conventional or robot-assisted training might improve sensory-motor function in PD patients. In order to provide efficient robot-assisted therapy, robotic devices have to be able to tailor the therapy difficulty to the individual impairment profile of each patient. For difficulty adaptation in robot-assisted therapy, it is important to assess the impairment profiles with the same robotic platform that would be used for therapy, therefore minimizing costs or potential errors coming from the use of different devices. However, up to now, little emphasis has been placed on providing sensory-motor robot-assisted therapy for the upper limbs to persons with PD based on their individual level of impairment.\n\nThe aim of this study is therefore to evaluate if the assessments of sensory-motor hand function implemented on a robotic device for hand rehabilitation, i.e. the ReHapticKnob, are suitable to measure the impairments of kinaesthesia and haptic perception observed in subjects with Parkinson's disease.\n\nIf the assessments implemented in the ReHapticKnob are sensitive enough to detect a difference between the sensory-motor function of PD patients and healthy subjects, the device might in the future be used to assess improvements before and after sensory-motor therapy. This is a necessary step before the investigators can use these assessments to tailor the difficulty level of the therapy performed with the ReHapticKnob and to investigate the benefits and impact of such a therapy on the kinaesthetic and haptic impairments of persons with PD.",
        "text": "Feasibility and Validity of Robotic Assessments With the ReHapticKnob to Characterize Kinaesthesia and Haptic Perception of the Hand in Patients With Parkinson's Disease: an Exploratory Study | It has been shown that patients with Parkinson's disease (PD) have impaired kinaesthesia and haptic perception of the upper limbs. In PD patients, these impairments might be involved in the development of hypometria or bradykinesia and may play a role in postural deficits, thereby significantly contributing to the overall disability level.\n\nDedicated conventional or robot-assisted training might improve sensory-motor function in PD patients. In order to provide efficient robot-assisted therapy, robotic devices have to be able to tailor the therapy difficulty to the individual impairment profile of each patient. For difficulty adaptation in robot-assisted therapy, it is important to assess the impairment profiles with the same robotic platform that would be used for therapy, therefore minimizing costs or potential errors coming from the use of different devices. However, up to now, little emphasis has been placed on providing sensory-motor robot-assisted therapy for the upper limbs to persons with PD based on their individual level of impairment.\n\nThe aim of this study is therefore to evaluate if the assessments of sensory-motor hand function implemented on a robotic device for hand rehabilitation, i.e. the ReHapticKnob, are suitable to measure the impairments of kinaesthesia and haptic perception observed in subjects with Parkinson's disease.\n\nIf the assessments implemented in the ReHapticKnob are sensitive enough to detect a difference between the sensory-motor function of PD patients and healthy subjects, the device might in the future be used to assess improvements before and after sensory-motor therapy. This is a necessary step before the investigators can use these assessments to tailor the difficulty level of the therapy performed with the ReHapticKnob and to investigate the benefits and impact of such a therapy on the kinaesthetic and haptic impairments of persons with PD.",
        "tokens": "['Feasibility', 'and', 'Validity', 'of', 'Robotic', 'Assessments', 'With', 'the', 'ReHapticKnob', 'to', 'Characterize', 'Kinaesthesia', 'and', 'Haptic', 'Perception', 'of', 'the', 'Hand', 'in', 'Patients', 'With', 'Parkinson', \"'s\", 'Disease', ':', 'an', 'Exploratory', 'Study', '|', 'It', 'has', 'been', 'shown', 'that', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'have', 'impaired', 'kinaesthesia', 'and', 'haptic', 'perception', 'of', 'the', 'upper', 'limbs', '.', 'In', 'PD', 'patients', ',', 'these', 'impairments', 'might', 'be', 'involved', 'in', 'the', 'development', 'of', 'hypometria', 'or', 'bradykinesia', 'and', 'may', 'play', 'a', 'role', 'in', 'postural', 'deficits', ',', 'thereby', 'significantly', 'contributing', 'to', 'the', 'overall', 'disability', 'level', '.', '\\n\\n', 'Dedicated', 'conventional', 'or', 'robot', '-', 'assisted', 'training', 'might', 'improve', 'sensory', '-', 'motor', 'function', 'in', 'PD', 'patients', '.', 'In', 'order', 'to', 'provide', 'efficient', 'robot', '-', 'assisted', 'therapy', ',', 'robotic', 'devices', 'have', 'to', 'be', 'able', 'to', 'tailor', 'the', 'therapy', 'difficulty', 'to', 'the', 'individual', 'impairment', 'profile', 'of', 'each', 'patient', '.', 'For', 'difficulty', 'adaptation', 'in', 'robot', '-', 'assisted', 'therapy', ',', 'it', 'is', 'important', 'to', 'assess', 'the', 'impairment', 'profiles', 'with', 'the', 'same', 'robotic', 'platform', 'that', 'would', 'be', 'used', 'for', 'therapy', ',', 'therefore', 'minimizing', 'costs', 'or', 'potential', 'errors', 'coming', 'from', 'the', 'use', 'of', 'different', 'devices', '.', 'However', ',', 'up', 'to', 'now', ',', 'little', 'emphasis', 'has', 'been', 'placed', 'on', 'providing', 'sensory', '-', 'motor', 'robot', '-', 'assisted', 'therapy', 'for', 'the', 'upper', 'limbs', 'to', 'persons', 'with', 'PD', 'based', 'on', 'their', 'individual', 'level', 'of', 'impairment', '.', '\\n\\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'therefore', 'to', 'evaluate', 'if', 'the', 'assessments', 'of', 'sensory', '-', 'motor', 'hand', 'function', 'implemented', 'on', 'a', 'robotic', 'device', 'for', 'hand', 'rehabilitation', ',', 'i.e.', 'the', 'ReHapticKnob', ',', 'are', 'suitable', 'to', 'measure', 'the', 'impairments', 'of', 'kinaesthesia', 'and', 'haptic', 'perception', 'observed', 'in', 'subjects', 'with', 'Parkinson', \"'s\", 'disease', '.', '\\n\\n', 'If', 'the', 'assessments', 'implemented', 'in', 'the', 'ReHapticKnob', 'are', 'sensitive', 'enough', 'to', 'detect', 'a', 'difference', 'between', 'the', 'sensory', '-', 'motor', 'function', 'of', 'PD', 'patients', 'and', 'healthy', 'subjects', ',', 'the', 'device', 'might', 'in', 'the', 'future', 'be', 'used', 'to', 'assess', 'improvements', 'before', 'and', 'after', 'sensory', '-', 'motor', 'therapy', '.', 'This', 'is', 'a', 'necessary', 'step', 'before', 'the', 'investigators', 'can', 'use', 'these', 'assessments', 'to', 'tailor', 'the', 'difficulty', 'level', 'of', 'the', 'therapy', 'performed', 'with', 'the', 'ReHapticKnob', 'and', 'to', 'investigate', 'the', 'benefits', 'and', 'impact', 'of', 'such', 'a', 'therapy', 'on', 'the', 'kinaesthetic', 'and', 'haptic', 'impairments', 'of', 'persons', 'with', 'PD', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 150,
                "end": 169,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 250,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 252,
                "end": 254,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 328,
                "end": 330,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 399,
                "end": 409,
                "text": "hypometria",
                "type": "CONDITION"
            },
            {
                "start": 413,
                "end": 425,
                "text": "bradykinesia",
                "type": "CONDITION"
            },
            {
                "start": 627,
                "end": 629,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1206,
                "end": 1208,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1538,
                "end": 1557,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 1693,
                "end": 1695,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 2103,
                "end": 2105,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04121858",
        "study_official_title": "Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease ",
        "study_brief_summary": " This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.",
        "text": "Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease | This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.",
        "tokens": "['Brain', 'Safe', ':', 'Consumer', 'Intervention', 'to', 'Reduce', 'Exposure', 'to', 'Drugs', 'Linked', 'to', 'Alzheimer', \"'s\", 'Disease', '|', 'This', 'study', 'is', 'an', 'RCT', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'Brain', 'Safe', 'on', 'reducing', 'anticholinergic', 'exposure', '.', 'Over', '42', 'months', ',', 'the', 'trial', 'will', 'enroll', '700', 'community', '-', 'dwelling', 'older', 'adults', 'who', 'were', 'prescribed', 'one', 'or', 'more', 'strong', 'anticholinergics', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'use', 'the', 'Brain', 'Safe', 'app', 'or', 'an', 'attention', 'control', 'medication', 'list', 'app', 'for', '12', 'months', ',', 'with', 'monthly', 'usage', 'reminders', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 10,
                "text": "Brain Safe",
                "type": "OTHER"
            },
            {
                "start": 72,
                "end": 91,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 158,
                "text": "Brain Safe",
                "type": "OTHER"
            },
            {
                "start": 371,
                "end": 385,
                "text": "Brain Safe app",
                "type": "OTHER"
            },
            {
                "start": 392,
                "end": 429,
                "text": "attention control medication list app",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02753725",
        "study_official_title": "Effect of Fentanyl Given Approximately Ten Minutes to the End of Surgery on Emergence Delirium in Children Undergoing Adeno-tonsilectomy at Kenyatta National Hospital: A Randomized Placebo Controlled Clinical Trial ",
        "study_brief_summary": " This study will be a randomized double blind placebo controlled clinical trial among children undergoing adeno-tonsillectomy in KNH. The intervention arm will comprise Fentanyl given at a dose of 1ug/while the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose, treatment will be administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed. The main outcome will be incidence of ED at the recovery room using Watcha scale and secondary outcomes will be delay in emergence time from anaesthesia and effectiveness of fentanyl in preventing ED.",
        "text": "Effect of Fentanyl Given Approximately Ten Minutes to the End of Surgery on Emergence Delirium in Children Undergoing Adeno-tonsilectomy at Kenyatta National Hospital: A Randomized Placebo Controlled Clinical Trial | This study will be a randomized double blind placebo controlled clinical trial among children undergoing adeno-tonsillectomy in KNH. The intervention arm will comprise Fentanyl given at a dose of 1ug/while the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose, treatment will be administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed. The main outcome will be incidence of ED at the recovery room using Watcha scale and secondary outcomes will be delay in emergence time from anaesthesia and effectiveness of fentanyl in preventing ED.",
        "tokens": "['Effect', 'of', 'Fentanyl', 'Given', 'Approximately', 'Ten', 'Minutes', 'to', 'the', 'End', 'of', 'Surgery', 'on', 'Emergence', 'Delirium', 'in', 'Children', 'Undergoing', 'Adeno', '-', 'tonsilectomy', 'at', 'Kenyatta', 'National', 'Hospital', ':', 'A', 'Randomized', 'Placebo', 'Controlled', 'Clinical', 'Trial', '|', 'This', 'study', 'will', 'be', 'a', 'randomized', 'double', 'blind', 'placebo', 'controlled', 'clinical', 'trial', 'among', 'children', 'undergoing', 'adeno', '-', 'tonsillectomy', 'in', 'KNH', '.', 'The', 'intervention', 'arm', 'will', 'comprise', 'Fentanyl', 'given', 'at', 'a', 'dose', 'of', '1ug', '/', 'while', 'the', 'placebo', 'arm', 'will', 'be', 'given', 'normal', 'saline', 'at', 'a', 'volume', 'equivalent', 'to', 'Fentanyl', 'dose', ',', 'treatment', 'will', 'be', 'administered', 'approximately', 'ten', 'minutes', 'to', 'the', 'end', 'of', 'surgery', 'determined', 'by', 'the', 'time', 'when', 'the', 'mouth', 'gag', 'will', 'be', 'removed', '.', 'The', 'main', 'outcome', 'will', 'be', 'incidence', 'of', 'ED', 'at', 'the', 'recovery', 'room', 'using', 'Watcha', 'scale', 'and', 'secondary', 'outcomes', 'will', 'be', 'delay', 'in', 'emergence', 'time', 'from', 'anaesthesia', 'and', 'effectiveness', 'of', 'fentanyl', 'in', 'preventing', 'ED', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 18,
                "text": "Fentanyl",
                "type": "DRUG"
            },
            {
                "start": 76,
                "end": 94,
                "text": "Emergence Delirium",
                "type": "CONDITION"
            },
            {
                "start": 118,
                "end": 136,
                "text": "Adeno-tonsilectomy",
                "type": "CONDITION"
            },
            {
                "start": 181,
                "end": 188,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 262,
                "end": 269,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 322,
                "end": 341,
                "text": "adeno-tonsillectomy",
                "type": "CONDITION"
            },
            {
                "start": 385,
                "end": 393,
                "text": "Fentanyl",
                "type": "DRUG"
            },
            {
                "start": 427,
                "end": 434,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 460,
                "end": 466,
                "text": "saline",
                "type": "CONTROL"
            },
            {
                "start": 493,
                "end": 501,
                "text": "Fentanyl",
                "type": "DRUG"
            },
            {
                "start": 684,
                "end": 686,
                "text": "ED",
                "type": "CONDITION"
            },
            {
                "start": 820,
                "end": 828,
                "text": "fentanyl",
                "type": "DRUG"
            },
            {
                "start": 843,
                "end": 845,
                "text": "ED",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01090297",
        "study_official_title": "CPAP Treatment : Fixed Versus Auto-adjusting Mode Impact on Clinical Blood Arterial Pressure. Randomised, Controlled and Double Blinded Trial in SAOS Patients ",
        "study_brief_summary": " Background: Continuous positive airway pressure (CPAP) is the first line therapy for obstructive sleep apnea syndrome (OSAS). Two positive airway pressure (PAP) modalities can be used: Fixed pressure, in which the effective pressure is set and kept constant all night, and auto CPAP devices where the positive pressure changes during the night depend on patient's requirements.\n\nHypothesis: Pressure variations associated with autoCPAP functioning can lead to sleep fragmentation and alterations in sleep structure. This can limit blood pressure dipping during sleep and then impact clinical blood pressure reduction.\n\nMain objective: To compare in a randomized controlled trial 4 months clinical blood pressure (BP) evolution depending on CPAP mode: fixed pressure versus autoCPAP. Secondary outcomes: Evolution of arterial stiffness, biological parameters, quality of life and symptoms.\n\nMethods: Patients will be randomised depending on CPAP mode. Baseline and 4 months evaluation will include: 24-h ambulatory blood pressure monitoring, clinical BP measurements and carotid-to-femoral pulse wave velocity (PWV). Patients will also complete quality of life and symptoms questionnaires.\n\n2 interim analysis will be carried out when 150 and 220 patients respectively will have completed the study. The Peto's method will be used to correct the p-values.",
        "text": "CPAP Treatment : Fixed Versus Auto-adjusting Mode Impact on Clinical Blood Arterial Pressure. Randomised, Controlled and Double Blinded Trial in SAOS Patients | Background: Continuous positive airway pressure (CPAP) is the first line therapy for obstructive sleep apnea syndrome (OSAS). Two positive airway pressure (PAP) modalities can be used: Fixed pressure, in which the effective pressure is set and kept constant all night, and auto CPAP devices where the positive pressure changes during the night depend on patient's requirements.\n\nHypothesis: Pressure variations associated with autoCPAP functioning can lead to sleep fragmentation and alterations in sleep structure. This can limit blood pressure dipping during sleep and then impact clinical blood pressure reduction.\n\nMain objective: To compare in a randomized controlled trial 4 months clinical blood pressure (BP) evolution depending on CPAP mode: fixed pressure versus autoCPAP. Secondary outcomes: Evolution of arterial stiffness, biological parameters, quality of life and symptoms.\n\nMethods: Patients will be randomised depending on CPAP mode. Baseline and 4 months evaluation will include: 24-h ambulatory blood pressure monitoring, clinical BP measurements and carotid-to-femoral pulse wave velocity (PWV). Patients will also complete quality of life and symptoms questionnaires.\n\n2 interim analysis will be carried out when 150 and 220 patients respectively will have completed the study. The Peto's method will be used to correct the p-values.",
        "tokens": "['CPAP', 'Treatment', ':', 'Fixed', 'Versus', 'Auto', '-', 'adjusting', 'Mode', 'Impact', 'on', 'Clinical', 'Blood', 'Arterial', 'Pressure', '.', 'Randomised', ',', 'Controlled', 'and', 'Double', 'Blinded', 'Trial', 'in', 'SAOS', 'Patients', '|', 'Background', ':', 'Continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'is', 'the', 'first', 'line', 'therapy', 'for', 'obstructive', 'sleep', 'apnea', 'syndrome', '(', 'OSAS', ')', '.', 'Two', 'positive', 'airway', 'pressure', '(', 'PAP', ')', 'modalities', 'can', 'be', 'used', ':', 'Fixed', 'pressure', ',', 'in', 'which', 'the', 'effective', 'pressure', 'is', 'set', 'and', 'kept', 'constant', 'all', 'night', ',', 'and', 'auto', 'CPAP', 'devices', 'where', 'the', 'positive', 'pressure', 'changes', 'during', 'the', 'night', 'depend', 'on', 'patient', \"'s\", 'requirements', '.', '\\n\\n', 'Hypothesis', ':', 'Pressure', 'variations', 'associated', 'with', 'autoCPAP', 'functioning', 'can', 'lead', 'to', 'sleep', 'fragmentation', 'and', 'alterations', 'in', 'sleep', 'structure', '.', 'This', 'can', 'limit', 'blood', 'pressure', 'dipping', 'during', 'sleep', 'and', 'then', 'impact', 'clinical', 'blood', 'pressure', 'reduction', '.', '\\n\\n', 'Main', 'objective', ':', 'To', 'compare', 'in', 'a', 'randomized', 'controlled', 'trial', '4', 'months', 'clinical', 'blood', 'pressure', '(', 'BP', ')', 'evolution', 'depending', 'on', 'CPAP', 'mode', ':', 'fixed', 'pressure', 'versus', 'autoCPAP', '.', 'Secondary', 'outcomes', ':', 'Evolution', 'of', 'arterial', 'stiffness', ',', 'biological', 'parameters', ',', 'quality', 'of', 'life', 'and', 'symptoms', '.', '\\n\\n', 'Methods', ':', 'Patients', 'will', 'be', 'randomised', 'depending', 'on', 'CPAP', 'mode', '.', 'Baseline', 'and', '4', 'months', 'evaluation', 'will', 'include', ':', '24', '-', 'h', 'ambulatory', 'blood', 'pressure', 'monitoring', ',', 'clinical', 'BP', 'measurements', 'and', 'carotid', '-', 'to', '-', 'femoral', 'pulse', 'wave', 'velocity', '(', 'PWV', ')', '.', 'Patients', 'will', 'also', 'complete', 'quality', 'of', 'life', 'and', 'symptoms', 'questionnaires', '.', '\\n\\n', '2', 'interim', 'analysis', 'will', 'be', 'carried', 'out', 'when', '150', 'and', '220', 'patients', 'respectively', 'will', 'have', 'completed', 'the', 'study', '.', 'The', 'Peto', \"'s\", 'method', 'will', 'be', 'used', 'to', 'correct', 'the', 'p', '-', 'values', '.']",
        "token_bio_labels": "['B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 4,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 145,
                "end": 149,
                "text": "SAOS",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 208,
                "text": "Continuous positive airway pressure",
                "type": "OTHER"
            },
            {
                "start": 210,
                "end": 214,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 246,
                "end": 278,
                "text": "obstructive sleep apnea syndrome",
                "type": "CONDITION"
            },
            {
                "start": 280,
                "end": 284,
                "text": "OSAS",
                "type": "CONDITION"
            },
            {
                "start": 346,
                "end": 360,
                "text": "Fixed pressure",
                "type": "OTHER"
            },
            {
                "start": 434,
                "end": 443,
                "text": "auto CPAP",
                "type": "OTHER"
            },
            {
                "start": 901,
                "end": 905,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 912,
                "end": 926,
                "text": "fixed pressure",
                "type": "OTHER"
            },
            {
                "start": 934,
                "end": 942,
                "text": "autoCPAP",
                "type": "OTHER"
            },
            {
                "start": 1101,
                "end": 1105,
                "text": "CPAP",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02429596",
        "study_official_title": "A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs ",
        "study_brief_summary": " Background. Anecdotal reports and uncontrolled studies have described an association between generic substitution of antiepileptic drugs (AEDs) and adverse events, including loss of seizure control. Although these results are likely to be influenced by methodological bias, they have led to a strong opposition, among physicians and patients, to the use of generic products in epilepsy.\n\nObjectives. The primary objective is to assess potential risks associated with substitution of the currently taken AED product with an equivalent product, using as endpoint changes in serum drug levels at steady-state after substitution compared with baseline. Secondary objectives will be the assessment of inter-subject variability in serum drug concentration on an unchanged treatment schedule, and evaluation of potential short-term changes in seizure control and adverse events rate.\n\nMethods. The study will use an experimental randomized open-label non-inferiority design. The population will consist of 200 adults stabilized on chronic treatment with carbamazepine, valproic acid, topiramate, oxcarbazepine, levetiracetam or lamotrigine and admitted to hospital for diagnostic evaluation or other indications, with no expected treatment changes during the subsequent 5 to 6 days. Patients will be randomized to two groups. One group will continue to receive the AED products used before enrollment (brand or generic), whereas the other group will be switched to an alternative equivalent product. Dosing schedules of the AEDs being tested as well as comedications will be unaltered throughout the 6- to 7day period of the study. Serum AED levels (mean of two values obtained at peak and trough, respectively in the evening and the next morning) will be measured on day 1 (baseline) and 5 days post-randomization (6 days for patients receiving AEDs with half-lives above 12 h). The primary outcome endpoint will be the proportion of patients who, post-randomization, show a greater than 25% change in serum drug concentration compared with baseline. Secondary endpoints will include comparison of distributions of rough serum concentration changes between groups, other pharmacokinetic parameters, time to first seizure, total number of seizures, and adverse events.",
        "text": "A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs | Background. Anecdotal reports and uncontrolled studies have described an association between generic substitution of antiepileptic drugs (AEDs) and adverse events, including loss of seizure control. Although these results are likely to be influenced by methodological bias, they have led to a strong opposition, among physicians and patients, to the use of generic products in epilepsy.\n\nObjectives. The primary objective is to assess potential risks associated with substitution of the currently taken AED product with an equivalent product, using as endpoint changes in serum drug levels at steady-state after substitution compared with baseline. Secondary objectives will be the assessment of inter-subject variability in serum drug concentration on an unchanged treatment schedule, and evaluation of potential short-term changes in seizure control and adverse events rate.\n\nMethods. The study will use an experimental randomized open-label non-inferiority design. The population will consist of 200 adults stabilized on chronic treatment with carbamazepine, valproic acid, topiramate, oxcarbazepine, levetiracetam or lamotrigine and admitted to hospital for diagnostic evaluation or other indications, with no expected treatment changes during the subsequent 5 to 6 days. Patients will be randomized to two groups. One group will continue to receive the AED products used before enrollment (brand or generic), whereas the other group will be switched to an alternative equivalent product. Dosing schedules of the AEDs being tested as well as comedications will be unaltered throughout the 6- to 7day period of the study. Serum AED levels (mean of two values obtained at peak and trough, respectively in the evening and the next morning) will be measured on day 1 (baseline) and 5 days post-randomization (6 days for patients receiving AEDs with half-lives above 12 h). The primary outcome endpoint will be the proportion of patients who, post-randomization, show a greater than 25% change in serum drug concentration compared with baseline. Secondary endpoints will include comparison of distributions of rough serum concentration changes between groups, other pharmacokinetic parameters, time to first seizure, total number of seizures, and adverse events.",
        "tokens": "['A', 'Randomized', 'Controlled', 'Trial', 'of', 'Generic', 'Substitution', 'of', 'Antiepileptic', 'Drugs', '|', 'Background', '.', 'Anecdotal', 'reports', 'and', 'uncontrolled', 'studies', 'have', 'described', 'an', 'association', 'between', 'generic', 'substitution', 'of', 'antiepileptic', 'drugs', '(', 'AEDs', ')', 'and', 'adverse', 'events', ',', 'including', 'loss', 'of', 'seizure', 'control', '.', 'Although', 'these', 'results', 'are', 'likely', 'to', 'be', 'influenced', 'by', 'methodological', 'bias', ',', 'they', 'have', 'led', 'to', 'a', 'strong', 'opposition', ',', 'among', 'physicians', 'and', 'patients', ',', 'to', 'the', 'use', 'of', 'generic', 'products', 'in', 'epilepsy', '.', '\\n\\n', 'Objectives', '.', 'The', 'primary', 'objective', 'is', 'to', 'assess', 'potential', 'risks', 'associated', 'with', 'substitution', 'of', 'the', 'currently', 'taken', 'AED', 'product', 'with', 'an', 'equivalent', 'product', ',', 'using', 'as', 'endpoint', 'changes', 'in', 'serum', 'drug', 'levels', 'at', 'steady', '-', 'state', 'after', 'substitution', 'compared', 'with', 'baseline', '.', 'Secondary', 'objectives', 'will', 'be', 'the', 'assessment', 'of', 'inter', '-', 'subject', 'variability', 'in', 'serum', 'drug', 'concentration', 'on', 'an', 'unchanged', 'treatment', 'schedule', ',', 'and', 'evaluation', 'of', 'potential', 'short', '-', 'term', 'changes', 'in', 'seizure', 'control', 'and', 'adverse', 'events', 'rate', '.', '\\n\\n', 'Methods', '.', 'The', 'study', 'will', 'use', 'an', 'experimental', 'randomized', 'open', '-', 'label', 'non', '-', 'inferiority', 'design', '.', 'The', 'population', 'will', 'consist', 'of', '200', 'adults', 'stabilized', 'on', 'chronic', 'treatment', 'with', 'carbamazepine', ',', 'valproic', 'acid', ',', 'topiramate', ',', 'oxcarbazepine', ',', 'levetiracetam', 'or', 'lamotrigine', 'and', 'admitted', 'to', 'hospital', 'for', 'diagnostic', 'evaluation', 'or', 'other', 'indications', ',', 'with', 'no', 'expected', 'treatment', 'changes', 'during', 'the', 'subsequent', '5', 'to', '6', 'days', '.', 'Patients', 'will', 'be', 'randomized', 'to', 'two', 'groups', '.', 'One', 'group', 'will', 'continue', 'to', 'receive', 'the', 'AED', 'products', 'used', 'before', 'enrollment', '(', 'brand', 'or', 'generic', ')', ',', 'whereas', 'the', 'other', 'group', 'will', 'be', 'switched', 'to', 'an', 'alternative', 'equivalent', 'product', '.', 'Dosing', 'schedules', 'of', 'the', 'AEDs', 'being', 'tested', 'as', 'well', 'as', 'comedications', 'will', 'be', 'unaltered', 'throughout', 'the', '6-', 'to', '7day', 'period', 'of', 'the', 'study', '.', 'Serum', 'AED', 'levels', '(', 'mean', 'of', 'two', 'values', 'obtained', 'at', 'peak', 'and', 'trough', ',', 'respectively', 'in', 'the', 'evening', 'and', 'the', 'next', 'morning', ')', 'will', 'be', 'measured', 'on', 'day', '1', '(', 'baseline', ')', 'and', '5', 'days', 'post', '-', 'randomization', '(', '6', 'days', 'for', 'patients', 'receiving', 'AEDs', 'with', 'half', '-', 'lives', 'above', '12', 'h', ')', '.', 'The', 'primary', 'outcome', 'endpoint', 'will', 'be', 'the', 'proportion', 'of', 'patients', 'who', ',', 'post', '-', 'randomization', ',', 'show', 'a', 'greater', 'than', '25', '%', 'change', 'in', 'serum', 'drug', 'concentration', 'compared', 'with', 'baseline', '.', 'Secondary', 'endpoints', 'will', 'include', 'comparison', 'of', 'distributions', 'of', 'rough', 'serum', 'concentration', 'changes', 'between', 'groups', ',', 'other', 'pharmacokinetic', 'parameters', ',', 'time', 'to', 'first', 'seizure', ',', 'total', 'number', 'of', 'seizures', ',', 'and', 'adverse', 'events', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 57,
                "end": 76,
                "text": "Antiepileptic Drugs",
                "type": "DRUG"
            },
            {
                "start": 196,
                "end": 215,
                "text": "antiepileptic drugs",
                "type": "DRUG"
            },
            {
                "start": 217,
                "end": 221,
                "text": "AEDs",
                "type": "DRUG"
            },
            {
                "start": 261,
                "end": 268,
                "text": "seizure",
                "type": "CONDITION"
            },
            {
                "start": 456,
                "end": 464,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 582,
                "end": 585,
                "text": "AED",
                "type": "DRUG"
            },
            {
                "start": 915,
                "end": 922,
                "text": "seizure",
                "type": "CONDITION"
            },
            {
                "start": 1126,
                "end": 1139,
                "text": "carbamazepine",
                "type": "DRUG"
            },
            {
                "start": 1141,
                "end": 1154,
                "text": "valproic acid",
                "type": "DRUG"
            },
            {
                "start": 1156,
                "end": 1166,
                "text": "topiramate",
                "type": "DRUG"
            },
            {
                "start": 1168,
                "end": 1181,
                "text": "oxcarbazepine",
                "type": "DRUG"
            },
            {
                "start": 1183,
                "end": 1196,
                "text": "levetiracetam",
                "type": "DRUG"
            },
            {
                "start": 1200,
                "end": 1211,
                "text": "lamotrigine",
                "type": "DRUG"
            },
            {
                "start": 1437,
                "end": 1440,
                "text": "AED",
                "type": "DRUG"
            },
            {
                "start": 1596,
                "end": 1600,
                "text": "AEDs",
                "type": "DRUG"
            },
            {
                "start": 1710,
                "end": 1713,
                "text": "AED",
                "type": "DRUG"
            },
            {
                "start": 1918,
                "end": 1922,
                "text": "AEDs",
                "type": "DRUG"
            },
            {
                "start": 2286,
                "end": 2293,
                "text": "seizure",
                "type": "CONDITION"
            },
            {
                "start": 2311,
                "end": 2319,
                "text": "seizures",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01456910",
        "study_official_title": "Evaluation and Effects of a Resistance Training Program and Its Relationship With the Labor Inclusion of the Disabled Intellectual ",
        "study_brief_summary": " Resistance exercise (RE) has been proposed as a possible strategy for prevention and rehabilitation of diseases. The increase in both muscle strength and the ability to perform tasks of day-to-day work environment and are well-characterized benefits of this type of training. The literature has been investigating the effectiveness of the RE for humans, yet few studies have been conducted with intellectual disabilities (ID). It is known that a sedentary lifestyle contributes to the development of cardiovascular disease, type 2 diabetes, hypertension, arthritis, and stress, depression, difficulty in socializing, stigma and discrimination. In particular, the ID is less active and is more likely to develop secondary diseases.",
        "text": "Evaluation and Effects of a Resistance Training Program and Its Relationship With the Labor Inclusion of the Disabled Intellectual | Resistance exercise (RE) has been proposed as a possible strategy for prevention and rehabilitation of diseases. The increase in both muscle strength and the ability to perform tasks of day-to-day work environment and are well-characterized benefits of this type of training. The literature has been investigating the effectiveness of the RE for humans, yet few studies have been conducted with intellectual disabilities (ID). It is known that a sedentary lifestyle contributes to the development of cardiovascular disease, type 2 diabetes, hypertension, arthritis, and stress, depression, difficulty in socializing, stigma and discrimination. In particular, the ID is less active and is more likely to develop secondary diseases.",
        "tokens": "['Evaluation', 'and', 'Effects', 'of', 'a', 'Resistance', 'Training', 'Program', 'and', 'Its', 'Relationship', 'With', 'the', 'Labor', 'Inclusion', 'of', 'the', 'Disabled', 'Intellectual', '|', 'Resistance', 'exercise', '(', 'RE', ')', 'has', 'been', 'proposed', 'as', 'a', 'possible', 'strategy', 'for', 'prevention', 'and', 'rehabilitation', 'of', 'diseases', '.', 'The', 'increase', 'in', 'both', 'muscle', 'strength', 'and', 'the', 'ability', 'to', 'perform', 'tasks', 'of', 'day', '-', 'to', '-', 'day', 'work', 'environment', 'and', 'are', 'well', '-', 'characterized', 'benefits', 'of', 'this', 'type', 'of', 'training', '.', 'The', 'literature', 'has', 'been', 'investigating', 'the', 'effectiveness', 'of', 'the', 'RE', 'for', 'humans', ',', 'yet', 'few', 'studies', 'have', 'been', 'conducted', 'with', 'intellectual', 'disabilities', '(', 'ID', ')', '.', 'It', 'is', 'known', 'that', 'a', 'sedentary', 'lifestyle', 'contributes', 'to', 'the', 'development', 'of', 'cardiovascular', 'disease', ',', 'type', '2', 'diabetes', ',', 'hypertension', ',', 'arthritis', ',', 'and', 'stress', ',', 'depression', ',', 'difficulty', 'in', 'socializing', ',', 'stigma', 'and', 'discrimination', '.', 'In', 'particular', ',', 'the', 'ID', 'is', 'less', 'active', 'and', 'is', 'more', 'likely', 'to', 'develop', 'secondary', 'diseases', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 55,
                "text": "Resistance Training Program",
                "type": "PHYSICAL"
            },
            {
                "start": 109,
                "end": 130,
                "text": "Disabled Intellectual",
                "type": "CONDITION"
            },
            {
                "start": 133,
                "end": 152,
                "text": "Resistance exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 154,
                "end": 156,
                "text": "RE",
                "type": "PHYSICAL"
            },
            {
                "start": 472,
                "end": 474,
                "text": "RE",
                "type": "PHYSICAL"
            },
            {
                "start": 528,
                "end": 553,
                "text": "intellectual disabilities",
                "type": "CONDITION"
            },
            {
                "start": 555,
                "end": 557,
                "text": "ID",
                "type": "CONDITION"
            },
            {
                "start": 633,
                "end": 655,
                "text": "cardiovascular disease",
                "type": "CONDITION"
            },
            {
                "start": 657,
                "end": 672,
                "text": "type 2 diabetes",
                "type": "CONDITION"
            },
            {
                "start": 674,
                "end": 686,
                "text": "hypertension",
                "type": "CONDITION"
            },
            {
                "start": 688,
                "end": 697,
                "text": "arthritis",
                "type": "CONDITION"
            },
            {
                "start": 703,
                "end": 709,
                "text": "stress",
                "type": "CONDITION"
            },
            {
                "start": 711,
                "end": 721,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 796,
                "end": 798,
                "text": "ID",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05564169",
        "study_official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study of Masitinib as add-on Therapy in Patients With Mild to Moderate Alzheimer's Disease ",
        "study_brief_summary": " Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.",
        "text": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study of Masitinib as add-on Therapy in Patients With Mild to Moderate Alzheimer's Disease | Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.",
        "tokens": "['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', '-', 'group', 'Phase', '3', 'Study', 'of', 'Masitinib', 'as', 'add', '-', 'on', 'Therapy', 'in', 'Patients', 'With', 'Mild', 'to', 'Moderate', 'Alzheimer', \"'s\", 'Disease', '|', 'Masitinib', 'is', 'an', 'orally', 'administered', 'tyrosine', 'kinase', 'inhibitor', 'that', 'targets', 'activated', 'cells', 'of', 'the', 'neuroimmune', 'system', '(', 'mast', 'cells', 'and', 'microglia', ')', '.', 'Study', 'AB21004', 'will', 'evaluate', 'masitinib', 'as', 'an', 'adjunct', 'to', 'cholinesterase', 'inhibitor', 'and/or', 'memantine', 'in', 'patients', 'with', 'mild', '-', 'to', '-', 'moderate', 'Alzheimer', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 48,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 93,
                "end": 102,
                "text": "Masitinib",
                "type": "DRUG"
            },
            {
                "start": 138,
                "end": 174,
                "text": "Mild to Moderate Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 186,
                "text": "Masitinib",
                "type": "DRUG"
            },
            {
                "start": 213,
                "end": 238,
                "text": "tyrosine kinase inhibitor",
                "type": "DRUG"
            },
            {
                "start": 350,
                "end": 359,
                "text": "masitinib",
                "type": "DRUG"
            },
            {
                "start": 377,
                "end": 401,
                "text": "cholinesterase inhibitor",
                "type": "DRUG"
            },
            {
                "start": 409,
                "end": 418,
                "text": "memantine",
                "type": "DRUG"
            },
            {
                "start": 436,
                "end": 472,
                "text": "mild-to-moderate Alzheimer's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04855032",
        "study_official_title": "Proactive and Reactive Perturbation Training to Reduce Falls and Improve Gait Stability in People With Chronic Stroke ",
        "study_brief_summary": " Following a stroke, many individuals have a high risk of falls, which can negatively influence quality of life. Unfortunately, current treatments have not effectively addressed this problem. This study investigates whether two methods of delivering mechanical perturbations during walking have the potential to improve post-stroke walking balance and reduce real-world fall incidence.",
        "text": "Proactive and Reactive Perturbation Training to Reduce Falls and Improve Gait Stability in People With Chronic Stroke | Following a stroke, many individuals have a high risk of falls, which can negatively influence quality of life. Unfortunately, current treatments have not effectively addressed this problem. This study investigates whether two methods of delivering mechanical perturbations during walking have the potential to improve post-stroke walking balance and reduce real-world fall incidence.",
        "tokens": "['Proactive', 'and', 'Reactive', 'Perturbation', 'Training', 'to', 'Reduce', 'Falls', 'and', 'Improve', 'Gait', 'Stability', 'in', 'People', 'With', 'Chronic', 'Stroke', '|', 'Following', 'a', 'stroke', ',', 'many', 'individuals', 'have', 'a', 'high', 'risk', 'of', 'falls', ',', 'which', 'can', 'negatively', 'influence', 'quality', 'of', 'life', '.', 'Unfortunately', ',', 'current', 'treatments', 'have', 'not', 'effectively', 'addressed', 'this', 'problem', '.', 'This', 'study', 'investigates', 'whether', 'two', 'methods', 'of', 'delivering', 'mechanical', 'perturbations', 'during', 'walking', 'have', 'the', 'potential', 'to', 'improve', 'post', '-', 'stroke', 'walking', 'balance', 'and', 'reduce', 'real', '-', 'world', 'fall', 'incidence', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 44,
                "text": "Proactive and Reactive Perturbation Training",
                "type": "OTHER"
            },
            {
                "start": 55,
                "end": 60,
                "text": "Falls",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 117,
                "text": "Chronic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 138,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 182,
                "text": "falls",
                "type": "CONDITION"
            },
            {
                "start": 369,
                "end": 408,
                "text": "mechanical perturbations during walking",
                "type": "OTHER"
            },
            {
                "start": 444,
                "end": 450,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 489,
                "end": 493,
                "text": "fall",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03386669",
        "study_official_title": "Novel Neuroimage Study in Tauopathies With Parkinsonism ",
        "study_brief_summary": " The aims of this study are: 18F-THK5351 PET(Positron Emission Tomography) can defect the tau burden in PSP(Progressive Supranuclear Palsy) and CBS (Corticobasal syndrome)correlating with the known NFT(neurofibrillary tangles) topology of those diseases, 18F-THK5351 PET will differentiate subjects with suspected tauopathy due to PSP and CBS from subjects with suspected synucleinopathy due to idiopathic PD(Parkinson's disease). The distribution of PHF(paired helical filament) tau burden will correlate with specific motor and cognitive features of PSP and CBS; and regional PHF tau burden will be associated with cortical thinning. Together, these efforts will establish the potential for developing 18F-THK5351 PET imaging as a biomarker and diagnostic tool for the parkinsonian tauopathies.",
        "text": "Novel Neuroimage Study in Tauopathies With Parkinsonism | The aims of this study are: 18F-THK5351 PET(Positron Emission Tomography) can defect the tau burden in PSP(Progressive Supranuclear Palsy) and CBS (Corticobasal syndrome)correlating with the known NFT(neurofibrillary tangles) topology of those diseases, 18F-THK5351 PET will differentiate subjects with suspected tauopathy due to PSP and CBS from subjects with suspected synucleinopathy due to idiopathic PD(Parkinson's disease). The distribution of PHF(paired helical filament) tau burden will correlate with specific motor and cognitive features of PSP and CBS; and regional PHF tau burden will be associated with cortical thinning. Together, these efforts will establish the potential for developing 18F-THK5351 PET imaging as a biomarker and diagnostic tool for the parkinsonian tauopathies.",
        "tokens": "['Novel', 'Neuroimage', 'Study', 'in', 'Tauopathies', 'With', 'Parkinsonism', '|', 'The', 'aims', 'of', 'this', 'study', 'are', ':', '18F', '-', 'THK5351', 'PET(Positron', 'Emission', 'Tomography', ')', 'can', 'defect', 'the', 'tau', 'burden', 'in', 'PSP(Progressive', 'Supranuclear', 'Palsy', ')', 'and', 'CBS', '(', 'Corticobasal', 'syndrome)correlating', 'with', 'the', 'known', 'NFT(neurofibrillary', 'tangles', ')', 'topology', 'of', 'those', 'diseases', ',', '18F', '-', 'THK5351', 'PET', 'will', 'differentiate', 'subjects', 'with', 'suspected', 'tauopathy', 'due', 'to', 'PSP', 'and', 'CBS', 'from', 'subjects', 'with', 'suspected', 'synucleinopathy', 'due', 'to', 'idiopathic', 'PD(Parkinson', \"'s\", 'disease', ')', '.', 'The', 'distribution', 'of', 'PHF(paired', 'helical', 'filament', ')', 'tau', 'burden', 'will', 'correlate', 'with', 'specific', 'motor', 'and', 'cognitive', 'features', 'of', 'PSP', 'and', 'CBS', ';', 'and', 'regional', 'PHF', 'tau', 'burden', 'will', 'be', 'associated', 'with', 'cortical', 'thinning', '.', 'Together', ',', 'these', 'efforts', 'will', 'establish', 'the', 'potential', 'for', 'developing', '18F', '-', 'THK5351', 'PET', 'imaging', 'as', 'a', 'biomarker', 'and', 'diagnostic', 'tool', 'for', 'the', 'parkinsonian', 'tauopathies', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 37,
                "text": "Tauopathies",
                "type": "CONDITION"
            },
            {
                "start": 43,
                "end": 55,
                "text": "Parkinsonism",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 204,
                "text": "CBS",
                "type": "CONDITION"
            },
            {
                "start": 371,
                "end": 380,
                "text": "tauopathy",
                "type": "CONDITION"
            },
            {
                "start": 388,
                "end": 391,
                "text": "PSP",
                "type": "CONDITION"
            },
            {
                "start": 396,
                "end": 399,
                "text": "CBS",
                "type": "CONDITION"
            },
            {
                "start": 429,
                "end": 444,
                "text": "synucleinopathy",
                "type": "CONDITION"
            },
            {
                "start": 609,
                "end": 612,
                "text": "PSP",
                "type": "CONDITION"
            },
            {
                "start": 617,
                "end": 620,
                "text": "CBS",
                "type": "CONDITION"
            },
            {
                "start": 828,
                "end": 840,
                "text": "parkinsonian",
                "type": "CONDITION"
            },
            {
                "start": 841,
                "end": 852,
                "text": "tauopathies",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01474746",
        "study_official_title": "A Controlled Trial of Sertraline in Young Children With Fragile X Syndrome ",
        "study_brief_summary": " This study is a control trial of sertraline (Zoloft) in fragile X syndrome children aged 2 years to 5 years 8 months old. The trial is six months long, and each participant will receive a series of tests at both the beginning and end of the study. The researchers hope to show improvements in language and a decrease in autistic symptoms.",
        "text": "A Controlled Trial of Sertraline in Young Children With Fragile X Syndrome | This study is a control trial of sertraline (Zoloft) in fragile X syndrome children aged 2 years to 5 years 8 months old. The trial is six months long, and each participant will receive a series of tests at both the beginning and end of the study. The researchers hope to show improvements in language and a decrease in autistic symptoms.",
        "tokens": "['A', 'Controlled', 'Trial', 'of', 'Sertraline', 'in', 'Young', 'Children', 'With', 'Fragile', 'X', 'Syndrome', '|', 'This', 'study', 'is', 'a', 'control', 'trial', 'of', 'sertraline', '(', 'Zoloft', ')', 'in', 'fragile', 'X', 'syndrome', 'children', 'aged', '2', 'years', 'to', '5', 'years', '8', 'months', 'old', '.', 'The', 'trial', 'is', 'six', 'months', 'long', ',', 'and', 'each', 'participant', 'will', 'receive', 'a', 'series', 'of', 'tests', 'at', 'both', 'the', 'beginning', 'and', 'end', 'of', 'the', 'study', '.', 'The', 'researchers', 'hope', 'to', 'show', 'improvements', 'in', 'language', 'and', 'a', 'decrease', 'in', 'autistic', 'symptoms', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 32,
                "text": "Sertraline",
                "type": "DRUG"
            },
            {
                "start": 56,
                "end": 74,
                "text": "Fragile X Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 110,
                "end": 120,
                "text": "sertraline",
                "type": "DRUG"
            },
            {
                "start": 122,
                "end": 128,
                "text": "Zoloft",
                "type": "DRUG"
            },
            {
                "start": 133,
                "end": 151,
                "text": "fragile X syndrome",
                "type": "CONDITION"
            },
            {
                "start": 397,
                "end": 405,
                "text": "autistic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02549885",
        "study_official_title": "Efficacy of Proprioceptive Neuromuscular Facilitation in Pain Relief in Women With Migraine ",
        "study_brief_summary": " The purpose of this study is to determine whether the contract-relax technique of proprioceptive neuromuscular facilitation, and the static stretching exercise are effective in reducing the frequency, intensity and duration of headache and in improving the perception of quality of life in women with migraine.",
        "text": "Efficacy of Proprioceptive Neuromuscular Facilitation in Pain Relief in Women With Migraine | The purpose of this study is to determine whether the contract-relax technique of proprioceptive neuromuscular facilitation, and the static stretching exercise are effective in reducing the frequency, intensity and duration of headache and in improving the perception of quality of life in women with migraine.",
        "tokens": "['Efficacy', 'of', 'Proprioceptive', 'Neuromuscular', 'Facilitation', 'in', 'Pain', 'Relief', 'in', 'Women', 'With', 'Migraine', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'the', 'contract', '-', 'relax', 'technique', 'of', 'proprioceptive', 'neuromuscular', 'facilitation', ',', 'and', 'the', 'static', 'stretching', 'exercise', 'are', 'effective', 'in', 'reducing', 'the', 'frequency', ',', 'intensity', 'and', 'duration', 'of', 'headache', 'and', 'in', 'improving', 'the', 'perception', 'of', 'quality', 'of', 'life', 'in', 'women', 'with', 'migraine', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 53,
                "text": "Proprioceptive Neuromuscular Facilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 57,
                "end": 61,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 83,
                "end": 91,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 148,
                "end": 217,
                "text": "contract-relax technique of proprioceptive neuromuscular facilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 227,
                "end": 253,
                "text": "static stretching exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 321,
                "end": 329,
                "text": "headache",
                "type": "CONDITION"
            },
            {
                "start": 395,
                "end": 403,
                "text": "migraine",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00311363",
        "study_official_title": "A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome. ",
        "study_brief_summary": " The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).",
        "text": "A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome. | The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).",
        "tokens": "['A', 'Long', '-', 'Term', 'Study', 'of', 'XP13512', 'Versus', 'Placebo', 'Treatment', 'Assessing', 'Maintenance', 'of', 'Efficacy', 'and', 'Safety', 'in', 'Patients', 'With', 'Restless', 'Legs', 'Syndrome', '.', '|', 'The', 'primary', 'objective', 'of', 'this', 'trial', 'is', 'to', 'assess', 'the', 'maintenance', 'of', 'efficacy', 'of', 'gabapentin', 'enacarbil', '(', 'GEn', ',', 'XP13512', ')', 'taken', 'once', 'daily', 'in', 'the', 'long', '-', 'term', 'treatment', 'of', 'patients', 'suffering', 'from', 'Restless', 'Legs', 'Syndrome', '(', 'RLS', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 28,
                "text": "XP13512",
                "type": "DRUG"
            },
            {
                "start": 36,
                "end": 43,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 116,
                "end": 138,
                "text": "Restless Legs Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 222,
                "end": 242,
                "text": "gabapentin enacarbil",
                "type": "DRUG"
            },
            {
                "start": 244,
                "end": 247,
                "text": "GEn",
                "type": "DRUG"
            },
            {
                "start": 249,
                "end": 256,
                "text": "XP13512",
                "type": "DRUG"
            },
            {
                "start": 329,
                "end": 351,
                "text": "Restless Legs Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 353,
                "end": 356,
                "text": "RLS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01550718",
        "study_official_title": "Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial ",
        "study_brief_summary": " Alzheimer's disease (AD) is increasing exponentially, with a projected quadrupling of cases by the mid 21st century. Individuals with AD are at increased risk for a host of medical and psychiatric conditions, and evidence is accumulating supporting the efficacy and effectiveness of psychosocial interventions for improving their mood, function, health, and quality of life. Such interventions are likely to be most effective when they are implemented during the early stages of dementia, when individuals and their family members are coping with the initial diagnosis and associated changes in abilities and activities. Recent randomized clinical trials by the Principal Investigator and colleagues have developed two non-pharmacologic interventions to reduce the social, psychological, physical, and behavioral impact of dementia. This investigation is focused on facilitating their translation into ongoing community-based programs, such as those provided by Alzheimer's Association chapters, senior centers, retirement homes, and other health care providers. The core content of each intervention has been retained in order to maintain or improve their efficacy, and each has been modified to a 4-week group format to increase efficiency of delivery. These modified interventions (ESML-Social and ESML-Ex) will be compared to each other and to a usual care (UC) control group. Outcomes will be assessed at baseline, 1-month post treatment, and 4 month follow-up. Primary outcomes at the 1-month assessment include: social activity participation, family communication, physical activity participation, and physical function. Primary outcomes at 4-month follow up include overall quality of life and depression. It is hypothesized that ESML-Ex and ESML-Social both will have greater improvements than UC. It is hypothesized that ESML-Social will have greater improvements in social participation and family communication than ESML-Ex and UC. It is hypothesized that ESML-Ex will have greater improvements in physical activity participation and physical functioning than ESML-Social and UC. If successful, these 4-week programs may be developed into \"modules\" that can be incorporated into programming for individuals with early stage dementia in a variety of community settings.",
        "text": "Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial | Alzheimer's disease (AD) is increasing exponentially, with a projected quadrupling of cases by the mid 21st century. Individuals with AD are at increased risk for a host of medical and psychiatric conditions, and evidence is accumulating supporting the efficacy and effectiveness of psychosocial interventions for improving their mood, function, health, and quality of life. Such interventions are likely to be most effective when they are implemented during the early stages of dementia, when individuals and their family members are coping with the initial diagnosis and associated changes in abilities and activities. Recent randomized clinical trials by the Principal Investigator and colleagues have developed two non-pharmacologic interventions to reduce the social, psychological, physical, and behavioral impact of dementia. This investigation is focused on facilitating their translation into ongoing community-based programs, such as those provided by Alzheimer's Association chapters, senior centers, retirement homes, and other health care providers. The core content of each intervention has been retained in order to maintain or improve their efficacy, and each has been modified to a 4-week group format to increase efficiency of delivery. These modified interventions (ESML-Social and ESML-Ex) will be compared to each other and to a usual care (UC) control group. Outcomes will be assessed at baseline, 1-month post treatment, and 4 month follow-up. Primary outcomes at the 1-month assessment include: social activity participation, family communication, physical activity participation, and physical function. Primary outcomes at 4-month follow up include overall quality of life and depression. It is hypothesized that ESML-Ex and ESML-Social both will have greater improvements than UC. It is hypothesized that ESML-Social will have greater improvements in social participation and family communication than ESML-Ex and UC. It is hypothesized that ESML-Ex will have greater improvements in physical activity participation and physical functioning than ESML-Social and UC. If successful, these 4-week programs may be developed into \"modules\" that can be incorporated into programming for individuals with early stage dementia in a variety of community settings.",
        "tokens": "['Two', 'Interventions', 'for', 'Early', 'Stage', 'Dementia', ':', 'A', 'Comparative', 'Efficacy', 'Trial', '|', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', 'is', 'increasing', 'exponentially', ',', 'with', 'a', 'projected', 'quadrupling', 'of', 'cases', 'by', 'the', 'mid', '21st', 'century', '.', 'Individuals', 'with', 'AD', 'are', 'at', 'increased', 'risk', 'for', 'a', 'host', 'of', 'medical', 'and', 'psychiatric', 'conditions', ',', 'and', 'evidence', 'is', 'accumulating', 'supporting', 'the', 'efficacy', 'and', 'effectiveness', 'of', 'psychosocial', 'interventions', 'for', 'improving', 'their', 'mood', ',', 'function', ',', 'health', ',', 'and', 'quality', 'of', 'life', '.', 'Such', 'interventions', 'are', 'likely', 'to', 'be', 'most', 'effective', 'when', 'they', 'are', 'implemented', 'during', 'the', 'early', 'stages', 'of', 'dementia', ',', 'when', 'individuals', 'and', 'their', 'family', 'members', 'are', 'coping', 'with', 'the', 'initial', 'diagnosis', 'and', 'associated', 'changes', 'in', 'abilities', 'and', 'activities', '.', 'Recent', 'randomized', 'clinical', 'trials', 'by', 'the', 'Principal', 'Investigator', 'and', 'colleagues', 'have', 'developed', 'two', 'non', '-', 'pharmacologic', 'interventions', 'to', 'reduce', 'the', 'social', ',', 'psychological', ',', 'physical', ',', 'and', 'behavioral', 'impact', 'of', 'dementia', '.', 'This', 'investigation', 'is', 'focused', 'on', 'facilitating', 'their', 'translation', 'into', 'ongoing', 'community', '-', 'based', 'programs', ',', 'such', 'as', 'those', 'provided', 'by', 'Alzheimer', \"'s\", 'Association', 'chapters', ',', 'senior', 'centers', ',', 'retirement', 'homes', ',', 'and', 'other', 'health', 'care', 'providers', '.', 'The', 'core', 'content', 'of', 'each', 'intervention', 'has', 'been', 'retained', 'in', 'order', 'to', 'maintain', 'or', 'improve', 'their', 'efficacy', ',', 'and', 'each', 'has', 'been', 'modified', 'to', 'a', '4', '-', 'week', 'group', 'format', 'to', 'increase', 'efficiency', 'of', 'delivery', '.', 'These', 'modified', 'interventions', '(', 'ESML', '-', 'Social', 'and', 'ESML', '-', 'Ex', ')', 'will', 'be', 'compared', 'to', 'each', 'other', 'and', 'to', 'a', 'usual', 'care', '(', 'UC', ')', 'control', 'group', '.', 'Outcomes', 'will', 'be', 'assessed', 'at', 'baseline', ',', '1', '-', 'month', 'post', 'treatment', ',', 'and', '4', 'month', 'follow', '-', 'up', '.', 'Primary', 'outcomes', 'at', 'the', '1', '-', 'month', 'assessment', 'include', ':', 'social', 'activity', 'participation', ',', 'family', 'communication', ',', 'physical', 'activity', 'participation', ',', 'and', 'physical', 'function', '.', 'Primary', 'outcomes', 'at', '4', '-', 'month', 'follow', 'up', 'include', 'overall', 'quality', 'of', 'life', 'and', 'depression', '.', 'It', 'is', 'hypothesized', 'that', 'ESML', '-', 'Ex', 'and', 'ESML', '-', 'Social', 'both', 'will', 'have', 'greater', 'improvements', 'than', 'UC', '.', 'It', 'is', 'hypothesized', 'that', 'ESML', '-', 'Social', 'will', 'have', 'greater', 'improvements', 'in', 'social', 'participation', 'and', 'family', 'communication', 'than', 'ESML', '-', 'Ex', 'and', 'UC', '.', 'It', 'is', 'hypothesized', 'that', 'ESML', '-', 'Ex', 'will', 'have', 'greater', 'improvements', 'in', 'physical', 'activity', 'participation', 'and', 'physical', 'functioning', 'than', 'ESML', '-', 'Social', 'and', 'UC', '.', 'If', 'successful', ',', 'these', '4', '-', 'week', 'programs', 'may', 'be', 'developed', 'into', '\"', 'modules', '\"', 'that', 'can', 'be', 'incorporated', 'into', 'programming', 'for', 'individuals', 'with', 'early', 'stage', 'dementia', 'in', 'a', 'variety', 'of', 'community', 'settings', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 42,
                "text": "Early Stage Dementia",
                "type": "CONDITION"
            },
            {
                "start": 75,
                "end": 94,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 98,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 211,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 554,
                "end": 562,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 1360,
                "end": 1371,
                "text": "ESML-Social",
                "type": "OTHER"
            },
            {
                "start": 1376,
                "end": 1383,
                "text": "ESML-Ex",
                "type": "OTHER"
            },
            {
                "start": 1425,
                "end": 1435,
                "text": "usual care",
                "type": "CONTROL"
            },
            {
                "start": 1437,
                "end": 1439,
                "text": "UC",
                "type": "CONTROL"
            },
            {
                "start": 1813,
                "end": 1820,
                "text": "ESML-Ex",
                "type": "OTHER"
            },
            {
                "start": 1825,
                "end": 1836,
                "text": "ESML-Social",
                "type": "OTHER"
            },
            {
                "start": 1878,
                "end": 1880,
                "text": "UC",
                "type": "CONTROL"
            },
            {
                "start": 1906,
                "end": 1917,
                "text": "ESML-Social",
                "type": "OTHER"
            },
            {
                "start": 2003,
                "end": 2010,
                "text": "ESML-Ex",
                "type": "OTHER"
            },
            {
                "start": 2015,
                "end": 2017,
                "text": "UC",
                "type": "CONTROL"
            },
            {
                "start": 2043,
                "end": 2050,
                "text": "ESML-Ex",
                "type": "OTHER"
            },
            {
                "start": 2147,
                "end": 2158,
                "text": "ESML-Social",
                "type": "OTHER"
            },
            {
                "start": 2163,
                "end": 2165,
                "text": "UC",
                "type": "CONTROL"
            },
            {
                "start": 2299,
                "end": 2319,
                "text": "early stage dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05679505",
        "study_official_title": "EFFECTS OF VAGUS NERVE STIMULATION IN POST COVID-19 SYNDROME: A RANDOMIZED CONTROLLED TRIAL ",
        "study_brief_summary": " The aim of this study is to increase parasympathetic activity and decrease the severity of symptoms by providing vagal stimulation with the t-VNS method in order to suppress the increased sympathetic activity in patients with prolonged Covid symptoms.The main question[s] it aims to answer are:\n\nQuestion 1:Is left ear transcutaneous vagus nerve stimulation effective in suppressing the symptoms of patients in Post Covid syndrome?\n\nQuestion 2:Is bilateral auricular transcutaneous vagus nerve stimulation effective in suppressing the symptoms of patients in Post Covid syndrome?\n\nA 5-minute heart rate variability measurement will be performed to measure the effectiveness of vagus nerve stimulation in participants.HRV is a non-invasive method used to evaluate ANS activity and is a measure of heart rate change over a period of time",
        "text": "EFFECTS OF VAGUS NERVE STIMULATION IN POST COVID-19 SYNDROME: A RANDOMIZED CONTROLLED TRIAL | The aim of this study is to increase parasympathetic activity and decrease the severity of symptoms by providing vagal stimulation with the t-VNS method in order to suppress the increased sympathetic activity in patients with prolonged Covid symptoms.The main question[s] it aims to answer are:\n\nQuestion 1:Is left ear transcutaneous vagus nerve stimulation effective in suppressing the symptoms of patients in Post Covid syndrome?\n\nQuestion 2:Is bilateral auricular transcutaneous vagus nerve stimulation effective in suppressing the symptoms of patients in Post Covid syndrome?\n\nA 5-minute heart rate variability measurement will be performed to measure the effectiveness of vagus nerve stimulation in participants.HRV is a non-invasive method used to evaluate ANS activity and is a measure of heart rate change over a period of time",
        "tokens": "['EFFECTS', 'OF', 'VAGUS', 'NERVE', 'STIMULATION', 'IN', 'POST', 'COVID-19', 'SYNDROME', ':', 'A', 'RANDOMIZED', 'CONTROLLED', 'TRIAL', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'increase', 'parasympathetic', 'activity', 'and', 'decrease', 'the', 'severity', 'of', 'symptoms', 'by', 'providing', 'vagal', 'stimulation', 'with', 'the', 't', '-', 'VNS', 'method', 'in', 'order', 'to', 'suppress', 'the', 'increased', 'sympathetic', 'activity', 'in', 'patients', 'with', 'prolonged', 'Covid', 'symptoms', '.', 'The', 'main', 'question[s', ']', 'it', 'aims', 'to', 'answer', 'are', ':', '\\n\\n', 'Question', '1', ':', 'Is', 'left', 'ear', 'transcutaneous', 'vagus', 'nerve', 'stimulation', 'effective', 'in', 'suppressing', 'the', 'symptoms', 'of', 'patients', 'in', 'Post', 'Covid', 'syndrome', '?', '\\n\\n', 'Question', '2', ':', 'Is', 'bilateral', 'auricular', 'transcutaneous', 'vagus', 'nerve', 'stimulation', 'effective', 'in', 'suppressing', 'the', 'symptoms', 'of', 'patients', 'in', 'Post', 'Covid', 'syndrome', '?', '\\n\\n', 'A', '5', '-', 'minute', 'heart', 'rate', 'variability', 'measurement', 'will', 'be', 'performed', 'to', 'measure', 'the', 'effectiveness', 'of', 'vagus', 'nerve', 'stimulation', 'in', 'participants', '.', 'HRV', 'is', 'a', 'non', '-', 'invasive', 'method', 'used', 'to', 'evaluate', 'ANS', 'activity', 'and', 'is', 'a', 'measure', 'of', 'heart', 'rate', 'change', 'over', 'a', 'period', 'of', 'time']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 34,
                "text": "VAGUS NERVE STIMULATION",
                "type": "OTHER"
            },
            {
                "start": 38,
                "end": 60,
                "text": "POST COVID-19 SYNDROME",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 246,
                "text": "vagal stimulation with the t-VNS method",
                "type": "OTHER"
            },
            {
                "start": 320,
                "end": 335,
                "text": "prolonged Covid",
                "type": "CONDITION"
            },
            {
                "start": 404,
                "end": 451,
                "text": "left ear transcutaneous vagus nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 505,
                "end": 524,
                "text": "Post Covid syndrome",
                "type": "CONDITION"
            },
            {
                "start": 541,
                "end": 599,
                "text": "bilateral auricular transcutaneous vagus nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 653,
                "end": 672,
                "text": "Post Covid syndrome",
                "type": "CONDITION"
            },
            {
                "start": 771,
                "end": 794,
                "text": "vagus nerve stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04844333",
        "study_official_title": "Effect of Extubation Under Deep Anesthesia on Emergence Agitation of Nasal Surgery ",
        "study_brief_summary": " This study analyzed the relationship between extubation timing and Emergence agitation in 18-60 years old adults undergoing nasal surgery, such as nasal septum correction, endoscopic sinus surgery, and nasal bone fracture reduction. The number of agitation, sedation score, pain score, operation method, analgesic drugs and other data were recorded to analyze the effect of deep anesthesia extubation on agitation in patients with nasal surgery. It also provides a clinical basis for the prevention and treatment of agitation during the recovery period of such operations in adults.",
        "text": "Effect of Extubation Under Deep Anesthesia on Emergence Agitation of Nasal Surgery | This study analyzed the relationship between extubation timing and Emergence agitation in 18-60 years old adults undergoing nasal surgery, such as nasal septum correction, endoscopic sinus surgery, and nasal bone fracture reduction. The number of agitation, sedation score, pain score, operation method, analgesic drugs and other data were recorded to analyze the effect of deep anesthesia extubation on agitation in patients with nasal surgery. It also provides a clinical basis for the prevention and treatment of agitation during the recovery period of such operations in adults.",
        "tokens": "['Effect', 'of', 'Extubation', 'Under', 'Deep', 'Anesthesia', 'on', 'Emergence', 'Agitation', 'of', 'Nasal', 'Surgery', '|', 'This', 'study', 'analyzed', 'the', 'relationship', 'between', 'extubation', 'timing', 'and', 'Emergence', 'agitation', 'in', '18', '-', '60', 'years', 'old', 'adults', 'undergoing', 'nasal', 'surgery', ',', 'such', 'as', 'nasal', 'septum', 'correction', ',', 'endoscopic', 'sinus', 'surgery', ',', 'and', 'nasal', 'bone', 'fracture', 'reduction', '.', 'The', 'number', 'of', 'agitation', ',', 'sedation', 'score', ',', 'pain', 'score', ',', 'operation', 'method', ',', 'analgesic', 'drugs', 'and', 'other', 'data', 'were', 'recorded', 'to', 'analyze', 'the', 'effect', 'of', 'deep', 'anesthesia', 'extubation', 'on', 'agitation', 'in', 'patients', 'with', 'nasal', 'surgery', '.', 'It', 'also', 'provides', 'a', 'clinical', 'basis', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'agitation', 'during', 'the', 'recovery', 'period', 'of', 'such', 'operations', 'in', 'adults', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 46,
                "end": 65,
                "text": "Emergence Agitation",
                "type": "CONDITION"
            },
            {
                "start": 69,
                "end": 82,
                "text": "Nasal Surgery",
                "type": "CONDITION"
            },
            {
                "start": 152,
                "end": 171,
                "text": "Emergence agitation",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 222,
                "text": "nasal surgery",
                "type": "CONDITION"
            },
            {
                "start": 232,
                "end": 255,
                "text": "nasal septum correction",
                "type": "CONDITION"
            },
            {
                "start": 257,
                "end": 281,
                "text": "endoscopic sinus surgery",
                "type": "CONDITION"
            },
            {
                "start": 287,
                "end": 316,
                "text": "nasal bone fracture reduction",
                "type": "CONDITION"
            },
            {
                "start": 332,
                "end": 341,
                "text": "agitation",
                "type": "CONDITION"
            },
            {
                "start": 516,
                "end": 529,
                "text": "nasal surgery",
                "type": "CONDITION"
            },
            {
                "start": 601,
                "end": 610,
                "text": "agitation",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00360789",
        "study_official_title": "The Effects of Standardized Physical Therapy and Functional Strength Training on Upper Limb Function and Neuromuscular Weakness After Stroke: a Pilot Study ",
        "study_brief_summary": " The purpose of this study is to test the hypothesis that adding functional strength training to UK conventional therapy improves muscle function and walking than either UK conventional therapy alone or increased intensity of UK conventional therapy.",
        "text": "The Effects of Standardized Physical Therapy and Functional Strength Training on Upper Limb Function and Neuromuscular Weakness After Stroke: a Pilot Study | The purpose of this study is to test the hypothesis that adding functional strength training to UK conventional therapy improves muscle function and walking than either UK conventional therapy alone or increased intensity of UK conventional therapy.",
        "tokens": "['The', 'Effects', 'of', 'Standardized', 'Physical', 'Therapy', 'and', 'Functional', 'Strength', 'Training', 'on', 'Upper', 'Limb', 'Function', 'and', 'Neuromuscular', 'Weakness', 'After', 'Stroke', ':', 'a', 'Pilot', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'test', 'the', 'hypothesis', 'that', 'adding', 'functional', 'strength', 'training', 'to', 'UK', 'conventional', 'therapy', 'improves', 'muscle', 'function', 'and', 'walking', 'than', 'either', 'UK', 'conventional', 'therapy', 'alone', 'or', 'increased', 'intensity', 'of', 'UK', 'conventional', 'therapy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 15,
                "end": 44,
                "text": "Standardized Physical Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 49,
                "end": 77,
                "text": "Functional Strength Training",
                "type": "PHYSICAL"
            },
            {
                "start": 134,
                "end": 140,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 222,
                "end": 250,
                "text": "functional strength training",
                "type": "PHYSICAL"
            },
            {
                "start": 257,
                "end": 277,
                "text": "conventional therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 330,
                "end": 356,
                "text": "conventional therapy alone",
                "type": "CONTROL"
            },
            {
                "start": 360,
                "end": 406,
                "text": "increased intensity of UK conventional therapy",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00448916",
        "study_official_title": "A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures ",
        "study_brief_summary": " The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.",
        "text": "A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures | The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.",
        "tokens": "['A', '12', '-', 'month', 'Open', '-', 'label', 'Extension', 'Study', 'Evaluating', 'The', 'Safety', 'And', 'Tolerability', 'Of', 'Flexible', 'Doses', 'Of', 'Pregabalin', 'In', 'Pediatric', 'Patients', 'With', 'Partial', 'Onset', 'Seizures', '|', 'The', 'study', 'will', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'pregabalin', 'in', 'pediatric', 'patients', ',', 'age', '1', 'month', 'through', '16', 'years', ',', 'with', 'partial', 'onset', 'seizures', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 98,
                "end": 108,
                "text": "Pregabalin",
                "type": "DRUG"
            },
            {
                "start": 136,
                "end": 158,
                "text": "Partial Onset Seizures",
                "type": "CONDITION"
            },
            {
                "start": 226,
                "end": 236,
                "text": "pregabalin",
                "type": "DRUG"
            },
            {
                "start": 295,
                "end": 317,
                "text": "partial onset seizures",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05443542",
        "study_official_title": "Virtual Reality in Cognitive Rehabilitation of Processing Speed for Persons With Acquired Brain Injury ",
        "study_brief_summary": " One hundred participants with acquired brain injury (ABI) will be included in a randomized controlled trial, with one group playing a commercially available VR game and the control group doing activities in their everyday as cognitive training. The trial aims to investigate how VR can affect processing speed in the ABI population, and if these effects can transfer into everyday activities. The training will be performed in the participants homes, with assistance provided by the project group via phone or video conference. The training period will last five weeks. Participant's cognitive functions will be measured with questionnaires and neuropsychological tests at the start of the training period, at the end of training and sixteen weeks after the start of the intervention. In depth experiences with VR as a training method will be gathered through performing focus group interviews with some of the participants from the VR group, in addition to self-reported questionnaires from all the participants.",
        "text": "Virtual Reality in Cognitive Rehabilitation of Processing Speed for Persons With Acquired Brain Injury | One hundred participants with acquired brain injury (ABI) will be included in a randomized controlled trial, with one group playing a commercially available VR game and the control group doing activities in their everyday as cognitive training. The trial aims to investigate how VR can affect processing speed in the ABI population, and if these effects can transfer into everyday activities. The training will be performed in the participants homes, with assistance provided by the project group via phone or video conference. The training period will last five weeks. Participant's cognitive functions will be measured with questionnaires and neuropsychological tests at the start of the training period, at the end of training and sixteen weeks after the start of the intervention. In depth experiences with VR as a training method will be gathered through performing focus group interviews with some of the participants from the VR group, in addition to self-reported questionnaires from all the participants.",
        "tokens": "['Virtual', 'Reality', 'in', 'Cognitive', 'Rehabilitation', 'of', 'Processing', 'Speed', 'for', 'Persons', 'With', 'Acquired', 'Brain', 'Injury', '|', 'One', 'hundred', 'participants', 'with', 'acquired', 'brain', 'injury', '(', 'ABI', ')', 'will', 'be', 'included', 'in', 'a', 'randomized', 'controlled', 'trial', ',', 'with', 'one', 'group', 'playing', 'a', 'commercially', 'available', 'VR', 'game', 'and', 'the', 'control', 'group', 'doing', 'activities', 'in', 'their', 'everyday', 'as', 'cognitive', 'training', '.', 'The', 'trial', 'aims', 'to', 'investigate', 'how', 'VR', 'can', 'affect', 'processing', 'speed', 'in', 'the', 'ABI', 'population', ',', 'and', 'if', 'these', 'effects', 'can', 'transfer', 'into', 'everyday', 'activities', '.', 'The', 'training', 'will', 'be', 'performed', 'in', 'the', 'participants', 'homes', ',', 'with', 'assistance', 'provided', 'by', 'the', 'project', 'group', 'via', 'phone', 'or', 'video', 'conference', '.', 'The', 'training', 'period', 'will', 'last', 'five', 'weeks', '.', 'Participant', \"'s\", 'cognitive', 'functions', 'will', 'be', 'measured', 'with', 'questionnaires', 'and', 'neuropsychological', 'tests', 'at', 'the', 'start', 'of', 'the', 'training', 'period', ',', 'at', 'the', 'end', 'of', 'training', 'and', 'sixteen', 'weeks', 'after', 'the', 'start', 'of', 'the', 'intervention', '.', 'In', 'depth', 'experiences', 'with', 'VR', 'as', 'a', 'training', 'method', 'will', 'be', 'gathered', 'through', 'performing', 'focus', 'group', 'interviews', 'with', 'some', 'of', 'the', 'participants', 'from', 'the', 'VR', 'group', ',', 'in', 'addition', 'to', 'self', '-', 'reported', 'questionnaires', 'from', 'all', 'the', 'participants', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 15,
                "text": "Virtual Reality",
                "type": "OTHER"
            },
            {
                "start": 81,
                "end": 102,
                "text": "Acquired Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 156,
                "text": "acquired brain injury",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 161,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 239,
                "end": 269,
                "text": "commercially available VR game",
                "type": "OTHER"
            },
            {
                "start": 298,
                "end": 326,
                "text": "activities in their everyday",
                "type": "CONTROL"
            },
            {
                "start": 384,
                "end": 386,
                "text": "VR",
                "type": "OTHER"
            },
            {
                "start": 422,
                "end": 425,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 916,
                "end": 918,
                "text": "VR",
                "type": "OTHER"
            },
            {
                "start": 1038,
                "end": 1040,
                "text": "VR",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04755712",
        "study_official_title": "Comparison of Two Analgesic Strategies After Scheduled Caesarean : Block of the Lumbar Region With Ropivacaine Versus Intrathecal Morphine ",
        "study_brief_summary": " To demonstrate the superiority of square lumbar block to ropivacaine compared to intrathecal morphine in the efficacy of postoperative analgesia following scheduled caesarean.",
        "text": "Comparison of Two Analgesic Strategies After Scheduled Caesarean : Block of the Lumbar Region With Ropivacaine Versus Intrathecal Morphine | To demonstrate the superiority of square lumbar block to ropivacaine compared to intrathecal morphine in the efficacy of postoperative analgesia following scheduled caesarean.",
        "tokens": "['Comparison', 'of', 'Two', 'Analgesic', 'Strategies', 'After', 'Scheduled', 'Caesarean', ':', 'Block', 'of', 'the', 'Lumbar', 'Region', 'With', 'Ropivacaine', 'Versus', 'Intrathecal', 'Morphine', '|', 'To', 'demonstrate', 'the', 'superiority', 'of', 'square', 'lumbar', 'block', 'to', 'ropivacaine', 'compared', 'to', 'intrathecal', 'morphine', 'in', 'the', 'efficacy', 'of', 'postoperative', 'analgesia', 'following', 'scheduled', 'caesarean', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 55,
                "end": 64,
                "text": "Caesarean",
                "type": "CONDITION"
            },
            {
                "start": 99,
                "end": 110,
                "text": "Ropivacaine",
                "type": "DRUG"
            },
            {
                "start": 130,
                "end": 138,
                "text": "Morphine",
                "type": "DRUG"
            },
            {
                "start": 198,
                "end": 209,
                "text": "ropivacaine",
                "type": "DRUG"
            },
            {
                "start": 234,
                "end": 242,
                "text": "morphine",
                "type": "DRUG"
            },
            {
                "start": 306,
                "end": 315,
                "text": "caesarean",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03617497",
        "study_official_title": "Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease ",
        "study_brief_summary": " Alzheimer disease is the most common of the neurodegenerative diseases. Epilepsy and sleep wake disorders are co-morbid conditions of Alzheimer disease. The investigators propose a prospective study using long-term EEG monitoring in combination with polysomnography to determine prevalence of epilepsy and sleep wake disorders in Alzheimer disease, and correlate these findings with clinical data, Alzheimer disease biomarkers and imaging studies (MRI and amyloid/tau-PET). In selected patients, the investigators will perform EEG studies with foramen ovale electrodes. The ultimate goal is to improve the outcome of patients with Alzheimer disease by early treatment of epilepsy and restoring sleep-wake disturbances.",
        "text": "Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease | Alzheimer disease is the most common of the neurodegenerative diseases. Epilepsy and sleep wake disorders are co-morbid conditions of Alzheimer disease. The investigators propose a prospective study using long-term EEG monitoring in combination with polysomnography to determine prevalence of epilepsy and sleep wake disorders in Alzheimer disease, and correlate these findings with clinical data, Alzheimer disease biomarkers and imaging studies (MRI and amyloid/tau-PET). In selected patients, the investigators will perform EEG studies with foramen ovale electrodes. The ultimate goal is to improve the outcome of patients with Alzheimer disease by early treatment of epilepsy and restoring sleep-wake disturbances.",
        "tokens": "['Prevalence', 'of', 'Epilepsy', 'and', 'Sleep', 'Wake', 'Disorders', 'in', 'Alzheimer', 'Disease', '|', 'Alzheimer', 'disease', 'is', 'the', 'most', 'common', 'of', 'the', 'neurodegenerative', 'diseases', '.', 'Epilepsy', 'and', 'sleep', 'wake', 'disorders', 'are', 'co', '-', 'morbid', 'conditions', 'of', 'Alzheimer', 'disease', '.', 'The', 'investigators', 'propose', 'a', 'prospective', 'study', 'using', 'long', '-', 'term', 'EEG', 'monitoring', 'in', 'combination', 'with', 'polysomnography', 'to', 'determine', 'prevalence', 'of', 'epilepsy', 'and', 'sleep', 'wake', 'disorders', 'in', 'Alzheimer', 'disease', ',', 'and', 'correlate', 'these', 'findings', 'with', 'clinical', 'data', ',', 'Alzheimer', 'disease', 'biomarkers', 'and', 'imaging', 'studies', '(', 'MRI', 'and', 'amyloid', '/', 'tau', '-', 'PET', ')', '.', 'In', 'selected', 'patients', ',', 'the', 'investigators', 'will', 'perform', 'EEG', 'studies', 'with', 'foramen', 'ovale', 'electrodes', '.', 'The', 'ultimate', 'goal', 'is', 'to', 'improve', 'the', 'outcome', 'of', 'patients', 'with', 'Alzheimer', 'disease', 'by', 'early', 'treatment', 'of', 'epilepsy', 'and', 'restoring', 'sleep', '-', 'wake', 'disturbances', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 22,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 27,
                "end": 47,
                "text": "Sleep Wake Disorders",
                "type": "CONDITION"
            },
            {
                "start": 51,
                "end": 68,
                "text": "Alzheimer Disease",
                "type": "CONDITION"
            },
            {
                "start": 71,
                "end": 88,
                "text": "Alzheimer disease",
                "type": "CONDITION"
            },
            {
                "start": 143,
                "end": 151,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 156,
                "end": 176,
                "text": "sleep wake disorders",
                "type": "CONDITION"
            },
            {
                "start": 205,
                "end": 222,
                "text": "Alzheimer disease",
                "type": "CONDITION"
            },
            {
                "start": 364,
                "end": 372,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 377,
                "end": 397,
                "text": "sleep wake disorders",
                "type": "CONDITION"
            },
            {
                "start": 401,
                "end": 418,
                "text": "Alzheimer disease",
                "type": "CONDITION"
            },
            {
                "start": 469,
                "end": 486,
                "text": "Alzheimer disease",
                "type": "CONDITION"
            },
            {
                "start": 702,
                "end": 719,
                "text": "Alzheimer disease",
                "type": "CONDITION"
            },
            {
                "start": 742,
                "end": 750,
                "text": "epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 765,
                "end": 788,
                "text": "sleep-wake disturbances",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05228990",
        "study_official_title": "Clinical Study on Efficacy and Safety of Warm Acupuncture in Treatment of Cold-sensitive Fibromyalgia Syndrome ",
        "study_brief_summary": " Non-pharmaceutical therapies, such as acupuncture, hydrotherapy, and meditative exercises (such as Qigong (including Tai Chi and Ba-Duan-Jin), have been shown to reduce pain and improve physical function. The management recommendations of fibromyalgia issued by the European Union, Canada, Germany and Israel have all affirmed the \"first-line\" role of Non-pharmaceutical therapy. Because of its good efficacy and safety, acupuncture therapy has been recommended in the management guidelines and has broad application prospects. Warm acupuncture is a therapy combining acupuncture and moxibustion, which is widely used in the treatment of various painful diseases in China, especially for cold-sensitive patients . This study aims to observe the safety and effectiveness of warm acupuncture in the treatment of cold-sensitive fibromyalgia patients, in order to provide a more alternative non-drug therapy for this particular type of patients with fibromyalgia .",
        "text": "Clinical Study on Efficacy and Safety of Warm Acupuncture in Treatment of Cold-sensitive Fibromyalgia Syndrome | Non-pharmaceutical therapies, such as acupuncture, hydrotherapy, and meditative exercises (such as Qigong (including Tai Chi and Ba-Duan-Jin), have been shown to reduce pain and improve physical function. The management recommendations of fibromyalgia issued by the European Union, Canada, Germany and Israel have all affirmed the \"first-line\" role of Non-pharmaceutical therapy. Because of its good efficacy and safety, acupuncture therapy has been recommended in the management guidelines and has broad application prospects. Warm acupuncture is a therapy combining acupuncture and moxibustion, which is widely used in the treatment of various painful diseases in China, especially for cold-sensitive patients . This study aims to observe the safety and effectiveness of warm acupuncture in the treatment of cold-sensitive fibromyalgia patients, in order to provide a more alternative non-drug therapy for this particular type of patients with fibromyalgia .",
        "tokens": "['Clinical', 'Study', 'on', 'Efficacy', 'and', 'Safety', 'of', 'Warm', 'Acupuncture', 'in', 'Treatment', 'of', 'Cold', '-', 'sensitive', 'Fibromyalgia', 'Syndrome', '|', 'Non', '-', 'pharmaceutical', 'therapies', ',', 'such', 'as', 'acupuncture', ',', 'hydrotherapy', ',', 'and', 'meditative', 'exercises', '(', 'such', 'as', 'Qigong', '(', 'including', 'Tai', 'Chi', 'and', 'Ba', '-', 'Duan', '-', 'Jin', ')', ',', 'have', 'been', 'shown', 'to', 'reduce', 'pain', 'and', 'improve', 'physical', 'function', '.', 'The', 'management', 'recommendations', 'of', 'fibromyalgia', 'issued', 'by', 'the', 'European', 'Union', ',', 'Canada', ',', 'Germany', 'and', 'Israel', 'have', 'all', 'affirmed', 'the', '\"', 'first', '-', 'line', '\"', 'role', 'of', 'Non', '-', 'pharmaceutical', 'therapy', '.', 'Because', 'of', 'its', 'good', 'efficacy', 'and', 'safety', ',', 'acupuncture', 'therapy', 'has', 'been', 'recommended', 'in', 'the', 'management', 'guidelines', 'and', 'has', 'broad', 'application', 'prospects', '.', 'Warm', 'acupuncture', 'is', 'a', 'therapy', 'combining', 'acupuncture', 'and', 'moxibustion', ',', 'which', 'is', 'widely', 'used', 'in', 'the', 'treatment', 'of', 'various', 'painful', 'diseases', 'in', 'China', ',', 'especially', 'for', 'cold', '-', 'sensitive', 'patients', '.', 'This', 'study', 'aims', 'to', 'observe', 'the', 'safety', 'and', 'effectiveness', 'of', 'warm', 'acupuncture', 'in', 'the', 'treatment', 'of', 'cold', '-', 'sensitive', 'fibromyalgia', 'patients', ',', 'in', 'order', 'to', 'provide', 'a', 'more', 'alternative', 'non', '-', 'drug', 'therapy', 'for', 'this', 'particular', 'type', 'of', 'patients', 'with', 'fibromyalgia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 57,
                "text": "Warm Acupuncture",
                "type": "OTHER"
            },
            {
                "start": 74,
                "end": 110,
                "text": "Cold-sensitive Fibromyalgia Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 151,
                "end": 162,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 282,
                "end": 286,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 352,
                "end": 364,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 534,
                "end": 545,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 641,
                "end": 657,
                "text": "Warm acupuncture",
                "type": "OTHER"
            },
            {
                "start": 681,
                "end": 692,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 697,
                "end": 708,
                "text": "moxibustion",
                "type": "OTHER"
            },
            {
                "start": 886,
                "end": 902,
                "text": "warm acupuncture",
                "type": "OTHER"
            },
            {
                "start": 923,
                "end": 950,
                "text": "cold-sensitive fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 1059,
                "end": 1071,
                "text": "fibromyalgia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01678755",
        "study_official_title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers ",
        "study_brief_summary": " This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.",
        "text": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers | This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.",
        "tokens": "['A', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', ',', 'Phase', '2', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'ABT-126', 'in', 'the', 'Treatment', 'of', 'Cognitive', 'Deficits', 'in', 'Schizophrenia', '(', 'CDS', ')', 'in', 'Smokers', '|', 'This', 'is', 'an', 'efficacy', 'study', 'evaluating', 'a', 'experimental', 'treatment', 'for', 'cognitive', 'deficits', 'in', 'adults', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 108,
                "end": 115,
                "text": "ABT-126",
                "type": "DRUG"
            },
            {
                "start": 136,
                "end": 154,
                "text": "Cognitive Deficits",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 171,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 176,
                "text": "CDS",
                "type": "CONDITION"
            },
            {
                "start": 181,
                "end": 188,
                "text": "Smokers",
                "type": "CONDITION"
            },
            {
                "start": 257,
                "end": 275,
                "text": "cognitive deficits",
                "type": "CONDITION"
            },
            {
                "start": 291,
                "end": 304,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00035815",
        "study_official_title": "Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) ",
        "study_brief_summary": " The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.",
        "text": "Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) | The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.",
        "tokens": "['Insulin', '-', 'like', 'Growth', 'Factor-1', 'in', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'The', 'purpose', 'of', 'this', 'multicenter', 'study', 'is', 'to', 'determine', 'if', 'insulin', '-', 'like', 'growth', 'factor-1', '(', 'IGF', '-', 'I', ')', 'slows', 'the', 'progressive', 'weakness', 'in', 'amyotrophic', 'lateral', 'sclerosis', '(', 'ALS', ')', 'patients', '.', 'Study', 'participants', 'will', 'be', 'followed', 'for', '2', 'years', 'once', 'enrolled', '.', 'They', 'will', 'receive', 'either', 'placebo', 'or', 'the', 'active', 'IGF', '-', 'I.', 'Examinations', 'will', 'take', 'place', 'at', 'approximately', '6', '-', 'month', 'intervals', '.']",
        "token_bio_labels": "['B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 28,
                "text": "Insulin-like Growth Factor-1",
                "type": "DRUG"
            },
            {
                "start": 32,
                "end": 61,
                "text": "Amyotrophic Lateral Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 63,
                "end": 66,
                "text": "ALS",
                "type": "CONDITION"
            },
            {
                "start": 127,
                "end": 155,
                "text": "insulin-like growth factor-1",
                "type": "DRUG"
            },
            {
                "start": 157,
                "end": 162,
                "text": "IGF-I",
                "type": "DRUG"
            },
            {
                "start": 198,
                "end": 227,
                "text": "amyotrophic lateral sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 229,
                "end": 232,
                "text": "ALS",
                "type": "CONDITION"
            },
            {
                "start": 332,
                "end": 339,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 354,
                "end": 360,
                "text": "IGF-I.",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00817128",
        "study_official_title": "Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I ",
        "study_brief_summary": " The current Dutch CBO guideline treatment of Complex Regional Pain Syndrome Type I (CRPS-1) is very disappointing with chronification, disability and subsequent high medical costs and personal suffering. A possible better treatment is intensive function-oriented physical therapy or Pain Exposure in Physical Therapy (PEPT). However, there are no adequate studies performed that demonstrate the efficacy of PEPT and therefore PEPT is lacking in the Dutch CBO CRPS-1 guidelines. Despite a lacking scientific argumentation, the PEPT approach or Macedonian therapy, is now being adopted on a large scale among physical therapists in The Netherlands. There are two level C retrospective cohort studies demonstrating a promising and clinical relevant beneficial effect on pain and function after PEPT. In response to the growing demand for scientific argumentation among doctors and physical therapists with respect to the efficacy of PEPT, we conducted a pilot study at the UMC St Radboud Nijmegen. The results of this pilot study were very promising and therefore, we decided to design a large RCT to investigate the treatment effects and costs in CRPS patients treated with PEPT compared to CRPS patients treated with usual therapy according to the Dutch CBO guidelines.",
        "text": "Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I | The current Dutch CBO guideline treatment of Complex Regional Pain Syndrome Type I (CRPS-1) is very disappointing with chronification, disability and subsequent high medical costs and personal suffering. A possible better treatment is intensive function-oriented physical therapy or Pain Exposure in Physical Therapy (PEPT). However, there are no adequate studies performed that demonstrate the efficacy of PEPT and therefore PEPT is lacking in the Dutch CBO CRPS-1 guidelines. Despite a lacking scientific argumentation, the PEPT approach or Macedonian therapy, is now being adopted on a large scale among physical therapists in The Netherlands. There are two level C retrospective cohort studies demonstrating a promising and clinical relevant beneficial effect on pain and function after PEPT. In response to the growing demand for scientific argumentation among doctors and physical therapists with respect to the efficacy of PEPT, we conducted a pilot study at the UMC St Radboud Nijmegen. The results of this pilot study were very promising and therefore, we decided to design a large RCT to investigate the treatment effects and costs in CRPS patients treated with PEPT compared to CRPS patients treated with usual therapy according to the Dutch CBO guidelines.",
        "tokens": "['Pain', 'Exposure', 'Physical', 'Therapy', 'Or', 'Conservative', 'Therapy', 'for', 'Patients', 'With', 'Complex', 'Regional', 'Pain', 'Syndrome', 'Type', 'I', '|', 'The', 'current', 'Dutch', 'CBO', 'guideline', 'treatment', 'of', 'Complex', 'Regional', 'Pain', 'Syndrome', 'Type', 'I', '(', 'CRPS-1', ')', 'is', 'very', 'disappointing', 'with', 'chronification', ',', 'disability', 'and', 'subsequent', 'high', 'medical', 'costs', 'and', 'personal', 'suffering', '.', 'A', 'possible', 'better', 'treatment', 'is', 'intensive', 'function', '-', 'oriented', 'physical', 'therapy', 'or', 'Pain', 'Exposure', 'in', 'Physical', 'Therapy', '(', 'PEPT', ')', '.', 'However', ',', 'there', 'are', 'no', 'adequate', 'studies', 'performed', 'that', 'demonstrate', 'the', 'efficacy', 'of', 'PEPT', 'and', 'therefore', 'PEPT', 'is', 'lacking', 'in', 'the', 'Dutch', 'CBO', 'CRPS-1', 'guidelines', '.', 'Despite', 'a', 'lacking', 'scientific', 'argumentation', ',', 'the', 'PEPT', 'approach', 'or', 'Macedonian', 'therapy', ',', 'is', 'now', 'being', 'adopted', 'on', 'a', 'large', 'scale', 'among', 'physical', 'therapists', 'in', 'The', 'Netherlands', '.', 'There', 'are', 'two', 'level', 'C', 'retrospective', 'cohort', 'studies', 'demonstrating', 'a', 'promising', 'and', 'clinical', 'relevant', 'beneficial', 'effect', 'on', 'pain', 'and', 'function', 'after', 'PEPT', '.', 'In', 'response', 'to', 'the', 'growing', 'demand', 'for', 'scientific', 'argumentation', 'among', 'doctors', 'and', 'physical', 'therapists', 'with', 'respect', 'to', 'the', 'efficacy', 'of', 'PEPT', ',', 'we', 'conducted', 'a', 'pilot', 'study', 'at', 'the', 'UMC', 'St', 'Radboud', 'Nijmegen', '.', 'The', 'results', 'of', 'this', 'pilot', 'study', 'were', 'very', 'promising', 'and', 'therefore', ',', 'we', 'decided', 'to', 'design', 'a', 'large', 'RCT', 'to', 'investigate', 'the', 'treatment', 'effects', 'and', 'costs', 'in', 'CRPS', 'patients', 'treated', 'with', 'PEPT', 'compared', 'to', 'CRPS', 'patients', 'treated', 'with', 'usual', 'therapy', 'according', 'to', 'the', 'Dutch', 'CBO', 'guidelines', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 30,
                "text": "Pain Exposure Physical Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 34,
                "end": 54,
                "text": "Conservative Therapy",
                "type": "CONTROL"
            },
            {
                "start": 73,
                "end": 110,
                "text": "Complex Regional Pain Syndrome Type I",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 195,
                "text": "Complex Regional Pain Syndrome Type I",
                "type": "CONDITION"
            },
            {
                "start": 197,
                "end": 203,
                "text": "CRPS-1",
                "type": "CONDITION"
            },
            {
                "start": 348,
                "end": 392,
                "text": "intensive function-oriented physical therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 396,
                "end": 429,
                "text": "Pain Exposure in Physical Therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 431,
                "end": 435,
                "text": "PEPT",
                "type": "PHYSICAL"
            },
            {
                "start": 520,
                "end": 524,
                "text": "PEPT",
                "type": "PHYSICAL"
            },
            {
                "start": 539,
                "end": 543,
                "text": "PEPT",
                "type": "PHYSICAL"
            },
            {
                "start": 572,
                "end": 578,
                "text": "CRPS-1",
                "type": "CONDITION"
            },
            {
                "start": 639,
                "end": 643,
                "text": "PEPT",
                "type": "PHYSICAL"
            },
            {
                "start": 656,
                "end": 674,
                "text": "Macedonian therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 880,
                "end": 884,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 904,
                "end": 908,
                "text": "PEPT",
                "type": "PHYSICAL"
            },
            {
                "start": 1043,
                "end": 1047,
                "text": "PEPT",
                "type": "PHYSICAL"
            },
            {
                "start": 1258,
                "end": 1262,
                "text": "CRPS",
                "type": "CONDITION"
            },
            {
                "start": 1285,
                "end": 1289,
                "text": "PEPT",
                "type": "PHYSICAL"
            },
            {
                "start": 1302,
                "end": 1306,
                "text": "CRPS",
                "type": "CONDITION"
            },
            {
                "start": 1329,
                "end": 1342,
                "text": "usual therapy",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05287503",
        "study_official_title": "Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial ",
        "study_brief_summary": " The present multicenter, randomized, double-blind, placebo-controlled clinical trial will investigate whether the prolonged administration of high-dose oral Ambroxol over 52 weeks is safe, tolerable, able to change Glucocerebrosidase enzyme activity and alpha-synuclein levels in the central nervous system and, ultimately, to reduce the progression of cognitive decline and motor disability in 60 individuals with Parkinson's disease with mutations of the glucocerebrosidase gene (GBA1; OMIM 606463).\n\nParticipants will undergo clinical, biomarker blood and cerebrospinal fluid analysis, neuropsychological, neuroimaging assessment throughout the course of the study.",
        "text": "Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial | The present multicenter, randomized, double-blind, placebo-controlled clinical trial will investigate whether the prolonged administration of high-dose oral Ambroxol over 52 weeks is safe, tolerable, able to change Glucocerebrosidase enzyme activity and alpha-synuclein levels in the central nervous system and, ultimately, to reduce the progression of cognitive decline and motor disability in 60 individuals with Parkinson's disease with mutations of the glucocerebrosidase gene (GBA1; OMIM 606463).\n\nParticipants will undergo clinical, biomarker blood and cerebrospinal fluid analysis, neuropsychological, neuroimaging assessment throughout the course of the study.",
        "tokens": "['Ambroxol', 'as', 'a', 'Disease', '-', 'modifying', 'Treatment', 'to', 'Reduce', 'the', 'Risk', 'of', 'Cognitive', 'Impairment', 'in', 'GBA', '-', 'associated', 'Parkinson', \"'s\", 'Disease', '.', 'A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Phase', '2', 'Trial', '|', 'The', 'present', 'multicenter', ',', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', 'clinical', 'trial', 'will', 'investigate', 'whether', 'the', 'prolonged', 'administration', 'of', 'high', '-', 'dose', 'oral', 'Ambroxol', 'over', '52', 'weeks', 'is', 'safe', ',', 'tolerable', ',', 'able', 'to', 'change', 'Glucocerebrosidase', 'enzyme', 'activity', 'and', 'alpha', '-', 'synuclein', 'levels', 'in', 'the', 'central', 'nervous', 'system', 'and', ',', 'ultimately', ',', 'to', 'reduce', 'the', 'progression', 'of', 'cognitive', 'decline', 'and', 'motor', 'disability', 'in', '60', 'individuals', 'with', 'Parkinson', \"'s\", 'disease', 'with', 'mutations', 'of', 'the', 'glucocerebrosidase', 'gene', '(', 'GBA1', ';', 'OMIM', '606463', ')', '.', '\\n\\n', 'Participants', 'will', 'undergo', 'clinical', ',', 'biomarker', 'blood', 'and', 'cerebrospinal', 'fluid', 'analysis', ',', 'neuropsychological', ',', 'neuroimaging', 'assessment', 'throughout', 'the', 'course', 'of', 'the', 'study', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "Ambroxol",
                "type": "DRUG"
            },
            {
                "start": 88,
                "end": 122,
                "text": "GBA-associated Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 358,
                "end": 366,
                "text": "Ambroxol",
                "type": "DRUG"
            },
            {
                "start": 616,
                "end": 681,
                "text": "Parkinson's disease with mutations of the glucocerebrosidase gene",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04039048",
        "study_official_title": "Effects of Cerebellar Transcranial Direct Current Stimulation During Balance Training on Cerebellar Ataxia ",
        "study_brief_summary": " Cerebellar ataxia is a neurologic symptom caused by damage or dysfunction in the cerebellum and its pathways that results in loss of coordination, balance and postural control. There is a high rate (93%) of fallings for this population that could limit daily life activities. Pharmacological interventions are not able to modify the balance, therefore, new approaches to rehabilitate must be studied. ctDCS is a non-invasive brain stimulation that seems to be a new and innovator technique to restore ataxia symptoms. The purpose of this study is to evaluate the effects of ctDCS associated with balance training on cerebellar ataxia patients. A counterbalanced crossover, sham-controlled, triple blind trial will be performed. All subjects will receive the real and sham ctDCS associated to balance training. The anodal ctDCS (2 mA, 20 minutes) or sham (2mA, 30 seconds) will be applied during balance training at Biodex Balance System (BBS). The balance will be the primary outcome and will be evaluated through Posture Control at Biodex Balance System. Ataxia' severity and functional mobility will be the secondary outcomes and will be evaluated by the scale for the assessment and rating of ataxia (SARA) and 10 meters walking test, respectively.",
        "text": "Effects of Cerebellar Transcranial Direct Current Stimulation During Balance Training on Cerebellar Ataxia | Cerebellar ataxia is a neurologic symptom caused by damage or dysfunction in the cerebellum and its pathways that results in loss of coordination, balance and postural control. There is a high rate (93%) of fallings for this population that could limit daily life activities. Pharmacological interventions are not able to modify the balance, therefore, new approaches to rehabilitate must be studied. ctDCS is a non-invasive brain stimulation that seems to be a new and innovator technique to restore ataxia symptoms. The purpose of this study is to evaluate the effects of ctDCS associated with balance training on cerebellar ataxia patients. A counterbalanced crossover, sham-controlled, triple blind trial will be performed. All subjects will receive the real and sham ctDCS associated to balance training. The anodal ctDCS (2 mA, 20 minutes) or sham (2mA, 30 seconds) will be applied during balance training at Biodex Balance System (BBS). The balance will be the primary outcome and will be evaluated through Posture Control at Biodex Balance System. Ataxia' severity and functional mobility will be the secondary outcomes and will be evaluated by the scale for the assessment and rating of ataxia (SARA) and 10 meters walking test, respectively.",
        "tokens": "['Effects', 'of', 'Cerebellar', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'During', 'Balance', 'Training', 'on', 'Cerebellar', 'Ataxia', '|', 'Cerebellar', 'ataxia', 'is', 'a', 'neurologic', 'symptom', 'caused', 'by', 'damage', 'or', 'dysfunction', 'in', 'the', 'cerebellum', 'and', 'its', 'pathways', 'that', 'results', 'in', 'loss', 'of', 'coordination', ',', 'balance', 'and', 'postural', 'control', '.', 'There', 'is', 'a', 'high', 'rate', '(', '93', '%', ')', 'of', 'fallings', 'for', 'this', 'population', 'that', 'could', 'limit', 'daily', 'life', 'activities', '.', 'Pharmacological', 'interventions', 'are', 'not', 'able', 'to', 'modify', 'the', 'balance', ',', 'therefore', ',', 'new', 'approaches', 'to', 'rehabilitate', 'must', 'be', 'studied', '.', 'ctDCS', 'is', 'a', 'non', '-', 'invasive', 'brain', 'stimulation', 'that', 'seems', 'to', 'be', 'a', 'new', 'and', 'innovator', 'technique', 'to', 'restore', 'ataxia', 'symptoms', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effects', 'of', 'ctDCS', 'associated', 'with', 'balance', 'training', 'on', 'cerebellar', 'ataxia', 'patients', '.', 'A', 'counterbalanced', 'crossover', ',', 'sham', '-', 'controlled', ',', 'triple', 'blind', 'trial', 'will', 'be', 'performed', '.', 'All', 'subjects', 'will', 'receive', 'the', 'real', 'and', 'sham', 'ctDCS', 'associated', 'to', 'balance', 'training', '.', 'The', 'anodal', 'ctDCS', '(', '2', 'mA', ',', '20', 'minutes', ')', 'or', 'sham', '(', '2mA', ',', '30', 'seconds', ')', 'will', 'be', 'applied', 'during', 'balance', 'training', 'at', 'Biodex', 'Balance', 'System', '(', 'BBS', ')', '.', 'The', 'balance', 'will', 'be', 'the', 'primary', 'outcome', 'and', 'will', 'be', 'evaluated', 'through', 'Posture', 'Control', 'at', 'Biodex', 'Balance', 'System', '.', 'Ataxia', \"'\", 'severity', 'and', 'functional', 'mobility', 'will', 'be', 'the', 'secondary', 'outcomes', 'and', 'will', 'be', 'evaluated', 'by', 'the', 'scale', 'for', 'the', 'assessment', 'and', 'rating', 'of', 'ataxia', '(', 'SARA', ')', 'and', '10', 'meters', 'walking', 'test', ',', 'respectively', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 61,
                "text": "Cerebellar Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 69,
                "end": 85,
                "text": "Balance Training",
                "type": "PHYSICAL"
            },
            {
                "start": 89,
                "end": 106,
                "text": "Cerebellar Ataxia",
                "type": "CONDITION"
            },
            {
                "start": 109,
                "end": 126,
                "text": "Cerebellar ataxia",
                "type": "CONDITION"
            },
            {
                "start": 510,
                "end": 515,
                "text": "ctDCS",
                "type": "OTHER"
            },
            {
                "start": 610,
                "end": 616,
                "text": "ataxia",
                "type": "CONDITION"
            },
            {
                "start": 683,
                "end": 688,
                "text": "ctDCS",
                "type": "OTHER"
            },
            {
                "start": 725,
                "end": 742,
                "text": "cerebellar ataxia",
                "type": "CONDITION"
            },
            {
                "start": 782,
                "end": 786,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 876,
                "end": 886,
                "text": "sham ctDCS",
                "type": "CONTROL"
            },
            {
                "start": 930,
                "end": 935,
                "text": "ctDCS",
                "type": "OTHER"
            },
            {
                "start": 958,
                "end": 962,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 1004,
                "end": 1020,
                "text": "balance training",
                "type": "PHYSICAL"
            },
            {
                "start": 1024,
                "end": 1045,
                "text": "Biodex Balance System",
                "type": "PHYSICAL"
            },
            {
                "start": 1047,
                "end": 1050,
                "text": "BBS",
                "type": "PHYSICAL"
            },
            {
                "start": 1142,
                "end": 1163,
                "text": "Biodex Balance System",
                "type": "PHYSICAL"
            },
            {
                "start": 1165,
                "end": 1171,
                "text": "Ataxia",
                "type": "CONDITION"
            },
            {
                "start": 1305,
                "end": 1311,
                "text": "ataxia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00906958",
        "study_official_title": "Comparison of the Efficacy and Subjective Comfort of a Modified AutoSet Device With an Existing AutoSet Device (VPAP Auto) in Treating Obstructive Sleep Apnea ",
        "study_brief_summary": " The purpose of this study is to determine if the performance of the modified AutoSet device is equivalent or better than the existing AutoSet device (VPAP Auto) in the efficacy of the treatment and the subjective comfort.",
        "text": "Comparison of the Efficacy and Subjective Comfort of a Modified AutoSet Device With an Existing AutoSet Device (VPAP Auto) in Treating Obstructive Sleep Apnea | The purpose of this study is to determine if the performance of the modified AutoSet device is equivalent or better than the existing AutoSet device (VPAP Auto) in the efficacy of the treatment and the subjective comfort.",
        "tokens": "['Comparison', 'of', 'the', 'Efficacy', 'and', 'Subjective', 'Comfort', 'of', 'a', 'Modified', 'AutoSet', 'Device', 'With', 'an', 'Existing', 'AutoSet', 'Device', '(', 'VPAP', 'Auto', ')', 'in', 'Treating', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'the', 'performance', 'of', 'the', 'modified', 'AutoSet', 'device', 'is', 'equivalent', 'or', 'better', 'than', 'the', 'existing', 'AutoSet', 'device', '(', 'VPAP', 'Auto', ')', 'in', 'the', 'efficacy', 'of', 'the', 'treatment', 'and', 'the', 'subjective', 'comfort', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 55,
                "end": 78,
                "text": "Modified AutoSet Device",
                "type": "OTHER"
            },
            {
                "start": 96,
                "end": 110,
                "text": "AutoSet Device",
                "type": "CONTROL"
            },
            {
                "start": 112,
                "end": 121,
                "text": "VPAP Auto",
                "type": "CONTROL"
            },
            {
                "start": 135,
                "end": 158,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 229,
                "end": 252,
                "text": "modified AutoSet device",
                "type": "OTHER"
            },
            {
                "start": 295,
                "end": 309,
                "text": "AutoSet device",
                "type": "CONTROL"
            },
            {
                "start": 311,
                "end": 320,
                "text": "VPAP Auto",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02684825",
        "study_official_title": "Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) ",
        "study_brief_summary": " The primary objective of this study is to evaluate whether, in patients with first-ever atherothrombotic or lacunar stroke without any previous history of atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT), the detection of AF/AFL/AT (silent or symptomatic) by using a continuous cardiac rhythm monitoring with implantable loop recorder (ILR) during the first 12 months of observation is higher than the detection by using a standard cardiac monitoring (physical exam, 12-lead electrocardiogram [ECG] at baseline, 3, 6, and 12 months and Holter ECG at 3 months) in the same period of time.",
        "text": "Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) | The primary objective of this study is to evaluate whether, in patients with first-ever atherothrombotic or lacunar stroke without any previous history of atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT), the detection of AF/AFL/AT (silent or symptomatic) by using a continuous cardiac rhythm monitoring with implantable loop recorder (ILR) during the first 12 months of observation is higher than the detection by using a standard cardiac monitoring (physical exam, 12-lead electrocardiogram [ECG] at baseline, 3, 6, and 12 months and Holter ECG at 3 months) in the same period of time.",
        "tokens": "['Detection', 'of', 'Silent', 'Atrial', 'Fibrillation', 'aFter', 'Ischemic', 'StrOke', '(', 'SAFFO', ')', 'Guided', 'by', 'Implantable', 'Loop', 'Recorder', '.', 'Multicentre', 'Italian', 'Trial', 'Based', 'on', 'Stroke', 'Unit', 'Network', 'With', 'Paired', 'Cardio', '-', 'Arrhythmology', 'Units', '(', 'Italian', 'Neurocardiology', 'Unit', 'Network', ')', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', ',', 'in', 'patients', 'with', 'first', '-', 'ever', 'atherothrombotic', 'or', 'lacunar', 'stroke', 'without', 'any', 'previous', 'history', 'of', 'atrial', 'fibrillation', '(', 'AF)/atrial', 'flutter', '(', 'AFL)/atrial', 'tachycardia', '(', 'AT', ')', ',', 'the', 'detection', 'of', 'AF', '/', 'AFL', '/', 'AT', '(', 'silent', 'or', 'symptomatic', ')', 'by', 'using', 'a', 'continuous', 'cardiac', 'rhythm', 'monitoring', 'with', 'implantable', 'loop', 'recorder', '(', 'ILR', ')', 'during', 'the', 'first', '12', 'months', 'of', 'observation', 'is', 'higher', 'than', 'the', 'detection', 'by', 'using', 'a', 'standard', 'cardiac', 'monitoring', '(', 'physical', 'exam', ',', '12', '-', 'lead', 'electrocardiogram', '[', 'ECG', ']', 'at', 'baseline', ',', '3', ',', '6', ',', 'and', '12', 'months', 'and', 'Holter', 'ECG', 'at', '3', 'months', ')', 'in', 'the', 'same', 'period', 'of', 'time', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 39,
                "text": "Silent Atrial Fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 46,
                "end": 61,
                "text": "Ischemic StrOke",
                "type": "CONDITION"
            },
            {
                "start": 319,
                "end": 364,
                "text": "first-ever atherothrombotic or lacunar stroke",
                "type": "CONDITION"
            },
            {
                "start": 397,
                "end": 416,
                "text": "atrial fibrillation",
                "type": "CONDITION"
            },
            {
                "start": 463,
                "end": 465,
                "text": "AT",
                "type": "CONDITION"
            },
            {
                "start": 485,
                "end": 487,
                "text": "AF",
                "type": "CONDITION"
            },
            {
                "start": 488,
                "end": 491,
                "text": "AFL",
                "type": "CONDITION"
            },
            {
                "start": 492,
                "end": 494,
                "text": "AT",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03790085",
        "study_official_title": "Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals ",
        "study_brief_summary": " This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.",
        "text": "Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals | This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.",
        "tokens": "['Identification', 'of', 'Multi', '-', 'modal', 'Bio', '-', 'markers', 'for', 'Early', 'Diagnosis', 'and', 'Treatment', 'Prediction', 'in', 'Schizophrenia', 'Individuals', '|', 'This', 'study', 'aims', 'to', 'screen', 'and', 'validate', 'multi', '-', 'scale', 'bio', '-', 'markers', 'for', 'early', 'diagnosis', 'and', 'medication', 'monitoring', 'for', 'early', 'schizophrenia', ',', 'including', 'the', 'genetic', ',', 'neurobiochemistry', ',', 'neuroimaging', 'and', 'eletrophysiological', 'measures', '.', 'Based', 'on', 'the', 'validated', 'bio', '-', 'markers', ',', 'the', 'present', 'study', 'further', 'tries', 'to', 'build', 'several', 'prediction', 'models', 'for', 'early', 'differential', 'diagnosis', 'of', 'schizophrenia', 'from', 'healthy', 'controls', 'and', 'other', 'mental', 'diseases', '(', 'such', 'as', 'the', 'major', 'depression', 'and', 'anxiety', 'disorders', ')', ',', 'biological', 'sub', '-', 'typing', 'and', 'diagnosis', 'of', 'the', 'schizophrenia', 'sub', '-', 'types', ',', 'and', 'early', 'prediction', 'of', 'the', 'medication', 'effects', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 90,
                "end": 103,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 250,
                "text": "early schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 480,
                "end": 493,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 639,
                "end": 652,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04091100",
        "study_official_title": "Effects of Electroacupuncture and Myofascial Release on Pain, Neck Functions and Depression Status in Patients With Tension-Type Headaches ",
        "study_brief_summary": " Tension-type headaches (TTH) last from thirty minutes to seven days, were ranked second among the primary types of headaches. The diagnosis of TTH is made according to the diagnostic criteria of the Second Beta version of the International Classification of Headache Disorders. The causes of TTH include the activation of extremely tense peripheric afferent neurons through the head and neck muscles, muscle sensitivity and stress. Additionally, a limited range of motion (ROM) in the neck may also lead to TTH.\n\nThe treatment of TTH involve both pharmacological and non-pharmacological methods. It is known that the pharmacological treatment of TTH has a limited effect. However, previous studies have shown that physical therapy programs that include methods such as acupuncture, Transcutaneous Electrical Nerve Stimulation (TENS), exercise, biofeedback, manipulation, cryotherapy, massage, strengthening of the neck muscles, stretching exercises are effective in alleviating TTH.\n\nIt has been observed that the trigger points in muscles play a role in TTH. Trigger points are generally defined as hyper-irritable points inside taut bands. It has been demonstrated that myofascial release, which is applied to the trigger points and is effective in relaxation treatments through stimulation of the neuromuscular system, relieves headaches via muscle relaxation. Electroacupuncture is another method used in relieving myofascial pain origin that involves the application of acupuncture needles to particular points and delivery of an electrical current at a specific frequency. The stimulation of muscle and skin tissues in affected areas is carried out by means of needles and the electrical current relieves pain and muscle spasms. In a meta-analysis study, it was found that electroacupuncture had a higher pain-relieving effect. However, a review of related studies deemed them to be lacking because the assessments were too limited to make it possible to unequivocally state that electroacupuncture has a high level of therapeutic efficacy.\n\nThe studies performed, however, did not examine the efficacy of electroacupuncture and myofascial release on TTH. Given that situation, the purpose of our study is to investigate the effects of electroacupuncture and myofascial release applied to points of tension in the neck muscles and trigger points of people suffering from TTH in terms of the headache intensity and frequency, neck functions, sleep quality and depression status.",
        "text": "Effects of Electroacupuncture and Myofascial Release on Pain, Neck Functions and Depression Status in Patients With Tension-Type Headaches | Tension-type headaches (TTH) last from thirty minutes to seven days, were ranked second among the primary types of headaches. The diagnosis of TTH is made according to the diagnostic criteria of the Second Beta version of the International Classification of Headache Disorders. The causes of TTH include the activation of extremely tense peripheric afferent neurons through the head and neck muscles, muscle sensitivity and stress. Additionally, a limited range of motion (ROM) in the neck may also lead to TTH.\n\nThe treatment of TTH involve both pharmacological and non-pharmacological methods. It is known that the pharmacological treatment of TTH has a limited effect. However, previous studies have shown that physical therapy programs that include methods such as acupuncture, Transcutaneous Electrical Nerve Stimulation (TENS), exercise, biofeedback, manipulation, cryotherapy, massage, strengthening of the neck muscles, stretching exercises are effective in alleviating TTH.\n\nIt has been observed that the trigger points in muscles play a role in TTH. Trigger points are generally defined as hyper-irritable points inside taut bands. It has been demonstrated that myofascial release, which is applied to the trigger points and is effective in relaxation treatments through stimulation of the neuromuscular system, relieves headaches via muscle relaxation. Electroacupuncture is another method used in relieving myofascial pain origin that involves the application of acupuncture needles to particular points and delivery of an electrical current at a specific frequency. The stimulation of muscle and skin tissues in affected areas is carried out by means of needles and the electrical current relieves pain and muscle spasms. In a meta-analysis study, it was found that electroacupuncture had a higher pain-relieving effect. However, a review of related studies deemed them to be lacking because the assessments were too limited to make it possible to unequivocally state that electroacupuncture has a high level of therapeutic efficacy.\n\nThe studies performed, however, did not examine the efficacy of electroacupuncture and myofascial release on TTH. Given that situation, the purpose of our study is to investigate the effects of electroacupuncture and myofascial release applied to points of tension in the neck muscles and trigger points of people suffering from TTH in terms of the headache intensity and frequency, neck functions, sleep quality and depression status.",
        "tokens": "['Effects', 'of', 'Electroacupuncture', 'and', 'Myofascial', 'Release', 'on', 'Pain', ',', 'Neck', 'Functions', 'and', 'Depression', 'Status', 'in', 'Patients', 'With', 'Tension', '-', 'Type', 'Headaches', '|', 'Tension', '-', 'type', 'headaches', '(', 'TTH', ')', 'last', 'from', 'thirty', 'minutes', 'to', 'seven', 'days', ',', 'were', 'ranked', 'second', 'among', 'the', 'primary', 'types', 'of', 'headaches', '.', 'The', 'diagnosis', 'of', 'TTH', 'is', 'made', 'according', 'to', 'the', 'diagnostic', 'criteria', 'of', 'the', 'Second', 'Beta', 'version', 'of', 'the', 'International', 'Classification', 'of', 'Headache', 'Disorders', '.', 'The', 'causes', 'of', 'TTH', 'include', 'the', 'activation', 'of', 'extremely', 'tense', 'peripheric', 'afferent', 'neurons', 'through', 'the', 'head', 'and', 'neck', 'muscles', ',', 'muscle', 'sensitivity', 'and', 'stress', '.', 'Additionally', ',', 'a', 'limited', 'range', 'of', 'motion', '(', 'ROM', ')', 'in', 'the', 'neck', 'may', 'also', 'lead', 'to', 'TTH', '.', '\\n\\n', 'The', 'treatment', 'of', 'TTH', 'involve', 'both', 'pharmacological', 'and', 'non', '-', 'pharmacological', 'methods', '.', 'It', 'is', 'known', 'that', 'the', 'pharmacological', 'treatment', 'of', 'TTH', 'has', 'a', 'limited', 'effect', '.', 'However', ',', 'previous', 'studies', 'have', 'shown', 'that', 'physical', 'therapy', 'programs', 'that', 'include', 'methods', 'such', 'as', 'acupuncture', ',', 'Transcutaneous', 'Electrical', 'Nerve', 'Stimulation', '(', 'TENS', ')', ',', 'exercise', ',', 'biofeedback', ',', 'manipulation', ',', 'cryotherapy', ',', 'massage', ',', 'strengthening', 'of', 'the', 'neck', 'muscles', ',', 'stretching', 'exercises', 'are', 'effective', 'in', 'alleviating', 'TTH', '.', '\\n\\n', 'It', 'has', 'been', 'observed', 'that', 'the', 'trigger', 'points', 'in', 'muscles', 'play', 'a', 'role', 'in', 'TTH', '.', 'Trigger', 'points', 'are', 'generally', 'defined', 'as', 'hyper', '-', 'irritable', 'points', 'inside', 'taut', 'bands', '.', 'It', 'has', 'been', 'demonstrated', 'that', 'myofascial', 'release', ',', 'which', 'is', 'applied', 'to', 'the', 'trigger', 'points', 'and', 'is', 'effective', 'in', 'relaxation', 'treatments', 'through', 'stimulation', 'of', 'the', 'neuromuscular', 'system', ',', 'relieves', 'headaches', 'via', 'muscle', 'relaxation', '.', 'Electroacupuncture', 'is', 'another', 'method', 'used', 'in', 'relieving', 'myofascial', 'pain', 'origin', 'that', 'involves', 'the', 'application', 'of', 'acupuncture', 'needles', 'to', 'particular', 'points', 'and', 'delivery', 'of', 'an', 'electrical', 'current', 'at', 'a', 'specific', 'frequency', '.', 'The', 'stimulation', 'of', 'muscle', 'and', 'skin', 'tissues', 'in', 'affected', 'areas', 'is', 'carried', 'out', 'by', 'means', 'of', 'needles', 'and', 'the', 'electrical', 'current', 'relieves', 'pain', 'and', 'muscle', 'spasms', '.', 'In', 'a', 'meta', '-', 'analysis', 'study', ',', 'it', 'was', 'found', 'that', 'electroacupuncture', 'had', 'a', 'higher', 'pain', '-', 'relieving', 'effect', '.', 'However', ',', 'a', 'review', 'of', 'related', 'studies', 'deemed', 'them', 'to', 'be', 'lacking', 'because', 'the', 'assessments', 'were', 'too', 'limited', 'to', 'make', 'it', 'possible', 'to', 'unequivocally', 'state', 'that', 'electroacupuncture', 'has', 'a', 'high', 'level', 'of', 'therapeutic', 'efficacy', '.', '\\n\\n', 'The', 'studies', 'performed', ',', 'however', ',', 'did', 'not', 'examine', 'the', 'efficacy', 'of', 'electroacupuncture', 'and', 'myofascial', 'release', 'on', 'TTH', '.', 'Given', 'that', 'situation', ',', 'the', 'purpose', 'of', 'our', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'electroacupuncture', 'and', 'myofascial', 'release', 'applied', 'to', 'points', 'of', 'tension', 'in', 'the', 'neck', 'muscles', 'and', 'trigger', 'points', 'of', 'people', 'suffering', 'from', 'TTH', 'in', 'terms', 'of', 'the', 'headache', 'intensity', 'and', 'frequency', ',', 'neck', 'functions', ',', 'sleep', 'quality', 'and', 'depression', 'status', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 29,
                "text": "Electroacupuncture",
                "type": "OTHER"
            },
            {
                "start": 34,
                "end": 52,
                "text": "Myofascial Release",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 60,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 81,
                "end": 91,
                "text": "Depression",
                "type": "CONDITION"
            },
            {
                "start": 116,
                "end": 138,
                "text": "Tension-Type Headaches",
                "type": "CONDITION"
            },
            {
                "start": 141,
                "end": 163,
                "text": "Tension-type headaches",
                "type": "CONDITION"
            },
            {
                "start": 165,
                "end": 168,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 256,
                "end": 265,
                "text": "headaches",
                "type": "CONDITION"
            },
            {
                "start": 284,
                "end": 287,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 436,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 648,
                "end": 651,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 671,
                "end": 674,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 787,
                "end": 790,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 910,
                "end": 921,
                "text": "acupuncture",
                "type": "OTHER"
            },
            {
                "start": 1119,
                "end": 1122,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 1196,
                "end": 1199,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 1313,
                "end": 1331,
                "text": "myofascial release",
                "type": "OTHER"
            },
            {
                "start": 1472,
                "end": 1481,
                "text": "headaches",
                "type": "CONDITION"
            },
            {
                "start": 1486,
                "end": 1503,
                "text": "muscle relaxation",
                "type": "OTHER"
            },
            {
                "start": 1505,
                "end": 1523,
                "text": "Electroacupuncture",
                "type": "OTHER"
            },
            {
                "start": 1571,
                "end": 1575,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1852,
                "end": 1856,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1920,
                "end": 1938,
                "text": "electroacupuncture",
                "type": "OTHER"
            },
            {
                "start": 1952,
                "end": 1956,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 2127,
                "end": 2145,
                "text": "electroacupuncture",
                "type": "OTHER"
            },
            {
                "start": 2253,
                "end": 2271,
                "text": "electroacupuncture",
                "type": "OTHER"
            },
            {
                "start": 2276,
                "end": 2294,
                "text": "myofascial release",
                "type": "OTHER"
            },
            {
                "start": 2298,
                "end": 2301,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 2383,
                "end": 2401,
                "text": "electroacupuncture",
                "type": "OTHER"
            },
            {
                "start": 2406,
                "end": 2424,
                "text": "myofascial release",
                "type": "OTHER"
            },
            {
                "start": 2518,
                "end": 2521,
                "text": "TTH",
                "type": "CONDITION"
            },
            {
                "start": 2538,
                "end": 2546,
                "text": "headache",
                "type": "CONDITION"
            },
            {
                "start": 2606,
                "end": 2616,
                "text": "depression",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00370838",
        "study_official_title": "Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome ",
        "study_brief_summary": " The goal of this study is to confirm that levetiracetam has a better tic-suppressing profile than that of the widely used tic-suppressing medication, clonidine. More specifically, the investigators hypothesize that in a 15 week placebo run-in, double-blind, medication cross-over trial; levetiracetam will be more effective and have fewer side-effects than clonidine.",
        "text": "Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome | The goal of this study is to confirm that levetiracetam has a better tic-suppressing profile than that of the widely used tic-suppressing medication, clonidine. More specifically, the investigators hypothesize that in a 15 week placebo run-in, double-blind, medication cross-over trial; levetiracetam will be more effective and have fewer side-effects than clonidine.",
        "tokens": "['Comparison', 'of', 'Keppra', 'and', 'Clonidine', 'in', 'the', 'Treatment', 'of', 'Tics', 'in', 'Children', 'With', 'Tourette', 'Syndrome', '|', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'confirm', 'that', 'levetiracetam', 'has', 'a', 'better', 'tic', '-', 'suppressing', 'profile', 'than', 'that', 'of', 'the', 'widely', 'used', 'tic', '-', 'suppressing', 'medication', ',', 'clonidine', '.', 'More', 'specifically', ',', 'the', 'investigators', 'hypothesize', 'that', 'in', 'a', '15', 'week', 'placebo', 'run', '-', 'in', ',', 'double', '-', 'blind', ',', 'medication', 'cross', '-', 'over', 'trial', ';', 'levetiracetam', 'will', 'be', 'more', 'effective', 'and', 'have', 'fewer', 'side', '-', 'effects', 'than', 'clonidine', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 20,
                "text": "Keppra",
                "type": "DRUG"
            },
            {
                "start": 25,
                "end": 34,
                "text": "Clonidine",
                "type": "DRUG"
            },
            {
                "start": 55,
                "end": 59,
                "text": "Tics",
                "type": "CONDITION"
            },
            {
                "start": 77,
                "end": 94,
                "text": "Tourette Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 152,
                "text": "levetiracetam",
                "type": "DRUG"
            },
            {
                "start": 166,
                "end": 169,
                "text": "tic",
                "type": "CONDITION"
            },
            {
                "start": 219,
                "end": 222,
                "text": "tic",
                "type": "CONDITION"
            },
            {
                "start": 247,
                "end": 256,
                "text": "clonidine",
                "type": "DRUG"
            },
            {
                "start": 325,
                "end": 332,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 384,
                "end": 397,
                "text": "levetiracetam",
                "type": "DRUG"
            },
            {
                "start": 454,
                "end": 463,
                "text": "clonidine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00904826",
        "study_official_title": "An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica ",
        "study_brief_summary": " The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.",
        "text": "An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.",
        "tokens": "['An', 'Open', 'Label', 'Study', 'of', 'the', 'Effects', 'of', 'Eculizumab', 'in', 'Neuromyelitis', 'Optica', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'the', 'drug', 'eculizumab', 'reduces', 'the', 'attack', 'rate', 'and', 'improves', 'outcome', 'in', 'patients', 'with', 'neuromyelitis', 'optica', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 38,
                "end": 48,
                "text": "Eculizumab",
                "type": "DRUG"
            },
            {
                "start": 52,
                "end": 72,
                "text": "Neuromyelitis Optica",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 139,
                "text": "eculizumab",
                "type": "DRUG"
            },
            {
                "start": 202,
                "end": 222,
                "text": "neuromyelitis optica",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04055376",
        "study_official_title": "Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation ",
        "study_brief_summary": " In this trial, the safety and effect of daily exposure to light and sound stimulation on people with mild Alzheimer's Disease (AD) will be studied.\n\nCOVID-19 Amendment: Due to the ongoing suspension of all in-person humans subject research across MIT in response to the COVID-19 pandemic, all enrolled participants who have not completed their 6-month visit will have their visit postponed to 9 months with a follow up at 18 months. Subjects who have completed their 6-month visit will still be instructed to continue and return at Month 12 for an evaluation.\n\nOPTIONAL: If the subject would like to come in for an evaluation between Month 9 and 18, we will invite participants to come on Month 12 to complete cognitive testing and EEG.",
        "text": "Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation | In this trial, the safety and effect of daily exposure to light and sound stimulation on people with mild Alzheimer's Disease (AD) will be studied.\n\nCOVID-19 Amendment: Due to the ongoing suspension of all in-person humans subject research across MIT in response to the COVID-19 pandemic, all enrolled participants who have not completed their 6-month visit will have their visit postponed to 9 months with a follow up at 18 months. Subjects who have completed their 6-month visit will still be instructed to continue and return at Month 12 for an evaluation.\n\nOPTIONAL: If the subject would like to come in for an evaluation between Month 9 and 18, we will invite participants to come on Month 12 to complete cognitive testing and EEG.",
        "tokens": "['Chronic', 'Treatment', 'of', 'Alzheimer', \"'s\", 'Disease', 'With', 'Gamma', 'Frequency', 'Stimulation', '|', 'In', 'this', 'trial', ',', 'the', 'safety', 'and', 'effect', 'of', 'daily', 'exposure', 'to', 'light', 'and', 'sound', 'stimulation', 'on', 'people', 'with', 'mild', 'Alzheimer', \"'s\", 'Disease', '(', 'AD', ')', 'will', 'be', 'studied', '.', '\\n\\n', 'COVID-19', 'Amendment', ':', 'Due', 'to', 'the', 'ongoing', 'suspension', 'of', 'all', 'in', '-', 'person', 'humans', 'subject', 'research', 'across', 'MIT', 'in', 'response', 'to', 'the', 'COVID-19', 'pandemic', ',', 'all', 'enrolled', 'participants', 'who', 'have', 'not', 'completed', 'their', '6', '-', 'month', 'visit', 'will', 'have', 'their', 'visit', 'postponed', 'to', '9', 'months', 'with', 'a', 'follow', 'up', 'at', '18', 'months', '.', 'Subjects', 'who', 'have', 'completed', 'their', '6', '-', 'month', 'visit', 'will', 'still', 'be', 'instructed', 'to', 'continue', 'and', 'return', 'at', 'Month', '12', 'for', 'an', 'evaluation', '.', '\\n\\n', 'OPTIONAL', ':', 'If', 'the', 'subject', 'would', 'like', 'to', 'come', 'in', 'for', 'an', 'evaluation', 'between', 'Month', '9', 'and', '18', ',', 'we', 'will', 'invite', 'participants', 'to', 'come', 'on', 'Month', '12', 'to', 'complete', 'cognitive', 'testing', 'and', 'EEG', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 40,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 46,
                "end": 73,
                "text": "Gamma Frequency Stimulation",
                "type": "OTHER"
            },
            {
                "start": 116,
                "end": 161,
                "text": "daily exposure to light and sound stimulation",
                "type": "OTHER"
            },
            {
                "start": 177,
                "end": 201,
                "text": "mild Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 203,
                "end": 205,
                "text": "AD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01433315",
        "study_official_title": "Physiologic Effects of Sleep Restriction ",
        "study_brief_summary": " Evidence suggests a relationship between sleep deprivation and cardiovascular disease. The investigators wish to determine whether 9 nights of modest sleep restriction results in activation of cardiovascular disease mechanisms, thus potentially increasing the risk of cardiovascular disease. The investigators hypothesize that sleep restriction will result in elevated blood pressure, inflammation, and neurocognitive deficits.",
        "text": "Physiologic Effects of Sleep Restriction | Evidence suggests a relationship between sleep deprivation and cardiovascular disease. The investigators wish to determine whether 9 nights of modest sleep restriction results in activation of cardiovascular disease mechanisms, thus potentially increasing the risk of cardiovascular disease. The investigators hypothesize that sleep restriction will result in elevated blood pressure, inflammation, and neurocognitive deficits.",
        "tokens": "['Physiologic', 'Effects', 'of', 'Sleep', 'Restriction', '|', 'Evidence', 'suggests', 'a', 'relationship', 'between', 'sleep', 'deprivation', 'and', 'cardiovascular', 'disease', '.', 'The', 'investigators', 'wish', 'to', 'determine', 'whether', '9', 'nights', 'of', 'modest', 'sleep', 'restriction', 'results', 'in', 'activation', 'of', 'cardiovascular', 'disease', 'mechanisms', ',', 'thus', 'potentially', 'increasing', 'the', 'risk', 'of', 'cardiovascular', 'disease', '.', 'The', 'investigators', 'hypothesize', 'that', 'sleep', 'restriction', 'will', 'result', 'in', 'elevated', 'blood', 'pressure', ',', 'inflammation', ',', 'and', 'neurocognitive', 'deficits', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 106,
                "end": 128,
                "text": "cardiovascular disease",
                "type": "CONDITION"
            },
            {
                "start": 236,
                "end": 258,
                "text": "cardiovascular disease",
                "type": "CONDITION"
            },
            {
                "start": 311,
                "end": 333,
                "text": "cardiovascular disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03497468",
        "study_official_title": "Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis ",
        "study_brief_summary": " Multiple Sclerosis (MS) is inflammatory, demyelinating and autoimmune disease of the central nervous system. It is usually seen with relapses and genetic and environmental factors play a role in the etiology. Neurological symptoms seen in MS restrict the patient's daily activity and social role participation. Mobility problems and fatigue are the most important reasons of role limitations and decreased quality of life. The importance of exercise training in disease management has been emphasized in recent years. However, few studies have investigated the effects of task-oriented trainings on symptoms of the disease. The aim of this sudy is to investigate the effects of task-oriented training additional to combined exercise training on functional capacity, mobility, balance, fatigue and quality of life in patients with MS.",
        "text": "Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis | Multiple Sclerosis (MS) is inflammatory, demyelinating and autoimmune disease of the central nervous system. It is usually seen with relapses and genetic and environmental factors play a role in the etiology. Neurological symptoms seen in MS restrict the patient's daily activity and social role participation. Mobility problems and fatigue are the most important reasons of role limitations and decreased quality of life. The importance of exercise training in disease management has been emphasized in recent years. However, few studies have investigated the effects of task-oriented trainings on symptoms of the disease. The aim of this sudy is to investigate the effects of task-oriented training additional to combined exercise training on functional capacity, mobility, balance, fatigue and quality of life in patients with MS.",
        "tokens": "['Effects', 'of', 'Task', '-', 'oriented', 'Training', 'on', 'Functional', 'Mobility', 'and', 'Fatigue', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '|', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'is', 'inflammatory', ',', 'demyelinating', 'and', 'autoimmune', 'disease', 'of', 'the', 'central', 'nervous', 'system', '.', 'It', 'is', 'usually', 'seen', 'with', 'relapses', 'and', 'genetic', 'and', 'environmental', 'factors', 'play', 'a', 'role', 'in', 'the', 'etiology', '.', 'Neurological', 'symptoms', 'seen', 'in', 'MS', 'restrict', 'the', 'patient', \"'s\", 'daily', 'activity', 'and', 'social', 'role', 'participation', '.', 'Mobility', 'problems', 'and', 'fatigue', 'are', 'the', 'most', 'important', 'reasons', 'of', 'role', 'limitations', 'and', 'decreased', 'quality', 'of', 'life', '.', 'The', 'importance', 'of', 'exercise', 'training', 'in', 'disease', 'management', 'has', 'been', 'emphasized', 'in', 'recent', 'years', '.', 'However', ',', 'few', 'studies', 'have', 'investigated', 'the', 'effects', 'of', 'task', '-', 'oriented', 'trainings', 'on', 'symptoms', 'of', 'the', 'disease', '.', 'The', 'aim', 'of', 'this', 'sudy', 'is', 'to', 'investigate', 'the', 'effects', 'of', 'task', '-', 'oriented', 'training', 'additional', 'to', 'combined', 'exercise', 'training', 'on', 'functional', 'capacity', ',', 'mobility', ',', 'balance', ',', 'fatigue', 'and', 'quality', 'of', 'life', 'in', 'patients', 'with', 'MS', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 33,
                "text": "Task-oriented Training",
                "type": "PHYSICAL"
            },
            {
                "start": 61,
                "end": 68,
                "text": "Fatigue",
                "type": "CONDITION"
            },
            {
                "start": 86,
                "end": 104,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 125,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 127,
                "end": 129,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 346,
                "end": 348,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 418,
                "end": 435,
                "text": "Mobility problems",
                "type": "CONDITION"
            },
            {
                "start": 440,
                "end": 447,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 548,
                "end": 565,
                "text": "exercise training",
                "type": "PHYSICAL"
            },
            {
                "start": 679,
                "end": 702,
                "text": "task-oriented trainings",
                "type": "PHYSICAL"
            },
            {
                "start": 785,
                "end": 807,
                "text": "task-oriented training",
                "type": "PHYSICAL"
            },
            {
                "start": 822,
                "end": 848,
                "text": "combined exercise training",
                "type": "PHYSICAL"
            },
            {
                "start": 892,
                "end": 899,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 937,
                "end": 939,
                "text": "MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02104323",
        "study_official_title": "Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping ",
        "study_brief_summary": " 1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an objective basis for an enlarged randomized double-blind trial.",
        "text": "Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping | 1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an objective basis for an enlarged randomized double-blind trial.",
        "tokens": "['Recombinant', 'Human', 'Endostatin', 'Injection', 'Study', 'for', 'Patients', 'With', 'Neurofibromatosis', 'Type', '2', '(', 'NF2', ')', 'and', 'NF2', '-', 'Related', 'Tumors', 'by', 'Continuous', 'Intravenous', 'Pumping', '|', '1)Preliminarily', 'evaluate', 'the', 'treatment', 'effect', 'of', 'continuous', 'vein', 'injection', 'of', 'recombinant', 'human', 'endostatin', 'on', 'NF2', ';', '2)Preliminarily', 'evaluate', 'the', 'safety', 'and', 'the', 'patient', \"'s\", 'tolerance', 'of', 'the', 'treatment', 'of', 'endostatin', ';', '3)Provide', 'an', 'objective', 'basis', 'for', 'an', 'enlarged', 'randomized', 'double', '-', 'blind', 'trial', '.']",
        "token_bio_labels": "['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 28,
                "text": "Recombinant Human Endostatin",
                "type": "DRUG"
            },
            {
                "start": 63,
                "end": 87,
                "text": "Neurofibromatosis Type 2",
                "type": "CONDITION"
            },
            {
                "start": 89,
                "end": 92,
                "text": "NF2",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 116,
                "text": "NF2-Related Tumors",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 259,
                "text": "recombinant human endostatin",
                "type": "DRUG"
            },
            {
                "start": 263,
                "end": 266,
                "text": "NF2",
                "type": "CONDITION"
            },
            {
                "start": 352,
                "end": 362,
                "text": "endostatin",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT02791321",
        "study_official_title": "Fragility Assessment in Adults With ADHD and Mental Retardation, Advancing Age ",
        "study_brief_summary": " Frailty is a age dependent physiological state of vulnerability. Frailty is screened by the phenotypic model (5 clinical criteria) or the cumulative model (various clinical and biological criteria). Currently, aging with autism spectrum disorder and mental retardation (ADS-MR) is poor described. Nevertheless many data indicate that people with ADS-MR may present an early aging.\n\nPrincipal aim of this study is to determine if frailty in people with ADS-MR aged over 20 years depend on age. Secondary aims are to evaluate frailty prevalence, to describe with details health according to age, and to verify the frailty index validity for predicting falls, hospitalisation and death, in this population of ADS-MR patients aged over 20 years.\n\nThis monocentric and prospective study will include 60 ADS-MR patients aged over 20 years and living in Languedoc-Roussillon's medico-social care homes. Patients are evaluated at the time of inclusion. Frailty index is calculated from 104 clinical and biological criteria. Furthermore the investigator staff collect data about ADS severity (CARS), adaptative and intellectual functionning (Vineland), and psychiatric and somatic comorbidities (Reiss scale, DSQIID and CIRS). Falls, hospitalisations or death occurrence is then collected every year during 5 years.\n\nThe connection between frailty index and age will be studied using linear regression. The frailty index validity will be analysed using ROC curves. Modelisation of the falls, hospitalisations or death risk in the 5 years after the initial evaluation will help in identification of the more frailty predictive criteria.",
        "text": "Fragility Assessment in Adults With ADHD and Mental Retardation, Advancing Age | Frailty is a age dependent physiological state of vulnerability. Frailty is screened by the phenotypic model (5 clinical criteria) or the cumulative model (various clinical and biological criteria). Currently, aging with autism spectrum disorder and mental retardation (ADS-MR) is poor described. Nevertheless many data indicate that people with ADS-MR may present an early aging.\n\nPrincipal aim of this study is to determine if frailty in people with ADS-MR aged over 20 years depend on age. Secondary aims are to evaluate frailty prevalence, to describe with details health according to age, and to verify the frailty index validity for predicting falls, hospitalisation and death, in this population of ADS-MR patients aged over 20 years.\n\nThis monocentric and prospective study will include 60 ADS-MR patients aged over 20 years and living in Languedoc-Roussillon's medico-social care homes. Patients are evaluated at the time of inclusion. Frailty index is calculated from 104 clinical and biological criteria. Furthermore the investigator staff collect data about ADS severity (CARS), adaptative and intellectual functionning (Vineland), and psychiatric and somatic comorbidities (Reiss scale, DSQIID and CIRS). Falls, hospitalisations or death occurrence is then collected every year during 5 years.\n\nThe connection between frailty index and age will be studied using linear regression. The frailty index validity will be analysed using ROC curves. Modelisation of the falls, hospitalisations or death risk in the 5 years after the initial evaluation will help in identification of the more frailty predictive criteria.",
        "tokens": "['Fragility', 'Assessment', 'in', 'Adults', 'With', 'ADHD', 'and', 'Mental', 'Retardation', ',', 'Advancing', 'Age', '|', 'Frailty', 'is', 'a', 'age', 'dependent', 'physiological', 'state', 'of', 'vulnerability', '.', 'Frailty', 'is', 'screened', 'by', 'the', 'phenotypic', 'model', '(', '5', 'clinical', 'criteria', ')', 'or', 'the', 'cumulative', 'model', '(', 'various', 'clinical', 'and', 'biological', 'criteria', ')', '.', 'Currently', ',', 'aging', 'with', 'autism', 'spectrum', 'disorder', 'and', 'mental', 'retardation', '(', 'ADS', '-', 'MR', ')', 'is', 'poor', 'described', '.', 'Nevertheless', 'many', 'data', 'indicate', 'that', 'people', 'with', 'ADS', '-', 'MR', 'may', 'present', 'an', 'early', 'aging', '.', '\\n\\n', 'Principal', 'aim', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'frailty', 'in', 'people', 'with', 'ADS', '-', 'MR', 'aged', 'over', '20', 'years', 'depend', 'on', 'age', '.', 'Secondary', 'aims', 'are', 'to', 'evaluate', 'frailty', 'prevalence', ',', 'to', 'describe', 'with', 'details', 'health', 'according', 'to', 'age', ',', 'and', 'to', 'verify', 'the', 'frailty', 'index', 'validity', 'for', 'predicting', 'falls', ',', 'hospitalisation', 'and', 'death', ',', 'in', 'this', 'population', 'of', 'ADS', '-', 'MR', 'patients', 'aged', 'over', '20', 'years', '.', '\\n\\n', 'This', 'monocentric', 'and', 'prospective', 'study', 'will', 'include', '60', 'ADS', '-', 'MR', 'patients', 'aged', 'over', '20', 'years', 'and', 'living', 'in', 'Languedoc', '-', 'Roussillon', \"'s\", 'medico', '-', 'social', 'care', 'homes', '.', 'Patients', 'are', 'evaluated', 'at', 'the', 'time', 'of', 'inclusion', '.', 'Frailty', 'index', 'is', 'calculated', 'from', '104', 'clinical', 'and', 'biological', 'criteria', '.', 'Furthermore', 'the', 'investigator', 'staff', 'collect', 'data', 'about', 'ADS', 'severity', '(', 'CARS', ')', ',', 'adaptative', 'and', 'intellectual', 'functionning', '(', 'Vineland', ')', ',', 'and', 'psychiatric', 'and', 'somatic', 'comorbidities', '(', 'Reiss', 'scale', ',', 'DSQIID', 'and', 'CIRS', ')', '.', 'Falls', ',', 'hospitalisations', 'or', 'death', 'occurrence', 'is', 'then', 'collected', 'every', 'year', 'during', '5', 'years', '.', '\\n\\n', 'The', 'connection', 'between', 'frailty', 'index', 'and', 'age', 'will', 'be', 'studied', 'using', 'linear', 'regression', '.', 'The', 'frailty', 'index', 'validity', 'will', 'be', 'analysed', 'using', 'ROC', 'curves', '.', 'Modelisation', 'of', 'the', 'falls', ',', 'hospitalisations', 'or', 'death', 'risk', 'in', 'the', '5', 'years', 'after', 'the', 'initial', 'evaluation', 'will', 'help', 'in', 'identification', 'of', 'the', 'more', 'frailty', 'predictive', 'criteria', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 36,
                "end": 40,
                "text": "ADHD",
                "type": "CONDITION"
            },
            {
                "start": 45,
                "end": 63,
                "text": "Mental Retardation",
                "type": "CONDITION"
            },
            {
                "start": 81,
                "end": 88,
                "text": "Frailty",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 153,
                "text": "Frailty",
                "type": "CONDITION"
            },
            {
                "start": 302,
                "end": 326,
                "text": "autism spectrum disorder",
                "type": "CONDITION"
            },
            {
                "start": 331,
                "end": 349,
                "text": "mental retardation",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 357,
                "text": "ADS-MR",
                "type": "CONDITION"
            },
            {
                "start": 427,
                "end": 433,
                "text": "ADS-MR",
                "type": "CONDITION"
            },
            {
                "start": 510,
                "end": 517,
                "text": "frailty",
                "type": "CONDITION"
            },
            {
                "start": 533,
                "end": 539,
                "text": "ADS-MR",
                "type": "CONDITION"
            },
            {
                "start": 605,
                "end": 612,
                "text": "frailty",
                "type": "CONDITION"
            },
            {
                "start": 787,
                "end": 793,
                "text": "ADS-MR",
                "type": "CONDITION"
            },
            {
                "start": 879,
                "end": 885,
                "text": "ADS-MR",
                "type": "CONDITION"
            },
            {
                "start": 1151,
                "end": 1154,
                "text": "ADS",
                "type": "CONDITION"
            },
            {
                "start": 1679,
                "end": 1686,
                "text": "frailty",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05619133",
        "study_official_title": "Effects and Underlying Mechanisms of Photobiomodulation (PBM) on Health and Well-Being ",
        "study_brief_summary": " The goal of this clinical study is to assess the effects of different photobiomodulation (PBM) conditions in men and women between 25 and 65 years old with daytime sleepiness/drowsiness and /or mild mood complaints but be otherwise healthy. The main question it aims to answer are:\n\nDoes PBM significantly affect health and well-being?\nAre PBM effects wavelength dependent?\nAre PBM effects pulse dependent?\nAre the eyes needed to assert an PBM effect or is exposure only to the skin sufficient?\nWhat are the cellular, metabolic pathways underlying the systemic effects of PBM.\n\nParticipants will have to:\n\nExposed themselves 5 times per week during 2 weeks to the PBM stimuli between 9:30 and 12:30.\nA week before the baseline measurement, participants will have to start wearing a Fitbit Versa 3, and will have to continuously wear until the end of the study.\nIn the afternoon of the baseline day as well as in the afternoons after 5 and 10 PBM sessions (week 1 and week 2, respectively), participants will have to go to the lab for blood withdraw.\nIn the evening of the baseline day as well as in the evenings after 5 and 10 PBM sessions (week 1 and week 2, respectively), participants will have to collect saliva samples as well as to complete questionnaires.\n\nIt will be a double-blind placebo-controlled field study with a between subject comparison.",
        "text": "Effects and Underlying Mechanisms of Photobiomodulation (PBM) on Health and Well-Being | The goal of this clinical study is to assess the effects of different photobiomodulation (PBM) conditions in men and women between 25 and 65 years old with daytime sleepiness/drowsiness and /or mild mood complaints but be otherwise healthy. The main question it aims to answer are:\n\nDoes PBM significantly affect health and well-being?\nAre PBM effects wavelength dependent?\nAre PBM effects pulse dependent?\nAre the eyes needed to assert an PBM effect or is exposure only to the skin sufficient?\nWhat are the cellular, metabolic pathways underlying the systemic effects of PBM.\n\nParticipants will have to:\n\nExposed themselves 5 times per week during 2 weeks to the PBM stimuli between 9:30 and 12:30.\nA week before the baseline measurement, participants will have to start wearing a Fitbit Versa 3, and will have to continuously wear until the end of the study.\nIn the afternoon of the baseline day as well as in the afternoons after 5 and 10 PBM sessions (week 1 and week 2, respectively), participants will have to go to the lab for blood withdraw.\nIn the evening of the baseline day as well as in the evenings after 5 and 10 PBM sessions (week 1 and week 2, respectively), participants will have to collect saliva samples as well as to complete questionnaires.\n\nIt will be a double-blind placebo-controlled field study with a between subject comparison.",
        "tokens": "['Effects', 'and', 'Underlying', 'Mechanisms', 'of', 'Photobiomodulation', '(', 'PBM', ')', 'on', 'Health', 'and', 'Well', '-', 'Being', '|', 'The', 'goal', 'of', 'this', 'clinical', 'study', 'is', 'to', 'assess', 'the', 'effects', 'of', 'different', 'photobiomodulation', '(', 'PBM', ')', 'conditions', 'in', 'men', 'and', 'women', 'between', '25', 'and', '65', 'years', 'old', 'with', 'daytime', 'sleepiness', '/', 'drowsiness', 'and', '/or', 'mild', 'mood', 'complaints', 'but', 'be', 'otherwise', 'healthy', '.', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'are', ':', '\\n\\n', 'Does', 'PBM', 'significantly', 'affect', 'health', 'and', 'well', '-', 'being', '?', '\\n', 'Are', 'PBM', 'effects', 'wavelength', 'dependent', '?', '\\n', 'Are', 'PBM', 'effects', 'pulse', 'dependent', '?', '\\n', 'Are', 'the', 'eyes', 'needed', 'to', 'assert', 'an', 'PBM', 'effect', 'or', 'is', 'exposure', 'only', 'to', 'the', 'skin', 'sufficient', '?', '\\n', 'What', 'are', 'the', 'cellular', ',', 'metabolic', 'pathways', 'underlying', 'the', 'systemic', 'effects', 'of', 'PBM', '.', '\\n\\n', 'Participants', 'will', 'have', 'to', ':', '\\n\\n', 'Exposed', 'themselves', '5', 'times', 'per', 'week', 'during', '2', 'weeks', 'to', 'the', 'PBM', 'stimuli', 'between', '9:30', 'and', '12:30', '.', '\\n', 'A', 'week', 'before', 'the', 'baseline', 'measurement', ',', 'participants', 'will', 'have', 'to', 'start', 'wearing', 'a', 'Fitbit', 'Versa', '3', ',', 'and', 'will', 'have', 'to', 'continuously', 'wear', 'until', 'the', 'end', 'of', 'the', 'study', '.', '\\n', 'In', 'the', 'afternoon', 'of', 'the', 'baseline', 'day', 'as', 'well', 'as', 'in', 'the', 'afternoons', 'after', '5', 'and', '10', 'PBM', 'sessions', '(', 'week', '1', 'and', 'week', '2', ',', 'respectively', ')', ',', 'participants', 'will', 'have', 'to', 'go', 'to', 'the', 'lab', 'for', 'blood', 'withdraw', '.', '\\n', 'In', 'the', 'evening', 'of', 'the', 'baseline', 'day', 'as', 'well', 'as', 'in', 'the', 'evenings', 'after', '5', 'and', '10', 'PBM', 'sessions', '(', 'week', '1', 'and', 'week', '2', ',', 'respectively', ')', ',', 'participants', 'will', 'have', 'to', 'collect', 'saliva', 'samples', 'as', 'well', 'as', 'to', 'complete', 'questionnaires', '.', '\\n\\n', 'It', 'will', 'be', 'a', 'double', '-', 'blind', 'placebo', '-', 'controlled', 'field', 'study', 'with', 'a', 'between', 'subject', 'comparison', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 55,
                "text": "Photobiomodulation",
                "type": "OTHER"
            },
            {
                "start": 57,
                "end": 60,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 159,
                "end": 177,
                "text": "photobiomodulation",
                "type": "OTHER"
            },
            {
                "start": 179,
                "end": 182,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 245,
                "end": 263,
                "text": "daytime sleepiness",
                "type": "CONDITION"
            },
            {
                "start": 264,
                "end": 274,
                "text": "drowsiness",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 303,
                "text": "mild mood complaints",
                "type": "CONDITION"
            },
            {
                "start": 377,
                "end": 380,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 429,
                "end": 432,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 467,
                "end": 470,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 529,
                "end": 532,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 661,
                "end": 664,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 753,
                "end": 756,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 871,
                "end": 885,
                "text": "Fitbit Versa 3",
                "type": "OTHER"
            },
            {
                "start": 1031,
                "end": 1034,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 1216,
                "end": 1219,
                "text": "PBM",
                "type": "OTHER"
            },
            {
                "start": 1379,
                "end": 1386,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03694028",
        "study_official_title": "Neuromuscular and Biomechanical Control of Lower Limb Loading in Individuals With Chronic Stroke ",
        "study_brief_summary": " Stroke is the leading cause of long-term disability in the U.S. Individuals with hemiparesis due to stroke often have difficulty bearing weight on their legs and transferring weight from one leg to the other. The ability to bear weight on the legs is important during functional movements such as rising from a chair, standing and walking. Diminished weight transfer contributes to asymmetries during walking which commonly leads to greater energy expenditure. Moreover, deficits in bearing weight on the paretic leg contribute to lateral instability and are associated with decreased walking speed and increased risk of falling in individuals post-stroke. These functional limitations affect community participation and life quality. Thus, restoring the ability to bear weight on the legs, i.e., limb loading, is a critical goal for rehabilitation post-stroke. The purpose of this research is to identify the impairments in neuromechanical mechanisms of limb loading and determine whether limb loading responses can be retrained by induced forced limb loading.",
        "text": "Neuromuscular and Biomechanical Control of Lower Limb Loading in Individuals With Chronic Stroke | Stroke is the leading cause of long-term disability in the U.S. Individuals with hemiparesis due to stroke often have difficulty bearing weight on their legs and transferring weight from one leg to the other. The ability to bear weight on the legs is important during functional movements such as rising from a chair, standing and walking. Diminished weight transfer contributes to asymmetries during walking which commonly leads to greater energy expenditure. Moreover, deficits in bearing weight on the paretic leg contribute to lateral instability and are associated with decreased walking speed and increased risk of falling in individuals post-stroke. These functional limitations affect community participation and life quality. Thus, restoring the ability to bear weight on the legs, i.e., limb loading, is a critical goal for rehabilitation post-stroke. The purpose of this research is to identify the impairments in neuromechanical mechanisms of limb loading and determine whether limb loading responses can be retrained by induced forced limb loading.",
        "tokens": "['Neuromuscular', 'and', 'Biomechanical', 'Control', 'of', 'Lower', 'Limb', 'Loading', 'in', 'Individuals', 'With', 'Chronic', 'Stroke', '|', 'Stroke', 'is', 'the', 'leading', 'cause', 'of', 'long', '-', 'term', 'disability', 'in', 'the', 'U.S.', 'Individuals', 'with', 'hemiparesis', 'due', 'to', 'stroke', 'often', 'have', 'difficulty', 'bearing', 'weight', 'on', 'their', 'legs', 'and', 'transferring', 'weight', 'from', 'one', 'leg', 'to', 'the', 'other', '.', 'The', 'ability', 'to', 'bear', 'weight', 'on', 'the', 'legs', 'is', 'important', 'during', 'functional', 'movements', 'such', 'as', 'rising', 'from', 'a', 'chair', ',', 'standing', 'and', 'walking', '.', 'Diminished', 'weight', 'transfer', 'contributes', 'to', 'asymmetries', 'during', 'walking', 'which', 'commonly', 'leads', 'to', 'greater', 'energy', 'expenditure', '.', 'Moreover', ',', 'deficits', 'in', 'bearing', 'weight', 'on', 'the', 'paretic', 'leg', 'contribute', 'to', 'lateral', 'instability', 'and', 'are', 'associated', 'with', 'decreased', 'walking', 'speed', 'and', 'increased', 'risk', 'of', 'falling', 'in', 'individuals', 'post', '-', 'stroke', '.', 'These', 'functional', 'limitations', 'affect', 'community', 'participation', 'and', 'life', 'quality', '.', 'Thus', ',', 'restoring', 'the', 'ability', 'to', 'bear', 'weight', 'on', 'the', 'legs', ',', 'i.e.', ',', 'limb', 'loading', ',', 'is', 'a', 'critical', 'goal', 'for', 'rehabilitation', 'post', '-', 'stroke', '.', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'identify', 'the', 'impairments', 'in', 'neuromechanical', 'mechanisms', 'of', 'limb', 'loading', 'and', 'determine', 'whether', 'limb', 'loading', 'responses', 'can', 'be', 'retrained', 'by', 'induced', 'forced', 'limb', 'loading', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O']",
        "entities": [
            {
                "start": 82,
                "end": 96,
                "text": "Chronic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 99,
                "end": 105,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 180,
                "end": 191,
                "text": "hemiparesis",
                "type": "CONDITION"
            },
            {
                "start": 199,
                "end": 205,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 743,
                "end": 754,
                "text": "post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 948,
                "end": 959,
                "text": "post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 1132,
                "end": 1159,
                "text": "induced forced limb loading",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT01355627",
        "study_official_title": "TachoSil\u00ae Versus Current Practice in Dura Sealing Techniques for the Prevention of Post-operative Cerebrospinal Fluid (CSF) Leaks in Patients Undergoing Skull Base Surgery: An Open Label, Randomised, Controlled, Multi-centre, Parallel Group Efficacy and Safety Trial. ",
        "study_brief_summary": " The primary objective is to demonstrate superiority of TachoSil\u00ae compared to current practice as an adjunct in sealing the dura mater. The efficacy of the dura mater sealing must be evaluated post-operatively. The secondary objective is to evaluate the safety of TachoSil\u00ae as an adjunct in sealing the dura mater.\n\nThe trial population will consist of 726 randomised (1:1) patients elected for skull base surgery. The trial duration consists of screening, surgery, efficacy follow-up after 7\u00b11 weeks and safety follow-up 28\u00b12 weeks after surgery.",
        "text": "TachoSil\u00ae Versus Current Practice in Dura Sealing Techniques for the Prevention of Post-operative Cerebrospinal Fluid (CSF) Leaks in Patients Undergoing Skull Base Surgery: An Open Label, Randomised, Controlled, Multi-centre, Parallel Group Efficacy and Safety Trial. | The primary objective is to demonstrate superiority of TachoSil\u00ae compared to current practice as an adjunct in sealing the dura mater. The efficacy of the dura mater sealing must be evaluated post-operatively. The secondary objective is to evaluate the safety of TachoSil\u00ae as an adjunct in sealing the dura mater.\n\nThe trial population will consist of 726 randomised (1:1) patients elected for skull base surgery. The trial duration consists of screening, surgery, efficacy follow-up after 7\u00b11 weeks and safety follow-up 28\u00b12 weeks after surgery.",
        "tokens": "['TachoSil', '\u00ae', 'Versus', 'Current', 'Practice', 'in', 'Dura', 'Sealing', 'Techniques', 'for', 'the', 'Prevention', 'of', 'Post', '-', 'operative', 'Cerebrospinal', 'Fluid', '(', 'CSF', ')', 'Leaks', 'in', 'Patients', 'Undergoing', 'Skull', 'Base', 'Surgery', ':', 'An', 'Open', 'Label', ',', 'Randomised', ',', 'Controlled', ',', 'Multi', '-', 'centre', ',', 'Parallel', 'Group', 'Efficacy', 'and', 'Safety', 'Trial', '.', '|', 'The', 'primary', 'objective', 'is', 'to', 'demonstrate', 'superiority', 'of', 'TachoSil', '\u00ae', 'compared', 'to', 'current', 'practice', 'as', 'an', 'adjunct', 'in', 'sealing', 'the', 'dura', 'mater', '.', 'The', 'efficacy', 'of', 'the', 'dura', 'mater', 'sealing', 'must', 'be', 'evaluated', 'post', '-', 'operatively', '.', 'The', 'secondary', 'objective', 'is', 'to', 'evaluate', 'the', 'safety', 'of', 'TachoSil', '\u00ae', 'as', 'an', 'adjunct', 'in', 'sealing', 'the', 'dura', 'mater', '.', '\\n\\n', 'The', 'trial', 'population', 'will', 'consist', 'of', '726', 'randomised', '(', '1:1', ')', 'patients', 'elected', 'for', 'skull', 'base', 'surgery', '.', 'The', 'trial', 'duration', 'consists', 'of', 'screening', ',', 'surgery', ',', 'efficacy', 'follow', '-', 'up', 'after', '7\u00b11', 'weeks', 'and', 'safety', 'follow', '-', 'up', '28\u00b12', 'weeks', 'after', 'surgery', '.']",
        "token_bio_labels": "['B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 8,
                "text": "TachoSil",
                "type": "OTHER"
            },
            {
                "start": 17,
                "end": 33,
                "text": "Current Practice",
                "type": "CONTROL"
            },
            {
                "start": 83,
                "end": 129,
                "text": "Post-operative Cerebrospinal Fluid (CSF) Leaks",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 171,
                "text": "Skull Base Surgery",
                "type": "CONDITION"
            },
            {
                "start": 325,
                "end": 333,
                "text": "TachoSil",
                "type": "OTHER"
            },
            {
                "start": 533,
                "end": 541,
                "text": "TachoSil",
                "type": "OTHER"
            },
            {
                "start": 664,
                "end": 682,
                "text": "skull base surgery",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04846036",
        "study_official_title": "A Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial Disease ",
        "study_brief_summary": " This a randomized placebo controlled, double-blind phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of which the gene defect is known to decrease one or more oxidative phosphorylation system enzymes and who suffer from motor symptoms (\"KHENERGYC\").",
        "text": "A Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial Disease | This a randomized placebo controlled, double-blind phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of which the gene defect is known to decrease one or more oxidative phosphorylation system enzymes and who suffer from motor symptoms (\"KHENERGYC\").",
        "tokens": "['A', 'Randomized', 'Placebo', 'Controlled', ',', 'Double', '-', 'blind', 'Phase', 'II', 'Study', 'to', 'Explore', 'the', 'Safety', ',', 'Efficacy', 'and', 'Pharmacokinetics', 'of', 'Sonlicromanol', 'in', 'Children', 'With', 'Genetically', 'Confirmed', 'Mitochondrial', 'Disease', '|', 'This', 'a', 'randomized', 'placebo', 'controlled', ',', 'double', '-', 'blind', 'phase', 'II', 'study', 'to', 'explore', 'the', 'pharmacokinetics', ',', 'safety', 'and', 'efficacy', 'of', 'sonlicromanol', 'in', 'children', '(', 'from', 'birth', 'to', '17', 'years', ')', 'with', 'genetically', 'confirmed', 'mitochondrial', 'disease', 'of', 'which', 'the', 'gene', 'defect', 'is', 'known', 'to', 'decrease', 'one', 'or', 'more', 'oxidative', 'phosphorylation', 'system', 'enzymes', 'and', 'who', 'suffer', 'from', 'motor', 'symptoms', '(', '\"', 'KHENERGYC', '\"', ')', '.']",
        "token_bio_labels": "['O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 20,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 117,
                "end": 130,
                "text": "Sonlicromanol",
                "type": "DRUG"
            },
            {
                "start": 170,
                "end": 191,
                "text": "Mitochondrial Disease",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 219,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 316,
                "end": 329,
                "text": "sonlicromanol",
                "type": "DRUG"
            },
            {
                "start": 394,
                "end": 415,
                "text": "mitochondrial disease",
                "type": "CONDITION"
            },
            {
                "start": 535,
                "end": 549,
                "text": "motor symptoms",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00183625",
        "study_official_title": "The Effectiveness of Supplementing Supported Employment With Behavioral Skills Training ",
        "study_brief_summary": " This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients maintain a job.",
        "text": "The Effectiveness of Supplementing Supported Employment With Behavioral Skills Training | This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients maintain a job.",
        "tokens": "['The', 'Effectiveness', 'of', 'Supplementing', 'Supported', 'Employment', 'With', 'Behavioral', 'Skills', 'Training', '|', 'This', 'study', 'will', 'compare', 'employment', 'support', 'with', 'behavioral', 'skills', 'training', 'to', 'employment', 'support', 'alone', 'in', 'schizophrenia', 'patients', 'taking', 'either', 'risperidone', 'or', 'olanzapine', 'to', 'determine', 'which', 'is', 'more', 'effective', 'in', 'helping', 'the', 'patients', 'maintain', 'a', 'job', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 87,
                "text": "Supported Employment With Behavioral Skills Training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 114,
                "end": 164,
                "text": "employment support with behavioral skills training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 168,
                "end": 186,
                "text": "employment support",
                "type": "CONTROL"
            },
            {
                "start": 196,
                "end": 209,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 233,
                "end": 244,
                "text": "risperidone",
                "type": "DRUG"
            },
            {
                "start": 248,
                "end": 258,
                "text": "olanzapine",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT01345136",
        "study_official_title": "A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma ",
        "study_brief_summary": " The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients.\n\nRAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors.",
        "text": "A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma | The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients.\n\nRAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors.",
        "tokens": "['A', 'Single', 'Arm', ',', 'Monocenter', 'Phase', 'II', 'Trial', 'of', 'RAD001', 'as', 'Monotherapy', 'in', 'the', 'Treatment', 'of', 'Neurofibromatosis', 'Type', '2', '-', 'Related', 'Vestibular', 'Schwannoma', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'if', 'RAD001', 'treatment', 'will', 'shrink', 'or', 'slow', 'the', 'growth', 'of', 'the', 'vestibular', 'schwannoma(s', ')', 'in', 'Neurofibromatosis', '2', '(', 'NF2', ')', 'patients', '.', 'Secondary', 'objectives', 'include', 'determining', 'if', 'RAD001', 'treatment', 'will', 'improve', 'hearing', 'ability', 'in', 'NF2', 'patients', '.', '\\n\\n', 'RAD001', 'is', 'an', 'oral', 'drug', 'that', 'is', 'approved', 'by', 'Food', 'and', 'Drug', 'Administration', '(', 'FDA', ')', 'for', 'other', 'types', 'of', 'tumors', ',', 'it', 'is', 'not', 'approved', 'by', 'the', 'FDA', 'for', 'treatment', 'of', 'NF2', 'related', 'tumors', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 49,
                "text": "RAD001",
                "type": "DRUG"
            },
            {
                "start": 85,
                "end": 109,
                "text": "Neurofibromatosis Type 2",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 141,
                "text": "Vestibular Schwannoma",
                "type": "CONDITION"
            },
            {
                "start": 188,
                "end": 194,
                "text": "RAD001",
                "type": "DRUG"
            },
            {
                "start": 243,
                "end": 267,
                "text": "vestibular schwannoma(s)",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 290,
                "text": "Neurofibromatosis 2",
                "type": "CONDITION"
            },
            {
                "start": 292,
                "end": 295,
                "text": "NF2",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 357,
                "text": "RAD001",
                "type": "DRUG"
            },
            {
                "start": 400,
                "end": 403,
                "text": "NF2",
                "type": "CONDITION"
            },
            {
                "start": 415,
                "end": 421,
                "text": "RAD001",
                "type": "DRUG"
            },
            {
                "start": 512,
                "end": 518,
                "text": "tumors",
                "type": "CONDITION"
            },
            {
                "start": 567,
                "end": 570,
                "text": "NF2",
                "type": "CONDITION"
            },
            {
                "start": 579,
                "end": 585,
                "text": "tumors",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04856527",
        "study_official_title": "The Motor Control Consequences of Excessive Physical Therapist Support in Individuals With Stroke ",
        "study_brief_summary": " The purpose of this study is to systematically determine the effect of unnecessary physical therapist assistance in individuals after stroke during the practice of an upper limb task on an individual's task performance and their underlying motor control patterns when learning (or re-learning) motor skills.",
        "text": "The Motor Control Consequences of Excessive Physical Therapist Support in Individuals With Stroke | The purpose of this study is to systematically determine the effect of unnecessary physical therapist assistance in individuals after stroke during the practice of an upper limb task on an individual's task performance and their underlying motor control patterns when learning (or re-learning) motor skills.",
        "tokens": "['The', 'Motor', 'Control', 'Consequences', 'of', 'Excessive', 'Physical', 'Therapist', 'Support', 'in', 'Individuals', 'With', 'Stroke', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'systematically', 'determine', 'the', 'effect', 'of', 'unnecessary', 'physical', 'therapist', 'assistance', 'in', 'individuals', 'after', 'stroke', 'during', 'the', 'practice', 'of', 'an', 'upper', 'limb', 'task', 'on', 'an', 'individual', \"'s\", 'task', 'performance', 'and', 'their', 'underlying', 'motor', 'control', 'patterns', 'when', 'learning', '(', 'or', 're', '-', 'learning', ')', 'motor', 'skills', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 91,
                "end": 97,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 234,
                "end": 240,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01848509",
        "study_official_title": "A Telemedicine System for the Follow-up of Patients With SAS ",
        "study_brief_summary": " Objective: Set up an interoperable telemedicine system for the follow-up of patients with sleep apnea syndrome.",
        "text": "A Telemedicine System for the Follow-up of Patients With SAS | Objective: Set up an interoperable telemedicine system for the follow-up of patients with sleep apnea syndrome.",
        "tokens": "['A', 'Telemedicine', 'System', 'for', 'the', 'Follow', '-', 'up', 'of', 'Patients', 'With', 'SAS', '|', 'Objective', ':', 'Set', 'up', 'an', 'interoperable', 'telemedicine', 'system', 'for', 'the', 'follow', '-', 'up', 'of', 'patients', 'with', 'sleep', 'apnea', 'syndrome', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 2,
                "end": 21,
                "text": "Telemedicine System",
                "type": "OTHER"
            },
            {
                "start": 57,
                "end": 60,
                "text": "SAS",
                "type": "CONDITION"
            },
            {
                "start": 84,
                "end": 117,
                "text": "interoperable telemedicine system",
                "type": "OTHER"
            },
            {
                "start": 153,
                "end": 173,
                "text": "sleep apnea syndrome",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02011321",
        "study_official_title": "Clevidipine for Vasospasm After Subarachnoid Hemorrhage ",
        "study_brief_summary": " Vasospasm occurs frequently after aneurysmal subarachnoid hemorrhage and can lead to strokes. The investigators will investigate if infusion of a novel drug, clevidipine, will decrease vasospasm during the infusion and post infusion period using transcranial doppler monitoring of patients with subarachnoid hemorrhage and moderate severity vasospasm",
        "text": "Clevidipine for Vasospasm After Subarachnoid Hemorrhage | Vasospasm occurs frequently after aneurysmal subarachnoid hemorrhage and can lead to strokes. The investigators will investigate if infusion of a novel drug, clevidipine, will decrease vasospasm during the infusion and post infusion period using transcranial doppler monitoring of patients with subarachnoid hemorrhage and moderate severity vasospasm",
        "tokens": "['Clevidipine', 'for', 'Vasospasm', 'After', 'Subarachnoid', 'Hemorrhage', '|', 'Vasospasm', 'occurs', 'frequently', 'after', 'aneurysmal', 'subarachnoid', 'hemorrhage', 'and', 'can', 'lead', 'to', 'strokes', '.', 'The', 'investigators', 'will', 'investigate', 'if', 'infusion', 'of', 'a', 'novel', 'drug', ',', 'clevidipine', ',', 'will', 'decrease', 'vasospasm', 'during', 'the', 'infusion', 'and', 'post', 'infusion', 'period', 'using', 'transcranial', 'doppler', 'monitoring', 'of', 'patients', 'with', 'subarachnoid', 'hemorrhage', 'and', 'moderate', 'severity', 'vasospasm']",
        "token_bio_labels": "['B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 0,
                "end": 11,
                "text": "Clevidipine",
                "type": "DRUG"
            },
            {
                "start": 16,
                "end": 25,
                "text": "Vasospasm",
                "type": "CONDITION"
            },
            {
                "start": 32,
                "end": 55,
                "text": "Subarachnoid Hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 58,
                "end": 67,
                "text": "Vasospasm",
                "type": "CONDITION"
            },
            {
                "start": 92,
                "end": 126,
                "text": "aneurysmal subarachnoid hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 216,
                "end": 227,
                "text": "clevidipine",
                "type": "DRUG"
            },
            {
                "start": 243,
                "end": 252,
                "text": "vasospasm",
                "type": "CONDITION"
            },
            {
                "start": 353,
                "end": 376,
                "text": "subarachnoid hemorrhage",
                "type": "CONDITION"
            },
            {
                "start": 381,
                "end": 408,
                "text": "moderate severity vasospasm",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00515619",
        "study_official_title": "An International Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral Lacosamide (SPM 927) in Patients With Partial Seizures ",
        "study_brief_summary": " The main purpose of this trial is to determine safety and efficacy of Lacosamide under long term therapy.",
        "text": "An International Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral Lacosamide (SPM 927) in Patients With Partial Seizures | The main purpose of this trial is to determine safety and efficacy of Lacosamide under long term therapy.",
        "tokens": "['An', 'International', 'Open', '-', 'label', 'Extension', 'Trial', 'to', 'Determine', 'Safety', 'and', 'Efficacy', 'of', 'Long', '-', 'term', 'Oral', 'Lacosamide', '(', 'SPM', '927', ')', 'in', 'Patients', 'With', 'Partial', 'Seizures', '|', 'The', 'main', 'purpose', 'of', 'this', 'trial', 'is', 'to', 'determine', 'safety', 'and', 'efficacy', 'of', 'Lacosamide', 'under', 'long', 'term', 'therapy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 95,
                "end": 105,
                "text": "Lacosamide",
                "type": "DRUG"
            },
            {
                "start": 107,
                "end": 114,
                "text": "SPM 927",
                "type": "DRUG"
            },
            {
                "start": 133,
                "end": 149,
                "text": "Partial Seizures",
                "type": "CONDITION"
            },
            {
                "start": 222,
                "end": 232,
                "text": "Lacosamide",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05458011",
        "study_official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients ",
        "study_brief_summary": " Primary Objective:\n\nTo demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine.\n\nSecondary Objectives:\n\nTo further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections.\nTo evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.",
        "text": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients | Primary Objective:\n\nTo demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine.\n\nSecondary Objectives:\n\nTo further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections.\nTo evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.",
        "tokens": "['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Efficacy', 'and', 'Safety', 'Study', 'With', 'an', 'Open', '-', 'Label', 'Treatment', 'Period', 'of', 'Fremanezumab', 'Administered', 'Subcutaneously', 'Monthly', 'or', 'Quarterly', 'for', 'the', 'Preventive', 'Treatment', 'of', 'Migraine', 'in', 'Adult', 'Chinese', 'Patients', '|', 'Primary', 'Objective', ':', '\\n\\n', 'To', 'demonstrate', 'the', 'efficacy', 'of', 'fremanezumab', 'administered', 'as', 'monthly', 'and', 'quarterly', 'subcutaneous', '(', 'sc', ')', 'injections', 'to', 'adult', 'Chinese', 'participants', 'with', 'migraine', '.', '\\n\\n', 'Secondary', 'Objectives', ':', '\\n\\n', 'To', 'further', 'demonstrate', 'the', 'efficacy', 'of', 'fremanezumab', 'administered', 'as', 'monthly', 'and', 'quarterly', 'sc', 'injections', '.', '\\n', 'To', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'fremanezumab', 'administered', 'as', 'monthly', 'and', 'quarterly', 'sc', 'injections', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 41,
                "end": 48,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 125,
                "end": 137,
                "text": "Fremanezumab",
                "type": "DRUG"
            },
            {
                "start": 219,
                "end": 227,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 307,
                "end": 319,
                "text": "fremanezumab",
                "type": "DRUG"
            },
            {
                "start": 422,
                "end": 430,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 495,
                "end": 507,
                "text": "fremanezumab",
                "type": "DRUG"
            },
            {
                "start": 604,
                "end": 616,
                "text": "fremanezumab",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03178786",
        "study_official_title": "Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease ",
        "study_brief_summary": " The purpose of this dual phase cross-sectional, controlled and prospective, open label, exploratory study is to determine the general characteristics of visuospatial exploration and its neural substrate in subjects with Parkinson's Disease (PD) and to explore the impact of professional art therapy intervention in a cohort of subjects with Parkinson's Disease on visuospatial exploration, visuomotor integration, neuropsychological and emotional sphere, quality of daily living and motor symptoms.",
        "text": "Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease | The purpose of this dual phase cross-sectional, controlled and prospective, open label, exploratory study is to determine the general characteristics of visuospatial exploration and its neural substrate in subjects with Parkinson's Disease (PD) and to explore the impact of professional art therapy intervention in a cohort of subjects with Parkinson's Disease on visuospatial exploration, visuomotor integration, neuropsychological and emotional sphere, quality of daily living and motor symptoms.",
        "tokens": "['Visual', 'Spatial', 'Exploration', 'and', 'Art', 'Therapy', 'Intervention', 'in', 'Patients', 'Diagnosed', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'dual', 'phase', 'cross', '-', 'sectional', ',', 'controlled', 'and', 'prospective', ',', 'open', 'label', ',', 'exploratory', 'study', 'is', 'to', 'determine', 'the', 'general', 'characteristics', 'of', 'visuospatial', 'exploration', 'and', 'its', 'neural', 'substrate', 'in', 'subjects', 'with', 'Parkinson', \"'s\", 'Disease', '(', 'PD', ')', 'and', 'to', 'explore', 'the', 'impact', 'of', 'professional', 'art', 'therapy', 'intervention', 'in', 'a', 'cohort', 'of', 'subjects', 'with', 'Parkinson', \"'s\", 'Disease', 'on', 'visuospatial', 'exploration', ',', 'visuomotor', 'integration', ',', 'neuropsychological', 'and', 'emotional', 'sphere', ',', 'quality', 'of', 'daily', 'living', 'and', 'motor', 'symptoms', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 42,
                "text": "Art Therapy",
                "type": "OTHER"
            },
            {
                "start": 83,
                "end": 102,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 325,
                "end": 344,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 346,
                "end": 348,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 392,
                "end": 403,
                "text": "art therapy",
                "type": "OTHER"
            },
            {
                "start": 446,
                "end": 465,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00199407",
        "study_official_title": "A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy. ",
        "study_brief_summary": " To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.",
        "text": "A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy. | To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.",
        "tokens": "['A', '12', '-', 'week', ',', 'Double', 'Blind', ',', 'Placebo', '-', 'controlled', ',', 'Randomized', ',', 'Parallel', 'Group', ',', 'Multicenter', ',', 'Fixed', 'Dose', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'a', '20', 'mg', '/', 'd', 'Oral', 'Dose', 'of', 'KW-6002', '(', 'Istradefylline', ')', 'as', 'Treatment', 'for', 'Parkinson', \"'s\", 'Disease', 'in', 'Patients', 'With', 'Motor', 'Response', 'Complications', 'on', 'Levodopa', '/', 'Carbidopa', 'Therapy', '.', '|', 'To', 'establish', 'the', 'efficacy', 'of', 'a', '20', 'mg', '/', 'day', 'dose', 'of', 'istradefylline', 'for', 'reducing', 'the', 'percentage', 'of', 'OFF', 'time', 'in', 'patients', 'with', 'advanced', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'treated', 'with', 'levodopa', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 32,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 165,
                "end": 172,
                "text": "KW-6002",
                "type": "DRUG"
            },
            {
                "start": 174,
                "end": 188,
                "text": "Istradefylline",
                "type": "DRUG"
            },
            {
                "start": 207,
                "end": 226,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 244,
                "end": 272,
                "text": "Motor Response Complications",
                "type": "CONDITION"
            },
            {
                "start": 276,
                "end": 284,
                "text": "Levodopa",
                "type": "DRUG"
            },
            {
                "start": 285,
                "end": 294,
                "text": "Carbidopa",
                "type": "DRUG"
            },
            {
                "start": 355,
                "end": 369,
                "text": "istradefylline",
                "type": "DRUG"
            },
            {
                "start": 427,
                "end": 455,
                "text": "advanced Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 457,
                "end": 459,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 474,
                "end": 482,
                "text": "levodopa",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05818189",
        "study_official_title": "Cortical Correlates of Gait Automaticity and Daily Life Mobility in Parkinson's Disease ",
        "study_brief_summary": " The purpose of the study is to determine the effects of a novel, personalized, tactile cueing system on gait automaticity. The researchers hypothesized that step-synchronized tactile cueing will reduce prefrontal cortex activity (improve automaticity) and improve gait variability (as well as gait speed). The researchers predict that improved automaticity with improved gait variability will be associated with increased activation of other than prefrontal cortical areas while walking (i.e., sensory-motor). To determine the effects of cueing, 60 participants with PD from will be randomized into one, of two, cueing interventions: 1) personalized, step-synchronized tactile cueing and 2) tactile cueing at fixed intervals as an active control group. In addition, the researchers will explore the feasibility and potential benefits of independent use of tactile cueing during a week in daily life for a future clinical trial.\n\nThis project will characterize the cortical correlates of gait automaticity, the changes in gait automaticity with cueing in people with PD, and how these changes translate to improvement in gait and turning. The long-term goal is to unravel the mechanisms of impaired gait automaticity in PD.",
        "text": "Cortical Correlates of Gait Automaticity and Daily Life Mobility in Parkinson's Disease | The purpose of the study is to determine the effects of a novel, personalized, tactile cueing system on gait automaticity. The researchers hypothesized that step-synchronized tactile cueing will reduce prefrontal cortex activity (improve automaticity) and improve gait variability (as well as gait speed). The researchers predict that improved automaticity with improved gait variability will be associated with increased activation of other than prefrontal cortical areas while walking (i.e., sensory-motor). To determine the effects of cueing, 60 participants with PD from will be randomized into one, of two, cueing interventions: 1) personalized, step-synchronized tactile cueing and 2) tactile cueing at fixed intervals as an active control group. In addition, the researchers will explore the feasibility and potential benefits of independent use of tactile cueing during a week in daily life for a future clinical trial.\n\nThis project will characterize the cortical correlates of gait automaticity, the changes in gait automaticity with cueing in people with PD, and how these changes translate to improvement in gait and turning. The long-term goal is to unravel the mechanisms of impaired gait automaticity in PD.",
        "tokens": "['Cortical', 'Correlates', 'of', 'Gait', 'Automaticity', 'and', 'Daily', 'Life', 'Mobility', 'in', 'Parkinson', \"'s\", 'Disease', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'the', 'effects', 'of', 'a', 'novel', ',', 'personalized', ',', 'tactile', 'cueing', 'system', 'on', 'gait', 'automaticity', '.', 'The', 'researchers', 'hypothesized', 'that', 'step', '-', 'synchronized', 'tactile', 'cueing', 'will', 'reduce', 'prefrontal', 'cortex', 'activity', '(', 'improve', 'automaticity', ')', 'and', 'improve', 'gait', 'variability', '(', 'as', 'well', 'as', 'gait', 'speed', ')', '.', 'The', 'researchers', 'predict', 'that', 'improved', 'automaticity', 'with', 'improved', 'gait', 'variability', 'will', 'be', 'associated', 'with', 'increased', 'activation', 'of', 'other', 'than', 'prefrontal', 'cortical', 'areas', 'while', 'walking', '(', 'i.e.', ',', 'sensory', '-', 'motor', ')', '.', 'To', 'determine', 'the', 'effects', 'of', 'cueing', ',', '60', 'participants', 'with', 'PD', 'from', 'will', 'be', 'randomized', 'into', 'one', ',', 'of', 'two', ',', 'cueing', 'interventions', ':', '1', ')', 'personalized', ',', 'step', '-', 'synchronized', 'tactile', 'cueing', 'and', '2', ')', 'tactile', 'cueing', 'at', 'fixed', 'intervals', 'as', 'an', 'active', 'control', 'group', '.', 'In', 'addition', ',', 'the', 'researchers', 'will', 'explore', 'the', 'feasibility', 'and', 'potential', 'benefits', 'of', 'independent', 'use', 'of', 'tactile', 'cueing', 'during', 'a', 'week', 'in', 'daily', 'life', 'for', 'a', 'future', 'clinical', 'trial', '.', '\\n\\n', 'This', 'project', 'will', 'characterize', 'the', 'cortical', 'correlates', 'of', 'gait', 'automaticity', ',', 'the', 'changes', 'in', 'gait', 'automaticity', 'with', 'cueing', 'in', 'people', 'with', 'PD', ',', 'and', 'how', 'these', 'changes', 'translate', 'to', 'improvement', 'in', 'gait', 'and', 'turning', '.', 'The', 'long', '-', 'term', 'goal', 'is', 'to', 'unravel', 'the', 'mechanisms', 'of', 'impaired', 'gait', 'automaticity', 'in', 'PD', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 68,
                "end": 87,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 190,
                "text": "personalized, tactile cueing system",
                "type": "OTHER"
            },
            {
                "start": 247,
                "end": 279,
                "text": "step-synchronized tactile cueing",
                "type": "OTHER"
            },
            {
                "start": 657,
                "end": 659,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 727,
                "end": 773,
                "text": "personalized, step-synchronized tactile cueing",
                "type": "OTHER"
            },
            {
                "start": 781,
                "end": 814,
                "text": "tactile cueing at fixed intervals",
                "type": "CONTROL"
            },
            {
                "start": 946,
                "end": 960,
                "text": "tactile cueing",
                "type": "OTHER"
            },
            {
                "start": 1134,
                "end": 1140,
                "text": "cueing",
                "type": "OTHER"
            },
            {
                "start": 1156,
                "end": 1158,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1309,
                "end": 1311,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00111267",
        "study_official_title": "The Effect of Oral Vitamin B12 Supplementation on Cognitive Performance in Elderly People: the Brain12 Study ",
        "study_brief_summary": " The purpose of this trial is to study the effects of oral vitamin B12 supplementation and vitamin B12 combined with folic acid supplementation on cognitive performance for 24 weeks in elderly people with mild vitamin B12 deficiency.",
        "text": "The Effect of Oral Vitamin B12 Supplementation on Cognitive Performance in Elderly People: the Brain12 Study | The purpose of this trial is to study the effects of oral vitamin B12 supplementation and vitamin B12 combined with folic acid supplementation on cognitive performance for 24 weeks in elderly people with mild vitamin B12 deficiency.",
        "tokens": "['The', 'Effect', 'of', 'Oral', 'Vitamin', 'B12', 'Supplementation', 'on', 'Cognitive', 'Performance', 'in', 'Elderly', 'People', ':', 'the', 'Brain12', 'Study', '|', 'The', 'purpose', 'of', 'this', 'trial', 'is', 'to', 'study', 'the', 'effects', 'of', 'oral', 'vitamin', 'B12', 'supplementation', 'and', 'vitamin', 'B12', 'combined', 'with', 'folic', 'acid', 'supplementation', 'on', 'cognitive', 'performance', 'for', '24', 'weeks', 'in', 'elderly', 'people', 'with', 'mild', 'vitamin', 'B12', 'deficiency', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 19,
                "end": 30,
                "text": "Vitamin B12",
                "type": "DRUG"
            },
            {
                "start": 169,
                "end": 180,
                "text": "vitamin B12",
                "type": "DRUG"
            },
            {
                "start": 201,
                "end": 212,
                "text": "vitamin B12",
                "type": "DRUG"
            },
            {
                "start": 227,
                "end": 237,
                "text": "folic acid",
                "type": "DRUG"
            },
            {
                "start": 315,
                "end": 342,
                "text": "mild vitamin B12 deficiency",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01933438",
        "study_official_title": "Does Early Supination and External Rotation Repositioning in Children With Birth Related Brachial Plexus Injury Have Benefit? A Randomized Controlled Trial of the Sup-ER Protocol. ",
        "study_brief_summary": " This study evaluates the ability of a supination and external rotation protocol to improve the arm function and anatomy of children with birth related brachial plexus injuries.",
        "text": "Does Early Supination and External Rotation Repositioning in Children With Birth Related Brachial Plexus Injury Have Benefit? A Randomized Controlled Trial of the Sup-ER Protocol. | This study evaluates the ability of a supination and external rotation protocol to improve the arm function and anatomy of children with birth related brachial plexus injuries.",
        "tokens": "['Does', 'Early', 'Supination', 'and', 'External', 'Rotation', 'Repositioning', 'in', 'Children', 'With', 'Birth', 'Related', 'Brachial', 'Plexus', 'Injury', 'Have', 'Benefit', '?', 'A', 'Randomized', 'Controlled', 'Trial', 'of', 'the', 'Sup', '-', 'ER', 'Protocol', '.', '|', 'This', 'study', 'evaluates', 'the', 'ability', 'of', 'a', 'supination', 'and', 'external', 'rotation', 'protocol', 'to', 'improve', 'the', 'arm', 'function', 'and', 'anatomy', 'of', 'children', 'with', 'birth', 'related', 'brachial', 'plexus', 'injuries', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 5,
                "end": 21,
                "text": "Early Supination",
                "type": "OTHER"
            },
            {
                "start": 26,
                "end": 57,
                "text": "External Rotation Repositioning",
                "type": "OTHER"
            },
            {
                "start": 75,
                "end": 111,
                "text": "Birth Related Brachial Plexus Injury",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 230,
                "text": "supination",
                "type": "OTHER"
            },
            {
                "start": 235,
                "end": 252,
                "text": "external rotation",
                "type": "OTHER"
            },
            {
                "start": 319,
                "end": 357,
                "text": "birth related brachial plexus injuries",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05606653",
        "study_official_title": "Physiological Study of the Critical Closing Airway Pressure in a Population of Didgeridoo Players ",
        "study_brief_summary": " Obstructive sleep apnea is characterised by an abnormal upper airway collapsibility. Upper airway collapsibility can be evaluated through critical closure airway pressure (Pcrit). Didgeridoo is a traditional australian musical instrument involving circular respiration, a breathing technique involving mouth muscles. We hypothesize that didgeridoo players have a lower risk of airway collapsibility due to circular breathing technique",
        "text": "Physiological Study of the Critical Closing Airway Pressure in a Population of Didgeridoo Players | Obstructive sleep apnea is characterised by an abnormal upper airway collapsibility. Upper airway collapsibility can be evaluated through critical closure airway pressure (Pcrit). Didgeridoo is a traditional australian musical instrument involving circular respiration, a breathing technique involving mouth muscles. We hypothesize that didgeridoo players have a lower risk of airway collapsibility due to circular breathing technique",
        "tokens": "['Physiological', 'Study', 'of', 'the', 'Critical', 'Closing', 'Airway', 'Pressure', 'in', 'a', 'Population', 'of', 'Didgeridoo', 'Players', '|', 'Obstructive', 'sleep', 'apnea', 'is', 'characterised', 'by', 'an', 'abnormal', 'upper', 'airway', 'collapsibility', '.', 'Upper', 'airway', 'collapsibility', 'can', 'be', 'evaluated', 'through', 'critical', 'closure', 'airway', 'pressure', '(', 'Pcrit', ')', '.', 'Didgeridoo', 'is', 'a', 'traditional', 'australian', 'musical', 'instrument', 'involving', 'circular', 'respiration', ',', 'a', 'breathing', 'technique', 'involving', 'mouth', 'muscles', '.', 'We', 'hypothesize', 'that', 'didgeridoo', 'players', 'have', 'a', 'lower', 'risk', 'of', 'airway', 'collapsibility', 'due', 'to', 'circular', 'breathing', 'technique']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 79,
                "end": 89,
                "text": "Didgeridoo",
                "type": "OTHER"
            },
            {
                "start": 100,
                "end": 123,
                "text": "Obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 162,
                "end": 183,
                "text": "airway collapsibility",
                "type": "CONDITION"
            },
            {
                "start": 280,
                "end": 290,
                "text": "Didgeridoo",
                "type": "OTHER"
            },
            {
                "start": 437,
                "end": 447,
                "text": "didgeridoo",
                "type": "OTHER"
            },
            {
                "start": 477,
                "end": 498,
                "text": "airway collapsibility",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05216315",
        "study_official_title": "Non-invasive Transcranial Direct Current Stimulation to Improve Cognitive Efficiency ",
        "study_brief_summary": " Normal aging is associated with a progressive decline in cognitive functions, especially memory. This decline in cognitive function can negatively impact the quality of life of older adults. Although there are currently few possibilities to prevent and/or slow the signs of cognitive decline, both those associated with age and neurodegenerative pathologies, one of the non-invasive brain stimulation techniques that has gained attention in recent years is Transcranial Direct Current Stimulation (tDCS). tDCS is a technique based on the application of a low-intensity (< 2 mA) direct electrical current between two large-area electrodes placed on various surface areas of the head. Moreover, according to safety-related meta-analyses it is a very safe technique, without any major side effects, provided that internationally established safety protocols are taken into account in its application. This technique has recently been investigated as a potential treatment for both healthy elderly people and people with mild cognitive impairment and Alzheimer's disease in several cognitive variables, having shown encouraging results in working memory learning curves, modulation of plasticity and recognition tasks. This project aims to implement an intervention using transcranial direct current stimulation in healthy older adults, MCI and AD. The main objective is to test if there is an improvement in cognitive efficiency and if the changes are maintained over time (1 month). For this purpose, the effect of the technique will be studied on participants assigned to treatment and control groups, analyzing the possible modifications in the following cognitive variables: cognitive plasticity and learning potential, recognition and familiarity and false alarms.",
        "text": "Non-invasive Transcranial Direct Current Stimulation to Improve Cognitive Efficiency | Normal aging is associated with a progressive decline in cognitive functions, especially memory. This decline in cognitive function can negatively impact the quality of life of older adults. Although there are currently few possibilities to prevent and/or slow the signs of cognitive decline, both those associated with age and neurodegenerative pathologies, one of the non-invasive brain stimulation techniques that has gained attention in recent years is Transcranial Direct Current Stimulation (tDCS). tDCS is a technique based on the application of a low-intensity (< 2 mA) direct electrical current between two large-area electrodes placed on various surface areas of the head. Moreover, according to safety-related meta-analyses it is a very safe technique, without any major side effects, provided that internationally established safety protocols are taken into account in its application. This technique has recently been investigated as a potential treatment for both healthy elderly people and people with mild cognitive impairment and Alzheimer's disease in several cognitive variables, having shown encouraging results in working memory learning curves, modulation of plasticity and recognition tasks. This project aims to implement an intervention using transcranial direct current stimulation in healthy older adults, MCI and AD. The main objective is to test if there is an improvement in cognitive efficiency and if the changes are maintained over time (1 month). For this purpose, the effect of the technique will be studied on participants assigned to treatment and control groups, analyzing the possible modifications in the following cognitive variables: cognitive plasticity and learning potential, recognition and familiarity and false alarms.",
        "tokens": "['Non', '-', 'invasive', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'to', 'Improve', 'Cognitive', 'Efficiency', '|', 'Normal', 'aging', 'is', 'associated', 'with', 'a', 'progressive', 'decline', 'in', 'cognitive', 'functions', ',', 'especially', 'memory', '.', 'This', 'decline', 'in', 'cognitive', 'function', 'can', 'negatively', 'impact', 'the', 'quality', 'of', 'life', 'of', 'older', 'adults', '.', 'Although', 'there', 'are', 'currently', 'few', 'possibilities', 'to', 'prevent', 'and/or', 'slow', 'the', 'signs', 'of', 'cognitive', 'decline', ',', 'both', 'those', 'associated', 'with', 'age', 'and', 'neurodegenerative', 'pathologies', ',', 'one', 'of', 'the', 'non', '-', 'invasive', 'brain', 'stimulation', 'techniques', 'that', 'has', 'gained', 'attention', 'in', 'recent', 'years', 'is', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', '.', 'tDCS', 'is', 'a', 'technique', 'based', 'on', 'the', 'application', 'of', 'a', 'low', '-', 'intensity', '(', '<', '2', 'mA', ')', 'direct', 'electrical', 'current', 'between', 'two', 'large', '-', 'area', 'electrodes', 'placed', 'on', 'various', 'surface', 'areas', 'of', 'the', 'head', '.', 'Moreover', ',', 'according', 'to', 'safety', '-', 'related', 'meta', '-', 'analyses', 'it', 'is', 'a', 'very', 'safe', 'technique', ',', 'without', 'any', 'major', 'side', 'effects', ',', 'provided', 'that', 'internationally', 'established', 'safety', 'protocols', 'are', 'taken', 'into', 'account', 'in', 'its', 'application', '.', 'This', 'technique', 'has', 'recently', 'been', 'investigated', 'as', 'a', 'potential', 'treatment', 'for', 'both', 'healthy', 'elderly', 'people', 'and', 'people', 'with', 'mild', 'cognitive', 'impairment', 'and', 'Alzheimer', \"'s\", 'disease', 'in', 'several', 'cognitive', 'variables', ',', 'having', 'shown', 'encouraging', 'results', 'in', 'working', 'memory', 'learning', 'curves', ',', 'modulation', 'of', 'plasticity', 'and', 'recognition', 'tasks', '.', 'This', 'project', 'aims', 'to', 'implement', 'an', 'intervention', 'using', 'transcranial', 'direct', 'current', 'stimulation', 'in', 'healthy', 'older', 'adults', ',', 'MCI', 'and', 'AD', '.', 'The', 'main', 'objective', 'is', 'to', 'test', 'if', 'there', 'is', 'an', 'improvement', 'in', 'cognitive', 'efficiency', 'and', 'if', 'the', 'changes', 'are', 'maintained', 'over', 'time', '(', '1', 'month', ')', '.', 'For', 'this', 'purpose', ',', 'the', 'effect', 'of', 'the', 'technique', 'will', 'be', 'studied', 'on', 'participants', 'assigned', 'to', 'treatment', 'and', 'control', 'groups', ',', 'analyzing', 'the', 'possible', 'modifications', 'in', 'the', 'following', 'cognitive', 'variables', ':', 'cognitive', 'plasticity', 'and', 'learning', 'potential', ',', 'recognition', 'and', 'familiarity', 'and', 'false', 'alarms', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 52,
                "text": "Non-invasive Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 133,
                "end": 163,
                "text": "decline in cognitive functions",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 218,
                "text": "decline in cognitive function",
                "type": "CONDITION"
            },
            {
                "start": 361,
                "end": 378,
                "text": "cognitive decline",
                "type": "CONDITION"
            },
            {
                "start": 457,
                "end": 498,
                "text": "non-invasive brain stimulation techniques",
                "type": "OTHER"
            },
            {
                "start": 544,
                "end": 583,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 585,
                "end": 589,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 592,
                "end": 596,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 1104,
                "end": 1129,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 1134,
                "end": 1153,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 1355,
                "end": 1394,
                "text": "transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 1420,
                "end": 1423,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 1428,
                "end": 1430,
                "text": "AD",
                "type": "CONDITION"
            }
        ]
    }
]